<SEC-DOCUMENT>0001193125-24-172392.txt : 20240628
<SEC-HEADER>0001193125-24-172392.hdr.sgml : 20240628
<ACCEPTANCE-DATETIME>20240628164546
ACCESSION NUMBER:		0001193125-24-172392
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		65
FILED AS OF DATE:		20240628
DATE AS OF CHANGE:		20240628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bellevue Life Sciences Acquisition Corp.
		CENTRAL INDEX KEY:			0001840425
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				845052822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280590
		FILM NUMBER:		241086442

	BUSINESS ADDRESS:	
		STREET 1:		10900 NE 4TH STREET, SUITE 2300
		CITY:			BELLEVUE
		STATE:			WA
		ZIP:			98004
		BUSINESS PHONE:		425-635-7700

	MAIL ADDRESS:	
		STREET 1:		10900 NE 4TH STREET, SUITE 2300
		CITY:			BELLEVUE
		STATE:			WA
		ZIP:			98004
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>d476668ds4.htm
<DESCRIPTION>S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:blacu="http://BellevueLifeSciencesAcquisitionCorp.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-4</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To03_31_2024" id="ixv-114642">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2024To03_31_2024" id="ixv-114643">0001840425</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden117833403" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">WA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden117833404" contextRef="P01_01_2024To03_31_2024">WA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="blacu-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To02_14_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2024-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2023To11_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_13_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_09_2024To04_09_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-09</xbrli:startDate> <xbrli:endDate>2024-04-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_12_2024To03_12_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-12</xbrli:startDate> <xbrli:endDate>2024-03-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2024To02_09_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-09</xbrli:startDate> <xbrli:endDate>2024-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis_NoLongerSubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:NoLongerSubjectToForfeitureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_IPOMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrivatePlacementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis_SubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:SubjectToForfeitureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EquityParticipationMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-14</xbrli:startDate> <xbrli:endDate>2023-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-17</xbrli:startDate> <xbrli:endDate>2023-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-17</xbrli:startDate> <xbrli:endDate>2023-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-25</xbrli:startDate> <xbrli:endDate>2022-04-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-17</xbrli:startDate> <xbrli:endDate>2022-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_23_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JunChulWhangMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2024_JcwPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:JcwPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:UnsecuredPromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-09</xbrli:startDate> <xbrli:endDate>2024-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_08_2024To03_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-08</xbrli:startDate> <xbrli:endDate>2024-03-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_12_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:UnsecuredPromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-12</xbrli:startDate> <xbrli:endDate>2024-03-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-08</xbrli:startDate> <xbrli:endDate>2024-04-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_08_2024_AprilSponsorNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:AprilSponsorNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_08_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-09</xbrli:startDate> <xbrli:endDate>2024-04-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-01</xbrli:startDate> <xbrli:endDate>2023-03-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-16</xbrli:startDate> <xbrli:endDate>2024-04-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:MayTwoThousandAndTwentyFourPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_14_2024To05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:MayTwoThousandAndTwentyFourPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-14</xbrli:startDate> <xbrli:endDate>2024-05-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-10</xbrli:startDate> <xbrli:endDate>2024-05-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_17_2024To04_17_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-17</xbrli:startDate> <xbrli:endDate>2024-04-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_17_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JunChulWhangMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_EquityParticipationMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_IPOMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">As&#160;filed with the Securities and Exchange Commission on June 28, 202<div style="letter-spacing: 0px; top: 0px;display:inline;">4.</div> </div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Registration No.&#160;333-&#8195;&#8195;&#8195; </div></div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED STATES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2024To03_31_2024" id="ixv-115917">S-4</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">REGISTRATION STATEMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To03_31_2024" id="ixv-115918">BELLEVUE LIFE SCIENCES ACQUISITION CORP.</ix:nonNumeric>* </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact Name of Registrant as Specified in Charter) </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 32%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 32%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:stateprovnameen" id="ixv-115919">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-115920">6770</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-115921">84-5052822</ix:nonNumeric></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(State or Other Jurisdiction of<br/>Incorporation)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To03_31_2024" id="ixv-115922">10900 NE 4th Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To03_31_2024" id="ixv-115923">Suite 2300</ix:nonNumeric> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To03_31_2024" id="ixv-115924">Bellevue</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden117833404;display:inline;">WA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To03_31_2024" id="ixv-115925">98004</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To03_31_2024" id="ixv-115926">425</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-115927">635-7700</ix:nonNumeric> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115928">Kuk Hyoun Hwang</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115929">10900 NE 4th Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115930">Suite 2300</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115931">Bellevue</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden117833403;display:inline;">WA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115932">98004</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Telephone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115933">425</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-115934">635-7700</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies </div></div></div><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">to: </div></div></div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 50%;"><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="width: 48%;"><div style="display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Gary J. Kocher, Esq.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Mark R. Beatty</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Julie F. Rizzo, Esq.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">10900 NE 4th Street</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">K&amp;L Gates LLP</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Suite 1850</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">925 Fourth Avenue, Suite 2900</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Bellevue, WA 98004</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Seattle, WA 98104</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(425) 990-4026</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Telephone: (206) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">623-7580</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;"></div></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Approximate </div></div>date of commencement of proposed sale of the securities to the public: <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Business Combination Agreement described herein.</div></div> </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box&#8194;&#9744; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, a smaller reporting company, or emerging growt<div style="letter-spacing: 0px; top: 0px;display:inline;">h </div>company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 16%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 59%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 20%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:entityfilercategoryen" id="ixv-115935">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:boolballotbox" id="ixv-115936">&#9746;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:boolballotbox" id="ixv-115937">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:boolballotbox" id="ixv-115938">&#9744;</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 50%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 95%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Exchange Act <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;13e-4(i)</div> (Cross-Border Issuer Tender Offer)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;text-align:right;"/>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Exchange Act <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;14d-1(d)</div> (Cross-Border Third-Party Tender Offer)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;text-align:right;"/>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left;"><div style="display:inline;">*</div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="display:inline;">The Registrant is currently named Bellevue Life Sciences Acquisition Corp. Upon closing of the business combination described herein, the Registrant will change its name to OSR Holdings, Inc.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary proxy statement/prospectus is not complete and may be changed. These securities may not be issued until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">PRELIMINARY PROXY STATEMENT/PROSPECTUS </span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED JUNE 28, 2024 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROXY STATEMENT FOR THE SPECIAL MEETING OF BELLEVUE LIFE SCIENCES ACQUISITION CORP. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AND </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">PROSPECTUS FOR [</span>&#9679;<span style="font-weight:bold"></span><span style="font-weight:bold">] SHARES OF COMMON STOCK OF BELLEVUE LIFE SCIENCES ACQUISITION CORP. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders of Bellevue Life Sciences Acquisition Corp.: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the special meeting (the &#8220;<span style="text-decoration:underline"></span><span style="text-decoration:underline">Special Meeting</span>&#8221;) of Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="text-decoration:underline">BLAC</span>&#8221;), at [&#9679;] Eastern Time, on [&#9679;], 2024 at [&#9679;], or at such other time, on such other date to which the meeting may be adjourned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Special Meeting, BLAC stockholders will be asked to consider and vote upon a proposal, which is referred to herein as the &#8220;<span style="text-decoration:underline">Business</span><span style="text-decoration:underline">&#160;Combination Proposal</span>&#8221;&#160;to approve and adopt the Amended and Restated Business Combination Agreement dated as of May 23, 2024 (as may be amended, supplemented or otherwise modified from time to time, the &#8220;<span style="text-decoration:underline">Business Combination Agreement</span>&#8221;), a copy of which is attached to the accompanying proxy statement/prospectus as Annex A, by and among BLAC, OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (&#8220;<span style="text-decoration:underline">OSR Holdings</span>&#8221;), each stockholder of OSR Holdings that executes a Participating Stockholder Joinder thereto (each such person, a &#8220;<span style="text-decoration:underline">Participating Company Stockholder</span>&#8221;), and each stockholder of OSR Holdings that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder thereto (each such person, a &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221;, and together with the Participating Company Stockholders, the &#8220;<span style="text-decoration:underline">OSR Holdings Stockholders</span>&#8221;), including the transactions contemplated thereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As further described in the accompanying proxy statement/prospectus, subject to the terms and conditions of the Business Combination Agreement, the following transactions will occur (collectively, the &#8220;Business Combination&#8221;): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) On the Closing Date, (i)&#160;BLAC shall issue to the Participating Company Stockholders an aggregate of up to 24,461,214 shares of BLAC common stock, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">BLAC Common Stock</span>&#8221;), and the Participating Company Stockholders will transfer their respective shares of OSR Holdings&#8217; Series A common stock, with a par value of KRW 5,000 per share (&#8220;<span style="text-decoration:underline">OSR Holdings Common Stock</span>&#8221;) to BLAC (the &#8220;<span style="text-decoration:underline">Share Exchange</span>&#8221;), and (ii)&#160;the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders will continue to hold their shares of OSR Holdings Common Stock subject to their <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders entered into with BLAC on or before the Closing Date. As of the date of this proxy statement/prospectus, the Per Share Consideration that the Participating Company Stockholders will receive at Closing equates to $129.62. Upon consummation of the Share Exchange, BLAC will directly own at least 60% of the shares of OSR Holdings Common Stock outstanding on the Closing Date, with all of the remaining shares of OSR Holdings Common Stock held by the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders. Pursuant to the terms of the Non-Participating Stockholder Joinders, BLAC will have rights to acquire the shares of the Non-Participating Company Stockholders. The Non-Participating Stockholder Joinder contains put and call rights for the Non-Participating Company Stockholder and BLAC, respectively, whereby the Non-Participating Company Stockholder shall have the right to cause BLAC to purchase (the &#8220;Put Right&#8221;) and BLAC shall have the right to cause the Non-Participating Company Stockholder to sell (the &#8220;Call Right&#8221;) to BLAC or its designee all of the shares of OSR Holdings Common Stock owned and held of record by such Non-Participating Company Stockholder. These rights become exercisable on or after January 1, 2026, or the date that the Non-Participating Company Stockholder is notified by BLAC of a transaction that will result in a change in control (as defined in the Non-Participating Stockholder Joinder) of BLAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with the Closing, BLAC and certain of the Participating Company Stockholders will enter into <span style="white-space:nowrap">lock-up</span> agreements (the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;) providing for certain restrictions on transfer applicable to BLAC Common Stock (the <span style="white-space:nowrap">&#8220;Lock-Up</span> Shares&#8221;), which shall exclude 30% of the shares of BLAC Common Stock held by such Participating Company Stockholders. The <span style="white-space:nowrap">lock-up</span> period under the <span style="white-space:nowrap">Lock-Up</span> Agreement will last until December&#160;31, 2025. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination and giving effect to the Aggregate Consideration Value of $244,612,136, BLAC anticipates that, assuming that none of BLAC&#8217;s public stockholders exercise redemption rights, an aggregate of 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) are issued to the Participating Company Stockholders at consummation of the Business Combination, BLAC&#8217;s existing stockholders will hold in the aggregate approximately 22% of BLAC Common Stock (approximately 12% held by the public stockholders and 10% held by the Sponsor, the officers and directors of BLAC, their respective affiliates and Chardan Capital Markets, LLC), Toonon Partners Co., Ltd., a Korean investment firm (&#8220;Toonon&#8221;), will hold approximately 10.3% and OSR Holdings Stockholders will hold approximately 67.7% of BLAC Common Stock. If 943,110 public shares of the BLAC Common Stock are redeemed for cash, which assumes a 50% redemption of public shares of BLAC Common Stock, and an aggregate of 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) is issued to the Participating Company Stockholders at consummation of the Business Combination, BLAC&#8217;s existing stockholders will hold in the aggregate approximately 18.5% of BLAC Common Stock (7.9% held by our public stockholders and 10.6% held by the Sponsor, the officers and directors of BLAC, their respective affiliates and Chardan Capital Markets, LLC), Toonon will hold approximately 10.7% and OSR Holdings Stockholders will hold approximately 70.8% of BLAC Common Stock. If 1,886,221 public shares of the BLAC Common Stock are redeemed for cash, which assumes 100% of public shares of BLAC Common Stock are redeemed, and an aggregate of 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) is issued to the Participating Company Stockholders at consummation of the Business Combination, BLAC&#8217;s existing stockholders will hold in the aggregate approximately 14.6% of BLAC Common Stock (3.5% held by our public stockholders and 11.1% held by the Sponsor, the officers and directors of BLAC, their respective affiliates and Chardan Capital Markets, LLC), Toonon will hold approximately 11.23% and OSR Holdings Stockholders will hold approximately 74.17% of BLAC Common Stock. These ownership percentages take into account the conversion of all BLAC rights. These ownership percentages do not take into account (1) any warrants to purchase BLAC Common Stock as the warrants do not become exercisable until 30 days after the consummation of the Business Combination, or (2) any equity awards that may be issued under the proposed Bellevue Life Sciences Acquisition Corp. 2024 Omnibus Incentive Plan (the &#8220;<span style="text-decoration:underline">Omnibus Plan</span>&#8221;) following the Business Combination. See &#8220;<span style="font-style:italic">Questions and Answers &#8212; What equity stake will current BLAC stockholders and current OSR Holdings stockholders hold in BLAC immediately after the consummation of the Business Combination?</span>&#8221; for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">After the completion of the Business Combination, Mr.&#160;Kuk Hyoun Hwang, a director and Chief Executive Officer of BLAC, and Chairman of the Board and Chief Executive Officer of OSR Holdings, will control a majority of the voting power for the election of directors of New OSR Holdings, the post-combination company, owning approximately 60% (assuming that none of BLAC&#8217;s public stockholders exercise redemption rights), 63% (assuming that 50% of BLAC&#8217;s public stockholders exercise redemption rights) or 66% (assuming that all of BLAC&#8217;s public stockholders exercise redemption rights) of the outstanding shares of New OSR Holdings common stock. As a result, New OSR Holdings will be a &#8220;controlled company&#8221; within the meaning of the rules of The&#160;Nasdaq&#160;Stock Market LLC (&#8216;&#8216;Nasdaq&#8217;&#8217;) and may elect not to comply with certain corporate governance standards. </span>While New OSR Holdings does not presently intend to rely on these exemptions, New OSR Holdings may opt to utilize these exemptions in the future as long as it remains a&#160;controlled company. See &#8220;<span style="font-weight:bold"></span><span style="font-style:italic">Risk Factors </span><span style="font-weight:bold">&#8212; </span><span style="font-style:italic">Following the Business Combination, New OSR Holdings will be a&#160;controlled company&#160;within the meaning of the&#160;Nasdaq&#160;Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Stockholders of New OSR Holdings may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span><span style="font-weight:bold"></span>&#8221;<span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement is subject to the satisfaction or waiver of certain other closing conditions as described in the accompanying proxy statement/prospectus. There can be no assurance that the parties to the Business Combination Agreement would waive any such provision of the Business Combination Agreement. BLAC must complete a Business Combination by November 14, 2024 (subject to extension by approval of the Company&#8217;s stockholders). If BLAC does not complete a Business Combination by November 14, 2024 (subject to extension by approval of the Company&#8217;s stockholders), BLAC will cease operations and liquidate. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 9, 2023, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which BLAC must complete its initial business combination to February 14, 2024 (from November 14, 2023) and with an option for the board of directors of BLAC, in its discretion, to extend again to May 14, 2024. In February 2024, the board of directors of BLAC decided to extend the period of time in which BLAC must complete its initial business combination to May 14, 2024. In connection with the special meeting, holders of 3,432,046 shares of BLAC Common Stock elected to redeem such shares, representing approximately 50% of the outstanding public shares of BLAC Common Stock as of November 7, 2023, for a per share redemption price of approximately $10.49, resulting in an aggregate reduction of the amount in the Trust Account by $35,995,727.58, representing approximately 49% of the total amount in the Trust Account. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 14, 2024, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which BLAC must complete its initial business combination from May 14, 2024 to November 14, 2024. In connection with the special meeting, holders of 1,581,733 shares of BLAC Common Stock elected to redeem such shares, representing approximately 46% of the outstanding public shares of BLAC Common Stock as of May 8, 2024, for a per share redemption price of approximately $10.78, resulting in an aggregate reduction of the amount in the Trust Account by $17,045,763.24, representing approximately 45% of the total amount in the Trust Account. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because BLAC&#8217;s Sponsor is controlled by and has substantial ties with non-U.S. persons, and will own approximately 6.7% of the issued and outstanding BLAC Common Stock following the Business Combination (assuming that all of BLAC&#8217;s public stockholders exercise redemption rights), we may be considered a &#8220;foreign person&#8221; under rules promulgated by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and the Business Combination may fall within the scope of a &#8220;covered transaction&#8221; subject to CFIUS review. See &#8220;<span style="font-style:italic">Risk Factors &#8212;&#160;We may not be able to complete an </span><span style="font-style:italic">initial business combination with a </span><span style="font-style:italic">U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and ultimately prohibited.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is actively pursuing entering into one or more subscription agreements (collectively, the &#8220;<span style="text-decoration:underline">Subscription Agreements</span>&#8221;) with certain institutional and accredited investors (collectively, the &#8220;<span style="text-decoration:underline">PIPE Investors</span>&#8221;) pursuant to which the PIPE Investors will agree to purchase, prior to or substantially concurrently with the closing of the Business Combination, equity, or debt or preferred securities issuable by BLAC and/or OSR Holdings convertible into BLAC Common Stock, for aggregate gross proceeds of at least $20,000,000 (the &#8220;<span style="text-decoration:underline">PIPE Financing</span>&#8221;). The securities to be issued to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act&#8221;</span>), in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act and/or Regulation S adopted thereunder. BLAC has obtained a letter of intent from Toonon Partners Co., Ltd. (&#8220;<span style="text-decoration:underline">Toonon</span>&#8221;), a Korean investment firm, dated June 24, 2024, pursuant to which Toonon indicated its interest to purchase $20,000,000 of BLAC&#8217;s equity securities in connection with the closing of the Business Combination. The terms of the proposed transaction are under current negotiation and, assuming all terms are finalized, will be set forth in a definitive agreement to be executed between BLAC and Toonon. The PIPE Financing, if completed, will dilute the ownership of existing BLAC stockholders, and may depress the value of shares of New OSR Holdings Common Stock. It is not currently anticipated that Sponsor or any BLAC or OSR Holdings affiliates will participate in the PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Business Combination Proposal, you will also be asked to consider and vote upon (a)&#160;the adoption of BLAC&#8217;s Second Amended and Restated Certificate of Incorporation (the &#8220;<span style="text-decoration:underline">Amended Charter</span>&#8221;), which supersedes the existing Amended and Restated Certificate of Incorporation of BLAC (the &#8220;<span style="text-decoration:underline">Current Charter</span>&#8221;), which is referred to herein as the &#8220;<span style="text-decoration:underline">Charter Proposal</span>,&#8221; (b) to consider and vote, on a <span style="white-space:nowrap">non-binding</span> advisory basis, upon six separate governance proposals relating to material differences between BLAC&#8217;s Existing Governing Documents and the Proposed Governing Documents to be in effect upon the completion of the Business Combination in accordance with the requirements of the U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">SEC</span>&#8221;). These proposals are referred to as the &#8220;<span style="text-decoration:underline">Advisory Governance Proposals</span>&#8221; or &#8220;<span style="text-decoration:underline">Advisory Proposals <span style="white-space:nowrap">3A-3F</span></span>,&#8221; (c) a proposal to approve and adopt the Omnibus Plan in form and substance reasonably acceptable to BLAC and OSR Holdings, a copy of which is attached to the accompanying proxy statement as Annex G, which is referred to herein as the &#8220;<span style="text-decoration:underline">Incentive Plan Proposal</span>,&#8221; (d) a proposal to elect up to nine (9)&#160;directors, effective as of and contingent upon the consummation of the Business Combination, to serve on BLAC&#8217;s board of directors </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until the expiration of their applicable term, and until their respective successors are duly elected and qualified or until their earlier resignation, removal or death, which is referred to herein as the &#8220;<span style="text-decoration:underline">Director Election Proposal,</span>&#8221; and (e)&#160;a proposal to adjourn the special meeting to a later date or dates to the extent necessary, which is referred to herein as the &#8220;<span style="text-decoration:underline">Adjournment Proposal</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be consummated only if the Business Combination Proposal, the Charter Proposal, the Incentive Plan Proposal and the Director Election Proposal (collectively, the &#8220;<span style="text-decoration:underline">Condition Precedent Proposals</span>&#8221;) are approved at the special meeting. The Advisory Governance Proposals and the Adjournment Proposal are not conditioned upon the approval of any other proposal. Each of these proposals is more fully described in the accompanying proxy statement/prospectus, which each stockholder is encouraged to read carefully and in its entirety. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal provides for a vote to adjourn the special meeting to a later date or dates (a)&#160;to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus is provided to the BLAC stockholders or, if as of the time for which the special meeting is scheduled, there are insufficient shares of BLAC Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the special meeting, (b)&#160;in order to solicit additional proxies from the BLAC stockholders in favor of one or more of the proposals at the special meeting or (c)&#160;if the BLAC stockholders redeem an amount of the public shares such that (i) it will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or (ii) the conditions to consummate the Business Combination that the aggregate cash proceeds to be received by BLAC from the trust account in connection with the Business Combination satisfy the following threshold: such aggregate proceeds, including all other cash and cash equivalents of BLAC, equal no less than $5,000,001 (after deducting any amounts to be paid to BLAC&#8217;s stockholders that exercise their redemption rights in connection with the Business Combination, plus any other transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing), as conditions to OSR Holdings&#8217; obligation to close would not be satisfied at Closing (such aggregate proceeds, the &#8220;<span style="text-decoration:underline">Minimum Available</span><span style="text-decoration:underline">&#160;Cash,</span>&#8221; and such conditions to the consummation of the Business Combination, the &#8220;<span style="text-decoration:underline">Minimum Available Cash Condition&#8221;</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain related agreements have been, or will be entered into on or prior to the closing of the Business Combination, including the <span style="white-space:nowrap">Lock-Up</span> Agreements. See &#8220;<span style="font-style:italic">Certain Agreements Related to the Business Combination &#8212; Related Agreements</span><span style="font-style:italic"> &#8212; Lock-Up Agreements</span>&#8221; in the accompanying proxy statement for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s public units, public shares, public warrants and public rights are currently listed on Nasdaq under the symbols &#8220;BLACU,&#8221; &#8220;BLAC,&#8221; &#8220;BLACW,&#8221; and &#8220;BLACR,&#8221; respectively. Upon the consummation of the Business Combination, BLAC will be renamed &#8220;OSR Holdings, Inc.&#8221; (&#8220;<span style="text-decoration:underline">New OSR Holdings</span>&#8221; or the &#8220;<span style="text-decoration:underline">Combined Company</span>&#8221;). BLAC will also apply for listing, to be effective at the time of the Business Combination, of New OSR Holdings common stock (&#8220;<span style="text-decoration:underline">New OSR Holdings Common Stock</span>&#8221;) and warrants on Nasdaq under the proposed symbols &#8220;OSRB&#8221; and &#8220;OSRBW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Current Charter and the Bylaws of BLAC (the &#8220;<span style="text-decoration:underline">Current Bylaws</span>&#8221; and, together with the Current Charter, the &#8220;<span style="text-decoration:underline">Existing Governing Documents</span>&#8221;), a holder of BLAC&#8217;s public shares of common stock (a &#8220;<span style="text-decoration:underline">public stockholder&#8221;</span>) may request that BLAC redeem all or a portion of such public shares for cash if the Business Combination is consummated. In order to redeem public shares underlying units, holders of units must elect to separate their units into the underlying public shares, public warrants and public rights prior to exercising redemption rights with respect to such public shares. Holders that hold their units in an account at a brokerage firm or bank must notify their broker or bank that they elect to separate the units into the underlying public shares, public warrants and public rights, or if a holder holds units registered in its own name, the holder must contact Continental Stock Transfer&#160;&amp; Trust Company (&#8220;<span style="text-decoration:underline">Continental&#8221;</span>), BLAC&#8217;s transfer agent, directly and instruct it to do so. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares.<span style="font-weight:bold">&#160;Public stockholders may elect to redeem their public shares even if they vote &#8220;for&#8221; the Business Combination Proposal</span>. If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public stockholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share certificates (if any) to Continental, BLAC will redeem such public shares for a per share price, payable in cash, equal to the pro rata portion of the trust account established at the consummation of BLAC&#8217;s initial public offering, calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, based on [&#9679;] shares subject to possible redemption as of [&#9679;],&#160;2024 and including interest and prior to the payment of taxes, this would have amounted to approximately $[&#9679;] per issued and outstanding public share. If a public stockholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption will take place prior to the Business Combination. See &#8220;<span style="font-style:italic">The Special Meeting of BLAC Stockholders &#8212; Redemption Rights and Procedures</span>&#8221; in the accompanying proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a public stockholder, together with any affiliate of such public stockholder or any other person with whom such public stockholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act&#8221;</span>)), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the public shares without the prior consent of BLAC. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">BLAC is providing the accompanying proxy statement/prospectus and accompanying proxy card to BLAC&#8217;s stockholders in connection with the solicitation of proxies to be voted at the special meeting and at any adjournments of the special meeting. Information about the special meeting, the Business Combination and other related business to be considered by BLAC&#8217;s stockholders at the special meeting is included in the accompanying proxy statement/prospectus.&#160;Whether or not you plan to attend the special meeting, all of BLAC&#8217;s stockholders are urged to read the accompanying proxy statement/prospectus, including the Annexes and other documents referred to therein, carefully and in their entirety. You should also carefully consider the risk factors described in</span><span style="font-weight:bold"><span style="font-style:italic">&#160;&#8220;</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><a href="#rom476668_11">Risk Factors</a></span></span><span style="font-weight:bold">&#8221; beginning on page&#160;50 of the accompanying proxy statement/prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">After careful consideration, the board of directors of BLAC has unanimously approved the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination, and unanimously recommends that stockholders vote &#8220;FOR&#8221; the adoption of the Business Combination Agreement and approval of the transactions contemplated thereby, including the Business Combination, and &#8220;FOR&#8221; all other proposals presented to BLAC&#8217;s stockholders in the accompanying proxy statement/prospectus. When you consider the recommendation of these proposals by the board of directors of BLAC, you should keep in mind that BLAC&#8217;s directors and officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section &#8220;</span><span style="font-weight:bold"><span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span></span><span style="font-weight:bold">&#8221; in the accompanying proxy statement/prospectus for a further discussion of these considerations. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Your vote is very important</span></span><span style="font-weight:bold">. Whether or not you plan to attend the special meeting, please vote as soon as possible by following the instructions in the accompanying proxy statement/prospectus to make sure that your shares are represented at the special meeting. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the special meeting. The Business Combination will be consummated only if the Condition Precedent Proposals are approved at the special meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of each other. The Advisory Governance Proposals and the Adjournment Proposal are not conditioned on the approval of any other proposal set forth in the accompanying proxy statement/prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted FOR each of the proposals presented at the special meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the special meeting, the effect will be, among other things, that your shares will not be counted for purposes of determining whether a quorum is present at the special meeting. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR PUBLIC SHARES ARE REDEEMED FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO BLAC&#8217;S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE SPECIAL MEETING. IN ORDER TO EXERCISE YOUR REDEMPTION RIGHT, YOU NEED TO IDENTIFY YOURSELF AS A BENEFICIAL HOLDER AND PROVIDE YOUR LEGAL NAME, PHONE NUMBER AND ADDRESS IN YOUR WRITTEN DEMAND. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE (IF ANY) TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of BLAC&#8217;s board of directors, I would like to thank you for your support and look forward to the successful completion of the Business Combination. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:46%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Bellevue, WA</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">By Order of the Board of Directors,</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#8195;&#8195;&#8195;&#8195;&#8194;, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTIONS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS, PASSED UPON THE MERITS OR FAIRNESS OF EITHER THE BUSINESS COMBINATION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED THEREBY, OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement/prospectus is dated [&#9679;],&#160;2024 and is first being mailed to stockholders on or about [&#9679;],&#160;2024. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA, 98004 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICE OF SPECIAL MEETING </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">TO BE HELD ON [</span>&#9679;<span style="font-weight:bold">], 2024</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE STOCKHOLDERS OF BELLEVUE LIFE SCIENCES ACQUISITION CORP.: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that a special meeting (the &#8220;<span style="text-decoration:underline">special meeting</span>&#8221;) of Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="text-decoration:underline">BLAC</span>&#8221;), will be held at [&#9679;], Eastern Time, on [&#9679;],&#160;2024. You are cordially invited to attend the special meeting, which will be held for the following purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1 &#8212; The Business Combination Proposal &#8212; </span>to consider and vote upon a proposal that (i)&#160;BLAC&#8217;s entry into (a)&#160;the Amended and Restated Business Combination Agreement dated as of May 23, 2024 (as may be amended, supplemented or otherwise modified from time to time, the &#8220;<span style="text-decoration:underline">Business</span><span style="text-decoration:underline">&#160;Combination Agreement&#8221;</span>), a copy of which is attached to the proxy statement/prospectus as Annex A, by and among BLAC, OSR Holdings, Ltd., a corporation organized under the laws of the Republic of Korea (&#8220;<span style="text-decoration:underline">OSR Holdings&#8221;</span>), each holder of OSR Holdings Common Stock (as defined herein) that will be converted to OSR Holdings Common Stock prior to closing) that executes a Participating Stockholder Joinder thereto (each such person, a &#8220;<span style="text-decoration:underline">Participating Company Stockholder</span>&#8221;), and each stockholder of OSR Holdings that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder thereto (each such person, a &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221;, and together with the Participating Company Stockholders, the &#8220;<span style="text-decoration:underline">OSR Holdings Stockholders</span>&#8221;), pursuant to which, among other things, (A)&#160;the Participating Company Stockholders will transfer their respective shares of OSR Holdings Common Stock to BLAC in exchange for shares of BLAC Common Stock (the &#8220;<span style="text-decoration:underline">Share Exchange</span>&#8221;), and (B)&#160;the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders will continue to hold their shares of OSR Holdings Common Stock subject to their <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders entered into with BLAC on or before the Closing Date, and (b)&#160;certain related agreements (including <span style="white-space:nowrap">lock-up</span> agreements (the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;), each in the form attached hereto), and the transactions contemplated thereby, be approved, ratified and confirmed in all respects. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2 &#8212; The Charter Proposal</span><span style="font-weight:bold"></span>&#160;&#8212;&#160;to consider and vote upon a proposal to approve the Second Amended and Restated Certificate of Incorporation of BLAC, a copy of which is attached to the proxy statement/prospectus as Annex E. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposals No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3A&#8212;3F &#8212; The Advisory Governance Proposals</span><span style="font-weight:bold"></span>&#160;&#8212;&#160;to consider and vote, on a <span style="white-space:nowrap">non-binding</span> advisory basis, upon six separate governance proposals relating to material differences between BLAC&#8217;s Current Charter and the Amended Charter to be in effect upon the completion of the Business Combination in accordance with the requirements of the SEC. These proposals are referred to as the &#8220;<span style="font-weight:bold">Advisory Governance Proposals</span>&#8221; or &#8220;<span style="font-weight:bold">Advisory Proposals 3A&#8212;3F</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Name Change</span> <span style="font-weight:bold">&#8212;</span> to change BLAC&#8217;s name to &#8220;OSR Holdings, Inc;&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Preferred Stock &#8212;</span> to increase the number of shares of preferred stock that can be issued from 1,000,000 shares to 10,000,000 shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Increase Vote Required for Removal of Directors</span> &#8212; to provide that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Corporate Opportunity</span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">&#160;&#8212;</span>&#160;to eliminate the current limitations on the corporate opportunity doctrine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Change in Quorum</span> <span style="font-style:italic">&#8212;</span>&#160;to provide that the quorum required for stockholder meetings is the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of the then outstanding shares of capital stock entitled to vote at the meeting; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Additional Charter Amendments</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span>&#160;to approve all other changes including eliminating certain provisions related to special purpose acquisition corporations that will no longer be relevant following the closing of the Business Combination (the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;). </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4 &#8212; The Incentive Plan Proposal &#8212; </span>to consider and vote upon a proposal for the new omnibus incentive plan in form and substance reasonably acceptable to BLAC and OSR Holdings, a copy of which is attached to the proxy statement as Annex G, be adopted and approved. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5 &#8212; The Director Election Proposal &#8212; </span>to elect nine (9) directors to the New OSR Holdings Board. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6 &#8212;</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;The</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;Adjournment Proposal</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;&#8212; </span>to adjourn special meeting to a later date or dates (a)&#160;to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus is provided to the BLAC stockholders or, if as of the time for which the special meeting is scheduled, there are insufficient shares of BLAC Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the special meeting, (b)&#160;in order to solicit additional proxies from the BLAC stockholders in favor of one or more of the proposals at the special meeting or (c)&#160;if BLAC stockholders redeem an amount of the public shares such that (i) it will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or (ii) one of the conditions to consummate the Business Combination that the aggregate cash proceeds to be received by BLAC from the trust account in connection with the Business Combination, including all other cash and cash equivalents of BLAC, equal to no less than $5,000,001 (after deducting any amounts to be paid to BLAC&#8217;s stockholders that exercise their redemption rights in connection with the Business Combination, plus any other transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing) would not be satisfied at Closing (such aggregate proceeds, the &#8220;<span style="text-decoration:underline">Minimum Available Cash</span>,&#8221; and such conditions to the consummation of the Business Combination, the &#8220;<span style="text-decoration:underline">Minimum Available Cash Condition</span>&#8221;), be approved. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Business Combination Proposal, the Charter Proposal, the Incentive Plan Proposal and the Director Election Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. The Advisory Governance Proposals and Adjournment Proposal are not conditioned on any other proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These items of business are described in the proxy statement/prospectus, which we encourage you to read carefully and in its entirety before voting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The special meeting will be convened on [&#9679;], 2024 at [&#9679;], Eastern Time, at [&#9679;]. Stockholders may attend, vote and examine the list of BLAC&#8217;s stockholders entitled to vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of shares of BLAC Common Stock at the close of business on [&#9679;],&#160;2024 are entitled to notice of and to vote and have their votes counted at the special meeting and any adjournment of the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus and accompanying proxy card is being provided to BLAC&#8217;s stockholders in connection with the solicitation of proxies to be voted at the special meeting and at any adjournment of the special meeting.<span style="font-weight:bold">&#160;Whether or not you plan to attend the special meeting, all of BLAC&#8217;s stockholders are urged to read the proxy statement, including the Annexes and the documents referred to therein carefully and in their entirety. You should also carefully consider the risk factors described in &#8220;</span><span style="font-weight:bold">Risk Factors</span><span style="font-weight:bold">&#8221; beginning on page</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold">50 of the proxy statement/prospectus</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">After careful consideration, the board of directors of BLAC has unanimously approved the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination, and unanimously recommends that stockholders vote &#8220;FOR&#8221; the adoption of the Business Combination Agreement and approval of the transactions contemplated thereby, including the Business Combination, and &#8220;FOR&#8221; all other proposals presented to BLAC&#8217;s stockholders in the proxy statement/prospectus. When you consider the recommendation of these proposals by the board of directors of BLAC, you should keep in mind that BLAC&#8217;s directors and officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled &#8220;</span><span style="font-weight:bold"><span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span></span><span style="font-weight:bold">&#8221; in the proxy statement/prospectus for a further discussion of these considerations. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Existing Governing Documents, a public stockholder may request that BLAC redeem all or a portion of its public shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">(a) hold public shares or (b)&#160;if you hold public shares through units, you elect to separate your units into the underlying public shares, public warrants and public rights prior to exercising your redemption rights with respect to the public shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">submit a written request to Continental, BLAC&#8217;s transfer agent, in which you (i)&#160;request that BLAC redeem all or a portion of your public shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">deliver your share certificates (if any) to Continental, BLAC&#8217;s transfer agent, physically or electronically through The Depository Trust Company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to [&#9679;], Eastern Time, on [&#9679;], 2024 (two business days before the special meeting) in order for their shares to be redeemed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of units must elect to separate the units into the underlying public shares, public warrants and public rights prior to exercising redemption rights with respect to the public shares. Public holders that hold their units in an account at a brokerage firm or bank, must notify their broker or bank that they elect to separate the units into the underlying public shares, public warrants and public rights, or if a holder holds units registered in its own name, the holder must contact Continental, BLAC&#8217;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. Public stockholders may elect to redeem public shares regardless of if or how they vote in respect of the Business Combination Proposal. If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public stockholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its share certificates (if any) to Continental, BLAC&#8217;s transfer agent, BLAC will redeem such public shares for a per share price, payable in cash, equal to the pro rata portion of the trust account established at the consummation of BLAC&#8217;s initial public offering (the &#8220;<span style="text-decoration:underline">trust account&#8221;</span>), calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, this would have amounted to approximately $[&#9679;] per issued and outstanding public share (including interest and prior to the payment of taxes), based on [&#9679;] shares subject to possible redemption as of [&#9679;], 2024. If a public stockholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. See &#8220;<span style="font-style:italic">The Special Meeting of BLAC Stockholders &#8212; Redemption Rights</span> <span style="font-style:italic">and Procedures</span>&#8221; in this proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a public stockholder, together with any affiliate of such public stockholder or any other person with whom such public stockholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the public shares without the prior consent of BLAC. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement is subject to the satisfaction or waiver of certain other closing conditions as described in this proxy statement/prospectus. There can be no assurance that the parties to the Business Combination Agreement would waive any such provision of the Business Combination Agreement. For further details, <span style="font-style:italic">see &#8220;The Business Combination Agreement &#8212; Conditions to Closing the Business Combination</span>.<span style="font-style:italic">&#8221;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal and the Adjournment Proposal requires the affirmative vote of the holders of a majority </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. In order to be elected as a director as described in the Director Election Proposal, a nominee must receive a plurality of all the votes cast only by holders of the BLAC Common Stock at the special meeting, which means that the nominees with the most votes are elected. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum so long as a stockholder has given the broker or other nominee voting instructions on at least one of the proposals set forth in this proxy statement/prospectus, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Your vote is very important.</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold">&#160;Whether or not you plan to attend the special meeting, please vote as soon as possible by following the instructions in the proxy statement/prospectus to make sure that your shares are represented at the special meeting. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the special meeting. The Business Combination will be consummated only if the Condition Precedent Proposals are approved at the special meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of each other. The Advisory Governance Proposals and the Adjournment Proposal are not conditioned on the approval of any other proposal set forth in the proxy statement/prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted FOR each of the proposals presented at the special meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the special meeting, the effect will be, among other things, that your shares will not be counted for purposes of determining whether a quorum is present at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your attention is directed to the remainder of the proxy statement/prospectus following this notice (including the Annexes and other documents referred to herein) for a more complete description of the proposed Business Combination and related transactions and each of the proposals. You are encouraged to read the proxy statement/prospectus carefully and in its entirety, including the Annexes and other documents referred to herein. If you have any questions or need assistance voting your shares of BLAC Common Stock, please contact Advantage Proxy, our proxy solicitor, by calling (206) <span style="white-space:nowrap">870-8568,</span> or toll free at (877) <span style="white-space:nowrap">870-8565,</span> or by emailing ksmith@advantageproxy.com. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thank you for your participation. We look forward to your continued support. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors of Bellevue Life Sciences Acquisition Corp., </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#9679;] </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#9679;] </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR SHARES OF COMMON STOCK ARE REDEEMED FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO BLAC&#8217;S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE SPECIAL MEETING. IN ORDER TO EXERCISE YOUR REDEMPTION RIGHT, YOU NEED TO IDENTIFY YOURSELF AS A BENEFICIAL HOLDER AND PROVIDE YOUR LEGAL NAME, PHONE NUMBER AND ADDRESS IN YOUR WRITTEN DEMAND. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE (IF ANY) TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_1">About This Proxy Statement/Prospectus</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_2">Market and Industry Data</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_3">Trademarks, Tradenames and Service Marks</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_4">Frequently Used Terms</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_5">Questions and Answers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_6">Summary of The Proxy Statement/Prospectus</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_7">Selected Historical Financial Data of BLAC</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_8">Selected Historical Financial Data of OSR Holdings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_9">Selected Unaudited Pro Forma Condensed Combined Financial Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_10">Cautionary Note Regarding Forward-looking Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_11">Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_12">Unaudited Pro Forma Condensed Combined Financial Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_13">Comparative Per Share Data</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_14">The Special Meeting of BLAC Stockholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_15">The Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_16">The Business Combination Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_17">Certain Agreements Related to The Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_18">Material U.S. Federal Income Tax Consequences</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_19">Proposal No. 1&#160;- The Business Combination Proposal</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_20">Proposal No. 2&#160;- The Charter Proposal</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_21">Proposals No. 3A&#160;- 3F&#160;- The Advisory Governance Proposals</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_22">Proposal No. 4&#160;- The Incentive Plan Proposal</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_23">Proposal No. 5&#160;- The Director Election Proposal</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_24">Proposal No. 6&#160;- The Adjournment Proposal</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_25">Business of OSR Holdings and Certain Information About OSR Holdings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_26">Management of OSR Holdings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_27">Executive and Director Compensation of OSR Holdings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_28">OSR Holdings Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_29">Certain OSR Holdings Relationships and Related Person Transactions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_30">Information About BLAC</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_31">Executive Officers and Directors of BLAC</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_32">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of BLAC</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_33">Certain BLAC Relationships and Related Person Transactions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_34">Management Following The Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_35">Description of Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_36">Comparison of Corporate Governance and Stockholders Rights</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_37">Beneficial Ownership of Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_38">Market Price and Dividend Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_39">Additional Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_40">Legal Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_41">Experts</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_42">Where You Can Find More Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_43">Index to Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_44">Annex A: Amended and Restated Business Combination Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_45">Annex B: Joinder (Participating Stockholder Form)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">B-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_46">Annex C: Joinder <span style="white-space:nowrap">(Non-Participating</span> Stockholder Form)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">C-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_47">Annex D: <span style="white-space:nowrap">Lock-Up</span> Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">D-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_48">Annex E: Second Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp.</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">E-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_49">Annex F: Amended and Restated Bylaws of OSR Holdings, Inc.</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_50">Annex G: Bellevue Life Sciences Acquisition Corp. 2024 Omnibus Incentive Plan</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">G-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_52">Annex H: Draft of Fairness Opinion</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">H-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><a href="#rom476668_51">Annex I: Form of Proxy Card</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">I-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_1">ABOUT THIS PROXY STATEMENT/PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document, which forms part of a registration statement on Form&#160;S-4&#160;filed with the SEC, by BLAC (File No. [&#9679;]) (the &#8220;Registration Statement&#8221;), constitutes a prospectus of BLAC under Section&#160;5 of the Securities Act, with respect to the shares of BLAC Common Stock to be issued if the Business Combination described herein is consummated. This document also constitutes a notice of meeting and a proxy statement under Section&#160;14(a)&#160;of the Exchange&#160;Act with respect to the special meeting of BLAC&#8217;s stockholders at which BLAC&#8217;s stockholders will be asked to consider and vote upon a proposal to approve the Business Combination by the approval and adoption of the Business Combination Agreement, among other matters. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_2">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains estimates, projections, and other information concerning OSR Holdings&#8217; industry and business, as well as data regarding market research, estimates, and forecasts prepared by OSR Holdings&#8217; management. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which OSR Holdings operates is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; Unless otherwise expressly stated, OSR Holdings obtained industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry and general publications, government data, and similar sources. In some cases, OSR Holdings does not expressly refer to the sources from which this data is derived. In that regard, when OSR Holdings refers to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from sources that OSR Holdings paid for, sponsored, or conducted, unless otherwise expressly stated or the context otherwise requires. While OSR Holdings has compiled, extracted, and reproduced industry data from these sources, OSR Holdings has not independently verified the data. Forecasts and other forward-looking&#160;information with respect to industry, business, market, and other data are subject to the same qualifications and additional uncertainties regarding the other forward-looking&#160;statements in this proxy statement/prospectus. See &#8220;<span style="font-style:italic">Cautionary</span><span style="font-style:italic">&#160;Note</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Regarding</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Forward-Looking</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Statements.</span>&#8221; </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_3">TRADEMARKS, TRADENAMES AND SERVICE MARKS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus includes trademarks, tradenames and service marks, certain of which belong to BLAC or OSR Holdings and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this proxy statement/prospectus appear without the <sup style="font-size:75%; vertical-align:top">&#174;</sup>, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that BLAC or OSR Holdings will not assert their rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. Neither BLAC nor OSR Holdings intend that their use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of BLAC or OSR Holdings by, these other parties. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_4">FREQUENTLY USED TERMS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Aggregate Consideration</span>&#8221; means an aggregate of 24,461,214 shares of BLAC Common Stock derived by the quotient of (a)&#160;the Aggregate Consideration Value divided by (b) $10.00. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Aggregate Consideration Value</span>&#8221; means $244,612,136. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Aggregate Participating Consideration</span>&#8221; means the aggregate number of shares of BLAC Common Stock issuable to the Participating Company Stockholders at Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Amended Bylaws</span>&#8221; means the Amended and Restated Bylaws of BLAC, to be in effect following the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Amended Charter</span>&#8221; means the Second Amended and Restated Certificate of Incorporation of BLAC, to be in effect following the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Ancillary Agreements</span>&#8221; means the <span style="white-space:nowrap">Lock-Up</span> Agreements, the PIPE Subscription Agreements, and all other agreements, certificates and instruments executed and delivered by BLAC, OSR Holdings or OSR Holdings Stockholders in connection with the Transactions and specifically contemplated by the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC</span>&#8221; means Bellevue Life Sciences Acquisition Corp., a Delaware corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Board</span>&#8221; means the board of directors of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Common Stock</span>&#8221; means BLAC&#8217;s common stock, par value $0.0001 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC M&amp;A Committee</span>&#8221; means the committee established by the BLAC Board consisting of directors that do not have any material interest in OSR Holdings or the Transactions contemplated by the Business Combination Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC IPO Prospectus</span>&#8221; means the prospectus issued by BLAC in connection with its initial public offering of BLAC Units, dated February&#160;9, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Organizational Documents</span>&#8221; means the BLAC Certificate of Incorporation, Bylaws, and the Trust Agreement, in each case as amended, modified or supplemented from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Preferred Stock</span>&#8221; means BLAC&#8217;s preferred stock, par value $0.0001 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Proposals</span>&#8221; means, collectively, The Business Combination Proposal, The Charter Proposal, The Advisory Governance Proposals, The Incentive Plan Proposal, The Director Election Proposal and The Adjournment Proposal, as described in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Right</span>&#8221; means one right entitling the holder thereof to receive <span style="white-space:nowrap">one-tenth</span> (1/10) of a share of BLAC Common Stock upon the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Stockholders&#8217; Meeting</span>&#8221; means the special meeting of BLAC at [&#9679;], Eastern Time, on [&#9679;], 2024, or at such other time, on such other date to which the meeting may be adjourned. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Unit</span>&#8221; means one unit issued by BLAC in connection with its initial public offering, consisting of one share of BLAC Common Stock, one BLAC Warrant and one BLAC Right. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">BLAC Warrant</span>&#8221; means one warrant entitling the holder thereof to purchase one share of BLAC Common Stock at a price of $11.50 per share, subject to adjustment as described in the BLAC IPO Prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Business Combination</span>&#8221; means the business combination transaction whereby BLAC issues shares of BLAC Common Stock to the Participating Company Stockholders and, in consideration, the Participating Company Stockholders transfer each of their respective shares of OSR Holdings Common Stock to BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Business Combination Agreement</span>&#8221; means that certain Amended and Restated Business Combination Agreement, by and among BLAC, OSR Holdings and OSR Holdings Stockholders, attached hereto as Annex A. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Closing</span>&#8221; means the closing of the Share Exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Closing Date</span>&#8221; means the date on which the Closing occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Combined Company</span>&#8221; means OSR Holdings, Inc., following the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">COVID-19</span> Measures</span>&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; workforce reduction, social distancing, shut down, closure, sequester, workplace safety or similar law promulgated by any Governmental Authority, including the Centers for Disease Control and Prevention and the World Health Organization, in each case, in connection with or in response to <span style="white-space:nowrap">COVID-19,</span> including the CARES Act and Families First Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Current Bylaws</span>&#8221; means the Bylaws of BLAC, such may have been amended, supplemented or modified from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Current Charter</span>&#8221; means the Amended and Restated Certificate of Incorporation of BLAC filed with the Secretary of the State of the State of Delaware on February&#160;13, 2023, the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BLAC filed with the Secretary of the State of the State of Delaware on November 9, 2023, the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BLAC filed with the Secretary of the State of the State of Delaware on February 9, 2024, and the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BLAC filed with the Secretary of the State of the State of Delaware on May 14, 2024, as such may have been amended, supplemented or modified from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Effective Time</span>&#8221; means the time at which the Closing occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Existing Governing Documents</span>&#8221; means the Amended and Restated Certificate of Incorporation of BLAC and the Bylaws of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Governmental Authority</span>&#8221; means any United States federal, state, county or local or <span style="white-space:nowrap">non-United</span> States government, governmental or quasi-governmental, regulatory or administrative authority or office, any political or other subdivision thereof, agency, instrumentality, bureau, authority, body or commission or any court, tribunal, or judicial or arbitral body. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">HSR Act</span>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">IRS</span>&#8221; means the U.S. Internal Revenue Service. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Joinders</span>&#8221; means, collectively, the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder and the Participating Stockholder Joinder. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221; means <span style="white-space:nowrap">Lock-Up</span> Agreements to be executed at Closing between BLAC and certain Participating Company Stockholders, pursuant to which such Participating Company Stockholders will agree to certain restrictions on transfer applicable to BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">New OSR Holdings</span>&#8221; means OSR Holdings, Inc., following the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221; means each holder of OSR Holdings Common Stock that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder to the Business Combination Agreement on or prior to the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder</span>&#8221; means the agreement of each <span style="white-space:nowrap">Non-Participating</span> Company Stockholder to become a party to the Business Combination Agreement after November 16, 2023 (the date of the initial Business Combination Agreement), and prior to Closing substantially in the form attached as Exhibit C to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings</span>&#8221; means OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Board</span>&#8221; means the board of directors of the OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Capital Stock</span>&#8221; means the OSR Holdings Common Stock and any other class or series of OSR Holdings capital stock issued or issuable upon exercise of any security convertible into, or exchangeable for capital stock of OSR Holdings outstanding at the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Common Stock</span>&#8221; means the Company&#8217;s series A common stock, with a par value of KRW 5,000 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Fully Diluted Share Amount</span>&#8221; means, without duplication, the aggregate number of shares of OSR Holdings Common Stock outstanding on a fully diluted basis, including all shares issuable upon the conversion or exercise of all options, warrants and other securities convertible into or exchangeable for shares of OSR Holdings Common Stock, as of immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Stockholders</span>&#8221; means, collectively, the Participating Company Stockholders and the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">OSR Holdings Subsidiaries</span>&#8221; means the subsidiaries of OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Participating Company Stockholder</span>&#8221; means each holder of OSR Holdings Common Stock that executes a Participating Stockholder Joinder to the Business Combination Agreement on or prior to the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Participating Stockholder Joinder</span>&#8221; means the agreement of each Participating Company Stockholder to become a party to the Business Combination Agreement after November 16, 2023 (the date of the initial Business Combination Agreement), and prior to Closing substantially in the form attached as Exhibit B to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Per Share Consideration</span>&#8221; means, with respect to each share of OSR Holdings Capital Stock held immediately prior to the Effective Time, the Aggregate Consideration divided by the OSR Holdings Fully Diluted Share Amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Proposed Governing Documents</span>&#8221; means the Amended Charter and the Amended Bylaws. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Share Exchange</span>&#8221; means the transactions contemplated by the Business Combination Agreement, whereby (i)&#160;BLAC shall issue the Aggregate Participating Consideration to the Participating Company Stockholders, and (ii)&#160;the Participating Company Stockholders shall sell, transfer, convey, assign and deliver all of their respective shares of OSR Holdings Common Stock to BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Transaction Documents</span>&#8221; means the Business Combination Agreement, including all Schedules and Exhibits thereto, the Joinders, the Company Disclosure Schedule, the Ancillary Agreements, and all other agreements, certificates and instruments executed and delivered by BLAC, the Company or the Company Stockholders in connection with the Transactions and specifically contemplated by the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Transactions</span>&#8221; means the transactions contemplated by the Business Combination Agreement and the Transaction Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Trust Account</span>&#8221; means trust account at J.P. Morgan Chase Bank, N.A. maintaining the Trust Fund. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Trust Agreement</span>&#8221; means the Investment Management Trust Agreement, dated as of February&#160;7, 2023, as amended by Amendment No.&#160;1 dated as of November&#160;10, 2023, by between BLAC and the Trustee, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Trustee</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="text-decoration:underline">Trust Fund</span>&#8221; means the trust fund established by BLAC for the benefit of its public stockholders. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_5">QUESTIONS AND ANSWERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The questions and answers below highlight only selected information from this document and only briefly address some commonly asked questions about the proposals to be presented at the special meeting, including with respect to the proposed Business Combination. The following questions and answers do not include all the information that is important to BLAC&#8217;s stockholders. We urge stockholders to read this proxy statement/prospectus, including the Annexes and the other documents referred to herein, carefully and in their entirety to fully understand the proposed Business Combination and the voting procedures for the special meeting, which will be held at [&#9679;], on [&#9679;],&#160;2024, unless the special meeting is adjourned. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Why am I receiving this proxy statement/prospectus? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>BLAC stockholders are being asked to consider and vote upon, among other proposals, a proposal to approve and adopt the Business Combination Agreement and approve the transactions contemplated thereby, including the Business Combination. In accordance with the terms and subject to the conditions of the Business Combination Agreement on the Closing Date, the parties will affect the Share Exchange. For further details, see &#8220;<span style="font-style:italic">The Business Combination</span>.&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A copy of the Business Combination Agreement is attached to this proxy statement as Annex A and you are encouraged to read the Business Combination Agreement in its entirety. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each of the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal and the Adjournment Proposal requires the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. In order to be elected as a director as described in the Director Election Proposal, a nominee must receive a plurality of all the votes cast by holders of the shares of BLAC Common Stock at the special meeting, which means that the nominees with the most votes are elected. Abstentions and broker <span style="white-space:nowrap">non-votes,</span> while considered present for the purposes of establishing a quorum so long as a stockholder has given the broker or other nominee voting instructions on at least one of the proposals set forth in this proxy statement/prospectus, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Certain of the provisions of the Proposed Governing Documents will differ materially from the Existing Governing Documents. Please see <span style="font-style:italic">&#8220;Why is BLAC proposing the Charter Proposal and Advisory Governance Proposals?&#8221;</span> below. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE VOTE OF STOCKHOLDERS IS IMPORTANT. STOCKHOLDERS ARE ENCOURAGED TO VOTE AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS PROXY STATEMENT. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What proposals are stockholders of BLAC being asked to vote upon? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>At the special meeting, BLAC is asking holders of the BLAC Common Stock to consider and vote upon six&#160;(6)&#160;separate proposals: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1 &#8212; The Business Combination Proposal &#8212; </span>To consider and vote upon a proposal to approve and adopt the Business Combination Agreement, including the Business Combination, and the transactions contemplated thereby. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2 &#8212; The Charter Proposal</span>&#160;&#8212; To consider and vote upon a proposal to adopt the Amended Charter, which supersedes the Current Charter. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposals No. 3A&#8212;3F &#8212; The Advisory Governance Proposals</span>&#160;&#8212; To consider and vote, on a <span style="white-space:nowrap">non-binding</span> advisory basis, upon six separate governance proposals relating to material differences </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
between (i) BLAC&#8217;s Current Charter and Current Bylaws and (ii) the Amended Charter and Amended Bylaws to be in effect upon the completion of the Business Combination in accordance with the requirements of the SEC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Name Change</span> <span style="font-weight:bold">&#8212;</span> to change BLAC&#8217;s name to &#8220;OSR Holdings, Inc.;&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Preferred Stock</span> <span style="font-weight:bold">&#8212;</span> to increase the number of shares of preferred stock that can be issued from 1,000,000 shares to 10,000,000 shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Increase Vote Required for Removal of Directors</span> &#8212; to provide that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Corporate Opportunity</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-style:italic">&#8212;</span>&#160;to eliminate the current limitations on the corporate opportunity doctrine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Change in Quorum</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-style:italic">&#8212;</span>&#160;to provide that the quorum required for shareholder meetings is the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of the then outstanding shares of capital stock entitled to vote at the meeting; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Additional Charter Amendments</span><span style="font-style:italic"> &#8212;</span>&#160;to approve all other changes including eliminating certain provisions related to special purpose acquisition corporations that will no longer be relevant following the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4 &#8212; The Incentive Plan Proposal &#8212;</span><span style="font-weight:bold"></span>&#160;To consider and vote upon a proposal to approve and adopt a new omnibus incentive plan in form and substance reasonably acceptable to BLAC and OSR Holdings, a copy of which is attached to the accompanying proxy statement as Annex&#160;G. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5</span>&#160;&#8212;<span style="font-weight:bold">&#160;The Director Election Proposal</span>&#160;&#8212; To consider and vote upon a proposal to elect up to nine&#160;(9) directors, effective as of and contingent upon the consummation of the Business Combination, to serve on New OSR Holdings&#8217; board of directors until the expiration of their applicable term, and until their respective successors are duly elected and qualified or until their earlier resignation, removal or death. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6</span>&#160;&#8212;<span style="font-weight:bold">&#160;The Adjournment Proposal</span>&#160;&#8212; To consider and vote upon a proposal to approve the adjournment of the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Condition Precedent Proposals (as defined elsewhere in this proxy statement/prospectus), if New OSR Holdings will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or if the Minimum Available Cash Condition is not satisfied. The Adjournment Proposal will only be presented at the special meeting if there are not sufficient votes to approve the Condition Precedent Proposals or if the Minimum Available Cash Condition is not satisfied. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please see the sections entitled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;1 &#8212; The Business Combination Proposal,&#8221; &#8220;Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2 &#8212; The Charter Proposal,&#8221; &#8220;Proposals No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;3A&#8212;3F &#8212; The Advisory Governance Proposals,&#8221; &#8220;Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4 &#8212; The Incentive Plan Proposal,&#8221; &#8220;Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;5 &#8212; The Director Election Proposal&#8221; and &#8220;Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;6 &#8212; The Adjournment Proposal</span>.&#8221; The Business Combination is conditioned on the approval of the Condition Precedent Proposals at the special meeting. If New OSR Holdings will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination or the Minimum Available Cash Condition is not satisfied, we would not proceed with the Business Combination. The election of up to nine director nominees in the Director Election Proposal is conditioned on the approval of the Condition Precedent Proposals. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BLAC will hold the special meeting to consider and vote upon these proposals. This proxy statement/prospectus contains important information about the Business Combination and the other matters to be acted upon at the special meeting. Stockholders of BLAC should read it carefully. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">After careful consideration, the BLAC Board has determined that the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal, the</span> <span style="font-weight:bold">Director Election Proposal and the Adjournment Proposal are in the best interests of BLAC and its</span> <span style="font-weight:bold">stockholders and unanimously recommends that you vote or give instruction to vote &#8220;FOR&#8221; each of those proposals.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of one or more of BLAC&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of BLAC and its stockholders and what he or they may believe is best for himself or themselves in determining to recommend that stockholders vote for the proposals. In addition, BLAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; for a further discussion of these considerations. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Why is BLAC proposing the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span><span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>BLAC is a blank check company which was incorporated on February&#160;25, 2020 for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this proxy statement/prospectus as BLAC&#8217;s initial business combination. Based on BLAC&#8217;s business activities, it is a &#8220;shell company&#8221; as defined under the Exchange Act because it has no operations and nominal assets consisting almost entirely of cash. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Consistent with BLAC&#8217;s business strategy, we have identified the following profile of our target business and the general criteria and guidelines to support the investment case. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Target Profile: A healthcare holding company</span>&#160;is a business that operates by acquiring and managing a portfolio of subsidiaries and investments in companies engaged in the research, development, manufacturing, and distribution of healthcare products in the areas of our primary interests such as pharmaceutical, medical devices and healthcare technologies (for example, artificial intelligence-driven bioinformatics). The business model for a healthcare holding company, especially in the pharmaceutical sector, which is the main area of our interests, is typically based on building a diverse portfolio of subsidiaries by acquiring and investing in companies at different stages of development, from early-stage research to POC (proof of concept)-stage clinical trials and commercialization. The goal is to create a diversified portfolio of subsidiaries and investments that have a pipeline of products and product candidates in development, with some close to commercialization and others in earlier stages of development. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The management strategy for a healthcare holding company involves several key elements: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Portfolio management</span>: The holding company must carefully manage its subsidiaries and investments to ensure that it is balanced and diversified. The company must also be prepared to make strategic decisions about which companies to acquire, invest in, or divest. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Financial management</span>: The holding company must have strong financial management capabilities to ensure that it can provide financial support to its subsidiaries and investments as needed. This may involve raising capital through debt or equity financing, or through divestment from its holdings in certain companies at appropriate timing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Regulatory expertise</span>: The healthcare industry is heavily regulated, and the holding company must have a deep understanding of the regulatory environment in order to successfully navigate the development and commercialization of new products. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Business development</span>: The holding company must be actively engaged in business development activities to identify and pursue new opportunities for its subsidiaries and investments. This may involve partnering with other companies, acquiring new companies, or licensing new technologies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Talent management</span>: The holding company must have a strong management team with expertise in biotherapeutics, medical device, diagnostics and bioinformatics, and other relevant disciplines in healthcare, as well as corporate finance and business development. The company must also be able to attract and retain talented executives and scientists to lead and support its subsidiaries and investments. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Although the BLAC M&amp;A Committee and the BLAC Board believe that the Business Combination with OSR Holdings presents a unique business combination opportunity and is in the best interests of BLAC and its stockholders, the BLAC M&amp;A Committee did consider certain potentially material negative factors in arriving at that conclusion. These factors are discussed in greater detail in the sections entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span>&#8221; and &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to the Business Combination and Business Combination Agreement.</span>&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Will the BLAC M&amp;A Committee of the BLAC Board obtain a third-party valuation or fairness opinion in determining whether or not to recommend that the BLAC Board approve the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>Yes. In approving the Business Combination Agreement, the BLAC M&amp;A Committee noted that the closing of the transaction is conditioned on the receipt of a fairness opinion, in form and substance acceptable to the BLAC M&amp;A Committee, concluding that the Business Combination is fair, from a financial point of view, to BLAC stockholders as required by the Company&#8217;s Amended and Restated Certificate of Incorporation. The BLAC M&amp;A Committee initially engaged a financial advisor based in Switzerland to render the fairness opinion. This decision was made at the time that it was anticipated that OSR Holdings would acquire Landmark Bio Ventures AG (&#8220;LBV&#8221;) and the resulting company would be more heavily oriented in Europe. However, when OSR Holdings and LBV terminated their agreement, the BLAC M&amp;A Committee determined that it would be more appropriate to engage a financial advisor in Korea because OSR Holdings&#8217; operations would be more heavily weighted toward that geography. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In April 2024, the BLAC M&amp;A Committee retained Choloc Asset Investment Advisory Co., Ltd., a financial advisory firm based in Seoul, Korea (&#8220;Choloc&#8221;), to evaluate the fairness, from a financial point of view, of the Business Combination to the BLAC stockholders. On June 23, 2024, Choloc advised the BLAC M&amp;A Committee that it was prepared to render a fairness opinion on the Business Combination, to the effect that, as of that date and based on and subject to the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken described in such opinion, the Business Combination is fair, from a financial point of view, to the BLAC stockholders. A draft copy of the fairness opinion that Choloc is prepared to deliver is included as Annex H to this proxy statement. For additional information, see &#8220;<span style="font-style:italic">The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination &#8212; Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd.</span>&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the officers and directors of BLAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries including healthcare and concluded that their experience and background, together with the experience of their representatives, also enabled them to make the necessary analyses and determinations regarding the Business Combination, prior to obtaining, but ultimately subject to the receipt of, a fairness opinion. See &#8220;<span style="font-style:italic">The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination &#8212; Comparable Company Analysis&#8221; and &#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination &#8212; Fair Market Value&#8221; for discussions on the BLAC M&amp;A Committee&#8217;s analysis of comparable companies of OSR Holdings and the fair market value reports on OSR Holdings&#8217; subsidiaries</span>. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What will OSR Holdings&#8217; equity holders receive in return for the Business Combination with BLAC? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Following the consummation of the Share Exchange, on the Closing Date, BLAC will transfer shares of BLAC Common Stock to those equity holders of OSR Holdings that execute Participating Stockholder Joinders in exchange for their shares of OSR Holdings Common Stock (such equity holders, the &#8220;<span style="text-decoration:underline">Participating Company Stockholders</span>&#8221;). Any fractional share of BLAC Common Stock that would otherwise be issuable to such Participating Company Stockholder following such conversion shall be rounded up or down to the nearest whole share of BLAC Common Stock. At the Closing of&#160;the Business Combination, the Participating Company Stockholders will receive an aggregate of at least 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) as consideration for the shares of OSR Holdings Common Stock exchanged in the course of the Share Exchange as described above. Those equity holders of OSR Holdings that execute <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders (such equity holders, the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-Participating</span> Company Stockholders</span>&#8221;) will continue to hold their shares of OSR Holdings Common Stock following the Closing of the Business Combination, subject to the terms of such <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For further details, see &#8220;<span style="font-style:italic">The Business Combination Agreement &#8212; Structure of the Transactions</span>.&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">How will the Combined Company be managed following the business combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>Following the Closing, it is expected that OSR Holdings will be managed by New OSR Holdings and operated as a majority owned subsidiary of New OSR Holdings. Pursuant to the Business Combination Agreement, the Amended Charter and the Amended Bylaws, the board of directors of New OSR Holdings (the &#8220;<span style="text-decoration:underline">New OSR Holdings Board</span>&#8221;) will consist of up to nine (9)&#160;directors, with at least five&#160;(5)&#160;of whom shall be &#8220;independent&#8221; for purposes of the applicable SEC and Nasdaq regulations. Please see the section entitled &#8220;<span style="font-style:italic">Management Following the Business Combination</span>&#8221; for further information. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What equity stake will current BLAC stockholders and current OSR Holdings stockholders hold in BLAC immediately after the consummation of the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of the date of this proxy statement/prospectus, there are 4,041,221 shares of BLAC Common Stock issued and outstanding, which includes an aggregate of 2,155,000 shares of BLAC Common Stock held by the Sponsor, the directors and former directors, and the Chief Financial Officer of BLAC and their respective affiliates (including 34,500 shares of BLAC Common Stock held in escrow pending the closing of the business combination by Chardan Capital Markets, LLC). In addition, as of the date of this proxy statement/prospectus, there is outstanding an aggregate of 7,330,000 BLAC Warrants, comprised of 430,000 private placement warrants held by the Sponsor, BLAC&#8217;s Chief Financial Officer and two of BLAC&#8217;s former directors, and 6,900,000 public warrants, and 7,330,000 BLAC Rights, comprised of 430,000 private placement rights held by the Sponsor and 6,900,000 public rights, to acquire shares of BLAC Common Stock. Each whole warrant entitles the holder thereof to purchase one share of BLAC Common Stock. Each whole right entitles the holder thereof to receive <span style="white-space:nowrap">one-tenth</span> of one share of BLAC Common Stock. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination and assuming that none of BLAC&#8217;s outstanding public shares are redeemed in connection with the Business Combination), BLAC&#8217;s fully diluted share capital, giving effect to the exercise of all of the private placement warrants, public warrants, private placement rights and public rights, would be 12,104,221 shares of BLAC Common Stock. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates varying ownership levels in BLAC Common Stock immediately following the consummation of the Business Combination based on the varying levels of redemptions by the public stockholders and the following additional assumptions: (i) 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) are issued to the Participating Company Stockholders at consummation of the Business Combination, (ii) all </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
BLAC Rights have been converted to shares of BLAC Common Stock, and (iii) $20,000,000 of PIPE financing is raised through the sale of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. The table below does not take into account (i) the exercise of any BLAC Warrants as the warrants do not become exercisable until 30 days after the consummation of the Business Combination, and (ii) the issuance of any equity awards under the Omnibus Plan as there will be no awards issued under the Omnibus Plan immediately following the consummation of the Business Combination. See &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; for more details. If the actual facts differ from these assumptions, the ownership percentages in BLAC will be different and totals may not add up to 100% due to rounding. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming<br/>No Redemptions) </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming<br/>50% Redemptions)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming Maximum<br/>Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Sponsor and Related Parties<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.44</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC public stockholders<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.49</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes (i) 60% of the Aggregate Consideration of 24,461,214 shares of BLAC Common Stock pursuant to the Business Combination Agreement will be issued by BLAC to the Participating Company Stockholders at consummation of the Business Combination, and (ii) the remaining 40% of the Aggregate Consideration, or 9,784,486 shares of BLAC Common Stock, will be issuable by BLAC to the Non-Participating Company Stockholders upon exercise of the put/call rights set forth in the Non-Participating Stockholder Joinders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,035,000 shares of BLAC Common Stock held by the Sponsor, (ii) 20,000 shares of BLAC Common Stock held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, (iii) 20,000 shares of BLAC Common Stock held by Jin Whan Park, a current director of BLAC, and (iv) 20,000 shares of BLAC Common Stock held by each of the following former directors of BLAC: Dr. Steven Reed, Dr. Inchul Chung, Mr. Hosun Euh, and Dr. Radclyffe Roberts. It also assumes the conversion of 430,000 private placement rights held by the Sponsor into 43,000 shares of BLAC Common Stock upon the consummation of the Business Combination. Excludes 34,500 shares currently held in escrow and due to Chardan Capital Markets, LLC upon closing of the Business Combination. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the conversion of 6,900,000 public rights into 690,000 shares of BLAC Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes an aggregate of $20,000,000 raised from the issuance of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stockholders will experience additional dilution to the extent the Post-Combination&#160;Company issues additional shares after the Closing. The table above does not include (i) up to 6,900,000&#160;shares of New OSR Holdings Common Stock that will be issuable upon exercise of the public warrants, which have an initial exercise price of $11.50 per share (subject to adjustment in accordance with the Warrant Agreement), (ii) up to 430,000&#160;shares of New OSR Holdings Common Stock that will be issuable upon exercise of the private warrants, which have an initial exercise price of $11.50 per share (subject to adjustment in accordance with the Warrant Agreement), and (iii) 6,300,000 shares of New OSR Holdings Common Stock, the maximum number of shares currently reserved for issuance under the Omnibus Plan. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates the impact on relative ownership levels assuming the issuance of all such shares. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming<br/>No Redemptions) </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming<br/>50% Redemptions)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming Maximum<br/>Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41.57</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Sponsor and Related Parties<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.47</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC public stockholders<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.47</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares underlying the Private Warrants<sup style="font-size:75%; vertical-align:top">(</sup><sup style="font-size:75%; vertical-align:top">5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares underlying the Public Warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.54</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omnibus Plan<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,303,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,360,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,416,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes (i) 60% of the Aggregate Consideration of 24,461,214 shares of BLAC Common Stock pursuant to the Business Combination Agreement will be issued by BLAC to the Participating Company Stockholders at consummation of the Business Combination, and (ii) the remaining 40% of the Aggregate Consideration, or 9,784,486 shares of BLAC Common Stock, will be issuable by BLAC to the Non-Participating Company Stockholders upon exercise of the put/call rights set forth in the Non-Participating Stockholder Joinders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,035,000 shares of BLAC Common Stock held by the Sponsor, (ii) 20,000 shares of BLAC Common Stock held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, (iii) 20,000 shares of BLAC Common Stock held by Jin Whan Park, a current director of BLAC, and (iv) 20,000 shares of BLAC Common Stock held by each of the following former directors of BLAC: Dr. Steven Reed, Dr. Inchul Chung, Mr. Hosun Euh, and Dr. Radclyffe Roberts. It also assumes the conversion of 430,000 private placement rights held by the Sponsor into 43,000 shares of BLAC Common Stock upon the consummation of the Business Combination. Excludes 34,500 shares currently held in escrow and due to Chardan Capital Markets, LLC upon closing of the Business Combination. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the conversion of 6,900,000 public rights into 690,000 shares of BLAC Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes an aggregate of $20,000,000 raised from the issuance of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 370,000 private warrants held by Sponsor, (ii) 20,000 private warrants held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, and (iii) 20,000 private warrants held by each of Dr. Steven Reed and Dr.&#160;Inchul Chung. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">6,300,000 is the maximum number of shares to be reserved for issuance under the Omnibus Plan. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For further details, see&#160;&#8220;<span style="font-style:italic">The Business Combination Agreement &#8212; Structure of the Transactions</span>.&#8221; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Why is BLAC proposing the Charter Proposal and Advisory Governance Proposals? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We are asking our stockholders to approve material differences between the organizational documents of New OSR Holdings that will be in effect upon the closing of the Business Combination and our Existing Governing Documents. The proposed material differences that we are asking our stockholders to approve include the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The name of the new public entity will be &#8220;OSR Holdings, Inc.&#8221; as opposed to &#8220;Bellevue Life Sciences Acquisition Corp.,&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Increasing the number of shares of preferred stock that can be issued from 1,000,000 shares to 10,000,000 shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Providing that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Eliminating the current limitations on the corporate opportunity doctrine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Provide that the quorum required for shareholder meetings is the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of the then outstanding shares of capital stock entitled to vote at the meeting; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Other changes including eliminating certain provisions related to special purpose acquisitions corporations that will no longer be relevant following the Closing. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For further details, see&#160;the sections entitled <span style="font-style:italic">&#8220;Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2 &#8212; The Charter Proposal&#8221; and &#8220;Proposals No.</span><span style="font-style:italic"></span><span style="font-style:italic"><span style="white-space:nowrap">&#160;3A-3F</span> &#8212; The Advisory Governance Proposals.&#8221;</span> </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Why is BLAC proposing the Incentive Plan Proposal? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span><span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The purpose of the Omnibus Plan is to provide eligible employees, directors and consultants of New OSR Holdings with the opportunity to receive stock-based incentive awards in order to encourage such persons to contribute materially to the growth of New OSR Holdings and align their economic interests with those of its stockholders. Nasdaq Listing Rule 5635(c) requires stockholder approval of certain equity compensation plans. Accordingly, we are proposing the Incentive Plan Proposal to request such stockholder approval of the Omnibus Plan. In addition, pursuant to the Business Combination Agreement, approval of the Incentive Plan Proposal is a condition to consummation of the Transactions. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Do I have redemption rights? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span><span style="font-weight:bold"></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>If you are a holder of public shares, you have the right to request that we redeem all or a portion of your public shares for cash provided that you follow the procedures and deadlines described elsewhere in this proxy statement/prospectus.&#160;Public stockholders may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. If you wish to exercise your redemption rights, please see the answer to the next question: &#8220;<span style="font-style:italic">How do I exercise my redemption rights?</span>&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a public stockholder, together with any affiliate of such public stockholder or any other person with whom such public stockholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the public shares without the prior consent of BLAC. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Sponsor, BLAC&#8217;s directors and officers, certain of their affiliates and Chardan have agreed to waive their redemption rights with respect to all of its shares of BLAC Common Stock acquired prior to the IPO in connection with the consummation of the Business Combination. Such shares will be excluded from the pro rata calculation used to determine the per share redemption price. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">How do I exercise my redemption rights? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>In connection with the proposed Business Combination, pursuant to the Existing Governing Documents, BLAC&#8217;s public stockholders may request that BLAC redeem all or a portion of such public shares for cash if the Business Combination is consummated. If you are a public stockholder and wish to exercise your right to redeem the public shares, you must: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">(a) hold public shares or (b)&#160;if you hold public shares through units, you elect to separate your units into the underlying public shares, public warrants and public rights prior to exercising your redemption rights with respect to the public shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">submit a written request to Continental, BLAC&#8217;s transfer agent, in which you (i)&#160;request that we redeem all or a portion of your public shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">deliver your share certificates (if any) to Continental, our transfer agent, physically or electronically through The Depository Trust Company (&#8220;<span style="text-decoration:underline">DTC</span>&#8221;). </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to [</span>&#9679;<span style="font-weight:bold"></span><span style="font-weight:bold">], Eastern Time, on [</span>&#9679;<span style="font-weight:bold"></span><span style="font-weight:bold">],&#160;2024 (two business days before the special meeting) in order for their shares to be redeemed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The address of Continental, BLAC&#8217;s transfer agent, is listed under the question &#8220;<span style="font-style:italic">Who can help answer my questions?</span>&#8221; below. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders of units must elect to separate the units into the underlying public shares, public warrants and public rights prior to exercising redemption rights with respect to the public shares. Public holders that hold their units in an account at a brokerage firm or bank, must notify their broker or bank that they elect to separate the units into the underlying public shares, public warrants and public rights, or if a holder holds units registered in its own name, the holder must contact Continental, BLAC&#8217;s transfer agent, directly and instruct them to do so. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Public stockholders will be entitled to request that their public shares be redeemed for a pro rata portion of the amount then on deposit in the trust account as of two business days prior to the consummation of the Business Combination including interest earned on the funds held in the trust account and not previously released to us (net of taxes payable). For illustrative purposes, this would have amounted to approximately $[&#9679;] per issued and outstanding public share (including interest and prior to the payment of taxes), based on [&#9679;] shares subject to possible redemption as of [&#9679;],&#160;2024. However, the proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority over the claims of our public stockholders, regardless of whether such public stockholders vote or, if they do vote, irrespective of if they vote for or against the Business Combination Proposal. Therefore, the per share distribution from the trust account in such a situation may be less than originally expected due to such claims. Whether you vote, and if you do vote irrespective of how you vote, on any proposal, including the Business Combination Proposal, will have no impact on the amount you will receive upon exercise of your redemption rights. It is expected that the funds to be distributed to public stockholders electing to redeem their public shares will be distributed promptly after the consummation of the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any request for redemption, once made by a holder of public shares, may not be withdrawn once submitted to BLAC unless the Board of Directors of BLAC determines (in its sole discretion) to permit the withdrawal </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of such redemption request (which they may do in whole or in part). If you deliver your share certificates (if any) for redemption to Continental, BLAC&#8217;s transfer agent, and later decide prior to the special meeting not to elect redemption, you may request that our transfer agent return the shares (physically or electronically) to you. You may make such request by contacting Continental, BLAC&#8217;s transfer agent, at the phone number or address listed at the end of this section. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any corrected or changed written exercise of redemption rights must be received by Continental, BLAC&#8217;s transfer agent, prior to the vote taken on the Business Combination Proposal at the special meeting.<span style="font-weight:bold">&#160;No</span> <span style="font-weight:bold">request for redemption will be honored unless the holder&#8217;s certificates (if any) for public shares have</span> <span style="font-weight:bold">been delivered (either physically or electronically) to Continental, BLAC&#8217;s transfer agent, at least two business days prior to the vote at the special meeting.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a holder of public shares properly makes a request for redemption and the certificates (if any) for public shares are delivered as described above, then, if the Business Combination is consummated, we will redeem the public shares for a pro rata portion of funds deposited in the trust account, calculated as of two business days prior to the consummation of the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of public shares and you exercise your redemption rights, such exercise will not result in the loss of any public warrants and public rights that you may hold. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">If I am a holder of units, can I exercise redemption rights with respect to my units? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">No. Holders of issued and outstanding units must elect to separate the units into the underlying public shares, public warrants and public rights prior to exercising redemption rights with respect to the public shares. If you hold your units in an account at a brokerage firm or bank, you must notify your broker or bank that you elect to separate the units into the underlying public shares, public warrants and public rights, or if you hold units registered in your own name, you must contact Continental, BLAC&#8217;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. You are requested to cause your public shares to be separated and delivered to Continental, our transfer agent, by [&#9679;], Eastern Time, on [&#9679;],&#160;2024 (two business days before the special meeting) in order to exercise your redemption rights with respect to your public shares. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What are the U.S. federal income tax consequences of exercising my redemption rights? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>It is expected that a U.S. Holder (as defined in &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences</span>&#8221;) that exercises its redemption rights to receive cash from the trust account in exchange for public shares will generally be treated as selling such public shares resulting in the recognition of capital gain or capital loss. There may be certain circumstances, however, in which the redemption may be treated as a distribution for U.S. federal income tax purposes depending on the amount of BLAC Common Stock that such U.S. Holder owns or is deemed to own. For a more complete discussion of the material U.S. federal income tax considerations for holders of public shares with respect to the exercise of redemption rights, see &#8220;<span style="font-style:italic"></span><span style="font-style:italic">Material U.S. Federal Income Tax Consequences &#8212; U.S. Holders &#8212; U.S. Federal Income Tax Consequences to U.S Holders of BLAC Common Stock Exercising Redemption Rights</span>.&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All holders considering exercising redemption rights are urged to consult their tax advisor on the tax consequences to them of an exercise of redemption rights, including the applicability and effect of U.S. federal, state, local and <span style="white-space:nowrap">non-U.S.</span> tax laws. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What happens to the funds deposited in the trust account after consummation of the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>As of [&#9679;], 2024, funds in the trust account totaled approximately $[&#9679;]. These funds will remain in the trust account, except for the withdrawal of interest to pay taxes, if any, until the earliest of (i)&#160;the completion of a business combination (including the closing of the Business Combination) or (ii)&#160;the redemption of all of the public shares if we are unable to complete a business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), subject to applicable law. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If our initial business combination is paid for using equity or debt securities or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination or used for redemptions or purchases of the public shares, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of New OSR Holdings, the payment of principal or interest due on indebtedness incurred in completing our Business Combination, to fund the purchase of other companies or for working capital. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What happens if a substantial number of the public stockholders vote in favor of the Business Combination Proposal and exercise their redemption rights? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A</span>:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Our public stockholders are not required to vote &#8220;FOR&#8221; the Business Combination in order to exercise their redemption rights. Accordingly, the Business Combination may be consummated even though the funds available from the trust account and the number of public stockholders are reduced as a result of redemptions by public stockholders, subject to the satisfaction or waiver of the Minimum Available Cash Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally, as a result of redemptions, the trading market for New OSR Holdings Common Stock may be less liquid than the market for the public shares was prior to consummation of the Business Combination and we may not be able to meet the listing standards for Nasdaq or another national securities exchange. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What conditions must be satisfied to complete the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The consummation of the Business Combination is conditioned upon, among other things, (i)&#160;the approval by the BLAC stockholders of the Condition Precedent Proposals; and (ii)&#160;the aggregate cash proceeds from BLAC&#8217;s trust account, including any proceeds from the PIPE Financing, equaling no less than $5,000,001 (after deducting any amounts paid to BLAC&#8217;s stockholders that exercise their redemption rights in connection with the Business Combination). Therefore, unless these conditions are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any party to the Business Combination Agreement may, at any time prior to the Closing, by action taken by its board of directors or equivalent governing body, officers thereunto duly authorized, or individually in the case of independent stockholders, waive in writing any of its or their rights or conditions in its or their favor under the Business Combination Agreement. Notwithstanding the foregoing, pursuant to BLAC&#8217;s current certificate of incorporation, BLAC cannot consummate the Business Combination if New OSR Holdings would have less than $5,000,001 of net tangible assets remaining after the Closing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The existence of the financial and personal interests of the directors may result in a conflict of interest on the part of one or more of them between what such director may believe is best for BLAC and what such director may believe is best for such director in determining whether or not to grant a waiver in a specific situation. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more information about conditions to the consummation of the Business Combination, see &#8220;<span style="font-style:italic">The Business Combination Agreement &#8212; Conditions to Closing the Business Combination</span>.&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">When do you expect the Business Combination to be completed? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>It is currently anticipated that the Business Combination will be consummated in the second quarter of 2024, but in no event later than November&#160;14, 2024. This date depends on, among other things, the approval of the proposals to be put to BLAC stockholders at the special meeting. However, such special meeting could be adjourned if the Adjournment Proposal is adopted by our stockholders at the special meeting and we elect to adjourn the special meeting to a later date or dates to consider and vote upon a proposal to approve the adjournment of the special meeting to a later date or dates (a)&#160;to the extent necessary to ensure that any required supplement or amendment to this proxy statement is provided to BLAC stockholders or, if as of the time for which the special meeting is scheduled, there are insufficient shares of BLAC Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the special meeting, (b)&#160;in order to solicit additional proxies from BLAC stockholders in favor of one or more of the proposals at the special meeting or (c)&#160;if BLAC stockholders redeem an amount of public shares such that (i) it will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or (ii) the Minimum Available Cash Condition would not be satisfied. For a description of the conditions to the consummation of the Business Combination, see &#8220;<span style="font-style:italic">The Business Combination &#8212; Conditions to Closing the Business Combination</span>.&#8221; </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What happens if the Business Combination is not consummated? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>If BLAC is not able to consummate the Business Combination with OSR Holdings nor able to complete another business combination by November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), we will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii)&#160;and (iii), to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What do I need to do now? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>We urge you to read this proxy statement/prospectus, including the Annexes and the documents referred to herein, carefully and in their entirety and to consider how the Business Combination will affect you as a stockholder and/or warrant holder. Our stockholders should then vote as soon as possible in accordance with the instructions provided in this proxy statement and on the enclosed proxy card. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">How do I vote? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>If you hold your shares in &#8220;street name,&#8221; which means your shares are held of record by a broker, bank or nominee, and were a holder of record of shares of BLAC Common Stock on [&#9679;], 2024, the record date for the special meeting, you may vote with respect to the proposals at the special meeting, or by completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. All holders of shares in registered form on the day of the special meeting are entitled to vote at the special meeting. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">If my shares are held in &#8220;street name,&#8221; will my broker, bank or nominee automatically vote my shares for me? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>No. If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the &#8220;beneficial holder&#8221; of the shares held for you in what is known as &#8220;street name.&#8221; If this is the case, this proxy statement/prospectus may have been forwarded to you by your brokerage firm, bank or other nominee, or its agent. As the beneficial holder, you have the right to direct your broker, bank or other nominee as to how to vote your shares. If you do not provide voting instructions to your broker on a particular proposal on which your broker does not have discretionary authority to vote, your shares will not be voted on that proposal. This is called a &#8220;broker <span style="white-space:nowrap">non-vote.&#8221;</span> Abstentions and broker <span style="white-space:nowrap">non-votes,</span> while considered present for the purposes of establishing a quorum so long as a stockholder has given the broker or other nominee voting instructions on at least one of the proposals set forth in this proxy statement/prospectus, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. If you decide to vote, you should provide instructions to your broker, bank or other nominee on how to vote in accordance with the information and procedures provided to you by your broker, bank or other nominee. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">When and where will the special meeting be held? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The special meeting will be held at [&#9679;], Eastern Time, on [&#9679;], 2024, unless the special meeting is adjourned. Stockholders may attend, vote and examine the list of BLAC&#8217;s stockholders entitled to vote at the special meeting. Only stockholders who held shares of BLAC Common Stock at the close of business on the Record Date will be entitled to vote at the special meeting. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Who is entitled to vote at the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We have fixed [&#9679;],&#160;2024 as the record date for the special meeting (the &#8220;<span style="text-decoration:underline">Record Date</span>&#8221;). If you were a stockholder of BLAC at the close of business on the Record Date, you are entitled to vote on matters that come before the special meeting. However, a stockholder may only vote his or her shares if he or she is present in person or is represented by proxy at the special meeting. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What actions must OSR Holdings stockholders take to approve the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>No further actions are required by OSR Holdings stockholders to approve the Business Combination but they must elect whether to sign a Joinder to the Business Combination Agreement. The OSR Holdings stockholders may elect to either (i) sign a Joinder to become a Participating Company Stockholder, (ii) sign a Joinder to become a <span style="white-space:nowrap">Non-Participating</span> Stockholder, or (iii) elect not to sign either Joinder. It is a condition to closing of the Business Combination that holders of at least 60% of the OSR Holdings Fully-Diluted Shares execute a Joinder to become a Participating Company Stockholder. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">How many votes do I have? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>BLAC stockholders are entitled to one vote at the special meeting for each share of BLAC Common Stock held of record as of the Record Date. As of the close of business on the Record Date, there were [&#9679;] shares of BLAC Common Stock issued and outstanding, of which [&#9679;] were issued and outstanding public shares. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What constitutes a quorum? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>A quorum of BLAC stockholders is necessary to hold a valid meeting. A quorum will be present at the special meeting if one or more stockholders who together hold not less than a majority of the issued and outstanding shares of BLAC Common Stock entitled to vote at the special meeting are represented in person or by proxy at the special meeting. As of the Record Date, [&#9679;] shares of BLAC Common Stock would be required to achieve a quorum. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What vote is required to approve each proposal at the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The following votes are required for each proposal at the special meeting: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Business Combination Proposal:</span></span>&#160;The Business Combination Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Charter Proposal:</span></span>&#160;The Charter Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Advisory Governance Proposals:</span></span>&#160;The Advisory Governance Proposals require the approval of the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Incentive Plan Proposal:</span></span>&#160;The Incentive Plan Proposal requires the approval of the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Director Election Proposal:</span></span>&#160;The Director Election Proposal requires the approval of a plurality of the votes cast, pursuant to the Existing Charter and permitted under Delaware law. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Adjournment Proposal:</span></span>&#160;The Adjournment Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, BLAC had [&#9679;] shares of BLAC Common Stock issued and outstanding. BLAC stockholders are entitled to one vote at the special meeting for each share of BLAC Common Stock held of record as of the Record Date. Assuming all holders that are entitled to vote on such matter vote all of their shares of BLAC Common Stock in person or by proxy, [&#9679;] shares will need to be voted in favor of each of the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal and the Adjournment Proposal in order to approve each of the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal and the Adjournment Proposal. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What are the recommendations of the BLAC Board? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The BLAC Board believes that the Business Combination Proposal and the other proposals to be presented at the special meeting are in the best interest of BLAC and its stockholders and unanimously recommends that its stockholders vote &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Charter Proposal, &#8220;FOR&#8221; the Advisory Governance Proposals, &#8220;FOR&#8221; the Incentive Plan Proposal, &#8220;FOR&#8221; the Director Election Proposal and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented to the special meeting. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of one or more of BLAC&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of BLAC and its stockholders and what he or they may believe is best for himself or themselves in determining to recommend that stockholders vote for the proposals. In addition, BLAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; for a further discussion of these considerations. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">How does the Sponsor intend to vote its shares? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>Our Sponsor, and other holders of BLAC Common Stock issued prior to the IPO and in the private placement, including Mr. Yoo, BLAC&#8217;s Chief Financial Officer, Mr. Jin Whan Park, a current director of BLAC, and Dr. Steven Reed, Dr. In Chul Chung, Dr. Radclyffe Roberts, and Mr. Hosun Euh, former directors of BLAC, have agreed to vote all of their shares in favor of all the proposals being presented at the special meeting. As of the date of this proxy statement/prospectus, those shares of Common Stock referred to in the prior sentence constitute, collectively, approximately 53.3% of the issued and outstanding shares of BLAC Common Stock. See &#8220;<span style="font-style:italic">Risk Factors &#8212; BLAC&#8217;s Initial Stockholders have agreed to vote their shares in favor of the Business Combination, regardless of how BLAC&#8217;s Public Stockholders vote.</span>&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At any time at or prior to the Business Combination, during a period when they are not then aware of any material <span style="white-space:nowrap">non-public</span> information regarding us or our securities, our Sponsor, OSR Holdings and/or their respective directors, officers, advisors or respective affiliates may purchase public shares from institutional and other investors who vote, or indicate an intention to vote, against any of the Condition Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire public shares or vote their public shares in favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such stockholder, although still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that the Sponsor, OSR Holdings and/or their directors, officers, advisors or respective affiliates who have agreed to vote in favor of this transaction purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholder would be required to revoke their prior elections to redeem their shares. Such purchases shall be effected at purchase prices that are no higher than the redemption price for the shares. Any shares so purchased would not be voted by the Sponsor, OSR Holdings and/or their respective directors, officers, advisors or respective affiliates at the special meeting and would not be redeemable.&#160;The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements that (i)&#160;the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal, and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued shares of BLAC Common Stock present or represented by proxy at the special meeting and entitled to vote on such matter, and (ii)&#160;otherwise limit the number of public shares electing to redeem their public shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in circumstances where such consummation could not otherwise occur. BLAC will file or submit a Current Report on Form <span style="white-space:nowrap">8-K</span> to disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be put to the special meeting or the redemption threshold. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. See &#8220;<span style="font-style:italic">Risk Factors &#8212; </span><span style="font-style:italic">The Sponsor and its affiliates may enter into agreements concerning BLAC&#8217;s securities prior to the BLAC Stockholders&#8217; Meeting, which may have the effect of increasing the likelihood of completion of the Business Combination or decreasing the value of the BLAC Common Stock.</span>&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What interests do the Sponsor and BLAC&#8217;s current officers and directors have in the Business Combination? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Sponsor, the members of the BLAC Board and BLAC&#8217;s officers have interests in the business combination that are different from or in addition to (and which may conflict with) your interests. These interests include but are not limited to (i)&#160;the fact that the Sponsor has agreed not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve the Business </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Combination, (ii)&#160;the fact that the Sponsor paid an aggregate of $25,000 (or $0.014 per share) for 1,725,000&#160;shares of BLAC Common Stock, which such securities will have a significantly higher value at the time of the Business Combination, (iii)&#160;the fact that Sponsor purchased 430,000 private placement units (including the underlying securities) for an aggregate purchase price of $4,300,000 (or $10.00 per unit) in which the warrants and rights included in the private placement units would be worthless if a business combination is not consummated by November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), (iv) the fact that Mr.&#160;Hwang, BLAC&#8217;s Chief Executive Officer and a Director, is the Chief Executive Officer and Chairman of the Board of OSR Holdings, (v)&#160;the fact that the Sponsor and BLAC&#8217;s directors and officers may be incentivized to complete the Business Combination, or an alternative initial business combination with a less favorable company or on terms less favorable to stockholders, rather than to liquidate, in which case the Sponsor would lose its entire investment, and as a result, the Sponsor may have a conflict of interest in determining whether OSR Holdings is an appropriate business with which to effectuate a business combination and/or in evaluating the terms of the Business Combination, (vi)&#160;the fact that Sponsor and Bellevue Capital Management LLC, or its affiliates, have previously loaned money to BLAC&#160;(or to the sponsor for BLAC&#8217;s benefit) in an aggregate amount of $3,905,000 to fund operating and transaction expenses in connection with the proposed Business Combination, $3,525,000 of which remains outstanding as of the date of this proxy statement/prospectus (none of which contain conversion rights), and may make additional loans after the date of this proxy statement/prospectus for such purposes (if the Business Combination is not consummated or another business combination is not otherwise completed, the foregoing loans may not be repaid and would be forgiven except to the extent there are funds available to BLAC outside of the Trust Account), (vii)&#160;the fact that director Jun Chul Whang has loaned an aggregate of $75,000 to BLAC for working capital purposes, (viii) the fact that the Sponsor transferred 20,000 shares to current and former directors of BLAC for their board service and Mr.&#160;Yoo for his service as Chief Financial Officer and 20,000 private placement warrants to each of the former chairman of the board of directors, as the former chair of the audit committee, and Mr.&#160;Yoo for his service as Chief Financial Officer, and (ix)&#160;the fact that BLAC may be entitled to distribute or pay over funds held by BLAC outside the trust account to the Sponsor or any of its affiliates prior to the Closing. </td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Sponsor was not granted any consideration or incentive to agree not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination, and in recommending to the BLAC stockholders that they vote in favor of the proposals presented at the special meeting, including the Business Combination Proposal. Stockholders should take these interests into account in deciding whether to approve the Business Combination. Please see the sections entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; and &#8220;<span style="font-style:italic"></span><span style="font-style:italic">Certain BLAC Relationships and Related Person Transactions</span>&#8221; for additional information. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What happens if I sell my shares of BLAC Common Stock before the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The Record Date for the special meeting is earlier than the date of the special meeting and earlier than the date that the Business Combination is expected to be completed. If you transfer your public shares after the Record Date, but before the special meeting, unless you grant a proxy to the transferee, you will retain your right to vote at the special meeting. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">May I change my vote after I have mailed my signed proxy card? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>Yes. Stockholders may send a later-dated, signed proxy card to Jun Chul Whang at our address set forth below so that it is received prior to the vote at the special meeting (which is scheduled to take place on </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
[&#9679;],&#160;2024) or attend the special meeting in person and vote. Stockholders also may revoke their proxy by sending a notice of revocation to Jun Chul Whang, which must be received prior to the vote at the special meeting. However, if your shares are held in &#8220;street name&#8221; by your broker, bank or another nominee, you must contact your broker, bank or other nominee to change your vote. </td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What happens if I fail to take any action with respect to the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>If you fail to vote with respect to the special meeting and the Business Combination is approved by stockholders and the Business Combination is consummated, you will become a stockholder and warrant holder of New OSR Holdings. If you fail to vote with respect to the special meeting and the Business Combination is not approved, you will remain a unit, stock, warrant and/or right holder of BLAC. However, if you fail to vote with respect to the special meeting, you will nonetheless be able to elect to redeem your public shares in connection with the Business Combination. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">What should I do if I receive more than one set of voting materials? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>Stockholders may receive more than one set of voting materials, including multiple copies of this proxy statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your shares of BLAC Common Stock. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Who will solicit and pay the cost of soliciting proxies for the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">BLAC will pay the cost of soliciting proxies for the special meeting. BLAC has engaged Advantage Proxy, as proxy solicitor (&#8220;<span style="text-decoration:underline">Advantage Proxy</span>&#8221;) to assist in the solicitation of proxies for the special meeting. BLAC has agreed to pay Advantage Proxy a fee of $12,500, and will reimburse Advantage Proxy for its reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses and indemnify Advantage Proxy and its affiliates against certain claims, liabilities, losses, damages and expenses. BLAC will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing beneficial owners of shares of BLAC Common Stock for their expenses in forwarding soliciting materials to beneficial owners of shares of BLAC Common Stock and in obtaining voting instructions from those owners. BLAC&#8217;s directors and officers may also solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Where can I find the voting results of the special meeting? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>The preliminary voting results will be announced at the special meeting. BLAC will publish final voting results of the special meeting in a Current Report on Form <span style="white-space:nowrap">8-K</span> within four business days after the special meeting. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Who can help answer my questions? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">A:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"></span>If you have questions about the Business Combination or if you need additional copies of the proxy statement or the enclosed proxy card you should contact: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Bellevue Life Sciences Acquisition Corp. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10900 NE 4th Street, Suite 2300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Bellevue, WA 98004 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: Jun Chul Whang </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Email: group@bellevuecm.com </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">jcwhang@bellevuecm.com </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may also contact the Company&#8217;s proxy solicitor at: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Advantage Proxy, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">P.O.&#160;Box 10904 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Yakima, WA&#160;98909 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: Karen Smith </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Toll Free <span style="white-space:nowrap">Telephone:&#160;(877)&#160;870-8565</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Main <span style="white-space:nowrap">Telephone:&#160;(206)&#160;870-8565</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">E-mail:&#160;ksmith@advantageproxy.com</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You also may obtain additional information about BLAC from documents filed with the SEC by following the instructions in the section entitled<span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8220;Where You Can Find More Information.&#8221;</span>&#160;If you are a holder of public shares and you intend to seek redemption of your public shares, you will need to deliver your share certificates (either physically or electronically) to Continental, BLAC&#8217;s transfer agent, at the address below prior to the special meeting.<span style="font-weight:bold"></span><span style="font-weight:bold">&#160;Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to [</span>&#9679;<span style="font-weight:bold">], Eastern Time, on [</span>&#9679;<span style="font-weight:bold">],</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2024 (two business days before the special meeting) in order for their shares to be redeemed.</span>&#160;If you have questions regarding the certification of your position or delivery of your share certificates, please contact: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Continental Stock Transfer&#160;&amp; Trust Company </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 State Street, 30th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">New York, New York 10004 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Number: <span style="white-space:nowrap"><span style="white-space:nowrap">212-509-4000</span></span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">E-mail:</span> cstmail@continentalstock.com </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_6">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information from this proxy statement/prospectus and does not contain all of the information that may be important to you. To better understand the proposals to be considered at the special meeting, including the Business Combination Proposal, whether or not you plan to attend the special meeting, we urge you to read this entire proxy statement (including the Annexes) carefully, including the section entitled &#8220;Risk Factors&#8221; beginning on page 50. See also the section entitled &#8220;Where You Can Find More Information.&#8221; </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise specified, all share amounts and share calculations: (i)&#160;assume no exercise of redemption rights by our public stockholders, (ii)&#160;do not include (a)&#160;any warrants to purchase BLAC Common Stock that will be outstanding following the Business Combination, (b)&#160;any rights converted into shares of BLAC Common Stock upon the consummation of the Business Combination, or (c)&#160;any equity awards that may be issued under our proposed Omnibus Plan following the Business Combination. Certain figures included in this section have been rounded for ease of presentation and, as a result, percentages may not sum to 100%. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Parties to the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Bellevue Life Sciences Acquisition Corp. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Delaware corporation incorporated on February&#160;25, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our securities are traded on Nasdaq under the ticker symbols &#8220;BLAC,&#8221; &#8220;BLACU,&#8221; &#8220;BLACW,&#8221; and &#8220;BLACR.&#8221; Following the Business Combination, we expect to change our name to OSR Holdings, Inc. BLAC will also apply for listing, to be effective at the time of the Business Combination, of New OSR Holdings common stock (&#8220;<span style="text-decoration:underline">New OSR Holdings Common Stock</span>&#8221;) and warrants on Nasdaq under the proposed symbols &#8220;OSRB&#8221; and &#8220;OSRBW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mailing address of the Company&#8217;s principal executive office is 10900 NE 4th Street, Suite 2300, Bellevue, Washington 98004 and the telephone number of the Company&#8217;s principal executive office is <span style="white-space:nowrap">(425)&#160;635-7700.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OSR Holdings Co., Ltd. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings, a corporation organized under the laws of the Republic of Korea, is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Our current operating businesses (through our three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical devices and systems distribution in Korea. OSR Holdings&#8217; vision is to acquire and operate a portfolio of innovative health-care related companies globally. The telephone number for OSR Holdings is +82 31 948 9419 and the principal mailing address is <span style="white-space:nowrap">Hoedong-gil</span> <span style="white-space:nowrap">37-36,</span> Paju, Gyeonggido, Republic of Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From inception through December 31, 2023, OSR Holdings has incurred significant operating losses and negative cash flows from its operations. OSR Holdings&#8217; operating losses were KRW 784.7 million and KRW 14.7 billion for the years ended December 31, 2022 and December 31, 2023, respectively. As of December 31, 2023, OSR Holdings had an accumulated deficit of KRW 13.5 billion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, OSR Holdings will be managed by New OSR Holdings and operated as a majority owned subsidiary of New OSR Holdings. Please see the section entitled &#8220;<span style="font-style:italic">Management Following the Business Combination</span>&#8221; for further information. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;<span style="text-decoration:underline">JOBS Act</span>&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (the &#8220;<span style="text-decoration:underline">Sarbanes-Oxley Act</span>&#8221;), reduced disclosure obligations regarding executive compensation in periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. BLAC has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, BLAC, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of BLAC&#8217;s financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC could remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of BLAC&#8217;s initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the last business day of its most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.00&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, BLAC is a &#8220;smaller reporting company&#8221; as defined in Item&#160;10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our shares of BLAC Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June&#160;30, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our shares of BLAC Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June&#160;30th. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;16, 2023, BLAC and OSR Holdings entered into a Business Combination Agreement. The Business Combination Agreement was amended and restated on May 23, 2024. Prior to the Closing, each Participating Company Stockholder and each <span style="white-space:nowrap">Non-Participating</span> Company Stockholder will be joined as parties to the Business Combination Agreement. At the effective time of the Closing (i)&#160;BLAC shall issue to the Participating Company Stockholders shares of BLAC Common Stock equal to the Aggregate Participating Consideration and the Participating Company Stockholders will transfer their respective shares of OSR Holdings Common Stock to BLAC, and (ii)&#160;the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders will continue to hold their shares of OSR Holdings Common Stock subject to their <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders entered into with </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BLAC on or before the date of the Closing. Upon consummation of the Share Exchange, BLAC will directly own at least 60% of the shares of OSR Holdings Common Stock, with the remaining shares of OSR Holdings Common Stock held by the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders. Pursuant to the terms of the Non-Participating Stockholder Joinders, BLAC will have rights to acquire the shares of the Non-Participating Company Stockholders. The Non-Participating Stockholder Joinder contains put and call rights for the Non-Participating Company Stockholder and BLAC, respectively, whereby the Non-Participating Company Stockholder shall have the right to cause BLAC to purchase (the &#8220;<span style="text-decoration:underline">Put Right</span>&#8221;) and BLAC shall have the right to cause the Non-Participating Company Stockholder to sell (the &#8220;<span style="text-decoration:underline">Call Right</span>&#8221;) to BLAC or its designee all of the shares of OSR Holdings Common Stock owned and held of record by such Non-Participating Company Stockholder. These rights become exercisable on or after January 1, 2026, or the date that the Non-Participating Company Stockholder is notified by BLAC of a transaction that will result in a change in control (as defined in the Non-Participating Stockholder Joinder) of BLAC. Capitalized terms used in this summary but not otherwise defined herein have the meanings given to them in the Business Combination Agreement, a copy of which is attached hereto as Annex A and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Share Exchange: (i)&#160;the Participating Company Stockholders shall transfer and convey all of the shares of OSR Holdings Common Stock held by the Participating Company Stockholders to BLAC, in each case, free and clear of any claims or interest of any person previously entitled thereto; (ii)&#160;BLAC shall effect the transfer and conveyance of all of the shares of BLAC Common Stock representing the Aggregate Participating Consideration to the Participating Company Stockholders, in each case, free and clear of any claims or interest of any person previously entitled thereto; (iii)&#160;any fractional share of BLAC Common Stock that would otherwise be issuable to a Participating Company Stockholder following such exchange shall be rounded up or down to the nearest whole share of BLAC Common Stock; (iv)&#160;all OSR Holdings Common Stock held by Non-Participating Company Stockholders will not be exchanged for shares of BLAC Common Stock at Closing, and such OSR Holdings Common Stock will be subject to the terms of the Non-Participating Stockholder Joinder, including the Put Right and Call Right set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some officers and directors of BLAC, including Mr.&#160;Kuk Hyoun Hwang, have interests in the Business Combination as individuals that are in addition to, and that may be different from, the interests of BLAC stockholders. Mr.&#160;Hwang is the Chief Executive Officer and a member of the Board of Directors of BLAC and Chief Executive Officer and Chairman of the Board of OSR Holdings. The Board of Directors of BLAC formed a separate committee (the &#8220;<span style="text-decoration:underline">M&amp;A Committee</span>&#8221;), consisting of three independent directors, Dr.&#160;Steven Reed, Dr.&#160;Radclyffe Roberts and Mr.&#160;Jin Whan Park, to review and consider these interests during the negotiation of the Business Combination Agreement and in evaluating and unanimously approving, as members of the BLAC Board, the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Closing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with (i)&#160;the terms and subject to the conditions of the Business Combination Agreement, and (ii)&#160;the consummation of the PIPE Financing, the Closing shall take place by electronic delivery of documents (by PDF (portable document format) and/or electronic mail), all of which will be deemed to be originals, at a time to be agreed by the parties to the Business Combination Agreement on the first date on which all conditions set forth below shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver thereof) or such other time and place as the parties may mutually agree in writing. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conditions to Closing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Closing is subject to customary closing conditions for special purpose acquisition companies, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">approval by BLAC&#8217;s stockholders of the BLAC Proposals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">no Governmental Authority shall have enacted, issued, promulgated, enforced or entered any law, rule, regulation, judgment, decree, executive order, or award which is then in effect and has the effect of making the Transactions, including the Business Combination, illegal or otherwise prohibiting consummation of the Transactions, including the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">all required regulatory filings and approvals in the United States and outside the United States, shall have been completed and any applicable waiting period (and any extension thereof) applicable to the consummation of the Transactions shall have expired or been terminated, and any <span style="white-space:nowrap">pre-Closing</span> approvals or clearances reasonably required thereunder shall have been obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">all required consents, approvals and authorizations shall have been obtained from and made with all Governmental Authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the shares of BLAC Common Stock shall be listed on Nasdaq as of the Closing Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">no material adverse effects on BLAC or OSR Holdings shall have occurred between November 16, 2023 (the date of the initial Business Combination Agreement), and the Closing Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(vii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the <span style="white-space:nowrap">Lock-Up</span> Agreements shall have been duly executed by BLAC and certain holders of OSR Holdings Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(viii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">OSR Holdings shall have delivered to BLAC (a)&#160;Participating Stockholder Joinders duly executed by Participating Company Stockholders holding at least 60% of the OSR Holdings Fully Diluted Share Amount, and <span style="white-space:nowrap">(b)&#160;Non-Participating</span> Stockholder Joinders executed by the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ix)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the BLAC M&amp;A Committee shall have received an opinion from an advisor engaged by the BLAC M&amp;A Committee that the Transactions are fair, from a financial point of view, to BLAC and its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(x)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a supplemental listing shall have been filed with Nasdaq as of the Closing Date to list the shares constituting the Aggregate Participating Consideration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(xi)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on or prior to the Closing, OSR Holdings shall deliver to BLAC a properly executed certification that shares of OSR Holdings Common Stock are not &#8220;U.S. real property interests&#8221; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS in accordance with the provisions of <span style="white-space:nowrap">Section&#160;1.897-2(h)(2)</span> of the Treasury Regulations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(xii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">customary bringdown conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the obligations of OSR Holdings and the OSR Holdings Stockholders to consummate the Transactions are conditioned upon, among other things, a minimum available cash condition such that the (a)&#160;amount of cash and cash equivalents available in the Trust Account immediately prior to the Closing, plus (b)&#160;all other cash and cash equivalents of BLAC, plus (c)&#160;the aggregate amount of cash proceeds received from the PIPE Financing prior to or substantially concurrently with the Closing (without, for the avoidance of doubt, taking into consideration any transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing), shall be equal to or greater than $5,000,001 (the &#8220;<span style="text-decoration:underline">Minimum Available Cash Condition</span>&#8221;). See the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement &#8212; Conditions to Closing the Business Combination</span>.&#8221; </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Waiver </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any party to the Business Combination Agreement may, at any time prior to the Closing, by action taken by its board of directors or equivalent governing body, officers thereunto duly authorized, or individually in the case of independent stockholders, waive in writing any of its or their rights or conditions in its or their favor under the Business Combination Agreement. Notwithstanding the foregoing, pursuant to BLAC&#8217;s current certificate of incorporation, BLAC cannot consummate the Business Combination if New OSR Holdings would have less than $5,000,001 of net tangible assets remaining after the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the financial and personal interests of the directors may result in a conflict of interest on the part of one or more of them between what such director may believe is best for BLAC and what such director may believe is best for such director in determining whether or not to grant a waiver in a specific situation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains exclusivity provisions restricting the parties from engaging in any Alternative Transaction (as defined below) for a period ending on the earlier of (i)&#160;the Closing and/or (ii)&#160;the termination of the Business Combination Agreement. An &#8220;<span style="text-decoration:underline">Alternative Transaction</span>&#8221; includes (A)&#160;any sale of assets of OSR Holdings equal to 5% or more of OSR Holdings&#8217; assets or to which 5% or more of OSR Holdings&#8217; revenues or earnings are attributable, (B)&#160;the issuance or acquisition of 5% or more of the outstanding capital stock (on an as converted to OSR Holdings Common Stock basis) or other voting securities representing 5% or more of the combined voting power of the OSR Holdings, or (3)&#160;any conversion, consolidation, merger, liquidation, dissolution or similar transaction which, if consummated, would result in any person or other entity or group beneficially owning 5% or more of the combined voting power of OSR Holdings, other than with BLAC and certain of its affiliates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Representations, Warranties and Covenants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains customary representations, warranties and covenants of (a)&#160;OSR Holdings, (b)&#160;BLAC and (c)&#160;OSR Holdings Stockholders relating to, among other things, their ability to enter into the Business Combination Agreement and the Joinders, as applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be terminated, and the Business Combination and the other Transactions may be abandoned at any time prior to the Effective Time, notwithstanding any requisite approval and adoption of the Business Combination Agreement and the Transactions by the stockholders of OSR Holdings or BLAC, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by mutual written consent of BLAC and OSR Holdings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either BLAC or OSR Holdings if the Effective Time shall not have occurred prior to November 14, 2024 (the &#8220;<span style="text-decoration:underline">Outside Date</span>&#8221;) subject to certain exemptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either BLAC or OSR Holdings if any Governmental Authority, including in the United States or the Republic of Korea, shall have taken action to prevent or prohibit the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either BLAC or OSR Holdings if any of the BLAC Proposals shall fail to receive the requisite vote for approval at the BLAC Stockholders&#8217; Meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">e)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by BLAC upon a material breach of any representation, warranty, covenant or agreement on the part of OSR Holdings set forth in the Business Combination Agreement; or </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">f)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by OSR Holdings upon a material breach of any representation, warranty, covenant or agreement on the part of BLAC set forth in the Business Combination Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect of Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is terminated, the Business Combination Agreement will forthwith become void, and there will be no liability under the Business Combination Agreement on the part of any party thereto, except as set forth in the Business Combination Agreement or in the case of termination subsequent to a willful material breach of the Business Combination Agreement by a party thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the Business Combination Agreement, all expenses incurred in connection with the Business Combination Agreement and the Transactions shall be paid by the party incurring such expenses, whether or not the Business Combination or any other Transactions are consummated except that BLAC and OSR Holdings will each pay one half of all expenses relating to all SEC and other regulatory filing fees incurred in connection with the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Business Combination Agreement is qualified in its entirety by reference to the full text of the Business Combination Agreement attached hereto as Annex A. The Business Combination Agreement is not intended to provide any other factual information about BLAC, OSR Holdings or the other parties thereto. In particular, the assertions embodied in representations and warranties by BLAC, OSR Holdings, and the OSR Holdings Stockholders contained in the Business Combination Agreement are qualified by information in the disclosure schedules provided by the parties in connection with the signing of the Business Combination Agreement. These disclosure schedules contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Business Combination Agreement. Moreover, certain representations and warranties in the Business Combination Agreement were used for the purpose of allocating risk between the parties, rather than establishing matters as facts. Accordingly, security holders should not rely on the representations and warranties in the Business Combination Agreement as characterizations of the actual state of facts about BLAC, OSR Holdings or the OSR Holdings Stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Agreements Related to the Business Combination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Closing, BLAC and certain stockholders of OSR Holdings will enter into <span style="white-space:nowrap">Lock-Up</span> Agreements providing for certain restrictions on transfers applicable to BLAC Common Stock, which shall exclude 30% of the shares of BLAC Common Stock held by such stockholders. Generally, the <span style="white-space:nowrap">Lock-Up</span> Agreement prohibits stockholders from (i)&#160;selling, offering to sell, contracting or agreeing to sell, hypothecating, pledging, granting any option to purchase or otherwise disposing of or agreeing to dispose of, directly or indirectly, or establishing or increasing a put equivalent position or liquidating or decreasing a call equivalent position within the meaning of Section&#160;16 of the Exchange Act, and the rules and regulations of the SEC promulgated thereunder with respect to the <span style="white-space:nowrap">Lock-Up</span> Shares, (ii)&#160;entering into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of the <span style="white-space:nowrap">Lock-Up</span> Shares, whether any such transaction is to be settled by delivery of <span style="white-space:nowrap">Lock-Up</span> Shares or other securities, in cash or otherwise, or (iii)&#160;publicly announcing any intention to effect any transaction specified in the immediately preceding subsections (i)&#160;or (ii), subject to certain limited exceptions set forth in the <span style="white-space:nowrap">Lock-Up</span> Agreement. The <span style="white-space:nowrap">lock-up</span> period under <span style="white-space:nowrap">Lock-Up</span> Agreement lasts until December&#160;31, 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pipe Subscription Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is actively pursuing entering into one or more subscription agreements (collectively, the &#8220;<span style="text-decoration:underline">Subscription Agreements</span>&#8221;) with certain institutional and accredited investors (collectively, the &#8220;<span style="text-decoration:underline">PIPE</span> </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="text-decoration:underline">Investors</span>&#8221;) pursuant to which the PIPE Investors will agree to purchase, prior to or substantially concurrently with the closing of the Business Combination, equity, or debt or preferred securities issuable by BLAC and/or OSR Holdings convertible into BLAC Common Stock, for aggregate gross proceeds of at least $20,000,000 (the &#8220;<span style="text-decoration:underline">PIPE Financing</span>&#8221;). The securities to be issued to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;), in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act and/or Regulation S adopted thereunder. BLAC has obtained a letter of intent from Toonon Partners Co., Ltd. (&#8220;Toonon&#8221;), a Korean investment firm, dated June 24, 2024, pursuant to which Toonon indicated its interest to purchase $20,000,000 of BLAC&#8217;s equity securities in connection with the closing of the Business Combination. The terms of the proposed transaction are under current negotiation and, assuming all terms are finalized, will be set forth in a definitive agreement to be executed between BLAC and Toonon. The PIPE Financing, if completed, will dilute the ownership of existing BLAC stockholders, and may depress the value of shares of New OSR Holdings Common Stock. It is not currently anticipated that Sponsor or any BLAC or OSR Holdings affiliates will participate in the PIPE Financing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of BLAC Directors and Executive Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of our board of directors in favor of approval of the Business Combination, you should keep in mind that our board of directors and officers have interests in the Business Combination that are different from, or in addition to, your interests as a stockholder. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve a proposed initial business combination (the Sponsor was not granted any consideration or incentive to agree not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve the Business Combination); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor paid an aggregate of $25,000 (or $0.014 per share) for 1,725,000&#160;shares of BLAC Common Stock, which will have a significantly higher value at the time of the Business Combination. If unrestricted and freely tradable, such shares would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;]&#160;per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement and an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;]&#160;per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the Record Date, but given the restrictions on those shares, we believe those shares have less value; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor purchased 430,000 private placement units (including the underlying securities) for an aggregate purchase price of $4,300,000 (or $10.00 per unit) in which the warrants and rights included in the private placement units would be worthless if a business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents). Such private placement units had an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;]&#160;per public unit on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement/prospectus and an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;] per public unit on Nasdaq on [&#9679;], 2024, the Record Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed to waive its rights to liquidating distributions from the trust account with respect to any shares of BLAC Common Stock (other than public shares) held by it if BLAC fails to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Mr. Hwang, Mr. Whang and affiliates of the Sponsor have a financial interest in OSR Holdings. Mr. Hwang is the CEO and a Director of BLAC and CEO and Chairman of the Board of OSR Holdings and Mr. Whang is a director of BLAC. As such, Mr. Hwang, Mr. Whang and affiliates of the Sponsor who have a financial interest in OSR Holdings are incentivized to complete the Business Combination with OSR Holdings; </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor transferred 20,000 shares to each of Drs. Chung, Reed and Roberts and Mr. Park, which are current and former BLAC directors for their board service, and Mr. Yoo for his service as chief financial officer.&#160;The Sponsor additionally transferred 20,000 Private Placement Warrants to each of Dr. Reed for his service as the former chairman of the board of directors, Dr. Chung for his service as the former chair of the audit committee, and Mr. Yoo for his service as chief financial officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors will lose their entire investment in BLAC and will not be reimbursed for any out-of-pocket expenses, if any, if an initial business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents) and, as a result, the Sponsor and BLAC&#8217;s officers and directors may have a conflict of interest in determining whether OSR Holdings is an appropriate business with which to effectuate a business combination and/or in evaluating the terms of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor has invested an aggregate of $4,325,000 (consisting of $25,000 for the founder shares, or approximately $0.014&#160;per share, and $4,300,000 for the private placement units, or $10.00 per unit, means that the Sponsor and our officers and directors stand to make a significant profit on their investment and could potentially recoup their entire investment in BLAC even if the trading price of BLAC Common Stock was as low as approximately $2.00 per share (assuming no redemptions and even if the private placement warrants and rights are worthless) and therefore our Sponsor, officers and directors may experience a positive rate of return on their investment, even if BLAC&#8217;s public stockholders experience a negative rate of return on their investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors (or their affiliates) may make Working Capital Loans from time to time to BLAC to fund certain capital requirements (&#8220;Working Capital Loans&#8221;). Sponsor, BLAC&#8217;s officers, and its and their affiliates, have previously loaned money to BLAC (or to the sponsor for BLAC&#8217;s benefit) in an aggregate amount of $3,905,000 to fund operating and transaction expenses in connection with the proposed Business Combination, $3,525,000 of which remains outstanding as of the date of this proxy statement/prospectus (none of which contain conversion rights), and may make additional loans after the date of this proxy statement/prospectus for such purposes. If the Business Combination is not consummated or another business combination is not otherwise completed, the loans may not be repaid and would be forgiven except to the extent there are funds available to BLAC outside of the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, although no compensation of any kind was or will be paid by BLAC to the Sponsor, BLAC&#8217;s executive officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of an initial business combination, these individuals may be reimbursed for any out-of-pocket expenses incurred in connection with activities on BLAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. As of the date of this proxy statement/prospectus, there are no outstanding out-of-pocket expenses for which the Sponsor or BLAC&#8217;s officers or directors are awaiting reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that if the trust account is liquidated, including in the event BLAC is unable to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), the Sponsor has agreed to indemnify BLAC to ensure that the proceeds in the trust account are not reduced below $10.175&#160;per public share, or such lesser per public share amount as is in the trust account on the liquidation date, by the claims of prospective target businesses with which BLAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to BLAC, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the trust account; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that BLAC may be entitled to distribute or pay over funds held by BLAC outside the trust account to the Sponsor or any of its affiliates prior to the Closing. </p></td></tr></table> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time at or prior to the Business Combination, during a period when they are not then aware of any material non-public information regarding BLAC or BLAC&#8217;s securities, BLAC&#8217;s Sponsor, OSR Holdings and/or their directors, officers, advisors or respective affiliates may purchase public shares from institutional and other investors who vote, or indicate an intention to vote, against any of the Condition Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire public shares or vote their public shares in favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such stockholder, although still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that BLAC&#8217;s Sponsor, OSR Holdings and/or their directors, officers, advisors or respective affiliates who have agreed to vote in favor of this transaction purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholder would be required to revoke their prior elections to redeem their shares. Such purchases shall be effected at purchase prices that are no higher than the redemption price for the shares. Any shares so purchased would not be voted by BLAC&#8217;s Sponsor, OSR Holdings and/or their respective directors, officers, advisors or respective affiliates at the special meeting and would not be redeemable. The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements that (i)&#160;the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued shares of BLAC Common Stock present in person or represented by proxy at the special meeting and entitled to vote on such matter, special meeting, and (ii)&#160;otherwise limit the number of public shares electing to redeem. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in circumstances where such consummation could not otherwise occur. BLAC will file or submit a Current Report on Form 8-K to disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be put to the special meeting. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. See &#8220;<span style="font-style:italic">Risk Factors &#8212; </span><span style="font-style:italic">The Sponsor and its affiliates may enter into agreements concerning BLAC&#8217;s securities prior to the BLAC Stockholders&#8217; Meeting, which may have the effect of increasing the likelihood of completion of the Business Combination or decreasing the value of the BLAC Common Stock.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The BLAC Board&#8217;s Reasons for the Approval of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, the BLAC Board, with the recommendation of the BLAC M&amp;A Committee, recommends that BLAC&#8217;s stockholders vote &#8220;FOR&#8221; each proposal being submitted to a vote of the BLAC stockholders at the special meeting. For a description of the BLAC M&amp;A Committee&#8217;s reasons for the approval of the Business Combination and the recommendation of BLAC&#8217;s board of directors, see the section entitled <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ownership of BLAC </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, there are 4,041,221&#160;shares of BLAC Common Stock issued and outstanding, which includes an aggregate of 2,155,000&#160;shares of BLAC Common Stock held by the Sponsor, current and former directors of BLAC, the Chief Financial Officer of BLAC, and their respective affiliates (including 34,500 shares of BLAC Common Stock held in escrow pending the closing of the business combination by Chardan Capital Markets, LLC). In addition, as of the date of this proxy statement/prospectus, there is outstanding an aggregate of 7,330,000&#160;BLAC Warrants, comprised of 430,000 private placement warrants held by the Sponsor, BLAC&#8217;s Chief Financial Officer, and two of BLAC&#8217;s former directors, and 6,900,000 public warrants, and 7,330,000 BLAC Rights, comprised of 430,000 private placement rights held by </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Sponsor and 6,900,000 public rights, to acquire shares of BLAC Common Stock. Each whole warrant entitles the holder thereof to purchase one share of BLAC Common Stock. Each whole right entitles the holder thereof to receive one-tenth of one share of BLAC Common Stock. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination and assuming that none of BLAC&#8217;s outstanding public shares are redeemed in connection with the Business Combination), BLAC&#8217;s fully diluted share capital, giving effect to the exercise of all of the private placement warrants, public warrants, private placement rights and public rights, would be 12,104,221&#160;shares of BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates varying ownership levels in BLAC Common Stock immediately following the consummation of the Business Combination based on the varying levels of redemptions by the public stockholders and the following additional assumptions: (i) 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) are issued to the Participating Company Stockholders at consummation of the Business Combination, (ii) all BLAC Rights have been converted to shares of BLAC Common Stock, and (iii) $20,000,000 of PIPE financing is raised through the sale of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. The table below does not take into account (i) the exercise of any BLAC Warrants as the warrants do not become exercisable until 30 days after the consummation of the Business Combination, and (ii) the issuance of any equity awards under the Omnibus Plan as there will be no awards issued under the Omnibus Plan immediately following the consummation of the Business Combination. See &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; for more details. If the actual facts differ from these assumptions, the ownership percentages in BLAC will be different and totals may not add up to 100% due to rounding. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span><br/><span style="font-weight:bold">(Assuming </span><br/><span style="font-weight:bold">No Redemptions) </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span><br/><span style="font-weight:bold">(Assuming </span><br/><span style="font-weight:bold">50% Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span><br/><span style="font-weight:bold">(Assuming Maximum</span><br/><span style="font-weight:bold">Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">Shares </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span><br/><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span><br/><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">Shares </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span><br/><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Sponsor and Related Parties<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.44</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC public stockholders<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.49</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes (i) 60% of the Aggregate Consideration of 24,461,214 shares of BLAC Common Stock pursuant to the Business Combination Agreement will be issued by BLAC to the Participating Company Stockholders at consummation of the Business Combination, and (ii) the remaining 40% of the Aggregate Consideration, or 9,784,486 shares of BLAC Common Stock, will be issuable by BLAC to the Non-Participating Company Stockholders upon exercise of the put/call rights set forth in the Non-Participating Stockholder Joinders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,035,000 shares of BLAC Common Stock held by the Sponsor, (ii) 20,000 shares of BLAC Common Stock held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, (iii) 20,000 shares of BLAC Common Stock held by Jin Whan Park, a current director of BLAC, and (iv) 20,000 shares of BLAC Common Stock held by each of the following former directors of BLAC: Dr. Steven Reed, Dr. Inchul Chung, Mr. Hosun Euh, and Dr. Radclyffe Roberts. It also assumes the conversion of 430,000 private placement rights held by the Sponsor into 43,000 shares of BLAC Common Stock upon the consummation of the Business Combination. Excludes 34,500 shares currently held in escrow and due to Chardan Capital Markets, LLC upon closing of the Business Combination. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the conversion of 6,900,000 public rights into 690,000 shares of BLAC Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes an aggregate of $20,000,000 raised from the issuance of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders will experience additional dilution to the extent the Post-Combination&#160;Company issues additional shares after the Closing. The table above does not include (i) up to 6,900,000&#160;shares of New OSR Holdings Common Stock that will be issuable upon exercise of the public warrants, which have an initial exercise price of $11.50 per share (subject to adjustment in accordance with the Warrant Agreement), (ii) up to 430,000&#160;shares of New OSR Holdings Common Stock that will be issuable upon exercise of the private warrants, which have an initial exercise price of $11.50 per share (subject to adjustment in accordance with the Warrant Agreement), and (iii) 6,300,000 shares of New OSR Holdings Common Stock, the maximum number of shares currently reserved for issuance under the Omnibus Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates the impact on relative ownership levels assuming the issuance of all such shares. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming</span><br/><span style="font-weight:bold">No Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming </span><br/><span style="font-weight:bold">50%&#160;Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined<br/>(Assuming Maximum<br/>Redemptions)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41.57</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Sponsor and Related Parties<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.47</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC public stockholders<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.47</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares underlying the Private Warrants<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">430,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares underlying the Public Warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.54</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omnibus Plan<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.85</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,303,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,360,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,416,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes (i) 60% of the Aggregate Consideration of 24,461,214 shares of BLAC Common Stock pursuant to the Business Combination Agreement will be issued by BLAC to the Participating Company Stockholders at consummation of the Business Combination, and (ii) the remaining 40% of the Aggregate Consideration, or 9,784,486 shares of BLAC Common Stock, will be issuable by BLAC to the Non-Participating Company Stockholders upon exercise of the put/call rights set forth in the Non-Participating Stockholder Joinders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,035,000 shares of BLAC Common Stock held by the Sponsor, (ii) 20,000 shares of BLAC Common Stock held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, (iii) 20,000 shares of BLAC Common Stock held by Jin Whan Park, a current director of BLAC, and (iv) 20,000 shares of BLAC Common Stock held by each of the following former directors of BLAC: Dr. Steven Reed, Dr. Inchul Chung, Mr. Hosun Euh, and Dr. Radclyffe Roberts. It also assumes the conversion of 430,000 private placement rights held by </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
the Sponsor into 43,000 shares of BLAC Common Stock upon the consummation of the Business Combination. Excludes 34,500 shares currently held in escrow and due to Chardan Capital Markets, LLC upon closing of the Business Combination. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the conversion of 6,900,000 public rights into 690,000 shares of BLAC Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes an aggregate of $20,000,000 raised from the issuance of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 370,000 private warrants held by Sponsor, (ii) 20,000 private warrants held by Mr. Yoo, BLAC&#8217;s Chief Financial Officer, and (iii) 20,000 private warrants held by each of Dr. Steven Reed and Dr.&#160;Inchul Chung. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">6,300,000 is the maximum number of shares to be reserved for issuance under the Omnibus Plan. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For further details, see&#160;&#8220;<span style="font-style:italic">The Business Combination Agreement &#8212; Structure of the Transactions</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Organizational Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Prior to the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram shows the current ownership structure of BLAC. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Pre-IPO BLAC </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00y13.jpg" alt="LOGO" style="width:0.757817in;height:1.48088in"/>
 </p></div><div style="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Post-IPO BLAC </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00y12.jpg" alt="LOGO" style="width:1.84028in;height:1.28522in"/>
 </p></div><div style="clear:both; height:0pt; font-size:0pt">&#160;</div>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more information about the ownership interests of our initial stockholders, including the Sponsor, prior to the Business Combination, please see the section entitled &#8220;<span style="font-style:italic">Beneficial Ownership of Securities</span>&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram shows the current structure of OSR Holdings: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Pre-BC OSR </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00d20.jpg" alt="LOGO" style="width:2.69272in;height:2.46785in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For more information about the ownership interests of OSR Holdings, prior to the Business Combination, please see the section entitled &#8220;<span style="font-style:italic">Beneficial Ownership of Securities</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">After the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram shows the structure after the Business Combination: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Post-BC </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g79s64.jpg" alt="LOGO" style="width:3.62145in;height:2.32981in"/>
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes holders of 60% of OSR Holdings common stock execute Participating Stockholder Joinders to the Amended and Restated Business Combination Agreement, the minimum amount required thereunder. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors of New OSR Holdings Following the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the Board will consist of the following members: Kuk Hyoun Hwang, Jun Chul Whang, Phil Geon Lee, Alcide Barberis, Seng Chin Mah, Jin Whan Park, Sang Hyun Kim, [&#9679;], and [&#9679;]. In addition, following the Closing, we expect that a majority of the directors will be &#8220;independent&#8221; under applicable Nasdaq listing rules. See&#160;&#8220;<span style="font-style:italic">Management Following the Business Combination</span>&#8221; for more information. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposals to be put to the Stockholders of BLAC at the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the proposals to be put to the special meeting of BLAC and certain transactions contemplated by the Business Combination Agreement. Each of the proposals below, except the Advisory Governance Proposals and the Adjournment Proposal, is cross-conditioned on the approval of other proposals. The Advisory Governance Proposals and the Adjournment Proposal are not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus. The transactions contemplated by the Business Combination Agreement will be consummated only if the Condition Precedent Proposals are approved at the special meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Business Combination Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in this proxy statement/prospectus, BLAC is asking its stockholders to approve the Business Combination Agreement, pursuant to which, among other things, on the Closing Date, in accordance with the terms and subject to the conditions of the Business Combination Agreement, (i)&#160;the Participating Company Stockholders will transfer their respective shares of OSR Holdings Common Stock to BLAC in exchange for shares of BLAC Common Stock, and (ii)&#160;the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders will continue to hold their shares of OSR Holdings Common Stock subject to their <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders entered into with BLAC on or before the Closing Date. Upon consummation of the Share Exchange, BLAC will directly own at least 60% of the shares of OSR Holdings Common Stock, with the remaining shares of OSR Holdings Common Stock held by the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders. Pursuant to the terms of the Non-Participating Stockholder Joinders, BLAC will have rights to acquire the shares of the Non-Participating Company Stockholders. The Non-Participating Stockholder Joinder contains put and call rights for the Non-Participating Company Stockholder and BLAC, respectively, whereby the Non-Participating Company Stockholder shall have the right to cause BLAC to purchase (the &#8220;Put Right&#8221;) and BLAC shall have the right to cause the Non-Participating Company Stockholder to sell (the &#8220;Call Right&#8221;) to BLAC or its designee all of the shares of OSR Holdings Common Stock owned and held of record by such Non-Participating Company Stockholder. These rights become exercisable on or after January 1, 2026, or the date that the Non-Participating Company Stockholder is notified by BLAC of a transaction that will result in a change in control (as defined in the Non-Participating Stockholder Joinder) of BLAC. For further details, see &#8220;<span style="font-style:italic">The Business Combination Agreement&#160;&#8212; Structure of the Transactions.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After consideration of the factors identified and discussed in the section entitled &#8220;<span style="font-style:italic">The Business Combination&#160;&#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span>,&#8221; the BLAC Board concluded that the Business Combination met all of the requirements disclosed in the prospectus for BLAC&#8217;s initial public offering, including that the businesses of OSR Holdings had a fair market value of at least 80% of the balance of the funds in the trust account at the time of execution of the Business Combination Agreement. For more information about the transactions contemplated by the Business Combination Agreement, see &#8220;<span style="font-style:italic">The Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Charter Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC will ask its stockholders to approve the Charter Proposal in connection with the replacement of the Amended and Restated Certificate of Incorporation, under Delaware law, with the Second Amended and Restated Certificate of Incorporation. The BLAC Board has unanimously approved the Charter Proposal and believes such proposal is necessary to adequately address the needs of BLAC after the Business Combination. Approval of the Charter Proposal is a condition to the consummation of the Business Combination. BLAC encourages stockholders to carefully consider the information set out in the section entitled &#8220;<span style="font-style:italic">Proposal No.&#160;2&#160;&#8212; The Charter Proposal</span>&#8221; and the full text of the Second Amended and Restated Certificate of Incorporation of BLAC, attached hereto as Annex&#160;E. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advisory Governance Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC will ask its stockholders to consider and vote, on a <span style="white-space:nowrap">non-binding</span> advisory basis, upon six separate governance proposals relating to material differences between BLAC&#8217;s Current Charter and Current Bylaws the Amended Charter and Amended Bylaws to be in effect upon the completion of the Business Combination in accordance with the requirements of the SEC. These proposals include (a)&#160;changing BLAC&#8217;s name to &#8220;OSR Holdings, Inc.,&#8221; (b) increasing the number of share of preferred stock authorized for issuance from 1,000,000 shares to 10,000,000 shares, (c)&#160;providing that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power, (d)&#160;eliminating the current limitations on the corporate opportunity doctrine, (e)&#160;providing that the quorum required for stockholder meetings is the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of the then outstanding shares of capital stock entitled to vote at the meeting, and (f)&#160;approving all other changes including eliminating certain provisions related to special purpose acquisition corporations that will no longer be relevant following the Closing. BLAC encourages stockholders to carefully consider the information set out in the section entitled &#8220;<span style="font-style:italic">Proposals No.&#160;3A&#160;&#8212; 3F&#160;&#8212; The Advisory Governance Proposals</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Incentive Plan&#160;Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders are also being asked to approve the Incentive Plan Proposal. Pursuant to the Omnibus Plan, a number of shares of BLAC Common Stock equal to 6,3000,000 of the total number of shares of capital stock of BLAC outstanding after the Closing will be reserved for issuance under the Omnibus Incentive Plan. For additional information, see &#8220;<span style="font-style:italic">Proposal No.&#160;4&#160;&#8212;Incentive Plan Proposal</span>.&#8221; The full text of the Omnibus Plan is attached hereto as Annex&#160;G. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Director Election Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders are also being asked to consider and vote upon a proposal to elect, effective as of, and contingent upon, the consummation of the Business Combination, up to nine (9)&#160;persons to serve as directors on New OSR Holdings&#8217; board of directors, until the expiration of their applicable term, and until their respective successors are duly elected and qualified or until their earlier resignation, removal or death. See the section entitled &#8220;<span style="font-style:italic">Proposal No.&#160;5&#160;&#8212;The Director Election Proposal</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adjournment&#160;Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, based on the tabulated vote, there are not sufficient votes at the time of the special meeting to authorize BLAC to consummate the Business Combination, the BLAC Board may submit a proposal to consider and vote upon a proposal to approve the adjournment of the special meeting to a later date or dates. For additional information, see &#8220;<span style="font-style:italic">Proposal No.&#160;6&#160;&#8212;Adjournment Proposal</span>.&#8221; The Adjournment Proposal is not conditioned on any other proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Date and Time of Special Meeting of BLAC&#8217;s Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The special meeting of BLAC, will be held at [&#9679;], Eastern Time, on [&#9679;], 2024, unless the special meeting is adjourned, to consider and vote upon the proposals to be put to the special meeting, including if necessary, the Adjournment Proposal, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, each of the Condition Precedent Proposals have not been approved. Stockholders may attend, vote and examine the list of BLAC&#8217;s stockholders entitled to vote at the special meeting. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Power; Record Date </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC stockholders will be entitled to vote or direct votes to be cast at the special meeting if they owned shares of BLAC Common Stock at the close of business on [&#9679;], 2024, which is the Record Date for the special meeting. Stockholders will have one vote for each share of BLAC Common Stock owned at the close of business on the Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. BLAC&#8217;s warrants and rights do not have voting rights. As of the close of business on the Record Date, there were [&#9679;] shares of BLAC Common Stock issued and outstanding, of which [&#9679;] were issued and outstanding public shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quorum and Vote of BLAC Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of BLAC stockholders is necessary to hold a valid meeting. A quorum will be present at the special meeting if one or more stockholders who together hold not less than a majority of the issued and outstanding shares of BLAC Common Stock entitled to vote at the special meeting are represented or by proxy at the special meeting. As of the Record Date, [&#9679;] shares of BLAC Common Stock would be required to achieve a quorum. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposals presented at the special meeting require the following votes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">Business Combination Proposal:</span></span>&#160;The Business Combination Proposal requires the approval the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">Charter Proposal:</span></span>&#160;The Charter Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">Advisory Governance Proposals:</span></span>&#160;The Advisory Governance Proposals require the approval of the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">Incentive Plan Proposal:</span></span>&#160;The Incentive Plan Proposal requires the approval of the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Director Election Proposal:</span></span>&#160;This proposal requires the approval of the holders of a plurality of the BLAC Common Stock under Delaware law. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">Adjournment Proposal:</span></span>&#160;The Adjournment Proposal requires the approval of the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption&#160;Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Existing Governing Documents, a public stockholder may request that BLAC redeem all or a portion of its public shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">(a) hold public shares or (b)&#160;if you hold public shares through units, you elect to separate your units into the underlying public shares, public warrants and public rights prior to exercising your redemption rights with respect to the public shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">submit a written request to Continental, BLAC&#8217;s transfer agent, in which you (i)&#160;request that BLAC redeem all or a portion of your public shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">deliver your share certificates (if any) to Continental, BLAC&#8217;s transfer agent, physically or electronically through DTC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to [</span>&#9679;<span style="font-weight:bold">], Eastern Time, on [</span>&#9679;<span style="font-weight:bold">], 2024 (two business days before the special meeting) in order for their shares to be redeemed.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of units must elect to separate the units into the underlying public shares, public warrants and public rights prior to exercising redemption rights with respect to the public shares. Public holders that hold their units in an account at a brokerage firm or bank, must notify their broker or bank that they elect to separate the units into the underlying public shares, public warrants and public rights, or if a holder holds units registered in its own name, the holder must contact Continental, BLAC&#8217;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. Public stockholders may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public stockholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its share certificates (if any) to Continental, BLAC&#8217;s transfer agent, BLAC will redeem such public shares for a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the pro rata portion of the trust account, calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, this would have amounted to approximately $[&#9679;] per issued and outstanding public share (including interest and prior to the payment of taxes), based on [&#9679;] shares subject to possible redemption as of [&#9679;], 2024. If a public stockholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. See &#8220;<span style="font-style:italic">The Special Meeting of BLAC Stockholders&#160;&#8212; Redemption Rights and Procedures</span>&#8221; in this proxy/prospectus statement for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a public stockholder, together with any affiliate of such public stockholder or any other person with whom such public stockholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the public shares without the prior consent of BLAC. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the warrants will not have redemption rights with respect to the warrants. Holders of the rights will not have redemption rights with respect to the rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of BLAC stockholders, unit holders, warrant holders or rights holders have appraisal rights in connection with the Business Combination under the Delaware General Corporation Law (&#8220;<span style="text-decoration:underline">DGCL</span>&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proxy Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proxies may be solicited by mail, telephone or in person. BLAC has engaged Advantage Proxy to assist in the solicitation of proxies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stockholder grants a proxy, it may still vote its shares in person if it revokes its proxy before the special meeting. A stockholder also may change its vote by submitting a later-dated proxy as described in the section entitled &#8220;<span style="font-style:italic">The Special Meeting of BLAC Stockholders &#8212; Revoking Your Proxy</span>.&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation to Stockholders of BLAC </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes that the Business Combination Proposal and the other proposals to be presented at the special meeting are in the best interest of BLAC and its stockholders and unanimously recommends that its stockholders vote &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Charter Proposal, &#8220;FOR&#8221; the Advisory Governance Proposals, &#8220;FOR&#8221; the Incentive Plan Proposal, &#8220;FOR&#8221; the Director Election Proposal and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of one or more of BLAC&#8217;s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of BLAC and its stockholders and what he or they may believe is best for himself or themselves in determining to recommend that stockholders vote for the proposals. In addition, BLAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; for a further discussion of these considerations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Expected Accounting Treatment </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Th</span></span>e<span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;B</span></span>u<span style="font-weight:bold"><span style="font-style:italic">sin</span></span>e<span style="font-weight:bold"><span style="font-style:italic">s</span></span>s<span style="font-weight:bold"><span style="font-style:italic">&#160;Combi</span></span>n<span style="font-weight:bold"><span style="font-style:italic">ation</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP and the Accounting Standard Codification (ASC) which is the current single source of U.S. GAAP. Under this method of accounting, BLAC will be treated as the &#8220;acquired&#8221; company and OSR Holdings will be considered the accounting acquirer for accounting purposes as set forth by the guidance in ASC 805-10. This conclusion is supported by the voting interest model referenced in ASC 805-10-55-12 as 67.7% (no redemption), 70.8% (50% redemption) and 74.2% (maximum redemption) of the voting interest scenarios in New OSR Holdings which will be held by the historical shareholder group of OSR Holdings. Further, Bellevue Capital Management LLC (&#8220;BCM&#8221;) and its affiliates are the largest single owner of shares of OSR Holdings, and will also be the largest single owner of shares in the combined company in each of the no redemption, 50% redemption, and maximum redemption scenarios. The stockholders of OSR Holdings will have sufficient voting power to elect or remove a majority of the board of directors of the combined company. The compositions of the governing body and senior management team of the combined entity present a less defined indicator as Kuk Hyoun Hwang is an officer and director of both OSR Holdings and BLAC. No other officers of BLAC will be officers of the combined company. The composition of New OSR Holdings is being negotiated by Kuk Hyoun Hwang who represents both BLAC and OSR Holdings so that it is difficult to conclude that one party controls the appointment of the directors of the combined company. Accordingly, given the supermajority of voting shares to be held by OSR Holdings stockholders in the combined company and the other factors described above, for accounting purposes, the Business Combination will be treated as the equivalent of a capital transaction in which BLAC is issuing securities for the net assets of OSR Holdings. Operations prior to the Business Combination will be those of OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described immediately below, neither of BLAC and OSR Holdings is aware of any material regulatory approvals or actions that are required for completion of the Business Combination. It is presently contemplated that if any regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because BLAC&#8217;s Sponsor is controlled by and has substantial ties with non-U.S. persons, and will own approximately 6.7% of the issued and outstanding BLAC Common Stock following the Business Combination (assuming that all of BLAC&#8217;s public stockholders exercise redemption rights), we may be considered a &#8220;foreign person&#8221; under rules promulgated by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and the Business Combination may fall within the scope of a &#8220;covered transaction&#8221; subject to CFIUS review. See </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;Risk Factors &#8212;&#160;<span style="font-style:italic">We may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and ultimately prohibited.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a detailed discussion of certain U.S. federal income tax consequences of the Business Combination, see the sections titled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Consequences</span>&#8221; in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a number of risks of which you should be aware before making an investment decision. You should read this summary together with the description of each risk factor contained in the &#8220;<span style="font-style:italic">Risk</span> <span style="font-style:italic">Factors</span>&#8221; section of this proxy statement/prospectus, as well as other documents to be filed by BLAC from time to time with the SEC, for a more detailed discussion of certain risks that could materially adversely affect our financial conditions and the market price of our securities. The following list describes some of the principal risk factors applicable to the Business Combination, BLAC, OSR Holdings and New OSR Holdings: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Business Combination and Business Combination Agreement </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Business Combination is not approved or if for any reason the Business Combination does not close within the time frame approved by a majority of our stockholders, BLAC would cease all operations except for the purpose of winding up and BLAC would redeem its public shares and liquidate, in which case BLAC&#8217;s public stockholders may only receive $[&#9679;] per share, or less than such amount in certain circumstances, and BLAC&#8217;s warrants and rights will expire worthless. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Adjournment Proposal is not approved and either an insufficient number of votes have been obtained to approve the Condition Precedent Proposals, the requirement for BLAC to have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or the Minimum Available Cash Condition has not been met, the BLAC Board may not have the ability to adjourn the BLAC Stockholders&#8217; Meeting to a later date and, therefore, the necessary approvals may not be obtained, and, therefore, the Business Combination may not be consummated. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor and BLAC&#8217;s directors and officers have interests that are different from or that conflict with the interests of BLAC&#8217;s stockholders and that may have influenced their analysis of whether the Business Combination with OSR Holdings is appropriate as BLAC&#8217;s initial business combination. Such interests include that the Sponsor will lose its entire investment in BLAC if the Business Combination is not completed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Following the consummation of the Business Combination, BLAC&#8217;s only significant asset will be its ownership of OSR Holdings, and such ownership may not be sufficient to pay its expenses or satisfy other financial obligations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The level of due diligence conducted in connection with the Business Combination may not be as high as would be the case if OSR Holdings were to raise capital through an underwritten public offering, which could result in defects with OSR Holdings&#8217; business or problems with OSR Holdings&#8217; management to be overlooked. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC may not have sufficient funds to consummate the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC does not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for BLAC to complete the Business Combination with which a substantial majority of its investors do not agree. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If, before distributing the proceeds in the Trust Account to the public stockholders, BLAC files a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against BLAC that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of BLAC investors and the per-share amount that would otherwise be received by BLAC investors in connection with BLAC&#8217;s liquidation may be reduced. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to New OSR Holdings Securities </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The price of New OSR Holdings Common Stock and warrants may be volatile. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An active, liquid trading market for New OSR Holdings Common Stock and warrants may not develop, which may limit your ability to sell New OSR Holdings Common Stock and warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC stockholders who do not redeem their shares of Common Stock of BLAC will experience immediate and material dilution upon closing of the Business Combination. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to OSR Holdings Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings&#8217; limited operating history, the early stage of its development programs and the inherent uncertainties and risks involved in pharmaceutical product development may make it difficult for it to execute on its business model. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to New OSR Holdings&#8217; Strategy to Grow the Business </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be successful in our efforts to acquire, <span style="white-space:nowrap">in-license</span> or discover and develop new product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently have no marketing and sales organization for pharmaceutical products and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our pharmaceutical products, we may not be able to generate pharmaceutical product revenue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to New OSR Holdings&#8217; Requirements for Additional Capital </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts and/or other operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risk Related to New OSR Holdings&#8217; Management of the Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance with its public company responsibilities and corporate governance practices. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; management team has limited experience managing and operating a U.S. public company. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to International Operations of New OSR Holdings&#8217; Business </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If economic conditions in South Korea deteriorate, our current business and future growth could be materially and adversely affected. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Development of New OSR Holdings&#8217; Product Candidates </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business includes subsidiaries that are developing oral immunotherapies for the treatment of cancer and design-augmented biologics. These companies have a limited operating history, and their programs are in early stages of development. This may make it difficult to evaluate our prospects and likelihood of success. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to New OSR Holdings&#8217; Reliance on Third Parties </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently outsource, and intend to continue to outsource, much of our discovery, clinical development, and manufacturing functions to third-party providers or consultants. Outsourcing these functions has significant risks, and our failure to manage these risks successfully could materially adversely affect our business, results of operations, and financial condition. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to New OSR Holdings&#8217; Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_7">SELECTED HISTORICAL FINANCIAL DATA OF BLAC </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information presented below is derived from BLAC&#8217;s audited financial statements included elsewhere in this proxy statement/prospectus as of and for the years ended December&#160;31, 2023 and 2022 (the &#8220;<span style="text-decoration:underline">Financial Statements</span>&#8221;). The information presented below should be read alongside BLAC&#8217;s Financial Statements and accompanying footnotes included elsewhere in this proxy statement/prospectus. You should read the following financial data together with &#8220;<span style="font-style:italic">Information About BLAC</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of BLAC</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights key measures of BLAC&#8217;s financial condition and results of operations. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For&#160;the&#160;Year&#160;Ended<br/>December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For&#160;the&#160;Year&#160;Ended<br/>December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">EXPENSES</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,830,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,830,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other income:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in the Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,775,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,775,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">944,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(540,811</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">NET INCOME (LOSS)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">WEIGHTED AVERAGE SHARES OUTSTANDING</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,688,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,719,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">NET INCOME (LOSS) PER SHARE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_8">SELECTED HISTORICAL FINANCIAL DATA OF OSR HOLDINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information presented below is derived from OSR Holdings&#8217; unaudited consolidated financial statements and audited consolidated financial statements included elsewhere in this proxy statement/prospectus as of and for the year ended December&#160;31, 2023 and 2022 (the &#8220;Consolidated Financial Statements&#8221;). The information presented below should be read alongside OSR Holdings&#8217; Consolidated Financial Statements and accompanying footnotes included elsewhere in this proxy statement/prospectus. You should read the following financial data together with &#8220;<span style="font-style:italic">Business of OSR Holdings and Certain Information About OSR Holdings</span>&#8221; and &#8220;<span style="font-style:italic">OSR Holdings Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights key measures of OSR Holdings&#8217; financial condition and results of operations (in Thousand Korean Won): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Years Ended<br/>December&#160;31</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,453,551</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,930,194</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,742,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-operating</span> income (loss):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,308,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(489,682</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,964</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(685,462</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(183,077</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(989,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,129,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,732,365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,130,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,601,661</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,601,661</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other comprehensive income (loss) for the year:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation gain (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total other comprehensive income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,432,720</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,432,720</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Earnings (loss) per share attributable to the equity holders of the parent:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per ordinary share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(8</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_9">SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected unaudited pro&#160;forma condensed combined financial information (the &#8220;<span style="text-decoration:underline">Selected Pro Forma Information</span>&#8221;) gives effect to the Transactions and the other events described in the section entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information.</span>&#8221; The Transactions are expected to be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, BLAC is expected to be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, OSR Holdings will be deemed to be the accounting acquirer in the transaction and, consequently, the transaction is treated as a recapitalization of OSR Holdings. Accordingly, the assets and liabilities and the historical operations that are reflected in the financial statements are those of OSR Holdings and are recorded at the historical cost basis of OSR Holdings. BLAC&#8217;s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of OSR Holdings after consummation of the acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selected Pro Forma Information for the year ended December&#160;31, 2023 give effect to the Transactions and the other events as if consummated on January&#160;1, 2023, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selected Pro Forma Information has been derived from, and should be read in conjunction with, the more detailed unaudited pro&#160;forma condensed combined financial information prepared in accordance with Article&#160;11 of <span style="white-space:nowrap">Regulation&#160;S-X</span> of BLAC appearing elsewhere in this proxy statement/prospectus and the accompanying notes in the section entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>.&#8221; The unaudited pro&#160;forma condensed combined financial information is derived from, and should be read in conjunction with, the historical financial statements and accompanying notes of OSR Holdings and BLAC for the applicable periods included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selected Pro Forma Information is not necessarily indicative of what the New OSR Holdings&#8217; balance sheet or statement of operations actually would have been had the Business Combination and the related proposed financing transactions been completed as of the dates indicated, nor do they purport to project the future financial position or operating results of New OSR Holdings. The unaudited pro&#160;forma condensed combined financial information is presented for illustrative purposes only and does not reflect the costs of any integration activities or cost savings or synergies that may be achieved as a result of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments reflecting the consummation of the Business Combination and related proposed financing transactions are based on certain currently available information and certain assumptions and methodologies that BLAC believes are reasonable under the circumstances. The transaction accounting adjustments, which are described in the notes in the section entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221;, may be revised as additional information becomes available. Therefore, it is likely that the actual adjustments will differ from the transaction accounting adjustments, and it is possible that the difference may be material. BLAC believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Business Combination and the related proposed financing transactions based on information available to management at this time. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Year Ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;50%<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming Maximum<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US&#160;Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-operating</span> income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in the Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other comprehensive income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total other comprehensive income (loss)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income (loss) for year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Earning (loss) per share attributable to the equity holders of the Parent:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earning (loss) per ordinary share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_10">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements in this proxy statement/prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding BLAC, OSR Holdings or BLAC&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this proxy statement/prospectus may include, for example, statements about: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC&#8217;s ability to consummate the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the benefits of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; financial performance following the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain or maintain the listing of the New OSR Holdings&#8217; securities on Nasdaq, following the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; strategy, future operations, financial position, revenues, projected costs, prospects and plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; ability to successfully and efficiently integrate future expansion plans and opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; ability to grow its business in a cost-effective manner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the implementation, market acceptance and success of New OSR Holdings&#8217; business model; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments and projections relating to New OSR Holdings&#8217; competitors and industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New OSR Holdings&#8217; expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of <span style="white-space:nowrap">COVID-19</span> type pandemics on New OSR Holdings&#8217; business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in applicable laws or regulations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any known and unknown litigation and regulatory proceedings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this proxy statement/prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing BLAC&#8217;s views as of any subsequent date, and BLAC does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on these forward-looking statements in deciding how to vote your proxy or instruct how your vote should be cast on the proposals set forth in this proxy statement/prospectus. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ include the risks and uncertainties described in this proxy statement/prospectus, including those described under the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_11">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In addition to the other information contained in (or incorporated by reference into) this proxy statement/prospectus, including the matters addressed under the heading &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; you should carefully consider the following risk factors in deciding how to vote on the proposals presented in this proxy statement/prospectus. If the Business Combination is completed, New OSR Holdings will operate in a market environment that is difficult to predict and that involves significant risks, many of which will be beyond its control. You should carefully consider the risks described below before voting your shares. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on New OSR Holdings&#8217; business, reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of New OSR Holdings securities could decline, and you could lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this proxy statement/prospectus to OSR Holdings&#8217; business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, the business, reputation, financial condition, results of operations, revenue and future prospects of New OSR Holdings. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Business Combination and Business Combination Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">If the Business Combination is not approved or if for any reason the Business Combination does not close within the time frame approved by a majority of our stockholders, BLAC would cease all operations except for the purpose of winding up and BLAC would redeem its public shares and liquidate, in which case BLAC&#8217;s public stockholders may only receive $</span></span>[&#9679;]<span style="font-weight:bold"><span style="font-style:italic"> per share, or less than such amount in certain circumstances, and BLAC&#8217;s warrants and rights will expire worthless.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has received approval from our stockholders to extend the time period for completing the Business Combination to November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents). If BLAC has not completed our initial business combination by that date, it will: (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&#160;as promptly as reasonably possible following such redemption dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In such case, our public stockholders may only receive $[&#9679;] per share, and our warrants and rights will expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s Initial Stockholders have agreed to vote their shares in favor of the Business Combination, regardless of how BLAC&#8217;s Public Stockholders vote. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Proposal must be approved by a majority of the issued and outstanding shares of Common Stock present and entitled to vote at the meeting. In connection with the Business Combination, the holders of BLAC&#8217;s Common Stock issued prior to the IPO and in the private placement including the Sponsor, and those who received BLAC Common Stock and BLAC Warrants from the Sponsor, including Mr. Yoo, BLAC&#8217;s Chief Financial Officer, Mr. Jin Whan Park, a current director of BLAC, and Dr. Steven Reed, Dr. In Chul Chung, Dr. Radclyffe Roberts, and Mr. Hosun Euh, former directors of BLAC, have agreed to vote those shares in favor of the Business Combination. Those shares of Common Stock referred to in the prior sentence constitute, collectively, approximately 53.3% of the issued and outstanding shares of common stock of BLAC as of&#160;[&#9679;], 2024. Accordingly, BLAC will not need the affirmative vote of any shares of common stock held by public stockholders (assuming only a quorum is present at the BLAC Stockholders&#8217; Meeting) to approve the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination. Each of Dr. Reed, Dr. Roberts, Dr. Chung, Mr. Hun, Mr. Parn and Mr. Yoo obtained their shares in exchange for their services provided as executive officers or directors of BLAC and were not provided with any other consideration for their agreement to vote their shares in favor of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Adjournment Proposal is not approved and either an insufficient number of votes have been obtained to approve the Condition Precedent Proposals, the requirement for BLAC to have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or the Minimum Available Cash Condition has not been met, the BLAC Board may not have the ability to adjourn the BLAC Stockholders&#8217; Meeting to a later date and, therefore, the necessary approvals may not be obtained, and, therefore, the Business Combination may not be consummated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal, if adopted by BLAC stockholders, will allow the BLAC Board to adjourn the BLAC Stockholders&#8217; Meeting to a later date or dates to permit further solicitation of proxies with respect to the Condition Precedent Proposals, or if BLAC will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination or the Minimum Available Cash Condition has not been met. If the Adjournment Proposal is not approved by the BLAC stockholders, the BLAC Board may not be able to adjourn the BLAC Stockholders&#8217; Meeting to a later date in the event that, based on the tabulated votes, there are not sufficient votes at the time of the applicable meeting to approve one or more of the proposals presented at such meeting, or if BLAC will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination or the Minimum Available Cash Condition has not been met. In such event, BLAC may not be able to obtain the requisite shareholder approvals, and the Business Combination may not be consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s Chief Executive Officer and one of our directors is Chief Executive Officer and Chairman of the Board of OSR Holdings. These dual positions (1)&#160;create conflicts of interest in the performance of his duties; and (2)&#160;may provide for him to receive compensation following the Business Combination that amplifies his conflicts of interest in determining whether the business combination is the most advantageous. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s Chief Executive Officer and one of its directors, Mr. Hwang, is Chief Executive Officer and Chairman of the Board of OSR Holdings<span style="font-weight:bold">, </span>BLAC&#8217;s target company for the Business Combination. Such dual positions may cause him to have conflicts of interest in performing his duties to both companies, since BLAC and OSR Holdings are directly adverse in the negotiations of the Business Combination Agreement. Further, Mr.&#160;Hwang is expected to remain with New OSR Holdings after the completion of the Business Combination and receive future compensation in the form of cash payments and/or New OSR Holdings securities for services he would render to New OSR Holdings after the completion of the Business Combination. The personal and financial interests of Mr.&#160;Hwang may influence his motivation in negotiating the Business Combination. Despite the approval of the terms of the Business Combination Agreement by a majority of our independent directors (<span style="font-style:italic">i.e.</span>, the BLAC M&amp;A Committee), potential conflicts of interest still may exist and, as a result, the terms of the Business Combination may not be as advantageous to our public stockholders as they would be absent any conflicts of interest. Mr. Hwang is expected to beneficially own 13,014,123 shares of the post-combination company and control 60%, 63%, and 66% for the no redemption scenario, 50% redemption scenario, and maximum redemption scenario, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Sponsor and BLAC&#8217;s directors and officers have interests that are different&#160;from or that conflict with&#160;the interests of BLAC&#8217;s stockholders&#160;and that may have influenced their analysis of&#160;whether the Business Combination with OSR Holdings is appropriate as BLAC&#8217;s initial business combination. Such interests include that the Sponsor will lose its entire investment in BLAC if the Business Combination is not completed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of BLAC&#8217;s Board in favor of approval of the Business Combination, you should keep in mind that BLAC&#8217;s directors and officers have interests in the Business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination that are different from, or in addition to, your interests as a stockholder. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve a proposed initial business combination (the Sponsor was not granted any consideration or incentive to agree not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve the Business Combination); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor paid an aggregate of $25,000 (or $0.014 per share) for 1,725,000 shares of BLAC Common Stock, which will have a significantly higher value at the time of the Business Combination. If unrestricted and freely tradable, such shares would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement and an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the Record Date, but given the restrictions on those shares, we believe those shares have less value; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor purchased 430,000 private placement units (including the underlying securities) for an aggregate purchase price of $4,300,000 (or $10.00 per unit) in which the warrants and rights included in the private placement units would be worthless if a business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents). Such private placement units had an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;] per public unit on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement/prospectus and an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;] per public unit on Nasdaq on [&#9679;], 2024, the Record Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed to waive its rights to liquidating distributions from the trust account with respect to any shares of BLAC Common Stock (other than public shares) held by it if BLAC fails to complete an initial business combination by November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Mr. Hwang, Mr. Whang and affiliates of the Sponsor have a financial interest in OSR Holdings. Mr. Hwang is the CEO and a Director of BLAC and CEO and Chairman of the Board of OSR Holdings and Mr. Whang is a director of BLAC. As such, Mr. Hwang, Mr. Whang and affiliates of the Sponsor who have a financial interest in OSR Holdings are incentivized to complete the Business Combination with OSR Holdings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor transferred 20,000 shares to each of Drs. Chung, Reed and Roberts and Mr.&#160;Park, which are current and former BLAC directors for their board service, and Mr. Yoo for his service as chief financial officer. The Sponsor additionally transferred 20,000 Private Placement Warrants to each of Dr. Reed for his service as the former chairman of the board of directors, Dr.&#160;Chung for his service as the former chair of the audit committee, and Mr. Yoo for his service as chief financial officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors will lose their entire investment in BLAC and will not be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses, if any, if an initial business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents) and, as a result, the Sponsor and BLAC&#8217;s officers and directors may have a conflict of interest in determining whether OSR Holdings is an appropriate business with which to effectuate a business combination and/or in evaluating the terms of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor has invested an aggregate of $4,325,000 (consisting of $25,000 for the founder shares, or approximately $0.014 per share, and $4,300,000 for the private placement units, or $10.00 per unit, means that the Sponsor and our officers and directors stand to make a significant profit on their investment and could potentially recoup their entire investment in BLAC even if the trading price </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of BLAC Common Stock was as low as approximately $2.00&#160;per share (assuming no redemptions and even if the private placement warrants and rights are worthless) and therefore our Sponsor, officers and directors may experience a positive rate of return on their investment, even if BLAC&#8217;s public stockholders experience a negative rate of return on their investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors (or their affiliates) may make Working Capital Loans from time to time to BLAC to fund certain capital requirements (&#8220;Working Capital Loans&#8221;). Sponsor, BLAC&#8217;s officers, and its and their affiliates, have previously loaned money to BLAC (or to the sponsor for BLAC&#8217;s benefit) in an aggregate amount of $3,905,000 to fund operating and transaction expenses in connection with the proposed Business Combination, $3,525,000 of which remains outstanding as of the date of this proxy statement/prospectus (none of which contain conversion rights), and may make additional loans after the date of this proxy statement/prospectus for such purposes. If the Business Combination is not consummated or another business combination is not otherwise completed, the loans may not be repaid and would be forgiven except to the extent there are funds available to BLAC outside of the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, although no compensation of any kind was or will be paid by BLAC to the Sponsor, BLAC&#8217;s executive officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of an initial business combination, these individuals may be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on BLAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. As of the date of this proxy statement/prospectus, there are no outstanding <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses for which the Sponsor or BLAC&#8217;s officers or directors are awaiting reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that if the trust account is liquidated, including in the event BLAC is unable to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), the Sponsor has agreed to indemnify BLAC to ensure that the proceeds in the trust account are not reduced below $10.175&#160;per public share, or such lesser per public share amount as is in the trust account on the liquidation date, by the claims of prospective target businesses with which BLAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to BLAC, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the trust account; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that BLAC may be entitled to distribute or pay over funds held by BLAC outside the trust account to the Sponsor or any of its affiliates prior to the Closing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The personal and financial interests of the Sponsor as well as BLAC&#8217;s directors and officers may have influenced their motivation in identifying and selecting OSR Holdings as a business combination target, completing an initial business combination with OSR Holdings and may influence the operation of the business following the initial business combination. In considering the recommendations of BLAC&#8217;s board of directors to vote for the proposals, its stockholders should consider these interests. For additional information on the interests and relationships of the Sponsor, Initial Stockholders, directors and officers in the Business Combination. See &#8220;<span style="font-style:italic">The Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Interests of BLAC&#8217;s Directors and Officers in the Business Combination.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s Current Charter contains a waiver of the corporate opportunities doctrine for our directors and officers, and therefore such persons have no obligations to make opportunities available to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article X of the Current Charter provides that the doctrine of corporate opportunity, or any other analogous doctrine, shall not apply with respect to BLAC or any of its officers or directors in circumstances where the application of any such doctrine would conflict with any fiduciary duties or contractual obligations they may have as of the date of the Current Charter or in the future. BLAC renounces any expectancy that any of the directors or officers of BLAC will offer any such corporate opportunity of which he may become aware to BLAC, except, the doctrine of corporate opportunity shall apply with respect to any of the directors or officers of BLAC with respect to a corporate opportunity that was offered to such person solely in his or her capacity as a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
director or officer of BLAC and such opportunity is one BLAC is legally and contractually permitted to undertake and would otherwise be reasonable for BLAC to pursue. There could have been business combination targets that have been appropriate for a business combination with BLAC but were not offered due to a BLAC director&#8217;s or officer&#8217;s duties to another entity. BLAC and its management are not aware of any such corporate opportunities not being offered to BLAC and do not believe that the waiver of the corporate opportunity doctrine in the Current Charter interfered with BLAC&#8217;s ability to identify an acquisition target, including the decision to pursue the Business Combination with OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s directors&#160;and officers will have&#160;discretion&#160;on whether to agree&#160;to changes in the terms of, or waivers of closing conditions to, the Business Combination&#160;and their interests in exercising that discretion&#160;may conflict&#160;with those&#160;of BLAC&#8217;s stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the period leading up to the consummation of the Business Combination, events may occur that, pursuant to the Business Combination Agreement, would require BLAC to agree to amend the Business Combination Agreement, to consent to certain actions taken by OSR Holdings or to waive rights that BLAC is entitled to under the Business Combination Agreement, including rights or closing conditions favorable to BLAC and its stockholders. Such events could arise because of changes in the course of OSR Holdings&#8217; business, a request by OSR Holdings to undertake actions that would otherwise be prohibited by the terms of the Business Combination Agreement or the occurrence of other events that would have a material adverse effect on OSR Holdings&#8217; business and would entitle BLAC to terminate the Business Combination Agreement. In any of such circumstances, it would be at BLAC&#8217;s discretion, acting through its board of directors, to grant its consent or waive those rights or closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the financial and personal interests of the directors of BLAC described in the preceding risk factors may result in a conflict of interest on the part of one or more of the directors between what such director may believe is best for BLAC and what such director may believe is best for himself or herself in determining whether or not to take the requested action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that BLAC, OSR Holdings and the other parties to the Business Combination Agreement authorize an amendment to the Business Combination Agreement, or waive any closing condition to the Business Combination, that does not require further approval by the BLAC stockholders, BLAC will inform such stockholders of the amendment or waiver by press release or other public communication. In the event that BLAC, OSR Holdings and the other parties to the Business Combination Agreement authorize an amendment to the Business Combination Agreement, or waive any closing condition to the Business Combination, that is material and otherwise requires further approval by the BLAC stockholders, a proxy supplement or an amended proxy statement/prospectus would be delivered to such stockholders and proxies would be <span style="white-space:nowrap">re-solicited&#160;for</span> approval of such amendment or such waiver of a closing condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The parties to the Business Combination Agreement may waive one or more of the closing conditions to the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties to the Business Combination Agreement may agree to waive, in whole or in part, some of the closing conditions to its or their obligations to complete the Business Combination to the extent permitted by applicable laws, and, in the case of BLAC, to the extent permitted by its existing charter. The waiver of closing conditions in favor of BLAC and its stockholders could adversely affect BLAC, its stockholders, and the post-combination company. See the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement&#8212;Conditions to Closing the Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to consummate a business combination, any loans made by Sponsor or its affiliates or directors may not be repaid, resulting in a potential conflict of interest in determining whether a potential transaction is in our stockholders&#8217; best interest. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to meet our working capital needs, the Sponsor and its affiliates have loaned us funds, in the amount of $75,000 on February 9, 2024, $60,000 on March&#160;8, 2024, $1,200,000 on April 8, 2024, $50,000 on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
April&#160;17, 2024 and $140,000 on May&#160;14, 2024. The loans are <span style="white-space:nowrap">non-interest</span> bearing and are payable in full on the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which we consummate an initial business combination. If we fail to consummate a business combination within the required time period, the loans may not be repaid. Consequently, Sponsor and its affiliates have a conflict of interest in determining whether the terms, conditions and timing of the business combination with OSR Holdings are appropriate and in our stockholders&#8217; best interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The unaudited pro forma condensed combined financial information included in this proxy statement/prospectus may not be indicative of what New OSR Holdings&#8217; actual financial position or results of operations would have been. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information in this proxy statement/prospectus is presented for illustrative purposes only and is not necessarily indicative of what New OSR Holdings&#8217; actual financial position or results of operations would have been had the Business Combination been completed on the dates indicated. The unaudited pro forma financial information does not reflect future events that may occur after the Business Combination and does not consider potential impacts of future market conditions on revenues or expenses. The pro forma financial information included in the section titled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed</span> <span style="font-style:italic">Combined Financial Information</span>&#8221; has been derived from BLAC&#8217;s and OSR Holdings&#8217; historical financial statements and certain adjustments and assumptions have been made regarding New OSR Holdings after giving effect to the Business Combination. There may be differences between preliminary estimates in the pro forma financial information and the final acquisition accounting, which could result in material differences from the pro forma information presented in this proxy statement/prospectus in respect of the estimated financial position and results of operations of New OSR Holdings. See the section titled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial</span><span style="font-style:italic">&#160;Information</span>&#8221; for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the assumptions used in preparing the pro forma financial information may not prove to be accurate and other factors may affect New OSR Holdings&#8217; financial condition or results of operations following the Business Combination. Any potential decline in New OSR Holdings&#8217; financial condition or results of operations may cause significant variations in the stock price of New OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If BLAC is unable to complete the Business Combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), it may further extend the time period that it needs to complete the Business Combination provided that BLAC had sought and obtained an approval from its stockholders for such&#160;extension&#160;by amending its Amended and Restated Certificate of Incorporation and provided public stockholders with the opportunity to&#160;redeem&#160;their BLAC Common Stock in connection with such&#160;extension. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, in the event that this proxy statement/prospectus has not been disseminated to BLAC stockholders prior to November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), BLAC is required to seek approval of BLAC&#8217;s stockholders to extend the period of time to complete the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;9, 2023, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which BLAC must complete its initial business combination to February&#160;14, 2024 (from November&#160;14, 2023) and with an option for the board of directors of BLAC, in its discretion, to extend again to May&#160;14, 2024. In February 2024, the board of directors of BLAC decided to extend the period of time in which BLAC must complete its initial business combination to May 14, 2024. In connection with the special meeting, holders of 3,432,046 shares of BLAC Common Stock elected to redeem such shares, representing approximately 50% of the outstanding public shares of BLAC Common Stock as of November&#160;7, 2023, for a per share redemption price of approximately $10.49, resulting in an aggregate reduction of the amount in the Trust Account by $35,995,727.58, representing approximately 50% of the total amount in the Trust Account as of November&#160;7, 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 14, 2024, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which BLAC must complete its initial business combination to November&#160;14, 2024 (from May&#160;14, 2024). In connection with the special meeting, holders of 1,581,733 shares of BLAC Common Stock elected to redeem such shares, representing approximately 46% of the outstanding public shares of BLAC Common Stock as of May&#160;8, 2024, for a per share redemption price of approximately $10.78, resulting in an aggregate reduction of the amount in the Trust Account by $17,045,763.24, representing approximately 45% of the total amount in the Trust Account. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC cannot guarantee that it will be able to complete the Business Combination within the time period given by its Amended and Restated Certificate of Incorporation, or the amount of redemptions that may occur in connection with an amendment to its Amended and Restated Certificate of Incorporation to further extend the date by which BLAC must complete its initial business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Following the consummation of the Business Combination, BLAC&#8217;s only significant asset will be its ownership of OSR Holdings, and such ownership may not be sufficient to pay its expenses or satisfy other financial obligations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, BLAC will be a holding company and will not directly own any operating assets other than its ownership of interests in OSR Holdings.&#160;BLAC will depend on OSR Holdings for distributions, loans and other payments to generate the funds necessary to meet its financial obligations, including its expenses as a publicly traded company. The earnings from, or other available assets of, OSR Holdings may not be sufficient to pay expenses or satisfy BLAC&#8217;s other financial obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The level of due diligence conducted in connection with the Business Combination may not be as high as would be the case if OSR Holdings were to raise capital through an underwritten public offering, which could result in defects with OSR Holdings&#8217; business or problems with OSR Holdings&#8217; management to be overlooked. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If OSR Holdings were to raise capital through an underwritten public offering, the underwriters would be subject to liability under Section&#160;11 of the Securities Act for material misstatements and omissions in the initial public offering registration statement. In general, an underwriter is able to avoid liability under Section&#160;11 if it can prove that, it &#8220;had, after reasonable investigation, reasonable ground to believe and did believe, at the time the registration statement became effective, that the statements therein were true and that there was no omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading.&#8221; As no such review will be conducted by an independent third-party&#160;underwriter in connection with the Business Combination, BLAC Stockholders must rely on the information in this proxy statement/prospectus and will not have the benefit of an independent review and investigation of the type normally performed by an independent underwriter in a public securities offering. In addition, the amount of due diligence conducted by BLAC and its advisors in connection with the Business Combination may not be as high as would have been undertaken by an underwriter in connection with an initial public offering of OSR Holdings. Accordingly, it is possible that defects in OSR Holdings&#8217; business or problems with OSR Holdings&#8217; management that would have been discovered if OSR Holdings conducted an underwritten public offering will not be discovered in connection with the Business Combination, which could adversely affect the market price of New OSR Holdings Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if BLAC conducts thorough due diligence on OSR Holdings&#8217; business, this diligence may not surface all material issues that may be present inside its business. And, regardless of how comprehensive BLAC&#8217;s diligence may be, factors outside of the target business and outside of BLAC&#8217;s control may arise later. As a result of these factors, New OSR Holdings may be forced to later write-down or write-off assets, restructure its operations, or incur impairment or other charges that could result in New OSR Holdings reporting losses. Even if BLAC&#8217;s due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with BLAC&#8217;s preliminary risk analysis. Even though these charges may be non-cash items and not have an immediate impact on New OSR Holdings&#8217; liquidity, the fact that New OSR Holdings reports charges of this nature could contribute to negative market perceptions about New </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OSR Holdings or New OSR Holdings&#8217; securities. In addition, charges of this nature may cause New OSR Holdings to violate net worth or other covenants to which New OSR Holdings may be subject to by virtue of New OSR Holdings obtaining post-combination debt financing. Accordingly, any BLAC stockholders who choose to remain stockholders of New OSR Holdings following the Business Combination could suffer a reduction in the value of their shares of common stock from any such write-down or write-downs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC may not have sufficient funds to consummate the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&#160;March 31, 2024, BLAC had approximately $3,637&#160;available to it outside the Trust Account to fund its working capital requirements. If BLAC is required to seek additional capital, it would need to borrow funds from the Sponsor, its management team or other third parties to operate or it may be forced to liquidate. None of such persons is under any obligation to advance funds to BLAC in such circumstances. Any such advances would be repaid only from funds held outside the Trust Account or from funds released to BLAC upon completion of the Business Combination. BLAC does not currently expect that the amount of working capital held outside the Trust Account will be sufficient to repay all or any portion of such loaned amounts in the event the Business Combination or another business combination is not consummated. If BLAC is unable to consummate the Business Combination because it does not have sufficient funds available, BLAC will be forced to cease operations and liquidate the Trust Account. Consequently, holders of shares of BLAC Common Stock may receive less than $10.175 per share and their warrants will expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the conditions to the Business Combination Agreement are not met, the Business Combination may not occur. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The completion of the Business Combination is subject to a number of conditions. The completion of the Business Combination is not assured and is subject to risks, including the risks that approval of the Business Combination by holders of BLAC Common Stock. Even if the Business Combination Agreement is approved by the stockholders of BLAC, specified conditions must be satisfied or waived before the parties to the Business Combination Agreement are obligated to complete the Business Combination. For a list of the material closing conditions contained in the Business Combination Agreement, see the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement&#8212;Conditions to Closing the Business Combination</span>.&#8221; BLAC and OSR Holdings may not satisfy all of the closing conditions in the Business Combination Agreement. If the closing conditions are not satisfied or waived, the Business Combination will not occur, or will be delayed pending later satisfaction or waiver, and such delay may cause OSR Holdings and BLAC to each lose some or all of the intended benefits of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC may waive one or more of the conditions to the Business Combination without resoliciting stockholder approval for the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC may agree to waive, in whole or in part, some of the conditions to its obligations to complete the Business Combination, to the extent permitted by applicable laws. The BLAC Board will evaluate the materiality of any waiver to determine whether amendment of this proxy statement/prospectus and resolicitation of proxies is warranted. In some instances, if the BLAC Board determines that a waiver is not sufficiently material to warrant resolicitation of stockholders, BLAC has the discretion to complete the Business Combination without seeking further stockholder approval. For example, it is a condition to BLAC&#8217;s obligations to close the Business Combination that there be no applicable law and no injunction or other order restraining or imposing any condition on the consummation of the Business Combination; however, if the BLAC Board determines that any such order or injunction is not material to the business of OSR Holdings, then the BLAC Board may elect to waive that condition without stockholder approval and close the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s principal stockholders and management own a significant percentage of our Common Stock and are able to exert significant control over matters subject to stockholder approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, directors and their affiliates and our principal stockholders beneficially hold, in the aggregate, approximately 53.3% of BLAC&#8217;s outstanding voting stock. These stockholders, acting together, would </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that stockholders may feel are in their best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC and OSR Holdings will incur significant transaction costs in connection with transactions contemplated by the Business Combination Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC and OSR Holdings will incur significant transaction costs in connection with the Business Combination. If the Business Combination is not consummated, BLAC may not have sufficient funds to seek an alternative business combination and may be forced to liquidate and dissolve. OSR Holdings may also incur additional costs to retain key employees. All expenses incurred in connection with the Business Combination Agreement and the transactions contemplated thereby, including all legal, accounting, consulting, and other fees, expenses and costs, will be for the account of the party incurring such fees, expenses and costs, provided that if the Closing occurs, New OSR Holdings will bear and pay at or promptly after Closing all transaction expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate transaction expenses for BLAC and OSR Holdings as a result of the Business Combination are expected to be approximately $6,000,000. The&#160;per-share&#160;amount distributed to BLAC Stockholders who properly exercise their redemption rights will not be reduced by the transaction expenses and after such redemptions, the&#160;per-share&#160;value of shares held by&#160;non-redeeming&#160;BLAC Stockholders will reflect New OSR Holdings&#8217; obligation to pay the transaction expenses. The aggregate transaction expenses on a per share basis are approximately $0.28, $0.29, and $0.30 under the 0% redemption, 50% redemption, and 100% redemption scenarios, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Business Combination may be completed even though material adverse effects may result from the announcement of the Business Combination, industry-wide changes and other causes. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, either BLAC or OSR Holdings may refuse to complete the Business Combination if there is a material adverse effect affecting the other party between November 16, 2023 (the date of the initial Business Combination Agreement), and the planned closing. However, certain types of changes do not permit either party to refuse to consummate the Business Combination, even if such change could be said to have a material adverse effect on OSR Holdings or BLAC, including, but not limited to the following events (except, in certain cases where the change has a disproportionate effect on a party): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any change or proposed change in or change in the interpretation of any applicable laws or GAAP; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">events or conditions generally affecting the industries or geographic areas in which the parties operate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any downturn in general economic conditions, including changes in the credit, debt, securities, financial or capital markets (including changes in interest or exchange rates, prices of any security or market index or commodity or any disruption of such markets); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks (including <span style="white-space:nowrap">COVID-19)</span> or any escalation or worsening of any such acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks, or changes in global, national, regional, state or local political or social conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any hurricane, tornado, flood, earthquake, natural disaster, or other acts of God; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any actions taken or not taken by the parties as required by the Business Combination Agreement or any ancillary agreement to the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any effect attributable to the announcement or execution, pendency, negotiation or consummation of the Business Combination or any of the other transactions contemplated by the Business Combination Agreement; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any actions taken, or failures to take action, or such other changes or events; in each case, which either party has requested or to which it has consented or which actions are contemplated by the Business Combination Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, BLAC or OSR Holdings may waive the occurrence of a material adverse effect affecting the other party. If a material adverse effect occurs and the parties still consummate the Business Combination, the market trading price of the shares of New OSR Holdings Common Stock and New OSR Holdings Warrants may suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in completing the Business Combination may substantially reduce the expected benefits of the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Satisfying the conditions to, and completion of, the Business Combination may take longer than, and could cost more than, BLAC expects. Any delay in completing or any additional conditions imposed in order to complete the Business Combination may materially adversely affect the benefits that BLAC expects to achieve from the Business Combination. If the Business Combination is not consummated by November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), BLAC will need to amend the Current Charter to extend its deadline to complete a business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">During the pendency of the Business Combination, BLAC will be subject to certain restrictions in the Business Combination Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Covenants in the Business Combination Agreement impede the ability of BLAC to make acquisitions or complete other transactions that are not in the ordinary course of business pending completion of the Business Combination. As a result, BLAC may be at a disadvantage to its competitors during that period. In addition, while the Business Combination Agreement is in effect, BLAC may not, other than pursuant to the PIPE Subscription Agreements, issue, sell, pledge, dispose of, grant or encumber, or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, any shares of any class of capital stock or other securities of BLAC, or any options, warrants, convertible securities or other rights of any kind to acquire any shares of such capital stock, or any other ownership interest (including, without limitation, any phantom interest), of BLAC, or enter into any agreement or commitment to do any of the foregoing. These provisions may prevent BLAC from negotiating or entering into an agreement for a business combination with another party while the Business Combination Agreement is in effect. In addition, if the Business Combination is not completed, these provisions will make it more difficult to complete an alternative business combination following the termination of the Business Combination Agreement due to the passage of time during which these provisions have remained in effect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC will not have any right to make damage claims against OSR Holdings&#8217; investors for the breach of any representation, warranty or covenant made by OSR Holdings in the Business Combination Agreement. OSR Holdings will not have any right to make damage claims against BLAC&#8217;s investors for the breach of any representation, warranty or covenant made by BLAC in the Business Combination Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement provides that all of the representations, warranties and covenants of the parties contained therein shall not survive the closing of the Business Combination, except for those covenants that by their terms apply or are to be performed in whole or in part after the Closing, and then only with respect to breaches occurring after Closing. Accordingly, there are no remedies available to the parties with respect to any breach of the representations, warranties, covenants or agreements of the parties to the Business Combination Agreement after the Closing of the Business Combination, except for covenants to be performed in whole or in part after the Closing. As a result, BLAC will have no remedy available to it if the Business Combination is consummated and it is later revealed that there was a breach of any of the representations, warranties and covenants made by OSR Holdings at the time of the Business Combination. Further, OSR Holdings will have no remedy available to it if the Business Combination is consummated and it is later revealed that there was a breach of any of the representations, warranties and covenants made by BLAC at the time of the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A 1% U.S. federal excise tax may be imposed on BLAC in connection with our redemptions of shares in connection with an initial business combination or other stockholder vote pursuant to which stockholders would have a right to submit their shares for redemption (a &#8220;<span style="text-decoration:underline">Redemption Event</span>&#8221;). </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inflation Reduction Act of 2022 (the &#8220;<span style="text-decoration:underline">IRA</span>&#8221;), which commenced in 2023, a 1% U.S. federal excise tax is imposed on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation and not on its stockholders. The amount of the excise tax is equal to 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. The U.S. Department of the Treasury (the &#8220;<span style="text-decoration:underline">Treasury Department</span>&#8221;) has authority to promulgate regulations and provide other guidance regarding the excise tax. Under U.S. Internal Revenue Service guidance, liquidating distributions made by publicly traded domestic corporations are exempt from the excise tax. In addition, any redemptions that occur in the same taxable year as a liquidation is completed will also be exempt from such tax. Accordingly, redemptions of BLAC&#8217;s public shares in connection with the Special Meeting may subject us to the excise tax, unless one of the two exceptions above apply. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the outside deadline for us to complete an initial business combination (currently November&#160;14, 2024 (unless such date is extended in accordance with the Existing Governing Documents)) is extended, our public stockholders will have the right to require us to redeem their public shares. Any redemption or other repurchase may be subject to the excise tax. The extent to which we would be subject to the excise tax in connection with a Redemption Event would depend on a number of factors, including: (i)&#160;the fair market value of the redemptions and repurchases in connection with the Redemption Event, (ii)&#160;the nature and amount of any &#8220;PIPE&#8221; or other equity issuances in connection with an initial business combination (or otherwise issued not in connection with the Redemption Event but issued within the same taxable year of an initial business combination), (iii) if BLAC fails to timely consummate an initial business combination and liquidates in a taxable year following a Redemption Event and (iv)&#160;the content of any proposed or final regulations and other guidance from the Treasury Department. In addition, because the excise tax would be payable by BLAC and not by the redeeming holders, the mechanics of any required payment of the excise tax remains to be determined. Any excise tax payable by BLAC in connection with a Redemption Event may cause a reduction in the cash available to BLAC to complete an initial business combination and could affect our ability to complete an initial business combination; however, we will not use the funds held in the trust account and any additional amounts deposited into the trust account, as well as interest earned thereon, to pay the excise tax. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC does not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for BLAC to complete the Business Combination with which a substantial majority of its investors do not agree. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s Charter imposes that BLAC shall have at least $5,000,001 of net tangible assets. For more details see &#8220;<span style="font-style:italic">The Business Combination Agreement&#8212;Conditions to Closing the Business Combination</span>.&#8221; If BLAC enters into a PIPE Financing, the PIPE Financing would be expected to satisfy the obligation to have at least $5,000,001 of net tangible assets and BLAC may be able to complete the Business Combination even though a substantial majority of the BLAC public stockholders do not vote to approve the Business Combination and have redeemed their shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC may complete the Business Combination, even if BLAC public stockholders exercise their redemption rights with respect to a large number of the BLAC Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of entering into the Business Combination Agreement, BLAC did not know how many stockholders may exercise their redemption rights, and therefore, BLAC structured the transaction based on BLAC&#8217;s expectations as to the number of shares that will be submitted for redemption. The consummation of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination is conditioned upon, among other things (a)&#160;the accuracy of OSR Holdings&#8217; and BLAC&#8217;s representations and warranties made in the Business Combination<span style="font-weight:bold"><span style="font-style:italic"> </span></span>Agreement; (b)&#160;BLAC having at least $5,000,001 of net tangible assets (as determined in accordance with <span style="white-space:nowrap">Rule&#160;3a51-1(g)(1)&#160;of</span> the Exchange Act); (c)&#160;the absence of any law or order by any governmental authority enjoining or prohibiting the consummation of the Business Combination or the other transactions contemplated by the Business Combination Agreement; and (d)&#160;the <span style="white-space:nowrap">Form&#160;S-4&#160;registration</span> statement of which this proxy statement/prospectus is a part, being declared effective and no stop order suspending the effectiveness of the <span style="white-space:nowrap">Form&#160;S-4&#160;registration</span> statement having been issued and no proceedings for that purpose having been initiated by the SEC that have not been withdrawn. Therefore, unless these conditions are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. For further details, see the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement&#8212;Conditions to Closing the Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC is requiring stockholders who wish to redeem their BLAC Common Stock in connection with the proposed Business Combination to comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline for exercising such rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is requiring stockholders who wish to redeem their BLAC Common Stock to either tender their certificates to Continental or to deliver their BLAC Common Stock to Continental electronically using the DTC&#8217;s DWAC (Deposit/Withdrawal At Custodian) System at least two business days before the BLAC Stockholders&#8217; Meeting. In order to obtain a physical certificate, a shareholder&#8217;s broker and/or clearing broker, DTC and Continental will need to act to facilitate this request. It is BLAC&#8217;s understanding that stockholders should generally allot at least two weeks to obtain physical certificates from Continental. However, because BLAC does not have any control over this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical certificate. While BLAC has been advised that it takes a short time to deliver BLAC Common Stock through the DWAC System, BLAC cannot assure you of this fact. Accordingly, if it takes longer than BLAC anticipates for stockholders to deliver their BLAC Common Stock, stockholders who wish to redeem may be unable to meet the deadline for exercising their redemption rights and thus may be unable to redeem their BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, this proxy statement/prospectus describes various other procedures that must be complied with in order for a shareholder to validly redeem its shares of BLAC Common Stock. In the event that a shareholder fails to comply with these procedures, its shares may not be redeemed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC will require its public stockholders who wish to redeem their BLAC Common Stock in connection with the Business Combination to comply with specific requirements for redemption described above, and such redeeming stockholders may be unable to sell their securities when they wish to in the event that the Business Combination is not consummated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If BLAC requires public stockholders who wish to redeem their BLAC Common Stock in connection with the proposed Business Combination to comply with specific requirements for redemption as described above and the Business Combination is not consummated, BLAC will promptly return such certificates to its public stockholders. Accordingly, stockholders who attempted to redeem their BLAC Common Stock in such a circumstance will be unable to sell their securities after the failed acquisition until BLAC has returned their securities to them. The market price of BLAC Common Stock may decline during this time and you may not be able to sell your securities when you wish to, even while other stockholders that did not seek redemption may be able to sell their securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If, before distributing the proceeds in the Trust Account to the public stockholders, BLAC files a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against BLAC that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of BLAC investors and <span style="white-space:nowrap">the&#160;per-share&#160;amount</span> that would otherwise be received by BLAC investors in connection with BLAC&#8217;s liquidation may be reduced. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, before distributing the proceeds in the Trust Account to the public stockholders, BLAC files a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against BLAC that is not dismissed, the proceeds held in the Trust Account could be subject to applicable bankruptcy law, and may be included in BLAC&#8217;s bankruptcy estate and subject to the claims of third parties with priority over the claims of BLAC&#8217;s investors. To the extent any bankruptcy claims deplete the Trust Account, <span style="white-space:nowrap">the&#160;per-share&#160;amount</span> that would otherwise be received by BLAC&#8217;s investors in connection with BLAC&#8217;s liquidation may be reduced. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no guarantee that a BLAC public stockholder&#8217;s decision whether to redeem its shares for a pro rata portion of the Trust Account will put the stockholder in a better future economic position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC can give no assurance as to the price at which a BLAC public shareholder may be able to sell the shares of New OSR Holdings Common Stock in the future following the completion of the Business Combination or any alternative merger. Certain events following the consummation of any initial merger, including the Business Combination, may cause an increase in BLAC&#8217;s stock price, and may result in a lower value realized now than a BLAC public stockholder might realize in the future had the stockholder not redeemed its shares. Similarly, if a BLAC public stockholder does not redeem its shares, the stockholder will bear the risk of ownership of New OSR Holdings Common Stock after the consummation of the Business Combination, and there can be no assurance that a stockholder can sell its shares of New OSR Holdings Common Stock in the future for a greater amount than the redemption price set forth in this proxy statement/prospectus. A BLAC public stockholder should consult his, her or its own tax and/or financial advisor for assistance on how this may affect his, her or its individual situation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Sponsor and its affiliates may enter into agreements concerning BLAC&#8217;s securities prior to the BLAC Stockholders&#8217; Meeting, which may have the effect of increasing the likelihood of completion of the Business Combination or decreasing the value of the BLAC Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the BLAC Stockholders&#8217; Meeting, during a period when they are not then aware of any material nonpublic information regarding BLAC or its securities, the Sponsor and its affiliates may enter into a written plan to purchase BLAC&#8217;s securities pursuant to <span style="white-space:nowrap">Rule&#160;10b5-1&#160;under</span> the Exchange Act, and may engage in other public market purchases, as well as private purchases, of securities. In addition, at any time prior to the BLAC Stockholders&#8217; Meeting, during a period when they are not then aware of any material nonpublic information regarding BLAC or its securities, the Sponsor and its affiliates may (a)&#160;purchase shares from institutional and other investors, (b)&#160;execute agreements to purchase such shares from institutional and other investors in the future, and/or (c)&#160;enter into transactions with institutional and other stockholders to provide such persons with incentives to acquire BLAC Common Stock. Such an agreement may include a contractual acknowledgement that such shareholder, although still the record holder of such shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that the Sponsor or its affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling public stockholders would be required to revoke their prior elections to redeem their shares. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options and the transfer of shares owned by the Sponsor for nominal value to such investors or holders. Any BLAC Common Stock acquired by the persons described above would not be voted in connection with the Business Combination Proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of such share purchases and other transactions would be to increase the likelihood that the conditions to the consummation of the Business Combination are satisfied or to provide additional financing to New OSR Holdings following the closing of the Business Combination; however, pursuant to SEC guidance, BLAC&#8217;s Sponsor or its affiliates, as applicable, may not vote such purchased shares in favor of approving the Business Combination. This may result in the completion of BLAC&#8217;s business combination that may not otherwise have been possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entering into any such incentive arrangements may have a depressive effect on the BLAC Common Stock. For example, as a result of these arrangements, a stockholder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he owns, either prior to or immediately after the BLAC Stockholders&#8217; Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, there have been no such discussions and no agreements to such effect have been entered into with any such stockholder. BLAC will file a Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;prior</span> to the BLAC Stockholders&#8217; Meeting to disclose any arrangements entered into or significant purchases made by any of the aforementioned persons. Any such report will include (a)&#160;the amount of BLAC Common Stock purchased and the purchase price; (b)&#160;the purpose of such purchases; (c)&#160;the impact of such purchases on the likelihood that the Business Combination will be approved; (d)&#160;the identities or characteristics of security holders who sold shares if not purchased in the open market or the nature of the sellers; and (e)&#160;the number of BLAC Common Stock for which BLAC has received redemption requests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">The Business Combination &#8212; Potential Actions to Secure Requisite Stockholder Approvals</span>&#8221; for a description of how the BLAC Sponsor or any of its affiliates may effectuate such purchases in compliance with applicable law and SEC guidance, including the selection of stockholders to purchase securities from in any private transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (&#8220;<span style="text-decoration:underline">CFIUS</span>&#8221;), and ultimately prohibited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s sponsor is controlled by and has substantial ties with non-U.S. persons who are nationals of South Korea. CFIUS is an interagency committee chaired by the Treasury Department that is authorized to review certain &#8220;covered transactions,&#8221; which include direct and indirect control acquisitions of and certain non-control investments in U.S. businesses by foreign persons, in order to determine whether such covered transactions threaten to impair the national security of the United States. If CFIUS determines that a covered transaction threatens to impair U.S. national security, it has the authority to undertake mitigation measures including recommending that the President prohibit the transaction or require divestment by the foreign person if the transaction has been completed. The potential for CFIUS review of a covered transaction depends on a number of factors including the nature and structure of the transaction, the operations of the U.S. business including whether the business is a &#8220;TID U.S. business&#8221; as defined in 31 C.F.R. &#167; 800.248, and the foreign persons involved in the transaction including their nationality, intermediate and ultimate shareholders, and operations elsewhere globally. CFIUS has the discretion to initiate review of a covered transaction. Parties to a covered transaction may submit a notice voluntarily to CFIUS to request clearance, which is a safe harbor against future review of that same transaction. Certain covered transactions involving a TID U.S. business, however, may be subject to a mandatory notice requirement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we may be considered a foreign person, under CFIUS regulations, an initial proposed business combination may fall within the scope of a covered transaction and be subject to CFIUS review jurisdiction. If so, we may be required to make a mandatory filing or, if no mandatory filing is required, we may decide to submit a voluntary notice to CFIUS or proceed with the initial business combination without notifying CFIUS and risk CFIUS intervention before or after closing the initial business combination. CFIUS may decide to block </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or delay our initial business combination, impose conditions to mitigate national security concerns with respect to such initial business combination, or order us to divest all or a portion of a U.S. business of the combined company if we had proceeded without first obtaining CFIUS clearance. The potential impact of CFIUS may limit the attractiveness of a transaction with us or prevent us from pursuing certain initial business combination opportunities that we believe would otherwise be beneficial to us and our shareholders. As a result, the pool of potential targets with which we could complete an initial business combination may be limited and we may be adversely affected in terms of competing with other special purpose acquisition companies that do not have similar foreign ownership issues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the process of review by CFIUS may be lengthy. Because we have only a limited time to complete our initial business combination, our failure to obtain required approvals within the requisite time period may require us to liquidate. If we liquidate, our warrants and rights would expire worthless. This will also cause you to lose any potential investment opportunity in a target company and the chance of realizing future gains on your investment through any price appreciation in the combined company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The SEC issued final rules to regulate special purpose acquisition companies that may materially adversely affect our business, including our ability to complete, and the costs associated with, our initial business combination and results of operations.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 24, 2024, the SEC issued final rules (the &#8220;<span style="text-decoration:underline">2024 SPAC Rules</span>&#8221;), effective as of 125 days following the publication of the 2024 SPAC Rules in the Federal Register, that formally adopted some of the SEC&#8217;s proposed rules for special purpose acquisition companies (&#8220;<span style="text-decoration:underline">SPACs</span>&#8221;) that were released on March 30, 2022. The 2024 SPAC Rules, among other items, impose additional disclosure requirements in initial public offerings by SPACs and business combination transactions involving SPACs and private operating companies; amend the financial statement requirements applicable to business combination transactions involving such companies; update and expand guidance regarding the general use of projections in SEC filings, as well as when projections are disclosed in connection with proposed business combination transactions; increase the potential liability of certain participants in proposed business combination transactions; and could impact the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940. The 2024 SPAC Rules may materially adversely affect our business, including our ability to complete, and the costs associated with, our initial business combination, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we were deemed to be an investment company for purposes of the Investment Company Act, we may be forced to abandon our efforts to complete the Business Combination and instead be required to liquidate and dissolve BLAC. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether a SPAC is an investment company as defined in the Investment Company Act is a question of facts and circumstances according to the adopting release to the SPAC Rules, which added, &#8220;Given the individualized nature of this analysis, and because, depending on the facts and circumstances, a SPAC could be an investment company at any stage of its operations such that a specific duration limitation may not be appropriate, we have decided not to adopt proposed Rule&#160;3a-10.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, it is possible that a claim could be made that we have been operating as an unregistered investment company. If we were deemed to be an investment company for purposes of the Investment Company Act, we might be forced to register as an investment company under the Investment Company Act or abandon our efforts to complete the Business Combination and instead be required to liquidate and dissolve. If we are required to liquidate and dissolve, our investors would not be able to realize the benefits of owning stock in a successor operating business, including the potential appreciation in the value of our stock, rights and warrants following such a transaction, and our warrants would expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The funds in the Trust Account have, since our IPO, been held only in U.S.&#160;government treasury securities within the meaning set forth in Section&#160;2(a)(16)&#160;of the Investment Company Act, with a maturity of 185&#160;days or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
less, or in money market funds meeting certain conditions under Rule&#160;2a-7&#160;under the Investment Company Act that invests only in direct U.S.&#160;government treasury obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to New OSR Holdings Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The price of the New OSR Holdings&#8217; Common Stock and warrants may be volatile. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price of the New OSR Holdings&#8217; Common Stock and warrants may fluctuate due to a variety of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated fluctuations in its quarterly and annual results and those of other public companies in the same or similar industry; mergers and strategic alliances in the industry in which it operates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market prices and conditions in the industry in which it operates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in government regulation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential or actual military conflicts or acts of terrorism; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure of securities analysts to publish research about us, or shortfalls in its operating results compared to levels forecasts by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning New OSR Holdings or its competitors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the general state of the securities markets. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These market and industry factors may materially reduce the market price of New OSR Holdings&#8217; Common Stock and warrants, regardless of its operating performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Following the Business Combination, New OSR Holdings will be a&#160;controlled company&#160;within the meaning of the&#160;Nasdaq&#160;Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Stockholders of New OSR Holdings may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Business Combination, Mr.&#160;Kuk Hyoun Hwang, BLAC&#8217;s Chief Executive Officer will control a majority of the voting power of the outstanding shares of New OSR Holdings Common Stock. As a result, New OSR Holdings will be a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of&#160;Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements. For example, controlled companies: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a board that is composed of a majority of &#8220;independent directors&#8221; as defined under the&#160;Nasdaq&#160;listing rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a compensation committee that is composed entirely of independent directors or have a written charter addressing the committee&#8217;s purpose and responsibilities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While New OSR Holdings does not initially intend to rely on these exemptions, New OSR Holdings may opt to utilize these exemptions in the future as long as it remains a&#160;controlled company. Accordingly, New OSR Holdings stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of&#160;Nasdaq. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New OSR Holdings ceases to be a &#8220;controlled company&#8221; in the future, it will be required to comply with the Nasdaq Listing Rules, which may require replacing a number of its directors and may require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase New OSR Holdings&#8217; legal and administrative costs, will make some activities more difficult, time-consuming, and costly and may also place additional strain on New OSR Holdings&#8217; personnel, systems and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active, liquid trading market for New OSR Holdings Common Stock and warrants may not develop, which may limit your ability to sell such Common Stock and warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we will apply to list New OSR Holdings Common Stock and warrants on Nasdaq upon the Effective Time under the ticker symbols &#8220;OSRB&#8221; and &#8220;OSRBW&#8221;, respectively, an active trading market for New OSR Holdings Common Stock and warrants may never develop or be sustained following the consummation of the Business Combination. A public trading market having the desirable characteristics of depth, liquidity and orderliness depends upon the existence of willing buyers and sellers at any given time, such existence being dependent upon the individual decisions of buyers and sellers over which neither we nor any market maker has control. The failure of an active and liquid trading market to develop and continue would likely have a material adverse effect on the value of the New OSR Holdings Common Stock and warrants. An inactive market may also impair our ability to raise capital to continue to fund operations by issuing New OSR Holdings Common Stock and warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the price of New OSR Holdings securities after the Business Combination can vary due to general economic conditions and forecasts, its general business condition and the release of its financial reports. Additionally, if its securities are not listed on, or becomes delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of its securities may be more limited than if it were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">New OSR Holdings does not intend to pay dividends on its common stock so any returns will be limited to the value of our stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New OSR Holdings currently anticipates that it will retain future earnings for the development, operation and expansion of New OSR Holdings&#8217; business and does not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on New OSR Holdings&#8217; Common Stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC&#8217;s current stockholders will have a reduced ownership and voting interest in New OSR Holdings after the Business Combination and will exercise less influence over management of New OSR Holdings and its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of the shares of BLAC Common Stock to OSR Holdings Stockholders, current BLAC stockholders&#8217; percentage ownership will be diluted. Assuming no remaining public stockholders exercise their redemption rights, and excluding the shares owned by BLAC&#8217;s sponsor, directors, officers and their respective affiliates, current BLAC public stockholders&#8217; percentage ownership in New OSR Holdings immediately after Closing and following the issuance of shares of BLAC Common Stock to New OSR Holdings stockholders would be 11.9%. Assuming 50% of the BLAC Common Stock that could be redeemed is redeemed in connection with the Business Combination, and excluding the shares owned by BLAC&#8217;s sponsor, directors, officers and their respective affiliates, current BLAC public stockholders&#8217; percentage ownership in New OSR Holdings following the issuance of shares of stock to New OSR Holdings stockholders would be 7.9%. Assuming that the maximum number of BLAC Common Stock that could be redeemed are redeemed in connection with the Business Combination, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding the shares owned by BLAC&#8217;s sponsor, directors, officers and their respective affiliates, current BLAC public stockholders&#8217; percentage ownership in New OSR Holdings following the issuance of shares of stock to New OSR Holdings stockholders would be 3.49%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The&#160;percentage of New OSR Holdings Common Stock that will be owned by current BLAC stockholders as a group will vary based on the number of BLAC Common Stock for which the holders thereof request redemption in connection with the Business Combination. Because of this, current BLAC public stockholders, as a group, will have less influence on the board of directors, management and policies of New OSR Holdings than they now have on the board of directors, management and policies of BLAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC stockholders who do not redeem their shares of Common Stock of BLAC will experience immediate and material dilution upon closing of the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, BLAC stockholders who do not redeem their shares of Common Stock will experience immediate and material dilution in their respective percentage of New OSR Holdings upon closing of the Business Combination. The extent of the dilution will depend upon the number of BLAC stockholders who do redeem their shares, the number of shares of BLAC stock issued or issuable to the PIPE Investors (and convertible into New OSR Holdings common stock), warrant exercises, conversion of rights into common stock and equity incentives issuable pursuant to the Omnibus Plan. As such, BLAC stockholders who do not redeem their shares of Common Stock of BLAC will experience immediate and material dilution upon closing of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales, or the perception of future sales, by New OSR Holdings or its stockholders in the public market could cause the market price for New OSR Holdings Common Stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of shares of New OSR Holdings Common Stock in the public market, or the perception that such sales could occur, by New OSR Holdings or its stockholders or warrant holders could harm the prevailing market price of shares of New Holdings Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for New OSR Holdings to sell equity securities in the future at a time and at a price that it deems appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If New OSR Holdings issues additional equity securities or debt securities, those securities offerings may adversely affect the market price of its Common Stock and Warrants, and may be dilutive to existing stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, New OSR Holdings is likely to issue additional common stock or issue preferred stock or incur debt. Debt and preferred stock will generally have priority upon liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that New OSR Holdings issues in the future may have rights, preferences and privileges more favorable than those of New OSR Holdings Common Stock. Because the decision to issue debt or equity in the future will depend on market conditions and other factors beyond New OSR Holdings&#8217; control, we cannot predict or estimate the amount, timing, nature or success of our future capital raising efforts. As a result, future capital raising efforts may reduce the market price of New OSR Holdings Common Stock and warrants and be dilutive to existing stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC granted registration rights to certain stockholders and others and the future exercise of such rights may adversely affect the market price of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an agreement entered into in connection with the issuance and sale of the securities in the BLAC IPO, certain of BLAC&#8217;s stockholders and their permitted transferees can demand that BLAC register the placement warrants, the placement rights, the shares of common stock issuable upon exercise of the placement warrants, the shares of common stock included in the placement units, and the shares of common stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underlying the placement rights. Additionally, holders of units that may be issued upon conversion of working capital loans can demand that BLAC register the warrants and rights included in such units, the shares of common stock issuable upon exercise of such warrants, the shares of common stock included in such units, and the shares of common stock underlying such rights. New OSR Holdings will bear the cost of registering these securities. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of New OSR Holdings Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The New OSR Holdings Bylaws require, to the fullest extent permitted by law, that derivative actions brought in our name, as applicable, against their respective directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, which may have the effect of discouraging lawsuits against our directors, officers, other employees or stockholders, as applicable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Bylaws, unless New OSR Holdings consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to us or our stockholders; (iii)&#160;any civil action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware; (iv)&#160;any civil action to interpret, apply, enforce or determine the validity of the New OSR Holdings Charter and New OSR Holdings Bylaws; or (v)&#160;any action asserting a claim governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware forum provision. This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternate forum, the United States District Courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the federal forum provision, as our principal office is located in Bellevue, Washington. In addition, the Amended Bylaws, provides that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware forum provision and the federal forum provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware forum provision and the federal forum provision may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. In addition, these forum selection clauses in the Amended Bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If the federal forum provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other claim for which the federal courts have exclusive jurisdiction. Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such claims. As noted above, the Amended Bylaws provides that the federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act. Due to the concurrent jurisdiction for federal and state courts created by Section&#160;22 of the Securities Act over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, there is uncertainty as to whether a court would enforce the exclusive forum provision. Investors also cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions contained in the New OSR Holdings Charter and the New OSR Holdings Bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Charter and the New OSR Holdings Bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a requirement that special meetings of stockholders be called only by the chairperson of the board of directors, the chief executive officer, or by the directors entitled to cast a majority of the votes of the whole board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance notice requirements for stockholder proposals and nominations for election to our board of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in the New OSR Holdings Charter and the New OSR Holdings Bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If, following the Business Combination, securities or industry analysts do not publish or cease publishing research or reports about New OSR Holdings, its business, or its market, or if they change their recommendations regarding New OSR Holdings securities adversely, then the price and trading volume of New OSR Holdings securities could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for New OSR Holdings securities will be influenced by the research and reports that industry or securities analysts may publish about New OSR Holdings, its business, its market, or its competitors. Securities and industry analysts may never publish research on New OSR Holdings. If no securities or industry analysts commence coverage of New OSR Holdings, the securities price and trading volume would likely be negatively impacted. If any of the analysts who may cover New OSR Holdings change their recommendation regarding New OSR Holdings securities adversely, or provide more favorable relative recommendations about New OSR Holdings&#8217; competitors, the price of New OSR Holdings&#8217; securities would likely decline. If any analyst who may cover BLAC were to cease coverage of New OSR Holdings or fail to regularly publish reports on it, New OSR Holdings could lose visibility in the financial markets, which could cause New OSR Holdings&#8217; securities price or trading volume to decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There can be no assurance that New OSR Holdings will be able to comply with the continued listing standards of Nasdaq. New OSR Holdings failure to meet the continued listing requirements of Nasdaq could result in a delisting of New OSR Holdings Common Stock and warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New OSR Holdings will apply for listing, to be effective at the time of the Business Combination, of New OSR Holdings Common Stock and warrants on Nasdaq under the proposed symbols &#8220;OSRB&#8221; and &#8220;OSRBW,&#8221; respectively. New OSR Holdings&#8217; eligibility for listing on Nasdaq depends on its ability to comply with Nasdaq&#8217;s continued listing standards, including requirements relating to the trading price and trading volume of its securities, and other corporate governance requirements. If New OSR Holdings is not able to comply with the continued listing standards of Nasdaq, New OSR Holdings and its stockholders could face significant material adverse consequences including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a limited availability of market quotations for its securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced liquidity for New OSR Holdings securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination that New OSR Holdings Common Stock is a &#8220;penny stock,&#8221; which will require brokers trading in New OSR Holdings Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for New OSR Holdings Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a limited amount of or no analyst coverage; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a decreased ability to issue additional securities or obtain additional financing in the future. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; As long as New OSR Holdings&#8217; Common Stock and warrants are listed on Nasdaq, they will be considered covered securities. If the New OSR Holdings&#8217; securities were no longer listed on Nasdaq, the securities would not be covered securities and would therefore be subject to regulation in each state in which the New OSR Holdings offers its securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, after listing, the New OSR Holdings fails to satisfy the continued listing requirements of Nasdaq such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist the New OSR Holdings&#8217; securities. Such a delisting would likely have a negative effect on the price of the securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, and no assurance can be provided that any action taken to restore compliance with listing requirements would allow the securities to become listed again, stabilize the market price or improve the liquidity of its securities, prevent its securities from dropping below the Nasdaq minimum bid price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. Additionally, if the New OSR Holdings&#8217; securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on any of the markets offered by OTC Markets Group Inc., the liquidity and price of these securities may be more limited than if they were quoted or listed on Nasdaq or another national securities exchange. New OSR Holdings securityholders may be unable to sell their securities unless a market can be established or sustained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, BLAC notified Nasdaq that BLAC is not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the &#8220;<span style="text-decoration:underline">Listing Rule</span>&#8221;), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. Pursuant to section (c)(4)(B) of the Listing Rule, BLAC has until the earlier of the next annual shareholders meeting or one year from the occurrence of the event that caused the failure to comply with this requirement; provided, however, that if the annual shareholders meeting occurs no later than 180 days following the event that caused the vacancy, BLAC shall instead have 180 days from such event to regain compliance. The Listing Rule requires the Audit Committee (the &#8220;<span style="text-decoration:underline">Audit Committee</span>&#8221;) of the BLAC Board to be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. BLAC&#8217;s Audit Committee is comprised of two independent directors and one vacancy and, therefore, does not currently comply with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Nasdaq&#8217;s audit committee requirements as set forth in the Listing Rule. Pursuant to the Listing Rule&#8217;s section (c)(4)(B), BLAC is entitled to a cure period to regain compliance with the Listing Rule. BLAC regained compliance with this Listing Rule on June 23, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 15, 2024, BLAC received a letter (&#8220;<span style="text-decoration:underline">Notice</span>&#8221;) from the Listing Qualifications Department of Nasdaq notifying BLAC that it no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the &#8220;<span style="text-decoration:underline">Minimum Public Holders Requirement</span>&#8221;). In accordance with Nasdaq rules, BLAC had 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 1, 2024, BLAC submitted to Nasdaq its plan to regain compliance with the Minimum Public Holders Requirement. On April 17, 2024, BLAC received written notice from Nasdaq indicating that the staff of Nasdaq (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Staff</span></span>&#8221;) determined, based on its review of BLAC&#8217;s compliance plan, to grant BLAC an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August 13, 2024, BLAC must file with Nasdaq documentation from its transfer agent, or an independent source, demonstrating that its common stock has a minimum of 300 public holders. In the event BLAC does not satisfy the terms, the Staff will provide written notification that BLAC&#8217;s securities will be delisted. At that time, BLAC may appeal the Staff&#8217;s determination to a Listing Qualifications Panel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We anticipate that New OSR Holdings will qualify as an &#8220;emerging growth company&#8221; as well as a &#8220;smaller reporting company&#8221; within the meaning of the Securities Act, and if New OSR Holdings takes advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make its securities less attractive to investors and may make it more difficult to compare its performance with other public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate New OSR Holdings will qualify as an &#8220;emerging growth company&#8221; within the meaning of Section&#160;2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, New OSR Holdings may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies for as long as it continues to be an emerging growth company, including, but not limited to, (i)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, (ii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, New OSR Holdings stockholders may not have access to certain information they may deem important. New OSR Holdings would remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which the market value of New OSR Holdings Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700,000,000 as of the end of that year&#8217;s second fiscal quarter, (ii)&#160;the last day of the fiscal year in which New OSR Holdings has total annual gross revenue of $1,235,000,000 or more during such fiscal year (as indexed for inflation), (iii) the date on which New OSR Holdings has issued more than $1,000,000,000 in <span style="white-space:nowrap">non-convertible</span> debt in the prior three-year period or (iv)&#160;the last day of the fiscal year following the fifth anniversary of the date of the first sale of BLAC Common Stock, as defined by the JOBS Act. Investors may find New OSR Holdings&#8217; securities less attractive because it may rely on these exemptions. If some investors find New OSR Holdings&#8217; securities less attractive as a result of its reliance on these exemptions, the trading prices of its securities may be lower than they otherwise would be, there may be a less active trading market for its securities and the trading prices of its securities may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we anticipate New OSR Holdings will qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K</span> promulgated by the SEC. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. New OSR Holdings will remain a smaller reporting company for so long as the market value of its common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million measured on the last business day of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its second fiscal quarter, or its annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of its common stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million measured on the last business day of its second fiscal quarter. To the extent New OSR Holdings takes advantage of such reduced disclosure obligations, it may also make comparison of its financial statements with other public companies difficult or impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">New OSR Holdings may redeem unexpired public warrants after they become exercisable and prior to their exercise at a time that is disadvantageous to the holders, thereby making your public warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New OSR Holdings has the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of our Common Stock equals or exceeds $16.50 per share for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending on the third trading day prior to the date we give notice of redemption. New OSR Holdings will not redeem the warrants as described above unless a registration statement under the Securities Act covering the shares of the common stock issuable upon exercise of such warrants is effective and a current prospectus relating to shares of the common stock is available throughout the 30-day redemption period. If and when the public warrants become redeemable by New OSR Holdings, it may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding public warrants could force the holders (i)&#160;to exercise their public warrants and pay the exercise price therefor at a time when it may be disadvantageous for them to do so, (ii)&#160;to sell their public warrants at the then-current market price when you might otherwise wish to hold your public warrants or (iii)&#160;to accept the nominal redemption price which, at the time the outstanding public warrants are called for redemption, is likely to be substantially less than the market value of their public warrants. The value received upon exercise of the public warrants (1) may be less than the value the holders would have received if they had exercised their public warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the public warrants. The fair value of the public warrants that may be retained by redeeming shareholders is $[&#9679;] based on recent trading prices, and [&#9679;] public warrants held by public shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The private placement warrants are identical to the public warrants, except that the private placement warrants and the shares of common stock issuable upon the exercise of the private placement warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions, and none of the private placement warrants will be redeemable by us so long as they are held by their initial purchasers or their permitted transferees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event New OSR Holdings determines to redeem the warrants, holders of our redeemable warrants would be notified of such redemption as described in our warrant agreement. Specifically, in the event that New OSR Holdings elects to redeem all of the redeemable warrants as described above, New OSR Holdings will fix a date for the redemption (the &#8220;<span style="font-weight:bold">Redemption Date</span>&#8221;). Notice of redemption will be mailed by first class mail, postage prepaid, by New OSR Holdings not less than 30 days prior to the Redemption Date to the registered holders of the redeemable warrants to be redeemed at their last addresses as they appear on the registration books. Any notice mailed in the manner provided in the warrant agreement will be conclusively presumed to have been duly given whether or not the registered holder received such notice. Accordingly, if a holder fails to actually receive the notice of or otherwise fails to respond on a timely basis, it could lose the benefit of being a holder of a New OSR Holdings public warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing price of BLAC&#8217;s common stock has not exceeded $16.50 per share for any of the 30 trading days prior to the date of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to OSR Holdings Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the business and operations of OSR Holdings, which, following the closing of the Business Combination, will be the business and operations of New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our limited operating history, the early stage of our development programs and the inherent uncertainties and risks involved in pharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global drug development company with a limited operating history upon which you can evaluate our business and prospects. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring our portfolio companies, establishing our intellectual property portfolio and performing research and development in support of our product candidates. We have no pharmaceutical product candidates approved for commercial sale and our product candidates have not generated any revenue. Our approach to the discovery and development of product candidates from early stage to drug launch is unproven, and we do not know whether we will be able to develop any products of commercial value. Except for a few clinical stage candidates in our portfolio, most of our other candidates are in the preclinical stages of development and will require additional preclinical studies and future clinical development as well as regulatory review and approval, which may not be granted. Since we are still in preclinical and clinical development, we would need to receive regulatory approvals, gain access to sufficient commercial manufacturing capacity and implement marketing efforts before we could begin generating revenue from product sales or arrange for a third party to do so on our behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business is dependent on the success of our product candidates that we advance into clinical trials and ultimately commercial distribution, which will require managing complex scientific, regulatory, management, sales, licensing and other issues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully develop new product candidates through our drug development strategy and advance those product candidates <span style="white-space:nowrap">into&#160;pre-clinical&#160;studies</span> and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete <span style="white-space:nowrap">ongoing&#160;pre-clinical&#160;studies</span> and clinical trials and obtain regulatory approvals for our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain experienced management and advisory teams; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">add operational, financial and management information systems and personnel, including personnel to support clinical, <span style="white-space:nowrap">pre-clinical</span> manufacturing and planned future commercialization efforts and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed and the price of our common shares and warrants may be negatively impacted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of our product candidates encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business could be significantly harmed. Before we can generate any revenue from sales of any of our product candidates, we must undergo additional preclinical and clinical development, regulatory review and approval in one or more jurisdictions. In addition, if one or more of our product candidates are approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the financial resources to continue development of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development is a highly speculative business requiring substantial investments that may not ever generate operating cash flow. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in drug development is highly speculative because it entails substantial upfront capital and operating expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage drug development companies in rapidly evolving fields. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates will require substantial development time &#8211; including extensive clinical, and in many <span style="white-space:nowrap">cases&#160;pre-clinical,&#160;research</span> and development &#8211; and resources before we would be able to apply for or receive applicable regulatory approvals and begin generating revenue from product sales. Because of the numerous risks and uncertainties associated with drug development, we are unable to predict precisely the timing or amount of increased expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never generated any operating profits and incurred operating losses of KRW&#160;784.6 million and KRW&#160;12.29 billion for years ending 2022 and 2023, respectively. We have an accumulated deficit of KRW&#160;13.19 billion as of December 31, 2023. We are likely to continue to incur operating losses in the future. While our RMC subsidiary generated revenues of KRW 4.38 billion and profits of KRW 78.1 million in 2023, none of our other subsidiaries have generated any revenues from product sales because none of their current product candidates have received marketing or other required regulatory approvals anywhere in the world. We may never generate product revenue from the commercial sales of our pharmaceutical product candidates or achieve profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we obtain regulatory approval for any of our product candidates, we still may never achieve profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do successfully obtain regulatory approval to market product candidates, our revenue will be dependent upon, in part and among other things, the size of the markets in the geographic areas for which we gain regulatory approval, the number of competitors in such markets, the accepted price for product candidates and whether we own the commercial rights for those territories. If the indication approved by regulatory authorities is narrower than expected, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of our product candidates, even if approved (especially for products receiving orphan drug designations). We cannot assure you that we will be profitable even if we successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if a product candidate we develop receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product candidate we own or develop receives regulatory approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, such as Medicare and Medicaid programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efficacy and potential advantages compared to alternative treatments; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to offer our products, if approved, for sale at competitive prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the convenience and ease of administration compared to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the price we pay or any of our future collaborators charge for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strength of marketing and distribution support; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain sufficient third-party coverage and adequate reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any side effects; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and effectiveness of our sales, marketing and distribution support. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and reimbursement may be limited or unavailable for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the insurance coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory approval will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and other third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a covered benefit under its health plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safe, effective and medically necessary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appropriate for the specific patient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither experimental nor investigational.</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <span style="white-space:nowrap">co-payments</span> that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <span style="white-space:nowrap">follow-up</span> evaluations required following the use of product candidates, once approved. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our ability to obtain and maintain coverage for our products by certain government health care programs may depend on our participation in certain government pricing programs, such as the Medicaid Drug Rebate Program and the 340B program. These programs often include complex reporting and payment obligations, which are subject to frequent change. If we fail to provide timely and accurate information under these programs or comply with any rebate or discount pricing requirements, we may have reimbursement obligations or be subject to penalties or other sanctions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to currently applicable laws and state and federal healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have multiple programs and product candidates under development and are pursuing a variety of target indications and treatment modalities, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have multiple subsidiaries with their own drug development plans, all of which will compete for financial resources to advance their development and commercialization. Due to our constrained financial and personnel resources, we will likely be unable to fund all of those opportunities. As a result, we may need to postpone or cancel the pursuit of potential target conditions or product candidates that may later prove to have higher commercial potential compared to those we actually fund. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investments in ongoing and upcoming research and development programs might not yield any commercially viable candidates in the future. In addition, we may fail to accurately assess the commercial potential or target market for a particular product candidate leading us to relinquish valuable rights to that candidate through collaborations, licensing, or royalty arrangements, even when it would have been more advantageous for us to retain exclusive development and commercialization rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to license or acquire early or development-stage technologies or programs, which introduces additional risks for our company. Identifying, selecting, and acquiring product candidates demands significant technical, financial, and human resources expertise. These efforts may not lead to the acquisition or licensing of a viable product candidate, potentially resulting in the diversion of our management&#8217;s time and the expenditure of resources without any resulting tangible benefits. If we struggle to identify programs that eventually result in successful commercial products, we could spend substantial amounts of our capital and resources on evaluating, acquiring, and developing products that ultimately do not generate returns on our investments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in our efforts to build a robust pipeline of product candidates with commercial value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to acquire companies, programs, product candidates, technologies or intellectual property that we believe are novel, employ differentiated mechanisms of action, are more advanced in development than competitors, or have a combination of these attributes. In addition, we plan to seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties. We face significant competition in these opportunities, and the negotiation process is time-consuming and complex. We may not be successful in our efforts in building a robust pipeline of product candidates through acquisitions, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensing or through internal development or in progressing these product candidates through clinical development. Although we analyze whether we can replicate scientific results observed prior to our acquisition or investment in a product candidate, we may not be successful in doing so after our investment. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of unacceptable toxicity or other characteristics that indicate that they are unlikely to receive approval from the U.S. Food and Drug Administration (&#8220;<span style="text-decoration:underline">FDA</span>&#8221;) or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market opportunities for our product candidates may vary widely as we intend to develop product candidates to address unmet diseases, with some product candidates having smaller target markets, and our estimates of the prevalence of our target patient populations may be inaccurate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired, and seek to create or acquire, companies or select intellectual property with the potential as breakthrough designations for unmet diseases, including rare or orphan diseases. While we believe our efforts can result in commercial success, if our estimates of the target patient populations are too optimistic, if the target patient population is relatively small, or if our drug candidates do not address the entire target patient population of a rare disease for example, such drug candidates may not generate significant product revenue and could adversely affect our financial position and our stock price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our subsidiaries may become a party to certain agreements that provide our licensors, collaborators or other stockholders in our subsidiaries with rights that could delay or impact the potential sale of our subsidiaries or could impact the ability of our subsidiaries to sell assets, or enter into strategic alliances, collaborations or licensing arrangements with other third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our subsidiaries may directly or indirectly license intellectual property from third parties and may be partially or majority owned by third party investors. These third parties may have certain rights that could delay collaboration, licensing or other arrangements with another third party, and the existence of these rights may adversely impact the ability to attract an acquirer or partner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may form additional subsidiaries and enter into similar agreements with future partners or investors, or our subsidiaries may enter into further agreements, that in each case may contain similar provisions or other terms that are not favorable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Although we currently own 100% of our subsidiaries (i.e., there are no third-party, minority investors), we may, in the future, acquire companies that have minority shareholders or we may make investments where we are a minority shareholder. Where we are the majority shareholder, we will have certain duties to minority shareholders, which may limit our ability to integrate operations with our other subsidiaries. If we make an investment as a minority investor, we are unlikely to exert much, if any, control over the business and we may be limited in our ability to realize value from those investments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently own wholly-owned subsidiaries, and plan to be the majority owner of future subsidiaries. In the event that we acquire a majority ownership interest or make an investment in another company, or if any of our subsidiaries require additional capital and such additional capital is obtained from third party investors rather than from us, we may be (or may become) a minority shareholder and unable to control the business and operations of those companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the companies in which we are a minority shareholder conduct their business in a manner detrimental to our interests, business, or reputation, our returns may be adversely affected. Companies in which we are a minority shareholder may not consult us on business decisions and could take actions without our consent, which could have an adverse impact on our returns. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ownership of majority-owned subsidiaries creates additional risks because we must be sure that any contracts between such subsidiaries and our company or any of our other subsidiaries are conducted on an &#8220;arms-length&#8221; basis. As a result, we will be unable to manage majority-owned subsidiaries in the same fashion as our wholly-owned subsidiaries (where contracts with affiliates need not be on an arms-length basis). These constraints may require management to incur time and resources to determine &#8220;arms-length&#8221; provisions of contracts with majority-owned subsidiaries. Minority shareholders of majority-owned subsidiaries may, after the fact, claim breach of fiduciary duties with respect to contracts that they assert are not &#8220;arms-length&#8221; or not fair to the minority shareholders. These types of claims may result in judgments or settlements that require us or our subsidiaries to pay damages to the minority shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A single or limited number of portfolio companies may comprise a large proportion of our value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A large proportion of our value may, at any time, reside in one or two of our subsidiaries, including intellectual property rights and the value ascribed to the product candidate or program that it is developing. Our consolidated financial condition and prospects may be materially diminished if the clinical development or potential commercialization prospects of a subsidiary&#8217;s product candidate or program or one or more of the intellectual property rights held by a specific subsidiary becomes impaired. Furthermore, a large proportion of our consolidated revenue may at any time be derived from one, or a small number of, licensed technologies, and termination or expiration of licenses to these technologies would likely have a material adverse effect on our consolidated revenue. Any material adverse impact on the value of a particular subsidiary, including its intellectual property rights or the clinical development of its product candidate or program, could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The business of our subsidiary that is a distributor of medical products is subject to other risks, including risks related to its holding inventory that may decline in value, its dependency on sales agency agreements and the risks relating to economic conditions and government regulation of the healthcare industry in Korea. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our Korean subsidiary, RMC, is a distributor of medical products currently serving only the Korea market. RMC is required under some of its sales agency agreements to make annual minimum purchases of products, which if not sold may decline in value and require RMC to write-down the value under accounting standards. In addition, failure to meet sales goals may result in termination of RMC&#8217;s contracts with medical product manufacturers. RMC&#8217;s sales are currently exclusively to hospitals, hospital networks and physicians across Korea, so that its business is highly dependent upon economic conditions and government regulation of the healthcare industry in Korea. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal assets are our interests in our various subsidiaries, and accordingly, we will depend on distributions and dividends from our subsidiaries to make additional cash investments, pay taxes and cover our corporate and other overhead expenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a holding company and have no material assets other than our ownership interest in our subsidiaries. We are dependent on our subsidiaries for generating revenue or cash flow and have no other means of generating revenue or cash flow. In the future, we may be limited, however, in our ability to cause our subsidiaries to make dividend payments or other distributions to us due to restrictions contained in any credit agreement to which our subsidiaries are bound. To the extent that we need funds and our subsidiaries are restricted from making dividend payments or other distributions under applicable law or regulation or under the terms of their financing arrangements or are otherwise unable to provide such funds, our liquidity and financial condition could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to New OSR Holdings&#8217; Strategy to Grow the Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the growth strategy of OSR Holdings, which, following the closing of the Business Combination, will be the growth strategy of New OSR</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-style:italic">Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in our efforts to <span style="white-space:nowrap">acquire,&#160;in-license&#160;or</span> discover and develop new product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business is highly dependent on our ability to successfully identify new product candidates, whether through acquisitions <span style="white-space:nowrap">or&#160;in-licensing&#160;transactions,</span> or through our internal capabilities. Our acquisition <span style="white-space:nowrap">and&#160;in-licensing&#160;efforts</span> focus on identifying assets in development by third parties across a diverse range of therapeutic areas. Our strategy often entails designing&#160;optimal, efficient&#160;studies that result in <span style="white-space:nowrap">quick&#160;&#8220;go/no-go&#8221;&#160;decisions</span> when deciding whether or how to proceed with future development for a given asset. We may decide to proceed with the development of a drug candidate on this basis and later determine that the more costly and time intensive trials do not support the initial value the product was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at the time of initial investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities, many of which have considerably greater financial and technical resources. If we are unable to identify a sufficient number of such product candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate returns and implement our investment strategy and our business and results of operations may suffer materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently have no marketing and sales organization for pharmaceutical products and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our pharmaceutical products, we may not be able to generate pharmaceutical product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no internal sales, marketing or distribution capabilities for pharmaceutical products (one subsidiary markets and sells medical products and devices), nor have we commercialized a product. If any of our pharmaceutical product candidates ultimately receive regulatory approval, we expect to establish either an internal or external pharmaceutical marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in applicable major markets, which will be expensive and, to the extent we establish such an organization <span style="white-space:nowrap">in-house,</span> time consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in establishing or managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal or external pharmaceutical sales, marketing and distribution capabilities would adversely impact the commercialization of these products. If we choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we may not be able to enter into collaborations or hire consultants or external service providers to assist us in pharmaceutical product sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our pharmaceutical product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any pharmaceutical products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our pharmaceutical products effectively. If we are not successful in commercializing our pharmaceutical products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future pharmaceutical product revenue and we would incur significant additional losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our investment strategy and future growth relies on a number of assumptions, some or all which may not be realized. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy for investment and plans for future expansion are founded upon a range of assumptions. These assumptions, particularly for our pharmaceutical product candidates, include considerations related to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adoption of a specific therapy, the price at which the product candidate might be sold (or reimbursed by third party payors), the occurrence of a particular medical condition, the preference for our product candidate over competing therapies, and the size of patient populations. Some or all of these assumptions might prove to be inaccurate because our ability to predict whether our product candidates will attain significant market acceptance or if a market for our product candidates will indeed materialize as anticipated, is inherently uncertain. If any of these assumptions turn out to be incorrect or overly optimistic, it could have a substantial and adverse impact on our results and future prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future success depends on our ability to retain key employees, directors, consultants and advisors and to attract, retain and motivate qualified personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We heavily depend on the expertise of our executive officers, directors, and scientific teams for their expertise in areas such as management, research and development, drug development, finance, and business development, both for OSR Holdings and our subsidiaries and investments. Their departure could adversely impact our research, development, and our licensing pursuits, and impede the execution of our business strategy. We do not carry &#8220;key person&#8221; insurance for our executives or staff so that replacing them might be challenging due to our inability to pay premium salaries or signing bonuses, together with the scarcity of individuals with the required breadth of skills and experience in our industry. We might struggle to attract, train, retain, or motivate them given the numerous competing pharmaceutical and biotechnology companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on a central team consisting of a limited number of employees who provide various administrative, research and development and other services to all our subsidiaries presents operational challenges that may adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, we had 18 full-time employees and two part-time employees whom we rely on for drug development planning, employee relations, financing accounting matters and other support services for our company and all of its subsidiaries. These individuals may not have sufficient time and bandwidth to perform effectively their respective responsibilities, potentially hindering the achievement of our goals and jeopardizing the execution of our business strategy. While our current structure helps us minimize certain overhead expenses, the relatively small size of our central team limits our ability to allocate enough personnel, time, and resources to effectively manage our subsidiaries and investments creation of effective drug development plans, employee recruitment and retention, and overseeing financial and accounting matters. Members of our central team may lack sufficient information about various aspects of our subsidiaries&#8217; business and operations to adequately address these responsibilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate expanding our roster of full-time employees, which will require significant management time and attention to hire qualified employees, which will divert a disproportionate amount of attention away from our daily operations and dedicate significant time to overseeing these growth initiatives. We will face challenges in effectively managing the expansion of our operations, which could lead to operational errors, missed business prospects, employee attrition, and decreased productivity among those who remain. Anticipated growth could necessitate substantial capital investments and potentially divert financial resources from other projects, including the advancement of additional product candidates. If our management team struggles to manage our growth effectively, it could lead to higher-than-expected expenses, curtailed revenue generation and growth capabilities, and potential obstacles in executing our business strategy. The success of our future financial performance and our ability to effectively bring product candidates to market and maintain competitiveness will hinge, in part, on our capacity to adeptly manage any forthcoming expansion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to New OSR Holdings&#8217; Requirements for Additional Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to additional capital requirements of OSR Holdings, which, following the closing of the Business Combination, will be the additional capital</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-style:italic">requirements of New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts and/or other operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years. OSR Holdings&#8217; operations, through its subsidiaries, have consumed substantial amounts of cash since inception. We currently do not have sufficient committed sources of additional capital to fund our operations. We expect our expenses to increase in connection with our ongoing activities, particularly as we advance our preclinical and clinical development programs, seek regulatory approvals for our product candidates, and launch and commercialize any products for which we receive regulatory approval. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain or expand our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that, following the Closing, we will be able to fund our operating expenses and capital expenditure requirements into 2026. However, our actual capital requirements may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and necessary activities associated with the development of our product candidates are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates, including whether and when to advance our diverse portfolio of product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical development plans we establish for these product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timelines of our clinical trials and the overall costs to finish the clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and characteristics of product candidates that we develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and cost of meeting regulatory requirements established by the FDA, European Medicines Agency and other comparable foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we enter into additional collaboration agreements with regard to product discovery or acquire or <span style="white-space:nowrap">in-license</span> products or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of completion of commercial-scale outsourced manufacturing activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.&#160;This additional funding may not be sufficient for us to fund any of our products through regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility and unforeseen events, such as the <span style="white-space:nowrap">COVID-19</span> pandemic and the conflict between Russia and Ukraine or in the Middle-East, could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to obtain additional financing to adequately capitalize New OSR Holdings after we complete the Business Combination or to fund the operations and growth of a target business, which could adversely affect the future prospects of New OSR Holdings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to have substantial proceeds from BLAC&#8217;s IPO in which to provide capital to New OSR Holdings and fund its growth following the Business Combination. As a result, even if the PIPE Financing is completed, or not completed at the amount we anticipate, we may be required to seek additional financing to provide such operating capital. We cannot assure you that such financing will be available on acceptable terms, if at all. We may require such financing to fund the operations or growth of New OSR Holdings. The failure to secure additional financing could have a material adverse effect on the continued development or growth of New OSR Holdings. None of BLAC&#8217;s Sponsor, officers, directors or their affiliates is required to provide any financing to us in connection with or after the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to spend substantial capital to complete the development of, seek regulatory approvals for and commercialize our pharmaceutical product candidates. We are unable to estimate the actual funds we will require to execute on our strategy because the length of time and activities associated with successful development of our pharmaceutical product candidates is highly uncertain, and due to the inherent challenges and uncertainties associated with the development of novel healthcare technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The additional capital that we need to fund our operations may not be available at all, or on terms that allow us to continue operations or provide any hope of generating future profits. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional capital will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of any product candidate, delay the launch or expansion of a given product or potentially discontinue our operations altogether. In addition, attempting to secure additional capital may divert the time and attention of our management <span style="white-space:nowrap"><span style="white-space:nowrap">from&#160;day-to-day&#160;activities</span></span> and harm our business. Because of the numerous risks and uncertainties associated with our business, we are unable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to estimate the amounts of increased capital outlays, operating expenditures and capital requirements associated with our current product development programs and technology products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future cash flows from operations are unlikely to satisfy our capital needs so that we will continue to need to obtain financing through other means that may involve dilution of our stockholders, limits on our financing activities or reductions of our interest in our subsidiaries and investments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, that we can generate substantial operating revenues, we expect to continue to finance our cash needs through a&#160;combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations. To the extent that we raise additional capital by issuing equity securities at the parent or subsidiary level, our existing stockholders&#8217; ownership, or our ownership in our subsidiaries, may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of our stockholders. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. The foregoing restrictions associated with potential sources of additional capital may make it more difficult for us to raise additional capital or to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, if and when we require it, our ability to grow or support our business and to respond to business challenges could be significantly limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we enter into acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring new product candidates, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased operating expenses and cash requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the assumption of indebtedness or contingent liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of our or our subsidiaries&#8217; equity securities which would result in dilution to our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates, intellectual property, and regulatory approvals; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Related to New OSR Holdings&#8217; Management of the Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the management of the business and operations of OSR Holdings, which, following the closing of the Business Combination, will be the</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-style:italic">management of the business and operations of New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance with its public company responsibilities and corporate governance practices. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that OSR Holdings did not incur as a private company, and these expenses may increase even more after we are no longer an emerging growth company, as defined in Section&#160;2(a) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. EGCs are permitted to implement many of these requirements over a longer period. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income, if any, and/or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">New OSR Holdings&#8217; management team has limited experience managing and operating a U.S.&#160;public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of New OSR Holdings&#8217; management team have limited experience managing and operating a U.S.&#160;publicly traded company, interacting with U.S.&#160;public company investors, and complying with the increasingly complex laws pertaining to U.S.&#160;public companies. As a U.S.&#160;public company, New OSR Holdings will be subject to significant regulatory oversight and reporting obligations under the U.S.&#160;federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from its senior management and could divert their attention away from <span style="white-space:nowrap"><span style="white-space:nowrap">the&#160;day-to-day&#160;management</span></span> of its business. New OSR Holdings may not have adequate personnel with the appropriate level of knowledge, experience, and training in the accounting policies, practices or internal controls over financial reporting required of U.S.&#160;public companies. The development and implementation of the standards and controls necessary for New OSR Holdings to achieve the level of accounting standards required of a public company may require costs greater than expected. To support its operations as a U.S.&#160;public company, New OSR Holdings plans to recruit additional qualified employees or external consultants with relevant experience, which will increase its operating costs in future periods. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to successfully effect the Business Combination and successfully operate the business thereafter will depend largely upon the efforts of certain key personnel, including the key personnel of OSR Holdings and its subsidiaries, all of whom we expect to remain employed (or retained as consultants) with New OSR Holdings or its subsidiaries following the Business Combination. The loss of such key personnel could adversely affect the operations and profitability of New OSR Bioscience&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our ability to recognize certain benefits of the Business Combination and successfully operate New OSR Holdings&#8217; business following the Business Combination will depend upon the efforts of its key personnel. Although we expect all of such key personnel to remain with New OSR Holdings following the Business Combination, the unexpected loss of key personnel may adversely affect its operations and profitability. In addition, New OSR Holdings&#8217; future success depends in part on its ability to identify and retain key personnel to succeed senior management. Furthermore, while we have closely scrutinized the skills, abilities and qualifications of the key OSR Holdings&#8217; or its subsidiaries&#8217; personnel that will be employed by New OSR Holdings, our assessment may not prove to be correct. If such personnel do not possess the skills, qualifications or abilities we expect or those necessary to manage a public company, the operations and profitability of New OSR Holdings&#8217; business may be negatively impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Charter and New OSR Holdings Bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the DGCL, the New OSR Holdings Charter, New OSR Holdings Bylaws and the indemnification agreements that we entered into with our directors and officers provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at its request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are not obligated pursuant to the New OSR Holdings Charter and New OSR Holdings Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights conferred in the New OSR Holdings Charter and New OSR Holdings Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The outbreak of new, novel diseases, similar to the world&#8217;s recent experience with <span style="white-space:nowrap">COVID-19,</span> could adversely impact our business, including our preclinical studies and clinical trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of the coronavirus disease, <span style="white-space:nowrap">COVID-19,</span> was identified in Wuhan, China. The virus spread globally and government measures taken in response had a significant impact, both direct and indirect, on businesses and commerce, resulting in worker shortages, disruption of supply chains, and closure of offices, laboratories, and production facilities. Demand for certain goods and services, such as medical services </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and supplies, spiked, while demand for other goods and services, such as travel, fell dramatically. If a new disease began to spread, we may experience disruptions that could severely impact our business, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruptions in preclinical studies due to restricted or limited operations at our laboratory facilities or at facilities of our collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of, or delays in receiving, supplies for preclinical studies and/or clinical trials from our Contract Research Organizations (&#8220;CROs&#8221;), Contract Manufacturing Organizations (&#8220;<span style="text-decoration:underline">CMOs</span>&#8221;) or other collaborators due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption or delays to our sourced research and discovery and clinical activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in commencing enrollment of patients in our clinical trials, enrolling and retaining patients in our clinical trials in adequate numbers and difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial participant visits and study procedures that are deemed nonessential, which may impact the integrity of participant data and clinical trial endpoints; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption or delays in the operations of the FDA, European Medicines Agency or other regulatory authorities, which may impact review and approval timelines. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which an outbreak impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of any disease, the duration of any pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shareholder litigation and regulatory inquiries and investigations are expensive and could harm New OSR Holdings&#8217; business, financial condition and operating results and could divert management attention. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since securities class action litigation and/or stockholder derivative litigation and inquiries or investigations by regulatory authorities often follows significant business transactions, such as the sale of a company or announcement of any other strategic transaction, such as the Business Combination, we may become subject to those types of lawsuits or investigations. Shareholder activism, which could take many forms or arise in a variety of situations, has been increasing recently. Any stockholder litigation, stockholder activism, including potential proxy contests, and/or regulatory investigations against New OSR Holdings, whether or not resolved in New OSR Holdings&#8217; favor, could result in substantial costs and divert New OSR Holdings&#8217; management&#8217;s attention from other business concerns, which could adversely affect New OSR Holdings&#8217; business and cash resources and the ultimate value New OSR Holdings&#8217; shareholders receive as a result of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be the target of securities class action and derivative lawsuits which could result in substantial costs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation, including class action litigation. We may be the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
target of this type of litigation in the future. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. We cannot predict whether any such lawsuits will be filed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The outcome of any future claims and litigation could have a material adverse impact on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, from time to time, be subject to claims and may become party to litigation in the normal course of business, including class action lawsuits. Such claims and litigation proceedings may be brought by third parties, including our customers, competitors, advisors, service providers, partners or collaborators, employees, and governmental or regulatory bodies. The final outcome of these claims and litigation, including any settlements, may be significant and may differ substantially from our expectations. We may not be able to determine the amount of any potential losses and other costs we may incur due to the inherent uncertainties of litigation and settlement negotiations. In the event we are required or decide to pay amounts in connection with any claims or lawsuits, such amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite having security measures in place, both our internal computer systems and those of our future CROs, contractors, collaborators and consultants could be susceptible to potential damage, disruption or failure as a result of hardware malfunctions, power outages, natural disasters, computer viruses, cyber-attacks, employee theft or misuse and other unauthorized access. While we don&#8217;t believe we have experienced any significant system failures or security breaches to date, the occurrence of such an event could lead to substantial disruptions in our development programs and overall business operations and subject us to governmental sanctions and private causes of action. For instance, the loss of clinical trial data, whether from completed, ongoing, or future trials, could lead to delays in our efforts to gain regulatory approval and result in substantial costs to recover or reproduce the lost data. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be held liable for monetary damages resulting from security breaches of our internal computer systems, and our insurance policies may be insufficient to cover potential losses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also incur liability for unauthorized disclosure of sensitive information, especially personal identifying information or personal health data. Specific data breaches may necessitate reporting to affected individuals, governmental bodies, and, in some instances, the media, under regulations like the Health Insurance Portability and Accountability Act (&#8220;<span style="text-decoration:underline">HIPAA</span>&#8221;) and other U.S. federal and state laws, as well as requirements from <span style="white-space:nowrap">non-U.S.</span> jurisdictions. Our existing insurance policies might not be sufficient to cover potential losses stemming from breaches, system failures, catastrophic events, or other forms of disruption to our infrastructure. Additionally, there&#8217;s a possibility that such insurance may not be available to us in the future on economically viable terms, or at all. Furthermore, our insurance might not cover all claims brought against us, and the process of defending a lawsuit, regardless of its merit, could be both expensive and divert management&#8217;s focus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We or the third parties upon whom we depend on may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating subsidiaries are located in South Korea and Switzerland. South Korea is subject to various natural disaster risks, including flooding, storms and typhoons, primarily during the summer season, and to a more infrequent extent, earthquakes. Switzerland, due to its topography, is particularly vulnerable to natural disasters such as flooding. Natural disasters could cause significant disruptions to the operations of our subsidiaries, which could seriously impact our business, financial condition, results of operations, and future </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospects. Our ability to sustain our business operations might be challenging, and in some cases, impossible for a considerable duration. Our current disaster recovery and business continuity plans have limitations and might not be sufficient to address a severe disaster or similar occurrence effectively. We might incur substantial expenses due to the inherent limitations of our disaster recovery and business continuity plans. The combination of these limitations along with our lack of earthquake insurance could lead to a significant adverse impact on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tensions with North Korea could have an adverse effect on our business, financial condition, and results of operations, and the price per share of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relations between South Korea and North Korea have fluctuated over the years. Tension between South Korea and North Korea may increase or change abruptly as a result of current and future events. In particular, there have been heightened security concerns in recent years stemming from North Korea&#8217;s nuclear weapon and ballistic missile programs as well as its hostile military actions against South Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">North Korea&#8217;s economy also faces severe challenges, which may further aggravate social and political pressures within North Korea and affect South Korea. Beginning in 2018, North Korea held a series of bilateral summit meetings with South Korea and the United States to discuss peace and denuclearization of the Korean peninsula. However, those discussions have ended and North Korea has since resumed its missile testing and bellicose statements, heightening tensions, and increasing uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further tensions in North Korean relations could develop due to a leadership crisis, breakdown in high-level inter-Korea contacts or military hostilities. Alternatively, tensions may be resolved through reconciliatory efforts, which may include peace talks, alleviation of sanctions or reunification. We cannot assure that future negotiations will even occur and, if they do, result in any lasting resolution of key issues, such as North Korea&#8217;s nuclear program, or that the level of tensions between South Korea and North Korea will not escalate. Any increase in the level of tension between South Korea and North Korea, an outbreak in military hostilities or other actions or occurrences, could adversely affect our business, prospects, financial condition, and results of operations and could lead to a decline in the price per share of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Except with respect to RMC, our Korean subsidiary engaged in the sale and distribution of medical products in Korea, we do not expect to carry any business interruption insurance or any other insurance (except for director and officer liability insurance). As a result, we may incur uninsured losses, increasing the possibility that you would lose your entire investment in New OSR Holdings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pharmaceutical products may expose us to product liability or other product claim risks. We currently do not have product liability or other insurance for such claims and may not be able to obtain such insurance on acceptable terms or that any insurance we do obtain will be sufficient to protect us against potential claims or that insurance will be available in the future in amounts sufficient to protect us. A product liability claim or other claim, as well as any claims for uninsured liabilities or in excess of insured liabilities, could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contracts and other arrangements that pharmaceutical manufacturers have with third-party payors, health care providers and customers create risk that the pharmaceutical manufacturers may violate broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute (&#8220;<span style="text-decoration:underline">AKS</span>&#8221;) and the federal False Claims Act (&#8220;<span style="text-decoration:underline">FCA</span>&#8221;). Those laws and regulations may constrain the business or financial arrangements and relationships through which pharmaceutical manufactures sell, market and distribute pharmaceutical products. In particular, the research of our product candidates, as well </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. If we do not strictly comply with these laws and regulations, we may be found to be criminally or civilly liable for violations under those laws and regulations, including a false or fraudulent claim, which could subject us (and, potentially, our employees) from significant fines and penalties, including prison. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws may be uncertain and subject to rapid change in the current environment of healthcare reform. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not successful in defending ourselves or asserting our rights, governmental or other actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities, all of which will require us to incur significant costs and expenses. In addition, we will be subject to continued compliance with the Current Good Manufacturing Practices (&#8220;<span style="text-decoration:underline">cGMP</span>&#8221;) and Good Clinical Practices (&#8220;<span style="text-decoration:underline">GCP</span>&#8221;) requirements for any clinical trials that we conduct post-approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not comply with regulatory requirements and applicable standards or if problems occur after a product reaches the market, the FDA or European Medicines Agency may impose consent decrees or withdraw approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">revisions to the labeling, including limitation on approved uses or the requirement of additional warnings, contraindications or other safety information, including boxed warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a Risk Evaluation and Mitigation Strategy (&#8220;<span style="text-decoration:underline">REMS</span>&#8221;), which may include distribution or use restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to conduct additional post-market clinical trials to assess the safety of the product; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention or refusal to permit the import or export of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s, European Medicines Agency&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA, European Medicines Agency and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, European Medicines Agency and other regulatory agencies strictly regulate the post-approval marketing, labeling, advertising, and promotion of products that are placed on the market. The FDA, European Medicines Agency and other regulatory agencies impose stringent restrictions on sponsors&#8217; communications regarding <span style="white-space:nowrap">off-label</span> use. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is not inconsistent with the labeling. The FDA, European Medicines Agency and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <span style="white-space:nowrap">off-label</span> use and has enjoined several companies from engaging in <span style="white-space:nowrap">off-label</span> promotion. Violation of the Federal Food, Drug, and Cosmetic Act and other statutes, including the FCA, and equivalent legislation in other countries relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state and other countries&#8217; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Affordable Care Act and the Inflation Reduction Act, as well as other ongoing healthcare legislative and regulatory reform measures, may have a material adverse effect on our business and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress and regulatory agencies in the United States (and to a lesser extent, state legislatures) have in recent years proposed and sometimes adopted substantial changes in laws and regulations that affect the healthcare and pharmaceutical industry. These laws, including what is known as the Affordable Care Act (the &#8220;<span style="text-decoration:underline">ACA</span>&#8221;), and the IRA, have substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry, including permitting the Centers for Medicare and Medicaid Services (the &#8220;<span style="text-decoration:underline">CMS</span>&#8221;), for the first time, to negotiate prices with pharmaceutical companies for selected drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many legislative and regulatory proposals have sought to reduce drug prices, increase competition, lower <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. These legislature and regulatory changes may significantly adversely impact our business and profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IRA was passed on August&#160;16, 2022 and, among other things, allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost drugs paid for by Medicare Part D starting in 2026, followed by up to 15 Part D drugs in 2027, up to 15 Part B or Part D drugs in 2028, and up to 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> drug expenses at $2,000. The effect of the IRA on our business and the healthcare industry in general is not yet known. We cannot predict how CMS will interpret the IRA or how the provisions of the law will affect our business once fully implemented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, requirements for substitution of generic products, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws, and future state and federal healthcare reform measures that may be adopted in the future, could adversely affect the prices we may obtain for any of our product candidates or the frequency with which any such product candidate is prescribed or used. We expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes, all of which may adversely affect our business and future profits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If New OSR Holdings&#8217; officers and directors serve as directors or officers of majority-owned subsidiaries, those individuals will have fiduciary and other duties to those subsidiaries and their minority stockholders, potentially causing conflicts of interest between their duties to New OSR Holdings and their duties to those subsidiaries. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our officers, including Mr.&#160;Hwang, are also directors and/or officers of one or more of our subsidiaries and, if those subsidiaries were to become majority-owned subsidiaries (as a result of third-party financing or investments), our officers would have fiduciary or other duties both to us and any majority-owned subsidiaries (including future subsidiaries). The conflicts of interest that arise from such duties could interfere with the management of those subsidiaries and their programs and product candidates, or result in disagreements with our majority-owned subsidiaries&#8217; other stockholders. For example, an individual who is both our director and a director of one of our subsidiaries, owes fiduciary duties to the subsidiary and to us, and such individual may encounter circumstances in which his or her decision or action may benefit the subsidiary while having a detrimental impact on us, or vice versa, or on another subsidiary. Further, our officers and directors who are also officers and directors of any majority-owned subsidiaries will need to allocate his or her time to responsibilities owed to us and each of the subsidiaries for which he or she serves as an officer or director, and will make decisions on behalf of one entity that may negatively impact others. In addition, disputes could arise between us and our subsidiaries&#8217; other directors, officers and stockholders regarding a conflict of interest. Those stockholders also may disagree with the amount and quality of resources that we devote to the subsidiary in which they are invested. Any such disputes or disagreements could lead to claims, and potential damages, of breach of fiduciary duties, and distract our management, interfere with our relations with those stockholders, and take significant time to resolve. Those issues could disrupt the development of our product candidates, delay our potential commercialization efforts, result in increased costs or make it less likely that other third parties will choose to partner with us in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, and partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face the potential risk of encountering fraudulent activities, misconduct, or other unlawful behaviors involving our employees, independent contractors, consultants, commercial partners, and vendors. This </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misconduct could encompass intentional, reckless, or negligent actions that result in failure to: adhere to the regulations of the FDA or similar foreign regulatory bodies; provide accurate and complete information to the FDA and equivalent foreign regulatory authorities; adhere to the manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar fraudulent misconduct laws in other countries; adhere to applicable privacy and data security laws in the United States and in other countries; or accurately report financial information or disclose unauthorized activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to International Operations of New OSR Holdings&#8217; Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the international operations of OSR Holdings, which, following the closing of the Business Combination, will be the international operations of New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If economic conditions in South Korea deteriorate, our current business and future growth could be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings is headquartered in the Republic of Korea (&#8220;<span style="text-decoration:underline">Korea</span>&#8221;) and significant operations and assets are located in Korea. As a result, we are subject to political, economic, legal and regulatory risks specific to Korea, and our performance and successful fulfilment of our operational strategies are dependent in part on the overall Korean economy. The economic indicators in Korea in recent years have shown mixed signs of growth and uncertainty, and starting in 2020, the Korean and global economies were affected as a result of <span style="white-space:nowrap">the&#160;COVID-19&#160;pandemic.</span> As a result, future growth of the Korean economy is subject to many factors beyond our control, including developments in the global economy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korean economy is closely tied to, and is affected by developments in, the global economy. In recent years, adverse conditions and volatility in the worldwide financial markets, fluctuations in oil and commodity prices, and <span style="white-space:nowrap">the&#160;COVID-19&#160;pandemic,</span> have contributed to the uncertainty of global economic prospects in general and have adversely affected, and may continue to adversely affect, the Korean economy. Due to liquidity and credit concerns and volatility in the global financial markets, the value of the Korean Won relative to the U.S. dollar and other foreign currencies and the stock prices of Korean companies have fluctuated significantly in recent years. Further declines in the Korea Composite Stock Price Index, and large amounts of sales of Korean securities by foreign investors and subsequent repatriation of the proceeds of such sales may adversely affect the value of the Korean Won, the foreign currency reserves held by financial institutions in Korea, and the ability of Korean companies to raise capital. Any future deterioration of the Korean economy or the global economy could adversely affect our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fluctuations in exchange rates could result in foreign currency exchange losses to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of the Korean Won and other currencies against the U.S.&#160;dollar has fluctuated, and may continue to fluctuate and is affected by, among other things, changes in political and economic conditions. It is difficult to predict how market forces or Korean or U.S.&#160;government policy, including any interest rate increases by the Federal Reserve, may impact the exchange rate between the Korean Won and the U.S.&#160;dollar in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A substantial percentage of our revenue and costs are denominated in Korean Won, and a significant portion of our financial assets are also denominated in Korean Won, while we anticipate that a substantial portion of any debt incurred will be denominated in U.S.&#160;dollars. We are a holding company and we may receive dividends, loans and other distributions on equity paid by our operating subsidiaries in Korea. Any significant fluctuations in the value of the Korean Won may materially and adversely affect our liquidity and cash flows. For example, the depreciation of the Korean Won and other foreign currencies against the U.S.&#160;dollar typically results in a material increase in the cost of hosting services and equipment purchased from outside of Korea and the cost of servicing debt denominated in currencies other than the Korean Won. As a result, any significant depreciation of the Korean Won or other major foreign currencies against the U.S.&#160;dollar may have a material adverse effect on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our results of operations. If we decide to convert our Korean Won into U.S.&#160;dollars for the purpose of repaying principal or interest expense on any future U.S.&#160;dollar-denominated&#160;debt, making payments for dividends on our common stock, or other business purposes, depreciation of the Korean Won or other foreign currencies against the U.S.&#160;dollar would have a negative effect on the U.S.&#160;dollar amount we would receive. Conversely, to the extent that we need to convert U.S.&#160;dollars into Korean Won for our operations, appreciation of the Korean Won against the U.S.&#160;dollar would have an adverse effect on the Korean Won amount we would receive. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There are special risks involved with investing in Korean companies, including the possibility of restrictions being imposed by the Korean government in emergency circumstances, accounting and corporate disclosure standards that differ from those in other jurisdictions, and the risk of direct or vicarious criminal liability for executive officers of our Korean affiliates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings is a Korean company and operates in a business and cultural environment that is different from that of other countries. For example, under the Foreign Exchange Transaction Act&#160;of&#160;Korea, if the Korean government determines that in certain emergency circumstances, including sudden fluctuations in interest rates or exchange rates, extreme difficulty in stabilizing the balance of payments or substantial disturbance in the Korean financial and capital markets are likely to occur, it may impose any necessary restriction such as requiring Korean or foreign investors to obtain prior approval from the Minister of Economy and Finance of Korea prior to entering into a capital markets transaction, repatriating interest, dividends or sales proceeds arising from Korean securities or from the disposition of such securities or other transactions involving foreign exchange. Although investors will hold shares of New OSR Holdings common stock, its majority owned subsidiary, OSR Holdings, may experience adverse risks and in turn could adversely impact New OSR Holdings&#8217; business, prospects, financial condition, and results of operations and could lead to a decline in the price per share of its common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Korean law, there are circumstances in which certain executive officers of a company may be investigated or held criminally liable either directly or vicariously for the actions of the company and its executives and employees. For example, complaints alleging infringement of intellectual property rights, breaches of certain Korean laws (<span style="font-style:italic">e.g.</span>, labor standards laws and fair trade laws), and product-related&#160;claims may be investigated and prosecuted as criminal offenses with both the company and the company&#8217;s executive officers being named as defendants in such proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these current and changing risks, OSR Holdings&#8217; executive officers may be named in the future in criminal investigations or proceedings stemming from its operations. In Korea, company executive officers being named in such investigations or proceedings are a common occurrence, even though in practice many such cases result in no liability to the individual. If OSR Holdings&#8217; executive officers were to be named in such criminal proceedings or held either directly or vicariously criminally liable for the actions of OSR Holdings and its executives and employees, New OSR Holdings&#8217; business, financial condition, and results of operations may be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">OSR Holdings is subject to certain requirements and restrictions under Korean law that may, in certain circumstances, require it to act in a manner that may not be in New OSR Holdings&#8217; or its stockholders</span></span>&#8217;<span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;best interest.</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable Korean law, directors of a Korean company, such as OSR Holdings, owe a fiduciary duty to the company itself rather than to its stockholders. This fiduciary duty obligates directors of a Korean company to perform their duties faithfully for the good of the company as a whole. In addition, while the facts and circumstances of each case will differ, the duty of care required of a director under Korean law may not be the same as the fiduciary duty of a director of a U.S. corporation. Although the &#8220;business judgment rule&#8221; concept exists in Korea, there is insufficient case law or precedent to provide guidance to the management and stockholders as to how it should be applied or interpreted. As a result, if circumstances arise in which the good of OSR Holdings conflicts with the good of New OSR Holdings or its stockholders, OSR Holdings may not be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted under applicable Korean law to act in a manner that is in the best interest of New OSR Holdings or its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the board of directors of a Korean company is required for, among other things, all transactions between a director or major stockholder (including a 10% or more stockholder) and the company for the director&#8217;s or the major stockholder&#8217;s account. As a result, intercompany transactions between New OSR Holdings and OSR Holdings (or any other Korean subsidiary we may own, from time to time), could arise in the future in which the directors of the Korean subsidiary are not able to act in New OSR Holdings or its stockholders&#8217; best interest as a result of competing interests of the subsidiary. Since substantially all of our operations are conducted by OSR Holdings, any such occurrence with respect to OSR Holdings could adversely affect our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OSR Holdings&#8217; transactions with related parties are subject to close scrutiny by the Korean tax authorities, which may result in adverse tax consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Korean tax law, there is an inherent risk that OSR Holdings&#8217; transactions with its subsidiaries, affiliates or any other person or company that is related to us may be challenged by the Korean tax authorities if such transactions are viewed as having been made on terms that were not on an <span style="white-space:nowrap">arm&#8217;s-length&#160;basis.</span> If the Korean tax authorities determine that any of its transactions with related parties were on other than <span style="white-space:nowrap">arm&#8217;s-length&#160;terms,</span> it may not be permitted to deduct as expenses, or may be required to include as taxable income, any amount which is found to be undue financial support between related parties in such transaction, which may have adverse tax consequences for us and, in turn, may adversely affect our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If&#160;we are deemed to have a&#160;&#8220;place of effective management&#8221;&#160;in Korea, we will be treated as a Korean company for the purpose of Korean corporate income tax with regards to our worldwide income. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Korean law, a corporation having a &#8220;place of effective management&#8221; in Korea will be subject to Korean corporate income tax. The &#8220;place of effective management&#8221; is determined on a case-by-case basis, taking into account factors such as the place where meetings of the board of directors are usually held, the place where the key executives usually perform their duties, the place where the day-to-day management of senior managers is carried out, and the place where accounting documents are routinely recorded and kept, etc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will assert that New OSR Holdings does not have a &#8220;place of effective management&#8221; in Korea, because we do not have any form of physical business office in Korea and most of our key executive officers will conduct business in the U.S. Further, our board of directors, a majority of whom are U.S. citizens (and only [&#9679;] of whom are Korean citizens or residents) will make significant decisions regarding our business, including decisions regarding capital raising and acquisitions, in the U.S., our headquarters will be in the U.S., and our books of account will be routinely recorded and maintained in the US. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Korean tax authorities may, however, challenge that conclusion given that (i) Mr. Kuk Hyoun Hwang, a director and our Chief Executive Officer and Chairman of the Board of Directors, is a Korean national, and Mr. Hwang spends most of the year working in Korea and will continue to do so after the Closing; (ii) most of the members of the board of directors of our largest subsidiary, OSR Holdings, are Korean; and (iii) after the Closing, important documents, including the accounting documents of our domestic business, may be maintained and controlled in Korea. If we are deemed to have a &#8220;place of effective management&#8221; in Korea, we will be required to file annual corporate income tax returns with the Korean tax authorities and be subject to Korean corporate income tax. Currently, the applicable rates are 11% (inclusive of local corporate taxes) for taxable income up to 200&#160;million Korean Won, 22% (inclusive of local corporate taxes) for taxable income exceeding 200&#160;million Korean Won and less than 20&#160;billion Korean Won, 24.2% (inclusive of local corporate taxes) for taxable income greater than 20&#160;billion won and less than 300&#160;billion Korean Won, and 27.5% (inclusive of local corporate tax) for taxable income greater than 300&#160;billion Korean Won. Taxable income would include any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
worldwide income, such as dividends we receive from our Korean operating company and any interest income earned outside of Korea. If we are required to pay Korean corporate income tax, it may reduce our cash flow and negatively impact the returns to investors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">If we are deemed to have a</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span>&#160;&#8220;<span style="font-weight:bold"><span style="font-style:italic">permanent establishment</span></span>&#8221;<span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;in Korea, we will be subject to Korean corporate income tax with regards to any Korean source income attributable to or effectively connected with such permanent establishment.</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CTA, where a foreign corporation has a fixed place for the operation of all or part of its domestic business, the foreign corporation shall be deemed to have a &#8220;permanent establishment&#8221; in Korea. In addition, even if a foreign corporation does not have a physical fixed place of business in Korea, it is deemed to have a &#8220;permanent establishment&#8221; in Korea if it operates the business in Korea through persons (the &#8220;Dependent Agent(s)&#8221;) who are authorized to conclude business contracts under the name of the foreign corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Supreme Court of Korea, in order for a foreign corporation to be considered to have a physical &#8220;permanent establishment&#8221; in Korea, the foreign corporation must have a fixed place of business, such as a building or facility in Korea that the foreign corporation has the right to dispose of or use, and the employees or persons under its direction must carry out essential and important business activities, rather than preliminary or auxiliary business activities. In addition, in order for a foreign corporation to be deemed to have a &#8220;permanent establishment&#8221; in Korea through a Dependent Agent, the agent must exercise the right to enter into contracts in the name of the foreign corporation on a regular basis in Korea, and the authority must be essential and important to the business activities, rather than preliminary or auxiliary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect that we are likely to be deemed as having a &#8220;permanent establishment&#8221; in Korea, because we do not have a principal office, branch office or any other form of business office in Korea, nor do we have any physical fixed place of business in Korea that we have the right to dispose of or use. Further, our essential and important business activities, including the acquisition of companies, are made in the United States through the decisions of our board and we have not authorized any person or entity to make decisions regarding whether or not to enter into a business acquisition agreement in Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we cannot rule out, on a conservative basis, the possibility that we may be deemed to have a &#8220;permanent establishment&#8221; in Korea after the Closing given that (i) Mr. Hwang, our Chief Executive Officer and the representative director of OSR Holdings, is a Korean national and will continue to perform his duties primarily in Korea and (ii) most of the members of the board of directors of OSR Holdings who will be performing substantial functions in connection with our business after the Closing are Korean. If we are deemed to have a &#8220;permanent establishment&#8221; as defined under Korean tax law, we would be required to file annual corporate income tax returns with the Korean tax office and be subject to Korean corporate income tax. The applicable rates are 9% (inclusive of local corporate taxes) for taxable income up to 200 million Korean Won, 19% (inclusive of local corporate taxes) for taxable income exceeding 200 million Korean Won and less than 20&#160;billion Korean Won, 21% (inclusive of local corporate taxes) for taxable income greater than 20 billion won and less than 300 billion Korean Won, and 24% (inclusive of local corporate tax) for taxable income greater than 300 billion Korean Won. Taxable income includes any Korean source income attributable to or effectively connected with such permanent establishment, such as dividends we receive from our Korean operating company. If we are required to pay Korean corporate income tax, it may reduce our cash flow and negatively impact the returns to investors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">New or higher taxes resulting from changes in tax regulations or the interpretation thereof in South Korea could adversely affect our results of operations and financial condition in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New tax laws and regulations, and uncertainties with respect to future tax policies pose risks to us. Changes in <span style="white-space:nowrap">tax-related</span> laws and regulations, and interpretations thereof, can create additional tax burdens on us and our businesses by increasing tax rates and fees, creating new taxes, limiting tax deductions, and/or eliminating </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">tax-based</span> incentives and <span style="white-space:nowrap">non-taxed</span> income. In addition, tax authorities and competent courts may interpret tax regulations differently than us, which could result in tax litigation and associated costs and penalties in part due to the novelty and complexity of new regulation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A focus on regulating copyright and patent infringement by the Korean government subjects OSR Holdings to extra scrutiny in its operations and could subject OSR Holdings to sanctions, fines, or other penalties, which could adversely affect New OSR Holdings&#8217; business and operations in Korea. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korean government has recently focused on addressing copyright and patent infringement in Korea Despite measures we have taken to address copyright and patent infringement, the Korean government may subject us to sanctions, fines, or other penalties, which could adversely affect our business and operations in Korea. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are a global organization with business operations in the United States, Korea, Switzerland, and in other European Union countries, which makes us subject to a variety of additional risks that may negatively impact our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and currently all of our subsidiaries and investments conduct operations outside of the United States, so that we are subject to the special considerations or risks associated with companies operating in the United States and in an international setting, including any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rules and regulations regarding currency exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complex corporate withholding taxes on individuals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">laws governing the manner in which future business combinations may be effected; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tariffs and trade barriers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulations related to customs and import/export matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">longer payment cycles and challenges in collecting accounts receivable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tax issues, including but not limited to tax law changes and variations in tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">currency fluctuations and exchange controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rates of inflation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cultural and language differences; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employment regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trade restrictions including limitations on imports or exports of components or assembled products, unilaterally or bilaterally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trade sanctions and related regulatory enforcement actions and other proceedings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential trade wars; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased scrutiny by the media and other third parties of labor practices within our industry (including but not limited to working conditions) which may result in allegations of violations, more stringent and burdensome labor laws and regulations and inconsistency in the enforcement and interpretation of such laws and regulations, higher labor costs, and/or loss of revenues if our customers become dissatisfied with our labor practices and diminish or terminate their relationship with us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of restrictions on currency conversion or the transfer of funds; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expropriation of private entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffective legal protection of our intellectual property rights in certain countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">deterioration of political relations with the United States; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">government appropriations of assets. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to adequately address these additional risks. If we were unable to do so, our operations might suffer, which may adversely impact our results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions, where we will become subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU and other companies have adopted legislation or regulations that, much like the U.S. AKS, restricts the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products. Violations of these laws could result in substantial fines and imprisonment. Failure to comply with these requirements could also result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about participants and healthcare providers (including information relating to their representatives) in connection with clinical trials. Processing of personal data, including health related information, is increasingly subject to legislation and regulations in numerous jurisdictions around the world, including General Data Protection Regulation (&#8220;<span style="text-decoration:underline">GDPR</span>&#8221;) and each of the California Consumer Privacy Act of 2018 and <span style="text-decoration:underline">HIPAA</span> in the United States, among many others. The application and enforcement of data protection laws and regulations may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others, including potential significant penalties. We expect the data protection laws will increase our compliance costs and potential liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional laws and regulations governing international operations could negatively impact or restrict our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act (&#8220;<span style="text-decoration:underline">FCPA</span>&#8221;) prohibits any U.S. individual or business entity from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and healthcare providers in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from the FCPA, we are subject to various other anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent&#160;years and broadly prohibit companies, their employees and third-party intermediaries to authorize, offer or provide, directly or indirectly, improper payments or benefits to recipients in the public or private sector. As we increase our international sales and business, we may engage with business partners and third-party intermediaries to market our products and to obtain necessary permits, licenses, and other regulatory approvals. In addition, we or our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or -affiliated entities. We could be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize such activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <span style="white-space:nowrap">non-U.S.</span> nationals, of information products classified for national security </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes, as well as certain products, technology and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Development of New OSR Holdings&#8217; Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the development of product candidates by OSR Holdings, which, following the closing of the Business Combination, will be the development</span> <span style="font-style:italic">of product candidates by New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business includes subsidiaries that are developing oral immunotherapies for the treatment of cancer and design-augmented biologics. These companies have a limited operating history, and their programs are in early stages of development. This may make it difficult to evaluate our prospects and likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business includes subsidiaries that are (i) developing oral immunotherapies for the treatment of cancer, and (ii) developing design-augmented biologics for age-related and other degenerative diseases. Each of these subsidiaries is an early-stage company with a limited operating history, has no pharmaceutical products approved for commercial sale and has not generated any revenue from sales of its products. Our approach to the discovery and development of any therapeutic product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. These product candidates will require substantial additional development and clinical research time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We do not yet have substantial experience progressing therapeutic product candidates through clinical trials. We may be unable to demonstrate safety and efficacy in clinical trials, obtain regulatory approval, manufacture at a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization of any of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet demonstrated the ability to progress any therapeutic product candidate through clinical trials to regulatory approval. Our oral immunotherapy candidates and design-augmented biologics are still in early-stage development and may not be able to obtain regulatory approval. Neither OSR Holdings nor any of its subsidiaries have (1) manufactured any product on a commercial scale, (2) contracted with a third party to produce any product on a commercial scale (we have contracted with a third party for limited quantities of our products necessary for testing and clinical trials), or (3) conducted sales and marketing activities for approved therapeutic products (RMC does conduct sales and marketing activities for medical devices designed and manufactured by third parties). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in drug development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors and risks frequently experienced by early-stage companies in rapidly evolving fields. Consequently, we have no meaningful history of drug development operations experience upon which to evaluate our drug development business, and predictions about its future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing therapeutic products. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates will, of necessity, be subjected to <span style="white-space:nowrap">pre-clinical</span> and clinical trials prior to commercialization. Delays in those trials, or if the results of the trials raise regulatory issues, may adversely impact our results of operations and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience setbacks that could delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely completion of our preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence, duration and severity of potential product-related side effects experienced by participants receiving our product candidates in our clinical trials or by individuals using drugs or therapeutics similar to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in submitting Investigational New Drug (&#8220;IND&#8221;) or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in enrolling participants in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">high <span style="white-space:nowrap">drop-out</span> rates of participants from clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater than anticipated clinical trial costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to compete with other therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">poor efficacy of our product candidates during clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays related to the impact of recessions, <span style="white-space:nowrap">man-made</span> and/or natural disasters, pandemics, and/or any other such events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">varying interpretations of data by the FDA and similar foreign regulatory agencies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of any of our product candidates, which may adversely impact our results of operations and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience delays in initiating or completing clinical trials. Clinical trials can be delayed or terminated for a variety of reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or institutional review boards (&#8220;<span style="text-decoration:underline">IRB</span>&#8221;) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with respect to dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The number of participants required for clinical trials of any product candidates may be larger than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <span style="white-space:nowrap">follow-up</span> at a higher rate than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from a clinical trial protocol or drop out of a trial, which may require that we add new clinical trial sites or investigators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may need to address any safety concerns that arise during the course of a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may experience delays and interruptions to our manufacturing supply chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with third-party service providers on whom we rely; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of our product candidates may be greater than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">logistical issues relating to any future clinical trials we may conduct; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may elect to, or regulators, IRBs, Data and Safety Monitoring Boards, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not have the financial resources available to begin and complete the planned trials, or the cost of clinical trials of any product candidates may be greater than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which such clinical trials are being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience additional delays in preclinical or clinical testing or in obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we do not achieve our product development goals in the time frames we announce and expect, the approval and commercialization of our product candidates may be delayed or prevented entirely. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trials <span style="white-space:nowrap">and&#160;pre-clinical&#160;studies</span> are very expensive, time-consuming, and difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials <span style="white-space:nowrap">or&#160;pre-clinical&#160;studies</span> on the expected timelines, if at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials <span style="white-space:nowrap">and&#160;pre-clinical&#160;studies</span> are very expensive, time-consuming and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The FDA, an IRB or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates, and during any such review, may identify unexpected efficacy or safety concerns, which may delay the approval of a New Drug Application (&#8220;<span style="text-decoration:underline">NDA</span>&#8221;), a Biologic License Application (&#8220;<span style="text-decoration:underline">BLA</span>&#8221;) or similar application. The FDA may also find that the benefits of any product candidate in any applicable indication do not outweigh its risks in a manner sufficient to grant regulatory approval or may find that our proposed development program is not sufficient to support a marketing authorization application, or that the proposed indication is considered to be too broad. Moreover, the FDA or other regulatory authorities may also refuse or impose certain restrictions on our reliance on data supporting our marketing authorization application should such data originate from studies outside of the relevant jurisdiction. In each case, this could delay the clinical development timeline for a given product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal investigators for our clinical trials may also serve as scientific advisors or consultants to our subsidiaries and investments, which may raise regulatory issues with the FDA or other regulatory authorities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of any of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Negative results or safety signals in our clinical trials may make it difficult or impossible to recruit and retain patients in our clinical trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any negative results or new safety signals we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. Also, marketing authorization of competitors in this same class of drugs may impair our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The results of our clinical trials may not support our proposed claims for our product candidates, or regulatory approvals on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results <span style="white-space:nowrap">of&#160;pre-clinical&#160;studies</span> and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed <span style="white-space:nowrap">through&#160;pre-clinical&#160;and</span> initial clinical trials. In addition, results from clinical trials <span style="white-space:nowrap">or&#160;pre-clinical&#160;studies</span> may require further evaluation, delaying the next stage of development or submission of an NDA/BLA or similar application. A future failure of a clinical trial to meet <span style="white-space:nowrap">its&#160;pre-specified&#160;endpoints</span> would likely cause us to abandon our product candidates. Any delay in, or termination of, our clinical trials will delay the submission of an NDA/BLA or other similar applications to the FDA or other relevant <span style="white-space:nowrap">comparable&#160;non-U.S.&#160;regulatory</span> authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenues. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidates. The FDA has substantial discretion in the review and approval process and may disagree that our data support the differentiated claims we propose. In addition, only a small percentage of product candidates under development result in the submission of an NDA/BLA or other similar application to the FDA and other <span style="white-space:nowrap">comparable&#160;non-U.S.&#160;regulatory</span> authorities and even fewer are approved for commercialization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Interim,&#160;top-line&#160;or</span> preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary <span style="white-space:nowrap">or&#160;top-line&#160;data</span> from our clinical trials, which is based on a preliminary analysis of <span style="white-space:nowrap">then-available&#160;top-line&#160;data,</span> and the results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary <span style="white-space:nowrap">and&#160;top-line&#160;results</span> that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully <span style="white-space:nowrap">evaluated.&#160;Top-line&#160;data</span> also remain subject to audit and verification procedures that may result in the final data being materially different from <span style="white-space:nowrap">the&#160;top-line&#160;data</span> we previously published. As a result, preliminary <span style="white-space:nowrap">and&#160;top-line&#160;data</span> should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between <span style="white-space:nowrap">preliminary,&#160;top-line&#160;or</span> interim data and final data could significantly harm our business prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to file INDs or IND amendments or comparable applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to file Investigational New Drug (&#8220;<span style="text-decoration:underline">IND</span>&#8221;) applications or other comparable applications for our product candidates on the timelines we expect. For example, we or our third party collaborators may experience manufacturing delays or other delays with <span style="white-space:nowrap">IND-enabling</span> studies or FDA or other regulatory authorities may require additional preclinical studies that we did not anticipate. Moreover, we cannot be sure that submission of an IND or other comparable application will result in the FDA or other regulatory authorities </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allowing clinical trials to begin, or that, once begun, issues will not arise that result in a decision by us, by institutional review boards or independent ethics committees, or by the FDA or other regulatory authorities to suspend or terminate clinical trials, including as a result of a clinical hold. Additionally, even if FDA or other regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or comparable application, we cannot guarantee that they will not change their requirements or expectations in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND or other comparable application. Any failure to file INDs or other comparable applications on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future seek orphan drug designation for our product candidates, but we may be unable to obtain orphan drug designation and, even if we obtain such designation, we may not be able to realize or maintain the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including the United States and other major markets, may designate products intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug or biologic product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. Orphan drug designation must be requested before submitting a marketing application. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <span style="white-space:nowrap">user-fee</span> waivers. After the FDA grants orphan drug designation, the generic identity of the drug or biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or foreign regulatory authorities from approving another marketing application for a product that constitutes the same drug treating the same indication for a period of seven (7)&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek orphan drug designation for some of our future product candidates in which there is a medically plausible basis for the use of these products. We may be unable to obtain and maintain orphan drug designation and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition in the United States. Even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, venture capital firms, hedge funds, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products, or already have products in the market, for the diseases in oncology and immunology. Although we believe that our approaches are or will be unique, there is no assurance that they will demonstrate advantages or even parity against competitive products from other companies<span style="font-style:italic">.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, more convenient, or less expensive than any products that we may develop. Furthermore, products currently approved for other indications could be discovered to be effective treatments as well, which could give such products significant regulatory and market timing advantages over our product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors. The availability of competitive products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of product candidates in human clinical trials. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for any product candidates or medicines that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant costs to defend the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to <span style="white-space:nowrap">out-license</span> our product candidates. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we intend to maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to New OSR Holdings&#8217; Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the reliance on third parties by OSR Holdings, which, following the closing of the Business Combination, will be the reliance on third parties by New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently outsource, and intend to continue to outsource, much of our discovery, clinical development, and manufacturing functions to third-party providers or consultants. Outsourcing these functions has significant risks, and our failure to manage these risks successfully could materially adversely affect our business, results of operations, and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business model relies upon the use of third parties, such as vendors and consultants, to conduct our drug discovery, preclinical testing, clinical trials, manufacturing, and all other aspects of clinical development. While our reliance on third parties allows us to purposely employ a small number of full-time employees, we may not be able to effectively manage and oversee the third parties that our business depends upon and we have less control over our operations due to our reliance on third parties. While we believe our business model significantly reduces overhead cost, we may not realize the efficiencies of this arrangement if we are unable to effectively manage third parties or if our employees are unable to manage the operations of each of our subsidiaries, including the development of their programs and product candidates. The failure to successfully and efficiently outsource operational functions or appropriately manage the operations of our subsidiaries could materially adversely affect our business, results of operations, and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct important aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend upon third parties to conduct important aspects of our preclinical studies and clinical trials, under agreements with CROs, CMOs, strategic collaborators and others. We expect to continue to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will rely heavily on third parties over the course of our preclinical studies and clinical trials, and, as a result, we control only certain aspects of their activities. When working with third parties, we have less direct control over the conduct, timing and completion of our preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we relied entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials are conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP and cGMP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP and cGMP requirements through periodic inspections of trial sponsors, clinical investigators, manufacturers and trial sites. If we or any of these third parties fail to comply with applicable GCP or cGMP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional preclinical studies or clinical trials or determine that our clinical trials do not comply with the GCP or cGMP requirements. Failure by us or by third parties we engage to comply with regulatory requirements can also result in fines, adverse publicity, and civil and criminal sanctions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any third parties conducting aspects of our preclinical studies, clinical trials or manufacturing process will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons or if due to federal or state orders or absenteeism they are unable to meet their contractual and regulatory obligations, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party CROs, CMOs or others terminate, we may not be able to enter into arrangements with alternative CROs, CMOs or other third parties in a timely manner or to do so on commercially reasonable terms. Switching or adding additional CROs or CMOs involves additional cost and requires extensive time and focus of our management. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines which may have a material adverse impact on our business, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party contract manufacturers to manufacture our product candidates for preclinical studies and clinical trials. We do not own manufacturing facilities for producing any commercial product supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. For example, the <span style="white-space:nowrap">COVID-19</span> pandemic would have significantly impacted our ability to procure sufficient supplies for the development of our product candidates. Any future pandemic or similar public health crisis may create delays or gaps in supply of materials driven by the response to any pandemic or similar public health crisis. In particular, any replacement of a contract manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials become limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability or bridging study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we enter into future manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to initiate or continue clinical trials of product candidates under development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of the cooperation of an existing or future collaborator; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to cease distribution or to recall batches of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates progress through preclinical to late stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are optimized along the way in an effort to improve yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <span style="white-space:nowrap">scale-up,</span> process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. Additionally, if we advance a biological candidate into <span style="white-space:nowrap">IND-enabling</span> studies, the manufacturing processes for biological products is more complex and expensive than with small molecule products and additional manufacturing suppliers may be needed to manufacture clinical supplies for these programs. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The manufacture of drug products, and particularly biologics, is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our current product candidates or any future product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing drugs, particularly biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <span style="white-space:nowrap">scale-up,</span> process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our current product candidates or any future product candidates, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to New OSR Holdings&#8217; Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors reference the risks and uncertainties relating to the intellectual property of OSR Holdings, which, following the closing of the Business Combination, will be the intellectual property of New OSR Holdings. References in this section to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to OSR Holdings prior to the closing of the Business Combination and to New OSR Holdings after closing.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and any future product candidates. We also seek to protect our proprietary position <span style="white-space:nowrap">by&#160;in-licensing&#160;or</span> acquiring intellectual property and filing patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect our product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive product candidates, or that an alteration to product candidates or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. The risks associated with patent rights generally apply to patent rights that <span style="white-space:nowrap">we&#160;in-license&#160;now</span> or in the future, as well as patent rights that we may own now or in the future.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter <span style="white-space:nowrap">into&#160;non-disclosure&#160;and</span> confidentiality agreements with parties who have access to confidential or patentable aspects of their research and development output, such as employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection. In addition, while we will <span style="white-space:nowrap">have&#160;pre-publication&#160;review</span> procedures in effect, premature or inadvertent publication of potentially patentable subject matter could preclude our ability to obtain patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose not to seek patent protection for certain innovations or product candidates and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable and, in any event, any patent protection we obtain may be limited. As a result, product candidates may not be protected by patents in all jurisdictions. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell product candidates and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell product candidates and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. The patent applications that we own <span style="white-space:nowrap">or&#160;in-license</span> may fail to result in issued patents with claims that cover product candidates in the United States or in other countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent applications that we own <span style="white-space:nowrap">or&#160;in-license&#160;may</span> fail to result in issued patents with claims that cover our product candidates or any future product candidate in the United States or in other countries. Our pending PCT patent applications are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications have been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate an issued patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may ultimately obtain. Even if patents do successfully issue and even if such patents cover our product candidates or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowly construed, invalidated, or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar product candidates or limit the length of terms of patent protection we may have for our product candidates and technologies. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing product candidates or practicing our own patented technology or impose a substantial royalty burden to do so. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our product candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our product candidates or other technologies, competitors and other third parties could market product candidates and use processes that are substantially similar to, or superior to, ours and our business would suffer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">If the patent applications we hold or have</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">&#160;in-licensed</span></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">&#160;with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a materially adverse effect on our business.</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) and its counterparts in other countries use to grant patents are not always applied predictably or uniformly. In addition, the laws of countries other than the United States may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in such jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other parties have developed technologies that may be related or competitive to our own technologies and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (the &#8220;<span style="text-decoration:underline">Leahy-Smith Act</span>&#8221;), could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act made significant changes to U.S. patent law, including the way patent applications are prosecuted, redefined prior art and provided more efficient and cost-effective avenues for competitors to challenge the validity of patents. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any patents that we have or may be issued provide us some protections but the patent issuance may be challenged on multiple grounds. We may in the future be subject to <span style="white-space:nowrap">third-party&#160;pre-issuance</span> submissions of prior art to the USPTO or its equivalents and we or our licensors have in the past, and may in the future, become involved in opposition, derivation, reexamination,<span style="font-style:italic">&#160;inter partes</span>&#160;review, post-grant review or interference proceedings in the U.S. or in other jurisdictions challenging our patent rights or the patent rights of others. A third party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, result in our inability to manufacture or commercialize product candidates </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without infringing third-party patent rights or result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in <span style="white-space:nowrap">a&#160;non-infringing&#160;manner.</span> For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that falls outside the scope of our patent protection. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, it may be open to competition from generic versions of such product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our own and, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms and their scope may be inadequate to protect our competitive position on current and future product candidates for an adequate amount of time.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest <span style="white-space:nowrap">U.S.&#160;non-provisional&#160;filing</span> date. In certain instances, the patent term may be adjusted to add additional days to compensate for delays incurred by the USPTO in issuing the patent. Also, the patent term may be extended for a period of time to compensate for at least a portion of the time a product candidate was undergoing FDA regulatory review. However, the life of a patent, and the protection it affords, is limited. Even if patents covering product candidates are obtained, once the patent life has expired, we may be open to competition from competitive product candidates, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not currently and may not in the future own or license any issued composition of matter patents covering certain of our product candidates, and we cannot be certain that any of our other issued patents will provide adequate protection for such product candidates.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Composition-of-matter&#160;patents</span></span> on the active pharmaceutical ingredient (&#8220;<span style="text-decoration:underline">API</span>&#8221;) in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. While we generally seek composition of matter patents for our product candidates, such patents may not be available for all of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Method-of-use&#160;patents</span></span> protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect <span style="white-space:nowrap"><span style="white-space:nowrap">to&#160;method-of-use</span></span> patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these <span style="white-space:nowrap">products&#160;off-label,&#160;or</span> patients may do so themselves. <span style="white-space:nowrap">Although&#160;off-label&#160;use</span> may infringe or contribute to the infringement <span style="white-space:nowrap"><span style="white-space:nowrap">of&#160;method-of-use&#160;patents,</span></span> the practice is common, and this type of infringement is difficult to prevent or prosecute.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary technology, product candidates and our target indications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidate begins to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, one or more of our U.S. patents may be eligible for a limited patent term extension (&#8220;<span style="text-decoration:underline">PTE</span>&#8221;) under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical <span style="white-space:nowrap">and&#160;pre-clinical&#160;data</span> to obtain approval of competing product candidates following our patent expiration and launch their product earlier than might otherwise be the case.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result <span style="white-space:nowrap">of&#160;non-compliance&#160;with</span> these requirements.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other patent agencies in other jurisdictions in several stages over the lifetime of the patent. The USPTO and various national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. <span style="white-space:nowrap">and&#160;non-U.S.&#160;patent</span> agencies and to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant <span style="white-space:nowrap">jurisdiction(s).&#160;Non-compliance&#160;events</span> that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent applications, failure to respond to official actions within prescribed time <span style="white-space:nowrap">limits,&#160;non-payment&#160;of</span> fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or any future product candidate, our competitors might be able to enter the market earlier than anticipated, which would have an adverse effect on our business.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third party claims or litigation alleging infringement, misappropriation or other violations of third-party patents or other proprietary rights or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of our product candidates and any future product candidate.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoidance of infringement, misappropriation and other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Our competitors or other third parties may assert infringement claims against us, alleging that our product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings,<span style="font-style:italic"></span><span style="font-style:italic">&#160;inter partes</span>&#160;review, and post-grant review before the USPTO, as well as oppositions and similar processes in other jurisdictions. Numerous U.S. <span style="white-space:nowrap">and&#160;non-U.S.&#160;issued</span> patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe that we are not aware of. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or <span style="white-space:nowrap">resulting&#160;know-how&#160;and</span> inventions, which could be time-consuming and divert the attention of senior management.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business, as well as potentially be liable for substantial, or even treble, damages. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons may seek injunctive or other equitable relief, which may prevent us from continuing to develop and commercialize our product candidates. The defense costs to such actions are substantial and require management and other knowledge employees to divert their attention from existing operations to defending such claims. In the event of a successful infringement or other intellectual property claim against it, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for wilful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because the competitors have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our product candidates, services, and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our common shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our product candidates.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November&#160;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Therefore, patent applications covering our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect and we may incorrectly conclude that a third-party patent is invalid or unenforceable. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, <span style="white-space:nowrap">obviousness,&#160;non-enablement&#160;or</span> lack of written description or statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as <span style="font-style:italic">ex parte</span> reexaminations,<span style="font-style:italic">&#160;inter partes</span>&#160;review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which it and the patent examiner were unaware during prosecution. For the patents and patent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business. Additionally, any adverse outcome could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some <span style="white-space:nowrap">other&#160;non-litigious&#160;action</span> or solution.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because many of the patents we own are owned by our subsidiaries and investments, and in certain cases by subsidiaries or investments that are not or will not be directly commercializing products, we may not be in a position to obtain a permanent injunction against a third party that is found to infringe our patents.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many patents that we own are assigned to our subsidiaries or investment companies. If a third party is found to be infringing such patents, we and our direct subsidiaries may not be able to permanently enjoin the third party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent in the United States or other jurisdictions when the patent is assigned to a subsidiary, which is not the entity that is or would be commercializing a potentially competitive product or service. In such a circumstance, such third party may be able to compete with us or our subsidiaries or investment companies, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, New OSR Holdings&#8217; success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law, including provisions </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that affect the way patent applications will be prosecuted and that may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first to file&#8221; system in which the first inventor to file a patent application is typically entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings, including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect New OSR Holdings&#8217; competitive position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken New OSR Holdings&#8217; ability to obtain new patents or to enforce patents that it might obtain in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, in June 2023, a new unitary patent system was introduced, which will significantly impact European patents, including those granted before the introduction of the system. Under the unitary patent system, after a European patent is granted, the patent proprietor can request unitary effect, thereby getting a European patent with unitary Effect, or a Unitary Patent. Each Unitary Patent is subject to the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be potentially vulnerable to a single <span style="white-space:nowrap">UPC-based</span> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of the new unitary patent system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States <span style="white-space:nowrap">and&#160;non-U.S.&#160;legislative</span> bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates or patents that cover our biologic product candidates can be challenged by third parties.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one of our product candidates is approved by the FDA and if a third party files an application under Section&#160;505(b)(2) or an abbreviated new drug application (&#8220;<span style="text-decoration:underline">ANDA</span>&#8221;) under Section&#160;505(j) for a generic product containing any of our product candidates, and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;<span style="text-decoration:underline">Orange Book</span>&#8221;) with respect to our NDA for the applicable approved product candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic product. A certification under 21 CFR &#167;&#160;314.94(a)(12)(i)(A)(4) that the new product will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the <span style="white-space:nowrap">required&#160;45-day&#160;period,</span> the third party&#8217;s ANDA will not be subject to <span style="white-space:nowrap">the&#160;30-month&#160;stay</span> of FDA approval.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio, which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products before an ANDA or 505(b)(2) NDA is filed we will be unable to obtain <span style="white-space:nowrap">a&#160;30-month&#160;stay</span> of FDA approval of a 505(b)(2) or ANDA.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For biologics, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological product candidates. Due to the large size and complexity of biological product candidates, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in the FDA&#8217;s Orange Book and does not include an <span style="white-space:nowrap">automatic&#160;30-month&#160;stay</span> of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a <span style="white-space:nowrap">formal&#160;pre-litigation&#160;process</span> which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, we may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims, it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding <span style="white-space:nowrap">of&#160;non-infringement.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in enforcing our patents against generics or biosimilars, our products could face competition prior to the expiration of the patents which cover such products, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, any such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with product candidates.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing product candidates made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and may also export infringing product candidates to territories where we have patent protection, but enforcement is not as strong as that in the United States. These product candidates may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have patent rights in all countries in which a market may exist. Moreover, in jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in other countries product candidates and services that are the same as or similar to our product candidates and services, and our competitive position would be harmed.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in other jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology product candidates, which could make it difficult for us to stop the infringement of our patents or marketing of competing product candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of any trade secrets, our business and competitive position would be harmed.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for any product candidates, we may rely on trade secrets, <span style="white-space:nowrap">including&#160;know-how,&#160;technology</span> and other proprietary information, to maintain our competitive position. We seek to protect this information, in part, by entering <span style="white-space:nowrap">into&#160;non-disclosure</span> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely and expect to continue to rely on third parties to manufacture our product candidates and future product candidates, and we collaborate and expect to continue to collaborate with third parties on the development of current and future product candidates, we must, at times, share trade secrets with them. If we conduct joint research and development programs, we may be required to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on <span style="white-space:nowrap">our&#160;know-how&#160;and</span> trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our or our licensors&#8217; intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors and other third parties may discover our trade secrets, including our proprietary software, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s or other third party&#8217;s discovery of our trade secrets, including our proprietary software, would impair our competitive position and have an adverse impact on our business.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that we have entered <span style="white-space:nowrap">into&#160;non-disclosure,&#160;confidentiality</span> agreements, material transfer agreements or consulting agreements with each party that may have or have had access to our trade secrets or proprietary software, technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and proprietary software, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets, including our proprietary software, were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, including our proprietary software, were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a combination of internally developed <span style="white-space:nowrap">and&#160;in-licensed&#160;intellectual</span> property rights and we or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned <span style="white-space:nowrap">or&#160;in-licensed&#160;patents,</span> trade secrets, or other intellectual property as an inventor <span style="white-space:nowrap">or&#160;co-inventor.&#160;For</span> example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or other third parties who are involved in developing product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned <span style="white-space:nowrap">or&#160;in-licensed&#160;patents,</span> trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees, contractors and other third parties who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our invention assignment agreements may not be self-executing or may be breached, and we may not have adequate remedies for any such breach. Additionally, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have <span style="white-space:nowrap">pre-existing</span> or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks as one means to distinguish product candidates that are approved for marketing from the product candidates of our competitors. Our current and future trademark applications in the United States and in other jurisdictions may not be allowed or may subsequently be opposed, challenged, infringed, circumvented, declared generic or determined to be infringing other marks. Additionally, once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties have in the past opposed, are currently opposing and may in the future oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand product candidates, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once granted, patents may remain open to invalidity challenges including opposition, <span style="white-space:nowrap">interference,&#160;re-examination,&#160;post-grant</span> review,<span style="font-style:italic">&#160;inter partes </span>review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make formulations or compositions that are the same as or similar to product candidates, but that are not covered by the claims of the patents that we own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make product candidates that are similar to product candidates that we intend to commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, our licensor or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or our licensor or any collaborators might not have been the first to file patent applications covering certain of our inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive product candidates for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop <span style="white-space:nowrap">or&#160;in-license&#160;additional</span> proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may harm our business; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose not to file a patent application in order to maintain certain trade secrets <span style="white-space:nowrap">or&#160;know-how,&#160;and</span> a third party may subsequently file a patent application covering such intellectual property.</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_12">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introduction </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;23, 2024, BLAC and OSR Holdings entered into an Amended&#160;&amp; Restated Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro&#160;forma condensed combined financial information (the &#8220;<span style="text-decoration:underline">Pro Forma Information</span>&#8221;) gives effect to the Business Combination and the other events described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP and the Accounting Standard Codification (ASC) which is the current single source of U.S. GAAP. Under this method of accounting, BLAC will be treated as the &#8220;acquired&#8221; company and OSR Holdings will be considered the accounting acquirer for accounting purposes as set forth by the guidance in ASC <span style="white-space:nowrap">805-10.</span> This conclusion is supported by the voting interest model referenced in ASC <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">805-10-55-12</span></span></span> as 67.7% (no redemption), 70.8% (50% redemption) and 74.2% (maximum redemption) of the voting interest scenarios in New OSR Holdings which will be held by the historical shareholder group of OSR Holdings. Further, Bellevue Capital Management LLC (&#8220;BCM&#8221;) and its affiliates are the largest single owner of shares of OSR Holdings, and will also be the largest single owner of shares in the combined company in each of the no redemption, 50% redemption, and maximum redemption scenarios. The stockholders of OSR Holdings will have sufficient voting power to elect or remove a majority of the board of directors of the combined company. The compositions of the governing body and senior management team of the combined entity present a less defined indicator as Kuk Hyoun Hwang is an officer and director of both OSR Holdings and BLAC. No other officers of BLAC will be officers of the combined company. The composition of New OSR Holdings is being negotiated by Kuk Hyoun Hwang who represents both BLAC and OSR Holdings so that it is difficult to conclude that one party controls the appointment of the directors of the combined company. Accordingly, given the supermajority of voting shares to be held by OSR Holdings stockholders in the combined company and the other factors described above, for accounting purposes, the Business Combination will be treated as the equivalent of a capital transaction in which BLAC is issuing securities for the net assets of OSR Holdings. Operations prior to the Business Combination will be those of OSR Holdings. The assets and liabilities and the historical operations that are reflected in the financial statements are those of OSR Holdings and are recorded at the historical cost basis of OSR Holdings. BLAC&#8217;s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of OSR Holdings after consummation of the acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro&#160;forma condensed combined balance sheet data as of December&#160;31, 2023 gives pro&#160;forma effect to the Transaction and the other events as if consummated on December&#160;31, 2023. The unaudited pro&#160;forma condensed combined statements of operations data for the year ended December&#160;31, 2023 give effect to the Transactions and the other events as if consummated on January&#160;1, 2023, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro&#160;forma condensed combined financial information is derived from, and should be read in conjunction with, the historical financial statements and accompanying notes of OSR Holdings and BLAC for the applicable periods included elsewhere in this proxy statement/prospectus. The Pro Forma Information has been presented for informational purposes only and is not necessarily indicative of what New OSR Holdings&#8217; financial position or results of operations actually would have been had the Transactions and the other events been completed as of the dates indicated. The Pro Forma Information does not purport to project the financial position or operating results of New OSR Holdings that may be expected for any other period in the future. The unaudited pro&#160;forma condensed combined financial information is presented for illustrative purposes only and does not reflect the costs of any integration activities or cost savings or synergies that may be achieved as a result of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments reflecting the consummation of the Business Combination and related proposed financing transactions are based on certain currently available information and certain </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions and methodologies that BLAC believes are reasonable under the circumstances. The transaction accounting adjustments, which are described in the accompanying notes, may be revised as additional information becomes available. Therefore, it is likely that the actual adjustments will differ from the transaction accounting adjustments, and it is possible that the difference may be material. BLAC believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Business Combination and the related proposed financing transactions based on information available to management at this time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Description of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing under the Business Combination Agreement, each holder of OSR Holdings&#8217; Common Stock that executes a Participating Stockholder Joinder to the Business Combination Agreement on or prior to the Closing, and each holder of OSR Holdings&#8217; Common Stock that executes <span style="white-space:nowrap">a&#160;Non-Participating&#160;Stockholder</span> Joinder on or prior to the Closing will be joined as parties to the Business Combination Agreement, pursuant to which at the Effective Time (i)&#160;BLAC shall issue the Aggregate Participating Consideration to the Participating Company Stockholders, and (ii)&#160;the Participating Company Stockholders shall sell, transfer, convey, assign and deliver all of their respective shares of OSR Holdings&#8217; Common Stock to BLAC. Pursuant to such Share Exchange, each share of OSR Holdings&#8217; Common Stock held by the Participating Company Stockholders immediately prior to the Effective Time shall be exchanged for the Per Share Consideration. It is a condition to closing under the Business Combination Agreement that holders of at least 60% of the shares of OSR Holdings Common Stock on a fully diluted basis execute a Participating Stockholder Joinder and exchange their shares of OSR Holdings Common Stock with BLAC and, as a result, BLAC will own at least 60% of the outstanding shares of OSR Holdings Common Stock at closing. For further details, see &#8220;<span style="font-style:italic">The Business Combination Agreement&#8212;Conditions to Closing the Business Combination.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time: (i)&#160;the Participating Company Stockholders shall transfer and convey all of the shares of OSR Holdings Common Stock held by the Participating Company Stockholders to BLAC, in each case, free and clear of any claims or interest of any person previously entitled thereto; (ii)&#160;BLAC shall effect the transfer and conveyance of all of the shares of BLAC Common Stock representing the Aggregate Participating Consideration to the Participating Company Stockholders, in each case, free and clear of any claims or interest of any person previously entitled thereto; (iii)&#160;any fractional share of BLAC Common Stock that would otherwise be issuable to a Participating Company Stockholder following such exchange shall be rounded up or down to the nearest whole share of BLAC Common Stock; (iv)&#160;all OSR Holdings Common Stock held by <span style="white-space:nowrap">Non-Participating</span> Company Stockholders will not be exchanged for shares of BLAC Common Stock at Closing, and such Company Capital Stock will be subject to the terms of the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder, including the Put Right and Call Right set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no specified maximum redemptions threshold stipulated under the Business Combination Agreement. Given that BLAC&#8217;s Public Stockholders may elect to redeem their public shares for cash even if they approve the Business Combination, this unaudited pro&#160;forma condensed combined information assumes that they redeem all of the shares subject to redemption in the preparation of the unaudited pro&#160;forma condensed combined financial statements under the Maximum Redemptions scenario. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three scenarios are considered in the unaudited pro&#160;forma condensed combined financial information presentation herein: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming No Redemptions&#8201;&#8212;&#8201;This scenario assumes that none of the BLAC&#8217;s Public Stockholders will elect to redeem their Common Stock for a pro&#160;rata portion of cash in the Trust Account, which becomes available for the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming 50% Redemptions&#8201;&#8212;&#8201;This scenario assumes that BLAC&#8217;s Public Stockholders will redeem approximately 0.94&#160;million shares of Common Stock upon consummation of the Business Combination at a redemption price of approximately $10.78&#160;per share. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming Maximum Redemptions&#8201;&#8212;&#8201;This scenario assumes that BLAC&#8217;s Public Stockholders will redeem approximately 1.89&#160;million shares of Common Stock upon consummation of the Business Combination at a redemption price of approximately $10.78&#160;per share. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates varying ownership levels in BLAC Common Stock immediately following the consummation of the Business Combination based on the varying levels of redemptions by the public stockholders and the following additional assumptions: (i) 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) are issued to the Participating Company Stockholders at consummation of the Business Combination, (ii)&#160;all BLAC Rights have been converted to shares of BLAC Common Stock, and (iii) $20,000,000 of PIPE financing is raised through the sale of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. The table below does not take into account (i)&#160;the exercise of any BLAC Warrants as the warrants do not become exercisable until 30 days after the consummation of the Business Combination, and (ii)&#160;the issuance of any equity awards under the Omnibus Plan as there will be no awards issued under the Omnibus Plan immediately following the consummation of the Business Combination. If the actual facts differ from these assumptions, the ownership percentages in BLAC will be different and totals may not add up to 100% due to rounding. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pro Forma Combined</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Assuming</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No Redemptions)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pro Forma Combined</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Assuming</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">50% Redemptions)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pro Forma Combined</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Assuming Maximum<br/>Redemptions)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Sponsor and Related Parties<sup style="font-size:75%; vertical-align:top">(2) </sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.44</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,163,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC public stockholders<sup style="font-size:75%; vertical-align:top">(3) </sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.49</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Shares<sup style="font-size:75%; vertical-align:top">(4) </sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes (i) 60% of the Aggregate Consideration of 24,461,214 shares of BLAC Common Stock pursuant to the Business Combination Agreement will be issued by BLAC to the Participating Company Stockholders at consummation of the Business Combination, and (ii)&#160;the remaining 40% of the Aggregate Consideration, or 9,784,486 shares of BLAC Common Stock, will be issuable by BLAC to the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders upon exercise of the put/call rights set forth in the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 2,035,000 shares of BLAC Common Stock held by the Sponsor, (ii) 20,000 shares of BLAC Common Stock held by Mr.&#160;Yoo, BLAC&#8217;s Chief Financial Officer, (iii) 20,000 shares of BLAC Common Stock held by Jin Whan Park, a current director of BLAC, and (iv) 20,000 shares of BLAC Common Stock held by each of the following former directors of BLAC: Dr.&#160;Steven Reed, Dr.&#160;Inchul Chung, Mr.&#160;Hosun Euh, and Dr.&#160;Radclyffe Roberts. It also assumes the conversion of 430,000 private placement rights held </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the conversion of 6,900,000 public rights into 690,000 shares of BLAC Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes an aggregate of $20,000,000 raised from the issuance of 2,222,222 shares of BLAC Common Stock at an average price of $9.00 per share. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COMBINED BALANCE SHEET </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DECEMBER&#160;31, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings&#160;Co.,<br/>Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">U.S. GAAP<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings&#160;Co.,<br/>Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">USD<br/>Conversion<br/>Rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings&#160;Co.,<br/>Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bellevue<br/>Life<br/>Sciences<br/>Acquisition<br/>Corp.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean Won)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean&#160;Won)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean Won)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar<br/>in&#160;unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar</span><span style="font-weight:bold"></span><span style="font-style:italic"><br/></span><span style="font-weight:bold"></span><span style="font-style:italic">in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-style:italic">(US Dollar<br/>in&#160;unit)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Tangible assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,726,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,726,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Intangible assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">278,365,579,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">278,365,579,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,887,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,887,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177,793,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177,793,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> other financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107,387,428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107,387,428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,605,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,605,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279,156,774,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279,156,774,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,501,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,605,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253,106,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">540,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">555,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,197,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,197,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,802,614,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,802,614,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,398,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,398,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Other assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,777,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,777,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,500,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,500,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,705,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,705,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,209,682,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,209,682,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,264,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,287,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">219,766,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,627,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256,393,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Equity attributable to the equity holders of the Parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Share capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,476,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,476,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Share premium</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186,571,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186,571,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Accumulated other comprehensive income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(360,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(360,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,477,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,907,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,384,922</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183,209,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,906,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179,302,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183,209,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,906,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179,302,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Commitments and Contingencies</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,426,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,426,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> Liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,657,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,657,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,328,007,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,328,007,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,603,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,603,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Severance payment</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,435,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,435,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred underwriting commissions</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,892,099,976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,892,099,976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,040,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,110,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,949,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,081,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,031,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Due to affiliate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105,829,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105,829,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current other liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106,140,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106,140,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,873,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,873,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">524,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">538,424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Excise tax payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,289.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">359,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">359,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Convertible note payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,244,143,521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,244,143,521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,516,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,038,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,554,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,136,243,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,136,243,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,556,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,108,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,664,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total liabilities and equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">219,766,138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,627,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256,393,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COMBINED BALANCE SHEET </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DECEMBER&#160;31, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming 50% Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming Maximum<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="right" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="right" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additional<br/>Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="right" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar<br/>in</span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;</span><span style="font-weight:bold"></span><span style="font-style:italic">unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar<br/>in</span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;</span><span style="font-weight:bold"></span><span style="font-style:italic">unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar in</span><span style="font-weight:bold"></span><span style="font-style:italic"><br/></span><span style="font-weight:bold"></span><span style="font-style:italic">unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar<br/>in</span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;</span><span style="font-weight:bold"></span><span style="font-style:italic">unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar</span><span style="font-weight:bold"></span><span style="font-style:italic"><br/></span><span style="font-weight:bold"></span><span style="font-style:italic">in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar<br/>in</span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;</span><span style="font-weight:bold"></span><span style="font-style:italic">unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Tangible assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Intangible assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,887,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,887,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,887,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> other financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,045,763</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(10</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(12</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,204,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,605,106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,501,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,501,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,501,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,204,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,403,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,239,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,076,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,363,181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(359,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(561,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(72,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(13</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(14</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,197,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,197,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,197,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,398,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,398,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,398,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Other assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,840,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,127,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,964,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,800,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256,629,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">246,465,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,302,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Equity attributable to the equity holders of the Parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Share capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,476,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Share premium</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(186,571,178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Accumulated other comprehensive income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(360,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(360,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(360,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(10</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(94</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(13</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(94</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(14</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194,044,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221,222,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211,058,555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,895,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,477,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,426,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,363,181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,045,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(10</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,999,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(12</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:7pt">(10,163,471</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt"><span style="font-weight:bold">&#160;</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:7pt"><span style="font-weight:bold">(13</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt"><span style="font-weight:bold">)&#160;</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:7pt">(10,163,461</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt"><span style="font-weight:bold">&#160;</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:7pt"><span style="font-weight:bold">(14</span></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:7pt"><span style="font-weight:bold">)&#160;</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,477,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,907,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,907,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,907,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,655,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,958,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206,794,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196,630,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,655,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,958,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206,794,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196,630,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Commitments and Contingencies</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,426,253</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> Liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">356,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,603,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,603,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,603,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Severance payment</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Deferred underwriting commissions</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,070,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,110,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,110,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,110,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,031,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,031,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,031,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Due to affiliate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(72,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current other liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Current tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(561,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Excise tax payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(359,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(993,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,560,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,560,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,560,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(993,914</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,671,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,671,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,671,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman;font-weight:bold">Total liabilities and equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256,629,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">246,465,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,163,555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,302,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOR THE YEAR ENDED DECEMBER&#160;31, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings<br/>Co., Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">U.S. GAAP<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings<br/>Co., Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">USD<br/>Conversion<br/>Rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR<br/>Holdings<br/>Co., Ltd.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bellevue&#160;Life<br/>Sciences<br/>Acquisition<br/>Corp.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(KRW)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(KRW)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(KRW)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US</span><span style="font-weight:bold"></span><span style="font-style:italic"></span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US</span><span style="font-weight:bold"></span><span style="font-style:italic"></span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,453,551,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,453,551,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,408,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,408,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,930,194,272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,930,194,272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,203,211</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,830,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,742,785,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,742,785,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,293,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,830,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-operating</span> income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(489,682,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(489,682,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest earned on investments held in the Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,775,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,775,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,571,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,571,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(685,461,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(685,461,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(989,579,991</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(989,579,991</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(758,060</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,775,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,017,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,732,365,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,732,365,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,051,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">944,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,107,074</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,632,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(540,811</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,419,454</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,015,674</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,419,454</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,015,674</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Other comprehensive income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Historical</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gain on foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1305.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total other comprehensive income (loss)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income (loss) for year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,653,544</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,249,764</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,653,544</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,249,764</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Earning (loss) per share attributable to the equity holders of the Parent:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic earning (loss) per ordinary share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,152.04</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,152.04</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.46</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOR THE YEAR ENDED DECEMBER&#160;31, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemptions</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US</span><span style="font-weight:bold"></span><span style="font-style:italic"></span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US</span><span style="font-weight:bold"></span><span style="font-style:italic"></span><span style="font-weight:bold"></span><span style="font-style:italic">&#160;Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold"></span><span style="font-style:italic">(US Dollar)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">(US Dollar)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,411,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,502,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">909,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,033,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,124,305</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-operating</span> income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Finance costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(375,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest earned on investments held in the Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(12</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,420,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(525,093</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,662,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,461,731</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Other comprehensive income (loss):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(363,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gain on foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total other comprehensive income (loss)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,090</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income (loss) for year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,604,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Earning (loss) per share attributable to the equity holders of the Parent:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic earning (loss) per ordinary share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 1&#8201;&#8212;&#8201;Basis of pro&#160;forma presentation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro&#160;forma condensed combined financial information was prepared under the conclusion that the Business Combination is accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with GAAP. Under this method of accounting, BLAC is expected to be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, OSR Holdings will be deemed to be the accounting acquirer in the Transaction and, consequently, the Transaction is treated as a recapitalization of OSR Holdings. Accordingly, the assets and liabilities and the historical operations that are reflected in the financial statements are those of OSR Holdings and are recorded at the historical cost basis of OSR Holdings. BLAC&#8217;s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of OSR Holdings after consummation of the acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical financial statements have been adjusted in the unaudited pro&#160;forma condensed combined financial information to reflect transaction accounting adjustments in connection with the Business Combination and related proposed financing transactions. Given that the Business Combination is accounted for as a reverse recapitalization, the direct and incremental transaction costs related to the Business Combination and related proposed financing transactions are deferred and offset against the additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital.</span></span> For OSR Holdings transaction costs that are expected to be incurred and expensed upon Closing, they will be recognized initially as an increase to OSR Holdings&#8217; accumulated deficit, which will then be reclassified to additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital</span></span> as part of the elimination of &#8220;acquired&#8221; company&#8217;s historical accumulated deficit in the reverse recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro&#160;forma basic and diluted loss per share amounts presented in the unaudited pro&#160;forma condensed combined statements of operations are using the historical weighted average shares outstanding and the issuance of additional shares in connection with the Business Combination, assuming the transaction occurred on January&#160;1, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 2&#8201;&#8212;&#8201;IFRS to US&#160;GAAP Reconciliation and Assessment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial statements have been presented from IFRS to US&#160;GAAP. The Company has assessed for IFRS to US&#160;GAAP differences and assessed the following significant and material accounting areas: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:76%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Area</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Critical and Material Accounting</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue Recognition</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when it transfers control over a good or service to a customer. A five-step process is applied before revenue from contract with customers can be recognized:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Identify contracts with customers</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Identify the separate performance obligation</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Determine the transaction price of the contract</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Allocate the transaction price to each of the separate performance obligations, and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Recognize the revenue as each performance obligation is satisfied</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s type of revenue transaction and in accordance with ASC&#160;606, Revenue Recognition, under US&#160;GAAP, there is no differences between IFRS and US&#160;GAAP for revenue recognition.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:76%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Area</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Critical and Material Accounting</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s current intangible assets and in accordance with ASC 350 Intangibles, Goodwill and Others, under US&#160;GAAP, there is no differences between IFRS and US&#160;GAAP for accounting for intangible assets. Furthermore, there has been no reversal of impairment losses, which is one of the major differences between IFRS and US&#160;GAAP.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognised for deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the temporary differences and the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits, together with future tax planning strategies.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under GAAP, those deferred tax assets and liabilities are recognized using the balance sheet method and recorded based on the tax rates and laws enacted at the reporting date for the period in which the deferred taxes are expected to reverse. Under IFRS, while there are similar recognition criteria, there are differences&#8212;e.g., deferred tax assets and liabilities are recorded based on the tax rates and laws enacted, or substantively enacted, at the reporting date. While GAAP requires gross presentation where deferred tax assets are recognized with a valuation allowance further recognized if it is not more likely than not that the deferred tax assets will be realized, IFRS requires net presentation where deferred tax assets are recognized only to the extent it&#8217;s probable that they will be realized.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s deferred tax assets are, among other timing differences, primarily comprised of future tax benefits from identifiable intangible assets such as patent technology and goodwill through business acquisitions. The Company&#8217;s assessment of deferred tax assets through IFRS have been applied consistently with US&#160;GAAP, resulting in no accounting differences between IFRS and US&#160;GAAP.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s assessment of significant and material accounting areas, the Company concludes no material or significant differences between IFRS to US&#160;GAAP on its financial statements. The Company further concludes that other areas accounting are materially and consistently applied in conformity with US&#160;GAAP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 3 &#8211; Foreign currency translation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings uses Korean Won (&#8220;KRW&#8221;) as its functional currency. The Company&#8217;s consolidated financial statements have been translated into US$, the reporting currency. Assets and liabilities accounts are translated using the exchange rate at each reporting period end date. Equity accounts are translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The KRW is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the KRW amounts could have been, or could be, converted into US$ at the rates used in translation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the currency exchange rates that were used in creating the consolidated financial statements in this report: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">December&#160;31,<br/>2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">December&#160;31,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">December&#160;31,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">December&#160;31,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">2020</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Year-end</span> spot rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1=KRW 1,289.40</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,267.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,185.50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,088.00</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1=KRW 1,305.41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,291.95</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,144.42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">US$1= KRW 1,180.05</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span><br/><span style="font-weight:bold">2019</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Year-end</span> spot rate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">US$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1=KRW&#160;1,157.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average rate for the period from July&#160;12, 2019 through December&#160;31, 2019</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">US$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1=KRW 1,185.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 4&#8201;&#8212;&#8201;Accounting Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the procedures of the Business Combination, management will perform a comprehensive review of the two entities&#8217; accounting policies. As a result of the review, management may identify differences between the accounting policies of the companies which, when conformed, could have a material impact on the combined financial statements. Based on its initial analysis, management has not identified any material differences in accounting policies that would have an impact on the unaudited pro&#160;forma condensed combined financial information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 5&#8201;&#8212;&#8201;Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro&#160;forma condensed combined balance sheet as of December&#160;31, 2023 are as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1) Reclassification of $20,204,686 of Investments held in Trust Account that becomes available for transaction consideration, transaction expenses, redemption of public shares and the operating activities following the Business Combination to cash and cash equivalents </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2) Reclassification of OSR Shares to BLAC Common Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3) Reflects the elimination of $10.5&#160;million of OSR&#8217;s historical accumulated deficit. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4) Represents the reclassification of $36.4&#160;million of 3.5&#160;million BLAC Common Stock subject to possible redemption to permanent equity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5) Reflects the payment of $7,208 transaction expense incurred and capitalized by BLAC. This includes legal fees accrued on the historical balance sheet of BLAC as of December&#160;31, 2023 to be paid upon consummation of the Business Combination. Given that BLAC capitalized the $7,208 under other assets, it will be reclassified to additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital</span></span> upon Closing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6) Reflects the transaction expense of $2.4&#160;million that are expected to be incurred and expensed by BLAC upon Business Combination. $2.4&#160;million will be deferred and charged against additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital</span></span> because they are legal, third-party advisory, investment banking, and other miscellaneous fees, which are direct and incremental to the Business Combination and related proposed financing transactions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7) Reflects $359,957 payment of excise tax payable upon consummation of the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8) Reflects the payment of $561,957 of tax payable in connection with the interest income earned on BLAC&#8217;s Trust Account. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9) Reflects the payment of $72,000 to the Sponsor for Due to affiliate due upon the Closing </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10) Reflects $17.0&#160;million withdrawal of funds from the trust account to fund the redemption of 1,581,733 shares of BLAC Class&#160;A common stock at approximately $10.78 per share. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11) Reflects $20,000,000 of PIPE financing at $9.00 per share for 2,222,222 shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12) Reflects $645,343 of interest earned in the trust account from January&#160;1, 2024 to April&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The additional pro&#160;forma adjustments assuming 50% and 100% Redemptions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13) Reflects $10.2&#160;million withdrawal of funds from the trust account to fund the redemption of 943,111 shares of BLAC Common Stock at approximately $10.78 per share. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14) Reflects $10.2&#160;million withdrawal of funds from the trust account to fund the redemption of 943,110 shares of BLAC Common Stock at approximately $10.78 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 6&#8201;&#8212;&#8201;Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro&#160;forma adjustments included in the unaudited pro&#160;forma condensed combined statements of operations for the year ended December&#160;31, 2023: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12) Reflects $645,343 of interest earned in the trust account from January&#160;1, 2024 to April&#160;30, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 7&#8201;&#8212;&#8201; Loss per Share Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro&#160;forma loss per share calculations have been performed for the year ended December&#160;31, 2023 and 2022 using the historical weighted average shares outstanding and the issuance of additional shares in connection with the Business Combination, assuming the transaction occurred on January&#160;1, 2022. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding for both basic and diluted loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. If the maximum number of shares are redeemed, this calculation is retroactively adjusted to eliminate such shares for the entire periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average number of shares underlying the pro&#160;forma basic loss per share calculation reflects 21.7&#160;million shares of BLAC Common Stock outstanding assuming No Redemptions and 20.7&#160;million shares of BLAC Common Stock outstanding assuming 50% Redemptions and 19.8&#160;million shares of BLAC Common Stock outstanding for the year ended December&#160;31, 2023. The weighted average number of shares underlying the pro&#160;forma basic loss per share calculation reflects 21.7&#160;million shares of BLAC Common Stock outstanding assuming No Redemptions and 20.7&#160;million shares of BLAC Common Stock outstanding assuming 50% Redemptions and 19.8&#160;million shares of BLAC Common Stock outstanding for the year ended December&#160;31, 2022. Pro&#160;forma diluted loss per share is the same as basic loss per share as potential outstanding securities are concluded to be anti-dilutive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended</span><br/><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended</span><br/><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;50%<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;50%<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Numerator:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) attributable to shareholders &#8211; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,370,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005,642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005,642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005,642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Denominator:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#8211; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pro forma basic and diluted earnings (loss) per share</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(0.43</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(0.45</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(0.47</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">0.05</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">0.05</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">0.05</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pro forma basic weighted average shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing OSR Holdings Holders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,676,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLAC Public Stockholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,576,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,633,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsors and related parties</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,198,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Stockholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total pro forma basic weighted average shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,673,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,730,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,786,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_13">COMPARATIVE PER SHARE DATA </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="4" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="4">&#160;&#160;</td>
<td colspan="2" rowspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">OSR&#160;holdings<br/>Co., Ltd.</span></td>
<td style="vertical-align:bottom" rowspan="4">&#160;</td>
<td style="vertical-align:bottom" rowspan="4">&#160;</td>
<td colspan="2" rowspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bellevue<br/>Life<br/>Sciences<br/>Acquisition<br/>Corp.</span></td>
<td style="vertical-align:bottom" rowspan="4">&#160;</td>
<td style="vertical-align:bottom" rowspan="4">&#160;</td>
<td colspan="2" rowspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma</span></td>
<td style="vertical-align:bottom" rowspan="4">&#160;</td></tr>


<tr style="page-break-inside:avoid ">
<td/></tr>
<tr style="page-break-inside:avoid ">
<td/></tr>
<tr style="font-size:1px">
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&#160;31, 2023 Earnings (loss) per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.06</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97.09</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.81</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year Ended December&#160;31, 2022 Earnings (loss) per share, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_14">THE SPECIAL MEETING OF BLAC STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is furnishing this proxy statement/prospectus to its stockholders as part of the solicitation of proxies by BLAC&#8217;s board of directors for use at the special meeting of BLAC to be held on [&#9679;], 2024, and at any adjournment or postponement thereof. This proxy statement/prospectus is first being furnished to BLAC&#8217;s stockholders on or about [&#9679;], 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Date and Time of Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The special meeting will be held at the offices of BLAC at [&#9679;] a.m., Eastern Time, on [&#9679;], 2024, or such other date and time to which such meeting may be adjourned or postponed, to consider and vote upon the proposals. Stockholders may attend, vote and examine the list of BLAC&#8217;s stockholders entitled to vote at the special meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Power; Record Date </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be entitled to vote or direct votes to be cast at the special meeting if you owned shares of BLAC Common Stock at the close of business on [&#9679;], 2024, which is the Record Date for the special meeting. You are entitled to one vote for each share of BLAC Common Stock that you owned as of the close of business on the Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker, bank or other nominee to ensure that shares held beneficially by you are voted in accordance with your instructions. On the Record Date, there were [&#9679;] shares of BLAC Common Stock outstanding, of which [&#9679;] are held by BLAC&#8217;s Sponsor and other affiliated parties, including certain of BLAC&#8217;s executive officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote of Initial Stockholder </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with BLAC&#8217;s initial public offering, BLAC entered into agreements with BLAC&#8217;s Sponsor, executive officers, former and current directors and their respective affiliates pursuant to which they agreed to vote any shares of BLAC Common Stock owned by them in favor of the Business Combination Proposal. Mr.&#160;Yoo, BLAC&#8217;s Chief Financial Officer, and the former and current directors of BLAC, including Dr. Reed, Dr. Roberts, Dr. Chung, Mr. Euh and Mr. Park, obtained their shares in exchange for their services provided as executive officers or directors of BLAC and were not provided with any other consideration for their agreement to vote their shares in favor of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, BLAC&#8217;s Sponsor, executive officers, former and current directors and affiliates hold, collectively, approximately 53.3% of the outstanding shares of BLAC Common Stock. Accordingly, BLAC will not need the affirmative vote of any of the shares of common stock held by public stockholders to approve the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quorum </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum will be present at the special meeting if a majority of the shares of BLAC Common Stock outstanding and entitled to vote at the special meeting is represented at the meeting or by proxy. An abstention from voting, shares represented at the special meeting or by proxy but not voted on one or more proposals or a <span style="white-space:nowrap">broker&#160;non-vote&#160;so</span> long as the stockholder has given the broker or other nominee voting instructions on at least one proposal in this proxy statement, will each count as present for the purposes of establishing a quorum. In the absence of a quorum, the chairman of the special meeting may adjourn the special meeting. As of the Record Date [&#9679;] shares of BLAC Common Stock would be required to achieve a quorum. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote for Proposals for the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter Proposal requires the approval of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Advisory Governance Proposals require the approval of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Plan Proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to be elected as a director as described in the Director Election Proposal, a nominee must receive a plurality of all the votes cast by holders of the shares of BLAC Common Stock at the special meeting, which means that the nominees with the most votes are elected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal requires the approval the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Business Combination Proposal, the Charter Proposal, the Incentive Plan Proposal and the Director Election Proposal, is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. The Advisory Governance Proposals and the Adjournment Proposal are not conditioned on any other proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of these proposals is more fully described in this proxy statement/prospectus, which each stockholder is encouraged to read carefully and in its entirety. It is important for you to note that if the Business Combination Proposal is not approved by BLAC&#8217;s stockholders, or if any other Condition Precedent Proposal is not approved by BLAC&#8217;s stockholders and BLAC and OSR Holdings do not waive the applicable closing condition under the Business Combination Agreement, then BLAC will not consummate the Business Combination. If BLAC does not consummate the Business Combination and fail to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), BLAC will be required to dissolve and liquidate our trust account by returning the then remaining funds in such account to the public stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the BLAC Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s board of directors believes that the Business Combination Proposal and the other proposals to be presented at the special meeting are in the best interests of BLAC and BLAC&#8217;s stockholders and unanimously recommends that BLAC&#8217;s stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; each of the proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of BLAC&#8217;s board of directors in favor of approval of the Business Combination Proposal, you should keep in mind that BLAC&#8217;s Sponsor, directors, officers and their affiliates have interests in the Business Combination that are different from or in addition to (or which may conflict with) your interests as a stockholder. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; for additional information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Broker <span style="white-space:nowrap">Non-Votes</span> and Abstentions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the rules of various national and regional securities exchanges your broker, bank or nominee cannot vote your shares with respect to <span style="white-space:nowrap">non-discretionary</span> matters unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank or nominee. BLAC believes the proposals presented to BLAC stockholders will be <span style="white-space:nowrap">considered&#160;non-discretionary</span> and therefore your broker, bank or nominee cannot vote your shares without your instruction. If you do not provide instructions to your bank, broker or other nominee, it may deliver a proxy card expressly indicating that it is NOT voting your shares; this indication that a bank, broker or nominee is not voting your shares is referred to as a <span style="white-space:nowrap">&#8220;broker&#160;non-vote.&#8221;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An abstention from voting, shares represented at the special meeting or by proxy but not voted on one or more proposals and a <span style="white-space:nowrap">broker&#160;non-vote&#160;will</span> each count as present for the purposes of establishing a quorum. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Your Shares </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of BLAC Common Stock that you own in your name entitles you to one vote on each of the proposals presented at the special meeting. Your proxy card or cards show the number of shares of BLAC Common Stock that you own. There are several ways to vote your shares of BLAC Common Stock: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can vote your shares by completing, signing, dating and returning the enclosed proxy card in the postage-paid envelope provided. If you hold your shares in &#8220;street name,&#8221; which means your shares are held of record by a broker, bank or other nominee, you should follow the instructions provided to you by your broker, bank or nominee to ensure that votes related to the shares you beneficially own are properly represented and voted at the meeting. If you vote by proxy card, your &#8220;proxy,&#8221; whose name is listed on the proxy card, will vote your shares as you instruct on the proxy card. If you sign and return the proxy card but do not give instructions on how to vote your shares, your shares of BLAC Common Stock will be voted as recommended by our board of directors. Our board of directors recommends voting &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Charter Proposal, &#8220;FOR&#8221; the Advisory Governance Proposals, &#8220;FOR&#8221; the Incentive Plan Proposal, &#8220;FOR&#8221; the Director Election Proposal and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented to the special meeting. Votes received after a matter has been voted upon at the special meeting will not be counted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can attend the special meeting in person and vote even if you have previously voted by submitting a proxy as described above. You will be able to attend, vote your shares and submit questions during the special meeting. However, if your shares of BLAC Common Stock are held in the name of your broker, bank or other nominee, you must get a legal proxy from the broker, bank or other nominee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revoking Your Proxy </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you give a proxy, you may revoke it at any time before the special meeting or at such meeting by doing any one of the following: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may send another proxy card with a later date; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may notify Kuk Hyoun Hwang, BLAC&#8217;s Chief Executive Officer, by telephone at <span style="white-space:nowrap"><span style="white-space:nowrap">425-635-7700,</span></span> or in writing to c/o Bellevue Life Sciences Acquisition Corp., 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004, before the special meeting that you have revoked your proxy; or </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may attend the special meeting, revoke your proxy, and vote, as indicated above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Additional Matters May Be Presented at the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The special meeting has been called only to consider the approval of the Business Combination Proposal, the Charter Proposal, the Advisory Governance Proposals, the Incentive Plan Proposal, the Director Election Proposal and the Adjournment Proposal. Under BLAC&#8217;s Existing Governing Documents, other than procedural matters incident to the conduct of the special meeting, no other matters may be considered at the special meeting if they are not included in this proxy statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who Can Answer Your Questions About Voting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions about how to vote or direct a vote in respect of your shares of BLAC Common Stock, you may call Advantage Proxy, BLAC&#8217;s proxy solicitor, at (206) <span style="white-space:nowrap">870-8565.</span> Banks and Brokerage Firms may call collect at: (877) <span style="white-space:nowrap">870-8565.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption Rights and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to BLAC&#8217;s Existing Governing Documents, any holders of BLAC&#8217;s public shares may demand that such shares be redeemed in exchange for a pro rata share of the aggregate amount on deposit in the trust account as of two business days prior to the consummation of the Business Combination. Public stockholders may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. If demand is properly made and the Business Combination is consummated, these shares, immediately prior to the Business Combination, will cease to be outstanding and will represent only the right to receive a pro rata share of the aggregate amount on deposit in the trust account (calculated as of two business days prior to the consummation of the Business Combination, less franchise and income taxes payable). For illustrative purposes, based on funds in the trust account of approximately $[&#9679;]&#160;million (including interest and prior to the payment of pay taxes) on [&#9679;], 2024, the estimated per share redemption price would have been approximately $[&#9679;]. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise your redemption rights, you must: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">(a) hold public shares or (b)&#160;if you hold public shares through units, you elect to separate your units into the underlying public shares, warrants and rights prior to exercising your redemption rights with respect to the public shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submit a request in writing that we redeem your public shares for cash. The request must identify the beneficial owner of the shares to be redeemed (including its legal name, phone number and address) and must be sent to Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent, at the following address: </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Continental Stock Transfer&#160;&amp; Trust Company </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">One State Street Plaza, 30th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">New York, New York 10004 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: SPAC Redemption Team </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">E-mail:&#160;spacredemptions@continentalstock.com</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">and </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">deliver your share certificates either physically or electronically through DTC to BLAC&#8217;s transfer agent at least two business days before the special meeting. Stockholders seeking to exercise redemption rights and opting to deliver physical certificates should allot sufficient time to obtain physical certificates from the transfer agent and time to effect delivery. It is our understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. However, we do not have any control over this process and it may take longer than two weeks. Stockholders who hold their shares in street name will have to coordinate with their bank, broker or other nominee to have the shares certificated or delivered electronically. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not properly comply with the procedures and requirements to redeem your public shares described above, your shares will not be redeemed. Any request for redemption, once made by a holder of public shares of BLAC Common Stock, may not be withdrawn once submitted to BLAC unless the Board of Directors of BLAC determines (in its sole discretion) to permit the withdrawal of such redemption request (which they may do in whole or in part). If you delivered your share certificates (if any) for redemption to our transfer agent and decide within the required timeframe not to exercise your redemption rights, you may request that our transfer agent return the shares (physically or electronically). You may make such request by contacting our transfer agent at the phone number or address listed above prior to the date of the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a condition to closing under the Business Combination Agreement that at least $5,000,001 remain after payment of all requested redemptions by our public stockholders and receipt of the gross proceeds of the PIPE Financing. Any redemptions by our public stockholders will decrease the funds in the trust account available to us to consummate the Business Combination and other related transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to exercising redemption rights, stockholders should verify the market price of our shares of BLAC Common Stock as they may receive higher proceeds from the sale of their shares of BLAC Common Stock in the public market than from exercising their redemption rights. We cannot assure you that you will be able to sell your shares of BLAC Common Stock in the open market, even if the market price per share is higher than the redemption price, as there may not be sufficient liquidity in our shares of BLAC Common Stock when you wish to sell your shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you exercise your redemption rights, your shares of BLAC Common Stock will cease to be outstanding immediately prior to the Business Combination and will only represent the right to receive a pro rata share of the aggregate amount on deposit in the trust account. You will no longer own those shares and will have no right to participate in, or have any interest in, the future growth of BLAC following the Business Combination, if any. You will be entitled to receive cash for these shares only if you properly and timely demand redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the warrants will not have redemption rights with respect to the warrants or and holders of the rights will not have redemption rights with respect to the rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is not approved and we do not consummate an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), BLAC will be required to dissolve and liquidate our trust account by returning the then remaining funds in such account to the public stockholders and our warrants and rights will expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of BLAC stockholders, unit holders, warrant holders or rights holders have appraisal rights in connection with the Business Combination under the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_15">THE BUSINESS COMBINATION </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Background of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Business Combination are the result of negotiations between representatives of BLAC and OSR Holdings. The following is a brief description of the background of these negotiations and the resulting Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were several important matters that were considered by BLAC in its search for a prospective business or assets to acquire in the initial business combination. Since the completion of BLAC&#8217;s IPO, BLAC considered a number of prospective businesses with which to consummate an initial business combination. Representatives of BLAC reviewed self-generated ideas, contacted and were contacted by a number of individuals, investment banks, private equity and venture capital firms, and companies in the life sciences, healthcare services, medical technology, devices, and diagnostics sectors. BLAC primarily considered businesses that BLAC believed could benefit from the substantial expertise, experience, and network of the BLAC management team, and relationship with its sponsor affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC originally had a <span style="white-space:nowrap">9-month</span> timeline (which has been extended to November&#160;14, 2024, in accordance with the Existing Governing Documents) to find and consummate a business combination with a target company. This original short timeline was decided upon in conjunction with advice from BLAC&#8217;s underwriters, Chardan, and BLAC&#8217;s knowledge of the general SPAC market conditions of the previous years (2021-2023) during which the timelines for completing business combinations had generally become increasingly shorter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the short time frame and the accompanying time pressure, BLAC was restricted in the total number of companies that it could review, analyze, conduct meetings with, and otherwise consider in connection with its efforts to find a company or companies with which to execute a business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, BLAC&#8217;s Current Charter contains a waiver of the corporate opportunity doctrine, and there could have been business combination targets that would have been appropriate for a combination with BLAC but were not offered due to a BLAC director&#8217;s or officer&#8217;s duties to another entity. BLAC and its management are not aware of any such corporate opportunities not being offered to BLAC and do not believe that the waiver of the corporate opportunity doctrine in the Current Charter interfered with BLAC&#8217;s ability to identify an acquisition target, including the decision to pursue the Business Combination with OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During BLAC&#8217;s search process, it engaged in discussions with and reviewed multiple prospective businesses, including OSR Holdings, which it began to consider as a target candidate on February&#160;20, 2023. A concern that was expressed repeatedly in formal and informal communications with potential target companies during BLAC&#8217;s search process was the general topic of the SPAC-market worldwide, extremely high investor redemptions, and the appurtenant need to secure PIPE Financing or other alternative financing in order to be able to complete a business combination. In BLAC&#8217;s case, PIPE Financing or alternative financing had not been secured or committed to by third parties during the first 12 weeks since its IPO, when BLAC was actively evaluating companies for a business combination. In BLAC&#8217;s experience and view, the issues of redemptions and PIPE or alternative financing, and more specifically questions or concerns about BLAC&#8217;s ability to raise additional capital in the face of anticipated redemptions, reduced the pool of potential target companies willing to engage in discussions with BLAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC/OSR Holdings Joint Review of Potential Target Companies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described below, members of BLAC and OSR Holdings (and executives of certain of OSR Holdings&#8217; subsidiaries) jointly reviewed and evaluated target companies&#8217; scientific models, theses and data. These joint exercises were performed for the sake of efficiency and streamlining, and to utilize BLAC and OSR Holdings&#8217; substantial internal resources and expertise. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC and OSR Holdings and its subsidiaries&#8217; executives and consultants together comprise a roster of experienced scientists and medical doctors. BLAC and OSR Holdings executives likewise have extensive experience in the Korean, U.S. and European capital markets and/or the biotech/biopharma industry. In addition to the benefit of BLAC and OSR Holdings members&#8217; and consultants&#8217; substantial collective experiences, given the short timeline for BLAC to execute a business combination, utilizing the collective internal resources of BLAC and OSR Holdings was the most time and cost-efficient manner in which to evaluate potential target companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Kuk Hyoun Hwang is Chief Executive Officer and a Director of BLAC and is also Chief Executive Officer of OSR Holdings, where he served as Chairman from July 2019 until April 2021 and from December 2022 to present. Due to the inherent conflict of interest presented by Mr.&#160;Hwang&#8217;s dual roles, the BLAC Board formed a special committee (the &#8220;<span style="text-decoration:underline">BLAC M&amp;A Committee</span>&#8221;) on June&#160;9, 2023 consisting of members of the BLAC Board that do not have any financial or other interest in OSR Holdings, from which Mr.&#160;Hwang was recused, and through which approval would be sought to pursue any business combination transaction, as well as other subsequent decisions to be taken by the BLAC M&amp;A Committee, including the ratification of actions taken by the BLAC Board and management prior to June&#160;9, 2023. The BLAC M&amp;A Committee was originally comprised of three independent members of the BLAC Board, Dr.&#160;Reed, Dr.&#160;Roberts and Mr.&#160;Park. Upon the resignations of Dr.&#160;Reed and Dr.&#160;Roberts in May 2024 and June 2024, respectively, Mr.&#160;Lee and Mr.&#160;Kim joined the BLAC M&amp;A Committee. The BLAC M&amp;A Committee ratified BLAC&#8217;s entry into a <span style="white-space:nowrap">non-disclosure</span> agreement with OSR Holdings, dated March&#160;30, 2023, and subsequently approved BLAC&#8217;s entry into a letter of intent between BLAC and OSR Holdings dated July&#160;11, 2023. Mr.&#160;Hwang continued to serve as an officer and director of both BLAC and OSR Holdings. For BLAC, he participated in evaluating companies as potential businesses combination targets while leading efforts to secure the necessary PIPE financing to complete such a business combination. For OSR Holdings, he continued to lead all operations and executive functions, including assessing potential businesses as acquisition targets to continue building OSR Holdings&#8217; portfolio of healthcare subsidiary companies. As described herein, BLAC began considering OSR Holdings as a target candidate on February&#160;20, 2023. Mr.&#160;Hwang, representing BLAC, first introduced the basic terms of a potential transaction between BLAC and OSR Holdings with management of OSR Holdings on May&#160;2, 2023, when a proposed draft letter of intent was initially distributed by legal counsel to BLAC. At such time, OSR Holdings was evaluating a range of other acquisition and strategic opportunities as part of its ongoing business operations but it had not reached any definitive or other agreements for any such transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to minimize the effects of any inherent conflicts of interest, Mr.&#160;Hwang left negotiations and discussions between BLAC and OSR Holdings largely in the hands of their respective management teams, boards of directors, and special committees, as applicable, and refrained from unilaterally making decisions regarding a business combination, or the terms thereof, without the input and approval of <span style="white-space:nowrap">non-conflicted</span> individuals, including the BLAC M&amp;A Committee. For the avoidance of doubt, any decisions that involved a material conflict of interest of Mr.&#160;Hwang were reviewed, considered, and resolved by the BLAC M&amp;A Committee. The individuals listed below (along with their relevant expertise) were involved in the initial discussions between BLAC and OSR Holdings, and, as described above, were also involved in the joint review of certain other potential target companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Steven&#160;G. Reed, former Director and BLAC M&amp;A Committee Member, BLAC (business, healthcare industry, science, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Radclyffe Roberts, former Director and BLAC M&amp;A Committee Member, BLAC (business, healthcare industry, science) </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Jin Whan Park, Director and BLAC M&amp;A Committee Member, BLAC (business, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Kuk Hyoun Hwang, CEO and Director, BLAC and CEO and Chairman, OSR Holdings (business, capital markets, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Jun Chul Whang, Partner and General Counsel, Bellevue Capital Management; Director, BLAC (business, legal, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Thomas Shin, employee of Sponsor (business, capital markets) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Josh Pan, Partner, Bellevue Capital Management (business, healthcare industry, science, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Sung Hoon Chung, former Managing Director, OSR Holdings (business, capital markets, transaction) </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Senyon (&#8220;<span style="text-decoration:underline">Teddy</span>&#8221;) Choe, Scientific Founder, Darnatein (subsidiary of OSR Holdings) (science) </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Yeseok Kim, Senior Analyst, OSR Holdings (business, science) </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Companies BLAC Considered for Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company A </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An alternative target that BLAC considered (&#8220;Company A&#8221;) was introduced to BLAC on March&#160;2, 2023 by Mr.&#160;Whang, who has known Company A&#8217;s current President and CEO professionally and socially for the past decade. The company has developed diagnostic applications in ophthalmology, infectious disease (including <span style="white-space:nowrap">COVID-19)</span> and oncology, and utilizes AI to analyze genetic data for early diagnosis of disease. Mr.&#160;Whang is also a personal acquaintance of a partner at a Seoul based law firm that has represented Company A as Korea Counsel for close to a decade. Mr.&#160;Whang was knowledgeable that at latest as of <span style="white-space:nowrap">mid-2019,</span> Company A was contemplating listing directly on the Korean public markets (KOSDAQ), but did not have any business or potential business relationships with Company A or its President and CEO until after BLAC&#8216;s IPO on February&#160;14, 2023. Mr.&#160;Whang received and shared Company A&#8217;s <span style="white-space:nowrap">non-Confidential</span> deck with BLAC and OSR Holdings via email dated March&#160;9, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, Company A entered into a <span style="white-space:nowrap">non-binding</span> letter of intent to combine with another SPAC and their exclusive negotiation period expired on March&#160;3, 2023. Immediately upon expiration of the exclusivity period, Company A requested a meeting with BLAC to gauge BLAC&#8217;s interest in Company A as a potential target company for its business combination. Company A had been aware of BLAC&#8217;s recent IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In New York City, on March&#160;10, 2023, Company A&#8217;s President and CEO (at the time Company A&#8217;s Chief Strategy Officer), met with Mr.&#160;Hwang, Mr.&#160;Shin and Mr.&#160;Whang to discuss Company A&#8217;s pursuit of a SPAC combination. Topics of discussion included an introduction to BLAC and its operational and acquisition strategy, and a status update on Company A&#8217;s search for a SPAC business combination partner. The parties discussed BLAC&#8217;s February&#160;14, 2023, $60&#160;million IPO, and its underwriter Chardan&#8217;s exercise of its 15% overallotment option, bringing the total in trust to $69&#160;million. Company A informed BLAC that at one point, Company A&#8217;s self-assessed valuation was over $1&#160;billion, but that due to Company <span style="white-space:nowrap">A-specific</span> issues, as well as biotech market conditions generally, the valuation had been substantially reduced. Company A offered to arrange for video conferences or <span style="white-space:nowrap">in-person</span> meetings with key members of Company A staff, and to open Company A&#8217;s data room to BLAC. Company A expressed concern about redemptions, as SPAC-market wide investor redemptions have averaged <span style="white-space:nowrap">95-99%;</span> specifically, they were concerned about BLAC&#8217;s ability to have enough funds to execute a business combination with Company A. The parties concluded the meeting agreeing to follow up over the following weeks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the March&#160;10, 2023 meeting with Company A, from March&#160;11 to 13, while Messrs. Hwang and Shin were in New York City, they met with Mr.&#160;Whang and had extensive discussions regarding the possibility of a direct business combination with Company A. They also discussed the possibility of a business combination with other companies to which BLAC had contacted by that time (see below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Whang exchanged further text and email messages with Company A&#8217;s President and CEO and Company A&#8217;s counsel in the following weeks. On April&#160;14, 2023, Company A and Messrs. Hwang and Whang conducted an extensive video conference to further discuss Company A&#8217;s and BLAC&#8217;s respective strategies, and BLAC disclosed to Company A that it was considering executing a business combination with OSR Holdings. The parties discussed whether Company A might consider becoming acquired by OSR Holdings. Company A&#8217;s President and CEO said he would discuss the issue with Company A&#8217;s Board of Directors, but said that Company A would probably prefer a direct business combination with BLAC. BLAC informed Company A that they would give more consideration to a direct business combination with Company A as well. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Whang followed up with Company A&#8217;s President and CEO during the weeks following the April&#160;14, 2023 video conference via text messages and phone calls. On or around April&#160;27, 2023, Mr.&#160;Whang informed Company A&#8217;s President and CEO that BLAC was considering a transaction with OSR Holdings, and that BLAC could not proceed with Company A if they were not open to the possibility of an acquisition by OSR Holdings. This was the last communication between BLAC and Company A. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company B </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another alternative target that BLAC considered (&#8220;Company B&#8221;) was introduced to BLAC on March&#160;10, 2023 by Mr.&#160;Whang, whose personal acquaintance is an investor and advisor to the company (&#8220;Investor A&#8221;). Mr.&#160;Whang had met with Investor A and a business partner of Investor A in September 2022 in New York City, during which time they discussed Company B&#8217;s technology and capital raising efforts. Company B produces affordable and portable home testing kits that produce rapid and accurate results, with applications to hematology, pathology, oncology and possibly other areas. Mr.&#160;Whang told Investor A about BLAC&#8217;s upcoming IPO, but did not discuss the possibility of Company B being a potential target for a business combination at this time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequently, after BLAC&#8217;s IPO on February&#160;14, 2023 and beginning on March&#160;9, 2023, Mr.&#160;Whang, via text messages, emails and phone calls, discussed with Investor A the possibility of a business combination between BLAC and Company B, and Investor A expressed an interest in exploring this possibility. Investor A was generally aware of the SPAC market, including the volatility in the SPAC market over the previous two years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Whang shared Company B&#8217;s <span style="white-space:nowrap">non-confidential</span> deck by email dated March&#160;10, 2023 with members of BLAC (Mr.&#160;Hwang) and OSR Holdings (Sean Chung, Jessi Kim and Sung Jae Yu) for a preliminary review of Company B&#8217;s science and technology and the company&#8217;s current and projected financial status. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By telephone communications in late March, Mr.&#160;Whang told Investor A that one strategy under consideration by BLAC was to pursue an affiliated transaction, executing a business combination with OSR Holdings. Given Company B&#8217;s current estimated self-valuation of the company (approximately <span style="white-space:nowrap">$35-40m),</span> Mr.&#160;Whang told Investor A that even if BLAC were to execute a direct business combination with Company B, BLAC would seek to execute a business combination with other companies. In connection with this strategy, Mr.&#160;Whang asked whether Company B would consider the possibility of being acquired by OSR Holdings, in addition to the possibility of a direct business combination with BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the following weeks, Messrs. Whang and Hwang and OSR Holdings were in communication with Investor A, and his colleague and business partner, to arrange for an <span style="white-space:nowrap">in-person</span> meeting at BLAC/OSR Holdings&#8217; offices in Seoul. Investor A proposed to bring another colleague from a manufacturing partner to the meeting. Investor A told Mr.&#160;Whang that such company would become Company B&#8217;s manufacturing partner for product distribution in Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon conducting initial due diligence and background checks, it was discovered that a key individual from the potential manufacturing partner was involved (as of April 2023) in litigation. Subsequently, BLAC decided not to pursue further discussions with Company B. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company C </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, BLAC received an unsolicited email from the Chief Business Officer of another potential target company of BLAC (&#8220;Company C&#8221;), inquiring about business combination opportunities that BLAC was considering. Company C is a clinical stage immune-oncology company with two broadly applicable platform technologies involving <span style="white-space:nowrap">CAR-CIK</span> Autologous RNA loaded dendritic cells. The Chief Business Officer of Company C wrote he had seen an announcement of BLAC&#8217;s recent listing on Nasdaq. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated April&#160;13, 2023, Company C sent BLAC its <span style="white-space:nowrap">non-confidential</span> company presentation. The presentation was circulated internally at BLAC and OSR Holdings for review. By email dated April&#160;24, 2023, Mr.&#160;Hwang inquired about Company C&#8217;s technology and asked for a mutually convenient time for a video conference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2023, officers of Company C, BLAC (Messrs. Hwang and Whang), OSR Holdings (Sean Chung and Dr.&#160;Senyeon Choe), Dr.&#160;Pan, and Mr.&#160;Shin, participated in a video conference. Mr.&#160;Hwang began by explaining that currently, BLAC was considering an affiliated transaction with OSR Holdings, that OSR Holdings was considering acquiring additional portfolio companies, and that any acquisition of Company C would have to be via acquisition by OSR Holdings. Company C&#8217;s Chief Business Officer said Company C was only considering a direct business combination with a SPAC. There were no further communications with Company C. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company D </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another potential target company (&#8220;Company D&#8221;) was introduced to former OSR Holdings Managing Director Sung Hoon Chung&#8217;s former colleague at Auerbach Grayson (&#8220;Broker&#8221;) on March&#160;23, 2023. Company D is a clinical stage biotech company with a pipeline of three clinical trials on Glioblastoma Multifore (GBM). On March&#160;23, 2023, Broker circulated a <span style="white-space:nowrap">non-confidential</span> company presentation to BLAC for review. Further emails were exchanged between BLAC/OSR Holdings and Broker to arrange a meeting in Korea with Company D and a Korean biopharma company with a controlling stake in Company D (&#8220;Parent D&#8221;). Mr.&#160;Whang met with Broker in New York City on April&#160;12, 2023 to further discuss Company D and BLAC&#8217;s business combination strategy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of further background, Parent D was formerly in the lifesaving boat business. Parent D acquired an American lifeboat company in the U.S. in 2009, and until then, had no prior involvement or business interest in the biotech space. For reasons unknown to BLAC, the US company acquired by Parent D held a controlling stake in an early-stage biotech. Post-takeover, Parent D management took an active interest in the acquired biotech investment and determined the company presented significant business opportunities, which led to the launch of Parent D specifically in the Korean biotech space. After 14 years of drug development progress, earlier in 2023, the acquired biotech company submitted a New Drug Application to the US Food and Drug Administration for its investigational drug, rivoceranib, for use in combination with an approved drug, camrelizumab, in China for unresectable hepatocellular carcinoma. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to its acquisition of Company D, Parent D transformed into one of the most visible biopharma groups in Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to Mr.&#160;Whang&#8217;s meeting with Mr.&#160;Shin, on or about July&#160;3, 2023, the newly-appointed CFO of Parent D requested a meeting with OSR Holdings as he had heard about Vaximm&#8217;s (a subsidiary of OSR Holdings) recent activity developing therapeutics in the glioblastoma space in Switzerland. Parent D&#8217;s CFO is not a scientist by training nor a professional with specific pharmaceutical drug development expertise but is experienced in the Korean capital markets/finance industry. The CFO of Parent D and Mr.&#160;Hwang also share a mutual acquaintance. As of late July 2023, OSR Holdings planned to have discussions with Parent D and Company D representatives regarding a potential business combination, and other potentially mutually beneficial business opportunities and synergies. Based on timing considerations and the need to proceed with an identified target company, the decision was made to cease discussions with Company D. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company E </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2023, another potential target company (&#8220;Company E&#8221;) was introduced to BLAC by Mr.&#160;Whang through an acquaintance, an independent investor and consultant based in New York City and Seoul (&#8220;Investor E&#8221;). Mr.&#160;Whang had told Investor E about BLAC&#8217;s February&#160;14, 2023 IPO, and the need to execute a business combination by November&#160;14, 2023, and Investor E informed Mr.&#160;Whang that he knew some companies </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that might be interested in a business combination opportunity with BLAC. Company E focuses on oral cancer diagnostics and therapeutics. On April&#160;18 and 21, 2023, Mr.&#160;Whang forwarded Company E&#8217;s <span style="white-space:nowrap">non-confidential</span> information to BLAC and OSR Holdings for review. Initial review by BLAC and OSR Holdings included assessment of Korean companies with competing or comparable technology. Mr.&#160;Whang had further communications with Investor E through May&#160;4, 2023. BLAC determined that Company E was not a viable candidate for a business combination, as the competitive landscape in the dental scanning technology space in Korea was too difficult to penetrate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Company F </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2023, another potential target company (&#8220;Company F&#8221;) was introduced to BLAC by Mr.&#160;Whang through Investor E. Company F develops novel diagnostic tests for cancer, including a urine test for bladder cancer. On April&#160;18, 2023, Mr.&#160;Whang shared publicly available information on Company F with BLAC and OSR Holdings. Mr.&#160;Whang had further communications with Investor E through May&#160;4, 2023. BLAC determined that Company F was not a viable candidate for a business combination, as OSR Holdings is focused primarily on drug development, while Company F is in the diagnostics space. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Others </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above listed companies, BLAC also was introduced to several other companies in the biotech/healthcare/medtech industries during the period from February&#160;15 to March&#160;9, 2023, but a decision was made not to pursue discussions with them for several reasons, including industry sector, stage of development of intellectual property, science, treatment or therapy, company size, revenue, growth potential, stage of funding, etc. The companies included the following: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company G</span></span><span style="font-weight:bold">&#8221;</span>, a medical equipment manufacturer. The company developed a fully integrated, automated instrument that delivers high-throughput, quantitative, single-molecule, single-cell data with spatial context and subcellular resolution by bringing together advancements in imaging, fluidics, chemistry and bioinformatics. The company was introduced to BLAC on February&#160;15, 2023 by a contact of OSR Holdings&#8217; Sean Chung at a Seoul-based early seed venture capital investor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company H</span></span><span style="font-weight:bold">&#8221;</span>, a therapeutics company, focused on developing treatments for CNS disorders and rare diseases such as Alzheimer&#8217;s, which developed the first and only resveratrol product that safely reaches therapeutic levels without gastrointestinal side effects. The product has Orphan Drug Exclusivity and Patent Protection in Global Markets through 2036, with additional patents pending. The company was introduced to BLAC on February&#160;18, 2023 by an asset management company that reached out directly to BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company I</span></span><span style="font-weight:bold">&#8221;</span>, which provides home healthcare, hospice&#160;&amp; aftercare services in three states, with over 237 employees. Company services include (but are not limited to): post-operative care; physical and speech therapy; pain management; hospice care; and funeral and burial services The company had over 97,000 patient encounters in 2022. The company was introduced to BLAC by an investment bank and wealth management firm, who reached out to BLAC directly on March&#160;2, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company J</span></span><span style="font-weight:bold">&#8221;</span>, a therapeutics company, developing fetal neural stem cell therapeutic platform targeting neurological diseases such as Parkinson&#8217;s, Lou Gehrig&#8217;s, stroke, etc. The founder of the Company is a respected expert in the fetal stem cell space. The company was introduced to BLAC on February&#160;28, 2023 by Jaechul Seo, a shareholder of OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company K</span></span><span style="font-weight:bold">&#8221;</span>, a clinical stage biopharmaceutical company, focusing on clinical development of medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines and proteostasis modulators. The company currently has four programs under pipeline in clinical stage, including its lead asset, AST301, a pDNA based cancer vaccine for breast cancer. The company also developed a machine-learning based immuno-informatics platform, <span style="white-space:nowrap">Th-VAC,</span> for its drug development, and entered <span style="white-space:nowrap">in-licensing</span> agreement a Seattle based </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biotech company. The company was introduced to BLAC on March&#160;6, 2023 by a Seoul, Korea based biotech company. Mr.&#160;Hwang of BLAC was also introduced to the company by Steven Reed of HDT Bio Corp., and a Director of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold"><span style="text-decoration:underline">Company L</span></span><span style="font-weight:bold">&#8221;</span>, a clinical stage company, with clinically proven stem cell expansion technology that also serves as starting material for generation of multiple immune effector cells. The company was the first group to develop clinical universal <span style="white-space:nowrap">non-HLA</span> matched allogeneic and <span style="white-space:nowrap"><span style="white-space:nowrap">off-the-shelf</span></span> cell therapies with excellent safety profiles and owns a diverse pipeline of multiple effector cells allows combination approaches to enhance efficacy and overcome the limitation of current treatment with <span style="white-space:nowrap">CAR-T</span> monotherapy. The company also developed a cell therapy for first line AML (Phase 2/3 ready program) with preliminary efficacy and safety data from global RCT phase 2. The company was introduced to BLAC on March&#160;9, 2023 by a Seattle, Washington based venture capital firm. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC and OSR Holdings Discussions regarding Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Initial Discussions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning several years ago, OSR Holdings has had and continues to have a standing policy of holding a firm-wide meeting every Monday morning at 10:00 AM Seoul Time to discuss all matters relating to OSR Holdings&#8217; business. Attendees include (now former) Managing Director Sung Hoon Chung, Managing Director and Chief Operating Officer Sung Jae Yu, (now former) Chief Financial Officer Soo Eun Nam, Technology Analyst Dr.&#160;Yeiseok Kim, Analyst Taemin Lee, as well as Chief Executive Officer and Chairman Kuk Hyoun Hwang. As noted previously, Mr.&#160;Hwang also serves as a director and Chief Executive Officer of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following BLAC&#8217;s IPO on February&#160;14, 2023, and as set forth fully below, BLAC began to consider companies with which to conduct a business combination. This included the possible option of a business combination with its affiliated company OSR Holdings. Thus, beginning the following week, on Monday, February&#160;20, 2023, BLAC began considering OSR Holdings as a target candidate, and OSR Holdings&#8217; group discussions began to include the topic of a possible business combination with BLAC. Discussions also included BLAC&#8217;s potential business combination with other companies, since BLAC turned to the scientific, medical, financial and other inhouse expertise of its affiliated company OSR Holdings (and OSR Holdings&#8217; subsidiaries) in evaluating its potential business targets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During these weekly meetings (as well as at other times), when discussing a potential BLAC/OSR Holdings business combination, Mr.&#160;Hwang was mindful of the fact that he held dual roles with BLAC and OSR Holdings, and mindful of the potential for a conflict of interests arising from his dual representation. Mr.&#160;Hwang made reasonable efforts to ensure that a BLAC/OSR Holdings business combination would be beneficial to each party separately, as well as both parties together, and made every reasonable effort to be a neutral and balanced advocate for both parties he represented. Mr.&#160;Hwang was aware that for BLAC, the benefits would include the execution of a business combination with a holding company with a portfolio of operating companies, which was in accordance with its publicly stated business strategy, and the ability to execute a complex business transaction with a company with which BLAC (through Mr.&#160;Hwang) was already familiar. From OSR Holdings&#8217; perspective, Mr.&#160;Hwang was aware that a business combination with BLAC could provide a capital infusion and a publicly traded security, which would enable it to pursue its goal of expanding its portfolio of companies in the biotech/medtech and biopharma spaces, as well as recruiting qualified individuals to expand its existing business to a global scale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC determined that it was an objectively reasonable business decision in its search for a target company to seek a business combination with OSR Holdings. BLAC did not consider any other alternative combination targets to be as compelling as OSR Holdings when evaluating potential alternative companies&#8217; business prospects, strategy, management teams, structure, likelihood of execution (including taking account of timelines for completion of a business combination) and valuation considerations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">February&#160;20, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on February&#160;20, 2023, in attendance were Mr.&#160;Hwang and OSR Holdings executives Sung Hoon Chung, Sung Jae Yu, Soo Eun Nam, Yeiseok Kim and Taemin Lee. Among other topics of discussion, as a representative of BLAC, Mr.&#160;Hwang said that while BLAC had initiated a search for a target company with which to conduct a business combination, BLAC would also simultaneously pursue the possibility of conducting a business combination with OSR Holdings. This was discussed in the context of OSR Holdings&#8217; historical plans from early 2020 for OSR Holdings to lead an effort to take Vaximm AG, a Swiss biotech company, public on the Korean stock exchange (KOSDAQ) by engaging a major Korean investment bank (Brokerage &#8220;S&#8221;) for which Mr.&#160;Hwang himself previously worked. As CEO of OSR Holdings, Mr.&#160;Hwang was actively involved in all aspects of discussions and decisions regarding such historical plans. In line with those plans, OSR Holdings&#8217; Swiss affiliate, BCM Europe, had made a minority investment in Vaximm in early 2020. Also in line with those plans, on December&#160;29, 2020, OSR Holdings had officially retained Brokerage S to be lead underwriter for the KOSDAQ IPO process. A Lead Manager Agreement was executed with Brokerage S for the purpose of taking Vaximm public via a traditional initial public offering on KOSDAQ and not by means of any transaction with a shell company on KOSDAQ (or elsewhere). As the engagement with Brokerage S was formalized and plans were taking shape in preparation for taking Vaximm AG public on KOSDAQ, in early 2022, OSR Holdings considered and ultimately modified its original plans of being a financial advisor and investor for its affiliates to becoming a biotech holding company that could itself list on KOSDAQ, with Vaximm as its lead biotech subsidiary. To that end, in December 2022, OSR Holdings acquired approximately 92% of Vaximm from its Swiss affiliate BCM Europe. By the end of January 2023, OSR Holdings acquired all of the remaining shares of Vaximm from BCM Europe, resulting in Vaximm becoming a wholly owned subsidiary of OSR Holdings. Additionally, on December&#160;31, 2022, OSR Holdings completed its acquisition of RMC, a medical device supply distribution company based in Korea, for its high growth and profitability, but also because RMC&#8217;s revenue stream would allow OSR Holdings to meet the Korean regulatory requirement for listing on KOSDAQ of a minimum revenue amount three years <span style="white-space:nowrap">post-IPO.</span> To continue building OSR Holdings as a biotech holding company in preparation for listing on KOSDAQ, OSR Holdings completed its acquisition of Darnatein, a Korean biotherapeutic company developing a pipeline of spinal fusion and cartilage regenerative therapies in March 2023. Because of the several and varied transactions OSR Holdings conducted, OSR Holdings was well-positioned to be taken public on KOSDAQ beginning February 2023 independent of engaging with BLAC. However, with the potential to combine with BLAC as an alternative route of going public, on February 20, 2023, Mr.&#160;Hwang requested that OSR Holdings&#8217; management carefully consider a business combination with BLAC as an alternative way of taking OSR Holdings public, and on NASDAQ rather than KOSDAQ. OSR Holdings had not considered entering into a business combination with a shell corporation prior to BLAC&#8217;s IPO. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">March&#160;20, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;20, 2023, while Mr.&#160;Hwang was traveling in the U.S., Mr.&#160;Hwang and OSR Holdings COO and Director Sung Jae Yu had a telephone conversation about both BLAC and OSR Holdings executing a Confidentiality Agreement in order to further pursue discussions with BLAC regarding a potential business combination between BLAC and OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">March&#160;27, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On Monday, March&#160;27, 2023, BLAC was introduced to LBV as further discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Klaus Breiner from Pureos Bioventures, a Swiss-based VC investor in the life sciences sector, is an industry acquaintance of Kuk Hyoun Hwang. Mr.&#160;Breiner was formerly a senior portfolio manager of Bellevue Asset Management&#8217;s private market team, which managed the fund that was one of the main shareholders in Vaximm AG. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Via video conference, Messrs. Breiner and Hwang initially discussed the need for Vaximm to identify and hire a new CEO, as the position was vacant after its October&#160;22, 2022 acquisition by OSR Holdings. Mr.&#160;Breiner told Mr.&#160;Hwang about a pharma business development specialist and entrepreneur active in the Swiss biotech hub of Basel named Zaki Sellam, and Mr.&#160;Hwang agreed to an introduction. Mr.&#160;Sellam is the lead founder and CEO of LBV, a biotech holding company based in Basel with four portfolio companies located in France.&#160;Mr.&#160;Breiner made a written introduction between Messrs. Hwang and Sellam via <span style="white-space:nowrap">e-mail</span> and the two agreed to meet via a video conference in early April. Mr.&#160;Sellam, at that point, was not looking for a CEO role within a biotech <span style="white-space:nowrap">start-up,</span> but was willing to have a discussion with Mr.&#160;Hwang. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">March&#160;30, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;20, 2023, BLAC and OSR Holdings executed a Confidentiality Agreement (signed by Mr.&#160;Yu as COO and Director of OSR Holdings and Jin Whan Park as Director of BLAC) covering discussions for a possible business combination between BLAC and OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;3, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2023, in attendance at OSR Holdings&#8217; weekly Monday morning meeting were Mr.&#160;Hwang and OSR Holdings executives Sung Hoon Chung, Sung Jae Yu, Soo Eun Nam, Yeiseok Kim and Taemin Lee. Mr.&#160;Hwang had returned to Seoul a few days before from an extended business trip to Switzerland, New York City and Seattle, and informed the OSR Holdings members that BLAC had a productive meeting with a potential target (Company A) for a business combination with BLAC in New York City, and that there were other companies with whom information had been exchanged through BLAC&#8217;s network of individuals, investment banks, and others. Mr.&#160;Hwang also told OSR Holdings members that since a Confidentiality Agreement had been executed, BLAC would further explore a business combination with OSR Holdings. Over the next several days, Mr.&#160;Hwang had informal meetings and conversations with OSR Holdings members regarding the possibility of a business combination with BLAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;5, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hwang and Mr.&#160;Sellam first met via video conference. Mr.&#160;Hwang initially questioned why Mr.&#160;Sellam held multiple <span style="white-space:nowrap">C-level</span> positions with several different companies on his CV, and expressed his concern about Mr.&#160;Sellam&#8217;s lack of focus on any one company; e.g., if Vaximm hired Mr.&#160;Sellam as its new CEO. First, Mr.&#160;Sellam reminded Mr.&#160;Hwang that he agreed to meet via video conference as a matter of courtesy and for networking purposes, and was not looking for a full time CEO role within another <span style="white-space:nowrap">start-up.</span> Mr.&#160;Sellam explained that his roles with LBV&#8217;s portfolio companies were structured as they were because he <span style="white-space:nowrap">co-founded</span> all four companies along with the respective scientific founders/principal investigators of each company. Mr.&#160;Sellam then presented a <span style="white-space:nowrap">top-line</span> review of LBV&#8217;s companies, their startup model designed by Mr.&#160;Sellam and his <span style="white-space:nowrap">co-founders</span> at LBV. Mr.&#160;Sellam also said that in his view, an optimal organization could be set up within each <span style="white-space:nowrap">start-up</span> without a full-time CEO for each, a model successfully implemented by LBV with its group of portfolio companies. Mr.&#160;Hwang told Mr.&#160;Sellam that there were similarities with BLAC&#8217;s own investment strategy as disclosed in the BLAC IPO prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the meeting, Mr.&#160;Hwang debriefed the BLAC team on LBV and the team agreed that more <span style="white-space:nowrap">in-depth</span> discussions on the businesses and sciences of LBV and its companies were in order. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;10, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on April&#160;10, 2023, members of OSR Holdings and Mr.&#160;Hwang, representing BLAC, discussed the relative advantages and disadvantages of OSR Holdings going public on NASDAQ via a transaction with BLAC compared to a traditional IPO and public listing in either Korea or Switzerland where Vaximm is based. They discussed Vaximm&#8217;s presence in Switzerland and Darnatein and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
RMC&#8217;s presence in Korea, and how OSR Holdings might have greater access to the life sciences industry and capital markets in these countries if OSR Holdings pursued a public listing in either of these countries instead of the United States. On the other hand, BLAC and OSR Holdings discussed the fact that BLAC, having completed its IPO and public listing in February, could provide a more time efficient manner in which to take OSR Holdings public. They also discussed how listing on NASDAQ could provide access to a larger pool of potential investors and more visibility generally. OSR Holdings members agreed to further consider a business combination with BLAC against the background of this information. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;13, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang and Jun Whang held a video conference with Zaki Sellam of LBV. Mr.&#160;Hwang told Mr.&#160;Sellam that BLAC had also had discussions with an Executive Director of a major global pharmaceutical company who was based in Germany regarding the CEO position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Sellam gave an introduction of LBV&#8217;s business strategy and its four current portfolio companies. Mr.&#160;Sellam then briefly introduced LBV&#8217;s executive team: Gary Brandam, Jacques Bauer, Mehdi Chelbi and Samson Fung. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hwang explained that it is actually BLAC&#8217;s investment strategy to identify a holding company with a portfolio of subsidiaries and investees in drug R&amp;D businesses and that LBV may possess the necessary qualities that BLAC is looking for as its business combination target. Mr.&#160;Hwang also continued to explain that OSR Holdings similarly operates as a holding company with three subsidiaries, and that in terms of BLAC&#8217;s business strategy, Roivant Sciences serves as a model. The parties agreed to further discuss a business combination between BLAC and LBV, and also to pursue different options for collaboration between the groups. The discussion then turned to a possible acquisition of LBV by OSR Holdings as an alternative to a direct merger by BLAC with LBV, since LBV&#8217;s total valuation for its portfolio companies alone might not be sufficiently large for a business combination with BLAC. Mr.&#160;Hwang told Mr.&#160;Sellam that if OSR Holdings were to acquire LBV, LBV could focus its efforts on managing its portfolio companies and leave capitalization and fundraising efforts to OSR Holdings. Mr.&#160;Sellam said that LBV would be open to further discussions about an acquisition by OSR Holdings. The call ended with an agreement to follow up with more detailed discussions in the near future, and a confidentiality agreement was executed between the parties shortly thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the video conference, Messrs. Hwang and Whang had further discussions regarding LBV as a possible target for a business combination with BLAC, and the need to conduct further scientific and financial due diligence on LBV, including the collective valuation of LBV&#8217;s portfolio companies. Given LBV&#8217;s self-valuation in the low to mid USD $30m range, a business combination between BLAC and LBV would have to be conducted as part of at least one or more additional businesses with which to combine in order to satisfy the requirement that the fair market value of the business combination exceed 80% of the assets held in trust. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;17, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on April&#160;17, 2023, members of OSR Holdings discussed with Mr.&#160;Hwang their findings from their research into market comparable companies on biopharmaceutical companies that became public via business combinations with SPACs. The team told Mr.&#160;Hwang that they would perform additional analyses on such transactions. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Comparable Company Analysis&#8221; and &#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value&#8221; </span>for detailed discussions on the comparable company analysis and the fair market value reports on OSR Holdings&#8217; subsidiaries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;19, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2023, Mr.&#160;Hwang participated in a conference call with representatives of K&amp;L Gates to discuss SEC guidelines surrounding related party transactions. After the conference call, Mr.&#160;Hwang convened a meeting with OSR Holdings executives Sung Hoon Chung, Sung Jae Yu and Soo Eun Nam to inform them that BLAC had received advice on conducting a business combination with an affiliated company. Mr.&#160;Hwang said that, along with continuing to review other potential targets, BLAC would also continue to explore conducting a business combination with OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;21, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;21, 2023, following up from the weekly meeting held on April&#160;17, the OSR Holdings&#8217; management discussed with Mr.&#160;Hwang their findings from the research into biopharma companies&#8217; share trading performance after going public via <span style="white-space:nowrap">de-SPAC</span> transaction. OSR Holdings team&#8217;s research indicated that several companies in this group had issued their PIPE shares at deep discounts against the new issuance price for their business combinations resulting in poor stock performances. To OSR Holdings management, this research suggested a risk (if BLAC were to issue their PIPE shares at a deep discount) that would have to be considered, should they agree to a transaction with BLAC compared to a traditional IPO on KOSDAQ. In addition, given that the market sentiment was still not very favorable to clinical-stage biotech businesses developing R&amp;D pipelines, OSR Holdings management informed Mr.&#160;Hwang that they would factor these findings into a decision regarding a business combination between BLAC and OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">April&#160;25, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC and OSR Holdings members (Kuk Hyoun Hwang, Sung Hoon Chung, Tom Shin, and Jun Whang) participated in a video conference with all current executive members of LBV: Zaki Sellam (Chief Executive Officer), Gary Brandam (Chief Operating Officer), Jacques Bauer (Chief Dev. Officer and Head of Intellectual Property), Mehdi Chelbi (Chief Business Officer), and Samson Fung (Chief Medical Officer). </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;1, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on May&#160;1, 2023, Mr.&#160;Hwang, representing BLAC, informed OSR Holdings executives Sung Hoon Chung, Sung Jae Yu and Soo Eun Nam that BLAC had communicated through Mr.&#160;Whang on April&#160;27, 2023 that BLAC would not be pursuing a business combination with Company A, and informed Company C of the same on a video conference call on Friday, April&#160;28, 2023. Mr.&#160;Hwang informed OSR Holdings that BLAC would most likely be pursuing a business combination with OSR Holdings conditional upon OSR Holdings&#8217; agreement to do so as well. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;2, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated May&#160;2, 2023, BLAC&#8217;s legal counsel at K&amp;L Gates sent Mr.&#160;Hwang a draft <span style="white-space:nowrap">Non-Binding</span> Letter of Intent (&#8220;LOI&#8221;) outlining basic terms for a potential transaction between BLAC and OSR Holdings. The same day, Mr.&#160;Hwang informed OSR Holdings executives Sung Hoon Chung, Sung Jae Yu and Soo Eun Nam that he was in receipt of the Draft LOI, and asked for a meeting to discuss general parameters of the LOI. Mr.&#160;Hwang also told OSR Holdings executives that the Draft LOI would be prepared using the indicative valuation range for OSR Holdings&#8217; equity value based on the latest fair market value as reflected in the share exchange transactions conducted with Vaximm, RMC and Darnatein. OSR Holdings executives acknowledged and agreed to the valuation terms proposed by Mr.&#160;Hwang. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial draft LOI distributed on May&#160;2, 2023, contained an outline of standard terms for a potential business combination, but did not contain any terms that had been negotiated by BLAC and OSR Holdings and was distributed as a basis for OSR Holdings and BLAC to begin negotiating specific terms. The outline </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained a number of placeholder terms, conditions and provisions that BLAC and OSR Holdings would need to negotiate and provide input on, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Valuation of OSR Holdings, which, as discussed above and elsewhere in this proxy statement/prospectus, was initially proposed based on historical fair market value reports; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Transaction structure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">Lock-up</span> terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PIPE financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Minimum cash condition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Registration rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Equity compensation plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Post-closing board governance; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Covenants, closing conditions, and representations and warranties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent drafts of the LOI, and, ultimately, the Business Combination Agreement, were negotiated based on the outlined terms in the May&#160;2, 2023 LOI, but ultimately the Business Combination Agreement varied in several ways from the first draft LOI. The parties&#8217; decisions to deviate from the LOI were the result of arms-length negotiations between the parties that were informed by, among other things, changes to the capital markets environment. For a detailed description of the terms included in the final draft of the LOI, please see below under &#8220;July 11, 2023.&#8221; For a description of the differences between the terms of the July&#160;11, 2023, executed version of the LOI and the executed version of the Business Combination Agreement, please see below under &#8220;November&#160;16, 2023.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The LOI proposed a valuation of OSR Holdings In the range of $200,000,000 to $240,000,000 in accordance with the indicative valuation range based on the latest fair market value calculations obtained in connection with the share exchange transactions conducted with Vaximm, RMC and Darnatein that the BLAC Board, BLAC M&amp;A Committee (once formed), and BLAC management agreed were well founded. The BLAC M&amp;A Committee (once formed) and the BLAC Board independently reviewed, and agreed with, the contents of the fair market value analyses, a summary of which is in the section entitled <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value</span>.<span style="font-style:italic">&#8221;</span> Although the BLAC Board considered the third-party valuation analyses provided by OSR Holdings in connection with its decision to approve the Business Combination, the BLAC Board took into account the fact that these reports were (i)&#160;not recently prepared, (ii)&#160;were not prepared giving effect to, or with regard to, the Business Combination, and (iii)&#160;were not prepared for, or delivered directly to, the BLAC Board. The BLAC Board considered the information along with the totality of information provided to the BLAC Board in connection with its diligence of OSR Holdings, and did not ascribe any particular or special weight to the third-party valuation reports. The reports merely affirm the BLAC Board&#8217;s findings in connection with its independent review of OSR Holdings, and its approval of the Business Combination was at all times subject to the receipt of a fairness opinion. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination&#8221; </span>for a detailed discussion on the material findings made in connection with due diligence of OSR Holdings, including with respect to the third-party valuation and fair market value reports. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;8, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In attendance at OSR Holdings&#8217; weekly Monday morning meeting on May&#160;8, 2023 were Mr.&#160;Hwang and OSR Holdings members Sung Hoon Chung, Sung Jae Yu, Soo Eun Nam, Yeiseok Kim and Taemin Lee. Mr.&#160;Hwang, representing BLAC, announced BLAC&#8217;s intent to seek a business combination with OSR Holdings, subject to approval by the BLAC Board. OSR Holdings members informed Mr.&#160;Hwang that, after careful consideration of all the factors regarding a business combination with BLAC discussed over the course of the past several months, they agreed in principle to pursue discussions for a business combination with BLAC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;18 and 19, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By emails on May&#160;18 and 19, 2023, Tom Shin emailed five <span style="white-space:nowrap">US-based</span> investment banking and financial advisory firms for a possible engagement by BLAC to provide a fairness opinion on a potential business combination between BLAC and OSR Holdings. After initial introductions and discussions, BLAC came to the view that none of these firms possessed the necessary expertise and qualifications to analyze foreign companies and their business structures and strategies, and more specifically, to analyze them within the context of the regulatory environments pharmaceutical research and development and distribution of medical device products (as in the case of OSR Holdings&#8217; subsidiary RMC). As none of OSR Holdings&#8217; subsidiaries, their businesses and customers are in the US, BLAC came to the decision that it should expand its search to look for valuation consulting companies with global exposure and experience, with a strong emphasis in the area of biopharmaceuticals, and informed OSR Holdings members of this decision. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;22, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on May&#160;22, 2023, Mr.&#160;Hwang suggested to OSR Holdings that BLAC would report to the BLAC Board with the following items: 1) a proposed <span style="white-space:nowrap">Non-Binding</span> Letter of Intent, 2) Business Combination Timeline (including potential need to request BLAC stockholder approval to extend the period for completion of the Business Combination), 3) Corporate slides of OSR Holdings, and 4) third party valuation reports on Vaximm (dated December&#160;5, 2022) and Darnatein (dated July 2022) as reference points for the BLAC Board to consider. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination&#8221; </span>for a detailed discussion on the material findings made in connection with due diligence of OSR Holdings, including with respect to the third-party valuation and fair market value reports, and the information contained in the OSR Holdings presentation. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;24, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated May&#160;24, 2023, Mr.&#160;Hwang sent to the BLAC Board and OSR Holdings a draft <span style="white-space:nowrap">Non-Binding</span> Letter of Intent prepared by BLAC&#8217;s counsel K&amp;L Gates with a summary of certain proposed terms and conditions, and a potential timeline for the Business Combination. Mr.&#160;Hwang noted in his email that an indicative valuation of OSR Holdings, with the three subsidiaries combined (Vaximm, Darnatein and RMC), had been supported by the fair market value reports secured from the valuation consultants in Korea in connection with OSR Holdings&#8217; share exchange transaction with the three companies. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value&#8221; </span>for detailed discussions on the fair market value reports on OSR Holdings&#8217; subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the BLAC Board considered the third-party valuation analyses provided by OSR Holdings in connection with its decision to approve the Business Combination, the BLAC Board took into account the fact that these reports were (i)&#160;not recently prepared, (ii)&#160;were not prepared giving effect to, or with regard to, the Business Combination, and (iii)&#160;were not prepared for, or delivered directly to, the BLAC Board. The BLAC Board considered the information along with the totality of information provided to the BLAC Board in connection with its diligence of OSR Holdings, and did not ascribe any particular or special weight to the third-party valuation reports. The reports merely affirm the BLAC Board&#8217;s findings in connection with its independent review of OSR Holdings, and its approval of the Business Combination was at all times subject to the receipt of a fairness opinion. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination&#8221;</span> for a detailed discussion on the material findings made in connection with due diligence of OSR Holdings, including with respect to the third-party valuation and fair market value reports. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;26, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated May&#160;26, 2023, Mr.&#160;Hwang sent to the BLAC Board of Directors and OSR Holdings another set of materials that included BLAC&#8217;s internal due diligence and review of OSR Holdings, which included the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate slides on OSR Holdings, and third-party valuation reports on Vaximm (dated December&#160;5, 2022) and Darnatein (dated July 2022), the two largest components in the overall <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">sum-of-the-parts</span></span></span> valuation of OSR Holdings. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination&#8221; </span>for a detailed discussion on the material findings made in connection with due diligence of OSR Holdings, including with respect to the third-party valuation and fair market value reports, and the information contained in the OSR Holdings presentation. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;7, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a video conference held on June&#160;7, 2023, the BLAC Board met while also inviting Mr.&#160;Hwang to the meeting to report on the overall status of discussions relating to the <span style="white-space:nowrap">Non-Binding</span> Letter of Intent. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;9, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By unanimous written consent of the BLAC Board effective on June&#160;9, 2023, the BLAC Board authorized the executive officers of BLAC to explore opportunities for a potential business combination with one or more target companies, including a potential transaction with OSR Holdings. In connection with such discussions, and as permitted by Article V of BLAC&#8217;s Bylaws, the BLAC Board established the BLAC M&amp;A Committee to consider the feasibility and terms of any such business combination, including consideration by the BLAC M&amp;A Committee of the fairness of any such business combination, and any other factors such BLAC M&amp;A Committee deems appropriate, and to recommend to the entire BLAC Board whether or not any such transaction is in the best interests of BLAC and its stockholders. The BLAC M&amp;A Committee initially consisted of the following independent directors of BLAC: Radclyffe Roberts, Hosun Euh and Jin Whan Park. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the BLAC M&amp;A Committee were further authorized to (i)&#160;approve the execution of confidentiality and other ancillary agreements with potential target companies, investors and their representatives, and other parties in connection with the business combination, and (ii)&#160;approve the execution and negotiation of agreements relating to the engagement of financial advisors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The resolutions adopted by the BLAC Board provided that any member of the BLAC Board (including any member of the BLAC M&amp;A Committee) that has a direct or indirect material personal interest in any potential Business Combination such that the potential transaction constitutes an Interested Director Transaction under applicable law shall be recused from consideration relating to such Interested Director Transaction and such BLAC Board member&#8217;s interest in and to such Interested Director Transaction shall be fully disclosed and considered in connection with the consideration of any such potential transaction by the BLAC M&amp;A Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;12, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a video conference held on June&#160;12, 2023 between Mr.&#160;Hwang and OSR Holdings, Sung Jae Yu, COO and Director of OSR Holdings presented to the participants on the call the valuation reports on OSR Holdings&#8217; subsidiaries prepared by third-party experts in the field of biopharma valuation from Switzerland and Korea. Mr.&#160;Yu explained why he believed the proposed business combination would be beneficial to BLAC stockholders, considering the market capitalization comparables of OSR Holdings&#8217; subsidiaries in cancer vaccine / immuno-oncology and disease-modifying osteoarthritis drug (DMOAD) sectors in the global biopharmaceutical industry and market. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value&#8221; </span>for detailed discussions on the fair market value reports on OSR Holdings&#8217; subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the video conference, the BLAC Board further reviewed the available market comparable dataset provided by OSR Holdings and assessed the relevance and justification for these companies as selected comparables of each of Vaximm and Darnatein. The BLAC Board considered several relevant metrics including </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutic modality, pipeline assets and related development stages, market capitalization, and private market indicative valuations. Collectively, between Vaximm and Darnatein comparable companies assessed based on the above considerations, applying a 50% discount to the comparable company dataset would imply a value of $351&#160;million for OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm comparable companies analyzed included Anixa Biosciences (NASDAQ: ANIX) and Hookipa Pharma (NASDAQ: HOOK). At the time of analysis, each company&#8217;s modality comparable lead programs had completed Phase 1 immuno-oncology clinical trials, which directly compared to Vaximm&#8217;s stage of development for its lead asset. At the time of analysis, relative to each company&#8217;s completion of Phase 1 clinical trials, market capitalization was $101&#160;million and $108&#160;million for Anixa and Hookipa, respectively. Additionally, several South Korean companies were also assessed as Vaximm comparables. These included immuno-oncology companies with Phase 2 clinical-stage lead programs, Vaxcell Biotherapeutics (KOSDAQ: 323990) and SillaJen (KOSDAQ: 215600). At the time of their Phase 2 clinical program announcements, Vaxcell Biotherapeutics had a market capitalization of approximately $685&#160;million while SillaJen&#8217;s market capitalization was approximately $450&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies comparable to Darnatein included 3 publicly-traded and a dozen &#8220;venture-backed&#8221; private companies. Of the 15 identified companies, OSR Holdings further employed a very explicit selection criteria limiting the market comparable companies to those developing disease-modifying osteoarthritis drugs (DMOADs) only. This distinction objectively differs from the existing standard of care approaches such as joint replacement surgery or symptomatic therapies to reduce pain. According to a National Library of Medicine (NLM) publication, &#8220;Latest Insights in Disease-modifying Osteoarthritis Drugs Development<sup style="font-size:75%; vertical-align:top">1</sup>&#8221;, only 4 companies (Merck KGaA, Galapagos, BioSplice Therapeutics (formerly Samumed), and Kolon TissueGene) were identified as comparable to Darnatein conducting <span style="white-space:nowrap"><span style="white-space:nowrap">mid-to-late</span></span> stage clinical trials developing potential DMOADs. OSR Holdings did not consider Merck KGaA and Galapagos as direct comparable companies because Merck is a major global pharma company with diverse pipelines and Galapagos has abandoned their DMOAD therapy after failed clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the public companies analyzed, Medipost (KOSDAQ: 078160) is the only company with an approved and commercially available DMOAD stem cell treatment in Korea. Approval was granted in 2012 by the Ministry of Food and Drug Safety of Korea. Medipost holds a market capitalization of approx. $175&#160;million as of April 2024. Kolon TissueGene&#8217;s (KOSDAQ: 950160) lead DMOAD candidate is currently in Phase 3 clinical trials and serves as the primary driver of their current $750&#160;million market capitalization as of March 2024. Carmell Therapeutics (NASDAQ: CMTX) had advanced a lead DMOAD candidate for bone and cartilage regeneration and healing into Phase 2 clinical trials at the time of an announced SPAC merger with Alpha Healthcare Acquisition Corp III with a valuation of $150&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, among the many private companies assessed and categorized as a DMOAD company according to the NLM publication, the most notable company comparable is Biosplice Therapeutics (formerly Samumed). Biosplice Therapeutics is developing small-molecule DMOAD therapeutics that recently completed its Phase 3 clinical trials for the treatment of osteoarthritis. According to publicly available information from Dealroom.co, the company&#8217;s valuation, as of the last capital increase was $11.6&#160;billion in April 2021. With a total of $884&#160;million invested capital (according to PitchBook.com) and based on our applied metrics and explicit criteria for determining comparable companies, Biosplice Therapeutics is the most direct comparable private company to Darnatein from OSR Holdings&#8217; research. Although Biosplice Therapeutics is further along in clinical development for their lead DMOAD candidate (Phase 3 vs preclinical), it is worth noting that Biosplice and Darnatein have similarities in their scientific approaches towards developing therapies for degenerative osteoarthritis. Both companies&#8217; lead candidates target distinct, yet specific pathways known to promote osteogenic differentiation (i.e. Wnt vs BMP). Both pathways are known to play active roles in osteogenesis (bone formation) and chondrogenesis (cartilage formation). However, Darnatein&#8217;s therapeutic approach may be further differentiated due to the potential synergistic effects on Wnt pathway by targeting BMP directly. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Published online on May&#160;13, 2023 on PubMed Central operated by National Library of Medicine </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It was the investment thesis held by OSR Holdings for its acquisition of Darnatein that, while currently in preclinical stage, the company would be able to demonstrate its unique design-augmenting chimera technology with clinical POCs (proof of concepts) to potentially compete or partner with larger companies operating in the same space such as Biosplice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Comparable Company Analysis&#8221; and &#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value&#8221;</span> for detailed discussions on the comparable company analysis and the fair market value reports on OSR Holdings&#8217; subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;15, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated June&#160;15, 2023, with OSR Holdings&#8217; approval, Mr.&#160;Hwang sent the BLAC M&amp;A Committee a package of material, including a revised presentation of OSR Holdings, and OSR Holdings&#8217; unaudited Consolidated Statements of Financial Position as of December&#160;31, 2022 and 2021, and Consolidated Statements of Comprehensive Income for years ended December&#160;31, 2022 and 2021. OSR Holdings was copied on the email. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;18, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing at 8:00 PM Eastern time on June&#160;18, 2023, the BLAC M&amp;A Committee met. All of the members of the BLAC M&amp;A Committee participated in the meeting. Also present from BLAC were Josh Pan and Tom Shin, and a representative of K&amp;L Gates, BLAC&#8217;s outside legal counsel, also participated. Legal counsel confirmed that all of the members of the BLAC M&amp;A Committee had received the materials circulated in advance of the meeting, including a draft Letter of Intent and financial and other information relating to a proposed business combination with OSR Holdings. The BLAC M&amp;A Committee noted that Mr.&#160;Hwang is the CEO of OSR Holdings, and as such is an interested director in the proposed transaction. Mr.&#160;Hwang recused himself from the BLAC M&amp;A Committee&#8217;s consideration of the proposed transaction and interest of Mr.&#160;Hwang in the proposed transaction had been disclosed to all members of the BLAC Board and BLAC M&amp;A Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee discussed the terms of the draft Letter of Intent and asked questions of the management members, including an analysis of all companies that were considered as targets for the proposed business combination. The BLAC M&amp;A Committee discussed how management had arrived at the proposed valuation of OSR Holdings and requested that management provide additional information to the BLAC M&amp;A Committee. Following discussion, the BLAC M&amp;A Committee authorized management to proceed with the execution of the Letter of Intent with OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee requested that management provide the BLAC M&amp;A Committee with additional information prior to executing the definitive agreements relating to the transaction with OSR Holdings, including additional financial and scientific diligence materials. The BLAC M&amp;A Committee noted that closing of the transaction would be conditioned on the BLAC M&amp;A Committee&#8217;s receipt of a fairness opinion from an independent investment bank providing that the terms of the transaction are fair from a financial perspective to BLAC stockholders. For further details, see <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;19, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At OSR Holdings&#8217; weekly Monday morning meeting on June&#160;19, 2023, Mr.&#160;Hwang informed OSR Holdings members Sung Hoon Chung, Sung Jae Yu, Soo Eun Nam, Yeiseok Kim and Taemin Lee that the BLAC M&amp;A Committee had authorized BLAC to execute the <span style="white-space:nowrap">non-binding</span> Letter of Intent for BLAC to seek a business combination with OSR Holdings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">June&#160;26, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a video conference held on June&#160;26, 2023, Mr.&#160;Hwang and OSR Holdings members discussed their respective independent research on a well-known market comparable biopharma holding company, Roivant Sciences (NASDAQ listed). Both BLAC and OSR Holdings had also conducted independent research into other comparable biotech holding companies, including BridgeBio, ElevateBio, Biohaven Pharmaceuticals and others. Mr.&#160;Hwang reported finding that Roivant&#8217;s percentage ownership of each of its subsidiaries was between 25% and 100%, and that the majority of its subsidiaries received external investments, leading to a dilution of Roivant&#8217;s ownership. OSR Holdings members reported the same finding. Mr.&#160;Hwang said that from BLAC&#8217;s perspective, in spite of dilution, the ability to raise external capital for its subsidiaries separately would be beneficial to BLAC&#8217;s shareholders, as it would reduce reliance on BLAC&#8217;s investment budget. Mr.&#160;Hwang reported that from BLAC&#8217;s perspective as a SPAC searching for a target for a business combination, the biotech holding company model as observed with Roivant was attractive because it would allow for risk-sharing between BLAC and public investors by providing the latter with the ability to selectively invest in particular subsidiaries, with the overall portfolio risk/return profile remaining with BLAC. OSR Holdings&#8217; management agreed with the overall investment thesis explained by Mr.&#160;Hwang on behalf of BLAC, based on its own research, and indicated that OSR Holdings management would be agreeable to the proposed business combination if the <span style="white-space:nowrap">per-share</span> valuation of OSR Holdings could be maintained, if not raised, at the same level from the price that was used in the share exchange transactions with all three subsidiaries which had taken place from December 2022 to February 2023. Mr.&#160;Hwang acknowledged OSR Holdings members&#8217; statements on this matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another issue discussed during this video conference was OSR Holdings&#8217; potential acquisition of LBV, and the impact the acquisition would have on current OSR Holdings&#8217; members in terms of corporate structure, post-merger integration, roles and responsibilities between the two groups following the potential business combination of OSR Holdings with BLAC. Mr.&#160;Hwang explained that BLAC envisioned the current Korean entity of OSR Holdings to continue as a Corporate Development Headquarter of the combined company. OSR Holdings members accepted and agreed with this plan for corporate structure development. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">July&#160;6, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;6, 2023, the BLAC M&amp;A Committee met via video conference to discuss the proposed valuation of OSR Holdings. The BLAC M&amp;A Committee was of the opinion that it could approve the valuation on the condition that a third-party valuation firm with an established track record and expertise in global biopharmaceutical transactions and licensing deals would provide a fairness opinion supporting the transaction as fair from a financial perspective to the stockholders of BLAC. In order to expedited the proposed business combination, it was recommended that the BLAC M&amp;A Committee expedite its process of identifying and engaging a capable, independent firm with biopharmaceutical experience and expertise as the fairness opinion advisor. Mr.&#160;Hwang, representing BLAC, relayed the BLAC M&amp;A Committee&#8217;s decision to OSR Holdings members. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">July&#160;7, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, OSR Holdings and LBV entered into a <span style="white-space:nowrap">Non-Binding</span> LOI for OSR Holdings to acquire 100% of LBV. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">July&#160;11, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;11, 2023, BLAC and OSR Holdings executed a <span style="white-space:nowrap">Non-Binding</span> Letter of Intent for BLAC to pursue a business combination with OSR Holdings. The LOI contained standard terms for a business combination, including, without limitation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:65%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation and Transaction Consideration</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The Transaction would value the outstanding shares of capital stock of OSR Holdings (&#8220;Company&#8221;) at an aggregate amount in the range of $200,000,000 to $240,000,000 (&#8220;Equity Value&#8221;).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The Transaction consideration will be in the form of common shares of the combined entity (&#8220;PubCo&#8221;, previously SPAC).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;All unvested stock-based compensation, the <span style="white-space:nowrap"><span style="white-space:nowrap">to-be-adopted</span></span> equity incentive plan of PubCo, and all outstanding equity-like securities of the Company will not be included in the Equity Value.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction Financing</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;PubCo will obtain binding written commitments in connection with PIPE transaction in an aggregate amount equal to between $50&#160;million and $100&#160;million <br/></p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimum Available Cash Condition</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Aggregate cash proceeds from SPAC&#8217;s trust account (after all redemptions) and the PIPE subscriptions are no less than $5,000,001</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Lock-Up</span> and Registration Rights</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Founder Shares, Founder Warrants, Founder Rights and any PubCo common shares held by the Sponsor will be subject to the <span style="white-space:nowrap">lock-up</span> as described in the BLAC IPO prospectus.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Certain Company shareholders will be subject to a <span style="white-space:nowrap">lock-up</span> that will expire 180 days following the Closing</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnout Shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The Company shareholders can elect to participate in an earnout facility for which a total of 6,000,000 PubCo common shares may be received by those who elect to participate (&#8220;Earnout Participants&#8221;)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Each Earnout Participant will agree to extend their applicable <span style="white-space:nowrap">lock-up</span> period to 24 months to be entitled to receive the Earnout Consideration as follows: (i) 3,000,000 Initial Earnout Shares if the volume-weighted average price (&#8220;VWAP&#8221;) of the PubCo common shares is greater than or equal to $15.00 per share over 20 trading days within any 30 trading days during the Earnout Period (24 months following the Closing); and (ii)&#160;additional 3,000,000 Final Earnout Shares if the VWAP is greater than or equal to $20.00 per share over 20 trading days within any 30 trading days during the Earnout Period.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The issuance of Earnout Shares would dilute the value of PubCo common shares outstanding at the time of issuance.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">M&amp;A Committee and Fairness Opinion</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;SPAC has appointed a special M&amp;A Committee consisting of independent directors of SPAC that has approved this confidential LOI and will approve the Definitive Agreement.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:65%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The Closing will be conditioned on receipt of a fairness opinion from a third-party investment bank or valuation firm.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Compensation Plan</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Prior to executing the Definitive Agreement, the Company will determine the terms of a post-Closing equity compensation plan and employee stock purchase plan. In connection with the Closing, PubCo will adopt such plans.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Closing Board / Governance</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Sponsor will have the right to designate two directors of the PubCo&#8217;s board of directors at the closing of the Transaction and the Company will have the right to designate all other directors and the initial Chairman of the Board.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;The management team of the combined company will consist solely of Company&#8217;s current management team including the CEO of SPAC who also serves as Company&#8217;s CEO.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the May&#160;2, 2023, version of the LOI simply contained standard general terms, placeholders and an outline of discussion topics regarding a potential business combination between BLAC and OSR Holdings, the executed version of the LOI deviated from the version initially circulated by K&amp;L Gates to Mr.&#160;Hwang on May&#160;2, 2023, because it reflected the foregoing negotiated, specific terms. Additionally, the Business Combination Agreement ultimately varied in certain ways from the July&#160;11, 2023, LOI, as described below under &#8220;November 16, 2023&#8221; (e.g., the structure of the transaction no longer involved a reverse merger, the concept of earnout shares was removed, certain company shareholders would no longer be subject to <span style="white-space:nowrap">lock-up,</span> etc.). The parties&#8217; decisions to deviate from the LOI were the result of arms-length negotiations between the parties that were informed by, among other things, changes to the capital markets environment and the positions of certain OSR Holdings&#8217; shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The LOI proposed a valuation of OSR Holdings in the range of $200,000,000 to $240,000,000 in accordance with the indicative valuation range based on the latest fair market value calculations obtained in connection with the share exchange transactions conducted with Vaximm, RMC and Darnatein that the BLAC Board, BLAC M&amp;A Committee, and BLAC management agreed were well founded. The BLAC M&amp;A Committee and the BLAC Board independently reviewed, and agreed with, the contents of the fair market value analysis, a summary of which is in the section entitled <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value.</span><span style="font-style:italic">&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">July&#160;12, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K&amp;L Gates, counsel to BLAC, circulated an initial draft of the Business Combination Agreement, and BLAC and OSR Holdings began negotiating the terms of such agreement. The material terms of the first draft of the Business Combination Agreement deviated from the LOI in the following ways, but otherwise substantively aligned with the LOI: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The transaction no longer contemplated an earnout (with no corresponding increase to the closing consideration). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There transaction no longer contemplated certain OSR Holdings&#8217; shareholders being subject to a <span style="white-space:nowrap">180-day</span> <span style="white-space:nowrap">lock-up,</span> but instead, certain OSR Holdings&#8217; shareholders would sign a <span style="white-space:nowrap">Non-participating</span> Stockholder Joinder which postpones the share exchange transaction with respect to those shareholders until January&#160;1, 2026 (or upon a change of control of the combined company) for those shareholders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement was negotiated and modified from time to time between July&#160;12, 2023, and November&#160;16, 2023. For a description of the modified terms based on negotiations, and the relevant positions of the parties, please see below under <span style="font-style:italic">&#8220;November 16, 2023</span>.<span style="font-style:italic">&#8221;</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">October&#160;28, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee entered into an engagement letter with a qualified financial advisory firm for delivery of a fairness opinion to the BLAC M&amp;A Committee in connection with BLAC&#8217;s proposed business combination with OSR Holdings. The fairness opinion provider is a Switzerland-based valuation firm that focuses on valuing early-stage life sciences companies. The provider was selected by the BLAC M&amp;A Committee to provide the fairness opinion because, at the that time, the majority of surviving company&#8217;s operations and business (including LBV) would have been conducted in Europe. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">November&#160;15, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee met, with all members participating. A representative of K&amp;L Gates, BLAC&#8217;s outside legal counsel, also participated. In addition, Kuk Hyoun Hwang, CEO of BLAC and OSR Holdings, and Jun Whang, the Sponsor&#8217;s General Counsel, also participated for a portion of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the members of the BLAC M&amp;A Committee confirmed they had received the materials circulated in advance of the meeting. They then discussed the material terms of the proposed Business Combination Agreement and asked questions of counsel and management. Following such conversation, members of management departed the meeting and the BLAC M&amp;A Committee discussed the proposed transaction and agreements submitted for consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee affirmed that BLAC is a blank check company that completed its initial public offering on February&#160;14, 2023 with a <span style="white-space:nowrap">9-month</span> time limitation to identify a target company and consummate a Business Combination. Due to the <span style="white-space:nowrap">9-month</span> time limitation, BLAC was restricted in the total number of companies that it could review, analyze, conduct meetings with, and otherwise consider as potential business combination targets (&#8220;Potential Targets&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the Potential Targets expressed concern and reservation about proceeding with a Business Combination with BLAC or any SPAC due to the high rate of investor redemptions being experienced in the SPAC market and thus placed a high degree of importance on the SPAC&#8217;s ability to complete a private financing (a &#8220;PIPE Transaction&#8221;) in combination with the Business Combination. The BLAC M&amp;A Committee noted that during discussions with the Potential Targets through the date of this meeting, BLAC has not secured any commitments for a PIPE Transaction in support of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee further noted that representatives of OSR Holdings and BLAC participated in numerous <span style="white-space:nowrap">in-depth</span> meetings, diligence calls and virtual meetings that covered all aspects of business, financial and technical due diligence, including a detailed review of OSR Holdings&#8217; business plan, financial model, growth strategy, target markets, intellectual property, and capital structure. The BLAC M&amp;A Committee also acknowledged that representatives of BLAC had numerous discussions with Potential Targets other than OSR Holdings, regarding the possibility of a Business Combination between BLAC and/or OSR Holdings, and none of such other Potential Targets were willing to engage in negotiations for a potential Business Combination solely with BLAC due to concerns over redemptions and BLAC&#8217;s lack of commitments for a PIPE Transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee acknowledged that certain of the directors and officers of BLAC are affiliates of OSR Holdings and have interests in the potential Business Combination with OSR Holdings and the transactions contemplated thereby which are different from those of BLAC&#8217;s stockholders generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to BLAC&#8217;s Amended and Restated Certificate of Incorporation, BLAC may not consummate any Business Combination with an entity that is affiliated with any of BLAC&#8217;s officers, directors or sponsor unless BLAC has obtained an opinion from an independent investment banking firm or another independent entity that such Business Combination is fair to BLAC from a financial point of view and a majority of the BLAC&#8217;s disinterested directors approve the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee noted that it has previously met and considered qualifications of the (now prior) fairness opinion provider and determined that it meets the requirements of BLAC&#8217;s Amended and Restated Certificate of Incorporation to render the Fairness Opinion relating to the Business Combination. The BLAC M&amp;A Committee also ratified and approved the engagement letter with the qualified financial advisory firm to render a Fairness Opinion as a condition to closing of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee, consisting of independent directors that have no material interest in the proposed Business Combination with OSR Holdings, was established to consider the feasibility and terms of a Business Combination, including consideration by the BLAC M&amp;A Committee of the fairness of any such Business Combination as well as an evaluation of any interested director transaction, and any other factors the BLAC M&amp;A Committee deems appropriate, and to recommend to the entire BLAC Board whether or not any such Business Combination is in the best interests of BLAC and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee noted that the terms of the Business Combination Agreement are the result of extensive negotiations between BLAC&#8217;s management team, with input from BLAC&#8217;s legal and tax advisors, and OSR Holdings, with input from OSR Holdings&#8217; legal, financial and tax advisors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After due and careful consideration, the BLAC M&amp;A Committee determined that the Business Combination Agreement and related documents and transactions are advisable and fair to and in the best interests of BLAC and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the meeting of the BLAC M&amp;A Committee, the full BLAC Board met, with all members participating except In Chul Chung. The BLAC Board determined that the Business Combination Agreement and other transaction contemplated thereby are advisable and fair to and in the best interests of BLAC and its stockholders and it authorized and approved the Business Combination Agreement and the transactions contemplated thereby. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">November&#160;16, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC and OSR Holdings executed the Business Combination Agreement. In addition to other updates made to the Business Combination Agreement, the material terms of the executed version of the Business Combination Agreement deviated from the July&#160;12, 2023 initial draft of the Business Combination Agreement in the following ways: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Business Combination Agreement no longer contemplated a reverse merger involving a merger subsidiary, which BLAC and OSR Holdings mutually agreed was in the best interest of all parties and their respective shareholders, as applicable, as the merger sub structure would require extraneous expense and Korean regulatory approvals and processes that provided no material incremental benefit to any party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC would no longer provide OSR Holdings with cash consideration at closing, which BLAC believed was in the best interest of its shareholders, as New OSR Holdings would need as much cash at closing as possible to operate the business post-closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings&#8217; stockholders were made party to the Business Combination Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A closing condition requiring a minimum number of Participating Stockholders was added to the Business Combination Agreement, which was negotiated by BLAC as a protection to ensure it would not be forced to close the Business Combination in the event that it was not able to obtain a certain amount of ownership of OSR Holdings at closing. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The foregoing updates necessitated other changes to the Business Combination Agreement with respect to the representations and warranties, and closing conditions, among other things, all of which were negotiated at arms-length between BLAC, OSR Holdings, and their respective counsel. Because OSR Holdings, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
BLAC M&amp;A Committee, and the BLAC Board all agreed that the historical fair market value reports provided the best basis for determining the value of OSR Holdings under the Business Combination Agreement, the Aggregate Consideration in the executed version of the Business Combination Agreement did not materially deviate from the OSR Holdings valuation proposed in the initial draft LOI distributed to the parties. See<span style="font-style:italic"> &#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fair Market Value&#8221; </span>for a description of the of the fair market value reports. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">November&#160;16 and 21, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By emails dated November&#160;16 and 21, 2023 counsel for OSR Holdings, Mr.&#160;Mamoudjy of BG2V, exchanged emails with Mr.&#160;Brandam regarding additional questions in relation to its due diligence report. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">November&#160;27, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By emails dated November&#160;27, 2023, LBV and their counsel, Fromer Advokatur und Notariat, and OSR Holdings and their counsel, BMKLP, exchanged emails regarding the SPA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated November&#160;27, 2023, counsel for OSR Holdings, Mr.&#160;Mamoudjy of BG2V, delivered its final due diligence report on LBV and its portfolio companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">December&#160;9 through 11, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By emails dated December&#160;9 through 11, 2023, Messrs. Sellam and Hwang exchanged drafts of a binding term sheet between OSR Holdings and LBV. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">December&#160;11, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By email dated December&#160;11, 2023, Mr.&#160;Hwang sent Mr.&#160;Sellam a version of a binding term sheet between OSR Holdings and LBV executed by OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">December&#160;12, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, OSR Holdings and LBV executed a binding term sheet for OSR Holdings&#8217; acquisition of LBV. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">March&#160;18, 2024 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2024, OSR Holdings and LBV mutually agreed to terminate the binding term sheet and letter of intent between them, and mutually agreed not to pursue the acquisition of LBV by OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee determined to terminate the engagement with the prior fairness opinion provider after OSR Holdings terminated its pursuit of an acquisition of LBV, because without LBV, the majority of OSR Holdings&#8217; operating assets will be located in Korea, in which case the BLAC M&amp;A Committee determined that it made more sense to engage a fairness opinion provider with a better understanding of the local Korean life sciences market rather than the European life sciences market. See <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd.&#8221; </span>for additional information on Choloc Asset Investment Advisory Co., Ltd., the current fairness opinion provider, and the draft fairness opinion provided to the BLAC M&amp;A Committee on June 23, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">March &#8211; April, 2024 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between the end of March and the end of April, 2024, the BLAC M&amp;A Committee discussed, via email, the qualifications of Choloc Investment Advisory Co., Ltd. (&#8220;<span style="text-decoration:underline">Choloc</span>&#8221;) and determined that Choloc meets the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements of BLAC&#8217;s Amended and Restated Certificate of Incorporation to render the fairness opinion relating to the Business Combination. The BLAC M&amp;A Committee also ratified and approved the engagement letter with Choloc to render a fairness opinion as a condition to closing of the Business Combination. For further details, see <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic"> Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;7, 2024 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee met, with all members participating. A representative of K&amp;L Gates, BLAC&#8217;s outside legal counsel, also participated. In addition, Kuk Hyoun Hwang, CEO of BLAC and OSR Holdings, and Jun Whang, member of the BLAC Board, also participated for a portion of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hwang convened the meeting and confirmed that all of the members of the BLAC M&amp;A Committee had received the materials circulated in advance of the meeting. The BLAC M&amp;A Committee discussed events that had transpired between OSR Holdings and LBV and the implications for the combined company following the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Hwang and counsel from K&amp;L Gates then discussed the impacts on the Business Combination Agreement dated November&#160;16, 2023, between BLAC and OSR Holdings and changes that would be warranted following the termination of the transaction between OSR Holdings and LBV. Counsel from K&amp;L Gates then described material terms of the proposed Amended and Restated Business Combination Agreement, a draft of which had been circulated to the members of the BLAC M&amp;A Committee in advance of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of the BLAC M&amp;A Committee asked questions of counsel and management and following such conversation, members of management of BLAC departed the meeting and the BLAC M&amp;A Committee discussed the proposed Amended and Restated Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee noted that on July&#160;7, 2023, OSR Holdings entered into a letter of intent with LBV for the acquisition of 100% of the equity interests in LBV and certain entities affiliated with LBV from the holders thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee further noted that, subsequent to the execution of the Business Combination Agreement, on March&#160;18, 2024, LBV and OSR Holdings mutually terminated the letter of intent regarding the LBV Acquisition, and OSR Holdings and LBV abandoned further discussions regarding the LBV Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee acknowledged that, in light of the termination of the proposed LBV Acquisition, the terms of the Business Combination Agreement need to be amended in order to remove references therein to LBV and to conform changes to the structure and terms of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee further acknowledged that BLAC&#8217;s management actively negotiated with OSR Holdings the terms and conditions of an Amended and Restated Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the BLAC M&amp;A Committee confirmed that they reviewed the draft Amended and Restated Business Combination Agreement, and the amended terms of the Business Combination and the transactions contemplated thereby, including: (i)&#160;the removal of references to the proposed acquisition by OSR Holdings of LBV, and incidental changes related thereto; (ii)&#160;a reduction in the Aggregate Consideration from 25,033,961 shares of BLAC Common Stock to 24,461,214 shares of BLAC Common Stock; (iii)&#160;a reduction in the Aggregate Consideration Value from $250,339,610 to $244,612,136; and (iv)&#160;changes to the designation of the post-closing board of directors of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After due and careful consideration, the BLAC M&amp;A Committee determined that it is advisable and in the best interests of BLAC and its stockholders for the BLAC Board to authorize and approve the Amended and Restated Business Combination Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the meeting of the BLAC M&amp;A Committee, the full BLAC Board met, with all members participating. The BLAC Board determined that the Amended and Restated Business Combination Agreement and other transaction contemplated thereby are advisable and fair to and in the best interests of BLAC and its stockholders and it authorized and approved the Amended and Restated Business Combination Agreement and the transactions contemplated thereby. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">May&#160;23, 2024 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC and OSR Holdings executed the Amended and Restated Business Combination Agreement, which included the following changes relative to the Business Combination Agreement executed on November&#160;16, 2023: (i) the removal of references to the proposed acquisition by OSR Holdings of LBV, and incidental changes related thereto; (ii)&#160;a reduction in the Aggregate Consideration from 25,033,961 shares of BLAC Common Stock to 24,461,214 shares of BLAC Common Stock; (iii)&#160;a reduction in the Aggregate Consideration Value from $250,339,610 to $244,612,136; and (iv)&#160;changes to the designation of the post-closing board of directors of BLAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The M&amp;A Committee of the BLAC Board (the &#8220;<span style="text-decoration:underline">BLAC M&amp;A Committee</span>&#8221;), in evaluating the Business Combination, consulted with BLAC&#8217;s management and legal advisors. In reaching its unanimous decision to approve the Business Combination Agreement and the transactions contemplated by the Business Combination Agreement, the BLAC M&amp;A Committee considered various factors in connection with its evaluation of the Business Combination. Due to the complexity of those factors, the BLAC M&amp;A Committee did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching its decision. The BLAC M&amp;A Committee viewed its decision as being based on all of the information available and the factors presented to and considered by it. In addition, individual members of the BLAC M&amp;A Committee may have given different weight to different factors. This explanation of the reasons for the BLAC M&amp;A Committee&#8217;s approval of the Business Combination, and all other information presented in this section, is forward-looking in nature and, therefore, should be read in light of the factors discussed in the section entitled. &#8220;<span style="font-style:italic">Cautionary Note Regarding Forward-Looking Statements</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering approving the Business Combination, the BLAC M&amp;A Committee and the full BLAC Board conditioned the approval on obtaining a fairness opinion from a financial advisory firm prior to the closing of the Business Combination. In addition, the officers and directors of BLAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries including healthcare and concluded that their experience and background, together with the experience of their representatives, also enabled them to make the necessary analyses and determinations regarding the Business Combination. For further details, see <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd.&#8221;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before reaching its decision, the BLAC M&amp;A Committee reviewed the results of the due diligence conducted by BLAC management on OSR Holdings. The due diligence conducted included: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">both virtual and in person meetings and calls with BLAC&#8217;s management team and OSR Holdings regarding operations and clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">research on public comparable companies with similar indications and modality as OSR Holdings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussions with other potential target companies, many of which expressed disinterest with BLAC&#8217;s long-term goal of operating multiple healthcare assets in a <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> fashion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review of intellectual property matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review of financial, tax, legal, insurance and accounting due diligence; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review of presentations prepared by OSR Holdings, which included details on OSR Holdings&#8217; and its subsidiaries&#8217; management teams, addressable markets, asset pipelines, and scientific information regarding their product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consultation with legal advisors and industry experts; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">industry track record of the OSR Holdings management team. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC management and the BLAC M&amp;A Committee considered the following material findings as a result of its and BLAC&#8217;s legal counsel&#8217;s due diligence conducted on OSR Holdings. The BLAC M&amp;A Committee determined that the material findings supported the BLAC M&amp;A Committee&#8217;s and the BLAC Board&#8217;s decision that the Business Combination with OSR Holdings would be fair to, advisable, and in the best interests of BLAC and its stockholders for reasons listed below: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Significant Market Opportunities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recurrent Glioblastoma (rGBM) Market </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM is a cancer with some of the highest unmet needs, and one of the most common and lethal primary brain tumors with very limited therapy options. The current standard of care consists of surgery followed by radiation and temozolomide (TMZ). Roche&#8217;s Avastin is the only targeted therapy approved for recurrent GBM (US and Japan), which has not demonstrated a survival benefit. Gliadel (carmustinewafer) implants are also an approved therapy. GBM patients have an overall survival of between one and two years (median survival 20.5 months). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global GBM treatment market was valued at $5.14&#160;billion in 2020 and is anticipated to reach $10.2&#160;billion by 2030<sup style="font-size:75%; vertical-align:top">2</sup>. The forecasted market size and growth are limited due to a dearth of treatment options available. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Hepatocellular Cancer (HCC) Market </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and accounts for 75&#8211;90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide. OSR&#8217;s research indicates that the prevalence of hepatocellular carcinoma will be high in China, followed by the US and Japan in 2023. The increasing prevalence of HCC is driving the hepatocellular carcinoma treatment market growth. According to estimates, more than 1&#160;million people will be affected with hepatocellular carcinoma annually by 2025.<sup style="font-size:75%; vertical-align:top">3</sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and since its launch, has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Nexavar&#8217;s patent protection in the 7MM market expired in December 2022, and generic sorafenib has entered the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global HCC treatment market is projected to be valued at $14.18&#160;billion by 2031, from $3.87&#160;billion in 2023 at a CAGR of 17.61%.<sup style="font-size:75%; vertical-align:top">4</sup> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Metastatic Colorectal Cancer (mCRC) Market </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market for global metastatic colorectal cancer is projected to grow at a CAGR of 3.58% for the period 2024-2031, growing from USD 3.91&#160;billion in 2023 to USD 5.18&#160;billion in 2031.<sup style="font-size:75%; vertical-align:top">5</sup> The increasing prevalence of </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">2</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">https://www.biospace.com/article/glioblastoma-multiforme-treatment-market-size-to-hit-10-2-bn-by-2030</span></span></span></span></span></span></span></span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">3</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">https://www.arizton.com/market-reports/hepatocellular-carcinoma-treatment-market </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">4</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">https://www.futurewiseresearch.com/healthcare-market-research/Hepatocellular-Carcinoma-(HCC)/11543 </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">5</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">https://www.giiresearch.com/report/mx1447722-metastatic-colorectal-cancer-market-assessment-by.html</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
colorectal cancer due to low fruit and vegetable intake, excessive alcohol consumption, sedentary lifestyle, smoking, obesity, and high intake of processed meats will create growth opportunities in the market to address the disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The growth of the metastatic colorectal cancer market is also driven by various factors including increased spending in the healthcare sector generally, rising support from governments globally, growing research and development activities, and increasing efforts towards development of novel diagnostic techniques and enhancement of existing techniques. Increasing awareness, an ageing population, and rising government initiatives to provide affordable treatment and diagnostic solutions in combination with the presence of favorable reimbursement policies also provide expanding growth opportunities to the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increasing approval for various diagnostic and treatment solutions by different regulatory bodies including the Food and Drug Administration (FDA) is further supporting market expansion in this sector. For instance, in 2023, the FDA approved Foundation Medicine&#8217;s FoundationOne Liquid CDx as a companion diagnostic for encorafenib combined with cetuximab. The combination therapy received FDA approval for patients with previously treated metastatic colorectal cancer with BRAF V600E alteration. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FoundationOne Liquid CDx became the first comprehensive genomic profiling test that was approved by the Food and Drug Administration for detecting BRAF V600E mutations in patients with metastatic colorectal cancer. The companion diagnostic indication provides oncologists with <span style="white-space:nowrap">non-invasive</span> and important genomic testing solutions for patients with metastatic cancers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Osteoarthritis (OA) Market </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. Osteoarthritis is a progressive degenerative disease of the joints, caused by the breakdown and loss of cartilage in one or more joints. Cartilage is a connective tissue found in joints between bones such as knees, ankle, and elbow, and provides lubrication to reduce friction in the joints. The goal of osteoarthritis treatment is to alleviate pain and enhance functionality of the joints. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The growth of the osteoarthritis therapeutics market is currently and will in the near-term future be driven by a number of factors, including a general increase in prevalence of the disease in an ageing global population that is also living longer. These factors include wider access to better treatment options as a result of technological advancements, increased investments in R&amp;D activities for drug development including in cell-based research activities, increased funding from private&#160;&amp; government organizations for the development of the healthcare sector and research centers generally, and a rise in the number of approvals for drugs by regulatory bodies. As an example of the latter, in June 2021, the FDA announced the approval of CyMedica&#8217;s Intellihab system, designed for the treatment of pain caused by debilitating knee osteoarthritis. Thus, on the other hand, the high cost of osteoarthritis drugs and risks associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as stomach ulcer, dizziness, and allergic reaction, are expected to restrict the osteoarthritis therapeutics market growth during the forecast period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global osteoarthritis therapeutics market size was valued at $6.75&#160;billion in 2020, and is estimated to reach $15.693&#160;billion by 2030, growing at a CAGR of 8.8% from 2021 to 2030.<sup style="font-size:75%; vertical-align:top">6</sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the BLAC M&amp;A Committee&#8217;s review of OSR Holdings&#8217; asset pipeline which includes Vaximm&#8217;s drug candidates for recurrent GBM, hepatocellular cancer, metastatic colorectal cancer, and Darnatein&#8217;s drug candidate for osteoarthritis and the foregoing market data relevant to such assets, the BLAC M&amp;A Committee determined that the total addressable market presents a favorable opportunity to OSR Holdings and considered such information in their conclusion that the Business Combination is fair to, advisable, and in the best interests of BLAC and its stockholders. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">6</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">https://www.alliedmarketresearch.com/osteoarthritis-treatment-market-A12691 </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">OSR Holdings&#8217; Business Model </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee considered it noteworthy and meaningful from its due diligence standpoint that OSR Holdings operates a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Hub-and-Spoke&#8221;</span></span> business model with a centralized portfolio management team of the holding company which owns and controls a growing portfolio of emerging biotech and medtech companies (in South Korea and Switzerland), as opposed to the traditional &#8220;single platform / single entity&#8221; biotech corporate model. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OSR Holdings&#8217; business objective is to optimize value creation for each of its product candidates and thereby continuously assess the best pathway for each, as it progresses through preclinical and clinical development processes, including through internal advancement, partnerships with established companies, and spin-outs or IPOs. OSR Holdings&#180; team is comprised of accomplished biopharma scientists, entrepreneurs, executives and employees with financial market, legal and medical industry experiences who bring together the interdisciplinary expertise and resources required to grow a pipeline of innovative biotech companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of discussions with the OSR Holdings management team and the RMC, Darnatein, and Vaximm management teams, the BLAC M&amp;A Committee concluded that, as a life sciences holding company, OSR Holdings provides valuable centralized leadership and resources to its subsidiaries across therapeutic areas, target indications and technologies. While OSR Holdings and its subsidiaries are still at an early stage, the BLAC M&amp;A Committee viewed the business model and subsidiary entities as possessing significant value and potential for future economic gains. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, OSR Holdings&#8217; track record of executing on its business model to acquire its current subsidiaries by negotiating with their historical shareholders provided a basis for the BLAC M&amp;A Committee to view the OSR Holdings team as capable of further scaling and supporting its subsidiary portfolios, particularly if OSR Holdings is able to secure broader access to the equity capital markets by listing on a stock exchange. In this regard, the BLAC M&amp;A Committee also recognized that OSR Holdings played a key role in Vaximm&#8217;s engagement with one of the largest investment banks in Korea (Shinhan Investment Corp.) regarding Vaximm&#8217;s potential Korean IPO in 2020. Although the engagement did not result in further action towards Vaximm&#8217;s contemplated IPO, the engagement provided the BLAC M&amp;A Committee with support for OSR Holdings&#8217; capability, if and when appropriate, to provide necessary support to its subsidiaries to independently list on the public markets, and in particular, on a Korean stock exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, the BLAC M&amp;A Committee analyzed the competitive advantages that OSR Holdings&#8217; <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> model had developed to date, and proposed to further develop, and concluded that consummating a business combination with OSR Holdings was fair to, advisable, and in the best interests of BLAC and its stockholders for the following reasons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Specialization and Focus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Core Expertise (Hub): The central hub (the &#8220;Holdco&#8221;) focuses on core competencies such as strategic decision-making on R&amp;D investments or partnering activities, regulatory affairs, and corporate governance. This allows the hub to develop deep expertise and maintain high standards in these critical areas. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Focused Operations (Spokes): Spokes can specialize in specific areas such as clinical trials, manufacturing, or specific therapeutic areas, allowing them to operate more efficiently and effectively. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Resource Optimization </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Efficient Resource Allocation: Resources such as capital, personnel, and technology can be allocated more effectively. The hub manages strategic resources while spokes focus on operational execution. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cost-Effectiveness: By centralizing high-cost functions such as R&amp;D in the hub and outsourcing or decentralizing other functions to spokes or external partners such as CROs, companies can reduce overhead costs and avoid redundancy. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Flexibility and Scalability </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adaptability: The model allows for rapid adaptation to changing market conditions, regulatory landscapes, and technological advancements. Spokes can be added, modified, or removed without disrupting the entire organization. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Scalability: As the company grows, additional spokes can be established to handle new projects or enter new markets, allowing for scalable growth without overwhelming the central hub. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Risk Management </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Risk Diversification: By spreading activities across multiple spokes, the company can mitigate risks. Issues in one spoke do not necessarily affect the entire organization, which helps in managing operational and financial risks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Focused Risk Mitigation: The hub can focus on strategic risk management, ensuring that the company&#8217;s overall direction is safeguarded, while spokes can manage operational risks specific to their activities. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Innovation and Collaboration </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enhanced Innovation: The hub can focus on driving innovation through advanced R&amp;D, while spokes can implement and refine these innovations in real-world applications, creating a feedback loop that enhances overall innovation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborative Synergies: Spokes can collaborate with external partners, including academic institutions, research organizations, and other biotech companies in their own fields of expertise and/or strategic interests, to leverage external expertise and resources, fostering a collaborative environment. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Speed to Market </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Accelerated Development: By decentralizing operational tasks to specialized spokes, companies can streamline processes and accelerate the development and commercialization of products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Regulatory Efficiency: The hub can focus on navigating complex regulatory environments, ensuring that spokes comply with necessary regulations, which can expedite approvals and market entry. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Market Reach and Customer Focus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Localized Operations: Spokes can be established in different geographic regions, allowing the company to tap into local markets, understand regional customer needs, and tailor products and services accordingly. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Customer-Centric Approach: Spokes can focus on specific customer segments or therapeutic areas, ensuring that their operations are closely aligned with customer needs and preferences. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Korean Corporate Investments and M&amp;A Trends in Biotech Industry </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Large Korean businesses, particularly the conglomerates known as &#8220;chaebols&#8221;, are increasingly engaging in biotechnology investments and mergers and acquisitions (M&amp;A) within the domestic and global healthcare markets. This trend is driven by a combination of strategic diversification, opportunities for growth, and a focus on innovative sectors with high potential. The BLAC Board and the BLAC M&amp;A Committee identified such trends by the Korean corporate investors as an opportunity for OSR Holdings to transact with those corporate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counterparties in Korea for potential licensing and/or M&amp;A deals in the future. Below are some key aspects of how these companies are engaging in the biotech and healthcare sectors as discussed by the BLAC Board, BLAC M&amp;A Committee and OSR Holdings management: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Strategic Investments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct Investments in Biotech Firms: Many Korean conglomerates are directly investing in biotech startups and established firms. These investments often focus on companies involved in cutting-edge research, pharmaceuticals, medical devices, and digital health technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joint Ventures and Partnerships: Collaborating with both domestic and international biotech firms, Korean companies are forming joint ventures and partnerships to leverage their strengths and access new technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Mergers and Acquisitions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquiring Biotech Firms: Korean companies are acquiring biotech firms to integrate new technologies, enhance their product portfolios, and enter new markets. These acquisitions often aim to strengthen capabilities in areas such as gene therapy, personalized medicine, and advanced diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global M&amp;A Activities: The M&amp;A activities are not confined to the domestic market. Korean firms are increasingly looking overseas to acquire companies with unique technologies and access to broader markets. The following are examples of notable transactions made by Korean corporate buyers in the global biopharmaceutical market, which the BLAC M&amp;A Committee deemed relevant to its due diligence review.<span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Samsung Biologics</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of Biogen&#8217;s Stake in Samsung Bioepis (2022): Samsung Biologics acquired Biogen&#8217;s entire stake in Samsung Bioepis for approximately $2.3&#160;billion, making it a wholly-owned subsidiary. This move was aimed at strengthening Samsung Biologics&#8217; position in the biosimilars market and expanding its global footprint. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">SK Group </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of AMPAC Fine Chemicals (2018): SK Holdings, part of the SK Group, acquired AMPAC Fine Chemicals, a U.S.-based contract development and manufacturing organization (CDMO). This acquisition was valued at around $700&#160;million and aimed to bolster SK&#8217;s capabilities in pharmaceutical manufacturing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">LG Chem </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of AVEO Pharmaceuticals (2023): LG Chem acquired AVEO Pharmaceuticals, a U.S.-based oncology-focused biopharmaceutical company, for approximately $566&#160;million. This acquisition aimed to enhance LG Chem&#8217;s oncology pipeline and strengthen its presence in the global biopharmaceutical market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Celltrion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of Plant in the UK from Hospira (2014): Celltrion acquired a biosimilar production facility in the UK from Hospira (now a subsidiary of Pfizer). This acquisition was part of Celltrion&#8217;s strategy to increase its manufacturing capacity and expand its presence in the European market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">GC Pharma </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of a Plasma Fractionation Plant from Biotest (2019): GC Pharma acquired a plasma fractionation plant in Germany from Biotest. This deal was aimed at expanding GC Pharma&#8217;s production capacity for <span style="white-space:nowrap">plasma-derived</span> therapies and enhancing its global supply chain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hanmi Pharmaceutical </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of Spectrum Pharmaceuticals&#8217; Rights to Rolontis (2019): Hanmi Pharmaceutical acquired the global rights (excluding China) to Rolontis, a long-acting granulocyte colony-stimulating factor, from Spectrum Pharmaceuticals. This deal, worth $160&#160;million, included an upfront payment and milestones. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lotte Group </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisition of Bristol-Myers Squibb&#8217;s Manufacturing Facility in Ireland (2021): Lotte Biologics, a subsidiary of Lotte Group, acquired Bristol-Myers Squibb&#8217;s biologics manufacturing facility in Swords, Ireland. The acquisition, valued at approximately $160&#160;million, was aimed at entering the biologics CDMO business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Research and Development (R&amp;D) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Establishing R&amp;D Centers: Large Korean companies are setting up dedicated R&amp;D centers focusing on biotechnology and healthcare. These centers aim to drive innovation and support the development of new products and solutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration with Academia: Partnerships with universities and research institutions are common, fostering innovation through collaborative research projects and access to academic expertise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Government Support and Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incentives and Funding: The Korean government provides various incentives and funding programs to support biotech and healthcare innovations, encouraging private sector investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory Environment: Efforts to streamline regulatory processes and provide a supportive framework for biotech development are ongoing, helping attract more investment in the sector. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fair Market Value </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OSR Holdings Indicative Valuation Reports </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with diligence performed by BLAC, OSR Holdings provided certain valuation reports that were considered by BLAC, among the other materials described herein, in its decision to pursue a business combination with OSR Holdings. The indicative values contained in such reports, as reported on each subsidiary, can be summarized as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:22%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:22%"/>

<td style="vertical-align:bottom"/>
<td style="width:21%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Company| (Domicile)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Valuation by:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Methodology used:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indicative Value<sup style="font-size:75%; vertical-align:top">1</sup></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaximm (Switzerland)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ghilin Accounting Corp.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;5, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow (rNPV)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD&#160;104.6&#160;million</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darnatein (Korea)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ghilin Accounting Corp.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;5, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow (rNPV)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KRW 176.5&#160;billion (USD&#160;136.4&#160;million)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMC (Korea)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ghilin Accounting Corp.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&#160;13, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KRW 12.3&#160;billion (USD 9.5 million)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="7"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sum of the Parts: <br/>(Exchange rate: KRW1,294.53 per USD as of 12/29/2023)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KRW 324.2&#160;billion (USD&#160;250.5&#160;million)</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1: The valuation consultants described herein were engaged for valuation work solely to be used by OSR Holdings and/or its affiliates in connection with OSR Holdings&#8217; acquisition of Vaximm, Darnatein and RMC. Such consultants were not engaged in connection with the Business Combination, nor were their reports furnished to the BLAC M&amp;A Committee or the BLAC Board. Because the reports were not prepared with any consideration of the Business Combination, the names of the consultants are blinded. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee reviewed the detailed analyses contained in the valuation reports, which details are provided below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vaximm AG </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:41%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">NPVs&#160;(In&#160;USD&#160;mil)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" rowspan="6" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">VXM01 &#8211; GBM</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">VXM01 &#8211; mCRC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">VXM01 &#8211; Liver</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">32.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">VXM01 &#8211; NF2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">21.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">VXM Tech Platform</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">61.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Subtotal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">157.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" rowspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">G&amp;A expenses</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(27.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(26.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Subtotal</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(53.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Indicative Equity Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">104.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Exchange rate (As of the date of report)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,292.90&#160;KRW&#160;/&#160;USD</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">In KRW mil.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">135,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Darnatein Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuation model of Darnatein employs the risk-adjusted net present value (rNPV) method which uses free cash flow (FCF) projections from the single development program of DRT 101, formerly known as SAB704<sup style="font-size:75%; vertical-align:top">7</sup>, a design-augmented (DA) biologic currently in preclinical stage to develop a disease-modifying osteoarthritis (OA) drug (OR &#8220;DMOAD&#8221;), of which the platform science was (co)invented by Dr.&#160;Senyon Choe et. al. during his tenure with the Salk Institute for Biological Studies. The following table shows the <span style="white-space:nowrap">30-year</span> free cash flow projection from DRT101 (no &#8220;Terminal Value&#8221; assumed) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Sum&#160;of&#160;NPVs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;1</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;2</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;3</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;4</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;5</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;6</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;7</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;8</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;9</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;10</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:middle" rowspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">161</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-6.27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-5.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-1.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-1.82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-1.57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year&#160;29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Year 30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, the BLAC M&amp;A Committee noted that Darnatein conducted a clinical study in Korea as a Drug-Device Convergence Medical Product, a relatively new regulatory pathway implemented by the Ministry of Food and Drug Safety (MFDS) of Korea, of DRT102 (formerly known as AB204), a bone regenerative program also based on the DA BMP chimera platform for the treatment of spinal disorders. A confirmatory trial for DRT102 was conducted in three study sites in Korea, which includes the Seoul National University Hospital. This study was originally designed to be conducted with a patient group of n=154, however the trial experienced difficulties in recruiting patients during the <span style="white-space:nowrap">Covid-19</span> pandemic leading to a smaller patient group of 15. While the size of patient group of n=15 is too small to indicate the trial&#8217;s results in any statistically meaningful way, the clinical study report prepared by Dt&amp;CRO Co., Ltd indicates that there was a 75% (bone fusion) success rate for the test group while the success rate for the control group was 28.57% with no signs of severe adverse effects observed from the 24<sup style="font-size:75%; vertical-align:top">th</sup> week post-operation safety <span style="white-space:nowrap">follow-up</span> examinations. However, the BLAC M&amp;A Committee noted that the valuation report excluded DRT102 (with clinical data) from its valuation model because the DRT102 clinical trial was abandoned due to a lack of financial resources, leaving only DRT101, a preclinical asset, as the single source of cash flow projection. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">7</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Prior to the company&#8217;s renaming from Biobetter Biologics into Darnatein, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As mentioned above, the valuation model of Darnatein was built on projected cash flows solely from the company&#8217;s cartilage regenerative program (DRT101) over a long-term period of 30 years (2023 - 2052) with a total <span style="white-space:nowrap">out-licensing</span> value of USD 2.16&#160;billion given the large addressable market (approximately $6.75&#160;billion in 2020 estimated to reach $15.7&#160;billion by 2030, according to Allied Markets Research<sup style="font-size:75%; vertical-align:top">8</sup>) and no effective disease-modifying OA drugs (DMOADs) approved by regulatory bodies so far<sup style="font-size:75%; vertical-align:top">9</sup>. The projected period of 30 years is based on the patent-protected period of 20 years<sup style="font-size:75%; vertical-align:top">10</sup> which is followed by additional 10 years with scaling-down revenues reflecting possible launches of generic competitors after the patent expiration. On the other hand, the report does not assume any &#8220;Terminal Value&#8221; which is normally built into the valuation model at the end of the projected cash flow period and often times occupies a significant portion of the entire valuation outcome, which means that a going concern was not assumed for the purposes of the valuation on Darnatein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee noted that one of the key assumptions used by the valuation report was a $2+ billion licensing deal that has not materialized. However, OSR Holdings confirmed in discussions with the BLAC M&amp;A Committee, that its initial due diligence on Darnatein uncovered that there have been discussions with global healthcare companies and negotiations for a licensing deal with Darnatein&#8217;s pipeline asset DRT101. Furthermore, under the new corporate structure as a subsidiary of OSR Holdings, Darnatein is expected to benefit from OSR Holdings&#8217; global relationships, and particularly in South Korea where OSR Holdings is based and has strong connections and increasing visibility and exposure. Therefore, the BLAC M&amp;A Committee viewed the assumption of a $2&#160;billion licensing deal for the purpose of the valuation report on Darnatein as reasonable, and otherwise considered the Darnatein valuation report in their decision to approve the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">RMC Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuation model of RMC employs the discounted cash flow (DCF) analysis as shown below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2020</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2028 +</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CAGR</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.53</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COGS</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avg. %</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SG&amp;A</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">% in revenues</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">21.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">19.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">18.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wages</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">678</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">710</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">742</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">776</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">812</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">849</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">889</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OP margin</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">10.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">13.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">15.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Growth</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">34.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">30.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">27.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(82</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(212</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(344</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net profit or losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">7.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">10.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">11.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D&amp;A</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CAPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terminal growth rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.57</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate &amp; PVF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5804</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PV of FCFs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">8</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">https://www.alliedmarketresearch.com/osteoarthritis-treatment-market-A12691 </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">9</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128067/ </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">10</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Article 33, TRIPS Agreement </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Additional Valuation Information Obtained During Diligence </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discussions between BLAC and OSR Holdings also included the valuation methodologies used in deriving the enterprise values of all three subsidiaries of OSR Holdings, but primarily Vaximm and Darnatein, the two drug development companies held by OSR Holdings. In reviewing valuation processes and results of these two main subsidiaries, the BLAC M&amp;A Committee reviewed the risk-adjusted net present value (&#8220;rNPV&#8221;) models prepared by third-party valuation consultants (as described above) engaged by OSR Holdings for the acquisitions of Vaximm and Darnatein from December 2022 and March 2023 respectively. The rNPV analysis is the most commonly used valuation methodology in the life sciences industry for its advantages of being able to separate the risks innate to certain company and market from the risks associated with clinical trials and regulatory affairs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While rNPV analysis is the &#8220;biopharma equivalent&#8221; of discounted cash flow (DCF) analysis, the BLAC M&amp;A Committee also reviewed the market comparable analyses included in the same valuation reports on Vaximm and Darnatein. The BLAC M&amp;A Committee considered such comparable company analyses as a meaningful way to compare Vaximm and Darnatein to their public market analogues. The BLAC M&amp;A Committee took a balanced approach to its consideration of the historical information by taking a weighted average of the comparable company analyses and the rNPV analyses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In discussions with the BLAC M&amp;A Committee, Mr.&#160;Hwang mentioned that Vaximm is not merely a biotech company with a drug development pipeline, but directly possesses its own platform technology underlying its pipeline which is based on a live attenuated bacterial vaccine strain. It is modified to stimulate patients&#8217; immune response and the products are orally administered to initiate a systematic <span style="white-space:nowrap">T-cell</span> response in the gut. Vaximm&#8217;s platform technology can be adapted to target a wide range of cancer-related antigens (so called &#8220;Plug and Play&#8221; adaptability). Therefore, the BLAC M&amp;A Committee concluded that it is important to consider the potential value of the Vaximm platform technology. The BLAC M&amp;A Committee also noted that the 2020 valuation report from Avance, although outdated by 3 years, still presents a meaningful data point to consider with respect to Vaximm&#8217;s valuation given the global pandemic which consumed almost 3 years between the publication of the report and their review thereof. The BLAC M&amp;A Committee took into consideration the fact that Vaximm has had difficulties in recruiting patients for its clinical studies which, coupled with the current fundraising environment for clinical-stage biopharmaceutical companies, has resulted in stagnant business development between the preparation of the Avance report and now. The BLAC M&amp;A Committee noted the major assumptions used in the Avance valuation report, including those relevant to VXM01, Vaximm&#8217;s lead asset, which were presented as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Target Indication: Recurrent Glioblastoma (rGBM), Addressable Market&#160;&amp; Market Share </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">GlobalData research indicates that by 2025 sales in the recurrent glioblastoma market are estimated to amount to $6.1B. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incident cases of GBM are allocated to China (urban) with approximately 40%. Therefore Avance allocated 40% of these sales to China ($2.4B) and the remainder ($3.6B) to ROW (Rest of the World). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With an expected average growth rate (AGR) of 2% for ROW, this would lead to an $4.2B addressable market in ROW. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For China, a 4% AGR is predicted leading to a $3.2B addressable market for China by 2037. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The report assumed VXM01 to be a <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> drug that is launched more than 5 years after the <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> drug which would lead to a predicted market share of 17%. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In line with historic data of oncology cancer therapeutics, the report modeled an adoption curve to peak sales of 7 years. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With sales starting in 2025, estimated peak sales of $1.2B by 2032 divided over ROW ($700M) and China ($500M). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM Market Competition </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Only three therapeutic products are approved for the treatment of GBM: Temodar (TMZ) from Merck, Gliadel implants from Eisai / Arbar, and Avastin for rGBM from Roche. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is a high unmet need in this indication and several companies are active in the space. The late-stage pipeline is dominated by immunotherapies and targeted therapies. There is a high failure rate due to the nature of the disease. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM Market Uptake </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Based on development timelines, VXM01 (in combination) will enter the market for rGBM in early 2026. A market share of 17%, matching a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> therapeutic profile with time to market of &gt;5&#160;years since <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class,</span></span> is achievable based on benchmarks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A launch curve of 7 years is modeled based on historic data from oncology products (Zytiga&#160;&amp; Xtandi). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development Costs and Timelines </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development costs and timelines are based on estimates by Vaximm&#8217;s management and reflect the best estimate at the time of analysis. Costs are in million and were originally stated in Euro and converted to U.S. Dollars at the exchange rate in effect on June 30, 2022 of 1:1.0447. The below formed the basis for our modelling. For purposes of the valuation, two of the early stage pipeline projects were assumed to advance in the relevant planning horizon. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:27%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom"/>
<td style="width:7%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" colspan="15" align="right"><span style="font-weight:bold">Currency: USD</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Program</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indication</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Initiation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Preclinical</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Phase 1/2a</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Phase2b/3</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Review</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total&#160;cost</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">to launch</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top">VXM01 with checkpoint inhibitor&#160;A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">rGBM</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">On-going Phase&#160;1/2a</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">4.94M&#160;(15&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">34.8M (28&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.36M (3&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">43.1M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">VXM01 with immune modulator</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">rGBM</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Q2 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">1.46M (24 months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">34.8M (28&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.36M (3&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">39.6M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top">VXM01 with checkpoint inhibitor&#160;A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">mCRC</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Q1 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.71M (25 months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">46.3M (36&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.36M (6&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">53.4M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">VXM01 with checkpoint inhibitor&#160;A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Liver Cancer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Q1 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.71M (25 months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">46.3M (36&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.36M (6&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">53.4M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top">VXM01 monotherapy</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Schwannoma NF2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Q2 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">0.67M (50 months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"><span style="white-space:nowrap">Ultra-orphan</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Accelerated approval</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">0.67M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top">VXM Platform, 4 programs</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Oncology</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">1<sup style="font-size:75%; vertical-align:top">st</sup>&#160;program&#160;-</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Q4 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">0.5M</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.3=7M&#160;(25&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">46.3M</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">(36 months)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">3.36M (12&#160;months)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="right">53.9M</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development Risks </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Avance report calculated the development risks based on the BIO meta-study evaluating a total of 9,985 clinical and regulatory phase transitions from 7,455 development programs, across 1,103 companies. Based on these data, an overall chance of approval of 5% has been taken into account. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:57%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Program</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Preclinical*</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase&#160;1</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase&#160;2</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Phase&#160;3</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Approval</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Overall</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VXM01</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(* Preclinical to Phase 1 transition statistics are not part of the BIO study. If a study has been initiated or is in advanced planning , the Report assumed 100%). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the firm&#8217;s research and comparable data, and the stage of the company&#8217;s eyeing a possible IPO, Avance has taken a discount rate of 12% into account for the purpose of building its valuation model on Vaximm. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC M&amp;A Committee took note of the foregoing analyses and assumptions, and considered the differences to Vaximm&#8217;s business and prospects under OSR Holdings ownership. Nevertheless, the BLAC M&amp;A Committee considered the foregoing analyses, among its other diligence findings, and concluded that such analyses serve as a useful basis and a benchmark to consider upon its own findings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">BLAC M&amp;A Committee&#8217;s Consideration of Certain Third-Party Valuation Reports </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the BLAC M&amp;A Committee considered the third-party valuation analyses provided by OSR Holdings in connection with its decision to approve the Business Combination, the BLAC M&amp;A Committee took into account the fact that these reports were (i)&#160;not recently prepared, (ii)&#160;were not prepared giving effect to, or with regard to, the Business Combination, and (iii)&#160;were not prepared for, or delivered directly to, the BLAC M&amp;A Committee. The BLAC M&amp;A Committee considered the information along with the totality of information provided to the BLAC M&amp;A Committee in connection with its diligence of OSR Holdings, and did not ascribe any particular or special weight to the third-party valuation reports. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Comparable Company Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with OSR Holdings&#8217; ongoing strategy of building a portfolio of subsidiaries and the ongoing need for various financings in order to execute its strategy, the OSR Holdings management team developed, and maintained over time, a list of comparable companies, which it used to benchmark its valuation. In connection with its due diligence, the BLAC Board obtained the list of comparable companies provided by the OSR Holdings management team, which it then provided to the BLAC M&amp;A Committee upon its formation. In connection with its due diligence efforts, the BLAC M&amp;A Committee collaborated with the OSR Holdings management team to prepare a more fulsome analysis of the comparable companies for the BLAC M&amp;A Committee to consider before approving the Business Combination Agreement. In doing so, the BLAC M&amp;A Committee reviewed and compared certain financial and operating information relating to OSR Holdings to corresponding publicly available information for 28 publicly traded companies (reinforced with 2 additional private-stage companies due to their importance in their respective categories). The BLAC M&amp;A Committee considered the following three categories of companies as the most meaningful for the purpose of the OSR Holdings comparable company analysis: i) <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke;</span></span> ii) Immuno-Oncology; and iii) Regenerative Medicines. The BLAC M&amp;A Committee considered the relatively larger market values of the companies belonging to the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> category, as compared to the market values of the companies belonging to the other two groups, as being attributed to the nature of the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> constituent companies&#8217; ownerships in their own portfolios of multiple subsidiaries and assets. The median market capitalization values for the immuno-oncology and the regenerative medicine groups were $229&#160;million and $273&#160;million respectively, while the median for the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> group was $2.920&#160;billion. In terms of enterprise value (EV), the median for the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> group was $3.412&#160;billion while the same for the immune-oncology and the regenerative medicine groups were $193&#160;million and $283&#160;million, respectively. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Comparable&#160;Companies</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">($&#160;in&#160;Millions)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Market<br/>Capitalization<sup style="font-size:75%; vertical-align:top">1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Enterprise<br/>Value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">A. Hub and Spoke&#160;Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Sciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BridgeBio Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortress Biotech</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-32.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimbus Therapeutics<sup style="font-size:75%; vertical-align:top">2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group A Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2920</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3412</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Comparable&#160;Companies</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">($&#160;in&#160;Millions)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Market<br/>Capitalization<sup style="font-size:75%; vertical-align:top">1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Enterprise<br/>Value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">B. Immuno-Oncology(I/O) Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anixa Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hookipa Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genelux</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immatics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">369</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immutep</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CEL SCI</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greenwich LifeSciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inovio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Northwest Biotherapeutics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Innate Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arcus Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaxcell Bio Therapeutics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sillajen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">genexine</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LigaChem Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABL Bio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MedPacto</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mendus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ultimovacs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group B Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">229</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">193</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">C. Regenerative Medicine (DMOAD) Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carmell Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kolon TissueGene</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEDIPOST</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biosplice Therapeutics<sup style="font-size:75%; vertical-align:top">3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group C Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">283</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">B+C I/O and DMOAD Comparison Group<sup style="font-size:75%; vertical-align:top">4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">502</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">476</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Transaction</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(%&#160;Discount&#160;to&#160;Peer&#160;Group)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(100%&#160;Redemption&#160;Rate)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(%&#160;Discount&#160;to&#160;Peer&#160;Group)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(0%&#160;Redemption&#160;Rate)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">288</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(%&#160;Discount&#160;to&#160;Peer Group)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1) As of November 15, 2023 from publicly available data </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2) As of September&#160;6, 2023 according to PrivCo. Enterprise value is an estimate due to company data not being publicly available. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3) As of February&#160;8, 2022 according to Tracxn.com. Enterprise value is an estimate due to company data not being publicly available. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4) &#8220;sum of the parts&#8221; valuation between I/O (representing Vaximm&#8217;s comparables) and DMOAD (representing Darnatein&#8217;s comparables) as a direct comparable to the current business portfolio of OSR Holdings consisting of Vaximm and Darnatein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the BLAC M&amp;A Committee&#8217;s view, it would not be appropriate to compare the valuation of OSR Holdings, a relatively new <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> company, directly against the valuations of the larger and more-established peers operating with the same corporate model. However, the BLAC M&amp;A Committee also evaluated </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and acknowledged that there is growing recognition by market participants of the competitive advantages that the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> model has demonstrated to the overall market and the industry in terms of business performance and share price performance relative to the composite index. The BLAC M&amp;A Committee is of the view that, when several individual high-risk assets are &#8220;bundled&#8221; into a portfolio, the holding company owning and managing the portfolio may be able to generate a superior risk-adjusted return for the company&#8217;s shareholders due to the portfolio effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supported by observations such as these, the BLAC M&amp;A Committee believes that if OSR Holdings can achieve its business objectives as presently reviewed, it is reasonable to view the valuation metrics of the more established <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> companies as a meaningful comparable reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, at the individual subsidiary level, each of the immuno-oncology (I/O) group and the regenerative medicine (DMOAD) companies (Vaximm and Darnatein respectively), could be viewed and evaluated as direct comparables to their industry peers. Both the I/O and DMOAD datasets includes &#8220;outliers&#8221;, i.e., companies with market capitalization and EV disproportionately larger than the other data points in the respective group. For instance, LigaChem Biosciences in the I/O group shows its market capitalization near $886&#160;million and EV almost $1&#160;billion, which is far greater than the values of most other comparables in the group. In the DMOAD group, Biosplice Therapeutics demonstrates values that are disproportionately greater than the rest of the group with an indicated private-market equity valuation of $12&#160;billion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Those outliers are the companies in very advanced phases of clinical developments in their respective field of treatments, and should therefore be relevant as target valuations for OSR Holdings if and when OSR Holdings reaches the later stages of its pipeline development. However, to take a more conservative approach, the BLAC M&amp;A Committee excluded the outliers from each dataset and compared the outcomes (the normalized market capitalizations and EVs) against the &#8220;observational analyses&#8221; with the outliers included. This way, the BLAC M&amp;A Committee has taken a conservative approach regarding the observational and normalized analyses on the comparable companies. Finally, the BLAC M&amp;A Committee calculated a &#8220;sum of the parts&#8221; valuation between I/O (representing Vaximm&#8217;s comparables) and DMOAD (representing Darnatein&#8217;s comparables) as a direct comparable to the current business portfolio of OSR Holdings consisting of Vaximm and Darnatein by adding the two together. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Normalized Medians for Comparable Groups (excluding LigaChem and BioSplice) (In USD million) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market&#160;Capitalization</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Enterprise&#160;Value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> (Target Values)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immuno-Oncology (I/O)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regenerative (DMOAD)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I/O and DMOAD combined</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Valuation for the Business Combination: $244,612,136 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Indicative discount against comparables (I/O + DMOAD): 25.8% approximately </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Indicative discount against &#8220;Target Values&#8221;: 96.1% approximately </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excluded companies for normalization: Fortress Biotech, Immatics, Arcus Biosciences, LigaChem Biosciences and Biosplice Therapeutics </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of note, Fortress Biotech, the outlier in the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> group, is disproportionately smaller in values compared to the other datapoints. This has been excluded for normalization purpose, which rendered the normalized median values to be greater than the observational medians for market capitalization and EV for the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> group. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Observational (Unnormalized) Medians for Comparable Groups (In USD million) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Market&#160;Capitalization</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Enterprise&#160;Value</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immuno-Oncology (I/O)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regenerative (DMOAD)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I/O and DMOAD combined</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Valuation for the Business Combination: $244,612,136 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Indicative discount against comparables (EV): 51.2% approximately </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Indicative discount against &#8220;Target Values&#8221; (EV): 92.8% approximately </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conclusion of Comparable Company Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The companies included in the comparable company analysis operate in the broadly defined industries in which the OSR Holdings subsidiaries operate and therefore the BLAC M&amp;A Committee believes that the selected companies provide a relevant basis to evaluate the fairness of the Business Combination, from a financial point of view, to BLAC and its stockholders. The selected companies generally had product candidates that were farther along in their development or had revenue producing drugs whereas OSR Holdings&#8217; subsidiaries are primarily <span style="white-space:nowrap">pre-revenue.</span> The BLAC M&amp;A Committee believed that it was important to consider both quantitative and qualitative information in its analysis of OSR Holdings versus comparable companies. With respect to quantitative information, the BLAC M&amp;A Committee reviewed the selected companies&#8217; total market capitalization and total enterprise value in its analysis. Additionally, with respect to qualitative information, the BLAC M&amp;A Committee reviewed the operational, business and/or financial characteristics of OSR Holdings and the selected companies to provide a context in which to consider the results of the quantitative analysis. In its review of qualitative information, OSR Holdings&#8217; <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> platform, disruptive nature, strong barriers to competitive entry, management team, product pipeline, and total addressable market were key qualitative factors. The BLAC M&amp;A Committee considered this analysis in concluding that the Business Combination is advisable, fair to, and in the best interests of BLAC and its stockholders, subject to the condition of receipt of a fairness opinion that finds the Business Combination is fair, from a financial point of view, to BLAC and its stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">IPO Investment Criteria </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, BLAC identified various criteria and guidelines to use in evaluating acquisition opportunities, but also noted that it may decide to enter into an initial business combination with a target business that did not meet all of some of these criteria and guidelines. The criteria and guidelines, among others, are highlighted by that BLAC would choose to enter into a business combination with a company that is well situated to act as a standalone public company, that has a novel platform with catalysts to drive shareholder value and for which there is opportunity for further value creation as a public company, through organic and inorganic growth. The BLAC M&amp;A Committee considered these factors in its evaluation of OSR Holdings and determined that OSR Holdings was an attractive business combination target taking these criteria and guidelines into consideration. In addition to the material findings uncovered during diligence, the BLAC M&amp;A Committee considered several factors pertaining to the Business Combination as generally supporting its decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including but not limited to, the following material factors: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IPO Prospectus (Form <span style="white-space:nowrap">S-1)</span> of BLAC refers to the following Investment Criteria: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We are focused on companies developing the next generation of biologics which include therapeutic antibodies, engineered protein and enzyme drugs, cellular therapies, engineered viruses and bacteria, and <span style="white-space:nowrap">DNA-</span> and <span style="white-space:nowrap">RNA-modifying</span> technologies, using advanced molecular biology and biochemistry. We will consider companies with pipeline programs in clinical <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Proof-of-Concept&#8221;</span></span> studies (often from Phase 1 to 2a) to develop novel medicines to address diseases which cannot yet be cured or sufficiently managed. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We seek to create stockholder value by leveraging our management&#8217;s and its advisors&#8217; experience and network to efficiently guide an emerging biotech company towards clinical advancement of key assets in their pipeline while helping to secure licensing deals and partnerships with major pharmaceutical companies globally. Consistent with our strategy, we have established the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses, from <span style="white-space:nowrap"><span style="white-space:nowrap">time-to-time,</span></span> we may deviate from these criteria and guidelines should we see fit to do so: </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biopharmaceutical Company Poised for Rapid Growth </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We intend primarily to seek the acquisition of one or more biotherapeutics companies in clinical stage development with a total equity value of greater than 5 to 6 times the amount of the proceeds of this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can benefit from a public listing and new capital for growth to support business development and/or to advance clinical programs. We do not intend to acquire a preclinical stage company without human data. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Focus on Innovation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We expect to identify target companies that are typically cash flow negative as they are in the business of scientific research and clinical development. We expect that our list of potential targets will be comprised of companies focused on innovation that are poised to be disruptive in biologics with the potential to become a &#8220;game changer&#8221; once a drug candidate is approved and commercialized. A prospective target should either use an innovative technology platform or aim to address novel disease targets (or mechanisms) or both. Novel technology platforms will involve, in most cases, new biologic drug formats or significant improvements to existing ones. In some cases, this may also include improved screening platforms or other technologies that significantly facilitate the drug development process. Depending on their nature, novel targets can be addressed either with novel or with existing drug formats, including chemical compounds. We will deprioritize investments in companies that focus on generic or biosimilar versions of existing drugs. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Attractive Risk-Adjusted Equity Returns (Potential Upside Weighed Against Any Identified Downside Risks) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We intend to seek target companies that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms and in a manner that leverages our experience. We expect to evaluate companies based on the potential to successfully achieve regulatory approval and to commercialize their product(s). We also expect to evaluate financial returns based on (i)&#160;risk-adjusted peak sales potential (ii)&#160;the overall market potential of pipeline products and/or the scientific platform(s)&#160;(iii) the ability to achieve systematic cost savings, (iv)&#160;the ability to accelerate growth via multiple shots on goal, and (v)&#160;the prospects for creating value through other value creation initiatives. Potential upside, for example, from the growth in the target business&#8217; earnings or an improved capital structure, will be weighed against identified downside risks. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Opportunities to Unlock and Maximize Value from Underappreciated Situation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We will focus on target companies that exhibit unrecognized value or other characteristics that we believe have been misevaluated by the marketplace based on company-specific analyses and due diligence. For a potential target company, this process will include, among other things, a review and analysis of the company&#8217;s technology platform and/or licensed technologies, intellectual property (&#8220;IP&#8221;) position, preclinical and any clinical data, potential for operational improvements, manufacturing competitiveness, corporate governance, pharmaceutical partners or scientific collaborators, customers, material contracts, and industry needs and trends. We intend to leverage our team&#8217;s collective operational experience and disciplined investment approach to identify opportunities to unlock and maximize value. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These criteria are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors, and criteria that our management may deem relevant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the BLAC M&amp;A Committee&#8217;s review, OSR Holdings&#8217; pipeline of assets primarily consists of biologics, including DNA cancer vaccines and engineered (&#8220;design-augmented&#8221;) chimeric protein. Certain assets include technology/research platforms geared toward target engagement which increased therapeutic index, which can be seen as an innovative and more precise approach to medicine. In this respect, the OSR Holdings franchise and portfolio fits the related investment criteria, especially the &#8220;Focus on Innovation&#8221; and &#8220;Attractive Risk-Adjusted Equity Returns.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each OSR Holdings asset is geared toward a specific unmet need and technology approach. The OSR Holdings team is a cross-functional team with a core expertise and ecosystem adapted to the current type and stage of assets in its portfolio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, the BLAC M&amp;A Committee concluded that it is fair to consider OSR Holdings as a target business that corresponds to the Investment Criteria set forth in the IPO Prospectus of BLAC. As noted above, BLAC identified various criteria and guidelines to use in evaluating acquisition opportunities, but also noted that it may decide to enter into an initial business combination with a target business that did not meet all of some of these criteria and guidelines. The criteria and guidelines, among others, are highlighted by that BLAC would choose to enter into a business combination with a company that is well situated to act as a standalone public company, that has a novel platform with catalysts to drive shareholder value and for which there is the opportunity for further value creation as a public company, through organic and inorganic growth. The BLAC M&amp;A Committee considered each of these factors in its evaluation of OSR Holdings, and determined that OSR Holdings was an attractive business combination target taking these criteria and guidelines into consideration. In addition to the material findings uncovered during diligence, the BLAC M&amp;A Committee considered a number of factors pertaining to the Business Combination as generally supporting the decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including but not limited to, the following material factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Strong management team</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The consolidated management team from the holding company to each subsidiary consists of experienced professionals coming from scientific, entrepreneurial, capital market and regulatory backgrounds who, as a team, are well positioned to create interdisciplinary synergies. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Strong business model</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> biotech model is one of the highest-performing business models in the global biopharmaceutical market over the past decade. Due to its risk/return profile as a portfolio of experimental drug R&amp;D assets, it is increasingly being perceived as a business model which provides competitive edges especially in terms of raising new capital. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Multiple channels to access capital across the U.S., South Korea and in Europe</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In addition to the U.S. capital market which OSR Holdings expects to be able to access post closing of the Business Combination, OSR Holdings&#8217; management team mainly consists of the financial market professionals in South Korea whose access to institutional investors and investment banks are highly likely to add value to the combined company&#8217;s fundraising and IR activities in Korea. Also, Vaximm as a Swiss company has a management team whose presence, network and track records of fundraising for a diverse group of biotech firms based in Switzerland and France could benefit the post-closing Company&#8217;s capital raising efforts going forward. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Significant value creation and growth opportunities</span> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">OSR Holdings&#8217; subsidiaries are developing drug candidates in some of the areas with the highest unmet medical needs such as glioblastoma (GBM), hepatocellular cancer (HCC) and disease modifying treatment for osteoarthritis (&#8220;DMOADs&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers and directors of BLAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and background enabled them to make the necessary analyses and determinations regarding the Business Combination. In the course of its deliberations, the BLAC M&amp;A Committee also considered a variety of uncertainties, risks and other potentially negative factors relevant to the Business Combination, including the following which are based upon our diligence: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC&#8217;s public stockholders will hold a minority share position in the post-combination company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC stockholders may object to and challenge the Business Combination and take actions that may prevent or delay the consummation of the Business Combination, including to vote down the proposals at the special meeting or exercise their redemption rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential for diversion of management and employee attention during the period prior to completion of the Business Combination, and the potential negative effects on OSR Holdings&#8217; business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that, despite the efforts of BLAC and OSR Holdings prior to the consummation of the Business Combination, OSR Holdings may lose key personnel, and the potential resulting negative effects on OSR Holdings&#8217; business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk associated with macroeconomic uncertainty and the effects it could have on OSR Holdings&#8217; revenues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Business Combination Agreement prohibits BLAC from soliciting or engaging in discussions regarding alternative transactions during the pendency of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks and costs to BLAC if the Business Combination is not completed, including the risk of liquidation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential changes in the regulatory landscape or new industry developments, including changes in client preferences, may adversely affect the business benefits anticipated to result from the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks that are associated with being a publicly traded company that is in its early, developmental stage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Current Charter contains a waiver of the corporate opportunity doctrine, and, although we are not aware of any, there could have been business combination targets that would have been appropriate for a combination with BLAC but were not offered due to a BLAC director&#8217;s or officer&#8217;s duties to another entity. BLAC and its management are not aware of any such corporate opportunities not being offered to BLAC and do not believe that the waiver of the corporate opportunity doctrine in the Current Charter interfered with BLAC&#8217;s ability to identify an acquisition target, including the decision to pursue the Business Combination with OSR Holdings; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks of the type and nature described under the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the review and consideration of all of the information presented and made available, the BLAC M&amp;A Committee and the BLAC Board unanimously determined that the Business Combination Agreement and the Business Combination, were advisable, fair to, and in the best interests of BLAC and its stockholders. The above discussion of the material factors considered by the BLAC M&amp;A Committee is not intended to be exhaustive but does set forth the principal factors considered by the BLAC M&amp;A Committee in deciding to approve the Business Combination and recommend that the BLAC Board approve the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As further described below, the BLAC M&amp;A Committee did not obtain a fairness opinion prior to its decision to approve the Business Combination. However, the closing of the Business Combination is conditioned on the receipt of a fairness opinion, as required by BLAC&#8217;s Amended and Restated Certificate of Incorporation. The officers and directors of BLAC, including the members of the BLAC M&amp;A Committee, have substantial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and background enabled them to make the necessary analyses and determinations regarding the Business Combination, as described herein, prior to receiving a fairness opinion, with the caveat that the closing of the Business Combination is subject to the receipt thereof. The BLAC M&amp;A Committee has reviewed the draft fairness opinion described below, and the contents and analyses contained therein, and believes that it supports its determination that the Business Combination is fair to, advisable, and in the best interests of BLAC stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fairness Opinion of Choloc Asset Investment Advisory Co., Ltd. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In approving the Business Combination Agreement, the BLAC M&amp;A Committee noted that the closing of the transaction is conditioned on the receipt of a fairness opinion, in form and substance acceptable to the BLAC M&amp;A Committee, concluding that the Business Combination is fair, from a financial point of view, to BLAC stockholders as required by the Company&#8217;s Amended and Restated Certificate of Incorporation. The BLAC M&amp;A Committee initially engaged a financial advisor based in Switzerland to render the fairness opinion. This decision was made at the time that it was anticipated that OSR Holdings would acquire LBV and the resulting company would be more heavily oriented in Europe. However, when OSR Holdings and LBV terminated their agreement, the BLAC M&amp;A Committee determined that it would be more appropriate to engage a financial advisor in Korea because OSR Holdings&#8217; operations would be more heavily weighted toward that geography. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, the BLAC M&amp;A Committee retained Choloc Asset Investment Advisory Co., Ltd., a financial advisory firm based in Seoul, Korea (&#8220;Choloc&#8221;), to evaluate the fairness, from a financial point of view, of the Business Combination to the BLAC stockholders. On June 23, 2024, Choloc presented to the BLAC M&amp;A Committee a draft fairness opinion that they are prepared to render on the Business Combination, to the effect that, as of that date and based on and subject to the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken described in such opinion, the Business Combination is fair, from a financial point of view, to the BLAC stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of Choloc&#8217;s draft written opinion, dated June&#160;23, 2024, which describes the assumptions made, procedures followed, matters considered, and qualifications and limitations on the review undertaken, is attached as Annex&#160;H and is incorporated by reference in this document. <span style="font-weight:bold">The summary of the written opinion of Choloc, dated June 23, 2024, set forth in this proxy statement/prospectus is qualified in its entirety by reference to the full text of Choloc&#8217;s opinion attached as Annex H. Choloc&#8217;s opinion is to be rendered to the BLAC M&amp;A Committee in connection with its evaluation of the Business Combination and it does not address any terms or other aspects (other than the consideration to the extent expressly specified in Choloc&#8217;s opinion) of the transactions contemplated by the Business Combination Agreement.&#160;Choloc&#8217;s opinion will not address the BLAC M&amp;A Committee&#8217;s or the BLAC Board&#8217;s underlying business decision to effect such transactions or the relative merits of such transaction as compared to any alternative business strategies or transactions that might be available to BLAC and will not address any legal, regulatory, tax, or accounting matters. Choloc&#8217;s opinion is not intended to and will not constitute a recommendation to the BLAC stockholders as to how such stockholders should vote or act with respect to the transactions contemplated by the Business Combination Agreement or any matter relating thereto.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the bullets listed below and in connection with rendering its opinion, although Choloc considered internal information provided to it with respect to the business, earnings, cash flow, assets and liabilities of OSR Holdings and discussions conducted with the management and representatives of OSR Holdings, Choloc is relying on financial models prepared by the Korean affiliate of a global accounting firm (&#8220;AF&#8221;) and Ghilin Accounting Corp. (&#8220;Ghilin&#8221;) that served as the basis for its analysis set forth herein and the opinion it rendered to the BLAC M&amp;A Committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its opinion, Choloc: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed certain internal information relating to the business, earnings, cash flow, assets and liabilities of OSR Holdings furnished to Choloc by the BLAC M&amp;A Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed the final prospectus of BLAC dated February&#160;9, 2023 (the &#8220;Prospectus&#8221;) contained in the Registration Statement on Form <span style="white-space:nowrap">S-1</span> of BLAC as filed with the U. S. Securities and Exchange Commission (Reg. <span style="white-space:nowrap">No.&#160;333-264597);</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed the Q1 2024 OSR Holdings Company Overview; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed financial projection models (rNPV analysis) prepared by AF for Vaximm, dated May 20, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed financial projection models (rNPV analysis) prepared by AF for Darnatein, dated May 20, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed Ghilin Accounting Corp.&#8217;s discounted cash flow analysis and valuation model for RMC, dated January 13, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">researched and analyzed recent transaction activity in the biopharmaceutical industry, including asset and equity transactions, tech access transactions, collaborations, and licensing deals, which are relevant to the assets, subsidiaries and business model of OSR; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">researched and analyzed materials concerning sales analogs of marketed drugs specific to the assets, subsidiaries and business model of OSR; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed and analyzed material made available to Choloc by OSR, including, for each OSR Holdings subsidiary, scientific data concerning OSR Holdings&#8217; and its subsidiaries&#8217; assets, intellectual property information, business model information, information on competitive landscape, research and development efforts, financial assumptions, and capital structure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducted discussions with the BLAC M&amp;A Committee and members of the management and representatives of OSR Holdings concerning the business, operations, financial condition and prospects of OSR Holdings and its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed publicly available financial and stock market data of certain other companies in lines of business that Choloc deemed relevant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed the Business Combination Agreement, dated as of November&#160;16, 2023, as amended on May&#160;23, 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducted such other financial studies and analyses and took into account such other information as Choloc deemed appropriate. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Choloc, with the BLAC M&amp;A Committee&#8217;s consent, relied upon the information supplied to, discussed with or reviewed by Choloc for purposes of its opinion being complete and accurate in all material respects. Choloc does not assume any responsibility for independent verification of, and did not independently verify, any of such information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Choloc&#8217;s opinion was necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to Choloc as of the date of its opinion. Choloc assumed no responsibility for updating its opinion based on developments after the date of its opinion. As stated above, Choloc&#8217;s opinion did not address the underlying business decision to effect the transactions contemplated by the Business Combination Agreement or the relative merits of the same as compared to any alternative business strategies or transactions that might be available to BLAC and does not address any legal, regulatory, tax, or accounting matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the BLAC M&amp;A Committee&#8217;s consent, Choloc did not opine on what the value of the shares of BLAC would be following consummation of the transactions contemplated by the Business Combination Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Choloc did not express any opinion as to fair value or the solvency of OSR Holdings or BLAC following the closing of the transactions contemplated by the Business Combination Agreement.&#160;In rendering its opinion, Choloc assumed, with the BLAC M&amp;A Committee&#8217;s consent, and without any independent verification that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the representations and warranties of all parties to the Business Combination Agreement and all related documents and instruments are true and correct; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each party to the Business Combination Agreement will fully and timely perform all of the covenants and agreements required to be performed by such party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all conditions to the consummation of the Transaction will be satisfied without waiver thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Transaction will be consummated in a timely manner in accordance with the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Transaction will be consummated in a manner that complies in all respects with all applicable federal and state statutes, rules, and regulations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all governmental, regulatory, and other consents and approvals necessary for the consummation of the Transaction will be obtained and that no delay, limitations, restrictions, or conditions will be imposed, or amendments, modifications or waivers made that would have an effect on the Transaction or on OSR Holdings that would be material to Choloc&#8217;s analyses or the Fairness Opinion. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Summary of the Financial Analyses of Choloc </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing to render its opinion to the BLAC M&amp;A Committee, Choloc performed a variety of financial and comparative analyses, and, for purposes of its opinion, used only those financial models that Choloc prepared, with the exception of the financial projection models prepared by AF and Ghilin. This summary does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying Choloc&#8217;s opinion, nor does the order of the financial analyses described represent the relative importance or weight given to those financial analyses. The preparation of a financial opinion or analysis is a complex process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a financial opinion or analysis is not readily susceptible to summary description. In arriving at its opinion, Choloc considered the results of all of the analyses undertaken by it and assessed as a whole and did not draw, in isolation, conclusions from or with regard to any particular factor or method of analysis considered by it. Rather, Choloc made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the analyses. Accordingly, Choloc believes that its analyses and factors summarized herein must be considered as a whole and in context. Choloc further believes that selecting portions of its analyses and factors or focusing on information presented in tabular format, without considering all analyses and factors or the narrative description of the analyses and factors, could create a misleading or incomplete view of the processes underlying its analyses and opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing its analyses, Choloc considered industry performance, general business, economic, market and financial conditions and other matters, existing as of the date of its opinion, many of which are beyond the control of BLAC and OSR Holdings. No company, business or transaction reviewed is identical or directly comparable to BLAC, OSR Holdings or their respective businesses or the Transaction. Accordingly, an evaluation of these analyses is not entirely mathematical. Rather, the analyses involve complex considerations and judgments concerning business, financial and operating characteristics and other factors that could affect the public trading, acquisition or other values of the companies, businesses or transactions reviewed or views regarding the comparability of such companies, businesses or transactions. Accordingly, such analyses may not necessarily include all companies, businesses or transactions that could be deemed relevant. The estimates of the future performance of BLAC and OSR Holdings in or underlying Choloc&#8217;s analyses and the ranges of valuations resulting from any particular analysis are not necessarily indicative of actual values or predictive of future results </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or values, which may be significantly more or less favorable than those estimates or those suggested by the analyses. In addition, analyses relating to the value of businesses or securities do not purport to be appraisals or to reflect the prices at which a company may actually be sold or the prices at which any securities have traded or may trade at any time in the future. Accordingly, the assumptions and estimates used in, and the ranges of valuations resulting from, any particular analysis described herein are inherently subject to substantial uncertainty and should not be taken as the views of Choloc regarding the actual values of OSR Holdings or BLAC. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before June&#160;23, 2024 and is not necessarily indicative of current market conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The type and amount of consideration payable in the Transaction contemplated by the Business Combination Agreement was determined through negotiations between the BLAC M&amp;A Committee and OSR Holdings, rather than by any financial advisor, and was approved by the BLAC Board, with the recommendation of the BLAC M&amp;A Committee. The decision to enter into the Business Combination Agreement was solely that of the BLAC Board, as recommended by the BLAC M&amp;A Committee, and the OSR Holdings board of directors. Receipt of Choloc&#8217;s opinion and analyses should not be viewed as determinative of the views of the BLAC M&amp;A Committee, the BLAC Board or management of BLAC with respect to the transaction or the consideration payable in the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Discounted Cash Flow (rNPV) Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Choloc reviewed the adequacies of the rNPV / DCF valuation analyses conducted by AF (for Vaximm and Darnatein) and Ghilin (for RMC), compiled the data and derived a <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">sum-of-the-parts</span></span></span> (SOTP) analysis on the business portfolio of OSR Holdings as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Company|</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Valuation&#160;model<br/>provided&#160;by:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Methodology&#160;used:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Discount&#160;rate<br/>applied:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Indicative value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vaximm</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">AF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">rNPV</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183.5&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Darnatein</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">AF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">rNPV</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.09</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 104.1&#160;billion</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">RMC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Ghilin&#160;Accounting&#160;Corp.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">DCF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 7.4&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sum of the Parts (SOTP):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold"> 295&#160;million</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Pre-Transaction</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">245&#160;million</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(% Discount to SOTP)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">16.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Exchange rate: KRW1,385.47 per USD as of 6/20/2024) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Vaximm and Darnatein, Choloc reviewed the adequacy of the key assumptions used in AF&#8217;s rNPV model and concluded that the assumptions used are reasonable for biopharmaceutical companies such as Vaximm and Darnatein. The rNPV analysis on Vaximm assumes that each of Vaximm&#8217;s drug candidates will receive regulatory approval from the FDA (or similar regulatory bodies in <span style="white-space:nowrap">non-U.S.</span> markets) by 2032 and commercialization by 2033, with patent protection for 15 years. The DCF valuation conducted by Ghilin in December 2022 suggested that Vaximm&#8217;s valuation at that time was approximately $104.6&#160;million, or approximately $78.9&#160;million less than the rNPV result of the model built by AF, which contained the latest inputs from OSR Holdings&#8217; management. Certain key assumptions in the analyses varied and can be summarized as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Likelihood of Approval (LOA): 5% vs. 12% </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">While Ghilin&#8217;s assumption of 5% LOA is conservative, the industry meta-analyses indicate that the LOA of <span style="white-space:nowrap">immuno-oncology</span> (I/O) studies from Phase I to approval was close to 12% (12.4%) while the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
LOA for the overall oncology studies from Phase I to approval was close to 5% (5.3%) based on the data compiled by BIO (Biotechnology Innovation Organization). Choloc determined that, as the entire pipeline and technology platform of Vaximm belongs to the I/O group, rather than the general category of oncology, it would be fair and reasonable to apply a 12% LOA to the rNPV analysis of Vaximm instead of the 5% rate which is more widely observed from the oncology database. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Size of Addressable Market </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Ghilin took a highly conservative approach by assuming that the size of the addressable market for Vaximm&#8217;s drug candidates won&#8217;t grow and will maintain its <span style="white-space:nowrap">&#8220;status-quo&#8221;</span> after the observed data from 2017 while AF and OSR Holdings used a more realistic assumption that the size of the pharmaceutical market for each of Vaximm&#8217;s target indications will grow over the period analyzed. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Market Dominance Profile </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Through comparative analysis, Choloc&#8217;s, Ghilin&#8217;s and AF&#8217;s analyses were based on different pharmaceutical product life cycles (also referred to as &#8220;market dominance profile&#8221;) which can be visualized (with some simplification) as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt; margin-left:9%">


<img src="g476668g75c17.jpg" alt="LOGO" style="width:5.67708in;height:1.94556in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">First, industry statistics suggest that it takes approximately 5 to 7 years to reach peak sales from product launch, which is consistent with the assumptions made in both the Ghilin and AF Models. However, the peak sales period was shorter in the Ghilin model, which assumed 4 years (vs. 6 years in the AF model) before the product faces patent expiration and generic competition. In Choloc&#8217;s view, both assumptions are reasonable and consistent with industry data<sup style="font-size:75%; vertical-align:top">11</sup> for biologics marketing exclusivity of approximately 12 years (counting from marketing approval by the FDA), but the Ghilin model didn&#8217;t reflect that the marketing exclusivity for the biologics in oncology (or &#8220;oncologics&#8221;) continued to generate significant revenues even after the <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-market</span></span> exclusivity, therefore the assumption of 2&#160;years for the product revenues to decline from the peak to bottom appears to be highly conservative in light of industry data<sup style="font-size:75%; vertical-align:top">12</sup> for the biologics in oncology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For RMC, Choloc reviewed the adequacy of the key assumptions taken by Ghilin&#8217;s DCF model and concluded that the assumptions used are reasonable for a company such as RMC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Choloc&#8217;s services as a financial advisor to the BLAC M&amp;A Committee, BLAC agreed to pay Choloc an aggregate fee of $45,000. In addition, BLAC has agreed to reimburse certain of Choloc&#8217;s expenses arising, and to indemnify Choloc against certain liabilities that may arise, out of Choloc&#8217;s engagement. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">11</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">allucent.com (&#8220;Types of Marketing Exclusivity in Drug Development&#8221;) </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">12</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Jamanetwork.com (&#8220;Comparison of Sales Income and R&amp;D Costs for <span style="white-space:nowrap">FDA-approved</span> Cancer Drugs&#8221;) </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the <span style="white-space:nowrap">two-year</span> period prior to the date of Choloc&#8217;s opinion, Choloc has not been engaged to provide financial advisory or other services to BLAC or OSR Holdings and Choloc has not received any compensation from BLAC or OSR Holdings during this period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Choloc was selected to act as the fairness opinion provider to the BLAC M&amp;A Committee because of its qualifications and expertise in valuing early stage life sciences companies, as well as its familiarity with the business of OSR Holdings, including the fact that OSR Holdings and its operations are primarily located in Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Choloc&#8217;s opinion is not intended to and does not constitute a recommendation to any BLAC stockholder as to how such stockholder should vote or act with respect to the transaction or any matter relating thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLAC M&amp;A Committee&#8217;s engagement of AF for valuation services </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AF was engaged by the BLAC M&amp;A Committee in April 2024 to prepare financial models on Darnatein and Vaximm based on various sets of assumptions, including business and cash flow projections, probability of preclinical and clinical development scenarios, markets and pricing, and competitive landscape.&#160;AF did not independently verify the information that it was provided in connection with the analyses and AF did not and does not render an opinion on the fairness of the transaction. AF understands its analyses have been provided to and relied upon by Choloc in connection with Choloc&#8217;s preparation of its fairness opinion.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Scope of AF&#8217;s services </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Review the financial information and assumptions presented by BLAC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provide support for rNPV model developments based on information supplied by BLAC; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Develop excel-based valuation models for Darnatein and Vaximm based on the foregoing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with AF&#8217;s engagement, BLAC agreed to pay AF an aggregate fee of KRW 30,000,000 (VAT&#160;excluded). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of BLAC&#8217;s Directors and Executive Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of BLAC&#8217;s Board in favor of approval of the Business Combination, you should keep in mind that BLAC&#8217;s directors and officers have interests in the Business Combination that are different from, or in addition to, your interests as a stockholder. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve a proposed initial business combination (the Sponsor was not granted any consideration or incentive to agree not to redeem any shares of BLAC Common Stock held by it in connection with a stockholder vote to approve the Business Combination); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor paid an aggregate of $25,000 (or $0.014 per share) for 1,725,000 shares of BLAC Common Stock, which will have a significantly higher value at the time of the Business Combination. If unrestricted and freely tradable, such shares would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement and an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per share of BLAC Common Stock on Nasdaq on [&#9679;], 2024, the Record Date, but given the restrictions on those shares, we believe those shares have less value; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor purchased 430,000 private placement units (including the underlying securities) for an aggregate purchase price of $4,300,000 (or $10.00 per unit) in which the warrants and rights included in the private placement units would be worthless if a business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents). Such private placement units had an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;] per public unit on Nasdaq on [&#9679;], 2024, the most recent practicable date prior to the date of this proxy statement/prospectus and an aggregate market value of approximately $[&#9679;] based upon the closing price of $[&#9679;] per public unit on Nasdaq on [&#9679;], 2024, the Record Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed to waive its rights to liquidating distributions from the trust account with respect to any shares of BLAC Common Stock (other than public shares) held by it if BLAC fails to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Mr.&#160;Hwang, Mr. Whang and affiliates of the Sponsor have a financial interest in OSR Holdings. Mr.&#160;Hwang is the CEO and a Director of BLAC and CEO and Chairman of the Board of OSR Holdings and Mr.&#160;Whang is a director of BLAC. As such, Mr.&#160;Hwang, Mr. Whang and affiliates of the Sponsor who have a financial interest in OSR Holdings are incentivized to complete the Business Combination with OSR Holdings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor transferred 20,000 shares to each of Drs. Chung, Reed and Roberts and Mr.&#160;Park, which are current and former BLAC directors for their board service, and Mr.&#160;Yoo for his service as chief financial officer.&#160;The Sponsor additionally transferred 20,000 Private Placement Warrants to each of Dr. Reed for his service as the former chairman of the board of directors, Dr.&#160;Chung for his service as the former chair of the audit committee, and Mr.&#160;Yoo for his service as chief financial officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors will lose their entire investment in BLAC and will not be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses, if any, if an initial business combination is not consummated by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents) and, as a result, the Sponsor and BLAC&#8217;s officers and directors may have a conflict of interest in determining whether OSR Holdings is an appropriate business with which to effectuate a business combination and/or in evaluating the terms of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor has invested an aggregate of $4,325,000 (consisting of $25,000 for the founder shares, or approximately $0.014 per share, and $4,300,000 for the private placement units, or $10.00 per unit, means that the Sponsor and our officers and directors stand to make a significant profit on their investment and could potentially recoup their entire investment in BLAC even if the trading price of BLAC Common Stock was as low as approximately $2.00 per share (assuming no redemptions and even if the private placement warrants and rights are worthless) and therefore our Sponsor, officers and directors may experience a positive rate of return on their investment, even if BLAC&#8217;s public stockholders experience a negative rate of return on their investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and BLAC&#8217;s officers and directors (or their affiliates) may make Working Capital Loans from time to time to BLAC to fund certain capital requirements (&#8220;Working Capital Loans&#8221;). Sponsor, BLAC&#8217;s officers, and its and their affiliates, have previously loaned money to BLAC (or to the sponsor for BLAC&#8217;s benefit) in an aggregate amount of $3,905,000 to fund operating and transaction expenses in connection with the proposed Business Combination, $3,525,000 of which remains outstanding as of the date of this proxy statement/prospectus (none of which contain conversion rights), and may make additional loans after the date of this proxy statement/prospectus for such purposes. If the Business Combination is not consummated or another business combination is not otherwise completed, the loans may not be repaid and would be forgiven except to the extent there are funds available to BLAC outside of the trust account; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, although no compensation of any kind was or will be paid by BLAC to the Sponsor, BLAC&#8217;s executive officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of an initial business combination, these individuals may be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on BLAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. As of the date of this proxy statement/prospectus, there are no outstanding <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses for which the Sponsor or BLAC&#8217;s officers or directors are awaiting reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that if the trust account is liquidated, including in the event BLAC is unable to complete an initial business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), the Sponsor has agreed to indemnify BLAC to ensure that the proceeds in the trust account are not reduced below $10.175 per public share, or such lesser per public share amount as is in the trust account on the liquidation date, by the claims of prospective target businesses with which BLAC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to BLAC, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the trust account; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that BLAC may be entitled to distribute or pay over funds held by BLAC outside the trust account to the Sponsor or any of its affiliates prior to the Closing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s M&amp;A Committee, consisting of independent directors, reviewed and considered these interests during their evaluation of the Business Combination and in unanimously approving and recommending that the full Board approve the Business Combination Agreement and the transactions contemplated therein, including the Business Combination. The BLAC M&amp;A Committee gave special consideration to the fact that Mr. Hwang, Mr. Whang, and certain affiliates of the Sponsor, have a financial interest in OSR Holdings, as well as the fact that Mr. Hwang is the President, CEO, and a director of both BLAC and OSR Holdings. In making their respective determinations, the BLAC M&amp;A Committee and the BLAC Board weighed the foregoing conflicts of interest against the fact that the Business Combination and the Business Combination Agreement were negotiated at arms-length and the independent BLAC M&amp;A Committee had full control over such negotiations, reducing the conflicted individuals&#8217; respective influence over the Business Combination and the Business Combination Agreement, and the BLAC Board and BLAC M&amp;A Committee ultimately concluded that the potential benefits that it expected BLAC and its stockholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination, including the potentially negative factors associated with the conflicts of interest presented by Mr. Hwang, Mr. Whang, and other affiliates. Accordingly, the board unanimously determined that the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination, were advisable, fair to, and in the best interests of BLAC&#8217;s stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Actions to Secure Requisite Stockholder Approvals </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential Purchases of Public Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the special meeting, during a period when they are not then aware of any material nonpublic information regarding BLAC or BLAC&#8217;s securities, BLAC&#8217;s Sponsor, directors, officers and their respective affiliates may purchase BLAC&#8217;s securities on the open market, and may enter into agreements to purchase shares from institutional and other investors who vote, or indicate an intention to vote, against the Business Combination Proposal, or who have elected or redeem, or indicate an intention to redeem, their shares in connection with the Business Combination. Any such privately negotiated purchases may be effected at purchase prices that are no higher than the redemption price for the shares. Any shares so purchased would not be voted by BLAC&#8217;s Sponsor, directors, officers or their respective affiliates at the special meeting and would not be redeemable by BLAC&#8217;s Sponsor, directors, officers or their respective affiliates. BLAC&#8217;s Sponsor, directors, officers, advisors and their respective affiliates may also enter into transactions with stockholders and others to provide them with incentives to acquire shares of BLAC Common Stock or vote their shares of BLAC Common Stock in favor of the Business Combination Proposal. While the exact nature of such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangements to protect such persons against potential loss in value of their shares, including the granting of put options and the transfer to such persons of shares or warrants for nominal value. BLAC&#8217;s Sponsor, directors, officers or their respective affiliates will not affect any such purchases when they are in possession of any <span style="white-space:nowrap">material&#160;non-public&#160;information</span> relating to BLAC or OSR Holdings, during a restricted period under Regulation M under the Exchange Act or in a transaction which would violate Section&#160;9(a)(2) or <span style="white-space:nowrap">Rule&#160;10(b)-5&#160;under</span> the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of such purchases and other transactions would be to increase the likelihood that the Business Combination Proposal is approved and to decrease the likelihood that holders request redemption of public shares and cause BLAC to be unable to consummate the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If BLAC&#8217;s Sponsor, directors, officers or their respective affiliates effect any purchases of our shares of BLAC Common Stock, such purchases may cause the Business Combination Proposal or any other proposal to be approved in circumstances where such approval could not otherwise be obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, no such agreements to sell or purchase shares prior to the Record Date have been entered into with any such investor or holder. BLAC will file a Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> to disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that are not described in this proxy statement and that would affect the vote on the Business Combination Proposal. See &#8220;<span style="font-style:italic">Risk Factors &#8212; The Sponsor and its affiliates may enter into agreements concerning BLAC&#8217;s securities prior to the BLAC Stockholders&#8217; Meeting, which may have the effect of increasing the likelihood of completion of the Business Combination or decreasing the value of the BLAC Common Stock.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Approvals Required for the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described immediately below, neither of BLAC or OSR Holdings is aware of any material regulatory approvals or actions that are required for completion of the Business Combination. It is presently contemplated that if any regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because BLAC&#8217;s Sponsor is controlled by and has substantial ties with non-U.S. persons, and will own approximately 6.7% of the issued and outstanding BLAC Common Stock following the Business Combination (assuming that all of BLAC&#8217;s public stockholders exercise redemption rights), we may be considered a &#8220;foreign person&#8221; under rules promulgated by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and the Business Combination may fall within the scope of a &#8220;covered transaction&#8221; subject to CFIUS review. See &#8220;Risk Factors &#8212; <span style="font-style:italic">We may not be able to complete an initial business combination with a U.S. target company since such initial business combination may be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;), and ultimately prohibited</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Litigation Relating to the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no proceedings brought against BLAC in relation to the Business Combination or the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing of the Combined Company securities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the listing on Nasdaq of the Combined Company securities to be issued in the Business Combination, subject to official notice of issuance, is a condition to each party&#8217;s obligation to complete the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Accounting Treatment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP and the Accounting Standard Codification (ASC) which is the current single source of U.S. GAAP. Under this method of accounting, BLAC will be treated as the &#8220;acquired&#8221; company and OSR Holdings will be considered the accounting acquirer for accounting purposes as set forth by the guidance in ASC 805-10. This conclusion is supported by the voting interest model referenced in ASC 805-10-55-12 as 67.7% (no redemption), 70.8% (50% redemption) and 74.2% (maximum redemption) of the voting interest scenarios in New OSR Holdings which will be held by the historical shareholder group of OSR Holdings. Further, Bellevue Capital Management LLC (&#8220;BCM&#8221;) and its affiliates are the largest single owner of shares of OSR Holdings, and will also be the largest single owner of shares in the combined company in each of the no redemption, 50% redemption, and maximum redemption scenarios. The stockholders of OSR Holdings will have sufficient voting power to elect or remove a majority of the board of directors of the combined company. The compositions of the governing body and senior management team of the combined entity present a less defined indicator as Kuk Hyoun Hwang is an officer and director of both OSR Holdings and BLAC. No other officers of BLAC will be officers of the combined company. The composition of New OSR Holdings is being negotiated by Kuk Hyoun Hwang who represents both BLAC and OSR Holdings so that it is difficult to conclude that one party controls the appointment of the directors of the combined company. Accordingly, given the supermajority of voting shares to be held by OSR Holdings stockholders in the combined company and the other factors described above, for accounting purposes, the Business Combination will be treated as the equivalent of a capital transaction in which BLAC is issuing securities for the net assets of OSR Holdings. Operations prior to the Business Combination will be those of OSR Holdings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_16">THE BUSINESS COMBINATION AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This section describes the material provisions of the Business Combination Agreement, but does not purport to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its entirety by reference to the complete text of the Business Combination Agreement, a copy of which is attached as Annex A hereto, which is incorporated herein by reference. BLAC&#8217;s stockholders and other interested parties are urged to read the Business Combination Agreement, carefully and in its entirety (and, if appropriate, with the advice of financial and legal counsel) because it is the primary legal document that governs the Business Combination and the Transactions. Certain figures included in this section have been rounded for ease of presentation and, as a result, percentages may not sum to 100%. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of the agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement are also modified in important part by the underlying disclosure schedules which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that these schedules contain information that is material to an investment decision. Additionally, the representations and warranties of the parties to the Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this proxy statement/prospectus. Accordingly, no person should rely on the representations and warranties in the Business Combination Agreement or the summaries thereof in this proxy statement as characterizations of the actual state of facts about BLAC, OSR Holdings or any other matter<span style="font-style:italic">.</span>&#160;Capitalized terms used in this section but not otherwise defined in this proxy statement/prospectus shall have the meaning given to them in the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Structure of the Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;16, 2023, BLAC and OSR Holdings entered into the Business Combination Agreement, which was amended and restated on May 23, 2024. Each holder of OSR Holdings Common Stock that executes a Participating Stockholder Joinder to the Business Combination Agreement on or prior to the Closing (each such Person, a &#8220;Participating Company Stockholder&#8221;), and each holder of OSR Holdings Common Stock that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder on or prior to the Closing (each such Person, a <span style="white-space:nowrap">&#8220;Non-Participating</span> Company Stockholder&#8221;, and together with the Participating Company Stockholders, the &#8220;OSR Holdings Stockholders&#8221;) shall become a party to the Business Combination Agreement. Pursuant to the Business Combination Agreement, (i)&#160;BLAC shall issue such number of shares of BLAC Common Stock (the &#8220;Aggregate Participating Consideration&#8221;) equivalent to the Aggregate Consideration Value of $244,612,136 divided by the aggregate number of outstanding shares of OSR Holdings common stock to the Participating Company Stockholders, and (ii)&#160;the Participating Company Stockholders shall sell, transfer, convey, assign and deliver all of their respective shares of OSR Holdings Common Stock to BLAC (subclauses (i)&#160;and (ii), collectively, the &#8220;Share Exchange&#8221;). Pursuant to such Share Exchange, each share of OSR Holdings Common Stock held by the Participating Company Stockholders immediately prior to the Effective Time shall be exchanged for the Per Share Consideration. Upon consummation of the Share Exchange, BLAC will hold at least 60% of the shares of OSR Holdings Common Stock outstanding on the Closing Date, with the remaining shares of OSR Holdings Common Stock held by the Non-Participating Company Stockholders. Pursuant to the terms of the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders, BLAC will have rights to acquire the shares of the Non-Participating Company Stockholders. The Non-Participating Stockholder Joinder contains put and call rights for the Non-Participating Company Stockholder and BLAC, respectively, whereby the Non-Participating Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholder shall have the right to cause BLAC to purchase (the &#8220;Put Right&#8221;) and BLAC shall have the right to cause the Non-Participating Company Stockholder to sell (the &#8220;Call Right&#8221;) to BLAC or its designee all of the shares of OSR Holdings Common Stock owned and held of record by such Non-Participating Company Stockholder. These rights become exercisable on or after January 1, 2026, or the date that the Non-Participating Company Stockholder is notified by BLAC of a transaction that will result in a change in control (as defined in the Non-Participating Stockholder Joinder) of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, subject to certain conditions set forth therein, in connection with the closing of the transactions contemplated by the Business Combination Agreement (the &#8220;Closing&#8221;, and the time at which the Closing actually occurs, the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Participating Company Stockholders shall transfer and convey all of the shares of OSR Holdings Common Stock held by the Participating Company Stockholders to BLAC, in each case, free and clear of any claims or interest of any person previously entitled thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC shall effect the transfer and conveyance of all of the shares of BLAC Common Stock representing the Aggregate Participating Consideration to the Participating Company Stockholders, in each case, free and clear of any claims or interest of any person previously entitled thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any fractional share of BLAC Common Stock that would otherwise be issuable to a Participating Company Stockholder following such exchange shall be rounded up or down to the nearest whole share of BLAC Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all OSR Holdings Common Stock held by Non-Participating Company Stockholders will not be exchanged for shares of BLAC Common Stock at Closing, and such Company Common Stock will be subject to the terms of the Non-Participating Stockholder Joinder, including the Put Right and Call Right set forth therein. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consideration paid to the OSR Holdings at Closing will be BLAC Common Stock. BLAC will receive OSR Holdings Common Stock in connection with the Share Exchange. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Representation and Warranties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, BLAC made customary representations and warranties relating to, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the organization and qualification of BLAC, including BLAC being duly organized, validly existing and in good standing under applicable laws and having requisite corporate or other organizational power and authority and all necessary governmental approvals to carry on its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the capitalization of BLAC, including the authorized and outstanding capital stock of BLAC, and a representation that there are no undisclosed derivative securities, commitments, agreements or arrangements relating to the issued or unissued capital stock of BLAC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC&#8217;s authority, including BLAC&#8217;s power and authority to perform its obligations under the Business Combination Agreement and to consummate the transactions contemplated thereby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">non-contravention, including a representation that the execution and delivery of the Business Combination Agreement by BLAC does not require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority (except for, if any, exchange act, blue sky law, and similar securities and state law requirements), or (i) conflict with or violate the organizational documents of BLAC, (ii) conflict with or violate any law, (iii) result in any breach of or constitute a default pursuant to any agreement, except with respect to clauses (ii) and (iii), such conflicts or breaches which do not constitute a BLAC Material Adverse Effect; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with laws and material agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SEC reports and financial statements, including with respect to (i) the timely filing of all required forms, reports, schedules, statements and other documents, (ii) compliance with securities laws and applicable listing rules and regulations, and (iii) appropriate disclosure controls and procedures (in each case except as and to the extent set forth in BLAC&#8217;s SEC filings); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of certain changes or events that would constitute a BLAC Material Adverse Effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of litigation, including a representation that there is no action pending or threatened against BLAC before any governmental authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC Board and BLAC M&amp;A Committee approval of the Business Combination Agreement and the transactions contemplated thereby, and the stockholder vote required in connection with the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any broker, finder or investment banker (other than Chardan Capital Markets, LLC) that is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC&#8217;s trust account, including with respect to (i) how the monies in such trust account are invested, (ii) the trust agreement governing such trust account, (iii) compliance with the terms of the trust agreement, and (iv) the general terms of the trust agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employees, including with respect to (i) there being no employees of BLAC, other than those officers described in public filings of BLAC, and (ii) the transactions contemplated by the Business Combination Agreement will not trigger any severance, acceleration, parachute or other similar payments or arrangements to any employees of BLAC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Taxes, including with respect to timely filing and payment of taxes, compliance with relevant tax laws, rules and regulations, and the existence of any tax obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Nasdaq stock market quotation, including with respect to (i) the registration of the BLAC units, BLAC warrants, BLAC rights, and BLAC common stock in accordance with applicable securities laws, and (ii) the absence of any action taken by Nasdaq or BLAC to threaten to delist, or attempt to delist or deregister, the BLAC units, BLAC warrants, BLAC rights, or BLAC common stock (except as and to the extent set forth in BLAC&#8217;s SEC filings); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC&#8217;s investigation and reliance, including with respect to (i) BLAC&#8217;s complete access to information regarding OSR Holdings and its subsidiaries and (ii) BLAC&#8217;s performance of its own independent investigation, review and analysis of OSR Holdings and its subsidiaries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, OSR Holdings made customary representations and warranties regarding itself and its subsidiaries relating to, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the organization and qualification of OSR Holdings and its subsidiaries, including OSR Holdings and its subsidiaries being duly organized, validly existing and in good standing under applicable laws and having requisite corporate or other organizational power and authority and all necessary governmental approvals to carry on their respective businesses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the subsidiaries of OSR Holdings, including a full list of all subsidiaries of OSR Holdings, their respective jurisdictions of organization, and OSR Holdings&#8217; respective ownership in each subsidiary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the capitalization of OSR Holdings, including the authorized and outstanding capital stock of OSR Holdings, and a representation that there are no undisclosed derivative securities, commitments, agreements or arrangements relating to the issued or unissued capital stock of OSR Holdings or any of its subsidiaries; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings&#8217; authority, including OSR Holdings&#8217; power and authority to perform its obligations under the Business Combination Agreement and to consummate the transactions contemplated thereby, including a representation that the board of directors of OSR Holdings has approved the Business Combination Agreement and the transactions contemplated thereby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">non-contravention, including a representation that the execution and delivery of the Business Combination Agreement by OSR Holdings does not require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority, or (i) conflict with or violate the organizational documents of OSR Holdings, (ii) conflict with or violate any law, (iii) result in any breach of or constitute a default pursuant to any material contract, except with respect to clauses (ii) and (iii), such conflicts or breaches which do not constitute a Company Material Adverse Effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">permits and compliance with laws of any governmental authority, including a representation that OSR Holdings and its subsidiaries are in possession of all required permits, except where the failure to have such permits would not reasonably be expected to have a Company Material Adverse Effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial statements, including with respect to the preparation and presentation of such statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of certain changes or events that would constitute a Company Material Adverse Effect or breach of certain covenants contained in the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of litigation, including a representation that there are no actions pending or threatened against OSR Holdings or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee benefits, including the disclosure of all company benefit plans, plan documentation, and liabilities of OSR Holdings related thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">labor and employment matters, including a list of all employees of OSR Holdings and its subsidiaries, and representations regarding compliance with labor and employment laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">validity of leased real property and related assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">intellectual property, including the identification of all of OSR Holdings&#8217; and its subsidiaries&#8217; material intellectual property and their respective sole and exclusive ownership thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">taxes, including with respect to timely filing and payment of taxes, compliance with relevant tax laws, rules and regulations, and the existence of any tax obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">possession of certain required licenses and permits issued by governmental regulatory agencies or bodies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory matters, including compliance with laws under relevant regulatory regimes and the absence of governmental proceedings to which OSR Holdings or any of its subsidiaries is the subject; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">healthcare laws, including compliance with relevant healthcare laws, proper authorization under relevant healthcare laws, and the absence of any proceedings under relevant healthcare laws to which OSR Holdings or any of its subsidiaries is the subject; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">environmental matters, including compliance with relevant environmental laws, the absence of release of hazardous substances, and possession of all required environmental licenses and permits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">material contracts, including a list of all material contracts, and representations that each material contract is a legal, valid and binding obligation of OSR Holdings or its subsidiaries, and OSR Holdings and its subsidiaries are not in breach of, or have received any claim or default under, any material contract; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with all international trade laws and possession of all required export and import licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">insurance, including a list of all insurance policies held by OSR Holdings and its subsidiaries, a representation that each such policy is legal, valid and binding and enforceable in accordance with its terms, and a representation that neither OSR Holdings or any of its subsidiaries is in material breach or default under any such policy; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings&#8217; board approval of the Business Combination Agreement and the transactions contemplated thereby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Compliance with all anti-corruption laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interested party transactions, including disclosure of any interested party transactions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any broker, finder or investment banker that is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Business Combination. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, OSR Holdings Stockholders made customary representations and warranties relating to, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Ownership of OSR Holdings Common Stock, including that each OSR Holdings Stockholder owns each of its or their shares of OSR Holdings Common Stock free and clear of all liens, options, rights of first refusal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the organization, as applicable, and the corporate and individual authority to execute and deliver the Joinders and perform the obligations thereunder and under the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">noncontravention, including that the execution and delivery of the Joinders does not violate organizational documents of any OSR Holdings stockholder, as applicable, or violate any law applicable to such stockholder, and that the execution and delivery by such stockholder does not require any consent, approval authorization or permit of, or filing with or notification to any governmental authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any actions pending or brought by or against any stockholder affecting such stockholders&#8217; ability to consummate the transactions contemplated by the Business Combination Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the absence of any broker, finder or investment banker that is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Business Combination. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">OSR Holdings Material Adverse Effect </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, certain representations and warranties of OSR Holdings are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and warranties has occurred. In addition, it is a condition to the performance of BLAC&#8217;s obligations that no OSR Holdings Material Adverse Effect occurs between signing and closing. Pursuant to the Business Combination Agreement, any event, circumstance, change, development, effect or occurrence (collectively &#8220;Effect&#8221;), individually or in the aggregate with all other Effects, will be deemed to have a &#8220;OSR Holdings Material Adverse Effect&#8221; on the OSR Holdings if, individually or in the aggregate, such Effect (a)&#160;is or would reasonably be expected to be materially adverse to the business, condition (financial or otherwise), assets, liabilities or operations of the OSR Holdings and the OSR Holdings Subsidiaries taken as a whole or (b)&#160;prevents, materially delays or materially impedes the performance by OSR Holdings of its obligations under the Business Combination Agreement or the consummation of the Business Combination or any of the other Transactions; provided, however, that none of the following shall be deemed to constitute, alone or in combination, or be taken into account in the determination of whether, there has been or will be a OSR Holdings Material Adverse Effect: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change or proposed change in or change in the interpretation of any Law (including any <span style="white-space:nowrap">COVID-19</span> Measures) or the Accounting Standards after November 16, 2023 (the date of the initial Business Combination Agreement); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) events or conditions generally affecting the industries or geographic areas in which the OSR Holdings and the OSR Holdings Subsidiaries operate; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any downturn in general economic conditions, including changes in the credit, debt, securities, financial or capital markets (including changes in interest or exchange rates, prices of any security or market index or commodity or any disruption of such markets); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks (including <span style="white-space:nowrap">COVID-19),</span> or any escalation or worsening of any such acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks, or changes in global, national, regional, state or local political or social conditions; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any hurricane, tornado, flood, earthquake, natural disaster, or other acts of God, </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) any actions taken or not taken by OSR Holdings or the OSR Holdings Subsidiaries as required by the Business Combination Agreement or any ancillary agreement thereto; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) any Effect attributable to the announcement or execution, pendency, negotiation or consummation of the Business Combination or any of the other Transactions (including the impact thereof on relationships with customers, suppliers, employees or Governmental Authorities); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) any failure to meet any projections, forecasts, guidance, estimates, milestones, budgets or financial or operating predictions of revenue, earnings, cash flow or cash position, provided that this clause (viii)&#160;shall not prevent a determination that any change, event, or occurrence underlying such failure has resulted in a OSR Holdings Material Adverse Effect; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) any actions taken, or failures to take action, or such other changes or events, in each case, which BLAC has requested or to which it has consented or which actions are contemplated by the Business Combination Agreement; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) any statements or items set forth in the OSR Holdings Disclosure Schedule, except in the cases of clauses (i)&#160;through (iii), to the extent that OSR Holdings and the OSR Holdings Subsidiaries, taken as a whole, are materially and disproportionately affected thereby as compared with other participants in the industries in which OSR Holdings and the OSR Holdings Subsidiaries operate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLAC Material Adverse Effect </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, certain representations and warranties of BLAC are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and warranties has occurred. In addition, it is a condition to the performance of OSR Holdings&#8217; obligations that no BLAC Material Adverse Effect occurs between signing and closing. Pursuant to the Business Combination Agreement, any Effect will be deemed to have a &#8220;BLAC Material Adverse Effect&#8221; on BLAC if, individually or in the aggregate, such Effect (a)&#160;is or would reasonably be expected to be materially adverse to the business, condition (financial or otherwise) or results of operations of BLAC; or (b)&#160;would prevent, materially delay or materially impede the performance by BLAC of its obligations under the Business Combination Agreement or the consummation of the Business Combination or any of the other Transactions; provided, however, that none of the following shall be deemed to constitute, alone or in combination, or be taken into account in the determination of whether, there has been or will be a BLAC Material Adverse Effect: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any change or proposed change in or change in the interpretation of any Law (including any <span style="white-space:nowrap">COVID-19</span> Measures) or GAAP after November 16, 2023 (the date of the initial Business Combination Agreement); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) events or conditions generally affecting the industries or geographic areas in which BLAC operates; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any downturn in general economic conditions, including changes in the credit, debt, securities, financial or capital markets (including changes in interest or exchange rates, prices of any security or market index or commodity or any disruption of such markets); </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks (including <span style="white-space:nowrap">COVID-19)</span> or any escalation or worsening of any such acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks, or changes in global, national, regional, state or local political or social conditions; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any hurricane, tornado, flood, earthquake, natural disaster, or other acts of God; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) any actions taken or not taken by BLAC as required by the Business Combination Agreement or any ancillary agreement thereto; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) any Effect attributable to the announcement or execution, pendency, negotiation or consummation of the Business Combination or any of the other Transaction; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) any actions taken, or failures to take action, or such other changes or events; in each case, which OSR Holdings has requested or to which it has consented or which actions are contemplated by the Business Combination Agreement, except in the cases of clauses (i)&#160;through (iii), to the extent that BLAC is materially and disproportionately affected thereby as compared with other participants in the industry in which BLAC operates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conduct of Business Pending Consummation of the Business Combination; Covenants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conduct of Business by OSR Holdings pending the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings has agreed that, between November 16, 2023 (the date of the initial Business Combination Agreement), and the Effective Time or the earlier termination of the Business Combination Agreement, except as (1)&#160;expressly contemplated by the Business Combination Agreement or any ancillary agreement thereto, or (2)&#160;required by applicable Law (including <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), unless BLAC shall otherwise consent in writing (which consent shall not be unreasonably conditioned, withheld or delayed): </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) OSR Holdings shall, and shall cause the OSR Holdings Subsidiaries to, conduct their business in the ordinary course of business and in a manner consistent with past practice; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) OSR Holdings shall use its commercially reasonable efforts to preserve substantially intact the business organization of OSR Holdings and the OSR Holdings Subsidiaries, to keep available the services of the current officers, key employees and Contingent Workers (as defined in the Business Combination Agreement) of OSR Holdings and the OSR Holdings Subsidiaries and to preserve the current relationships of OSR Holdings and the OSR Holdings Subsidiaries with customers, suppliers and other persons with which OSR Holdings or any OSR Holdings Subsidiary has significant business relations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of amplification and not limitation, except as (1)&#160;expressly contemplated by the Business Combination Agreement or any ancillary agreement thereto, and (2)&#160;required by applicable Law (including <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), OSR Holdings has agreed not to, and has agreed to cause each OSR Holdings Subsidiary not to, between November 16, 2023 (the date of the initial Business Combination Agreement), and the Effective Time or the earlier termination of the Business Combination Agreement, directly or indirectly, do any of the following without the prior written consent of BLAC (which consent shall not be unreasonably conditioned, withheld or delayed): </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) amend or otherwise change its articles of incorporation or equivalent organizational documents; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) issue, sell, pledge, dispose of, grant or encumber, or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, (A)&#160;any shares of any class of capital stock of OSR Holdings or any OSR Holdings Subsidiary, or any options, warrants, convertible securities or other rights of any kind to acquire any shares of such capital stock, or any other ownership interest (including, without limitation, any phantom interest), of OSR </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holdings or any OSR Holdings Subsidiary; or (B)&#160;any material assets of OSR Holdings or any OSR Holdings Subsidiary except in the ordinary course of business and consistent with past practice; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital stock; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of its capital stock, other than redemptions of equity securities from former employees upon the terms set forth in the underlying agreements governing such equity securities; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&#160;(A) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any corporation, partnership, other business organization or any division thereof in an amount in excess of $100,000; or (B)&#160;incur any indebtedness for borrowed money in excess of $100,000 or issue any debt securities or assume, guarantee or endorse, or otherwise become responsible for, the obligations of any person, or make any loans or advances, or intentionally grant any security interest in any of its assets, in each case, except in the ordinary course of business and consistent with past practice; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&#160;(A) grant any increase in the compensation, incentives or benefits payable or to become payable to any current or former director, officer, employee or Contingent Worker of OSR Holdings as of November 16, 2023 (the date of the initial Business Combination Agreement), other than increases in base compensation of employees in the ordinary course of business that do not exceed 20% of base compensation, individually or in the aggregate, and increases required by the terms of a Plan (as defined in the Business Combination Agreement) or applicable Law, (B)&#160;enter into any new, or amend any existing employment or severance or termination agreement with any current or former director, officer, employee or Contingent Worker, (C)&#160;accelerate or commit to accelerate the funding, payment, or vesting of any compensation or benefits to any current or former director, officer, employee or Contingent Worker, or (D)&#160;terminate or hire, or otherwise enter into any employment or consulting agreement or arrangement with, any person whose compensation would exceed, on an annualized basis, $100,000; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) other than as required by Law or pursuant to the terms of an agreement entered into prior to November&#160;16, 2023 (the date of the initial Business Combination Agreement), and reflected on Schedule 3.10(a) of the OSR Holdings Disclosure Schedule or that OSR Holdings is not prohibited from entering into after November 16, 2023 (the date of the initial Business Combination Agreement), grant any severance or termination pay to, any director or officer of OSR Holdings or of any OSR Holdings Subsidiary, other than in the ordinary course of business consistent with past practice; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) adopt, amend, and/or terminate any Plan except as may be required by applicable Law, is necessary in order to consummate the Transactions, or health and welfare plan renewals in the ordinary course of business; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) materially amend other than reasonable and usual amendments in the ordinary course of business, with respect to accounting policies or procedures, other than as required by the Accounting Standards; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) make, change or revoke any material Tax (as defined in the Business Combination Agreement) election, amend a material Tax Return (as defined in the Business Combination Agreement) or settle or compromise any material United States federal, state, local or <span style="white-space:nowrap">non-United</span> States income Tax liability; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) materially amend, or modify or consent to the termination (excluding any expiration in accordance with its terms) of any Material Contract (as defined in the Business Combination Agreement) or amend, waive, modify or consent to the termination (excluding any expiration in accordance with its terms) of the OSR Holdings&#8217; or any OSR Holdings Subsidiary&#8217;s material rights thereunder, in each case in a manner that is adverse to OSR Holdings or any OSR Holdings Subsidiary, taken as a whole, except in the ordinary course of business; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) make any alterations or improvements to the Owned Real Property (as defined in the Business Combination Agreement) or the Leased Real Property (as defined in the Business Combination Agreement), or amend any written or oral agreements affecting the Owned Real Property or the Leased Real Property; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) intentionally permit any material item of Company IP (as defined in the Business Combination Agreement) to lapse or to be abandoned, invalidated, dedicated to the public, or disclaimed, or otherwise become unenforceable or fail to perform or make any applicable filings, recordings or other similar actions or filings, or fail to pay all required fees and taxes required or advisable to maintain and protect its interest in each and every material item of Company IP; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) enter into any formal or informal agreement or otherwise make a binding commitment to do any of the foregoing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conduct of Business by BLAC pending the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly contemplated by the Business Combination Agreement or any ancillary agreement thereto (including entering into the PIPE Subscription Agreements, consummating the PIPE Financing, and as required by applicable Law (including any <span style="white-space:nowrap">COVID-19</span> Measures or as may be requested or compelled by any Governmental Authority), BLAC has agreed that from November 16, 2023 (the date of the initial Business Combination Agreement), until the earlier of the termination of the Business Combination Agreement and the Effective Time, unless OSR Holdings shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), the business of BLAC shall be conducted in the ordinary course of business and in a manner consistent with past practice. By way of amplification and not limitation, except as expressly contemplated by the Business Combination Agreement or any ancillary agreement thereto (including entering into the PIPE Subscription Agreements and consummating the PIPE Financing), or in connection with the terms and conditions of, the PIPE Subscription Agreements, or as required by applicable Law (including any <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), BLAC has agreed not to, between November 16, 2023 (the date of the initial Business Combination Agreement), and the Effective Time or the earlier termination of the Business Combination Agreement, directly or indirectly, do any of the following without the prior written consent of OSR Holdings, which consent shall not be unreasonably withheld, delayed or conditioned: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) amend or otherwise change the BLAC Organizational Documents or form any subsidiary of BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital stock, other than redemptions from the Trust Fund that are required pursuant to the BLAC Organizational Documents; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of the BLAC Common Stock, BLAC Warrants or BLAC Rights except for redemptions from the Trust Fund that are required pursuant to the BLAC Organizational Documents; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) other than pursuant to the PIPE Subscription Agreements, issue, sell, pledge, dispose of, grant or encumber, or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, any shares of any class of capital stock or other securities of BLAC, or any options, warrants, convertible securities or other rights of any kind to acquire any shares of such capital stock, or any other ownership interest (including, without limitation, any phantom interest), of BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any corporation, partnership, other business organization or enter into any strategic joint ventures, partnerships or alliances with any other person; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) engage in any conduct in a new line of business or engage in any commercial activities (other than to consummate the transactions contemplated by the Business Combination Agreement); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) incur any indebtedness for borrowed money or guarantee any such indebtedness of another person or persons, issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of BLAC, as applicable, enter into any &#8220;keep well&#8221; or other agreement to maintain any financial statement condition or enter into any arrangement having the economic effect of any of the foregoing, in each case, except in the ordinary course of business consistent with past practice; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) make any change in any method of financial accounting or financial accounting principles, policies, procedures or practices, except as required by a concurrent amendment in GAAP or applicable Law made subsequent to November 16, 2023 (the date of the initial Business Combination Agreement), as agreed to by its independent accountants; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) make any material Tax election or settle or compromise any material United States federal, state, local or <span style="white-space:nowrap">non-United</span> States income Tax liability, except in the ordinary course consistent with past practice; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) liquidate, dissolve, reorganize or otherwise wind up the business and operations of BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) amend the Trust Agreement or any other agreement related to the Trust Account; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&#160;(A) hire, or otherwise enter into any employment or consulting agreement or arrangement with, any person, (B)&#160;grant any material increase in the compensation of any current or former officer or director, (C)&#160;adopt any benefit plan for the benefit of any current or former officer or director, or (D)&#160;materially amend any existing agreement with any current or former officer or director; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) enter into any formal or informal agreement or otherwise make a binding commitment to do any of the foregoing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Closing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with (i)&#160;the terms and subject to the conditions of the Business Combination Agreement, and (ii)&#160;the consummation of the PIPE Financing, the Closing shall take place at a time to be agreed by BLAC and OSR Holdings on the first date on which all of the conditions described below under the subsection entitled &#8220;Conditions to the Closing&#8221; shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver thereof) or such other time and place as BLAC and OSR Holdings may mutually agree in writing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conditions to Closing the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditions to the Obligations of Each Party </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of OSR Holdings, BLAC and the OSR Holdings Stockholders to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The BLAC Proposals shall have been approved and adopted by the requisite affirmative vote of the stockholders of BLAC in accordance with the Proxy Statement, the DGCL, the BLAC Organizational Documents and the rules and regulations of Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any law, rule, regulation, judgment, decree, executive order, or award which is then in effect and has the effect of making the Transactions, including the Business Combination, illegal or otherwise prohibiting consummation of the Transactions, including the Business Combination; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All required filings under the HSR Act shall have been completed and any applicable waiting period (and any extension thereof) applicable to the consummation of the Transactions under the HSR Act shall have expired or been terminated, and any <span style="white-space:nowrap">pre-Closing</span> approvals or clearances reasonably required thereunder shall have been obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All necessary <span style="white-space:nowrap">pre-Closing</span> consents, approvals and authorizations shall have been obtained from and made with all Governmental Authorities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The shares of BLAC Common Stock shall be listed on Nasdaq as of the Closing Date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditions to the Obligations of BLAC </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of BLAC to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following additional conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The representations and warranties of OSR Holdings contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.01</span> (Organization and Qualification; Subsidiaries), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.03</span> (Capitalization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.04</span> (Authority Relative to this Agreement), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.27</span> (Brokers) in the Business Combination Agreement and the representations and warranties of each OSR Holdings Stockholder in <span style="text-decoration:underline">Article IV</span> of the Business Combination Agreement shall each be true and correct in all material respects as of the Closing Date as though made on the Closing Date (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;OSR Holdings Material Adverse Effect&#8221; or any similar limitation set forth therein), except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date. All other representations and warranties of OSR Holdings contained in the Business Combination Agreement shall be true and correct (without giving any effect to any limitation as to &#8220;materiality&#8221; or &#8220;OSR Holdings Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date, except (i)&#160;to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date and (ii)&#160;where the failure of such representations and warranties to be true and correct (whether as of the Closing Date or such earlier date), taken as a whole, does not result in a OSR Holdings Material Adverse Effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings and each Participating Company Stockholder shall have performed or complied in all material respects with all agreements and covenants required by the Business Combination Agreement to be performed, or complied with by it on or prior to the Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings shall have delivered to BLAC a certificate, dated the date of the Closing, signed by an officer of OSR Holdings, certifying as to the satisfaction of the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(d)</span> of the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No OSR Holdings Material Adverse Effect shall have occurred between November 16, 2023 (the date of the initial Business Combination Agreement), and the Closing Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Other than those persons identified as continuing directors as per <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08</span> of the Business Combination Agreement, all members of the OSR Holdings Board and the Board of Directors of the Company Subsidiaries (as defined in the Business Combination Agreement) shall have executed written resignations effective as of the Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings has delivered, or has caused to be delivered, to BLAC the <span style="white-space:nowrap">Lock-Up</span> Agreements duly executed by such holders of the OSR Holdings Common Stock as agreed between BLAC and OSR Holdings within 60 days from November 16, 2023 (the date of the initial Business Combination Agreement); provided, however, in the event all such holders of the OSR Holdings Common Stock outstanding as of immediately prior to the Effective Time do not execute the <span style="white-space:nowrap">Lock-Up</span> Agreements delivered to BLAC, this condition shall be deemed to be satisfied if (i)&#160;none of such <span style="white-space:nowrap">non-executing</span> stockholders hold OSR Holdings Common Stock in excess of 1% of the OSR Holdings Common Stock </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
outstanding immediately prior to the Effective Time, and (ii)&#160;the aggregate number of shares of OSR Holdings Common Stock held by all <span style="white-space:nowrap">non-executing</span> stockholders is less than 10% of the outstanding OSR Holdings Common Stock immediately prior to the Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings has delivered, or cause to be delivered, to BLAC (i)&#160;Participating Stockholder Joinders duly executed by the Participating Company Stockholders, including Participating Company Stockholders holding at least 60% of the OSR Holdings Fully Diluted Share Amount, (ii)&#160;and <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders executed by the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On or prior to the Closing, OSR Holdings shall deliver to BLAC a properly executed certification that shares of OSR Holdings Common Stock are not &#8220;U.S. real property interests&#8221; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS (which shall be filed by BLAC with the IRS following the Closing) in accordance with the provisions of <span style="white-space:nowrap">Section&#160;1.897-2(h)(2)</span> of the Treasury Regulations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The BLAC M&amp;A Committee shall have received an opinion from an advisor engaged by the BLAC M&amp;A Committee that the Transactions are fair, from a financial point of view, to BLAC and its stockholders. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditions to the Obligations of OSR Holdings and the OSR Holdings Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of OSR Holdings and the OSR Holdings Stockholders to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following additional conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The representations and warranties of BLAC contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.01</span> (Corporation Organization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.03</span> (Capitalization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.04</span> (Authority Relative to this Agreement), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.11</span> (Brokers) of the Business Combination Agreement shall each be true and correct in all material respects as of the Closing Date as though made on the Closing Date (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;BLAC Material Adverse Effect&#8221; or any similar limitation set forth therein), except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date. All other representations and warranties of BLAC contained in the Business Combination Agreement shall be true and correct (without giving any effect to any limitation as to &#8220;materiality&#8221; or &#8220;BLAC Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date, except (i)&#160;to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date and (ii)&#160;where the failure of such representations and warranties to be true and correct (whether as of the Closing Date or such earlier date), taken as a whole, does not result in a BLAC Material Adverse Effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC shall have performed or complied in all material respects with all agreements and covenants required by the Business Combination Agreement to be performed, or complied with, by it on or prior to the Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC shall have delivered to the Company a certificate, dated the date of the Closing, signed by an officer of BLAC, certifying as to the satisfaction of the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(b)</span>, and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(d)</span> of the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">No BLAC Material Adverse Effect shall have occurred between November 16, 2023 (the date of the initial Business Combination Agreement), and the Closing Date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A supplemental listing shall have been filed with Nasdaq as of the Closing Date to list the shares constituting the Aggregate Participating Consideration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BLAC shall have delivered a copy of the <span style="white-space:nowrap">Lock-Up</span> Agreements duly executed by BLAC; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The (i)&#160;amount of cash and cash equivalents available in the Trust Account immediately prior to the Closing, plus (ii)&#160;all other cash and cash equivalents of BLAC, plus (iii)&#160;the aggregate amount of cash proceeds received from the PIPE Financing prior to or substantially concurrently with the Closing (without, for the avoidance of doubt, taking into consideration any transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing), shall be equal to or greater than $5,000,001. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Waiver </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any party to the Business Combination Agreement may, at any time prior to the Closing, by action taken by its board of directors or equivalent governing body, officers thereunto duly authorized, or individually in the case of independent stockholders, waive in writing any of its or their rights or conditions in its or their favor under the Business Combination Agreement. Notwithstanding the foregoing, pursuant to BLAC&#8217;s current certificate of incorporation, BLAC cannot consummate the Business Combination if New OSR Holdings would have less than $5,000,001 of net tangible assets remaining after the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the financial and personal interests of the directors may result in a conflict of interest on the part of one or more of them between what such director may believe is best for BLAC and what such director may believe is best for such director in determining whether or not to grant a waiver in a specific situation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of the Business Combination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be terminated, and the Business Combination and the other Transactions may be abandoned at any time prior to the Effective Time, notwithstanding any requisite approval and adoption of the Business Combination Agreement and the Transactions by the stockholders of OSR Holdings or BLAC, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by mutual written consent of BLAC and OSR Holdings; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either BLAC or OSR Holdings if the Effective Time shall not have occurred prior to November&#160;14, 2024 (the &#8220;<span style="text-decoration:underline">Outside Date</span>&#8221;); provided, however, that the Business Combination Agreement may not be terminated under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(b)</span> thereof by or on behalf of any party that either directly or indirectly through its affiliates is in breach or violation of any representation, warranty, covenant, agreement or obligation contained in the Business Combination Agreement and such breach or violation is the principal cause of the failure of a condition set forth in <span style="text-decoration:underline">Article VIII</span> of the Business Combination Agreement on or prior to the Outside Date; or</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either BLAC or OSR Holdings if any Governmental Authority in the United States or the Republic of Korea shall have enacted, issued, promulgated, enforced, or entered any injunction, order, decree or ruling (whether temporary, preliminary or permanent) which has become final and nonappealable and has the effect of making consummation of the Transactions, including the Business Combination, illegal or otherwise preventing or prohibiting consummation of the Transactions or the Business Combination; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either BLAC or OSR Holdings if any of the BLAC Proposals shall fail to receive the requisite vote for approval at the BLAC Stockholders&#8217; Meeting; or</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by BLAC upon a breach of any representation, warranty, covenant or agreement on the part of OSR Holdings set forth in the Business Combination Agreement, or if any representation or warranty of OSR Holdings shall have become untrue, in either case such that the conditions set forth in <span style="text-decoration:underline">Sections 8.02(a)</span> and <span style="text-decoration:underline">8.02(b)</span> of the Business Combination Agreement would not be satisfied (&#8220;<span style="text-decoration:underline">Terminating OSR Holdings Breach</span>&#8221;); provided that BLAC has not waived such Terminating OSR Holdings Breach and BLAC is not then in material breach of its representations, warranties, covenants or agreements in the Business Combination Agreement; provided further that, if such Terminating Company Breach is curable by OSR Holdings, BLAC may not terminate the Business Combination Agreement under </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(e)</span> of the Business Combination Agreement for so long as OSR Holdings continues to exercise its reasonable efforts to cure such breach, unless such breach is not cured within thirty (30)&#160;days after notice of such breach is provided by BLAC to OSR Holdings; or</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by OSR Holdings upon a breach of any representation, warranty, covenant or agreement on the part of BLAC set forth in the Business Combination Agreement, or if any representation or warranty of BLAC shall have become untrue, in either case such that the conditions set forth in <span style="text-decoration:underline">Sections 8.03(a)</span> and <span style="text-decoration:underline">8.03(b)</span> of the Business Combination Agreement would not be satisfied (&#8220;<span style="text-decoration:underline">Terminating BLAC Breach</span>&#8221;); provided that OSR Holdings has not waived such Terminating BLAC Breach and OSR Holdings is not then in material breach of their representations, warranties, covenants or agreements in the Business Combination Agreement; provided, however, that, if such Terminating BLAC Breach is curable by BLAC, OSR Holdings may not terminate the Business Combination Agreement under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(f)</span> of the Business Combination Agreement for so long as BLAC continues to exercise their reasonable efforts to cure such breach, unless such breach is not cured within thirty (30)&#160;days after notice of such breach is provided by OSR Holdings to BLAC. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect of Termination of the Business Combination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is terminated, the Business Combination Agreement will forthwith become void, and there will be no liability under the Business Combination Agreement on the part of any party thereto, except as set forth in the Business Combination Agreement or in the case of termination subsequent to a willful material breach of the Business Combination Agreement by a party thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment; Waiver and Extension of the Business Combination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be amended in writing by the parties thereto at any time prior to the Effective Time. The Business Combination Agreement may not be amended except by an instrument in writing signed by each of the parties thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the Effective Time, (a)&#160;BLAC may (i)&#160;extend the time for the performance of any obligation or other act of OSR Holdings, (ii)&#160;waive any inaccuracy in the representations and warranties of OSR Holdings contained in the Business Combination Agreement or in any document delivered by OSR Holdings pursuant thereto, and (iii)&#160;waive compliance with any agreement of OSR Holdings or any condition to its own obligations contained in the Business Combination Agreement and (b)&#160;OSR Holdings may (i)&#160;extend the time for the performance of any obligation or other act of BLAC, (ii)&#160;waive any inaccuracy in the representations and warranties of BLAC contained in the Business Combination Agreement or in any document delivered by BLAC pursuant thereto, and (iii)&#160;waive compliance with any agreement of BLAC or any condition to its own obligations contained in the Business Combination Agreement. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the Party or Parties to be bound thereby. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governing Law; Consent to Jurisdiction </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. All Actions arising out of or relating to the Business Combination Agreement shall be heard and determined exclusively in the Court of Chancery of the State of Delaware or, if such court declines to exercise jurisdiction or if subject matter jurisdiction over the matter that is the subject of any such legal action or proceeding is vested exclusively in the U.S. federal courts, the U.S. District Court for the District of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties to the Business Combination Agreement (a)&#160;irrevocably submit to the exclusive jurisdiction of the aforesaid courts for themselves and with respect to their respective properties for the purpose of any Action arising out of or relating to the Business Combination Agreement brought by any party thereto, and (b)&#160;agree not to commence any Action relating thereto except in the courts described above in Delaware, other than Actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described in the Business Combination Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the Business Combination Agreement, all expenses incurred in connection with the Business Combination Agreement and the Transactions shall be paid by the party incurring such expenses, whether or not the Business Combination or any other Transactions are consummated except that BLAC and OSR Holdings will each pay one half of all expenses relating to all SEC and other regulatory filing fees incurred in connection with this proxy Statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board of Directors and Officers of BLAC following the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s board of directors and officers following the Business Combination will include the individuals identified in the section of this proxy statement entitled<span style="font-style:italic">&#160;&#8220;Management Following the Business Combination.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appraisal Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of BLAC stockholders, unit holders, warrant holders or rights holders have appraisal rights in connection with the Business Combination under the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Survival and Indemnification </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the representations, warranties, covenants or agreements in the Business Combination Agreement or in any instrument delivered pursuant to the Business Combination Agreement will survive the Closing and all rights, claims and causes of action (whether in contract or in tort or otherwise, or whether at law or in equity) with respect thereto will terminate at the Closing, other than (i)&#160;such representations and warranties solely to the extent required to enable a party to bring a claim for intentional fraud and (ii)&#160;covenants or agreements which by their terms are required to be performed or complied with in whole or in part following the Closing (which covenants and agreements will survive the Closing in accordance with their respective terms). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Trust Account Waiver </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings and its subsidiaries have agreed to waive any claim they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with BLAC and will not seek recourse against the trust account for any reason whatsoever; provided that the waiver does not apply to funds of BLAC held outside of the trust account or a claim for equitable relief (including a claim for BLAC to specifically perform its obligations under the Business Combination Agreement). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Satisfaction of 80% Test </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a requirement under our governing documents and under Nasdaq&#8217;s Listing Rules that any business we acquire have a fair market value equal to at least 80% of the balance of the funds in the trust account held for the benefit of our public stockholders at the time of the execution of a definitive agreement for an initial business combination. Our board of directors determined that the enterprise value of OSR Holdings equaled or exceeded 80% of the amount held by us in trust for the benefit of our public stockholders (excluding any deferred underwriters fees and taxes payable on the income earned on the trust account). As of November 16, 2023, the date of execution of the initial Business Combination Agreement, the balance of the funds in the trust account was approximately $70 million (excluding up to $2,070,000 of deferred underwriting fees) and 80% thereof represents approximately $56 million. In reaching its conclusion on the 80% asset test, the BLAC Board used as a fair market value the $250,339,610 equity value for OSR Holdings ($187,754,707 assuming holders of 75% of OSR Holdings common stock execute Participating Stockholder Joinders to the initial Business Combination Agreement, the minimum amount required thereunder), which was implied based on the terms of the transactions agreed to by the parties in negotiating the Business Combination Agreement and reflects the equity value of BLAC&#8217;s ownership in OSR Holdings following the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 23, 2024, the Business Combination Agreement was amended to (i) update the Aggregate Consideration Value of OSR Holdings to $244,612,136 and (ii) update the closing conditions to require holders of 60% of OSR Holdings common stock to execute Participating Stockholder Joinders to the Business Combination Agreement. At such time, the balance of the funds in the trust account was approximately $35 million (excluding up to $2,070,000 of deferred underwriting fees) and 80% thereof represents approximately $28 million. In reaching its conclusion on the 80% asset test, the BLAC Board used as a fair market value the $244,612,136 equity value for OSR Holdings ($146,767,281 assuming holders of 60% of OSR Holdings common stock execute Participating Stockholder Joinders to the Amended and Restated Business Combination Agreement, the minimum amount required thereunder), which was implied based on the terms of the transactions agreed to by the parties in negotiating the Amended and Restated Business Combination Agreement and reflects the equity value of BLAC&#8217;s ownership in OSR Holdings following the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board also considered qualitative factors such as OSR Holdings&#8217; business and financial condition and prospects, the experience and commitment of OSR Holdings&#8217; management team, as well as valuations and trading of publicly traded companies in similar and adjacent sectors. For additional information, see <span style="font-style:italic">&#8220;The Business Combination &#8212; The BLAC M&amp;A Committee&#8217;s Reasons for the Approval of the Business Combination &#8212; Comparable Company Analysis</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board determined that the consideration being paid in the Business Combination, which amount was negotiated at arm&#8217;s-length, was fair to, and in the best interests of, BLAC and its stockholders and appropriately reflected OSR Holdings&#8217; value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes that because of the financial skills and background of its directors, it was qualified to conclude that the acquisition of OSR Holdings met the 80% requirement at signing of the Business Combination Agreement on November 16, 2023, and at signing of the Amended and Restated Business Combination Agreement on May 23, 2024. Based on the foregoing, the BLAC Board determined that the fair market value of OSR Holdings was substantially in excess of 80% of the funds in the trust account and that the 80% test was met at signing of the Business Combination Agreement and at signing of the Amended and Restated Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rights of Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is a Delaware corporation governed by the DGCL. The DGCL and the Existing Governing Documents govern your rights as a stockholder. Subject to the approval of our stockholders of the Charter Proposals described in this proxy statement, the Existing Governing Documents will not differ materially from the certificate of incorporation and bylaws of BLAC following the Business Combination. See the section entitled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2 &#8212; The Charter Proposal</span>&#8221; and &#8220;<span style="font-style:italic">Comparison of Corporate Governance and Stockholder Rights</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Name; Headquarters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of BLAC after the Business Combination will be OSR Holdings, Inc. and its headquarters will be located at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Existing Governing Documents, holders of public shares may elect to have their shares redeemed for cash at the applicable redemption price per share calculated in accordance with our Existing Governing Documents. As of [&#9679;], 2024 this would have amounted to approximately $[&#9679;] per public share. If a holder of public shares exercises redemption rights, then such holder will be exchanging its public shares for cash and will no longer own our shares of BLAC Common Stock and will not own shares of BLAC Common Stock following completion of the Business Combination. Such a holder will be entitled to receive cash for its public </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares only if it properly demands redemption and delivers its shares (either physically or electronically) to our transfer agent in accordance with the procedures described in this proxy statement. See the section entitled<span style="font-style:italic">&#160;&#8220;The Special Meeting of BLAC Stockholders &#8212; Redemption Rights and Procedures&#8221;</span><span style="font-style:italic"></span>&#160;for the procedures to be followed if you wish to redeem your shares for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a condition to closing under the Business Combination Agreement that Minimum Available Cash equal or exceed $5,000,001, after giving effect to all demands for redemption from holders of our public shares. Any redemptions by our public stockholders will decrease the funds in the trust account available to us to consummate the Business Combination and related transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, the transactions contemplated by the Business Combination Agreement, including the Business Combination, cannot be completed unless the Business Combination Proposal is adopted by the affirmative vote of a majority of the votes cast by BLAC stockholders present or represented by proxy at the special meeting and entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned on the approval of this Business Combination Proposal as well as the other Condition Precedent Proposals. If the other Condition Precedent Proposals are not approved, this Business Combination Proposal will have no effect, even if approved by our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, our Sponsor, and those who received BLAC Common Stock from the Sponsor, including Mr. Yoo, BLAC&#8217;s Chief Financial Officer, Mr. Jin Whan Park, a current director of BLAC, and Dr. Steven Reed, Dr. In Chul Chung, Dr. Radclyffe Roberts, and Mr. Hosun Euh, former directors of BLAC, have agreed to vote those shares in favor of the Business Combination. Those shares of Common Stock referred to in the prior sentence constitute, collectively, approximately 53.3% of the issued and outstanding shares of common stock of BLAC as of&#160;[&#9679;], 2024. Accordingly, BLAC does not need the affirmative vote of any of the shares of common stock held by public stockholders to approve the Business Combination. Each of Dr. Reed, Dr. Roberts, Dr. Chung, Mr. Euh, Mr. Park and Mr. Yoo obtained their shares in exchange for their services provided as executive officers or directors of BLAC and were not provided with any other consideration for their agreement to vote their shares in favor of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE &#8220;FOR&#8221; THE BUSINESS COMBINATION PROPOSAL.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_17">CERTAIN AGREEMENTS RELATED TO THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up&#160;Agreements</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Closing, BLAC and certain stockholders of OSR Holdings will enter into <span style="white-space:nowrap">Lock-Up&#160;Agreements</span> providing for certain restrictions on transfer applicable to BLAC Common Stock, which shall exclude 30% of the shares of BLAC Common Stock held by such stockholders. Generally, the <span style="white-space:nowrap">Lock-Up</span> Agreement prohibits stockholders from (i)&#160;selling, offering to sell, contracting or agreeing to sell, hypothecating, pledging, granting any option to purchase or otherwise disposing of or agreeing to dispose of, directly or indirectly, or establishing or increasing a put equivalent position or liquidating or decreasing a call equivalent position within the meaning of Section&#160;16 of the Exchange Act, and the rules and regulations of the SEC promulgated thereunder with respect to the <span style="white-space:nowrap">Lock-Up</span> Shares, (ii)&#160;entering into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of <span style="white-space:nowrap">the&#160;Lock-Up&#160;Shares,</span> whether any such transaction is to be settled by delivery <span style="white-space:nowrap">of&#160;Lock-Up&#160;Shares</span> or other securities, in cash or otherwise, or (iii)&#160;publicly announcing any intention to effect any transaction specified in the immediately preceding subsections (i)&#160;or (ii), subject to certain limited exceptions set forth in <span style="white-space:nowrap">the&#160;Lock-Up&#160;Agreement.</span> <span style="white-space:nowrap">The&#160;lock-up&#160;period</span> <span style="white-space:nowrap">under&#160;Lock-Up&#160;Agreement</span> lasts until December&#160;31, 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PIPE Subscription Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is actively pursuing entering into one or more subscription agreements (collectively, the &#8220;Subscription Agreements&#8221;) with certain institutional and accredited investors (collectively, the &#8220;PIPE Investors&#8221;) pursuant to which the PIPE Investors will agree to purchase, prior to or substantially concurrently with the closing of the Business Combination, equity, or debt or preferred securities issuable by BLAC and/or OSR Holdings convertible into BLAC Common Stock, for aggregate gross proceeds of at least $20,000,000 (the &#8220;PIPE Financing&#8221;). The securities to be issued to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act and/or Regulation S adopted thereunder. BLAC has obtained a letter of intent from Toonon Partners Co., Ltd. (&#8220;Toonon&#8221;), a Korean investment firm, dated June 24, 2024, pursuant to which Toonon indicated its interest to purchase $20,000,000 of BLAC&#8217;s equity securities in connection with the closing of the Business Combination. The terms of the proposed transaction are under current negotiation and, assuming all terms are finalized, will be set forth in a definitive agreement to be executed between BLAC and Toonon. The PIPE Financing, if completed, will dilute the ownership of existing BLAC stockholders, and may depress the value of shares of New OSR Holdings Common Stock. It is not currently anticipated that Sponsor or any BLAC or OSR Holdings affiliates will participate in the PIPE Financing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal income tax consequences (i)&#160;of the exercise of redemption rights by U.S. Holders and <span style="white-space:nowrap">Non-U.S.</span> Holders (each, as defined below) of BLAC Common Stock, (ii)&#160;of the Business Combination for U.S. Holders and <span style="white-space:nowrap">Non-U.S.</span> Holders of OSR Holdings Common Stock, and (iii)&#160;following the Business Combination, of the ownership and disposition of BLAC Common Stock received in the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a holder as a result of the Business Combination or as a result of the ownership and disposition of Common Stock. In addition, this discussion does not address all aspects of U.S. federal income taxation that may be relevant to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal 3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the income tax, nor does it address any tax consequences arising under any tax laws other than the U.S. federal income tax law, such as gift or estate tax laws, U.S. state and local, or <span style="white-space:nowrap">non-U.S.</span> tax laws or, except as discussed herein, any tax reporting obligations of a holder of BLAC Common Stock or OSR Holdings Common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS regarding the U.S. federal income tax consequences of the Business Combination or any other related matter; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold BLAC Common Stock and OSR Holdings Common Stock, as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the U.S. tax laws, such as, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, or insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">traders in securities who elect to apply a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts and regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts, or other <span style="white-space:nowrap">tax-</span> deferred accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subchapter S corporations, partnerships or other pass-through entities or investors in such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">grantor trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. persons whose &#8220;functional currency&#8221; is not the U.S. dollar; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who received BLAC Common Stock or OSR Holdings Common Stock through the issuance of restricted stock under an incentive plan or through a <span style="white-space:nowrap">tax-qualified</span> retirement plan or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding BLAC Common Stock or OSR Holdings Common Stock, or, after the Business Combination, the issued BLAC Common Stock (excluding treasury shares); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">holders holding BLAC Common Stock or OSR Holdings Common Stock, as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to which there are one or more United States stockholders within the meaning of Treasury Regulation <span style="white-space:nowrap">Section&#160;1.367(b)-3(b)(1)(ii);</span> or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Sponsor or its affiliates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this proxy statement/prospectus, the term &#8220;<span style="text-decoration:underline">U.S. Holder</span>&#8221; means a beneficial owner of BLAC Common Stock or OSR Holdings Common Stock that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States or any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (i)&#160;if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Non-U.S.</span> Holder</span>&#8221; means a beneficial owner of BLAC Common Stock or OSR Holdings Common Stock that is, for U.S. federal income tax purposes, an individual, corporation, estate or trust that is not a U.S. Holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes, holds BLAC Common Stock or OSR Holdings Common Stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partner and the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the exercise of redemption rights, the Business Combination, and the subsequent ownership and disposition of BLAC Common Stock received in the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE EXERCISE OF REDEMPTION RIGHTS, THE BUSINESS COMBINATION OR THE OWNERSHIP AND DISPOSITION OF BLAC COMMON STOCK. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF BLAC COMMON STOCK AND OSR HOLDINGS COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF BLAC COMMON STOCK OR OSR HOLDINGS COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-weight:bold">BUSINESS COMBINATION, AND OF THE OWNERSHIP AND DISPOSITION OF BLAC COMMON STOCK AFTER THE BUSINESS COMBINATION, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences to U.S. Holders of BLAC Common Stock Exercising Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a U.S. Holder elects to redeem its BLAC Common Stock for cash, the treatment of the transaction for U.S. federal income tax purposes will depend on whether the redemption qualifies as a sale or exchange of the Common Stock under Section&#160;302 of the Code or is treated as a distribution under Section&#160;301 of the Code with respect to the U.S. Holder. If the redemption qualifies as a sale or exchange of the BLAC Common Stock, the U.S. Holder will be treated as recognizing capital gain or loss equal to the difference between the amount realized on the redemption and such U.S. Holder&#8217;s adjusted tax basis in the BLAC Common Stock surrendered in such redemption transaction. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the BLAC Common Stock redeemed exceeds one year. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders will be eligible to be taxed at reduced rates. However, it is unclear whether the redemption rights with respect to the Common Stock may prevent a U.S. Holder from satisfying the applicable holding period requirement. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you redeem your common stock and receive cash as described in &#8220;&#8221;The Special Meeting of BLAC Stockholders &#8212; Redemption Rights and Procedures,&#8221; the redemption generally will be treated as a sale of common stock described in the preceding paragraph (rather than as a dividend or distribution). The redemption will, however, be treated as a dividend or distribution and taxed as described in &#8220;&#8212; U.S. Federal Income Tax Consequences to U.S. Holders of Ownership and Disposition of BLAC Common Stock after the Business Combination &#8212; Distributions on BLAC Common Stock&#8221; above if your percentage ownership in us (including shares that you are deemed to own under certain attribution rules, such as the shares into which the warrants are exercisable) after the redemption is not meaningfully reduced from what your percentage ownership was prior to the redemption. If you have a relatively minimal stock interest and, taking into account the effect of redemption by other stockholders, your percentage ownership in us is reduced as a result of the redemption, you may be regarded as having suffered a meaningful reduction in interest. For example, the IRS has ruled that any reduction in the stockholder&#8217;s proportionate interest constituted a &#8220;meaningful reduction&#8221; in a transaction in which a holder held less than 1% of the shares of a corporation and did not have management control over the corporation. You should consult your own tax advisor as to whether redemption of your common stock will be treated as a sale or as a dividend under the Code and, if you actually or constructively own 5% (or, if our stock is not then publicly traded, 1%) or more of our common stock before redemption, whether you are subject to special reporting requirements with respect to such redemption. All U.S. Holders are urged to consult their tax advisors as to the tax consequences to them of a redemption of all or a portion of their Common Stock pursuant to an exercise of redemption rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercise or Expiration of Rights and Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion of rights into common stock should not be treated as a taxable transaction to a holder. Common stock received on such a conversion should have a tax basis equal to the tax basis of the rights converted. The holding period of such common stock should generally be tacked with the holding period of the rights from which they are converted. (It is not clear how the holding period of common stock received as the result of the conversion of rights with different holding periods will be treated.) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a right should be allowed a loss on the expiration of the right equal to the tax basis of such holder in such right. Such loss should be treated as a capital gain or loss to a holder in most cases. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the sale or other disposition of a warrant (other than by exercise), you will generally recognize capital gain or loss equal to the difference between the amount realized on the sale or other disposition and your tax basis in the warrant. This capital gain or loss will be long-term capital gain or loss if, at the time of the sale or other disposition, the warrant has been held by you for more than one year. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, you will not be required to recognize income, gain or loss upon exercise of a warrant for its exercise price. Your basis in a share of common stock received upon exercise will be equal to the sum of (1)&#160;your basis in the warrant and (2)&#160;the exercise price of the warrant. Your holding period in the shares received upon exercise will commence on the day after you exercise the warrants. Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we intend to take the position that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a <span style="white-space:nowrap">tax-free</span> recapitalization. In the former case, the holding period of the common stock should commence on the day after the warrant is exercised. In the latter case, the holding period of the common stock would include the holding period of the exercised warrants. However, our position is not binding on the IRS and the IRS may treat a cashless exercise of a warrant as a taxable exchange. You are urged to consult your own tax advisor as to the consequences of an exercise of a warrant on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a warrant expires without being exercised, you will recognize a capital loss in an amount equal to your basis in the warrant. Such loss will be long-term capital loss if, at the time of the expiration, the warrant has been held by you for more than one year. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences of the Business Combination to U.S. Holders of OSR Holdings Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion, <span style="font-style:italic"><span style="white-space:nowrap">&#8220;-U.S.</span> Federal Income Tax Consequences of the Business Combination to U.S. Holders of OSR Holdings Common Stock&#8221;</span> constitutes the opinion of K&amp;L Gates LLP as to the material U.S. federal income tax consequences of the Business Combination to U.S. Holders of OSR Holdings Common Stock, subject to the limitations, exceptions, beliefs, assumptions, and qualifications as set forth herein and in the opinion filed as Exhibit 8.1 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of the Share Exchange to U.S. Holders of OSR Holdings Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">In General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Share Exchange will constitute a taxable transaction to holders of OSR Holdings Common Stock and will not qualify as a <span style="white-space:nowrap">tax-free</span> &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code for U.S. federal income tax purposes. Accordingly, the OSR Holdings Stockholders will be treated as if they sold their OSR Holdings Common Stock in a fully taxable transaction. Each OSR Holdings Stockholder will recognize gain or loss with respect to the disposition of each of its shares of OSR Holdings Common Stock equal to the difference between (i)&#160;the OSR Holdings Stockholder&#8217;s basis in each such share of OSR Holdings Common Stock and (ii)&#160;the fair market value of the Parent Common Stock received in the Merger, determined as of the date such stock is received. Such gain or loss would be treated as capital gain or capital loss, and would be treated as long-term capital gain or loss if the OSR Holdings Common Stock has been held for more than one year as of the date of the Business Combination. A Company Stockholder&#8217;s aggregate tax basis in the Parent Common Stock so received would equal its fair market value as of the date such stock is received, and an Company Stockholder&#8217;s holding period for such Parent Common Stock would begin the day after such stock is received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings Stockholders should consult with their tax advisors regarding the tax consequences of the Share Exchange. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences to U.S. Holders of Ownership and Disposition of BLAC Common Stock after the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distributions on BLAC Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gross amount of any distribution on shares of BLAC Common Stock that is made from BLAC&#8217;s current or accumulated profits (as determined for U.S. federal income tax purposes) will generally be taxable to a U.S. Holder as ordinary dividend income on the date such distribution is actually or constructively received by such U.S. Holder. Any such dividends paid to corporate U.S. Holders generally will qualify for a dividends received deduction (pursuant to which a portion of the dividend may be deducted) if the requisite holding period is satisfied. Subject to applicable requirements and limitations, dividends paid to a <span style="white-space:nowrap">non-corporate</span> U.S. Holder generally will constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-corporate</span> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4) of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the amount of any distribution made by the BLAC on the BLAC Common Stock exceeds the BLAC&#8217;s current and accumulated earnings and profits for a taxable year (as determined under U.S. federal income tax principles), the distribution will first be treated as a <span style="white-space:nowrap">tax-free</span> return of capital, causing a reduction (but not below zero) in the adjusted basis of the U.S. Holder&#8217;s shares of BLAC Common Stock, and to the extent the amount of the distribution exceeds the U.S. Holder&#8217;s tax basis, the excess will be taxed as capital gain recognized on a sale or exchange as described below under &#8220;<span style="font-style:italic">- Sale, Exchange, Redemption or Other Taxable Disposition of Shares of BLAC Common Stock</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sale, Exchange, Redemption or Other Taxable Disposition of Shares of BLAC Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange, or other taxable disposition of the BLAC Common Stock. Any such gain or loss will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the BLAC Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (i)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&#160;the U.S. Holder&#8217;s adjusted tax basis in its BLAC Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its shares of BLAC Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such shares (or, in the case of BLAC Common Stock received upon exercise of a warrant, the U.S. Holder&#8217;s initial basis for such BLAC Common Stock, as discussed below), less any prior distributions treated as a return of capital. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the BLAC Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences to <span style="white-space:nowrap">Non-U.S.</span> Holders of BLAC Common Stock Exercising Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The characterization for U.S. federal income tax purposes of the redemption of a <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s Common Stock as a sale or exchange under Section&#160;302 of the Code or a distribution under Section&#160;301 of the Code with respect to shares of Common Stock will generally will correspond to the U.S. federal income tax characterization of such a redemption of a U.S. Holder&#8217;s Common Stock, as described above, and the corresponding consequences will be as described below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; <span style="white-space:nowrap">Non-U.S.</span> Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any gain realized by a <span style="white-space:nowrap">Non-U.S.</span> Holder on the redemption of Common Stock that is treated as a sale or exchange under Section&#160;302 of the Code generally will not be subject to U.S. federal income tax unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with a trade or business of the <span style="white-space:nowrap">Non-U.S.</span> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a United States permanent establishment or fixed base of the <span style="white-space:nowrap">Non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">Non-U.S.</span> Holder is an individual who is present in the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition, and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period for such Common Stock redeemed, and either (A)&#160;shares of Common Stock are not considered to be regularly traded on an established securities market or (B)&#160;such <span style="white-space:nowrap">Non-U.S.</span> Holder has owned or is deemed to have owned, at any time during the shorter of the five-year period preceding such disposition and such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period more than 5% of the outstanding shares of Common Stock. There can be no assurance that shares of Common Stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">non-corporate</span> <span style="white-space:nowrap">Non-U.S.</span> Holder described in the first bullet point immediately above will be subject to tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates. An individual <span style="white-space:nowrap">Non-U.S.</span> Holder described in the second bullet point immediately above will be subject to a flat 30% tax on the gain derived from the sale, which may be offset by certain United States source capital losses, even though the individual is not considered a resident of the United States, provided that the individual has timely filed U.S. federal income tax returns with respect to such losses. If a <span style="white-space:nowrap">Non-U.S.</span> Holder that is a corporation falls under the first bullet point immediately above, it will be subject to tax on its net gain in the same manner as if it were a United States person as defined under the Code and, in addition, may be subject to the branch profits tax equal to 30% (or such lower rate as may be specified by an applicable income tax treaty) of its effectively connected earnings and profits, subject to adjustments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the last bullet point immediately above applies to a <span style="white-space:nowrap">Non-U.S.</span> Holder, gain recognized by such <span style="white-space:nowrap">Non-U.S.</span> Holder on the redemption of Common Stock generally will be subject to tax at generally applicable U.S. federal income tax rates. In addition, we may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such redemption. We would generally be classified as a &#8220;U.S. real property holding corporation&#8221; if the fair market value of our &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests and our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. However, we believe that we are not and have not been at any time since our formation a U.S. real property holding corporation and we do not expect to be a U.S. real property holding corporation immediately after the Business Combination is completed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Treated as Corporate Distribution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any redemption treated as a corporate distribution under Section&#160;301 of the Code, provided such dividends are not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States, BLAC will be required to withhold U.S. tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E).</span></span> Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of the Common Stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This withholding tax does not apply to dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> Holder who provides a Form <span style="white-space:nowrap">W-8ECI,</span> certifying that the dividends are effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. income tax as if the <span style="white-space:nowrap">Non-U.S.</span> Holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A <span style="white-space:nowrap">Non-U.S.</span> corporation receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a rate of 30% (or a lower treaty rate).<span style="font-style:italic"> </span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sale, Other Disposition, Exercise or Expiration of Rights and Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion of Rights into common stock by a <span style="white-space:nowrap">Non-U.S.</span> Holder should not be treated as a taxable transaction to such <span style="white-space:nowrap">Non-U.S.</span> Holder. Common stock received on such a conversion should have a tax basis equal to the tax basis of the rights converted. The holding period of such common stock should generally be tacked with the holding period of the rights from which they are converted. (It is not clear how the holding period of common stock received as the result of the conversion of rights with different holding periods will be treated.) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder that owns a Right that expires should not be allowed a taxable loss for U.S. federal income tax purposes unless the loss is deemed effectively connected with a U.S. trade or business. Such loss should be treated as a capital gain or loss to a holder in most cases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the sale or other disposition of a Right or Warrant (other than by exercise), a <span style="white-space:nowrap">Non-U.S.</span> Holder will generally recognize capital gain or loss equal to the difference between the amount realized on the sale or other disposition and such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s tax basis in the Right or Warrant. Any such gain should not be subject to U.S. federal income tax except in the circumstances described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; <span style="white-space:nowrap">Non-U.S.</span> Holders</span>&#8221; above. The rules applicable to such gain in the event it is taxable are the same as those described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; <span style="white-space:nowrap">Non-U.S.</span> Holders</span>&#8221; above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, you will not be required to recognize income, gain or loss upon exercise of a Warrant for its exercise price. Your basis in a share of Common Stock received upon exercise will be equal to the sum of (1)&#160;your basis in the Warrant and (2)&#160;the exercise price of the Warrant. Your holding period in the Common Stock received upon exercise will commence on the day after you exercise the Warrants. Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a Warrant on a cashless basis, we intend to take the position that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a <span style="white-space:nowrap">tax-free</span> recapitalization. In the former case, the holding period of the Common Stock should commence on the day after the warrant is exercised. In the latter case, the holding period of the common stock would include the holding period of the exercised Warrants. However, our position is not binding on the IRS and the IRS may treat a cashless exercise of a warrant as a taxable exchange. You are urged to consult your own tax advisor as to the consequences of an exercise of a warrant on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder that owns a Right that expires should not be allowed a taxable loss for U.S. federal income tax purposes unless the loss is deemed effectively connected with a U.S. trade or business. Such loss should be treated as a capital gain or loss to a holder in most cases. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences of the Business Combination to <span style="white-space:nowrap">Non-U.S.</span> Holders of OSR Holdings Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion, <span style="font-style:italic"><span style="white-space:nowrap">&#8220;-U.S.</span> Federal Income Tax Consequences of the Business Combination to U.S. Holders of OSR Holdings Common Stock&#8221;</span> constitutes the opinion of K&amp;L Gates LLP as to the material U.S. federal income tax consequences of the Merger to U.S. Holders of OSR Holdings Common Stock, subject to the limitations, exceptions, beliefs, assumptions, and qualifications as set forth herein and in the opinion filed as Exhibit&#160;8.1 hereto. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of the Share Exchange to <span style="white-space:nowrap">Non-U.S.</span> Holders of OSR Holdings Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">In General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Share Exchange will constitute a taxable transaction to holders of OSR Holdings Common Stock and will not qualify as a <span style="white-space:nowrap">tax-free</span> &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code for U.S. federal income tax purposes. Accordingly, the OSR Holdings Stockholders that are <span style="white-space:nowrap">Non-U.S.</span> Holders will be treated as if they sold their OSR Holdings Common Stock in a fully taxable transaction. Each such <span style="white-space:nowrap">Non-U.S.</span> Holder will generally will not be subject to U.S. federal income tax of OSR Holdings Common Stock except in the circumstance described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange</span>&#8221; above. The rules applicable to such gain in the event it is taxable are the same as those described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange</span>&#8221; above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Income Tax Consequences to <span style="white-space:nowrap">Non-U.S.</span> Holders of Ownership and Disposition of BLAC Common Stock after the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distributions on BLAC Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions of cash or property to a <span style="white-space:nowrap">Non-U.S.</span> Holder in respect of BLAC Common Stock will generally constitute dividends for U.S. federal income tax purposes to the extent paid from BLAC&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds BLAC&#8217;s current and accumulated earnings and profits, the excess will generally be treated first as a <span style="white-space:nowrap">tax-free</span> return of capital to the extent of the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in the BLAC Common Stock. Any remaining excess will be treated as capital gain and will be treated as described below under &#8220;-<span style="font-style:italic">Sale, Exchange, Redemption or Other Taxable Disposition of BLAC Common Stock.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> Holder of BLAC Common Stock generally will be subject to withholding of U.S. federal income tax at a 30% rate, unless such <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate as described below. However, dividends that are effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> Holder within the United States (and, if required by an applicable income tax treaty, are attributable to a U.S. permanent establishment or fixed base of the <span style="white-space:nowrap">Non-U.S.</span> Holder) are not subject to such withholding tax, provided certain certification and disclosure requirements are satisfied (generally by providing an IRS FormW-8ECI). Instead, such dividends are subject to United States federal income tax on a net income basis in the same manner as if the <span style="white-space:nowrap">Non-U.S.</span> Holder were a United States person as defined under the Code. Any such effectively connected dividends received by a foreign corporation may be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder of BLAC Common Stock who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends will be required (a)&#160;to complete the applicable IRS <span style="white-space:nowrap">FormW-8</span> and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits or (b)&#160;if the shares of BLAC Common Stock are held through certain foreign intermediaries, to satisfy the relevant certification requirements of applicable United States Treasury Regulations. Special certification and other requirements apply to certain <span style="white-space:nowrap">Non-U.S.</span> Holders that are pass-through entities rather than corporations or individuals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder of BLAC Common Stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their own tax advisors regarding their entitlement to the benefits under any applicable income tax treaty. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sale, Exchange, Redemption or Other Taxable Disposition of BLAC Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a <span style="white-space:nowrap">Non-U.S.</span> Holder will not be subject to U.S. federal income or, subject to the discussion below under the headings &#8220;Information Reporting and Backup Withholding&#8221; and &#8220;Foreign Account Tax Compliance,&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding tax on any gain realized upon the sale or other disposition of shares of BLAC Common Stock u except in the circumstances described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; <span style="white-space:nowrap">Non-U.S.</span> Holders</span>&#8221; above. The rules applicable to such gain in the event it is taxable are the same as those described under the heading &#8220;<span style="font-style:italic">Redemption Treated as Sale or Exchange &#8211; <span style="white-space:nowrap">Non-U.S.</span> Holders</span>&#8221; above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain that is effectively connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax, net of certain deductions, at regular U.S. federal income tax rates. If the <span style="white-space:nowrap">Non-U.S.</span> Holder is a foreign corporation, the branch profits tax described above also may apply to such effectively connected gain. An individual <span style="white-space:nowrap">Non-U.S.</span> Holder who is subject to U.S. federal income tax because the <span style="white-space:nowrap">Non-U.S.</span> Holder was present in the United States for 183 days or more during the year of sale or other disposition of our securities will generally be subject to a flat 30% tax on the gain derived from such sale or other disposition, which may be offset by U.S. source capital losses, provided the <span style="white-space:nowrap">Non-U.S.</span> Holder has timely filed U.S. federal income tax returns with respect to such losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information Reporting and Backup Withholding </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC must report annually to the IRS and to each holder the amount of cash dividends (including constructive dividends) paid to and the tax withheld with respect to each holder. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable tax treaty. In the case of a <span style="white-space:nowrap">Non-U.S.</span> Holder, copies of this information also may be made available under the provisions of a specific treaty or agreement with the tax authorities in the country in which the <span style="white-space:nowrap">Non-U.S.</span> Holder resides or is established U.S. backup withholding tax (currently, at a rate of 24%) is imposed on certain payments to U.S. Holders that fail to furnish the information required under the U.S. information reporting rules. Dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> Holder generally will be exempt from backup withholding if the <span style="white-space:nowrap">Non-U.S.</span> Holder provides a properly executed IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> or otherwise establishes an exemption and establishes such exempt status. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. or <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s U.S. federal income tax liability, and a holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information. Holders should consult their tax advisors regarding the application of the backup withholding and the availability of and procedures for obtaining an exemption from backup withholding in their particular circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Account Tax Compliance Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (b)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which BLAC securities are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, BLAC securities held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners&#8221;, which will in turn be provided to the U.S. Department of Treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THE FOREGOING DISCUSSION IS NOT A COMPREHENSIVE DISCUSSION OF ALL OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF BLAC COMMON STOCK, RIGHTS AND WARRANTS AND OSR HOLDINGS COMMON STOCK. SUCH HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS TO DETERMINE THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGER, INCLUDI</span>NG THE A<span style="font-weight:bold">PPLICABILITY AND EFFECT OF ANY OTHER TAX LAWS, INCLUDING BUT NOT LIMITED TO, U.S. FEDERAL ESTATE AND GIFT TAX LAWS, ANY U.S. STATE OR LOCAL OR <span style="white-space:nowrap">NON-U.S.</span> TAX LAWS AND TAX TREATIES (AND ANY POTENTIAL FUTURE CHANGES THERETO).</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_19">PROPOSAL NO. 1 &#8212; THE BUSINESS COMBINATION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is asking its stockholders to approve and adopt the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination. BLAC&#8217;s stockholders should read carefully this proxy statement/prospectus in its entirety, including the sections above entitled &#8220;<span style="font-style:italic">The Business Combination</span>&#8221; and &#8220;<span style="font-style:italic">The Business Combination Agreement,</span>&#8221; for more detailed information concerning the Business Combination and the Business Combination Agreement. BLAC also urges our stockholders to read carefully the Business Combination Agreement in its entirety before voting on this proposal. A copy of the Business Combination Agreement is attached as Annex A to this proxy statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal requires the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the special meeting. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, the transactions contemplated by the Business Combination Agreement, including the Business Combination, cannot be completed unless the Business Combination Proposal is adopted by the affirmative vote of a majority of the votes cast by BLAC stockholders present or represented by proxy at the special meeting and entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned on the approval of this Business Combination Proposal as well as the other Condition Precedent Proposals. If the other Condition Precedent Proposals are not approved, this Business Combination Proposal will have no effect, even if approved by our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, BLAC&#8217;s Sponsor, and those who received BLAC Common Stock from the Sponsor, including Mr. Yoo, BLAC&#8217;s Chief Financial Officer, Mr. Jin Whan Park, a current director of BLAC, and Dr. Steven Reed, Dr. In Chul Chung, Dr. Radclyffe Roberts, and Mr. Hosun Euh, former directors of BLAC, have agreed to vote those shares in favor of the Business Combination. Those shares of Common Stock referred to in the prior sentence constitute, collectively, approximately 53.3% of the issued and outstanding shares of common stock of BLAC as of&#160;[&#9679;], 2024. Accordingly, BLAC does not need the affirmative vote of any of the shares of common stock held by public stockholders to approve the Business Combination. Each of Dr. Reed, Dr. Roberts, Dr. Chung, Mr. Euh, Mr. Park and Mr. Yoo obtained their shares in exchange for their services provided as executive officers or directors of BLAC and were not provided with any other consideration for their agreement to vote their shares in favor of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLAC&#8217;s BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT BLAC&#8217;s STOCKHOLDERS VOTE &#8220;FOR&#8221; THE BUSINESS COMBINATION PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_20">PROPOSAL NO. 2 &#8212; THE CHARTER PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s stockholders are being asked to consider and vote upon and to approve the Charter Proposal in connection with the replacement of the Current Charter with the Amended Charter. If the Businesses Combination Proposal is not approved, the Charter Proposal will have no effect, even if approved by holders of shares of BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary sets forth the key changes to be effected by the Amended Charter and is qualified by reference to the complete text of the Amended Charter, a copy of which is attached to this proxy statement/prospectus as Annex E. All stockholders are encouraged to read the Amended Charter in its entirety for a more complete description of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons for the Amendments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC stockholders are being asked to adopt the Amended Charter in the form attached hereto as&#160;<span style="text-decoration:underline">Annex E,</span> to this proxy statement/prospectus, which, in the judgment of the BLAC Board, is necessary to adequately address the needs of New OSR Holdings following the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a summary of the key differences between the Existing Governing Documents and the Proposed Governing Documents under the DGCL, please see &#8220;<span style="font-style:italic">Comparison of Corporate Governance and Stockholder Rights</span>.&#8221; The summary is qualified in its entirety by reference to the full text of the Amended Charter, a copy of which is included as&#160;Annex E&#160;to this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter Proposal require the approval of the affirmative vote of the holders of a majority of the shares of BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on the proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resolution to be Voted Upon </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the resolution to be passed is as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">RESOLVED</span><span style="font-weight:bold"></span>&#160;that the Second Amended and Restated Certificate of Incorporation of BLAC in the form attached to the proxy statement/prospectus be adopted.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the BLAC Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE BLAC BOARD UNANIMOUSLY RECOMMENDS THAT BLAC STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE CHARTER PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_21">PROPOSALS NO. 3A &#8212; 3F &#8212; THE ADVISORY GOVERNANCE PROPOSALS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s stockholders are being asked to consider and vote on six separate proposals with respect to certain governance provisions in the Amended Charter and Amended Bylaws, which are separately being presented in order to give BLAC stockholders the opportunity to present their separate views on important corporate governance provisions. These separate votes are not otherwise required by Delaware law separate and apart from the Charter Proposal and will be voted upon on a <span style="white-space:nowrap">non-binding</span> advisory basis. Accordingly, the stockholder votes regarding the Advisory Governance Proposals are advisory votes and are not binding on BLAC or the BLAC Board (separate and apart from the approval of the Charter Proposal). Furthermore, the Business Combination is not conditioned on the separate approval of the Advisory Governance Proposals (separate and apart from approval of the Charter Proposal). Accordingly, regardless of the outcome of the <span style="white-space:nowrap">non-binding</span> advisory vote on the Advisory Governance Proposals, BLAC intends that the Amended Charter will take effect upon the Closing (assuming approval of the Charter Proposal). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Advisory Governance Proposals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth a summary of the Advisory Governance Proposals. This summary is qualified by reference to the complete text of the Amended Charter, a copy of which is attached to this proxy statement/prospectus as&#160;Annex E and the Amended Bylaws, a copy of which is attached to this proxy statement/prospectus as Annex F. All shareholders are encouraged to read the Amended Charter and Amended Bylaws in their entirety for a more complete description of their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3A: Name Change </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amendment will change the name of the publicly traded entity from &#8220;Bellevue Life Sciences Acquisition Corp.&#8221; to &#8220;OSR Holdings, Inc.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reasons for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes that changing the name of BLAC upon the completion of the Business </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Combination is desirable to reflect the Business Combination and to clearly identify New OSR Holdings </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as the publicly traded entity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3B: Increase in Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amendment would increase the number of shares of preferred stock that New OSR Holdings is authorized to issue from 1,000,000 shares to 10,000,000 shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reasons for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes increasing the number of preferred shares that New OSR Holdings is authorized to issue will provide New OSR Holdings flexibility for future issuances of preferred stock if determined by New OSR Holdings&#8217; Board to be in the bests interest of New OSR Holdings without incurring the risk, delay and potential expense incident to obtaining stockholder approval for a particular issuance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3C: Increase Vote Required for Removal of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Current Bylaws provide that directors may only be removed from office for cause and by the affirmative vote of holders of a majority of the voting power. The Amended Charter provides that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reasons for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes that providing for a higher threshold for the removal of directors will increase board continuity and the likelihood that experienced board members with familiarity of New OSR Holdings&#8217; business operations would serve on the New OSR Holdings board at any given time. Requiring a higher vote threshold for directors to be removed may make it more difficult or expensive for a third party to acquire control of New OSR Holdings without the approval of its board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3D: Eliminate Limitations on the Corporate Opportunity Doctrine </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Current Charter includes language to the effect that the &#8220;corporate opportunity&#8221; doctrine or any other analogous doctrine shall not apply with respect to BLAC or any of its officers or directors in circumstances where the application of such doctrine would conflict with the fiduciary duties or contractual obligations they may have as of the date of the Current Charter or in the future. This amendment would remove this provision that waives the &#8220;corporate opportunity&#8221; doctrine or any other analogous doctrine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reasons for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes that it is desirable to amend the Current Charter to remove certain limitations on the corporate opportunity doctrine so that officers and directors will have a duty to communicate or present corporate opportunities to New OSR Holdings, not have the right to either hold any corporate opportunity for their (and their affiliates&#8217;) own account and benefit or to recommend, assign or otherwise transfer such corporate opportunity to persons other than New OSR Holdings, and will be prohibited from operating or investing in competing businesses without presenting it to New OSR Holdings first. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3E: Reduce the Quorum Requirement for Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Current Bylaws, a quorum will be present at a meeting of stockholders if one or more stockholders who together hold not less than a majority of the issued and outstanding shares of BLAC common stock entitled to vote at a meeting are represented at such meeting. Under the Amended Bylaws, a quorum will be present at a meeting of stockholders if the holders of one-third in voting power of the then outstanding shares of capital stock of New OSR Holdings entitled to vote at the meeting are represented as such meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reason for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes it is important to reduce the requisite quorum for a meeting of shareholders from a majority to one-third of the shares entitled to vote at such meeting so that New OSR Holdings stockholders have the ability to hold meetings when a minority of the New OSR Holdings stockholders are present. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal No. 3F: Removal of SPAC Provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Description of Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Current Charter contains various provisions applicable only to blank check companies. The Amended Charter removes those provisions applicable only to special purpose acquisition companies that will no longer be applicable after the consummation of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Reasons for the Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board believes the amendment to remove certain provisions related to BLAC&#8217;s status as a blank check company is desirable because these provisions will serve no purpose following the Business Combination. For example, these proposed amendments remove the requirement to dissolve the Combined Company and allow it to continue as a corporate entity with perpetual existence following consummation of the Business Combination. Perpetual existence is the usual period of existence for corporations and we believe it is the most appropriate period for New OSR Holdings following the Business Combination. In addition, certain other provisions in the Current Charter require that proceeds from the BLAC IPO be held in the Trust Account until a business combination or liquidation of merger has occurred. These provisions cease to apply once the Business Combination is consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Advisory Governance Proposals will be approved and adopted only if holders of at least a majority of the issued and outstanding shares of Common Stock present by teleconference or represented by proxy and entitled to vote at the special meeting vote &#8220;FOR&#8221; the Advisory Governance Proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is not conditioned upon the approval of the Advisory Governance Proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, a vote to approve each of the Advisory Governance Proposals is an advisory vote, and therefore, is not binding on BLAC, OSR Holdings or their respective boards of directors. Accordingly, regardless of the outcome of the <span style="white-space:nowrap">non-binding</span> advisory vote, BLAC and OSR Holdings intend that the Amended Charter, in the form attached to this proxy statement/prospectus as Annex E and containing the provisions noted above, will take effect at the Closing, assuming approval of the Charter Proposal (Proposal 2). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the BLAC Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THE BLAC BOARD UNANIMOUSLY RECOMMENDS THAT BLAC STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH OF THE ADVISORY GOVERNANCE PROPOSALS.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_22">PROPOSAL NO. 4 &#8212; THE INCENTIVE PLAN PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On [&#9679;], 2024, BLAC&#8217;s board of directors adopted the Omnibus Plan, subject to the receipt of stockholder approval at the special meeting. The ability to grant equity-based compensation awards is critical to attracting and retaining highly qualified individuals. BLAC&#8217;s board of directors believes that it is in the best interests of our stockholders for those individuals to have an ownership interest in BLAC in recognition for their contributions and to align their interests with those of our future stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notable Features of the Omnibus Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in more detail below, certain notable features of the Omnibus Plan include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">granting of options and stock appreciation rights only at a per share exercise price at least equal to the fair market value of a share of common stock on the grant date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">granting of options with a <span style="white-space:nowrap">ten-year</span> maximum term; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">awards are subject to potential clawback, forfeiture, repayment or other similar action pursuant to any clawback policy adopted by BLAC or an affiliate or applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no liberal share recycling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no payment of dividends or dividend equivalent rights on options or stock appreciation rights, and no current payment of dividends or dividend equivalent rights on unvested performance-based awards; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no repricing of options or stock appreciation rights without prior stockholder approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the Material Terms of the Omnibus Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the material terms of the Omnibus Plan is set forth below. The following is qualified in its entirety by the full text of the Omnibus Plan, which is attached to this proxy statement as Annex G and is incorporated by reference into this proposal. We encourage stockholders to read and refer to the complete plan document in Annex G for a more complete description of the Omnibus Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose and Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Omnibus Plan is to (i)&#160;provide eligible individuals with an incentive to contribute to BLAC&#8217;s success and to operate and manage BLAC&#8217;s business in a manner that provides for BLAC&#8217;s long-term growth and profitability and that benefits BLAC&#8217;s stockholders and other important stakeholders, including BLAC&#8217;s employees and customers, and (ii)&#160;provide a means of recruiting, rewarding, and retaining key personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity awards may be granted under the Omnibus Plan to officers, directors, including <span style="white-space:nowrap">non-employee</span> directors, other employees, advisors, consultants or other service providers of BLAC or BLAC&#8217;s subsidiaries or other affiliates, and to any other individuals who are approved by the Committee (as defined below) as eligible to participate in the Omnibus Plan. As of [&#9679;], 2024, there are [&#9679;] employees or directors that are eligible to participate in the Omnibus Plan, but we expect that [&#9679;] employees, including each of BLAC&#8217;s named executive officers, and approximately [&#9679;] <span style="white-space:nowrap">non-employee</span> directors, consultants, and advisors of BLAC will be eligible to participate in the Omnibus Plan after the consummation of the Business Combination. Only BLAC&#8217;s employees or employees of BLAC&#8217;s corporate subsidiaries are eligible to receive incentive stock options. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effective Date and Term </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved by stockholders at the special meeting, the Omnibus Plan will be effective as of [&#9679;], 2024, the date the plan was adopted by our board of directors (the &#8220;Effective Date&#8221;). The Omnibus Plan will terminate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
automatically at 11:59PM ET on the day before the tenth (10th) anniversary of the Effective Date unless earlier terminated by the BLAC Board or in accordance with the terms of the Omnibus Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration, Amendment and Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan will generally be administered by a committee composed of not fewer than two directors of BLAC designated by BLAC&#8217;s Board, each of whom will be a <span style="white-space:nowrap">&#8220;non-employee</span> director&#8221; and satisfy the composition requirements under the listing rules of any stock exchange on which BLAC&#8217;s common stock is listed (the &#8220;Committee&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where the authority to act on such matters is specifically reserved to the BLAC Board under the Omnibus Plan or applicable law, the Committee will have full power and authority to interpret and construe all provisions of the Omnibus Plan, any award, and any award agreement, and take all actions and to make all determinations required or provided for under the Omnibus Plan, any award, and any award agreement, including the authority to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">designate grantees of awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determine the type or types of awards to be made to a grantee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determine the number of shares of common stock subject to an award or to which an award relates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish the terms and conditions of each award; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prescribe the form of each award agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to limitations in the Omnibus Plan (including the prohibition on repricing of options or share appreciation rights without stockholder approval), amend, modify, or supplement the terms of any outstanding award; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make substitute awards. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board will also be authorized to appoint one or more committees of the BLAC Board consisting of one or more directors of BLAC who need not meet the independence requirements above for certain limited purposes permitted by the Omnibus Plan, and to the extent permitted by applicable law, the Committee will be authorized to delegate authority to the Chief Executive Officer of BLAC and/or any other officers of BLAC for certain limited purposes permitted by the Omnibus Plan. The BLAC Board will retain the authority under the Omnibus Plan to exercise any or all of the powers and authorities related to the administration and implementation of the Omnibus Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Board may amend, suspend, or terminate the Omnibus Plan at any time; provided that with respect to awards that are granted under the Omnibus Plan, no amendment, suspension or termination may materially impair the rights of the award holder without such holder&#8217;s consent. No such action may amend the Omnibus Plan without the approval of stockholders if the amendment is required to be submitted for stockholder approval by the BLAC Board, the terms of the Omnibus Plan, or applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards under the Omnibus Plan may be made in the form of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">stock options, which may be either incentive stock options or nonqualified stock options; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">stock appreciation rights or &#8220;SARs&#8221;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restricted stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restricted stock units; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other equity-based awards; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cash. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An incentive stock option is an option that meets the requirements of Section&#160;422 of the Code, and a nonqualified stock option is an option that does not meet those requirements. A SAR is a right to receive upon exercise, in the form of stock, cash or a combination of stock and cash, the excess of the fair market value of one share on the exercise date over the exercise price of the SAR. Restricted stock is an award of common stock subject to restrictions over restricted periods that subject the shares to a substantial risk of forfeiture, as defined in Section&#160;83 of the Code. A restricted stock unit is an award that represents a conditional right to receive shares in the future and that may be made subject to the same types of restrictions and risk of forfeiture as restricted stock. Other equity-based awards are awards representing a right or other interest that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to stock, other than an option, SAR, restricted stock or restricted stock unit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan provides that each award will be evidenced by an award agreement, which may specify terms and conditions of the award that differ from the terms and conditions that would otherwise apply under the Omnibus Plan in the absence of the different terms and conditions in the award agreement. In the event of any inconsistency between the Omnibus Plan and an award agreement, the provisions of the Omnibus Plan will control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards under the Omnibus Plan may be granted alone or in addition to, in tandem with, or in substitution or exchange for any other award under the Omnibus Plan, other awards under another compensatory plan of BLAC or any of its affiliates (or any business entity that has been a party to a transaction with BLAC or any of BLAC&#8217;s affiliates), or other rights to payment from BLAC or any of its affiliates. Awards granted in addition to or in tandem with other awards may be granted either at the same time or at different times. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may permit or require the deferral of any payment pursuant to any award into a deferred compensation arrangement in accordance with rules and procedures established by the Committee. Awards under the Omnibus Plan generally will be granted for no consideration other than past services by the grantee of the award or, if provided for in the award agreement or in a separate agreement, the grantee&#8217;s promise to perform future services to BLAC or one of its subsidiaries or other affiliates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forfeiture; Clawback </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC may reserve the right in an award agreement to cause a forfeiture of the gain realized by a grantee with respect to an award on account of actions taken by, or failed to be taken by, such grantee in violation or breach of, or in conflict with, any employment agreement, <span style="white-space:nowrap">non-competition</span> agreement, agreement prohibiting solicitation of employees or clients of BLAC or any affiliate, confidentiality obligations with respect to BLAC or any affiliate, or otherwise in competition with BLAC or any affiliate, to the extent specified in such award agreement. If the grantee is an employee and is terminated for &#8220;Cause&#8221; (as defined in the Omnibus Plan), the Committee may annul the grantee&#8217;s award as of the date of the grantee&#8217;s termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any award granted pursuant to the Omnibus Plan will be subject to mandatory repayment by the grantee to BLAC to the extent (i)&#160;set forth in the Omnibus Plan or in an award agreement, or (ii)&#160;the grantee is or becomes subject to a BLAC or affiliate clawback policy, or any applicable laws which impose mandatory recoupment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shares Subject to the Omnibus Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment as described below, the maximum number of shares of common stock reserved for issuance under the Omnibus Plan will be equal to 6,300,000. The maximum number of shares of BLAC&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock available for issuance pursuant to incentive stock options granted under the Omnibus Plan will be the same as the total number of shares of BLAC&#8217;s common stock reserved for issuance under the Omnibus Plan. Shares issued under the Omnibus Plan may be authorized and unissued shares, or treasury shares, or a combination of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any shares covered by an award, or portion of an award, granted under the Omnibus Plan that are not purchased or forfeited or canceled, or expire or otherwise terminate without the issuance of shares or are settled in cash in lieu of shares, will again be available for issuance under the Omnibus Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to an award granted under the Omnibus Plan shall be counted against the maximum number of shares reserved for issuance under the Omnibus Plan as one share for every one share subject to such an award. In addition, at least the target number of shares of stock issuable under an award that is subject to vesting, exercisability or settlement based on the achievement of performance goals shall be counted against the maximum number of shares reserved for issuance under the Omnibus Plan as of the grant date, but such number will be adjusted to equal the actual number of shares of stock issued upon settlement of the award to the extent different from such number initially counted against the share reserve. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares available for issuance under the Omnibus Plan shall not be increased by the number of shares of common stock: (i)&#160;tendered or withheld or subject to an award surrendered in connection with the purchase of shares upon exercise of an option; (ii)&#160;that were not issued upon the net settlement or net exercise of a stock-settled SAR, (iii)&#160;deducted or delivered from payment of an award in connection with BLAC&#8217;s tax withholding obligations; or (iv)&#160;purchased by BLAC with proceeds from option exercises. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan authorizes the Committee to grant incentive stock options (under Section&#160;422 of the Code) and options that do not qualify as incentive stock options. An option granted under the Omnibus Plan will be exercisable only to the extent that it is vested. Each option will become vested and exercisable at such times and under such conditions as the Committee may approve consistent with the terms of the Omnibus Plan. No option may be exercisable more than ten years after the option grant date, or five years after the option grant date in the case of an incentive stock option granted to a &#8220;ten percent stockholder&#8221; (as defined in the Omnibus Plan); provided that, to the extent deemed necessary or appropriate by the Committee to reflect differences in local law, tax policy, or custom with respect to any option granted to a grantee who is a foreign national or is a natural person who is employed outside of the United States, such option may terminate, and all rights to purchase shares of stock thereunder may cease, upon the expiration of a period longer than ten (10)&#160;years from the date of grant of such option as the Committee shall determine. The Committee may include in the option agreement provisions specifying the period during which an option may be exercised following termination of the grantee&#8217;s service. The exercise price of each option will be determined by the Committee, provided that the per share exercise price will be equal to or greater than 100% of the fair market value of a share of BLAC&#8217;s common stock on the grant date (other than as permitted for substitute awards). If BLAC were to grant incentive stock options to any ten percent stockholder, the per share exercise price will not be less than 110% of the fair market value of a share of BLAC&#8217;s common stock on the grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Incentive stock options and nonqualified stock options are generally <span style="white-space:nowrap">non-transferable,</span> except for transfers by will or the laws of descent and distribution. The Committee may, in its discretion, determine that a nonqualified stock option may be transferred to family members by gift or other transfers deemed not to be for value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan authorizes the Committee to grant SARs that provide the recipient with the right to receive, upon exercise of the SAR, cash, common stock, or a combination of the two. The amount that the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recipient will receive upon exercise of the SAR generally will equal the excess of the fair market value of shares of common stock on the date of exercise over the fair market value of shares of common stock on the grant date. SARs will become exercisable in accordance with terms determined by the Committee. SARs may be granted in tandem with an option grant or independently from an option grant. The term of a SAR cannot exceed ten (10)&#160;years from the date of grant. The per share exercise price of a SAR will be no less than the fair market value of one share of BLAC&#8217;s common stock on the grant date of such SAR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SARs will be nontransferable, except for transfers by will or the laws of descent and distribution. The Committee may determine that all or part of a SAR may be transferred to certain family members of the grantee by gift or other transfers deemed not to be for value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fair Market Value </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For so long as the common stock remains listed on the Nasdaq Capital Market, the fair market value of the common stock on an award&#8217;s grant date, or on any other date for which fair market value is required to be established under the Omnibus Plan, will be the closing price of the common stock as reported on the Nasdaq Capital Market on such date. If there is no such reported closing price on such date, the fair market value of the common stock will be the closing price of the common stock as reported on such market on the next preceding date on which any sale of common stock will have been reported. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the common stock ceases to be listed on the Nasdaq Capital Market and is listed on another established national or regional stock exchange, or traded on another established securities market, fair market value will similarly be determined by reference to the closing price of the common stock on the applicable date as reported on such other stock exchange or established securities market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the common stock ceases to be listed on the Nasdaq Capital Market or another established national or regional stock exchange, or traded on another established securities market, the Committee will determine the fair market value of the common stock by the reasonable application of a reasonable valuation method in a manner consistent with Section&#160;409A of the Code. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Repricing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in connection with a corporate transaction involving BLAC (including, without limitation, any stock dividend, distribution (whether in the form of cash, shares of stock, other securities or other property), stock split, extraordinary dividend, recapitalization, change in control, reorganization, merger, consolidation, <span style="white-space:nowrap">split-up,</span> <span style="white-space:nowrap">spin-off,</span> combination, repurchase or exchange of shares of stock or other securities or similar transaction), BLAC may not, without obtaining stockholder approval, (a)&#160;amend the terms of outstanding options or SARs to reduce the exercise price of such outstanding options or SARs, (b)&#160;cancel outstanding options or SARs in exchange for, or in substitution of, options or SARs with an exercise price that is less than the exercise price of the original options or SARs, (c)&#160;cancel outstanding options or SARs with an exercise price above the current price of common stock in exchange for cash or other securities, in each case, unless such action is (i)&#160;subject to and approved by BLAC&#8217;s stockholders or (ii)&#160;would not be deemed to be a repricing under the rules of any stock exchange or securities market on which the common stock is listed or publicly traded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock and Restricted Stock Units </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan authorizes the Committee to grant restricted stock and restricted stock units. Subject to the provisions of the Omnibus Plan, the Committee will determine the terms and conditions of each award of restricted stock and restricted stock units, including the restricted period for all or a portion of the award, the restrictions applicable to the award, and the purchase price, if any, for the shares of stock subject to the award. The restrictions, if any, may lapse over a specified period of time or through the satisfaction of conditions, in installments or otherwise, as the Committee may determine. A grantee of restricted stock will have all of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights of a stockholder as to those shares, including, without limitation, the right to vote the shares and receive dividends or distributions on the shares, except to the extent limited by the Committee. The Committee may provide in an award agreement evidencing a grant of restricted stock that any cash dividend payments or distributions paid on restricted stock will be reinvested in shares of stock, which may or may not be subject to the same vesting conditions and restrictions as applicable to such shares of restricted stock or any dividend payments or distributions declared or paid on shares of restricted stock will only be made or paid upon satisfaction of the vesting conditions and restrictions applicable to such shares of restricted stock. Dividend payments or distributions declared or paid on shares of restricted stock that vest or are earned based on the achievement of performance goals will not vest unless such performance goals for such shares of restricted stock are achieved, and if such performance goals are not achieved, the grantee of such shares of restricted stock will promptly forfeit and, to the extent already paid or distributed, repay to BLAC such dividend payments or distributions. Grantees of restricted stock units will have no voting or dividend rights or other rights associated with share ownership, although the Committee may award dividend equivalent rights on such units. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the restricted period, if any, when restricted stock and restricted stock units are <span style="white-space:nowrap">non-transferable</span> or forfeitable, a grantee is prohibited from selling, transferring, assigning, pledging, exchanging, hypothecating, or otherwise encumbering or disposing of the grantees&#8217; restricted stock and restricted stock units. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Equity-Based Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Omnibus Plan authorizes the Committee to grant other types of stock-based awards under the Omnibus Plan. The terms and conditions that apply to other equity-based awards are determined by the Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forms of Payment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for any option or the purchase price (if any) for restricted stock or vested restricted stock units is generally payable (i)&#160;in cash or in cash equivalents acceptable to BLAC, (ii)&#160;to the extent the award agreement provides, by the tender (or attestation of ownership) of shares of BLAC&#8217;s common stock having a fair market value on the date of tender (or attestation) equal to the exercise price or purchase price, (iii)&#160;to the extent permitted by law and to the extent permitted by the award agreement, through a broker-assisted cashless exercise, or (iv)&#160;to the extent the award agreement provides and/or unless otherwise specified in an award agreement, any other form permissible by applicable law, including net exercise or net settlement and service rendered to BLAC or BLAC&#8217;s affiliates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Capitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may adjust the terms of outstanding awards<span style="font-style:italic"> </span>under the Omnibus Plan to preserve the proportionate interests of the holders in such awards on account of any recapitalization, reclassification, share split, reverse share split, <span style="white-space:nowrap">spin-off,</span> combination of share, exchange of shares, share dividend or other distribution payable in capital shares, or other increase or decrease in such shares effected without receipt of consideration by BLAC. The adjustments will include proportionate adjustments to (i)&#160;the number and kind of shares subject to outstanding awards and (ii)&#160;the per share exercise price of outstanding options or SARs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transaction not Constituting a Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If BLAC is the surviving entity in any reorganization, merger, or consolidation of BLAC with one or more other entities that does not constitute a &#8220;change in control&#8221; (as defined in the Omnibus Plan), any awards will be adjusted to pertain to and apply to the securities to which a holder of the number of common shares subject to such award would have been entitled immediately after such transaction, with a corresponding proportionate adjustment to the per share price of options and SARs so that the aggregate price per share of each option or SAR thereafter is the same as the aggregate price per share of each option or SAR subject to the option or SAR immediately prior to such transaction. Further, in the event of any such transaction, any awards subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vesting, exercisability or settlement based on the achievement of performance goals (and the related performance goals if deemed appropriate by the Committee) shall be adjusted to apply to the securities that a holder of the number of common stock subject to such awards would have been entitled to receive following such transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect of a Change in Control in which Awards are not Assumed </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the applicable award agreement, upon the occurrence of a change in control in which outstanding awards are not being assumed or continued, the following provisions will apply to such awards, to the extent not assumed or continued: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Immediately prior to the occurrence of such change in control, in each case with the exception of awards subject to vesting, exercisability or settlement based on the achievement of performance goals, all outstanding shares of restricted stock and all restricted stock units shall be deemed to have vested, all shares of stock or cash subject to such awards will be delivered; and either or both of the following actions will be taken: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">At least fifteen (15)&#160;days prior to the scheduled consummation of such change in control, all options and SARs outstanding will become immediately exercisable and will remain exercisable for a period of fifteen (15)&#160;days. Any exercise of an option or SAR during this fifteen (15)&#160;day period will be conditioned on the consummation of the applicable change in control and will be effective only immediately before the consummation thereof. Upon consummation of such change in control, the Omnibus Plan and all outstanding but unexercised options and SARs will terminate, with or without consideration as determined by the Committee in its sole discretion; and/or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Committee may elect, in its sole discretion, to cancel any outstanding awards of options, SARs, restricted stock or restricted stock units and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in cash or capital stock having a value (as determined by the Committee acting in good faith), in the case of restricted stock or restricted stock units, equal to the formula or fixed price per share paid to holders of shares of stock pursuant to such change in control and, in the case of options or SARs, equal to the product of the number of shares of stock such subject to such options or SARs multiplied by the amount, if any, which (i)&#160;the formula or fixed price per share paid to holders of shares of stock pursuant to such change in control exceeds (ii)&#160;the option price or SAR price applicable to such options or SARs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For awards subject to vesting, exercisability or settlement based on the achievement of performance goals, actual performance to date shall be determined as of a date reasonably proximate to the date of consummation of the change in control as determined by the Committee, in its sole discretion, and that level of performance thus determined shall be treated as achieved prior to occurrence of the change in control. For purposes of the preceding sentence, if, based on the discretion of the Committee, actual performance is not determinable, the awards shall be treated as through the target performance has been achieved. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Other Equity-Based Awards will be governed by the terms of the applicable award agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect of a Change in Control in which Awards are Assumed </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the applicable award agreement, upon the occurrence of a change in control in which outstanding awards are being assumed or continued, the Omnibus Plan and the options, SARs, restricted stock, restricted stock units and other equity-based equity awards granted under the Omnibus Plan will continue in the manner and under the terms so provided in the event of any change in control to the extent that provision is made in writing in connection with such change in control for the assumption or continuation of such awards, or for the substitution for such awards of new options, SARs, restricted stock, restricted stock units and other equity-based awards relating to the capital stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustment as to the number of shares and exercise price of options and SARs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a &#8220;change in control&#8221; means: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a transaction or series of related transactions whereby a person or group (other than BLAC or any of its affiliates) becomes the beneficial owner of more than 50% or more of the total voting power of the BLAC&#8217;s voting stock on a fully diluted basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">individuals who, as of the Effective Date, constitute the BLAC Board (together with any new directors whose election was approved by at least a majority of the members of the BLAC Board then in office), cease to constitute a majority of the members of the BLAC Board then in office; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a merger or consolidation of BLAC, other than any such transaction in which the holders of BLAC&#8217;s voting stock immediately prior to the transaction own directly or indirectly at least a majority of the voting power of the surviving entity immediately after the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a sale of substantially all of BLAC&#8217;s assets to another person or entity; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the consummation of a plan or proposal for the dissolution or liquidation of BLAC. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Material U.S. Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax consequences of awards under the Omnibus Plan for grantees and BLAC will depend on the type of award granted. The summary does not contain a complete analysis of all the potential tax consequences relating to grants under the Omnibus Plan, including state, local or foreign tax consequences. This summary is intended for the information of our stockholders considering how to vote at the special meeting and not as tax guidance to grantees under the Omnibus Plan. This summary is not intended or written to be used, and cannot be used, for the purposes of avoiding taxpayer penalties. Tax consequences are subject to change, and a taxpayer&#8217;s particular situation may be such that some variation in application of the described rules is applicable. Accordingly, grantees are advised to consult their own tax advisors with respect to the tax consequences of receiving grants under the Omnibus Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Incentive Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An optionholder will not realize taxable income upon the grant of an incentive stock option under the Omnibus Plan. In addition, an optionholder generally will not realize taxable income upon the exercise of an incentive stock option. An optionholder&#8217;s alternative minimum taxable income, however, will be increased by the amount by which the aggregate fair market value of the shares underlying the option, which is generally determined as of the date of exercise, exceeds the aggregate exercise price of the option. Further, except in the case of an optionholder&#8217;s death or disability, if an option is exercised more than three months after the optionholder&#8217;s termination of employment, the option will cease to be treated as an incentive stock option and will be subject to taxation under the rules applicable to nonqualified stock options, as summarized below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an optionholder sells the shares acquired upon exercise of an incentive stock option, the tax consequences of the disposition will depend upon whether the disposition is &#8220;qualifying&#8221; or &#8220;disqualifying.&#8221; The disposition of the option shares will be a qualifying deposition if it is made at least two years after the date on which the incentive stock option was granted and at least one year after the date on which the incentive stock option was exercised. If the disposition of the option shares is qualifying, any excess of the sale price of the option shares over the exercise price of the option will be treated as long-term capital gain taxable to the optionholder at the time of the sale. If the disposition is a disqualifying disposition, the excess of the fair market value of the option shares on the date of disposition over the exercise price will be taxable income to the optionholder at the time of the disposition. Of that income, the amount up to the excess of the fair market value of the shares at the time the option was exercised over the exercise price will be ordinary income for income tax purposes and the balance, if any, will be long-term or short-term capital gain, depending upon whether or not the shares were sold more than one year after the option was exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless an optionholder engages in a disqualifying disposition, BLAC will not be entitled to a deduction with respect to an incentive stock option. If an optionholder engages in a disqualifying disposition, BLAC will be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled to a deduction equal to the amount of compensation income taxable to the optionholder if BLAC complies with applicable reporting requirements and subject to Section&#160;162(m) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an optionholder pays the exercise price of an incentive stock option by tendering shares with a fair market value equal to part or all of the exercise price, the exchange of shares will be treated as a nontaxable exchange, except that this treatment will not apply if the optionholder acquired the shares being tendered pursuant to the exercise of an incentive stock option and has not satisfied the special holding period requirements summarized above. The tax basis of the shares tendered to pay the exercise price will be treated as the substituted tax basis for an equivalent number of shares received, and the new shares will be treated as having been held for the same holding period as the holding period that expired with respect to the tendered shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nonqualified Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An optionholder will not realize taxable income upon the grant of a nonqualified stock option. When an optionholder exercises the option, however, the excess of the fair market value of the shares purchased pursuant to the option over the exercise price of the option will constitute compensation income taxable to the optionholder. BLAC will be entitled to a deduction equal to the amount of compensation income taxable to the optionholder if BLAC complies with applicable reporting requirements and subject to Section&#160;162(m) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an optionholder tenders shares in payment of part or all of the exercise price of a nonqualified stock option, no gain or loss will be recognized with respect to the shares tendered, even if the shares tendered were acquired pursuant to the exercise of an incentive stock option. In such an event, the optionholder will be treated as receiving an equivalent number of shares pursuant to the exercise of the option in a nontaxable exchange. The tax basis of the shares tendered will be treated as the substituted tax basis for an equivalent number of shares received, and the shares received will be treated as having been held for the same holding period as the holding period that expired with respect to the tendered shares. The excess of the fair market value of the shares received upon the exercise of the option over the exercise price will be taxed as ordinary income, just as if the optionholder had paid the exercise price in cash. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant of SARs will not result in taxable income to the grantee. Upon exercise of a SAR, the grantee will recognize ordinary income in an amount equal to the cash or the fair market value of the common shares received by the grantee. BLAC will be entitled to a deduction equal to the amount of any compensation income taxable to the grantee, subject to Section&#160;162(m) of the Code and if BLAC complies with applicable reporting requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock and Restricted Stock Units </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the grant of restricted stock or restricted stock units, there will be no tax consequences to the grantee. Generally, the grantee will recognize ordinary income on the date the award vests, in an amount equal to, in the case of restricted stock, the value of the shares on the vesting date, or, in the case of restricted stock units, the amount of cash paid and the fair market value of any shares delivered upon vesting. With respect to restricted stock, under Section&#160;83 of the Code, a grantee may elect to recognize income at the grant date rather than the date of vesting. If BLAC complies with applicable reporting requirements and subject to the restrictions of Section&#160;162(m) of the Code, BLAC will be entitled to a deduction in the same amount and generally at the same time as the grantee recognizes ordinary income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the taxes imposed on awards made under the Omnibus Plan may be made by withholding from payments otherwise due and owing to the grantee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grants under the Omnibus Plan will be made at the discretion of the Committee, and therefore, the benefits or number of shares subject to awards that may be granted in the future to BLAC&#8217;s executive officers, employees and directors is not currently determinable. Therefore, a New Plan Benefits Table is not provided. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming that a quorum is present at the special meeting, the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy at the special meeting and entitled to vote on this Incentive Plan Proposal is required to approve the Omnibus Plan. Accordingly, neither a stockholder&#8217;s failure to vote in person or by proxy, a broker <span style="white-space:nowrap">non-vote</span> nor an abstention will be considered a &#8220;vote cast,&#8221; and thus will have no effect on the outcome of this proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Incentive Plan Proposal is conditioned upon the approval and completion of the Business Combination Proposal, the Charter Proposal and the Director Election Proposal. If any of the Business Combination Proposal, the Charter Proposal or the Director Election Proposal is not approved, this proposal will have no effect even if approved by our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Because stockholder approval of this Incentive Plan Proposal is a condition to completion of the Business Combination under the Business Combination Agreement, if this proposal is not approved by our stockholders, the Business Combination will not occur unless we and OSR Holdings waive the applicable closing condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE &#8220;FOR&#8221; THE INCENTIVE PLAN PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_23">PROPOSAL NO. 5 &#8212; THE DIRECTOR ELECTION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, we intend for New OSR Holdings&#8217; board of directors to consist of up to nine (9)&#160;directors, with each director having a term that expires as described below until the applicable annual meeting of stockholders, or in each case until their respective successors are duly elected and qualified, or until their earlier resignation, removal or death. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on the experience of New OSR Holdings&#8217; director nominees, see the section entitled &#8220;<span style="font-style:italic">Management Following the Business Combination</span>&#8221; of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Proposal and each of the other proposals contained in this proxy statement/prospectus upon which it is conditioned are approved, each of BLAC&#8217;s existing directors will resign upon the closing of the Business Combination. See the section entitled &#8220;<span style="font-style:italic">Management Following the Business Combination</span>&#8221; of this proxy statement for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to be elected as a director, a nominee must receive a plurality of all the votes cast only by holders of the shares of BLAC Common Stock at the special meeting, which means that the nominees with the most votes are elected. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Director Election Proposal is conditioned on the approval and completion of the Business Combination Proposal, and the approval of the other Condition Precedent Proposals. If any of the Business Combination Proposal or the other Condition Precedent Proposals are not approved, this proposal will have no effect even if approved by our stockholders.<span style="font-weight:bold">&#160;The Director Election Proposal is a condition to completion of the Business Combination under the Business Combination Agreement. Accordingly, if this proposal is not approved by BLAC&#8217;s stockholders, the Business Combination will not occur unless BLAC and OSR Holdings waive the applicable closing condition.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resolution to be Voted Upon </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the resolution to be passed is as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;RESOLVED</span>, that Kuk Hyoun Hwang, Jun Chul Whang, Phil Geon Lee, Alcide Barberis, Seng Chin Mah, Jin Whan Park, Sang Hyun Kim, [&#9679;] and [&#9679;] are elected to serve on New OSR Holdings&#8217; board of directors upon the consummation of the Business Combination, until the expiration of their applicable term, and until their respective successors are duly elected and qualified or until their earlier resignation, removal or death.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLAC&#8217;s BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ELECTION OF EACH OF THE EIGHT&#160;(8)&#160;DIRECTOR NOMINEES TO THE BOARD OF DIRECTORS OF NEW OSR HOLDINGS AS PART OF THIS PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_24">PROPOSAL NO. 6 &#8212; THE ADJOURNMENT PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal, if adopted, will approve the chairman&#8217;s adjournment of the special meeting to a later date to permit further solicitation of proxies. The Adjournment Proposal will only be presented to BLAC&#8217;s stockholders in the event, based on the tabulated votes, there are not sufficient votes received at the time of the special meeting to approve any of the other presented proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Consequences if the Adjournment Proposal is Not Approved </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved by BLAC&#8217;s stockholders, the chairman will not adjourn the special meeting to a later date in the event, based on the tabulated votes, there are not sufficient votes received at the time of the special meeting to approve any of the other presented proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal requires the approval the affirmative vote of the holders of a majority of the BLAC Common Stock who, being present and entitled to vote at the special meeting, vote at the meeting. Abstentions and <span style="white-space:nowrap">broker&#160;non-votes,&#160;while</span> considered present for the purposes of establishing a quorum, will not count as votes cast at the special meeting, and otherwise will have no effect on a particular proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resolution to be Voted Upon </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the resolution to be passed is as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;RESOLVED</span>, that the adjournment of the special meeting to a later date or dates (A)&#160;to the extent necessary to ensure that any required supplement or amendment to the proxy statement is provided to BLAC stockholders or, if as of the time for which the special meeting is scheduled, there are insufficient shares of BLAC Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the special meeting, (B)&#160;in order to solicit additional proxies from BLAC stockholders in favor of one or more of the proposals at the special meeting or (C)&#160;if BLAC stockholders redeem an amount of the public shares such that (i) it will not have net tangible assets of at least $5,000,001 upon the consummation of the Business Combination, or (ii) one of the conditions to consummate the Business Combination that the aggregate cash proceeds to be received by BLAC from the trust account in connection with the Business Combination, together with all other cash and cash equivalents of BLAC, equal no less than $5,000,001&#160;million as a condition to OSR Holdings&#8217; obligation to close (after deducting any amounts paid to BLAC&#8217;s stockholders that exercise their redemption rights in connection with the Business Combination, together with any transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing) would not be satisfied at Closing, be approved.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLAC&#8217;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_25">BUSINESS OF OSR HOLDINGS AND CERTAIN INFORMATION ABOUT OSR HOLDINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Our current operating businesses (through our three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in Korea. OSR Holdings&#8217; vision is to acquire and operate a portfolio of innovative health-care related companies globally. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a global healthcare holding company, with operations in South Korea and Switzerland and an office in the United States, we are not limited by geographic boundaries. We intend to leverage our existing and expanding network of academic and industry leaders and investor network, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research. Subsidiary candidates are companies that are either already existing entities or new companies formed in connection with acquiring or licensing existing assets from pharmaceutical firms. We expect to attract industry partners either as co-investors or through technology licensing deals and may raise capital directly from private, strategic or public investors. We seek to chart a potentially more efficient and optimal route by pairing what we believe are the right team and pharmaceutical or medical device technologies that have the potential to treat diseases and improve healthcare outcomes with the necessary financial and other resources. Since our target markets feature large established global businesses with abundant capital that acquire healthcare companies, we hope to realize additional liquidity through the sale of our subsidiaries from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a data-driven company. We evaluate our subsidiary candidate opportunities by better understanding the target indications toward identifying new approaches and technologies to improve treatment outcomes. We collaborate with academic and industry leaders to promote a seamless integration and partnership between entrepreneurial scientists and seasoned business development and leadership teams. These technical and scientific experts from academia and industry bring innovative contributions and a high level of enthusiasm. Our holding company leadership team supports and empowers each subsidiary to transform their potentially breakthrough discoveries into impactful and viable commercial products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company&#8217;s collective expertise from industry veterans, seasoned scientists, capital market and legal professionals provides the core foundation of our global healthcare holding company. OSR Holdings operates as a hub-and-spoke business model with a centralized executive team partnering with subsidiary management teams to ensure overall program and corporate alignment by and between subsidiaries and holding company. Our overarching goal is to enhance value creation for our subsidiaries by continuously assessing optimal development options and exploring partnership and fundraising opportunities. We encourage cooperation and knowledge sharing among our subsidiaries to enhance our synergistic business model. We believe our strong foundational scientific conviction, entrepreneurial acumen and opportunistic approach positions us as a differentiated global company advancing pharmaceutical and medical device technologies in an efficient, cost-effective and meaningful manner. Our interdisciplinary team of accomplished scientists and entrepreneurial business leaders promotes the development and commercialization of a risk diversified portfolio to address unmet medical needs with resilience and efficiency. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate organization and ownership of subsidiaries is illustrated by the following chart*: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00d20.jpg" alt="LOGO" style="width:2.69272in;height:2.46785in"/>
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes a 33.3% interest in Taction Co. Ltd, a dormant Korea company with no operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Portfolio Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings&#8217; subsidiaries (other than RMC) have diverse scientific and technological developments, and are engaged in distinct areas of therapeutics research and development, including oral T-cell immunotherapies and recombinant biologics. This approach not only provides OSR Holdings with a broader scope of potential therapeutic solutions but also reduces the risks associated with a singular-asset approach. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 2 below summarizes our three subsidiaries, two of which have their own drug development pipelines. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g476668g19a08.jpg" alt="LOGO" style="width:6.30556in;height:1.73842in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span><span style="font-weight:bold"><span style="font-style:italic">Figure 2.</span></span><span style="font-style:italic"> New OSR Holdings portfolio company snapshot. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own or have in-licensed numerous patents and intellectual property underlying patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of the therapeutic product candidates in development by our portfolio companies, including related manufacturing processes and technologies. As of March 31, 2024, the patent portfolio of our subsidiaries includes 10 patent families of issued patents and pending patent applications in various stages of prosecution. Generally, the patents issued and patent applications pending are in multiple jurisdictions including the United States, Europe, Japan, India, and China, with anticipated expiration between 2032 to 2041, without considering patent term adjustments </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or patent term extensions. The below table summarizes the seven patent families that have been issued to-date for our subsidiary companies: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:10%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:9%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:19%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:12%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company<br/>Assignee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Family</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Status</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Granted Regions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration&#160;Year</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Vaximm</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>Manufacturing&#160;(1)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2013/091898, Method for Producing High Yield Attenuated Salmonella Strains</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Manufacturing</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">AU, CA, CN, EP, IN, JP, KR, US, ZA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2032</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>VXM01 &#8211; dosing (2)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2014/005683, DNA Vaccine for Use in Pancreatic Cancer Patients</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Formulation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">AU, CN, EP, JP, KR, US, ZA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2033</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>VXM06 &#8211; WT1 (3)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2014/173542, Salmonella-based vectors for cancer immunotherapy targeting Wilms&#8217; tumor gene</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Composition of Matter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">EP, JP, US</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2034</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="white-space:nowrap">VXM04-MSLN&#160;(4)</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2015/090584, Novel MSLN targeting DNA vaccine for cancer immunotherapy</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Composition of Matter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">EP, JP, US</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2034</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>VXM01 &#8211; combination (5)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2016/202459, VEGFR-2 targeting DNA vaccine for combination therapy</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Composition of Matter; Method of Use</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">AU, CA, CN, EP, IN, US, ZA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2036</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>VXM01 Tumor expression&#160;(7)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2018/149982, Novel VEGFR-2 targeting immunotherapy approach</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Owned</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Composition of Matter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">AU, US</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2038</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Darnatein</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Designer ligands of <span style="white-space:nowrap">TGF-&#223;</span> superfamily (0)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">WO 2010/099219</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Exclusive License</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Composition of Matter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">EP, KR, JP</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">2030</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patents are in force for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are in force for 20 years from the earliest nonprovisional filing date. In addition, in certain instances, a patent term can be adjusted or extended to recapture a portion of the term effectively lost as a result of the USPTO delay or the FDA regulatory review period (a patent term adjustment or patent term extension, respectively). The restoration period for FDA delay cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest nonprovisional filing date. However, the actual protection afforded by a patent varies on a <span style="white-space:nowrap">product-by-product</span> basis, from <span style="white-space:nowrap"><span style="white-space:nowrap">country-to-country,</span></span> and depends upon many factors, including the type of patent, the scope of its coverage, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When appropriate, we seek to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection as trade secrets. We seek to protect this intellectual property, in part, as trade secrets, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and advisors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vaximm </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Corporate Overview</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm is developing innovative oral immunotherapies for the treatment of cancer and immunological disorders. Based on over 20 years of research, Vaximm&#8217;s customizable immunotherapy platform has the potential to be efficiently and effectively adapted to treat various diseases and address specific patient needs. Vaximm currently has three clinical and <span style="white-space:nowrap">pre-clinical</span> drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm&#8217;s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma, which early-stage clinical trials suggest may be a potentially specific and effective treatment. VXM01 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for both glioblastoma and pancreatic cancer on August 31, 2017 from FDA and August 23, 2017 from EMA. An Orphan Drug Designation will permit Vaximm to receive additional years of market exclusivity upon regulatory approval, which provides a significant competitive advantage. While VXM01 moves into planned phase 2 clinical trials, we are continuing to advance Vaximm&#8217;s other preclinical candidates in investigational new drug (IND)-enabling studies. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM04: A preclinical-stage oral T-cell vaccine targeting mesothelin </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM06: A preclinical-stage oral T-cell vaccine targeting Wilms Tumor Protein (WT1) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM08: A preclinical-stage oral T-cell vaccine targeting CEA(Carcinoembryonic antigen) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM08: A preclinical-stage oral T-cell vaccine targeting PD-L1 </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These products are currently undergoing preclinical studies to evaluate their safety, immunogenicity, and anti-tumor efficacy. Vaximm will need to complete these preclinical studies and submit Investigational New Drug (IND) applications to the relevant regulatory authorities before initiating clinical trials for each of these product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Vaximm has direct experience advancing a therapeutic candidate from preclinical to late-stage clinical trials and developed a pipeline of other preclinical therapeutic candidates, Vaximm has never sought or received regulatory or marketing approval for any of its product candidates. As Vaximm continues to advance its line of oral immunotherapies, it will remain flexible and opportunistic to explore partnering options. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Opportunity</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current approaches to targeted immunotherapies have various limitations, such as drug biodistribution, <span style="white-space:nowrap">off-target</span> effects, immunotolerance and evasion. The complex and diverse makeup of tumor microenvironments creates further difficulties. Production of targeted immunotherapies is expensive and time-intensive, making tailor-made therapies challenging to produce and manufacture at scale and, thus, not readily accessible. Optimally, the development of innovative new strategies can overcome drug resistance, enhance druggability, and improve drug biodistribution to maximize treatment efficacy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm seeks to overcome these limitations by leveraging our foundational science and innovative platform of attenuated bacterial strains to produce effective, customizable, oral vaccines efficiently and cost-effectively. Vaximm&#8217;s lead product candidate, VXM01, targets the tumor vasculature and specific tumor antigens. VXM01 is currently being evaluated in a Phase 2 clinical trial in Europe for the treatment of recurrent glioblastoma. Vaximm also plans to initiate a new clinical trial of VXM01 in recurrent glioblastoma patients in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If VXM01 demonstrates efficacy in the treatment of recurrent glioblastoma, Vaximm intends to expand by developing oral cancer vaccines targeting other solid tumor indications. The company&#8217;s strategy generally involves the following key steps: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Identify novel tumor-specific antigens: Vaximm will leverage its expertise in antigen discovery to identify new tumor-specific antigens that can be targeted by Vaximm&#8217;s platform. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Conduct preclinical studies: Vaximm will perform preclinical studies to evaluate the safety, immunogenicity, and anti-tumor efficacy of its oral cancer vaccine candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Initiate clinical trials: Based on the preclinical data, the company will design and conduct additional Phase 1/2 clinical trials to assess the safety, tolerability, and preliminary efficacy of its oral cancer vaccines in other cancer indications. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Conduct Phase 3 clinical trials: Phase 3 trials are large-scale, randomized, controlled studies designed to provide additional supporting evidence of the efficacy and safety of therapeutic candidates. These trials typically involve hundreds to thousands of patients and are conducted at multiple sites worldwide. Vaximm will work closely with clinical investigators, regulatory authorities, and patient advocacy groups to design and execute Phase 3 clinical trials for its oral cancer vaccine candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Seek regulatory approval: Following the successful completion of Phase 3 clinical trials, Vaximm will compile the necessary data and documentation to submit a Biologics License Application (BLA) to the relevant regulatory authorities, such as the FDA or EMA. The company will work with these agencies to address any questions or concerns and to ensure that its oral cancer vaccines meet the required standards for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated timeframe for this process is as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Antigen discovery and vaccine formulation: 1-2 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Preclinical studies: 1-2 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1/2 clinical trials: 2-3 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3 clinical trials: 2-3 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Regulatory approval: 1-2 years </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on this timeline, Vaximm anticipates that its first oral cancer vaccine candidate beyond VXM01 could enter clinical trials within the next 3-5 years, with potential regulatory approval in the next 7-9 years. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Intellectual Property</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm actively maintains 8 patent families relating to Vaximm&#8217;s portfolio of assets, in the United States and in other major markets as described shown in the tables below of specific patents within each patent family that have been issued or are under examination. All patents within each of the active patent families have been issued or are currently under various stages of nationalization and are owned or in-licensed patent families by Vaximm and cover composition of matter, formulation and/or methods of use, are shown in the table below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Manufacturing (1)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2013/091898, Method for Producing High Yield Attenuated Salmonella Strains </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ.&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2012/005364</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2013/091898</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2012359166</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23/11/2017</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2012359166</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2012359166</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2,853,656</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29/12/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2,853,656</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2,853,656</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201280064144.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19/04/2017</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">104066834</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">104066834</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">12 808 264.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30/08/2017</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2 794 849</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2 794 849</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5386/DELNP/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/06/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">313960</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">IN05386DN2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014-547768</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/12/2017</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6251179</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2015-502162</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">KR</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2014-7020387</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23/08/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2015932</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2014-0105028</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14/366,186</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15/11/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9,493,738</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014-0349274</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">ZA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2012</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/04501</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/02/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/04501</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/04501</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/12/2032</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM01 &#8211; dosing (2)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2014/005683, DNA Vaccine for Use in Pancreatic Cancer Patients</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2013/001882</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/005683</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2013286335</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/12/2017</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2013286335</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2013286335</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">DIV</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2017258877</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14/03/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201725887</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2631924</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CA</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2,877,938</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2,877,938</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201380035905.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30/10/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">CN201380035905.6A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">104519908</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP*</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">13 732 833.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25/09/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2 869 836</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2 869 836</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IN</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">180/DELNP/2015</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">IN00180DN2015</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under&#160;examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2015-518890</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20/04/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6325534</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2015-522263</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">KR</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2015-7002939</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/03/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2090612</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10-2015-0036361</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14/409,434</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/08/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9,415,098</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2015-0165011</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">CON2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31/05/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">15/994,766</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21/05/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10,293,037</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2019-0008936</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">ZA</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2013</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/09156</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27/07/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/09156</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/09156</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/06/2033</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM06 - WT1 (3) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2014/173542, Salmonella-based vectors for cancer immunotherapy targeting Wilms&#8217; tumor gene </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2014/001099</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2014/173542</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14 721 208.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/06/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2 988 762</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2 988 762</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016-509326</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/10/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6416877</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016-518835</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14/786,652</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20/03/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,920,297</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14/786,652</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">CON</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">15/872,750</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27/10/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,815,455</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2018/0163169</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24/04/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM04-MSLN (4) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2015/090584, Novel MSLN targeting DNA vaccine for cancer immunotherapy</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2014/003403</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2015/090584</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">14 821 508.0</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28/08/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3 082 850</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3 082 850</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016-559513</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14/01/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6662787</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2017-502692</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">CON</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2014</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">15/785,743</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15/10/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,441,645</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2018/0064794</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/12/2034</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM01 &#8211; combination (5) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2016/202459, VEGFR-2 targeting DNA vaccine for combination therapy </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2016/001004</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016/202459</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016278588</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31/03/2022</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">AU2016278588A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2016278588</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CA</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2989247</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17/10/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">CA2989247A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2989247</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201680035593.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13/07/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">CN201680035593.2A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">107995868</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">16736381.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/11/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3 310 379</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3 310 379</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EPHK</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">118111736.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/12/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">HK1252435</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">HK1252435</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP(T1)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">DIV</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">19205420.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3626262</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">under&#160;examination</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IN</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201717043556</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08.11.2023</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">467201</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201717043556 A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2017-565248</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.09.2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">JP2017565248A</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2018517419</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">under examination</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">15/737,659</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/02/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10,905,752</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">US&#160;2018/0250345</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">CON</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">17/107,203</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">US20210077605A1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">pending</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">ZA</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2016</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2017/08439</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26/05/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2017/08439</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/06/2036</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">granted</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM01 Tumor expression (7)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2018/149982, Novel VEGFR-2 targeting immunotherapy approach </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2018/053918</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">WO&#160;2018/149982</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2018222777</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/02/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2018222777B9</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2018222777 A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">305833</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">305833 A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under<br/>examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201880012318.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">110291187 A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under<br/>examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">18 704 568.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3 583 200 A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under<br/>examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201917030262</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201917030262 a</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under<br/>examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2019-544614</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under<br/>examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">16/486,425</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20/04/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10980868B2</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2020038496 A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">granted</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM10 &#8211; PD-L1 (8)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2018/167290, Novel PD-L1 targeting DNA vaccine for cancer immunotherapy </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2018/056721</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">WO&#160;2018/167290</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">201880018761.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">110430893</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">18710879</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3 595 704</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2018</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2019-550795</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2020-511139</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16/02/2038</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under&#160;examination</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VXM01 in combination with an antibiotic (9)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">WO 20</span><span style="font-weight:bold">21</span><span style="font-weight:bold">/</span><span style="font-weight:bold">144254</span><span style="font-weight:bold">, </span>Salmonella-based DNA vaccines in combination with an antibiotic</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Type</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing no.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">WO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">PCT/EP2021/050470</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">WO&#160;2021/144254</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">AU</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2021208400</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2121208400</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under&#160;examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3162994</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3162994</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">202180008543.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">114980871</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">EP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">21700697</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4090321</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">IN</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">202217033481</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">202217033481</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">JP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2022542046</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2023510770</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">KR</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">1020227027291</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">1020220128638</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">PCT</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">17791282</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">20230121528</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/01/2041</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">under examination</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Darnatein </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Corporate Overview</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Darnatein is developing design-augmented (DA) biologics for age-related and other degenerative diseases, such as osteoarthritis and spine and joint disorders. Darnatein&#8217;s lead DA biologics are intended to be injected directly into pathological tissues to promote regeneration of target tissues such as bone or cartilage cells. Leveraging these innovative DA biologics to regenerate bone and cartilage has the potential to restore functionality and reduce pain across several degenerative conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Darnatein has identified and advanced two therapeutic candidates, DRT-102, a clinical-stage asset for spinal fusion, and DRT-101, a pre-clinical stage asset for osteoarthritis. A small exploratory, clinical trial of 15 patients with DRT-102 indicated potential efficacy compared to a placebo, with no serious adverse events reported. Larger clinical trials will be required to provide more extensive and accurate data on the effectiveness of DRT 102. A pre-clinical (non-human) trial of DRT-101 demonstrated cartilage regeneration and joint healing in animals, with no serious adverse events reported. Based on these preliminary results, Darnatein intends to continue the development and testing of DRT-101 and DRT-102. Darnatein has not previously advanced any therapeutic candidates into late-stage clinical trials nor received regulatory and marketing approvals for any commercial sales of its products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Opportunity</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Age-related</span> degeneration, such as osteoarthritis and spine disorders, is a naturally occurring process that may be accelerated due to chronic and cumulative impact over time. Limited therapeutic options exist and only offer limited and temporary symptomatic relief with no cure currently available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond therapeutic options, invasive surgical procedures may be available for spine and joint disorders but are not readily accessible and may not be a curative, pain-free, long-term solution. Additionally, neither symptomatic therapies nor invasive and costly surgical procedures address the underlying cause of chronic and <span style="white-space:nowrap">age-related</span> degenerative diseases. Darnatein&#8217;s novel Design Augmented (DA) approach has the potential to overcome these limitations of spine and joint disorders and osteoarthritis with a regenerative therapy to overcome degeneration in bone and cartilage. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development plan for DRT-101 and DRT-102 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on preliminary tests of DRT-101 and DRT-102 indicating some efficacy in the treatment of osteoarthritis and spine fusion, respectively, Darnatein intends to expand the potential application of (1) DRT-101 to other cartilage regeneration targets, including spinal cartilage in the treatment of lower back pain and (2) DRT-102 to other bone regeneration targets, including non-fusion bone fracture in the treatment of deformed bone tissue, respectively. The company&#8217;s strategy generally involves the following key steps: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Identify novel cartilage- and bone-degenerative disorders: Darnatein will leverage its expert knowledge and experience in tissue regenerative medicine to identify new cartilage- and bone-degenerative disorders that can be targeted by Darnatein&#8217;s DRT-101 and DRT-102 platforms. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Conduct preclinical studies: Darnatein will first perform preclinical studies to evaluate the safety, immunogenicity, and efficacy of regenerating the new target tissue candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Initiate clinical trials: Based on the preclinical data, the company will design and conduct additional Phase 1/2 clinical trials to assess the safety, tolerability, and preliminary efficacy of its regeneration of those new tissue candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Conduct Phase 2/3 and Phase 3 clinical trials: Phase 3 trials are large-scale, randomized, controlled studies designed to provide additional supporting evidence of the efficacy and safety of therapeutic candidates. These trials typically involve hundreds to thousands of patients and are typically conducted </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td align="left" style="vertical-align:top">
at multiple hospital sites worldwide. Darnatein will work closely with clinical investigators, regulatory authorities, and patient advocacy groups to design and execute initially Phase 2/3, and continue with Phase 3 clinical trials based on evaluation of Phase 2/3 studies for its tissue targets. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Seek regulatory approval: Following the successful completion of Phase 3 clinical trials, Darnatein will compile the necessary data and documentation to submit a Biologics License Application (BLA) to the relevant regulatory authorities, such as the FDA or EMA. The company will work with these agencies to address any questions or concerns and to ensure that its therapeutic tools meet the required standards for BLA approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated timeframe for this process is generally as follows, and it will also follow each target&#8217;s therapeutic and clinical outcomes and its business priority. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Target discovery and development of formulation: 1-2 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Preclinical studies: 1-2 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1/2 clinical trials: 2 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3 clinical trials: 2-3 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Regulatory approval: 1-2 years </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on this timeline, Darnatein anticipates that its first therapeutic regimen to enter clinical trials within the next 2-3 years, with potential regulatory approval in the next 7-11 years. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Intellectual Property</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Darnatein owns exclusive intellectual property rights covered under 2 patent families relating to <span style="white-space:nowrap">DRT-101,</span> <span style="white-space:nowrap">DRT-102</span> and other associated candidates filed in the United States and across major markets, including Europe, China, India, and Japan. This patent family covers composition of matter, with a priority date of 2019 and estimated expiry in 2039, not including potential patent term adjustments or patent term extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Designer ligands of TGF-&#223; superfamily (Licensed Patent Rights) (0)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2010/099219, Exclusive License Agreement between Joint Center for Biosciences and Darnatein</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:18%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing no.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ.&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">WO</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2010</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT/US2010/025260</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2010/099219</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">EP</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2010</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">10746779</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">10/02/2016</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2401293B1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2401293</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2030</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">KR</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2010</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1020117021911</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">12/10/2015</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1015586420000</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1020110121642</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2030</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">granted</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">CA</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2010</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2752647A1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2752647</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2030</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Under<br/>Examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">JP</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2010</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2011551315</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">20/11/2015</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">5841845</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2012518420</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">24/02/2030</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">granted</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DRT-101 (SAB-704) (1)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WO 2020/101366, Activin/bmp7 chimeras: super-active sab704 and sab715, and their respective noggin-sensitized variants, nab704 and nab715; and nab204 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:6%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Country<br/>Code</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing no.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant&#160;no.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Publ. No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expiry</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">WO</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT/KR2019/015478</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">2020/101366</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">US</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">20210395322</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">20210395322</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2039</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Under<br/>Examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">EP</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">19885240</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">3880695</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2039</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Under<br/>Examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">KR</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1020217018273</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">1020210077790</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2039</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Under<br/>Examination</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top">CN</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">PCT</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">201980075594.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">113039199</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">13/11/2039</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Under<br/>Examination</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">RMC </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Corporate Overview</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RMC is a Korea-based neurovascular intervention medical device and systems distribution company exclusively serving the Korea market currently. RMC distributes, but does not design or manufacture, commercial medical products, including cerebral surgical devices. The table below shows the products and related systems currently distributed by RMC. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Company</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Product and System</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Penumbra</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peumbra reperfusion catheter-RED72, RED68, RED62, RED43</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuron Delivery Catheter</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Penumbra Tubing/Canister</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Asahi Intecc</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chikai Guide Wire</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fubuki Guide Catheter</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Micoroport Neurotech</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" colspan="3">Numen coil system</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Opportunity</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RMC distributes cerebrovascular surgery equipment in South Korea and seeks growth opportunities in South Korea for other medical device products and systems. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a rapidly aging country, demand for medical equipment is expected to accompany the rise in cerebrovascular diseases such as strokes. RMC has established close relationships with leading university hospitals and general hospitals in Korea to supply cerebrovascular surgery equipment. These relationships provide opportunities for continued sales of products distributed by RMC as well as assisting RMC in identifying demand for other medical devices that RMC may add to enhance its product portfolio. This is expected to enhance RMC&#8217;s competitiveness in South Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RMC has established a nationwide sales network and logistics system, enabling it to swiftly and efficiently supply products to any region in the country. This serves as a significant strength compared to competitors and is expected to contribute to building long-term trust with medical institutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Intellectual Property</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for trade secrets related to operating a medical product distribution business, there is no significant intellectual property owned or licensed by RMC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition in our Industry </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Competition for Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from pharmaceutical and biotechnology companies to public and private research institutions, among others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our current and/or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Our product candidates, if any are approved, may compete with these existing drug and other therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the main competitors we have identified for Vaximm&#8217;s VXM01. Each of these identified competitors are developing therapies for glioblastoma and have active clinical trials ongoing assessing the safety and efficacy of their product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:14%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:19%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Drug Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Mechanism</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indication</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Clinical<br/>Phase</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">NCT Number(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Depatuxizumab mafodotin <span style="white-space:nowrap">(ABT-414)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">AbbVie</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Antibody-drug conjugate targeting EGFR</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Newly diagnosed glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase&#160;2/3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT02573324</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Durvalumab (MEDI4736)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">AstraZeneca</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="white-space:nowrap">PD-L1</span> checkpoint inhibitor</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Newly diagnosed and recurrent glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT02336165</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Regorafenib</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Bayer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Multi-kinase inhibitor</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Recurrent glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT02926222</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Tasadenoturev <span style="white-space:nowrap">(DNX-2401)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">DNAtrix</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Oncolytic adenovirus</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Recurrent glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT03178032</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Ofranergene obadenovec <span style="white-space:nowrap">(VB-111)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">VBL&#160;Therapeutics</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Dual-targeted gene therapy</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Recurrent glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT02511405</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><span style="white-space:nowrap"><span style="white-space:nowrap">AV-GBM-1</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Aivita Biomedical</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Personalized dendritic cell vaccine</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Newly diagnosed glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT03400917</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><span style="white-space:nowrap">VAL-083</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kintara&#160;Therapeutics</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="white-space:nowrap">DNA-targeting</span> agent</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Recurrent and newly diagnosed glioblastoma</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2/3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT02717962, NCT03050736</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Darnatein, competition takes two forms: pharmaceutical products (drugs) that address the underlying causes of osteoarthritis, and orthopedic solutions involving bone graft and other products. Several pharmaceutical companies and research institutions are actively working on developing Disease-Modifying </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Osteoarthritis Drugs (DMOADs) to address the underlying causes of osteoarthritis (current treatments primarily focus on symptom management). There are currently no approved DMOAD treatments for osteoarthritis but the table below identifies drugs under development: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the main competitors we have identified for Darnatein&#8217;s <span style="white-space:nowrap">DRT-101.</span> Each of these identified competitors are developing therapies for osteoarthritis and have active clinical trials ongoing assessing the safety and efficacy of their product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:14%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:19%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:14%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Drug Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Mechanism</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indication</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Clinical<br/>Phase</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">NCT Number(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Invossa</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kolon&#160;TissueGene</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Cell and gene therapy <span style="white-space:nowrap">(TGF-&#223;1</span> expressing chondrocytes)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Osteoarthritis</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase&#160;3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT03383471</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Lorecivivint</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Biosplice Therapeutics</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">CLK/DYRK1A inhibitor</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Osteoarthritis</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NCT03928184</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Sprifermin</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Merck KGaA/EMD serono</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Recombinant human fibroblast growth factor 18</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Osteoarthritis</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Phase 2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NCT01919164</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NCT01033994</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the main competitors we have identified for Darnatein&#8217;s <span style="white-space:nowrap">DRT-102.</span> Each of these identified competitors are commercialized orthopedic solutions. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Drug Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Mechanism</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indication</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Infuse&#160;Bone&#160;Graft</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Medtronic</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="white-space:nowrap">rhBMP-2</span> and collagen sponge</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Spinal fusion, long bone fractures, orthopedic surgery</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Osteocel Plus</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">NuVasive</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Demineralized bone matrix (DBM) and mesenchymal stem cells (MSC)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Spinal fusion, bone defects</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Bio<sup style="font-size:75%; vertical-align:top">4</sup></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stryker</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">A viable bone matrix containing endogenous bone forming cells</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Bone repair and regeneration</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><span style="white-space:nowrap">i-Factor</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Cerapedics</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="white-space:nowrap">P-15</span> peptide and anorganic bone matrix</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Spinal fusion, bone defects</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Novabone IRM</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Novabone</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Composed of bioactive glass, chemically bonds with bone and promotes new bone formation</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Bone defects, dental grafting</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With aging populations comes a higher number of cerebrovascular disease patients. There are a number of potential treatments such as drug therapy and open surgery. Minimally invasive procedures, such as neurovascular intervention, have been growing. Various international medical device brands are competing for market share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the main competitors we have identified for RMC: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Device Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Mechanism</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indication</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">React catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Medtronic</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Reperfusion catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Treatment of acute ischemic stroke</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">AXS infinity catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stryker</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neurovascular Delivery catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Delivery of therapeutic devices in neurovascular procedures</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">AXS catalyst 7 distal access catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stryker</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Distal access support canister</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neurovascular access and support for device delivery</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Synchro wire</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stryker</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neurovascular guide wire</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Navigation through neurovascular anatomy</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Traxcess wire</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Microvention</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neurovascular guide wire</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Navigation through neurovascular anatomy</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Envoy guide catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Cerenovous</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neurovascular guide catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Support and delivery of neurointerventional devices</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Guider soft tip guide catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Boston scientific</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Soft tip neurovascular Guide catheter</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Support and delivery of neurointerventional devices</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Microplex coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Microvention</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Detachable embolization coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Embolization of intracranial aneurysms</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">GDC coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Stryker</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Detachable Coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Embolization of intracranial aneurysms</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/>
<td style="height:3.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Axium prime coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Medtronic</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Detachable Coil system</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Embolization of intracranial aneurysms</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities or personnel at this time, except that Darnatein maintains and uses manufacturing facilities owned by Joint Center for Biosciences, Darnatein&#8217;s affiliate and OSR Holdings&#8217; shareholder, for purposes of R&amp;D and clinical and preclinical materials for its sole use. We currently rely on CMOs for the manufacture of our product candidates for preclinical and clinical testing in non-commercial quantities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates include small molecules, vaccines, and monoclonal and bispecific antibodies. Several contract manufacturing facilities exist that have expertise in each product type and we anticipate that our product candidates can be produced by them at scale and in a cost-effective manner. As needed, we also expect to rely on CMOs for the manufacturing of companion diagnostics, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vaximm has a master service agreement with Richter-Helm BioLogics GmbH &amp; Co. KG (&#8220;RHB&#8221;), a contract manufacturing organization (CMO) located in Germany, for the manufacture of Vaximm&#8217;s product candidates. RHB will provide cell line development, process development, manufacturing, and related services for Vaximm&#8217;s product candidates. The agreement became effective April 10, 2012, and will remain in effect until terminated by either party. Vaximm pays RHB for services rendered based on agreed-upon rates specified in individual work orders. Vaximm retains ownership of all intellectual property related to its product candidates, while RHB owns IP related to manufacturing processes developed under the agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercialization </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will objectively assess and choose each program&#8217;s commercialization option that maximizes potential value for patients and for our stockholders. We anticipate optimizing commercial value through various options, including internal advancement, strategic partnerships, and spin-outs or public offerings. If we opt to commercialize a particular candidate ourselves, we anticipate assembling a commercialization team inclusive of sales and marketing operations to promote and sell our products. Our focus will be the community of relevant medical practitioners who are the key specialists in treating the patient populations for which our product candidates are being developed. We may also enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have marketing and sales management operations for any of our pharmaceutical products and will rely, at least initially, on third parties for support. The responsibilities of marketing operations would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. We will reevaluate the sales operations from time to time and may eventually build an <span style="white-space:nowrap">in-house</span> marketing and sales management organization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to extensive regulation by government authorities in the countries in which we do business. Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, manufacture, testing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, as well as diagnostics. Generally, before a new drug, biologic or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">United States Government Regulation of Drug and Biological Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs and biologics primarily under the Federal Food, Drug, and Cosmetic Act, or &#8220;<span style="text-decoration:underline">FD&amp;C Act</span>,&#8221; the Public Health Service Act, or &#8220;<span style="text-decoration:underline">PHSA</span>,&#8221; regulations implementing the FD&amp;C Act and PHSA, and other federal statutes and regulations. These laws and regulations govern areas such as the safety and efficacy of drugs and biologics, approvals, <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials, advertising and promotion, quality control, storage, manufacturing, labeling, distribution, post-market safety surveillance and reporting, and record keeping. Both drugs and biologics also are subject to other federal, state and local statutes and regulations, such as those related to competition. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development, approval, or post-approval processes may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, the market acceptance of our products and our reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pharmaceutical product candidates must be approved by the FDA through either a New Drug Application (NDA) or a Biologics License Application (BLA) before they may be legally marketed in the United States. Prior to filing for regulatory review and approval of any pharmaceutical product candidate, clinical trials must be conducted in escalating numbers of patients to demonstrate efficacy and safety. Although our clinical stage pharmaceutical product candidates have completed early clinical trials, we have not yet advanced any of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these pharmaceutical product candidates to later stage clinical trials. Accordingly, none of our product candidates have received FDA approval, nor have we advanced any product candidate to a stage where we&#8217;ve been eligible to apply for approval. The regulatory approval process, in the US, generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with Good Laboratory Practice (&#8220;<span style="text-decoration:underline">GLP</span>&#8221;) requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND application, which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an Institutional Review Board, or IRB, or independent ethics committee at each clinical trial site before each human trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with IRB approved clinical trial protocols, applicable IND regulations, Good Clinical Practices (&#8220;<span style="text-decoration:underline">GCP</span>&#8221;) requirements and other clinical trial-related regulations to establish the safety, efficacy and quality of the investigational product for each intended indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of an NDA or BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of one or more FDA <span style="white-space:nowrap">pre-approval</span> or <span style="white-space:nowrap">pre-license</span> inspections of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with Current Good Manufacturing Practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the clinical trial sites that generated the data in support of the NDA or BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of user fees for FDA review of the NDA or BLA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and the regulatory scheme for drugs and biologics is evolving and subject to change at any time. We cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any drug or biologic product candidate in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry, stability and formulation, as well as<span style="font-style:italic">&#160;in vitro</span>&#160;and <span style="font-style:italic">in vivo</span> animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin in the United States. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the planned trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding concerns before the clinical trial can begin in the United States. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Additionally, the review of information in an IND application may prompt FDA to, among other things, scrutinize existing INDs or marketed products and could generate requests for information or clinical holds on other product candidates or programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Trials </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant inclusion and exclusion criteria, and the parameters to be used to monitor safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by a centralized or independent IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves participant-facing materials, including the informed consent form that must be provided to each clinical trial participant or their legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the study was conducted in accordance with GCP requirements, including review and approval by an independent ethics committee and informed consent from subjects, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials, generally, are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 1</span>&#160;clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side- effect tolerability and safety of the product candidate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 2</span>&#160;clinical trials involve studies in disease-affected patients to evaluate proof of concept and/or determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 3</span>&#160;clinical trials generally involve a larger number of patients at multiple geographically dispersed clinical trial sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product candidate and provide an adequate basis for approval and product labeling. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are conducted to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials, if required, could result in withdrawal of conditional approval for product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA requires annual progress reports on the results of clinical trials as well as written IND safety reports promptly after the occurrence of serious and unexpected suspected adverse events in the trial or from other studies (animal or<span style="font-style:italic">&#160;in vitro</span>&#160;testing) that suggest a significant risk for humans. The report must include any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of such information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Concurrent with clinical trials, sponsors usually complete additional animal studies and also must provide additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or &#8220;<span style="text-decoration:underline">PDUFA</span>,&#8221; as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <span style="white-space:nowrap">non-orphan</span> indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a standard new molecular entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA may conduct a <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve a product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within the required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter, or &#8220;<span style="text-decoration:underline">CRL</span>.&#8221; An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The CRL may require the applicant to obtain additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and/or to complete other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing activities. If a CRL is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may seek to develop and obtain approval of its product candidates under programs designed to accelerate the development, FDA review and approval of new drugs and biologics that meet certain criteria. For example, the FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that are intended to treat a serious or life threatening disease or condition and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. For a fast track-designated product, the FDA may consider sections of the NDA or BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to designate the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product for fast track status any time before receiving NDA or BLA approval, but ideally no later than the <span style="white-space:nowrap">pre-NDA</span> or <span style="white-space:nowrap">pre-BLA</span> meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development or review, such as priority review and accelerated approval. Priority review means that, for a new molecular entity or original BLA, the FDA sets a target date for FDA action on the marketing application at six months after accepting the application for filing as opposed to ten months. A product is eligible for priority review if it is designed to treat a serious or life-threatening disease condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in an effort to facilitate the review. If criteria are not met for priority review, the application for a new molecular entity or original BLA is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program gathers the requisite nonclinical and clinical data for approval as efficiently as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the NDA or BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of adverse experiences, providing the FDA with updated safety and efficacy information, complying with promotion and advertising requirements, which include limitations on industry-sponsored scientific and educational activities and restrictions on promoting products for unapproved uses or patient populations (known as <span style="white-space:nowrap">&#8220;off-label</span> use&#8221;). Although physicians may, in their independent medical judgment, prescribe legally available products for <span style="white-space:nowrap">off-label</span> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses, and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability, including investigation by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. The FDA may also place other conditions on approvals including additional clinical trials or other studies, and for medications with serious safety concerns, the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to help ensure the benefits of the medication outweigh its risk. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve the NDA or BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for <span style="white-space:nowrap">non-compliance</span> with regulatory standards or if problems occur following initial marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations require that products be manufactured in specific registered facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including recall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if an approval is granted, the FDA may issue enforcement letters or withdraw the approval of the product if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug or biologic reaches the market. Corrective action could delay drug or biologic distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a drug or biologic, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include restrictions on the marketing of the drug or biologic, withdrawal of the drug from the market, fines and warning letters, safety alerts, consent decrees, injunctions or civil or criminal penalties, among other things. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">United States Patent Term Restoration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <span style="white-space:nowrap">one-half</span> the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trade Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biosimilars and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates will be regulated as biologics. An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an <span style="white-space:nowrap">FDA-licensed</span> reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, or &#8220;<span style="text-decoration:underline">BPCI Act</span>,&#8221; as part of the Affordable Care Act, or &#8220;<span style="text-decoration:underline">ACA</span>.&#8221; This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Regulatory Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, the Office of Inspector General and the Office for Civil Rights, as well as other divisions of the U.S. Department of Health&#160;&amp; Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Healthcare Laws in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, and third party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current and future arrangements with healthcare providers and physicians and any future arrangements with third party payors, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal AKS, the False Claims Act, and the federal HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act, or &#8220;<span style="text-decoration:underline">HITECH</span>.&#8221; The AKS makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. Violations </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010, or collectively the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal FD&amp;C Act constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following laws may also affect our business operations: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA created new federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Civil Monetary Penalties Statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by HITECH, and their implementing regulations imposes data privacy and security regulations that mandate, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Physician Payments Sunshine Act within the ACA requires that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, and their immediate family members. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Similar federal, state and foreign fraud and abuse laws and regulations may apply to sales or marketing arrangements and claims involving healthcare items or services. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State laws that require the registration or licensure of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws may be uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have long scrutinized interactions between pharmaceutical manufacturers and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Increasing Efforts to Cap or Reduce Prices of or Reimbursements for Drugs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs of new drugs with patent protection (and substantial price increases for drugs whose patent protection expired) in the U.S. has drawn attention from across the political spectrum, resulting in various proposals to cap or reduce drug prices. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022 the Inflation Reduction Act of 2022 was passed, which among other things, allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by up to15 Part D drugs in 2027, up to 15 Part B or Part D drugs in 2028, and up to 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> drug expenses at $2,000. The effect of the Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, requirements for substitution of generic products, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws, and future state and federal healthcare reform measures, which may include changes in payment methodologies, may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Packaging and Distribution in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements will apply. Further, products must meet applicable child-resistant packaging requirements under the United States Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional federal and state requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant penalties, including criminal prosecution, fines, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing and distribution arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other United States Environmental, Health and Safety Laws and Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Drug Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the Member State regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or &#8220;<span style="text-decoration:underline">NCA</span>,&#8221; and one or more Ethics Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and ECs of the Member State where they occurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing transparency. In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014 (the &#8220;<span style="font-weight:bold">Regulation</span>&#8221;), which is set to replace the current Clinical Trials Directive 2001/20/EC. The European Commission confirmed January&#160;31, 2022 as the date of entry into application of the Regulation and the <span style="white-space:nowrap">go-live</span> of the Clinical Trials Information System (&#8220;<span style="font-weight:bold">CTIS</span>&#8221;) by publishing a notice in the Official Journal of the European Union on July&#160;31, 2021. The new Regulation is directly applicable in all Member States (and so does not require national implementing legislation in each Member State), and aims at simplifying and streamlining the approval of clinical trials in the EU, for instance by providing for a streamlined application procedure via a single point and strictly defined deadlines for the assessment of clinical trial applications. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Drug Review and Approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA, which is comprised of the Member States of the EU plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a marketing authorization, or MA. There are two main types of marketing authorizations. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or &#8220;<span style="text-decoration:underline">CHMP</span>,&#8221; of the EMA, and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which is in the interest of public health in the European Union. Under the centralized procedure, the maximum timeframe for the evaluation of an MA application by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MA application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MA application under the accelerated assessment procedure is of 150 days, excluding stop-clocks, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this national MA can be recognized in other Member States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or &#8220;SmPC,&#8221; and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States, or CMSs) for their approval. If the CMSs raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (<span style="font-style:italic">i.e.</span>, in the RMS and the CMSs). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized MAs (under the Northern Irish Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on January&#160;1, 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Data and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, innovative medicinal products qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s <span style="white-space:nowrap">pre-clinical</span> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EEA. During the additional <span style="white-space:nowrap">two-year</span> period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. The overall <span style="white-space:nowrap">ten-year</span> period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained a marketing authorization based on an application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Orphan Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions which either affect not more than 5 in 10,000 persons in the European Union, or where it is unlikely that the marketing of the medicine would generate sufficient financial returns to justify the necessary investment in its development. In each case, no satisfactory method of diagnosis, prevention or treatment must have been authorized (or, if such a method exists, the product in question would be of significant benefit to those affected by the condition). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted following marketing approval for the orphan product. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. During the period of market exclusivity, marketing authorization may only be granted to a &#8220;similar medicinal product&#8221; for the same therapeutic indication if certain criteria are satisfied. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Drug Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the AKS prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to induce or reward improper performance generally is usually governed by the national anti-bribery laws of EU Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU and UK laws and regulations prohibit gifts, pecuniary advantages or benefits in kind supplied, offered or promised to such persons to promote medicinal products unless they are inexpensive and relevant to the practice of medicine or pharmacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Brexit and the Regulatory Framework in the United Kingdom </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the UK&#8217;s departure from the EU (commonly referred to as Brexit), the UK, EU pharmaceutical law no longer applies to the UK. The MHRA, the UK medicines and medical devices regulator, has published detailed guidance for industry and organizations to follow from January&#160;1, 2021, which will be updated as the UK&#8217;s regulatory position on medicinal products evolves over time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">European Data Collection </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collection and use of personal health data in the European Economic Area, or the EEA, is governed by the <span style="text-decoration:underline">GDPR</span> which became effective May&#160;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that processes personal data in connection with the offering of goods or services to data subjects in the EU or the monitoring of the behavior of data subjects in the European Union. The Company&#8217;s business may be affected by the requirements of, and potential penalties or liabilities imposed by the GDPR. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Laws and Regulations Governing International Operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or &#8220;<span style="text-decoration:underline">FCPA</span>,&#8221; prohibits any United States individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on United States exchanges for violations of the FCPA&#8217;s accounting provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization of new drug products depends, in part, on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. For example, in order to have our products covered by Medicaid, we must offer rebates to state Medicaid programs on purchases of certain of our pharmaceutical products under the Medicaid Drug Rebate program, based on pricing data reported by us on a monthly and quarterly basis. Any company that participates in the Medicaid Drug Rebate program also must participate in the 340B drug pricing program, and the Federal Supply Schedule (&#8220;<span style="text-decoration:underline">FSS</span>&#8221;) pricing program. The 340B program, which is administered by the Health Resources and Services Administration, requires participating companies to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs. The 340B ceiling price is calculated using a statutory formula, which is based on pricing data calculated under the Medicaid Drug Rebate program. The FSS pricing program, which is administered by the Department of Veterans Affairs (&#8220;<span style="text-decoration:underline">VA</span>&#8221;), also requires participating companies to extend discounted prices to the VA, Department of Defense, Coast Guard, and Public Health Service. Similar to the 340B program, FSS prices are calculated utilizing pricing data reported by us to the VA on a quarterly and annual basis. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, the federal agency within the U.S. Department of Health&#160;&amp; Human Services that administers the Medicaid and Medicare programs. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <span style="white-space:nowrap">so-called</span> health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, including our portfolio companies, we had 18 full-time employees, including Seunghyon Choe (a.k.a Senyon Choe in his academic publications), Dongsoo Kim, and Yeiseok Kim with Ph.D. or M.D. degrees and two who are engaged in research and development activities, and two part-time employees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive offices are located at <span style="white-space:nowrap">Hoedong-gil,</span> <span style="white-space:nowrap">37-36,</span> Paju, Gyeonggido, Republic of Korea. We do not have any manufacturing facilities or personnel at this time. We currently rely, and expect to continue to rely, on contract manufacturing organizations for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacturing if our product candidates receive marketing approval. Research and development efforts of our portfolio companies have primarily been through contract research organizations or in established research facilities, including at Vaximm headquarters in Mannheim, Germany. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our access to preclinical and clinical research facilities are adequate for our current needs and that suitable facilities at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_26">MANAGEMENT OF OSR HOLDINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors of OSR Holdings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of the directors and executive officers and OSR Holdings. For biographical information concerning the directors and executive officers, see below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Executive Officers and Directors</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Kuk Hyoun Hwang</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and Chairman of the Board of Directors</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Sung Jae Yu</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">44</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Operating Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Gihyoun Bang</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Sang Hoon Kim</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Head of Strategic Investments</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Chan Kyoo Park</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Kuk Hyoun Hwang,</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;Chief Executive Officer and Chairman of the Board of Directors </span></span>Kuk Hyoun Hwang&#160;has been the Chief Executive Officer and a director of the OSR Holdings since March 2020. Mr. Hwang is also the Chief Executive Officer and a director of BLAC. Mr.&#160;Hwang is the Managing Partner of Bellevue Capital Management (BCM), which he founded in August 2012. Since then, he has led BCM&#8217;s and its subsidiaries&#8217; growth and expansion as a cross-border healthcare investment group in three countries: the U.S., South Korea and Switzerland. He is also the Chief Executive Officer of BCM Europe, a position he has held since March 2020, and the Chairman of the Board of Vaximm AG since November 2022. Since July&#160;2019 until April 2021 and December 2022 to present, Mr.&#160;Hwang has also served as Chief Executive Officer of OSR Holdings Co., Ltd., a global drug development company and a subsidiary of BCM, where he has also served as chairman since July 2019. Prior to founding BCM in 2012, Mr.&#160;Hwang served with financial services firms in Korea and the U.S., including North Head Capital Partners LLC from 2011-2012, Kim Eng Research Korea and Kim Eng Securities USA from 2006-2008, and Shinhan Investment Corp from 2002-2004 and 2006. Mr.&#160;Hwang received a BA in sociology from Korea University in 1998. We believe Mr.&#160;Hwang is well qualified as Executive Chairman of the Board of Directors because of his significant investment and capital markets expertise within the healthcare industry. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sung Jae Yu, Chief Operating Officer and Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sung Jae Yu is the Chief Operating Officer and Director of OSR Holdings, a position he has held since December 2019. From March 2008 to October 2019, Mr.&#160;Yu served as Manager in the Planning&#160;&amp; Research Office of the Korean Financial Investment Association (&#8220;<span style="text-decoration:underline">KOFIA</span>&#8221;), the sole self-regulatory organization of the Korean financial investment industry, whose responsibilities include the development of the nation&#8217;s capital market and financial investment services industry, enacting regulations and codes of best practices for fair business activities, registering and administering qualification exams for financial professionals, and mediating disputes between member companies and their customers. From March 2017 to December 2018, Mr.&#160;Yu also served on the Financial Reform <span style="white-space:nowrap">On-site</span> Inspection Task Force, a committee established by the Korean government and the Financial Supervisory Service. Mr.&#160;Yu is proficient in English. Mr.&#160;Yu earned his BA in Public Administration from Korea University in 2006. Mr.&#160;Yu earned his BA in Public Administration from Korea University in 2006. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gihyoun Bang, Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gihyoun Bang is the Chief Financial Officer of OSR Holdings, a position he has held since June 2024.&#160;Mr.&#160;Bang is responsible for planning, managing and running overall finance activities of OSR Holdings and its subsidiary companies, including producing the group&#8217;s consolidated financial statements for external </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
audits. Previously, Mr. Bang served as chief operating officer for Newlake Alliance Management Co., Ltd., a private equity firm based in Seoul, South Korea, from February 2019 to June 2024, where he led private equity investments, managed fund raising and managed the organization. Mr. Bang previously served as team head, equity capital markets, and other positions for Shinhan Securities Co. Ltd., in South Korea.&#160;Mr. Bang is a certified public accountant in the U.S., a certified credit analyst in Korea and a certified investment manager in Korea. Mr. Bang received his B.A. in Business Administration from Hansung University in 2002. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sang Hoon Kim, Head of Strategic Investments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sang Hoon Kim is Head of Strategic Investments of OSR Holdings, a position he has held since December 2023. Prior to joining OSR Holdings, he was Managing Director of APC Private Equity from August 2021 to September 2022. Before APC Private Equity, Mr. Kim was Head of Alternative Investment Division for over ten&#160;years at Meritz Asset Management from August 2012 to October 2021 where he managed diverse global investment funds totaling over two billion U.S dollars. Prior to Meritz Asset Management, from June 2000 to June 2007, he was Manager of Fixed Income Trading team at Hana Securities. Mr. Kim is proficient in English. He earned his LL.B from Konkuk University, Korea in 1998 and earned an LL.M from the University of Minnesota, Twin Cities in 2010. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Chan Kyoo Park, Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chan Kyoo Park is a Director of OSR Holdings, a position he has held since December 2022, when RMC became an OSR Holdings&#8217; subsidiary. Mr.&#160;Park is Chief Executive Officer of RMC, which he founded in 2015. Prior to establishing RMC, in 2007 he <span style="white-space:nowrap">co-founded</span> Hutem Co., Ltd., an importer and distributor of neuro-intervention medical devices in Korea. In 2014, he and his <span style="white-space:nowrap">co-founder</span> sold the company to Hugel, Inc., a KOSDAQ listed healthcare company. Previously, Mr.&#160;Park held sales and marketing positions with Boston Scientific Korea (2004-2007) and Janssen Korea (2000-2004). Mr.&#160;Park earned a BA in Economics from Kyunghee University (1998). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_27">EXECUTIVE AND DIRECTOR COMPENSATION OF OSR HOLDINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for OSR Holdings&#8217; executive officers who would be OSR Holdings&#8217; &#8220;named executive officers&#8221; if OSR Holdings was subject to the reporting requirements under the Exchange&#160;Act. We expect that at least some of these executive officers will be named executive officers of the Combined Company after the Closing. For the fiscal year ending December&#160;31, 2023, OSR Holdings&#8217; &#8220;named executive officers&#8221; and their positions were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Kuk Hyoun Hwang, Chief Executive Officer and Chairman of the Board of Directors </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Sung Jae Yu, Chief Operating Officer and a Board Director </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Soo Eun Nam, Chief Financial Officer </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Sang Hoon Kim, Head of Strategic Investments </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to OSR Holdings&#8217; named executive officers for the year ended December&#160;31, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br/>Awards<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span><br/>Incentive Plan<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer&#160;&amp; Chairman</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sung Jae Yu</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Operating Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soo Eun Nam(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sung Hoon Chung(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Managing Director</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sang Hoon Kim(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Head of Strategic Investments</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Resigned as of May 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Resigned as of August&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Hired December 1, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary element of compensation for OSR Holdings&#8217; named executive officers is base salary. OSR Holdings did not pay any bonus nor grant any equity awards to its named executive officers in 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Annual Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The salaries of OSR Holdings&#8217; named executive officers are set by the Board of Directors and reviewed and adjusted periodically. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two individuals of OSR Holdings&#8217; named executive officers, Soo Eun Nam, CFO, and Sang Hoon Kim, Head of Strategic Investments, are entitled to receive a cash bonus under the terms of their employment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements. The amount of their bonuses and the performance metrics and goals required to receive bonus are determined annually by the OSR Holdings&#8217; Board based on appropriate comparative company benchmarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For 2022, with respect to Ms. Nam, and 2023, with respect to Ms. Nam and Mr Kim, there were no bonuses or any other form of <span style="white-space:nowrap">non-equity</span> incentive compensation paid or accrued. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Defined Contribution Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings currently maintains a defined contribution plan for all of its officers and employees as required by Korean law. A defined contribution plan is a retirement pension plan in which OSR Holdings pays a fixed amount of contributions to a separate fund for the benefit of each employee, which is one twelfth (1/12) of annual salary to the retirement plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, all of the board directors of OSR Holdings have been also serving as executive officers of the company and received the cash compensation disclosed above, except for Mr.&#160;Hwang, who receives no cash compensation for his service as an executive officer or director. OSR Holdings does not pay directors any cash or equity-based compensation for their service as directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_28">OSR HOLDINGS MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion should be read in conjunction with &#8220;Unaudited Pro Forma Condensed Consolidated Combined Financial Information,&#8221; &#8220;Selected Historical Financial Data of OSR Holdings&#8221; and OSR Holdings&#8217; audited and unaudited condensed consolidated financial statements, including the notes thereto, included elsewhere in this proxy statement/prospectus. In addition to historical financial information, this discussion contains forward-looking&#160;statements based upon OSR Holdings&#8217; current expectations that involve risks and uncertainties. OSR Holdings&#8217; actual results could differ materially from such forward-looking&#160;statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this proxy statement/prospectus. Historical information contained in this section refers to OSR Holdings and its consolidated subsidiaries (where applicable) prior to the completion of the Business Combination; forward looking information contained in this section refers to New OSR Holdings following BLAC&#8217;s acquisition of OSR Holdings (as described below and in other sections of this proxy statement/prospectus). References included in this section to &#8220;we&#8221;, &#8220;its,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to OSR Holdings and its consolidated subsidiaries.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Introduction </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings is a global drug development company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformative therapies. Although we are indication agnostic, our initial focus is addressing unmet needs in oncology and immunology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a data-driven company, we leverage our existing and expanding network of academic and industry leaders by identifying and advancing therapeutic candidates based on innovative research to add to our current pipeline of potential <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> therapies (a class of therapies leveraging new and unique mechanisms of action). Relying on our experienced drug development and leadership teams, our model is to support and empower scientific leaders, allowing them to focus their undivided attention on research and scientific innovations while advancing therapeutic candidates through the drug development process. Our approach revolves around meticulously crafted disease strategies for our drug candidates, which enhances our overall pipeline strategy and therapeutic indication focus. By recognizing the need to bridge preclinical research within a translational clinical context, we aim to streamline the drug development process to optimize our path to market and maximize the potential for success. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combination and Public Company Costs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings has executed a Business Combination Agreement with BLAC pursuant to which stockholders of OSR Holdings will exchange their securities for common stock of BLAC. As a result of the Business Combination, OSR Holdings will become a majority-owned subsidiary of BLAC. The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, BLAC will be treated as the &#8220;acquired&#8221; company and OSR Holdings will be considered the accounting acquirer for accounting purposes. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of a capital transaction in which BLAC is issuing securities for the net assets of OSR Holdings. The net assets of OSR Holdings will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Business Combination, BLAC, under the name New OSR Holdings, will remain the <span style="white-space:nowrap">SEC-registered&#160;and</span> Nasdaq-listed&#160;company, which will require New OSR Holdings to hire or contract additional personnel and implement procedures and processes to address public company regulatory requirements and customary practices. New OSR Holdings expects to incur additional annual expenses as a public company for, among other things, directors&#8217; and officers&#8217; liability insurance, director fees, and additional internal and external accounting, legal, and administrative resources, including increased personnel costs, audit, and other professional service fees. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings was incorporated in the Republic of Korea in July 2019 and, in October 2019, Bellevue Capital Management LLC (&#8220;<span style="text-decoration:underline">BCM</span>&#8221;) invested KRW 505&#160;million in exchange for 101,000 shares, its first material capital infusion. In 2021, OSR Holdings raised equity capital three additional times from BCM and OSR Holdings&#8217; officers to raise a total of KRW one billion. In March 2022, OSR Holdings raised KRW 4.63&#160;billion from additional investors. As of the closing of the March 2022 investment, OSR Holdings had raised total equity capital of KRW 6.135&#160;billion to finance its business activities, primarily analyzing the pharmaceutical industry and strengthening its corporate capabilities. In March 2022, OSR Holdings subscribed for 1,750 preference shares of Bellevue Capital Management Europe (&#8220;<span style="text-decoration:underline">BCME</span>&#8221;), a wholly-owned subsidiary of BCM, for $3.5&#160;million. In February 2023, OSR Holdings issued convertible bonds with 1 year maturity, at an interest rate of 9.0%, raising KRW 5.09&#160;billion. All of these convertible bonds issued by OSR Holdings have been converted into shares of OSR Holdings common stock as of October&#160;17, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial startup period for OSR Holdings involved primarily building the company&#8217;s team, and structuring and conducting the capital raises needed for its business operations. The <span style="white-space:nowrap">COVID-19</span> pandemic delayed OSR Holdings&#8217; efforts to build its business by a few years, but beginning in 2022 and continuing in 2023, OSR Holdings has devoted its resources to run its business operations, including the acquisitions of its current subsidiaries (as described below), and to the business combination agreement with BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing in <span style="white-space:nowrap">mid-2022,</span> OSR Holdings&#8217; activities involved identifying, negotiating and structuring three acquisitions, as described below, including its &#8220;anchor acquisition,&#8221; Vaximm AG (&#8220;<span style="text-decoration:underline">Vaximm</span>&#8221;), a Basel, Switzerland-based company developing DNA cancer vaccine treatments. Vaximm was owned in part by BCME. On December&#160;13, 2022, OSR Holdings acquired 92.13% of the outstanding equity securities of Vaximm from BCME. The purchase price for the 92.13% of Vaximm was paid by issuing 696,225 shares of OSR Holdings&#8217; common stock to BCME in a stock swap transaction. OSR Holdings also acquired the remaining 7.87% of Vaximm&#8217;s outstanding equity through two subsequent transactions: (1)&#160;on January&#160;19, 2023, OSR Holdings exercised an option to acquire the 4.89%, or 38,909 shares, of Vaximm held by BCME, by exchanging 1,750 BCME preference shares held by OSR Holdings; and (2)&#160;on February&#160;2, 2023, OSR Holdings purchased 23,656 shares (2.98%) of Vaximm held by BCME for $3.6&#160;million in cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, OSR Holdings invested KRW 97,742,345 for a 33% interest in Taction Co., Ltd., a Korean software development and consulting firm. Taction has ceased operations and has no practical plan to generate revenue; OSR Holdings has recognized impairment loss amounting to its acquisition cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;26, 2022, OSR Holdings acquired all of the outstanding shares of RMC Co., Ltd., a South Korean neuro-intervention medical device distributor. OSR Holdings issued 70,847 shares of OSR Holdings&#8217; common stock to the sole shareholder of RMC, Mr.&#160;Chan Kyu Park, the founder and CEO of RMC, and also a minority shareholder of OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2023, OSR Holdings acquired all of the outstanding shares of Darnatein, an Incheon, South Korea-based corporation that is developing therapies for <span style="white-space:nowrap">age-related</span> and degenerative diseases and their associated chronic disorders and complications. OSR Holdings issued to the stockholders of Darnatein 590,425 shares of OSR Holdings&#8217; common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a consolidated basis, OSR Holdings has funded its operations primarily through the issuance of common shares, convertible preferred shares and convertible bonds. As of December&#160;31, 2023, on a consolidated basis, OSR Holdings has raised a cumulative KRW 11.64&#160;billion in gross proceeds through the issuance of common shares, convertible preferred shares and debt (including bank loans of KRW 443.25&#160;million made to RMC). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings has incurred net losses each year since inception except for 2022 when OSR Holdings recorded a net profit of KRW 1.3&#160;billion due to a <span style="white-space:nowrap">one-time</span> gain <span style="white-space:nowrap">(non-cash)</span> on the exchange of the 1,750 BCME </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">272 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preference shares for shares of Vaximm. OSR Holdings&#8217; net loss in 2021 was KRW 634.35&#160;million. OSR Holdings recorded a net profit of KRW 1.34&#160;billion in 2022 and a net loss of KRW 13.09&#160;billion for the year ended December&#160;31, 2023. New OSR Holdings expects to continue to incur significant losses for the foreseeable future due mainly to its R&amp;D expenses and working capital requirements as its subsidiaries continue to ramp up their development activities. As of December&#160;31, 2023, OSR Holdings had an accumulated deficit of KRW&#160;13.19&#160;billion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings expects its operating expenses to increase significantly in the second half of 2024 largely due to increased legal and other expenses incurred in connection with the Agreement and to a lesser extent the cost of product revenue. New OSR Holdings expects its operating expenses to increase further in 2025 as its subsidiaries continue to develop their pipelines of <span style="white-space:nowrap">pre-clinical</span> and clinical product candidates, while New OSR Holdings continues to identify and invest in startup and/or acquisition opportunities in the global healthcare sector. In addition, New OSR Holdings expects its selling, general and administrative expenses to increase beginning in 2024, after closing of the Business Combination, due to modest increases in headcount along with anticipated expenses associated with becoming a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings expects that current cash resources plus the gross proceeds of approximately $20&#160;million expected from the PIPE Financing, will provide sufficient funding to support its continued operations into 2026. The issuance of PIPE Financing may adversely affect the market price for New OSR Holdings common stock. Based on our current plans and estimates, we anticipate this financial runway will allow New OSR Holdings to fund the research and development, <span style="white-space:nowrap">pre-clinical</span> studies, clinical trials and administrative expenses of its portfolio companies into 2026. There are, however, a number of factors that could affect that timing, such as the timing of securing regulatory approval to initiate clinical trials, the timing of initiating enrollment of each study, the rate of enrollment, the loss of clinical trial participants to trial visits, the time it takes to finalize data analysis, the time to finalize content and deliver <span style="white-space:nowrap">top-line&#160;data,</span> as well as other factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings may seek additional funding through the issuance of its common shares or other securities. The issuance of common shares or other securities may adversely affect the market price for New OSR Holdings common stock. New OSR Holdings may seek to obtain new loan facilities, and may, over time, receive payments from licensing or selling its portfolio companies or their technologies, or through collaborations or partnerships with other companies. The amount and timing of New OSR Holdings&#8217; future funding requirements will depend on many factors, including the pace of, execution on, and strength of results from its clinical trials and other research, development, manufacturing and commercialization activities, as well as the potential receipt of revenues under future collaborations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is actively pursuing entering into one or more subscription agreements (collectively, the &#8220;<span style="text-decoration:underline">Subscription Agreements</span>&#8221;) with certain institutional and accredited investors (collectively, the &#8220;<span style="text-decoration:underline">PIPE Investors</span>&#8221;) pursuant to which the PIPE Investors will agree to purchase, prior to or substantially concurrently with the closing of the Business Combination, equity, or debt or preferred securities issuable by BLAC and/or OSR Holdings convertible into BLAC Common Stock, for aggregate gross proceeds of at least $20,000,000 (the &#8220;<span style="text-decoration:underline">PIPE Financing</span>&#8221;). The securities to be issued to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act&#8221;</span>), in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act and/or Regulation S adopted thereunder. BLAC has obtained a letter of intent from Toonon Partners Co., Ltd. (&#8220;<span style="text-decoration:underline">Toonon</span>&#8221;), a Korean investment firm, dated June 24, 2024, pursuant to which Toonon indicated its interest to purchase $20,000,000 of BLAC&#8217;s equity securities in connection with the closing of the Business Combination. The terms of the proposed transaction are under current negotiation and, assuming all terms are finalized, will be set forth in a definitive agreement to be executed between BLAC and Toonon. The PIPE Financing, if completed, will dilute the ownership of existing BLAC stockholders, and may depress the value of shares of New OSR Holdings Common Stock. It is not currently anticipated that Sponsor or any BLAC or OSR Holdings affiliates will participate in the PIPE Financing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">273 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impacts of <span style="white-space:nowrap">COVID-19</span> and Market Conditions on Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings has been actively monitoring the <span style="white-space:nowrap">COVID-19</span> situation and its impact globally, but we have not, except for delaying the implementation of our business plan, been significantly impacted. Disruption of global financial markets and a recession or market correction, including new public health emergencies, the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, the conflicts in the Middle East and other global macroeconomic factors such as inflation, could reduce New OSR Holdings&#8217; ability to access capital, which could, in the future, negatively affect our liquidity and could materially affect our business and the value of our common shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components and Comparison of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the&#160;Years Ended December&#160;31, 2022 and 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents OSR Holdings&#8217; statements of operations for the&#160;years ended December&#160;31, 2022 and 2023, and the Korean won (<span style="text-decoration:line-through">W</span>) and percentage change between the two&#160;years: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended December&#160;31,</span><br/><span style="font-weight:bold">(Korean won in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change $</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,453,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,453,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,930,194</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,958,119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,930</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,742,785</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,958,119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,779</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-operating</span> income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,129,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(989,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,119,205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(146</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,732,365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,077,323</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,270</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue was KRW 4.5B, consisting of sales of medical devices by the Company&#8217;s RMC subsidiary in South Korea, which was acquired by the Company in late December 2022, and the first year the Company had operating revenue (the Company had <span style="white-space:nowrap">non-operating</span> income in 2022 from a <span style="white-space:nowrap">one-time</span> gain on the disposition of certain financial assets, as described below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cost of sales </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of sales was KRW 3.3B, consisting of costs of medical devices purchased (for resale) by the Company&#8217;s RMC subsidiary in South Korea. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross profit </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit was KRW 1.2B from the sales of medical devices by the Company&#8217;s RMC subsidiary in South Korea. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Administrative expenses consist of personnel-related&#160;expenses, including salaries, benefits, bonus, and travel. Other administrative expenses include amortization of intangible assets, research and development expenses, professional services fees, such as legal, audit, and investor/press relations, research and development expenses, <span style="white-space:nowrap">non-income&#160;taxes,</span> insurance costs, cost of outside consultants and employee recruiting and training </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">274 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs. Administrative expenses increased 1,930% in 2023, primarily as a result of the amortization of acquired patents (81%) and consolidation of expenses acquired by subsidiaries (15%) which were not reflected in 2022 financial results. Moreover, New OSR Holdings expects to incur additional expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and SEC compliance and investor relations. New OSR Holdings expects quarterly selling, general and administrative expenses, excluding stock compensation expense, to increase to an average of approximately $1.5 million&#160;per quarter from <span style="white-space:nowrap">mid-2024</span> through the end of 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Operating</span> Income (Loss) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance income decreased from KRW 2.3&#160;billion in 2022 to KRW 25&#160;million in 2023. In 2022, the Company had a <span style="white-space:nowrap">one-time</span> gain from the disposal of financial assets of KRW 2.3&#160;billion. Other finance income, consisting of interest income, increased by 912% in 2023 from 2022, from KRW 2.5&#160;million to KRW 25&#160;million, as a result of higher balances on interest bearing funds. Finance costs, consisting of interest expense, increased by 2,626%, from KRW 18&#160;million to KRW 490&#160;million, as a result of outstanding indebtedness of KRW 960&#160;million during 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit (loss) before income tax decreased 1,270% from a profit of KRW 1.3B in 2022 to a loss of KRW&#160;15.7B in 2023, primarily (89%) due to the increase in administrative expenses, offset in part <span style="white-space:nowrap">(-7%)</span> by the gross profit from the Company&#8217;s RMC subsidiary. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the&#160;Years Ended December&#160;31, 2021 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents OSR Holdings&#8217; statements of operations for the&#160;years ended December&#160;31, 2021 and 2022, and the KRW and percentage change between the two&#160;years: (Note: the figures in the table are from the FY2022 audit report which did not consolidate the operating results of Vaximm and RMC for that year, as required by IFRS.) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:57%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended December&#160;31,</span><br/><span style="font-weight:bold">(Korean won in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change $</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634,910</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(149,757</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634,910</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(149,757</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634,910</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,667</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(149,757</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-operating</span> income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,129,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,129,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">379,124</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net profit (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634,348</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,979,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(312</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Administrative expenses increased by 24% in 2022, primarily due to increases in salary and benefits, and professional fees. New OSR Holdings expects to incur additional expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and SEC compliance and investor relations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Operating</span> Income (Loss) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance costs are attributable primarily to interest on outstanding loans. As of December&#160;31, 2022, OSR Holdings held interest-bearing debt positions with a Korean bank (Woori Bank) as well as with several </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">275 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals in a combined outstanding balance of KRW 1.6&#160;billion. The Woori Bank loan and the individual loan arrangements (each loan was short term debt) accrued interest at fixed rates of 5.54% and 7.0% respectively, were unsecured and had maturity dates of November&#160;3, 2023 and February&#160;2, 2024 while the long term Woori debt of KRW 160&#160;million accrued interest at KORIBOR+1.91%. See Note&#160;17 to our annual consolidated financial statements included elsewhere in this proxy statement/prospectus. RMC borrowed these funds prior to our acquisition for general corporate purposes (working capital loans). The Woori Bank loan was repaid on November&#160;3, 2023, while a combined balance of KRW one billion owed to several individual lenders was restructured into OSR Holdings convertible bonds on February&#160;2, 2023 and converted into OSR Holdings common stock on October&#160;17, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net profit (loss) increased from a loss of KRW 634.3&#160;million in 2021 to net income of KRW 1.3&#160;billion in 2022, primarily from the (noncash) gain on the 1,750 BCM preference shares used in the acquisition of shares of Vaximm, offset by slightly higher administrative expenses<span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From inception through December&#160;31, 2023, OSR Holdings has incurred significant operating losses and negative cash flows from its operations. OSR Holdings&#8217; operating losses were KRW 784.7&#160;million and KRW&#160;14.7&#160;billion for the&#160;years ended December&#160;31, 2022 and December&#160;31, 2023, respectively. As of December&#160;31, 2023, OSR Holdings had an accumulated deficit of KRW 13.5&#160;billion. OSR Holdings has funded its operations primarily through the issuance of common shares, convertible preferred shares, convertible bonds as well as from bank loans and, to a lesser extent, from RMC product revenue. OSR Holdings (primarily through its subsidiaries) has raised a cumulative KRW 11.6&#160;billion in gross proceeds through the issuance of common stock and convertible preferred shares. OSR Holdings had KRW 696.5&#160;million in cash and cash equivalents at December&#160;31, 2023, which consisted primarily of bank deposits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Funding Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings expects its operating expenses to increase significantly as New OSR Holdings continues to develop its pipeline of <span style="white-space:nowrap">pre-clinical</span> and clinical product candidates and while it continues to identify and invest in startup and acquisition opportunities. New OSR Holdings&#8217; R&amp;D spending is expected to increase from historical levels beginning in the second half of 2024 and for the foreseeable future as it funds all of the costs of its subsidiaries. In addition, New OSR Holdings expects its selling, general and administrative expenses to increase due to modest increases in headcount along with anticipated expenses associated with being a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings expects that current cash resources plus the gross proceeds of approximately $20&#160;million expected from the PIPE Financing will provide sufficient funding to support its continued operations into 2026. New OSR Holdings may seek additional funding through the issuance of New OSR Holdings&#8217; common shares, may make drawdowns on its existing or new loan facilities, or through payments from collaborations or partnerships with other companies, and/or may realize cash from collaborations or partnerships with other companies, and/or through divestment from the sale of some or all of its strategic holdings, although there are no assurances those sources of funding will be realized. The amount and timing of New OSR Holdings&#8217; future funding requirements will depend on many factors, including the pace of execution on and strength of results from its clinical trials and other research, development, manufacturing and commercialization activities or future collaborations. The issuance of New OSR Holdings&#8217; common shares and the PIPE Financing may adversely affect the market price of New OSR Holdings common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">276 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes OSR Holdings&#8217; cash flow data for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended December&#160;31,</span><br/><span style="font-weight:bold">(KRW in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(652,051</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,100,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,161,262</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,955,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,163,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,142,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,908,764</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings and its subsidiaries have entered into various contractual arrangements that involve future payments, such as on leases, clinical trials, other R&amp;D activities and minimum purchases of medical devices (for resale). New OSR Holdings&#8217; obligations for those payments in 2024, which vary in time and amount, are currently expected to be approximately KRW 7.55 billion, the material amounts of which are described in the following table. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:80%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span><br/><span style="font-weight:bold">(KRW&#160;in&#160;thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments related to clinical trials</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,426,262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments required for minimum purchases of medical devices and systems</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,376,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other required payments (none of which individually is material)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,572,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,552,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Currency Exchange Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our subsidiaries are located outside the U.S., including Korea, Switzerland, and France, and their expenses are generally denominated in the currencies of the jurisdictions in which they conduct operations. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. We experience fluctuations in net loss as a result of transaction gains or losses related to remeasuring certain assets and liability balances that are denominated in foreign currencies. These exposures may change over time as business practices evolve and economic conditions change. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and OSR Holdings has not engaged in any foreign currency hedging transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Segments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings operates and manages the business as one reportable and operating segment, which is the business of a global healthcare holding company creating, acquiring and developing pharmaceutical and healthcare technologies. Our chief executive officer reviews financial information on an aggregate basis for allocating and evaluating financial performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings did not have during the periods presented, and we do not currently have, any <span style="white-space:nowrap">off-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">277 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company and Smaller Reporting Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups (JOBS) Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. New OSR Holdings has elected to not &#8220;opt out&#8221; of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an emerging growth company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Bioscience is also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by <span style="white-space:nowrap">non-affiliates</span> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is expected to be less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#160;the market value of our stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700&#160;million. If we are a smaller reporting company at the time that we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <span style="white-space:nowrap">10-K</span> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings&#8217; financial statements are prepared in accordance with International Financial Reporting Standards (IFRS).&#160;The preparation of the financial statements in conformity with IFRS requires OSR Holdings&#8217; management to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. OSR Holdings evaluates its significant estimates on an ongoing basis, including estimates related to the total costs expected to be incurred from the imports and inventory investments for RMC&#8217;s medical device business, research and development prepayments, accruals and related expenses, and stock-based&#160;compensation. OSR Holdings bases its estimates on historical experience and on various other assumptions that OSR Holdings believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings believes that the accounting policies described below involve a significant degree of judgment and complexity. Accordingly, OSR Holdings believes these are the most critical to aid in fully understanding and evaluating its financial condition and results of operations. For further information, see Note&#160;2,<span style="font-style:italic"></span><span style="font-style:italic">&#160;Summary of Significant Accounting Policies</span>, to the audited financial statements included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue for sale of products by RMC at the point in time when the customer obtains control of the goods, which is generally at the time of delivery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings&#8217; revenues are currently comprised of product revenue from the sale of medical devices by RMC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The product revenues consist of a single performance obligation, and the payment terms are typically 30&#160;days. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">278 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Prepayments, Accruals and Related Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings incurs costs of R&amp;D activities conducted by third-party&#160;service providers, which include the conduct of preclinical studies and clinical trials. We are required to estimate our prepaid and accrued R&amp;D costs at each reporting period, which occurs on a quarterly basis. These estimates are made as of the reporting period of the work completed over the life of the individual study in accordance with agreements established with our service providers. OSR Holdings determines the estimates of R&amp;D activities incurred at the end of each reporting period through discussion with internal personnel and external service providers, as to the progress or stage of completion as of the end of the reporting period, pursuant to contracts with the third parties and the agreed upon fee to be paid for such services. Nonrefundable advance payments for goods or services to be received in the future for use in R&amp;D activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are accepted by OSR Holdings or the services are performed. Accruals are recorded for the amounts of services provided that have not yet been invoiced. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financial Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A financial instrument is any contract that allows a financial asset to be created for one of the parties to the transaction and a financial liability or equity instrument to be created for the counterparty. OSR Holdings classifies financial assets at subsequent initial recognition as financial assets at amortized cost, financial assets at fair value through other comprehensive income (&#8220;<span style="text-decoration:underline">FVOCI</span>&#8221;) and financial assets at fair value through profit or loss (&#8220;<span style="text-decoration:underline">FVTPL</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases or sales of financial assets (structured transactions) that are required to transfer financial assets within the timeframe set by the market arrangement or regulation are recognized on the transaction date. That is, the date OSR Holdings agrees to buy or sell financial assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Subsequent measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For subsequent measurement, financial assets are classified into the following four categories: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at amortized cost (debt instrument) </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVOCI reclassified cumulative gain or loss to profit or loss (debt instrument) </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVOCI for which the cumulative gain or loss on removal is not reclassified to profit or loss (equity instrument) </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVTPL </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) Financial assets at FVTPL </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss. This category includes derivative instruments and listed equity investments which OSR Holdings had not irrevocably elected to classify at fair value through other comprehensive income (&#8220;<span style="text-decoration:underline">OCI</span>&#8221;). Dividends on listed equity investments are recognized as other income in the statement of profit or loss when the right of payment has been established. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(2) Financial assets at FVOCI (debt instrument) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For debt instruments at fair value through OCI, interest income, foreign exchange revaluation and impairment losses or reversals are recognized in the statement of profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit or loss. OSR Holdings&#8217; debt instruments at fair value through OCI includes investments in quoted debt instruments under other <span style="white-space:nowrap">non-current</span> financial assets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">279 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(3) Financial assets at FVOCI (equity instrument) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon initial recognition, OSR Holdings can elect to classify irrevocably its equity investments as equity instruments designated at fair value through OCI when they meet the definition of equity under IAS 32 Financial Instruments: Presentation and are not held for trading. This classification is determined on an <span style="white-space:nowrap"><span style="white-space:nowrap">instrument-by-instrument</span></span> basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except when OSR Holdings benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment. OSR Holdings elected to classify irrevocably its <span style="white-space:nowrap">non-listed</span> equity investments under this category. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(4) Financial assets at amortized cost (debt instruments) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets at amortized cost are subsequently measured using the effective interest rate (&#8220;<span style="text-decoration:underline">EIR</span>&#8221;) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired. OSR Holdings&#8217; financial assets at amortized cost includes trade receivables and other financial assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Derecognition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from OSR Holdings&#8217; consolidated statement of financial position) when: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The rights to receive cash flows from the asset have expired, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">OSR Holdings has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a &#8216;pass-through&#8217; arrangement; and either (a)&#160;OSR Holdings has transferred substantially all the risks and rewards of the asset, or (b)&#160;OSR Holdings has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When OSR Holdings has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, OSR Holdings continues to recognize the transferred asset to the extent of its continuing involvement. In that case, OSR Holdings also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that OSR Holdings has retained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that OSR Holdings could be required to repay. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impairment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings assesses, on a forward-looking basis, the expected credit losses associated with its debt instruments carried at amortized cost and fair value through OCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk. However, for trade receivables and lease receivables, OSR Holdings applies the simplified method of recognizing expected credit losses over the entire period from the initial recognition of the receivables. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">280 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OSR Holdings evaluates whether credit risk in financial assets or financial assets significantly increases at the end of each reporting period and recognizes <span style="white-space:nowrap">12-month</span> expected credit losses or lifetime expected losses as loss allowance in three stages as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:65%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Stage</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Loss provision</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;No significant increase in credit risk after initial recognition</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="white-space:nowrap">12-month</span> expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;Significant increase in credit risk after initial recognition</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;Credit-impaired</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:middle">Lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant financial difficulties of the debtor, delinquency in interest or principal payments for more than 3 months, or the disappearance of an active market for that financial asset because of financial difficulties are considered evidence of impairment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial liabilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Initial recognition and measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. OSR Holdings&#8217; financial liabilities include trade and other payables, loans and borrowings include bank overdrafts, and derivative financial instruments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of subsequent measurement, financial liabilities are classified in two categories: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#8226;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial liabilities at fair value through profit or loss </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">&#8226;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial liabilities at amortized cost (loans and borrowings) </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Financial liabilities at fair value through profit or loss </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by OSR Holdings that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit or loss. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. OSR Holdings has not designated any financial liability at fair value through profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Financial liabilities at amortized cost </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is the category most relevant to OSR Holdings. After initial recognition, interest-bearing borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">281 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loss when the liabilities are derecognized as well as through the EIR amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit or loss. This category generally applies to interest-bearing loans and borrowings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derecognition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Offsetting of financial instruments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Classification as debt or equity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intangible assets acquired separately </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets with finite useful lives that are acquired separately are carried at cost, less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost, less accumulated impairment losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Internally</span>-<span style="font-weight:bold">generated</span> <span style="font-weight:bold">intangible</span> <span style="font-weight:bold">assets</span> <span style="font-weight:bold">&#8211;</span> <span style="font-weight:bold">research</span> <span style="font-weight:bold">and</span> <span style="font-weight:bold">development</span> <span style="font-weight:bold">expenditure</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following conditions have been demonstrated: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The technical feasibility of completing the intangible asset so that it will be available for use or sale </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The intention to complete the intangible asset and use or sell it </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The ability to use or sell the intangible asset </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">How the intangible asset will generate probable future economic benefits </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The ability to measure reliably the expenditure attributable to the intangible asset during its development </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">282 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to initial recognition, internally-generated intangible assets are reported at cost, less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intangible assets acquired in a business combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets acquired in a business combination and recognized separately from goodwill are recognized initially at their fair value at the acquisition date (which is regarded as their cost). Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Derecognition of intangible assets </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An intangible asset is derecognized upon disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impairment of equipment and vehicles and intangible assets excluding goodwill. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each reporting date, OSR Holdings reviews the carrying amounts of its equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, OSR Holdings estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash- generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is an indication at the end of a reporting period that the asset may be impaired. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a <span style="white-space:nowrap">pre-tax</span> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease and to the extent that the impairment loss is greater than the related revaluation surplus, the excess impairment loss is recognized in profit or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount so that the increased carrying amount does not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">283 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss to the extent that it eliminates the impairment loss which has been recognized for the asset in prior years. Any increase in excess of this amount is treated as a revaluation increase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combinations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Business combinations are initially accounted for on a provisional basis. The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the parent taking into consideration all available information at the reporting date. Fair value adjustments on the finalization of the business combination accounting are retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortization reported. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investments in Associates and Joint Ventures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An associate is an entity over which OSR Holdings has &#8220;significant influence&#8221;, which refers to the power to participate in the financial and operating policy decisions of the investee, but does not include control or joint control over those policies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The considerations made in determining significant influence or joint control are similar to those necessary to determine control over subsidiaries. OSR Holdings&#8217; investments in its associates and joint ventures are accounted for using the equity method. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the equity method, the investment in an associate or a joint venture is initially recognized at cost. The carrying amount of the investment is adjusted to recognize changes in OSR Holdings&#8217; share of net assets of the associate or joint venture since the acquisition date. Goodwill relating to the associate or joint venture is included in the carrying amount of the investment and is not tested for impairment separately. The statement of profit or loss reflects OSR Holdings&#8217; share of the results of operations of the associate or joint venture. Any change in OCI of those investees is presented as part of OSR Holdings&#8217; OCI. In addition, when there has been a change recognized directly in the equity of the associate or joint venture, OSR Holdings recognizes its share of any changes, when applicable, in the statement of changes in equity. Unrealized gains and losses resulting from transactions between OSR Holdings and the associate or joint venture are eliminated to the extent of the interest in the associate or joint venture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate of OSR Holdings&#8217; share of profit or loss of an associate or joint venture is shown on the face of the statement of profit or loss outside operating profit and represents profit or loss after tax and non-controlling interests in the subsidiaries of the associate or joint venture. The financial statements of the associate or joint venture are prepared for the same reporting period as OSR Holdings. When necessary, adjustments are made to bring the accounting policies in line with those of OSR Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After application of the equity method, OSR Holdings determines whether it is necessary to recognize an impairment loss on its investment in its associate or joint venture. At each reporting date, OSR Holdings determines whether there is objective evidence that the investment in the associate or joint venture is impaired. If there is such evidence, OSR Holdings calculates the amount of impairment as the difference between the recoverable amount of the associate or joint venture and its carrying value, and then recognizes the loss within &#8216;Gains or losses from equity method&#8217; in the statement of profit or loss. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">284 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon loss of significant influence over the associate or joint control over the joint venture, OSR Holdings measures and recognizes any retained investment at its fair value. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment and proceeds from disposal is recognized in profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inventories </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchased goods are stated at the lower of cost and net realizable value on a &#8216;first in first out&#8217; basis. Cost comprises of direct materials and delivery costs, direct labor, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity, and, where applicable, transfers from cash flow hedging reserves in equity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock in transit is stated at the lower of cost and net realizable value. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">285 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_29">CERTAIN OSR HOLDINGS RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, Mr.&#160;Sung Jae Yu loaned OSR Holdings $230,946 (KRW 300,000,000) pursuant to a Loan Agreement between Mr.&#160;Yu and OSR Holdings (the &#8220;<span style="text-decoration:underline">Yu Loan</span>&#8221;).&#160;The Yu Loan does not bear interest, is unsecured prior to default, and matured on February 14, 2024. Mr. Yu and OSR Holdings agreed (1) OSR Holdings would pay Mr. Yu approximately $38,491 (KRW 33,000,000) on April 1, 2024; and (2) to defer repayment of the balance of the Yu Loan until the closing of the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">286 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_30">INFORMATION ABOUT BLAC </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is a Delaware blank check company incorporated on February&#160;25, 2020 formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Business Combination with OSR Holdings is the result of an active search for a potential business combination transaction utilizing the network and investing and transaction experience of BLAC&#8217;s management team and the BLAC Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Significant Activities since Inception </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;14, 2023, BLAC consummated its initial public offering of an aggregate of 6,000,000 units, at $10.00 per unit (&#8220;<span style="text-decoration:underline">Units</span>&#8221;), generating gross proceeds of $60,000,000 before underwriting discounts and expenses. Simultaneously with the closing of BLAC&#8217;s IPO, the Sponsor purchased an aggregate of 430,000 units at a price of $10.00 per unit, for an aggregate purchase price of $4,300,000 (&#8220;<span style="text-decoration:underline">Private Placement Units</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the IPO, the underwriters were granted a <span style="white-space:nowrap">45-day</span> option from the date of IPO prospectus (the &#8220;<span style="text-decoration:underline">Over-Allotment Option</span>&#8221;) to purchase up to 900,000 additional Units to cover over-allotments (the &#8220;<span style="text-decoration:underline">Over-Allotment Units</span>&#8221;), if any. On February&#160;21, 2023, the underwriters purchased 900,000 Over-Allotment Units fully exercising the Over-Allotment Option. The Over-Allotment Units were sold at an offering price of $10.00 per Over-Allotment Unit, generating additional gross proceeds of $9,000,000 to BLAC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effecting a Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;16, 2023, BLAC entered into the Business Combination Agreement, which was amended and restated on May 23, 2024. As a result of the transaction and if approved at the BLAC Stockholders&#8217; Meeting, BLAC will change its name to &#8220;OSR Holdings, Inc.&#8221; while OSR Holdings will become a majority owned subsidiary of the BLAC. In the event that the Business Combination is not consummated by the Termination Date, BLAC&#8217;s corporate existence will cease and BLAC will distribute the proceeds held in the Trust Account to its Public Stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption Rights for Holders of Public Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC is providing its Public Stockholders with redemption rights upon consummation of the Business Combination. Public Stockholders electing to exercise their redemption rights will be entitled to receive the cash amount specified in the proxy statement/prospectus, provided that such stockholders follow the specific procedures for redemption set forth in this proxy statement/prospectus relating to the shareholder vote on the Business Combination. BLAC&#8217;s Public Stockholders are not required to vote against the Business Combination in order to exercise their redemption rights. If the Business Combination is not completed, then Public Stockholders electing to exercise their redemption rights will not be entitled to receive such payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor, BLAC&#8217;s officers and directors and their respective affiliates agreed, at the time of the IPO, in order to induce the underwriters of the IPO to enter into the underwriting agreement and for no additional separate consideration, to vote their BLAC&#160;shares of Common Stock in favor of the Business Combination and to waive their redemption rights with respect to any capital stock they may hold in connection with the consummation of the Business Combination. However, any BLAC shares of Common Stock acquired outside of the redemption offer set forth in this proxy statement/prospectus will not be voted in favor of approving the Business Combination Proposal and also will not carry redemption rights. See the section titled &#8220;<span style="font-style:italic">Proposal No. 1 &#8212; The Business Combination Proposal</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">287 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation on Redemption Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, our Amended and Restated Certificate of Incorporation provides that a public stockholder, together with its affiliates or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Exchange Act), will be restricted from exercising redemptions with respect to an aggregate of 15% or more of the shares sold in BLAC&#8217;s IPO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no full time employees and do not intend to have any full time employees prior to consummation of the Business Combination. Each of our executive officers and directors is engaged in other business endeavours and is not obligated to contribute any specific number of hours per week to our affairs, but they intend to devote as much of their time as they deem necessary to our affairs until we have completed the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently maintain our principal executive offices at 10900 NE 4th Street, Suite 2300, Bellevue, WA&#160;98004. The cost for this space is included in the $7,500 per-month&#160;fee (subject to deferral as described herein) payable to an affiliate of our Sponsor, for office space, utilities and secretarial services. Our agreement with an affiliate of our Sponsor provides that, commencing on March&#160;1, 2023 and until we consummate a business combination or we liquidate, such office space, as well as utilities and secretarial services, will be made available to us as may be required from time to time. We believe that the fee charged by an affiliate of our Sponsor is at least as favorable as we could have obtained from an unaffiliated person. We consider our current office space, combined with the other office space otherwise available to our executive officers, adequate for our current operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial condition or results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">288 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_31">EXECUTIVE OFFICERS AND DIRECTORS OF BLAC </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information about our directors and executive officers as of [&#9679;], 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:46%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Kuk Hyoun Hwang*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">David J. Yoo</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jun Chul Whang</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jin Whan Park</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Phil Geon Lee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Sang Hyun Kim</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Mr.&#160;Hwang&#8217;s biography, please see &#8220;<span style="font-style:italic">Management of OSR Holdings &#8212; Executive Officers and Directors</span> of OSR Holdings.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">David J. Yoo</span>&#160;has been the Chief Financial Officer of BLAC since September 2021. Mr.&#160;Yoo has over 25 years of experience in corporate finance, investment analysis and public company management. Since October 2022, Mr.&#160;Yoo has served as the Manager, Omnichannel Sales at Keeco LLC, a textile manufacturer. From July 2019, to October 2022 Mr.&#160;Yoo served as the executive director and operating management member of Decorstandard Corp., an early-stage designer and distributor of PVC and <span style="white-space:nowrap">PPU-based</span> interior solutions in Bergenfield, NJ. From March 2013 to January 2019, Mr.&#160;Yoo was the president and CEO of Agabang USA, Inc. the wholly-owned subsidiary of Agabang&#160;&amp; Company, Ltd, (KOSDAQ: 013990), a Korean vertically integrated retailer of infant and children&#8217;s apparel and accessories. Before Agabang, Mr.&#160;Yoo was the managing director and partner, from August 2010 to March 2013, of China Select Capital Partners Corp. subsequently acquired by Roadman Investments Corp, a TSXV-listed investment issuer. Mr.&#160;Yoo was the CFO of Ord Mountain Resources Corp., (TSXV: OSR) a portfolio company of Roadman Investments Corp, from July 2019 until February 2021. From 2008 to 2010, Mr.&#160;Yoo was the managing director at SF Investment, a Seoul-based private equity firm. Mr.&#160;Yoo was also at Early Bird Capital from 2004 to 2008, as a vice president in investment banking focused on Special Purpose Acquisition Companies. Mr.&#160;Yoo was previously in various investment analyst roles at firms including Dalewood Associates, Ardour Capital, KPMG International and the Doosan Group. He has served as a director and member of the audit committee at Tremisis Energy Acquisition Corp II (NYSE Amex: TGY). Mr.&#160;Yoo earned a BA in Psychology from the University of California at Berkeley and an MBA in finance from the Leonard N. Stern School of Business at New York University. We believe Mr.&#160;Yoo is well qualified as an officer because of his significant capital markets, investment and public company operating experiences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jun Chul Whang</span>&#160;has been a director of BLAC since August 2020. Mr.&#160;Whang has been an advisor to BCM since January 2015, and starting in June 2018, has served as General Counsel and consultant to BCM. In August 2020, he became a member of BCM. As a Member and as General Counsel, Mr.&#160;Whang provides legal and strategic advice to BCM across a range of matters. Mr.&#160;Whang is General Counsel to Minetta Brook Capital LLC (a capital raising firm) from December 2020 to present and was General Counsel to ELA Partners (an affiliate of Stonehaven, a global capital raising fintech platform) (2019-July 2023). From May 2016 to May 2018, Mr.&#160;Whang was Partner at the law firm of Greenspoon Marder (&#8220;<span style="text-decoration:underline">GM</span>&#8221;). Mr.&#160;Whang was also Partner (having joined as an associate) at the law firm of Jacob, Medinger&#160;&amp; Finnegan, LLP (&#8220;<span style="text-decoration:underline">JMF</span>&#8221;) from July 1992 until May 2016, when JMF merged with GM. From 1990 to 1992, Mr.&#160;Whang was an associate attorney with Cadwalader Wickersham&#160;&amp; Taft. During his career as an attorney, Mr.&#160;Whang represented major international companies in product liability litigation and regulatory risk management domestically and internationally (Europe and Korea). His language capabilities include Korean, Spanish, French and Japanese (conversational). Mr.&#160;Whang earned a BA in Government from Dartmouth College (1986), a JD from Cornell Law School (1989), and an LLM in International and Comparative Law from Georgetown Law Center (1990). We believe Mr.&#160;Whang is well </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">289 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified to serve as a director because of his varied and extensive legal experience, including his role as General Counsel to BCM since 2018. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jin Whan Park</span>&#160;has been a director at BLAC since February 2023. Mr.&#160;Park has served as Chief Executive Officer of JWP&#160;&amp; Partners since founding the firm in 2011. From 2006 to 2012, Mr.&#160;Park was Director and Head of Investment Banking at Yuhwa Securities, where he advised on M&amp;A transactions for corporate clients listed on the KOSDAQ. From 2008 to 2009, he was President of Biomass Korea, where he negotiated a supplier contract with Samsung Electronics and oversaw biomass production. From 2001 to 2006, he was Deputy Chief Executive Officer of AdNetworks where he provided investment consulting services for public companies in Korea. From 2000 to 2001, Mr.&#160;Park was Chief Financial Officer and Chief Marketing Officer at KRBIZ, which was an IT consulting business with major clients including Samsung, Korea University and Nonghyup Credit Agricole Asset Management. Mr.&#160;Park began his career at Hana Bank in their Corporate Finance Unit, where he worked as a loan officer and credit analyst from 1994 to 2000. Mr.&#160;Park is an active board member at Sungbo Scholarship Foundation, a family trust established in September 2018 by the founders of Yuhwa Securities. Mr.&#160;Park received his BA in Business Administration from Korea University (1994). We believe Mr.&#160;Park is well qualified to serve as a director considering his history of company leadership and track record in executing transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Phil Geon Lee</span>&#160;Phil Geon Lee<span style="font-weight:bold"> </span>has been a director of BLAC since May 2024. Mr.&#160;Lee possesses over 20&#160;years of experience in legal and investment fields. His areas of expertise cover a range of fund classes, including regulatory, transactional, and hedge funds, and encompass knowledge of financial regulatory frameworks in various jurisdictions such as the SEC (US), FCA (UK), MAS (Singapore), CSSF (Luxembourg), and FSS (Korea). His legal career includes significant experience in handling litigations and disputes in securities, consumer protection, antitrust laws across multiple countries including Korea, U.S., Germany, France, Japan, Poland, etc. Mr. Lee&#8217;s transactional experience includes managing over 300 deals in private equity and real estate transactions. Mr.&#160;Lee currently holds the position of Managing Director at IGIS (May 2023-Present), the largest real estate investment adviser in Korea (AUM US $48 billion). His previous roles include Chief Compliance Officer at IKR Co., Ltd. (a joint venture between IGIS Asset Management and KKR &amp; Co. Inc.) (February 2023 to April 2023), CEO of Tropics Private Equity Co., Ltd. (2021-2023), Managing Director at KDS Asset Management Co., Ltd. (2020-2021), Head of Legal at Korea Investment Corporation (2016-2019), Head of Legal at National Pension Service (2013-2016), and Head of Legal at Woori Asset Management Company (2011-2013). His earlier career also includes positions at Joowon (a Korean law firm, 2009-2011); Biomass Korea (former KOSDAQ-listed company, 2008-2009), Franklin Templeton Investment Management Co., Ltd. (a wholly-owned subsidiary of Franklin Resources, Inc., a NYSE-listed company 2002-2007), and Accenture (a NYSE-listed company 2000-2002). Mr.&#160;Lee earned a BA in Psychology from Korea University (1992), an MBA from Haas School of Business, University of California at Berkeley (1995), and a JD from Syracuse University College of Law (1999) with a final year at Georgetown University Law Center in Washington, D.C. We believe Mr.&#160;Lee is well qualified to serve as a Director because of his membership in the New York State Bar and extensive experience in both legal and investment sectors across various asset classes, demonstrating significant expertise in capital markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Sang Hyun Kim</span> has been a director at BLAC since June 2024.<span style="font-weight:bold"> </span>Sang Hyun Kim will become a Director at the closing of the business combination transaction. Mr. Kim currently serves as the Head of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd. the position held by him since January 2021. Prior to that, Mr. Kim has spent approximately 11 years working in different positions with Samsung Group&#8217;s financial business arms which include Samsung Fire and Marine Non-Life Insurance (Corporate Planning and Strategy Department) and Samsung Asset Management (as Chief Strategy Officer and the Regional Managing Director in Beijing, China). Prior to his tenure with Samsung Group, Mr. Kim spent about 6 years working as management consultant at Accenture and A.T. Kearney. Serving as management consultant, Mr. Kim has conducted a number of strategic consulting projects for the clients in financial industry such as major banks, brokers, insurances and credit card companies in Korea. Mr. Kim has passed the High-Level Government Official Examination in 1993 which led him to his government-sector career from 1994 through 2001 during which time he was able to participate in global trade negotiation projects in the field of agricultural goods, and he also joined the Korean </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">290 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
National Negotiation Team to represent South Korea in multilateral trade communications such as WTO, APEC and Bilateral Trade Consultations (FTA). Mr. Kim earned his MBA degree from Georgetown University in 2001, and his M.A. (Public Policy) and B.S. (International Economics) from Seoul National University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Number and Terms of Office of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s board of directors has five directors, three of whom are &#8220;independent&#8221; under SEC and Nasdaq rules, and two officers. In accordance with Nasdaq corporate governance requirements, BLAC is not required to hold an annual meeting until one year after its first fiscal year end following its listing on Nasdaq. The term of office of our initial directors will expire at our first annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s two officers were appointed by the BLAC Board and serve at the discretion of the BLAC Board, rather than for specific terms of office. The BLAC Board is authorized to appoint persons to the offices set forth in BLAC&#8217;s Current Bylaws as it deems appropriate. BLAC&#8217;s Bylaws provide that our officers may consist of a Chairman of the Board, a Chief Executive Officer, Chief Financial Officer, President, Vice Presidents, Secretary, Treasurer, Assistant Secretaries and such other offices as may be determined by the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of the Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has two standing committees: an audit committee and a compensation committee. Subject to <span style="white-space:nowrap">phase-in</span> rules and a limited exception, Nasdaq rules and Rule <span style="white-space:nowrap">10A-3</span> of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors, and Nasdaq rules require that the compensation committee of a listed company be comprised solely of independent directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has established an audit committee of the board of directors. Mr.&#160;Park, Mr. Lee and Mr. Kim serve as members of the audit committee, and Mr. Park is the chair of the audit committee. Under the Nasdaq listing standards and applicable SEC rules, BLAC is required to have at least three members of the audit committee, all of whom must be independent. Each of Mr.&#160;Park, Mr. Lee and Mr. Kim meet the independent director standard under Nasdaq listing standards and under Rule <span style="white-space:nowrap"><span style="white-space:nowrap">10-A-3(b)(1)</span></span> of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the audit committee is financially literate and BLAC&#8217;s Board has determined that Mr.&#160;Park qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has adopted an audit committee charter which details the principal functions of the audit committee, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by BLAC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> all audit and permitted <span style="white-space:nowrap">non-audit</span> services to be provided by the independent registered public accounting firm, including but not limited to, as required by applicable laws and regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">setting clear hiring policies for employees or former employees of the independent registered public accounting firm, including but not limited to, as required by applicable laws and regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">setting clear policies for audit partner rotation in compliance with applicable laws and regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i)&#160;the independent registered public accounting firm&#8217;s internal quality-control procedures, (ii)&#160;any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">291 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
any steps taken to deal with such issues and (iii)&#160;all relationships between the independent registered public accounting firm and BLAC to assess the independent registered public accounting firm&#8217;s independence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K</span> promulgated by the SEC prior to entering into such transaction; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise<span style="font-weight:bold"></span>&#160;material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other&#160;regulatory authorities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s Audit Committee Charter is included as an exhibit to its annual report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023. BLAC&#8217;s Audit Committee Charter can also be reviewed by accessing our public filings at the SEC&#8217;s web site at www.sec.gov. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has established a compensation committee of the board of directors. Mr. Lee and Mr. Kim serve as members of the compensation committee. Under the Nasdaq listing standards and applicable SEC rules, BLAC is required to have at least two members of the compensation committee, all of whom must be independent. Mr.&#160;Lee and Mr. Kim are independent and Mr. Lee is the chair of the compensation committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has adopted a compensation committee charter details the principal functions of the compensation committee, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, if any is paid by us, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving on an annual basis the compensation, if any is paid by us, of all of our other officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing on an annual basis our executive compensation policies and plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implementing and administering our incentive compensation equity-based remuneration plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting management in complying with our proxy statement and annual report disclosure requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if required, producing a report on executive compensation to be included in our annual proxy statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other advisor and will be directly responsible for the appointment, compensation and oversight of the work of any such advisor. However, before engaging or<span style="font-weight:bold"></span>&#160;receiving advice from a compensation consultant, external legal counsel or any other advisor, the compensation committee will consider the independence of each such advisor, including the factors required by Nasdaq and the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">292 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Nominations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC does not have a standing nominating committee though we intend to form a corporate governance and nominating committee as and when required to do so by law or Nasdaq rules. In accordance with Rule 5605 of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee. The directors who will participate in the consideration and recommendation of director nominees are Mr.&#160;Park, Mr Lee and Mr. Kim. In accordance with Rule 5605 of the Nasdaq rules, all such directors are independent. As there is no standing nominating committee, we do not have a nominating committee charter in place. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors will also consider director candidates recommended for nomination by our stockholders during such times as they are seeking proposed nominees to stand for election at the next annual meeting of stockholders (or, if applicable, a special meeting of stockholders). Our stockholders that wish to nominate a director for election to our board of directors should follow the procedures set forth in our bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has adopted a Code of Ethics applicable to our directors, officers and employees. BLAC&#8217;s Code of Ethics is included as an exhibit to its annual report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023. You can also review the Code of Ethics by accessing our public filings at the SEC&#8217;s web site at www.sec.gov. In addition, a copy of the Code of Ethics will be provided without charge upon request from us. BLAC intends to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a current report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">293 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a table summarizing the entities to which our executive officers and directors currently have fiduciary duties or contractual obligations: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:23%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:23%"/>

<td style="vertical-align:bottom"/>
<td style="width:21%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Individual<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Entity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Entity&#8217;s Business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Affiliation</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Kuk Hyoun Hwang</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Bellevue Capital Management</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Partner</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">OSR Holdings Ltd.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Healthcare Holding Company</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chairman of Board and CEO</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">BCM Europe</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Officer</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Bellevue Global Life Sciences Investors, LLC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Vaximm AG</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Biotech Company</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">David J. Yoo</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Keeco LLC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Textile Manufacturer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Manager, Omnichannel Sales</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jun Chul Whang</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Bellevue Capital Management</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">General Counsel and Member</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Minetta Brook Capital LLC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">General Counsel and Member</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Phil Geon Lee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">IGIS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Real Estate Investment Advisor</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Director</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Sang Hyun Kim</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Daesung Asset Management Co., Ltd.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Investment Advisor</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Head of Marketing, Private Equity Funds</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jin Whan Park</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">JWP&#160;&amp; Partners</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consulting</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Officer</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Sungbo Scholarship Foundation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Nonprofit</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each person has a fiduciary duty with respect to the listed entities next to their respective names. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation on Liability and Indemnification of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s Current Charter provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. BLAC&#8217;s Current Charter provides that our directors will not be personally liable for monetary damages to us or our stockholders for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our amended and restated certificate of incorporation. BLAC&#8217;s Current Bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We may, but are not obligated to, purchase a policy of directors&#8217; and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">294 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions, the directors&#8217; and officers&#8217; liability insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our officers has received any cash compensation for services rendered to us. We have paid and will continue to pay an affiliate of our Sponsor a total of $7,500 per month for office space, utilities and secretarial and administrative support. Upon completion of our initial business combination, we will cease paying these monthly fees. No compensation of any kind, including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to our Sponsor, officers, directors or any affiliate of our Sponsor, officers or directors, prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is) except that we may pay BCM and/or any of its affiliates, partners or employees a fee for financial advisory services rendered in connection with our identification, negotiation and consummation of our initial business combination; the amount of any fee we pay to BCM and/or any of its affiliates, partners or employees will be based upon the prevailing market for similar services for such transactions at such time, and will be subject to the review of our audit committee pursuant to the audit committee&#8217;s policies and procedures relating to transactions that may present conflicts of interest. Our officers and directors will be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers, directors, advisors or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the Trust Account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with identifying and consummating an initial business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor has transferred 20,000 founder shares to each of Drs. Chung, Reed and Roberts and Messrs. Euh and Mr. Park for his board service and Mr.&#160;Yoo for his service as chief financial officer.&#160;Our Sponsor additionally transferred 20,000 private placement warrants to each of Dr.&#160;Reed for his service as chairman of the board of directors, Dr.&#160;Chung for his service as chair of the audit committee, and Mr.&#160;Yoo for his service as chief financial officer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">295 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_32">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF BLAC </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering and the private placement units, the proceeds of the sale of our capital stock in connection with our initial business combination, shares issued to the owners of the target, debt issued to banks or other lenders or the owners of the target, or a combination of the foregoing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our entire activity since inception through March 31, 2024 related to our formation and initial public offering. We do not expect to generate any operating revenues until after the completion of an initial business combination. We generated <span style="white-space:nowrap">non-operating</span> income in the form of interest income on investments held after our initial public offering. We will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, an initial business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2024, we had net loss of $60,430 which consisted of income from investments held in the Trust Account of $480,824,&#160;offset by general and administrative expenses of $450,781&#160;and provision for income taxes of $90,473. For the three months ended March 31, 2023, we had net income of $110,305, which consisted of income from investments held in the Trust Account of $417,728, offset by general and administrative expenses of $278,102 and provision for income taxes of $29,321. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity, Capital Resources and Going Concern Consideration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our initial public offering, our liquidity needs were satisfied through the sale of our capital securities and the issuance of unsecured promissory notes to our Sponsor. Upon the closing of our initial public offering, the unsecured promissory notes were deemed to be repaid and settled. Further, we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. We received net proceeds of $70,610,000 from the sale of Units in our initial public offering and from the sale of our Private Placement Units. Of this amount, $70,207,500 was placed in the Trust Account, including $2,070,000 of deferred underwriting commissions. The proceeds held in the Trust Account are invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under <span style="white-space:nowrap">Rule&#160;2a-7&#160;under</span> the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;9, 2023, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which BLAC must complete its initial business combination to February&#160;14, 2024 (from November&#160;14, 2023) and with an option for the board of directors of BLAC, in its discretion, to extend again to May&#160;14, 2024. In February 2024, the board of directors of BLAC decided to extend the period of time in which BLAC must complete its initial business combination to May 14, 2024. In connection with the special meeting, holders of 3,432,046 shares of BLAC Common Stock elected to redeem such shares, representing approximately 50% of the outstanding public shares of BLAC Common Stock as of November 7, 2023, for a per share redemption price of approximately $10.49, resulting in an aggregate reduction of the amount in the Trust Account by $35,995,727.58, representing approximately 50% of the total amount in the Trust Account as of November 7, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 14, 2024, at a special meeting of the BLAC stockholders, BLAC stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to extend the period of time in which </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">296 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BLAC must complete its initial business combination to November&#160;14, 2024 (from May&#160;14, 2024). In connection with the special meeting, holders of 1,581,733 shares of BLAC Common Stock elected to redeem such shares, representing approximately 45.61% of the outstanding public shares of BLAC Common Stock as of May 22, 2024, for a per share redemption price of approximately $10.78, resulting in an aggregate reduction of the amount in the Trust Account by $17,045,763, representing approximately 45.61% of the total amount in the Trust Account as of May 22, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, the amount of funds currently held in the Trust Account is approximately $20,500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the trust account (less deferred underwriting commissions), to complete the Business Combination. We may withdraw interest to pay taxes. We estimate our annual franchise tax obligations, based on the number of authorized shares of our common stock, to be $200,000, which is the maximum amount of annual franchise taxes payable by us as a Delaware corporation per annum, which we may pay from funds held outside of the Trust Account or from interest earned on the funds held in our Trust Account and released to us for this purpose. Our annual income tax obligations will depend on the amount of interest and other income earned on the amounts held in the Trust Account. We expect the interest earned on the amount in the Trust Account will be sufficient to pay our income taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2024, BLAC had $3,637 in its operating bank account and a working capital deficit of $2,676,899. BLAC&#8217;s liquidity needs prior to the consummation of its initial public offering had been satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of its initial public offering, BLAC&#8217;s liquidity was satisfied through the net proceeds from the consummation of the initial public offering, the proceeds from the Private Placement Units held outside of the Trust Account and loans from the Sponsor, officers and directors and their affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to fund working capital requirements or finance transaction costs in connection with the Business Combination, our Sponsor, officers and directors or their affiliates may, but are not obligated to, loan us funds. Such loaned amounts will be repaid if we complete our initial business combination. In the event that our initial business combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,000,000 of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation of our initial business combination. The units would be identical to the private placement units. We do not expect to seek loans from parties other than our Sponsor, officers and directors or their affiliates as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. Loans made by Chardan, the representative of the underwriters in connection with our initial public offering, or any of its related persons, if any, will not be convertible into any of our securities and Chardan and its related persons will have no recourse with respect to their ability to convert their loans into any of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing and the limited amount of working capital that BLAC received into the operating account from the private placement, management believes that BLAC will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an initial business combination or 21&#160;months from the initial public offering. These conditions raise substantial doubt about BLAC&#8217;s ability to continue as a going concern. Over this time period, BLAC will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial business combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">297 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummating the initial business combination. Further needs for operating capital beyond BLAC&#8217;s current operating cash balance may need to be funded through loans from BLAC&#8217;s Sponsor. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If BLAC is unable to complete a business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents), BLAC will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether BLAC has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raises substantial doubt about BLAC&#8217;s ability to continue as a going concern. Management plans to evaluate potential business combination opportunities and intends to complete a business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no obligations, assets or liabilities which would be considered <span style="white-space:nowrap">off-balance</span> sheet arrangements as of March 31, 2024. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating <span style="white-space:nowrap">off-balance</span> sheet arrangements. We have not entered into any <span style="white-space:nowrap">off-balance</span> sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any <span style="white-space:nowrap">non-financial</span> assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any long-term debt, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities, other than an agreement to pay an affiliate of our Sponsor a&#160;monthly fee of $7,500, for office space, utilities and secretarial and administrative support. We began incurring these fees on March&#160;1, 2023 and will continue to incur these fees&#160;monthly until the earlier of the completion of our initial business combination or our liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chardan is entitled to a deferred underwriting commission of $2,070,000. The deferred fee will be waived by Chardan in the event that we do not complete an initial business combination, subject to the terms of the underwriting agreement. Also, we have incurred deferred legal fees payable upon consummation of our initial business combination of approximately $635,000 as of March 31, 2024. These fees will only become due and payable upon the consummation of a business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the founder shares, equity participation shares, private placement units, and units that may be issued upon conversion of working capital loans (and in each case holders of their component securities, as applicable) are entitled to registration rights pursuant to the registration rights agreement. These holders are entitled to make up to two demands, excluding short form registration demands, that we register such securities for sale under the Securities Act. In addition, these holders will have &#8220;piggyback&#8221; registration rights to include their securities in other registration statements filed by us. We will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the date of our prospectus issued in connection with our initial public offering and may not exercise its demand rights on more than one occasion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have not identified any critical accounting estimates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">298 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">JOBS Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;<span style="font-weight:bold">JOBS Act</span>&#8221;) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an &#8220;emerging growth company&#8221; and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging&#160;growth companies. As a result, the condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an &#8220;emerging growth company,&#8221; we choose to rely on such exemptions we may not be required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section&#160;404, (ii)&#160;provide all of the compensation disclosure that may be required of non-emerging&#160;growth public companies under the Dodd-Frank&#160;Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv)&#160;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO&#8217;s compensation to median employee compensation. These exemptions will apply for a period of five&#160;years following the completion of our IPO or until we are no longer an &#8220;emerging growth company,&#8221; whichever is earlier. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC management does not believe there are any recently issued, but not yet effective, accounting pronouncements, if currently adopted, that would have a material effect on our condensed consolidated financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">299 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_33">CERTAIN BLAC RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Founder Shares and Private Placement Units </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;30, 2020, BLAC issued an aggregate of 1,437,500 founder shares to the Sponsor for an aggregate purchase price of $25,000 in cash, or approximately $0.014 per share. On April&#160;25, 2022, BLAC executed a stock split, resulting in an aggregate of 1,725,000 founder shares held by the Sponsor (of which up to 225,000 shares were subject to forfeiture in the event the underwriter&#8217;s Over-Allotment Option was not exercised in full). At the closing of BLAC&#8217;s IPO, the Sponsor transferred 20,000 founder shares to each of Drs. Chung, Reed and Roberts and Mr. Park for their board service and 20,000 placement warrants each to our directors who are serving as our Chairman of the Board of Directors, Dr.&#160;Reed, and the chair of our audit committee, Dr.&#160;Chung. On March&#160;23, 2023, our Sponsor also transferred 20,000 founder shares and 20,000 placement warrants to Mr.&#160;Yoo for his service as Chief Financial Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per unit, for an aggregate purchase price of $4,300,000, at the closing of our initial public offering. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the founder shares or placement shares, and the placement warrants and placement rights will expire worthless if we do not consummate a business combination by November 14, 2024 (unless such date is extended in accordance with the Existing Governing Documents). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The founder shares and the placement units and securities contained therein are each subject to transfer restrictions pursuant <span style="white-space:nowrap">to&#160;lock-up&#160;provisions</span> in letter agreements with BLAC that were entered into by the Sponsor and BLAC&#8217;s officers and directors and, in the case of the founder shares, Continental as escrow agent. <span style="white-space:nowrap">Those&#160;lock-up&#160;provisions</span> provide that such securities are not transferable or saleable until 36 months after the date of the consummation of BLAC initial business combination, or earlier if, subsequent to BLAC&#8217;s initial business combination, BLAC consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of BLAC&#8217;s stockholders having the right to exchange their shares of common stock for cash, securities or other property, subject to certain exceptions as set forth in the BLAC IPO Prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Promissory Note &#8212; Related Party </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2022, BLAC&#8217;s Sponsor entered into a promissory note with BCM Europe in the principal amount of $3,400,000 with a maturity date of December&#160;9, 2023 (the &#8220;BCM Europe Note&#8221;). The proceeds of the BCM Europe Note were used to fund our Sponsor&#8217;s purchase of the Private Placement Units. The BCM Europe Note is convertible at the election of either our Sponsor or BCM Europe into (i) 310,000 Units identical to the Private Placement Units held by our Sponsor, (ii) 370,000 founder shares held by our Sponsor, and (iii) 60,000 warrants held by our Sponsor. The BCM Europe Note was amended on March&#160;27, 2024 to extend the maturity date to the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which the Company consummates a Business Combination. Additionally, on February&#160;2, 2023, our Sponsor entered into a promissory note with BCM Europe in the principal amount of $2,000,000 with a maturity date of February&#160;2, 2024 (the &#8220;BCM Europe Note 2023&#8221;). The proceeds of the BCM Europe Note 2023 will be used, if necessary, to fund expenses in connection with our initial business combination. The BCM Europe Note 2023 is not convertible into any BLAC securities held by our Sponsor. The BCM Europe Note 2023 was amended on April 12, 2024 to extend the maturity date to the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which the Company consummates a Business Combination. As of the date of the proxy statement/prospectus, the outstanding balance of the BCM Europe Note and the BCM Europe Note 2023 is $4,700,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor had loaned to us $1,200,000 under promissory notes which was used to pay a portion of the expenses of our IPO. These loans were&#160;non-interest&#160;bearing, unsecured and were due at the earlier of November&#160;29, 2023 or the closing of our IPO. At the closing of our IPO, the promissory notes were deemed to be repaid and settled in connection with the private placement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">300 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Party Loans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of BLAC&#8217;s officers and directors may, but are not obligated to, loan BLAC funds as may be required (&#8220;<span style="text-decoration:underline">Working Capital Loans</span>&#8221;). If BLAC completes a Business Combination, BLAC would repay the Working Capital Loans out of the Trust Account released to BLAC. In the event that a Business Combination does not close, BLAC may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,000,000&#160;of such Working Capital Loans may be convertible into Units at a price of $10.00&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#8217;s securities, and Chardan and its related persons will have no recourse with respect to their ability to convert their loans into any of the Company&#8217;s securities. As of the date of the proxy statement/prospectus,&#160;no&#160;Working Capital Loans were outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;23, 2023, BLAC issued an unsecured promissory note (the &#8220;<span style="text-decoration:underline">Note</span>&#8221;) in the principal amount of $200,000&#160;to the Sponsor to fund working capital requirements. The Note is <span style="white-space:nowrap">non-interest</span> bearing and is payable in full on the earlier of: (i)&#160;December 31, 2024&#160;or (ii)&#160;the date on which BLAC consummates a Business Combination. In the event that BLAC does not consummate a business combination, the Note will be repaid only from amounts remaining outside of BLAC&#8217;s trust account, if any. At the Sponsor&#8217;s discretion, the principal balance of the Note may be converted at any time prior to the consummation of a Business Combination into Units identical to the Private Placement Units at a price of $10.00&#160;per Unit. BLAC repaid the promissory note on December 4, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;13, 2023, BLAC issued an unsecured promissory note (the &#8220;<span style="text-decoration:underline">BCM Note</span>&#8221;) in the principal amount of $180,000&#160;to BCM to fund the payment to extend the date to consummate an initial business combination to February&#160;14, 2023. The BCM Note is <span style="white-space:nowrap">non-interest</span> bearing and is payable in full on the earlier of: (i)&#160;December 31, 2024 or (ii) the date on which BLAC consummates a Business Combination. In the event that BLAC does not consummate a business combination, the BCM Note will be repaid only from amounts remaining outside of BLAC&#8217;s Trust Account, if any. BLAC repaid the BCM Note on December 4, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 9, 2024, BLAC issued an unsecured promissory note (the &#8220;Whang&#160;Note&#8221;) in the principal amount of $75,000 to Mr. Whang, a director of BLAC, in part to fund the payment to extend the date to consummate an initial business combination to March 14, 2024, and in part for general working capital purposes. The Whang Note is non-interest bearing and is payable in full on the earlier of: (i) August 9, 2024&#160;or (ii)&#160;the date on which BLAC consummates a Business Combination. In the event that BLAC does not consummate a business combination, the Whang Note will be repaid only from amounts remaining outside of BLAC&#8217;s Trust Account, if any. As of&#160;the date of this proxy statement/prospectus, the&#160;outstanding balance was $75,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;8, 2024, BLAC issued an unsecured promissory note (the &#8220;JP Promissory Note&#8221;) in the principal amount of $60,000 to Josh Pan, a member of Bellevue Capital Management LLC. The JP Promissory Note is not interest bearing and is payable in full on the earlier of: (i)&#160;August&#160;8, 2024 or (ii)&#160;the date on which BLAC consummates an initial business combination (the &#8220;JP Maturity Date&#8221;). In the event that BLAC does not consummate a business combination on or prior to the time provided in BLAC&#8217;s Charter (as subject to extension), Mr.&#160;Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of BLAC&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JP Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;8, 2024, BLAC issued an unsecured promissory note (the &#8220;April Sponsor Note&#8221;) in the principal amount of $1,200,000 to Sponsor for its receipt of $1,200,000 to fund working capital and other expenses of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">301 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BLAC. The April Sponsor Note is&#160;non-interest&#160;bearing and is payable in full on the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which BLAC consummates a Business Combination. In the event that BLAC does not consummate a Business Combination, the April Sponsor Note will be repaid only from amounts remaining outside of BLAC&#8217;s Trust Account, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2024,&#160;BLAC issued an unsecured promissory note (the &#8220;Second April Sponsor Note&#8221;) in the principal amount of $50,000&#160;to&#160;the Sponsor. The Second April Sponsor Note is not interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which BLAC consummates an initial Business Combination (the &#8220;Second April Sponsor Notes Maturity Date&#8221;). In the event that BLAC does not consummate a Business Combination on or prior to the time provided in BLAC&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the Second April Sponsor Note, except to the extent of any funds remaining outside of BLAC&#8217;s Trust Account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Second April Sponsor Note Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 14, 2024, BLAC issued an unsecured promissory note (the &#8220;May Sponsor Note&#8221;) in the principal amount of $140,000&#160;to the Sponsor. The May Sponsor Note is&#160;not interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which BLAC consummates an initial Business Combination (the &#8220;May Sponsor Note Maturity Date&#8221;). In the event that BLAC does not consummate a Business Combination on or prior to the time provided in BLAC&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the May Sponsor Note, except to the extent of any funds remaining outside of BLAC&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within&#160;five business days of the May Sponsor Note Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Administrative Service Fee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on March&#160;1, 2023, BLAC agreed to pay an affiliate of members of the Sponsor a total of $7,500&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or BLAC&#8217;s liquidation, BLAC will cease paying these monthly fees.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the founder shares, equity participation shares, placement units, and units that may be issued upon conversion of working capital loans (and in each case holders of their component securities, as applicable) have registration rights to require BLAC to register a sale of any of BLAC&#8217;s securities held by them pursuant to a registration rights agreement signed at the closing of the BLAC IPO. These holders will be entitled to make up to two demands, excluding short form registration demands, that BLAC register such securities for sale under the Securities Act. In addition, these holders will have &#8220;piggy-back&#8221; registration rights to include their securities in other registration statements filed by us. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the BLAC IPO registration statement and may not exercise its demand rights on more than one occasion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Deferred Underwriting Fee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chardan is entitled to a deferred underwriting commission of $2,070,000. The amount of deferred underwriting fees to which&#160;Chardan&#160;is entitled will not be adjusted to account for redemptions of BLAC common stock by the public stockholders. Accordingly, the amount of the effective deferred underwriting fee due upon consummation of the Business Combination as a percentage of the aggregate proceeds remaining in the trust account will increase as the number of shares of BLAC common stock redeemed increases. The effective deferred underwriting fee due upon consummation of the Business Combination as a percentage of the aggregate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">302 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds remaining in the trust account of approximately $21,000,000 as of June 28, 2024 is 9.9%, 19.71%, and an incalculable percentage, assuming no redemptions, 50% redemptions, and 100% redemptions, respectively. The deferred fee will be waived by Chardan in the event that BLAC does not complete a Business Combination, subject to the terms of the underwriting agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Deferred Legal Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has incurred deferred legal fees payable upon consummation of a Business Combination of approximately&#160;$635,000 as of March 31, 2024. These fees will only become due and payable upon the consummation of a Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">303 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_34">MANAGEMENT FOLLOWING THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;OSR Holdings,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to OSR Holdings prior to the Business Combination and to New OSR Holdings and its consolidated subsidiaries after giving effect to the Business Combination. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information concerning the persons who are expected to serve as directors and executive officers of New OSR Holdings following the consummation of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors after the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, the business and affairs of New OSR Holdings will be managed by or under the direction of the New OSR Holdings Board. The following table sets forth the name, age and position of each of the expected directors, executive officers and certain key executives of New OSR Holdings following the consummation of the Business Combination. For biographical information concerning the directors, executive officers and key executives, see below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:32%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:64%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Chairman of the Board</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jun Chul Whang**</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gihyoun Bang*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">60<br/> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Legal Officer and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Executive</span> Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phil Geon Lee**</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director, Audit and Compensation Committee Member</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alcide Barberis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">66</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director, Compensation Committee Member</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seng Chin Mah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">65</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director, Compensation and Nomination Committee Member</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jin Whan Park**</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director, Audit and Nomination Committee Member</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sang Hyun Kim**</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director, Compensation Committee Member</p></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Mr. Hwang&#8217;s and Mr. Bang&#8217;s biographies, please see &#8220;<span style="font-style:italic">Management of OSR Holdings &#8212; Executive Officers and Directors</span> of OSR Holdings.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Mr. Whang&#8217;s, Mr. Lee&#8217;s, Mr. Park&#8217;s and Mr. Kim&#8217;s biographies, please see &#8220;<span style="font-style:italic">Executive Officers and Directors of BLAC</span>.&#8221; </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Executive</span> Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Alcide Barberis, PhD, Independent Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alcide Barberis&#160;will become<span style="font-weight:bold"> </span>a Director upon closing of the business combination transaction. He is a biotech entrepreneur, Board Member and Executive with over 25 years of management experience in the biotechnology industry, and scientific experience in the private and public research sectors. He is currently CEO&#160;&amp; Director of Mabylon AG (since 2017). Before joining Mabylon, he was CEO&#160;&amp; President of Humabs BioMed, now a subsidiary of VIR Biotechnology&#160;(2013-2016). His career has included senior positions at entrepreneurial startups <span style="white-space:nowrap">(Co-Founder</span> of ESBATech&#160;AG&#160;(1998)&#160;and Oncalis AG&#160;(2006) and senior Executive Management, R&amp;D Management and Business Development positions. He has been member of the Board of Directors of ESBATech (now a Novartis company, 1998&#8212;2004), Oncalis&#160;(2006-2012)&#160;and EffRx Pharmaceuticals (2016&#8212;2023), and he is currently&#160;(since March 2023)&#160;on the Board of Directors of Ontrack Biomedical. From 2016 through 2021 he was also Coordinator of the Startup Promotion Center of the University of Svizzera Italiana in Lugano, Switzerland. Dr.&#160;Barberis earned a PhD in Molecular Biology and Biochemistry from the University of Z&#252;rich (1988). We believe Dr.&#160;Barberis is well qualified to serve as Director because of his extensive management and leadership experience in the biotech industry, startup companies, and in the private and public scientific research sectors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">304 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Seng Chin Mah, PhD, Independent Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seng Chin Mah will become a Director upon closing of the business combination transaction. Dr.&#160;Mah&#160;has been Chairman of the Board of BioVersys AG since 2009. He was previously Chief Executive Officer of the Canyon Pharmaceuticals Group AG (2009-2021) and has over 30 years&#8217; experience in the pharma and biotech industry. Prior to Canyon Pharmaceuticals, he was Head of Development of the Integration Office during the integration of Chiron into Novartis (2005-2008) and held other positions at Novartis, including Global Head of Clinical Safety and Epidemiology (2001-2005); Head of Drug Regulatory Affairs Europe (1997-2001); and oversight responsibility for Clinical Quality Assurance (2001-2005). Dr.&#160;Mah was also a member of the Novartis Corporate Executive Group (2001-2005) and a member of the Board of Directors for Novartis Europharm Ltd. (1997-2005). During his tenure with Novartis and Ciba (1990-2008), he drove key drug development and regulatory programs, and led major business results including numerous global registrations of major products. He has held several research and academia positions (Ciba-Geigy Ltd., 1987-1988; National University of Singapore, 1989-1990). Dr.&#160;Mah was awarded The Frost&#160;&amp; Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants, which recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask<sup style="font-size:75%; vertical-align:top">&#174;</sup> (desirudin for injection). Dr.&#160;Mah earned a BS in Pharmacology from University of London (1984)&#160;and a PhD in Biochemistry from University of Basel (1987). We believe Dr.&#160;Mah is well qualified to serve as a Director because of his extensive knowledge and experience in strategic decision-making, late-stage clinical development and regulatory experience within the Pharma and Biotech industry. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who shall serve as the directors or executive officers of New OSR Holdings following the consummation of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Composition of the New OSR Holdings Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings business and affairs will be managed under the direction of the New OSR Holdings Board. New OSR Holdings anticipates that the New OSR Holdings Board will consist of nine (9) members upon Closing of the Business Combination. Mr.&#160;Kuk Hyoun Hwang will serve as Chief Executive Officer and Chairperson of the New OSR Holdings Board. Mr. Phil Geon Lee will serve as the lead independent director of New OSR Holdings. The primary responsibilities of the New OSR Holdings Board will be to provide oversight, strategic guidance, counseling and direction to New OSR Holdings&#8217; management. The New OSR Holdings Board will meet on a regular basis and on an&#160;ad hoc&#160;basis as required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the Amended Charter and subject to the rights of the holders of any series of New OSR Holdings Preferred Stock, any vacancy on the New OSR Holdings Board shall be filled only by the New OSR Holdings Board and not by the stockholders of New OSR Bioscience. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq rules generally require that independent directors must comprise a majority of a listed company&#8217;s board of directors. Based upon information requested from and provided by each proposed director concerning his or her background, employment and affiliations, including family relationships, we have determined that each of Drs. Mah and Barberis, and Mr.&#160;Lee, Mr. Park, Mr. Kim, [&#9679;], and [&#9679;] representing a majority of New OSR Holdings&#8217; proposed directors, will be &#8220;independent&#8221; as that term is defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. Mr.&#160;Lee will serve as the lead independent director of New OSR Holdings. In making these determinations, the Board considered the current and prior relationships that each <span style="white-space:nowrap">non-employee</span> director has with OSR Holdings and all other facts and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">305 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circumstances the Board deemed relevant in determining their independence, including the beneficial ownership of OSR Holdings capital stock by each <span style="white-space:nowrap">non-employee</span> director, and the transactions involving them described in the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Transactions</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;OSR Holdings</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Board will have extensive involvement in the oversight of risk management related to New OSR Holdings and its business as a whole, including its strategy, business performance, capital structure, management selection, compensation programs, stockholder engagement, corporate reputation, environmental, social, and governance matters, and ethical business practices. The New OSR Holdings Board will discharge various aspects of its oversight responsibilities through its standing committees, which will in turn report to the New OSR Holdings Board regularly regarding their activities. The audit committee will represent the New OSR Holdings Board by periodically reviewing New OSR Holdings&#8217; accounting, reporting and financial practices, including the integrity of its financial statements and the surveillance of administrative and financial controls, as well as enterprise risk management, cyber risk and review of related party transactions. Through its regular meetings with management, including the finance, legal, internal audit and information technology functions, the audit committee will review and discuss all significant areas of New OSR Holdings&#8217; business and summarize for the New OSR Holdings Board all areas of risk and the appropriate mitigating factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee will review the company&#8217;s incentive compensation arrangements to determine whether they encourage excessive risk-taking&#160;and discuss with management the relationship between risk management policies and practices and compensation. In addition, the New OSR Holdings Board will receive periodic detailed operating performance reviews from management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of the New OSR Holdings Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, the New OSR Holdings Board will reconstitute its audit committee and compensation committee. The board of directors will adopt a new charter for each of these committees, which will comply with the applicable requirements of current SEC and Nasdaq rules. New OSR Holdings intends to comply with future requirements to the extent applicable. Following the consummation of the Business Combination, copies of the charters for each committee will be available on the investor relations portion of New OSR Holdings&#8217; website. The New OSR Holdings Board may from time to time establish other committees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the members of our audit committee will consist of [&#9679;], Mr.&#160;Lee and Mr. Park, with Mr. Park serving as the chairperson of this audit committee and is an audit committee expert. Each member of the audit committee is financially literate. The composition of New OSR Holdings&#8217; audit committee will meet the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Each member of New OSR Holdings&#8217; audit committee is financially literate and the &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)&#160;of <span style="white-space:nowrap">Regulation&#160;S-K</span> will be Mr. Park as he has been serving in the same role for BLAC&#8217;s audit committee prior to the Business Combination.&#160;This designation does not impose on Mr. Park any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and the board of directors. The New OSR Holdings audit committee will be directly responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ensuring the independence of the independent registered public accounting firm; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">306 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and that firm, our interim and <span style="white-space:nowrap">year-end&#160;operating</span> results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering the adequacy of our internal controls and internal audit function; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing material related party transactions or those that require disclosure; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving or, as permitted, <span style="white-space:nowrap">pre-approving&#160;all</span> audit and <span style="white-space:nowrap">non-audit&#160;services</span> to be performed by our independent registered public accounting firm. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the members of New OSR Holdings&#8217; compensation committee will consist of Dr. Barberis, Dr. Mah and Mr. Kim, with Dr.&#160;Mah serving as the chairperson. Each member of this committee is a <span style="white-space:nowrap">non-employee&#160;director,</span> as defined by <span style="white-space:nowrap">Rule&#160;16b-3&#160;promulgated</span> under the Exchange&#160;Act, and an outside director, as defined pursuant to Section&#160;162(m)&#160;of the Code, and meets the requirements for independence under the current Nasdaq listing standards. The New OSR Holdings compensation committee will be responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our board of directors the compensation of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering our stock and equity incentive plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our overall compensation philosophy. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings will adopt a code of ethics that applies to all of its employees, officers and directors, including its principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. Upon completion of the Business Combination, the full text of New OSR Holdings&#8217; code of ethics will be posted on the investor relations section of its website. New OSR Holdings intends to disclose future amendments to its code of business conduct and ethics, or any waivers of such code, on its website. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation of Liability and Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Charter and the Amended Bylaws, once adopted, will limit a director&#8217;s and officer&#8217;s liability to the fullest extent permitted under the DGCL.&#160;The DGCL provides that directors and officers of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors or officers, except for liability: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any transaction from which the director or officer derives an improper personal benefit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for a director under Section&#160;174 of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any breach of a duty of loyalty to the corporation or its stockholders; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for an officer in any action by or in the right of the corporation. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">307 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of the directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law and the Amended Bylaws provide that New OSR Holdings will, in certain situations, indemnify its directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct payment, or reimbursement of reasonable expenses (including attorneys&#8217; fees and disbursements) in advance of the final disposition of the proceeding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, New OSR Holdings will enter into separate indemnification agreements with each of its directors and officers. These agreements, among other things, require New OSR Holdings to indemnify its directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of their services as one of its directors or officers or any other company or enterprise to which the person provides services at its request. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings plans to maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which its directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe these provisions in the Amended Charter and Amended Bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">308 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_35">DESCRIPTION OF SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, New OSR Holdings&#8217; authorized capital stock will consist of 100,000,000&#160;shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. As of [&#9679;], 2024, BLAC had [&#9679;] shares of BLAC Common Stock outstanding and no shares of BLAC Preferred Stock outstanding. Upon the consummation of the Business Combination, New OSR Holdings expects to have [&#9679;] (assuming no redemptions) shares of New OSR Holdings Common Stock outstanding and no shares of New OSR Holdings Preferred Stock outstanding. The following description of New OSR Holdings capital stock is intended as a summary only and is qualified in its entirety by reference to New OSR Holdings&#8217; proposed Amended Charter and Amended Bylaws to be in effect upon the consummation of the Business Combination, which are included as Annex E and Annex F, respectively, to this proxy statement, and to the applicable provisions of the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the rights, if any, of the holders of any outstanding series of preferred stock, the holders of outstanding shares of New OSR Holdings Common Stock will be entitled to receive dividends and other distributions out of assets legally available at the times and in the amounts as New OSR Holdings&#8217; Board may determine from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of New OSR Holdings&#8217; Common Stock will be entitled to one vote on all matters submitted to a vote of stockholders. Holders of shares of New OSR Holdings Common Stock shall have no cumulative voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preemptive Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings Common Stock will not be entitled to preemptive or other similar subscription rights to purchase any of New OSR Holdings&#8217; securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion or Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings Common Stock will be neither convertible nor redeemable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the rights, if any, of the holders of any outstanding series of preferred stock, in the event of any voluntary or involuntary liquidation, dissolution or winding up of New OSR Holdings, the holders of New OSR Holdings Common Stock will be entitled to receive all the remaining assets of New OSR Holdings available for distribution to stockholders, after payment or provision for payment of the debts and other liabilities of New OSR Holdings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with BLAC&#8217;s initial public offering, BLAC issued 6,900,000 warrants to purchase an aggregate of 6,900,000 shares of BLACK Common Stock (the &#8220;<span style="text-decoration:underline">Public Warrants</span>&#8221;). Simultaneously with its initial public offering, BLAC issued 430,000 warrants to purchase an aggregate of 430,000 shares of BLAC Common Stock in a private placement (the &#8220;<span style="text-decoration:underline">Private Warrants</span>&#8221; and together with the Public Warrants, the &#8220;<span style="text-decoration:underline">Warrants</span>&#8221;). As </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">309 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of [&#9679;], 2024, there were [&#9679;] Warrants outstanding. Each Warrant entitles the registered holder to purchase one share of common stock. The Warrants entitle the holders thereof to purchase shares of New OSR Holdings&#8217; common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on 30 days after the completion of the Business Combination. The Warrants have been issued in registered form under a warrant agreement between Continental, as warrant agent, and us (the &#8220;<span style="text-decoration:underline">Warrant Agreement</span>&#8221;). The Private Warrants are identical to the Public Warrants, except that the Private Warrants and the shares of common stock issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions, and none of the Private Warrants will be redeemable by us so long as they are held by their initial purchasers or their permitted transferees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants will expire five years after the completion of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings will not be obligated to deliver any shares of common stock pursuant to the exercise of a Warrant and will have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the Warrants is then effective and a prospectus relating thereto is current, subject to New OSR Holdings satisfying its obligations described below with respect to registration. No Warrant will be exercisable and we will not be obligated to issue shares of common stock upon exercise of a Warrant unless common stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant will not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless. In no event will New OSR Holdings be required to net cash settle any Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings may call the Warrants for redemption: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption given after the Warrants become exercisable (the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">30-day</span> redemption period</span>&#8221;) to each warrantholder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the reported last sale price of New OSR Common Stock equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period commencing once the Warrants become exercisable and ending three business days before we send the notice of redemption to the warrantholders. The closing price of BLAC&#8217;s common stock has not exceeded $16.50 per share for any of the 30 trading days prior to the date of this proxy statement/prospectus. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New OSR Holdings have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrantholder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of the common stock may fall below the $16.50 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) as well as the $11.50 warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New OSR Holdings call the Warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise its Warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their Warrants on a &#8220;cashless basis,&#8221; our management will consider, among other factors, our cash position, the number of Warrants that are outstanding and the dilutive effect on our stockholders of issuing the maximum number of shares of common stock issuable upon the exercise of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">310 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants. If our management takes advantage of this option, all holders of Warrants would pay the exercise price by surrendering their Warrants for that number of shares of common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of common stock underlying the Warrants, multiplied by the difference between the exercise price of the Warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of common stock to be received upon exercise of the Warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a Warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the Warrants after the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.9% (or such other amount as a holder may specify) of the shares of common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of common stock is increased by a stock dividend payable in shares of common stock, or by a <span style="white-space:nowrap">split-up</span> of shares of common stock or other similar event, then, on the effective date of such stock dividend, <span style="white-space:nowrap">split-up</span> or similar event, the number of shares of common stock issuable on exercise of each whole Warrant will be increased in proportion to such increase in the outstanding shares of common stock. A rights offering to holders of common stock entitling holders to purchase shares of common stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of common stock equal to the product of (i)&#160;the number of shares of common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for common stock) and (ii)&#160;one (1)&#160;minus the quotient of (x)&#160;the price per share of common stock paid in such rights offering divided by (y)&#160;the fair market value. For these purposes (i)&#160;if the rights offering is for securities convertible into or exercisable for common stock, in determining the price payable for common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;fair market value means the volume weighted average price of common stock as reported during the ten (10)&#160;trading day period ending on the trading day prior to the first date on which the shares of common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we, at any time while the Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of common stock on account of such shares of common stock (or other shares of our capital stock into which the Warrants are convertible), other than (a)&#160;as described above, (b)&#160;certain ordinary cash dividends, or (c)&#160;in connection with the redemption of our public shares upon our failure to complete the Business Combination, then the Warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of common stock in respect of such event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event New OSR Holdings determines to redeem the Warrants, holders of our redeemable Warrants would be notified of such redemption as described in our warrant agreement. Specifically, in the event that New OSR Holdings elects to redeem all of the redeemable Warrants as described above, New OSR Holdings will fix a date for the redemption (the &#8220;<span style="font-weight:bold">Redemption Date</span>&#8221;). Notice of redemption will be mailed by first class mail, postage prepaid, by New OSR Holdings not less than 30 days prior to the Redemption Date to the registered holders of the redeemable Warrants to be redeemed at their last addresses as they appear on the registration books. Any notice mailed in the manner provided in the warrant agreement will be conclusively presumed to have been duly given whether or not the registered holder received such notice. Accordingly, if a holder fails to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">311 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actually receive the notice of or otherwise fails to respond on a timely basis, it could lose the benefit of being a holder of a New OSR Holdings Public Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of our common stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of common stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of common stock issuable on exercise of each Warrant will be decreased in proportion to such decrease in outstanding shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of common stock purchasable upon the exercise of the Warrants is adjusted, as described above, the Warrant exercise price will be adjusted by multiplying the Warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of common stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of common stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding shares of common stock (other than those described above or that solely affects the par value of such shares of common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares of our common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised their Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of common stock in such a transaction is payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Warrant properly exercises the Warrant within thirty days following public disclosure of such transaction, the Warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes value (as defined in the warrant agreement) of the Warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the Warrants otherwise do not receive the full potential value of the Warrants in order to determine and realize the option value component of the Warrant. This formula is to compensate the warrantholder for the loss of the option value portion of the Warrant due to the requirement that the warrantholder exercise the Warrant within 30 days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least a majority of the then outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Warrants being exercised. The warrantholders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their Warrants and receive shares of common stock. After the issuance of shares of common stock upon </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">312 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of the Warrants, each holder will be entitled to one (1)&#160;vote for each share held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the Warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of common stock to be issued to the warrantholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, subject to applicable law, any action, proceeding or claim against us or the warrant agent arising out of or relating in any way to the Warrant Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and each of us irrevocably submits to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Transfer Agent, Warrant Agent and Rights Agent </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent for our common stock, warrant agent for our warrants and rights agent for our rights is Continental. We have agreed to indemnify Continental in its roles as transfer agent, warrant agent and rights agent, its agents and each of its stockholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Anti-Takeover Provisions of Delaware Law and the Amended Charter and Amended Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;<span style="text-decoration:underline">interested stockholder</span>&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an affiliate of an interested stockholder; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#8220;<span style="text-decoration:underline">business combination</span>&#8221; includes a merger or sale of more than 10% of our assets. However, the above provisions of Section&#160;203 do not apply if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our board of directors approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or subsequent to the date of the transaction, the initial business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">313 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusive forum for certain lawsuits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws require, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A)&#160;as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, (C)&#160;for which the Court of Chancery does not have subject matter jurisdiction, or (D)&#160;any action arising under the Securities Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall have concurrent jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws provide that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special meeting of stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws provide that special meetings of our stockholders may be called only by the Chairperson of our Board of Directors, our Chief Executive Officer, or by the directors entitled to cast a majority of the votes of the whole Board of Directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advance notice requirements for stockholder proposals and director nominations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&#8217;s notice will need to be received by the company secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the anniversary date of the immediately preceding annual meeting of stockholders. Pursuant to Rule <span style="white-space:nowrap">14a-8</span> of the Exchange Act, proposals seeking inclusion in our annual proxy statement must comply with the notice periods contained therein. Our bylaws also specify certain requirements as to the form and content of a stockholders&#8217; meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Amended Charter, the authorized number of directors may be changed only by resolution of the board of directors. Any or all of the directors may be removed from office at any time, but only by the affirmative vote of holders of at least sixty-six and two-thirds percent (66 2/3%) in voting power of all of the then outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">314 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rule 144 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144, a person who has beneficially owned restricted shares of our common stock for at least six months would be entitled to sell their securities provided that (i)&#160;such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii)&#160;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned restricted shares of our common stock for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1% of the total number of shares of common stock then outstanding, which will equal 78,900 shares immediately after this offering (or 90,150 shares if the underwriters exercise their over-allotment option in full); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the average weekly reported trading volume of the common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form <span style="white-space:nowrap">8-K;</span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rule 701 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule&#160;701 of the Securities Act as currently in effect, each of New OSR Holdings&#8217; employees, consultants or advisors who purchases equity shares from New OSR Holdings in connection with a compensatory stock plan or other written agreement executed prior to the completion of the Business Combination is eligible to resell those equity shares in reliance on Rule&#160;144, but without compliance with some of the restrictions, including the holding period, contained in Rule&#160;144. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Lock-up</span> Agreements and Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the founder shares, equity participation shares, placement units (including component securities contained therein) and units (including component securities contained therein) that may be issued upon conversion of working capital loans will be entitled to registration rights pursuant to a registration rights </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">315 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement to be signed prior to or on the effective date of this offering, requiring us to register such securities for resale. The holders of the majority of these securities are entitled to make up to two demands, excluding short form demands, that we register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to our completion of our initial business combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the registration date of which this prospectus forms a part and may not exercise its demand rights on more than one occasion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">316 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_36">COMPARISON OF CORPORATE GOVERNANCE AND STOCKHOLDER RIGHTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the material differences between the rights of BLAC stockholders before the consummation of the Business Combination and the rights of the New OSR Holdings stockholders after the Business Combination. These differences in stockholder rights result from the differences between the respective governing documents of BLAC, on the one hand (the &#8220;<span style="text-decoration:underline">Existing Governing Documents</span>&#8221;), and the New OSR Holdings, on the other hand (the &#8220;<span style="text-decoration:underline">Proposed Governing Documents</span>&#8221;) (and assumes the approval of the New OSR Holdings Charter by BLAC&#8217;s stockholders).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section does not include a complete description of all differences among such rights, nor does it include a complete description of such rights. Furthermore, the identification of some of the differences of these rights as material is not intended to indicate that other differences that may be equally important do not exist. This summary is qualified in its entirety by reference to the full text of BLAC&#8217;s and the New OSR Holdings&#8217; governing documents, which Amended Charter is attached hereto as Annex E and Amended Bylaws is attached hereto Annex F. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Governance Documents of BLAC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">New OSR Holdings Governance Documents</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Rights of Preferred Stock</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC Board has the power to authorize the issuance of shares of preferred stock in one or more series and to fix for each such series such voting rights, full or limited, if any, and such designations, powers, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article IV, Sec. 1 of the BLAC Charter.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Board has the power to authorize the issuance of shares of preferred stock in one or more series and to establish the number of shares to be included in each such series, and to determine the following terms with respect to each such series:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the designation of the series;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the number of shares of the series;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the amounts which dividends will be payable on, and the preferences, if any, of shares of the series in respect of dividends, and whether such dividends shall be cumulative or noncumulative;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the dates on which any dividends shall be payable;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the redemption rights and price or prices, if any, for shares of the series;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the terms and amount of any sinking fund, if any, provided for the purchase or redemption of shares of the series;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the amounts payable on, and the preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the company;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;whether the shares of the series shall be convertible into or exchangeable for any other security of the Corporation or any other corporation, and, if so, the specification of such other class or series or</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">317 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Governance Documents of BLAC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">New OSR Holdings Governance Documents</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Rights of Preferred Stock</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">such other security, the conversion or exchange price or prices or rate or rates, any adjustments thereof, the date or dates at which such shares shall be convertible or exchangeable and all other terms and conditions upon which such conversion or exchange may be made;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;restrictions on the issuance of shares of the same series or any other class or series;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;the voting power, if any, of the holders of shares of the series generally or upon specified events; and</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;any other powers, preferences and relative, participating, optional or other special rights of each series of preferred stock, and any qualifications, limitations, or restrictions of such shares.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article Fourth, Sec. 3 of the New OSR Holdings Charter.</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Removal of Directors</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any or all of the directors may be removed, but only for cause, by the affirmative vote of holders of more than a majority of the voting power of the outstanding shares entitled to vote generally in the election of directors, voting together as a single class.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article III, Sec. A of the BLAC Bylaws.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New OSR Governance Documents are silent as to the removal of directors. Consequently, pursuant to the DGCL, directors can be removed with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No corresponding section</span>.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Special Meetings of Stockholders</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings of stockholders may only be called by the Chief Executive Officer or the BLAC Board pursuant to a resolution adopted by a majority of the BLAC Board.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article II, Sec. B of the BLAC Bylaws.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings of the New OSR Holdings Board may only be called by the Chairperson of the New OSR Holdings Board, the Chief Executive Officer or by the directors entitled to cast at least half of the votes of the whole New OSR Holdings Board.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article I, Sec. 1.2 of the New OSR Holdings Bylaws</span>.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Quorum</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority of the voting power of all outstanding shares of capital stock of the BLAC entitled to vote at such meeting vote, represented in person or by proxy, constitutes a quorum, except as otherwise provided by applicable law, the BLAC Charter or the BLAC Bylaws. When specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series shall constitute a quorum of such class or series for the transaction of such business.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article II, Sec. D of the BLAC Bylaws.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by applicable law, by or pursuant to the New OSR Holdings Charter or the New OSR Holdings Bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock of the Corporation entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article I, Sec. 1.5 of the New OSR Holdings Bylaws</span>.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">318 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Governance Documents of BLAC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">New OSR Holdings Governance Documents</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Limitation of Liability of Directors and Officers</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC Charter provides that a director shall not be personally liable to BLAC or its stockholders for monetary damages for breach of their fiduciary duty, except for (i)&#160;breaches of the duty of loyalty, (ii)&#160;lack of good faith or intentional misconduct, or knowing violation of law, (iii)&#160;unlawful stock purchases, redemptions, or dividends under Section&#160;174 of the DGCL, or (iv)&#160;improper personal benefit. The BLAC Charter permits limitation of liability to the fullest extent permitted by the DGCL.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article VII of the BLAC Charter.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Charter provides that a director or officer shall not be personally liable to New OSR Holdings or its stockholders for monetary damages for a breach of fiduciary duty unless exemption from liability or limitation thereof is not permitted under the DGCL.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article Seventh of the New OSR Holdings Charter</span>.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Dividends and Distributions, Stock Repurchases</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC Board may declare, and BLAC may pay, dividends payable in cash, property or securities, on BLAC&#8217;s outstanding shares of capital stock, subject to applicable law and the BLAC Charter.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See BLAC Bylaws Article IX Sec. F.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the rights, if any, of the holders of any other class or series of capital stock, the New OSR Holdings Board may declare and pay dividends on capital stock at such times and in such amounts as the New OSR Holdings Board in its discretion shall determine.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article Fourth, Sec. 2(a) and Sec. 3(c) of the New OSR Holdings Charter.</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Choice of Forum</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC Charter provides that, unless BLAC consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any stockholder to bring (i)&#160;any derivative action or proceeding brought on behalf of BLAC, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of BLAC to BLAC or BLAC&#8217;s stockholders, or any claim for aiding and abetting such alleged breach, (iii)&#160;any action asserting a claim against BLAC, its directors, officers or employees arising pursuant to any provision of the DGCL or the BLAC Charter or the Bylaws, or (iv)&#160;any action asserting a claim against BLAC, its directors, officers or employees governed by the internal affairs doctrine, except for (a)&#160;any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or (b)&#160;any claim arising under the federal securities laws, including the Securities Act, and the rules and regulations thereunder as to which the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum. The forum selection provisions do not apply to any action arising from a claim under the Exchange Act, or the rules and regulations thereunder.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article IX, Sec. 1 of the BLAC Charter.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Bylaws provide that, unless the New OSR Holdings consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for any stockholder to bring (i)&#160;any derivative action or proceeding brought on behalf of New OSR Holdings, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or employee of New OSR Holdings to New OSR Holdings or the New OSR Holdings&#8217;s stockholders, (iii)&#160;any civil action to interpret, apply or enforce any provision of the DGCL, (iv)&#160;any civil action to interpret, apply, enforce or determine the validity of the provisions of the Certificate of Incorporation or Bylaws or (v)&#160;any action asserting a claim governed by the internal affairs doctrine, unless the Court of Chancery lacks jurisdiction. The federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, as amended. The forum selection provisions do not apply to any action arising from a claim under the Exchange Act.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article VII, Sec. 7.7 of the New OSR Holdings Bylaws</span></p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">319 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Governance Documents of BLAC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">New OSR Holdings Governance Documents</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Provisions Specific to a Special Purpose Acquisition Company</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Article V of the BLAC Charter sets forth various provisions related to BLAC&#8217;s operations as a special purpose acquisition company prior to the consummation of an initial business combination as well as the process for consummating such a transaction.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">See Article V of the BLAC Charter.</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New OSR Holdings Charter will make certain other changes that the board of directors deems appropriate for a public operating company, including (a)&#160;eliminating certain provisions relating to an initial business combination that will no longer be applicable to the New OSR Holdings following the Closing, including provisions relating to (i) &#8220;IPO Shares&#8221;, (ii) redemption rights with respect to IPO Shares, (iii)&#160;the &#8220;Trust Account&#8221;, (iv) share issuances prior to the consummation of the initial business combination, and (iv)&#160;approval of the initial business combination, and (b)&#160;to change the post-combination company&#8217;s name to &#8220;OSR Holdings, Inc.&#8221;</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No corresponding section</span>.</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">320 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_37">BENEFICIAL OWNERSHIP OF SECURITIES </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding (i)&#160;the beneficial ownership of BLAC Common Stock as of [&#9679;], 2024 and (ii)&#160;the expected beneficial ownership of shares of New OSR Holdings&#8217; Common Stock immediately following consummation of the Business Combination (assuming a &#8220;no redemption&#8221; scenario and assuming an additional &#8220;redemption&#8221; scenario as described herein) by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is known to be the beneficial owner of more than 5% of BLAC Common Stock and is expected to be the beneficial owner of more than 5% of shares of New OSR Holdings&#8217; common stock post-Business&#160;Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of BLAC&#8217;s current executive officers and directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is expected to become an executive officer or director of New OSR Holdings&#8217; post-Business&#160;Combination; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all executive officers and directors of BLAC as a group <span style="white-space:nowrap">pre-Business&#160;Combination,</span> and all executive officers and directors of New OSR Holdings post-Business&#160;Combination. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60&#160;days. Shares subject to warrants that are currently exercisable or exercisable within 60 days of [&#9679;], 2024, or rights that are converted at closing of the Business Combination, are considered outstanding and beneficially owned by the person holding such warrants or rights for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of shares of BLAC Common Stock <span style="white-space:nowrap">pre-Business&#160;Combination</span> is based on 4,041,221 shares of BLAC Common Stock issued and outstanding as of [&#9679;], 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of shares of New OSR Holdings common stock post-Business Combination assumes two scenarios: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a &#8220;no redemption&#8221; scenario where (i)&#160;no public stockholders exercise their redemption rights in connection with the Business Combination, (ii)&#160;BLAC issues 14,676,728&#160;shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement), and (iii) 2,222,222 shares of BLAC Common Stock are issued to Toonon; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">a &#8220;maximum redemption&#8221; scenario where (i)&#160;1,886,221 shares of BLAC&#8217;s outstanding public stock are redeemed in connection with the Business Combination, (ii)&#160;BLAC issues&#160;14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement), and (iii) 2,222,222 shares of BLAC Common Stock are issued to Toonon. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing assumptions, we estimate that there would be 21,673,171 shares of New OSR Holdings&#8217; common stock issued and outstanding immediately following the consummation of the Business Combination in the &#8220;no redemption&#8221; scenario and 19,786,950&#160;shares of New OSR Holdings&#8217; common stock issued and outstanding immediately following the consummation of the Business Combination in the &#8220;maximum redemption&#8221; scenario. If the actual facts are different from the foregoing assumptions, ownership figures in the combined company and the columns under Post-Business&#160;Combination in the table that follows will be different. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">321 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated and subject to applicable community property and similar laws, BLAC believes that all persons named in the table below have sole voting and investment power with respect to the voting securities beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Prior to the Transactions</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After the Transactions</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Approximate<br/>Percentage&#160;of<br/>Outstanding<br/>Common&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemptions<br/>Approximate<br/>Percentage&#160;of<br/>Outstanding<br/>Common&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemptions<br/>Approximate<br/>Percentage&#160;of<br/>Outstanding<br/>Common&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Officers and Directors Prior to the Transactions</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang<sup style="font-size:75%; vertical-align:top">(4) </sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,320,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32.68</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,074,123</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(13)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,074,123</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(13)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Yoo<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sang Hyun Kim</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phil Geon Lee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jin Whan Park<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jun Chul Whang<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All such executive officers and directors as a group (6&#160;individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,360,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33.67</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,134,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60.57</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,134,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Officer and Directors After the Transactions</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,320,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32.68</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,074,123</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(13)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60.29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,074,123</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(13)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gihyoun Bang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jun Chul Whang<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alcide Barberis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sang Hyun Kim</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phil Geon Lee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seng Chin Mah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jin Whan Park<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All such executive officers and directors as a group (8&#160;individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,340,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,094,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,094,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Greater than 5% Stockholders**</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bellevue Global Life Sciences Investors LLC<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,320,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32.68</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,332,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,332,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCM Europe AG<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">680,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,617,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39.04</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,617,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42.69</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bellevue Capital Management LLC<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,123,971</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.41</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,123,971</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.79</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Protein Central<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,933,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.53</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,933,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.82</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invites Ventures Co., Ltd.<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,840,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,840,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toonon Partners Co., Ltd. <sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DUKSUNG CO., LTD. (<sup style="font-size:75%; vertical-align:top">10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,420,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,420,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PARK CHAN KYOO<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,062,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,062,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Center for Biosciences<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,020,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,020,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Number of shares beneficially owned and percentage of outstanding common stock following the closing of the Business Combination assumes (i) the listed individuals or entities are Participating Company </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">322 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Stockholders under the Business Combination Agreement, (ii) each such beneficial owner exchanges all of their outstanding shares of OSR Holdings pursuant to the Share Exchange, and (iii) an aggregate of 14,676,728 shares of BLAC Common Stock (or 60% of the Aggregate Consideration issuable by BLAC pursuant to the Business Combination Agreement) is issued to Participating Company Stockholders. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of each of these entities and individuals is at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98036 unless otherwise noted. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Sponsor transferred 20,000 shares of BLAC common stock to Mr. Yoo and Mr. Park. Additionally, the Sponsor transferred 20,000 Private Placement Warrants to Mr. Yoo. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest does not include shares of BLAC common stock held by BLAC&#8217;s Sponsor. Mr. Whang is a minority owner of Bellevue Capital Management LLC, the general partner of BLAC&#8217;s Sponsor. but has no voting or dispositive power over the shares of BLAC common stock held by BLAC&#8217;s Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of (i) 1,725,000 founder shares of BLAC common stock, (ii) the transfer of 34,500 shares of BLAC common stock to Chardan, (iii) 430,000 placement shares held of record by BLAC&#8217;s Sponsor, (iv)&#160;the transfer of 120,000 shares of BLAC common stock by BLAC&#8217;s Sponsor to BLAC&#8217;s Chief Financial Officer, Mr. Yoo, and the directors of BLAC at the time of the IPO, and (v) the transfer of 310,000 Private Placement Units identical held by BLAC&#8217;s Sponsor and 370,000 founder shares held by BLAC&#8217;s Sponsor to BCM Europe AG. Sponsor&#8217;s ownership post-closing includes an additional 12,000 shares underlying the Private Placement Rights that convert at the closing of the Business Combination. Mr. Hwang, BLAC&#8217;s Chief Executive Officer and a Director, is the founder and managing partner of Bellevue Capital Management LLC, the general partner of BLAC&#8217;s Sponsor, and has voting and dispositive power over the shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest prior to the Transactions consists of 370,000 founder shares and 310,000 Private Placement Units convertible at the election of either BLAC&#8217;s Sponsor or BCM Europe AG, a subsidiary of Bellevue Capital Management LLC, on or after the commencement of BLAC&#8217;s IPO pursuant to the promissory note between BLAC&#8217;s Sponsor and BCM Europe AG. Interests after the Transactions consists of the 370,000 founder shares and 310,000 Private Placement Units mentioned in the previous sentence (including the exercise of 310,000 Private Placement Warrants into 310,000 shares of New OSR Holdings common stock, the conversion of 310,000 Private Placement Rights into 31,000 shares of New OSR Holdings common stock, and the exercise of 60,000 Private Placement Warrants that were also transferred to BCM Europe AG by BLAC&#8217;s Sponsor pursuant to the promissory note into 60,000 shares of New OSR Holdings common stock) and 581,418 shares of OSR Holdings common stock held by BCM Europe AG prior to the closing of the Business Combination. The 581,418 shares of OSR Holdings common stock are being exchanged for 7,536,652 shares of New OSR Holdings common stock pursuant to the Share Exchange. BCM Europe is a wholly-owned subsidiary of Bellevue Capital Management LLC. The business address of BCM Europe AG is Gotthardstrasse 26 6300 Zug Switzerland. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of 241,000 shares of OSR Holdings common stock held by Bellevue Capital Management LLC prior to the closing of the Business Combination. The 241,000 shares of OSR Holdings common stock are being exchanged for 3,123,971 shares of New OSR Holdings common stock pursuant to the Share Exchange. Mr.&#160;Hwang has voting and dispositive over such shares. The business address of Bellevue Capital Management LLC is 10900 NE 4th Street, 2300, Bellevue, WA 98004. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of (i) 200,868 shares of OSR Holdings common stock held by Joint Protein Central (&#8220;JPC&#8221;) prior to the closing of the Business Combination, and (ii) 25,412 shares of OSR Holdings common stock held by Dr. Seung Hyon Choe, the founder and CEO of JPC, prior to the closing of the Business Combination. The 226,280 shares of OSR Holdings common stock are being exchanged for 2,933,163&#160;shares of New OSR Holdings common stock pursuant to the Share Exchange. The business address of JPC is 3 Jeongungro Namaeup Cheoingu Yonginsi Gyeonggido, Republic of Korea. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of (i) 83,999 shares of OSR Holdings common stock held by CG Invites Co., Ltd. (&#8220;CGI&#8221;) prior to the closing of the Business Combination, and (ii) 135,129 shares held by Invites Ventures Co., Ltd., a subsidiary of CGI prior to the closing of the Business Combination. The 219,128 shares of OSR Holdings common stock are being exchanged for 2,840,455 shares of New OSR Holdings common stock pursuant to the Share Exchange. The business address of CGI is 38, Magokjungang 8-ro, Gangseo-gu, Seoul, Republic of Korea. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">323 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of (i) 2,222,222 PIPE Shares pursuant to the PIPE Financing. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of (i) 63,912 shares of OSR Holdings common stock held by Duksung Co., Ltd. (&#8220;Duksung&#8221;) prior to the closing of the Business Combination, and (ii) 45,651 shares of OSR Holdings common stock held by Duksung P&amp;T Co., Ltd., an affiliate of Duksung, prior to the closing of the Business Combination. The 109,563 shares of OSR Holdings common stock are being exchanged for 1,420,214&#160;shares of New OSR Holdings common stock pursuant to the Share Exchange. The business address of Duksung is 25 Sinwonro Yeongtonggu Suwonsi Gyeonggido, Republic of Korea. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of 81,970 shares of OSR Holdings common stock held by Park Chan Kyoo prior to the Closing of the Business Combination. The 81,970&#160;shares of OSR Holdings common stock are being exchanged for 1,062,539 shares of New OSR Holdings common stock pursuant to the Share Exchange. The business address of Park Chan Kyoo is Misagangbyeonbukro 65, 1005-2804, Hanam-si, Gyeonggido, Republic of Korea. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of 78,720 shares of OSR Holdings common stock held by Joint Center for Biosciences prior to the closing of the Business Combination. The 78,720 shares of OSR Holdings common stock are being exchanged for 1,020,411 shares of New OSR Holdings common stock pursuant to the Share Exchange. The business address of Joint Center for Biosciences is Songdomirae-ro 30, Smart Valley B-301, Yeonsu-gu, Incheon, Republic of Korea. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interest consists of the shares of New OSR Holdings held by Sponsor as disclosed in footnote 4 above, BCM, and BCME upon consummation of the Business Combination. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">324 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_38">MARKET PRICE AND DIVIDEND INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLAC </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAC Common Stock, Units, Warrants and Rights are listed on Nasdaq under the symbols BLAC, BLACU, BLACW and BLACR, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of the BLAC Common Stock, Units, Warrants and Rights on November&#160;15, 2023, the last trading day before announcement of the execution of the Business Combination Agreement, was $10.43, $10.69, $0.03, and $0.15, respectively. As of&#160;[&#9679;], 2024, the Record Date, the most recent closing price for each of the BLAC Common Stock, Units, Warrants and Rights was $[&#9679;], $[&#9679;], $[&#9679;]&#160;and $[&#9679;], respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the BLAC Common Stock, Units, Warrants and Rights should obtain current market quotations for their securities. The market price of BLAC&#8217;s securities could vary at any time before the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of [&#9679;], 2024, there were [&#9679;] holder of record of BLAC&#8217;s Common Stock, [&#9679;] holder of record of BLAC&#8217;s Units, [&#9679;] holders of record of BLAC&#8217;s Warrants and [&#9679;] holders of record of BLAC&#8217;s Rights. The number of holders of record does not include a substantially greater number of &#8220;street name&#8221; holders or beneficial holders whose Common Stock, Units, Shares and Warrants are held of record by banks, brokers and other financial institutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC has not paid any cash dividends on its Common Stock to date and does not intend to pay cash dividends prior to the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon the Combined Company&#8217;s revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment of any cash dividends subsequent to the Business Combination will be within the discretion of the Combined Company&#8217;s board of directors at such time. The Combined Company&#8217;s ability to declare dividends may also be limited by restrictive covenants pursuant to any debt financing agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historical market price for OSR Holdings&#8217; capital stock is not provided because there is no public market for OSR Holdings&#8217; capital stock. See the section entitled &#8220;<span style="font-style:italic">OSR Holdings&#8217; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">325 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_39">ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Submission of Future Stockholder Proposals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAC&#8217;s board of directors is aware of no other matter that may be brought before the special meeting. Under Delaware law, only business that is specified in the notice of special meeting to stockholders may be transacted at the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is completed, you will be entitled to attend and participate in New OSR Holdings&#8217; annual meetings of stockholders. If New OSR Holdings holds a 2024 annual meeting of stockholders, it will provide notice of or otherwise publicly disclose the date on which the 2024 annual meeting of stockholders will be held. If the 2024 annual meeting of stockholders is held, stockholder proposals will be eligible for consideration by the board of directors of New OSR Holdings for inclusion in the proxy statement for the 2024 annual meeting of stockholders in accordance with Rule 14a-8 under the Exchange Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Delivery of Documents to Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the rules of the SEC, we and servicers that we employ to deliver communications to our stockholders are permitted to deliver to two or more stockholders sharing the same address a single copy of this proxy statement/prospectus. Upon written or oral request, we will deliver a separate copy of this proxy statement/prospectus to any stockholder at a shared address to which a single copy of this proxy statement/prospectus was delivered and who wishes to receive separate copies in the future. Stockholders receiving multiple copies of this proxy statement/prospectus may likewise request that we deliver single copies of any proxy statement/prospectus in the future. Stockholders may notify us of their requests by emailing or writing us at our principal executive offices at group@bellevuecm.com or 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Register </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent for the securities of BLAC is Continental Stock Transfer&#160;&amp; Trust Company. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_40">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the BLAC Common Stock to be issued in connection with the Business Combination will be passed upon by K&amp;L Gates LLP and the material U.S.&#160;federal income tax consequences of the Business Combination will be passed upon by K&amp;L Gates. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_41">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Bellevue Life Sciences Acquisition Corp. as of December 31, 2023 and 2022&#160;included in this proxy statement/prospectus have been so included in reliance on the report of WithumSmith+Brown, PC, an independent registered public accounting firm, which includes an explanatory paragraph as to the ability of Bellevue Life Sciences Acquisition Corp. to continue as a going concern, upon the authority of said firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of OSR Holdings Co., Ltd. and Darnatein Co., Ltd. as of December 31, 2022 and 2023 included in this proxy statement/prospectus have been so included in reliance upon the report of RSM Shinhan Accounting Corporation independent registered public accountants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">326 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_42">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file reports, proxy statements and other information with the SEC as required by the Exchange Act. You can read BLAC&#8217;s SEC filings, including this proxy statement, over the Internet at the SEC&#8217;s website at<span style="font-style:italic">&#160;http://www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy statement or if you have questions about the Business Combination or the proposals to be presented at the special meeting, you should contact us at the following address or by email: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Bellevue Life Sciences Acquisition Corp. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10900 NE 4th Street, Suite 2300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Bellevue, WA 98004 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: Jun Chul Whang </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Email: group@bellevuecm.com </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">jcwhang@bellevuecm.com </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also obtain these documents by requesting them in writing or by telephone from our proxy solicitation agent at the following address and telephone number: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Advantage Proxy, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">P.O.&#160;Box 10904 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Yakima, WA&#160;98909 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Attn: Karen Smith </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Toll Free <span style="white-space:nowrap">Telephone:&#160;(877)&#160;870-8565</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Main <span style="white-space:nowrap">Telephone:&#160;(206)&#160;870-8565</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">E-mail:&#160;ksmith@advantageproxy.com</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">If you are a stockholder of BLAC and would like to request documents, please do so by no later than five business days before the special meeting in order to receive them before the special meeting.</span><span style="font-weight:bold"></span>&#160;If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All information contained in this proxy statement relating to BLAC has been supplied by BLAC, and all such information relating to OSR Holdings has been supplied by OSR Holdings. Information provided by either BLAC or OSR Holdings does not constitute any representation, estimate or projection of any other party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is a proxy statement of BLAC for the special meeting. We have not authorized anyone to give any information or make any representation about the Business Combination, us or OSR Holdings that is different from, or in addition to, that contained in this proxy statement. Therefore, if anyone does give you information of this sort, you should not rely on it. The information contained in this proxy statement speaks only as of the date of this proxy statement unless the information specifically indicates that another date applies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">327 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="index"><span id="rom476668_43"></span>INDEX TO FINANCIAL STATEMENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#fintoc476668_1">Bellevue Life Sciences Acquisition Corp. Unaudited Condensed Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_2">Condensed Balance Sheets as of March&#160;31, 2024 (unaudited) and December&#160;31, 2023</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_3">Condensed Statements of Operations (unaudited) for the three months ended March&#160;31, 2024 and 2023</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_4">Condensed Statements of Changes in Stockholders&#8217; Deficit (unaudited) for the three months ended March&#160;31, 2024 and 2023</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_5">Condensed Statements of Cash Flows (unaudited) for the three months ended March&#160;31, 2024 and 2023</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_6">Notes to Condensed Financial Statements (unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#fintoc476668_7">Bellevue Life Sciences Acquisition Corp. Audited Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_8">Report of Independent Registered Public Accounting Firm (PCAOB ID #100)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_9">Balance Sheets as of December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_10">Statements of Operations for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_11">Statements of Changes in Stockholder&#8217;s Deficit for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_12">Statements of Cash Flows for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_13">Notes to Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#fintoc476668_13a">OSR Holdings Co., Ltd. Audited Consolidated Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_14">Independent Auditors&#8217; Report</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_15">Consolidated Statements of Financial Position as at December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_16">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_17">Consolidated Statements of Changes in Equity for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_18">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023 and 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_19">Notes to the Consolidated Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:StockholdersEquityNoteStockSplit" id="hidden117832660" contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#8217;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</ix:nonNumeric><ix:nonNumeric name="us-gaap:StockholdersEquityNoteStockSplit" id="hidden117832661" contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#8217;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" id="hidden117833430" contextRef="P04_09_2024To04_09_2024">2024-05-14</ix:nonNumeric><ix:nonNumeric name="blacu:NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" id="hidden117832595" contextRef="P05_14_2024To05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P5D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="blacu-20240331.xsd"/></ix:references></ix:header></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div><div id="fintoc476668_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONDENSED BALANCE SHEETS </div></div></div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"><div style="display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">March&#160;31,&#160;2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">(unaudited) </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115947">3,637</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115948">15,419</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115949">64,543</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115950">7,208</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115951">68,180</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115952">22,627</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115953">37,205,930</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115954">36,605,106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115955">37,274,110</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115956">36,627,733</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115957">1,548,087</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115958">1,081,753</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115959">615,035</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115960">524,562</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Excise tax payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115961">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115962">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Notes payable&#160;-&#160;related party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115963">135,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-115964">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Due to affiliate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115965">87,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115966">72,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115967">2,745,079</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115968">2,038,272</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred underwriting commissions</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:DeferredUnderwritingCommissions" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115969">2,070,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:DeferredUnderwritingCommissions" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115970">2,070,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115971">4,815,079</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115972">4,108,272</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Commitments and Contingencies</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-115973"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-115974"/></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="display:inline;">Common stock subject to possible redemption, </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115975"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115976">3,467,954</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued and outstanding at redemption value<br/> of $</div><div style="display:inline;"><ix:nonFraction name="blacu:CommonStockRedemptionValue" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-115977">10.60</ix:nonFraction></div><div style="display:inline;"> per share and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115978"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115979">3,467,954</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued and outstanding at redemption value of $</div><div style="display:inline;"><ix:nonFraction name="blacu:CommonStockRedemptionValue" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-115980">10.50</ix:nonFraction></div><div style="display:inline;"> per share<br/> at March&#160;31, 2024 and December&#160;31, 2023, respectively</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115981">36,766,604</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-115982">36,426,253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Preferred stock, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-115983"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-115984">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value;</div><div style="display:inline;"> <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115985"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115986">1,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-115987"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-115988"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-115989"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-115990">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="display:inline;">ne issued or outstanding at March&#160;31, 2024 and December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-115991">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-115992">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Common stock; $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-115993"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-115994">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115995"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115996">100,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115997"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115998"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-115999"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116000">2,155,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> issued and outstanding (excluding </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116001"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116002"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116003"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116004">3,467,954</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares subject to possible redemption) at March&#160;31, 2024 and December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116005">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116006">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116007">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116008">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116009">4,307,789</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116010">3,907,008</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116011">4,307,573</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116012">3,906,792</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Liabilities and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116013">37,274,110</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116014">36,627,733</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div><div id="fintoc476668_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">CONDENSED STATEMENTS OF OPERATIONS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"><div style="display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the three months ended<br/>March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">EXPENSES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">General and administrative expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116015">450,781</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116016">278,102</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116017">450,781</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116018">278,102</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Other income:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Interest earned on investments held in the Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116019">480,824</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116020">417,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total other income</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116021">480,824</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116022">417,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Income before provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116023">30,043</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116024">139,626</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116025">90,473</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116026">29,321</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">NET INCOME (LOSS)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116027">60,430</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116028">110,305</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC AND DILUTED</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116029"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116030">5,622,954</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116031"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116032">5,231,461</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116033"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116034">0.01</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116035"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116036">0.02</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><div style="clear:both;max-height:0pt;"></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;text-indent: 0px;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;font-weight:bold;display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div><div id="fintoc476668_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;font-weight:bold;display:inline;">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;font-weight:bold;display:inline;">For the Three Months Ended March&#160;31, 2024 and 2023 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;font-weight:bold;display:inline;">(UNAUDITED)</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 47%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Additional</div><br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in&#160;Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accumulated</div><br/><div style="display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div><br/><div style="display:inline;">Stockholders&#8217;</div><br/><div style="display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116037">2,155,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116038">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116039">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116040">3,907,008</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116041">3,906,792</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Accretion of common stock to redemption value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116042">340,351</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116043">340,351</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Net loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116044">60,430</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116045">60,430</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, March&#160;31, 2024 (unaudited)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116046">2,155,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116047">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116048">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116049">4,307,789</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116050">4,307,573</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td colspan="4" style="height:12pt"/>
<td colspan="4" style="height:12pt"/>
<td colspan="4" style="height:12pt"/>
<td colspan="4" style="height:12pt"/>
<td colspan="4" style="height:12pt"/></tr>
<tr style="break-inside: avoid; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div> Capital</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accumulated</div><br/><div style="display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div><br/><div style="display:inline;">Stockholders&#8217;</div><br/><div style="display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116051">1,725,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116052">173</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116053">24,827</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116054">62,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116055">37,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Sale of </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116056">430,000</ix:nonFraction></div><div style="display:inline;"> Private Placement Units</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116057">430,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116058">43</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116059">4,299,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116060">4,300,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116061">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116062">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Accretion of common stock to redemption value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116063">5,561,311</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116064">1,878,249</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116065">7,439,560</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;">Net income</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116066">110,305</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116067">110,305</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, March&#160;31, 2023 (unaudited)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116068">2,155,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116069">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116070">1,830,452</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116071">1,830,236</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-3 </div></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div><div id="fintoc476668_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONDENSED STATEMENTS OF CASH FLOWS </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(UNAUDITED) </div></div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the three months ended<br/>March 31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116072">60,430</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116073">110,305</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Interest earned on investments held in the Trust Account</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116074">480,824</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116075">417,728</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116076">57,335</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116077">81,073</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116078">466,334</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116079">340,070</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116080">90,473</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows used in operating activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116081">41,782</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116082">48,426</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Cash deposited in Trust Account</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116083">120,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116084">70,207,500</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows used in investing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116085">120,000</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116086">70,207,500</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from Initial Public Offering, net of underwriters&#8217; fees</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116087">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116088">59,670,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from over-allotment option</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2024To03_31_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116089">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To03_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116090">9,157,500</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from private placement</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116091">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116092">4,300,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Proceeds from note payable&#160;-&#160;related party</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116093">135,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116094">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Payment of offering costs</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116095">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116096">1,447,273</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Repayments to note payable&#160;-&#160;Sponsor</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2024To03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116097">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2023To03_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116098">1,200,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from affiliate</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116099">15,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2023To03_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116100">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows provided by financing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116101">150,000</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116102">70,480,227</ix:nonFraction></div></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">NET CHANGE IN CASH</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116103">11,782</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116104">224,301</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH, BEGINNING OF PERIOD</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116105">15,419</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116106">124,501</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH, END OF PERIOD</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116107">3,637</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116108">348,802</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Supplemental disclosure of noncash investing and financing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred underwriters&#8217; discount payable charged to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116109">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116110">2,070,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div><div id="fintoc476668_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO CONDENSED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">MARCH&#160;31, 2024 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833433" id="ixv-38461"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 1&#8211;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Life Sciences Acquisition Corp. (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;</div><ix:nonFraction name="blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" contextRef="PAsOn03_31_2024" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116111">one</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or more businesses or entities (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;March 31, 2024, the Company had not commenced any operations. All activity since inception relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">generate&#160;non-operating&#160;income</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in the form of interest income from the proceeds derived from the Initial Public Offering.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering (the &#8220;Registration Statement&#8221;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116112">6,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;units (&#8220;Units&#8221; and, with respect to the common stock included in the Units being offered, the &#8220;Public Shares&#8221;), generating gross proceeds of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116113">60,000,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, which is described in Note 3.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#8220;Over-Allotment Option Units&#8221;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116114">900,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Over-Allotment Option Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116115">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per unit generated total gross proceeds of $</div><ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116116">9,000,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#8220;Private Placement&#8221;) of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116117">430,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units (the &#8220;Private Placement Units&#8221;), to Bellevue Global Life Sciences Investors LLC (the &#8220;Sponsor&#8221;) at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116118">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Placement Unit, for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116119">4,300,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Each Unit and Private Placement Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116120">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, par value $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116121">0.0001</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;(the &#8220;Common Stock&#8221;), a warrant to purchase&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116122">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock (the &#8220;Public Warrants&#8221; and &#8220;Private Placement Warrants&#8221; and collectively, the &#8220;Warrants&#8221;) and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116123">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock (the &#8220;Public Rights&#8221; and Private Placement Rights&#8221; and collectively, the &#8220;Rights&#8221;), as described in Notes 3 and 4.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;</div><ix:nonFraction name="blacu:PercentageOfTrustAccountRequiredForBusinessCombination" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116124">80</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;</div><ix:nonFraction name="blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116125">50</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of $</div><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116126">70,207,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">was placed in a trust account (&#8220;Trust&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude><div style="letter-spacing: 0px; top: 0px;display:inline;">F-5</div></ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833433" continuedAt="TextSelectionAppend_117833433_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_1" continuedAt="TextSelectionAppend_117833433_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_2" continuedAt="TextSelectionAppend_117833433_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_3" continuedAt="TextSelectionAppend_117833433_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Account&#8221;) located in the United States with Continental Stock Transfer&#160;&amp; Trust Company acting as trustee, and invested only in United States &#8220;government securities&#8221; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;) having a maturity of 185 days or less or in money market funds meeting certain conditions under </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;2a-7&#160;promulgated</div><div style="display:inline;"> under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.39in; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentRedemptionDescription" contextRef="P01_01_2024To03_31_2024" id="ixv-116128">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).</ix:nonNumeric>&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least<div style="display:inline;">&#160;</div></div></div></div><div style="display:inline;">$</div><div style="display:inline;"><ix:nonFraction name="blacu:NetTangibleAssets" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116129">5,000,001</ix:nonFraction></div><div style="display:inline;">&#160;upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial&#160;Public Offering in favor of a Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">material&#160;non-public&#160;information</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and (ii)&#160;to clear all trades with the Company&#8217;s legal counsel or compliance officer prior to execution. In addition, the Company&#8217;s Sponsor and any other holders of the Company&#8217;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#8220;Initial Stockholders&#8221;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;</div><ix:nonFraction name="blacu:RedemptionLimitPercentage" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116130">15</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-6</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_4" continuedAt="TextSelectionAppend_117833433_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;text-indent: 0px;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833433_5" continuedAt="TextSelectionAppend_117833433_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_6" continuedAt="TextSelectionAppend_117833433_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_7" continuedAt="TextSelectionAppend_117833433_8"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s Initial Stockholders and Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;</div><ix:nonFraction name="blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116132">100</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of its Public Shares if the Company does not complete a Business Combination within&#160;</div><ix:nonNumeric name="blacu:PeriodToConsummateBusinessCombination" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:durwordsen" id="ixv-38583"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">nine months</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#8220;Combination Period&#8221;) or (B)&#160;with respect to any other provision relating to&#160;stockholders&#8217;&#160;rights </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">or&#160;pre-initial&#160;Business</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.</div></div><br/></div></ix:continuation></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117833433_8" continuedAt="TextSelectionAppend_117833433_9"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than </div>ten</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> business days thereafter, redeem&#160;</div><ix:nonFraction name="blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116133">100</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $</div><ix:nonFraction name="blacu:MaximumAllowedDissolutionExpenses" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116134">100,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</div></div></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_9" continuedAt="TextSelectionAppend_117833433_10"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $10.175 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed t</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">o<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Extension of Termination Date and Redemptions from the Trust Account </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an extension of the date by which the Company must </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-7</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_10" continuedAt="TextSelectionAppend_117833433_11"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833433_11" continuedAt="TextSelectionAppend_117833433_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_12" continuedAt="TextSelectionAppend_117833433_13"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_13" continuedAt="TextSelectionAppend_117833433_14"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors (the &#8220;Board&#8221;) the authority in its discretion to amend the Charter to extend the date by which the Company must consummate a business combination from February&#160;14, 2024 to May&#160;14, 2024. In connection with the Special </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Meeting,&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn02_14_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116137">3,432,046</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of common stock of the Company were tendered for redemption at a redemption price of approximately $</div><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn02_14_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116138">10.49</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share for an aggregate redemption amount of $</div><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="PAsOn02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116139">35,995,728</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, leaving $</div><ix:nonFraction name="us-gaap:CommonStockValueOutstanding" contextRef="PAsOn02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116140">36,372,335</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $</div><ix:nonFraction name="blacu:InterestIncomeHeldInTheTrustAccount" contextRef="P11_14_2023To02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116141">561,957</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Additionally, the Company deposited $</div><ix:nonFraction name="blacu:InvestmentOfCashInTrustAccount" contextRef="PAsOn11_13_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116142">180,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;into the Trust Account on November&#160;</div>13</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2023</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in connection with the extension of the date by which the Company must consummate a business combination from November&#160;</div>14</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2023</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to February&#160;</div>14</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In </div>February 2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Board authorized and approved a second Certificate of Amendment to the Charter. The second Certificate of Amendment to the Charter was filed with the Delaware Secretary of State, with an effective date of February&#160;</div>9</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, and extended the date by which the Company must consummate a business combination to the May&#160;</div>14</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. In connection with the extension by which the Company must consummate a business combination to May&#160;</div>14</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company deposited $</div><ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P02_09_2024To02_09_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116143"><ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P03_12_2024To03_12_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116144">60,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> into the Trust Account on each of February&#160;</div>9</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and March&#160;</div>12</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. In connection with the $</div><ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P02_09_2024To02_09_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116145">60,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> deposited into the Trust Account on February&#160;</div>9</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company issued an unsecured promissory note in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_09_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116146">75,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to Jun Chul Whang, a member of the Board. In connection with the $</div><ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P03_12_2024To03_12_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116147">60,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> deposited into the Trust Account on March&#160;</div>12</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company issued an unsecured promissory note in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_12_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116148">60,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to Josh Pan, an individual member of Bellevue Capital Management, LLC, which wholly owns the Sponsor.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Franchise and Income Tax Withdrawal </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In </div>November 2023</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company withdrew $</div><ix:nonFraction name="blacu:InterestIncomeHeldInTheTrustAccount" contextRef="P11_01_2023To11_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116149">561,957</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through March&#160;</div>31</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#8217;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#8217;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of March&#160;</div>31</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company&#8217;s obligations for franchise and income tax purposes remain payable.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#8220;GAAP&#8221;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the </div>three</div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> months ended </div>March 31, 2024</div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> are not necessarily indicative of the results to be expected for the year ending </div>December 31, 2024</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> or for any future interim periods.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form </div>10</div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">-K as of and for the year ended </div>December 31, 2023</div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> as filed with SEC on </div>April 17, 2024</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Liquidity and Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;</div>31</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company had $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116150">3,637</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in its operating bank account and a working capital deficit of $</div><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116151">2,676,899</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering had been</div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-8</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_14" continuedAt="TextSelectionAppend_117833433_15"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833433_15" continuedAt="TextSelectionAppend_117833433_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_16" continuedAt="TextSelectionAppend_117833433_17"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_17" continuedAt="TextSelectionAppend_117833433_18"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement Units held outside of the Trust Account and loans from the Sponsor, officers and directors and their affiliates.</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or 21 months from the Initial Public Offering (subject to extension by approval of the Company&#8217;s stockholders). These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160;Over this time period, the Company has used and will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#8217;s current operating cash balance may need to be funded through loans from the Company&#8217;s Sponsor, officers and directors and their affiliates. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">If the Company is unable to complete a Business Combination by November 14, 2024 (subject to extension by approval of the Company&#8217;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management will seek to complete a business combination.</div></div></ix:continuation></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117833433_18" continuedAt="TextSelectionAppend_117833433_19"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Emerging Growth Company</div></div></div></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_19" continuedAt="TextSelectionAppend_117833433_20"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the&#160;Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply </div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;">to&#160;non-emerging&#160;growth</div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"> companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in&#160;accounting&#160;standards used.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-9</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_20" continuedAt="TextSelectionAppend_117833433_21"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833433_21" continuedAt="TextSelectionAppend_117833433_22"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833433_22" continuedAt="TextSelectionAppend_117833433_23"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833433_23"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nasdaq Listing Rules Compliance </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">As previously reported by the Company on Form&#160;8-K&#160;filed on June&#160;14, 2023, due to the resignation of a director effective on June&#160;21, 2023, the Company notified the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on June&#160;27, 2023 that the Company was not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the &#8220;Listing Rule&#8221;), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Company has until the earlier of its next annual shareholders&#8217; meeting or June&#160;21, 2024 to regain compliance.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Listing Rule requires the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of the director&#8217;s resignation from the Company&#8217;s Board and Audit Committee, the Company&#8217;s Audit Committee has been comprised of two independent directors and one vacancy and, therefore, does not currently comply with Nasdaq&#8217;s audit committee requirements as set forth in the Listing Rule. Pursuant to the Listing Rule&#8217;s section (c)(4)(B), the Company is entitled to a cure period to regain compliance with the Listing Rule. The Company is evaluating the appropriate membership and composition of its Board and Board committees and intends to regain compliance with Listing Rule prior to the expiration of the applicable cure period.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">On February&#160;15, 2024, the Company received a notification from the Listing Qualifications Department of Nasdaq notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the &#8220;Minimum Public Holders Requirement&#8221;). The notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of securities on the Nasdaq Capital Market. In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement.</div></div></ix:continuation><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117832453" id="ixv-38882"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTE 2&#8211;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-38886"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Use of Estimates </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from thos<div style="display:inline;">e </div>estimates.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-38903"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Cash and Cash Equivalents</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116155">3,637</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116156">15,419</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in cash held in its operating account as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The Company had&#160;</div><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116157"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116158">no</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;cash equivalents as of March&#160;31, 2024 and December&#160;31, 2023.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-38914"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Fair Value of Financial Instruments</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the unaudited condensed financial statements, primarily due to their short-term nature.</div></div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude><div style="letter-spacing: 0px; top: 0px;display:inline;">F-10</div></ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832453" continuedAt="TextSelectionAppend_117832453_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_1" continuedAt="TextSelectionAppend_117832453_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_2" continuedAt="TextSelectionAppend_117832453_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832453_3" continuedAt="TextSelectionAppend_117832453_4"><ix:nonNumeric name="blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-38938"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Investments Held in Trust Account </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in the Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-38945"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Fair Value Measurements</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash and amounts due to related parties are estimated to approximate the carrying values as of&#160;March 31, 2024 due to the short maturities of such instruments. </div></div></div></div></ix:nonNumeric><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39019"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">then&#160;re-valued&#160;at</div><div style="display:inline;"> each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed financial statements as current </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">or&#160;non-current</div><div style="display:inline;"> based on whether or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">not&#160;net-cash&#160;settlement</div><div style="display:inline;"> or conversion of the instrument could be required within 12 months of the condensed balance sheet date. </div></div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-11</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_4" continuedAt="TextSelectionAppend_117832453_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117832453_5" continuedAt="TextSelectionAppend_117832453_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_6" continuedAt="TextSelectionAppend_117832453_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832453_7" continuedAt="TextSelectionAppend_117832453_8"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39051"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$</div><ix:nonFraction name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116160">250,000</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div></ix:nonNumeric></ix:continuation> </div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832453_8" continuedAt="TextSelectionAppend_117832453_9"><ix:nonNumeric name="blacu:WarrantInstrumentsPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39065"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Warrant Instruments</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div></ix:nonNumeric><ix:nonNumeric name="blacu:RightsPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39070"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Rights </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116161">6,900,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Units, each Public Unit is comprised of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116162">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116163">0.0001</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;par value, a&#160;warrant to purchase&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116164">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116165">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116166">430,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;815-40.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div></ix:nonNumeric> <ix:nonNumeric name="blacu:EquityParticipationSharesPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39097"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116167">34,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representative shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116168">4,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-12</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_9" continuedAt="TextSelectionAppend_117832453_10"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117832453_10" continuedAt="TextSelectionAppend_117832453_11"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_11" continuedAt="TextSelectionAppend_117832453_12"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832453_12" continuedAt="TextSelectionAppend_117832453_13"><ix:nonNumeric name="blacu:NetLossPerCommonSharePolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39133"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Net Income (Loss) per Common Share</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div><ix:nonFraction name="blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116170">7,330,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is received by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39140"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;March 31, 2024 and</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="display:inline;">December&#160;31, 2023,&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116171"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116172">3,467,954</ix:nonFraction></ix:nonFraction></div>&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s condensed balance sheets. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833477" id="ixv-39150"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary diff<div style="display:inline;">er</div>ences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets w<div style="display:inline;">er</div>e deemed to be de minimis as of March&#160;31, 2024 and&#160;December 31, 2023.</div></div><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39157"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the three months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116173">90,473</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116174">29,321</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116175">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116176">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Total provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116177">90,473</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116178">29,321</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-13</ix:exclude> </div></div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_117833477" continuedAt="TextSelectionAppend_117833477_1"><ix:continuation id="TextSelectionAppend_117832453_13" continuedAt="TextSelectionAppend_117832453_14"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833477_1" continuedAt="TextSelectionAppend_117833477_2"><ix:continuation id="TextSelectionAppend_117832453_14" continuedAt="TextSelectionAppend_117832453_15"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832453_15" continuedAt="TextSelectionAppend_117832453_16"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833477_2" continuedAt="TextSelectionAppend_117833477_3"><ix:continuation id="TextSelectionAppend_117832453_16" continuedAt="TextSelectionAppend_117832453_17"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39322"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Provision/(benefit) at statutory rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116180">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116181">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">State tax provision/(benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116182">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116183">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Change in fair value of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116184">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116185">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116186">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116187">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116188">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116189">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116190">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116191">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr></table></ix:nonNumeric></ix:continuation></ix:continuation> </div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117832453_17" continuedAt="TextSelectionAppend_117832453_18"><ix:continuation id="TextSelectionAppend_117833477_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely than not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116192"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116193">no</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;March 31, 2024 and&#160;December&#160;31, 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116194">No</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">amounts were accrued for the payment interest and penalties for the three months ended March&#160;31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div></div></ix:continuation></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832453_18"><ix:nonNumeric name="blacu:OfferingCostsPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39503"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1,&#160;SEC</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39513"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting sta<div style="letter-spacing: 0px; top: 0px;display:inline;">nd</div>a<div style="letter-spacing: 0px; top: 0px;display:inline;">r</div>ds, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed financial statements.</div></div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="blacu:InitialPublicOfferingTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39522"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 3&#8211;INITIAL PUBLIC OFFERING </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Initial Public Offering, the Company sold&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116195">6,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116196">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116197">900,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units. Each Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116198">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock,&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116199">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder thereof to purchase&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116200">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock at a price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116201">11.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustme<div style="letter-spacing: 0px; top: 0px;display:inline;">nt,</div> and&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116202">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock (see Note 6). Each warrant will become exercisable&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durday" id="ixv-39547"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the consummation of an initial business combination, and will expire&#160;</div><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen" id="ixv-39551"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of an initial business combination, or earlier upon redemption or liquidation. Each right entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;</div><ix:nonFraction name="blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116203">ten</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;rights entitle the holder thereof to receive one share of common <div style="letter-spacing: 0px; top: 0px;display:inline;">sto</div>ck at the closing of a business combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-14 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833423" id="ixv-39572"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 4&#8211;RELATED PARTY TRANSACTIONS </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Founder Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;30, 2020, the Sponsor purchased&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116204">1,437,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of the Company&#8217;s Common Stock (the&#160;&#8220;Founder Shares&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116205">25,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, or approximately $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-116206">0.017</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share.&#160;</div><div style="-sec-ix-hidden:hidden117832661;display:inline;">On</div> April&#160;25, 2022, the Company executed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">a&#160;1.2-for-one&#160;stock</div></div> split, resulting in an aggregate of&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116207">1,725,000</ix:nonFraction></div><div style="display:inline;">&#160;Founder Shares held by the Company&#8217;s sponsor, of which up to&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116208">225,000</ix:nonFraction></div><div style="display:inline;">&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part.</div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A)</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><ix:nonNumeric name="blacu:SharesOutstandingHoldingTermAfterBusinessCombination" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durwordsen" id="ixv-39600"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">three years</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116209">12.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-39606"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">20</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;trading days </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">within&#160;any&#160;</div></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-116210">30</ix:nonNumeric>-day&#160;trading</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> period commencing at least&#160;</div><ix:nonNumeric name="blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-39614"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">150</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">property.&#160;</div></div>&#160;<br/></div></div><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Private Placement Units</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has purchased an aggregate of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116211">430,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Private Placement Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116212">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116213">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock,&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116214">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder to purchase&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116215">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116216">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116217">11.50</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will <div style="letter-spacing: 0px; top: 0px;display:inline;">be </div>included in the liquidating distribution to the holders of the Public Shares.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor and the Company&#8217;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-39648"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the completion of the Business Combination.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Promissory Notes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by&#160;non-interest-bearing</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> promissory notes in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116218">1,200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The promissory notes were due at the earlier of&#160;</div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-39660"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">November 29, 2023</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">On June 23, 2023, the Sponsor loaned to the Company $</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116219">200,000</ix:nonFraction> to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $</div></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_23_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116220">200,000</ix:nonFraction>. This </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate an initial Business Combination, the note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. At the Sponsor&#8217;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">of $</div></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116221">10.00</ix:nonFraction> per Unit. As of March 31, 2024 and December 31, 2023, the outstanding balance of this note was $</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116222">0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-15</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833423" continuedAt="TextSelectionAppend_117833423_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833423_1" continuedAt="TextSelectionAppend_117833423_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833423_2" continuedAt="TextSelectionAppend_117833423_3"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November 13, 2023, Bellevue Capital Management LLC (&#8220;BCM&#8221;) loaned to the Company $</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116224">180,000</ix:nonFraction> and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $</div></div></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116225">180,000</ix:nonFraction>. The proceeds of this loan were used to fund the payment to extend the date by which the Company must consummate an initial Business Combination to February 14, 2024. The note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. As of March 31, 2024 and December 31, 2023, the outstanding balance of this </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> note was $</div></div></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116226"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116227">0</ix:nonFraction></ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#8220;JCW Promissory Note&#8221;) in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_09_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116228">75,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">to </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Jun Chul Whang, a member of the Company&#8217;s Board. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August 9, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JCW Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s trust account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note was<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">$</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116229">75,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;JP Promissory Note&#8221;) in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116230">60,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Josh Pan, a member of Bellevue Capital Management LLC. The JP Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August&#160;8, 2024 or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JP Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JP Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116231">60,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833423_3" continuedAt="TextSelectionAppend_117833423_4"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Working Capital Loans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">$</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116232">1,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;of such Working Capital Loans may be convertible into Units at a price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116233">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#8217;s securities, and Chardan and its related persons will have&#160;</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116234">no</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;recourse with respect to their ability to convert their loans into any of the Company&#8217;s securities. As of March&#160;31, 2024 and&#160;December 31, 2023,&#160;</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116235"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116236">no</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;Working Capital Loans were outstanding.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Administrative Support Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $</div><ix:nonFraction name="blacu:MonthlyAdministrativeFeesExpense" contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116237">7,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-16</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833423_4" continuedAt="TextSelectionAppend_117833423_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833423_5" continuedAt="TextSelectionAppend_117833423_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833423_6" continuedAt="TextSelectionAppend_117833423_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833423_7"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="display:inline;">the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. During <div style="letter-spacing: 0px; top: 0px;display:inline;">the three months ended March 31, 2024 and 2023, the Company</div>&#160;incurred $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116240">22,500</ix:nonFraction></div><div style="display:inline;">&#160;and $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116241">7,500</ix:nonFraction></div><div style="display:inline;">, respectively, of administrative support fees which are included in general and administrative expenses in the <div style="letter-spacing: 0px; top: 0px;display:inline;">accompanying condensed statements</div>&#160;of operations. As of March&#160;31, 2024 and December&#160;31, 2023, the outstanding balance was $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116242">30,000</ix:nonFraction></div><div style="display:inline;"> and $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116243">15,000</ix:nonFraction></div><div style="display:inline;">, respectively,&#160;recorded as due to affiliate. </div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Due to Affiliate </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116244">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On February&#160;17, 2022, the Company repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116245">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116246">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On April&#160;29, 2022, the Sponsor agreed to advance an additional $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116247">7,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. These advances are due on </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">demand and are non-interest bearing. During the year ended</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;December 31, 2023, the Sponsor advanced $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116248">180,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of funds to the Company and Company repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116249">140,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $</div><ix:nonFraction name="blacu:MonthlyAdministrativeFeesExpense" contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116250">7,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The outstanding balance was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116251"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116252">57,000</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;as of&#160;March 31, 2024 and December&#160;31, 2023, recorded as due to affiliate.</div></div></ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833347" id="ixv-39822"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 5&#8211;COMMITMENTS&#160;AND&#160;CONTINGENCIES </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Registration Rights </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;</div><ix:nonFraction name="blacu:MaximumNumberOfDemandsForRegistrationOfSecurities" contextRef="PAsOn03_31_2024" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116253">two</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"></div> <div style="display:inline;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Underwriting Agreement </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company granted the underwriters </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;45-day&#160;option</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> from the final prospectus relating to the Initial Public Offering to purchase up to&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116254">900,000</ix:nonFraction><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The underwriters were entitled to an underwriting discount of $</div><ix:nonFraction name="blacu:UnderwritingCashDiscountPerUnit" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116255">0.20</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or $</div><ix:nonFraction name="blacu:AggregateUnderwriterCashDiscount" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116256">1,200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate, equal to&#160;</div><ix:nonFraction name="blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116257">2</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the gross proceeds of the Initial Public Offering (or $</div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116258">1,380,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate if the underwriters&#8217; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $</div><ix:nonFraction name="blacu:UnderwritingCashDiscountPerUnit" contextRef="PAsOn03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-116259">0.125</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit payable in cash. In addition, $</div><ix:nonFraction name="blacu:UnderwritingExpensePricePerShare" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116260">0.30</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or approximately&#160;$</div><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116261">1,800,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate (or $</div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116262">2,070,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#8217; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-17</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833347" continuedAt="TextSelectionAppend_117833347_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833347_1" continuedAt="TextSelectionAppend_117833347_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833347_2" continuedAt="TextSelectionAppend_117833347_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="display:inline;">entitled to receive&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116264">30,000</ix:nonFraction></div><div style="display:inline;">&#160;shares of Common Stock (or&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116265">34,500</ix:nonFraction></div><div style="display:inline;">&#160;shares if the underwriters&#8217; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#8220;Equity Participation Shares.&#8221; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) and are therefore subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;lock-up&#160;for</div> a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.</div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Excise Tax </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Inflation Reduction Act (&#8220;IR Act&#8221;) of 2022 imposes a&#160;</div><ix:nonFraction name="blacu:EffectiveExciseTaxRate" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116266">1</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December&#160;31, 2022. For purposes of the Excise Tax, a repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#8220;SPAC&#8221;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#8217;s </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">initial</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">a&#160;de-SPAC&#160;transaction</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> within the required time set forth in its constituent documents, or (iii)&#160;in connection with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">the&#160;wind-up&#160;and</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;</div><ix:nonFraction name="blacu:EffectiveExciseTaxRate" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116267">1</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% has </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">been included in these unaudited condensed financial statements.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#8217;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $</div><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116268">359,957</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;excise tax liability as of March 31, 2024. The Company will continue to monitor for updates to the Company&#8217;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#8217;s tax provision in future periods.</div><br/></div></ix:continuation></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117833347_3" continuedAt="TextSelectionAppend_117833347_4"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Risks and Uncertainties</div></div></ix:continuation></div></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833347_4" continuedAt="TextSelectionAppend_117833347_5"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-18</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_117833347_5" continuedAt="TextSelectionAppend_117833347_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_117833347_6" continuedAt="TextSelectionAppend_117833347_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833347_7" continuedAt="TextSelectionAppend_117833347_8"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833347_8"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial business combination and any target business with which the Company may ultimately consummate an initial business combination.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The excise tax included in the IR Act of 2022 may decrease the value of the Company&#8217;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.</div></div></ix:continuation> <ix:nonNumeric name="blacu:CommonStockSubjectToPossibleRedemptionTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39959"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 6&#8211;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Company&#8217;s common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s condensed balance sheets.</div></div> <ix:nonNumeric name="blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-39966"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of March&#160;31, 2024:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Common<br/>Stock<br/>Subject to<br/>Possible<br/>Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116270">69,000,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116271">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116272">4,791,126</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116273">35,995,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116274">9,449,634</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116275">36,426,253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2024To03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116276">340,351</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Balance, March&#160;31, 2024</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116277">36,766,604</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117832454" id="ixv-40099"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">NOTE 7&#8211;STOCKHOLDERS&#8217; DEFICIT</div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Preferred Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company is authorized to issue&#160;</div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116278"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116279">1,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock with a par value of $</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116280"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116281">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. As of </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">December</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;31, 2024 and March&#160;31, 2023, there were&#160;</div><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116282"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116283"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116284"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116285">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock issued or outstanding.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Common Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116286">100,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Common Stock at a</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;$</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116287">0.0001</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;par value.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-19</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832454" continuedAt="TextSelectionAppend_117832454_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832454_1" continuedAt="TextSelectionAppend_117832454_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832454_2" continuedAt="TextSelectionAppend_117832454_3"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;March 31, 2024 and December&#160;31, 2023, there were&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116289"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116290">2,155,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Common </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Stock outstanding, excluding&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116291">3,467,954</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of common stock subject to possible redemption that are reflected in temporary equity in the </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">condensed&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">balance sheets.</div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0.13in;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2024To03_31_2024" id="ixv-116292">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.</ix:nonNumeric> </div></div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0.13in;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Warrants </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2024 and December&#160;31, 2023, there were&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116293"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116294">7,330,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Warrants outstanding. The Warrants that are a part of the Units (the &#8220;Warrants&#8221;) may be exercised at a price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2024_IPOMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116295">11.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-40169"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the completion of a Business Combination.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Warrants have an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116296">11.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share and will expire&#160;</div><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen" id="ixv-40177"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Redemption of warrants when the price per Common Stock equals or exceeds $16.50.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Once the Warrants become exercisable, the Company may call the Warrants for redemption:</div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">at a price of $</div><div style="display:inline;"><ix:nonFraction name="blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116297">0.01</ix:nonFraction></div><div style="display:inline;">&#160;per Warrant; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">upon not less than&#160;</div><div style="display:inline;"><ix:nonNumeric name="blacu:NoticePeriodForWarrantRedemption" contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116298">30</ix:nonNumeric></div><div style="display:inline;">&#160;days&#8217; prior written notice of redemption given after the Warrants become exercisable; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">if, and only if, the reported last sale price of the Common Stock equals or exceeds $</div><div style="display:inline;"><ix:nonFraction name="blacu:WarrantRedemptionConditionMinimumSharePrice" contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116299">16.50</ix:nonFraction></div><div style="display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="display:inline;"><ix:nonNumeric name="blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116300">20</ix:nonNumeric></div><div style="display:inline;">&#160;trading days <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">within&#160;a&#160;</div></div><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116301">30</ix:nonNumeric>-trading&#160;day</div> period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">entire&#160;30-day&#160;trading</div> period referred to above and continuing each day thereafter until the date of redemption.</div> </div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;text-indent: 0px;"></div></ix:continuation> </div></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117832454_3" continuedAt="TextSelectionAppend_117832454_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.</div></div></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832454_4" continuedAt="TextSelectionAppend_117832454_5"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-20</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117832454_5" continuedAt="TextSelectionAppend_117832454_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117832454_6" continuedAt="TextSelectionAppend_117832454_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832454_7" continuedAt="TextSelectionAppend_117832454_8"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832454_8"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s Board), (y) the aggregate gross proceeds from such issuances represent more than</div>&#160;</div><ix:nonFraction name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116303">60</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116304">9.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;</div><ix:nonFraction name="blacu:WarrantExercisePriceAdjustmentPercentage" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116305">115</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value, and the $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116306">16.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;</div><ix:nonFraction name="blacu:RedemptionTriggerPriceAdjustmentPercentage" contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116307">165</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;</div><div style="display:inline;"><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_EquityParticipationMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116308">34,500</ix:nonFraction></div><div style="display:inline;">&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.</div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="display:inline;">The Company complies with the requirements of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div><div style="display:inline;"> SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. </div></div></div><div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Rights </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="color: red; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="display:inline;">Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="display:inline;"> (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#8217;s certificate of incorporation with respect to its </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-business</div><div style="display:inline;"> combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="display:inline;"> (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div><div style="display:inline;"> into common stock basis. </div></div></div></ix:continuation><div style="color: red; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833424" id="ixv-40330"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">NOTE 8&#8211;FAIR VALUE MEASUREMENTS</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117833426" id="ixv-40335"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of March&#160;31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">March&#160;31,<br/>2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116309">37,205,930</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116310">37,205,930</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116311">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116312">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-21</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833426" continuedAt="TextSelectionAppend_117833426_1"><ix:continuation id="TextSelection_117833424" continuedAt="TextSelectionAppend_117833424_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833424_1" continuedAt="TextSelectionAppend_117833424_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833424_2"><ix:continuation id="TextSelectionAppend_117833426_1"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="font-size: 11pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investments held in Trust Account</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116314">36,605,106</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116315">36,605,106</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116316">&#8212;</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116317">&#8212;</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">There were no transfers between Levels 1, 2 and 3 during the three months ended March&#160;31, 2024.</div><div style="background-color: initial; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_117832452" id="ixv-40762"><div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 9&#8211;SUBSEQUENT EVENTS </div></div><div style="font-weight:bold;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Company evaluated subsequent events to determine if events or transactions occurred after the condensed balance sheet date up to the date the unaudited condensed financial statements&#160;were&#160;issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements, other than the following:</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April 1, 2024, the Company submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq. On April 17, 2024, the Company received written notice from Nasdaq indicating that the staff of Nasdaq (the &#8220;Staff&#8221;) determined, based on its review of the Company&#8217;s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August&#160;13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or an independent source, demonstrating that its <div style="letter-spacing: 0px; top: 0px;display:inline;">common </div>stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the Staff will provide written notification that the Company&#8217;s securities will be delisted. At that time, the Company may appeal the Staff&#8217;s determination to a Listing Qualifications Panel. </div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;April Sponsor Note&#8221;) in the principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_08_2024_AprilSponsorNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116318">1,200,000</ix:nonFraction></div><div style="display:inline;">&#160;to the Sponsor. The April Sponsor Note is&#160;not interest&#160;bearing and is payable in full on the earlier of (i)&#160;</div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116319">December 31, 2024</ix:nonNumeric></div><div style="display:inline;">&#160;or (ii)&#160;the date on which the Company consummates an initial <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> (the &#8220;April Sponsor Note Maturity Date&#8221;). In the event that the Company does not consummate a <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the April Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div>, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;9, 2024, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116320">60,000</ix:nonFraction></div><div style="display:inline;">&#160;was deposited in the&#160;Trust Account&#160;in connection with the&#160;extension of the date by which the Company must consummate a business combination from&#160;</div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116321">April 15, 2024</ix:nonNumeric>&#160;</div><div style="display:inline;">to </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116322">May 14, 2024</ix:nonNumeric></div><div style="display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">In connection with the November 2023 withdrawal of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116323">561,957</ix:nonFraction></div><div style="display:inline;">&#160;of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">. As</div> of April&#160;16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#8217;s Sponsor and the Company has paid its federal tax obligations on time. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;17, 2024,&#160;the Company issued an unsecured promissory note (the &#8220;Second April Sponsor Note&#8221;) in the principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_17_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116324">50,000</ix:nonFraction></div><div style="display:inline;"> to <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">the Sponsor. The Second April Sponsor Note is not</div></div></div></td></tr></table><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-22</ix:exclude> </div></div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832452" continuedAt="TextSelectionAppend_117832452_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832452_1" continuedAt="TextSelectionAppend_117832452_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832452_2" continuedAt="TextSelectionAppend_117832452_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832452_3">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">interest bearing and is&#160;payable in full on the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the&#160;date on which the Company consummates an initial Business Combination (the &#8220;Second April Sponsor Notes Maturity Date&#8221;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">)</div></div><div style="display:inline;">. In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the Second April Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the Second April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;17, 2024, the Company withdr<div style="letter-spacing: 0px; top: 0px;display:inline;">ew</div>&#160;$</div><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_17_2024To04_17_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116326">100,000</ix:nonFraction></div><div style="display:inline;"> of interest income earned in the Trust Account for payment of the Company&#8217;s state franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"><div style="display:inline;">On May&#160;10, 2024, the Company <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">convened</div> a special meeting of its stockholders (the &#8220;2024 Special Meeting<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#8221;) as scheduled and adjourned the 2024 Special Meeting without any business being conducted. As announced at the 2024 Special Meeting, it was reconvened on May 14, 2024.</div>&#160;At the 2024 Special Meeting, the Company&#8217;s stockholders approved <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">the proposal to extend</div> the date by which the Company must consummate a <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> from </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116327">May 14, 2024</ix:nonNumeric></div><div style="display:inline;"> to </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116328">November 14, 2024</ix:nonNumeric></div><div style="display:inline;">.<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;Following such approval by the Company&#8217;s stockholders, the Company subsequently amended its Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a Business Combination to November 14, 2024. <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">The Company also</div></div> deposited $</div></div><div style="display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116329">50,000</ix:nonFraction> into the Trust Account on May 14, 2024.</div>&#160;In connection with the Special Meeting,&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116330">1,581,733</ix:nonFraction></div>&#160;shares of common stock of the Company were tendered for redemption.</div> </div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May 14, 2024, the Company issued an unsecured promissory note (the &#8220;May Sponsor Note&#8221;) in the principal amount of $</div></div><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_14_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116331">140,000</ix:nonFraction> to the Sponsor. The May Sponsor Note is </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen" id="ixv-116332">no</ix:nonFraction></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">t interest bearing and is payable in full on the earlier of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>(i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination (the &#8220;May Sponsor Note Maturity Date&#8221;). In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the May Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden117832595;display:inline;">five</div></div> business days of the May Sponsor Note Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-23 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fintoc476668_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 95%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_8" style="display:inline;">Report of Independent Registered Public Accounting Firm (PCAOB ID #100)</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-25</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Financial Statements:</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_9" style="display:inline;">Balance Sheets as of December&#160;31, 2023 and 2022 </a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-27</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_10" style="display:inline;">Statements of Operations for the years ended December&#160;31, 2023 and 2022 </a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-28</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_11" style="display:inline;">Statements of Changes in Stockholder&#8217;s Deficit for the years ended December&#160;31, 2023 and 2022 </a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-29</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_12" style="display:inline;">Statements of Cash Flows for the years ended December&#160;31, 2023 and 2022 </a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-30</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fintoc476668_13" style="display:inline;">Notes to Financial Statements </a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-31</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-24 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fintoc476668_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">To the Stockholders and the Board of Directors of </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Bellevue Life Sciences Acquisition Corp.: </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Opinion on the Financial Statements </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">We have audited the accompanying balance sheets of Bellevue Life Sciences Acquisition Corp. (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related statements of operations, changes in stockholder&#8217;s deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Emphasis of a Matter </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As discussed in Note 1 to the financial statements, the Company withdrew $561,957 of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through December&#160;31, 2023, the Company did not use such funds to pay its tax obligations and instead deposited the funds in the Company&#8217;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#8217;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Going Concern </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs and complete a business combination by May&#160;14, 2024, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Basis for Opinion </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-25 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">/s/ WithumSmith+Brown, PC </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">New York, New York </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">April&#160;17, 2024 </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">PCAOB Number 100 </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-26 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div> <div id="fintoc476668_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BALANCE SHEETS</div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 69%;"><div style="display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116333">15,419</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116334">124,501</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116335">7,208</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116336">22,627</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116337">124,501</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred offering costs</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116338">1,101,353</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116339">36,605,106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116340">36,627,733</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116341">1,225,854</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116342">1,081,753</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116343">34,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116344">524,562</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Excise tax payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116345">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:AccruedOfferingCostsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116346">12,362</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Notes payable&#160;-&#160;related party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116347">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116348">1,200,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Due to affiliate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116349">72,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116350">17,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116351">2,038,272</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116352">1,263,362</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred underwriting commissions</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:DeferredUnderwritingCommissions" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116353">2,070,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116354">4,108,272</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116355">1,263,362</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Commitments and Contingencies</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-116356"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true" id="ixv-116357"/></div></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Common stock subject to possible redemption, </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116358"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116359">3,467,954</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued and outstanding at redemption value of $</div><div style="display:inline;"><ix:nonFraction name="blacu:CommonStockRedemptionValue" contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116360"><ix:nonFraction name="blacu:CommonStockRedemptionValue" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116361">10.50</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> per share and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116362"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116363">0</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued and outstanding at December&#160;31, 2023 and&#160;2022, respectively</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116364">36,426,253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">Stockholders&#8217; Deficit</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;text-align:right;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Preferred stock, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116365"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116366">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116367"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116368">1,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; <div style="letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116369"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116370"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116371"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-116372">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="display:inline;">ne issued or outstanding at December&#160;31, 2023&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">and<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116373">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116374">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Common stock; $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116375"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116376">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116377"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116378">100,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116379"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116380">2,155,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> issued and outstanding (excluding </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116381"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116382">3,467,954</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares subject to possible redemption) and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116383"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116384">1,725,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> issued and outstanding at December&#160;31, 2023 and&#160;2022, respectively</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116385">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116386">173</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116387">24,827</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116388">3,907,008</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116389">62,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116390">3,906,792</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116391">37,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Liabilities and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116392">36,627,733</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116393">1,225,854</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="display:inline;">The accompanying notes are an integral part of the financial statements.</div> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-27 </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div></div></div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div> <div id="fintoc476668_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">STATEMENTS OF OPERATIONS </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the Years ended<br/>December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">EXPENSES</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116394">1,830,700</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116395">35,388</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116396">1,830,700</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116397">35,388</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Interest earned on investments held in the Trust Account</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116398">2,775,291</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total other income</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116399">2,775,291</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income (loss) before provision for income taxes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116400">944,591</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116401">35,388</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Provision for income taxes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116402">540,811</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">NET INCOME (LOSS)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116403">403,780</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116404">35,388</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">WEIGHTED AVERAGE SHARES OUTSTANDING</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116405">7,688,260</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116406">1,500,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116407">7,719,699</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116408">1,500,000</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">NET INCOME (LOSS) PER SHARE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"/> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116409">0.05</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116410">0.01</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116411">0.05</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116412">0.01</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="display:inline;">The accompanying notes are an integral part of the financial statements.</div> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-28 </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div> <div id="fintoc476668_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022 </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 47%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in&#160;Capital</div></div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116413">1,725,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116414">173</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116415">24,827</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116416">27,120</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116417">2,120</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Net loss</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116418">35,388</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116419">35,388</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116420">1,725,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116421">173</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116422">24,827</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116423">62,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116424">37,508</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Sale of </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116425">430,000</ix:nonFraction></div><div style="display:inline;"> Private Placement Units</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116426">430,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116427">43</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116428">4,299,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116429">4,300,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116430">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116431">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accretion of common stock to <div style="letter-spacing: 0px; top: 0px;display:inline;">possible&#160;</div>redemption value</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116432">5,561,311</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116433">3,888,323</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116434">9,449,634</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Net income</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116435">403,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116436">403,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Excise tax payable attributable to redemption of common stock</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116437">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116438">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Balance, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116439">2,155,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116440">216</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116441">3,907,008</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116442">3,906,792</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="display:inline;">The accompanying notes are an integral part of the financial statements.</div> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-29 </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div> <div id="fintoc476668_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">STATEMENTS OF CASH FLOWS </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8201;&#8195;&#8195;2023&#8195;&#8195;&#8201;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8201;&#8195;&#8195;2022&#8195;&#8195;&#8201;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116443">403,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116444">35,388</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Interest earned on investments held in the Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116445">2,775,291</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116446">7,208</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116447">1,035,391</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116448">31,153</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116449">524,562</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.2em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows used in operating activities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116450">818,766</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116451">4,235</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash withdrawn from Trust Account for payment to redeeming stockholders</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116452">35,995,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investment of cash in Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116453">180,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash deposited in Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:CashDepositedInTheTrustAccount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116454">70,207,500</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Withdrawal of interest from Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:GainLossFromTrustAccountToPayExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116455">561,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.2em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows used in investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116456">33,829,815</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Redemption of common stock</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116457">35,995,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from Initial Public Offering, net of underwriters&#8217; fees</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116458">59,670,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from over-allotment option</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116459">9,157,500</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from private placement</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116460">4,300,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116461">1,447,273</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116462">683,021</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from note payable - Sponsor</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116463">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116464">800,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Repayments to note payable - Sponsor</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116465">1,200,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from affiliate</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116466">395,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116467">17,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Repayments to affiliate</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116468">340,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116469">10,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7.2em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash flows provided by financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116470">34,539,499</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116471">123,979</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">NET CHANGE IN CASH</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116472">109,082</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116473">119,744</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH, BEGINNING OF PERIOD</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116474">124,501</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116475">4,757</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">CASH, END OF PERIOD</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116476">15,419</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116477">124,501</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="line-height: 0pt; font-size: 0pt;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt; width: 5%;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt; width: 5%;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td> </tr>
<tr>
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Supplemental disclosures of cash flow information</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Cash paid during the periods for:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;background-color:rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;">Income <div style="letter-spacing: 0px; top: 0px;display:inline;">taxes</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116478">16,249</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 74%;background-color:rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Supplemental disclosure of noncash investing and financing activities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Excise tax payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116479">359,957</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 74%;background-color:rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;background-color:rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Deferred underwriters&#8217; discount payable charged to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116480">2,070,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);text-align:right;background-color:rgb(204, 238, 255);"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);background-color:rgb(204, 238, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 74%;background-color:rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);text-align:right;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 74%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:DeferredOfferingCostsIncludedInAccruedOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116481">12,362</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 74%;background-color:rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 5%;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt;background-color:rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;display:inline;">30</div> </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </div></div></div></div></div><div id="fintoc476668_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">DECEMBER&#160;31, 2023 </div></div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="display:inline;font-weight:bold;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833434" id="ixv-43740"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 1&#8211;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Life Sciences Acquisition Corp. (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;</div><ix:nonFraction name="blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116482">one</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or more businesses or entities (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;December&#160;31, 2023, the Company had not commenced any operations. All activity since inception relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will generate </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> income in the form of interest income from the proceeds derived from the Initial Public Offering.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering (the &#8220;Registration Statement&#8221;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116483">6,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;units (&#8220;Units&#8221; and, with respect to the common stock included in the Units being offered, the &#8220;Public Shares&#8221;), generating gross proceeds of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116484">60,000,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, which is described in Note 3.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#8220;Over-Allotment Option Units&#8221;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116485">900,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Over-Allotment Option Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116486">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per unit generated total gross proceeds of $</div><ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116487">9,000,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#8220;Private Placement&#8221;) of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116488">430,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units (the &#8220;Private Placement Units&#8221;), to Bellevue Global Life Sciences Investors LLC (the &#8220;Sponsor&#8221;) at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116489">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Placement Unit, for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116490">4,300,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Each Unit and Private Placement Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116491">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, par value $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116492">0.0001</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;(the &#8220;Common Stock&#8221;), a warrant to purchase&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116493">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock (the &#8220;Public Warrants&#8221; and &#8220;Private Placement Warrants&#8221; and collectively, the &#8220;Warrants&#8221;) and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116494">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock (the &#8220;Public Rights&#8221; and Private Placement Rights&#8221; and collectively, the &#8220;Rights&#8221;), as described in Notes 3 and 4.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;</div><ix:nonFraction name="blacu:PercentageOfTrustAccountRequiredForBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116495">80</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;</div><ix:nonFraction name="blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116496">50</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of</div>&#160;$</div><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116497">70,207,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">was placed in a trust account (&#8220;Trust Account&#8221;) located in the United States with Continental Stock Transfer &amp; Trust Company acting as trustee, and</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;display:inline;">31</div></ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833434" continuedAt="TextSelectionAppend_117833434_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_1" continuedAt="TextSelectionAppend_117833434_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_2" continuedAt="TextSelectionAppend_117833434_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833434_3" continuedAt="TextSelectionAppend_117833434_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">invested only in United States &#8220;government securities&#8221; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;) having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2a-7</div><div style="display:inline;"> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div></div></div><div style="color: red; text-decoration-line: underline; text-indent: 0px; background-color: rgb(204, 204, 204); font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentRedemptionDescription" contextRef="P01_01_2023To12_31_2023" id="ixv-116499">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).</ix:nonNumeric>&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">$</div><ix:nonFraction name="blacu:NetTangibleAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116500">5,000,001</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination.&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any material </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> information and (ii)&#160;to clear all trades with the Company&#8217;s legal counsel or compliance officer prior to execution. In addition, the Company&#8217;s Sponsor and any other holders of the Company&#8217;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#8220;Initial Stockholders&#8221;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;</div><ix:nonFraction name="blacu:RedemptionLimitPercentage" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116501">15</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s Initial Stockholders and Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#8217;s Amended and</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-32</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_4" continuedAt="TextSelectionAppend_117833434_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833434_5" continuedAt="TextSelectionAppend_117833434_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_6" continuedAt="TextSelectionAppend_117833434_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833434_7" continuedAt="TextSelectionAppend_117833434_8"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;</div><ix:nonFraction name="blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116504">100</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of its Public Shares if the Company does not complete a Business Combination within&#160;</div><ix:nonNumeric name="blacu:PeriodToConsummateBusinessCombination" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durwordsen" id="ixv-43867"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">nine months</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#8220;Combination Period&#8221;) or (B)&#160;with respect to any other provision relating to </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">stockholders&#8217;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> rights or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">pre-initial</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.</div></div><br/></div></ix:continuation></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117833434_8" continuedAt="TextSelectionAppend_117833434_9"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than ten business days thereafter, redeem&#160;</div><ix:nonFraction name="blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116505">100</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $</div><ix:nonFraction name="blacu:MaximumAllowedDissolutionExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116506">100,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</div></div></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833434_9" continuedAt="TextSelectionAppend_117833434_10"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $</div>10.175</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Extension of Termination Date and Redemptions from the Trust Account </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors the authority in its discretion to amend the Charter to extend the date by which the</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-33</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_10" continuedAt="TextSelectionAppend_117833434_11"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833434_11" continuedAt="TextSelectionAppend_117833434_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_12" continuedAt="TextSelectionAppend_117833434_13"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833434_13" continuedAt="TextSelectionAppend_117833434_14"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Company must consummate a business combination from the First Extended Date to May&#160;14, 2024. In connection with the Special Meeting, </div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn02_14_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116509">3,432,046</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of common stock of the Company were tendered for redemption at a redemption price of approximately $</div><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn02_14_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116510">10.49</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share for an aggregate redemption amount of $</div><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="PAsOn02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116511">35,995,728</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, leaving $</div><ix:nonFraction name="us-gaap:CommonStockValueOutstanding" contextRef="PAsOn02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116512">36,372,335</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $</div><ix:nonFraction name="blacu:InterestIncomeHeldInTheTrustAccount" contextRef="P11_14_2023To02_14_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116513">561,957</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Additionally, the Company deposited $</div><ix:nonFraction name="blacu:InvestmentOfCashInTrustAccount" contextRef="PAsOn11_13_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116514">180,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> into the Trust Account on November&#160;13, 2023 in connection with the extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Franchise and Income Tax Withdrawal </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In November 2023, the Company withdrew $</div><ix:nonFraction name="blacu:InterestIncomeHeldInTheTrustAccount" contextRef="P11_01_2023To11_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116515">561,957</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> <div style="letter-spacing: 0px; top: 0px;display:inline;">of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through December 31, 2023, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#8217;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#8217;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of December 31, 2023, the Company&#8217;s obligations for franchise and income tax purposes remain payable.&#160;</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Basis of Presentation </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#8220;GAAP&#8221;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Liquidity and Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, the Company had $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116516">15,419</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in its operating bank account and a working capital deficit of $</div><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116517">2,015,645</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.&#160;The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering had been satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement held outside of the Trust Account.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or fifteen months from the Initial Public Offering. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160;Over this time period, the Company will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#8217;s current operating cash balance may need to be funded through loans from the Company&#8217;s Sponsor. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">If the Company is unable to complete a Business Combination by May&#160;14, 2024 (subject to extension by approval of the Company&#8217;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management intends to complete a business combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-34</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_14" continuedAt="TextSelectionAppend_117833434_15"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833434_15" continuedAt="TextSelectionAppend_117833434_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833434_16" continuedAt="TextSelectionAppend_117833434_17"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833434_17"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Emerging Growth Company</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-emerging</div><div style="display:inline;"> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></div></div></ix:continuation><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"></div></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117832796" id="ixv-43998"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">NOTE 2&#8211;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44001"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Use of Estimates </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44008"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116519">15,419</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;and $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116520">124,501</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in cash held in its operating account as of December&#160;31, 2023 and 2022, respectively. The Company had&#160;</div><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116521"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116522">no</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;cash equivalents as of December&#160;31, 2023 and 2022.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44019"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-35</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832796" continuedAt="TextSelectionAppend_117832796_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_1" continuedAt="TextSelectionAppend_117832796_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_2" continuedAt="TextSelectionAppend_117832796_3"><ix:nonNumeric name="blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44042"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Investments Held in Trust Account</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44047"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of&#160;December&#160;31, 2023 due to the short maturities of such instruments. </div></div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44117"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the financial statements as current or </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> based on whether or not </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</div></div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-36</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_3" continuedAt="TextSelectionAppend_117832796_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117832796_4" continuedAt="TextSelectionAppend_117832796_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_5" continuedAt="TextSelectionAppend_117832796_6"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_6" continuedAt="TextSelectionAppend_117832796_7"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44148"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Concentration of Credit Risk</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div></ix:nonNumeric><ix:nonNumeric name="blacu:WarrantInstrumentsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44153"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Warrant Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and <div style="display:inline;">wh</div>ether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a c<div style="display:inline;">ir</div>cumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div></ix:nonNumeric></ix:continuation></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_117832796_7" continuedAt="TextSelectionAppend_117832796_8"><ix:nonNumeric name="blacu:RightsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833173" id="ixv-44163"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Rights </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to <ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116525">6,900,000</ix:nonFraction> Public Units, each Public Unit is comprised of&#160;<ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116526">one</ix:nonFraction>&#160;share of common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116527">0.0001</ix:nonFraction>&#160;par value, a warrant to purchase<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116528">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116529">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to receive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116530">430,000</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div></ix:nonNumeric></ix:continuation></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_8" continuedAt="TextSelectionAppend_117832796_9"><ix:continuation id="TextSelection_117833173"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40.</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div></div></ix:continuation><ix:nonNumeric name="blacu:EquityParticipationSharesPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44194"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116531">34,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representati<div style="letter-spacing: 0px; top: 0px;display:inline;">ve</div> shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116532">4,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div></ix:nonNumeric><ix:nonNumeric name="blacu:NetLossPerCommonSharePolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833171" id="ixv-44211"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Net Income (Loss) per Common Share </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the </div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_117833171" continuedAt="TextSelectionAppend_117833171_1"><ix:continuation id="TextSelectionAppend_117832796_9" continuedAt="TextSelectionAppend_117832796_10"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-37 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_10" continuedAt="TextSelectionAppend_117832796_11"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117833171_1" continuedAt="TextSelectionAppend_117833171_2"><ix:continuation id="TextSelectionAppend_117832796_11" continuedAt="TextSelectionAppend_117832796_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_12" continuedAt="TextSelectionAppend_117832796_13"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_13" continuedAt="TextSelectionAppend_117832796_14"><ix:continuation id="TextSelectionAppend_117833171_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div><ix:nonFraction name="blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116533">7,330,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is rec<div style="letter-spacing: 0px; top: 0px;display:inline;">ei</div>ved by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div></ix:continuation><ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44245"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;December&#160;31, 2023 and</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2022,&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116534">3,467,954</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116535">0</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s balance sheets, respectively.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117832326" id="ixv-44256"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December&#160;31, 2023 and 2022.</div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44264"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116536">540,811</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116537">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">$</div><br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116538">540,811</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-38</ix:exclude> </div></div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_117832326" continuedAt="TextSelectionAppend_117832326_1"><ix:continuation id="TextSelectionAppend_117832796_14" continuedAt="TextSelectionAppend_117832796_15"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_117832326_1" continuedAt="TextSelectionAppend_117832326_2"><ix:continuation id="TextSelectionAppend_117832796_15" continuedAt="TextSelectionAppend_117832796_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832796_16" continuedAt="TextSelectionAppend_117832796_17"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_17" continuedAt="TextSelectionAppend_117832796_18"><ix:continuation id="TextSelectionAppend_117832326_2"><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44380"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 12%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Provision/(Benefit) at Statutory Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116540">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">State Tax Provision/(Benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116541">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Change in FV of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116542">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116543">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116544">0.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-116545">21.0</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely th<div style="letter-spacing: 0px; top: 0px;display:inline;">an</div> not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116546"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116547">no</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;December&#160;31, 2023 and&#160;2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116548">No</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;amounts were accrued for the payment interest and penalties for the year ended&#160;December&#160;31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div></ix:continuation><ix:nonNumeric name="blacu:OfferingCostsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44511"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1,</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SEC SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div></ix:nonNumeric></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832796_18"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44526"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</div></div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="blacu:InitialPublicOfferingTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44531"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 3&#8211;INITIAL PUBLIC OFFERING </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Initial Public Offering, the Company sold&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116549">6,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116550">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116551">900,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units. Each Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116552">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock,&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116553">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder thereof <div style="display:inline;">to</div> purchase&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116554">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock at a price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116555">11.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment, and&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116556">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock (see Note 6). Each warrant will become exercisable&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durday" id="ixv-44556"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the consummation of an initial business combination, and will expire&#160;</div><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen" id="ixv-44560"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of an initial bus<div style="display:inline;">in</div>ess combination, or earli<div style="display:inline;">er</div> upon redemption or liquidation. Each right entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;</div><ix:nonFraction name="blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116557">ten</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;rig<div style="display:inline;">ht</div>s entitle the holder thereof to receive one share of common stock at the closing of a business combination.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-39 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117832408" id="ixv-44583"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 4&#8211;RELATED PARTY TRANSACTIONS </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Founder Shares </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;30, 2020, the Sponsor purchased&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116558">1,437,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of the Company&#8217;s Common Stock (the&#160;&#8220;Founder Shares&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116559">25,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, or approximately $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-116560">0.017</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share.&#160;</div><div style="-sec-ix-hidden:hidden117832660;display:inline;">On</div> April&#160;25, 2022, the Company executed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1.2-for-one</div></div> stock split, resulting in an aggregate of&#160;</div><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116561">1,725,000</ix:nonFraction></div><div style="display:inline;">&#160;Founder Shares held by the Company&#8217;s sponsor, of which up to</div><div style="display:inline;">&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116562">225,000</ix:nonFraction></div><div style="display:inline;">&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&#160;</div><ix:nonNumeric name="blacu:SharesOutstandingHoldingTermAfterBusinessCombination" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durwordsen" id="ixv-44608"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">three years</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116563">12.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-44614"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">20</div></ix:nonNumeric></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;trading days within </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">any&#160;</div></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-116564">30</ix:nonNumeric>-day</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> trading period commencing at least&#160;</div><ix:nonNumeric name="blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-44622"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">150</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for ca<div style="display:inline;">s</div>h, securities or other property.</div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Private Placement Units </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has purchased an aggregate of&#160;</div><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116565">430,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Private Placement Units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116566">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;</div><ix:nonFraction name="blacu:NumberOfSharesIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116567">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock,&#160;</div><ix:nonFraction name="blacu:NumberOfWarrantsIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116568">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder to purchase&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116569">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div><ix:nonFraction name="blacu:NumberOfRightsIssuedPerUnit" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116570">one</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock. The Private Placement Warrants are exercisable only t<div style="display:inline;">o p</div>urchase whole shares of Common Stock at an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116571">11.50</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be included in the liquidating distribution to the holders of the Public Shares.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor and the Company&#8217;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis" format="ixt-sec:durday" id="ixv-44651"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the completion of the Business Combination.</div>&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;font-weight:bold;display:inline;">Promissory Notes</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced by </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non<div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">-</div></div>interest<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing promissory notes in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116572">1,200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The promissory notes were due at the earlier of&#160;</div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-44667"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">November 29, 2023</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;23, 2023, the Sponsor loaned to the Company $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116573">200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116574">200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. This note is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing and is payable in full on the earlier of: (i)&#160;December 31, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;Business Combination&#8221;). In the event that the Company does not consummate a business combination, the note will be repaid only from amounts remaining outside of the Company&#8217;s trust account, if any. At the Sponsor&#8217;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price of $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116575">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116576">0</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-40</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832408" continuedAt="TextSelectionAppend_117832408_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832408_1" continuedAt="TextSelectionAppend_117832408_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832408_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;13, 2023, </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Capital Management LLC (&#8220;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">BCM</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#8221;)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> loaned to the Company $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116578">180,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116579">180,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The proceeds of this loan were used to fund the payment to extend the Termination Date by which the Company must consummate an initial business combination to February&#160;14, 2024. The note is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> bearing and is payable in full on the earlier of: (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which the Company consummates the Business Combination. In the even</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">t</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116580">0</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="display:inline;font-weight:bold;display:inline;">Working Capital Loans </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116581">1,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of such Working Capital Loans may be convertible into Units at a price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116582">10.00</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#8217;s securities, and Chardan and its related persons will have </div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116583">no</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> recourse with respect to their ability to convert their loans into any of the Company&#8217;s securities. As of December&#160;31, </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2023 and&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2022,&#160;</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116584"><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2022To12_31_2022_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116585">no</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Working Capital Loans were outstanding.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Administrative Support Agreement </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $</div><ix:nonFraction name="blacu:MonthlyAdministrativeFeesExpense" contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116586">7,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. During the years ended December&#160;31, 2023 and December&#160;31, 2022, the Company incurred $</div><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116587">90,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> and $</div><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116588">75,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">, respectively, of administrative support fees which are included in general and administrative expenses in the accompanying statements of operations. As of December&#160;31, 2023, the outstanding balance was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116589">15,000</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> recorded as due to affiliate.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Due to Affiliate </div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116590">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On February&#160;17, 2022, the Company repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116591">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116592">10,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On April&#160;29, 2022, the Sponsor agreed to advance an additional $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116593">7,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. These advances are due on demand and are </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing. During the year ended&#160;December 31, 2023, the Sponsor advanced $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116594">180,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of funds to the Company and Company repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116595">140,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $</div><ix:nonFraction name="blacu:MonthlyAdministrativeFeesExpense" contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116596">7,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The outstanding balance was $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116597">57,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and $</div><ix:nonFraction name="us-gaap:ShorttermDebtAverageOutstandingAmount" contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116598">17,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> as of&#160;December 31, 2023 and December&#160;31, 2022, respectively</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">, recorded as due to affiliate</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">F-<div style="letter-spacing: 0px; top: 0px;display:inline;">4</div><div style="letter-spacing: 0px; top: 0px;display:inline;">1</div> </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833045" id="ixv-44794"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 5&#8211;COMMITMENTS&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">AND</div> CONTINGENCIES </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Registration Rights </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;</div><ix:nonFraction name="blacu:MaximumNumberOfDemandsForRegistrationOfSecurities" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116599">two</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Underwriting Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company granted the underwriters a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">45-day</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> option from the final prospectus relating to the Initial Public Offering to purchase up to&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116600">900,000</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The underwriters were entitled to an underwriting discount of $</div><ix:nonFraction name="blacu:UnderwritingCashDiscountPerUnit" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116601">0.20</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or $</div><ix:nonFraction name="blacu:AggregateUnderwriterCashDiscount" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116602">1,200,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate, equal to&#160;</div><ix:nonFraction name="blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116603">2</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the gross proceeds of the Initial Public Offering (or $</div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116604">1,380,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate if the underwriters&#8217; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $</div><ix:nonFraction name="blacu:UnderwritingCashDiscountPerUnit" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-116605">0.125</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit payable in cash. In addition, $</div><ix:nonFraction name="blacu:UnderwritingExpensePricePerShare" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116606">0.30</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or approximately&#160;$</div><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116607">1,800,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate (or $</div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116608">2,070,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#8217; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are entitled to receive&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116609">30,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock (or&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116610">34,500</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares if the underwriters&#8217; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#8220;Equity Participation Shares.&#8221; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) and are therefore subject to a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lock-up</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> for a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Excise Tax </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Inflation Reduction Act (&#8220;IR Act&#8221;) of 2022 imposes a&#160;</div><ix:nonFraction name="blacu:EffectiveExciseTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116611">1</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% <div style="letter-spacing: 0px; top: 0px;display:inline;">Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December 31, 2022. For purposes of the Excise Tax, a&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;display:inline;">42</div></ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833045" continuedAt="TextSelectionAppend_117833045_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833045_1" continuedAt="TextSelectionAppend_117833045_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833045_2" continuedAt="TextSelectionAppend_117833045_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833045_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#8220;SPAC&#8221;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#8217;s Initial Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-SPAC</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> transaction within the required time set forth in its constituent documents, or (iii)&#160;in connection with the </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">wind-up</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;</div><ix:nonFraction name="blacu:EffectiveExciseTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116612">1</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% has been included in these financial statements.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#8217;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $359,957&#160;excise tax liability as of December&#160;31, 2023. The Company will continue to monitor for updates to the Company&#8217;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#8217;s tax provision in future periods.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risks and Uncertainties </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication (&#8220;SWIFT&#8221;) payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial business combination and any target business with which we may ultimately consummate an initial business combination.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The excise tax included in the Inflation Reduction Act of 2022 may decrease the value of the Company&#8217;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.</div></div></ix:continuation> <ix:nonNumeric name="blacu:CommonStockSubjectToPossibleRedemptionTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833206" id="ixv-44891"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 6&#8211;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION </div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to </div></div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;display:inline;">4</div><div style="letter-spacing: 0px; top: 0px;display:inline;">3</div></ix:exclude> </div> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_117833206" continuedAt="TextSelectionAppend_117833206_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_117833206_1" continuedAt="TextSelectionAppend_117833206_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833206_2" continuedAt="TextSelectionAppend_117833206_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833206_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s balance sheets. </div></div></div></div><ix:nonNumeric name="blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-44925"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of December&#160;31, 2023:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:83%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Possible</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116613">69,000,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116614">1,236,527</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"><div style="display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116615">4,791,126</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-116616">35,995,728</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="blacu:AccretionForCommonStockToRedemptionValue" contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116617">9,449,634</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116618">36,426,253</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117832460" id="ixv-45031"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 7&#8211;STOCKHOLDERS&#8217; DEFICIT </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Preferred Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company is authorized to issue&#160;</div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116619"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116620">1,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock with a par value of $</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116621"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116622">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. As of December&#160;31, 2023 and 2022, there were&#160;</div><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116623"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116624"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116625"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-116626">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock issued or outstanding.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Common Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116627">100,000,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock, $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-116628">0.0001</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;par value.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2022, there were&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2022To12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116629">1,725,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock outstanding. Of the </div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116630">1,725,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock, an aggregate of up to&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis_SubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116631">225,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares was subject to forfeiture to the Company by the Sponsor for no consideration to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement of&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_PrivatePlacementMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116632">430,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares. On February&#160;21, 2023, the underwriters fully exercised their over-allotment option and the&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis_NoLongerSubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116633">225,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Founder Shares are no longer subject to forfeiture. As of&#160;December&#160;31, 2023, there were&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116634">2,155,000</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock outstanding, excluding&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-116635">3,467,954</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of common stock subject to possible redemption that are reflected in temporary equity in the balance sheet</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">s</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="display:inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2023To12_31_2023" id="ixv-116636">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.</ix:nonNumeric> </div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; text-indent: 9%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Warrants </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, there were </div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116637">7,330,000</ix:nonFraction><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and no Warrants outstanding, respectively. The Warrants that are a part of the Units (the &#8220;Warrants&#8221;) may be exercised at a price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_IPOMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116638">11.50</ix:nonFraction><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;</div><ix:nonNumeric name="blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-45086"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></ix:nonNumeric><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the completion of a Business Combination.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-44</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_117832460" continuedAt="TextSelectionAppend_117832460_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832460_1" continuedAt="TextSelectionAppend_117832460_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832460_2" continuedAt="TextSelectionAppend_117832460_3"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Warrants have an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116640">11.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share and will expire&#160;</div><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen" id="ixv-45113"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Redemption of warrants when the price per Common Stock equals or exceeds $16.50. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Once the Warrants become exercisable, the Company may call the Warrants for redemption: </div></div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">at a price of $</div><div style="display:inline;"><ix:nonFraction name="blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116641">0.01</ix:nonFraction></div><div style="display:inline;">&#160;per Warrant; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">upon not less than&#160;</div><div style="display:inline;"><ix:nonNumeric name="blacu:NoticePeriodForWarrantRedemption" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116642">30</ix:nonNumeric></div><div style="display:inline;">&#160;days&#8217; prior written notice of redemption given after the Warrants become exercisable; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">if, and only if, the reported last sale price of the Common Stock equals or exceeds $</div><div style="display:inline;"><ix:nonFraction name="blacu:WarrantRedemptionConditionMinimumSharePrice" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116643">16.50</ix:nonFraction></div><div style="display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="display:inline;"><ix:nonNumeric name="blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116644">20</ix:nonNumeric></div><div style="display:inline;">&#160;trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;</div></div><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-116645">30</ix:nonNumeric>-trading</div> day period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors), (y) the aggregate gross proceeds from such issuances represent more than&#160;</div><ix:nonFraction name="blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116646">60</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116647">9.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;</div><ix:nonFraction name="blacu:WarrantExercisePriceAdjustmentPercentage" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116648">115</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value, and the $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-116649">16.50</ix:nonFraction></div><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;</div><ix:nonFraction name="blacu:RedemptionTriggerPriceAdjustmentPercentage" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-116650">165</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;</div><ix:nonFraction name="blacu:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_EquityParticipationMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116651">34,500</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-45</ix:exclude> </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_117832460_3" continuedAt="TextSelectionAppend_117832460_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_117832460_4" continuedAt="TextSelectionAppend_117832460_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117832460_5" continuedAt="TextSelectionAppend_117832460_6"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117832460_6"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;">Rights </div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="display:inline;"> (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#8217;s certificate of incorporation with respect to its </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-business</div><div style="display:inline;"> combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="display:inline;"> (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div><div style="display:inline;"> into common stock basis. </div></div></div></ix:continuation> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-45261"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">N</div>OTE 8&#8211;FAIR VALUE MEASUREMENTS </div></div></div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-45268"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div></div><div style="color: red; font-size: 10pt; letter-spacing: 0px; text-decoration-line: underline; text-indent: 9%; top: 0px;display:inline;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116653">36,605,106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116654">36,605,106</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116655">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-116656">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">There were no transfers between Levels 1, 2 and 3 during the year ended December&#160;31, 2023.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_117833399" id="ixv-45436"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 9&#8211;SUBSEQUENT EVENTS </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluated subsequent events to determine if events or transactions occurred after the balance sheet date up to the date the financial statements </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">were</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, other than the following:</div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#8220;JCW Promissory Note&#8221;) in the principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_09_2024_JcwPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116657">75,000</ix:nonFraction></div><div style="display:inline;"> to Jun Chul Whang, a member of the Company&#8217;s Board of Directors. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of: (i)&#160;</div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116658">August 9, 2024</ix:nonNumeric></div><div style="display:inline;"> or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JCW Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s trust account,</div></div></td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-46</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_117833399" continuedAt="TextSelectionAppend_117833399_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_117833399_1" continuedAt="TextSelectionAppend_117833399_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_117833399_2">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="vertical-align: top; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On February&#160;9, 2024, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116660">60,000</ix:nonFraction> </div><div style="display:inline;">was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div> in connection with the extension of the date by which the Company must consummate a business combination from </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116661">February 14, 2024</ix:nonNumeric></div><div style="display:inline;"> to </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116662">March 14, 2024</ix:nonNumeric></div><div style="display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"><div style="display:inline;">On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;JP Promissory Note&#8221;) in the principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116663">60,000</ix:nonFraction></div><div style="display:inline;"> to Josh Pan, a member of Bellevue Capital Management LLC. <div style="letter-spacing: 0px; top: 0px;display:inline;">The JP Promissory Note is not interest bearing and is payable in full on the earlier of: (i) <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_08_2024To03_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116664">August 8, 2024</ix:nonNumeric> or (ii) the date on which the Company consummates an initial business combination (the &#8220;JP Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr. Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the JP Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action.&#160;</div> </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On March&#160;12, 2024, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116665">60,000</ix:nonFraction></div><div style="display:inline;"> was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div> in connection with the extension of the date by which the Company must consummate a business combination from </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116666">March 14, 2024</ix:nonNumeric></div><div style="display:inline;"> to </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" contextRef="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116667">April 15, 2024</ix:nonNumeric></div><div style="display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;April Sponsor Note&#8221;) in the principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_08_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116668">1,200,000</ix:nonFraction></div><div style="display:inline;"> to Sponsor for its receipt of $</div><div style="display:inline;"><ix:nonFraction name="blacu:WorkingCapitalFundAndOtherExpenses" contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116669">1,200,000</ix:nonFraction></div><div style="display:inline;"> to fund working capital and other expenses of the Company. The April Sponsor Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing and is payable in full on the earlier of (i)&#160;</div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116670">December 31, 2024</ix:nonNumeric></div><div style="display:inline;"> or (ii)&#160;the date on which the Company consummates a Business Combination. In the event that the Company does not consummate a Business Combination, the April Sponsor Note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">On April&#160;9 2024, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116671">60,000</ix:nonFraction></div><div style="display:inline;"> was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div>&#160;in connection with the <div style="letter-spacing: 0px; top: 0px;display:inline;">extension </div>of the date by which the Company must consummate a business combination from </div><div style="display:inline;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDateRangeStart1" contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-116672">April 15, 2024</ix:nonNumeric></div><div style="display:inline;"> to </div><div style="display:inline;"><div style="-sec-ix-hidden:hidden117833430;display:inline;">May14, 2024</div></div><div style="display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="display:inline;">In connection with the November 2023 withdrawal of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-116673">561,957</ix:nonFraction></div><div style="display:inline;"> of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account, as of April 16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#8217;s Sponsor and the Company has paid its fedral tax obligations on time.</div> </div></td></tr></table></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-<div style="letter-spacing: 0px; top: 0px;display:inline;">47</div> </div> </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">and its subsidiaries </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">for the years ended December&#160;31, 2023 and 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">with the independent auditors&#8217; report </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table of contents </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:88%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Page</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_14">Report of Independent Registered Public Accounting Firm</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">F-50</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated financial statements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_15">Consolidated statements of financial position</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">F-51</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_16">Consolidated statements of comprehensive income</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">F-52</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_17">Consolidated statements of changes in equity</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">F-53</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fintoc476668_18">Consolidated statements of cash flows</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">F-54</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><a href="#fintoc476668_19">Notes to the consolidated financial statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">F-55&#160;-&#160;F-102</span></span></span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g476668g04j81.jpg" alt="LOGO" style="width:1.51333in;height:0.823333in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Shinhan Accounting Corporation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">8th FL, 8, Uisadang-daero</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right"><span style="white-space:nowrap">Yeongdeungpo-gu,Seoul,</span> 07236, Korea</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Telephone: <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">82-2-782-9940</span></span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Telefax: <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">82-2-782-9941</span></span></span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">www.rsm.global/korea</p></td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fintoc476668_14">Report of Independent Registered Public Accounting Firm </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors of </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OSR Holdings Co., Ltd. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opinion on the Financial Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated statements of financial position of OSR Holdings Co., Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, and the related consolidated statement of comprehensive income, changes in equity and cash flows for each of the years in the three-year period ended December&#160;31, 2023, and the related notes (collectively, the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022 and the results of its operations and its cash flows for each of the years in the three-year period ended December&#160;31, 2023 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basis for Opinion </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g476668g82m88.jpg" alt="LOGO" style="width:3.26667in;height:0.463333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shinhan Accounting Corporation </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seoul, Korea </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&#160;31, 2024 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="fintoc476668_15">Consolidated statements of financial position </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">As at December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Korean won in unit) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>22,726,614</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>26,507,938</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">15</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177,793,886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">376,071,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">278,365,579,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> other financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">6,10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">349,347,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107,387,428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,132,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279,156,774,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146,927,115,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,6,7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">6,8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624,460,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,802,614,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,362,517,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,500,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,610,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current other financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">6,10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,777,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,705,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,528,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,209,682,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,578,983,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>152,506,098,514</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity attributable to the equity holders of the Parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,20</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,6,17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,15</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,657,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311,935,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,328,007,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,480,344,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for retirement benefits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,435,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,892,099,976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,952,280,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,6,16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,764,469,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,6,17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,436,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4,15</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105,829,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,511,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">18</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">106,140,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132,572,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,873,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,396,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,244,143,521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,401,565,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,136,243,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,353,845,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total liabilities and equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>283,366,457,465</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>152,506,098,514</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="fintoc476668_16">Consolidated statements of comprehensive income </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">For the years ended December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Korean won in unit) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,453,551,060</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cost of sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">23,26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,266,142,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,187,408,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">25,26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,930,194,272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,666,873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,742,785,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(784,666,873</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-operating</span> income (loss):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,308,214,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(489,682,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,964,454</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,571,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,452,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(685,461,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(183,077,459</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(989,579,991</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,129,624,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Profit (loss) before income tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,732,365,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Income tax profit (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other comprehensive income (loss) for the year, net of tax</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity holders of the parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,432,720,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Earnings (loss) per share attributable to the equity holders of the Parent:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per ordinary share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(8,152</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,445</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="fintoc476668_17">Consolidated statements of changes in equity </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">For the years ended December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Korean won in unit) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Attributable to the equity holders of the Parent</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold"><span style="white-space:nowrap">Non-controlling</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share premium</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Accumulated&#160;Other<br/>Comprehensive<br/>Income</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Retained earnings</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Sub-total</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">interests</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total equity</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,505,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,237,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(1,277,883,962</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>231,353,038</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8195;&#8195;&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>231,353,038</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Total comprehensive loss for the year:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss for the year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Transactions with owners recognized in equity:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of share capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,298,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,277,582,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,575,942,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,575,942,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Total comprehensive income for the year:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net profit for the year</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">OCI&#8212;foreign currency translation of foreign operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Transactions with owners recognized in equity:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of share capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,631,990,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,878,691,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,510,681,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,510,681,119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Balance at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>168,940,276</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>236,230,213,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">F-53</span> </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="fintoc476668_18">Consolidated statements of cash flows </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">For the years ended December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">(Korean won in unit) </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cash flows from operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net profit (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(15,716,438,670</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,722,866</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile profit (loss) before tax to net cash flows:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,272,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(183,330,206</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,325,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,358,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,419,687,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allowance for expected credit loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">489,682,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,964,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Losses on foreign currency translation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194,721,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,252,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Impairment loss on intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">402,355,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Impairment loss on investment in associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Severance payment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,730,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gains on disposals of property, plant and equipment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,362,637</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reversal of inventory valuation allowance</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,560,715</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gains on termination of lease contract</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(435,178</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation gains</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(97,393,101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,441,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,470,673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gain on disposal of FVTPL financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,305,743,718</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in working capital:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease (increase) in trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(960,317,887</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,212,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in other assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(67,889,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,981,399</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in inventories</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(427,536,519</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase (decrease) in trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,465,348,760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,004,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase (decrease) in other liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(34,809,659</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,206,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,062,383,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(821,938,544</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest received</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,332,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">789,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest paid</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(63,009,749</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,267,133</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax paid (refunded)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,947,721</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183,364,406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net cash flow used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,100,008,323</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(652,051,302</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cash flows from investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease in deposits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of FVTPL financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,313,105,181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment of lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,793,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Disposal of equipment and vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,350,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of equipment and vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,436,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,589,573</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in deposits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,058,299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in cash and cash equivalents from business combination</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,249,585,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net cash flow produced by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,210,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,161,262,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cash flows from financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,443,140,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,574,166,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in short-term loan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(636,263,607</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of convertible bonds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,000,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issue of share capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,609,463,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment of borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(544,538,903</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(200,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment of lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(81,497,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,290,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of stock issuance costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,806,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net cash flow provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,163,034,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,955,339,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Net increase (decrease) in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,908,764,063</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,142,026,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Effects of changes in exchange rate on cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(40,012,115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,252,148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cash and cash equivalents at the beginning of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,645,318,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">441,091,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cash and cash equivalents at the end of the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="fintoc476668_19">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. General information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of OSR Holdings Co., Ltd. (the &#8220;Company&#8221; or the &#8220;Parent&#8221;) and its subsidiaries (collectively, the &#8220;Group&#8221;) for the year ended December&#160;31, 2023 were authorized for issuance in accordance with a resolution of the directors meeting on March&#160;29, 2024. The registered office is located at <span style="white-space:nowrap">37-36</span> <span style="white-space:nowrap">Hoedong-gil,</span> <span style="white-space:nowrap">Paju-si,</span> <span style="white-space:nowrap">Gyeongi-do,</span> Republic of Korea. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a global life sciences holding company based on South Korea and is actively engaging in drug development, dedicating to advance healthcare outcome and driving social progress. Through open innovation and responsible investment, the Company aims to make a lasting impact across the industry as well as our society. With a strong focus on oncology and immunology, the Company&#8217;s mission is to build a robust portfolio of ventures, bringing innovative and transformative therapies to market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of shareholders as at December&#160;31, 2023 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of shareholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">ordinary&#160;share</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage&#160;of<br/>ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bellevue Capital Management LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">580,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30.77</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bellevue Capital Management Europe AG</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">241,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.77</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Protein Central</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.64</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invites Ventures Co., Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CG Invites Co., Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PARK, CHAN KYOO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Center For Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,720</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">484,061</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,887,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of investments in subsidiary at December&#160;31, 2023 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of subsidiary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage&#160;of<br/>ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Principal activities</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Country of</span><br/><span style="font-weight:bold">incorporation</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAXIMM AG (&#8220;VAXIMM&#8221;)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,203,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Biotech&#160;(drug&#160;development)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Switzerland</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMC Co., Ltd. (&#8220;RMC&#8221;)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Medical&#160;device&#160;distribution</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Republic&#160;of&#160;Korea</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darnatein Co., Ltd. (&#8220;Darnatein&#8221;)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,466,667,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Biotech&#160;(drug&#160;development)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Republic of Korea</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key financial information of the subsidiaries at December&#160;31, 2023 are as follows (Korean won in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of subsidiary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Asset</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Liability</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Sales</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Net income</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAXIMM</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,656,712</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>190,821</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,465,891</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>74,225</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(875,529</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,821,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,653,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,167,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,379,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darnatein</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">714,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">409,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">305,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(234,337</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. General information&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summaries of entities, which are newly included in consolidation scope for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="5" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the year ended December&#160;31, 2023</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of subsidiary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Reason</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of purchase consideration</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Darnatein</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Acquisition (*1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">New shares of the Parent and other financial assets</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="5"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="5" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the year ended December&#160;31, 2022</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of subsidiary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Reason</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type of purchase consideration</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">VAXIMM</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Acquisition (*2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">New shares of the Parent and other financial assets</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">RMC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Acquisition (*2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">New shares of the Parent</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Parent acquired subsidiary in March 2023 and accounted the acquisitions at June&#160;30, 2023, which is deemed the acquisition date. The Parent is a private company in Korea therefore does not bear obligations to report its financial statements on a quarterly basis. Therefore, the closest date on which interim financial statements of the Parent have been prepared was June&#160;30, 2023, and for the purpose of financial reporting, the acquisition is deemed to have been closed on the closest financial statements date which is June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Parent acquired subsidiaries in December 2022 and accounted the acquisitions at December&#160;31, 2022, which is deemed the acquisition date. Accordingly, operation results of new subsidiaries for the year ended December&#160;31, 2022 are not reflected on the Group&#8217;s consolidated financial statements. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.1 New or amended accounting standards and interpretations adopted </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated entity applied for the first-time certain standards and amendments, which are effective for annual periods beginning on or after January&#160;1, 2023. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Definition of accounting estimates&#8212;Amendments to IFRS 1008 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1008 clarify the distinction between changes in accounting estimates, changes in accounting policies and the correction of errors. They also clarify how entities use measurement techniques and inputs to develop accounting estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments had no impact on the Group&#8217;s consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Disclosure of accounting policies&#8212;Amendments to IFRS 1001 and IFRS Practice Statement 2 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1001 and IFRS Practice Statement 2 Making Materiality Judgements provide guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.1 New or amended accounting standards and interpretations adopted&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their &#8216;significant&#8217; accounting policies with a requirement to disclose their &#8216;material&#8217; accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments have had an impact on the Group&#8217;s disclosures of accounting policies, but not on the measurement, recognition or presentation of any items in the Group&#8217;s financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Deferred tax related to assets and liabilities arising from a single transaction &#8211; Amendments to IFRS 1012 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1012 Income Tax narrow the scope of the initial recognition exception, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences such as leases and decommissioning liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments had no impact on the Group&#8217;s consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) International tax reform: The Pillar Two Model Rules &#8211; Amendments to IFRS 1012 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1012 have been introduced in response to the OECD&#8217;s BEPS Pillar Two Model Rules and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a mandatory temporary exception to the recognition and disclosure of deferred taxes arising from the jurisdictional implementation of the Pillar Two Model Rules; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disclosure requirements for affected entities to help users of the financial statements better understand an entity&#8217;s exposure to Pillar Two income taxes arising from that legislation, particularly before its effective date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments had no impact on the Group&#8217;s consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.2 Standards issued but not yet effective </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Group&#8217;s financial statements are disclosed below. The Group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Amendments to IFRS 1116: Lease liability in a sale and leaseback </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1116 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments are effective for annual reporting periods beginning on or after January&#160;1, 2024 and must applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS&#160;1116. Earlier application is permitted and that fact must be disclosed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.2 Standards issued but not yet effective&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments are not expected to have a material impact on the Group&#8217;s financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Amendments to IFRS 1001: Classification of liabilities as current or <span style="white-space:nowrap">non-current</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to paragraphs 69 to 76 of IFRS 1001 specify the requirements for classifying liabilities as current or <span style="white-space:nowrap">non-current.</span> The amendments clarify: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">what is meant by a right to defer settlement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">that a right to defer must exist at the end of the reporting period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">that classification is unaffected by the likelihood that an entity will exercise its deferral right; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as <span style="white-space:nowrap">non-current</span> and the entity&#8217;s right to defer settlement is contingent on compliance with future covenants within twelve months. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments are effective for annual reporting periods beginning on or after January&#160;1, 2024 and must be applied retrospectively. The Group is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Supplier finance arrangements&#8212;Amendments to IFRS 1007 and IFRS 1107 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments to IFRS 1007 Statement of Cash Flows and IFRS 1107 Financial Instruments: Disclosures clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity&#8217;s liabilities, cash flows and exposure to liquidity risk. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments will be effective for annual reporting periods beginning on or after January&#160;1, 2024. Early adoption is permitted but will need to be disclosed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments are not expected to have a material impact on the Group&#8217;s financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.3 Basis of preparation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Basis of Accounting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Measuring standards </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments, etc., unless stated otherwise in the accounting policies below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.3 Basis of preparation&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Functional and presentation currency </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s consolidated financial statements are presented in Korean won (KRW), which is also the Parent&#8217;s functional currency, except when otherwise stated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Going concern </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors have, at the time of approving the consolidated financial statements, a reasonable expectation that the Group have adequate resources to remain in operation for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.4 Basis of consolidation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the assets and liabilities of all subsidiaries of the Parent as at December&#160;31, 2023, and also include the operation results of all subsidiaries (except for Darnatein) for the year then ended. Darnatein&#8217;s operation results for the <span style="white-space:nowrap">six-month</span> period ended December&#160;31, 2023 are included in the consolidated financial statements as the acquisition date is deemed at June&#160;30, 2023. The Parent and its subsidiaries are collectively referred to in these financial statements as the &#8220;Group&#8221; or &#8220;Consolidated Entity&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidiaries are all entities that is controlled by the Consolidated Entity. The Consolidated Entity controls an entity when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Consolidated Entity. They are <span style="white-space:nowrap">de-consolidated</span> from the date that control ceases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intercompany transactions, balances and unrealized gains on transactions between entities in the Consolidated Entity are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Consolidated Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the <span style="white-space:nowrap">non-controlling</span> interest acquired is recognized directly in equity attributable to the Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interest in the results and equity of subsidiaries are shown separately in the statement of comprehensive income, statement of financial position and statement of changes in equity of the Consolidated Entity. Losses incurred by the Consolidated Entity are attributed to the <span style="white-space:nowrap">non-controlling</span> interest in full, even if that results in a deficit balance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the Consolidated Entity loses control over a subsidiary, it derecognizes the assets including goodwill, liabilities and <span style="white-space:nowrap">non-controlling</span> interest in the subsidiary together with any cumulative translation differences recognized in equity. The Consolidated Entity recognizes the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.5 Business combinations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any <span style="white-space:nowrap">non-controlling</span> interest in the acquiree. For each business combination, the <span style="white-space:nowrap">non-controlling</span> interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree&#8217;s identifiable net assets. All acquisition costs are expensed as incurred to profit or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the acquisition of a business, the Consolidated Entity assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the Consolidated Entity&#8217;s operating or accounting policies and other pertinent conditions in existence at the acquisition date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the business combination is achieved in stages, the Consolidated Entity remeasures its previously held equity interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognized in profit or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contingent consideration to be transferred by the acquirer is recognized at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognized in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any <span style="white-space:nowrap">non-controlling</span> interest in the acquiree and the fair value of the consideration transferred and the fair value of any <span style="white-space:nowrap">pre-existing</span> investment in the acquiree is recognized as goodwill. If the consideration transferred and the <span style="white-space:nowrap">pre-existing</span> fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognized as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the <span style="white-space:nowrap">non-controlling</span> interest in the acquiree, if any, the consideration transferred and the acquirer&#8217;s previously held equity interest in the acquirer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognized and also recognizes additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii)&#160;when the acquirer receives all the information possible to determine fair value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.6 Investment in associates and joint ventures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not in control or joint control over those policies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.6 Investment in associates and joint ventures&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The considerations made in determining significant influence or joint control are similar to those necessary to determine control over subsidiaries. The Group&#8217;s investment in its associate and joint venture are accounted for using the equity method. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the equity method, the investment in an associate or a joint venture is initially recognized at cost. The carrying amount of the investment is adjusted to recognize changes in the Group&#8217;s share of net assets of the associate or joint venture since the acquisition date. Goodwill relating to the associate or joint venture is included in the carrying amount of the investment and is not tested for impairment separately. The statement of profit or loss reflects the Group&#8217;s share of the results of operations of the associate or joint venture. Any change in other comprehensive income (&#8220;OCI&#8221;) of those investees is presented as part of the Group&#8217;s OCI. In addition, when there has been a change recognized directly in the equity of the associate or joint venture, the Group recognizes its share of any changes, when applicable, in the statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and the associate or joint venture are eliminated to the extent of the interest in the associate or joint venture. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate of the Group&#8217;s share of profit or loss of an associate and a joint venture is shown on the face of the statement of profit or loss outside operating profit and represents profit or loss after tax and <span style="white-space:nowrap">non-controlling</span> interests in the subsidiaries of the associate or joint venture. The financial statements of the associate or joint venture are prepared for the same reporting period as the Group. When necessary, adjustments are made to bring the accounting policies in line with those of the Group. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After application of the equity method, the Group determines whether it is necessary to recognize an impairment loss on its investment in its associate or joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the associate or joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate or joint venture and its carrying value, and then recognizes the loss within &#8216;Gains or losses from equity method&#8217; in the statement of profit or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon loss of significant influence over the associate or joint control over the joint venture, the Group measures and recognizes any retained investment at its fair value. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment and proceeds from disposal is recognized in profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.7 Foreign currency translation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Items included in the financial statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment in which each entity operates (the &#8220;functional currency&#8221;). The consolidated financial statements are presented in Korean won, which is the Parent&#8217;s functional and presentation currency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign currency transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into functional currency units using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.7 Foreign currency translation&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and from the translation at financial <span style="white-space:nowrap">year-end</span> exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets and liabilities of foreign operations are translated into functional currency units using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into functional currency units using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognized in OCI through the foreign currency reserve in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foreign currency reserve is recognized in profit or loss when the foreign operation or net investment is disposed of. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.8 Cash and cash equivalents </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.9 Financial instruments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A financial instrument is any contract that allows a financial asset to be created for one of the parties to the transaction and a financial liability or equity instrument to be created for the counterparty. The Group classifies financial assets at subsequent initial recognition as financial assets at amortized cost, financial assets at fair value through other comprehensive income (&#8220;FVOCI&#8221;) and financial assets at fair value through profit or loss (&#8220;FVTPL&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Initial recognition and measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of a financial asset at initial recognition depends on the nature of the contractual cash flows of the financial asset and the business model of the Group to manage the financial asset. Except for trade receivables that do not contain significant financial elements or that are accounted for using the practical simplification method, the Group initially measures financial assets at fair value plus, and if not for financial assets at FVTPL, transaction costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To measure a financial asset at amortized cost or FVOCI, the cash flows must consist of sole payments of principal and interest (&#8220;SPPI&#8221;) only. This assessment is called SPPI testing and is performed at the individual item level. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s business model for the management of financial assets involves the management of financial assets to generate cash flows. The business model determines whether the source of the cash flows is the receipt, sale or both of the contractual cash flows of the financial asset. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.9 Financial instruments&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases or sales of financial assets (structured transactions) that are required to transfer financial assets within the time frame set by the market arrangement or regulation are recognized on the transaction date. That is, the date the Group agrees to buy or sell financial assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Subsequent measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For subsequent measurement, financial assets are classified into the following four categories: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at amortized cost (debt instrument) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVOCI reclassified cumulative gain or loss to profit or loss (debt instrument) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVOCI for which the cumulative gain or loss on removal is not reclassified to profit or loss (equity instrument) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial assets at FVTPL </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) Financial assets at FVTPL </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss. This category includes derivative instruments and listed equity investments which the Group had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognized as other income in the statement of profit or loss when the right of payment has been established. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(2) Financial assets at FVOCI (debt instrument) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For debt instruments at fair value through OCI, interest income, foreign exchange revaluation and impairment losses or reversals are recognized in the statement of profit or loss and computed in the same manner as for financial assets measured at amortised cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit or loss. The Group&#8217;s debt instruments at fair value through OCI includes investments in quoted debt instruments included under other <span style="white-space:nowrap">non-current</span> financial assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(3) Financial assets at FVOCI (equity instrument) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity instruments designated at fair value through OCI when they meet the definition of equity under IAS 32 Financial Instruments: Presentation and are not held for trading. The classification is determined on an <span style="white-space:nowrap"><span style="white-space:nowrap">instrument-by-instrument</span></span> basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment. The Group elected to classify irrevocably its <span style="white-space:nowrap">non-listed</span> equity investments under this category. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.9 Financial instruments&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(4) Financial assets at amortised cost (debt instruments) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets at amortised cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired. The Group&#8217;s financial assets at amortised cost includes trade receivables and other financial assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Derecognition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group&#8217;s consolidated statement of financial position) when: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The rights to receive cash flows from the asset have expired, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a &#8216;pass-through&#8217; arrangement; and either (a)&#160;the Group has transferred substantially all the risks and rewards of the asset, or (b)&#160;the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass- through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impairment </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized cost and fair value through OCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk. However, for trade receivables and lease receivables, the Group applies the simplified method of recognizing expected credit losses over the entire period from the initial recognition of the receivables. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.9 Financial instruments&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluates whether credit risk in financial assets or Company of financial assets significantly increases at the end of each reporting period and recognizes <span style="white-space:nowrap">12-month</span> expected credit losses or lifetime expected losses as loss allowance in three stages as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Stage</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Loss provision</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;No significant increase in credit risk after initial recognition</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">12-month</span> expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;Significant increase in credit risk after initial recognition</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td style="vertical-align:middle" rowspan="2">Lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;Credit-impaired</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant financial difficulties of the debtor, delinquency in interest or principal payments for more than 3 months; or the disappearance of an active market for that financial asset because of financial difficulties are considered evidence of impairment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial liabilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Initial recognition and measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group&#8217;s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, and derivative financial instruments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Subsequent measurement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of subsequent measurement, financial liabilities are classified in two categories: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial liabilities at fair value through profit or loss </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial liabilities at amortised cost (loans and borrowings) </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) Financial liabilities at fair value through profit or loss </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit or loss. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. The Group has not designated any financial liability as at fair value through profit or loss. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.9 Financial instruments&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(2) Financial liabilities at amortised cost </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the category most relevant to the Group. After initial recognition, interest-bearing borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit or loss. This category generally applies to interest-bearing loans and borrowings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Derecognition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Offsetting of financial instruments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Classification as debt or equity </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.10 Inventories </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchased goods are stated at the lower of cost and net realisable value on a &#8216;first in first out&#8217; basis. Cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity, and, where applicable, transfers from cash flow hedging reserves in equity. Costs of purchased inventory are determined after deducting rebates and discounts received or receivable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock in transit is stated at the lower of cost and net realisable value. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.11 Equipment and vehicles </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment and vehicles are stated at historical cost less accumulated depreciation and accumulated impairment losses. Historical cost includes expenditure that is directly attributable to the acquisition of the items. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.11 Equipment and vehicles&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation of all equipment and vehicles is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Estimated useful lives</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Vehicles</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Facility equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">3~13 years</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets&#8217; depreciation method, residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.12 Intangible assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Intangible assets acquired separately</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Internally - generated intangible assets &#8211; research and development expenditure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following conditions have been demonstrated: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The technical feasibility of completing the intangible asset so that it will be available for use or sale </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The intention to complete the intangible asset and use or sell it </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The ability to use or sell the intangible asset </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">How the intangible asset will generate probable future economic benefits </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The ability to measure reliably the expenditure attributable to the intangible asset during its development </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.12 Intangible assets&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intangible assets acquired in a business combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets acquired in a business combination and recognized separately from goodwill are recognized initially at their fair value at the acquisition date (which is regarded as their cost). Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Derecognition of intangible assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impairment of equipment and vehicles and intangible assets excluding goodwill. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting date, the Group reviews the carrying amounts of its equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is an indication at the end of a reporting period that the asset may be impaired. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a <span style="white-space:nowrap">pre-tax</span> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease and to the extent that the impairment loss is greater than the related revaluation surplus, the excess impairment loss is recognized in profit or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">exceed the carrying amount that would have been determined had no impairment loss been recognized for the </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss to the extent that it eliminates the impairment loss which has been recognized for the asset in prior years. Any increase in excess of this amount is treated as a revaluation increase. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.13 Lease </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of a contract, the Group assesses whether the contract is, or contains, a lease considering if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consolidated Entity applies the following practical expedients in applying IFRS 16: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For contracts prior to January&#160;1, 2019, the date of initial application, no <span style="white-space:nowrap">re-judgment</span> is made as to whether the contract is or contains a lease on the date of initial application. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The exemption rule for not recognizing <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets and lease liabilities applies to leases with a lease period of 12 months or less, or leases of <span style="white-space:nowrap">low-value</span> assets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Excluding direct lease opening costs from the <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset measurement at the date of initial application. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the contract includes options to extend or terminate the lease, use hindsight when determining the lease term. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognizes <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). <span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date, less any lease incentives received. <span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Estimated useful lives</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">1~3.75 years</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. <span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets are subject to impairment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Lease liabilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the commencement date of the lease, the Group recognizes lease liabilities at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including <span style="white-space:nowrap">in-substance</span> fixed payments), less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period in which the event or condition that triggers the payment occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.13 Lease&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the <span style="white-space:nowrap">in-substance</span> fixed-lease payments or a change in the assessment to purchase the underlying asset. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Short-term lease and leases of <span style="white-space:nowrap">low-value</span> assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group applies the short-term lease recognition exemption to other equipment, etc. (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of <span style="white-space:nowrap">low-value</span> assets recognition exemption to leases of other equipment that are considered of low value (i.e., below $5,000 or <span style="text-decoration:line-through">W</span>5,000 thousand). Lease payments on short-term leases and leases of <span style="white-space:nowrap">low-value</span> assets are recognized as expense on a straight-line basis over the lease term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Significant judgment in determining the lease term of contracts with renewal options </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determines the lease term as the <span style="white-space:nowrap">non-cancellable</span> term of the lease together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group applies judgment in evaluating whether it is reasonably certain to exercise the option to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that are within its control and affect its ability to exercise (or not to exercise) the option to renew (e.g., a change in business strategy). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A lease liability is recognized at the commencement date of a lease. The lease liability is initially recognized at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Consolidated Entity&#8217;s incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities are measured at amortized cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding <span style="white-space:nowrap">right-of</span> use asset, or to profit or loss if the carrying amount of the <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset is fully written down. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.14 Revenue recognition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consolidated Entity recognizes revenue when it transfers control over a good or service to a customer. A five-step process is applied before revenue from contract with customers can be recognized: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Identify contracts with customers </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Identify the separate performance obligation </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.14 Revenue recognition&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Determine the transaction price of the contract </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Allocate the transaction price to each of the separate performance obligations, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Recognize the revenue as each performance obligation is satisfied </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue from contracts with customers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is recognized at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognizes revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the &#8216;expected value&#8217; or &#8216;most likely amount&#8217; method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognized as a refund liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sale of goods </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from the sale of goods is recognized at the point in time when the customer obtains control of the goods, which is generally at the time of delivery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rendering of services </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from a contract to provide services is recognized over time as the services are rendered based on either a fixed price or an hourly rate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other revenue </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other revenue is recognized when it is received or when the right to receive payment is established. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.15 Employee benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s retirement pension plan is a defined contribution plan. A defined contribution plan is a retirement pension plan in which the Group pays a fixed amount of contributions to a separate fund, and the contributions are recognized as an expense when employees have rendered service. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.16 Impairment of <span style="white-space:nowrap">non-financial</span> assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#8217;s fair value less costs of disposal and value in use. <span style="white-space:nowrap">Non-financial</span> assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.17 Current and deferred tax </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax expense for the period consists of current and deferred tax. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in OCI or directly in equity. In this case, the tax is also recognized in OCI or directly in equity, respectively. The tax expense is measured at the amount expected to be paid to the taxation authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. The Group recognizes current income tax on the basis of amounts expected to be paid to the tax authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred income tax is not recognized when it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting profit (or loss) nor taxable income (or tax loss). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognizes a deferred tax liability of all taxable temporary differences associated with investments in subsidiaries, associates, and interests in joint arrangements, except to the extent that the Group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. In addition, The Group recognizes a deferred tax asset for all deductible temporary differences arising from such investments to the extent that it is probable the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends to settle on a net basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Significant accounting policies&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2.18 Earnings per share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated entity calculates basic earnings per share and diluted earnings per share for continuing operations and net profit or loss attributable to common stocks of the parent company and presents them in the consolidated statement of comprehensive income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Basic earnings per share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings per share is calculated by dividing the profit attributable to the owners of the Parent, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Diluted earnings per share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Critical accounting estimates and assumptions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements requires the Group to make estimates and assumptions concerning the future. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3.1 Income taxes </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s taxable income generated from these operations are subject to income taxes based on tax laws and interpretations of tax authorities in numerous jurisdictions. There are many transactions and calculations during the ordinary course of business for which the ultimate tax determination is uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognised for deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the temporary differences and the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits, together with future tax planning strategies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3.2 Business combinations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Business combinations are initially accounted for on a provisional basis. The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the Parent taking into consideration all available information at the reporting date. Fair value adjustments on the finalization of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortization reported. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Financial risk management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.1 Overview of financial risk management policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group is exposed to various financial risks such as market risk (exchange risk, interest rate risk), credit risk and liquidity risk due to various activities. The Group&#8217;s overall risk management policy focuses on volatility in the financial markets and focuses on minimizing any negative impact on financial performance. Risk management is conducted under the supervision of the finance department according to the policy approved by the Board of Directors. The finance department identifies, evaluates and manages financial risks in close cooperation with the sales departments. The Board of Directors provides written policies on overall risk management principles and specific areas such as foreign exchange risk, interest rate risk, credit risk, use of derivative and <span style="white-space:nowrap">non-derivative</span> financial instruments, and investments in excess of liquidity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.2 Market risk management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market risk is the risk of possible losses which arise from the changes of market factors, such as interest rate, stock price, foreign exchange rate, commodity value and other market factors related to the fair value or future cash flows of the financial instruments, such as securities, derivatives and others. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) Currency risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the result of foreign currency translation into Korean won for financial assets and liabilities denominated in foreign currency of the Group as of December&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">EUR</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">CHF</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">USD</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">EUR</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets in foreign currency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>29,220,473</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>301,368,136</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>744,194,360</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,094,039,015</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities in foreign currency</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,470,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,289,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,365,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the impact of strengthening (or weakening) of the Korean won by a hypothetical 10% against each foreign currency on the Group&#8217;s <span style="white-space:nowrap">after-tax</span> profit (or loss), assuming all other variables remain constant. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Rise</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fall</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Rise</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fall</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(3,524,953</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,524,953</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>103,067,402</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(103,067,402</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EUR</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,507,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,507,900</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74,419,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(74,419,436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(2) Interest rate risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest rate risk refers to the risk that interest income and interest expenses arising from deposits or borrowings will fluctuate due to changes in market interest rates in the future, which mainly arises from deposits and borrowings with floating interest rates. The goal of interest rate risk management is to maximize corporate value by minimizing uncertainty caused by interest rate fluctuations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the end of the reporting period, there are no financial instruments subject to a variable interest rate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Financial risk management&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.2 Market risk management&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(3) Price risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Price risk is the risk that the fair value of a financial instrument or future cash flows will change due to changes in market prices other than interest rate or foreign exchange rate. As of the end of the reporting period, the Group is not exposed to commodity price risk. Investments in financial instruments are made on a <span style="white-space:nowrap">non-recurring</span> basis according to management&#8217;s judgment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.3 Credit risk management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Credit risk is the risk of possible losses in an asset portfolio in the events of counterparty&#8217;s default, breach of contract and deterioration in the credit quality of the counterparty. For the risk management reporting purposes, the Group manages the credit risk systematically and pursues value maximization and continuous growth of the Group by efficient resource allocation and monitoring <span style="white-space:nowrap">non-performing</span> loans. In order to reduce the risks that may occur in transactions with financial institutions, such as cash and cash equivalents and various deposits, the Group conducts transactions only with financial institutions with high creditworthiness. As of December&#160;31, 2023, the Group believes that there are low signs of material default, and the maximum exposure to credit risk as of December&#160;31, 2023 is equal to the book value of financial instruments (excluding cash). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.4 Liquidity risk management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group constantly monitors its liquidity positions to ensure that no borrowing limits or commitments are breached to meet operating capital needs. In estimating liquidity, we also take into account external laws or legal requirements, such as the group&#8217;s financing plan, compliance with agreements, internal target financial ratios and currency restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s liquidity risk analysis details as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book value</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cashflows by<br/>contract</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Remaining maturity</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">With in</span><br/><span style="font-weight:bold">a year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">1 year to</span><br/><span style="font-weight:bold">3 year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">More than</span><br/><span style="font-weight:bold">3 year</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>960,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,000,657,534</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>523,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>477,657,534</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,490,623,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,490,623,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,490,623,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207,486,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">259,101,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114,981,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134,120,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,658,109,975</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,750,382,185</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,128,604,371</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>611,777,814</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="20"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book value</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cashflows by<br/>contract</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Remaining maturity</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">With in</span><br/><span style="font-weight:bold">a year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">1 year to</span><br/><span style="font-weight:bold">3 year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">More than</span><br/><span style="font-weight:bold">3 year</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,596,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,628,827,375</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,628,827,375</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,764,469,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,617,804,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,617,804,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174,882,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,281,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85,601,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>7,735,531,550</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>7,421,514,529</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>7,313,913,129</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>85,601,400</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>22,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Financial risk management&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.5 Capital risk management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital includes issued capital, share premium and all other equity reserves attributable to the equity holders of the Group. The primary objective of the Group&#8217;s capital management is to maximize the shareholder value. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group uses the debt ratio as a capital management indicator. This ratio is calculated by dividing total liabilities by total equity, and total liabilities and total equity are calculated based on the amounts in the Group&#8217;s financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The group&#8217;s debt ratio as at December&#160;31, 2023 and 2022 are as follows. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:53%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net borrowings (A)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>960,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,596,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">207,486,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less) cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">470,944,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,585,803,576</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Equity (B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,570,220,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,152,253,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt ratio (= A/B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(*)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Debt ratios are not presented as net borrowings and debt ratios are negative as at December&#160;31, 2022. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. Fair value </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5.1 Book value and fair value of financial instruments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the carrying amount and fair value of the Group&#8217;s financial assets and liabilities as at December&#160;31, 2023 and 2022 are insignificant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5.2 Fair value hierarchy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Level&#160;1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair values of the Group&#8217;s financial assets and liabilities as at December&#160;31, 2023 and 2022, which are accounted as amortized cost, are categorized as Level&#160;3. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. Fair value&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5.3 Recurring transfer between levels of the fair value hierarchy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no transfer of fair value hierarchy among Level&#160;1, Level&#160;2 and Level&#160;3 for the years ended December&#160;31, 2023 and 2022, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Financial instruments by category </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6.1 Book value of financial instruments category </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying value of financial instruments category as of December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><span style="font-size:8pt"><span style="font-style:italic">(Korean won in unit)</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">December&#160;31, 2023</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial assets<br/>at&#160;amortized cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial&#160;assets<br/>at fair value</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial liabilities<br/>at amortized cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and other receivables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> other financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other payables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Long-term</span> borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="16"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><span style="font-size:8pt"><span style="font-style:italic">(Korean won in unit)</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">December&#160;31, 2022</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial assets<br/>at&#160;amortized cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial&#160;assets<br/>at fair value</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Financial liabilities<br/>at amortized cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables and other receivables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624,460,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624,460,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> other financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">349,347,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">349,347,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other payables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,764,469,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,764,469,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,436,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,436,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Long-term</span> borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Financial instruments by category&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6.2 Net gains or losses by financial instrument category </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net gains or losses by financial instrument category for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:55%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortized cost:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,470,673</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange gains</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,005,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on foreign currency translation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,737,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,441,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(447,915,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,267,133</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on foreign currencies transaction</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(86,945,552</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(59,059,511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on foreign currency translation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(194,721,576</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,252,148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets measured at fair value through profit or loss:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on disposition</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,305,743,718</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">7. Cash and cash equivalents </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of cash and cash equivalents as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>696,542,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,556,865,658</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">8. Trade and other receivables </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of trade and other receivables as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><span style="font-size:8pt"><span style="font-style:italic">(Korean won in unit)</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">&#160;</span></span></td>
<td colspan="5" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">December&#160;31, 2023</span></span></td>
<td style="vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">&#160;</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">&#160;</span></span></td>
<td colspan="5" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">December&#160;31, 2022</span></span></td>
<td style="vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">&#160;</span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,520,894,893</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>470,304,368</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Allowance for expected credit losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net trade receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,475,402,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">470,304,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,140,332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154,156,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,543,542,712</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>624,460,396</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">8. Trade and other receivables&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes of allowance for expected credit losses on trade and other receivables for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for expected credit losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write-offs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aging analysis of trade receivables as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expected credit</span><br/><span style="font-weight:bold">loss rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Carrying amount</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Allowance for expected</span><br/><span style="font-weight:bold">credit losses</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span><br/><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span><br/><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span><br/><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not past due</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>457,674,248</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>107,636,697</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than 90 days</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">699,413,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">254,412,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">91~360 days</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">313,814,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108,255,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Over 360 days</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,992,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,520,894,893</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>470,304,368</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">9. Inventories </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of inventories as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merchandised goods</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,812,931,553</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,385,395,034</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowances for valuation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,316,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,877,415</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,802,614,853</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,362,517,619</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes of allowance for inventory valuation for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(22,877,415</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for inventory valuation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,560,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others(*)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,877,415</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(10,316,700</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(22,877,415</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The valuation allowance for inventory recorded in the consolidated financial statements as at December&#160;31, 2022 resulted from fair value measurement on the acquisition date of business combination, as described in Note 33. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">10. Other financial assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other financial assets as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold guarantee deposits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>68,777,020</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>34,917,468</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>66,719,787</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other deposits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,947,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,677,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,421,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">275,950,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>68,777,020</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>483,286,651</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>349,347,363</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">11. Other assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other assets as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>58,543,364</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>20,610,753</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,957,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>91,500,706</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>20,610,753</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">12. Investments in associates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of investments in associates as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:18%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:7%"/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Location</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Main business</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book&#160;value</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book&#160;value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taction&#160;Co.,&#160;Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korea</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software&#160;development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The summarized financial information of investments in associates as of the closing date and for the current period is as follows. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023 or for the year then ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assets</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Liabilities</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Revenue</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Net income</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Comprehensive<br/>income</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taction Co., Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>143,966,473</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>48,194,665</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(109,868,483</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(109,868,483</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes of book value of investments in associate accounted using equity method for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Acquisition</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Impairment&#160;loss</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taction Co., Ltd</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">12. Investments in associates&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:49%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Acquisition</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Impairment loss</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taction Co., Ltd</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Taction Co., Ltd. was incorporated to engage in software development and IT consulting. As no practical plan to generate revenue and maintain going-concern basis in the foreseeable future was provided, the Parent recognized impairment loss amounting to acquisition cost. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">13. Equipment and vehicles </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in book value of equipment and vehicles for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Machinery and<br/>equipment</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Tools and<br/>instruments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Office<br/>equipment</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Facilities</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vehicles</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition cost:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>16,274,259</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,241,386</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>75,947,865</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>252,463,510</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition and disposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,230,860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,162,516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(49,393,376</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,709,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,350,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,286,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">227,858,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">317,203,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>32,709,091</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>33,350,272</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>39,560,713</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>374,868,705</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>39,785,349</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>520,274,130</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated depreciation:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(9,400,291</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(149,600,271</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(66,955,010</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(225,955,572</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,368,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,364,251</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(96,119,814</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,496,709</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(108,349,524</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Disposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,743,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,097,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,841,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,057,091</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33,331,272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,721,054</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(222,673,511</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(307,782,928</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(30,425,841</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(33,331,272</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(35,485,596</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(369,950,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(497,547,516</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>6,873,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>10,641,115</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>8,992,855</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>26,507,938</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,283,250</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>19,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,075,117</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,917,737</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>11,431,510</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>22,726,614</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">13. Equipment and vehicles&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Office<br/>equipment</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Facilities</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vehicles</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition cost:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>16,274,259</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>16,274,259</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition and disposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,897,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,845,273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other change (*)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,897,072</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(87,845,273</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,241,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,947,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,189,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>16,274,259</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,241,386</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>75,947,865</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>252,463,510</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated depreciation:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(6,145,439</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(6,145,439</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,254,852</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,254,852</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(149,600,271</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(66,955,010</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(216,555,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(9,400,291</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(149,600,271</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(66,955,010</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(225,955,572</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>10,128,820</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>10,128,820</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>6,873,968</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>10,641,115</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>8,992,855</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>26,507,938</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Parent invested <span style="white-space:nowrap">in-kind</span> with office equipment and facilities amounting to <span style="text-decoration:line-through">W</span>97,742&#160;thousand in its associate, Taction Co., Ltd., for the year ended December&#160;31, 2022. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">14. Intangible assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in book value of intangible assets for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Technology<br/>license</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Goodwill</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Customer</span><br/><span style="font-weight:bold">relationship</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Patent technology</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition cost:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>44,054,115</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,320,277,436</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>129,927,437,789</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition and disposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,589,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,597,681,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,607,271,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination (Note 33)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,196,310,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,751,929,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,948,239,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other changes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,699,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86,699,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>140,342,664</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>47,516,587,634</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>242,277,049,512</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>290,785,267,149</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated depreciation:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(109,946,192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(170,257,468</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,139,483,501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,419,687,161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(109,946,192</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(170,257,468</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(12,139,483,501</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(12,419,687,161</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>44,054,025</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,320,277,436</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>129,927,437,789</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>30,396,472</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>47,516,587,634</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>681,029,871</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>230,137,566,011</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>278,365,579,988</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">14. Intangible assets&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Technology<br/>license</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Goodwill</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Customer</span><br/><span style="font-weight:bold">relationship</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Patent technology</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition cost:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition and disposal</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business combination (Note&#160;33)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,054,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,320,277,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,927,437,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>44,054,115</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,320,277,436</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>129,927,437,789</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated depreciation:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carrying amount as at December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>44,054,115</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,320,277,436</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>129,927,437,789</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>146,143,056,589</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">15. <span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-uses</span></span> assets as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Acquisition cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Accumulated</span><br/><span style="font-weight:bold">depreciation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>328,810,596</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(158,790,638</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>170,019,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,205,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,773,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>342,790,028</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(164,996,142</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>177,793,886</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="12"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Acquisition cost</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Accumulated</span><br/><span style="font-weight:bold">depreciation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Book value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>369,057,833</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(6,967,248</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>362,090,585</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>383,037,265</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(6,967,248</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>376,070,017</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">15. <span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in book value of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/</span><br/><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Decrease</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Depreciation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>362,091,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>110,181,086</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(230,783,566</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(71,469,520</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>170,019,958</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,205,504</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,773,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>376,071,390</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>110,181,086</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(230,783,566</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(77,675,024</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>177,793,886</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/</span><br/><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Decrease</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Depreciation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>38,698,274</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>369,059,206</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(19,561,765</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(26,103,757</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>362,090,585</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,979,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>38,698,274</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>383,038,638</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(19,561,765</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(26,103,757</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>376,071,390</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in lease liabilities for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/</span><br/><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Decrease</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Interest</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Repayment</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease&#160;liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>134,552,527</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(233,231,393</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>29,600,531</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(97,881,120</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>207,486,724</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/</span><br/><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Interest</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Repayment</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>38,698,274</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>360,340,584</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,697,321</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(28,290,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of cash outflow and expense from lease contracts for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cash outflow</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expense</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash outflow from lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>97,881,120</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>108,237,083</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Low-value</span> assets lease expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,250,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,250,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash outflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>105,131,717</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>115,487,680</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="8"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cash outflow</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Expense</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash outflow from lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>28,290,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>30,236,256</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shor-term lease expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">544,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">544,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash outflow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>28,834,817</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>30,781,073</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">16. Trade and other payables </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of trade and other payables as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Current</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-current</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>973,280,276</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>661,654,188</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">982,465,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,713,092,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">558,554,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">389,722,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,514,301,098</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,764,469,468</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">17. Borrowings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of short-term borrowings as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Purpose</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Interest<br/>rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woori Bank Co., Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Working&#160;capital</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>283,250,903</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Individual and others</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Working capital</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,153,365,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,436,615,903</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of long-term borrowings as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Purpose</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Interest<br/>rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woori Bank Co., Ltd</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Working&#160;capital</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Individual and others</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">Working capital</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td colspan="4" style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>460,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">18. Other liabilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other liabilities as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expense for annual leave</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>27,797,324</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>18,064,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholdings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,342,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114,507,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>106,140,035</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>132,572,190</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">19. Post-employment benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group maintains a defined contribution retirement benefit plan for its employees. The Group is obligated to pay fixed contributions to an independent fund, and the amount of future retirement benefits to be paid to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">19. Post-employment benefits&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees is determined by the contributions made to the fund, etc., and the investment income generated from those contributions. Plan assets are managed independently from the Group&#8217;s assets in a fund managed by a trustee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Danatein&#8217;s pension plan has converted from the DB type to the DC type at the end of March&#160;31, 2017, and is obligated to pay severance payment as DB type which incurred before the March&#160;31, 2017. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meanwhile, expenses recognized by the Group in relation to the defined contribution retirement benefit plan for the years ended December&#160;31, 2023 and 2022 are <span style="text-decoration:line-through">W</span>119,411&#160;thousand and <span style="text-decoration:line-through">W</span>22,458&#160;thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">20. Share capital </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of share capital as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit and number of shares)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Par&#160;value</span><br/><span style="font-weight:bold">per share</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares<br/>authorized</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares<br/>issued&#160;and<br/>outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,887,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit and number of shares)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Par&#160;value</span><br/><span style="font-weight:bold">per share</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares<br/>authorized</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares<br/>issued and<br/>outstanding</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,160,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in number of ordinary shares and share capital for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit and number of shares)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended<br/>December&#160;31,&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>ordinary<br/>shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&#160;1, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,160,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of share capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">669,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,345,725,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Convertible bonds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">286,265,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,887,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>9,435,350,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit and number of shares)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended<br/>December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>ordinary<br/>shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Share capital</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&#160;1, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">301,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,505,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of share capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">859,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,298,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,160,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,803,360,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">21. Share premium </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other components of equity as at December&#160;31, 2023 and 2022, are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Paid-in</span> capital in excess of par value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in share premium for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,237,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of share capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115,641,230,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,277,582,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible bonds</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,237,460,949</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>240,160,510,296</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>119,281,819,177</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">22. Retained earnings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of retained earnings (accumulated deficit) as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings (accumulated deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in accumulated deficit for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(1,277,883,962</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,534,586,604</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>67,073,904</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">23. Revenue and cost of sales </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of revenue for the years ended December&#160;31, 2023 and 2022, are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales of medical devices</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,379,326,075</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74,224,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>4,453,551,060</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of cost of sales for the years ended December&#160;31, 2023 and 2022, are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of medical devices</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,266,142,216</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24. Commitment and contingencies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24.1 Commitment with financial institution </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The details of the limit of financial transaction contracts and execution amounts entered with financial institutions as of December&#160;31, 2022 is as follows (nil as of December&#160;31, 2023): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Details</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Commitment&#160;amount</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Executed amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woori Bank Co., Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Woori&#160;trust-on&#160;guarantee&#160;loan</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>330,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>283,250,903</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24.2 Collateral and guarantee provided for others </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The details of the collateral and payment guarantee provided by the Group for others as of December&#160;31, 2022 is as follows(nil as of December&#160;31, 2023): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Guarantee&#160;amount</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrantee</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Reason of provision</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korea Credit Guarantee Fund</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="text-decoration:line-through">W</span>267,300,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">Woori&#160;Bank&#160;Co.,&#160;Ltd.</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">Guarantee&#160;for&#160;borrowings</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24.3 Pending litigation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No litigation cases are pending as of December&#160;31, 2023 and 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24.4 Restrictions on assets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No financial assets are restricted in use as of December&#160;31, 2023 and 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">24.5 Other commitment </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has entered into various contractual commitments related to the acquisition of VAXIMM including a future financial obligation of CHF 143,356 underlying as of December&#160;31, 2023. Meanwhile, both parties have agreed to remove section 6.1.3 of the license agreement that states that in the event of the Company&#8217;s sale to a third party, the Licensor shall reimburse the Licensee for reasonable costs and expenses incurred in the preparation, submission, maintenance, prosecution, and enforcement process. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">25. Administrative expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of administrative expenses for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,081,263,640</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>434,573,002</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement payment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,441,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,996,154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,035,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,396,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,919,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,909,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entertainment expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,884,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,208,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Communication cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,973,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,285,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and due</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,741,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,217,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186,024,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,358,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,310,159,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,620,353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repair fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,751,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,876,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,364,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicle maintenance fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,552,429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,644,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for expected credit losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,492,513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">323,591,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,232,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Training cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">292,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publishing fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">956,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,117,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office supplies fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consumable cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,622,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,577,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions and professional fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">736,699,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">181,043,845</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building management fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">712,429,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,701,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advertising expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,925,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personal services</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,800,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,930,194,272</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>784,666,873</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">26. Nature of expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of expenses broken down into nature for the years ended December&#160;31, 2023 and 2022, is as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in inventories</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(440,097,234</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials and consumables used</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,706,239,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee salary</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,232,705,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">464,569,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,035,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,396,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,496,183,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,358,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental cost</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,620,353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions and professional fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">736,699,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">181,044,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,919,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,909,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entertainment expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,884,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,208,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and due</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,741,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,217,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,226,402,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,547,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>19,196,336,488</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>784,666,873</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">27. Finance income and costs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of finance income and costs for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,470,673</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on disposal of FVTPL financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,305,743,718</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>24,992,432</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,308,214,391</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>489,682,118</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>17,964,454</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">28. Other income and costs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other income for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on foreign currency transaction</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>47,005,063</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on foreign currency translation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,737,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,441,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on disposition of equipment and vehicles</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,362,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on disposition of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">435,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,920,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,576,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>160,571,422</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>22,452,261</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of other costs for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on foreign currency transaction</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>86,945,552</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>59,059,511</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on foreign currency translation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194,721,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,252,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment losses on investments in associates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment losses on intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">402,355,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous losses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,439,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>685,461,727</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>183,077,459</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">29. Income tax expense </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Income tax expenses for the years ended December&#160;31, 2023 and 2022 are composed of as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax on profit for the year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments on prior years</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relating to origination and reversal of temporary differences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax recognized in other than net income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense reported in the statement of profit or loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">There is no deferred tax recognized in other than net income during for the years ended December&#160;31, 2023 and 2022 </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Explanations of the relationship between income tax expense and accounting profit for the years ended December&#160;31, 2023 and 2022 are as follows: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit (loss) before tax</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,722,866</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax based on statutory tax rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,822,947,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">273,839,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-deductible</span> expenses (profits) for tax purposes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,679,707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special tax for rural areas</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">792,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reduction in tax rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(933,388</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized changes in temporary differences</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(842,809,329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(295,067,339</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others (changes in effective tax rate)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,121,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax profit (expenses)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,130,704,911</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate (*)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The effective tax rates for the years ended December&#160;31, 2023 is not presented due to net loss before income tax expense. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">29. Income tax expense&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of unrecognized deductible (taxable) temporary differences and deferred tax assets (liabilities) as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning&#160;balance</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Profit (loss)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending balance</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable (annual leave)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,965,062</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>408,663</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>6,373,725</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">519,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,064,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,366</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,060,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,449,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,322,354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,126,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Right of use</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,365,155</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,900,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23,464,748</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued interest</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(279,255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,428</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(321,683</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Present value discount debt</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">999,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,175,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,813,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,463,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,277,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable (severance)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76,449,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,129,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,578,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Fees</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">774,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">774,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Impairment losses on investments in associate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,428,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,428,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gains on disposal of FVTPL financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(481,900,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(481,900,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation gains</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,249,523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,652,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,902,012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,547,101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,141,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(406,032</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Inventory allowance</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,781,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,625,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,156,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Losses on disposal of vehicle</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,918,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,918,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carryover tax deduction</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">429,444,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290,022,295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">719,466,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax loss carryforwards</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,060,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,060,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">PPA effect</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,520,257,288</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,114,778,162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,024,086,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(43,328,007,126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap">Sub-total</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,405,647,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,985,876,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,024,086,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,342,299,635</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrecognized deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,565,206</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(835,754,857</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(878,320,063</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(19,448,212,933</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,150,121,234</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(25,024,086,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(43,220,619,698</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">29. Income tax expense&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-style:italic">(Korean won in unit)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning<br/>balance</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Profit (loss)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Business<br/>combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending balance</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable (annual leave)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,647,095</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>128,470</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>2,189,497</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,965,062</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,025,165</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,113,879</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,513,620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,653,350</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,204,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,064,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,935,331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,513,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,449,087</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Right of use</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,513,620</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,711,467</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,140,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,365,155</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued interest</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(273,938</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(279,255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Present value discount debt</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">577,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">421,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">999,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,017,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,616,263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179,707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,813,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable (severance)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,775,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,254,864</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,418,438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76,449,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Fees</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">774,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">774,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Impairment losses on investments in associate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,428,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,428,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gains on disposal of FVTPL financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(481,900,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(481,900,437</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation gains</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,486,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,237,177</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,249,522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation losses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,227,169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,680,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,547,101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Inventory allowance</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,781,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,781,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Losses on disposal of vehicle</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,918,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,918,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Carryover tax deduction</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268,416,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161,027,332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">429,444,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax loss carryforwards</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,060,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,060,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">PPA effect</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,520,257,288</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,520,257,288</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap">Sub-total</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">333,886,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(291,321,390</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,448,212,933</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,405,647,727</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrecognized deferred tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(333,886,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">291,321,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,565,206</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(19,448,212,933</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(19,448,212,933</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">30. Earnings per share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings per share for the years ended December&#160;31, 2023 and 2022 are calculated as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit and number of shares)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) (A)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(13,601,660,508</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,344,957,866</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding (B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,668,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per ordinary share<br/>(=A/B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(8,152</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,445</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">30. Earnings per share&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding for the years ended December&#160;31, 2023 and 2022 are calculated as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(number of shares)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares outstanding at the beginning</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,160,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">301,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted number of ordinary shares newly issued</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">446,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">89,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted number of ordinary shares newly issued</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Convertible bonds</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,668,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The group&#8217;s diluted earnings per share is the same as basic earnings per share because there is no dilution effect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31. Related party disclosure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31.1 Related parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Group&#8217;s related parties are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Type</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Related parties</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ultimate parent entity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bellevue Capital Management LLC.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Major shareholder of the Parent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCM Europe AG</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiaries</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAXIMM, RMC, Darnatein</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Associate</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taction Co., Ltd.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other related parties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Bellevue Global Life Sciences Investors LLC</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31.2 Transactions with related parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no sales and procurement transactions and treasury transactions with related parties for the years ended December&#160;31, 2023 and 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31.3 Assets or liabilities from related party transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of receivables and payables from related party transactions as at December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December 31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Related&#160;parties</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Short-term&#160;borrowings</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Individuals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>500,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="4" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December 31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Related&#160;parties</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Short-term&#160;borrowings</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Individuals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>700,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31. Related party disclosure&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31.4 Renumeration for key management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensations paid or accrued to key management of the Parent for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>615,446,525</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>269,492,304</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#8217;s key management includes registered directors who have important authority and responsibility for planning, operation, and control of the Group&#8217;s business activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">31.5 Collateral or guarantee provided for or received from related parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No collateral or guarantee were provided for related parties and were received from related parties as at December&#160;31, 2023 and 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">32. <span style="white-space:nowrap">Non-cash</span> transaction </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">32.1 Significant <span style="white-space:nowrap">non-cashflow</span> transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant transactions without cash inflows or outflows for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement of short-term borrowings to convertible bonds</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,090,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of intangible assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,000,037,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity swap for acquisition of subsidiaries</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105,004,724,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment <span style="white-space:nowrap">in-kind</span> using equipment for associate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,742,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity swap for acquisition of subsidiaries</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,135,651,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,782,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposition of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,698,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">32.2 Changes in liabilities arising from financing activities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of reconciliation of liabilities arising from financing activities for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-cash</span> movements</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Interest</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cashflow</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">expense</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Others</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(97,881,120</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>29,600,531</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(98,678,866</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>207,486,724</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">32. <span style="white-space:nowrap">Non-cash</span> transaction&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">32.2 Changes in liabilities arising from financing activities&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the year ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-cash</span> movements</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Interest</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beginning</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Cashflow</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">expense</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Others</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ending</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>38,698,274</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(28,290,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>3,697,321</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>360,340,584</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>374,446,179</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent acquired Darnatein (a novel drug development company) (referred as the &#8220;Acquiree&#8221; herein) as it executes on its business plan to further expand its business by discovering and investing in innovative healthcare companies with cutting-edge technology and creating operating synergies between subsidiaries. As the Parent and the Aquiree former owners exchanged only equity interests in business combination transactions and the acquisition-date fair value of the Parent&#8217;s equity interests could not reliably be measured, the Parent determined the amount of goodwill by using the acquisition-date fair value of the Acquiree equity interests instead of the acquisition-date fair value of the shares transferred. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vaximm and Darnatein can be reasonably categorized as &#8220;(bio) platform companies&#8221; which differ from the companies only with drug development pipelines. Bioplatforms can be defined as biotechnologies that, once created and harnessed, allow for the intentional and repeatable generation of multiple medicines or agricultural and sustainability products. Both Vaximm and Darnatein are biotech companies whose drug R&amp;D pipelines are based on their own <span style="white-space:nowrap">in-house</span> platform technologies that are protected by either patents or trade secrets. According to the <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;hub-and-spoke&#8221;</span></span> business model of OSR Holdings, the Parent has assumed the position to either own or control the technology platforms of Vaximm and Darnatein through the Business Combinations, which means that the Parent will be able to launch new services to external clients or create additional drug candidates by a new <span style="white-space:nowrap">start-up</span> or Joint Venture with business partners based on their direct ownership or control over the platform technologies acquired from the Business Combinations. Such quality would support the goodwill recognition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.1 Summary of business combinations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of business combinations that occurred for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the years ended December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Acquisition</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Acquiree</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Main&#160;business</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">date</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">(%)</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">consideration</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darnatein</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New drug development, etc.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap"><span style="white-space:nowrap">2023-06-30</span></span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:top" align="right"><span style="text-decoration:line-through"></span>105,004,724,500</td>
<td style="white-space:nowrap;vertical-align:top"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of business combinations that occurred for the year ended December&#160;31, 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the years ended December&#160;31, 2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Acquisition</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Acquiree</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Main&#160;business</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">date</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">(%)</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">consideration</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMC</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical device distribution, etc.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap"><span style="white-space:nowrap">2022-12-31</span></span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:top" align="right"><span style="text-decoration:line-through"></span>5,449,676,000</td>
<td style="white-space:nowrap;vertical-align:top"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAXIMM</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New drug development, etc.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right"><span style="white-space:nowrap"><span style="white-space:nowrap">2022-12-31</span></span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:line-through">W</span></td>
<td style="vertical-align:top" align="right"><span style="text-decoration:line-through"></span>124,558,971,196</td>
<td style="white-space:nowrap;vertical-align:top"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.2 Assets acquired and liabilities assumed </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of identifiable assets and liabilities and goodwill, which are recognized as the result of business combination that occurred for the year ended December&#160;31, 2023 are set forth in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Darnatein</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of total identifiable assets:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>88,452,978</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,593,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">368,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and vehicles (Note 13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,421,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">94,273,525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets (Note 14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,348,738,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> financial assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,420,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,548,267,447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of total identifiable liabilities:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,567,854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,339,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current other liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,377,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> liabilities:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance payment (Note 19)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,435,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,796,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities (Note 29)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,024,086,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,244,602,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of identifiable net assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,303,665,352</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,701,059,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase consideration transferred (*)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>105,004,724,550</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition-date fair value of Darnatein was measured using the Discount Cash Flow (&#8220;DCF&#8221;) method and the Risk adjusted Net Present Value <span style="white-space:nowrap">(&#8220;r-NPV&#8221;)</span> method by outside valuation professionals. Key estimations and assumptions used in measuring the fair value of Darnatein are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">19.88% of discount rate (Weighted Average Cost of Capital: WACC) used in discounting operating cashflows </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patent technology will generate operating revenue for 20 years </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(*) OSR ordinary shares issued for purchase consideration of KRW 105,004,724,550 is 590,425 shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.2 Assets acquired and liabilities assumed&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of identifiable assets and liabilities and goodwill, which are recognized as the result of business combinations that occurred for the year ended December&#160;31, 2022 are set forth in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:55%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">RMC</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">VAXIMM</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of total identifiable assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>492,332,061</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>1,757,253,007</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">546,515,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76,608,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory (Note 9)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,362,517,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,394,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,528,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and vehicles (Note&#160;13)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,992,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,641,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> assets (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96,363,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">230,783,566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets (Note 14)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851,287,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,971,491,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> financial assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,829,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">681,310,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets (Note 28)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,044,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,470,412,402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,700,222,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of total identifiable liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">986,986,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">184,086,765</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283,250,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,471,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,060,410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,909,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,396,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term borrowings</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities (Note 15)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59,874,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233,231,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities (Note&#160;28)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122,090,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,398,166,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,652,734,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,829,530,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of identifiable net assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,817,678,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112,870,691,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,631,997,741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,688,279,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase consideration transferred (*1)(*2)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>5,449,676,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>124,558,971,196</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition-date fair value of RMC and VAXIMM were measured using the Discount Cash Flow (&#8220;DCF&#8221;) method and the Risk adjusted Net Present Value <span style="white-space:nowrap">(&#8220;r-NPV&#8221;)</span> method by outside valuation professionals. Key estimations and assumptions used in measuring the fair value of VAXIMM are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">13.6% of discount rate (Weighted Average Cost of Capital: WACC) used in discounting operating cashflows </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.2 Assets acquired and liabilities assumed&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patent technology will generate operating revenue for 20 years </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Penetration ratio will reach at 100% in 7 years since approval of new drug </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">OSR ordinary shares issued for the purchase consideration transferred of <span style="text-decoration:line-through">W</span>5,449,676,000 is 70,847 shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">OSR ordinary shares issued, transfer of BCME preferred shares held by OSR, and cash consideration for the purchase consideration transferred of <span style="text-decoration:line-through">W</span>124,558,971,196 are 696,225 shares, 1,750 shares, and 3.6 USDm, respectively. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.3 Patent technology from business combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of patent technology recognized from the acquisition of Darnatein that occurred for the year ended December&#160;31, 2023 are set forth in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:77%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in thousand)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent technology project code:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DRT 101</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>94,788,203</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) <span style="white-space:nowrap">DRT-101</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">DRT-101</span> is a synthetic <span style="white-space:nowrap">bio-signaling</span> molecule that replaces BMPRII-binding segments of <span style="white-space:nowrap">BMP-7,</span> one of the bone-forming proteins, with high affinity ActRII binding segments of Activin A, a member of the transforming growth factor <span style="FONT-FAMILY:SYMBOL">b</span> (TGF-<span style="FONT-FAMILY:SYMBOL">b</span>) superfamily along with <span style="white-space:nowrap">BMP-7.</span> In nature, endogenous BMP7 promotes chondrogenesis in damaged cartilage tissue by signaling primarily via the type II receptor BMPRII and to a lesser extent via the activin type II receptor ActRII, which it binds with lower affinity. <span style="white-space:nowrap">DRT-101</span> amplifies intracellular regeneration signaling capacity compared to natural <span style="white-space:nowrap">BMP-7</span> and allows for regeneration and restoration of mechanically depleted cartilage cells to normal levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Osteoarthritis is the most common joint disorder in the aging population. Although surgical treatment of osteoar- thritis can reduce pain and improve joint mobility and function, the operative management of osteoarthritis is associated with significant cost and morbidity. Unmet medical needs for <span style="white-space:nowrap">DRT-101</span> for Osteoarthritis are enormous specially with aging population. Unique market opportunity of DRT-101 relies on novel Mechanism of Action of DRT-101 that can lead to potential <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> DMOAD (Disease-Modifying Osteoarthritis Drug) in the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Darnatein is pursuing <span style="white-space:nowrap">pre-clinical</span> studies of DRT-101 targeting osteoarthritis and plans to file Investigational New Drug Application (IND) to the U.S. Food and Drug Administration by 2025 for Phase 1 clinical trial, with aims of FDA approval by 2032. Darnatein will seek to create cashflow via licensing deals from the preclinical and clinical developments of its pipeline assets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.3 Patent technology from business combination&#8201;(cont&#8217;d) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of patent technology recognized from the acquisition of VAXIMM that occurred for the year ended December&#160;31, 2022 are set forth in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in thousand)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent technology project code:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">VMX01-GBM</span> (ROW and China)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>15,481,599</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VMX01-mCRC (ROW and China)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,256,642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VMX01-Liver (ROW and China)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,927,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">VMX01-NF2</span> (ROW and China)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,214,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">VXM-Preclinical</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,047,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>129,927,438</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Rest of the world (&#8220;ROW&#8221;) represents 7 major countries except China. These markets were separated purely from a licensing perspective, as the <span style="white-space:nowrap">pre-determined</span> terms would be applied when licensing out its technologies due to the license agreement with China Medical System Corp. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(1) VXM01 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VXM01 is an oral <span style="white-space:nowrap">T-cell</span> immunotherapy that is designed to activate <span style="white-space:nowrap">T-cells</span> to attack the tumor vasculature and tumor cells. VXM01 carries the vascular endothelial growth factor <span style="white-space:nowrap">receptor-2</span> (VEGFR2), which is highly overexpressed on the tumor vasculature. The active, <span style="white-space:nowrap">T-cell-mediated</span> destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:76%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Project code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Supplementary explanation of project</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">VXM01-GBM</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">GBM is a cancer with some of the highest unmet needs. It is one of the most common and most lethal primary brain tumors. The current standard of care consists of surgery followed by radiation and temozolomide. However, there is no standard therapy which prove extension of survival rate. Therefore, it is expected that VXM01 can be applied to GBM and prove its efficacy in treating GBM.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">VXM01-mCRC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Colorectal cancer is the third most commonly occurring cancer worldwide and the second most deadly cancer. In early stage, CRC is commonly treated with surgery, while metastatic CRC treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors. However, patients still become refractory to these drugs. Therefore, it is expected that VXM01 can be applied to mCRC and prove its efficacy in treating mCRC.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">VXM01-Liver</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and accounts for 75&#8211;90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide. The current approved therapy has shown a low response rate for the limited number of patients. Therefore, it is expected that VXM01 can be applied to liver cancer and prove its efficacy in treating liver cancer.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33. Business combinations&#8201;(cont&#8217;d) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.3 Patent technology from business combination&#8201;(cont&#8217;d) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:76%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Project code</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Supplementary explanation of project</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">VXM01-NF2</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Neurofibromatosis (NF) is a tumor originating in the nervous system. In neurofibromatosis type 2, the most common tumors are vestibular schwannomas or acoustic neuromas, noncancerous growths that develop along the auditory nerve. There are currently no approved therapeutics for this disease, Therefore, it is expected that VXM01 can be applied to Neurofibromatosis and prove its efficacy in treating Neurofibromatosis.</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(2) <span style="white-space:nowrap">VXM-Preclinical</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VAXIMM&#8217;s preclinical programs are composed of 4 different pipelines: VXM04, VXM06, VXM08 and VXM10 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM04 carries human mesothelin as the target antigen. Mesothelin is a protein that is overexpressed in several solid tumors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM06 targets WT1. WT1 is overexpressed in several hematological malignancies and solid tumors. In preclinical studies, VXM06 has shown potent <span style="white-space:nowrap">T-cell</span> activation against WT1 and stand-alone therapeutic activity in models of leukemia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM08 targets CEA, a human tumor-associated antigen overexpressed in many solid tumors. In preclinical studies, VXM08 has shown potent <span style="white-space:nowrap">T-cell</span> activation against its target antigen as well as stand-alone therapeutic activity in models of colorectal and lung cancer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">VXM10 targets <span style="white-space:nowrap">PD-L1,</span> an immunomodulatory antigen upregulated in many solid tumors as well as hematological malignancies. VXM10 is currently in preclinical development and has shown stand-alone therapeutic activity in models of leukemia. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">33.4 Net cashflow from acquisition for the years ended December&#160;31, 2023 and 2022 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash outflow arising from acquisition of Darnatein:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: cash and cash equivalent balances acquired</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,452,978</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(88,452,978</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">(Korean won in unit)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash outflow arising from acquisition of VAXIMM and RMC:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: cash and cash equivalent balances acquired</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,249,584,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through">W</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="text-decoration:line-through"></span>(2,249,584,807</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="text-decoration:line-through"></span>)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings Co., Ltd. and its subsidiaries </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notes to the consolidated financial statements </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">December&#160;31, 2023 and 2022 </p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">34. Operating Segments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For business management purposes of the Consolidated Entity, sales consist of pharmaceutical manufacturing and medical device distribution, considered as a single operating division. Therefore, we did not disclose information by operating segments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="fintoc476668_19a">There are no external customers that account for more than 10% of sales for the reporting period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="ii476668_1anxa">ANNEX A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">by and among </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OSR HOLDINGS CO., LTD., </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE COMPANY STOCKHOLDERS (AS DEFINED HEREIN) </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:4%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Page</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_1">ARTICLE I CERTAIN DEFINITIONS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_2">Certain Definitions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_3">Construction</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_4">ARTICLE II THE BUSINESS COMBINATION; CLOSING </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_5">Share Exchange</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_6">Delivery of Shares</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_7">Treatment of Company Capital Stock held by <span style="white-space:nowrap">Non-Participating</span> Company Stockholders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_8">Withholding</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_9">Closing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.06</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_10">Closing Deliverables</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.07</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_11">Certificate of Incorporation; Bylaws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.08</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_12">Directors and Officers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_13">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_14">Organization and Qualification; Subsidiaries</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_15">Articles of Incorporation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_16">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_17">Authority Relative to this Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_18">No Conflict; Required Filings and Consents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.06</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_19">Permits; Compliance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.07</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_20">Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.08</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_21">Absence of Certain Changes or Events</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.09</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_22">Absence of Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_23">Employee Benefit Plans</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_24">Labor and Employment Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_25">Real Property; Title to Assets</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_26">Intellectual Property</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_27">Reserved</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_28">Taxes</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_29">Possession of Licenses and Permits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_30">Regulatory Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_31">Healthcare Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_32">Environmental Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_33">Material Contracts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_34">International Trade Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_35">Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_36">Board Approval</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_37">Anti-Corruption Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.25</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_38">Interested Party Transactions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.26</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_39">Exchange Act</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.27</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_40">Brokers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.28</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_41">Exclusivity of Representations and Warranties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_42">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF COMPANY STOCKHOLDERS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_43">Ownership of Company Common Stock</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_44">Organization and Authority</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_45">No Conflict; Required Filings and Consents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:4%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_46">Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_47">Broker</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_48">ARTICLE V REPRESENTATIONS AND WARRANTIES OF BLAC </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_49">Corporate Organization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_50">Certificate of Incorporation and Bylaws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_51">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_52">Consents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_53">No Conflict; Required Filings and Consents.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.06</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_54">Compliance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.07</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_55">SEC Filings; Financial Statements; Sarbanes-Oxley</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.08</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_56">Absence of Certain Changes or Events; Transactions with Affiliates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.09</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_57">Absence of Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_58">BLAC M&amp;A Committee and BLAC Board Approval; Vote Required</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_59">Brokers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_60">BLAC Trust Fund</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_61">Employees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_62">Taxes</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.15</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_63">Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.16</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_64">BLAC&#8217;s Investigation and Reliance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.17</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_65">Exclusivity of Representations and Warranties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_66">ARTICLE VI CONDUCT OF THE BUSINESS PENDING THE BUSINESS COMBINATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_67">Conduct of Business by the Company Pending the Business Combination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_68">Conduct of Business by BLAC Pending the Business Combination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_69">Claims against Trust Account</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_70">ARTICLE VII ADDITIONAL AGREEMENTS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_71">Proxy Statement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_72">BLAC Stockholders&#8217; Meetings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_73">Minimum Participation by Company Stockholders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_74">Access to Information; Confidentiality</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_75">Exclusivity</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.06</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_76">Employee Benefit Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.07</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_77">Notification of Certain Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.08</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_78">Further Action; Reasonable Best Efforts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.09</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_79">Public Announcements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_80">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.11</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_81">Stock Exchange Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_82">Antitrust.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.13</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_83">Trust Account</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.14</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_84">Section&#160;16 Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_85">ARTICLE VIII CONDITIONS TO THE BUSINESS COMBINATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_86">Conditions to the Obligations of Each Party</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_87">Conditions to the Obligations of BLAC</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_88">Conditions to the Obligations of the Company</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_89">ARTICLE IX TERMINATION, AMENDMENT AND WAIVER </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_90">Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_91">Effect of Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_92">Expenses</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:86%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_93">Amendment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_94">Waiver</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxatoc476668_95">ARTICLE X GENERAL PROVISIONS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.01</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_96">Notices</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.02</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_97"><span style="white-space:nowrap">Non-survival</span> of Representations, Warranties and Covenants</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.03</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_98">Severability</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.04</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_99">Entire Agreement; Assignment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.05</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_100">Parties in Interest</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.06</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_101">Governing Law</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.07</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_102">WAIVER OF JURY TRIAL</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.08</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_103">Headings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.09</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_104">Counterparts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxatoc476668_105">Specific Performance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">EXHIBITS </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Exhibit A</span> &#8211; Form of Participating Stockholder Joinder </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Exhibit B</span> &#8211; Form of <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Company Disclosure Schedule </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_44"><span style="text-decoration:underline">AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amended and Restated Business Combination Agreement (this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;) amends and restates the Business Combination Agreement (the &#8220;<span style="font-weight:bold">Original Agreement</span>&#8221;), dated as of November&#160;16, 2023 (the &#8220;<span style="font-weight:bold">Execution Date</span>&#8221;), by and among Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="font-weight:bold">BLAC</span>&#8221;), OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the &#8220;<span style="font-weight:bold">Company</span>&#8221;), each holder of Company Common Stock that executes a Participating Stockholder Joinder to this Agreement on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold">Participating Company Stockholder</span>&#8221;), and each holder of Company Common Stock that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221;, and together with BLAC, the Company and the Participating Company Stockholders, the &#8220;<span style="font-weight:bold">Parties</span>&#8221; and each a &#8220;<span style="font-weight:bold">Party</span>&#8221;). The Participating Company Stockholders and the <span style="white-space:nowrap">Non-Participating</span> Stockholders are collectively referred to herein as the &#8220;<span style="font-weight:bold">Company Stockholders</span>&#8221;, and each a &#8220;<span style="font-weight:bold">Company Stockholder</span>&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, BLAC is a Delaware blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, upon the terms and subject to the conditions of this Agreement, the Parties desire to enter into a business combination transaction (the &#8220;<span style="font-weight:bold">Business Combination</span>&#8221;) whereby BLAC issues shares of BLAC Common Stock (as defined herein) to the Participating Company Stockholders and in consideration, the Participating Company Stockholders transfer each of their respective shares of Company Common Stock (as defined herein) to BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Closing, and upon exercise of each Put Right or each Call Right set forth in each <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder, BLAC shall issue shares of BLAC Common Stock to the <span style="white-space:nowrap">Non-Participating</span> Company Stockholder party to such <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder, and in consideration, such <span style="white-space:nowrap">Non-Participating</span> Company Stockholder shall transfer each of its shares of Company Common Stock to BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the conditions to Closing in this Agreement include, among others, the requirements that (i)&#160;holders of Company Common Stock representing at least 60% of Company Fully-Diluted Share Amount (as defined below) execute Participating Stockholder Joinders to this Agreement and become Participating Company Stockholders on or prior to the Closing, and (ii)&#160;the Company shall use best efforts to cause all other holders of Company Common Stock (other than Excluded Company Shares) that do not sign a Participating Stockholder Joinder to execute a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder, and pursuant to the terms of this Agreement, the Company shall use its best effort to cause the fulfillment of such conditions on or prior to Closing; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#8220;<span style="font-weight:bold">Company Board</span>&#8221;) has unanimously (a)&#160;determined that the Business Combination is fair to, and in the best interests of, the Company and its stockholders and has approved the terms of the Business Combination and declared their advisability and approved the other transactions contemplated by the Business Combination, and (b)&#160;have authorized and directed the representative director of the Company to enter into all agreements he deems necessary to effectuate the Business Combination and to take such actions he deems necessary, appropriate or advisable to consummate the Business Combination; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of BLAC (the &#8220;<span style="font-weight:bold">BLAC Board</span>&#8221;) has established a committee (the &#8220;<span style="font-weight:bold">BLAC M&amp;A Committee</span>&#8221;) consisting of directors that do not have any material interest in the Company or the transactions contemplated by this Agreement and the M&amp;A Committee has determined that the transactions contemplated by this Agreement are fair and in the best interests of BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following recommendation by the M&amp;A Committee, the BLAC Board has (a)&#160;approved and adopted this Agreement and declared its advisability and approved the payment of the Per Share Consideration to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Participating Company Stockholders at Closing pursuant to this Agreement and the other transactions contemplated by this Agreement, (b)&#160;approved and adopted the form of <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder and the transactions contemplated thereby, and (c)&#160;recommended the approval and adoption of this Agreement and the transactions contemplated by this Agreement by the stockholders of BLAC; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Closing, BLAC and certain stockholders of the Company shall enter into <span style="white-space:nowrap">Lock-Up</span> Agreements in the forms to be agreed among the parties thereto (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, prior to Closing, the Parties anticipate that BLAC and/or the Company will enter into one or more subscription agreements in a form to be mutually agreed between BLAC and the Company (all such subscription agreements, collectively the &#8220;<span style="font-weight:bold">PIPE Subscription Agreements</span>&#8221;), pursuant to which one or more investors shall purchase debt or preferred equity securities of BLAC and/or the Company convertible into BLAC Common Stock in a private placement or placements (the &#8220;<span style="font-weight:bold">PIPE Investment</span>&#8221;) to be consummated in connection with the consummation of the Business Combination and the other transactions contemplated hereby; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on July&#160;7, 2023, the Company entered into a letter of intent (the &#8220;<span style="font-weight:bold">LOI</span>&#8221;) with Landmark BioVentures AG (&#8220;<span style="font-weight:bold">LBV</span>&#8221;) for the acquisition of 100% of the equity interests in LBV in exchange for the issuance by the Company of 3,062,374 shares of Company Common Stock; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on March&#160;18, 2024, LBV terminated the LOI, and the Company and LBV abandoned further discussions regarding an acquisition; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in accordance with Section&#160;9.04 of the Original Agreement, the Parties now desire to amend and restate the Original Agreement as of the Amendment Date; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereto hereby agree as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_1">ARTICLE I </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTAIN DEFINITIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_2">1.01 <span style="text-decoration:underline">Certain Definitions</span>. For purposes of this Agreement: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">2023 Balance Sheet</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.07(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Action</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.09</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">affiliate</span>&#8221; of a specified person means a person who, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified person; provided, however, that for purposes of this Agreement, BLAC on the one hand, and the Company and its Subsidiaries, on the other hand, shall not be considered affiliates of one another. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Aggregate Consideration</span>&#8221; means an aggregate of 24,461,214 shares of BLAC Common Stock derived by the quotient of (a)&#160;the Aggregate Consideration Value divided by (b) $10.00. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Aggregate Consideration Value</span>&#8221; means $244,612,136. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Aggregate Participating Consideration</span>&#8221; means the aggregate number of shares of BLAC Common Stock issuable to the Participating Company Stockholders at Closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Alternative Transaction</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.05(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Amendment Date</span>&#8221; means the date of execution of this Amended and Restated Business Combination Agreement as set forth on the signature page hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Ancillary Agreements</span>&#8221; means the <span style="white-space:nowrap">Lock-Up</span> Agreements, the PIPE Subscription Agreements, and all other agreements, certificates and instruments executed and delivered by BLAC, the Company or the Company Stockholders in connection with the Transactions and specifically contemplated by this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Anti-Corruption Laws</span>&#8221; means the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act of 2010, and any other applicable anti-corruption/anti-bribery laws and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Antitrust Laws</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.12(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Board</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Certificate of Incorporation</span>&#8221; means the Amended and Restated Certificate of Incorporation of BLAC filed with the Secretary of the State of the State of Delaware on February&#160;13, 2023, as such may have been amended, supplemented or modified from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Common Stock</span>&#8221; means BLAC&#8217;s common stock, par value $0.0001 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Directors</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC IPO Prospectus</span>&#8221; means the Prospectus issued by BLAC in connection with its initial public offering of BLAC Units, dated February&#160;9, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC M&amp;A Committee</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Material Adverse Effect</span>&#8221; means any Effect that, individually or in the aggregate with all other Effects, (a)&#160;is or would reasonably be expected to be materially adverse to the business, condition (financial or otherwise) or results of operations of BLAC; or (b)&#160;would prevent, materially delay or materially impede the performance by BLAC of its obligations under this Agreement or the consummation of the Business Combination or any of the other Transactions; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that none of the following shall be deemed to constitute, alone or in combination, or be taken into account in the determination of whether, there has been or will be a BLAC Material Adverse Effect: (i)&#160;any change or proposed change in or change in the interpretation of any Law (including any <span style="white-space:nowrap">COVID-19</span> Measures) or GAAP after the Execution Date; (ii)&#160;events or conditions generally affecting the industries or geographic areas in which BLAC operates; (iii)&#160;any downturn in general economic conditions, including changes in the credit, debt, securities, financial or capital markets (including changes in interest or exchange rates, prices of any security or market index or commodity or any disruption of such markets); (iv) acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks (including <span style="white-space:nowrap">COVID-19)</span> or any escalation or worsening of any such acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks, or changes in global, national, regional, state or local political or social conditions; (v)&#160;any hurricane, tornado, flood, earthquake, natural disaster, or other acts of God; (vi)&#160;any actions taken or not taken by BLAC as required by this Agreement or any Ancillary Agreement; (vii)&#160;any Effect attributable to the announcement or execution, pendency, negotiation or consummation of the Business Combination or any of the other Transaction; or (viii)&#160;any actions taken, or failures to take action, or such other changes or events; in each case, which the Company has requested or to which it has consented or which actions are contemplated by this Agreement, except in the cases of clauses (i)&#160;through (iii), to the extent that BLAC is materially and disproportionately affected thereby as compared with other participants in the industry in which BLAC operates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Organizational Documents</span>&#8221; means the BLAC Certificate of Incorporation, Bylaws, and the Trust Agreement, in each case as amended, modified or supplemented from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Preferred Stock</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.03(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Proposals</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.01(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Right</span>&#8221; means one right entitling the holder thereof to receive <span style="white-space:nowrap">one-tenth</span> (1/10) of a share of BLAC Common Stock upon the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC SEC Reports</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.07(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Stockholders&#8217; Meeting</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.01(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Unit</span>&#8221; means one unit issued by BLAC in connection with its initial public offering, consisting of one share of BLAC Common Stock, one BLAC Right and one BLAC Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">BLAC Warrant</span>&#8221; means one warrant entitling the holder thereof to purchase one share of BLAC Common Stock at a price of $11.50 per share, subject to adjustment as described in the BLAC IPO Prospectus. Each BLAC Warrant will become exercisable 30 days after the consummation of the Business Combination, and will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Blue Sky Laws</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.05(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Combination</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Data</span>&#8221; means all business information and data, including Personal Information (whether of employees, contractors, consultants, customers, consumers, or other persons and whether in electronic or any other form or medium) that is accessed, collected, used, processed, stored, shared, distributed, transferred, disclosed, destroyed, or disposed of by any of the Business Systems or otherwise in the course of the conduct of the business of the Company Business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Day</span>&#8221; means any day on which the principal offices of the SEC in Washington, D.C. are open to accept filings, or, in the case of determining a date when any payment is due, any day on which banks are not required or authorized to close in New York, NY. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Systems</span>&#8221; means all Software, computer hardware (whether general or special purpose), electronic data processing, information, record keeping, communications, telecommunications, networks, interfaces, platforms, servers, peripherals, and computer systems, including any outsourced systems and processes, that are owned or used or held for use in the conduct of the Company Business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Claims</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.03</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Closing</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.05</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Closing Date</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.05</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Board</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Business</span>&#8221; means the business of the Company and the Company Subsidiaries as currently conducted and currently proposed to be conducted as of the Execution Date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Capital Stock</span>&#8221; means the Company Common Stock and any other class or series of Company capital stock issued or issuable upon exercise of any security convertible into, or exchangeable for capital stock of the Company outstanding at the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Common Stock</span>&#8221; means the Company&#8217;s series A common stock, with a par value of KRW 5,000 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Directors</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(c)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Disclosure Schedule</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Article</span> III. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Fully Diluted Share Amount</span>&#8221; means, without duplication, the aggregate number of shares of Company Common Stock outstanding on a fully diluted basis, including all shares issuable upon the conversion or exercise of all options, warrants and other securities convertible into or exchangeable for shares of Company Common Stock, as of immediately prior to the Effective Time other than the Excluded Company Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company IP</span>&#8221; means, collectively, all Company-Owned IP and Company-Licensed IP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company-Licensed IP</span>&#8221; means all Intellectual Property rights owned or purported to be owned by a third party and licensed to the Company or to any Company Subsidiary in connection with the Company Business currently or at any time during the past five (5)&#160;years, whether exclusively, <span style="white-space:nowrap">non-exclusively,</span> through a license, through a covenant, or on any other basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Material Adverse Effect</span>&#8221; means any event, circumstance, change, development, effect or occurrence (collectively &#8220;<span style="text-decoration:underline">Effect</span>&#8221;) that, individually or in the aggregate with all other Effects, (a)&#160;is or would reasonably be expected to be materially adverse to the business, condition (financial or otherwise), assets, liabilities or operations of the Company and the Company Subsidiaries taken as a whole or (b)&#160;prevents, materially delays or materially impedes the performance by the Company of its obligations under this Agreement or the consummation of the Business Combination or any of the other Transactions; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that none of the following shall be deemed to constitute, alone or in combination, or be taken into account in the determination of whether, there has been or will be a Company Material Adverse Effect: (i)&#160;any change or proposed change in or change in the interpretation of any Law (including any <span style="white-space:nowrap">COVID-19</span> Measures) or the Accounting Standards (as defined herein) after the Execution Date; (ii)&#160;events or conditions generally affecting the industries or geographic areas in which the Company and the Company Subsidiaries operate; (iii)&#160;any downturn in general economic conditions, including changes in the credit, debt, securities, financial or capital markets (including changes in interest or exchange rates, prices of any security or market index or commodity or any disruption of such markets); (iv) acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks (including <span style="white-space:nowrap">COVID-19),</span> or any escalation or worsening of any such acts of war, sabotage, civil unrest, terrorism, epidemics, pandemics or disease outbreaks, or changes in global, national, regional, state or local political or social conditions; (v)&#160;any hurricane, tornado, flood, earthquake, natural disaster, or other acts of God, (vi)&#160;any actions taken or not taken by the Company or the Company Subsidiaries as required by this Agreement or any Ancillary Agreement, (vii)&#160;any Effect attributable to the announcement or execution, pendency, negotiation or consummation of the Business Combination or any of the other Transactions (including the impact thereof on relationships with customers, suppliers, employees or Governmental Authorities), (viii) any failure to meet any projections, forecasts, guidance, estimates, milestones, budgets or financial or operating predictions of revenue, earnings, cash flow or cash position, <span style="text-decoration:underline">provided</span> that this clause (viii)&#160;shall not prevent a determination that any change, event, or occurrence underlying such failure has resulted in a Company Material Adverse Effect, (ix)&#160;any actions taken, or failures to take action, or such other changes or events, in each case, which BLAC has requested or to which it has consented or which actions are contemplated by this Agreement or (x)&#160;any statements or items set forth in the Company Disclosure Schedule, except in the cases of clauses (i)&#160;through (iii), to the extent that the Company and the Company Subsidiaries, taken as a whole, are materially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and disproportionately affected thereby as compared with other participants in the industries in which the Company and the Company Subsidiaries operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company-Owned IP</span>&#8221; means all Intellectual Property rights that are currently, or that were at any time during the past five (5)&#160;years owned or purported to be owned by the Company or any of the Company Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Permits</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.06</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Products</span>&#8221; means any and all products in respect of the Company Business that were at any time during the past five (5)&#160;years, or that are currently manufactured, distributed, sold, licensed, or otherwise offered or commercialized, or under development in any material respect by the Company or any Company Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Services</span>&#8221; means all services in respect of the Company Business that were at any time during the past five (5)&#160;years, or that are currently delivered, provided, offered or commercialized, or under development in any material respect by the Company or any Company Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Software</span>&#8221; means Software that was at any time during the past five (5)&#160;years, or that is currently owned or purported to be owned by or developed by or for the Company or any Company Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Subsidiary</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.01(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Confidentiality Agreement</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.04(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Confidential Information</span>&#8221; means all information constituting or relating to Intellectual Property, technology, product development, price, customer and supplier lists, pricing and marketing plans, policies and strategies, details of client and consultant contracts, operations methods, product development techniques, business acquisition plans or new personnel acquisition plans and all other confidential or proprietary information with respect to a party and its customers and vendors. Confidential Information includes any information, knowledge or data concerning the businesses and affairs of the Company, the Company Subsidiaries, or any Suppliers or customers of the Company or any Company Subsidiaries or BLAC or its subsidiaries (as applicable) that is not already generally available to the public. Notwithstanding the foregoing, &#8220;Confidential Information&#8221; shall not include (a)&#160;issued Patents and published Patent applications or (b)&#160;information that is or becomes generally available to the public or general industry knowledge through no action or inaction by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contingent Worker</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.11(g)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contribution</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(e)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contributor</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(e)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">control</span>&#8221; (including the terms &#8220;<span style="text-decoration:underline">controlled by</span>&#8221; and &#8220;<span style="text-decoration:underline">under common control with</span>&#8221;) means the possession, directly or indirectly, or as trustee or executor, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, as trustee or executor, by contract or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Copyleft License</span>&#8221; means any license that requires, as a condition of use, modification or distribution of Software or other technology subject to such license, that such Software or other technology subject to such license, or other Software or other technology incorporated into, derived from, used or distributed with such Software or other technology subject to such license (a)&#160;in the case of Software, be made available or distributed in a form other than binary (e.g., source code form), (b) be licensed for the purpose of preparing derivative </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
works, (c)&#160;be licensed under terms that allow the Company Products, other products or Software, or portions thereof or interfaces therefor to be reverse engineered, reverse assembled or disassembled (other than by operation of Law) or (d)&#160;be redistributable at no license fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">COVID-19</span></span>&#8221; shall mean <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> or <span style="white-space:nowrap">COVID-19,</span> and any evolutions or mutations thereof or related or associated epidemics, pandemic or disease outbreaks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">COVID-19</span> Measures</span>&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; workforce reduction, social distancing, shut down, closure, sequester, workplace safety or similar Law promulgated by any Governmental Authority, including the Centers for Disease Control and Prevention and the World Health Organization, in each case, in connection with or in response to <span style="white-space:nowrap">COVID-19,</span> including the CARES Act and Families First Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Data Security Requirements</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(i)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">DGCL</span>&#8221; shall mean the Delaware General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Disabling Devices</span>&#8221; means Software viruses, time bombs, logic bombs, trojan horses, trap doors, back doors, or other computer instructions, intentional devices or techniques that are designed to threaten, infect, assault, vandalize, defraud, disrupt, damage, disable, maliciously encumber, hack into, incapacitate, infiltrate or slow or shut down a computer system or any component of such computer system, including any such device affecting system security or compromising or disclosing user data in an unauthorized manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Domain Names</span>&#8221; means any and all Internet domain names and numerical addresses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Effective Time</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.05</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Environmental Laws</span>&#8221; means any United States federal, state or local or <span style="white-space:nowrap">non-United</span> States laws relating to: (a)&#160;releases or threatened releases of Hazardous Substances or materials containing Hazardous Substances; (b)&#160;the manufacture, handling, transport, use, treatment, storage, exposure to or disposal of Hazardous Substances or materials containing Hazardous Substances; or (c)&#160;pollution or protection of human health, safety, or the environment or natural resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Environmental Permit</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.19</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Equity Plan</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.06(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Exchange Act</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.27</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Excluded Company Shares</span>&#8221; means all shares of Company Common Stock issued or issuable at or as of the Effective Time pursuant to the PIPE Investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Execution Date</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">FDA Laws</span>&#8221; means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and its implementing regulations and guidance documents, the Public Health Service Act (42 U.S.C. &#167; 201 et seq.) and its implementing regulations and guidance documents, and any other applicable Law, including Laws that regulate the design, development, research, testing, studying, manufacturing, processing, storing, handling, importing or exporting, licensing, labeling, packaging, distributing, or marketing of drug products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Financial Statements</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.07(a)</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Foreign Exchange Rate</span>&#8221; means the exchange rate between Korean Won to U.S. Dollars determined on the date of the Effective Time as published in the exchange rate section of the Wall Street Journal, or, if not published in the Wall Street Journal, then the average of the opening bid and ask rates on such date at which such currency may be exchanged for U.S.&#160;Dollar as quoted by JPMorgan Chase Bank, NA (or any successor thereto or any other major money center commercial bank agreed to by the Parties). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">GAAP</span>&#8221; means United States generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Authority</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.05(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Licenses</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.16</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Hazardous Substance(s)</span>&#8221; means: (a)&#160;those substances defined in or regulated under the following United States federal statutes and their state counterparts, as each may be amended from time to time, and all regulations thereunder: the Hazardous Materials Transportation Act, the Resource Conservation and Recovery Act, the Comprehensive Environmental Response, Compensation and Liability Act, the Clean Water Act, the Safe Drinking Water Act, the Atomic Energy Act, the Federal Insecticide, Fungicide, and Rodenticide Act and the Clean Air Act; (b)&#160;petroleum and petroleum products, including crude oil and any fractions thereof; (c)&#160;natural gas, synthetic gas, and any mixtures thereof; (d)&#160;polychlorinated biphenyls, asbestos, <span style="white-space:nowrap">per-</span> and polyfluoroalkyl substances, and radon; and (e)&#160;any substance, material or waste regulated by any Governmental Authority pursuant to any Environmental Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Health Care Laws</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">HSR Act</span>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Inbound Licenses</span>&#8221; means all Contracts pursuant to which the Company or any Company Subsidiary has received a license or sublicense, or has otherwise been granted rights in, to, or under any Intellectual Property from any Person, or otherwise received from any Person any immunity, authorization, release, covenant not to sue or other right with respect to any Intellectual Property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Institutions</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(q)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Intellectual Property</span>&#8221; means: all intellectual property rights, anywhere in the world, whether statutory, common law or otherwise, including (a)&#160;Patents, (b) copyrights and all other rights with respect to works of authorship, (c)&#160;all other rights with respect to Software, including registrations thereof and applications therefor, (d)&#160;registered and unregistered design rights and registrations thereof and applications therefor, (e)&#160;rights with respect to Trademarks, and all registrations thereof and applications therefor, (f)&#160;rights with respect to Domain Names, including registrations thereof and applications therefor, (g)&#160;rights with respect to trade secrets or Confidential Information, including rights to limit the use or disclosure thereof by any Person, (h)&#160;rights with respect to databases, including registrations thereof and applications therefor, (i)&#160;publicity and privacy rights, including all rights with respect to use of a Person&#8217;s name, signature, likeness, image, photograph, voice, identity, personality, and biographical and personal information and materials, and (j)&#160;rights in Software and (k)&#160;any rights equivalent or similar to any of the foregoing. Without limiting the foregoing, &#8220;Intellectual Property&#8221; includes rights to derivatives, improvements, modifications, enhancements, revisions, and releases to any of the foregoing, claims and causes of action arising out of or related to infringement, misappropriation or violation of any of the foregoing and other proprietary or intellectual property rights now known or hereafter recognized in any jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">International Trade Laws</span>&#8221; means (i)&#160;all U.S. import and export Laws (including those Laws administered by the U.S. Departments of Commerce (Bureau of Industry and Security) codified at 15 C.F.R., Parts <span style="white-space:nowrap">700-774;</span> Homeland Security (Customs and Border Protection) codified at 19 C.F.R., Parts <span style="white-space:nowrap">1-192;</span> State </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Directorate of Defense Trade Controls) codified at 22 C.F.R., Parts 103, <span style="white-space:nowrap">120-130;</span> and the Treasury (Office of Foreign Assets Control) codified at 31 C.F.R., Parts <span style="white-space:nowrap">500-598)</span> and (ii)&#160;all comparable applicable Laws outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Initial Post-Closing BLAC Directors</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Joinders</span>&#8221; means, collectively, the Participating Stockholder Joinders and the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">knowledge</span>&#8221; or &#8220;<span style="font-weight:bold">to the knowledge</span>&#8221; of a person shall mean in the case of the Company, the actual knowledge of Kuk Hyoun Hwang, Sung Jae Yu, Soo Eun Nam, Sung Hoon Chung, and Dae Ho Kim after reasonable inquiry, and in the case of BLAC, the actual knowledge of Kuk Hyoun Hwang, Jun Whang and Tom Shin after reasonable inquiry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Korea IFRS</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Law</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.05(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">LBV</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Lease</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Lease Documents</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Leased Real Property</span>&#8221; means the real property leased by the Company or Company Subsidiaries as tenant, together with, to the extent leased by the Company or Company Subsidiaries, all buildings and other structures, facilities or improvements located thereon and all easements, licenses, rights and appurtenances of the Company or Company Subsidiaries relating to the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Lien</span>&#8221; means any lien, security interest, mortgage, pledge, adverse claim or other encumbrance of any kind that secures the payment or performance of an obligation (other than those created under applicable securities laws). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">LOI</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Material Contracts</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Mutually Nominated Directors</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder</span>&#8221; means the agreement of each <span style="white-space:nowrap">Non-Participating</span> Company Stockholder to become a party to this Agreement after the Execution Date and prior to Closing substantially in the form attached as <span style="text-decoration:underline">Exhibit B</span> hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">OFAC</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.21(b)(ii)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-Shelf</span></span> Software</span>&#8221; means Software, <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">software-as-a-service,</span></span></span> or other technology that is licensed on a <span style="white-space:nowrap">non-exclusive</span> basis under a &#8220;shrink-wrap&#8221; or &#8220;click-through&#8221; Contract or other Contract containing standard terms and Software, <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">software-as-a-service,</span></span></span> or other technology that is generally available through commercial distributors, in consumer retail stores or through online distribution sources on standard terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Open Source License</span>&#8221; means any license meeting the Open Source Definition (as promulgated by the Open Source Initiative), the Free Software Definition (as promulgated by the Free Software Foundation), any Creative Commons License, or any substantially similar license, including any license approved by the Open Source Initiative. For the avoidance of doubt, Open Source Licenses include Copyleft Licenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Open Source Materials</span>&#8221; means any Software or other Intellectual Property subject to an Open Source License. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Original Agreement</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Outbound Licenses</span>&#8221; means Contracts pursuant to which the Company or any Company Subsidiary has licensed or sublicensed or otherwise granted rights in, to, or under any Company-Owned IP to any Person, or granted to any Person any immunity, authorization, release, covenant not to sue or other right with respect to any Company-Owned IP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Outside Date</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Owned Real Property</span>&#8221; means the land owned by the Company or any of the Company Subsidiaries (collectively, the &#8220;<span style="text-decoration:underline">Land</span>&#8221;), together with all buildings and other structures, facilities, and other improvements located thereon (collectively, the &#8220;<span style="text-decoration:underline">Improvements</span>&#8221;); all right, title and interest of the Company or any Company Subsidiary, as applicable, if any, in and to any and all appurtenances, strips or gores, roads, easements, streets, alleys, drainage facilities and <span style="white-space:nowrap"><span style="white-space:nowrap">rights-of-way</span></span> bounding any of the Land; all utility capacity, utilities, water rights, licenses, permits, entitlements, and bonds, if any, and all other rights and benefits attributable to the Land; and all rights of ingress and egress thereto; all transferable consents, authorizations, variances or waivers, licenses, permits and approvals from any Governmental Authority in connection with the Land or the Improvements held by or granted to the Company or any Company Subsidiary, as applicable, any of their respective predecessors in title, and/or the agents thereof with respect to the Land or the Improvements; all right, title and interest of the Company or any Company Subsidiary, as applicable, in and to all site plans, surveys, soil and substratus studies, and engineering and architectural drawings, plans and specifications, in the possession or control of the Company or any Company Subsidiary, as applicable, relating to the Land or Improvements; all equipment and other personal property owned by the Company or any Company Subsidiary, as applicable, located on and/or exclusively used in connection with the operation of the Land or Improvements; and all written service and maintenance contracts and other written contracts, if any, relating to the Land or Improvements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Participating Stockholder Joinder</span>&#8221; means the agreement of each Participating Company Stockholder to become a party to this Agreement after the Execution Date and prior to Closing substantially in the form attached as <span style="text-decoration:underline">Exhibit A</span> hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Patents</span>&#8221; means any domestic or foreign patents, utility models and applications, drafts and disclosures relating thereto (and any patents or utility models that issue as a result of such applications, drafts and disclosures) and any reissues, divisions, divisionals, continuations, <span style="white-space:nowrap"><span style="white-space:nowrap">continuations-in-part,</span></span> provisionals, renewals, extensions, substitutions, reexaminations or invention registrations related to such patents, utility models and applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Liens</span>&#8221; means: (a)&#160;such imperfections of title, easements, encumbrances, Liens or restrictions that do not materially impair the current use of the Company&#8217;s or any Company Subsidiary&#8217;s assets that are subject thereto; (b)&#160;materialmen&#8217;s, mechanics&#8217;, carriers&#8217;, workmen&#8217;s, warehousemen&#8217;s, repairmen&#8217;s, landlord&#8217;s and other similar Liens arising in the ordinary course of business, or deposits to obtain the release of such Liens; (c)&#160;Liens for Taxes not yet due and payable, or being contested in good faith through appropriate proceedings and for which adequate reserves have been established in accordance with GAAP or the Accounting Standards, as applicable; (d)&#160;zoning, entitlement, conservation restriction and other land use and environmental regulations promulgated by Governmental Authorities; <span style="white-space:nowrap">(e)&#160;non-exclusive</span> licenses, sublicenses or other rights to Intellectual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Property owned by or licensed to the Company or the Company Subsidiaries granted to any licensee in the ordinary course of business; <span style="white-space:nowrap">(f)&#160;non-monetary</span> Liens, encumbrances and restrictions on real property (including easements, covenants, rights of way and similar restrictions of record) that do not materially interfere with the present uses of such real property; (g)&#160;Liens identified in the Financial Statements; and (h)&#160;Liens on leases, subleases, easements, licenses, rights of use, rights to access and rights of way arising from the provisions of such agreements or benefiting or created by any superior estate, right or interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Person</span>&#8221; means an individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (including, without limitation, a &#8220;person&#8221; as defined in Section&#160;13(d)(3) of the Exchange Act), trust, association or entity or government, political subdivision, agency or instrumentality of a government. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Personal Information</span>&#8221; means (a)&#160;information related to an identified or identifiable individual (e.g., name, address telephone number, email address, financial account number, health information, government-issued identifier); (b) any other data used or intended to be used or which allows one to identify, contact, or precisely locate an individual, device or household, including any internet protocol address or other persistent identifier; and (c)&#160;any other, similar information or data regulated by Privacy/Data Security Laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Per Share Consideration</span>&#8221; means, with respect to each share of Company Capital Stock held immediately prior to the Effective Time, the Aggregate Consideration divided by the Company Fully Diluted Share Amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">PIPE Investment</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">PIPE Subscription Agreements</span>&#8221; has the meaning set forth in the Recitals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Plans</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.10(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Privacy/Data Security Laws</span>&#8221; means all Laws, self-regulatory standards, third party system and platform requirements, and industry regulations governing (a)&#160;the receipt, collection, use, storage, processing, sharing, security, disclosure, transfer, sale, unauthorized access or modification, theft, loss, inaccessibility, breach, or transfer of Personal Information, Confidential Information, the Company&#8217;s Business Systems or Business Data and (b)&#160;unfair and deceptive practices, accessibility, advertising, communications (e.g., text messages, emails, calls), <span style="white-space:nowrap">PCI-DSS,</span> location tracking and marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Proceeding</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Products</span>&#8221; mean any products or services, developed, manufactured, performed, <span style="white-space:nowrap">out-licensed,</span> sold, distributed other otherwise made available by or on behalf of the Company or any Company Subsidiary, from which the Company or any Company Subsidiary has derived previously, is currently deriving or is scheduled to derive, revenue from the sale or provision thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Program Requirements</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(i)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Proxy Statement</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.01(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Redemption Rights</span>&#8221; means the redemption rights provided for in <span style="text-decoration:underline">Article Fifth</span> of the BLAC Certificate of Incorporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Registered Company IP</span>&#8221; means all of the registrations for Company-Owned IP with any Governmental Authority or Domain Name. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Regulatory Authorizations</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Remedies Exceptions</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.04</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Release</span>&#8221; means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, or migrating through, in, on, under, or into the indoor or ambient environment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Reports</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Representatives</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.04(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SEC</span>&#8221; means the U.S. Securities and Exchange Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Securities Act</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.07(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Share Exchange</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.01(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Software</span>&#8221; means (a)&#160;computer programs, firmware, software (whether in source code, object code or other form), models, algorithms, methodologies and implementations thereof; (b)&#160;development tools, descriptions and flow charts; (c)&#160;data, metadata, databases and compilations of data, whether machine readable or otherwise; and (d)&#160;programmers&#8217; annotations, notes, documentation, product user manuals, training materials and other work product used to design, plan, organize, maintain, support or develop any of the foregoing, irrespective of the media on which it is recorded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Standards Organizations</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.13(u)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">subsidiary</span>&#8221; or &#8220;<span style="font-weight:bold">subsidiaries</span>&#8221; of the Company or BLAC or any other person means an affiliate controlled by such person, directly or indirectly, through one or more intermediaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Supplier</span>&#8221; means any person that supplies inventory or other materials or personal property, components, or other goods or services that are utilized in or comprise the Products of the Company or any of the Company Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(q)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax Returns</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(q)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Terminating BLAC Breach</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(f)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Terminating Company Breach</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(e)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Trademarks</span>&#8221; means unregistered and registered trademarks and service marks, trademark and service mark applications, common law trademarks and service marks, trade dress and logos, trade names, business names, corporate names, product names and other source or business identifiers and the goodwill associated with any of the foregoing and any renewals and extensions of any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Transaction Documents</span>&#8221; means this Agreement, including all Schedules and Exhibits hereto, the Joinders, the Company Disclosure Schedule, the Ancillary Agreements, and all other agreements, certificates and instruments executed and delivered by BLAC, the Company or the Company Stockholders in connection with the Transactions and specifically contemplated by this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Transactions</span>&#8221; means the transactions contemplated by this Agreement and the Transaction Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Treasury Regulations</span>&#8221; means the United States Treasury regulations issued pursuant to the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Trust Account</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.12</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Trust Agreement</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.12</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Trustee</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.12</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Trust Fund</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.12</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">WARN Act</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.11(c)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Written Consent</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.03</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_3">1.02 <span style="text-decoration:underline">Construction.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Unless the context of this Agreement otherwise requires, (i)&#160;words of any gender include each other gender, (ii)&#160;words using the singular or plural number also include the plural or singular number, respectively, (iii)&#160;the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereto&#8221; and derivative or similar words refer to this entire Agreement, (iv)&#160;the terms &#8220;Article,&#8221; &#8220;Section,&#8221; &#8220;Schedule&#8221; and &#8220;Exhibit&#8221; refer to the specified Article, Section, Schedule or Exhibit of or to this Agreement, (v)&#160;the word &#8220;including&#8221; means &#8220;including without limitation,&#8221; (vi) the word &#8220;or&#8221; shall be disjunctive but not exclusive, (vii)&#160;references to agreements and other documents shall be deemed to include all subsequent amendments and other modifications thereto, and (viii)&#160;references to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent and no rule of strict construction shall be applied against any Party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified. If any action is to be taken or given on or by a particular calendar day, and such calendar day is not a Business Day, then such action may be deferred until the next Business Day. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All accounting terms used herein and not expressly defined herein shall have the meanings given to them under GAAP. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_4">ARTICLE II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE BUSINESS COMBINATION; CLOSING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_5">2.01 <span style="text-decoration:underline">Share </span><span style="text-decoration:underline">Exchange</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon the terms and subject to the conditions of this Agreement, at the Closing (as defined below), (i) BLAC shall issue the Aggregate Participating Consideration to the Participating Company Stockholders, and (ii)&#160;the Participating Company Stockholders shall sell, transfer, convey, assign and deliver all of their respective shares of Company Common Stock to BLAC (subclauses (i)&#160;and (ii), collectively, the &#8220;<span style="font-weight:bold">Share Exchange</span>&#8221;). Pursuant to such Share Exchange, each share of Company Common Stock held by the Participating Company Stockholders immediately prior to the Effective Time shall be exchanged for the Per Share Consideration. Based on the Company&#8217;s representations in Section&#160;3.03, the Per Share Consideration would be $129.62 as of the Amendment Date. Such amount is subject to adjustment in the event the Company Fully Diluted Share Amount changes prior to Closing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fractional share of BLAC Common Stock that would otherwise be issuable to a Participating Company Stockholder following such exchange shall be rounded up or down to the nearest whole share of BLAC Common Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Upon consummation of the Share Exchange, BLAC will hold at least 60% of the Company Fully Diluted Share Amount. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_6">2.02 <span style="text-decoration:underline">Delivery of Shares</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, the Participating Company Stockholders shall transfer and convey all of the shares of Company Common Stock held by the Participating Company Stockholders to BLAC, in each case, free and clear of any claims or interest of any person previously entitled thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, BLAC shall effect the transfer and conveyance of all of the shares of BLAC Common Stock representing the Aggregate Participating Consideration to the Participating Company Stockholders, in each case, free and clear of any claims or interest of any person previously entitled thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Per Share Consideration payable upon conveyance of the Company Common Stock held by the Participating Company Stockholders in accordance with the terms hereof shall be deemed to have been paid and issued in full satisfaction of all rights pertaining to such Company Common Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) BLAC shall not be liable to any stockholders of the Company for any such Company Common Stock (or dividends or distributions with respect thereto) or cash delivered to a public official pursuant to any abandoned property, escheat or similar Law in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.02</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact in form and substance, including an indemnity, acceptable to BLAC, by the person claiming such Certificate to be lost, stolen or destroyed, BLAC will issue in exchange for such lost, stolen or destroyed Certificate, the Per Share Consideration that such holder is otherwise entitled to receive pursuant to, and in accordance with, the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.01</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_7">2.03 <span style="text-decoration:underline">Treatment of Company Capital Stock held by <span style="white-space:nowrap">Non-Participating</span> Company Stockholders</span>. All Company Capital Stock held by each <span style="white-space:nowrap">Non-Participating</span> Company Stockholder as of Closing will not be exchanged for shares of BLAC Common Stock at Closing, and such Company Capital Stock will be subject to the terms of the <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder between such <span style="white-space:nowrap">Non-Participating</span> Company Stockholder and BLAC, including the Put Right and Call Right set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_8">2.04 <span style="text-decoration:underline">Withholding</span>. Each of BLAC and the Company, and their respective affiliates and agents shall be entitled to deduct and withhold from any amounts otherwise deliverable or payable under this Agreement such amounts that any such Persons are required to deduct and withhold with respect to any of the deliveries and payments contemplated by this Agreement under the Code or any other applicable Law (as defined herein). To the extent that BLAC or the Company, or their respective Affiliates withholds or deducts such amounts with respect to any Person and properly remits such withheld or deducted amounts to the applicable Governmental Authority (as defined herein), such withheld or deducted amounts shall be treated as having been paid to or on behalf of such Person in respect of which such withholding or deduction was made for all purposes. In the case of any such payment payable to employees of the Company or its affiliates in connection with the Business Combination treated as compensation, the Parties shall cooperate to pay such amounts through the Company&#8217;s or an affiliate&#8217;s payroll to facilitate applicable withholding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_9">2.05 <span style="text-decoration:underline">Closing</span>. In accordance with (i)&#160;the terms and subject to the conditions of this Agreement, and (ii)&#160;the consummation of the PIPE Investment, the closing of the Share Exchange (the &#8220;<span style="font-weight:bold">Closing</span>&#8221;) shall take place by electronic delivery of documents (by PDF (portable document format) and/or electronic mail), all of which will be deemed to be originals, at a time to be agreed by the Parties on the first date on which all conditions set forth in Article VIII shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver thereof) or such other time and place as the Parties may mutually agree in writing. The date on which the Closing actually occurs is referred to in this Agreement as the &#8220;<span style="font-weight:bold">Closing Date</span>&#8221; and the time on which the Closing actually occurs is referred to in this Agreement as the &#8220;<span style="font-weight:bold">Effective Time</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_10">2.06 <span style="text-decoration:underline">Closing Deliverables</span>. Upon the terms and subject to the conditions of this Agreement: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Closing, BLAC will deliver or cause to be delivered: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to the Company on behalf of the Participating Company Stockholders, a certificate duly signed by an authorized officer of BLAC, dated the Closing Date, certifying that, to the knowledge and belief of such officer, the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(d)</span> have been fulfilled; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to each Participating Company Stockholder, such number of shares of BLAC Common Shares equivalent to the Per Share Consideration payable to such Participating Company Stockholder; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to the Company, the written resignations of all of the directors and officers of BLAC (other than those Persons identified as the initial directors and officers, respectively, of BLAC, after the Closing, in accordance with the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08</span>), effective as of, and subject to, the Closing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) to the Company on behalf of the Participating Company Stockholders, copies of the BLAC Amended and Restated Organizational Documents in the forms as may be mutually agreed in writing between BLAC and the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) all other documents, instruments or certificates as shall reasonably be required by the Company and its counsel in order to consummate the Transactions, including, without limitation, such of the foregoing required for purposes of the Korea Foreign Exchange Transaction Act, or any other relevant Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Closing, the Company will deliver or cause to be delivered to BLAC: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Joinders, duly executed by each of the Company Stockholders; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a certificate of <span style="white-space:nowrap">non-issuance</span> of share certificates and approval of transfer of shares, accounting for all the issued and outstanding shares of Company Common Stock held by the Participating Company Stockholders to be transferred to BLAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an updated Company shareholder registry reflecting the transactions performed under the Share Exchange; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a certificate duly signed by an authorized officer of the Company, dated the Closing Date, certifying that, to the knowledge and belief of such officer, the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(d)</span> have been fulfilled; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the <span style="white-space:nowrap">Lock-Up</span> Agreements duly executed by certain of the Participating Company Stockholders; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) all other documents, instruments or certificates as shall reasonably be required by BLAC and its counsel in order to consummate the Transactions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) On the Closing date, concurrently with the Share Exchange, BLAC shall make, or cause to be made, any payments to the stockholders of BLAC required to be made in connection with the Redemption Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_11">2.07 <span style="text-decoration:underline">Certificate of Incorporation; Bylaws</span>. At the Closing, BLAC shall amend and restate, effective as of the Effective Time, the BLAC Certificate of Incorporation, which, shall among other things, result in BLAC being renamed as OSR Biosciences Inc. and shall trade publicly on the NASDAQ under a new ticker symbol mutually agreed upon by BLAC and the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_12">2.08 <span style="text-decoration:underline">Directors and Officers</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each of the Parties hereto shall take all such action within its power as may be necessary or appropriate such that, effective as of the Closing, (i)&#160;the BLAC Board shall consist of up to 9 directors; (ii)&#160;the initial members of the BLAC Board are the individuals determined in accordance with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(c)</span>, as applicable; (iii)&#160;the initial members of the compensation committee, audit committee and nominating and corporate governance committee of the BLAC Board are the individuals determined in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(d)</span>; and (iv)&#160;the officers of BLAC and the Company are the individuals determined in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08(e)</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) BLAC shall provide to the Company a list of up to 3 individuals who shall serve as directors on the BLAC Board effective as of the Closing (the &#8220;<span style="font-weight:bold">BLAC Directors</span>&#8221;). BLAC may, with the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed), replace any such individual with any other individual prior to the filing of the Proxy Statement with the SEC by amending such list to include such replacement individual. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall provide to BLAC a list of up to 6 individuals who shall serve as directors on the BLAC Board effective as of the Closing (the &#8220;<span style="font-weight:bold">Company Directors</span>&#8221;). The Company may, with the prior written consent of BLAC (such consent not to be unreasonably withheld, conditioned or delayed), replace any such individual with any other individual prior to the filing of the Proxy Statement with the SEC by amending such list to include such replacement individual. The BLAC Directors and the Company Directors are referred to collectively herein as the &#8220;<span style="font-weight:bold">Initial Post-Closing BLAC Directors</span>.&#8221; Notwithstanding the foregoing, a majority of the individuals designated to serve as the Initial Post-Closing Directors must be &#8220;independent directors&#8221; under The Nasdaq Capital Market Listing Rules and regulations applicable to service on committees of the BLAC Board, and if the requirement set forth in this sentence is not met, BLAC shall omit from its proxy materials any such nominee, and any such nomination shall be disregarded and no vote on any such nominee will occur, notwithstanding that proxies in respect of such vote may have been received by BLAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) BLAC and the Company shall mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either BLAC or the Company) on any director or directors to initially serve on the BLAC Board effective as of the Closing who are not designated pursuant to the provisions of paragraph (b)&#160;or (c) of this Section&#160;2.08 and the directors to be appointed to serve on the compensation committee, audit committee and nominating and corporate governance committee of the BLAC Board effective as of the Closing prior to the filing of the definitive Proxy Statement with the SEC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) BLAC and the Company shall mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either BLAC or the Company) on the officers of BLAC and the Company effective immediately after the Closing, with each such individual holding the title set forth opposite his or her name. BLAC and the Company may mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or BLAC) to replace any such individual with any other individual prior to the filing of the definitive Proxy Statement with the SEC by amending such Schedule to include such replacement individual. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_13">ARTICLE III </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the Company&#8217;s disclosure schedule delivered by the Company in connection with this Agreement (the &#8220;<span style="font-weight:bold">Company Disclosure Schedule</span>&#8221;), the Company hereby represents and warrants to BLAC as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_14">3.01 <span style="text-decoration:underline">Organization and Qualification; Subsidiaries</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and each subsidiary of the Company (each a &#8220;<span style="font-weight:bold">Company Subsidiary</span>&#8221;), is a corporation or other organization duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and has the requisite corporate or other organizational power and authority and all necessary governmental approvals to own, lease and operate its properties and to carry on its business as it is now being conducted. The Company and each Company Subsidiary is duly qualified </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or licensed as a foreign corporation or other organization to do business, and is in good standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its business makes such qualification or licensing necessary, except for such failures to be so qualified or licensed and in good standing that do not constitute a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) A true and complete list of all the Company Subsidiaries, together with the jurisdiction of incorporation of each Company Subsidiary and the percentage of the outstanding capital stock of each Company Subsidiary owned by the Company and each other Company Subsidiary, is set forth in <span style="text-decoration:underline">Schedule 3.01(b)</span> of the Company Disclosure Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_15">3.02 <span style="text-decoration:underline">Articles of Incorporation</span>. The Company has prior to the Execution Date made available a complete and correct copy of the articles of incorporation or equivalent organizational documents, each as amended to date, of the Company and each Company Subsidiary. Such articles of incorporation or equivalent organizational documents are in full force and effect. Neither the Company nor any Company Subsidiary is in violation of any of the provisions of its articles of incorporation or equivalent organizational documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_16">3.03 <span style="text-decoration:underline">Capitalization.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company consists of 4,000,000 shares of Company Common Stock. As of the Amendment Date, (i) 1,887,070 shares of Company Common Stock are issued and outstanding and (ii)&#160;the Company Fully Diluted Share Amount is 1,887,070. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) There are no options, restricted shares, restricted share units, phantom equity awards, warrants, preemptive rights, calls, convertible securities, conversion rights or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued capital stock of the Company or any Company Subsidiary or obligating the Company or any Company Subsidiary to issue or sell any shares of capital stock of, or other equity interests in, the Company or any Company Subsidiary. Neither the Company nor any Company Subsidiary is a party to, or otherwise bound by, and neither the Company nor any Company Subsidiary has granted, any equity appreciation rights, participations, phantom equity or similar rights. There are no voting trusts, voting agreements, proxies, shareholder agreements or other agreements with respect to the voting or transfer of the Company Common Stock, Company preferred stock or any of the equity interests or other securities of the Company or any of the Company Subsidiaries. Except as set forth in <span style="text-decoration:underline">Schedule 3.03(b)</span> of the Company Disclosure Schedule, the Company does not directly or indirectly own any equity or similar interests in, or any interest convertible into or exchangeable or exercisable for any equity or similar interest in, any Person, other than the Company Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no outstanding contractual obligations of the Company or any Company Subsidiary to repurchase, redeem or otherwise acquire any shares of the Company or any capital stock of any Company Subsidiary or to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise) in any person other than a Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All outstanding shares of the Company and all outstanding shares of capital stock of each Company Subsidiary have been issued and granted in compliance with (A)&#160;all applicable securities laws and other applicable laws and (B)&#160;all <span style="white-space:nowrap">pre-emptive</span> rights and other requirements set forth in applicable contracts to which the Company or any Company Subsidiary is a party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each outstanding share of capital stock of each Company Subsidiary is duly authorized, validly issued, fully paid and nonassessable, and each such share is owned by the Company or another Company Subsidiary free and clear of all Liens, options, rights of first refusal and limitations on the Company&#8217;s or any Company Subsidiary&#8217;s voting rights, other than transfer restrictions under applicable securities laws and their respective organizational documents. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The stockholders of the Company collectively own directly and beneficially and of record, all of the equity of the Company (which are represented by the issued and outstanding shares of the Company). Except for the shares of the Company held by the stockholders of the Company, no shares or other equity or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
voting interest of the Company, or options, warrants or other rights to acquire any such shares or other equity or voting interest of the Company, is authorized or issued and outstanding. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All outstanding shares of Company Common Stock and all outstanding shares of capital stock or other equity securities (as applicable) of each Company Subsidiary have been issued and granted in compliance with (A)&#160;applicable securities laws and other applicable laws and (B)&#160;any <span style="white-space:nowrap">pre-emptive</span> rights and other similar requirements set forth in applicable contracts to which the Company or any Company Subsidiary is a party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_17">3.04 <span style="text-decoration:underline">Authority Relative to this Agreement</span>. The Company has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the Transactions. The execution and delivery of this Agreement by the Company and the consummation by the Company of the Transactions have been duly and validly authorized by all necessary corporate action, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement or to consummate the Transactions. This Agreement has been duly and validly executed and delivered by the Company and, assuming the due authorization, execution and delivery by BLAC, constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, by general equitable principles (the &#8220;<span style="font-weight:bold">Remedies Exceptions</span>&#8221;). The Company Board has approved this Agreement and the Transactions, and such approvals are sufficient so that the restrictions on business combinations set forth in Section&#160;203 of the DGCL shall not apply to the Business Combination, this Agreement, any Ancillary Agreement or any of the other Transactions. To the knowledge of the Company, no other state takeover statute is applicable to the Business Combination or the other Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_18">3.05 <span style="text-decoration:underline">No Conflict; Required Filings and Consents.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement by the Company does not, and subject to receipt of the consents, approvals, authorizations or permits, filings and notifications contemplated by <span style="text-decoration:underline">Schedule 3.05(a)</span> of the Company Disclosure Schedule, the performance of this Agreement by the Company will not (i)&#160;conflict with or violate the certificate of incorporation or bylaws or any equivalent organizational documents of the Company or any Company Subsidiary, (ii)&#160;conflict with or violate any statute, law, ordinance, regulation, rule, code, executive order, injunction, judgment, decree or other order, in each case, of any Governmental Authority (&#8220;<span style="font-weight:bold">Law</span>&#8221;) applicable to the Company or any Company Subsidiary or by which any property or asset of the Company or any Company Subsidiary is bound or affected, or (iii)&#160;result in any breach of or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien (other than any Permitted Lien) on any material property or asset of the Company or any Company Subsidiary pursuant to, any Material Contract, except, with respect to clauses (ii)&#160;and (iii), for any such conflicts, violations, breaches, defaults or other occurrences which do not constitute a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company will not, require any consent, approval, authorization or permit of, or filing with or notification to, any United States federal, state, county or local or <span style="white-space:nowrap">non-United</span> States government, governmental or quasi-governmental, regulatory or administrative authority or office, any political or other subdivision thereof, agency, instrumentality, bureau, authority, body or commission or any court, tribunal, or judicial or arbitral body (a &#8220;<span style="font-weight:bold">Governmental Authority</span>&#8221;), except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, does not constitute a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_19">3.06 <span style="text-decoration:underline">Permits; Compliance</span>. Each of the Company and the Company Subsidiaries is in possession of all material franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, certificates, approvals and orders of any Governmental Authority necessary for each of the Company or the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company Subsidiaries to own, lease and operate its properties or to carry on its business as it is now being conducted (the &#8220;<span style="font-weight:bold">Company Permits</span>&#8221;), except where the failure to have such Company Permits would not reasonably be expected to have a Company Material Adverse Effect. No suspension or cancellation of any of the Company Permits is pending or, to the knowledge of the Company, threatened in writing. Neither the Company nor any Company Subsidiary is in conflict with, or in default, breach or violation of, (a)&#160;any Law, including FDA Laws, applicable to the Company or any Company Subsidiary or by which any property or asset of the Company or any Company Subsidiary is bound or affected, or (b)&#160;any Material Contract or Company Permit, except, in each case, for any such conflicts, defaults, breaches or violations that do not constitute a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_20">3.07 <span style="text-decoration:underline">Financial Statements.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to BLAC true and complete copies of (i)&#160;the unaudited consolidated balance sheets and the related unaudited consolidated statements of operations and cash flows of the Company and the Company Subsidiaries in respect of the Company Business for the three months ended March&#160;31, 2024, and (ii)&#160;the audited consolidated balance sheets and the related unaudited consolidated statements of operations and cash flows of the Company and the Company Subsidiaries in respect of the Company Business for the years ended December&#160;31, 2021, 2022 and 2023 ((i) and (ii)&#160;collectively, the &#8220;<span style="font-weight:bold">Financial Statements</span>&#8221;), which are attached as <span style="text-decoration:underline">Schedule 3.07(a)</span> of the Company Disclosure Schedule. Each of the Financial Statements (including the notes thereto)&#160;(i) was prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (the &#8220;<span style="font-weight:bold">Accounting Standards</span>&#8221;) applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto) and (ii)&#160;fairly presents, in all material respects, the financial position, results of operations and cash flows of the Company and the Company Subsidiaries in respect of the Company Business as at the date thereof and for the period indicated therein, except as otherwise noted therein and subject to the absence of notes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as and to the extent set forth on the Financial Statements, neither the Company nor any Company Subsidiary has any liability or obligation of a nature (whether accrued, absolute, contingent or otherwise) required to be reflected on a balance sheet prepared in accordance with the Accounting Standards except for: (i)&#160;liabilities that were incurred in the ordinary course of business since the date of the consolidated balance sheet for the year ended December 2023 set forth above (the &#8220;<span style="font-weight:bold">2023 Balance Sheet</span>&#8221;, (ii) obligations for future performance under any contract to which the Company or any Company Subsidiary is a party, or (iii)&#160;liabilities and obligations which are not, individually or in the aggregate, expected to result in a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Since January&#160;1, 2024, (i) neither the Company nor any Company Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, employee, auditor, accountant or Representative of the Company or any Company Subsidiary, has received or otherwise had or obtained knowledge of any complaint, allegation, assertion or claim, whether written or, to the knowledge of the Company, oral, regarding the accounting or auditing practices, procedures, methodologies or methods of the Company or any Company Subsidiary or their respective internal accounting controls, including any such complaint, allegation, assertion or claim that the Company or any Company Subsidiary has engaged in questionable accounting or auditing practices and (ii)&#160;there have been no internal investigations regarding accounting or revenue recognition discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, general counsel, the Company Board or any committee thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of the Company, no employee of the Company or any Company Subsidiary has provided or is providing information to any law enforcement agency regarding the commission or possible commission of any crime or the violation or possible violation of any applicable Law. None of the Company, any Company Subsidiary or, to the knowledge of the Company any officer, employee, contractor, subcontractor or agent of the Company or any such Company Subsidiary has discharged, demoted, suspended, threatened, harassed or in any other manner discriminated against an employee of the Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or any Company Subsidiary in the terms and conditions of employment because of any act of such employee described in 18 U.S.C. Sec. 1514A(a). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All accounts receivable of the Company and the Company Subsidiaries reflected on the Financial Statements or arising after the date of the 2023 Balance Sheet have arisen from bona fide transactions in the ordinary course of business consistent with past practices and in accordance with the Accounting Standards and are collectible, subject to bad debts reserved in the Financial Statements. To the knowledge of the Company, such accounts receivable are not subject to valid defenses, setoffs or counterclaims, other than routine credits granted for errors in ordering, shipping, pricing, discounts, rebates, returns in the ordinary course of business and other similar matters. The Company&#8217;s reserve for contractual allowances and doubtful accounts is adequate in all material respects and has been calculated in a manner consistent with past practices. Since December&#160;31, 2023, neither the Company nor any of the Company Subsidiaries has modified or changed in any material respect its sales practices or methods including, without limitation, such practices or methods in accordance with which the Company or any of the Company Subsidiaries record revenue. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) All accounts payable of the Company and the Company Subsidiaries reflected on the Financial Statements or arising after the date of the 2023 Balance Sheet are the result of bona fide transactions in the ordinary course of business and have been paid or are not yet due or payable. Since December&#160;31, 2023, the Company and the Company Subsidiaries have not altered in any material respects their practices for the payment of such accounts payable, including the timing of such payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_21">3.08 <span style="text-decoration:underline">Absence of Certain Changes or Events</span>. Since December&#160;31, 2023, and prior to the Amendment Date, except as otherwise reflected in the Financial Statements, or as expressly contemplated by this Agreement, (a)&#160;the Company and the Company Subsidiaries have conducted their respective businesses in all material respects in the ordinary course and in a manner consistent with past practice, (b)&#160;the Company and the Company Subsidiaries have not sold, assigned or otherwise transferred any right, title, or interest in or to any of their material assets (including Intellectual Property and Business Systems) other than <span style="white-space:nowrap">non-exclusive</span> licenses or assignments or transfers in the ordinary course of business, (c)&#160;there has not been any Company Material Adverse Effect, and (d)&#160;none of the Company or any Company Subsidiary has taken any action that, if taken after the Amendment Date, would constitute a material breach of any of the covenants set forth in Section&#160;6.01. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_22">3.09 <span style="text-decoration:underline">Absence of Litigation</span>. There is no material litigation, suit, claim, action, proceeding, audit or investigation by or before any Governmental Authority (an &#8220;<span style="font-weight:bold">Action</span>&#8221;) pending or, to the knowledge of the Company, threatened against the Company or any Company Subsidiary, or any directors, officers or employees thereof, or any property or asset of the Company or any Company Subsidiary before any Governmental Authority. Neither the Company nor any Company Subsidiary nor any material property or asset of the Company or any Company Subsidiary is, subject to any continuing order of, consent decree, settlement agreement or other similar written agreement with, or, to the knowledge of the Company, continuing investigation by, any Governmental Authority, or any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_23">3.10 <span style="text-decoration:underline">Employee Benefit Plans.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Schedule 3.10(a)</span> of the Company Disclosure Schedule sets forth a true and complete list of all bonus, stock option, stock purchase, restricted stock, equity or equity-based, incentive, deferred compensation, retiree medical or life insurance, retirement, supplemental retirement, severance, retention, separation, change in control, health, welfare, fringe benefit, sick pay and vacation plans or arrangements or other material employee benefit plans, programs, ex gratia promises, policies, agreements or arrangements, whether formal or informal, in each case which are maintained, sponsored by, or contributed to by (or for which there is an obligation to contribution to by) the Company or any Company Subsidiary for the benefit of any current or former employee, officer, director, individual independent contractor and/or consultant, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with respect to which the Company or any Company Subsidiary has or could incur any present or future liability (contingent or otherwise) (collectively, the &#8220;<span style="font-weight:bold">Plans</span>&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to each Plan, the Company has made available to BLAC, if applicable, a list of all relevant Plans together with (i)&#160;a true and complete copy of the current plan document and all amendments thereto and each trust or other funding arrangement, and (ii)&#160;any material <span style="white-space:nowrap">non-routine</span> correspondence from any Governmental Authority with respect to any Plan within the past three (3)&#160;years. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Neither the execution and delivery of this Agreement nor the other Ancillary Agreements nor the consummation of the Transactions will or could reasonably be expected to (alone or in combination with any other event)&#160;(i) result in (A)&#160;an increase in the amount of compensation or benefits to or in respect of any current or former employee, officer, director, individual independent contractor or consultant; (B)&#160;any payment or benefit becoming due to or in respect of any current or former employee, officer, director, individual independent contractor or consultant; (C)&#160;the acceleration of the vesting, funding or timing of payment of any compensation or benefits payable to or in respect of any current or former employee, officer, director, individual independent contractor or consultant; or (D)&#160;any increased or accelerated funding obligation with respect to any Plan; or (ii)&#160;limit the right to merge, amend or terminate any Plan. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) None of the Plans provide for, nor does the Company nor any Company Subsidiary have or reasonably expect to have any liability or obligation to provide any post-employment or post-service health or welfare benefits or retiree medical or life insurance to any current or former employee, officer, director, individual independent contractor or consultant of the Company or any Company Subsidiary after termination of employment or service except (i)&#160;as set forth in any existing employment or severance agreement or (ii)&#160;as may be required under applicable Law for which the covered individual pays the full cost of coverage. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In all material respects, (i)&#160;each Plan has been established, maintained and administered in accordance with its terms and in compliance with the requirements of all applicable Laws and (ii)&#160;other than routine claims for benefits in the ordinary course of business, no actions, litigation, claims, lawsuits, audits, inquiries, arbitrations, investigations, or proceedings are pending or, to the knowledge of Company, threatened, from any Governmental Authority in connection with any Plan or by or on behalf of any participant in any Plan, or otherwise involving or relating to any Plan or the assets of any Plan or any trust thereunder or the plan sponsor or plan administrator of any Plan (acting in such individual&#8217;s capacity as plan sponsor or plan administrator) and, to the knowledge of the Company, no facts or circumstances exist that could reasonably be expected to give rise to any such action, litigation, claim, lawsuit, audit, inquiry, arbitration, investigation or proceeding. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as would not result in material liability to the Company and the Company Subsidiaries, taken as a whole, either individually or in the aggregate, there have been no acts or omissions by the Company or Company Subsidiary with respect to any Plan that have given or could reasonably be expected to give rise to any fines, penalties or related charges under applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All material liabilities or expenses of the Company or any Company Subsidiary in respect of any Plan which have not been paid have been properly accrued on the Company&#8217;s or any Company Subsidiary&#8217;s most recent financial statements in compliance with the Accounting Standards. With respect to each Plan, all material contributions or payments (including all employer contributions, employee salary reduction contributions, and premium or benefit payments) that are due or are required to be made under the terms of any Plan or in accordance with applicable Laws have been made within the time periods prescribed by the terms of each such Plan and applicable Laws, as the case may be, except as would not result in material liability to the Company, and all such contributions or payments that are not yet due or required to be made under the terms of any Plan or in accordance with applicable Laws have been properly accrued in accordance with the Accounting Standards, applied on a consistent basis, and reflected on the Company&#8217;s or any Company Subsidiary&#8217;s audited financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_24">3.11 <span style="text-decoration:underline">Labor and Employment Matters.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Schedule 3.11(a)</span> of the Company Disclosure Schedule sets forth a true, correct and complete list of all employees of the Company and any Company Subsidiary as of the Execution Date, including any employee who is on a leave of absence of any nature, authorized or unauthorized, and sets forth for each such individual the following: (i)&#160;title or position (including whether full or part time); and (ii)&#160;location and employing entity. All employees of the Company and the Company Subsidiaries are employed at will. Except as set forth on <span style="text-decoration:underline">Schedule 3.11(a)</span> of the Company Disclosure Schedule, as of the Execution Date, all compensation, including wages, commissions and bonuses and any termination indemnities, due and payable to all current and former employees of the Company and any Company Subsidiary for services performed on or prior to the Execution Date have been paid in full (or accrued in full in the Company&#8217;s financial statements). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) There are no Actions pending or, to the knowledge of the Company, threatened against the Company or any Company Subsidiary by any of their respective current or former employees or other service providers, which Actions would be material to the Company and the Company Subsidiaries, taken as a whole; (ii)&#160;neither the Company nor any Company Subsidiary is, nor have been for the past five (5)&#160;years, a party to, bound by, or negotiating any collective bargaining agreement or other contract with a union, works council or labor organization applicable to persons employed by the Company or any Company Subsidiary, nor, to the knowledge of the Company, are there any activities or proceedings of any labor union to organize any such employees; (iii)&#160;there are no unfair labor practice complaints threatened or pending against the Company or any Company Subsidiary before the National Labor Relations Board or similar state or foreign labor relations agency; and (iv)&#160;there has never been, nor, to the knowledge of the Company, has there ever been any threat of any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute with respect to the Company or any Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company and the Company Subsidiaries are and have been in compliance in all respects with all applicable Laws and contracts relating to the employment, employment practices, employment discrimination, harassment and retaliation, terms and conditions of employment, termination and discharge, mass layoffs and plant closings (including the Worker Adjustment and Retraining Notification Act of 1988, as amended, and any similar state, local or foreign Law (collectively, the &#8220;<span style="font-weight:bold">WARN Act</span>&#8221;), or any similar state or local Laws), reasonable accommodation, disability rights or benefits, immigration, hiring, meal and rest breaks, overtime, payroll documents and wage statements, pay equity, affirmative action obligations, workers&#8217; compensation, family and medical leave, sick leave, occupational safety and health requirements (including any federal, state or local Laws and orders by Governmental Entities related to <span style="white-space:nowrap">COVID-19),</span> and all Laws related to wages, hours, collective bargaining and the payment and withholding of taxes and other sums and social contributions as required by the appropriate Governmental Authority and are not liable for any arrears of wages, taxes, social contributions, penalties or other sums for failure to comply with any of the foregoing. The Company and each of its Company Subsidiaries are in compliance with the requirements of the Immigration Reform Control Act of 1986. All current and former employees of the Company and the Company Subsidiaries, as applicable, have at all times been properly classified as exempt or <span style="white-space:nowrap">non-exempt</span> under the Fair Labor Standards Act and applicable state wage and hour Laws. All current and former independent contractors and temporary workers of the Company or the Company Subsidiaries, as applicable, have been properly classified. There have been no misclassification claims filed or threatened against the Company or any Company Subsidiary by any current or former employees, independent contractors or temporary workers or by any Governmental Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) (i) The Company and each Company Subsidiary have complied and are in compliance in all material respects with, have not materially violated, and are not in material violation of, and have not received any notices of material <span style="white-space:nowrap">non-compliance</span> or violation or alleged material <span style="white-space:nowrap">non-compliance</span> or violation with respect to, any Law relating or pertaining to <span style="white-space:nowrap">COVID-19;</span> and (ii)&#160;the Company and each Company Subsidiary have taken reasonable steps to minimize potential workplace exposure in light of <span style="white-space:nowrap">COVID-19,</span> and the Company has delivered to BLAC accurate and complete copies of all (1)&#160;workplace </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
communications from the Company and any Company Subsidiary to employees regarding actions or changes in workplace schedules, employee travel, remote work practices, onsite meetings, or other changes that have been implemented in response to <span style="white-space:nowrap">COVID-19;</span> (2) contingency plans for workplace cessation in light of <span style="white-space:nowrap">COVID-19;</span> and (3)&#160;policies implemented in relation to <span style="white-space:nowrap">COVID-19.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There has been and will be no layoff, plant closing, termination, redundancy or any other forms of employment losses in the <span style="white-space:nowrap">six-month</span> period prior to the Closing that would trigger the obligations of the Company or any Company Subsidiary under the WARN Act or similar Laws applicable to the Company or any Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) In the past five (5)&#160;years, there have been no allegations of sexual harassment or misconduct involving any current or former director, officer, employee or independent contractor of the Company or any Company Subsidiary, and neither the Company nor any Company Subsidiary has entered into any settlement agreements related to allegations of sexual harassment or sexual misconduct by any current or former director, officer, employee or independent contractor of the Company or any Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Section 3.11(g)</span> of the Company Disclosure Schedule sets forth, as of the Execution Date, a true, correct and complete list of all of the independent contractors, consultants, temporary employees, and leased employees employed or used by the Company or any Company Subsidiary and classified by the Company or any Company Subsidiary as other than employees, or compensated other than through wages paid by the Company or any subsidiary through such entity&#8217;s payroll department (each, a &#8220;<span style="font-weight:bold">Contingent Worker</span>&#8221;) of the Company and each Company Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_25">3.12 <span style="text-decoration:underline">Real Property; Title to Assets.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company has no Owned Real Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Schedule 3.12(b)</span> of the Company Disclosure Schedule lists the street address of each parcel of Leased Real Property, and sets forth a list of each lease, sublease, and license pursuant to which the Company or any Company Subsidiary leases, subleases or licenses any real property (each, a &#8220;<span style="font-weight:bold">Lease</span>&#8221;), with the name of the lessor and the date of the Lease in connection therewith and each material amendment to any of the foregoing (collectively, the &#8220;<span style="font-weight:bold">Lease Documents</span>&#8221;). True, correct, and complete copies of all Lease Documents have been made available to BLAC. Except as otherwise set forth in <span style="text-decoration:underline">Schedule 3.12(b)</span> of the Company Disclosure Schedule, (i)&#160;there are no leases, subleases, concessions, or other contracts granting to, and neither the Company nor any Company Subsidiary is a party to any lease, sublease, concession or other contract granting to the Company or Company Subsidiaries, the right to use or occupy any real property, and (ii)&#160;all such Leases are in full force and effect, are valid and enforceable in accordance with their respective terms, subject to the Remedies Exceptions, and there is not, under any of such Leases, any existing default or event of default (or event which, with notice or lapse of time, or both, would constitute a default) by the Company or any Company Subsidiary or, to the Company&#8217;s knowledge, by the other party(ies) to such Leases, except as would not, individually or in the aggregate, allow the landlord under such Lease to terminate such Lease or otherwise be material to the Company and the Company Subsidiaries, taken as a whole. Neither the Company nor any Company Subsidiary, has leased, subleased, sublicensed or otherwise granted to any person any right to use, occupy or possess any portion of the Leased Real Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no contractual or legal restrictions that preclude or restrict the ability of the Company or Company Subsidiary to use any Leased Real Property by such party for the purposes for which it is currently being used. There are no latent defects or adverse physical conditions affecting the Leased Real Property, and improvements thereon, other than those that would not have a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of the Company and the Company Subsidiaries has legal and valid title to, or, in the case of Leased Real Property and assets, valid leasehold or subleasehold interests in, all of its properties and assets, including the Target Assets, tangible and intangible, real, personal and mixed, used or held for use in its business, free and clear of all Liens other than Permitted Liens, except as would not, individually or in the aggregate, be material to the Company and the Company Subsidiaries, taken as a whole. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_26">3.13 <span style="text-decoration:underline">Intellectual Property</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Schedule 3.13(a)</span> of the Company Disclosure Schedule contains a true, correct and complete list of all of the following: (i)&#160;Registered Company IP (showing in each, as applicable, the filing date, date of issuance and registration or application number); (ii) other Company-Owned IP material to the Company Business, including material unregistered trademarks and copyrights, (iii)&#160;all Patents licensed to the Company on an exclusive basis, including the identity of the licensor and of the owner thereof (if different), (iv) all Company Software, (v)&#160;all Company Products, (vi)&#160;all Company Services, (vii)&#160;all Business Systems owned or purported to be owned by the Company or any Company Subsidiary that would have a replacement cost of more than $50,000; and (viii)&#160;all other Company-Licensed IP that is material to the Company Business. The Intellectual Property specified on <span style="text-decoration:underline">Schedule 3.13(a)</span> of the Company Disclosure Schedule constitutes all material Intellectual Property rights used or held for use in the operation of the Company Business and is sufficient for the conduct of the Company Business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company or one of the Company Subsidiaries solely and exclusively owns and possesses, free and clear of all Liens (other than Permitted Liens), all right, title and interest in and to the Company-Owned IP, all Company Products, and all Company Services. The consummation of the transactions contemplated hereby will not result in (a)&#160;any loss or impairment of the Company&#8217;s or any Company Subsidiary&#8217;s right to own or use any Company IP, including any loss of exclusivity or decrease in license scope, (b)&#160;any increase in royalty or other payment obligations of the Company or of any Company Subsidiary, (c)&#160;the grant of any new license, or an increase in the scope of any license granted by the Company or any Company Subsidiary, or (d)&#160;any other change in the terms or conditions applicable to the Company IP immediately prior to the Closing. All Company-Owned IP is subsisting and, excluding any Registered Company IP that consists solely of an application for registration, and to the Company&#8217;s knowledge, is valid and enforceable. No Governmental Authority has issued any judgement, decree, executive order, or award materially adversely affecting the validity or enforceability of the Company&#8217;s or the Company Subsidiaries&#8217; ownership or us of, or rights in or to, any Registered Company IP. All Registered Company IP is currently in compliance with all applicable legal requirements. There is no loss or expiration of any of the Company-Owned IP or Company-Licensed IP pending, and to the Company&#8217;s knowledge, no such loss or expiration is threatened. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company and each of its applicable Company Subsidiaries have taken reasonable actions to maintain, protect and enforce Intellectual Property rights in and to all Company-Owned IP, all Patents licensed to the Company on an exclusive basis for the Company Business all Company Products, and all Company Services, including the secrecy, confidentiality and value of its trade secrets, Personal Information and other Confidential Information. Neither the Company nor any Company Subsidiaries have disclosed any trade secrets, Personal Information or other Confidential Information that is material to the business of the Company and/or any applicable Company Subsidiaries to any other person other than pursuant to a written confidentiality agreement under which such other person agrees to maintain the confidentiality and protect such trade secrets, Personal Information and Confidential Information. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) (i) There have been no claims filed and served, or threatened in writing (including email), against the Company or any Company Subsidiary in any forum, by any person during the past three (3)&#160;years (A) contesting the validity, use, ownership, enforceability, patentability or registrability of any of the Company IP or Patents licensed to the Company on an exclusive basis for the Company Business, or (B)&#160;alleging any infringement, violation or misappropriation of, or other conflict with, any Intellectual Property rights of other persons (including any demands or unsolicited offers to license any Intellectual Property rights from any other person); (ii), the operation of the Company Business (including the use, development, manufacture, marketing, license, sale, distribution or furnishing of any Company Software, Company Products, and/or Company Services) has not and does not infringe, misappropriate or violate, any Intellectual Property rights of other persons or constitute, unfair competition or trade practices under the Laws of any applicable jurisdiction; (iii)&#160;to the knowledge of the Company, no person, including any employee or former employee of Company or any Company Subsidiary, has infringed, misappropriated or violated any of the Company-Owned IP or any Patents licensed to the Company on an exclusive basis for the Company Business; (iv)&#160;none of the Company-Owned IP, and/or Patents licensed to the Company on an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
exclusive basis for the Company Business, Company Products, and/or Company Services are subject to any proceeding, or outstanding order, agreement, settlement or stipulation restricting in any manner the use, enforcement, development, manufacture, marketing, licensing, sale, distribution, furnishing or disposition by the Company or any of the Company Subsidiaries of any Company-Owned IP, and/or Patents licensed to the Company on an exclusive basis for the Company Business, Company Products, and/or Company Services; and (v)&#160;neither the Company nor any of the Company Subsidiaries has received any formal written opinions of counsel regarding any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All persons who have contributed, developed or conceived (each, a &#8220;<span style="font-weight:bold">Contributor</span>&#8221;) any Intellectual Property (i)&#160;for or on behalf of Company or any of the Company Subsidiaries, or (ii)&#160;in the course of and related to his, her, or its relationship with the Company or the applicable Company Subsidiary (in each case a &#8220;<span style="font-weight:bold">Contribution</span>&#8221;) have executed valid, written agreements with the Company or one of the Company Subsidiaries, substantially in the form made available to BLAC, and pursuant to which such persons have irrevocably assigned to the Company or the applicable Company Subsidiary all of their entire right, title, and interest in and to any Contribution and, to the extent applicable, waived moral rights without further future consideration or any restrictions or obligations whatsoever, including on the use or other disposition or ownership of such Intellectual Property. All such assignments are enforceable and fully effective to vest sole and exclusive ownership of any and all Contributions in the Company or the applicable Company Subsidiary and were made in compliance with all requirements of applicable Law, including if required, a timely agreement formalizing such transfer, payment of remuneration, and registration with the applicable Governmental Authority. No current or former officer, employee, or Contingent Worker of the Company or any of the Company Subsidiaries: (A)&#160;is, nor has been, in violation of any term or covenant of any agreement (including, without limitation, any employment or settlement agreement or stipulation) with any other person, or any order or judgment of any court, arbitrator or other Governmental Authority, by virtue of such employee or Contingent Worker being employed by, performing services for, or developing Intellectual Property used by, the Company or any Company Subsidiary, or is, nor has been while such employee or Contingent Worker has been employed by, performed services for, or developed Intellectual Property used by, the Company or any Company Subsidiary, using trade secrets or proprietary information of others without permission; (B)&#160;has any right, license, claim or interest whatsoever in or with respect to any Company IP; or (C)&#160;has developed any Intellectual Property for the Company or any of the Company Subsidiaries that is subject to any agreement under which such employee or Contingent Worker has assigned or otherwise granted to any third party any rights in or to such Intellectual Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of the Company Subsidiaries or, to the Company&#8217;s knowledge, any other person is in material breach or in material default of any agreement required to be disclosed in <span style="text-decoration:underline">Schedules 3.13(e)</span> or <span style="text-decoration:underline">3.13(k)</span> of the Company Disclosure Schedule. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company does not own or rely on any proprietary Software and the only Software used in the Company Business is <span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-Shelf</span></span> Software. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <span style="text-decoration:underline">Open Source</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) All use, licensing, providing, delivery and distribution of Company Software, Company Products, Company Services and Open Source Materials by or through the Company and each of the Company Subsidiaries is in full compliance with all Open Source Licenses applicable thereto, including all copyright notice and attribution requirements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <span style="text-decoration:underline">Schedule 3.13(h)(ii)</span> of the Company Disclosure Schedule sets forth a true, correct and complete list of all Open Source Materials incorporated or embedded into, or combined or linked with, any Company Software, Company Products and/or Company Services, or otherwise used by the Company, including in development or testing of any Company Software, Company Products and/or Company Services, and (A)&#160;identifies the Open Source License applicable thereto, and (B)&#160;describes the manner in which such Open Source Materials were or are used by the Company and/or distributed or made available by the Company to any other person. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company has not incorporated, embedded, bundled, used, distributed, linked, or otherwise provided any Open Source Materials into, with, or in connection with any Company Software, Company Products and/or Company Services in a manner that requires any Company Software, Company Products and/or Company Services, any products or Software of any other person (including Company&#8217;s customers, licensees, or vendors), or any portion thereof, or any other Intellectual Property, to be subject to Copyleft Licenses, or requires the Company, any Company Subsidiary, BLAC, any of BLAC&#8217;s affiliates, or any other person (including any of Company&#8217;s customers, licensees, or vendors) to grant any Patent license or other Patent rights. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company and/or one of the Company Subsidiaries owns, leases, licenses, or otherwise has the legal right to use all Business Systems, and such Business Systems are sufficient for the immediate and anticipated future needs of the Company Business. There has never been any material failure with respect to any of the Business Systems that has not been remedied. The Company and each of the Company Subsidiaries maintain business continuity and disaster recovery plans consistent with industry standards for companies with similar resources in the same sector. The Company and each of the Company Subsidiaries have purchased a sufficient number of seat licenses for their Business Systems. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company and each of the Company Subsidiaries currently and previously have complied with (i)&#160;all applicable Privacy/Data Security Laws, (ii)&#160;any applicable privacy, data protection, security and other policies and procedures of the Company and/or the Company Subsidiary, respectively, concerning the processing, collection, disclosure, dissemination, storage, security, sale or use of Personal Information, Confidential Information or other Business Data, (iii)&#160;industry standards to which the Company or any Company Subsidiary is bound, and (iv)&#160;all Program Requirements (as defined below) and contractual commitments that the Company or any Company Subsidiary has entered into or is otherwise bound with respect to privacy, data protection, transfer and/or security (collectively, the &#8220;<span style="font-weight:bold">Data Security Requirements</span>&#8221;). At all times, the Company and the Company Subsidiaries have each implemented and maintained, and have required third parties that process Personal Information or Confidential Information for or on behalf of the Company or the Company Subsidiaries to implement and maintain, a written information security program and reasonable and industry standard physical, technical and administrative security safeguards to protect the security and integrity of its Business Systems, Personal Information, Confidential Information and any Business Data, including conducting regular vulnerability scans, risk assessments and remediation activities and implementing industry standard procedures preventing unauthorized access, modification, disclosure, misuse, loss, or unavailability of the foregoing and/or the introduction of Disabling Devices (&#8220;<span style="font-weight:bold">Program Requirements</span>&#8221;). Neither the Company nor any Company Subsidiaries has inserted, and no other person has inserted or alleged to have inserted any Disabling Device in any of the Business Systems, Company Software, Company Product and/or Company Service. Neither the Company nor any of the Company Subsidiaries has (x)&#160;experienced any data or security breaches or unauthorized access, modification, disclosure, misuse, loss, or unavailability of Personal Information, Business Data, Business Systems, Company Software, Company Product and/or Company Service including those that were required to be reported under applicable Data Security Requirements; or (y)&#160;been subject to or received written notice of any audits, proceedings or investigations by any Governmental Authority or any person, or received any material claims or complaints regarding the processing, collection, disclosure, dissemination, storage, security, sale, or use of Personal Information or Confidential Information, or the violation of any applicable Data Security Requirements, and, to the Company&#8217;s knowledge, there is no reasonable basis for the same. Neither the Company nor any Company Subsidiary has engaged in the sale of Personal information. The Company and the Company Subsidiaries have valid and legal rights to process all Personal Information and Confidential Information that is processed by or on behalf of the Company and the Company Subsidiaries, and the execution, delivery, or performance of this Agreement will not affect these rights or violate any applicable Data Security Requirements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company and/or one of the Company Subsidiaries (i)&#160;exclusively owns and possesses all right, title and interest in and to the Business Data free and clear of any restrictions of any nature or (ii)&#160;has all rights to use, exploit, publish, reproduce, process, distribute, license, sell, and create derivative works of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Business Data, in whole or in part, in the manner in which the Company and the Company Subsidiaries receive and use such Business Data prior to the Closing Date. The Company and the Company Subsidiaries are not subject to any Data Security Requirements or other legal obligations, including based on the Transactions contemplated hereunder, that would prohibit BLAC from receiving or using Personal Information or other Business Data, in the manner in which the Company and the Company Subsidiaries receive and use such Personal Information and other Business Data prior to the Closing Date or result in liabilities in connection with Data Security Requirements. No employee, officer, director, or agent of BLAC has been debarred or otherwise forbidden by any applicable Law or any Governmental Authority (including judicial or agency order) from involvement in the operations of a business such as that of the Company and the Company Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) All current officers, management employees, technical and professional employees, and Contingent Workers of the Company and the Company Subsidiaries are under obligation to the Company and the Company Subsidiaries to maintain in confidence all confidential or proprietary information acquired by them in the course of their employment and to assign to the Company and the Company Subsidiaries all Intellectual Property made by them within the scope of their employment during such employment. To the Company&#8217;s knowledge, no past or current officers, management employees, technical or professional employees, and Contingent Workers of the Company or any Company Subsidiaries are in breach of any such obligations to the Company or any of the Company Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) No person other than the Company or the Company Subsidiaries has any ownership interest in or exclusive rights to any Intellectual Property incorporated in the Company Software, Company Products or the Company Services, any Company-Owned IP, or any improvements made by or for the Company or the Company Subsidiaries to any Company Software, Company Products or Company Services. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) During the past five (5)&#160;years, neither the Company nor any of the Company Subsidiaries has (i)&#160;transferred ownership of, or granted any exclusive license or exclusive right under or with respect to, or authorized the retention of any exclusive right with respect to or joint ownership of, any Intellectual Property or technology that is or was at any time owned or purported to be owned by the Company or any Company Subsidiary to any other person; (ii)&#160;abandoned, sold, transferred, assigned, exclusively licensed, or otherwise disposed of any Company-Owned IP, Patents licensed to the Company on an exclusive basis, Company Software, Company Products, and/or Company Services, or any other Intellectual Property developed or otherwise acquired by the Company or by any Company Subsidiary; or (iii)&#160;granted to any person any right to bring any claim or cause of action arising out of or related to infringement, misappropriation or violation of any Company-Owned IP or any Patent licensed to the Company on an exclusive basis. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Neither this Agreement nor any transactions contemplated by this Agreement will result in any of the following under or pursuant to any Contracts to which the Company or any of the Company Subsidiaries is a party, or by which any assets or properties of the Company or of any of the Company Subsidiaries are bound: (i)&#160;any person being granted rights or access to, or the placement in or release from escrow of, any Software source code or other technology, (ii)&#160;BLAC or any of its affiliates granting to any person any ownership interest in, or any license, covenant not to sue or right under or with respect to, any Intellectual Property or technology, or (iii)&#160;BLAC or any of its affiliates or any of their Intellectual Property being bound by, or subject to, any <span style="white-space:nowrap">non-compete</span> or other restriction on the operation or scope of their respective businesses, or any obligation to make any payment to any other person in connection with Intellectual Property or commercial Contracts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <span style="text-decoration:underline">Schedule 3.13(p)</span> of the Company Disclosure Schedule sets forth a true, correct and complete list of all Contracts pursuant to which any person (i)&#160;has been provided any Company Software in source code format, or any formula, bill of materials or other information enabling such person to produce or reproduce any Company Product or Company Service, or any other material, product, substance or process developed or otherwise commercialized by the Company or by any Company Subsidiary, or (ii)&#160;has obtained or may obtain rights to receive any Company Software in source code form, or any formula, bill of materials or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
other information enabling such person to produce or reproduce any Company Product or Company Service, or any other material, product, substance or process developed or otherwise commercialized by the Company or by any Company Subsidiary, through or from the Company or any Company Subsidiary, any escrow agent or any other person. The Company has not disclosed or delivered to any escrow agent or any other person any source code for any Company Software or any formula, bill of materials or other information enabling such person to produce or reproduce any Company Product or Company Service, or any other material, product, substance or process developed or otherwise commercialized by the Company or by any Company Subsidiary, and no person has any right, contingent or otherwise, to obtain access to or use any such source code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) No Governmental Authority, and no other national, multi-national, <span style="white-space:nowrap">bi-national</span> or international governmental organization, governmental research center, university, college, other educational institution, foundation, research center or <span style="white-space:nowrap">non-profit</span> institution (collectively, &#8220;<span style="font-weight:bold">Institutions</span>&#8221;) provided or provides funding, facilities, personnel, Intellectual Property, technology, research, equipment, or other resources for the invention, creation, development or registration of any Company-Owned IP, Patents licensed to the Company on an exclusive basis, Company Software, Company Products, and/or Company Services, or has any rights to any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) To the knowledge of the Company, no person has infringed, misappropriated, misused or violated, or is infringing, misappropriating, misusing or violating, any Company-Owned IP, Patents licensed to the Company on an exclusive basis, Company Software, Company Products, and/or Company Services. The Company has not made any claim against any person alleging any infringement, misappropriation, misuse or violation of any Company-Owned IP, Patents licensed to the Company on an exclusive basis, Company Software, Company Products, and/or Company Services. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <span style="text-decoration:underline">Schedule 3.13(s)</span> of the Company Disclosure Schedule sets forth a true, correct and complete list of all Outbound IP Licenses. None of the Outbound IP Licenses will, after the Closing, apply to BLAC or BLAC&#8217;s affiliates other than the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <span style="text-decoration:underline">Schedule 3.13(t)</span> of the Company Disclosure Schedule sets forth a true, correct and complete list of all Inbound IP Licenses, excluding Contracts for <span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-Shelf</span></span> Software or licenses for Open Source Materials. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) The Company has paid, in full, all mandatory compensation the Company is required to pay to employees, contractors and consultants of the Company in relation to all Company-Owned IP, and neither this Agreement nor any transactions contemplated by this Agreement will result in any further amounts being payable to any current or former employees, contractors or consultants of the Company in relation to any Company-Owned IP. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Company has not made, directly or indirectly, any commitments, promises, submissions, suggestions, statements or declarations to any standards-setting bodies, industry groups or other similar organizations (&#8220;<span style="font-weight:bold">Standards Organizations</span>&#8221;) (including any commitments, promises, submissions, suggestions, statements or declarations that would obligate the Company or any Company Subsidiary to grant licenses to any person or otherwise impair or limit the Company&#8217;s or any of the Company&#8217;s Subsidiaries&#8217; control of any Company-Owned IP. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) Neither the Company nor any Company Subsidiary has received any notice or request to indemnify, defend or hold harmless any Person with respect to any claim of infringement, misappropriation, misuse or violation of any Intellectual Property during the past five (5)&#160;years. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Each Company Product and Company Service conforms in all material respects to the specifications and documentation therefor, all applicable contractual commitments and express and implied warranties therefor, and all applicable Laws. Other than individual warranty or other claims in the ordinary course of business consistent with past practice, neither the Company, nor any Company Subsidiary has received notice of any actual or threatened action, claim or legal proceeding, or indicating an intention on the part of any person to bring any action, claim or legal proceeding, and no action, claim or legal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
proceeding has been filed by any person or is otherwise pending before any Governmental Authority, with respect to any Company Product, Company Software or Company Service, or the breach of any Contract with respect to any Company Product, Company Software and Company Service (including, without limitation, breach of any epidemic failure provision). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_27">3.14 <span style="text-decoration:underline">Reserved</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_28">3.15 <span style="text-decoration:underline">Taxes</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and each of its Company Subsidiaries: (i)&#160;have duly and timely filed (taking into account any extension of time within which to file) all income and other material Tax Returns required by Law to be filed by any of them and all such filed Tax Returns are complete and accurate in all material respects; (ii)&#160;have timely paid all Taxes required by Law to be paid (whether or not shown on any Tax Return), except with respect to Taxes that are being contested in good faith through appropriate proceedings for which adequate reserves have been established in accordance with Korea IFRS and that are disclosed in <span style="text-decoration:underline">Schedule 3.15(a)</span> of the Company Disclosure Schedule, and no material penalties or charges are due with respect to the late filing of any Tax Return required to be filed by or with respect to any of them on or before the Effective Time; (iii)&#160;with respect to all income and other material Tax Returns filed by or with respect to any of them, have not waived any statute of limitations with respect to Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency; (iv)&#160;do not have any deficiency, assessment, claim, audit, examination, investigation, litigation or other proceeding, in each case, in respect of Taxes or Tax matters pending, asserted or proposed or threatened in writing by a Governmental Authority, for a Tax period which the statute of limitations for assessments remains open; and (v)&#160;have provided adequate reserves in accordance with Korea IFRS in the most recent consolidated financial statements of the Company, for any material Taxes of the Company that have not been paid, whether or not shown as being due on any Tax Return. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any Company Subsidiary is a party to, is bound by or has an obligation under any Tax sharing agreement, Tax indemnification agreement, Tax allocation agreement or similar contract or arrangement (including any agreement, contract or arrangement providing for the sharing or ceding of credits or losses) or has a potential liability or obligation to any person as a result of or pursuant to any such agreement, contract, arrangement or commitment other than an agreement, contract, arrangement or commitment entered into in the ordinary course of business the primary purpose of which does not relate to Taxes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) None of the Company and its Company Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in method of accounting for a taxable period ending on or prior to the Closing Date under Section&#160;481(c) of the Code (or any corresponding or similar provision of state, local or foreign income Tax law); (ii) &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date; (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;intercompany transaction or any excess loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law) entered into or created on or prior to the Closing Date; or (v)&#160;prepaid amount received on or prior to the Closing Date outside the ordinary course of business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of the Company and the Company Subsidiaries has withheld and paid to the appropriate Tax authority all material Taxes required by Law to have been withheld and paid in connection with amounts, or benefits under any Plan, paid or owing to any current or former employee, Contingent Worker, creditor, shareholder or other third party and has complied in all material respects with all applicable laws, rules and regulations relating to the payment and withholding of Taxes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No person holds shares of Company Common Stock that are <span style="white-space:nowrap">non-transferable</span> and subject to a substantial risk of forfeiture within the meaning of Section&#160;83 of the Code with respect to which a valid election under Section&#160;83(b) of the Code has not been timely made. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline">Schedule 3.15(f)</span> of the Company Disclosure Schedule lists all service providers of the Company and any Company Subsidiary who are reasonably believed by the Company to be &#8220;disqualified individuals&#8221; (within the meaning of Section&#160;280G of the Code). None of the Company, any Company Subsidiary or any affiliate of the Company has made any payments, or is obligated to make any payments or is a party to any Plan or Contract or other benefit that would reasonably be expected to obligate it to make any payments that would not be deductible under Section&#160;280G of the Code or result in the payment of an excise tax by any person under Section&#160;4999 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of the Company Subsidiaries has been a member of an affiliated group filing a consolidated, combined or unitary U.S. federal, state, local or foreign income Tax Return (other than a group of which the Company was the common parent). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any of the Company Subsidiaries has any liability for the Taxes of any person (other than the Company and the Company Subsidiaries) under Treasury Regulation <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local or foreign law), as a transferee or successor, by contract, or otherwise. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of the Company Subsidiaries (i)&#160;has any request for a ruling in respect of Taxes pending between the Company or any Company Subsidiary and any Tax authority; or (ii)&#160;has entered into any closing agreement, private letter ruling technical advice memoranda or similar agreements with any Tax authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company has made available to BLAC true, correct and complete copies of the Tax Returns filed by the Company and its Company Subsidiaries for tax years 2020, 2021, 2022 and 2023. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of the Company Subsidiaries has in any year for which the applicable statute of limitations remains open distributed stock of another person, or has had its stock distributed by another person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 or Section&#160;361 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its Company Subsidiaries has engaged in or entered into a &#8220;reportable transaction&#8221; within the meaning of Treasury Regulation <span style="white-space:nowrap">Section&#160;1.6011-4(b)(2).</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Neither the IRS nor any other United States or <span style="white-space:nowrap">non-United</span> States taxing authorities or agencies has asserted in writing or, to the knowledge of the Company or any of the Company Subsidiaries, has threatened to assert against the Company or any Company Subsidiary any deficiency or claim for any Taxes or interest thereon or penalties in connection therewith. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) There are no Tax liens upon any assets of the Company or any of the Company Subsidiaries except for Permitted Liens. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) None of the Company and the Company Subsidiaries has been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code. None of the Company and its Company Subsidiaries: (A)&#160;is a &#8220;controlled foreign corporation&#8221; as defined in Section&#160;957 of the Code, (B)&#160;is a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297 of the Code, or (C)&#160;has received written notice from the Republic of Korea or other taxing authority that it has a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country in which it is organized. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Neither the Company nor any Company Subsidiary has received written notice of any claim for a Tax authority in a jurisdiction in which the Company or such Company Subsidiary does not file Tax Returns stating that the Company or such Company Subsidiary is or may be subject to Tax in such jurisdiction, which claim currently remains unresolved. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) As used in this Agreement, (i)&#160;the term &#8220;<span style="font-weight:bold">Tax</span>&#8221; (including, with correlative meaning, the term &#8220;<span style="font-weight:bold">Taxes</span>,&#8221;) includes all federal, state, local and foreign income, profits, franchise, gross receipts, environmental, capital stock, severances, stamp, payroll, sales, employment, unemployment, disability, use, property, withholding, excise, production, value added, social insurance, customs, duties, tariffs, occupancy and other fees, assessments or governmental charges in the nature of a tax, together with all interest, penalties and additions imposed with respect to such amounts and any interest in respect of such penalties and additions, and (ii)&#160;the term &#8220;<span style="font-weight:bold">Tax Return</span>&#8221; includes all returns and reports (including customs entries and summaries, elections, declarations, disclosures, schedules, estimates and information returns, as well as attachments thereto and amendments thereof), in each case, supplied or required to be supplied to a Tax authority relating to Taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_29">3.16 <span style="text-decoration:underline">Possession of Licenses and Permits</span>. The Company and the Company Subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, &#8220;<span style="font-weight:bold">Governmental Licenses</span>&#8221;) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies necessary to conduct the business now operated by them; and, except as would not, individually or in the aggregate, result in a Company Material Adverse Effect, the Company and the Company Subsidiaries are in compliance with the terms and conditions of all such Governmental Licenses, all such Governmental Licenses are valid and in full force and effect; and neither the Company nor any of the Company Subsidiaries have received any notice of proceedings relating to the revocation or modification of any such Governmental Licenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_30">3.17 <span style="text-decoration:underline">Regulatory Matters</span>. There is no legal or governmental proceeding to which the Company or any Company Subsidiary is a party or of which any property or assets of the Company or any subsidiary is the subject, including any proceeding before any Governmental Authorities which singularly or in the aggregate, if determined adversely to the Company or any Company Subsidiary, could reasonably be expected to have a Company Material Adverse Effect; and to the best of the Company&#8217;s knowledge, no such proceedings are threatened or contemplated by Governmental Authorities or threatened by others. The Company and each Company Subsidiary are in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business, or any other federal, state or foreign agencies or bodies engaged in the regulation of biopharmaceuticals, except where noncompliance would not, singularly or in the aggregate, have a Company Material Adverse Effect. All preclinical studies and clinical trials, conducted by or on behalf of the Company and any Company Subsidiary are being and have been conducted by the Company or any Company Subsidiary, or to the Company&#8217;s knowledge, by third parties, in compliance with all applicable protocols, standard medical and scientific research procedures, and federal, state or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance as could not reasonably be expected to have, singularly or in the aggregate, a Company Material Adverse Effect. Each description of the results of studies is accurate and complete in all material respects and fairly presents the data derived from such studies or trials. The Company is not aware of any other preclinical studies or clinical trials, the results of which reasonably call into question the results; and the Company has not received any notices or correspondence from any Governmental Authority requiring the termination, suspension, material modification or clinical hold of any preclinical studies or clinical trials conducted by or on behalf of the Company. Neither the Company nor its subsidiaries, nor any of its or their respective officers, employees or directors, nor any of its or their respective agents or clinical investigators, has been excluded, suspended, disqualified or debarred from participation, for example, in any U.S. federal health care program or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, disqualification, suspension, or exclusion, or convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law. The Company and the Company Subsidiaries have made all filings and obtained all approvals, including approvals to conduct preclinical studies and clinical trials, as may be required any Government Authorities to conduct such studies or trials; and the Company and the Company Subsidiaries have not received any notice of, or correspondence from, any Governmental Authorities requiring the termination, suspension or modification of any of its preclinical studies or clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_31">3.18 <span style="text-decoration:underline">Healthcare Laws</span>. To the Company&#8217;s knowledge, the Company and each Company Subsidiary: (i)&#160;has operated and currently operates its business in compliance with applicable provisions of the health care laws, including all federal, state and local laws and regulations of any Governmental Authority applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company&#8217;s or the Company Subsidiaries&#8217; product candidates, (collectively the &#8220;<span style="font-weight:bold">Health Care Laws</span>&#8221;) except as would not, singly or in the aggregate, result in a Company Material Adverse Effect; (ii)&#160;has not received any written notice of adverse finding, warning letter, untitled letter or other correspondence or notice from any court or arbitrator or governmental or regulatory authority alleging or asserting <span style="white-space:nowrap">non-compliance</span> with (A)&#160;any Health Care Laws or (B)&#160;or any licenses, approvals, clearances, exemptions, permits, registrations, authorizations, and supplements or amendments thereto required by any such Health Care Laws (&#8220;<span style="font-weight:bold">Regulatory Authorizations</span>&#8221;); (iii) possesses all material Regulatory Authorizations required to conduct the business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and the Company and each Company Subsidiary is not in violation in any material respect of any term of any such Regulatory Authorizations; (iv)&#160;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action (&#8220;<span style="font-weight:bold">Proceeding</span>&#8221;) from any Governmental Authority including any regulatory agency or any other third party alleging a material violation of any Health Care Laws or Regulatory Authorizations or limiting, suspending, modifying, or revoking any material Regulatory Authorizations, and has no knowledge that any Governmental Authority including any regulatory agencies or any other third party is considering any Proceeding; (v)&#160;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations (&#8220;<span style="font-weight:bold">Reports</span>&#8221;) and that all such Reports were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); and (vii)&#160;is not a party to or has no ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Governmental Authority including any regulatory agencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_32">3.19 <span style="text-decoration:underline">Environmental Matters</span>. (a)&#160;None of the Company nor any of the Company Subsidiaries has materially violated since the date of its formation or is in material violation of any Environmental Law or any permit, license or other authorization required of each of the Company and each Company Subsidiary under applicable Environmental Law (&#8220;<span style="font-weight:bold">Environmental Permit</span>&#8221;) and all past <span style="white-space:nowrap">non-compliance</span> has been resolved without ongoing obligations or costs; (b)&#160;there has been no Release of Hazardous Substances at any of the properties or facilities currently or formerly owned, leased or operated by the Company or any Company Subsidiary or at any location or facility where wastes from the business or assets of the Company or the Company Subsidiaries are disposed of or recycled; (c)&#160;none of the Company or any of the Company Subsidiaries is, in any material respect, actually, potentially or allegedly liable pursuant to applicable Environmental Laws for any <span style="white-space:nowrap">off-site</span> contamination by Hazardous Substances; (d)&#160;each of the Company and each Company Subsidiary has timely obtained and maintained all Environmental Permits; (e)&#160;all Environmental Permits are in full force and effect and there are no facts or circumstances that would be reasonably expected to result in the revocation or modification of any Environmental Permit; (f)&#160;none of the Company nor any of the Company Subsidiaries is the subject of any claims, actions or suits relating to Hazardous Substances or arising under Environmental Laws, and there are no facts or circumstances that would be reasonably expected to result in any future claims, liabilities or actions; (g)&#160;none of the Company or any of the Company Subsidiaries is subject to any material outstanding order, writ, judgment, injunction, temporary restraining order, stipulation, determination, decree or award of any Governmental Authority under Environmental Laws and all other orders, writs, judgments, injunctions, temporary restraining orders, stipulations, determinations, decrees or awards of any Governmental Authority under Environmental Laws have been resolved without material ongoing obligations or costs; (h)&#160;no consent, approval or authorization of or registration or filing with any Governmental Authority is required by Environmental Laws or Environmental Permits in connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated by this Agreement; (i)&#160;none of the Company or any of the Company Subsidiaries has assumed, undertaken, or provided an unexpired indemnity with respect to any material liability, in each case relating to Hazardous Substances or relating to Environmental </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Law; and (j)&#160;the Company has made available to BLAC correct and complete copies of all environmental reports, environmental health and safety audits or inspections, and material documents related to any Proceeding or unresolved material liability arising under Environmental Laws relating to the Company or any of the Company Subsidiaries or their current or former properties, facilities or operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_33">3.20 <span style="text-decoration:underline">Material Contracts.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Schedule 3.20(a)</span> of the Company Disclosure Schedule lists, as of the Execution Date, the following types of contracts and agreements to which the Company or any Company Subsidiary is a party (such contracts and agreements as are required to be set forth <span style="text-decoration:underline">Schedule 3.20(a)</span> of the Company Disclosure Schedule along with any Plan listed on <span style="text-decoration:underline">Schedule 3.10(a)</span> of the Company Disclosure Schedule being the &#8220;<span style="font-weight:bold">Material Contracts</span>&#8221;): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) each Contract with consideration paid or payable to the Company or any of the Company Subsidiaries of more than $100,000, in the aggregate, over the past 12 months; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each Contract involving expenditures paid or payable by the Company or any Company Subsidiary of more than $100,000, in the aggregate, over the past 12 months; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) all broker, distributor, dealer, manufacturer&#8217;s representative, franchise, agency, sales promotion, market research, marketing consulting and advertising contracts and agreements to which the Company or any Company Subsidiary is a party that are material to the business of the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) all management and employment contracts (excluding <span style="white-space:nowrap">at-will</span> contracts for employment or <span style="white-space:nowrap">at-will</span> offer letters that do not contain any severance or change of control provisions) and all contracts with Contingent Workers, including any contracts involving the payment of royalties or other amounts calculated based upon the revenues or income of the Company or any Company Subsidiary or income or revenues related to any Product of the Company or any Company Subsidiary to which the Company or any Company Subsidiary is a party; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) all collective bargaining agreements or other contracts with any labor union; (vi)&#160;all contracts and agreements evidencing indebtedness for borrowed money in an amount greater than $100,000, and any pledge agreements, security agreements or other collateral agreements in which the Company or any Company Subsidiary granted to any person a security interest in or lien on any of the property or assets of the Company or any Company Subsidiary; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) all partnership agreements or other joint venture agreements, or any Contract involving a distributor, reseller, sales representative, marketing, or advertising arrangement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) all contracts relating to the settlement of any material internal complaint, grievance, claim, investigation, or other dispute with the Company or any of its Company Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) all contracts and agreements with any Governmental Authority to which the Company or any Company Subsidiary is a party, other than any Company Permits; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) all contracts and agreements that limit, or purport to limit, the ability of the Company or any Company Subsidiary to compete in any line of business or with any person or entity or in any geographic area or during any period of time, excluding customary confidentiality agreements and agreements that contain customary confidentiality clauses; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) all contracts or arrangements that result in any person or entity holding a power of attorney from the Company or any Company Subsidiary that relates to the Company, any Company Subsidiary or their respective businesses; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) all leases or master leases of personal property reasonably likely to result in annual payments of $100,000 or more in a <span style="white-space:nowrap">12-month</span> period; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) each Contract that includes any grant by the Company or any Company Subsidiary to any person of any express license, right or covenant not to sue with respect to any Patents, other than a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
nonexclusive license granted incidental to a sale of Company Products, license of Company Software, or provision of Company Services; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) any Contract that grants any (A)&#160;exclusive license, supply, distribution or other rights, (B) &#8220;most favored nation&#8221; rights, (C)&#160;rights of first refusal, rights of first negotiation or similar rights or (D)&#160;exclusive rights to purchase, license or receive any Company Product, Company Software and/or Company Service; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) any Contract providing for any minimum or guaranteed payments by the Company to any Person; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) any Contract that contains indemnification obligations of the Company in excess of $1,000,000 or pursuant to which the Company may reasonably incur liability in excess of $1,000,000 (including any Contract with an uncapped liability obligation for the Company or for any Company Subsidiary); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) any Contract that requires a consent (including any assignment consent) to or otherwise contains a provision relating to a &#8220;change of control&#8221; required to consummate the transactions contemplated by this Agreement, or that would prohibit or delay the consummation of the transactions contemplated by this Agreement; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) all agreements or instruments guarantying the debts or other obligations of any person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) Each Material Contract is a legal, valid and binding obligation of the Company or the Company Subsidiaries and, to the knowledge of the Company, the other parties thereto, and neither the Company nor any Company Subsidiary is in material breach or violation of, or material default under, any Material Contract nor has any Material Contract been canceled by the other party; (ii)&#160;to the Company&#8217;s knowledge, no other party is in material breach or violation of, or material default under, any Material Contract; and (iii)&#160;the Company and the Company Subsidiaries have not received any written, or to the knowledge of the Company, oral claim of default under any such Material Contract. The Company has furnished or made available to BLAC true and complete copies of all Material Contracts, including amendments thereto that are material in nature. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_34">3.21 <span style="text-decoration:underline">International Trade Laws</span><span style="text-decoration:underline">.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and the Company Subsidiaries are, and have been for the past five years, in compliance in all material respects with all International Trade Laws applicable to them. Without limiting the foregoing: (i)&#160;the Company and the Company Subsidiaries have obtained all export and import licenses and other approvals required for their respective imports and exports of products, software and technologies required by any International Trade Law, and all such approvals and licenses are in full force and effect; (ii)&#160;the Company and the Company Subsidiaries are in compliance with the terms of such applicable export and import licenses or other approvals; (iii)&#160;there are no claims pending or threatened in writing against any Company or Company Subsidiaries with respect to such export and import licenses or other approvals; and (iv)&#160;the Company and the Company Subsidiaries have processes in place to ensure that any imported merchandise into the United States is properly declared, marked and labeled in accordance with all U.S. Laws at the time of importation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and the Company Subsidiaries have not, to its knowledge, </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <span style="white-space:nowrap">re-exported,</span> transferred, or brokered the sale of any goods, services, technology, or technical data to any destination to which, or individual for whom, a license or other authorization is required under the International Trade Laws; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) exported, <span style="white-space:nowrap">re-exported,</span> or transferred any goods, services, technology, or technical data to, on behalf of, or for the benefit of any person or entity identified on, any restricted party lists maintained by the U.S. Government, including the Specially Designated Nationals and Blocked Persons List, and Foreign Sanctions Evaders List, maintained by Office of Foreign Assets Control of the U.S. Treasury </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Department (&#8220;<span style="font-weight:bold">OFAC</span>&#8221;); and the Denied Persons List, Entity List, Military End User List, or Unverified List, maintained by the U.S. Department of Commerce&#8217;s Bureau of Industry and Security; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) exported, <span style="white-space:nowrap">re-exported,</span> or transferred any goods, services, technology, or technical data that have been or will be (A)&#160;used for any purposes associated with nuclear activities, missiles, chemical or biological weapons, or terrorist activities, or (B)&#160;used, transshipped, or diverted contrary to applicable International Trade Laws; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) exported, <span style="white-space:nowrap">re-exported,</span> transferred, or imported any goods, services, technology, or technical data to or from Burma/Myanmar, Cuba, Crimea, Iran, North Korea, Sudan, Syria or Venezuela during a time at which such country or region and/or its government was subject to U.S. comprehensive trade embargoes under OFAC regulations, the Export Administration Regulations, or any other applicable statute or executive order; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) manufactured any defense article as defined in the International Traffic in Arms Regulations, including within the United States and without regard to whether such defense article was subsequently exported, without being registered and in good standing with the Directorate of Defense Trade Controls, U.S. Department of State; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) received from any governmental authority or any other person any notice, inquiry, or internal or external allegation, or made any voluntary or involuntary disclosure to a governmental authority concerning any actual or potential violation or wrongdoing related to International Trade Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company nor any Company Subsidiary nor any director of or officer of any of the Company or any Company Subsidiary or, to the Company&#8217;s knowledge (as defined in the relevant International Trade Laws), any other representative or agent acting on behalf of the Company or any Company Subsidiary is currently identified on the Specially Designated Nationals List or otherwise currently subject to any U.S. sanctions administered by OFAC. The Company and the Company Subsidiaries have not, directly or indirectly in the last five years, used any funds, or loaned, contributed or otherwise made available such funds to any Company Subsidiary, joint venture partner or other person, in connection with any transactions, sales or operations in violation of U.S. sanctions administered by OFAC or for the purpose of unlawfully financing the activities of any person currently subject to, or otherwise in violation of, any U.S. sanctions administered by OFAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_35">3.22 <span style="text-decoration:underline">Insurance.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Schedule 3.22(a)</span> of the Company Disclosure Schedule sets forth, with respect to each insurance policy under which the Company or any Company Subsidiary is an insured, a named insured or otherwise the principal beneficiary of coverage as of the Execution Date the names of the insurer, the principal insured and each named insured that is the Company or any Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to each such insurance policy: (i)&#160;the policy is legal, valid, binding and enforceable in accordance with its terms (subject to the Remedies Exceptions) and, except for policies that have expired under their terms in the ordinary course, is in full force and effect; (ii)&#160;neither the Company nor any Company Subsidiary is in material breach or default (including any such breach or default with respect to the payment of premiums or the giving of notice), and no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or permit termination or modification, under the policy; (iii)&#160;to the knowledge of the Company, no insurer on the policy has been declared insolvent or placed in receivership, conservatorship or liquidation; and (iv)&#160;no insurer has indicated in writing or, to the knowledge of the Company otherwise, that it will be cancelling or reducing coverage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_36">3.23 <span style="text-decoration:underline">Board Approval</span>. The Company Board, by resolutions duly adopted by unanimous vote of those voting at a meeting duly called and held and not subsequently rescinded or modified in any way, or by unanimous written consent, has duly (a)&#160;reviewed relevant materials in regard to the Business Combination, and (b)&#160;approved the Business Combination and the other transactions contemplated by the Business Combination and declared its advisability. No further vote or authorization is required of the Company&#8217;s Board of Directors or Stockholders to adopt this Agreement and approve the Transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_37">3.24 <span style="text-decoration:underline">Anti-Corruption Laws.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries are, and for the last six years have been, in compliance with all applicable Anti-Corruption Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any Company Subsidiaries, nor any shareholders, officers, directors, executives, employees, agents, or representatives of the Company or any Company Subsidiaries, has used, offered, authorized, promised, provided, paid, or received, whether directly or indirectly through a third party, on behalf of the Company or any Company Subsidiary or in connection with the Company&#8217;s or any Company Subsidiary&#8217;s business, any bribes, kickbacks, or anything else of value, regardless of form or amount, to any entity or person for any improper purpose, including for obtaining or retaining business or securing an improper business advantage. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company and all Company Subsidiaries have adopted and maintained adequate policies, procedures, and controls to ensure that the Company and all Company Subsidiaries have complied and are in compliance with all Anti-Corruption Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company and all Company Subsidiaries have at all times maintained accounting and financial controls adequate to ensure that: (i)&#160;all payments and activities have been accurately recorded in the books, records and accounts of the Company and all Company Subsidiaries; (ii)&#160;there have been no false, inaccurate, misleading, or incomplete entries made in the Company&#8217;s books, records, and accounts; and (iii)&#160;the Company and all Company Subsidiaries have not established or maintained any secret or unrecorded funds or accounts. The books, records, and accounts of the Company and all Company Subsidiaries accurately reflect in reasonable detail the character and amount of all transactions, and the Company and all Company Subsidiaries have not had or maintained any bank or other financial account that is not or was not accurately disclosed in their books, records, and accounts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Neither the U.S. government nor any other Governmental Authority has notified the Company or any Company Subsidiary of any actual or alleged violation or breach of Anti-Corruption Laws. Neither the Company nor any Company Subsidiary has undergone and is not undergoing any review, investigation, inspection, or examination of records relating to the Company&#8217;s or any Company Subsidiary&#8217;s compliance with Anti-Corruption Laws. Neither the Company nor any Company Subsidiary has been and is now under any administrative, civil, or criminal investigation, prosecution, or indictment, and are not party to any actions involving alleged false statements, false claims or other improprieties relating to the Company&#8217;s or any Company Subsidiary&#8217;s compliance with Anti-Corruption Laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_38">3.25 <span style="text-decoration:underline">Interested Party Transactions</span>. Except as set forth in <span style="text-decoration:underline">Schedule 3.25</span> of the Company Disclosure Schedule and for employment relationships and the payment of compensation, benefits and expense reimbursements and advances in the ordinary course of business, no director, officer or other affiliate of the Company or any Company Subsidiary, to the Company&#8217;s knowledge, has or has had, directly or indirectly: (a)&#160;an economic interest in any person that has furnished or sold, or furnishes or sells, services or Products that the Company or any Company Subsidiary furnishes or sells, or proposes to furnish or sell; (b)&#160;an economic interest in any person that purchases from or sells or furnishes to, the Company or any Company Subsidiary, any goods or services; (c)&#160;a beneficial interest in any contract or agreement disclosed in <span style="text-decoration:underline">Schedule 3.20(a)</span> of the Company Disclosure Schedule; or (d)&#160;any contractual or other arrangement with the Company or any Company Subsidiary, other than customary indemnity arrangements; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that ownership of no more than five percent (5%) of the outstanding voting stock of a publicly traded corporation shall not be deemed an &#8220;economic interest in any person&#8221; for purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.25</span>. The Company and the Company Subsidiaries have not, since the date of formation, (i)&#160;extended or maintained credit, arranged for the extension of credit or renewed an extension of credit in the form of a personal loan to or for any director or executive officer (or equivalent thereof) of the Company, or (ii)&#160;materially modified any term of any such extension or maintenance of credit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_39">3.26 <span style="text-decoration:underline">Exchange Act</span>. Neither the Company nor any Company Subsidiary is currently (or has previously been) subject to the requirements of Section&#160;12 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_40">3.27 <span style="text-decoration:underline">Brokers</span>. Except as set forth on <span style="text-decoration:underline">Schedule 3.27</span> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Company or any Company Subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_41">3.28 <span style="text-decoration:underline">Exclusivity of Representations and Warranties</span>. Except as otherwise expressly provided in this Article III (as modified by the Company Disclosure Schedule), the Company hereby expressly disclaims and negates, any other express or implied representation or warranty whatsoever (whether at Law or in equity) with respect to the Company, its affiliates, and any matter relating to any of them, including their affairs, the condition, value or quality of the assets, liabilities, financial condition or results of operations, or with respect to the accuracy or completeness of any other information made available to BLAC, its affiliates or any of their respective Representatives by, or on behalf of, Company, and any such representations or warranties are expressly disclaimed. Without limiting the generality of the foregoing, except as expressly set forth in this Agreement, neither Company nor any other person on behalf of Company has made or makes, any representation or warranty, whether express or implied, with respect to any projections, forecasts, estimates or budgets made available to BLAC, its affiliates or any of their respective Representatives of future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of the Company (including the reasonableness of the assumptions underlying any of the foregoing), whether or not included in any management presentation or in any other information made available to BLAC, its affiliates or any of their respective Representatives or any other person, and that any such representations or warranties are expressly disclaimed. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_42">ARTICLE IV </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF COMPANY STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Company Stockholder, upon their execution of a Joinder, and on a several and not joint and several basis, represents and warrants to BLAC as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_43">4.01 <span style="text-decoration:underline">Ownership of Company Common Stock</span>. Each share of Company Common Stock owned by such Company Stockholder is owned free and clear of all Liens, options, rights of first refusal and limitations on such Company Stockholder&#8217;s voting rights, other than transfer restrictions under applicable securities laws and the Company&#8217;s organizational documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_44">4.02 <span style="text-decoration:underline">Organization and Authority</span>. If such Company Stockholder is a corporation or other organization, such Company Stockholder is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization. Such Company Stockholder has all necessary power and authority to execute and deliver the Joinder, to perform its obligations thereunder and hereunder and to consummate the Transactions. The execution and delivery of the Joinder by the Company Stockholder and the consummation by the Company Stockholder of the Transactions have been duly and validly authorized by all necessary individual or corporate action, as applicable, and no other individual or corporate proceedings, as applicable, on the part of the Company Stockholder are necessary to authorize the Joinder or to consummate the Transactions. Such Company Stockholder&#8217;s Joinder has been duly and validly executed and delivered by the Company Stockholder and, assuming the due authorization, execution and delivery by BLAC, constitutes a legal, valid and binding obligation of the Company Stockholder, enforceable against the Company Stockholder in accordance with its terms, except as limited by the Remedies Exception. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_45">4.03 <span style="text-decoration:underline">No Conflict; Required Filings and Consents</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of the Joinder by such Company Stockholder does not, and subject to receipt of the consents, approvals, authorizations or permits, filings and notifications contemplated by <span style="text-decoration:underline">Schedule 4.03(a)</span> of the Company Disclosure Schedule, the performance of the Joinder by such Company Stockholder will not (i)&#160;if such Company Stockholder is a corporation or other organization, conflict with or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
violate the certificate of incorporation or bylaws or any equivalent organizational documents, (ii)&#160;conflict with or violate any Law applicable to such Company Stockholder. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of the Joinder by such Company Stockholder does not, and the performance of the Joinder by such Company Stockholder will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_46">4.04 <span style="text-decoration:underline">Litigation</span>. There are no Actions pending or, to the knowledge of such Company Stockholder, threatened, brought by or against such Company Stockholder or their real or personal property or assets affecting such Company Stockholder&#8217;s ability to consummate the Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_47">4.05 <span style="text-decoration:underline">Broker</span>. Except as set forth on <span style="text-decoration:underline">Schedule 3.27</span> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of such Company Stockholder. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_48">ARTICLE V </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF BLAC </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the BLAC SEC Reports (to the extent the qualifying nature of such disclosure is readily apparent from the content of such BLAC SEC Reports, but excluding disclosures referred to in &#8220;Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221;, and any other disclosures therein to the extent they are of a predictive or cautionary nature or related to forward-looking statements) (it being acknowledged that nothing disclosed in such a BLAC SEC Report will be deemed to modify or qualify the representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.01</span> (Corporate Organization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.03</span> (Capitalization), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.04</span> (Authority Relative to This Agreement)), BLAC hereby represents and warrants to the Company as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_49">5.01 Corporate Organization. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) BLAC is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite corporate power and authority and all necessary governmental approvals to own, lease, and operate its properties and to carry on its business as it is now being conducted, except where the failure to have such power, authority and governmental approvals would not be a BLAC Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) BLAC does not directly or indirectly own any equity or similar interest in, or any interest convertible into or exchangeable or exercisable for any equity or similar interest in, any corporation, partnership, joint venture or business association or other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_50">5.02 <span style="text-decoration:underline">Certificate of Incorporation and Bylaws</span>. BLAC has heretofore furnished to the Company complete and correct copies of the BLAC Organizational Documents. The BLAC Organizational Documents are in full force and effect. BLAC is not in violation of any of the provisions of the BLAC Organizational Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_51">5.03 <span style="text-decoration:underline">Capitalization</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of BLAC consists of (i) 100,000,000 shares of BLAC Common Stock, and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share (&#8220;<span style="font-weight:bold">BLAC Preferred Stock</span>&#8221;). As of the Amendment Date (i) 4,041,221 shares of BLAC Common Stock are issued and outstanding (which includes 1,886,221 shares subject to Redemption Rights), all of which are validly issued, fully paid and <span style="white-space:nowrap">non-assessable</span> and not subject to any preemptive rights, (ii)&#160;no shares of BLAC Common Stock are held in the treasury of BLAC, (iii) 7,330,000 BLAC Warrants are issued and outstanding, (iv) 7,330,000 shares of BLAC Common Stock are reserved for future issuance pursuant to the BLAC Warrants, (v) 7,330,000 BLAC Rights are issued and outstanding, and (vi) 733,000 shares of BLAC Common Stock are reserved for future issuance pursuant to the BLAC Rights. As of the Amendment Date, there are no shares of BLAC Preferred Stock issued and outstanding. Each BLAC Warrant is exercisable for one share of BLAC Common Stock at an exercise price of $11.50 per share, exercisable 30 days after consummation of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Share Exchange. Each BLAC Right entitles the holder thereof to receive <span style="white-space:nowrap">one-tenth</span> (1/10) of a share of BLAC Common Stock upon the consummation of the Share Exchange. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All outstanding BLAC Units, shares of BLAC Common Stock, BLAC Warrants and BLAC Rights have been issued and granted in compliance with all applicable securities laws and other applicable Laws and were issued free and clear of all Liens other than transfer restrictions under applicable securities laws and the BLAC Organizational Documents. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Aggregate Participating Consideration being delivered by BLAC hereunder shall be duly and validly issued, fully paid and nonassessable, and each such share or other security shall be issued free and clear of preemptive rights and all Liens, other than transfer restrictions under applicable securities laws and the BLAC Organizational Documents. The Aggregate Participating Consideration will be issued in compliance with all applicable securities Laws and other applicable Laws and without contravention of any other person&#8217;s rights therein or with respect thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except for securities issued pursuant to the PIPE Subscription Agreements, securities issued by BLAC as permitted by this Agreement and the BLAC Warrants and BLAC Rights, BLAC has not issued any options, warrants, preemptive rights, calls, convertible securities or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued capital stock of BLAC or obligating BLAC to issue or sell any shares of capital stock of, or other equity interests in, BLAC. All shares of BLAC Common Stock subject to issuance as aforesaid, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be duly authorized, validly issued, fully paid and <span style="white-space:nowrap">non-assessable.</span> Neither BLAC nor any subsidiary of BLAC is a party to, or otherwise bound by, and neither BLAC nor any subsidiary of BLAC has granted, any equity appreciation rights, participations, phantom equity or similar rights. BLAC is not a party to any voting trusts, voting agreements, proxies, shareholder agreements or other agreements with respect to the voting or transfer of BLAC Common Stock or any of the equity interests or other securities of BLAC or any of its subsidiaries. There are no outstanding contractual obligations of BLAC to repurchase, redeem or otherwise acquire any shares of BLAC Common Stock. There are no outstanding contractual obligations of BLAC to make any investment (in the form of a loan, capital contribution or otherwise) in, any person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_52">5.04 <span style="text-decoration:underline">Consents</span>. BLAC has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the Transactions. The execution and delivery of this Agreement by BLAC and the consummation by BLAC of the Transactions, have been duly and validly authorized by all necessary corporate action, and no other corporate proceedings on the part of BLAC are necessary to authorize this Agreement or to consummate the Transactions (other than (a)&#160;with respect to the Business Combination, the approval and adoption of this Agreement by the holders of a majority of the then-outstanding shares of BLAC Common Stock, and (b)&#160;with respect to the issuance of BLAC Common Stock and the amendment and restatement of the BLAC Certificate of Incorporation pursuant to this Agreement, the approval of a majority of the then-outstanding shares of BLAC Common Stock). This Agreement has been duly and validly executed and delivered by BLAC and, assuming due authorization, execution and delivery by the Company, constitutes a legal, valid and binding obligation of BLAC, enforceable against BLAC in accordance with its terms subject to the Remedies Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_53">5.05 <span style="text-decoration:underline">No Conflict; Required Filings and Consents.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement by BLAC does not, and the performance of this Agreement by BLAC will not, (i)&#160;conflict with or violate the BLAC Organizational Documents, (ii)&#160;assuming that all consents, approvals, authorizations and other actions described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.05(b)</span> have been obtained and all filings and obligations described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.05(b)</span> have been made, conflict with or violate any Law, rule, regulation, order, judgment or decree applicable to BLAC or by which any of its property or assets is bound or affected, or (iii)&#160;result in any breach of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien on any property </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or asset of BLAC pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which BLAC is a party or by which BLAC or any of its property or assets is bound or affected, except, with respect to clauses (ii)&#160;and (iii), for any such conflicts, violations, breaches, defaults or other occurrences which would not have or reasonably be expected to have a BLAC Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of this Agreement by BLAC do not, and the performance of this Agreement by BLAC will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority, except (i)&#160;for applicable requirements, if any, of the Exchange Act, Blue Sky Laws and state takeover laws, and filing and recordation of appropriate documents as required by the DGCL and (ii)&#160;where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not, individually or in the aggregate, prevent or materially delay consummation of any of the Transactions or otherwise prevent BLAC from performing its material obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_54">5.06 <span style="text-decoration:underline">Compliance</span>. BLAC is not and has not been in conflict with, or in default, breach or violation of, (a)&#160;any Law applicable to BLAC or by which any property or asset of BLAC is bound or affected, or (b)&#160;any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which BLAC is a party or by which BLAC or any property or asset of BLAC is bound, except, in each case, for any such conflicts, defaults, breaches or violations that would not have or reasonably be expected to have a BLAC Material Adverse Effect. BLAC is in possession of all material franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, certificates, approvals, and orders of any Governmental Authority necessary for BLAC to own, lease and operate its properties or to carry on its business as it is now being conducted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_55">5.07 <span style="text-decoration:underline">SEC Filings; Financial Statements; Sarbanes-Oxley</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) BLAC has filed all forms, reports, schedules, statements and other documents, including any exhibits thereto, required to be filed by it with the Securities and Exchange Commission (the &#8220;<span style="font-weight:bold">SEC</span>&#8221;) since February&#160;13, 2023, together with any amendments, restatements or supplements thereto (collectively, the &#8220;<span style="font-weight:bold">BLAC SEC Reports</span>&#8221;). BLAC has heretofore furnished to the Company true and correct copies of all amendments and modifications that have not been filed by BLAC with the SEC to all agreements, documents and other instruments that previously had been filed by BLAC with the SEC and are currently in effect. As of their respective dates, the BLAC SEC Reports (i)&#160;complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold">Securities Act</span>&#8221;), the Exchange Act and the Sarbanes-Oxley Act, and the rules and regulations promulgated thereunder, and (ii)&#160;did not, at the time they were filed, or, if amended, as of the date of such amendment, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each director and executive officer of BLAC has filed with the SEC on a timely basis all documents required with respect to BLAC by Section&#160;16(a) of the Exchange Act and the rules and regulations thereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of the financial statements (including, in each case, any notes thereto) contained in the BLAC SEC Reports was prepared in accordance with GAAP (applied on a consistent basis) and Regulation <span style="white-space:nowrap">S-X</span> and Regulation <span style="white-space:nowrap">S-K,</span> as applicable, throughout the periods indicated (except as may be indicated in the notes thereto or, in the case of unaudited financial statements, as permitted by Form <span style="white-space:nowrap">10-Q</span> of the SEC) and each fairly presents, in all material respects, the financial position, results of operations, changes in stockholders equity and cash flows of BLAC as at the respective dates thereof and for the respective periods indicated therein, (subject, in the case of unaudited statements, to normal and recurring <span style="white-space:nowrap">year-end</span> adjustments which have not had, and would not reasonably be expected to individually or in the aggregate be material). BLAC has no <span style="white-space:nowrap">off-balance</span> sheet arrangements that are not disclosed in the BLAC SEC Reports. No financial statements other than those of BLAC are required by GAAP to be included in the consolidated financial statements of BLAC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as and to the extent set forth in the BLAC SEC Reports, BLAC has no liability or obligation of a nature (whether accrued, absolute, contingent or otherwise) required to be reflected on a balance sheet prepared in accordance with GAAP, except for liabilities and obligations arising in the ordinary course of BLAC&#8217;s business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as and to the extent set forth in the BLAC SEC Reports, BLAC is in compliance in all material respects with the applicable listing and corporate governance rules and regulations of Nasdaq. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) BLAC has established and maintains disclosure controls and procedures (as defined in Rule <span style="white-space:nowrap">13a-15</span> under the Exchange Act). Such disclosure controls and procedures are designed to ensure that material information relating to BLAC and other material information required to be disclosed by BLAC in the reports and other documents that it files or furnishes under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such material information is accumulated and communicated to BLAC&#8217;s principal executive officer and its principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the certifications required pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act. Except as and to the extent set forth in the BLAC SEC Reports, such disclosure controls and procedures are effective in timely alerting BLAC principal executive officer and principal financial officer to material information required to be included in BLAC&#8217;s periodic reports required under the Exchange Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) BLAC maintains systems of internal control over financial reporting that are sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance: (i)&#160;that BLAC maintains records that in reasonable detail accurately and fairly reflect, in all material respects, its transactions and dispositions of assets; (ii)&#160;that transactions are recorded as necessary to permit the preparation of financial statements in conformity with GAAP; (iii)&#160;that receipts and expenditures are being made only in accordance with authorizations of management and its board of directors; and (iv)&#160;regarding prevention or timely detection of unauthorized acquisition, use or disposition of its assets that could have a material effect on its financial statements. BLAC has no knowledge of any fraud or whistle-blower allegations, whether material, that involve management or other employees or consultants who have or had a significant role in the internal control over financial reporting of BLAC. Except as and to the extent set forth in the BLAC SEC Reports, since February&#160;13, 2023, there have been no material changes in BLAC internal control over financial reporting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There are no outstanding loans or other extensions of credit made by BLAC to any executive officer (as defined in Rule <span style="white-space:nowrap">3b-7</span> under the Exchange Act) or director of BLAC. BLAC has not taken any action prohibited by Section&#160;402 of the Sarbanes-Oxley Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Except as and to the extent set forth in the BLAC SEC Reports, neither BLAC (including any employee thereof) nor BLAC&#8217;s independent auditors has identified or been made aware of (i)&#160;any significant deficiency or material weakness in the system of internal accounting controls utilized by BLAC, (ii)&#160;any fraud, whether or not material, that involves BLAC&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by BLAC, or (iii)&#160;any claim or allegation regarding any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As of the Execution Date, there are no outstanding SEC comments from the SEC with respect to the BLAC SEC Reports. To the knowledge of BLAC, none of the BLAC SEC Reports filed on or prior to the Execution Date is subject to ongoing SEC review or investigation as of the Execution Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_56">5.08 <span style="text-decoration:underline">Absence of Certain Changes or Events; Transactions with Affiliates</span>. Since December&#160;31, 2023, except as expressly contemplated by this Agreement, (a)&#160;BLAC has conducted its business in the ordinary course and in a manner consistent with past practice, and (b)&#160;there has not been any BLAC Material Adverse Effect. Except as disclosed in the BLAC SEC Reports, there are no agreements between BLAC, on the one hand, and any officer, director, employee, partner, member, manager, direct or indirect equityholder or affiliate of BLAC, on the other hand. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_57">5.09 <span style="text-decoration:underline">Absence of Litigation</span>. There is no Action pending or, to the knowledge of BLAC, threatened against BLAC, or any property or asset of BLAC before any Governmental Authority. Neither BLAC nor any material property or asset of BLAC is subject to any continuing order of, consent decree, settlement agreement or other similar written agreement with, or, to the knowledge of BLAC, continuing investigation by, any Governmental Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_58">5.10 <span style="text-decoration:underline">BLAC M&amp;A Committee and BLAC Board Approval; Vote Required</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The BLAC M&amp;A Committee has duly recommended to the BLAC Board that this Agreement and the transactions contemplated by this Agreement are fair and in the best interests of BLAC and its stockholders. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The BLAC Board, by resolutions duly adopted and not subsequently rescinded or modified in any way, has duly (i)&#160;determined that this Agreement and the transactions contemplated by this Agreement are fair to and in the best interests of BLAC and its stockholders, (ii)&#160;approved this Agreement and the transactions contemplated by this Agreement and declared their advisability, and (iii)&#160;recommended that the stockholders of BLAC approve and adopt this Agreement and the Business Combination, and directed that this Agreement and the Business Combination, be submitted for consideration by the stockholders of BLAC at the BLAC Stockholders&#8217; Meeting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The only vote of the holders of any class or series of capital stock of BLAC necessary to approve the transactions contemplated by this Agreement is the affirmative vote of the holders of a majority of the outstanding shares of BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_59">5.11 <span style="text-decoration:underline">Brokers</span>. Except for Chardan Capital Markets, LLC, no broker, finder, or investment banker is entitled to any brokerage, finder&#8217;s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_60">5.12 <span style="text-decoration:underline">BLAC Trust Fund</span>. As of the Execution Date, BLAC has no less than $5,000,001 in the trust fund established by BLAC for the benefit of its public stockholders (the &#8220;<span style="font-weight:bold">Trust Fund</span>&#8221;) maintained in a trust account at J.P. Morgan Chase Bank, N.A. (the &#8220;<span style="font-weight:bold">Trust Account</span>&#8221;). The monies of such Trust Account are invested in United States Government securities or money market funds meeting certain conditions under Rule <span style="white-space:nowrap">2a-7</span> promulgated under the Investment Company Act of 1940, as amended, and held in trust by Continental Stock Transfer&#160;&amp; Trust Company (the &#8220;<span style="font-weight:bold">Trustee</span>&#8221;) pursuant to the Investment Management Trust Agreement, dated as of February&#160;7, 2023, between BLAC and the Trustee, as amended by the First Amendment thereto dated as of November&#160;10, 2023 (the &#8220;<span style="font-weight:bold">Trust Agreement</span>&#8221;). The Trust Agreement has not been amended or modified (except by the First Amendment described in the prior sentence) and is valid and in full force and effect and is enforceable in accordance with its terms, subject to the Remedies Exceptions. BLAC has complied in all material respects with the terms of the Trust Agreement and is not in breach thereof or default thereunder and there does not exist under the Trust Agreement any event which, with the giving of notice or the lapse of time, would constitute such a breach or default by BLAC or the Trustee. There are no separate contracts, agreements, side letters or other understandings (whether written or unwritten, express or implied): (i) between BLAC and the Trustee that would cause the description of the Trust Agreement in the BLAC SEC Reports to be inaccurate in any material respect; or (ii)&#160;to the knowledge of BLAC, that would entitle any person (other than stockholders of BLAC who shall have elected to redeem their shares of BLAC Common Stock pursuant to the BLAC Organizational Documents) to any portion of the proceeds in the Trust Account. Prior to the Closing, none of the funds held in the Trust Account may be released except: (A)&#160;to pay income and franchise taxes from any interest income earned in the Trust Account; and (B)&#160;upon the exercise of Redemption Rights in accordance with the provisions of the BLAC Organizational Documents. As of the Execution Date, there are no Actions pending or, to the knowledge of BLAC, threatened in writing with respect to the Trust Account. Upon consummation of the Business Combination and notice thereof to the Trustee pursuant to the Trust Agreement, BLAC shall cause the Trustee to, and the Trustee shall thereupon be obligated to, release to BLAC as promptly as practicable, the Trust Funds in accordance with the Trust Agreement at which point the Trust Account shall terminate; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span> that the liabilities and obligations of BLAC due and owing or incurred at or prior to the Effective Time </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be paid as and when due, including all amounts payable (a)&#160;to stockholders of BLAC who shall have exercised their Redemption Rights; (b)&#160;with respect to filings, applications and/or other actions taken pursuant to this Agreement required under Law; (c)&#160;to the Trustee for fees and costs incurred in accordance with the Trust Agreement; and (d)&#160;to third parties (e.g., professionals, printers, etc.) who have rendered services to BLAC in connection with its efforts to effect the Business Combination (including deferred fees owed by BLAC to Chardan Capital Markets, LLC pursuant to that certain Underwriting Agreement, dated February&#160;9, 2023, among Chardan Capital Markets, LLC, as representative of the several underwriters thereto and BLAC). As of the Execution Date, assuming the accuracy of the representations and warranties of the Company herein and the compliance by the Company with its respective obligations hereunder, BLAC has no reason to believe that any of the conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be available to BLAC at the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_61">5.13 <span style="text-decoration:underline">Employees</span>. Other than any officers as described in the BLAC SEC Reports, BLAC has never employed any employees or retained any contractors or consultants. Other than reimbursement of any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by BLAC&#8217;s officers and directors in connection with activities on BLAC&#8217;s behalf in an aggregate amount not in excess of the amount of cash held by BLAC outside of the Trust Account, BLAC has no unsatisfied material liability with respect to any employee, officer, or director. BLAC has never and do not currently maintain, sponsor, contribute to or have any liability, actual or contingent, under any employment agreement, or any employee benefit plan, nonqualified deferred compensation plan subject to Section&#160;409A of the Code, bonus, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree medical or life insurance, supplemental retirement, change in control, fringe benefit, sick pay, and vacation plans or arrangements or other employee benefit plans, programs or arrangements. Neither the execution and delivery of this Agreement by BLAC nor the consummation of the Transactions contemplated by this Agreement (either alone or in combination with another event) will (i)&#160;result in the payment of severance or any other amount to any employee, director, officer or independent contractor of BLAC, (ii)&#160;accelerate the time of payment or vesting, or increase the amount, of any benefit or other compensation due to any individual by BLAC, (iii)&#160;result in an &#8220;excess parachute payment&#8221; as defined in Section&#160;280G(b)(1) of the Code, or (iv)&#160;require a <span style="white-space:nowrap">&#8220;gross-up,&#8221;</span> indemnification for, or payment to any employee, director, officer or independent contractor of BLAC for any Taxes imposed under Section&#160;409A or Section&#160;4999 of the Code or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_62">5.14 <span style="text-decoration:underline">Taxes</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) BLAC (i)&#160;has duly and timely filed (taking into account any extension of time within which to file) all material Tax Returns required by Law to be filed by it as of the Execution Date and all such filed Tax Returns are complete and accurate in all material respects; (ii)&#160;has timely paid all Taxes required by Law to be paid that are shown as due on such filed Tax Returns and any other material Taxes that BLAC are otherwise required by Law to pay, except with respect to current Taxes not yet due and payable or otherwise being contested in good faith or that are described in clause (a)(v) below; (iii)&#160;with respect to all material Tax Returns filed by or with respect to any of them, has not waived any statute of limitations with respect to Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency, which waiver or extension remains outstanding; (iv)&#160;does not have any deficiency, assessment, claim, audit, examination, investigation, litigation or other proceeding, in each case, in respect of a material amount of Taxes or material Tax matters pending or threatened in writing by a Governmental Authority, for a Tax period which the statute of limitations for assessments remains open; and (v)&#160;has provided adequate reserves in accordance with GAAP in the most recent consolidated financial statements of BLAC, for any material Taxes of BLAC that have not been paid, whether or not shown as being due on any Tax Return. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) BLAC is not a party to, is bound by or has an obligation under any Tax sharing agreement, Tax indemnification agreement, Tax allocation agreement or similar contract or arrangement (including any agreement, contract or arrangement providing for the sharing or ceding of credits or losses) or has a potential liability or obligation to any person as a result of or pursuant to any such agreement, contract, arrangement or commitment other than an agreement, contract, arrangement, or commitment entered into in the ordinary course of business and the primary purpose of which does not relate to Taxes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) BLAC will not be required by Law to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in method of accounting made on or prior to the Closing Date under Section&#160;481(c) of the Code (or any corresponding or similar provision of state, local or foreign income Tax law); (ii) &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date; (iii)&#160;installment sale or open transaction made on or prior to the Closing Date; (iv)&#160;intercompany transaction or any excess loss account described in Treasury Regulations under Code Section&#160;1502 (or any corresponding or similar provision of state, local or foreign income Tax law) entered into or created on or prior to the Closing Date; or (v)&#160;prepaid amount received on or prior to the Closing Date outside the ordinary course of business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) BLAC has not been a member of an affiliated group filing a consolidated, combined, or unitary U.S. federal, state, local or foreign income Tax Return. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) BLAC has no liability for the Taxes of any person under Treasury Regulation <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local or foreign law), as a transferee or successor, by contract, or otherwise. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) BLAC (i)&#160;has no request for a ruling in respect of Taxes pending between BLAC, on the one hand, and any Tax authority, on the other hand, or (ii)&#160;has not entered into any closing agreement, private letter ruling technical advice memoranda or similar agreements with any Tax authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) BLAC has not in any year for which the applicable statute of limitations remains open distributed stock of another person, and has not had its stock distributed by another person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 or Section&#160;361 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) BLAC has not engaged in or entered into a &#8220;listed transaction&#8221; within the meaning of Treasury Regulation <span style="white-space:nowrap">Section&#160;1.6011-4(b)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_63">5.15 <span style="text-decoration:underline">Listing</span>. The issued and outstanding BLAC Units are registered pursuant to Section&#160;12(b) of the Exchange Act and are listed for trading on Nasdaq under the symbol &#8220;BLACU&#8221;. The issued and outstanding shares of BLAC Common Stock are registered pursuant to Section&#160;12(b) of the Exchange Act and are listed for trading on Nasdaq under the symbol &#8220;BLAC&#8221;. The issued and outstanding BLAC Warrants are registered pursuant to Section&#160;12(b) of the Exchange Act and are listed for trading on Nasdaq under the symbol &#8220;BLACW&#8221;. The issued and outstanding BLAC Rights are registered pursuant to Section&#160;12(b) of the Exchange Act and are listed for trading on Nasdaq under the symbol &#8220;BLACR&#8221;. As of the Execution Date, there is no Action pending or, to the knowledge of BLAC, threatened in writing against BLAC by Nasdaq or the SEC with respect to any intention by such entity to deregister the BLAC Units, the shares of BLAC Common Stock, the BLAC Warrants, the BLAC Rights, or terminate the listing of BLAC on Nasdaq. None of BLAC or any of its affiliates has taken any action in an attempt to terminate the registration of the BLAC Units, the shares of BLAC Common Stock, the BLAC Warrants or the BLAC Rights under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_64">5.16 <span style="text-decoration:underline">BLAC</span><span style="text-decoration:underline">&#8217;</span><span style="text-decoration:underline">s Investigation and Reliance</span>. BLAC is a sophisticated purchaser and has made its own independent investigation, review and analysis regarding the Company and any Company Subsidiary and the Transactions, which investigation, review and analysis were conducted by BLAC together with expert advisors, including legal counsel, that they have engaged for such purpose. BLAC and its Representatives have been provided with full and complete access to the Representatives, properties, offices, plants and other facilities, books and records of the Company and any Company Subsidiary and other information that they have requested in connection with their investigation of the Company and Company Subsidiary and the Transactions. BLAC is not relying on any statement, representation, or warranty, oral or written, express or implied, made by the Company or any Company Subsidiary or any of their respective Representatives, except as expressly set forth in Article III (as modified by the Company Disclosure Schedule). Neither the Company nor any of its respective stockholders, affiliates or Representatives shall have any liability to BLAC or any of its stockholders, affiliates or Representatives resulting from the use of any information, documents or materials made available to BLAC or any of its Representatives, whether orally or in writing, in any confidential information memoranda, &#8220;data </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rooms,&#8221; management presentations, due diligence discussions or in any other form in expectation of the Transactions. Neither the Company nor any of its stockholders, affiliates or Representatives is making, directly or indirectly, any representation or warranty with respect to any estimates, projections or forecasts involving the Company and/or any Company Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_65">5.17 <span style="text-decoration:underline">Exclusivity of Representations and Warranties</span>. Except as otherwise expressly provided in this Article V (as modified by the BLAC SEC Reports and any schedule to this Article V), BLAC hereby expressly disclaims and negates, any other express or implied representation or warranty whatsoever (whether at Law or in equity) with respect to BLAC, its affiliates, and any matter relating to any of them, including their affairs, the condition, value or quality of the assets, liabilities, financial condition or results of operations, or with respect to the accuracy or completeness of any other information made available to the Company, its affiliates or any of their respective Representatives by, or on behalf of, BLAC, and any such representations or warranties are expressly disclaimed. Without limiting the generality of the foregoing, except as expressly set forth in this Agreement, neither BLAC nor any other person on behalf of BLAC has made or makes, any representation or warranty, whether express or implied, with respect to any projections, forecasts, estimates or budgets made available to the Company, its affiliates or any of their respective Representatives of future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of BLAC (including the reasonableness of the assumptions underlying any of the foregoing), whether or not included in any management presentation or in any other information made available to the Company, its affiliates or any of their respective Representatives or any other person, and that any such representations or warranties are expressly disclaimed. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_66">ARTICLE VI </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDUCT OF THE BUSINESS PENDING THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_67">6.01 <span style="text-decoration:underline">Conduct of Business by the Company Pending the Business Combination.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees that, between the Execution Date and the Effective Time or the earlier termination of this Agreement, except as (1)&#160;expressly contemplated by any other provision of this Agreement or any Ancillary Agreement, or (2)&#160;required by applicable Law (including <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), unless BLAC shall otherwise consent in writing (which consent shall not be unreasonably conditioned, withheld or delayed): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Company shall, and shall cause the Company Subsidiaries to, conduct their business in the ordinary course of business and in a manner consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Company shall use its commercially reasonable efforts to preserve substantially intact the business organization of the Company and the Company Subsidiaries, to keep available the services of the current officers, key employees and Contingent Workers of the Company and the Company Subsidiaries and to preserve the current relationships of the Company and the Company Subsidiaries with customers, suppliers and other persons with which the Company or any Company Subsidiary has significant business relations; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) By way of amplification and not limitation, except as (1)&#160;expressly contemplated by any other provision of this Agreement, any Ancillary Agreement, and (2)&#160;required by applicable Law (including <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), the Company shall not, and shall cause each Company Subsidiary not to, between the Execution Date and the Effective Time or the earlier termination of this Agreement, directly or indirectly, do any of the following without the prior written consent of BLAC (which consent shall not be unreasonably conditioned, withheld or delayed): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) amend or otherwise change its articles of incorporation or equivalent organizational documents; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) issue, sell, pledge, dispose of, grant or encumber, or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, (A)&#160;any shares of any class of capital stock of the Company or any Company Subsidiary, or any options, warrants, convertible securities or other rights of any kind to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
acquire any shares of such capital stock, or any other ownership interest (including, without limitation, any phantom interest), of the Company or any Company Subsidiary; or (B)&#160;any material assets of the Company or any Company Subsidiary except in the ordinary course of business and consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital stock; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of its capital stock, other than redemptions of equity securities from former employees upon the terms set forth in the underlying agreements governing such equity securities; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) (A) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any corporation, partnership, other business organization or any division thereof in an amount in excess of $100,000; or (B)&#160;incur any indebtedness for borrowed money in excess of $100,000 or issue any debt securities or assume, guarantee or endorse, or otherwise become responsible for, the obligations of any person, or make any loans or advances, or intentionally grant any security interest in any of its assets, in each case, except in the ordinary course of business and consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) (A) grant any increase in the compensation, incentives or benefits payable or to become payable to any current or former director, officer, employee or Contingent Worker of the Company as of the Execution Date, other than increases in base compensation of employees in the ordinary course of business that do not exceed 20% of base compensation, individually or in the aggregate, and increases required by the terms of a Plan or applicable Law, (B)&#160;enter into any new, or amend any existing employment or severance or termination agreement with any current or former director, officer, employee or Contingent Worker, (C)&#160;accelerate or commit to accelerate the funding, payment, or vesting of any compensation or benefits to any current or former director, officer, employee or Contingent Worker, or (D)&#160;terminate or hire, or otherwise enter into any employment or consulting agreement or arrangement with, any person whose compensation would exceed, on an annualized basis, $100,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) other than as required by Law or pursuant to the terms of an agreement entered into prior to the Execution Date and reflected on <span style="text-decoration:underline">Schedule 3.10(a)</span> of the Company Disclosure Schedule or that the Company is not prohibited from entering into after the Execution Date, grant any severance or termination pay to, any director or officer of the Company or of any Company Subsidiary, other than in the ordinary course of business consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) adopt, amend, and/or terminate any Plan except as may be required by applicable Law, is necessary in order to consummate the Transactions, or health and welfare plan renewals in the ordinary course of business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) materially amend other than reasonable and usual amendments in the ordinary course of business, with respect to accounting policies or procedures, other than as required by the Accounting Standards; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) make, change or revoke any material Tax election, amend a material Tax Return or settle or compromise any material United States federal, state, local or <span style="white-space:nowrap">non-United</span> States income Tax liability; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) materially amend, or modify or consent to the termination (excluding any expiration in accordance with its terms) of any Material Contract or amend, waive, modify or consent to the termination (excluding any expiration in accordance with its terms) of the Company&#8217;s or any Company Subsidiary&#8217;s material rights thereunder, in each case in a manner that is adverse to the Company or any Company Subsidiary, taken as a whole, except in the ordinary course of business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) make any alterations or improvements to the Owned Real Property or the Leased Real Property, or amend any written or oral agreements affecting the Owned Real Property or the Leased Real Property; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) intentionally permit any material item of Company IP to lapse or to be abandoned, invalidated, dedicated to the public, or disclaimed, or otherwise become unenforceable or fail to perform or make any applicable filings, recordings or other similar actions or filings, or fail to pay all required fees and taxes required or advisable to maintain and protect its interest in each and every material item of Company IP; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) enter into any formal or informal agreement or otherwise make a binding commitment to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_68">6.02 <span style="text-decoration:underline">Conduct of Business by BLAC Pending the Business Combination</span>. Except as expressly contemplated by any other provision of this Agreement or any Ancillary Agreement (including entering into the PIPE Subscription Agreements, consummating the PIPE Investment, and as required by applicable Law (including any <span style="white-space:nowrap">COVID-19</span> Measures or as may be requested or compelled by any Governmental Authority), BLAC agrees that from the Execution Date until the earlier of the termination of this Agreement and the Effective Time, unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), the business of BLAC shall be conducted in the ordinary course of business and in a manner consistent with past practice. By way of amplification and not limitation, except as expressly contemplated by any other provision of this Agreement or any Ancillary Agreement (including entering into the PIPE Subscription Agreements and consummating the PIPE Investment), or in connection with the terms and conditions of, the PIPE Subscription Agreements, or as required by applicable Law (including any <span style="white-space:nowrap">COVID-19</span> Measures as may be requested or compelled by any Governmental Authority), BLAC shall not, between the Execution Date and the Effective Time or the earlier termination of this Agreement, directly or indirectly, do any of the following without the prior written consent of the Company, which consent shall not be unreasonably withheld, delayed or conditioned: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) amend or otherwise change the BLAC Organizational Documents or form any subsidiary of BLAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) declare, set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital stock, other than redemptions from the Trust Fund that are required pursuant to the BLAC Organizational Documents; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) reclassify, combine, split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of the BLAC Common Stock, BLAC Warrants or BLAC Rights except for redemptions from the Trust Fund that are required pursuant to the BLAC Organizational Documents; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) other than pursuant to the PIPE Subscription Agreements, issue, sell, pledge, dispose of, grant or encumber, or authorize the issuance, sale, pledge, disposition, grant or encumbrance of, any shares of any class of capital stock or other securities of BLAC, or any options, warrants, convertible securities or other rights of any kind to acquire any shares of such capital stock, or any other ownership interest (including, without limitation, any phantom interest), of BLAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any corporation, partnership, other business organization or enter into any strategic joint ventures, partnerships or alliances with any other person; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) engage in any conduct in a new line of business or engage in any commercial activities (other than to consummate the transactions contemplated by this Agreement); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) incur any indebtedness for borrowed money or guarantee any such indebtedness of another person or persons, issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of BLAC, as applicable, enter into any &#8220;keep well&#8221; or other agreement to maintain any financial statement condition or enter into any arrangement having the economic effect of any of the foregoing, in each case, except in the ordinary course of business consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) make any change in any method of financial accounting or financial accounting principles, policies, procedures or practices, except as required by a concurrent amendment in GAAP or applicable Law made subsequent to the Execution Date, as agreed to by its independent accountants; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) make any material Tax election or settle or compromise any material United States federal, state, local or <span style="white-space:nowrap">non-United</span> States income Tax liability, except in the ordinary course consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) liquidate, dissolve, reorganize or otherwise wind up the business and operations of BLAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) amend the Trust Agreement or any other agreement related to the Trust Account; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) (i) hire, or otherwise enter into any employment or consulting agreement or arrangement with, any person, (ii)&#160;grant any material increase in the compensation of any current or former officer or director, (iii)&#160;adopt any benefit plan for the benefit of any current or former officer or director, or (iv)&#160;materially amend any existing agreement with any current or former officer or director; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) enter into any formal or informal agreement or otherwise make a binding commitment to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_69">6.03 <span style="text-decoration:underline">Claims against Trust Account</span>. The Company agrees that, notwithstanding any other provision contained in this Agreement, the Company does not now have, and shall not at any time prior to the Effective Time have, any claim to, or make any claim against, the Trust Fund, regardless of whether such claim arises as a result of, in connection with or relating in any way to, the business relationship between the Company on the one hand, and BLAC on the other hand, this Agreement, or any other agreement or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.03</span> as the &#8220;<span style="font-weight:bold">Claims</span>&#8221;). Notwithstanding any other provision contained in this Agreement, the Company hereby irrevocably waives any Claim they may have, now or in the future and will not seek recourse against the Trust Fund for any reason whatsoever in respect thereof; provided, however, that the foregoing waiver will not limit or prohibit the Company from pursuing a claim against BLAC or any other person (a)&#160;for legal relief against monies or other assets of BLAC held outside of the Trust Account or for specific performance or other equitable relief in connection with the Transactions or (b)&#160;for damages for breach of this Agreement against BLAC (or any successor entity) in the event this Agreement is terminated for any reason and BLAC consummates a business combination transaction with another party. In the event that the Company commences any action or proceeding against or involving the Trust Fund in violation of the foregoing, BLAC shall be entitled to recover from the Company the associated reasonable legal fees and costs in connection with any such action, in the event BLAC prevails in such action or proceeding. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_70">ARTICLE VII </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ADDITIONAL AGREEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_71">7.01 <span style="text-decoration:underline">Proxy Statement.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the execution of this Agreement, BLAC (with the assistance and cooperation of the Company as reasonably requested by BLAC) shall prepare and file with the SEC a proxy statement/prospectus (as amended or supplemented, the &#8220;<span style="font-weight:bold">Proxy Statement</span>&#8221;) to be sent to the stockholders of BLAC for the meeting of BLAC&#8217;s stockholders (the &#8220;<span style="font-weight:bold">BLAC Stockholders</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold"> Meeting</span>&#8221;) to be held to consider approval and adoption of (1)&#160;this Agreement and the Business Combination, (2)&#160;the second amended and restated BLAC Certificate of Incorporation, (3)&#160;the Equity Plan, (4)&#160;the election of the Initial Post-Closing BLAC Directors to serve as the members of the BLAC Board as of immediately following the Effective Time and until their respective successors are duly elected or appointed and qualified, and (5)&#160;any other proposals the Parties deem necessary to effectuate the Business Combination (collectively, the &#8220;<span style="font-weight:bold">BLAC Proposals</span>&#8221;). The Company shall furnish all information concerning the Company and the Company Subsidiaries as BLAC may reasonably request in connection with the preparation of the Proxy Statement. BLAC and the Company each shall use their reasonable best efforts to (i)&#160;cause the Proxy Statement when filed with the SEC to comply in all material respects with all legal requirements applicable thereto, (ii)&#160;respond as promptly as reasonably practicable to and resolve all comments received from the SEC concerning the Proxy Statement, (iii)&#160;to keep the Proxy Statement current as long as is necessary to consummate the transactions contemplated hereby. Prior to the effective date of the Proxy Statement, BLAC shall take all or any action required under any applicable federal or state securities laws in connection with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the issuance of shares of BLAC Common Stock, in each case to be issued or issuable to the stockholders of the Company pursuant to this Agreement. As promptly as practicable after the Proxy Statement has been resolved of all comments from the SEC, each of the Company and BLAC shall mail the Proxy Statement to their respective stockholders. Each of BLAC and the Company shall furnish all information concerning it as may reasonably be requested by the other Party in connection with such actions and the preparation of the Proxy Statement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No filing of, or amendment or supplement to the Proxy Statement, will be made by BLAC without the approval of the Company (such approval not to be unreasonably withheld, conditioned, or delayed). BLAC will advise the Company, promptly after they receive notice thereof, of the time when the Proxy Statement has been resolved of all SEC comments or any supplement or amendment has been filed, of the issuance of any stop order, of the suspension of the qualification of the BLAC Common Stock to be issued or issuable to the stockholders of the Company in connection with this Agreement for offering or sale in any jurisdiction, or of any request by the SEC for amendment of the Proxy Statement or comments thereon and responses thereto or requests by the SEC for additional information. Each of BLAC and the Company shall cooperate and mutually agree upon (such agreement not to be unreasonably withheld or delayed), any response to comments of the SEC or its staff with respect to the Proxy Statement and any amendments or supplements filed in response thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) BLAC represents that the information supplied by BLAC for inclusion in the Proxy Statement shall not, at (i)&#160;the time the Proxy Statement (or any amendment thereof or supplement thereto) is first mailed to the stockholders of BLAC, (ii)&#160;the time of the BLAC Stockholders&#8217; Meeting, and (iii)&#160;the Effective Time, contain any untrue statement of a material fact or fail to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If, at any time prior to the Effective Time, any event or circumstance relating to BLAC or its officers or directors, should be discovered by BLAC which should be set forth in an amendment or a supplement to the Proxy Statement, BLAC shall promptly inform the Company. All documents that BLAC is responsible for filing with the SEC in connection with the Business Combination or the other transactions contemplated by this Agreement will comply as to form and substance in all material respects with the applicable requirements of the Securities Act and the rules and regulations thereunder and the Exchange Act and the rules and regulations thereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company represents that the information supplied by the Company for inclusion in the Proxy Statement shall not, at (i)&#160;the time the Proxy Statement (or any amendment thereof or supplement thereto) is first mailed to the stockholders of BLAC, (ii)&#160;the time of the BLAC Stockholders&#8217; Meeting, and (iii)&#160;the Effective Time, contain any untrue statement of a material fact or fail to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If, at any time prior to the Effective Time, any event or circumstance relating to the Company or any Company Subsidiary, or their respective officers or directors, should be discovered by the Company which should be set forth in an amendment or a supplement to the Proxy Statement, the Company shall promptly inform BLAC. All documents that the Company is responsible for filing with the SEC in connection with the Business Combination or the other transactions contemplated by this Agreement will comply as to form and substance in all material respects with the applicable requirements of the Securities Act and the rules and regulations thereunder and the Exchange Act and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_72">7.02 <span style="text-decoration:underline">BLAC Stockholders</span><span style="text-decoration:underline">&#8217;</span><span style="text-decoration:underline"> Meetings.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) BLAC shall call and hold the BLAC Stockholders&#8217; Meeting as promptly as practicable after the date on which the Proxy Statement becomes effective for the purpose of voting solely upon the BLAC Proposals, and BLAC shall use its reasonable best efforts to hold the BLAC Stockholders&#8217; Meeting as soon as practicable after the date on which the Proxy Statement has been resolved of all comments from the SEC (but in any event no later than 30 days after the date on which the Proxy Statement is mailed to stockholders of BLAC). BLAC shall use its reasonable best efforts to obtain the approval of the BLAC Proposals at the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
BLAC Stockholders&#8217; Meeting, including by soliciting from its stockholders&#8217; proxies as promptly as possible in favor of the BLAC Proposals, and shall take all other action necessary or advisable to secure the required vote or consent of its stockholders. The BLAC Board shall recommend to its stockholders that they approve the BLAC Proposals and shall include such recommendation in the Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_73">7.03 <span style="text-decoration:underline">Minimum Participation by Company Stockholders</span>. The Company shall use its best efforts to cause the holders of (a)&#160;at least 60% of the Company Fully Diluted Share Amount to execute Participating Stockholder Joinders to this Agreement and become Participating Company Stockholders on or prior to the Closing, and (b) 100% of the Company Fully Diluted Share Amount to execute Joinders to this Agreement prior to the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_74">7.04 <span style="text-decoration:underline">Access to Information; Confidentiality.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From the Execution Date until the Effective Time, the Company and BLAC shall (and shall cause their respective subsidiaries to): (i) provide to the other party (and the other party&#8217;s officers, directors, employees, accountants, consultants, legal counsel, agents and other representatives, collectively, &#8220;<span style="font-weight:bold">Representatives</span>&#8221;) reasonable access at reasonable times upon prior notice to the officers, agents, properties, offices and other facilities of such party and its subsidiaries and to the books and records thereof; and (ii)&#160;furnish promptly to the other party such information concerning the business, properties, contracts, assets, liabilities, personnel and other aspects of such party and its subsidiaries as the other party or its Representatives may reasonably request. Notwithstanding the foregoing, neither the Company nor BLAC shall be required to provide access to or disclose information where the access or disclosure would (i)&#160;jeopardize the protection of attorney-client privilege or contravene applicable Law including <span style="white-space:nowrap">COVID-19</span> Measures or (ii)&#160;require providing access that such party reasonably determines, in light of <span style="white-space:nowrap">COVID-19</span> or <span style="white-space:nowrap">COVID-19</span> Measures, would jeopardize the health and safety of any employee of such party (it being agreed that the parties shall use their commercially reasonable efforts to cause such information to be provided in a manner that would not result in such jeopardy or contravention). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All information obtained by the parties pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.04</span> shall be kept confidential in accordance with the confidentiality agreement, dated March&#160;30, 2023 (the &#8220;<span style="font-weight:bold">Confidentiality Agreement</span>&#8221;), between BLAC and the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_75">7.05 <span style="text-decoration:underline">Exclusivity.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From the Execution Date and ending on the earlier of (i)&#160;the Closing and/or (ii)&#160;the termination of this Agreement, the Company shall not, and shall cause its Representatives not to, directly or indirectly, (A)&#160;enter into, solicit, initiate or continue any discussions or negotiations with, or encourage or respond to any inquiries or proposals by, or participate in any negotiations with, or provide any information to, or otherwise cooperate in any way with, any person or other entity or &#8220;group&#8221; within the meaning of Section&#160;13(d) of the Exchange Act, concerning (1)&#160;any sale of assets of the Company equal to 5% or more of the Company&#8217;s assets or to which 5% or more of the Company&#8217;s revenues or earnings are attributable, (2)&#160;the issuance or acquisition of 5% or more of the outstanding capital stock (on an as converted to Company Common Stock basis) or other voting securities representing 5% or more of the combined voting power of the Company, or (3)&#160;any conversion, consolidation, merger, liquidation, dissolution or similar transaction which, if consummated, would result in any person or other entity or group beneficially owning 5% or more of the combined voting power of the Company, other than with BLAC and its Representatives (an &#8220;<span style="font-weight:bold">Alternative Transaction</span>&#8221;), (B) enter into any agreement regarding, continue or otherwise participate in any discussions regarding, or furnish to any person any information with respect to, or cooperate in any way that would otherwise reasonably be expected to lead to, any Alternative Transaction, or (C)&#160;commence, continue or renew any due diligence investigation regarding any Alternative Transaction; <span style="text-decoration:underline">provided</span>, that the execution, delivery and performance of this Agreement and the Transaction Documents and the consummation of the transactions contemplated hereby shall not be deemed a violation of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.05(a)</span>. The Company shall, and shall cause its affiliates and Representatives to, immediately cease any and all existing discussions or negotiations with any person conducted heretofore with respect to any Alternative Transaction. The Company also agrees that it will promptly request each person (other than the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
parties hereto and their respective Representatives) that has prior to the Execution Date executed a confidentiality agreement in connection with its, his or her consideration of acquiring the Company to return or destroy all Confidential Information furnished to such person by or on behalf of it, him, or her prior to the Execution Date. If the Company or any of its Representatives receives any inquiry or proposal with respect to an Alternative Transaction at any time prior to the Closing, then the Company shall promptly (and in no event later than twenty-four (24)&#160;hours after the Company become aware of such inquiry or proposal) notify such person in writing that the Company is subject to an exclusivity agreement with respect to the sale of the Company that prohibits it from considering such inquiry or proposal, and will provide BLAC with a copy of any such written inquiry or proposal or a detailed summary of any such verbal inquiry or proposal, including in each case the identity of the person making such inquiry or proposal. Without limiting the foregoing, the parties agree that any violation of the restrictions set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.05(a)</span> by the Company or its affiliates or Representatives shall be deemed to be a breach of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.05(a)</span> by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_76">7.06 <span style="text-decoration:underline">Employee Benefit Matters.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) BLAC and the Company shall cooperate to establish an equity incentive award plan, wherein BLAC, upon consummation of the Business Combination, may grant cash and equity incentive awards and compensation to management and eligible service providers, with an initial award pool of BLAC Common Stock equal to the lesser of twenty percent of the shares of BLAC Common Stock outstanding as of immediately after the Effective Time (rounded up to the nearest whole share) or 6,300,000 shares of BLAC Common Stock, which plan shall include an &#8220;evergreen&#8221; provision pursuant to which such award pool will automatically increase on each January 1<sup style="font-size:75%; vertical-align:top">st </sup>that occurs within the ten year period following shareholder approval of such plan by an amount equal to three percent of the shares of BLAC Common Stock outstanding as of 12:01 a.m. (Eastern Time) on such date, and which plan shall be effective at and after the Closing (the &#8220;<span style="font-weight:bold">Equity Plan</span>&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.06</span> are solely for the benefit of the Parties to the Agreement, and nothing contained in this Agreement, express or implied, shall confer upon any employees or legal representative or beneficiary or dependent thereof, or any other person, any rights or remedies of any nature or kind whatsoever under or by reason of this Agreement, whether as a third-party beneficiary or otherwise, including, without limitation, any right to employment or continued employment for any specified period, or level of compensation or benefits. Nothing contained in this Agreement, express or implied, shall constitute an amendment or modification of any employee benefit plan of the Company or shall require the Company or BLAC, and each of its subsidiaries to continue any Plan or other employee benefit arrangements, or prevent their amendment, modification, or termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_77">7.07 <span style="text-decoration:underline">Notification of Certain Matters</span>. The Company shall give prompt notice to BLAC, and BLAC shall give prompt notice to the Company, of any event which a Party becomes aware of between the Execution Date and the Closing (or the earlier termination of this Agreement in accordance with Article IX), the occurrence, or <span style="white-space:nowrap">non-occurrence</span> of which causes or would reasonably be expected to cause any of the conditions set forth in Article VIII to fail to be satisfied at the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_78">7.08 <span style="text-decoration:underline">Further Action; Reasonable Best Efforts.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon the terms and subject to the conditions of this Agreement, each of the Parties hereto shall use its reasonable best efforts to take, or cause to be taken, appropriate action, and to do, or cause to be done, such things as are necessary, proper or advisable under applicable Laws or otherwise to consummate and make effective the Transactions, including, without limitation, using its reasonable best efforts to obtain all permits, consents, approvals, authorizations, qualifications and orders of Governmental Authorities and parties to contracts with the Company and the Company Subsidiaries as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.05</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.03</span> necessary for the consummation of the Transactions and to fulfill the conditions to the Business Combination. In case, at any time after the Effective Time, any further action is necessary or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
desirable to carry out the purposes of this Agreement, the proper officers and directors of each Party shall use their reasonable best efforts to take all such action. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of the Parties shall keep each other apprised of the status of matters relating to the Transactions, including promptly notifying the other Parties of any communication it or any of its affiliates receives from any Governmental Authority relating to the matters that are the subject of this Agreement and permitting the other Parties to review in advance, and to the extent practicable consult about, any proposed communication by such Party to any Governmental Authority in connection with the Transactions. No Party to this Agreement shall agree to participate in any meeting with any Governmental Authority in respect of any filings, investigation, or other inquiry unless it consults with the other Parties in advance and, to the extent permitted by such Governmental Authority, gives the other Parties the opportunity to attend and participate at such meeting. Subject to the terms of the Confidentiality Agreement, the Parties will coordinate and cooperate fully with each other in exchanging such information and providing such assistance as the other Parties may reasonably request in connection with the foregoing. Subject to the terms of the Confidentiality Agreement, the Parties will provide each other with copies of all material correspondence, filings, or communications, including any documents, information and data contained therewith, between them or any of their Representatives, on the one hand, and any Governmental Authority or members of its staff, on the other hand, with respect to this Agreement and the Transactions contemplated hereby. No Party shall take or cause to be taken any action before any Governmental Authority that is inconsistent with or intended to delay its action on requests for a consent or the consummation of the Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_79">7.09 <span style="text-decoration:underline">Public Announcements</span>. The initial press release relating to this Agreement shall be a joint press release the text of which has been agreed to by each of BLAC and the Company. Thereafter, between the Execution Date and the Closing Date (or the earlier termination of this Agreement in accordance with Article IX) unless otherwise prohibited by applicable Law or the requirements of Nasdaq, each of BLAC and the Company shall each consult with each other before issuing any press release or otherwise making any public statements with respect to this Agreement, the Business Combination or any of the other Transactions, and shall not issue any such press release or make any such public statement without the prior written consent of the other Party. Furthermore, nothing contained in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.09</span> shall prevent BLAC or the Company and/or its respective affiliates from furnishing customary or other reasonable information concerning the Transactions to their investors and prospective investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_80">7.10 <span style="text-decoration:underline">Tax Matters</span>. To the extent that the SEC or any other Governmental Authority may require that an opinion be provided at or prior to the Closing in respect of the disclosure of the Tax consequences of the Transactions, each of BLAC and the Company will use its reasonable best efforts and reasonably cooperate with one another and their respective counsel in connection with the issuance to BLAC or the Company of such opinion, as applicable, described above, including using reasonable best efforts to deliver to the relevant counsel certificates (dated as of the necessary date and signed by an officer of BLAC or the Company, or their respective affiliates, as applicable) containing customary representations reasonably necessary or appropriate for such counsel to render such opinion. To the extent such opinion relates to BLAC or any owners thereof, Tax advisors for BLAC will provide any such opinion, and to the extent such opinion relates to the Company or any owners thereof, Tax advisors for the Company will provide any such opinion, in each case, to the extent reasonably possible subject to customary assumptions and limitations and consistent with such Tax advisor&#8217;s internal policies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_81">7.11 <span style="text-decoration:underline">Stock Exchange Listing</span>. BLAC will use its reasonable best efforts to cause the Aggregate Participating Consideration issued in connection with the Transactions to be approved for listing on Nasdaq at Closing. During the period from the Execution Date until the Closing, BLAC shall use its reasonable best efforts to keep the BLAC Units, BLAC Common Stock, BLAC Warrants and BLAC Rights listed for trading on Nasdaq. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_82">7.12 <span style="text-decoration:underline">Antitrust.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To the extent required under any Laws that are designed to prohibit, restrict, or regulate actions having the purpose or effect of monopolization or restraint of trade, including the HSR Act (&#8220;<span style="font-weight:bold">Antitrust Laws</span>&#8221;), each Party hereto agrees to promptly make any required filing or application under Antitrust Laws, as applicable. The Parties hereto agree to supply as promptly as reasonably practicable any additional information and documentary material that may be requested pursuant to Antitrust Laws and to use commercially reasonable efforts to take any other actions necessary, proper or advisable to cause the expiration or termination of the applicable waiting periods or obtain required approvals, as applicable under Antitrust Laws as soon as reasonably practicable, including by requesting early termination of the waiting period provided for under the HSR Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Party shall, in connection with its efforts to obtain all requisite approvals and authorizations for the Transactions under any Antitrust Law, use its commercially reasonable efforts to: (i)&#160;cooperate in all respects with each other Parties or their affiliates in connection with any filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private person; (ii)&#160;keep the other Parties reasonably informed of any communication received by such Party or its Representatives from, or given by such Party or its Representatives to, any Governmental Authority and of any communication received or given in connection with any proceeding by a private person, in each case regarding any of the Transactions; (iii)&#160;permit a Representative of the other Parties and their respective outside counsel to review any communication given by it to, and consult with each other in advance of any meeting or conference with, any Governmental Authority or, in connection with any proceeding by a private person, with any other person, and to the extent permitted by such Governmental Authority or other person, give a Representative or Representatives of the other Parties the opportunity to attend and participate in such meetings and conferences; (iv)&#160;in the event a Party&#8217;s Representative is prohibited from participating in or attending any meetings or conferences, the other Parties shall keep such Party promptly and reasonably apprised with respect thereto; and (v)&#160;use commercially reasonable efforts to cooperate in the filing of any memoranda, white papers, filings, correspondence or other written communications explaining or defending the Transactions, articulating any regulatory or competitive argument, and/or responding to requests or objections made by any Governmental Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No Party hereto shall take any action that could reasonably be expected to adversely affect or materially delay the approval of any Governmental Authority of any required filings or applications under Antitrust Laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_83">7.13 <span style="text-decoration:underline">Trust Account</span>. As of the Effective Time, the obligations of BLAC to dissolve or liquidate within a specified time period as contained in BLAC&#8217;s Certificate of Incorporation will be terminated and BLAC shall have no obligation whatsoever to dissolve and liquidate the assets of BLAC by reason of the consummation of the Business Combination or otherwise, and no stockholder of BLAC shall be entitled to receive any amount from the Trust Account. At least 48 hours prior to the Effective Time, BLAC shall provide notice to the Trustee in accordance with the Trust Agreement and shall deliver any other documents, opinions or notices required to be delivered to the Trustee pursuant to the Trust Agreement and cause the Trustee prior to the Effective Time to, and the Trustee shall thereupon be obligated to, transfer all funds held in the Trust Account to BLAC (to be held as available cash on the balance sheet of BLAC, and to be used for working capital and other general corporate purposes of the business following the Closing) and thereafter shall cause the Trust Account and the Trust Agreement to terminate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_84">7.14 <span style="text-decoration:underline">Section 16 Matters</span>. Prior to the Closing, BLAC shall take all such steps as may be required (to the extent permitted under applicable Law and <span style="white-space:nowrap">no-action</span> letters issued by the SEC) to cause any acquisition of BLAC Common Stock by each individual who is or will be subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to the post-closing company, to be exempt under Rule <span style="white-space:nowrap">16b-3</span> under the Exchange Act. BLAC shall provide such individuals with copies of any resolutions proposed to be adopted by the BLAC Board in connection with the foregoing prior to such adoption. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_85">ARTICLE VIII </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDITIONS TO THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_86">8.01 <span style="text-decoration:underline">Conditions to the Obligations of Each Party</span>. The obligations of the Company, BLAC and the Company Stockholders to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">BLAC Stockholders&#8217; Approval</span>(b) . The BLAC Proposals shall have been approved and adopted by the requisite affirmative vote of the stockholders of BLAC in accordance with the Proxy Statement, the DGCL, the BLAC Organizational Documents and the rules and regulations of Nasdaq. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">No Order</span>. No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law, rule, regulation, judgment, decree, executive order, or award which is then in effect and has the effect of making the Transactions, including the Business Combination, illegal or otherwise prohibiting consummation of the Transactions, including the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Regulatory Filings, Approvals and Waiting Periods</span>. All required regulatory filings and approvals in the United States and outside the United States, including under the HSR Act, shall have been completed and any applicable waiting period (and any extension thereof) applicable to the consummation of the Transactions under the HSR Act shall have expired or been terminated, and any <span style="white-space:nowrap">pre-Closing</span> approvals or clearances reasonably required thereunder shall have been obtained. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Consents</span>. All consents, approvals and authorizations set forth on <span style="text-decoration:underline">Schedule 3.05(a)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.03</span> of the Company Disclosure Schedule shall have been obtained from and made with all Governmental Authorities. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">Stock Exchange Listing</span>. The shares of BLAC Common Stock shall be listed on Nasdaq as of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_87">8.02 <span style="text-decoration:underline">Conditions to the Obligations of BLAC</span>. The obligations of BLAC to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following additional conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Representations and Warranties</span>. The representations and warranties of the Company contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.01</span> (Organization and Qualification; Subsidiaries), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.03</span> (Capitalization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.04</span> (Authority Relative to this Agreement), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.27</span> (Brokers) and the representations and warranties of each Company Stockholder in <span style="text-decoration:underline">Article IV</span> shall each be true and correct in all material respects as of the Closing Date as though made on the Closing Date (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein), except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date. All other representations and warranties of the Company contained in this Agreement shall be true and correct (without giving any effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date, except (i)&#160;to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date and (ii)&#160;where the failure of such representations and warranties to be true and correct (whether as of the Closing Date or such earlier date), taken as a whole, does not result in a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Agreements and Covenants</span>. The Company and each Participating Company Stockholder shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed, or complied with by it on or prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Officer Certificate</span>. The Company shall have delivered to BLAC a certificate, dated the date of the Closing, signed by an officer of the Company, certifying as to the satisfaction of the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.02(d)</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Material Adverse Effect</span>. No Company Material Adverse Effect shall have occurred between the Execution Date and the Closing Date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">Resignation</span>. Other than those persons identified as continuing directors as per <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.08</span> hereof, all members of the Company Board and the Board of Directors of the Company Subsidiaries shall have executed written resignations effective as of the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>. The Company has delivered, or has caused to be delivered, to BLAC the <span style="white-space:nowrap">Lock-Up</span> Agreements duly executed by such holders of the Company Common Stock as agreed between BLAC and the Company within 60 days from the date of execution of this Agreement; provided, however, in the event all such holders of the Company Common Stock outstanding as of immediately prior to the Effective Time do not execute the <span style="white-space:nowrap">Lock-Up</span> Agreements delivered to BLAC, this condition shall be deemed to be satisfied if (i)&#160;none of such <span style="white-space:nowrap">non-executing</span> stockholders hold Company Common Stock in excess of 1% of the Company Common Stock outstanding immediately prior to the Effective Time, and (ii)&#160;the aggregate number of shares of Company Common Stock held by all <span style="white-space:nowrap">non-executing</span> stockholders is less than 10% of the outstanding Company Common Stock immediately prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Joinders</span>. The Company has delivered, or cause to be delivered, to BLAC (i)&#160;Participating Stockholder Joinders duly executed by Participating Company Stockholders holding at least 60% of the Company Fully Diluted Share Amount, (ii)&#160;and <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinders executed by each of the <span style="white-space:nowrap">Non-Participating</span> Company Stockholders. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <span style="text-decoration:underline">FIRPTA Tax Certificates</span>. On or prior to the Closing, the Company shall deliver to BLAC a properly executed certification that shares of Company Common Stock are not &#8220;U.S. real property interests&#8221; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS (which shall be filed by BLAC with the IRS following the Closing) in accordance with the provisions of <span style="white-space:nowrap">Section&#160;1.897-2(h)(2)</span> of the Treasury Regulations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <span style="text-decoration:underline">Fairness Opinion</span>. The BLAC M&amp;A Committee shall have received an opinion from an advisor engaged by the BLAC M&amp;A Committee that the Transactions are fair, from a financial point of view, to BLAC and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_88">8.03 <span style="text-decoration:underline">Conditions to the Obligations of the Company</span><span style="text-decoration:underline"> and the Company Stockholders</span>. The obligations of the Company and the Company Stockholders to consummate the Transactions, including the Business Combination, are subject to the satisfaction or waiver (where permissible) at or prior to the Closing of the following additional conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Representations and Warranties</span>. The representations and warranties of BLAC contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.01</span> (Corporate Organization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.03</span> (Capitalization), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.04</span> (Authority Relative to this Agreement), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.11</span> (Brokers) shall each be true and correct in all material respects as of the Closing Date as though made on the Closing Date (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;BLAC Material Adverse Effect&#8221; or any similar limitation set forth therein), except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date. All other representations and warranties of BLAC contained in this Agreement shall be true and correct (without giving any effect to any limitation as to &#8220;materiality&#8221; or &#8220;BLAC Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date, except (i)&#160;to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date and (ii)&#160;where the failure of such representations and warranties to be true and correct (whether as of the Closing Date or such earlier date), taken as a whole, does not result in a BLAC Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Agreements and Covenants</span>. BLAC shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed, or complied with, by it on or prior to the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Officer Certificate</span>. BLAC shall have delivered to the Company a certificate, dated the date of the Closing, signed by an officer of BLAC, certifying as to the satisfaction of the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(b)</span>, and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.03(d)</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Material Adverse Effect</span>. No BLAC Material Adverse Effect shall have occurred between the Execution Date and the Closing Date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">Stock Exchange Listing</span>. A supplemental listing shall have been filed with Nasdaq as of the Closing Date to list the shares constituting the Aggregate Participating Consideration. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>. BLAC shall have delivered a copy of the <span style="white-space:nowrap">Lock-Up</span> Agreements duly executed by BLAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Minimum Available Cash Condition</span>. The (i)&#160;amount of cash and cash equivalents available in the Trust Account immediately prior to the Closing, <span style="font-style:italic">plus </span>(ii)&#160;all other cash and cash equivalents of BLAC, plus (iii)&#160;the aggregate amount of cash proceeds received from the PIPE Investment prior to or substantially concurrently with the Closing (without, for the avoidance of doubt, taking into consideration any transaction fees, costs and expenses paid or required to be paid by BLAC prior to the Closing), shall be equal to or greater than $5,000,001. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_89">ARTICLE IX </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TERMINATION, AMENDMENT AND WAIVER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_90">9.01 <span style="text-decoration:underline">Termination</span>. This Agreement may be terminated, and the Business Combination and the other Transactions may be abandoned at any time prior to the Effective Time, notwithstanding any requisite approval and adoption of this Agreement and the Transactions by the stockholders of the Company or BLAC, as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of BLAC and the Company; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) by either BLAC or the Company if the Effective Time shall not have occurred on or prior to November&#160;14, 2024 (the &#8220;<span style="font-weight:bold">Outside Date</span>&#8221;); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that this Agreement may not be terminated under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(b)</span> by or on behalf of any Party that either directly or indirectly through its affiliates is in breach or violation of any representation, warranty, covenant, agreement or obligation contained herein and such breach or violation is the principal cause of the failure of a condition set forth in Article VIII on or prior to the Outside Date; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) by either BLAC or the Company if any Governmental Authority, including in the United States or the Republic of Korea, shall have enacted, issued, promulgated, enforced, or entered any injunction, order, decree or ruling (whether temporary, preliminary or permanent) which has become final and nonappealable and has the effect of making consummation of the Transactions, including the Business Combination, illegal or otherwise preventing or prohibiting consummation of the Transactions or the Business Combination; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) by either BLAC or the Company if any of the BLAC Proposals shall fail to receive the requisite vote for approval at the BLAC Stockholders&#8217; Meeting; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) by BLAC upon a breach of any representation, warranty, covenant or agreement on the part of the Company set forth in this Agreement, or if any representation or warranty of the Company shall have become untrue, in either case such that the conditions set forth in <span style="text-decoration:underline">Sections 8.02(a)</span> and <span style="text-decoration:underline">8.02(b)</span> would not be satisfied (&#8220;<span style="font-weight:bold">Terminating </span><span style="font-weight:bold">Company Breach</span>&#8221;); <span style="text-decoration:underline">provided</span> that BLAC has not waived such Terminating Company Breach and BLAC is not then in material breach of its representations, warranties, covenants or agreements in this Agreement; <span style="text-decoration:underline">provided</span> <span style="text-decoration:underline">further</span> that, if such Terminating Company Breach is curable by the Company, BLAC may not terminate this Agreement under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(e)</span> for so long as the Company continues to exercise its reasonable efforts to cure such breach, unless such breach is not cured within thirty (30)&#160;days after notice of such breach is provided by BLAC to the Company; or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) by the Company upon a breach of any representation, warranty, covenant or agreement on the part of BLAC set forth in this Agreement, or if any representation or warranty of BLAC shall have become untrue, in either case such that the conditions set forth in <span style="text-decoration:underline">Sections 8.03(a)</span> and 8.03<span style="text-decoration:underline">(b)</span> would not be satisfied (&#8220;<span style="font-weight:bold">Terminating BLAC </span><span style="font-weight:bold">Breach</span>&#8221;); <span style="text-decoration:underline">provided</span> that the Company has not waived such Terminating BLAC Breach and the Company is not then in material breach of their representations, warranties, covenants or agreements in this Agreement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that, if such Terminating BLAC Breach is curable by BLAC, the Company may not terminate this Agreement under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01(f)</span> for so long as BLAC continues to exercise their reasonable efforts to cure such breach, unless such breach is not cured within thirty (30)&#160;days after notice of such breach is provided by the Company to BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_91">9.02 <span style="text-decoration:underline">Effect of Termination</span>. In the event of the termination of this Agreement pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.01</span>, this Agreement shall forthwith become void, and there shall be no liability under this Agreement on the part of any Party hereto, except as set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.02</span>, Article IX<span style="text-decoration:underline">,</span> and any corresponding definitions set forth in Article I, or in the case of termination subsequent to a willful material breach of this Agreement by a Party hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_92">9.03 <span style="text-decoration:underline">Expenses</span>. Except as set expressly set forth in this Agreement, all expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring such expenses, whether or not the Business Combination or any other Transaction is consummated except that BLAC and the Company shall each pay one half of all expenses relating to all SEC and other regulatory filing fees incurred in connection with the Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_93">9.04 <span style="text-decoration:underline">Amendment</span>. This Agreement may be amended in writing by the Parties hereto at any time prior to the Effective Time. This Agreement may not be amended except by an instrument in writing signed by each of the Parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_94">9.05 <span style="text-decoration:underline">Waiver</span>. At any time prior to the Effective Time, (a)&#160;BLAC may (i)&#160;extend the time for the performance of any obligation or other act of the Company, (ii)&#160;waive any inaccuracy in the representations and warranties of the Company contained herein or in any document delivered by the Company pursuant hereto, and (iii)&#160;waive compliance with any agreement of the Company or any condition to its own obligations contained herein and (b)&#160;the Company may (i)&#160;extend the time for the performance of any obligation or other act of BLAC, (ii)&#160;waive any inaccuracy in the representations and warranties of BLAC contained herein or in any document delivered by BLAC pursuant hereto, and (iii)&#160;waive compliance with any agreement of BLAC or any condition to its own obligations contained herein. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the Party or Parties to be bound thereby. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxatoc476668_95">ARTICLE X </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">GENERAL PROVISIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_96">10.01 <span style="text-decoration:underline">Notices</span>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by email or by registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.01</span>): </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to BLAC: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Bellevue Life Sciences Acquisition Corp. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">10900 NE 4th Street, Suite 2300 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Bellevue, WA 98004 </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Attention:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Jin Whan Park and Kuk Hyoun Hwang </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Email:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">[**] and [**] </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">K&amp;L Gates LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">925 Fourth Avenue, Suite 2900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Seattle, WA 98104 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">USA </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Attention:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Gary Kocher and Adam Heyd </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Phone:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">(206) <span style="white-space:nowrap">579-0092</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">(206) <span style="white-space:nowrap">370-6656</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Email:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">gary.kocher@klgates.com </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">adam.heyd@klgates.com </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">OSR Holdings, Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">37-36</span> <span style="white-space:nowrap">Hoedong-gil,</span> B 3F <span style="white-space:nowrap">Paju-si,</span> Gyeonggi-do </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Republic of Korea </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Attention:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Sung Jae Yoo, COO </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Email:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">[**] </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Baker McKenzie KL Partners </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">17th Floor, East Wing, Signature Tower, 100 Cheonggyecheon&#8211;ro, </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jung&#8211;gu, Seoul, Korea 04542 </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Attention:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Seong Hoon (Sean) Yi and Seung Wook Kim </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Phone:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">+82 <span style="white-space:nowrap">02-6226-7703</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">+82 <span style="white-space:nowrap">02-6226-7753</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">Email:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">seonghoon.yi@bakermckenziekorea.com </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">&#8195;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">sunguk.kim@bakermckenziekorea.com </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to any Company Stockholder, to the address indicated on such Company Stockholder&#8217;s Joinder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_97">10.02 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-survival</span> of Representations, Warranties and Covenants</span>. None of the representations, warranties, covenants, obligations or other agreements in this Agreement or in any certificate, statement or instrument delivered pursuant to this Agreement, including any rights arising out of any breach of such representations, warranties, covenants, obligations, agreements and other provisions, shall survive the Closing and all such representations, warranties, covenants, obligations or other agreements shall terminate and expire upon the occurrence of the Closing (and there shall be no liability after the Closing in respect thereof), except for (a)&#160;those covenants and agreements contained herein that by their terms expressly apply in whole or in part after the Closing and then only with respect to any breaches occurring after the Closing and (b)&#160;this Article X and any corresponding definitions set forth in Article I. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_98">10.03 <span style="text-decoration:underline">Severability</span>. If any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the Transactions be consummated as originally contemplated to the fullest extent possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_99">10.04 <span style="text-decoration:underline">Entire Agreement; Assignment</span>. This Agreement and the Ancillary Agreements constitute the entire agreement among the Parties with respect to the subject matter hereof and supersede, except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.04(b)</span>, all prior agreements, and undertakings, both written and oral, among the Parties, or any of them, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to the subject matter hereof, except for the Confidentiality Agreement. This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise) by any Party without the prior express written consent of the other Parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_100">10.05 <span style="text-decoration:underline">Parties in Interest</span>. This Agreement shall be binding upon and inure solely to the benefit of each Party hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit, or remedy of any nature whatsoever under or by reason of this Agreement, other than <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.07</span> (which is intended to be for the benefit of the persons covered thereby and may be enforced by such persons). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_101">10.06 <span style="text-decoration:underline">Governing Law</span>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to any conflict of law rule or principle that would result in the application of any laws other than the laws of the State of Delaware. All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in the Court of Chancery of the State of Delaware or, if such court declines to exercise jurisdiction or if subject matter jurisdiction over the matter that is the subject of any such legal action or proceeding is vested exclusively in the U.S. federal courts, the U.S. District Court for the District of Delaware. The Parties hereto hereby (a)&#160;irrevocably submit to the exclusive jurisdiction of the aforesaid courts for themselves and with respect to their respective properties for the purpose of any Action arising out of or relating to this Agreement brought by any Party hereto, and (b)&#160;agree not to commence any Action relating thereto except in the courts described above in Delaware, other than Actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the Parties further agrees that notice as provided herein shall constitute sufficient service of process and the Parties further waive any argument that such service is insufficient. Each of the Parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Action arising out of or relating to this Agreement or the transactions contemplated hereby, (a)&#160;any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b)&#160;that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c)&#160;that (i) the Action in any such court is brought in an inconvenient forum, (ii)&#160;the venue of such Action is improper or (iii)&#160;this Agreement, or the subject matter hereof, may not be enforced in or by such courts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_102">10.07 <span style="text-decoration:underline">WAIVER OF JURY TRIAL</span>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS. EACH OF THE PARTIES HERETO (A)&#160;CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (B)&#160;ACKNOWLEDGES THAT IT AND THE OTHER HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION 10.07</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_103">10.08 <span style="text-decoration:underline">Headings</span>. The descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_104">10.09 <span style="text-decoration:underline">Counterparts</span>. This Agreement may be executed and delivered electronically, and by the different Parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxatoc476668_105">10.10 <span style="text-decoration:underline">Specific Performance</span>. The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof, and, accordingly, that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof (including the Parties&#8217; obligation to consummate the Business Combination) in accordance with the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.06</span> without proof of actual damages or otherwise, in addition to any other remedy to which they are entitled at law or in equity as expressly permitted in this Agreement. Each of the Parties hereby further waives (a)&#160;any defense in any action for specific performance that a remedy at law would be adequate and (b)&#160;any requirement under any Law to post security or a bond as a prerequisite to obtaining equitable relief. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page Follows] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, BLAC and the Company have caused this Amended and Restated Business Combination Agreement to be executed as of the date set forth below (the &#8220;<span style="font-weight:bold">Amendment Date</span>&#8221;) by their respective officers thereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated: May&#160;23, 2024 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">BELLEVUE&#160;LIFE&#160;SCIENCES&#160;ACQUISITION&#160;CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">By:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold">/s/ Radclyffe Roberts</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Name: Radclyffe Roberts</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Title: &#8199;BLAC M&amp;A Committee Member</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">OSR HOLDINGS CO., LTD.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">By:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold">/s/ Sung Jae Yu</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Name: Sung Jae Yu</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Title: &#8199;Chief Operating Officer</span></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature page to Amended and Restated Business Combination Agreement] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXHIBIT A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Form of Participating Stockholder Joinder </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXHIBIT B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Form of <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_45">Annex B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">JOINDER </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Participating Stockholder Form) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This JOINDER (this &#8220;<span style="font-weight:bold">Joinder</span>&#8221;) is entered into by and between the undersigned Participating Company Stockholder set forth on the signature page hereto (the &#8220;<span style="font-weight:bold">Joined Party</span>&#8221;) and Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="font-weight:bold">BLAC</span>&#8221;). Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, BLAC, OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the &#8220;<span style="font-weight:bold">Company</span>&#8221;), each holder of Company Common Stock that executes a Participating Stockholder Joinder on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold">Participating Company Stockholder</span>&#8221;), and each holder of Company Common Stock that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221;, and together with BLAC, the Company and the Participating Company Stockholders, the &#8220;<span style="font-weight:bold">Parties</span>&#8221; and each a &#8220;<span style="font-weight:bold">Party</span>&#8221;) have entered into a Business Combination Agreement, dated as of November 16, 2023 (the &#8220;<span style="font-weight:bold">Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants, agreements and conditions contained herein and in the Agreement, the undersigned Participating Stockholder and BLAC, intending to be legally bound, hereby agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Agreement to be Bound as a Participating Company Stockholder under the Agreement</span>. The Joined Party hereby agrees that upon execution and delivery of this Joinder, it shall become a Party to the Agreement with all attendant rights, duties and obligations (including in respect of all of the representations, warranties, covenants, agreements and conditions of the Agreement), with the same force and effect as if originally named as a &#8220;Participating Company Stockholder&#8221; and shall be deemed a &#8220;Participating Company Stockholder&#8221; for all purposes thereof, and such references therein shall be construed as if the Joined Party executed the Agreement on the date thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Exchange of Shares</span>. At the Effective Time, pursuant to and in accordance with the Agreement, (i)&#160;the Joined Party hereby sells, transfers, conveys, assigns and delivers to BLAC the shares of Company Common Stock owned and held of record by the Joined Party as set forth on <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> hereto (the &#8220;<span style="font-weight:bold">Exchanged</span> <span style="font-weight:bold">Company</span> <span style="font-weight:bold">Shares</span>&#8221;) and (ii)&#160;BLAC agrees to issue to the Joined Party the number of shares of BLAC Common Stock set forth on <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> hereto (the &#8220;<span style="font-weight:bold">BLAC Shares</span>&#8221;) (such exchange, the &#8220;<span style="font-weight:bold">Exchange</span>&#8221;). In accordance with Section&#160;2.01 of the Agreement, the number of BLAC shares issuable to the Joined Party set forth on <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> is equal to the number of Exchanged Company Shares multiplied by the Per Share Consideration and any fractional share of BLAC Common Stock that would otherwise be issuable to the Joined Party shall be rounded up or down to the nearest whole share of BLAC Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Representations and Warranties</span>. The Joined Party hereby affirms to BLAC the representations and warranties the Joined Party makes as a Participating Company Stockholder as set forth in Article IV of the Agreement. In addition, the Joined Party hereby represents and warrants to BLAC on the date hereof and as of the Effective time as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Exchanged Company Shares constitute all Company Capital Stock held by the Joined Party and the Joined Party holds no other option, warrant, right or other instruments convertible into or exchangeable for Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Joined Party acknowledges that, prior to executing this Joinder, the Joined Party has carefully reviewed the Agreement, which the Joined Party acknowledges has been provided to such Joined Party. The Joined Party acknowledges that such Joined Party has been given an opportunity to ask questions of and receive answers from representatives of BLAC concerning the transactions contemplated by the Agreement. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determining whether to enter into this Joinder, the Joined Party has relied solely on Joined Party&#8217;s own knowledge and understanding of BLAC and its business based upon the Joined Party&#8217;s own due diligence investigation and the information furnished pursuant to this paragraph. The Joined Party understands that no person has been authorized to give any information or to make any representations which were not furnished pursuant to this paragraph and the Joined Party has not relied on any other representations or information in entering into this Joinder, whether written or oral, relating to BLAC, its operations and/or its prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Joined Party acknowledges that execution of this Joinder may involve tax and legal consequences and that the contents of the Agreement and this Joinder do not contain tax or legal advice or information. The Joined Party acknowledges that such Joined Party must retain, and has had the opportunity to retain, such Joined Party&#8217;s own professional tax, legal and other advisors to evaluate the tax, legal and other consequences of executing this Joinder and becoming a Party to the Agreement. The Joined Party represents that Joined Party is not relying on (and will not at any time rely on) any communication (written or oral) of BLAC, the Company or any of their respective officers, directors, employees or agents, as investment, tax, legal or other advice or as a recommendation to execute this Joinder, it being understood that information and explanations related to the terms and conditions of the this Joinder and the Agreement shall not be considered investment, tax, legal or other advice or a recommendation to execute this Joinder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Covenant Not to Sell, Transfer, or Assign the Exchanged Company Shares or any Interest therein</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Joined Party agrees not to sell, pledge, dispose of, grant or encumber, or authorize the sale, pledge, disposition, grant or encumbrance of, the Exchanged Company Shares, or any options, convertible securities or other rights of any kind to acquire the Exchanged Company Shares, or any other ownership interest, of the Exchanged Company Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">General Release of all Claims</span>. The Joined Party acknowledges and agrees that the delivery of the BLAC Shares in exchange for the Exchanged Company Shares pursuant to the Exchange in accordance with this Joinder represents payment in full and satisfies all obligations BLAC or the Company has to the Joined Party with regard to Company Capital Stock, including the Exchanged Company Shares. The Joined Party hereby agrees to and does release and forever discharge BLAC, the Company and each of its and their respective affiliates, successors, assigns, officers, directors, employees, agents, administrators and trustees (collectively, the &#8220;<span style="font-weight:bold">Released Parties</span>&#8221;) from any and all claims, losses, expenses, liabilities, rights and entitlements of every kind and description, whether known or unknown, that the Joined Party has now or may later claim to have had against any of the Released Parties in any way related to the Joined Party&#8217;s Company Capital Stock, including the Exchanged Company Shares, or status as a holder of Company Capital Stock; provided, that the foregoing release does not affect the Joined Party&#8217;s rights under and pursuant to the Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Indemnification of Released Parties</span>. The Joined Party agrees to indemnify, defend and hold harmless the Released Parties from and against any loss, liability, damage, cost or expense (including costs and reasonable attorneys&#8217; fees and disbursements) suffered, incurred or paid by a Released Party which would not have been suffered, incurred or paid if the representations and warranties of the Joined Party in the Agreement or this Joinder had been true, complete and correct in all material respects. The Joined Party will, upon request, execute any additional documents necessary or desirable to consummate the transactions contemplated in the Agreement with respect to the Exchanged Company Shares or any other Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Counterparts</span>. A copy of this Joinder may be executed and delivered electronically and in counterparts, and each such counterpart shall be deemed to be one and the same instrument and have the same legal effect as delivery of an original signed copy of this Joinder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">Notices</span>. All notices, demands and other communications to the Joined Party shall be sent to the address set forth on the signature page hereto. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Miscellaneous</span>. Unless otherwise specifically set forth in this Joinder, the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.01</span> (<span style="font-style:italic">Notices</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.03</span> (<span style="font-style:italic">Severability</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.06</span> (<span style="font-style:italic">Governing Law</span>), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.08</span> (<span style="font-style:italic">Headings</span>) of the Agreement are incorporated by reference herein and shall be deemed applicable to this Joinder <span style="font-style:italic">mutatis mutandis</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature pages follow] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Joined Party has executed this Joinder as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">JOINED PARTY</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">If Joined Party is an Individual:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Individual Participating Company Stockholder as documented in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Address:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">If Joined Party is an Entity:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Name of Participating Company Stockholder Entity as it appears in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Address:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td></tr>
</table></div> <p style="margin-top:238pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to Participating Company Stockholder Joinder] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, BLAC has executed this Joinder as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">BELLEVUE LIFE SCIENCES ACQUISITION CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div> <p style="margin-top:560pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to Participating Company Stockholder Joinder] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Schedule A<sup style="font-size:75%; vertical-align:top">1</sup> </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exchanged Company Shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">BLAC Shares</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">[&#9679;]</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">[&#9679;]</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All references to the number of Company Shares and the BLAC Shares in this Joinder are subject to appropriate adjustment to reflect any stock split, reverse stock split, stock dividend or other change in the Company Common Stock or BLAC Common Stock which may be made by the Company or BLAC after the date of this Joinder. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_46"><span id="anxc"></span>Annex C </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">JOINDER </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">(Non-Participating</span> Stockholder Form) </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This JOINDER (this &#8220;<span style="font-weight:bold">Joinder</span>&#8221;) is entered into by and between the undersigned <span style="white-space:nowrap">Non-Participating</span> Company Stockholder set forth on the signature page hereto (the &#8220;<span style="font-weight:bold">Joined Party</span>&#8221;) and Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="font-weight:bold">BLAC</span>&#8221;). Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, BLAC, OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the &#8220;<span style="font-weight:bold">Company</span>&#8221;), each holder of Company Common Stock that executes a Participating Stockholder Joinder on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold">Participating Company Stockholder</span>&#8221;), and each holder of Company Common Stock that executes a <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder on or prior to the Closing (each such Person, a &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Participating</span> Company Stockholder</span>&#8221;, and together with BLAC, the Company and the Participating Company Stockholders, the &#8220;<span style="font-weight:bold">Parties</span>&#8221; and each a &#8220;<span style="font-weight:bold">Party</span>&#8221;) have entered into a Business Combination Agreement, dated as of November 16, 2023 (the &#8220;<span style="font-weight:bold">Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants, agreements and conditions contained herein and in the Agreement, the undersigned <span style="white-space:nowrap">Non-Participating</span> Company Stockholder and BLAC, intending to be legally bound, hereby agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Agreement to be Bound as a <span style="white-space:nowrap">Non-Participating</span> Company Stockholder under the Agreement</span>. The Joined Party hereby agrees that upon execution and delivery of this Joinder, it shall become a Party to the Agreement with all attendant rights, duties and obligations (including in respect of all of the representations, warranties, covenants, agreements and conditions of the Agreement), with the same force and effect as if originally named as a <span style="white-space:nowrap">&#8220;Non-Participating</span> Company Stockholder&#8221; and shall be deemed a <span style="white-space:nowrap">&#8220;Non-Participating</span> Company Stockholder&#8221; for all purposes thereof, and such references therein shall be construed as if the Joined Party executed the Agreement on the date thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Put and Call Rights</span>. The Joined Party shall have the right to cause BLAC to purchase (the &#8220;<span style="font-weight:bold">Put Right</span>&#8221;) and BLAC shall have the right to cause the Joined Party to sell to BLAC or its designee (the &#8220;<span style="font-weight:bold">Call Right</span>&#8221;) all of the shares of Company Common Stock owned and held of record by Joined Party as set forth on <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> hereto (the &#8220;<span style="font-weight:bold">Company Shares</span>&#8221;) on the terms and conditions set forth herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Put Right</span>. At any time on or after the Trigger Date (as defined below), the Joined Party may give written notice (the &#8220;<span style="font-weight:bold">Put Notice</span>&#8221;) to BLAC that the Joined Party elects to exercise the Put Right to require BLAC to acquire all but not less than all of the Joined Party&#8217;s Company Shares in exchange for the number of shares of BLAC Common Stock set forth on <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> hereto (the &#8220;<span style="font-weight:bold">BLAC Shares</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Call Right</span>. At any time on or after the Trigger Date, BLAC may give written notice (the &#8220;<span style="font-weight:bold">Call Notice</span>&#8221;) to the Joined Party of BLAC&#8217;s election to exercise the Call Right to require the Joined Party to sell to BLAC (or BLAC&#8217;s designee) all of the Company Shares in exchange for the BLAC Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Trigger Date and Notice of Change in Control</span>. For purposes of this Joinder, the term &#8220;<span style="font-weight:bold">Trigger Date</span>&#8221; shall mean January&#160;1, 2026 or the date that the Joined Party is notified by BLAC of a transaction that will result in a Change in Control (as defined in <span style="font-weight:bold"><span style="text-decoration:underline">Schedule A</span></span> hereto). BLAC hereby covenants and agrees that it shall provide the Joined Party written notice of any transaction that will result in a Change in Control at least 20 business days (or such shorter period to which the Joined Party consents) prior to the closing of such Change in Control transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Closing of Put and Call Transaction</span>. The closing of the Put Right or Call Right hereunder (the &#8220;<span style="font-weight:bold">Put/Call Closing</span>&#8221;) shall occur as soon as reasonably practicable (but in no event later than the 10th day) after </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receipt by (i)&#160;BLAC of the Put Notice, in the case of exercise of the Put Right, or (ii)&#160;the Joined Party of the Call Notice, in the case of exercise of the Call Right; <span style="text-decoration:underline">provided</span>, however, in the event of a Change in Control, the exercise of the Put Right or Call Right and the Put/Call Closing shall be conditioned on the consummation of such Change in Control and shall be effective immediately before the consummation thereof. At the Put/Call Closing, (i)&#160;the Joined Party agrees to deliver to BLAC the Company Shares and such documents, certificates and agreements as reasonably requested by BLAC to effect transfer to and evidence the ownership of the Company Shares by BLAC or its designee, free and clear of all liens, security interests, mortgages, pledges, charges, claims, limitations or any other restriction of any kind, including any restriction on the ownership, use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership (collectively, &#8220;<span style="font-weight:bold">Liens</span>&#8221;) and (ii)&#160;BLAC agrees to deliver to the Joined Party the BLAC Shares, which shall validly issued, fully-paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">BLAC Conditions to Put Closing</span>. The obligations of BLAC to consummate the Put Closing are subject to the satisfaction or waiver (where permissible) at or prior to the Put Closing of the following additional conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <span style="text-decoration:underline">Representations and Warranties</span>. The representations and warranties of the Joined Party in <span style="text-decoration:underline">Article IV</span> of the Agreement and in this Joinder shall each be true and correct in all material respects as of the Put Closing as though made on the date of the Put Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <span style="text-decoration:underline">Agreements and Covenants</span>. The Joined Party shall have performed or complied in all material respects with all agreements and covenants required by the Agreement and this Joinder to be performed, or complied with by it on or prior to the Put Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Representations and Warranties</span>. The Joined Party hereby affirms to BLAC the representations and warranties the Joined Party makes as a <span style="white-space:nowrap">Non-Participating</span> Company Stockholder as set forth in Article IV of the Agreement. In addition, the Joined Party hereby represents and warrants to BLAC on the date hereof and as of the date of the Put/Call Closing as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company Shares constitute all Company Capital Stock held by the Joined Party and the Joined Party holds no other option, warrant, right or other instruments convertible into or exchangeable for Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Joined Party acknowledges that, prior to executing this Joinder, the Joined Party has carefully reviewed the Agreement, which the Joined Party acknowledges has been provided to such Joined Party. The Joined Party acknowledges that such Joined Party has been given an opportunity to ask questions of and receive answers from representatives of BLAC concerning the transactions contemplated by the Agreement. In determining whether to enter into this Joinder, the Joined Party has relied solely on Joined Party&#8217;s own knowledge and understanding of BLAC and its business based upon the Joined Party&#8217;s own due diligence investigation and the information furnished pursuant to this paragraph. The Joined Party understands that no person has been authorized to give any information or to make any representations which were not furnished pursuant to this paragraph and the Joined Party has not relied on any other representations or information in entering into this Joinder, whether written or oral, relating to BLAC, its operations and/or its prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Joined Party acknowledges that execution of this Joinder may involve tax and legal consequences and that the contents of the Agreement and this Joinder do not contain tax or legal advice or information. The Joined Party acknowledges that such Joined Party must retain, and has had the opportunity to retain, such Joined Party&#8217;s own professional tax, legal and other advisors to evaluate the tax, legal and other consequences of executing this Joinder and becoming a Party to the Agreement. The Joined Party represents that Joined Party is not relying on (and will not at any time rely on) any communication (written or oral) of BLAC, the Company or any of their respective officers, directors, employees or agents, as investment, tax, legal or other advice or as a recommendation to execute this Joinder, it being understood that information and explanations related to the terms and conditions of the this Joinder and the Agreement shall not be considered investment, tax, legal or other advice or a recommendation to execute this Joinder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Covenant Not to Sell, Transfer, or Assign the Company Shares or any Interest therein</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Joined Party agrees not to sell, pledge, dispose of, grant or encumber, or authorize the sale, pledge, disposition, grant or encumbrance of, the Company Shares, or any options, convertible securities or other rights of any kind to acquire the Company Shares, or any other ownership interest, of the Company Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">General Release of all Claims</span>. The Joined Party acknowledges and agrees that the delivery of the BLAC Shares in exchange for the Company Shares pursuant to the exercise of the Put Right or Call Right in accordance with this Joinder represents payment in full and satisfies all obligations BLAC or the Company has to the Joined Party with regard to Company Capital Stock, including the Company Shares. The Joined Party hereby agrees to and does release and forever discharge BLAC, the Company and each of its and their respective affiliates, successors, assigns, officers, directors, employees, agents, administrators and trustees (collectively, the &#8220;<span style="font-weight:bold">Released Parties</span>&#8221;) from any and all claims, losses, expenses, liabilities, rights and entitlements of every kind and description, whether known or unknown, that the Joined Party has now or may later claim to have had against any of the Released Parties in any way related to the Joined Party&#8217;s Company Capital Stock, including the Company Shares, or status as a holder of Company Capital Stock; provided, that the foregoing release does not affect the Joined Party&#8217;s rights under and pursuant to the Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Indemnification of Released Parties</span>. The Joined Party agrees to indemnify, defend and hold harmless the Released Parties from and against any loss, liability, damage, cost or expense (including costs and reasonable attorneys&#8217; fees and disbursements) suffered, incurred or paid by a Released Party which would not have been suffered, incurred or paid if the representations and warranties of the Joined Party in the Agreement or this Joinder had been true, complete and correct in all material respects. The Joined Party will, upon request, execute any additional documents necessary or desirable to consummate the transactions contemplated in the Agreement with respect to the Company Shares or any other Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Counterparts</span>. A copy of this Joinder may be executed and delivered electronically and in counterparts, and each such counterpart shall be deemed to be one and the same instrument and have the same legal effect as delivery of an original signed copy of this Joinder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">Notices</span>. All notices, demands and other communications to the Joined Party shall be sent to the address set forth on the signature page hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Miscellaneous</span>. Unless otherwise specifically set forth in this Joinder, the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.01</span> (<span style="font-style:italic">Notices</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.03</span> (<span style="font-style:italic">Severability</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.06</span> (<span style="font-style:italic">Governing Law</span>), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.08</span> (<span style="font-style:italic">Headings</span>) of the Agreement are incorporated by reference herein and shall be deemed applicable to this Joinder <span style="font-style:italic">mutatis mutandis</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature pages follow] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Joined Party has executed this Joinder as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">JOINED PARTY</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">If Joined Party is an Individual:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Individual <span style="white-space:nowrap">Non-Participating</span> Company Stockholder as documented in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Address:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">If Joined Party is an Entity:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Name of <span style="white-space:nowrap">Non-Participating</span> Company Stockholder Entity as it appears in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Address:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td></tr>
</table></div> <p style="margin-top:226pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, BLAC has executed this Joinder as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">BELLEVUE LIFE SCIENCES ACQUISITION CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div> <p style="margin-top:560pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page to <span style="white-space:nowrap">Non-Participating</span> Stockholder Joinder] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Schedule A<sup style="font-size:75%; vertical-align:top">1</sup> </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Company Shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">BLAC Shares</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">[&#9679;]</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">[&#9679;]</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Change in Control</span>&#8221; means the occurrence of any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) A transaction or a series of related transactions whereby any Person or group (other than BLAC or any affiliate of BLAC) becomes the beneficial owner of more than 50% of the total voting power of the voting stock of BLAC, on a fully diluted basis; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) BLAC consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, BLAC (regardless of whether BLAC is the surviving Person), other than any such transaction in which the holders of equity securities representing 100% of the voting stock of BLAC immediately prior to such a transaction own directly or indirectly at least a majority of the voting power of the voting stock of the surviving Person in such merger or consolidation immediately after such transaction; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The consummation of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization, merger, or consolidation), in one transaction or a series of related transactions, of all or substantially all of the assets of BLAC and its subsidiaries, taken as a whole, to any Person or group (other than BLAC or any affiliate of BLAC), except any such transaction or series of transactions in which the holders of equity securities representing 100% of the voting stock of BLAC immediately prior to such a transaction own directly or indirectly at least a majority of the voting power of the voting stock of such Person or group immediately after such transaction or series of transactions; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The consummation of a plan or proposal for the liquidation, winding up or dissolution of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The board of BLAC shall have full and final authority, in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control, and any incidental matters relating thereto. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All references to the number of Company Shares and the BLAC Shares in this Joinder are subject to appropriate adjustment to reflect any stock split, reverse stock split, stock dividend or other change in the Company Common Stock or BLAC Common Stock which may be made by the Company or BLAC after the date of this Joinder. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_47"><span id="anxd"></span>Annex D </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT (this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;) is dated as of [&#8195;], 2024 by and between the undersigned stockholder (the &#8220;<span style="font-weight:bold">Holder</span>&#8221;) and [Bellevue Life Sciences Acquisition Corp., a Delaware corporation (&#8220;<span style="font-weight:bold">BLAC</span>&#8221;)]<sup style="font-size:75%; vertical-align:top">1</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, BLAC, OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the &#8220;<span style="font-weight:bold">Company</span>&#8221;), each Participating Company Stockholder, and each <span style="white-space:nowrap">Non-Participating</span> Company Stockholder entered into a Business Combination Agreement dated as of November&#160;16, 2023 (the &#8220;<span style="font-weight:bold">Business Combination Agreement</span>&#8221;). Capitalized terms used, but not otherwise defined herein, shall have the meanings ascribed to such terms in the Business Combination Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Business Combination Agreement, upon the consummation of the transactions contemplated thereby (the &#8220;<span style="font-weight:bold">Closing</span>&#8221;), BLAC holds [&#9679;]% of the Company Fully Diluted Share Amount; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to and in accordance with the Business Combination, at the Closing, the Holder became the record and/or beneficial owner of BLAC Common Stock; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition of, and as a material inducement for BLAC to enter into and consummate the transactions contemplated by the Business Combination Agreement, the Holder has agreed to execute and deliver this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in consideration of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, agree as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">AGREEMENT </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span></span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&#160;4 below, during the <span style="white-space:nowrap">Lock-Up</span> Period, the Holder agrees that it, he or she will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any of the <span style="white-space:nowrap">Lock-Up</span> Shares (as defined herein), enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the <span style="white-space:nowrap">Lock-Up</span> Shares or otherwise, publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, or engage in any Short Sales (as defined below) with respect to the <span style="white-space:nowrap">Lock-Up</span> Shares (any of the foregoing, a &#8220;<span style="font-weight:bold">Prohibited Transfer</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In furtherance of the foregoing, during the <span style="white-space:nowrap">Lock-Up</span> Period, BLAC will (i)&#160;place a stop order on all the <span style="white-space:nowrap">Lock-Up</span> Shares, including those which may be covered by a registration statement, and (ii)&#160;notify BLAC&#8217;s transfer agent in writing of the stop order and the restrictions on the <span style="white-space:nowrap">Lock-Up</span> Shares under this Agreement and direct BLAC&#8217;s transfer agent not to process any attempts by the Holder to resell or transfer any <span style="white-space:nowrap">Lock-Up</span> Shares, except in compliance with this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes hereof, &#8220;<span style="font-weight:bold">Short Sales</span>&#8221; include all &#8220;short sales&#8221; as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;), and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through <span style="white-space:nowrap">non-US</span> broker dealers or foreign regulated brokers. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Name to be updated following name change. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The term &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Period</span>&#8221; means the date from the Closing until the &#8220;<span style="font-weight:bold">Trigger Date</span>&#8221; set forth on the Holder&#8217;s signature page hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Agreement, &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Shares</span>&#8221; means the shares of BLAC Common Stock issued to the Holder upon consummation of the Business Combination subject to any Excluded Shares set forth on the Holder&#8217;s signature page hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Permitted Transfers</span>. Notwithstanding the foregoing, and subject to the conditions below, a Prohibited Transfer will not include, and the undersigned may transfer <span style="white-space:nowrap">Lock-Up</span> Shares in connection with (a)&#160;transfers or distributions to the Holder&#8217;s direct or indirect affiliates (within the meaning of Rule 405 under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold">Securities Act</span>&#8221;)) or to the estates of any of the foregoing; (b)&#160;transfers by bona fide gift to a member of the Holder&#8217;s immediate family (for purposes of this Agreement, &#8220;immediate family&#8221; shall mean with respect to any natural person, any of the following: such person&#8217;s spouse, the siblings of such person and his or her spouse, and the direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses and siblings) or to a trust, the beneficiary of which is the Holder or a member of the Holder&#8217;s immediate family for estate planning purposes; (c)&#160;by virtue of the laws of descent and distribution upon death of the Holder; (d)&#160;pursuant to a qualified domestic relations order, (e)&#160;transfers to BLAC&#8217;s officers, directors or their affiliates, (f)&#160;transfers as a dividend or distribution to limited partners, shareholders, members of, or owners of similar equity interests in the Holder, (g)&#160;pledges of <span style="white-space:nowrap">Lock-Up</span> Shares as security or collateral in connection with a borrowing or the incurrence of any indebtedness by the Holder, <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that such borrowing or incurrence of indebtedness is secured by either a portfolio of assets or equity interests issued by multiple issuers, (h)&#160;transfers pursuant to a bona fide third-party tender offer, merger, stock sale, recapitalization, consolidation or other transaction involving a change of control of BLAC; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that in the event that such tender offer, merger, recapitalization, consolidation or other such transaction is not completed, the <span style="white-space:nowrap">Lock-Up</span> Shares subject to this Agreement shall remain subject to this Agreement, and (i)&#160;the establishment of a trading plan pursuant to Rule <span style="white-space:nowrap">10b5-1</span> promulgated under the Exchange Act; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that such plan does not provide for the transfer of <span style="white-space:nowrap">Lock-Up</span> Shares during the <span style="white-space:nowrap">Lock-Up</span> Period; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that, in the case of any transfer pursuant to the foregoing (a)&#160;through (f) clauses, it shall be a condition to any such transfer that (i)&#160;the transferee/donee agrees to be bound by the terms of this Agreement (including the restrictions set forth in Section&#160;1) to the same extent as if the transferee/donee were a party hereto; and (ii)&#160;each party (donor, donee, transferor or transferee) shall not be required by law (including the disclosure requirements of the Securities Act and the Exchange Act) to make, and shall agree to not voluntarily make, any filing or public announcement of the transfer or disposition prior to the expiration of the <span style="white-space:nowrap">Lock-Up</span> Period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Representations and Warranties.</span> Each of the parties hereto, by their respective execution and delivery of this Agreement, hereby represents and warrants to the other that (a)&#160;such party has the full right, capacity and authority to enter into, deliver and perform its respective obligations under this Agreement, (b)&#160;this Agreement has been duly executed and delivered by such party and is a binding and enforceable obligation of such party and, enforceable against such party in accordance with the terms of this Agreement, and (c)&#160;the execution, delivery and performance of such party&#8217;s obligations under this Agreement will not conflict with or breach the terms of any other agreement, contract, commitment or understanding to which such party is a party or to which the assets or securities of such party are bound. The Holder has independently evaluated the merits of his/her/its decision to enter into and deliver this Agreement, and such Holder confirms that he/she/it has not relied on the advice of BLAC, the Company, their respective legal counsels, or any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">No Additional Fees/Payment.</span> Other than the consideration specifically referenced herein to be issued in connection with the Business Combination Agreement, the parties hereto agree that no fee, payment or additional consideration in any form has been or will be paid to the Holder in connection with this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Notices.</span> All notices, demands and other communications to the Holder shall be sent to the address set forth on the Holder&#8217;s signature page hereto. All notices, demands and other communications to BLAC shall be sent to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Bellevue Life Sciences Acquisition Corp. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">10900 NE 4th Street, Suite 2300 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Bellevue, WA 98004 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">USA </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;&#8195;Jin Whan Park and Kuk Hyoun Hwang </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8195;&#8199;jinwhanpark@gmail.com and peter.hwang@bellevuecm.com </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">with a copy to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">K&amp;L Gates LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">925 Fourth Avenue, Suite 2900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Seattle, WA 98104 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">USA </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;&#8195;Gary Kocher and Adam Heyd </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Phone:&#8195;&#8195;&#8195;&#8195;&#8201;(206) <span style="white-space:nowrap">579-0092</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;(206) <span style="white-space:nowrap">370-6656</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8195;&#8201;gary.kocher@klgates.com </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;adam.heyd@klgates.com </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Termination of Business Combination Agreement</span>. This Agreement shall be binding upon the Holder upon the Holder&#8217;s execution and delivery of this Agreement, but this Agreement shall only become effective upon the Closing. Notwithstanding anything to the contrary contained herein, in the event that the Business Combination Agreement is terminated in accordance with its terms prior to the Closing, this Agreement and all rights and obligations of the parties hereunder shall automatically terminate and be of no further force or effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Enumeration and Headings; Interpretation.</span> The enumeration and headings contained in this Agreement are for convenience of reference only and shall not control or affect the meaning or construction of any of the provisions of this Agreement. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i)&#160;any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa; (ii) &#8220;including&#8221; (and with correlative meaning &#8220;include&#8221;) means including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words &#8220;without limitation&#8221;; and (iii)&#160;the words &#8220;herein,&#8221; &#8220;hereto,&#8221; and &#8220;hereby&#8221; and other words of similar import shall be deemed in each case to refer to this Agreement as a whole and not to any particular section or other subdivision of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">Counterparts.</span> This Agreement may be executed and delivered electronically, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Successors and Assigns.</span> This Agreement and the terms, covenants, provisions and conditions hereof shall be binding upon, and shall inure to the benefit of, the respective heirs, successors and assigns of the parties hereto. The Holder hereby acknowledges and agrees that this Agreement is entered into for the benefit of and is enforceable by BLAC and its successors and assigns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <span style="text-decoration:underline">No Third Parties</span>. Nothing contained in this Agreement or in any instrument or document executed by any party in connection with the transactions contemplated hereby shall create any rights in, or be deemed to have been executed for the benefit of, any person or entity that is not a party hereto or thereto or a successor or permitted assign of such a party. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <span style="text-decoration:underline">Severability.</span> If any provision of this Agreement is held to be invalid or unenforceable for any reason, such provision will be conformed to prevailing law rather than voided, if possible, in order to achieve the intent of the parties and, in any event, the remaining provisions of this Agreement shall remain in full force and effect and shall be binding upon the parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <span style="text-decoration:underline">Amendment and Waivers.</span> This Agreement may be amended or modified, or any provision hereof waived, by written agreement executed by each of the parties hereto. No failure or delay by a party in exercising any right hereunder shall operate as a waiver thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <span style="text-decoration:underline">Further Assurances.</span> Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <span style="text-decoration:underline">No Strict Construction.</span> The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <span style="text-decoration:underline">Governing Law.</span> Section&#160;10.06 of the Business Combination Agreement is incorporated by reference herein to apply with full force to any disputes arising under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <span style="text-decoration:underline">Entire Agreement; Controlling Agreement</span>. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled; provided, that, for the avoidance of doubt, the foregoing shall not affect the rights and obligations of the parties under the Business Combination Agreement or any Ancillary Agreement. To the extent the terms of this Agreement (as amended, supplemented, restated or otherwise modified from time to time) directly conflict with any provisions in the Business Combination Agreement, the terms of this Agreement shall control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Pages Follow] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, BLAC has executed this <span style="white-space:nowrap">Lock-Up</span> Agreement as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">[BELLEVUE LIFE SCIENCES</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACQUISITION CORP.]</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[BLAC Signature Page to Lock-Up Agreement] </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Holder has executed this <span style="white-space:nowrap">Lock-Up</span> Agreement as of the date set forth below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Trigger Date<sup style="font-size:75%; vertical-align:top">2</sup>:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Holder</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">If Holder is an Individual:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Holder as documented in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">[Number of Excluded Shares<sup style="font-size:75%; vertical-align:top">3</sup>:]</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Address:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">If Holder is an Entity:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Name of Entity as it appears in the records of the Company:</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Address:</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date:</p></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">2</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Trigger date is 12:01 a.m. Eastern Standard Time on January&#160;1, 2026 for all parties other than BCM Europe AG and Bellevue Capital Management LLC, which have a <span style="white-space:nowrap">lock-up</span> period that ends 36 months after Closing. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">3</sup></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">30% of the shares issued in the Business Combination. This number is subject to appropriate adjustment to reflect any stock split, reverse stock split, stock dividend or other change in the BLAC Common Stock which may be made by BLAC after the date of this Agreement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Holder Signature Page to Lock-Up Agreement] </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_48"><span id="ii476668_1"></span>ANNEX E </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECOND AMENDED AND RESTATED </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTIFICATE OF INCORPORATION </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The present name of the corporation is &#8220;Bellevue Life Sciences Acquisition Corp.&#8221; The corporation was incorporated under the name &#8220;Bellevue Life Sciences Acquisition Corp.&#8221; by the filing of its original certificate of incorporation with the Secretary of State of the State of Delaware on February&#160;25, 2020. The original certificate of incorporation was subsequently amended by the filing of (i)&#160;a Certificate of Validation of Certificate of Amendment on January&#160;20, 2021, (ii) an Amended and Restated Certificate of Incorporation on April&#160;25, 2022, (iii) an Amended and Restated Certificate of Incorporation on May&#160;9, 2022, (iv) an Amended and Restated Certificate of Incorporation on February&#160;13, 2023, and (v)&#160;a Certificate of Amendment to the Amended and Restated Certificate of Incorporation on November&#160;9, 2023. This Amended and Restated Certificate of Incorporation of the corporation, which both restates and further amends the provisions of the corporation&#8217;s certificate of incorporation, was duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware. The corporation&#8217;s certificate of incorporation is hereby amended and restated to read in its entirety as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIRST</span>. The name of the corporation is OSR Holdings, Inc. (the &#8220;<span style="font-weight:bold">Corporation</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">SECOND</span>. The address of the Corporation&#8217;s registered office in the State of Delaware is 8 The Green STE R, Dover, County of Kent, Delaware 19901. The name of its registered agent at such address is Resident Agents Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIRD</span>. The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (as the same exists or may hereafter be amended, the &#8220;<span style="font-weight:bold">General Corporation Law</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FOURTH</span>. <span style="text-decoration:underline">Capital Stock</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.<span style="text-decoration:underline">&#160;Authorized Shares of Capital Stock</span>. The total number of shares of all classes of capital stock that the Corporation shall have authority to issue is 100,000,000 shares of common stock, par value $0.0001 per share (the &#8220;<span style="font-weight:bold">Common Stock</span>&#8221;); and (ii) 10,000,000 shares, par value $0.0001 per share, of preferred stock (&#8220;<span style="font-weight:bold">Preferred Stock</span>&#8221;). Subject to the special rights of holders of any outstanding series of Preferred Stock, the number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the General Corporation Law, without the separate vote of the holders of the Preferred Stock as a class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.<span style="text-decoration:underline">&#160;Common Stock</span>. The powers (including voting powers), if any, and the preferences and relative, participating, optional, special or other rights, if any, and the qualifications, limitations or restrictions, if any, of Common Stock are as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)<span style="font-style:italic">&#160;Dividends</span>. Subject to applicable law and the rights, if any, of the holders of any other class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the certificate of incorporation of the Corporation (including any certificate filed with the Secretary of State of the State of Delaware establishing a series of Preferred Stock) (as the same may be amended or amended and restated, the &#8220;<span style="font-weight:bold">Certificate of Incorporation</span>&#8221;) and then outstanding, dividends may be declared and paid on Common Stock at such times and in such amounts as the Board of Directors of the Corporation (the &#8220;<span style="font-weight:bold">Board of Directors</span>&#8221;) in its discretion shall determine. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;Voting. Except as otherwise provided by applicable law or by or pursuant to the provisions of the Certificate of Incorporation, each holder of one or more outstanding shares of Common Stock, as such, shall be entitled to one (1)&#160;vote for each outstanding share of Common Stock held of record by such holder on all matters on which stockholders are generally entitled to vote. Notwithstanding any other provision of this Certificate of Incorporation to the contrary, the holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Preferred Stock Designation (as defined below)) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation (including any Preferred Stock Designation) or the General Corporation Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#160;Liquidation, Dissolution or Winding Up. Subject to applicable law and the rights, if any, of the holders of any other class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the Certificate of Incorporation and then outstanding, in the event of any liquidation, dissolution or winding up of the Corporation, the holders of outstanding shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of outstanding shares of Common Stock held by them. None of a merger or consolidation of the Corporation with or into any other corporation or other entity, or a sale, lease or exchange of all or substantially all of the Corporation&#8217;s property and assets which, in each case, shall not in fact result in the liquidation, dissolution or winding up of the Corporation and the distribution of its assets, shall not be deemed to be a liquidation, dissolution or winding up of the Corporation within the meaning of this Section&#160;2(c) of this Article FOURTH. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.<span style="text-decoration:underline">&#160;Preferred Stock</span>. Shares of Preferred Stock may be issued from time to time in one or more series. The Board of Directors is hereby authorized to provide by resolution or resolutions from time to time for the issuance, out of the unissued shares of Preferred Stock, of one or more series of Preferred Stock, without stockholder approval, by filing a certificate pursuant to the applicable law of the State of Delaware (the &#8220;<span style="font-weight:bold">Preferred Stock Designation</span>&#8221;), setting forth such resolution and, with respect to each such series, establishing the number of shares to be included in such series, and fixing the voting powers, full or limited, or no voting power of the shares of such series, and the designation, preferences and relative, participating, optional or other special rights, if any, of the shares of each such series and any qualifications, limitations or restrictions thereof. The powers, designation, preferences, and relative, participating, optional, and other special rights of each series of Preferred Stock, and the qualifications, limitations, and restrictions thereof, if any, may differ from those of any and all other series of Preferred Stock at any time outstanding. The authority of the Board of Directors with respect to each series of Preferred Stock shall include, but not be limited to, the determination of the following, all ((a)&#8212;(k) below) as may be determined from time to time by the Board of Directors and stated in the resolution or resolutions providing for the issuance of such Preferred Stock: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the designation of the series, which may be by distinguishing number, letter, or title; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the number of shares of the series, which number the Board of Directors may thereafter (except where otherwise provided in the Preferred Stock Designation) increase or decrease (but not below the number of shares thereof then outstanding); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the amounts or rates at which dividends will be payable on, and the preferences, if any, of shares of the series in respect of dividends, and whether such dividends, if any, shall be cumulative or noncumulative; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the dates on which dividends, if any, shall be payable; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the redemption rights and price or prices, if any, for shares of the series; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the terms and amount of any sinking fund, if any, provided for the purchase or redemption of shares of the series; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the amounts payable on, and the preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) whether the shares of the series shall be convertible into or exchangeable for, shares of any other class or series, or any other security, of the Corporation or any other corporation, and, if so, the specification of such other class or series or such other security, the conversion or exchange price or prices or rate or rates, any adjustments thereof, the date or dates at which such shares shall be convertible or exchangeable and all other terms and conditions upon which such conversion or exchange may be made; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) restrictions on the issuance of shares of the same series or any other class or series; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) the voting power, if any, of the holders of shares of the series generally or upon specified events; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) any other powers, preferences and relative, participating, optional or other special rights of each series of Preferred Stock, and any qualifications, limitations, or restrictions of such shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIFTH</span>. <span style="text-decoration:underline">Board of Directors</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#160;Management. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#160;Removal of Directors. Any director or the entire Board of Directors may be removed solely and exclusively by the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%) in voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#160;Vacancies and Newly Created Directorships. Subject to applicable law and the rights, if any, of the holders of any class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the Certificate of Incorporation and then outstanding, newly created directorships resulting from an increase in the authorized number of directors or any vacancies on the Board of Directors resulting from the death, resignation, disqualification, removal or other cause, shall be filled solely and exclusively by a majority of the directors then in office, although less than a quorum, or by the sole remaining director. Any director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced and until his or her successor shall be elected and qualified, subject to such director&#8217;s earlier death, resignation, disqualification or removal. No decrease in the number of directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#160;Automatic Increase/Decrease in Total Authorized Number of Directors. During any period when the holders of any class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the Certificate of Incorporation and then outstanding have the right to elect one or more directors (collectively, the &#8220;Class/Series Directors&#8221; and each, a &#8220;Class/Series Director&#8221;), then upon commencement of, and for the duration of, the period during which such right continues: (a)&#160;the then otherwise total authorized number of directors of the Corporation shall automatically be increased by such specified Class/Series Director or Class/Series Directors, and the holders of such class or series of capital stock shall be entitled to elect such Class/Series Director or Class/Series Directors; and (b)&#160;each such Class/Series Director shall serve until such Class/Series Director&#8217;s successor shall have been duly elected and qualified, or until such Class/Series Director&#8217;s right to hold such office terminates by or pursuant to the provisions of the Certificate of Incorporation, whichever occurs earlier, subject to such Class/Series Director&#8217;s earlier death, resignation, disqualification or removal. Except as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided by or pursuant to the provisions of this Certificate of Incorporation, whenever the holders of any class or series of capital stock then outstanding having the right to elect one or more Class/Series Directors by or pursuant to the provisions of the Certificate of Incorporation are divested of such right by or pursuant to the provisions of this Certificate of Incorporation, the term of office of each such Class/Series Director elected by the holders of such class or series of capital stock, or elected to fill any vacancy resulting from the death, resignation, disqualification or removal of each such Class/Series Director, shall forthwith terminate and the total authorized number of directors of the Corporation shall automatically be decreased by such specified number of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#160;No Written Ballot. Unless and except to the extent that the bylaws of the Corporation shall so require, the election of directors of the Corporation need not be by written ballot. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#160;Amendment of Bylaws. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to make, alter, amend and repeal the bylaws of the Corporation. In addition to any affirmative vote required by or pursuant to the provisions of the Certificate of Incorporation, any bylaw that is to be made, altered, amended or repealed by the stockholders of the Corporation shall receive the affirmative vote of the holders of at least a majority in voting power of all of the then outstanding shares of capital stock of the Corporation generally entitled to vote, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#160;Special Meetings of Stockholders. Except as otherwise provided by or pursuant to the provisions of the Certificate of Incorporation, special meetings of stockholders for any purpose or purposes may be called at any time, but solely and exclusively by the Chairperson of the Board of Directors, the Chief Executive Officer or the directors entitled to cast a majority of the votes of the whole Board of Directors. Except as provided in the foregoing sentence, special meetings of stockholders may not be called by any other person or persons. Any special meeting of stockholders may be postponed by action of the Board of Directors or by the person calling such meeting (if other than the Board of Directors) at any time in advance of such meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">SIXTH</span>. <span style="text-decoration:underline">Stockholder Action</span>. Subject to the terms of any series of Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation may be taken either (i)&#160;upon the vote of stockholders at an annual or special meeting duly noticed and called in accordance with the General Corporation Law, as amended from time to time, and the Bylaws, or (ii)&#160;by written consent of the stockholders without a meeting; provided that, and notwithstanding the foregoing, during any period during which any equity security of the Corporation is listed or quoted on a national securities exchange or electronic quotation system that restricts or precludes action taken by written consent of the stockholders without a meeting, no action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be effected by consent of stockholders in lieu of a meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">SEVENTH</span>. <span style="text-decoration:underline">Exculpation</span>. A director or officer of the Corporation shall not be liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable, except to the extent such exemption from liability or limitation thereof is not permitted under the General Corporation Law. Any amendment, modification, repeal or elimination of the foregoing sentence shall not adversely affect any right or protection of a director or officer of the Corporation under this <span style="text-decoration:underline">Article SEVENTH</span> in respect of any act or omission occurring prior to the time of such amendment, modification, repeal or elimination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">EIGHTH</span>. <span style="text-decoration:underline">Amendment</span>. The Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in the Certificate of Incorporation, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by applicable law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to the Certificate of Incorporation are granted subject to the rights reserved in this <span style="text-decoration:underline">Article EIGHTH</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NINTH</span>. <span style="text-decoration:underline">Severability</span>. If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i)&#160;the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii)&#160;to the fullest extent possible, the provisions of this Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit of the Corporation to the fullest extent permitted by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature Page Follows] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has executed and acknowledged this Second Amended and Restated Certificate of Incorporation this&#8195;&#8195;&#8195;&#8195;day of&#8195;&#8195;&#8195;&#8195;, 202&#8195; . </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">BELLEVUE LIFE SCIENCES ACQUISITION CORP.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_49"><span id="ii476668_2"></span>ANNEX F </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDED AND RESTATED </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BYLAWS </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OSR HOLDINGS, INC. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE I </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Meetings of Stockholders </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.1 <span style="text-decoration:underline">Annual Meetings.</span> If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution or resolutions of the Board of Directors (the &#8220;<span style="font-weight:bold">Board of Directors</span>&#8221;) of OSR Holdings, Inc. (as such name may be changed in accordance with applicable law, the &#8220;<span style="font-weight:bold">Corporation</span>&#8221;) from time to time. Any annual meeting of stockholders may be postponed by action of the Board of Directors at any time in advance of such meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.2 <span style="text-decoration:underline">Special Meetings</span>. Except as otherwise provided by or pursuant to the provisions of the Corporation&#8217;s certificate of incorporation (including any certificate filed with the Secretary of State of the State of Delaware establishing a series of preferred stock of the Corporation) (as the same may be amended or amended and restated, the &#8220;<span style="font-weight:bold">Certificate of Incorporation</span>&#8221;), special meetings of stockholders for any purpose or purposes may be called at any time, but solely and exclusively by the Chairperson of the Board of Directors, the Chief Executive Officer or by the directors entitled to cast a majority of the votes of the whole Board of Directors. Except as provided in the foregoing sentence, special meetings of stockholders may not be called by any other person or persons. Any special meeting of stockholders may be postponed by action of the Board of Directors or by the person calling such meeting (if other than the Board of Directors) at any time in advance of such meeting. Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.3 <span style="text-decoration:underline">Notice of Meetings</span>. Whenever stockholders are required or permitted to take any action at a meeting, a notice of the meeting shall be given that shall state the place, if any, date and hour of the meeting, the record date for determining stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by applicable law, the Certificate of Incorporation or these Amended and Restated Bylaws (as the same may be amended or amended and restated, these &#8220;<span style="font-weight:bold">Bylaws</span>&#8221;), the notice of any meeting shall be given not less than ten (10)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting, as of the record date for determining the stockholders entitled to notice of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.4 <span style="text-decoration:underline">Adjournments</span>. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, if any, and notice need not be given of any such adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person or by proxy and vote at such adjourned meeting are (a)&#160;announced at the meeting at which the adjournment is taken, (b)&#160;displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (c)&#160;set forth in the notice of meeting in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.3</span> of these Bylaws. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&#160;days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.8</span> of these Bylaws, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.5 <span style="text-decoration:underline">Quorum</span>. Except as otherwise provided by applicable law, by or pursuant to the Certificate of Incorporation or by these Bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of <span style="white-space:nowrap">one-third</span> in voting power of the then outstanding shares of capital stock of the Corporation entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. In the absence of a quorum, the stockholders so present may, by a majority in voting power thereof, adjourn the meeting from time to time in the manner provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.4</span> of these Bylaws until a quorum shall attend. Shares of the Corporation&#8217;s capital stock shall neither be entitled to vote nor be counted for quorum purposes if such shares belong to (a)&#160;the Corporation, (b)&#160;to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly by the Corporation or (c)&#160;any other entity, if a majority of the voting power of such other entity is held, directly or indirectly by the Corporation or if such other entity is otherwise controlled, directly or indirectly, by the Corporation; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the foregoing shall not limit the right of the Corporation to vote stock, including but not limited to its own capital stock, held by it in a fiduciary capacity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.6 <span style="text-decoration:underline">Organization</span>. Meetings of stockholders shall be presided over by the Chairperson of the Board of Directors, if any, or in his or her absence by the Chief Executive Officer, if any, or in his or her absence, by a chairperson designated by the Board of Directors, or in the absence of such designation by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.7 <span style="text-decoration:underline">Voting; Proxies</span>. Except as otherwise provided by applicable law or by or pursuant to the provisions of the Certificate of Incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one (1)&#160;vote for each share of capital stock of the Corporation held by such stockholder which has voting power upon the matter in question. Each stockholder entitled to vote at a meeting of stockholders or to consent to corporate action without a meeting, if any, may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three (3)&#160;years from its date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary a revocation of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot. Except as otherwise provided by the Certificate of Incorporation, at all meetings of stockholders for the election of directors at which a quorum is present, a plurality of the votes cast shall be sufficient to elect. When a quorum is present at any meeting of stockholders, all other elections, questions or business presented to the stockholders at such meeting shall be decided by the affirmative vote of a majority of votes cast with respect to any such election, question or business presented to the stockholders unless the election, question or business is one which, by express provision of the Certificate of Incorporation, these Bylaws, the rules or regulations of any stock exchange applicable to the Corporation, any regulation applicable to the Corporation or its securities or the laws of the State of Delaware, a vote of a different number or voting by class or series is required, in which case, such express provision shall govern. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1.8 <span style="text-decoration:underline">Fixing Date for Determination of Stockholders of Record</span>. In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, or to consent to corporate action without a meeting (where permitted by or pursuant to the provisions of the Certificate of Incorporation), or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date: (a)&#160;in the case of a determination of stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, shall, unless otherwise required by applicable law, not be more than sixty (60)&#160;nor less than ten (10)&#160;days before the date of such meeting and, unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for determining the stockholders entitled to vote at such meeting, the record date for determining the stockholders entitled to notice of such meeting shall also be the record date for determining the stockholders entitled to vote at such meeting; (b)&#160;in the case of a determination of stockholders entitled to consent to corporate action without a meeting (where permitted by or pursuant to the provisions of the Certificate of Incorporation), shall not be more than ten (10)&#160;days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and (c)&#160;in the case of any other action, shall not be more than sixty (60)&#160;days prior to such other action. If no record date is fixed: (i)&#160;the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (ii)&#160;the record date for determining stockholders entitled to consent to corporate action without a meeting, if any, when no prior action of the Board of Directors is required by applicable law, shall be the first date on which a signed consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable law, or, if prior action by the Board of Directors is required by applicable law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action; and (iii)&#160;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for the stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled to vote in accordance with the foregoing provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.8</span> at the adjourned meeting.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.9 <span style="text-decoration:underline">List of Stockholders Entitled to Vote</span>. The Corporation shall prepare, no later than the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day before each meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, if the record date for determining the stockholders entitled to vote is less than ten (10)&#160;days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day before the meeting date, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing contained in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.9</span> shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of ten (10)&#160;days ending on the day before the meeting date (a)&#160;on a reasonably accessible electronic network, <span style="text-decoration:underline">provided</span> that the information required to gain access to such list is provided with the notice of meeting, or (b)&#160;during ordinary business hours, at the principal place of business of the Corporation. The list of stockholders must also be open to examination at the meeting as required by applicable law. Except as otherwise provided by applicable law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.9</span> or to vote in person or by proxy at any meeting of stockholders. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.10 <span style="text-decoration:underline">Action By Consent in Lieu of Meeting</span>. Any action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be effected by consent of stockholders in lieu of a meeting of stockholders except as otherwise precluded pursuant to the provisions of the Certificate of Incorporation. When, as permitted by or pursuant to the provisions of the Certificate of Incorporation, action required or permitted to be taken at any annual or special meeting of stockholders is taken without a meeting, without prior notice and without a vote, a consent or consents, setting forth the action so taken, shall be given by the holders of outstanding capital stock of the Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with applicable law. When, as permitted by or pursuant to the provisions of the Certificate of Incorporation, action required or permitted to be taken at any annual or special meeting of stockholders is taken without a meeting, without prior notice and without a vote, prompt notice of the taking of the corporate action without a meeting by less than unanimous consent shall be given to those stockholders who are entitled thereto under applicable law.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.11 <span style="text-decoration:underline">Inspectors of Election</span>. The Corporation may, and shall if required by applicable law, in advance of any meeting of stockholders, appoint one or more inspectors of election, who may be employees of the Corporation, to act at the meeting or any adjournment thereof and to make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. In the event that no inspector so appointed or designated is able to act at a meeting of stockholders, the individual presiding over the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath to execute faithfully the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector or inspectors so appointed or designated shall (a)&#160;ascertain the number of shares of capital stock of the Corporation outstanding and the voting power of each such share, (b)&#160;determine the shares of capital stock of the Corporation represented at the meeting and the validity of proxies and ballots, (c)&#160;count all votes and ballots, (d)&#160;determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors and (e)&#160;certify their determination of the number of shares of capital stock of the Corporation represented at the meeting and such inspectors&#8217; count of all votes and ballots. Such certification and report shall specify such other information as may be required by applicable law. In determining the validity and counting of proxies and ballots cast at any meeting of stockholders, the inspectors may consider such information as is permitted by applicable law. No individual who is a candidate for an office at an election may serve as an inspector at such election. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.12 <span style="text-decoration:underline">Conduct of Meetings</span>. The date and time of the opening and the closing of the polls for each election, question or business upon which the stockholders will vote at a meeting of stockholders shall be announced at the meeting by the individual presiding over the meeting. The Board of Directors may adopt (by resolution or resolutions thereof) such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the individual presiding over any meeting of stockholders shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such individual, are appropriate for the proper conduct of the meeting of stockholders. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the individual presiding over the meeting of stockholders, may include, without limitation, the following: (a)&#160;the establishment of an agenda or order of business for the meeting of stockholders; (b)&#160;rules and procedures for maintaining order at the meeting of stockholders and the safety of those present; (c)&#160;limitations on attendance at or participation in the meeting of stockholders to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the individual presiding over the meeting of stockholders shall determine; (d)&#160;restrictions on entry to the meeting of stockholders after the time fixed for the commencement thereof; and (e)&#160;limitations on the time allotted to questions or comments by participants in the meeting of stockholders. The Board of Directors or, in addition to making any other determinations that may be appropriate to the conduct of the meeting of stockholders, the individual presiding over any meeting of stockholders, in each case, shall have the power and duty to determine whether any election, question or business was or was not properly made, proposed or brought before the meeting of stockholders and therefore shall be disregarded and not be considered or transacted at the meeting, and, if the Board of Directors or the individual presiding over the meeting, as the case may be, determines that such election, question or business was not properly made, proposed or brought before the meeting of stockholders and shall be disregarded and not be considered or transacted at the meeting, the individual presiding over the meeting shall declare to the meeting that such election, question or business was not properly made, proposed or brought before the meeting and shall be disregarded and not be considered or transacted at the meeting, and any such election, question or business shall not be considered or transacted at the meeting. Unless and to the extent determined by the Board of Directors or the individual presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;1.13 <span style="text-decoration:underline">Notice of Stockholder Business and Nominations</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Annual Meetings of Stockholders</span>. (i)&#160;Nominations of one or more individuals for election to the Board of Directors by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude nominations of one or more individuals for election as Class/Series Directors) (each, a &#8220;<span style="font-weight:bold">Nomination</span>,&#8221; and more than one, &#8220;<span style="font-weight:bold">Nominations</span>&#8221;) and the proposal of any question or business other than a Nomination or Nominations to be considered by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude any question or business other than a Nomination or Nominations required by or pursuant to the provisions of the Certificate of Incorporation to be voted on solely and exclusively by the holders of any class (voting separately as a class) or series (voting separately as a series) of capital stock of the Corporation then outstanding) (collectively, &#8220;<span style="font-weight:bold">Business</span>&#8221;) may be made at an annual meeting of stockholders only (A)&#160;pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that reference in the Corporation&#8217;s notice of meeting to the election of directors or the election of members of the Board of Directors shall not include or be deemed to include a Nomination or Nominations, (B)&#160;by or at the direction of the Board of Directors or (C)&#160;by any stockholder of the Corporation who was a stockholder of record of the Corporation at the time the notice provided for in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> is delivered to the Secretary, who is entitled to vote at the meeting and who complies with the procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) For Nominations or Business to be properly brought before an annual meeting of stockholders by a stockholder pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13(a)(i)(C)</span>, the stockholder must have given timely notice thereof in writing to the Secretary and any proposed Business must constitute a proper matter for stockholder action. To be timely, a stockholder&#8217;s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90<sup style="font-size:75%; vertical-align:top">th</sup>) day nor earlier than the close of business on the one hundred twentieth (120<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to the first anniversary of the preceding year&#8217;s annual meeting of stockholders; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that in the event that the date of the annual meeting is more than thirty (30)&#160;days before or more than seventy (70)&#160;days after such anniversary date, notice by the stockholder must be so delivered not earlier than the close of business on the one hundred twentieth (120<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to such annual meeting or the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement of an annual meeting of stockholders commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above. Such stockholder&#8217;s notice shall set forth: (A)&#160;as to each Nomination to be made by such stockholder, (1)&#160;all information relating to the individual subject to such Nomination that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;), without regard to the application of the Exchange Act to either the Nomination or the Corporation, (2)&#160;such individual&#8217;s written consent to being named in any proxy statement as a nominee and to serving as director if elected, (3)&#160;a description of any direct or indirect compensation or benefit (including, without limitation, indemnification and/or advancement rights) to which the individual subject to such Nomination may be entitled under any agreement, arrangement or understanding with any person other than the Corporation (including, without limitation, the amount of any such monetary compensation) in connection with such individual&#8217;s nomination or service as a director of the Corporation and (4)&#160;a description of any other material relationship or relationships between or among the individual subject to such Nomination and/or such individual&#8217;s affiliates and associates, on the one hand, and the stockholder giving the notice and the beneficial owner, if any, on whose behalf the Nomination or Nominations is/are made and/or such stockholder&#8217;s or beneficial owner&#8217;s respective affiliates and associates, or others acting in concert with such stockholder or beneficial owner or their respective affiliates and associates, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation <span style="white-space:nowrap">S-K</span> if such stockholder, beneficial owner, affiliate, associate or other person were the &#8220;registrant&#8221; for purposes of such rule and the individual subject to such Nomination was a director or officer of such registrant; (B)&#160;as to the Business proposed by such stockholder, a brief description of the Business, the text of the proposed Business (including the text of any resolution or resolutions proposed for consideration and in the event that such Business includes a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposal to amend these Bylaws, the text of the proposed amendment), the reason or reasons for conducting such Business at the meeting and any material interest or interests in such Business of such stockholder and of the beneficial owner, if any, on whose behalf the Business is proposed; and (C)&#160;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the Nomination, Nominations or Business is/are made (1)&#160;the name and address of such stockholder, as they appear on the Corporation&#8217;s books, and of such beneficial owner, if any, and any of their respective affiliates or associates or others acting in concert with them, (2)&#160;the class, series and number of shares of capital stock of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner, if any, (3)&#160;a representation that the stockholder is a holder of record of shares of capital stock of the Corporation entitled to vote at such meeting and such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the meeting to propose such Nomination, Nominations or Business and (4)&#160;a representation as to whether the stockholder or the beneficial owner, if any, intends or is part of a group which intends (x)&#160;to deliver by proxy statement and/or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding capital stock required to approve or adopt the Business or elect the nominee or nominees subject to the Nomination or Nominations and/or (y)&#160;to otherwise solicit proxies from stockholders of the Corporation in support of such Nomination, Nominations or Business; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that if the Business is otherwise subject to Rule <span style="white-space:nowrap">14a-8</span> (or any successor thereto) promulgated under the Exchange Act (&#8220;<span style="font-weight:bold">Rule <span style="white-space:nowrap">14a-8</span></span>&#8221;), the foregoing notice requirements shall be deemed satisfied by a stockholder if the stockholder has notified the Corporation of his, her or its intention to present such Business at an annual meeting of stockholders in compliance with Rule <span style="white-space:nowrap">14a-8,</span> and such Business has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting of stockholders. The Corporation may require (1)&#160;any individual subject to such Nomination to furnish such other information as the Corporation may reasonably require to determine the eligibility of such individual subject to such Nomination to serve as a director of the Corporation if elected and (2)&#160;the stockholder giving notice to furnish such other information as the Corporation may reasonably require to demonstrate that any Business is a proper matter for stockholder action at an annual meeting of stockholders.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding anything in the second sentence of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13(a)(ii)</span> to the contrary, in the event that the number of directors to be elected to the Board of Directors by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude any Class/Series Directors) at an annual meeting of stockholders is increased and there is no public announcement by the Corporation naming the nominees for election to the additional directorships at least one hundred (100)&#160;days prior to the first (1<sup style="font-size:75%; vertical-align:top">st</sup>) anniversary of the preceding year&#8217;s annual meeting of stockholders, a stockholder&#8217;s notice required by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> shall also be considered timely, but only with respect to nominees for election to such additional directorships, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day following the day on which such public announcement is first made by the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Special Meetings of Stockholders.</span> Only such Business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that reference therein to the election of directors or the election of members of the Board of Directors shall not include or be deemed to include Nominations. Nominations may be made at a special meeting of stockholders at which one or more directors are to be elected by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude any Class/Series Directors) pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto) as aforesaid (<span style="text-decoration:underline">provided</span> that the Board of Directors has determined that directors shall be elected at such meeting)&#160;(i) by or at the direction of the Board of Directors or (ii)&#160;by any stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> is delivered to the Secretary, who is entitled to vote at the meeting and upon such election and who complies with the notice procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span>. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude any Class/Series Directors), any such stockholder entitled to vote in such election may make a Nomination or Nominations of one or more individuals (as the case may be) for election to such position(s) as specified in the Corporation&#8217;s notice of meeting pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13(a)(i)(A)</span>, if the stockholder&#8217;s notice required by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13(a)(ii)</span> shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the close of business on the one hundred twentieth (120<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to such special meeting and not later than the close of business on the later of the ninetieth (90<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to such special meeting or the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day following the day on which public announcement is first made of the date of such special meeting and of the nominee(s) proposed by the Board of Directors to be elected at such special meeting. In no event shall the public announcement of an adjournment or postponement of a special meeting of stockholders commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">General. </span>(i)&#160;Only individuals subject to a Nomination made in compliance with the procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> shall be eligible for election at an annual or special meeting of stockholders, and only such Business shall be conducted at an annual or special meeting of stockholders as shall have been brought before such meeting in accordance with the procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span>. Except as otherwise provided by applicable law, the Board of Directors or the individual presiding over an annual or special meeting of stockholders shall have the power and duty to determine whether (A)&#160;a Nomination or any Business proposed to be brought before the meeting was or was not made, proposed or brought, as the case may be, in accordance with the procedures set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> and (B)&#160;any proposed Nomination, Nominations or Business shall be disregarded or that such Nomination, Nominations or Business shall not be considered or transacted at the meeting. Notwithstanding the foregoing provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span>, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders to present a Nomination, Nominations or Business, such Nomination, Nominations or Business shall be disregarded and such Nomination, Nominations or Business shall not be considered or transacted at the meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) For purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span>, &#8220;<span style="font-weight:bold">public announcement</span>&#8221; shall include disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with or publicly furnished by the Corporation to the Securities and Exchange Commission pursuant to Section&#160;13, 14 and 15(d) (or any successor thereto) of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Nothing in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.13</span> shall be deemed to affect any (A)&#160;rights or obligations, if any, of stockholders with respect to inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule <span style="white-space:nowrap">14a-8</span> (to the extent the Corporation or such proposals are subject to Rule <span style="white-space:nowrap">14a-8),</span> (B) rights or obligations, if any, of stockholders with respect to the inclusion of a nominee in a universal proxy card pursuant to Rule <span style="white-space:nowrap">14a-19</span> (or any successor thereto) promulgated under the Exchange Act or (C)&#160;rights, if any, of the holders of any class or series of capital stock of the Corporation as provided for or filed by or pursuant to the Certificate of Incorporation and then outstanding to, solely and exclusively, elect one or more directors outstanding (collectively, the &#8220;<span style="font-weight:bold">Class/Series Directors</span>&#8221; and each, a &#8220;<span style="font-weight:bold">Class/Series Director</span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Board of Directors </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.1 <span style="text-decoration:underline">Number; Qualifications</span>. Except for any Class/Series Directors, the Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution or resolutions of the Board of Directors. Directors need not be stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.2 <span style="text-decoration:underline">Resignation; Vacancies and Newly Created Directorships</span>. Any director may resign at any time upon notice to the Corporation. Subject to the rights, if any, of the holders of any class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the Certificate of Incorporation and then outstanding, newly created directorships resulting from an increase in the authorized number of directors or any vacancies on the Board of Directors resulting from the death, resignation, disqualification, removal or other cause, shall be filled solely and exclusively by a majority of the directors then in office, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
although less than a quorum, or by the sole remaining director. Any director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced and until his or her successor shall be elected and qualified, subject to such director&#8217;s earlier death, resignation, disqualification or removal. No decrease in the number of directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.3 <span style="text-decoration:underline">Regular Meetings</span>. Regular meetings of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of Directors may from time to time determine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.4 <span style="text-decoration:underline">Special Meetings</span>. Special meetings of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the Chairperson of the Board of Directors, the Chief Executive Officer or by the directors entitled to cast at least half of the votes of the whole Board of Directors. Notice of a special meeting of the Board of Directors shall be given by or at the direction of the person or persons calling the meeting (a)&#160;in the case of notice delivered by mail, at least five (5)&#160;days before the special meeting, (b)&#160;in the case of notice delivered by courier, at least forty-eight (48)&#160;hours before the special meeting, or (c)&#160;in the case of notice delivered by electronic mail, at least twenty-four (24)&#160;hours before the special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.5 <span style="text-decoration:underline">Telephonic Meetings Permitted</span>. Members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting thereof by means of conference telephone or other communications equipment by means of which all individuals participating in the meeting can hear each other, and participation in a meeting pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5</span> shall constitute presence in person at such meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.6 <span style="text-decoration:underline">Quorum; Vote Required for Action</span>. At all meetings of the Board of Directors the directors entitled to cast a majority of the votes of the whole Board of Directors shall constitute a quorum for the transaction of business. Except in cases in which the Certificate of Incorporation, these Bylaws or applicable law otherwise provides, a majority of the votes entitled to be cast by the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.7 <span style="text-decoration:underline">Organization</span>. Meetings of the Board of Directors shall be presided over by the Chairperson of the Board of Directors, if any, or in his or her absence, by the Chief Executive Officer, if any, or in his or her absence, by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any individual to act as secretary of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;2.8 <span style="text-decoration:underline">Action by Unanimous Consent of Directors</span>. Unless otherwise restricted by or pursuant to the Certificate of Incorporation or by these Bylaws, (a)&#160;any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or such committee, as the case may be, consent thereto in writing or by electronic transmission and (b)&#160;a consent may be documented, signed and delivered in any manner permitted by Section&#160;116 of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-weight:bold">General Corporation Law</span>&#8221;). After action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board of Directors, or the committee thereof, in the same paper or electronic form as the minutes are maintained. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE III </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committees </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;3.1 <span style="text-decoration:underline">Committees</span>. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent permitted by applicable law and to the extent provided in the resolution of the Board of Directors or these Bylaws, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 3.2 <span style="text-decoration:underline">Committee Rules</span>. Unless the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to <span style="text-decoration:underline">Article II</span> of these Bylaws. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE IV </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Officers </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;4.1 <span style="text-decoration:underline">Executive Officers; Election; Qualifications; Term of Office, Resignation; Removal; Vacancies</span>. The Board of Directors shall elect a Chief Executive Officer, Chief Financial Officer and a Secretary, and shall choose a Chairperson of the Board of Directors from among its members. The Board of Directors may also choose a President, one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers and such other officers as it shall from time to time deem necessary or desirable. Each such officer shall hold office until the first meeting of the Board of Directors after the annual meeting of stockholders next succeeding his or her election, and until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. Any officer may resign at any time upon written notice to the Corporation. Except as otherwise provided by or pursuant to the Certificate of Incorporation, the Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation. Any number of offices may be held by the same person. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;4.2 <span style="text-decoration:underline">Powers and Duties of Officers</span>. The officers of the Corporation shall have such powers and duties in the management of the Corporation as may be prescribed in these Bylaws or a resolution by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his or her duties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;4.3 <span style="text-decoration:underline">Appointing Attorneys and Agents; Voting Securities of Other Entities</span>. Unless otherwise provided by resolution or resolutions adopted by the Board of Directors, the Chairperson of the Board of Directors or the Chief Executive Officer may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, for, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation or other entity, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation or other entity, or to consent, in the name of the Corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consents, and may execute or cause to be executed for, in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such proxies or other instruments as he or she may deem necessary or proper. Any of the rights set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3</span> which may be delegated to an attorney or agent may also be exercised directly by the Chairperson of the Board of Directors or the Chief Executive Officer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE V </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;5.1 <span style="text-decoration:underline">Certificates</span>. Every holder of capital stock of the Corporation represented by certificates shall be entitled to have a certificate signed by, or in the name of, the Corporation by any two (2)&#160;authorized officers of the Corporation representing the number of shares registered in certificate form. Each of the Chairperson of the Board of Directors, the Chief Executive Officer and the Secretary, in addition to any other officers of the Corporation authorized by the Board of Directors (by resolution or resolutions thereof) or these Bylaws, is hereby authorized to sign certificates by, or in the name of, the Corporation. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent, or registrar at the date of issue. The Corporation shall not have the power to issue a certificate in bearer form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;5.2 <span style="text-decoration:underline">Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or Uncertificated Shares</span>. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#8217;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;5.3 <span style="text-decoration:underline">Restrictions</span>. If the Corporation issues any shares that are not registered under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold">Securities Act</span>&#8221;), and registered or qualified under the applicable state securities laws, such shares may not be transferred without the consent of the Corporation and the certificates evidencing such shares or the notice required by Delaware law, as the case may be, shall contain substantially the following legend (or such other legend adopted by resolution or resolutions of the Board of Directors):</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY SET FORTH IN THE CORPORATION&#8217;S AMENDED AND RESTATED BYLAWS (AS THE SAME MAY BE AMENDED OR AMENDED AND RESTATED) AND MAY NOT BE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM, WITHOUT THE CONSENT OF THE CORPORATION. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VI </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Indemnification </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.1 <span style="text-decoration:underline">Right to Indemnification</span>. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;<span style="font-weight:bold">proceeding</span>&#8221;), by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (hereinafter an &#8220;<span style="font-weight:bold">Indemnitee</span>&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys&#8217; fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection with such proceeding; provided, however, that, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except as provided in Section&#160;6.3 with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by such Indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.2 <span style="text-decoration:underline">Right to Advancement of Expenses</span>. In addition to the right to indemnification conferred in Section&#160;6.1, an Indemnitee shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including, without limitation, attorneys&#8217; fees) incurred in defending or otherwise participating in any such proceeding in advance of its final disposition (hereinafter an &#8220;<span style="font-weight:bold">advancement of expenses</span>&#8221;); provided, however, that, if the DGCL requires, an advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon the Corporation&#8217;s receipt of an undertaking (hereinafter an &#8220;<span style="font-weight:bold">undertaking</span>&#8221;), by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.3 <span style="text-decoration:underline">Right of Indemnitee to Bring Suit</span>. If a claim under Section&#160;6.1 or Section&#160;6.2 is not paid in full by the Corporation within 60 days after a written claim therefor has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall also be entitled to be paid the expense of prosecuting or defending such suit. In (a)&#160;any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by an Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b)&#160;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<span style="font-weight:bold">final adjudication</span>&#8221;) that, the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including a determination by its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, shall be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI or otherwise shall be on the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.4 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Exclusivity</span> of Rights</span>. The rights provided to any Indemnitee pursuant to this Article VI shall not be exclusive of any other right, which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Incorporation, these Bylaws, an agreement, a vote of stockholders or disinterested directors, or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.5 <span style="text-decoration:underline">Insurance</span>. The Corporation may maintain insurance, at its expense, to protect itself and/or any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.6 <span style="text-decoration:underline">Indemnification of Other Persons</span>. This Article VI shall not limit the right of the Corporation to the extent and in the manner authorized or permitted by law to indemnify and to advance expenses to persons </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other than Indemnitees. Without limiting the foregoing, the Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions of this Article VI with respect to the indemnification and advancement of expenses of Indemnitees under this Article VI. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.7 <span style="text-decoration:underline">Amendments</span>. Any repeal or amendment of this Article VI by the Board of Directors or the stockholders of the Corporation or by changes in applicable law, or the adoption of any other provision of these Bylaws inconsistent with this Article VI, will, to the extent permitted by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way diminish or adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision; provided however, that amendments or repeals of this Article VI by stockholders shall require the affirmative vote of the stockholders holding at least 65% of the voting power of all outstanding shares of capital stock of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.8 <span style="text-decoration:underline">Certain Definitions</span>. For purposes of this Article VI, (a)&#160;references to &#8220;other enterprise&#8221; shall include any employee benefit plan; (b)&#160;references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect to an employee benefit plan; (c)&#160;references to &#8220;serving at the request of the Corporation&#8221; shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants, or beneficiaries; and (d)&#160;a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;not opposed to the best interest of the Corporation&#8221; for purposes of Section&#160;145 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.9 <span style="text-decoration:underline">Contract Rights</span>. The rights provided to Indemnitees pursuant to this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the Indemnitee&#8217;s heirs, executors and administrators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;6.10 <span style="text-decoration:underline">Severability</span>. If any provision or provisions of this Article VI shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&#160;the validity, legality and enforceability of the remaining provisions of this Article VI shall not in any way be affected or impaired thereby; and (b)&#160;to the fullest extent possible, the provisions of this Article VI (including, without limitation, each such portion of this Article VI containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VII </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Miscellaneous </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;7.1 <span style="text-decoration:underline">Fiscal Year</span>. The fiscal year of the Corporation shall be determined by resolution or resolutions of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;7.2 <span style="text-decoration:underline">Seal</span>. The corporate seal of the Corporation shall have the name of the Corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;7.3 <span style="text-decoration:underline">Manner of Notice</span>. Except as otherwise provided in these Bylaws or permitted by applicable law, notices to directors and stockholders shall be in writing or electronic transmission and delivered by mail, courier service or electronic mail to the directors or stockholders at their addresses appearing on the records of the Corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;7.4 <span style="text-decoration:underline">Waiver of Notice of Meetings of Stockholders, Directors and Committees</span>. Any waiver of notice, given by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in a waiver of notice.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;7.5 <span style="text-decoration:underline">Form of Records</span>. Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); <span style="text-decoration:underline">provided</span> that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, that the records so kept comply with applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 7.6 <span style="text-decoration:underline">Amendment of Bylaws</span>. These Bylaws may be altered, amended or repealed, and new bylaws made, by the Board of Directors, but the stockholders may make additional bylaws and may alter and repeal any bylaws whether adopted by them or otherwise. In addition to any affirmative vote required by or pursuant to the provisions of the Certificate of Incorporation, any bylaw that is to be made, altered, amended or repealed by the stockholders of the Corporation shall require the affirmative vote of the holders of at least a majority in voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 7.7 <span style="text-decoration:underline">Forum for Adjudication of Disputes</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Delaware Courts</span>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Corporation, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&#160;any civil action to interpret, apply or enforce any provision of the General Corporation Law, (iv)&#160;any civil action to interpret, apply, enforce or determine the validity of the provisions of the Certificate of Incorporation or these Bylaws or (v)&#160;any action asserting a claim governed by the internal affairs doctrine; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, in the event that the Court of Chancery of the State of Delaware lacks jurisdiction over such action, the sole and exclusive forum for such action shall be another state or federal court located within the State of Delaware, in all cases, subject to such court having personal jurisdiction over the indispensable parties named as defendants. For the avoidance of doubt, this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.7(a)</span> shall not apply to the resolution of any complaint asserting a cause of action arising under the Securities Act.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Federal Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Application. Failure to enforce the foregoing provisions of this Section&#160;7.7 would cause the Corporation irreparable harm and the Corporation shall, to the fullest extent permitted by applicable law, be entitled to equitable relief, including injunctive relief and specific performance, to enforce the foregoing provisions. Any person purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section&#160;7.7. This Section&#160;7.7 shall not apply to any action asserting claims arising under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted Effective As of &#8195;&#8195;&#8195;, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="rom476668_50"><span id="anxg"></span>Annex G </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BELLEVUE LIFE SCIENCES ACQUISITION CORP. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">2024 OMNIBUS INCENTIVE PLAN </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BELLEVUE LIFE SCIENCES ACQUISITION CORP. 2024 OMNIBUS INCENTIVE PLAN </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. PURPOSE </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is intended to (a)&#160;provide eligible individuals with an incentive to contribute to the success of the Company and to operate and manage the Company&#8217;s business in a manner that provides for the Company&#8217;s long-term growth and profitability and that benefits its stockholders and other important stakeholders, including its employees and customers, and (b)&#160;provide a means of recruiting, rewarding, and retaining key personnel. To this end, the Plan provides for the grant of Awards of Options, SARs, Restricted Stock, RSUs, Other Equity-Based Awards and cash bonus awards. Any of these Awards may, but need not, be made as performance incentives to reward the holders of such Awards for the achievement of performance goals in accordance with the terms of the Plan. Options granted under the Plan may be Nonqualified Stock Options or Incentive Stock Options. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. DEFINITIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of interpreting the Plan documents, including the Plan and Award Agreements, the following capitalized terms shall have the meanings specified below, unless the context clearly indicates otherwise: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.1 </span>&#8220;<span style="font-weight:bold">Affiliate</span>&#8221; shall mean any Person that controls, is controlled by, or is under common control with the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary. For purposes of making a grant of Options or SARs, an entity shall not be considered an Affiliate unless the Company holds a Controlling Interest in such entity. The preceding sentence does not, however, apply for purposes of determining whether Service is uninterrupted for purposes of vesting, exercisability or expiration of Options and SARs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.2 </span>&#8220;<span style="font-weight:bold">Award</span>&#8221; shall mean a grant under the Plan of an Option, a SAR, Restricted Stock, a RSU, an Other Equity-Based Award or cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.3 </span>&#8220;<span style="font-weight:bold">Award Agreement</span>&#8221; shall mean the written agreement, in such written, electronic or other form as determined by the Committee, between the Company and a Grantee that evidences and sets forth the terms and conditions of an Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.4 </span>&#8220;<span style="font-weight:bold">Beneficial Owner</span>&#8221; shall have the meaning set forth in Rule <span style="white-space:nowrap">13d-3</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.5 </span>&#8220;<span style="font-weight:bold">Benefit Arrangement</span>&#8221; shall mean any formal or informal plan or other arrangement for the direct or indirect provision of compensation to a Grantee (including groups or classes of Grantees or beneficiaries of which the Grantee is a member), whether or not such compensation is deferred, is in cash or is in the form of a benefit to or for the Grantee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.6 </span>&#8220;<span style="font-weight:bold">Board</span>&#8221; shall mean the Board of Directors of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.7 </span>&#8220;<span style="font-weight:bold">Capital Stock</span>&#8221; shall mean, with respect to any Person, any and all shares, interests, participations or other equivalents (however designated, whether voting or <span style="white-space:nowrap">non-voting)</span> in equity of such Person, whether outstanding on the Effective Date or issued thereafter, including, without limitation, all shares of Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.8 </span>&#8220;<span style="font-weight:bold">Cause</span>&#8221; shall have the meaning set forth in an applicable agreement between a Grantee and the Company or an Affiliate, and in the absence of any such agreement, shall mean, with respect to any Grantee and as determined by the Committee, (a)&#160;gross negligence or willful misconduct in connection with the performance of duties; (b)&#160;conviction of, or pleading guilty or <span style="font-style:italic">nolo contendere</span> to, a criminal offense (other than minor traffic offenses); or (c)&#160;material breach of any term of any employment, consulting or other services, confidentiality, intellectual property or <span style="white-space:nowrap">non-competition</span> agreements, if any, between such Grantee and the Company or an Affiliate. Any determination by the Committee regarding whether an event constituting Cause has occurred shall be final, binding and conclusive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.9 </span>&#8220;<span style="font-weight:bold">Change in Control</span>&#8221; shall mean, subject to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.11</span>, the occurrence of any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) A transaction or a series of related transactions whereby any Person or Group (other than the Company or any Affiliate) becomes the Beneficial Owner of more than 50% of the total voting power of the Voting Stock of the Company, on a Fully Diluted Basis; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Individuals who, as of the Effective Date, constitute the Board (the &#8220;<span style="font-weight:bold">Incumbent Board</span>&#8221;) (together with any new directors whose election by such Incumbent Board or whose nomination by such Incumbent Board for election by the stockholders of the Company was approved by a vote of at least a majority of the members of such Incumbent Board then in office who either were members of such Incumbent Board or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the members of such Board then in office; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, the Company (regardless of whether the Company is the surviving Person), other than any such transaction in which the Prior Stockholders own directly or indirectly at least a majority of the voting power of the Voting Stock of the surviving Person in such merger or consolidation immediately after such transaction; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The consummation of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization, merger, or consolidation), in one transaction or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any Person or Group (other than the Company or any Affiliate), except any such transaction or series of transactions in which the Prior Stockholders own directly or indirectly at least a majority of the voting power of the Voting Stock of such Person or Group immediately after such transaction or series of transactions; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The consummation of a plan or proposal for the liquidation, winding up or dissolution of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Board shall have full and final authority, in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control, and any incidental matters relating thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.10 </span>&#8220;<span style="font-weight:bold">Code</span>&#8221; shall mean the Internal Revenue Code of 1986, as amended, as now in effect or as hereafter amended, and any successor thereto. References in the Plan to any Code section shall be deemed to include, as applicable, regulations and guidance promulgated under such Code section. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.11 </span>&#8220;<span style="font-weight:bold">Committee</span>&#8221; shall mean a committee of, and designated from time to time by resolution of, the Board, which shall be constituted as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1.2</span> and <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1.3</span> (or, if no Committee has been so designated, the Board). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.12 </span>&#8220;<span style="font-weight:bold">Company</span>&#8221; shall mean Bellevue Life Sciences Acquisition Corp., a Delaware corporation, and any successor thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.13 </span>&#8220;<span style="font-weight:bold">Controlling Interest</span>&#8221; shall have the meaning set forth in Treasury Regulation <span style="white-space:nowrap">&#167;&#160;1.414(c)-2(b)(2)(i);</span> provided that (a)&#160;except as specified in clause (b), an interest of &#8220;at least 50 percent&#8221; shall be used instead of an interest of &#8220;at least 80 percent&#8221; in each case where &#8220;at least 80 percent&#8221; appears in Treasury Regulation &#167; <span style="white-space:nowrap">1.414(c)-2(b)(2)(i),</span> and (b)&#160;where a grant of Options or SARs is based on a legitimate business criterion, an interest of &#8220;at least 20 percent&#8221; shall be used instead of an interest of &#8220;at least 80 percent&#8221; in each case where &#8220;at least 80 percent&#8221; appears in Treasury Regulation <span style="white-space:nowrap">&#167;&#160;1.414(c)-2(b)(2)(i).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.14 </span>&#8220;<span style="font-weight:bold">Disability</span>&#8221; shall mean the inability of a Grantee to perform each of the essential duties of such Grantee&#8217;s position by reason of a medically determinable physical or mental impairment that is potentially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permanent in character or that can be expected to last for a continuous period of not less than 12 months. With respect to rules regarding the expiration of an Incentive Stock Option following termination of a Grantee&#8217;s Service, Disability shall mean the inability of such Grantee to engage in any substantial gainful activity by reason of a medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.15 </span>&#8220;<span style="font-weight:bold">Effective Date</span>&#8221; shall mean the date the Plan is adopted by the Board, subject to approval of the Plan by the Company&#8217;s stockholders in accordance with <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.16 </span>&#8220;<span style="font-weight:bold">Employee</span>&#8221; shall mean, as of any date of determination, an employee (including an officer) of the Company or an Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.17 </span>&#8220;<span style="font-weight:bold">Exchange Act</span>&#8221; shall mean the Securities Exchange Act of 1934, as amended, as now in effect or as hereafter amended, and any successor thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.18 </span>&#8220;<span style="font-weight:bold">Fair Market Value</span>&#8221; shall mean the fair market value of a share of Stock for purposes of the Plan, which shall be, as of any date of determination: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If on such date the shares of Stock are listed on a Stock Exchange, or are publicly traded on another Securities Market, the Fair Market Value of a share of Stock shall be the closing price of the Stock as reported on such Stock Exchange or such Securities Market (provided that, if there is more than one such Stock Exchange or Securities Market, the Committee shall designate the appropriate Stock Exchange or Securities Market for purposes of the Fair Market Value determination). If there is no such reported closing price on such date, the Fair Market Value of a share of Stock shall be the closing price of the Stock on the next preceding day on which any sale of Stock shall have been reported on such Stock Exchange or such Securities Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If on such date the shares of Stock are not listed on a Stock Exchange or publicly traded on a Securities Market, the Fair Market Value of a share of Stock shall be the value of the Stock as determined by the Committee by the reasonable application of a reasonable valuation method, in a manner consistent with Code &#167; 409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.18 </span>or <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span>, for purposes of determining taxable income and the amount of the related tax withholding obligation pursuant to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span>, the Fair Market Value shall be determined by the Committee in good faith using any reasonable method it deems appropriate, to be applied consistently with respect to Grantees; provided that the Committee shall determine the Fair Market Value of shares of Stock for tax withholding obligations due in connection with sales, by or on behalf of a Grantee, of such shares of Stock subject to an Award to pay the Option Price, SAR Price, or any tax withholding obligation on the same date on which such shares may first be sold pursuant to the terms of the applicable Award Agreement (including broker-assisted cashless exercises of Options and SARs, as described in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;12.3</span>,<span style="font-weight:bold"> </span>and <span style="white-space:nowrap"><span style="white-space:nowrap">sell-to-cover</span></span> transactions) in any manner consistent with applicable provisions of the Code, including, without limitation, by using the sale price of such shares on such date (or if sales of such shares are effectuated at more than one sale price, the weighted average sale price of such shares on such date) as the Fair Market Value of such shares, so long as such Grantee has provided the Company, or its designee or agent, with advance written notice of such sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.19 </span>&#8220;<span style="font-weight:bold">Family Member</span>&#8221; shall mean, with respect to any Grantee as of any date of determination, (a)&#160;a Person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, <span style="white-space:nowrap"><span style="white-space:nowrap">mother-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">father-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">son-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">daughter-in-law,</span></span> brother, sister, <span style="white-space:nowrap"><span style="white-space:nowrap">brother-in-law</span></span> or <span style="white-space:nowrap"><span style="white-space:nowrap">sister-in-law,</span></span> including adoptive relationships, of such Grantee, (b)&#160;any Person sharing such Grantee&#8217;s household (other than a tenant or employee), (c) a trust in which any one or more of the Persons specified in clauses (a)&#160;and (b) (and such Grantee) own more than 50% of the beneficial interest, (d)&#160;a foundation in which any one or more of the Persons specified in clauses (a)&#160;and (b) (and such Grantee) control the management of assets and (e)&#160;any other entity in which one or more of the Persons specified in clauses (a)&#160;and (b) (and such Grantee) own more than 50% of the voting interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.20 </span>&#8220;<span style="font-weight:bold">Fully Diluted Basis</span>&#8221; shall mean, as of any date of determination, the sum of (a)&#160;the number of shares of Voting Stock outstanding as of such date of determination plus (b)&#160;the number of shares of Voting Stock issuable upon the exercise, conversion, or exchange of all then-outstanding warrants, options, convertible Capital Stock or indebtedness, exchangeable Capital Stock or indebtedness, or other rights exercisable for or convertible or exchangeable into, directly or indirectly, shares of Voting Stock, whether at the time of issue or upon the passage of time or upon the occurrence of some future event, and whether or not <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> as of such date of determination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.21 </span>&#8220;<span style="font-weight:bold">Grant Date</span>&#8221; shall mean, as determined by the Committee, the latest to occur of (a)&#160;the date as of which the Committee approves the Award, (b)&#160;the date on which the recipient of an Award first becomes eligible to receive an Award under <span style="font-weight:bold">Article 6</span> (for example, in the case of a new hire, the first date on which such new hire performs any Service) or (c)&#160;such date later than the dates specified in clauses (a)&#160;and (b) specified by the Committee in the corporate action approving the Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.22 </span>&#8220;<span style="font-weight:bold">Grantee</span>&#8221; shall mean a Person who receives or holds an Award under the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.23 </span>&#8220;<span style="font-weight:bold">Group</span>&#8221; shall have the meaning set forth in Exchange Act &#167;&#167; 13(d) and 14(d)(2). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.24 </span>&#8220;<span style="font-weight:bold">Incentive Stock Option</span>&#8221; shall mean an &#8220;incentive stock option&#8221; within the meaning of Code &#167;&#160;422. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.25 </span>&#8220;<span style="font-weight:bold">Nonqualified Stock Option</span>&#8221; shall mean an Option that is not an Incentive Stock Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.26 </span>&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director</span>&#8221; shall have the meaning set forth in Rule <span style="white-space:nowrap">16b-3</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.27 </span>&#8220;<span style="font-weight:bold">Officer</span>&#8221; shall have the meaning set forth in Rule <span style="white-space:nowrap">16a-1(f)</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.28 </span>&#8220;<span style="font-weight:bold">Option</span>&#8221; shall mean an option to purchase one or more shares of Stock at a specified Option Price awarded to a Grantee pursuant to <span style="font-weight:bold">Article 8</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.29 </span>&#8220;<span style="font-weight:bold">Option Price</span>&#8221; shall mean the per share exercise price for shares of Stock subject to an Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.30 </span>&#8220;<span style="font-weight:bold">Other Agreement</span>&#8221; shall mean any agreement, contract, or understanding heretofore or hereafter entered into by a Grantee with the Company or an Affiliate, except an agreement, contract or understanding that expressly addresses Code &#167;&#167; 280G or 4999. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.31 </span>&#8220;<span style="font-weight:bold">Other Equity-Based Award</span>&#8221; shall mean an Award representing a right or other interest that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to Stock, other than an Option, a SAR, Restricted Stock or an RSU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.32 </span>&#8220;<span style="font-weight:bold">Person</span>&#8221; shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust, or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof; provided that, for purposes of <span style="font-weight:bold">Sections 2.9(a)</span> and <span style="font-weight:bold">2.9(d)</span>, Person shall have the meaning set forth in Exchange Act &#167;&#167; 13(d) and 14(d)(2). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.33 </span>&#8220;<span style="font-weight:bold">Plan</span>&#8221; shall mean this Bellevue Life Sciences Acquisition Corp. 2024 Omnibus Incentive Plan, as amended or restated from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.34 </span>&#8220;<span style="font-weight:bold">Prior Stockholders</span>&#8221; shall mean the holders of equity securities that represented 100% of the Voting Stock of the Company immediately prior to a reorganization, merger, or consolidation involving the Company or any sale or other disposition of all or substantially all of the assets of the Company and its Subsidiaries, taken as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a whole (or other equity securities into which the Stock or such other equity securities are converted as part of such reorganization, merger, or consolidation transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.35 </span>&#8220;<span style="font-weight:bold">Restricted Period</span>&#8221; shall mean a period of time established by the Committee during which an Award of Restricted Stock or RSUs is subject to restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.36 </span>&#8220;<span style="font-weight:bold">Restricted Stock</span>&#8221; shall mean shares of Stock awarded to a Grantee pursuant to <span style="font-weight:bold">Article</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;10</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.37 </span>&#8220;<span style="font-weight:bold">RSU</span>&#8221; shall mean restricted stock unit, which is a bookkeeping entry representing the equivalent of one share of Stock awarded to a Grantee pursuant to <span style="font-weight:bold">Article 10</span> that may be settled, subject to the terms and conditions of the applicable Award Agreement, in shares of Stock, cash, or a combination thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.38 </span>&#8220;<span style="font-weight:bold">SAR</span>&#8221; shall mean a stock appreciation right granted to a Grantee pursuant to <span style="font-weight:bold">Article 9</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.39 </span>&#8220;<span style="font-weight:bold">SAR Price</span>&#8221; shall mean the per share exercise price of a SAR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.40 </span>&#8220;<span style="font-weight:bold">Securities Act</span>&#8221; shall mean the Securities Act of 1933, as amended, as now in effect or as hereafter amended, and any successor thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.41 </span>&#8220;<span style="font-weight:bold">Securities Market</span>&#8221; shall mean an established securities market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.42 </span>&#8220;<span style="font-weight:bold">Separation from Service</span>&#8221; shall have the meaning set forth in Code &#167; 409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.43 </span>&#8220;<span style="font-weight:bold">Service</span>&#8221; shall mean service qualifying a Grantee as a Service Provider to the Company or an Affiliate. Unless otherwise provided in the applicable Award Agreement, a Grantee&#8217;s change in position or duties shall not result in interrupted or terminated Service, so long as such Grantee continues to be a Service Provider to the Company or an Affiliate. Subject to the preceding sentence, any determination by the Committee whether a termination of Service shall have occurred for purposes of the Plan shall be final, binding, and conclusive. If a Service Provider&#8217;s employment or other Service relationship is with an Affiliate and the applicable entity ceases to be an Affiliate, a termination of Service shall be deemed to have occurred when such entity ceases to be an Affiliate unless the Service Provider transfers his or her employment or other Service relationship to the Company or any other Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.44 </span>&#8220;<span style="font-weight:bold">Service Provider</span>&#8221; shall mean (a)&#160;an Employee or director of the Company or an Affiliate or (b)&#160;a consultant or adviser to the Company or an Affiliate (i)&#160;who is a natural person, (ii)&#160;who is currently providing bona fide services to the Company or an Affiliate and (iii)&#160;whose services are not in connection with the Company&#8217;s sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#8217;s Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.45 </span>&#8220;<span style="font-weight:bold">Service Recipient Stock</span>&#8221; shall have the meaning set forth in Code &#167; 409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.46 </span>&#8220;<span style="font-weight:bold">Share Limit</span>&#8221; shall have the meaning set forth in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.47 </span>&#8220;<span style="font-weight:bold">Stock</span>&#8221; shall mean the common stock, par value $0.0001 per share, of the Company, or any security into which shares of Stock may be changed or for which shares of Stock may be exchanged as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.48 </span>&#8220;<span style="font-weight:bold">Stock Exchange</span>&#8221; shall mean the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or another established national or regional stock exchange. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.49 </span>&#8220;<span style="font-weight:bold">Subsidiary</span>&#8221; shall mean any corporation (other than the Company) or <span style="white-space:nowrap">non-corporate</span> entity with respect to which the Company owns, directly or indirectly, 50% or more of the total combined voting power of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all classes of Voting Stock. In addition, any other entity may be designated by the Committee as a Subsidiary, provided that (a)&#160;such entity could be considered as a subsidiary according to generally accepted accounting principles in the United States of America and (b)&#160;in the case of an Award of Options or SARs, such Award would be considered to be granted in respect of Service Recipient Stock under Code &#167; 409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.50 </span>&#8220;<span style="font-weight:bold">Substitute Award</span>&#8221; shall mean an Award granted upon assumption of, or in substitution for, outstanding awards previously granted under a compensatory plan of the Company, an Affiliate or a business entity acquired or to be acquired by the Company or an Affiliate or with which the Company or an Affiliate has combined or shall combine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.51 </span>&#8220;<span style="font-weight:bold">Ten Percent Stockholder</span>&#8221; shall mean a natural Person who owns more than 10% of the total combined voting power of all classes of Voting Stock of the Company, the Company&#8217;s parent (if any), or any of the Company&#8217;s Subsidiaries. In determining stock ownership, the attribution rules of Code &#167; 424(d) shall be applied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.52 </span>&#8220;<span style="font-weight:bold">Voting Stock</span>&#8221; shall mean, with respect to any Person, Capital Stock of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person. Without limiting the generality of the foregoing, the Stock shall be Voting Stock of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. ADMINISTRATION OF THE PLAN </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">3.1 Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.1.1 </span><span style="font-weight:bold">Powers and Authorities</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Committee shall administer the Plan and shall have such powers and authorities related to the administration of the Plan as are consistent with the Company&#8217;s certificate of incorporation and bylaws and Applicable Laws. Without limiting the generality of the foregoing, the Committee shall have full power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award, or any Award Agreement and shall have full power and authority to take all such other actions and to make all such other determinations not inconsistent with the specific terms and provisions of the Plan that the Committee deems to be necessary or appropriate to the administration of the Plan, any Award, or any Award Agreement. All such actions and determinations shall be made by (a)&#160;the affirmative vote of a majority of the members of the Committee present at a meeting at which a quorum is present, or (b)&#160;the unanimous consent of the members of the Committee executed in writing or evidenced by electronic transmission in accordance with the Company&#8217;s certificate of incorporation and bylaws and Applicable Laws. Unless otherwise expressly determined by the Board, the Committee shall have the authority to interpret and construe all provisions of the Plan, any Award and any Award Agreement, and any such interpretation or construction, and any other determination contemplated to be made under the Plan or any Award Agreement, by the Committee shall be final, binding and conclusive on all Persons, whether or not expressly provided for in any provision of the Plan, such Award, or such Award Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event that the Plan, any Award, or any Award Agreement provides for any action to be taken by the Board or any determination to be made by the Board, such action may be taken or such determination may be made by the Committee constituted in accordance with this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1</span> if the Board has delegated the power and authority to do so to such Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.1.2 </span><span style="font-weight:bold">Composition of the Committee</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Committee shall be a committee composed of not fewer than two directors of the Company designated by the Board to administer the Plan. Each member of the Committee shall be a <span style="white-space:nowrap">Non-Employee</span> Director and satisfy the composition requirements of any Stock Exchange on which the Stock is listed. Any action taken by the Committee shall be valid and effective whether or not members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1.2</span> or otherwise provided in any charter of the Committee. Without </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limiting the generality of the foregoing, the Committee may be the Compensation Committee of the Board or a subcommittee thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.1.3 </span><span style="font-weight:bold">Other Committees</span><span style="font-weight:bold">.</span> The Board also may appoint one or more committees of the Board, each composed of one or more directors of the Company, which (a)&#160;may administer the Plan with respect to Grantees who are not Officers or directors of the Company, (b)&#160;may grant Awards under the Plan to such Grantees and (c)&#160;may determine all terms of such Awards subject, if applicable, to the requirements of Rule <span style="white-space:nowrap">16b-3</span> under the Exchange Act and the rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.1.4 </span><span style="font-weight:bold">Delegation by the Committee.</span><span style="font-weight:bold"> </span>If and to the extent permitted by Applicable Laws, the Committee, by resolution, may delegate some or all of its authority with respect to the Plan and Awards to the Chief Executive Officer of the Company and/or any other officer of the Company designated by the Committee, provided that the Committee may not delegate its authority hereunder (a)&#160;to make Awards to directors of the Company, (b)&#160;to make Awards to Employees who are (i)&#160;Officers or (ii)&#160;officers of the Company who are delegated authority by the Committee pursuant to this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1.4</span>, or (c)&#160;to interpret the Plan, any Award, or any Award Agreement. Any delegation shall be subject to the restrictions and limits that the Committee specifies at the time of such delegation or thereafter. Nothing in the Plan shall be construed as obligating the Committee to delegate authority to any officer of the Company, and the Committee may at any time rescind the authority delegated to an officer of the Company appointed hereunder and delegate authority to one or more other officers of the Company. At all times, an officer of the Company delegated authority pursuant to this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1.4</span> shall serve in such capacity at the pleasure of the Committee. Any action undertaken by any such officer of the Company in accordance with the Committee&#8217;s delegation of authority shall have the same force and effect as if undertaken directly by the Committee, and any reference in the Plan to the &#8220;Committee&#8221; shall, to the extent consistent with the terms and limitations of such delegation, be deemed to include a reference to each such officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.2 </span><span style="font-weight:bold">Board</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Board, from time to time, may exercise any or all of the powers and authorities related to the administration and implementation of the Plan, as set forth in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1</span> and other applicable provisions of the Plan, as the Board shall determine, consistent with the Company&#8217;s certificate of incorporation and bylaws and Applicable Laws.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">3.3 Terms of Awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.3.1 </span><span style="font-weight:bold">Committee Authority</span><span style="font-weight:bold">.</span> Subject to the other terms and conditions of the Plan, the Committee shall have full and final authority to: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) designate Grantees; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) determine the type or types of Awards to be made to a Grantee; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) determine the number of shares of Stock to be subject to an Award or to which an Award relates; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) establish the terms and conditions of each Award (including the Option Price of any Option, the SAR Price for any SAR, and the purchase price for applicable Awards, the nature and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer, or forfeiture of an Award or the shares of Stock subject thereto, the treatment of an Award in the event of a Change in Control (subject to applicable agreements), and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) prescribe the form of each Award Agreement evidencing an Award; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) subject to the limitation on repricing in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.4</span>, amend, modify, or supplement the terms of any outstanding Award, which authority shall include the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to make Awards or to modify outstanding Awards made to eligible natural Persons who are foreign nationals or are natural Persons who are employed outside the United States to reflect differences in local law, tax policy, or custom; provided that, notwithstanding the foregoing, no amendment, modification, or supplement of the terms of any outstanding Award shall, without the consent of the Grantee thereof, impair such Grantee&#8217;s rights under such Award; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) make Substitute Awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.3.2 </span><span style="font-weight:bold">Forfeiture; Recoupment</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Committee may reserve the right in an Award Agreement to cause a forfeiture of the gain realized by a Grantee with respect to an Award thereunder on account of actions taken by, or failed to be taken by, such Grantee in violation or breach of, or in conflict with, any (a)&#160;employment agreement, <span style="white-space:nowrap">(b)&#160;non-competition</span> agreement, (c)&#160;agreement prohibiting solicitation of Employees or clients of the Company or an Affiliate, (d)&#160;confidentiality obligation with respect to the Company or an Affiliate, (e)&#160;policy or procedure of the Company or an Affiliate, (f)&#160;other agreement, or (g)&#160;other obligation of such Grantee to the Company or an Affiliate, as and to the extent specified in such Award Agreement. If the Grantee of an outstanding Award is an Employee of the Company or an Affiliate and such Grantee&#8217;s Service is terminated for Cause, the Committee may annul such Grantee&#8217;s outstanding Award as of the date of the Grantee&#8217;s termination of Service for Cause. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Any Award granted pursuant to the Plan shall be subject to mandatory repayment by the Grantee to the Company to the extent set forth in the Plan or an Award Agreement or to the extent the Grantee is, or in the future becomes, subject to (1)&#160;any Company or Affiliate &#8220;clawback&#8221; or recoupment policy that is adopted to comply with the requirements of any Applicable Laws, or (2)&#160;any Applicable Laws that impose mandatory recoupment, under circumstances set forth in such Applicable Laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.4 </span><span style="font-weight:bold">No Repricing Without Stockholder Approval</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, shares of Stock, other securities, or other property), stock split, extraordinary dividend, recapitalization, Change in Control, reorganization, merger, consolidation, <span style="white-space:nowrap">split-up,</span> <span style="white-space:nowrap">spin-off,</span> combination, repurchase or exchange of shares of Stock or other securities or similar transaction), the Company may not (a)&#160;amend the terms of outstanding Options or SARs to reduce the Option Price or SAR Price, as applicable, of such outstanding Options or SARs, (b)&#160;cancel outstanding Options or SARs in exchange for, or in substitution of, Options or SARs with an Option Price or SAR Price, as applicable, that is less than the Option Price or SAR Price, as applicable, of the original Options or SARs or (c)&#160;cancel outstanding Options or SARs with an Option Price or SAR Price, as applicable, above the current Fair Market Value in exchange for cash or other securities, in each case, unless such action (i)&#160;is subject to and approved by the Company&#8217;s stockholders or (ii)&#160;would not be deemed to be a repricing under the rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.5 </span><span style="font-weight:bold">Deferral Arrangement</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Committee may permit or require the deferral of any payment pursuant to any Award into a deferred compensation arrangement, subject to such rules and procedures as it may establish, in connection therewith, provisions for converting such credits into RSUs that comply with the requirements of Code &#167; 409A and for restricting deferrals to comply with hardship distribution rules affecting <span style="white-space:nowrap">tax-qualified</span> retirement plans subject to Code &#167; 401(k)(2)(B)(IV). Any such deferrals shall be made in a manner that complies with Code &#167; 409A, including, if applicable, with respect to when a Separation from Service occurs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.6 </span><span style="font-weight:bold">Registration; Share Certificates</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Notwithstanding any provision of the Plan to the contrary, the ownership of the shares of Stock issued under the Plan may be evidenced in such a manner as the Committee, in its sole discretion, deems appropriate, including by book-entry or direct registration (including transaction advices) or the issuance of one or more share certificates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. STOCK SUBJECT TO THE PLAN </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">4.1 </span><span style="font-weight:bold">Number of Shares of Stock Available for Awards</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to such additional shares of Stock as shall be available for issuance under the Plan pursuant to <span style="font-weight:bold">Sections 4.2</span> and <span style="font-weight:bold">4.3(c)</span>, and subject to adjustment pursuant to <span style="font-weight:bold">Article 14</span>, the maximum number of shares of Stock reserved for issuance under the Plan shall be equal to 6,300,000 shares of Stock. Such shares of Stock may be authorized and unissued shares of Stock, treasury shares of Stock or any combination of the foregoing, as may be determined from time to time by the Board or by the Committee. Any of the shares of Stock reserved and available for issuance under the Plan may be used for any type of Award under the Plan, and any or all of the shares of Stock reserved for issuance under the Plan shall be available for issuance pursuant to Incentive Stock Options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">4.2 </span><span style="font-weight:bold">Adjustments in Authorized Shares of Stock</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>In connection with mergers, reorganizations, separations or other transactions to which Code &#167; 424(a) applies, the Committee shall have the right to cause the Company to assume awards previously granted under a compensatory plan of another business entity that is a party to such transaction and to grant Substitute Awards under the Plan for such awards. The Share Limit pursuant to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1</span> shall be increased by the number of shares of Stock subject to any such assumed awards and Substitute Awards. Shares available for issuance under a stockholder-approved plan of a business entity that is a party to such transaction (as appropriately adjusted, if necessary, to reflect such transaction) may be used for Awards under the Plan and shall not reduce the number of shares of Stock otherwise available for issuance under the Plan, subject to applicable rules of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">4.3 Share Usage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Shares of Stock covered by an Award shall be counted as used as of the Grant Date for purposes of calculating the number of shares of Stock available for issuance under <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Any shares of Stock that are subject to Awards, including shares of Stock acquired through dividend reinvestment pursuant to <span style="font-weight:bold">Article 10</span>, shall be counted against the Share Limit set forth in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1 </span>as one share of Stock for every one share of Stock subject to an Award.<span style="font-weight:bold"> </span>The number of shares of Stock subject to an Award of SARs shall be counted against the Share Limit set forth in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1 </span>as one share of Stock for every one share of Stock subject to such Award regardless of the number of shares of Stock actually issued to settle such SARs upon the exercise of the SARs. At least the target number of shares of Stock issuable under an Award that is subject to vesting, exercisability or settlement based on the achievement of performance goals shall be counted against the Share Limit set forth in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1</span> as of the Grant Date, but such number shall be adjusted to equal the actual number of shares of Stock issued upon settlement of the Award to the extent different from such target number of shares of Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If any shares of Stock covered by an Award granted under the Plan are not purchased or are forfeited or expire or if an Award otherwise terminates without delivery of any Stock subject thereto or is settled in cash in lieu of shares, then the number of shares of Stock counted against the Share Limit with respect to such Award shall, to the extent of any such forfeiture, termination, expiration or settlement, again be available for making Awards under the Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The number of shares of Stock available for issuance under the Plan shall not be increased by the number of shares of Stock (i)&#160;tendered, withheld or subject to an Award granted under the Plan surrendered in connection with the purchase of shares of Stock upon exercise of an Option, (ii)&#160;that were not issued upon the net settlement or net exercise of a Stock-settled SAR granted under the Plan, (iii)&#160;deducted or delivered from payment of an Award granted under the Plan in connection with the Company&#8217;s tax withholding obligations as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span> or (iv)&#160;purchased by the Company with proceeds from Option exercises. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. TERM, AMENDMENT AND TERMINATION </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">5.1 Term</span>. The Plan shall become effective as of the Effective Date, subject to approval of the Plan by the Company&#8217;s stockholders within 12 months of the Effective Date. Upon approval of the Plan by the Company&#8217;s stockholders, all Awards made under the Plan on or after the Effective Date shall be fully effective as if the stockholders of the Company had approved the Plan on the Effective Date. If the Stockholders do not approve the Plan within 12 months of the Effective Date, any Awards made under the Plan on or after the Effective Date shall not be exercisable, settleable or deliverable, except to the extent such Awards could have otherwise been made under the Plan. The Plan shall terminate on the first to occur of (a) 11:59PM ET on the day before the tenth anniversary of the Effective Date, (b)&#160;the date determined in accordance with Section&#160;5.2 and (c)&#160;the date determined in accordance with Section <span style="font-weight:bold">14.3</span>. Upon such termination of the Plan, all outstanding Awards shall continue to have full force and effect in accordance with the provisions of the terminated Plan and the applicable Award Agreement (or other documents evidencing such Awards). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">5.2 </span><span style="font-weight:bold">Amendment, Suspension and Termination</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Board may, at any time and from time to time, amend, suspend or terminate the Plan; provided that, with respect to Awards previously granted under the Plan, no amendment, suspension or termination of the Plan shall, without the consent of any Grantee affected thereby, impair the rights or obligations under any such Award. The effectiveness of any amendment to the Plan shall be conditioned on approval of such amendment by the Company&#8217;s stockholders to the extent provided by the Board or required by Applicable Laws; provided that no amendment shall be made to the <span style="white-space:nowrap">no-repricing</span> provisions of <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.4</span>, the Option pricing provisions of <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.1</span> or the SAR pricing provisions of <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.1</span> without the approval of the Company&#8217;s stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. AWARD ELIGIBILITY AND LIMITATIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">6.1 </span><span style="font-weight:bold">Eligible Grantees</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to this <span style="font-weight:bold">Article 6</span>, Awards may be made under the Plan to any Service Provider, as the Committee shall determine and designate from time to time, and any other individual whose participation in the Plan is determined to be in the best interests of the Company by the Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">6.2 </span><span style="font-weight:bold">Stand-Alone, Additional, Tandem and Substitute Awards</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.4</span>, Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or in substitution or exchange for, (a)&#160;any other Award, (b)&#160;any award granted under another plan of the Company, an Affiliate or any business entity that has been a party to a transaction with the Company or an Affiliate or (c)&#160;any other right of a Grantee to receive payment from the Company or an Affiliate. Such additional, tandem, exchange or Substitute Awards may be granted at any time. If an Award is granted in substitution or exchange for another Award or for an award granted under another plan of the Company, an Affiliate or any business entity that has been a party to a transaction with the Company or an Affiliate, the Committee shall require the surrender of such other Award or award under such other plan in consideration for the grant of such exchange or Substitute Award. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash payments under other plans of the Company or an Affiliate. Notwithstanding <span style="font-weight:bold">Sections 8.1</span> and <span style="font-weight:bold">9.1</span>, but subject to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.4</span>, the Option Price of an Option or the SAR Price of a SAR that is a Substitute Award may be less than 100% of the Fair Market Value of a share of Stock on the original Grant Date; provided that such Option Price or SAR Price is determined in accordance with the principles of Code &#167;&#160;424 for any Incentive Stock Option and consistent with Code &#167; 409A for any other Option or SAR. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">7. AWARD AGREEMENT </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Award granted pursuant to the Plan shall be evidenced by an Award Agreement, which shall be in such forms as the Committee from time to time determines. Award Agreements utilized under the Plan from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an Award of Options shall specify whether such Options are intended to be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Nonqualified Stock Options or Incentive Stock Options. In the absence of such specification, such Options shall be deemed to constitute Nonqualified Stock Options. In the event of any inconsistency between the Plan and an Award Agreement, the provisions of the Plan shall control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">8. TERMS AND CONDITIONS OF OPTIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.1 </span><span style="font-weight:bold">Option Price</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Option Price of each Option shall be fixed by the Committee and stated in the Award Agreement evidencing such Option. Except in the case of Substitute Awards, the Option Price of each Option shall be at least the Fair Market Value of one share of Stock on the Grant Date (provided that, in the event that a Grantee is a Ten Percent Stockholder, the Option Price of an Option granted to such Grantee that is intended to be an Incentive Stock Option shall be not less than 110% of the Fair Market Value of one share of Stock on the Grant Date). In no case shall the Option Price of any Option be less than the par value of one share of Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.2 </span><span style="font-weight:bold">Vesting and Exercisability</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to <span style="font-weight:bold">Sections 8.3</span> and <span style="font-weight:bold">14.3</span>, each Option granted under the Plan shall become vested or exercisable at such times and under such conditions as determined by the Committee and stated in the Award Agreement, which may include the achievement of performance goals. However, no Option shall be granted to Grantees who are entitled to overtime under Applicable Laws that shall vest or be exercisable within a <span style="white-space:nowrap">six-month</span> period starting on the Grant Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.3 </span><span style="font-weight:bold">Term</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Each Option granted under the Plan shall terminate, and all rights to purchase shares of Stock thereunder shall cease, on the tenth anniversary of the Grant Date of such Option, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Committee and stated in the Award Agreement relating to such Option (provided that, in the event that the Grantee is a Ten Percent Stockholder, an Option granted to such Grantee that is intended to be an Incentive Stock Option shall not be exercisable after the fifth anniversary of the Grant Date of such Option). To the extent deemed necessary or appropriate by the Committee to reflect differences in local law, tax policy or custom with respect to any Option granted to a Grantee who is a foreign national or is a natural Person who is employed outside the United States, such Option may terminate, and all rights to purchase shares of Stock thereunder may cease, upon the expiration of a period longer than ten years from the Grant Date of such Option as the Committee shall determine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.4 </span><span style="font-weight:bold">Termination of Service</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Each Award Agreement with respect to the grant of an Option shall set forth the extent to which the Grantee shall have the right to exercise such Option following termination of such Grantee&#8217;s Service, it at all. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options issued pursuant to the Plan and may reflect distinctions based on the reasons for termination of Service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.5 </span><span style="font-weight:bold">Limitations on Exercise of Option</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Notwithstanding any provision of the Plan to the contrary, in no event may any Option be exercised, in whole or in part, after the occurrence of an event referred to in <span style="font-weight:bold">Article 14</span> that results in the termination of such Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.6 </span><span style="font-weight:bold">Method of Exercise</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to <span style="font-weight:bold">Article 12</span> and <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span>, an Option that is exercisable may be exercised by the Grantee&#8217;s delivery to the Company or its designee or agent of notice of exercise on any business day, at the Company&#8217;s principal office or the office of such designee or agent, on the form specified by the Company and in accordance with any additional procedures specified by the Committee. Such notice shall specify the number of shares of Stock with respect to which such Option is being exercised and shall be accompanied by payment in full of the Option Price of the shares of Stock for which such Option is being exercised, plus the amount (if any) of federal and other taxes that the Company may, in its judgment, be required to withhold with respect to the exercise of such Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.7 </span><span style="font-weight:bold">Rights of Holders of Options</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Unless otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising an Option shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares of Stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to such Option, to direct the voting of the shares of Stock subject to such Option or to receive notice of any meeting of the Company&#8217;s stockholders) until the shares of Stock subject thereto are fully paid and issued to such Grantee or other Person. Except as provided in <span style="font-weight:bold">Article 14</span>, no adjustment shall be made for dividends, distributions or other rights with respect to any shares of Stock subject to an Option for which the record date is prior to the date of issuance of such shares of Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.8 </span><span style="font-weight:bold">Delivery of Stock</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Promptly after the exercise of an Option by a Grantee and the payment in full of the Option Price with respect thereto, such Grantee shall be entitled to receive such evidence of such Grantee&#8217;s ownership of the shares of Stock subject to such Option as shall be consistent with <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.6</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.9 </span><span style="font-weight:bold">Transferability of Options</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Except as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10</span>, during the lifetime of a Grantee of an Option, only such Grantee (or, in the event of such Grantee&#8217;s legal incapacity or incompetency, such Grantee&#8217;s guardian or legal representative) may exercise such Option. Except as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10</span>, no Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.10 </span><span style="font-weight:bold">Family Transfers</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>If authorized in the applicable Award Agreement and by the Committee, in its sole discretion, a Grantee may transfer, not for value, all or part of an Option that is not an Incentive Stock Option to any Family Member. For the purpose of this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10</span>, a transfer &#8220;not for value&#8221; is a transfer that is a gift, a transfer under a domestic relations order in settlement of marital property rights or a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Grantee) in exchange for an interest in such entity (unless Applicable Laws do not permit such transfer). Following a transfer under this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10</span>, any such Option shall continue to be subject to the same terms and conditions as were applicable thereto immediately prior to such transfer. Subsequent transfers of transferred Options shall be prohibited except to Family Members of the original Grantee in accordance with this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10</span> or by will or the laws of descent and distribution. The provisions of <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.4</span> relating to termination of Service shall continue to be applied with respect to the original Grantee of the Option, following which such Option shall be exercisable by the transferee only to the extent, and for the periods specified, in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.4</span>.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.11 </span><span style="font-weight:bold">Limitations on Incentive Stock Options.</span><span style="font-weight:bold"> </span>An Option shall constitute an Incentive Stock Option only (a)&#160;if the Grantee of such Option is an Employee of the Company or any corporate Subsidiary, (b)&#160;to the extent specifically provided in the related Award Agreement and (c)&#160;to the extent that the aggregate Fair Market Value (determined at the time such Option is granted) of the shares of Stock with respect to which all Incentive Stock Options held by such Grantee become exercisable for the first time during any calendar year (under the Plan and all other plans of the Company and its Affiliates) does not exceed $100,000. Except to the extent provided in the regulations under Code &#167; 422, this limitation shall be applied by taking Options into account in the order in which they were granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">8.12 </span><span style="font-weight:bold">Notice of Disqualifying Disposition.</span><span style="font-weight:bold"> </span>If any Grantee disposes of shares of Stock issued pursuant to the exercise of an Incentive Stock Option under the circumstances provided in Code &#167; 421(b) (relating to certain disqualifying dispositions), such Grantee shall notify the Company of such disposition immediately but in no event later than ten days thereafter. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">9. TERMS AND CONDITIONS OF SARS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.1 </span><span style="font-weight:bold">Right to Payment and SAR Price</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>A SAR shall confer on the Grantee to whom it is granted a right to receive, upon exercise thereof, the excess of (a)&#160;the Fair Market Value of one share of Stock on the date of exercise, over (b)&#160;the SAR Price as determined by the Committee. The Award Agreement for a SAR shall specify the SAR Price, which shall be no less than the Fair Market Value of one share of Stock on the Grant Date of such SAR. SARs may be granted in tandem with all or part of an Option granted under the Plan or at any subsequent time during the term of such Option, in combination with all or any part of any other Award or without regard to any Option or other Award, provide that a SAR that is granted in tandem with all or part of an Option shall have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same term, and expire at the same time, as the related Option. A SAR that is granted subsequent to the Grant Date of a related Option must have a SAR Price that is no less than the Fair Market Value of one share of Stock on the Grant Date of such SAR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.2 </span><span style="font-weight:bold">Other Terms</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Committee shall determine, on the Grant Date or thereafter, the time or times at which, and the circumstances under which, a SAR may be exercised in whole or in part (including based on achievement of performance goals and/or future Service requirements), the time or times at which SARs shall cease to be or become exercisable following termination of Service or upon other conditions, the method of exercise, method of settlement, form of consideration payable in settlement, method by or forms in which shares of Stock shall be delivered or deemed to be delivered to Grantees, whether or not a SAR shall be granted in tandem or in combination with any other Award and any and all other terms and conditions of any SAR. However, no SARs shall be granted to Grantees who are entitled to overtime under Applicable Laws that shall vest or be exercisable within a <span style="white-space:nowrap">six-month</span> period starting on the Grant Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.3 </span><span style="font-weight:bold">Term</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Each SAR granted under the Plan shall terminate, and all rights thereunder shall cease, on the tenth anniversary of the Grant Date of such SAR or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Committee and stated in the Award Agreement relating to such SAR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.4 </span><span style="font-weight:bold">Rights of Holders of SARs.</span><span style="font-weight:bold"> </span>Unless otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising a SAR shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares of Stock underlying such SAR, to direct the voting of the shares of Stock underlying such SAR or to receive notice of any meeting of the Company&#8217;s stockholders) until the shares of Stock underlying such SAR, if any, are issued to such Grantee or other Person. Except as provided in <span style="font-weight:bold">Article 14</span>, no adjustment shall be made for dividends, distributions, or other rights with respect to any shares of Stock underlying a SAR for which the record date is prior to the date of issuance of such shares of Stock, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.5 </span><span style="font-weight:bold">Transferability of SARs</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Except as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.6</span>, during the lifetime of a Grantee of a SAR, only the Grantee (or, in the event of such Grantee&#8217;s legal incapacity or incompetency, such Grantee&#8217;s guardian or legal representative) may exercise such SAR. Except as provided in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.6</span>, no SAR shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">9.6 </span><span style="font-weight:bold">Family Transfers</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>If authorized in the applicable Award Agreement and by the Committee, in its sole discretion, a Grantee may transfer, not for value, all or part of a SAR to any Family Member. For the purpose of this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.6</span>, a transfer &#8220;not for value&#8221; is a transfer that is a gift, a transfer under a domestic relations order in settlement of marital property rights or a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Grantee) in exchange for an interest in such entity (unless Applicable Laws do not permit such transfer). Following a transfer under this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.6</span>, any such SAR shall continue to be subject to the same terms and conditions as were in effect immediately prior to such transfer. Subsequent transfers of transferred SARs shall be prohibited except to Family Members of the original Grantee in accordance with this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.6</span> or by will or the laws of descent and distribution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">10. TERMS AND CONDITIONS OF RESTRICTED STOCK AND RSUS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.1 </span><span style="font-weight:bold">Grant of Restricted Stock and RSUs</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Awards of Restricted Stock and RSUs may be made for consideration or for no consideration, other than the par value of the shares of Stock, which shall be deemed paid by past Service or, if so provided in the related Award Agreement or a separate agreement, the promise by the Grantee to perform future Service to the Company or an Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.2 </span><span style="font-weight:bold">Restrictions</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>At the time a grant of Restricted Stock or RSUs is made, the Committee may, in its sole discretion, establish a Restricted Period applicable to such Restricted Stock or RSUs and prescribe restrictions in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition to or other than the expiration of the Restricted Period, including the achievement of corporate or individual performance goals, which may be applicable to all or any portion of such Restricted Stock or RSUs as provided in <span style="font-weight:bold">Article 11</span>. Awards of Restricted Stock and RSUs may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of during the Restricted Period or prior to the satisfaction of any other restrictions prescribed by the Committee with respect to such Awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.3 </span><span style="font-weight:bold">Registration; Restricted Stock Certificates</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Pursuant to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.6</span>, to the extent that ownership of Restricted Stock is evidenced by a book-entry registration or direct registration (including transaction advices), such registration shall be notated to evidence the restrictions imposed on such Award of Restricted Stock under the Plan and the applicable Award Agreement. Subject to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.6 </span>and the immediately following sentence, the Company may issue, in the name of each Grantee to whom Restricted Stock has been granted, certificates representing the total number of shares of Restricted Stock granted to the Grantee, as soon as reasonably practicable after the Grant Date of such Restricted Stock. The Committee may provide in an Award Agreement with respect to an Award of Restricted Stock that either the Secretary of the Company shall hold such certificates for such Grantee&#8217;s benefit until such time as such shares of Restricted Stock are forfeited to the Company or the restrictions applicable thereto lapse and such Grantee shall deliver a stock power to the Company with respect to each certificate or such certificates shall be delivered to such Grantee, provided<span style="font-style:italic"> </span>that such certificates shall bear legends that comply with Applicable Laws and make appropriate reference to the restrictions imposed on such Award of Restricted Stock under the Plan and such Award Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.4 </span><span style="font-weight:bold">Rights of Holders of Restricted Stock</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Unless the Committee provides otherwise in an Award Agreement and subject to the restrictions set forth in the Plan, any applicable Company program, and the applicable Award Agreement, holders of Restricted Stock shall have the right to vote such shares of Restricted Stock and the right to receive any dividend payments or distributions declared or paid with respect to such shares of Restricted Stock. The Committee may provide in an Award Agreement evidencing a grant of Restricted Stock that any cash dividend payments or distributions paid on Restricted Stock shall be reinvested in shares of Stock, which may or may not be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock or any dividend payments or distributions declared or paid on shares of Restricted Stock shall only be made or paid upon satisfaction of the vesting conditions and restrictions applicable to such shares of Restricted Stock. Dividend payments or distributions declared or paid on shares of Restricted Stock that vest or are earned based on the achievement of performance goals shall not vest unless such performance goals for such shares of Restricted Stock are achieved, and if such performance goals are not achieved, the Grantee of such shares of Restricted Stock shall promptly forfeit and, to the extent already paid or distributed, repay to the Company such dividend payments or distributions. All stock dividend payments or distributions, if any, received by a Grantee with respect to shares of Restricted Stock as a result of any stock split, stock dividend, combination of stock, or other similar transaction shall be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.5 </span><span style="font-weight:bold">Rights of Holders of RSUs</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>A holder of RSUs shall have no rights other than those of a general unsecured creditor of the Company. RSUs represent unfunded and unsecured obligations of the Company, subject to the terms and conditions of the applicable Award Agreement. Holders of RSUs shall have no rights as stockholders of the Company (for example, the right to receive dividend payments or distributions attributable to the shares of Stock underlying such RSUs to direct the voting of the shares of Stock underlying such RSUs, or to receive notice of any meeting of the Company&#8217;s stockholders). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.6 </span><span style="font-weight:bold">Termination of Service</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, but prior to termination of Grantee&#8217;s Service, upon the termination of such Grantee&#8217;s Service, any Restricted Stock or RSUs held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of such Restricted Stock or RSUs, the Grantee shall have no further rights with respect thereto, including any right to vote such Restricted Stock or any right to receive dividends, with respect to such Restricted Stock or RSUs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.7 </span><span style="font-weight:bold">Purchase of Restricted Stock and Shares of Stock Subject to RSUs</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Grantee of an Award of Restricted Stock or vested RSUs shall be required, to the extent required by Applicable Laws, to purchase such Restricted Stock or the shares of Stock subject to such vested RSUs from the Company at a purchase price equal to the greater of (a)&#160;the aggregate par value of the shares of Stock represented by such Restricted Stock or such vested RSUs or (b)&#160;the purchase price, if any, specified in the Award Agreement relating to such Restricted Stock or such vested RSUs. Such purchase price shall be payable in a form provided in <span style="font-weight:bold">Article 12</span> or, in the sole discretion of the Committee, in consideration for Service rendered or to be rendered by the Grantee to the Company or an Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">10.8 </span><span style="font-weight:bold">Delivery of Shares of Stock</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Upon the expiration or termination of any Restricted Period and the satisfaction of any other conditions prescribed by the Committee, including, without limitation, any performance goals or delayed delivery period, the restrictions applicable to Restricted Stock or RSUs settled in shares of Stock shall lapse and, unless otherwise provided in the applicable Award Agreement, a book-entry or direct registration (including transaction advices) or a certificate evidencing ownership of such shares of Stock shall, consistent with <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.6</span>, be issued, free of all such restrictions, to the Grantee thereof or such Grantee&#8217;s beneficiary or estate, as the case may be. Neither the Grantee, nor the Grantee&#8217;s beneficiary or estate, shall have any further rights with regard to an RSU once the shares of Stock represented by such RSU have been delivered in accordance with this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;10.8</span>. <span style="font-weight:bold"></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">11. TERMS AND CONDITIONS OF OTHER EQUITY-BASED AWARDS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may, in its sole discretion, grant Awards in the form of Other Equity-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan. Awards granted pursuant to this <span style="font-weight:bold">Article 11</span> may be granted with vesting, value or payment contingent on the achievement of one or more performance goals. The Committee shall determine the terms and conditions of Other Equity-Based Awards on the Grant Date or thereafter. Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, but prior to termination of Grantee&#8217;s Service, upon the termination of a Grantee&#8217;s Service, any Other Equity-Based Awards held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of any Other Equity-Based Award, the Grantee thereof shall have no further rights with respect to such Other Equity-Based Award. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">12. FORMS OF PAYMENT </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">12.1 </span><span style="font-weight:bold">General Rule</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Payment of the Option Price for the shares of Stock purchased pursuant to the exercise of an Option or the purchase price, if any, for Restricted Stock or vested RSUs shall be made in cash or in cash equivalents acceptable to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">12.2 </span><span style="font-weight:bold">Surrender of Shares of Stock</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>To the extent that the applicable Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option or the purchase price, if any, for Restricted Stock or vested RSUs may be made all or in part through the tender or attestation to the Company of shares of Stock, which shall be valued, for purposes of determining the extent to which such Option Price or purchase price has been paid thereby, at their Fair Market Value on the date of such tender or attestation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">12.3 </span><span style="font-weight:bold">Cashless Exercise</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>To the extent permitted by Applicable Laws and to the extent the Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option may be made all or in part by delivery (on a form acceptable to the Committee) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell shares of Stock and to deliver all or part of the proceeds of such sale to the Company in payment of such Option Price and any withholding taxes described in <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">12.4 </span><span style="font-weight:bold">Other Forms of Payment</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>To the extent that the applicable Award Agreement so provides or unless otherwise specified in an Award Agreement, payment of the Option Price for shares of Stock purchased pursuant to exercise of an Option or the purchase price, if any, for Restricted Stock or vested RSUs may be made in any other form that is consistent with Applicable Laws, including (a)&#160;with respect to Restricted Stock or vested RSUs only, Service rendered or to be rendered by the Grantee thereof to the Company or an Affiliate and (b)&#160;with the consent of the Company, by withholding the number of shares of Stock that would otherwise vest or be issuable in an amount equal in value to the Option Price or purchase price or the required tax withholding amount. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">13. REQUIREMENTS OF LAW </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">13.1 </span><span style="font-weight:bold">General</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Company shall not be required to offer, sell or issue any shares of Stock under any Award, whether pursuant to the exercise of an Option or a SAR, the settlement of a RSU or otherwise, if the offer, sale or issuance of such shares of Stock would constitute a violation by the Grantee, the Company, an Affiliate or any other Person of any provision of the Company&#8217;s certificate of incorporation or bylaws or of Applicable Laws, including any federal or state securities laws or regulations. If at any time the Company determines, in its discretion, that the listing, registration or qualification of any shares of Stock subject to an Award on any Stock Exchange or Securities Market or under any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the offering, sale, issuance or purchase of shares of Stock in connection with any Award, no shares of Stock may be offered, sold or issued to the Grantee or any other Person under such Award, whether pursuant to the exercise of an Option or a SAR, the settlement of a RSU or otherwise, unless such listing, registration or qualification shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way affect the date of termination of such Award. Without limiting the generality of the foregoing, upon the exercise of any Option or any SAR that may be settled in shares of Stock or the delivery of any shares of Stock underlying an Award, unless a registration statement under the Securities Act is in effect with respect to the shares of Stock subject to such Award, the Company shall not be required to offer, sell or issue such shares of Stock unless the Committee receives evidence satisfactory to it that the Grantee or any other Person exercising such Option or SAR or accepting delivery of such shares may acquire such shares of Stock pursuant to an exemption from registration under the Securities Act. Any determination by the Committee in connection with the foregoing shall be final, binding and conclusive. The Company may register, but shall in no event be obligated to register, any shares of Stock or other securities issuable pursuant to the Plan pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or a SAR or the issuance of shares of Stock or other securities issuable pursuant to the Plan or any Award to comply with any Applicable Laws. As to any jurisdiction that expressly imposes the requirement that an Option or SAR that may be settled in shares of Stock shall not be exercisable until the shares of Stock subject to such Option or SAR are registered under the securities laws thereof or are exempt from such registration, the exercise of such Option or SAR under circumstances in which the laws of such jurisdiction apply shall be deemed to be conditioned on the effectiveness of such registration or the availability of such an exemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">13.2 </span><span style="font-weight:bold">Rule <span style="white-space:nowrap">16b-3</span></span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>During any time when the Company has any class of common equity securities registered under Exchange Act &#167; 12, it is the intention of the Company that Awards pursuant to the Plan and the exercise of Options and SARs that would otherwise be subject to Exchange Act &#167; 16(b) shall qualify for the exemption provided by Rule <span style="white-space:nowrap">16b-3</span> under the Exchange Act. To the extent that any provision of the Plan or action by the Committee does not comply with the requirements of Rule <span style="white-space:nowrap">16b-3,</span> such provision or action shall be deemed inoperative with respect to such Awards to the extent permitted by Applicable Laws and deemed advisable by the Committee and shall not affect the validity of the Plan. In the event that Rule <span style="white-space:nowrap">16b-3</span> is revised or replaced, the Committee may exercise its discretion to modify the Plan in any respect necessary or advisable in its judgment to satisfy the requirements of or to permit the Company to avail itself of the benefits of the revised exemption or its replacement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">14. EFFECT OF CHANGES IN CAPITALIZATION </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.1 Changes in Stock</span>. If the number of outstanding shares of Stock is increased or decreased or the shares of Stock are changed into or exchanged for a different number of shares or kind of Capital Stock or other securities of the Company on account of any recapitalization, reclassification, stock split, reverse stock split, <span style="white-space:nowrap">spin-off,</span> combination of stock, exchange of stock, stock dividend or other distribution payable in capital stock or other increase or decrease in shares of Stock effected without receipt of consideration by the Company occurring after the Effective Date, the number and kinds of shares of Capital Stock for which grants of Options and other Awards may be made under the Plan, including the Share Limit set forth in Section&#160;4.1, which includes the number and kinds of issued shares of Capital Stock by which the Plan reserve may be increased annually, shall be adjusted proportionately and accordingly by the Committee. In addition, the number and kind of shares of Capital Stock for which Awards are outstanding shall be adjusted proportionately and accordingly by the Committee so that the proportionate interest of the Grantee therein immediately following such event shall, to the extent practicable, be the same as immediately before such event. Any such adjustment in outstanding Options or SARs shall not change the aggregate Option Price or SAR Price payable with respect to shares that are subject to the unexercised portion of such outstanding Options or SARs, as applicable, but shall include a corresponding proportionate adjustment in the per share Option Price or SAR Price, as the case may be. The conversion of any convertible securities of the Company shall not be treated as an increase in shares effected without receipt of consideration. Notwithstanding the foregoing, in the event of any distribution to the Company&#8217;s stockholders of securities of any other entity or other assets (including an extraordinary dividend, but excluding a <span style="white-space:nowrap">non-extraordinary</span> dividend, declared and paid by the Company) without receipt of consideration by the Company, the Board or the Committee constituted pursuant to Section <span style="font-weight:bold">3.1.2</span> shall, in such manner as the Board or the Committee deems appropriate, adjust the number and kind of shares of Capital Stock subject to outstanding Awards and the aggregate and per share Option Price of outstanding Options and the aggregate and per share SAR Price of outstanding SARs as required to reflect such distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.2 </span><span style="font-weight:bold">Transactions That Do Not Constitute a Change in Control</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Subject to <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.3</span>, if the Company is the surviving entity in any reorganization, merger or consolidation of the Company with one or more other entities that does not constitute a Change in Control, any Award granted pursuant to the Plan shall pertain to and apply to the Capital Stock to which a holder of the number of shares of Stock subject to such Award would have been entitled immediately following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the per share Option Price or SAR Price of any outstanding Option or SAR so that the aggregate Option Price or SAR Price thereafter shall be the same as the aggregate Option Price or SAR Price of the shares of Stock remaining subject to the Option or SAR as in effect immediately prior to such reorganization, merger or consolidation. Subject to any contrary language in an Award Agreement, any restrictions applicable to such Award shall apply as well to any replacement shares of Capital Stock subject to such Award received by the Grantee as a result of such reorganization, merger or consolidation. In the event of any reorganization, merger or consolidation of the Company referred to in this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.2</span>, any Awards subject to vesting, exercisability or settlement based on the achievement of performance goals shall be adjusted (including any adjustment to the performance goals applicable to such Awards deemed appropriate by the Committee) so as to apply to the Capital Stock that a holder of the number of shares of Stock subject to such Awards would have been entitled to receive immediately following such reorganization, merger or consolidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.3 </span><span style="font-weight:bold">Change in Control in which Awards are not Assumed</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Except as otherwise provided in the applicable Award Agreement, upon the occurrence of a Change in Control in which outstanding Awards are not being assumed or continued, the following provisions shall apply to such Awards, to the extent not assumed or continued: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Immediately prior to the occurrence of such Change in Control, in each case with the exception of Awards subject to vesting, exercisability or settlement based on the achievement of performance goals, all outstanding shares of Restricted Stock and all RSUs shall be deemed to have vested, all shares of Stock or cash subject to such Awards shall be delivered and either or both of the following actions shall be taken: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) At least 15 days prior to the scheduled consummation of such Change in Control, all Options and SARs outstanding under the Plan shall become immediately exercisable and shall remain exercisable for a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period of 15 days. Any exercise of an Option or SAR during this <span style="white-space:nowrap">15-day</span> period shall be conditioned on the consummation of the applicable Change in Control and shall be effective only immediately before the consummation thereof. Upon consummation of such Change in Control, the Plan and all outstanding but unexercised Options and SARs shall terminate, with or without consideration (including, without limitation, consideration in accordance with <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.3(a)(ii)</span>) as determined by the Committee in its sole discretion. The Committee shall send notice of an event that shall result in such a termination to all Persons who hold Options and SARs not later than the time at which the Company gives notice thereof to its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Committee may elect, in its sole discretion, to cancel any outstanding Awards of Options, SARs, Restricted Stock or RSUs and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in cash or Capital Stock having a value (as determined by the Committee acting in good faith), in the case of Restricted Stock or RSUs, equal to the formula or fixed price per share paid to holders of shares of Stock pursuant to such Change in Control and, in the case of Options or SARs, equal to the product of the number of shares of Stock subject to such Options or SARs multiplied by the amount, if any, by which (1)&#160;the formula or fixed price per share paid to holders of shares of Stock pursuant to such transaction exceeds (2)&#160;the Option Price or SAR Price applicable to such Options or SARs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For Awards subject to vesting, exercisability or settlement based on the achievement of performance goals, actual performance to date shall be determined as of a date reasonably proximate to the date of consummation of the Change in Control as determined by the Committee, in its sole discretion, and that level of performance thus determined shall be treated as achieved immediately prior to occurrence of the Change in Control. For purposes of the preceding sentence, if, based on the discretion of the Committee, actual performance is not determinable, the Awards shall be treated as though the target performance has been achieved. After application of this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.3(b)</span>, if any Awards arise from application of this <span style="font-weight:bold">Article 14</span>, such Awards shall be settled under the applicable provision of <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;14.3(a)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Other Equity-Based Awards shall be governed by the terms of the applicable Award Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.4 </span><span style="font-weight:bold">Change in Control in which Awards are Assumed</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Except as otherwise provided in the applicable Award Agreement, upon the occurrence of a Change in Control in which outstanding Awards are being assumed or continued, the Plan and the Options, SARs, Restricted Stock, RSUs and Other Equity-Based Awards granted under the Plan shall continue in the manner and under the terms so provided in the event of any Change in Control to the extent that provision is made in writing in connection with such Change in Control for the assumption or continuation of such Options, SARs, Restricted Stock, RSUs and Other Equity-Based Awards or for the substitution for such Options, SARs, Restricted Stock, RSUs and Other Equity-Based Awards of new stock options, stock appreciation rights, restricted stock, restricted stock units and other equity-based awards relating to the Capital Stock of a successor entity or a parent or subsidiary thereof, with appropriate adjustments as to the number of shares (disregarding any consideration that is not common stock) and exercise prices of options and stock appreciation rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.5 </span><span style="font-weight:bold">Adjustments</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Adjustments under this <span style="font-weight:bold">Article 14</span> related to shares of Stock or other Capital Stock of the Company shall be made by the Committee, whose determination in that respect shall be final, binding and conclusive. No fractional shares or other securities shall be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest whole share. The Committee may provide in the applicable Award Agreement as of the Grant Date for different provisions to apply to an Award in place of those provided in <span style="font-weight:bold">Sections 14.1, 14.2, 14.3</span> and <span style="font-weight:bold">14.4</span>. This <span style="font-weight:bold">Article 14</span> shall not limit the Committee&#8217;s ability to provide for alternative treatment of Awards outstanding under the Plan in the event of a change in control event involving the Company that is not a Change in Control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">14.6 </span><span style="font-weight:bold">No Limitations on Company</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The making of Awards pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or assets (including all or any part of the business or assets of any Subsidiary or other Affiliate) or to engage in any other transaction or activity. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">15. PARACHUTE LIMITATIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Grantee is a disqualified individual as defined in Code &#167; 280G(c), then, notwithstanding any other provision of the Plan or of any Other Agreement to the contrary and notwithstanding any Benefit Arrangement, any right of such Grantee to any exercise, vesting, payment or benefit under the Plan shall be reduced or eliminated (a)&#160;to the extent that such right to exercise, vesting, payment or benefit, taking into account all other rights, payments or benefits to or for the Grantee under the Plan, all Other Agreements and all Benefit Arrangements, would cause any exercise, vesting, payment or benefit to such Grantee under the Plan to be considered a parachute payment (as defined by Code &#167; 280G(b)(2)) and (b)&#160;if, as a result of receiving such parachute payment, the aggregate <span style="white-space:nowrap">after-tax</span> amounts received by the Grantee from the Company under the Plan, all Other Agreements and all Benefit Arrangements would be less than the maximum <span style="white-space:nowrap">after-tax</span> amount that could be received by the Grantee without causing any such payment or benefit to be considered a parachute payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by Code &#167; 409A or to the extent that Code &#167; 409A permits discretion, the Committee shall have the right, in the Committee&#8217;s sole discretion, to designate those rights, payments or benefits under the Plan, all Other Agreements and all Benefit Arrangements that should be reduced or eliminated so as to avoid having such rights, payments or benefits be considered a parachute payment. To the extent any payment or benefit constitutes deferred compensation under Code &#167; 409A, to comply with Code &#167; 409A, except as otherwise provided in an applicable agreement between a Grantee and the Company or an Affiliate, the Company shall instead accomplish such reduction by first reducing or eliminating any cash payments (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any accelerated vesting of Awards subject to vesting, exercisability or settlement based on the achievement of performance goals, then by reducing or eliminating any accelerated vesting of Options or SARs, then by reducing or eliminating any accelerated vesting of Restricted Stock or RSUs, then by reducing or eliminating any other remaining parachute payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">16. GENERAL PROVISIONS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.1 </span><span style="font-weight:bold">Disclaimer of Rights</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>No provision in the Plan, any Award, or any Award Agreement shall be construed (a)&#160;to confer on any individual the right to remain in the Service of the Company or an Affiliate, (b)&#160;to interfere in any way with any contractual or other right or authority of the Company or an Affiliate either to increase or decrease the compensation or other payments to any Person at any time, or (c)&#160;to terminate any Service or other relationship between any Person and the Company or an Affiliate. In addition, notwithstanding any provision of the Plan to the contrary, unless otherwise stated in the applicable Award Agreement, in another agreement with the Grantee, or otherwise in writing, no Award granted under the Plan shall be affected by any change of duties or position of the Grantee, so long as such Grantee continues to provide Service. The obligation of the Company to pay any benefits pursuant to the Plan shall be interpreted as a contractual obligation to pay only those amounts provided herein, in the manner and under the conditions prescribed herein. The Plan and Awards shall in no way be interpreted to require the Company to transfer any amounts to a third-party trustee or otherwise to hold any amounts in trust or escrow for payment to any Grantee or beneficiary under the terms of the Plan.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.2 </span><span style="font-weight:bold">Nonexclusivity of the Plan</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Neither the adoption of the Plan nor the submission of the Plan to the stockholders of the Company for approval shall be construed as creating any limitations on the right and authority of the Board or the Committee to adopt such other incentive compensation arrangements (which arrangements may be applicable either generally to one or more classes of individuals or specifically to one or more particular individuals) as the Board or the Committee in their discretion determine desirable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.3 </span><span style="font-weight:bold">Withholding Taxes</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any federal, state, local or foreign taxes of any kind required by Applicable Laws to be withheld with respect to the vesting of or other lapse of restrictions applicable to an Award or upon the issuance of any shares of Stock upon the exercise of an Option or SAR, settlement of a RSU or pursuant to any other Award. At the time of such vesting, lapse of restrictions, exercise or settlement, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Grantee shall pay in cash to the Company or an Affiliate, as the case may be, any amount that the Company or such Affiliate may reasonably determine to be necessary to satisfy such withholding obligation. If there is a <span style="white-space:nowrap">same-day</span> sale of shares of Stock subject to an Award, the Grantee shall pay such withholding obligation on the day on which such <span style="white-space:nowrap">same-day</span> sale is completed. Subject to the prior approval of the Company or an Affiliate, which may be withheld by the Company or such Affiliate, as the case may be, in its sole discretion, the Grantee may elect to satisfy such withholding obligation, in whole or in part, by causing the Company or such Affiliate to withhold shares of Stock otherwise issuable to the Grantee or by delivering to the Company or such Affiliate shares of Stock already owned by the Grantee. The shares of Stock so withheld or delivered shall have an aggregate Fair Market Value equal to such withholding obligation. The Fair Market Value of the shares of Stock used to satisfy such withholding obligation shall be determined by the Company or such Affiliate as of the date on which the amount of tax to be withheld is to be determined. A Grantee who has made an election pursuant to this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.3</span> may satisfy such Grantee&#8217;s withholding obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. The maximum number of shares of Stock that may be withheld from any Award to satisfy any federal, state, local or foreign tax withholding requirements upon the exercise, vesting, lapse of restrictions or settlement applicable to any Award or payment of shares of Stock pursuant to such Award, as applicable, may not exceed such number of shares of Stock having a Fair Market Value equal to the minimum statutory amount required by the Company or the applicable Affiliate to be withheld and paid to any such federal, state, local or foreign taxing authority with respect to such exercise, vesting, lapse of restrictions, settlement or payment of shares of Stock. However, for so long as Accounting Standards Update <span style="white-space:nowrap">2016-09</span> or a similar rule remains in effect, the Board or the Committee has full discretion to choose, or to allow a Grantee to elect, to withhold a number of Shares having an aggregate Fair Market Value that is greater than the applicable minimum statutory required withholding obligation (but such withholding may in no event be in excess of the maximum required statutory withholding amounts in such Grantee&#8217;s relevant tax jurisdiction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.4 </span><span style="font-weight:bold">Captions</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> T</span>he use of captions in the Plan or any Award Agreement is for convenience of reference only and shall not affect the meaning of any provision of the Plan or such Award Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.5 </span><span style="font-weight:bold">Construction</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Unless the context otherwise requires, all references in the Plan to &#8220;including&#8221; shall mean &#8220;including without limitation.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.6 </span><span style="font-weight:bold">Other Provisions</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>Each Award granted under the Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Committee, in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.7 </span><span style="font-weight:bold">Number and Gender</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>With respect to words used in the Plan, the singular form shall include the plural form, and the masculine gender shall include the feminine gender, as the context requires. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.8 </span><span style="font-weight:bold">Severability</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>If any provision of the Plan or any Award Agreement is determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions of the Plan and Award Agreement shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.9 </span><span style="font-weight:bold">Governing Law</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Plan and the instruments evidencing the Awards shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of the Plan and the instruments evidencing any Awards to the substantive laws of any other jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.10 </span><span style="font-weight:bold">Foreign Jurisdictions</span><span style="font-weight:bold">. </span>To the extent the Committee determines that the material terms set by the Committee imposed by the Plan preclude the achievement of the material purposes of the Plan in jurisdictions outside the United States, the Committee shall have the authority and discretion to modify those terms and provide for such additional terms and conditions as the Committee determines to be necessary, appropriate or desirable to accommodate differences in local law, policy or custom or to facilitate administration of the Plan. The Committee may adopt or approve <span style="white-space:nowrap">sub-plans,</span> appendices or supplements to, or amendments, restatements or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alternative versions of the Plan as in effect for any other purposes. The special terms and any <span style="white-space:nowrap">sub-plans,</span> appendices, supplements, amendments, restatements or alternative versions, however, shall not include any provisions that are inconsistent with the terms of the Plan as in effect, unless the Plan could have been amended to eliminate such inconsistency without further approval by the Company&#8217;s stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.11 Language.</span> If the Plan or any other document related to the Plan is translated into a language other than English, and if the translated version is different from the English version, the English language version shall take precedence. By acceptance of the Award, the Participant confirms having read and understood the documents relating to the Plan that were provided in English, including, without limitation, the Plan and the Award Agreement, and waives any requirement for the Company or its Affiliates to provide these documents in any other language. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.12 </span><span style="font-weight:bold">Code </span><span style="font-weight:bold">&#167;</span><span style="font-weight:bold"> 409A</span><span style="font-weight:bold">.</span><span style="font-weight:bold"> </span>The Plan is intended to comply with Code &#167; 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance with Code &#167; 409A. Any payments described in the Plan that are due within the short-term deferral period as defined under Code &#167; 409A shall not be treated as deferred compensation unless Applicable Laws require otherwise. Any grant of an Option or SAR pursuant to the Plan is intended to comply with the &#8220;stock rights&#8221; exemption from Code &#167; 409A. Notwithstanding any provision of the Plan to the contrary, to the extent required to avoid accelerated taxation and tax penalties under Code &#167; 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the <span style="white-space:nowrap">six-month</span> period immediately following the Grantee&#8217;s Separation from Service shall instead be paid on the first payroll date after the <span style="white-space:nowrap">six-month</span> anniversary of the Grantee&#8217;s Separation from Service (or the Grantee&#8217;s death, if earlier). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding anything in the Plan to the contrary, in the case of an Award that is characterized as deferred compensation under Code &#167; 409A, and pursuant to which settlement and delivery of the cash or shares of Stock subject to the Award is triggered based on a Change in Control, in no event shall a Change in Control be deemed to have occurred for purposes of such settlement and delivery of cash or shares of Stock if the transaction is not also a &#8220;change in the ownership or effective control of&#8221; the Company or &#8220;a change in the ownership of a substantial portion of the assets of&#8221; the Company as determined under Treasury Regulation &#167; <span style="white-space:nowrap">1.409A-3(i)(5)</span> (without regard to any alternative definition thereunder). If an Award characterized as deferred compensation under Code &#167; 409A is not settled and delivered on account of the provision of the preceding sentence, the settlement and delivery shall occur on the next succeeding settlement and delivery triggering event that is a permissible triggering event under Code &#167; 409A. No provision of this paragraph shall in any way affect the determination of a Change in Control for purposes of vesting in an Award that is characterized as deferred compensation under Code &#167; 409A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Grantee under Code &#167; 409A, and neither the Company or an Affiliate nor the Board or the Committee shall have any liability to any Grantee for such tax or penalty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">16.13 </span><span style="font-weight:bold">Limitation on Liability.</span><span style="font-weight:bold"> </span>No member of the Board or the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any Award or any Award Agreement. Notwithstanding any provision of the Plan to the contrary, neither the Company, an Affiliate, the Board, the Committee nor any person acting on behalf of the Company, an Affiliate, the Board or the Committee shall be liable to any Grantee or to the estate or beneficiary of any Grantee or to any other holder of an Award under the Plan by reason of any acceleration of income or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Code &#167;&#167; 422 or 409A, by reason of Code &#167; 4999 or otherwise asserted with respect to the Award, provided, that this <span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.13</span> shall not affect any of the rights or obligations set forth in an applicable agreement between the Grantee and the Company or an Affiliate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Remainder of Page Intentionally Left Blank] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">G-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex H </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00t01.jpg" alt="LOGO" style="width:4.24528in;height:0.383647in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center" id="rom476668_52">June&#160;23, 2024 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M&amp;A Committee of the </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors of </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bellevue Life Sciences Acquisition Corp. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Choloc Asset Investment Advisory Co., Ltd. (&#8220;<span style="font-weight:bold">Choloc</span>&#8221;) has been mandated by the M&amp;A committee of the Board of Directors (the &#8220;<span style="font-weight:bold">M&amp;A Committee</span>&#8221;) of Bellevue Life Sciences Acquisition Corp. (&#8220;<span style="font-weight:bold">BLAC</span>&#8221;), to provide an independent opinion to the M&amp;A committee in connection with the Aggregate Consideration to be paid to the stockholders of OSR Holdings Co., Ltd. (&#8220;<span style="font-weight:bold">OSR</span>&#8221; or the &#8220;<span style="font-weight:bold">Company</span>&#8221;) in the contemplated share exchange transaction between BLAC and the stockholders of OSR (the &#8220;<span style="font-weight:bold">Transaction</span>&#8221; or the &#8220;<span style="font-weight:bold">Business Combination</span>&#8221;) pursuant to the Amended and Restated Business Combination Agreement dated May 23, 2024 executed between BLAC and OSR (the &#8220;<span style="font-weight:bold">Business Combination Agreement</span>&#8221;). Capitalized terms used but not defined herein, have the meanings assigned to them in the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a healthcare holding company headquartered in South Korea utilizing a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Hub-and-Spoke&#8221;</span></span> business model with centralized portfolio management team (at the parent company) through which it conducts operations through three subsidiary entities which are emerging biotech and medtech companies in South Korea as well as in Switzerland. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Table of Content </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. No conflict of interest </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Scope of the Fairness Opinion </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The Transaction subject to the Fairness Opinion </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. OSR business model and comparable companies </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Fairness Opinion in connection with the Investment Criteria </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Fairness Opinion in connection with the Value of the Aggregate Consideration </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">No conflict of interest </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Choloc has no present or contemplated material interest in the business or assets that are the subject of this report and has never received any form of compensation from OSR in the past.&#160;We have no personal interest or bias with respect to the subject matter of this report or the parties involved. In accordance with recognized professional ethics, the professional fee for this service is not contingent upon Choloc&#8217;s conclusion of value or the consummation of the Transaction, and neither Choloc nor any of its employees has a present or intended financial interest in BLAC, OSR or any of their respective subsidiaries or affiliates.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Scope of the Fairness Opinion </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The M&amp;A Committee has requested that Choloc provide a fairness opinion to the M&amp;A Committee as to whether, as of the date hereof, the Aggregate Consideration to be paid in the Transaction is fair from a financial perspective to the public stockholders of BLAC and as per the Investment Criteria (as defined below), based on our knowledge of the early-stage life sciences market. We refer to such opinion herein as the &#8220;Fairness Opinion&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fairness Opinion is directed only to the M&amp;A Committee, and, by extension, the Board or Directors of BLAC and addresses only the fairness of the Transaction from a financial perspective and as per the Investment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Criteria, based on our knowledge of the early-stage life sciences market. The Fairness Opinion is made as the date hereof, and Choloc is not required to update this Fairness Opinion as of a later date, anything to the contrary contained herein notwithstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fairness Opinion does not provide any view or opinion as to the price or range of prices at which the BLAC shares may trade or otherwise be transferable at any time before or after consummation of the Transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fairness Opinion is limited to our field of expertise and does not purport to be <span style="white-space:nowrap">all-inclusive</span> or to contain all of the information the public stockholders of BLAC may desire. No opinion is expressed for matters that require legal, accounting, tax, scientific, intellectual property or specialized expertise, investigation, or knowledge beyond that customarily employed by firms engaged in the business of rendering valuation opinions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fairness Opinion does not address the underlying business decision to proceed with the Transaction, or the merits of the Business Combination as compared to any alternative business strategies and does not constitute a recommendation to any stakeholders as individuals or as a class. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Fairness Opinion is based on and subject to the scope and assumptions set forth herein and relies on information about OSR which contains forward looking statements, assumptions and estimates with respect to the projected future business conduct and performance of OSR&#8217;s subsidiaries and assets which translates into valuation ranges that are not necessarily indicative of actual values or predictive of future results or values. Actual results will vary from the projections and such variations may be material. No representations are made as to the accuracy of such statements, estimates or projections. There is no guarantee that any of these estimates will be achieved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Fairness Opinion is furnished for the use of the M&amp;A Committee (in its capacity as such) in connection with the Transaction. It is not to be used, circulated, quoted, reprinted, or otherwise referred to (either in its entirety or through excerpts or summaries) for any other purposes, without prior written consent of Choloc. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this Fairness Opinion, we have made such reviews, analyses and inquiries as we have deemed necessary and appropriate under the circumstances. Among other things, we have: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reviewed the final prospectus of BLAC dated February&#160;9, 2023 (the &#8220;<span style="font-weight:bold">Prospectus</span>&#8221;) as filed with the U.&#160;S. Securities and Exchange Commission on February&#160;13, 2024 (File <span style="white-space:nowrap">No.&#160;333-264597);</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed AF&#8217;s (as defined below) projected revenue and expenses model (rNPV analysis) for Vaximm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed AF&#8217;s projected revenue and expenses model (rNPV analysis) for Darnatein; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed Ghilin Accounting Corp.&#8217;s DCF analysis and valuation model for RMC Co. Ltd. (&#8220;<span style="font-weight:bold">RMC</span>&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed comparable public and privately-held company analysis provided by the M&amp;A Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">researched and analyzed recent deal activities in the biopharma field (i.e., asset, equity, tech access, collaboration, license deals) which are relevant to the assets, companies and business model of OSR; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">researched and analyzed materials concerning sales analogs of marketed drugs specific to the assets, companies and business model of OSR; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewed and analyzed data rooms content made available by OSR, containing on a per company, per asset basis, information related to scientific, IP, business model, competitive landscape, R&amp;D and financial assumptions and capitalization table to date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interviewed certain members of the management of OSR regarding the business, operations, financial conditions and prospects of OSR and its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considered publicly available financial terms of certain transactions that we deemed to be relevant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducted such other tests, analysis and inquiries, as we deemed necessary and appropriate under the circumstances. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon and assumed, without independent verification, the accuracy, good faith and completeness of all data, material or other information furnished, or otherwise made available to us, discussed with or reviewed by us, or publicly available, and do not assume any responsibility with respect to such data, material, and other information. In addition, we assume that the information supplied by management of OSR and others represented a good faith effort to describe OSR&#8217;s subsidiaries and assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon and assumed, without independent verification, that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the representations and warranties of all parties to the Business Combination Agreement and all related documents and instruments are true and correct; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each party to the Business Combination Agreement will fully and timely perform all of the covenants and agreements required to be performed by such party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all conditions to the consummation of the Transaction will be satisfied without waiver thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Transaction will be consummated in a timely manner in accordance with the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Transaction will be consummated in a manner that complies in all respects with all applicable federal and state statutes, rules, and regulations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all governmental, regulatory, and other consents and approvals necessary for the consummation of the Transaction will be obtained and that no delay, limitations, restrictions, or conditions will be imposed, or amendments, modifications or waivers made that would have an effect on the Transaction or on OSR that would be material to our analyses or this Fairness Opinion. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conducting this engagement, we have not been requested to make, and have not made, any physical inspection or independent appraisal or evaluation of any of the assets, properties, or liabilities (fixed, contingent, derivative, <span style="white-space:nowrap">off-balance-sheet</span> or otherwise) of OSR or its subsidiaries or any other party, nor were we provided with any such appraisal or evaluation except as described above. We have undertaken no independent analysis of any potential or actual litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which OSR or its subsidiaries are or may be a party or are or may be subject, or of any governmental investigation of any possible unasserted claims or other contingent liabilities to which OSR or its subsidiaries are or may be a party or are or may be subject. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless express written notice of noncompliance is delivered and brought to the attention of Choloc, we assume that the Company is in compliance with all laws and regulations of any government or agency significant and relevant to its operations. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">The Transaction subject to this Fairness Opinion </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contemplated Transaction set forth in the Business Combination Agreement is as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Aggregate Consideration will be paid solely in 24,461,214 shares of common stock of BLAC valued at $10.00 per share. Holders of a minimum of 60% of the Company Common Stock will agree to exchange their shares upon Closing of Business Combination (the &#8220;<span style="font-weight:bold">Participating Stockholders</span>&#8221;) and the holders of the balance of the Company Common Stock will agree to exchange their shares on or after January&#160;1, 2026 through the exercise of put/call options held by such holders of OSR Common Stock (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-participating</span> Stockholders</span>&#8221;) and BLAC, respectively.&#160;Each share of OSR Common Stock will be exchanged for the Per Share Consideration, which is the Aggregate Consideration divided by the Company Fully Diluted Share Amount. The Aggregate Consideration Value specified in the Business Combination Agreement reflects the <span style="white-space:nowrap">pre-Transaction</span> value of OSR of approximately $244.6&#160;million. The Aggregate Consideration is to be paid solely in shares of BLAC Common Stock and there is no component of cash or other contingent consideration as part of the Transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">OSR Business model and Comparable Companies </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OSR operates in <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Hub-and-Spoke&#8221;</span></span> business model with centralized portfolio management team of the holding company which owns and controls emerging biotech and medtech companies in South Korea and Switzerland. The subsidiary portfolio of OSR consists of life sciences companies developing biotherapeutics and a medical device supply chain service business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As life sciences holding company, OSR provides centralized leadership and resources to subsidiaries across therapeutic areas, target indications and technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OSR&#180;s team is comprised of biopharma scientists, entrepreneurs, executives and employees with financial market, legal and medical industry experiences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows some of the most prominent public comparables with the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> biotech model which we were able to identify from the publicly available sources (see citations below the table) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 1: &#8195;Market comparables with <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> business models </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:13%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Roivant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">BridgeBio</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Centessa</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fortress</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Nimbus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PureTech</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Founding (HQ)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">2014<br/>(Basel, Switzerland)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2015<br/>(Palo Alto, California)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">2020 (Cambridge, Massachusetts)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">2006<br/>(New York, New York)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2009 (Cambridge, Massachusetts)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2005 (Boston, Massachusetts)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Financing</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Public</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Public</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Public</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Public</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Private</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Public</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Formation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Central</span><span style="font-weight:bold"> </span><span style="font-weight:bold">company founded;</span>&#160;first subsidiary (Axovant) from a GSK acquisition</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Central</span><span style="font-weight:bold"> </span><span style="font-weight:bold">company founded</span> in 2017 with seven subsidiaries</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Merger of 10 private biotech companies</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Formed from Coronado Biosciences, a failed public biopharma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Central</span><span style="font-weight:bold"> </span><span style="font-weight:bold">company founded</span> by VC Atlas Venture and in silico drug developer Schrodinger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Central company founded</span> with internal assets in development with partners</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Enterprise focus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Diversified</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Rare&#160;genetic disease</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Diversified</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Diversified</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Diversified</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Diversified</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Business model</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">In-licenses</span> external assets into subsidiaries Leverages proprietary tech for drug discovery, building into subsidiaries<br/>Tech can be licensed out or purchased as a service</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Primarily <span style="white-space:nowrap">in-licenses</span> programs from academia Leadership redeploys capital and specialist staffing among subsidiaries<br/>based on development needs</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Acquisition of single-asset or -pathway companies Acts as an accelerator for largely autonomous subsidiaries Performance-based capital allocation from centralized funds</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Focused on <span style="white-space:nowrap">in-licensing</span> assets Focus on commercially undervalued, <span style="white-space:nowrap">low-cost,</span> high-growth-potential, clinical-stage assets Extensive partnerships<br/>with academia and biopharma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Computational chemistry drug discovery approach Subsidiaries are legal entities<br/>that hold the rights to a program</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">in-licenses</span> external early-stage assets Leverages proprietary tech for drug discovery, building into subsidiaries Historically, developed assets in subsidiaries only; now has a pipeline at the parent level</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:19%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:12%"/>

<td style="vertical-align:bottom"/>
<td style="width:12%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:12%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Roivant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">BridgeBio</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Centessa</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fortress</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Nimbus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PureTech</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Centralized resources</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span> BD expertise R&amp;D support Operational support</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span> Operational support Regulatory support</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span> BD expertise R&amp;D support Operational support Regulatory support</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span><span style="font-weight:bold"> </span>BD expertise</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span><span style="font-weight:bold"> </span>Operational support</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">Management and financing activities</span> BD expertise R&amp;D support</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Subsidiary<br/>*number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">~25</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">~5**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">8</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Strategic<br/>focus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">TAs,<br/>modalities or<br/>platforms(incl.<br/><span style="white-space:nowrap">non-pharma</span><br/>adjacencies)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Genetic or<br/>rare diseases<br/>and<br/>etiologies(e.g.,<br/>some cancers)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">High-value<br/>TAs or rare<br/>diseases with<br/>unmet need</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">TAs</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Causal<br/>targets in<br/>highly<br/>prevalent<br/>human<br/>diseases</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Brain-<br/><span style="white-space:nowrap">immune-gut</span><br/>(BIG)<br/>interface<br/>pathologies</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Mix of public<br/>and private</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Private</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Private</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Mix of public<br/>and private</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Private</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Mix of public<br/>and private</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Source: L.E.K Consulting &#8220;The <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> Model: An Emerging Biopharma Trend&#8221;) </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes partner companies as well as wholly or partially owned subsidiaries </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Estimated based on three subsidiaries noted for Nimbus on Cortellis and two additional subsidiaries noted on clinicaltrials.gov </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">VC=venture</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">capital, BD=business development, TA=therapeutic area </p></td></tr></table> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: Our market comparable analysis on OSR has taken major references from the research published by L.E.K. Consulting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OSR continuously assesses the best pathway for each of its portfolio companies and assets, as the innovation progresses through the preclinical and clinical development process &#8212; including through internal advancement, partnerships, spin-offs, M&amp;A trade sale or initial public offerings (IPOs). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> business model of OSR incorporates best practices from venture capital and big pharma and typically provides benefits for the parent, its subsidiaries and its investors, including </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Specialization and Focus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Core Expertise (Hub): The central hub (the &#8220;Holdco&#8221;) focuses on core competencies such as strategic decision-making on R&amp;D investments or partnering activities, regulatory affairs, and corporate governance. This allows the hub to develop deep expertise and maintain high standards in these critical areas. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Focused Operations (Spokes): Spokes can specialize in specific areas such as clinical trials, manufacturing, or specific therapeutic areas, allowing them to operate more efficiently and effectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Resource Optimization </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Efficient Resource Allocation: Resources such as capital, personnel, and technology can be allocated more effectively. The hub manages strategic resources while spokes focus on operational execution. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cost-Effectiveness: By centralizing high-cost functions such as R&amp;Ds in the hub and outsourcing or decentralizing other functions to spokes or external partners such as CROs, companies can reduce overhead costs and avoid redundancy. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Flexibility and Scalability </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adaptability: The model allows for rapid adaptation to changing market conditions, regulatory landscapes, and technological advancements. Spokes can be added, modified, or removed without disrupting the entire organization. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Scalability: As the company grows, additional spokes can be established to handle new projects or enter new markets, allowing for scalable growth without overwhelming the central hub. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Risk Management </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Risk Diversification: By spreading activities across multiple spokes, the company can mitigate risks. Issues in one spoke do not necessarily affect the entire organization, which helps in managing operational and financial risks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Focused Risk Mitigation: The hub can focus on strategic risk management, ensuring that the company&#8217;s overall direction is safeguarded, while spokes can manage operational risks specific to their activities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Innovation and Collaboration </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enhanced Innovation: The hub can focus on driving innovation through advanced R&amp;D, while spokes can implement and refine these innovations in real-world applications, creating a feedback loop that enhances overall innovation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborative Synergies: Spokes can collaborate with external partners, including academic institutions, research organizations, and other biotech companies in their own fields of expertise and/or strategic interests, to leverage external expertise and resources, fostering a collaborative environment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Speed to Market </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Accelerated Development: By decentralizing operational tasks to specialized spokes, companies can streamline processes and accelerate the development and commercialization of products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Regulatory Efficiency: The hub can focus on navigating complex regulatory environments, ensuring that spokes comply with necessary regulations, which can expedite approvals and market entry. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Market Reach and Customer Focus </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Localized Operations: Spokes can be established in different geographic regions, allowing the company to tap into local markets, understand regional customer needs, and tailor products and services accordingly. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Customer-Centric Approach: Spokes can focus on specific customer segments or therapeutic areas, ensuring that their operations are closely aligned with customer needs and preferences. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> biotech business model can offer competitive advantages in the above listed areas when properly equipped with capable management and sufficient capital. It is our assessment that OSR&#8217;s management team has the right capabilities in terms of professional experiences and track records in the capital market, M&amp;A, private equity/venture capital and legal industries, as well as the scientific and clinical development backgrounds and experiences held by the subsidiary founders and management, in order to deploy successfully the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> biotech business model. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">5.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Fairness Opinion in connection with the Investment Criteria </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BLAC Prospectus refers to the following Investment Criteria (&#8220;<span style="font-weight:bold">Investment Criteria</span>&#8221;): </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We are focused on companies developing the next generation of biologics which include therapeutic antibodies, engineered protein and enzyme drugs, cellular therapies, engineered viruses and bacteria, and <span style="white-space:nowrap">DNA-</span> and <span style="white-space:nowrap">RNA-modifying&#160;technologies,</span> using advanced molecular biology and biochemistry. We will consider companies with pipeline programs in <span style="white-space:nowrap"><span style="white-space:nowrap">clinical&#160;&#8220;Proof-of-Concept&#8221;&#160;studies</span></span> (often from Phase 1 to 2a) to develop novel medicines to address diseases which cannot yet be cured or sufficiently managed. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We seek to create stockholder value by leveraging our management&#8217;s and its advisors&#8217; experience and network to efficiently guide an emerging biotech company towards clinical advancement of key assets in their pipeline while helping to secure licensing deals and partnerships with major pharmaceutical companies globally. Consistent with our strategy, we have established the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses, <span style="white-space:nowrap"><span style="white-space:nowrap">from&#160;time-to-time,&#160;we</span></span> may deviate from these criteria and guidelines should we see fit to do so: </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biopharmaceutical Company Poised for Rapid Growth </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We intend primarily to seek the acquisition of one or more biotherapeutics companies in clinical stage development with a total equity value of greater than 5 to 6 times the amount of the proceeds of this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can benefit from a public listing and new capital for growth to support business development and/or to advance clinical programs. We do not intend to acquire a preclinical stage company without human data. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Focus on Innovation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We expect to identify target companies that are typically cash flow negative as they are in the business of scientific research and clinical development. We expect that our list of potential targets will be comprised of companies focused on innovation that are poised to be disruptive in biologics with the potential to become a &#8220;game changer&#8221; once a drug candidate is approved and commercialized. A prospective target should either use an innovative technology platform or aim to address novel disease targets (or mechanisms) or both. Novel technology platforms will involve, in most cases, new biologic drug formats or significant improvements to existing ones. In some cases, this may also include improved screening platforms or other technologies that significantly facilitate the drug development process. Depending on their nature, novel targets can be addressed either with novel or with existing drug formats, including chemical compounds. We will deprioritize investments in companies that focus on generic or biosimilar versions of existing drugs. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Attractive Risk-Adjusted Equity Returns (Potential Upside Weighed Against Any Identified Downside Risks) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We intend to seek target companies that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms and in a manner that leverages our experience. We expect to evaluate companies based on the potential to successfully achieve regulatory approval and to commercialize their product(s). We also expect to evaluate financial returns based on (i)&#160;risk-adjusted peak sales potential (ii)&#160;the overall market potential of pipeline products and/or the scientific platform(s)&#160;(iii) the ability to achieve systematic cost savings, (iv)&#160;the ability to accelerate growth via multiple shots on goal, and (v)&#160;the prospects for creating value through other value creation initiatives. Potential upside, for example, from the growth in the target business&#8217; earnings or an improved capital structure, will be weighed against identified downside risks. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Opportunities to Unlock and Maximize Value from Underappreciated Situation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We will focus on target companies that exhibit unrecognized value or other characteristics that we believe have been misevaluated by the marketplace based on company-specific analyses and due diligence. For a potential </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">
target company, this process will include, among other things, a review and analysis of the company&#8217;s technology platform and/or licensed technologies, intellectual property (&#8220;IP&#8221;) position, preclinical and any clinical data, potential for operational improvements, manufacturing competitiveness, corporate governance, pharmaceutical partners or scientific collaborators, customers, material contracts, and industry needs and trends. We intend to leverage our team&#8217;s collective operational experience and disciplined investment approach to identify opportunities to unlock and maximize value. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">These criteria are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From our review, OSR&#8217;s pipeline of assets primarily consists of biologics, including DNA cancer vaccines, engineered (&#8220;design-augmented&#8221;) chimeric protein. Certain assets include technology/research platforms geared toward target engagement and increased therapeutic index, which can be seen as a novel approach as well as in view of greater precision medicine. In this respect, the OSR franchise and portfolio fits the Investment Criteria. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each OSR asset is geared toward a specific unmet need and technology approach. The OSR team is a cross-functional team with a core expertise and ecosystem adapted to the current type and stage of assets in its portfolio. Consequently, we find that it is fair to consider that the OSR business corresponds to the Investment Criteria of BLAC. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">6.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Fairness Opinion in connection with the Value of the Aggregate Consideration </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novel, innovative and potentially commercially-viable biomedical products in research and clinical development are inherently difficult to make accurate fair valuation estimates. Results in drug developments are often binary. Novel pharmaceutical products in development are heterogeneous, often with unique benefits and adverse features, meaning that there are often no useful, direct comparables. Also, these product development projects provide no reasonable periodic income or profit that can be capitalized at an objective yield or multiple. Trying to predict the probability and financial impact of achieving key development milestones and market potential is highly speculative, even on active markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The business model of biotech companies requires long capital-intensive R&amp;D periods without revenues. As a result, the value and value development of projects, pipelines and companies are event driven. The assets are mostly intangible, in the form of IP and scientific data. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intangible nature of the assets in the biopharma industry is commonly quantified under Income-based approaches. One of the most broadly and commonly accepted methods in the industry is the rNPV (risk-adjusted Net Present Value) approach. Additionally, market-based approaches in the form of comparables and analogs, allow for the sourcing and corroboration of several assumptions, mostly at project and portfolio company level. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In estimating the total Enterprise Value of OSR, we relied on the results from multiple scenarios using rNPV method, with consistency checks using market-based comparables and analogs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The NPV method estimates the future debt-free cash flows that an asset is expected to generate. Expected costs (cash outflows) mainly cover R&amp;D, manufacturing, license fee payable to licensors (i.e., innovation sourced from universities or other industry players), general and administrative costs (G&amp;A) and taxes and, in case the company is expected to commercialize the asset on its own, all cost of goods (COGs) and cost of marketing and sales (M&amp;S). Expected revenues (cash inflows) depend on the conduction strategy and opportunities, they can be in the form of upfront, milestones and royalties in the case an asset is transferred to a third party for R&amp;D continuation and commercialization (i.e., license of an asset), or in the form of sales may the biotech turn into a commercial-stage company with its own sales force, or in the form of service revenues. Expected revenues can also be a mix of these approaches, i.e., an asset may be conducted differently on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Expected revenues may also include grants, which is a common type of R&amp;D subsidies in some countries and/or for some R&amp;D field or indications (i.e., from foundations and patient associations). These future cash flows are converted to their present value equivalents using an estimated discount rate (or required rate of return). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rNPV method relies on these same principles of the NPV method, and additionally involves certain risk adjustments which more closely reflect the inherent R&amp;D and regulatory risks of drug development. A wealth of data in the biopharma area is made publicly available to track historical LOA (Likelihood of Approval) across the R&amp;D fields (i.e., type of molecule, of indication, of regulatory designation). These LOAs allow to account for risks at each R&amp;D step. For this, the expected cash flow for a given risk phase is multiplied by the probability of it occurring. The discount rate in the case of rNPV is lower than in the case of NPV, as here, the R&amp;D and regulatory risks have already been factored in. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of biopharma innovation, there is typically no terminal value accounted for. However, the cash flows are computed, risk adjusted and discounted until the end of the patent-protection period of an asset. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Engagement of AF </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The M&amp;A Committee retained the Korean affiliate of a global accounting firm (&#8220;AF&#8221;) to prepare financial models based on the commercial potential of OSR&#8217;s pipeline drug candidates for Vaximm and Darnatein (based upon Target Product Profiles (TPPs) for each asset that were developed based upon the preclinical efficacy and safety that OSR and its subsidiaries have seen to date), to understand the potential levels of revenues that could be obtained if they obtained regulatory approval (including FDA approval) and were introduced into the market. AF provided estimates of revenues from each drug candidate using differing market penetration assumptions (from start to peak market shares) per each drug candidate. AF&#8217;s resulting rNPV models for the two drug R&amp;D subsidiaries of OSR assumed all product candidates obtain FDA approvals (or the corresponding approvals in other countries&#8217; markets) and are introduced into the market. OSR&#8217;s programs are either in the preclinical phase or in early PoC <span style="white-space:nowrap"><span style="white-space:nowrap">(proof-of-concept)</span></span> clinical studies, and they will face clinical, manufacturing and regulatory hurdles as they progress through Phase 1, Phase 2 and Phase 3 trials before possible regulatory approval in the US market. AF used estimated costs relating to the development and sale of each of its drug candidates in order to derive its model depicting EBITDA, after tax operating profit and free cash flow estimates for each drug candidate assuming each of its product candidates obtained regulatory approval and were introduced into the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The resulting free cash flow estimates were then probability-adjusted and thereafter combined to arrive at the models for adjusted free cash flows of Vaximm and Darnatein, the two main subsidiaries of OSR in the drug R&amp;D business. The probability adjustments reflected the appropriate probabilities for the therapeutic area/modality and disease indication (12.4% for immune-oncology, 8.98% for regenerative medicine, and 9.4% for protein modality) to account for clinical, manufacturing and regulatory (including FDA) approval risks in bringing a new drug candidate to market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is unlikely that all of OSR&#8217;s current programs will obtain FDA approval or be introduced into the market within the projected timeframes, but the probability-weighted adjustments in the rNPV analysis take into account the probability of the product candidates coming to market. It should be noted that if some or all of OSR&#8217;s current product candidates do not obtain FDA approval or other regulatory approval, or are not introduced into the market because of technical, competitive, and other impediments, its actual free cash flow will vary from the financial projections. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While OSR&#8217;s financial projections forecast that OSR may obtain profitability in the future, to the extent its programs are delayed, fail to obtain FDA approval, or are not introduced to the market, the projected financial results will be less likely to be achieved and it will take longer for OSR to obtain profitability, if it does at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, OSR has a portfolio of multiple programs, not all of which have to obtain FDA approval or be introduced to the market in order for OSR to be profitable or to derive a positive exit transaction with respect to a subsidiary company. The probability adjustments made by AF to its models of OSR&#8217;s free cash flow are intended to account for these factors and we considered the models prepared by AF in deriving our own assessment and valuation outcomes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Determination of the Probabilities of Success </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of the projects being developed by subsidiaries of OSR relate to novel therapeutical approaches, primarily in the field of immune-oncology and regenerative medicine. Based on the BIO (Biotechnology Innovation Organization) meta-study conducted between 2012 and 2020 evaluating a total of 12,728 clinical and regulatory phase transitions from 9,704 development programs, across 1,779 companies, we selected the LOA for Immuno-Oncology from the Oncology <span style="white-space:nowrap">Sub-category</span> dataset and Protein from Novel Modalities dataset, for the rNPV model assumptions of Vaximm and Darnatein respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Oncology <span style="white-space:nowrap">sub-category</span> phase transition success rates and LOA </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g476668g00t02.jpg" alt="LOGO" style="width:4.18868in;height:2.33019in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Phase transition success rates for drugs based on modality </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g476668g72a58.jpg" alt="LOGO" style="width:4.46541in;height:4.19182in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on conversation with OSR management and our own research, we allocated a specific LOA set to each project to reflect their own characteristics and added early-stage chance of successes (from Discovery to IND/CTA stage). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be noted that both subsidiary specific G&amp;A and OSR G&amp;A were not adjusted for risk in our models, and therefore, only discounted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Determination of the Discount Rate </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discount rate provides the hypothetical rate at which the stakeholders want their capital to accrete. There are two major classes of stakeholders, debtholders/bondholders, and stockholders. Both require compensation for the risk of their investment into a company. We reviewed the weighted average cost of capital (WACC) calculations used by AF for adequacy of the assumptions and adopted the information as provided in AF&#8217;s financial models on Vaximm and Darnatein as follows: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WACC calculation for Darnatein </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00m05.jpg" alt="LOGO" style="width:5.29667in;height:4.05667in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WACC calculation for Vaximm </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g476668g00m06.jpg" alt="LOGO" style="width:5.42in;height:4.14in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Determination of other inputs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this rNPV valuation work, our investigation and analysis included, but were not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reputable industry databases, including Globaldata; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reputable literature in the biopharma sector or regarding listed companies, including but not limited to publications from the Tufts University, the HBR (Harvard Business Review), publications edited by specialty editors such as Nature, The Lancet or Frontiers, and news and reports from specialty news providers in the biotech industry including but not only limited to Fierce Biotech, Endpoints News or Medscape; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reports published by biotech associations and public research institutes notably, but not only, the BIO in the United States, the Swiss Biotech Association and Korea Health Industry Development Institute; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Publicly available information from other biotech, large biopharma companies, early-stage venture funds and specialty consultancies, listed and privately held, including but not limited to companies&#180; website content, reports and posters, press releases and SEC filings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Broker notes and thematic publications from investment banks covering the biotech sector; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Information, analysis and forecasts made available by OSR based on typical list of required information in view of a fairness opinion in the biotech sector; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">In-field</span> exposure and experience of Choloc to early and clinical stage biotech sector; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Exchange rates to convert all inputs into USD, notably EUR/USD, CHF/USD, and KRW/USD; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Other sources of research and inquiries, as we deemed necessary and appropriate under the circumstances. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this stage, the majority of OSR&#8217;s subsidiaries, except for RMC, are <span style="white-space:nowrap">pre-revenue</span> R&amp;D stage and it is uncertain whether they will ever generate profits. Nonetheless, taxes are accounted for in the valuation. Taxes have been computed at company level, based on the currently known or expected headquarter country/region and depending on the conduction strategy of the assets. Some countries and regions have set specific tax rates for companies with R&amp;D intensive companies and/or intellectual property revenues. Consequently, for each company, we computed the taxes either based on the expected corporate tax rate (i.e., revenues generated from selling services and/or products) or <span style="white-space:nowrap">IP-specific</span> tax rate (i.e., in case of renting IP like in licensing). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Guideline Public Company Method </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reviewed a comparable company analysis provided by the M&amp;A Committee, which was prepared in collaboration with OSR Holdings. The comparable company analysis included 28 publicly traded companies (reinforced with 2 additional private-stage companies due to the importance of them in their respective categories) of which there are three categories to compare against which are i) <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> model; ii) Immuno-Oncology and ii) Regenerative Medicines. Upon reviewing the analysis, we considered the relatively larger market values of the companies belonging to the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> category, as compared to the market values of the companies belonging to the other two groups, as being attributed to by the nature of the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> constituent companies&#8217; ownerships in their own portfolios of multiple subsidiaries and assets. In the dataset provided to us, the median values for the immune-oncology and the regenerative medicine groups are $270&#160;million and $438&#160;million respectively, while the median for the <span style="white-space:nowrap"><span style="white-space:nowrap">hub-and-spoke</span></span> group was $3.52&#160;billion. The following table includes information on the comparable company analysis provided by the M&amp;A Committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Comparable&#160;Companies</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">($ in&#160;Millions)</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Market<br/>Capitalization<sup style="font-size:75%; vertical-align:top">1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Enterprise<br/>Value</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">A. Hub and Spoke&#160;Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Sciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BridgeBio Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortress Biotech</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimbus Therapeutics<sup style="font-size:75%; vertical-align:top">2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group A Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,522</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,029</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">B. Immuno-Oncology(I/O) Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anixa Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hookipa Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oncolytics Biotech</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genelux</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immatics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immutep</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CEL SCI</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greenwich LifeSciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inovio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Northwest Biotherapeutics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Innate Pharma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arcus Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaxcell Bio Therapeutics</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sillajen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">genexine</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LigaChem Biosciences</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABL Bio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MedPacto</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mendus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ultimovacs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group B Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">270</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">175</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">C. Regenerative Medicine (DMOAD) Companies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carmell Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kolon TissueGene</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">701</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEDIPOST</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biosplice Therapeutics<sup style="font-size:75%; vertical-align:top">3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Peer-Group C Median</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">438</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">475</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">B+C [I/O and DMOAD] Comparison Group<sup style="font-size:75%; vertical-align:top">4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">707</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">649</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">OSR Holdings</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Transaction</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(%&#160;Discount&#160;to&#160;Peer&#160;Group)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">65.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">62.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(100%&#160;Redemption&#160;Rate)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Transaction&#160;(%&#160;Discount&#160;to&#160;Peer&#160;Group)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">62.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">59.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Transaction&#160;(0%&#160;Redemption&#160;Rate)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">288</td>
<td style="white-space:nowrap;vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263</td>
<td style="white-space:nowrap;vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Transaction&#160;(%&#160;Discount&#160;to&#160;Peer Group)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">59.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">59.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of March&#160;31, 2024 from publicly available data. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of September&#160;6, 2023 according to PrivCo. Enterprise value is an estimate due to company data not being publicly available. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of February&#160;8, 2022 according to Tracxn.com. Enterprise value is an estimate due to company data not being publicly available. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">&#8220;sum of the parts&#8221; valuation between I/O (representing Vaximm&#8217;s comparables) and DMOAD (representing Darnatein&#8217;s comparables) as a direct comparable to the current business portfolio of OSR consisting of Vaximm and Darnatein. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the three categories presented in the comparable table above, from a financial perspective, OSR is not comparable to the companies belonging to the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> category from a size and, to a lesser extent, profitability perspective, but is comparable to those companies based on the business model. By 2029, based on OSR&#8217;s projections of its revenue and profitability, OSR is expected to be similar to the <span style="white-space:nowrap"><span style="white-space:nowrap">Hub-and-Spoke</span></span> group companies in terms of both size and profitability, more specifically Centessa Pharmaceuticals with a larger than $1&#160;billion market capitalization and no revenue-generating history until FY2022 according to Centessa&#8217;s 2022 <span style="white-space:nowrap">10-K</span> filing<sup style="font-size:75%; vertical-align:top">1</sup> and PureTech Health with a larger than $750&#160;million market capitalization and between <span style="white-space:nowrap">$11-to-$17&#160;million</span> total revenue range for the last 3 reported years (2020 &#8211; 2022), so we deem it as appropriate to use the valuations of those relatively larger companies belonging to the said group. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conclusion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, including the assumptions, qualifications and limitations set forth herein, it is our opinion as of the date hereof, that the Aggregate Consideration to be paid by BLAC in the Transaction is fair from a financial point of view to the public stockholders of BLAC and as per the defined Investment Criteria of BLAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of a fairness opinion is a complex process and is not necessarily susceptible to a partial analysis or summary description. In arriving at our Opinion, we considered the results of all of our analyses as a whole and did not attribute any particular weight to any analysis or factor considered by us. We believe that our analyses described above must be considered as a whole and that selecting portions of these analyses, without considering all of them, would create an incomplete view of the process underlying our analyses and Opinion; the range of valuations resulting from any particular analysis described above should not be taken to be Choloc&#8217;s view of the actual value of OSR. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Schedule 1, we attached AF&#8217;s financial model analyses on OSR&#8217;s free cash flows and rNPV models on Vaximm and Darnatein which we have considered in the process of rendering our fairness opinion. </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Centessa Pharmaceuticals generated approximately $6.85&#160;million in revenues and $151&#160;million in operating losses in FY2023 according to the financial statements reported in its <span style="white-space:nowrap">10-K.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">rNPV valuation model of Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total enterprise value of Vaximm AG is USD 183,461,000 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">(Unit: USD k)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Result</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Peak&#160;sales</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Royalty&#160;rate</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VXM 01</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">113,943</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">rGBM</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mCRC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liver Cancer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schwannoma NF2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VXM Technology platform</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">183,461</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recurrent Glioblastoma &#8211; 1/2 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the pipeline of recurrent glioblastoma are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,200</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,859</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,891</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,346</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,863</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">rGBM</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">552.89</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-36.32</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,156</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">905</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">56</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">55.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">16.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">53.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">2.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">5.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,929</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,703</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">986</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,291</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,807</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">83.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">44.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">52.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,341</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,933</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,341</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,933</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.9314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.8080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.7010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.6081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.5276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.4577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(89</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4,494</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,362</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,726</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">592</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(857</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">224</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,422</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,334</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,451</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recurrent Glioblastoma &#8211; 2/2 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,293</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,732</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,160</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,142</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,120</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,097</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,057</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,041</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,007</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,973</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,966</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,963</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,974</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">rGBM</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,057</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,973</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">69.06</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">40.92</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">28.98</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.07</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.09</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.09</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.17</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.07</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-16.78</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-20.16</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-25.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-33.45</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-50.10</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">58</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">60</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">62</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">64</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">66</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,236</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,675</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,102</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,083</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,060</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,037</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,996</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,978</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,944</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,909</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,902</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,898</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,908</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">99.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">98.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,787</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,060</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,193</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,317</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,303</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,286</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,268</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,237</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,224</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,157</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,091</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,045</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,002</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,970</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,060</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,193</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,317</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,303</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,286</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,268</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,237</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,224</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,157</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,091</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,045</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,002</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,970</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,963</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,402</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,690</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,332</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,021</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,751</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,517</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,315</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">949</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">657</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">426</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">245</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">105</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,451</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">metastatic Colorectal Cancer &#8211; 1/2 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the pipeline of metastatic colorectal cancer are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,200</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,859</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,891</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,458</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,628</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">mCRC</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">611.70</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-13.60</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,156</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">905</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">56</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">55.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">16.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">53.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">2.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">5.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,929</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,703</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">986</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,403</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,572</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">83.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">44.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">52.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">108.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">147.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">35.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,186</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,795</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,186</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,795</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.9314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.8080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.7010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.6081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.5276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.4577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(89</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4,494</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,362</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,726</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">592</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(857</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">224</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,641</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,978</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32,693</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">metastatic Colorectal Cancer &#8211; 2/2 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,926</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,390</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,021</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,404</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,785</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,172</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,459</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,779</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32,569</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">26,247</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,845</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,304</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,689</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">mCRC</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,845</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">71.36</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.48</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">30.40</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.04</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.02</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.02</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.75</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.83</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-16.01</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-19.41</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-24.39</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-32.96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-49.72</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">58</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">60</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">62</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">64</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">66</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,869</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,332</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">36,962</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,345</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,725</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,112</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,397</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,717</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32,506</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">26,183</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,781</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,239</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,623</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">149.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">151.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">153.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">154.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">156.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">158.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">159.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">161.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">162.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">163.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">165.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">166.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">166.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">36.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">36.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">36.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">37.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">37.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">38.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">38.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">38.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">39.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">39.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">39.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">40.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">40.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,532</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,091</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,382</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,671</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,965</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,182</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,425</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,705</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,899</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,033</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,061</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,033</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,532</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,091</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,382</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,671</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,965</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,182</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,425</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,705</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,899</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,033</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,061</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,033</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,946</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,645</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,125</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,615</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,168</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,777</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,427</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,123</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,081</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">708</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">178</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">32,693</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liver Cancer &#8211; 1/2 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the pipeline of liver cancer are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,200</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,859</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,891</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,080</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,676</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liver cancer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">644.55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-2.87</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,156</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">905</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">56</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">55.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">16.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">53.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">2.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">5.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,929</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,703</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">986</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,024</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,620</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">83.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">44.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">52.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">113.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">173.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">27.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">41.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,659</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,351</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,659</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,351</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.9314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.8080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.7010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.6081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.5276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.4577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(89</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4,494</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,362</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,726</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">592</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(857</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">224</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,763</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,328</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,226</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liver Cancer &#8211; 2/2 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,441</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,397</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">43,550</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">43,993</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">44,431</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">44,878</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">45,189</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">45,556</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,247</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">30,805</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,287</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,615</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,853</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liver cancer</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,805</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">71.40</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.47</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">30.40</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.02</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.69</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.81</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-16.04</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-19.46</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-24.41</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-32.95</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-49.71</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">58</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">60</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">62</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">64</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">66</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,384</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,340</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">43,492</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">43,934</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">44,372</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">44,817</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">45,127</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">45,494</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,184</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">30,742</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,223</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,550</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,786</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">175.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">178.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">180.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">182.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">184.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">186.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">187.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">189.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">190.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">192.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">194.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">195.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">195.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">43.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">43.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">44.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">44.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">45.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">45.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">45.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">46.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">46.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,772</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,338</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,054</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,390</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,722</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,061</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,297</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,575</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,020</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,364</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,649</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,818</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,918</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,772</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,338</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,054</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,390</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">33,722</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,061</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,297</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,575</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,020</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,364</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,649</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,818</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,918</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,467</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,289</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,853</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,253</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,727</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,265</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,852</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,495</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,816</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,269</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">831</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">483</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">210</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,226</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Schwannoma NF2 &#8211; 1/2 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the pipeline of schwannoma NF2 are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,200</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,573</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,261</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,825</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,183</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NF2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">837.96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-30.79</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,156</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">905</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">56</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">55.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">47.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">16.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">53.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">2.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">5.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,929</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">417</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">356</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,769</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,127</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">83.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">10.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">18.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">95.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">317</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,177</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,169</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,411</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,273</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">317</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,158</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,159</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,177</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.9314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.8080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.7010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.6081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.5276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.4577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.3445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.2249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(89</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(4,494</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,362</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,726</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">145</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(857</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(744</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">81</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,319</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,389</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,574</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Schwannoma NF2 &#8211; 2/2 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:17%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,836</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,500</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,154</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,137</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,117</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,096</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,056</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,041</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,842</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16,641</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,468</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,298</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,141</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NF2</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,836</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">69.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">40.94</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">28.99</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.06</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.16</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-0.06</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-16.77</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-20.16</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-25.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-33.45</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-50.09</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">58</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">60</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">62</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">64</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">65</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">66</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX&#8201;%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">0.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">1.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,779</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,443</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,095</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,078</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,057</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">25,035</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,994</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,979</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,779</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16,577</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,403</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,232</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,075</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">103.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">102.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,472</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,777</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,072</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,060</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,043</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,027</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,996</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,984</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,792</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,598</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,427</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,257</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,097</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,472</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">14,777</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,072</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,060</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,043</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,027</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,996</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">18,984</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,792</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,598</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,427</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,257</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,097</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1693</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,043</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,501</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,801</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,428</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,104</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,824</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,580</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,370</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">988</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">684</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">444</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">256</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">110</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,574</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Vaximm AG </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Technology Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A valuation projection for the company&#8217;s technology platform is shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y1</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y2</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y3</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y4</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y5</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Y6</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VXM Technology Platform</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Number of Project VXM</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Value-added to pipeline</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">28,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.9314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">26,532</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">23,017</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">19,968</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">69,517</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">rNPV valuation model of Darnatein Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total enterprise value of Darnatein is USD 104,417,000 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">(Unit: USD k)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Amount</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darnatein&#8217;s Enterprise Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,417,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DRT 101(Osteoarthritis) - 1/3 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the pipeline of osteoarthritis are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">Currency: USD k</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,360</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">51,800</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">41,440</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,658</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">400.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-20.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-91.17</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,733</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,573</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,225</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,439</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,952</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,960</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,956</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,451</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">575</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">67.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">15.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">58.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">341</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">15.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,733</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,573</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(17,225</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9,439</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,952</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,400</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">48,845</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,990</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,083</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">32.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">84.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,733</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,573</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(17,225</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9,439</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,952</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,615</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,562</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,983</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,371</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,733</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,573</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(17,225</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9,439</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,952</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,615</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,562</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">29,983</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,371</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.9241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,146</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,766</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11,611</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(5,434</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,910</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,098</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,470</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,183</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">620</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">104,147</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DRT 101(Osteoarthritis) - 2/3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">Currency: USD k</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">22,793</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">42,718</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63,460</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">85,043</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">107,492</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">130,836</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">155,100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">180,314</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">206,506</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">233,706</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">261,945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">237,664</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">523.04</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">87.42</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">48.55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">34.01</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.40</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">21.72</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">18.55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">16.26</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.53</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">13.17</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-9.27</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,557</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,610</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,705</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,843</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,028</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,259</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,538</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,867</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,246</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,679</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,486</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">21,247</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">40,161</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">59,850</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">80,338</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">101,649</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">123,808</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">146,842</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">170,776</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">195,640</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">221,460</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">248,266</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">225,177</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">93.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16,339</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">30,884</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">46,025</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61,780</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">78,168</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">95,208</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">112,921</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">131,327</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">150,447</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">170,303</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">190,916</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">173,161</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16,339</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">30,884</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">46,025</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">61,780</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">78,168</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">95,208</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">112,921</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">131,327</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">150,447</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">170,303</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">190,916</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">173,161</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,650</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,892</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,499</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,597</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,290</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,664</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,789</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,722</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,512</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,196</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,805</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,820</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">104,147</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DRT 101(Osteoarthritis) - 3/3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">Currency: USD k</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY48</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY49</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY50</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY51</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">212,264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">185,710</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">157,965</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">128,990</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">98,747</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">67,195</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">34,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-10.69</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-12.51</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-14.94</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-18.34</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-23.45</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-31.95</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">-48.96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,239</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,934</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,571</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,147</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,661</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,110</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,493</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">OPEX%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">7.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">R&amp;D %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">5.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">6.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">7.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">201,026</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">175,776</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">149,394</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">121,843</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">93,086</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63,085</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">31,800</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">94.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">93.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">92.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">154,589</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">135,172</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">114,884</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">93,697</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">71,583</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">48,512</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,454</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">&#916;Net working capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">NWC%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Free cash flow</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">154,589</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">135,172</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">114,884</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">93,697</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">71,583</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">48,512</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">24,454</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,200</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,883</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,819</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,963</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,281</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">741</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">319</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">rNet Present Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">104,147</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue Projection from <span style="white-space:nowrap">License-out</span> : DRT 101(Osteoarthritis) - 1/3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">49,171</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">306,354</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">574,172</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">852,956</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,143,046</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">523.04</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">87.42</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">48.55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">34.01</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">COGS</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,636</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">97,421</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">182,587</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">271,240</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">363,489</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">COGS%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,441</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,268</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16,908</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,110</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,612</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,089</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">12,784</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">79,652</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">149,285</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">221,769</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">297,192</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Clinical</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase I</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase II</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase III</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NDA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">SG&amp;A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">297,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,441</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,268</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(16,908</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9,110</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,612</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,089</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">129,281</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">242,301</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">359,948</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">482,365</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,864</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,971</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,441</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(8,268</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(16,908</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(9,110</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,612</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,089</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,957</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">99,417</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">186,329</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">276,800</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">370,939</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.9241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,877</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(6,526</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11,397</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(5,245</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3,742</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2,557</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,174</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">22,209</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">35,549</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">45,101</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">51,618</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Operating value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">655,588</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">L/O Value (Licensor) (A)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">262,235</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty value (*1) (B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">158,634</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Upfront + Milestone <span style="white-space:nowrap">(A-B)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">103,601</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">(*1) [Royalty value]</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-style:italic">Currency: USD k</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY19</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY20</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY21</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY22</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY23</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY24</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY25</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY26</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY27</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY28</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY29</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY30</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY31</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY32</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY33</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY34</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY35</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY36</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">49,171</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">306,354</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">574,172</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">852,956</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,143,046</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,658</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">22,793</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">42,718</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">63,460</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">85,043</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.9241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.4199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.3063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">957</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,092</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">8,150</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,340</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">11,834</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue Projection from <span style="white-space:nowrap">License-out</span> : DRT 101(Osteoarthritis) - 2/3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:16%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY48</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY49</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY50</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,444,790</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,758,546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,084,683</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,423,579</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,775,623</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,141,215</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,520,763</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,194,406</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,853,015</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,496,107</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,123,185</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,733,739</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,327,244</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">903,161</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.40</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">21.72</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">18.55</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">16.26</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">14.53</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">13.17</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">12.08</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-9.27</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-10.69</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-12.51</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-14.94</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-18.34</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-23.45</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-31.95</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">COGS</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">459,443</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">559,218</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">662,929</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">770,698</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">882,648</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">998,906</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,119,603</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,015,821</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">907,259</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">793,762</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">675,173</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">551,329</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">422,064</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">287,205</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">COGS%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">375,645</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">457,222</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">542,018</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">630,131</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">721,662</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">816,716</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">915,398</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">830,546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">741,784</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">648,988</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">552,028</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">450,772</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">345,083</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">234,822</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Clinical</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase I</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase II</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase III</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NDA</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">SG&amp;A</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">375,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">457,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">542,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">630,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">721,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">816,716</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">915,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">830,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">741,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">648,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">552,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">450,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">234,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX %</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">609,701</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">742,106</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">879,736</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,022,750</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,171,313</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,325,593</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,485,762</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,348,039</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,203,972</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,053,357</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">895,984</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">731,638</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">560,097</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">381,134</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">203,219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">306,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">343,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">278,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243,325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">468,860</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">570,680</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">676,517</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">786,495</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">900,740</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,019,381</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,142,551</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,036,642</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">925,855</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">810,032</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">689,012</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">562,629</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">430,715</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">293,092</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.1188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.1015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">55,722</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">57,924</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">58,644</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">58,226</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">56,951</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">55,045</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">52,691</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">40,829</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">31,143</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">23,271</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">16,905</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">11,789</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">7,708</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">4,479</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Operating value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">655,588</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">L/O Value (Licensor) (A)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">262,235</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty value (*1) (B)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">158,634</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Upfront + Milestone <span style="white-space:nowrap">(A-B)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">103,601</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">(*1) [Royalty value]</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY37</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY38</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY39</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY40</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY41</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY42</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY46</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY47</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY48</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY49</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY50</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,444,790</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,758,546</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,084,683</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,423,579</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,775,623</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,141,215</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,520,763</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,194,406</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,853,015</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,496,107</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,123,185</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,733,739</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,327,244</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">903,161</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">107,492</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">130,836</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">155,100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">180,314</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">206,506</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">233,706</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">261,945</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">237,664</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">212,264</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">185,710</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">157,965</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">128,990</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">98,747</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">67,195</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.1188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.1015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0540</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">12,775</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">13,280</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">13,445</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">13,349</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">13,057</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">12,620</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">12,080</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">9,361</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">7,140</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">5,335</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,876</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">2,703</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,767</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,027</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value Darnatein Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue Projection from <span style="white-space:nowrap">License-out</span> : DRT 101(Osteoarthritis) - 3/3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:81%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY51</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY52</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">460,937</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Growth%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-48.96</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">-100.00</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">COGS</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">146,578</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">COGS%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">31.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Other OPEX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">119,844</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Clinical</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase I</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase II</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Phase III</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">NDA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">SG&amp;A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Other OPEX %</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">26.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">EBIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">194,515</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">EBIT%</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">42.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">CIT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">% of EBIT</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">9.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-style:italic">n.a</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">NOPLAT</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">149,582</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">1,952</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Operating value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">655,588</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">L/O Value (Licensor) (A)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">262,235</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty value (*1) (B)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">158,634</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Upfront + Milestone <span style="white-space:nowrap">(A-B)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">103,601</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">(*1) [Royalty value]</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Currency: USD k</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY51</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">FY52</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">460,937</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Royalty revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">34,294</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28.5000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">PV Factor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">0.0111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Present Value of FCF</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">448</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DCF Valuation Results of RMC Co., Ltd. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total enterprise value of RMC is KRW 10,275,152,809 and the Company holds 100% of the equity. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:75%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">(Unit: KRW)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Amount</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RMC&#8217;s Enterprise Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,275,152,809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows to Calculate Enterprise Value RMC Co., Ltd. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s estimated operating cash flows for the next five years are shown below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(Unit: millions of KRW, %) </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Category</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Applied</span><br/><span style="font-weight:bold">rate</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2020</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After</span><br/><span style="font-weight:bold">2028</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">I. Sales</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,731</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,855</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,298</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,013</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,849</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,823</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,959</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,285</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,832</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Compound Annual Growth Rate<span style="font-style:italic">(A)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">16.66</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.53</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">II. Cost of Goods Sold</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,868</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,346</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,904</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">4,554</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,313</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,198</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,230</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Average cost rate <span style="font-style:italic">(A)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">66.75</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">III. Selling and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,017</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,195</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,309</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,438</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,583</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,749</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,938</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">SG&amp;A as a</span> percentage of revenue <span style="font-style:italic">(</span>annualized)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">23.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">21.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">19.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">18.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">17.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(1) Labor expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">678</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">710</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">742</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">776</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">812</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">849</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">889</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(2) Other expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">IV. Operating Profit (EBITDA)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">413</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">472</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">636</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">831</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,063</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,338</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,664</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating margin</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">10.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">13.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">15.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating profit growth rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">34.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">30.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">27.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">25.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">24.3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">V. Corporate tax effect</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(82</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(212</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(344</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effective corporate tax rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">22.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">VI. Net Operating Profit After Tax(NOPLAT)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">344</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">390</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">518</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">670</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">851</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,066</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,320</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">7.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.9</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">9.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">10.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">11.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">VII. <span style="white-space:nowrap">Non-Cash</span> Flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation x effective income tax rate</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Working capital recovery(investment)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">VIII. Capital Expenditures</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">IX. Operating cash flow (FCF)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">344</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">390</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">518</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">670</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">851</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">1,066</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">13,302</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating cash flow to operating income ratio</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">0.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">8.0</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">13.7</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">12.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">13.4</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">14.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">15.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">167.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">Continuous Value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Perpetual growth rate of operating cash flow</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">1.57</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount rates and present value</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-style:italic">11.50</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-style:italic">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.9470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.5804</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold">X. The Present value (with perpetual guarantee)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,275</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">369</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">440</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">511</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">582</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">653</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,720</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Revenue and Estimating Cost of Goods Sold </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating revenues were estimated by applying a three-year arithmetic average rate (16.66%) of the operating revenues of the past three years (2019 to 2022) to estimate future revenues, and a three-year average cost of sales rate (66.75%) of the previous three years, which resulted in the following. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(Unit: millions of KRW) </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After&#160;2028</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:middle" rowspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,013</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">5,849</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">6,823</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,959</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">9,285</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,832</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:middle" rowspan="3" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Cost&#160;of&#160;sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,346</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,904</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">4,554</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">5,313</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">6,198</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">7,230</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.74</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company analyzed the trend of sales changes based on the past four years of financial data and calculated the arithmetic average growth rate for the three years, which was used as an estimate of the growth rate of future operating revenues. The Company&#8217;s estimate is possible if the Company maintains the average sales growth rate of the past three years and maintains the average cost of sales rate, so the Company&#8217;s estimate may differ from actual results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating labor costs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future cash flows were estimated by assuming the nominal wage growth rate in Seoul (4.6%)(*1), which is higher than the national average at the end of December 2022, as the labor cost growth rate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(Unit: millions of KRW) </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After&#160;2028</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.72</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.51</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.58</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.64</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.56</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*&#8194;1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Source: Bank of Korea Economic Statistics System (ecos.bok.or.kr) </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Other Operating Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on historical financial data, we calculated the average <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-sales</span></span> ratio for the three-year period from 2020 to 2022, and estimated future other expenses by multiplying future operating revenue by the average <span style="white-space:nowrap"><span style="white-space:nowrap">cost-to-sales</span></span> ratio (9.69%). The estimated results are as follows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(Unit: millions of dollars) </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:8%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After&#160;2028</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating corporate tax expense </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expense assumes that there are no tax adjustments in operating income, and assumes that there is no change in corporate tax rate from 2022 onward, and applies 11% for the amount below 200&#160;million won and 22.00% for the amount above 200&#160;million won to estimate income taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Estimating Future Cash Flows </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the operating revenue and operating expense estimates, the estimated cash flows for each of the next years are as follows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">(Unit: millions of KRW) </p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:59%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2027</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">After&#160;2028</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IV. Operating Profit (EBITDA)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,063</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1189</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(82</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(161</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(212</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(272</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(344</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VI. Net Operating Profit After Tax (NOPLAT)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Investment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IX. Operating cash flow(FCF)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Present value of cash flows (FCFF)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">10,275</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">369</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">440</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">511</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">582</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">653</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">7,720</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(*1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Depreciation expense and net investment in wholesalers have not been considered as the impact of income tax savings on pro forma cash flows is not material. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Discount rate estimation results </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#8217;s enterprise value is determined by discounting the present value of estimated future operating cash flows using the weighted average cost of capital (WACC). The discount rate is calculated to be 11.495%, which is derived from the weighted average of the cost of equity (Ke = 14.70%), calculated using the beta value of comparable publicly traded companies, and the cost of debt (Kd = 9.58%), reflecting the corporate tax savings on the yield of unsecured <span style="white-space:nowrap">5-year</span> <span style="white-space:nowrap">BBB-</span> rated corporate bonds. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Discount rate estimation contents </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WACC = Kd &#215; <span style="white-space:nowrap">(1-T)</span> &#215; D/(D+E) + Ke &#215; E/(D+E) = 11.495%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Kd: Cost of debt, Ke: Cost of equity, T: Tax rate, D: Debt, E: Equity) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ke = Rf + <span style="white-space:nowrap">(Rm-Rf)&#215;&#223;</span> = 3.73% + 10.968%&#215;0.7291 = 11.728% </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rf: The risk-free rate of 3.73%, as published by Bloomberg on December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#223;: The beta value of 0.7291, used because the client company and the target company operate in similar industries, indicating similar stock price fluctuations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Rm-Rf</span> (market risk premium): The market risk premium of 10.97%, as published by Bloomberg at the end of December 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:14%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:76%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Note</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Kd</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">12.29%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Corporate Bond (Unsecured 5 <span style="white-space:nowrap">Year)BBB-</span> 5 Year Corporate Bond Yields</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Rf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">3.73%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">South Korea&#8217;s <span style="white-space:nowrap">10-year</span> government bond yield courtesy of Bloomberg</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Rm &#8211; Rf</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">(Risk&#160;Premium)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.97%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korea Market Risk Premium powered by Bloomberg</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(averaged over the past year prior to the valuation date)</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">&#223;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">0.7291</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">he beta value and target capital structure of the client company due to its industry. (debt : equity=10.99%: 89.01%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Ke</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">11.73%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Cost of equity</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">H-36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom476668_51">ANNEX I: FORM OF PROXY CARD </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">I-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;20. Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that all of our directors, officers, employees and agents shall be entitled to be indemnified by us to the fullest extent permitted by Section&#160;145 of the Delaware General Corporation Law (&#8220;<span style="text-decoration:underline">DGCL</span>&#8221;). A summary of certain provisions of Section&#160;145 of the DGCL concerning indemnification of officers, directors, employees and agents is set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section&#160;145 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Section&#160;102(b)(7) of the DGCL, our second amended and restated certificate of incorporation, will provide that no director or executive officer shall be personally liable to us or any of our stockholders for monetary damages resulting from breaches of their fiduciary duty as directors or executive officers, except to the extent such limitation on or exemption from liability is not permitted under the DGCL. The effect of this provision of our second amended and restated certificate of incorporation is to eliminate our rights and those of our stockholders (through stockholders&#8217; derivative suits on our behalf) to recover monetary damages against a director or executive officer for breach of the fiduciary duty of care as a director or executive officer, including breaches resulting from negligent or grossly negligent behavior, except, as restricted by Section&#160;102(b)(7) of the DGCL. However, this provision does not limit or eliminate our rights or the rights of any stockholder to <span style="white-space:nowrap">seek&#160;non-monetary&#160;relief,</span> such as an injunction or rescission, in the event of a breach of a director or executive officer&#8217;s duty of care. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation will also provide that we will, to the fullest extent authorized or permitted by applicable law, indemnify our current and former officers and directors, as well as those persons who, while directors or officers of our corporation, are or were serving as directors, officers, employees or agents of another entity, trust or other enterprise, including service with respect to an employee benefit plan, in connection with any threatened, pending or completed proceeding, whether civil, criminal, administrative or investigative, against all expense, liability and loss (including, without limitation, attorney&#8217;s </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred or suffered by any such person in connection with any such proceeding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a person eligible for indemnification pursuant to our second amended and restated certificate of incorporation will be indemnified by us in connection with a proceeding initiated by such person only if such proceeding was authorized by our board of directors, except for proceedings to enforce rights to indemnification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right to indemnification which will be conferred by our amended and restated certificate of incorporation is a contract right that includes the right to be paid by us the expenses incurred in defending or otherwise participating in any proceeding referenced above in advance of its final disposition, provided, however, that if the DGCL requires, an advancement of expenses incurred by our officer or director (solely in the capacity as an officer or director of our corporation) will be made only upon delivery to us of an undertaking, by or on behalf of such officer or director, to repay all amounts so advanced if it is ultimately determined that such person is not entitled to be indemnified for such expenses under our amended and restated certificate of incorporation or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws include the provisions relating to advancement of expenses and indemnification rights consistent with those which will be set forth in our amended and restated certificate of incorporation. In addition, our bylaws provide for a right of indemnity to bring a suit in the event a claim for indemnification or advancement of expenses is not paid in full by us within a specified period of time. Our bylaws also permit us to purchase and maintain insurance, at our expense, to protect us and/or any director, officer, employee or agent of our corporation or another entity, trust or other enterprise against any expense, liability or loss, whether or not we would have the power to indemnify such person against such expense, liability or loss under the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or amendment of provisions of our bylaws affecting indemnification rights, whether by our board of directors, stockholders or by changes in applicable law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will enter into indemnification agreements with each of our officers and directors a form of which is to be filed as an exhibit to this Registration Statement. These agreements will require us to indemnify these </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;21. Exhibits and Financial Statement Schedules </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:9%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1**#</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#ii476668_1anxa">Amended and Restated Business Combination Agreement, dated as of May&#160;23, 2024, between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. (attached as Annex&#160;A to the proxy statement/prospectus contained in this registration statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to BLAC&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. 001-41390) filed with the SEC on February&#160;15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523277417/d891511dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of November&#160;9, 2023 (incorporated by reference to Exhibit 3.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November&#160;15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843224000125/exh3-1.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of February&#160;9, 2024 (incorporated by reference to Exhibit&#160;3.1 to BLAC&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. 001-41390) filed with the SEC on February&#160;13, 2024)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.4*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312524138268/d838634dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of May&#160;14, 2024 (incorporated by reference to Exhibit&#160;3.1 to BLAC&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. 001-41390) filed with the SEC on May&#160;14, 2024)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.5*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522145580/d143161dex32.htm">By-Laws (incorporated by reference to Exhibit 3.2 to Amendment No.&#160;1 to BLAC&#8217;s Form <span style="white-space:nowrap">S-1</span> (File&#160;No. 333-264597) filed with the SEC on May&#160;10, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.6**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#ii476668_1">Form of Second Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp., to be effective immediately after the closing of the Business Combination (attached as Annex E to the proxy statement/prospectus contained in this registration statement)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.7**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#ii476668_2">Form of Amended and Restated Bylaws of OSR Holdings, Inc., to be effective immediately after the closing of the Business Combination (attached as Annex F to the proxy statement/prospectus contained in this registration statement)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522259711/d143161dex41.htm">Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to Amendment No.&#160;3 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on October&#160;7, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522134355/d143161dex42.htm">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to BLAC&#8217;s <span style="white-space:nowrap">Form&#160;S-1</span> (File No. 333-264597) filed with the SEC on April&#160;29, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522150293/d143161dex43.htm">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to Amendment No.&#160;2 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on May&#160;13, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex41.htm">Warrant Agreement, dated February&#160;9, 2023, between Continental Stock Transfer &amp; Trust Company and BLAC (incorporated by reference to Exhibit 4.1 to BLAC&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File No. 001-41390) filed with the SEC on February&#160;15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522259711/d143161dex45.htm">Specimen Rights Certificate (incorporated by reference to Exhibit 4.5 to Amendment No.&#160;3 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on October&#160;7, 2022)</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:8%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex42.htm">Rights Agreement, dated February 9, 2023, between Continental Stock Transfer &amp; Trust Company and BLAC (incorporated by reference to Exhibit 4.2 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843223000193/exh4-7.htm">Description of Securities (incorporated by reference to Exhibit 4.7 to BLAC&#8217;s Annual Report on Form 10-K (File No. 001-41390) filed with the SEC on March 31, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1***</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Opinion of K&amp;L Gates, LLP</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;8.1***</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Tax Opinion of K&amp;L Gates LLP</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522259711/d143161dex101.htm">Form of Letter Agreement among BLAC and its officers, directors, Chardan Capital Markets, LLC and Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.1 to Amendment No. 3 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on October 7, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex102.htm">Investment Management Trust Agreement, dated February 7, 2023, between Continental Stock Transfer &amp; Trust Company and BLAC (incorporated by reference to Exhibit 10.2 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523277417/d891511dex101.htm">Amendment No. 1 to Investment Management Trust Agreement, dated as of November 10, 2023, by and between BLAC and Continental Stock Transfer &amp; Trust Company. (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex103.htm">Registration Rights Agreement, dated February 9, 2023, between BLAC and certain security holders (incorporated by reference to Exhibit 10.3 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522134355/d143161dex104.htm">Amended and Restated Securities Subscription Agreement, dated April 22, 2022, between BLAC and Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.4 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on April 29, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex104.htm">Amended and Restated Placement Unit Purchase Agreement, dated February 9, 2023 between BLAC and Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.4 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312522134355/d143161dex106.htm">Form of Indemnity Agreement (incorporated by reference to Exhibit 10.6 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on April 29, 2022)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex106.htm">Amended and Restated Administrative Support Agreement, dated February 9, 2023, by and between BLAC and Bellevue Capital Management LLC (incorporated by reference to Exhibit 10.6 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523012151/d143161dex108.htm">Form of Letter Agreement regarding Sponsor Indemnification (Incorporated by reference to Exhibit 10.8 to Amendment No. 5 to BLAC&#8217;s Form S-1 (File No. 333-264597) filed with the SEC on January 20, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523040219/d466095dex108.htm">Stock Escrow Agreement, dated February 9, 2023, by and among BLAC, Continental Stock Transfer &amp; Trust Company, and Bellevue Global Life Sciences Investors, LLC (incorporated by reference to Exhibit 10.8 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#rom476668_45">Form of Participating Stockholder Joinder Agreement (attached as Annex B to the proxy statement/prospectus contained in this registration statement) </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:8%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#anxc">Form of Non-Participating Stockholder Joinder Agreement (attached as Annex C to the proxy statement/prospectus contained in this registration statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#anxd">Form of Lock-Up Agreement (attached as Annex D to the proxy statement/prospectus contained in this registration statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843223000419/exh10-1.htm">Promissory Note, dated June 23, 2023, issued by BLAC to Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on June 28, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523278858/d881994dex103.htm">Promissory Note, dated November 13, 2023, issued by BLAC to Bellevue Capital Management LLC (incorporated by reference to Exhibit 10.3 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 16, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843224000125/exh10-1.htm">Promissory Note, dated February 9, 2024, issued by BLAC to Jun Chul Whang (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 13, 2024) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843224000224/exh10-1.htm">Promissory Note, dated March 8, 2024, issued by BLAC to Josh Pan (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390 filed with the SEC on March 13, 2024) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000089843224000311/exh10-1.htm">Promissory Note, dated April 8, 2024, issued by BLAC to Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390 filed with the SEC on April 11, 2024) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312524104896/d828353dex101.htm">Promissory Note, dated April 17, 2024, issued by BLAC to Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.1 to BLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on April 22, 2024) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312524138268/d838634dex101.htm">Promissory Note, dated May 14, 2024, issued by BLAC to Bellevue Global Life Sciences Investors LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on May 14, 2024) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21**+</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#anxg">Bellevue Life Sciences Acquisition Corp. 2024 Omnibus Incentive Plan (attached as Annex G to the proxy statement/prospectus contained in this registration statement)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Loan Agreement dated November 6, 2023 between Sung Jae Yu and OSR Holdings Co., Ltd.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23*+</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1840425/000119312523278858/d881994dex103.htm">Incentive-Based Compensation Recovery Policy (incorporated by reference to Exhibit 10.3 to the Company&#8217;sBLAC&#8217;s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 16, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">List of Subsidiaries of Combined Company</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Consent of K&amp;L Gates, LLP (included in Exhibit 5.1)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d476668dex232.htm">Consent of WithumSmith+Brown, PC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.3**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d476668dex233.htm">Consent of RSM Shinhan Accounting Corporation </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on the signature page of this registration statement) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.1***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Proxy Card</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.2***</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Consent of Choloc Asset Investment Advisory Co., Ltd.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.3**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d476668dex993.htm">Consent of Alcide Barberis </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.4**</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d476668dex994.htm">Consent of Seng Chin Mah </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d476668dexfilingfees.htm">Calculation of Filing Fee Tables </a></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">***</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain schedules, annexes and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but will be furnished supplementally to the SEC upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Management contract or compensatory plan or arrangement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial Statement Schedules </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or the notes thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;22. Undertakings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by section 10(a)(3) of the Securities Act; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">B.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">C.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">D.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">E.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F. That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">G. That every prospectus (i)&#160;that is filed pursuant to paragraph (F)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of section 10(a)(3)&#160;of the Securities Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I. The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b), 11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J. To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 28<sup style="font-size:75%; vertical-align:top">th</sup> day of June, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-weight:bold">BELLEVUE LIFE SCIENCES ACQUISITION CORP</span>.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Kuk Hyoun Hwang</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Kuk Hyoun Hwang</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President, Chief Executive Officer and Director</td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned directors and officers of Bellevue Life Sciences Acquisition Corp. hereby severally constitute and appoint Kuk Hyoun Hwang acting as true and lawful <span style="white-space:nowrap">attorney-in-fact&#160;and</span> agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-4&#160;(including all pre-effective&#160;and post-effective&#160;amendments and registration statements filed pursuant to Rule&#160;462&#160;under the&#160;Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <span style="white-space:nowrap">attorney-in-fact&#160;and</span> agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that such <span style="white-space:nowrap">attorney-in-fact&#160;and</span> agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the&#160;Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated, in each case on June 28, 2024: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:57%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kuk Hyoun Hwang</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kuk Hyoun Hwang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">President and Chief Executive Officer and Director</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Principal Executive Officer)</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David J. Yoo</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David J. Yoo</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Chief Financial Officer</span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Principal Financial Officer and Principal Accounting Officer)</span></p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sang Hyun Kim</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sang Hyun Kim</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-style:italic">Director</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Phil Geon Lee</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phil Geon Lee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-style:italic">Director</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jin Whan Park</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jin Whan Park</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-style:italic">Director</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jun Chul Whang</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jun Chul Whang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-style:italic">Director</span></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>2
<FILENAME>d476668dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of our
report dated April&nbsp;17, 2024, relating to the financial statements of Bellevue Life Sciences Acquisition Corp., as of December&nbsp;31, 2023 and 2022 and for the years then ended, which is contained in that Prospectus. We also consent to the
reference to our firm under the caption &#147;Experts&#148; in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WithumSmith+Brown, PC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;28, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>3
<FILENAME>d476668dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g476668g04j81.jpg" ALT="LOGO" STYLE="width:1.51333in;height:0.823333in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Shinhan Accounting Corporation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">8th FL, 8, Uisadang-daero</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Yeongdeungpo-gu,Seoul, 07236, Korea</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Telephone: 82-2-782-9940</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Telefax:
82-2-782-9941</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>www.rsm.global/korea</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-4 of our report dated May 31, 2024 with respect to
our audit of the consolidtated financial statements of OSR Holdings Co., Ltd. and its Subsidiaries as of December 31, 2023 and 2022, and for the years then ended, which is contained in that Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to our Firm under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g476668g96m02.jpg" ALT="LOGO" STYLE="width:1.62431in;height:0.2125in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shinhan Accounting Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seoul, Korea </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 28, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d476668dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent to be Named as a Director Nominee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing by Bellevue Life Sciences Acquisition Corp. (the &#147;Company&#148;) of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the US Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a
nominee to the Board of Directors of the Company in the Registration Statement and any and all amendments and supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alcide Barberis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alcide Barberis</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;27, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>d476668dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent to be Named as a Director Nominee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing by Bellevue Life Sciences Acquisition Corp. (the &#147;Company&#148;) of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the US Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a
nominee to the Board of Directors of the Company in the Registration Statement and any and all amendments and supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seng Chin Mah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Seng Chin Mah</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;26, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>d476668dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bellevue Life
Sciences Acquisition Corp. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Security<BR>Class<BR>Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Fee<BR>Calculation<BR>or&nbsp;Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Amount<BR>Registered(1)&nbsp;(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Maximum<BR>Aggregate<BR>Offering<BR>Price&nbsp;(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Fee<BR>Rate (4)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Amount of<BR>Registration<BR>Fee (4)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward&#8201;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Form</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Type</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward&#8201;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">File</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry<BR>Forward&#8201;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Initial</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">effective&#8201;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">Filing Fee<BR>Previously<BR>Paid&nbsp;In<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to
be<BR>Carried<BR>Forward</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to Be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#8201;Equity&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Common&#8201;<BR>Stock,&nbsp;par&#8201;<BR>value&#8201;<BR>$0.0001&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">457(f)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">24,461,214</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$2,264,484&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">.00014760&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$334.24</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Total Offering Amounts&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$334.24</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Total Fees Previously Paid&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Total Fee Offsets&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Net Fee Due&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$334.24</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated based on the maximum number of shares of common stock, $0.0001 par value per share (&#147;Common
Stock&#148;), of Bellevue Life Sciences Acquisition Corp. (&#147;BLAC&#148;) issuable upon the consummation of the business combination (the &#147;Business Combination&#148;) between BLAC and OSR Holdings Co., Ltd. (&#147;OSR Holdings&#148;).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) of the Securities Act, there are also being registered an indeterminable number of
additional securities as may be issued to prevent dilution resulting from share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT> share dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OSR Holdings is a private company, no market exists for their securities and OSR Holdings has an accumulated
deficit. Therefore, estimated solely for purposes of calculating the registration fee in accordance with Securities Act Rule 457(f)(2), the proposed maximum aggregate offering price <FONT STYLE="white-space:nowrap">is&nbsp;one-third&nbsp;of</FONT>
the aggregate par value of the OSR Holdings securities expected to be exchanged in the Business Combination. This calculation results in a value per share of the securities to be received by BLAC upon the issuance of securities registered under this
form of $1.20. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule&nbsp;457(o) under the Securities Act at a rate equal to $147.60 per $1,000,000 of
the proposed maximum aggregate offering price, subject to offset pursuant to Rule 415(a)(6). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>blacu-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2024 [04:04:05] {PM}-->
<schema targetNamespace="http://BellevueLifeSciencesAcquisitionCorp.com/20240331" elementFormDefault="qualified" xmlns:blacu="http://BellevueLifeSciencesAcquisitionCorp.com/20240331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals" id="CondensedBalanceSheetsParentheticals">
<link:definition>1003 - Statement - CONDENSED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
<link:definition>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit" id="CondensedStatementsOfChangesInStockholdersDeficit">
<link:definition>1005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical" id="CondensedStatementsOfChangesInStockholdersDeficitParenthetical">
<link:definition>1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
<link:definition>1007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation" id="DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation">
<link:definition>1008 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering" id="InitialPublicOffering">
<link:definition>1010 - Disclosure - INITIAL PUBLIC OFFERING</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1011 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1012 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption" id="CommonStockSubjectToPossibleRedemption">
<link:definition>1013 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit" id="StockholdersDeficit">
<link:definition>1014 - Disclosure - STOCKHOLDER'S DEFICIT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1015 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables" id="CommonStockSubjectToPossibleRedemptionTables">
<link:definition>1019 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails" id="DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails">
<link:definition>1021 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>1022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails">
<link:definition>1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails">
<link:definition>1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails" id="InitialPublicOfferingDetails">
<link:definition>1025 - Disclosure - INITIAL PUBLIC OFFERING (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>1026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>1027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails" id="CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails">
<link:definition>1028 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails" id="StockholdersDeficitDetails">
<link:definition>1029 - Disclosure - STOCKHOLDER'S DEFICIT (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails" id="FairValueMeasurementsScheduleOfFairValueOfAssetsDetails">
<link:definition>1030 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>1031 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlowsAlternate1" id="CondensedStatementsOfCashFlowsAlternate1">
<link:definition>1032 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="blacu-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="blacu-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="blacu-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="blacu-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="DeferredUnderwritingCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_DeferredUnderwritingCommissions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedOfferingCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_AccruedOfferingCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonStockRedemptionValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_CommonStockRedemptionValue" substitutionGroup="xbrli:item" />
<element name="ExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_ExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="AccretionForCommonStockToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_AccretionForCommonStockToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_SponsorMember" substitutionGroup="xbrli:item" />
<element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="DeferredOfferingCostsIncludedInAccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_CashFlowsFromFinancingActivitiesAbstract" substitutionGroup="xbrli:item" />
<element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_CashFlowsFromInvestingActivitiesAbstract" substitutionGroup="xbrli:item" />
<element name="CashDepositedInTheTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_CashDepositedInTheTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossFromTrustAccountToPayExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_GainLossFromTrustAccountToPayExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromTrustAccountForPaymentToRedeemingStockholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_CashFlowsFromOperatingActivitiesAbstract" substitutionGroup="xbrli:item" />
<element name="InitialPublicOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_InitialPublicOfferingAbstract" substitutionGroup="xbrli:item" />
<element name="InitialPublicOfferingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_InitialPublicOfferingTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToPossibleRedemptionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_CommonStockSubjectToPossibleRedemptionAbstract" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToPossibleRedemptionTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_CommonStockSubjectToPossibleRedemptionTextBlock" substitutionGroup="xbrli:item" />
<element name="EquityParticipationSharesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_EquityParticipationSharesPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NetLossPerCommonSharePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NetLossPerCommonSharePolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="OfferingCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_OfferingCostsPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RightsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_RightsPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantInstrumentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_WarrantInstrumentsPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockSubjectToPossibleRedemptionTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UnsecuredPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_UnsecuredPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" substitutionGroup="xbrli:item" />
<element name="InterestIncomeHeldInTheTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_InterestIncomeHeldInTheTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InvestmentOfCashInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_InvestmentOfCashInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumAllowedDissolutionExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_MaximumAllowedDissolutionExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_NetTangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfRightsIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NumberOfRightsIssuedPerUnit" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NumberOfSharesIssuedPerUnit" substitutionGroup="xbrli:item" />
<element name="NumberOfWarrantsIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NumberOfWarrantsIssuedPerUnit" substitutionGroup="xbrli:item" />
<element name="PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" substitutionGroup="xbrli:item" />
<element name="PercentageOfTrustAccountRequiredForBusinessCombination" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_PercentageOfTrustAccountRequiredForBusinessCombination" substitutionGroup="xbrli:item" />
<element name="PeriodToConsummateBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_PeriodToConsummateBusinessCombination" substitutionGroup="xbrli:item" />
<element name="RedemptionLimitPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_RedemptionLimitPercentage" substitutionGroup="xbrli:item" />
<element name="ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" substitutionGroup="xbrli:item" />
<element name="UnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_UnitsIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ChardanCapitalMarketsLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_ChardanCapitalMarketsLLCMember" substitutionGroup="xbrli:item" />
<element name="EquityParticipationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_EquityParticipationMember" substitutionGroup="xbrli:item" />
<element name="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" substitutionGroup="xbrli:item" />
<element name="INITIALPUBLICOFFERINGDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_INITIALPUBLICOFFERINGDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="INITIALPUBLICOFFERINGDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_INITIALPUBLICOFFERINGDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" substitutionGroup="xbrli:item" />
<element name="WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" substitutionGroup="xbrli:item" />
<element name="RELATEDPARTYTRANSACTIONSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_RELATEDPARTYTRANSACTIONSDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PromissoryNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_PromissoryNotesMember" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalLoansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_WorkingCapitalLoansMember" substitutionGroup="xbrli:item" />
<element name="BcmMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_BcmMember" substitutionGroup="xbrli:item" />
<element name="JoshPanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_JoshPanMember" substitutionGroup="xbrli:item" />
<element name="JunChulWhangMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_JunChulWhangMember" substitutionGroup="xbrli:item" />
<element name="RELATEDPARTYTRANSACTIONSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="MonthlyAdministrativeFeesExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_MonthlyAdministrativeFeesExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SharesOutstandingHoldingTermAfterBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_SharesOutstandingHoldingTermAfterBusinessCombination" substitutionGroup="xbrli:item" />
<element name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="COMMITMENTSCONTINGENCIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_COMMITMENTSCONTINGENCIESDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_CommitmentsContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="AggregateUnderwriterCashDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_AggregateUnderwriterCashDiscount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" substitutionGroup="xbrli:item" />
<element name="EffectiveExciseTaxRate" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_EffectiveExciseTaxRate" substitutionGroup="xbrli:item" />
<element name="MaximumNumberOfDemandsForRegistrationOfSecurities" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" substitutionGroup="xbrli:item" />
<element name="UnderwritingCashDiscountPerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_UnderwritingCashDiscountPerUnit" substitutionGroup="xbrli:item" />
<element name="UnderwritingExpensePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_UnderwritingExpensePricePerShare" substitutionGroup="xbrli:item" />
<element name="UnderwritingAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_UnderwritingAgreementMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" substitutionGroup="xbrli:item" />
<element name="COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" substitutionGroup="xbrli:item" />
<element name="STOCKHOLDERSDEFICITDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_STOCKHOLDERSDEFICITDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="NoLongerSubjectToForfeitureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_NoLongerSubjectToForfeitureMember" substitutionGroup="xbrli:item" />
<element name="SubjectToForfeitureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_SubjectToForfeitureMember" substitutionGroup="xbrli:item" />
<element name="StockholdersDeficitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_StockholdersDeficitLineItems" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="NoticePeriodForWarrantRedemption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NoticePeriodForWarrantRedemption" substitutionGroup="xbrli:item" />
<element name="RedemptionTriggerPriceAdjustmentPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_RedemptionTriggerPriceAdjustmentPercentage" substitutionGroup="xbrli:item" />
<element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" substitutionGroup="xbrli:item" />
<element name="WarrantExercisePriceAdjustmentPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_WarrantExercisePriceAdjustmentPercentage" substitutionGroup="xbrli:item" />
<element name="WarrantRedemptionConditionMinimumSharePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_WarrantRedemptionConditionMinimumSharePrice" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFairValueOfAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_ScheduleOfFairValueOfAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" substitutionGroup="xbrli:item" />
<element name="AprilSponsorNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_AprilSponsorNoteMember" substitutionGroup="xbrli:item" />
<element name="JcwPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_JcwPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="MayTwoThousandAndTwentyFourPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalFundAndOtherExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="blacu_WorkingCapitalFundAndOtherExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>blacu-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2024 [04:04:05] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedBalanceSheets" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfOperations" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfCashFlows" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfCashFlowsAlternate1" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlowsAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredUnderwritingCommissions" xlink:label="loc_BLACU_DeferredUnderwritingCommissions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_BLACU_DeferredUnderwritingCommissions" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccruedOfferingCostsCurrent" xlink:label="loc_BLACU_AccruedOfferingCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_BLACU_AccruedOfferingCostsCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForAdvanceToAffiliate" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_BLACU_CashDepositedInTheTrustAccount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_BLACU_CashDepositedInTheTrustAccount" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_GainLossFromTrustAccountToPayExpenses" xlink:label="loc_BLACU_GainLossFromTrustAccountToPayExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_BLACU_GainLossFromTrustAccountToPayExpenses" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_BLACU_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_BLACU_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlowsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" use="optional" order="21" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossAttributableToParent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="loc_us-gaap_OtherIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="6" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xlink:label="loc_BLACU_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BLACU_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="5" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>blacu-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2024 [04:04:05] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CoverPage" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedBalanceSheets" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedBalanceSheetsParentheticals" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfChangesInStockholdersDeficit" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfChangesInStockholdersDeficitParenthetical" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfCashFlows" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#InitialPublicOfferingDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#RelatedPartyTransactionsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#StockholdersDeficitDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#FairValueMeasurementsScheduleOfFairValueOfAssetsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SubsequentEventsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_523" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_DocumentInformationTable_522" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_522" xlink:to="loc_us-gaap_StatementClassOfStockAxis_524" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_524" xlink:to="loc_us-gaap_ClassOfStockDomain_525" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_524" xlink:to="loc_us-gaap_ClassOfStockDomain_525_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_522" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1229" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1229" xlink:to="loc_dei_AddressTypeDomain_1230" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1229" xlink:to="loc_dei_AddressTypeDomain_1230_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1230" xlink:to="loc_dei_BusinessContactMember_1231" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_DocumentType_531" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_AmendmentFlag_535" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityCentralIndexKey_536" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityRegistrantName_530" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityIncorporationStateCountryCode_551" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityTaxIdentificationNumber_553" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_ContactPersonnelName_1233" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressAddressLine1_554" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressAddressLine2_555" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressCityOrTown_556" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressStateOrProvince_557" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressPostalZipCode_558" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_CityAreaCode_559" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_LocalPhoneNumber_560" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityFilerCategory_539" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntitySmallBusiness_544" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityEmergingGrowthCompany_545" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityExTransitionPeriod_547" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityPrimarySicNumber_1232" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_AssetsCurrentAbstract_107" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_109" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_AssetsCurrent_110" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_StatementTable_102" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_103" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_103" xlink:to="loc_us-gaap_ClassOfStockDomain_104" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_103" xlink:to="loc_us-gaap_ClassOfStockDomain_104_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_104" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_105" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_DeferredCosts_1237" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_112" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_Assets_1235" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_114" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_115" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_116" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_569" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccruedOfferingCostsCurrent" xlink:label="loc_blacu_AccruedOfferingCostsCurrent_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_blacu_AccruedOfferingCostsCurrent_117" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_NotesPayableCurrent_118" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_119" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesCurrent_120" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredUnderwritingCommissions" xlink:label="loc_blacu_DeferredUnderwritingCommissions_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_blacu_DeferredUnderwritingCommissions_121" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_Liabilities_122" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_CommitmentsAndContingencies_680" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_676" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_PreferredStockValue_124" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_CommonStockValue_125" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_AdditionalPaidInCapital_126" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_127" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_StockholdersEquity_128" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_129" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_136" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_StatementTable_132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_133" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133" xlink:to="loc_us-gaap_ClassOfStockDomain_134" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133" xlink:to="loc_us-gaap_ClassOfStockDomain_134_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_134" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_135" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_138" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockRedemptionValue" xlink:label="loc_blacu_CommonStockRedemptionValue_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_blacu_CommonStockRedemptionValue_139" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_140" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_141" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesIssued_142" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_143" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_144" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_145" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_174" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockholdersEquity_175" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StatementTable_165" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_166" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_166" xlink:to="loc_us-gaap_EquityComponentDomain_170" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_170_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_166" xlink:to="loc_us-gaap_EquityComponentDomain_170_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_CommonStockMember_167" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_168" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_RetainedEarningsMember_169" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_171" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_171" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_171" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" xlink:to="loc_us-gaap_PrivatePlacementMember_172" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_SharesIssued_176" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_179" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_181" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccretionForCommonStockToRedemptionValue" xlink:label="loc_blacu_AccretionForCommonStockToRedemptionValue_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_blacu_AccretionForCommonStockToRedemptionValue_182" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_570" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NetIncomeLoss_184" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_667" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_667" xlink:to="loc_us-gaap_StatementTable_663" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_663" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_664" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_664" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_664" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" xlink:to="loc_us-gaap_PrivatePlacementMember_666" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_667" xlink:to="loc_us-gaap_CommonUnitIssued_668" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_196" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromOperatingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProfitLoss_198" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" xlink:to="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease_1236" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" xlink:to="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_202" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_203" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_204" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_205" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_StatementTable_187" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" xlink:to="loc_us-gaap_RelatedPartyDomain_189" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" xlink:to="loc_us-gaap_RelatedPartyDomain_189_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_189" xlink:to="loc_blacu_SponsorMember_190" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_189" xlink:to="loc_srt_AffiliatedEntityMember_191" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_192" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" xlink:to="loc_us-gaap_OverAllotmentOptionMember_194" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" xlink:to="loc_us-gaap_PrivatePlacementMember_195" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromInvestingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_571" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_672" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_blacu_CashDepositedInTheTrustAccount_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_CashDepositedInTheTrustAccount_671" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_GainLossFromTrustAccountToPayExpenses" xlink:label="loc_blacu_GainLossFromTrustAccountToPayExpenses_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_GainLossFromTrustAccountToPayExpenses_573" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromFinancingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_574" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_210" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_675" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_212" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_214" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_673" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_215" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_216" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentsForAdvanceToAffiliate_217" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_218" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_219" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_220" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_576" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_577" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_223" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts_669" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_304" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_298" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_298" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_298" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_IPOMember_300" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_OverAllotmentOptionMember_301" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_PrivatePlacementMember_302" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xlink:to="loc_us-gaap_DebtInstrumentAxis_869" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_869" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1206" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_869" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1206_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnsecuredPromissoryNoteMember" xlink:label="loc_blacu_UnsecuredPromissoryNoteMember_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1206" xlink:to="loc_blacu_UnsecuredPromissoryNoteMember_1207" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_305" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_306" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonUnitIssued_307" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_SharePrice_308" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_309" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_310" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_311" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_312" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_313" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_314" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xlink:label="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination_315" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_316" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_AssetsHeldInTrust_317" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_318" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionLimitPercentage" xlink:label="loc_blacu_RedemptionLimitPercentage_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_RedemptionLimitPercentage_319" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_320" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumAllowedDissolutionExpenses" xlink:label="loc_blacu_MaximumAllowedDissolutionExpenses_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_MaximumAllowedDissolutionExpenses_321" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_Cash_322" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtCurrent_323" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NetTangibleAssets" xlink:label="loc_blacu_NetTangibleAssets_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NetTangibleAssets_578" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PeriodToConsummateBusinessCombination" xlink:label="loc_blacu_PeriodToConsummateBusinessCombination_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PeriodToConsummateBusinessCombination_579" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_580" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_581" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_582" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockValueOutstanding_583" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InterestIncomeHeldInTheTrustAccount" xlink:label="loc_blacu_InterestIncomeHeldInTheTrustAccount_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_InterestIncomeHeldInTheTrustAccount_584" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InvestmentOfCashInTrustAccount" xlink:label="loc_blacu_InvestmentOfCashInTrustAccount_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_InvestmentOfCashInTrustAccount_585" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_blacu_CashDepositedInTheTrustAccount_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_CashDepositedInTheTrustAccount_1203" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1204" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_Cash_340" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_327" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_327" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_328" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_327" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_328_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChardanCapitalMarketsLLCMember" xlink:label="loc_blacu_ChardanCapitalMarketsLLCMember_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_328" xlink:to="loc_blacu_ChardanCapitalMarketsLLCMember_329" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_StatementClassOfStockAxis_330" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_330" xlink:to="loc_us-gaap_ClassOfStockDomain_331" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_330" xlink:to="loc_us-gaap_ClassOfStockDomain_331_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_331" xlink:to="loc_us-gaap_OverAllotmentOptionMember_332" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_331" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_333" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_334" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_334" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_334" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_us-gaap_IPOMember_336" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_us-gaap_PrivatePlacementMember_337" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationMember" xlink:label="loc_blacu_EquityParticipationMember_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_blacu_EquityParticipationMember_338" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_341" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_342" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_343" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_344" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_345" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_346" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonUnitIssued_347" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xlink:label="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare_348" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_349" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_350" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_351" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_1228" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsLineItems" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsTable" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_355" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_355" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_355" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" xlink:to="loc_us-gaap_IPOMember_356" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" xlink:to="loc_us-gaap_OverAllotmentOptionMember_604" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_607" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_607" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_608" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_608_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_607" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_608_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_StatementClassOfStockAxis_610" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_610" xlink:to="loc_us-gaap_ClassOfStockDomain_611" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_610" xlink:to="loc_us-gaap_ClassOfStockDomain_611_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_SharePrice_359" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_360" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_361" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_363" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_364" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_365" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_366" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xlink:label="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity_367" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_670" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockSharesIssued_385" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsTable" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" xlink:to="loc_us-gaap_RelatedPartyDomain_372" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_372_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" xlink:to="loc_us-gaap_RelatedPartyDomain_372_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember" xlink:label="loc_us-gaap_AdministrativeServiceMember_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_us-gaap_AdministrativeServiceMember_373" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_srt_AffiliatedEntityMember_374" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_SponsorMember_615" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_BcmMember" xlink:label="loc_blacu_BcmMember_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_BcmMember_617" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JunChulWhangMember" xlink:label="loc_blacu_JunChulWhangMember_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_JunChulWhangMember_1214" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JoshPanMember" xlink:label="loc_blacu_JoshPanMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_JoshPanMember_1215" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_DebtInstrumentAxis_375" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_375" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_376" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_375" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_376_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PromissoryNotesMember" xlink:label="loc_blacu_PromissoryNotesMember_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_blacu_PromissoryNotesMember_377" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalLoansMember" xlink:label="loc_blacu_WorkingCapitalLoansMember_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_blacu_WorkingCapitalLoansMember_378" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_us-gaap_UnsecuredDebtMember_616" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_StatementClassOfStockAxis_379" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FounderSharesMember" xlink:label="loc_blacu_FounderSharesMember_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_blacu_FounderSharesMember_381" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_us-gaap_PrivatePlacementMember_382" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_us-gaap_IPOMember_383" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockValue_386" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_387" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_388" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_390" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xlink:label="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination_391" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_SharePrice_392" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_393" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_394" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_395" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonUnitIssued_396" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_397" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_398" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_399" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_400" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_401" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_402" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_403" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_404" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="loc_us-gaap_ShorttermDebtAverageOutstandingAmount_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ShorttermDebtAverageOutstandingAmount_405" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_407" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MonthlyAdministrativeFeesExpense" xlink:label="loc_blacu_MonthlyAdministrativeFeesExpense_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_MonthlyAdministrativeFeesExpense_408" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_409" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_RepaymentsOfDebt_411" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommitmentsContingenciesLineItems" xlink:label="loc_blacu_CommitmentsContingenciesLineItems_421" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities_422" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMITMENTSCONTINGENCIESDetailsTable" xlink:label="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_415" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_415" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_416" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_415" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_416_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingAgreementMember" xlink:label="loc_blacu_UnderwritingAgreementMember_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_416" xlink:to="loc_blacu_UnderwritingAgreementMember_417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" xlink:to="loc_us-gaap_RelatedPartyDomain_419" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_419_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" xlink:to="loc_us-gaap_RelatedPartyDomain_419_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_419" xlink:to="loc_blacu_SponsorMember_420" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_618" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_618" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_618" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" xlink:to="loc_us-gaap_IPOMember_655" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_StatementClassOfStockAxis_623" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_623" xlink:to="loc_us-gaap_ClassOfStockDomain_624" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_623" xlink:to="loc_us-gaap_ClassOfStockDomain_624_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_423" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingCashDiscountPerUnit" xlink:label="loc_blacu_UnderwritingCashDiscountPerUnit_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnderwritingCashDiscountPerUnit_424" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscount" xlink:label="loc_blacu_AggregateUnderwriterCashDiscount_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_AggregateUnderwriterCashDiscount_425" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xlink:label="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering_426" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingExpensePricePerShare" xlink:label="loc_blacu_UnderwritingExpensePricePerShare_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnderwritingExpensePricePerShare_427" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_428" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_CommonStockSharesIssued_429" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveExciseTaxRate" xlink:label="loc_blacu_EffectiveExciseTaxRate_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_EffectiveExciseTaxRate_626" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_658" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1220" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_280" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" xlink:to="loc_us-gaap_StatementClassOfStockAxis_277" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_277" xlink:to="loc_us-gaap_ClassOfStockDomain_628" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_277" xlink:to="loc_us-gaap_ClassOfStockDomain_628_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_628" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_629" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_281" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_DeferredOfferingCosts_282" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_627" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccretionForCommonStockToRedemptionValue" xlink:label="loc_blacu_AccretionForCommonStockToRedemptionValue_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_blacu_AccretionForCommonStockToRedemptionValue_283" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1238" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_StockholdersDeficitLineItems" xlink:label="loc_blacu_StockholdersDeficitLineItems_450" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_451" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_STOCKHOLDERSDEFICITDetailsTable" xlink:label="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_433" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_433" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_434" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_434_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_433" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_434_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SubjectToForfeitureMember" xlink:label="loc_blacu_SubjectToForfeitureMember_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_434" xlink:to="loc_blacu_SubjectToForfeitureMember_435" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoLongerSubjectToForfeitureMember" xlink:label="loc_blacu_NoLongerSubjectToForfeitureMember_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_434" xlink:to="loc_blacu_NoLongerSubjectToForfeitureMember_436" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_437" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_437" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_438" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_438_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_437" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_438_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_438" xlink:to="loc_us-gaap_IPOMember_439" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PublicWarrantsMember" xlink:label="loc_blacu_PublicWarrantsMember_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_438" xlink:to="loc_blacu_PublicWarrantsMember_440" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_StatementClassOfStockAxis_441" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FounderSharesMember" xlink:label="loc_blacu_FounderSharesMember_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_blacu_FounderSharesMember_443" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_445" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationMember" xlink:label="loc_blacu_EquityParticipationMember_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_blacu_EquityParticipationMember_446" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" xlink:to="loc_us-gaap_PrivatePlacementMember_449" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_us-gaap_PrivatePlacementMember_677" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_447" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_447" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_447" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_962" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_962" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1226" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_962" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1226_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1226" xlink:to="loc_us-gaap_SubsequentEventMember_1227" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_452" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_453" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesIssued_454" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_455" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_456" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesIssued_457" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_459" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_460" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockVotingRights_461" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_462" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_463" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_464" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_465" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_466" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoticePeriodForWarrantRedemption" xlink:label="loc_blacu_NoticePeriodForWarrantRedemption_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_NoticePeriodForWarrantRedemption_467" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_blacu_WarrantRedemptionConditionMinimumSharePrice_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantRedemptionConditionMinimumSharePrice_468" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_469" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_470" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds_471" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantExercisePriceAdjustmentPercentage" xlink:label="loc_blacu_WarrantExercisePriceAdjustmentPercentage_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantExercisePriceAdjustmentPercentage_472" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionTriggerPriceAdjustmentPercentage" xlink:label="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage_473" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_474" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_294" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" xlink:to="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_290" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_291" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_292" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_634" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_SubsequentEventTable_633" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_DebtInstrumentAxis_635" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_636" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_636_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_636_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JcwPromissoryNoteMember" xlink:label="loc_blacu_JcwPromissoryNoteMember_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_JcwPromissoryNoteMember_648" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AprilSponsorNoteMember" xlink:label="loc_blacu_AprilSponsorNoteMember_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_AprilSponsorNoteMember_1176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xlink:label="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember_1222" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_645" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_645" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_646" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_645" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_646_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_646" xlink:to="loc_us-gaap_SubsequentEventMember_647" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" xlink:to="loc_us-gaap_RelatedPartyDomain_650" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_650_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" xlink:to="loc_us-gaap_RelatedPartyDomain_650_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JoshPanMember" xlink:label="loc_blacu_JoshPanMember_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_650" xlink:to="loc_blacu_JoshPanMember_651" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_650" xlink:to="loc_blacu_SponsorMember_652" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_638" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_639" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_AssetsHeldInTrust_640" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_641" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_642" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalFundAndOtherExpenses" xlink:label="loc_blacu_WorkingCapitalFundAndOtherExpenses_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_blacu_WorkingCapitalFundAndOtherExpenses_643" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_InterestIncomeOther_644" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1210" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_1223" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xlink:label="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled_1224" use="optional" order="26" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>blacu-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2024 [04:04:05] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information Line Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xml:lang="en-US">Common Stock Subject to Mandatory Redemption [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xml:lang="en-US">Common Stock Subject to Mandatory Redemption [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:to="lab_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Asset, Held-in-Trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred Costs, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredUnderwritingCommissions" xlink:label="loc_blacu_DeferredUnderwritingCommissions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_DeferredUnderwritingCommissions" xml:lang="en-US">Deferred Underwriting Commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_DeferredUnderwritingCommissions" xml:lang="en-US">Deferred underwriting commissions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_DeferredUnderwritingCommissions" xlink:to="lab_blacu_DeferredUnderwritingCommissions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccruedOfferingCostsCurrent" xlink:label="loc_blacu_AccruedOfferingCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_AccruedOfferingCostsCurrent" xml:lang="en-US">Accrued Offering Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_AccruedOfferingCostsCurrent" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_AccruedOfferingCostsCurrent" xlink:to="lab_blacu_AccruedOfferingCostsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Due to affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Excise tax payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued (in Dollars)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Common stock subject to possible redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Balance as of Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockRedemptionValue" xlink:label="loc_blacu_CommonStockRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommonStockRedemptionValue" xml:lang="en-US">Common Stock Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CommonStockRedemptionValue" xml:lang="en-US">Common stock, redemption value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommonStockRedemptionValue" xlink:to="lab_blacu_CommonStockRedemptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">BASIC NET INCOME (LOSS) PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">DILUTED NET INCOME (LOSS) PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ExpensesAbstract" xlink:label="loc_blacu_ExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ExpensesAbstract" xml:lang="en-US">Expenses Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ExpensesAbstract" xml:lang="en-US">EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ExpensesAbstract" xlink:to="lab_blacu_ExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xml:lang="en-US">Income before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">NET INCOME (LOSS)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Component of Operating Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Other income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAbstract" xlink:to="lab_us-gaap_OtherIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xml:lang="en-US">Investment Income, Interest and Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xml:lang="en-US">Interest earned on investments held in the Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">WEIGHTED AVERAGE SHARES OUTSTANDING, DILUTED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccretionForCommonStockToRedemptionValue" xlink:label="loc_blacu_AccretionForCommonStockToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_AccretionForCommonStockToRedemptionValue" xml:lang="en-US">Accretion For Common Stock To Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_AccretionForCommonStockToRedemptionValue" xml:lang="en-US">Accretion of common stock to redemption value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_AccretionForCommonStockToRedemptionValue" xml:lang="en-US">Plus: Accretion on common stock subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_AccretionForCommonStockToRedemptionValue" xlink:to="lab_blacu_AccretionForCommonStockToRedemptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Excise tax payable attributable to redemption&#160;of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xml:lang="en-US">Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xml:lang="en-US">Less: Proceeds allocated to public warrants and rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of 430,000 Private Placement Units (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of 430,000 Private Placement Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common Unit, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common Unit, Issued (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common Unit, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssued" xlink:to="lab_us-gaap_CommonUnitIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_AffiliatedEntityMember" xml:lang="en-US">Affiliated Entity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_AffiliatedEntityMember" xml:lang="en-US">Affiliated Entity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_SponsorMember" xml:lang="en-US">Sponsor Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_SponsorMember" xlink:to="lab_blacu_SponsorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Changes In Operating Assets And Liabilities Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="lab_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash flows used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xml:lang="en-US">Interest Income, Interest-Earning Asset, Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xml:lang="en-US">Interest earned on investments held in the Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xlink:to="lab_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">CASH, END OF PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">CASH, BEGINNING OF PERIOD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">NET CHANGE IN CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred Offering Costs Included In Accrued Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred offering costs included in accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:to="lab_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred offering costs included in accrued offering costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Payments for Underwriting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Deferred underwriters' discount payable charged to additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Payments for Underwriting Expense (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromFinancingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CashFlowsFromFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CashFlowsFromFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract" xlink:to="lab_blacu_CashFlowsFromFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash flows provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForAdvanceToAffiliate" xml:lang="en-US">Payments for Advance to Affiliate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForAdvanceToAffiliate" xml:lang="en-US">Repayments to affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="lab_us-gaap_PaymentsForAdvanceToAffiliate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Redemption of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xml:lang="en-US">Proceeds from affiliate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Initial Public Offering, net of underwriters' fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Gross proceeds from Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from Issuance of Common Limited Partners Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from Issuance of Common Limited Partners Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from over-allotment option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from note payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments to note payable - Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromInvestingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CashFlowsFromInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CashFlowsFromInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract" xlink:to="lab_blacu_CashFlowsFromInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_blacu_CashDepositedInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CashDepositedInTheTrustAccount" xml:lang="en-US">Cash Deposited In The Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_blacu_CashDepositedInTheTrustAccount" xml:lang="en-US">Cash deposited in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CashDepositedInTheTrustAccount" xml:lang="en-US">Cash deposited in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CashDepositedInTheTrustAccount" xlink:to="lab_blacu_CashDepositedInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_CashDepositedInTheTrustAccount" xml:lang="en-US">Cash deposited in the trust account.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_GainLossFromTrustAccountToPayExpenses" xlink:label="loc_blacu_GainLossFromTrustAccountToPayExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_GainLossFromTrustAccountToPayExpenses" xml:lang="en-US">Gain Loss from Trust Account to Pay Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_GainLossFromTrustAccountToPayExpenses" xml:lang="en-US">Withdrawal of interest from Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_GainLossFromTrustAccountToPayExpenses" xlink:to="lab_blacu_GainLossFromTrustAccountToPayExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_GainLossFromTrustAccountToPayExpenses" xml:lang="en-US">Gain (loss) from trust account to pay expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash flows used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xml:lang="en-US">Payments to Acquire Restricted Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xml:lang="en-US">Investment of cash in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xml:lang="en-US">Proceeds From Trust Account for Payment to Redeeming Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xml:lang="en-US">Cash withdrawn from Trust Account for payment to redeeming stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xml:lang="en-US">Less: Redemption of common stock in connection with Trust extension</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:to="lab_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xml:lang="en-US">Proceeds from trust account for payment to redeeming stockholders.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromOperatingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CashFlowsFromOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CashFlowsFromOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CashFlowsFromOperatingActivitiesAbstract" xlink:to="lab_blacu_CashFlowsFromOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InitialPublicOfferingAbstract" xlink:label="loc_blacu_InitialPublicOfferingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_InitialPublicOfferingAbstract" xml:lang="en-US">Initial Public Offering Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_InitialPublicOfferingAbstract" xlink:to="lab_blacu_InitialPublicOfferingAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InitialPublicOfferingTextBlock" xlink:label="loc_blacu_InitialPublicOfferingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_InitialPublicOfferingTextBlock" xml:lang="en-US">Initial Public Offering Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_InitialPublicOfferingTextBlock" xml:lang="en-US">INITIAL PUBLIC OFFERING</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_InitialPublicOfferingTextBlock" xlink:to="lab_blacu_InitialPublicOfferingTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionAbstract" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommonStockSubjectToPossibleRedemptionAbstract" xml:lang="en-US">Common Stock Subject To Possible Redemption Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract" xlink:to="lab_blacu_CommonStockSubjectToPossibleRedemptionAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionTextBlock" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommonStockSubjectToPossibleRedemptionTextBlock" xml:lang="en-US">Common Stock Subject To Possible Redemption Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CommonStockSubjectToPossibleRedemptionTextBlock" xml:lang="en-US">COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommonStockSubjectToPossibleRedemptionTextBlock" xlink:to="lab_blacu_CommonStockSubjectToPossibleRedemptionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationSharesPolicyPolicyTextBlock" xlink:label="loc_blacu_EquityParticipationSharesPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_EquityParticipationSharesPolicyPolicyTextBlock" xml:lang="en-US">Equity Participation Shares Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_EquityParticipationSharesPolicyPolicyTextBlock" xml:lang="en-US">Equity Participation Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_EquityParticipationSharesPolicyPolicyTextBlock" xlink:to="lab_blacu_EquityParticipationSharesPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" xml:lang="en-US">Investments Held In Trust Account Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" xml:lang="en-US">Investments Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="lab_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NetLossPerCommonSharePolicyPolicyTextBlock" xlink:label="loc_blacu_NetLossPerCommonSharePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NetLossPerCommonSharePolicyPolicyTextBlock" xml:lang="en-US">Net Loss Per Common Share Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NetLossPerCommonSharePolicyPolicyTextBlock" xml:lang="en-US">Net Income (Loss) per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NetLossPerCommonSharePolicyPolicyTextBlock" xlink:to="lab_blacu_NetLossPerCommonSharePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_OfferingCostsPolicyPolicyTextBlock" xlink:label="loc_blacu_OfferingCostsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_OfferingCostsPolicyPolicyTextBlock" xml:lang="en-US">Offering Costs Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_OfferingCostsPolicyPolicyTextBlock" xml:lang="en-US">Offering Costs Associated with the Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_OfferingCostsPolicyPolicyTextBlock" xlink:to="lab_blacu_OfferingCostsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RightsPolicyPolicyTextBlock" xlink:label="loc_blacu_RightsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_RightsPolicyPolicyTextBlock" xml:lang="en-US">Rights Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_RightsPolicyPolicyTextBlock" xml:lang="en-US">Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_RightsPolicyPolicyTextBlock" xlink:to="lab_blacu_RightsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Common Stock Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantInstrumentsPolicyPolicyTextBlock" xlink:label="loc_blacu_WarrantInstrumentsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WarrantInstrumentsPolicyPolicyTextBlock" xml:lang="en-US">Warrant Instruments Policy Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WarrantInstrumentsPolicyPolicyTextBlock" xml:lang="en-US">Warrant Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WarrantInstrumentsPolicyPolicyTextBlock" xlink:to="lab_blacu_WarrantInstrumentsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Summary of the Company's Current and Deferred Tax Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" xml:lang="en-US">Common Stock Subject To Possible Redemption Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" xml:lang="en-US">Summary of common stock subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" xlink:to="lab_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" xml:lang="en-US">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" xlink:to="lab_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnsecuredPromissoryNoteMember" xlink:label="loc_blacu_UnsecuredPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_UnsecuredPromissoryNoteMember" xml:lang="en-US">Unsecured Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_UnsecuredPromissoryNoteMember" xlink:to="lab_blacu_UnsecuredPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_UnsecuredPromissoryNoteMember" xml:lang="en-US">Unsecured promissory note member.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" xml:lang="en-US">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" xlink:to="lab_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Asset, Held-in-Trust</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Asset, Held-in-Trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrust" xlink:to="lab_us-gaap_AssetsHeldInTrust" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xml:lang="en-US">Common Stock, Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xml:lang="en-US">Common Stock, Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssuanceValue" xml:lang="en-US">Common Unit, Issuance Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonUnitIssuanceValue" xml:lang="en-US">Common Unit, Issuance Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssuanceValue" xlink:to="lab_us-gaap_CommonUnitIssuanceValue" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xml:lang="en-US">Condition For Future Business Combination Number Of Businesses Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xml:lang="en-US">Condition For Future Business Combination Number Of Businesses Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="lab_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument, Redemption, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument, Redemption, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InterestIncomeHeldInTheTrustAccount" xlink:label="loc_blacu_InterestIncomeHeldInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_InterestIncomeHeldInTheTrustAccount" xml:lang="en-US">Interest Income Held in The Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_InterestIncomeHeldInTheTrustAccount" xml:lang="en-US">Interest Income Held in The Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_InterestIncomeHeldInTheTrustAccount" xlink:to="lab_blacu_InterestIncomeHeldInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_InterestIncomeHeldInTheTrustAccount" xml:lang="en-US">Interest income held in the trust account.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InvestmentOfCashInTrustAccount" xlink:label="loc_blacu_InvestmentOfCashInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_InvestmentOfCashInTrustAccount" xml:lang="en-US">Investment of Cash in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_InvestmentOfCashInTrustAccount" xlink:to="lab_blacu_InvestmentOfCashInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_InvestmentOfCashInTrustAccount" xml:lang="en-US">Investment of cash in trust account.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumAllowedDissolutionExpenses" xlink:label="loc_blacu_MaximumAllowedDissolutionExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_MaximumAllowedDissolutionExpenses" xml:lang="en-US">Maximum Allowed Dissolution Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_MaximumAllowedDissolutionExpenses" xml:lang="en-US">Maximum Allowed Dissolution Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_MaximumAllowedDissolutionExpenses" xlink:to="lab_blacu_MaximumAllowedDissolutionExpenses" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NetTangibleAssets" xlink:label="loc_blacu_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NetTangibleAssets" xml:lang="en-US">Net Tangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NetTangibleAssets" xml:lang="en-US">Net Tangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NetTangibleAssets" xlink:to="lab_blacu_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_NetTangibleAssets" xml:lang="en-US">Net tangible assets.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NumberOfRightsIssuedPerUnit" xml:lang="en-US">Number Of Rights Issued Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NumberOfRightsIssuedPerUnit" xml:lang="en-US">Number of Rights Issued Per Unit (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_NumberOfRightsIssuedPerUnit" xml:lang="en-US">Number of Rights Issued Per Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NumberOfRightsIssuedPerUnit" xlink:to="lab_blacu_NumberOfRightsIssuedPerUnit" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Number Of Shares Issued Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Number of Shares Issued Per Unit (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_NumberOfSharesIssuedPerUnit" xml:lang="en-US">Number of Shares Issued Per Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NumberOfSharesIssuedPerUnit" xlink:to="lab_blacu_NumberOfSharesIssuedPerUnit" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Number Of Warrants Issued Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Number of Warrants Issued Per Unit (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_NumberOfWarrantsIssuedPerUnit" xml:lang="en-US">Number of Warrants Issued Per Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NumberOfWarrantsIssuedPerUnit" xlink:to="lab_blacu_NumberOfWarrantsIssuedPerUnit" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xml:lang="en-US">Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xml:lang="en-US">Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="lab_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xlink:label="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xml:lang="en-US">Percentage Of Trust Account Required For Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xml:lang="en-US">Percentage Of Trust Account Required For Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xlink:to="lab_blacu_PercentageOfTrustAccountRequiredForBusinessCombination" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PeriodToConsummateBusinessCombination" xlink:label="loc_blacu_PeriodToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_PeriodToConsummateBusinessCombination" xml:lang="en-US">Period to Consummate Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_PeriodToConsummateBusinessCombination" xml:lang="en-US">Period To Consummate Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_PeriodToConsummateBusinessCombination" xlink:to="lab_blacu_PeriodToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_PeriodToConsummateBusinessCombination" xml:lang="en-US">Period to consummate business combination.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionLimitPercentage" xlink:label="loc_blacu_RedemptionLimitPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_RedemptionLimitPercentage" xml:lang="en-US">Redemption Limit Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_RedemptionLimitPercentage" xml:lang="en-US">Redemption Limit Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_RedemptionLimitPercentage" xlink:to="lab_blacu_RedemptionLimitPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xml:lang="en-US">Temporary Equity, Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xml:lang="en-US">Temporary Equity, Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xml:lang="en-US">Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xml:lang="en-US">Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:to="lab_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Units Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Units Issued During Period, Shares, New Issues (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_blacu_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Units Issued During Period, Shares, New Issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="lab_blacu_UnitsIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="lab_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChardanCapitalMarketsLLCMember" xlink:label="loc_blacu_ChardanCapitalMarketsLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ChardanCapitalMarketsLLCMember" xml:lang="en-US">Chardan Capital Markets LLCMember</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ChardanCapitalMarketsLLCMember" xml:lang="en-US">Chardan Capital Markets, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ChardanCapitalMarketsLLCMember" xlink:to="lab_blacu_ChardanCapitalMarketsLLCMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationMember" xlink:label="loc_blacu_EquityParticipationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_EquityParticipationMember" xml:lang="en-US">Equity Participation Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_EquityParticipationMember" xml:lang="en-US">Equity Participation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_EquityParticipationMember" xlink:to="lab_blacu_EquityParticipationMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="lab_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xlink:label="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xml:lang="en-US">Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xml:lang="en-US">Common Stock Shares Excluded From Calculation of Net Income(Loss) Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xlink:to="lab_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Accrued (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Provision/(benefit) at statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xlink:label="loc_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences Change In Fv Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xml:lang="en-US">Change in fair value of Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xlink:to="lab_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xml:lang="en-US">Effective income tax rate reconciliation permanent differences change in fv of warrant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State tax provision/(benefit) net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsTable" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_INITIALPUBLICOFFERINGDetailsTable" xml:lang="en-US">INITIAL PUBLIC OFFERING (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable" xlink:to="lab_blacu_INITIALPUBLICOFFERINGDetailsTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsLineItems" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_INITIALPUBLICOFFERINGDetailsLineItems" xml:lang="en-US">INITIAL PUBLIC OFFERING (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems" xlink:to="lab_blacu_INITIALPUBLICOFFERINGDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xlink:label="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xml:lang="en-US">Class Of Warrant Or Right Number Of Rights To Call One Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xml:lang="en-US">Class of Warrant or Right, Number of Rights to Call One Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xlink:to="lab_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xml:lang="en-US">Warrants Or Rights Outstanding Exercisable Term After Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xml:lang="en-US">Warrants or Rights Outstanding, Exercisable Term After Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:to="lab_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsTable" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_RELATEDPARTYTRANSACTIONSDetailsTable" xml:lang="en-US">RELATED PARTY TRANSACTIONS (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable" xlink:to="lab_blacu_RELATEDPARTYTRANSACTIONSDetailsTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PromissoryNotesMember" xlink:label="loc_blacu_PromissoryNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_PromissoryNotesMember" xml:lang="en-US">Promissory Notes Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_PromissoryNotesMember" xml:lang="en-US">Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_PromissoryNotesMember" xlink:to="lab_blacu_PromissoryNotesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalLoansMember" xlink:label="loc_blacu_WorkingCapitalLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WorkingCapitalLoansMember" xml:lang="en-US">Working Capital Loans Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WorkingCapitalLoansMember" xml:lang="en-US">Working Capital Loans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WorkingCapitalLoansMember" xlink:to="lab_blacu_WorkingCapitalLoansMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember" xlink:label="loc_us-gaap_AdministrativeServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdministrativeServiceMember" xml:lang="en-US">Administrative Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdministrativeServiceMember" xml:lang="en-US">Administrative Service [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdministrativeServiceMember" xlink:to="lab_us-gaap_AdministrativeServiceMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_BcmMember" xlink:label="loc_blacu_BcmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_BcmMember" xml:lang="en-US">BCM [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_BcmMember" xlink:to="lab_blacu_BcmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_BcmMember" xml:lang="en-US">Bcm member.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JoshPanMember" xlink:label="loc_blacu_JoshPanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_JoshPanMember" xml:lang="en-US">Josh Pan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_JoshPanMember" xml:lang="en-US">Josh Pan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_JoshPanMember" xlink:to="lab_blacu_JoshPanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_JoshPanMember" xml:lang="en-US">Josh pan member.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JunChulWhangMember" xlink:label="loc_blacu_JunChulWhangMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_JunChulWhangMember" xml:lang="en-US">Jun Chul Whang [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_JunChulWhangMember" xlink:to="lab_blacu_JunChulWhangMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_JunChulWhangMember" xml:lang="en-US">Jun chul whang.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" xml:lang="en-US">RELATED PARTY TRANSACTIONS (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" xlink:to="lab_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MonthlyAdministrativeFeesExpense" xlink:label="loc_blacu_MonthlyAdministrativeFeesExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_MonthlyAdministrativeFeesExpense" xml:lang="en-US">Monthly Administrative Fees Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_MonthlyAdministrativeFeesExpense" xml:lang="en-US">Administrative Fees Expense, Monthly</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_MonthlyAdministrativeFeesExpense" xlink:to="lab_blacu_MonthlyAdministrativeFeesExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other General and Administrative Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xlink:label="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xml:lang="en-US">Shares Outstanding Holding Term After Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xml:lang="en-US">Shares Outstanding, Holding Term After Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xlink:to="lab_blacu_SharesOutstandingHoldingTermAfterBusinessCombination" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="loc_us-gaap_ShorttermDebtAverageOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShorttermDebtAverageOutstandingAmount" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShorttermDebtAverageOutstandingAmount" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="lab_us-gaap_ShorttermDebtAverageOutstandingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplit" xml:lang="en-US">Stockholders' Equity Note, Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplit" xml:lang="en-US">Stockholders' Equity Note, Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplit" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xml:lang="en-US">Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xml:lang="en-US">Threshold Period After Business Combination in Which Specified Trading Days Within Any Specified Trading Day Period Commences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="lab_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xml:lang="en-US">Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xml:lang="en-US">Transfer, Assign, or Sell Any Shares or Warrants After Completion of Initial Business Combination Threshold Consecutive Trading Days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xml:lang="en-US">Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xml:lang="en-US">Transfer, Assign, or Sell Any Shares or Warrants after Completion of Initial Business Combination Threshold Trading Days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FounderSharesMember" xlink:label="loc_blacu_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_FounderSharesMember" xml:lang="en-US">Founder Shares Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_FounderSharesMember" xml:lang="en-US">Founder Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_FounderSharesMember" xlink:to="lab_blacu_FounderSharesMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMITMENTSCONTINGENCIESDetailsTable" xlink:label="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_COMMITMENTSCONTINGENCIESDetailsTable" xml:lang="en-US">COMMITMENTS &amp; CONTINGENCIES (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable" xlink:to="lab_blacu_COMMITMENTSCONTINGENCIESDetailsTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommitmentsContingenciesLineItems" xlink:label="loc_blacu_CommitmentsContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_CommitmentsContingenciesLineItems" xml:lang="en-US">COMMITMENTS CONTINGENCIES [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_CommitmentsContingenciesLineItems" xlink:to="lab_blacu_CommitmentsContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscount" xlink:label="loc_blacu_AggregateUnderwriterCashDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_AggregateUnderwriterCashDiscount" xml:lang="en-US">Aggregate Underwriter Cash Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_AggregateUnderwriterCashDiscount" xml:lang="en-US">Aggregate Underwriter Cash Discount (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_AggregateUnderwriterCashDiscount" xlink:to="lab_blacu_AggregateUnderwriterCashDiscount" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xlink:label="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xml:lang="en-US">Aggregate Underwriter Cash Discount Percent Of Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xml:lang="en-US">Aggregate Underwriter Cash Discount Percent Of Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xlink:to="lab_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveExciseTaxRate" xlink:label="loc_blacu_EffectiveExciseTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_EffectiveExciseTaxRate" xml:lang="en-US">Effective Excise Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_EffectiveExciseTaxRate" xml:lang="en-US">Effective Excise Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_EffectiveExciseTaxRate" xlink:to="lab_blacu_EffectiveExciseTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_EffectiveExciseTaxRate" xml:lang="en-US">Effective excise tax rate.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xml:lang="en-US">Maximum Number Of Demands For Registration Of Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xml:lang="en-US">Maximum Number of Demands for Registration of Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:to="lab_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingCashDiscountPerUnit" xlink:label="loc_blacu_UnderwritingCashDiscountPerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_UnderwritingCashDiscountPerUnit" xml:lang="en-US">Underwriting Cash Discount Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_UnderwritingCashDiscountPerUnit" xml:lang="en-US">Underwriting Cash Discount Per Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_UnderwritingCashDiscountPerUnit" xlink:to="lab_blacu_UnderwritingCashDiscountPerUnit" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingExpensePricePerShare" xlink:label="loc_blacu_UnderwritingExpensePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_UnderwritingExpensePricePerShare" xml:lang="en-US">Underwriting Expense Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_UnderwritingExpensePricePerShare" xml:lang="en-US">Underwriting Expense, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_UnderwritingExpensePricePerShare" xlink:to="lab_blacu_UnderwritingExpensePricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingAgreementMember" xlink:label="loc_blacu_UnderwritingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_UnderwritingAgreementMember" xml:lang="en-US">Underwriting Agreement Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_UnderwritingAgreementMember" xml:lang="en-US">Underwriting Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_UnderwritingAgreementMember" xlink:to="lab_blacu_UnderwritingAgreementMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" xlink:label="loc_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" xml:lang="en-US">Schedule Of Reconciliation Of Common Stock Subject To Possible Redemption Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" xlink:to="lab_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" xml:lang="en-US">COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" xlink:to="lab_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" xml:lang="en-US">COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" xlink:to="lab_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Offering costs allocated to common stock subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_STOCKHOLDERSDEFICITDetailsTable" xlink:label="loc_blacu_STOCKHOLDERSDEFICITDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_STOCKHOLDERSDEFICITDetailsTable" xml:lang="en-US">STOCKHOLDER'S DEFICIT (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable" xlink:to="lab_blacu_STOCKHOLDERSDEFICITDetailsTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PublicWarrantsMember" xlink:label="loc_blacu_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_PublicWarrantsMember" xml:lang="en-US">Public Warrants Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_PublicWarrantsMember" xlink:to="lab_blacu_PublicWarrantsMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoLongerSubjectToForfeitureMember" xlink:label="loc_blacu_NoLongerSubjectToForfeitureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NoLongerSubjectToForfeitureMember" xml:lang="en-US">No Longer Subject To Forfeiture Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NoLongerSubjectToForfeitureMember" xml:lang="en-US">No Longer Subject to Forfeiture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NoLongerSubjectToForfeitureMember" xlink:to="lab_blacu_NoLongerSubjectToForfeitureMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SubjectToForfeitureMember" xlink:label="loc_blacu_SubjectToForfeitureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_SubjectToForfeitureMember" xml:lang="en-US">Subject To Forfeiture Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_SubjectToForfeitureMember" xml:lang="en-US">Subject to Forfeiture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_SubjectToForfeitureMember" xlink:to="lab_blacu_SubjectToForfeitureMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_StockholdersDeficitLineItems" xlink:label="loc_blacu_StockholdersDeficitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_StockholdersDeficitLineItems" xml:lang="en-US">STOCKHOLDERS DEFICIT [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_StockholdersDeficitLineItems" xlink:to="lab_blacu_StockholdersDeficitLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="lab_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoticePeriodForWarrantRedemption" xlink:label="loc_blacu_NoticePeriodForWarrantRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NoticePeriodForWarrantRedemption" xml:lang="en-US">Notice Period For Warrant Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NoticePeriodForWarrantRedemption" xml:lang="en-US">Notice Period for Warrant Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NoticePeriodForWarrantRedemption" xlink:to="lab_blacu_NoticePeriodForWarrantRedemption" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionTriggerPriceAdjustmentPercentage" xlink:label="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_RedemptionTriggerPriceAdjustmentPercentage" xml:lang="en-US">Redemption Trigger Price Adjustment Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_RedemptionTriggerPriceAdjustmentPercentage" xml:lang="en-US">Redemption Trigger Price Adjustment Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage" xlink:to="lab_blacu_RedemptionTriggerPriceAdjustmentPercentage" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xml:lang="en-US">Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Percentage Of Total Equity Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xml:lang="en-US">Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Percentage Of Total Equity Proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xlink:to="lab_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantExercisePriceAdjustmentPercentage" xlink:label="loc_blacu_WarrantExercisePriceAdjustmentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WarrantExercisePriceAdjustmentPercentage" xml:lang="en-US">Warrant Exercise Price Adjustment Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WarrantExercisePriceAdjustmentPercentage" xml:lang="en-US">Warrant Exercise Price Adjustment Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WarrantExercisePriceAdjustmentPercentage" xlink:to="lab_blacu_WarrantExercisePriceAdjustmentPercentage" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_blacu_WarrantRedemptionConditionMinimumSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WarrantRedemptionConditionMinimumSharePrice" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WarrantRedemptionConditionMinimumSharePrice" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WarrantRedemptionConditionMinimumSharePrice" xlink:to="lab_blacu_WarrantRedemptionConditionMinimumSharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ScheduleOfFairValueOfAssetsAbstract" xlink:label="loc_blacu_ScheduleOfFairValueOfAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_ScheduleOfFairValueOfAssetsAbstract" xml:lang="en-US">Schedule Of Fair Value Of Assets Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_ScheduleOfFairValueOfAssetsAbstract" xlink:to="lab_blacu_ScheduleOfFairValueOfAssetsAbstract" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" xml:lang="en-US">FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" xlink:to="lab_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" xml:lang="en-US">FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" xlink:to="lab_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AprilSponsorNoteMember" xlink:label="loc_blacu_AprilSponsorNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_AprilSponsorNoteMember" xml:lang="en-US">April Sponsor Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_AprilSponsorNoteMember" xml:lang="en-US">Jcw Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_AprilSponsorNoteMember" xlink:to="lab_blacu_AprilSponsorNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_AprilSponsorNoteMember" xml:lang="en-US">April sponsor note member.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JcwPromissoryNoteMember" xlink:label="loc_blacu_JcwPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_JcwPromissoryNoteMember" xml:lang="en-US">Jcw Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_JcwPromissoryNoteMember" xml:lang="en-US">Jcw Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_JcwPromissoryNoteMember" xlink:to="lab_blacu_JcwPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_JcwPromissoryNoteMember" xml:lang="en-US">Jcw promissory note member.</label>
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xlink:label="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xml:lang="en-US">May Two Thousand And Twenty Four promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xml:lang="en-US">May 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xlink:to="lab_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xml:lang="en-US">May Two Thousand And Twenty Four promissory Note [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xlink:label="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xml:lang="en-US">Number Of Days After The Due Date Within Which The Loan Shall Be Settled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xml:lang="en-US">Number of days after the due date within which the loan shall be settled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xlink:to="lab_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xml:lang="en-US">Number Of Days After The Due Date Within Which The Loan Shall Be Settled.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Short term debt bearing fixed interest percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalFundAndOtherExpenses" xlink:label="loc_blacu_WorkingCapitalFundAndOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_blacu_WorkingCapitalFundAndOtherExpenses" xml:lang="en-US">Working Capital Fund And Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_blacu_WorkingCapitalFundAndOtherExpenses" xml:lang="en-US">Working Capital Fund And Other Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_blacu_WorkingCapitalFundAndOtherExpenses" xlink:to="lab_blacu_WorkingCapitalFundAndOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_blacu_WorkingCapitalFundAndOtherExpenses" xml:lang="en-US">Working capital fund and other expenses.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>blacu-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2024 [04:04:05] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CoverPage" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedBalanceSheets" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedBalanceSheetsParentheticals" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfOperations" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfChangesInStockholdersDeficit" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfChangesInStockholdersDeficitParenthetical" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CondensedStatementsOfCashFlows" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#InitialPublicOffering" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#RelatedPartyTransactions" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommitmentsAndContingencies" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommonStockSubjectToPossibleRedemption" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#StockholdersDeficit" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#FairValueMeasurements" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SubsequentEvents" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommonStockSubjectToPossibleRedemptionTables" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#FairValueMeasurementsTables" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#InitialPublicOfferingDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#RelatedPartyTransactionsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommitmentsAndContingenciesDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#StockholdersDeficitDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#FairValueMeasurementsScheduleOfFairValueOfAssetsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="blacu-20240331.xsd#SubsequentEventsDetails" roleURI="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails" />
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_520" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_520" xlink:to="loc_dei_DocumentInformationTable_522" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_522" xlink:to="loc_us-gaap_StatementClassOfStockAxis_524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_524" xlink:to="loc_us-gaap_ClassOfStockDomain_525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_522" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1229" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1229" xlink:to="loc_dei_AddressTypeDomain_1230" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1230" xlink:to="loc_dei_BusinessContactMember_1231" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_522" xlink:to="loc_dei_DocumentInformationLineItems_523" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_DocumentType_531" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_AmendmentFlag_535" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityCentralIndexKey_536" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityRegistrantName_530" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityIncorporationStateCountryCode_551" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityTaxIdentificationNumber_553" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_ContactPersonnelName_1233" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressAddressLine1_554" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressAddressLine2_555" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressCityOrTown_556" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressStateOrProvince_557" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityAddressPostalZipCode_558" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_CityAreaCode_559" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_LocalPhoneNumber_560" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityFilerCategory_539" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntitySmallBusiness_544" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityEmergingGrowthCompany_545" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityExTransitionPeriod_547" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_523" xlink:to="loc_dei_EntityPrimarySicNumber_1232" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101" xlink:to="loc_us-gaap_StatementTable_102" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_103" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_103" xlink:to="loc_us-gaap_ClassOfStockDomain_104" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_104" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_105" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_102" xlink:to="loc_us-gaap_StatementLineItems_106" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_AssetsCurrentAbstract_107" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_108" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_109" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_107" xlink:to="loc_us-gaap_AssetsCurrent_110" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_DeferredCosts_1237" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_112" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_Assets_1235" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_114" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_115" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_116" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_569" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccruedOfferingCostsCurrent" xlink:label="loc_blacu_AccruedOfferingCostsCurrent_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_blacu_AccruedOfferingCostsCurrent_117" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_NotesPayableCurrent_118" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_114" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_119" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesCurrent_120" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredUnderwritingCommissions" xlink:label="loc_blacu_DeferredUnderwritingCommissions_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_blacu_DeferredUnderwritingCommissions_121" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_Liabilities_122" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_CommitmentsAndContingencies_680" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_676" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_PreferredStockValue_124" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_CommonStockValue_125" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_AdditionalPaidInCapital_126" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_127" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_681" xlink:to="loc_us-gaap_StockholdersEquity_128" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_106" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_129" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_131" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_131" xlink:to="loc_us-gaap_StatementTable_132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_133" xlink:to="loc_us-gaap_ClassOfStockDomain_134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_134" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_135" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_132" xlink:to="loc_us-gaap_StatementLineItems_136" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_138" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockRedemptionValue" xlink:label="loc_blacu_CommonStockRedemptionValue_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_blacu_CommonStockRedemptionValue_139" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_140" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_141" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesIssued_142" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_143" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_144" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_136" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_145" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_147" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ExpensesAbstract" xlink:label="loc_blacu_ExpensesAbstract_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_blacu_ExpensesAbstract_148" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ExpensesAbstract_148" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_OtherIncomeAbstract_151" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_151" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_154" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_155" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_OtherIncome_153" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_NetIncomeLoss_156" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_158" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_159" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_EarningsPerShareBasic_161" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147" xlink:to="loc_us-gaap_EarningsPerShareDiluted_162" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_164" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_StatementTable_165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_166" xlink:to="loc_us-gaap_EquityComponentDomain_170" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_CommonStockMember_167" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_168" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_170" xlink:to="loc_us-gaap_RetainedEarningsMember_169" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_171" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_171" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_173" xlink:to="loc_us-gaap_PrivatePlacementMember_172" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_165" xlink:to="loc_us-gaap_StatementLineItems_174" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockholdersEquity_175" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_SharesIssued_176" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_179" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_181" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccretionForCommonStockToRedemptionValue" xlink:label="loc_blacu_AccretionForCommonStockToRedemptionValue_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_blacu_AccretionForCommonStockToRedemptionValue_182" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_570" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NetIncomeLoss_184" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StockholdersEquity_177" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_SharesIssued_178" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_661" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_661" xlink:to="loc_us-gaap_StatementTable_663" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_663" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_664" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_664" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_665" xlink:to="loc_us-gaap_PrivatePlacementMember_666" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_663" xlink:to="loc_us-gaap_StatementLineItems_667" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_667" xlink:to="loc_us-gaap_CommonUnitIssued_668" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_186" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_186" xlink:to="loc_us-gaap_StatementTable_187" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188" xlink:to="loc_us-gaap_RelatedPartyDomain_189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_189" xlink:to="loc_blacu_SponsorMember_190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_189" xlink:to="loc_srt_AffiliatedEntityMember_191" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_192" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" xlink:to="loc_us-gaap_OverAllotmentOptionMember_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_193" xlink:to="loc_us-gaap_PrivatePlacementMember_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_StatementLineItems_196" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromOperatingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromOperatingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProfitLoss_198" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" xlink:to="loc_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease_1236" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" xlink:to="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_202" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_203" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_204" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract_201" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_205" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromInvestingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_571" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_672" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_blacu_CashDepositedInTheTrustAccount_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_CashDepositedInTheTrustAccount_671" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_GainLossFromTrustAccountToPayExpenses" xlink:label="loc_blacu_GainLossFromTrustAccountToPayExpenses_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_blacu_GainLossFromTrustAccountToPayExpenses_573" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromInvestingActivitiesAbstract_206" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashFlowsFromFinancingActivitiesAbstract" xlink:label="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_574" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_210" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_675" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_212" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_214" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_673" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_215" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_216" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_PaymentsForAdvanceToAffiliate_217" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CashFlowsFromFinancingActivitiesAbstract_209" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_218" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_219" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_220" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_221" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_575" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_576" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_196" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_577" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_223" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_222" xlink:to="loc_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts_669" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_226" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_226" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_227" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_229" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_229" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InitialPublicOfferingAbstract" xlink:label="loc_blacu_InitialPublicOfferingAbstract_232" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InitialPublicOfferingTextBlock" xlink:label="loc_blacu_InitialPublicOfferingTextBlock_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_InitialPublicOfferingAbstract_232" xlink:to="loc_blacu_InitialPublicOfferingTextBlock_233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_235" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_235" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_238" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_238" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_239" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionAbstract" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract_241" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionTextBlock" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionTextBlock_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract_241" xlink:to="loc_blacu_CommonStockSubjectToPossibleRedemptionTextBlock_242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_244" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_244" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_245" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_247" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_247" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_248" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_250" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_250" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_251" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_253" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_UseOfEstimates_254" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_255" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock_256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_586" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_258" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantInstrumentsPolicyPolicyTextBlock" xlink:label="loc_blacu_WarrantInstrumentsPolicyPolicyTextBlock_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_WarrantInstrumentsPolicyPolicyTextBlock_260" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RightsPolicyPolicyTextBlock" xlink:label="loc_blacu_RightsPolicyPolicyTextBlock_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_RightsPolicyPolicyTextBlock_261" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationSharesPolicyPolicyTextBlock" xlink:label="loc_blacu_EquityParticipationSharesPolicyPolicyTextBlock_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_EquityParticipationSharesPolicyPolicyTextBlock_262" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NetLossPerCommonSharePolicyPolicyTextBlock" xlink:label="loc_blacu_NetLossPerCommonSharePolicyPolicyTextBlock_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_NetLossPerCommonSharePolicyPolicyTextBlock_263" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_264" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_265" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_OfferingCostsPolicyPolicyTextBlock" xlink:label="loc_blacu_OfferingCostsPolicyPolicyTextBlock_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_blacu_OfferingCostsPolicyPolicyTextBlock_266" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_267" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_588" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_588" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_589" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_588" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_590" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionAbstract" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract_269" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock" xlink:label="loc_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommonStockSubjectToPossibleRedemptionAbstract_269" xlink:to="loc_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock_270" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_272" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_272" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_273" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_296" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_296" xlink:to="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_298" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_298" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_IPOMember_300" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_OverAllotmentOptionMember_301" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_299" xlink:to="loc_us-gaap_PrivatePlacementMember_302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xlink:to="loc_us-gaap_DebtInstrumentAxis_869" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_869" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1206" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnsecuredPromissoryNoteMember" xlink:label="loc_blacu_UnsecuredPromissoryNoteMember_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1206" xlink:to="loc_blacu_UnsecuredPromissoryNoteMember_1207" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems" xlink:label="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable_297" xlink:to="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_304" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_305" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_306" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonUnitIssued_307" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_SharePrice_308" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_309" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_310" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_311" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_312" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_313" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_314" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageOfTrustAccountRequiredForBusinessCombination" xlink:label="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PercentageOfTrustAccountRequiredForBusinessCombination_315" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_316" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_AssetsHeldInTrust_317" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_318" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionLimitPercentage" xlink:label="loc_blacu_RedemptionLimitPercentage_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_RedemptionLimitPercentage_319" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_320" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumAllowedDissolutionExpenses" xlink:label="loc_blacu_MaximumAllowedDissolutionExpenses_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_MaximumAllowedDissolutionExpenses_321" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_Cash_322" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtCurrent_323" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NetTangibleAssets" xlink:label="loc_blacu_NetTangibleAssets_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_NetTangibleAssets_578" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PeriodToConsummateBusinessCombination" xlink:label="loc_blacu_PeriodToConsummateBusinessCombination_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_PeriodToConsummateBusinessCombination_579" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_580" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_581" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_582" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_CommonStockValueOutstanding_583" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InterestIncomeHeldInTheTrustAccount" xlink:label="loc_blacu_InterestIncomeHeldInTheTrustAccount_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_InterestIncomeHeldInTheTrustAccount_584" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InvestmentOfCashInTrustAccount" xlink:label="loc_blacu_InvestmentOfCashInTrustAccount_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_InvestmentOfCashInTrustAccount_585" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CashDepositedInTheTrustAccount" xlink:label="loc_blacu_CashDepositedInTheTrustAccount_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_blacu_CashDepositedInTheTrustAccount_1203" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems_303" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1204" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_325" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_325" xlink:to="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_327" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_327" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_328" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ChardanCapitalMarketsLLCMember" xlink:label="loc_blacu_ChardanCapitalMarketsLLCMember_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_328" xlink:to="loc_blacu_ChardanCapitalMarketsLLCMember_329" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_StatementClassOfStockAxis_330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_330" xlink:to="loc_us-gaap_ClassOfStockDomain_331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_331" xlink:to="loc_us-gaap_OverAllotmentOptionMember_332" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_331" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_333" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_334" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_334" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_us-gaap_IPOMember_336" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_us-gaap_PrivatePlacementMember_337" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationMember" xlink:label="loc_blacu_EquityParticipationMember_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_335" xlink:to="loc_blacu_EquityParticipationMember_338" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:label="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable_326" xlink:to="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_Cash_340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_341" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_342" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_343" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_344" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_345" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_346" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonUnitIssued_347" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare" xlink:label="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare_348" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_349" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_350" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_351" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_339" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_1228" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_592" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_592" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_593" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_592" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_594" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_592" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_595" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_597" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_598" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_599" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability" xlink:label="loc_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability_600" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_601" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_602" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_603" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_InitialPublicOfferingAbstract" xlink:label="loc_blacu_InitialPublicOfferingAbstract_353" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsTable" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_InitialPublicOfferingAbstract_353" xlink:to="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_355" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_355" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" xlink:to="loc_us-gaap_IPOMember_356" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_605" xlink:to="loc_us-gaap_OverAllotmentOptionMember_604" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_607" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_607" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_608" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_us-gaap_StatementClassOfStockAxis_610" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_610" xlink:to="loc_us-gaap_ClassOfStockDomain_611" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_INITIALPUBLICOFFERINGDetailsLineItems" xlink:label="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsTable_354" xlink:to="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_SharePrice_359" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_360" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_361" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_363" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_364" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_365" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_366" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity" xlink:label="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity_367" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_INITIALPUBLICOFFERINGDetailsLineItems_357" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_670" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_369" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsTable" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_369" xlink:to="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_371" xlink:to="loc_us-gaap_RelatedPartyDomain_372" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeServiceMember" xlink:label="loc_us-gaap_AdministrativeServiceMember_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_us-gaap_AdministrativeServiceMember_373" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srt_AffiliatedEntityMember_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_srt_AffiliatedEntityMember_374" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_SponsorMember_615" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_BcmMember" xlink:label="loc_blacu_BcmMember_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_BcmMember_617" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JunChulWhangMember" xlink:label="loc_blacu_JunChulWhangMember_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_JunChulWhangMember_1214" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JoshPanMember" xlink:label="loc_blacu_JoshPanMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_372" xlink:to="loc_blacu_JoshPanMember_1215" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_DebtInstrumentAxis_375" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_375" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_376" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PromissoryNotesMember" xlink:label="loc_blacu_PromissoryNotesMember_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_blacu_PromissoryNotesMember_377" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalLoansMember" xlink:label="loc_blacu_WorkingCapitalLoansMember_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_blacu_WorkingCapitalLoansMember_378" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_376" xlink:to="loc_us-gaap_UnsecuredDebtMember_616" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_us-gaap_StatementClassOfStockAxis_379" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FounderSharesMember" xlink:label="loc_blacu_FounderSharesMember_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_blacu_FounderSharesMember_381" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_us-gaap_PrivatePlacementMember_382" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_380" xlink:to="loc_us-gaap_IPOMember_383" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems" xlink:label="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsTable_370" xlink:to="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockSharesIssued_385" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockValue_386" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_387" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_388" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_390" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SharesOutstandingHoldingTermAfterBusinessCombination" xlink:label="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_SharesOutstandingHoldingTermAfterBusinessCombination_391" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_SharePrice_392" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_393" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_394" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_395" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_CommonUnitIssued_396" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfSharesIssuedPerUnit" xlink:label="loc_blacu_NumberOfSharesIssuedPerUnit_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfSharesIssuedPerUnit_397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_blacu_NumberOfWarrantsIssuedPerUnit_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfWarrantsIssuedPerUnit_398" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_399" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfRightsIssuedPerUnit" xlink:label="loc_blacu_NumberOfRightsIssuedPerUnit_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_NumberOfRightsIssuedPerUnit_400" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_401" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_402" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_403" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_404" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:label="loc_us-gaap_ShorttermDebtAverageOutstandingAmount_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_ShorttermDebtAverageOutstandingAmount_405" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_407" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MonthlyAdministrativeFeesExpense" xlink:label="loc_blacu_MonthlyAdministrativeFeesExpense_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_blacu_MonthlyAdministrativeFeesExpense_408" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_409" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems_384" xlink:to="loc_us-gaap_RepaymentsOfDebt_411" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMITMENTSCONTINGENCIESDetailsTable" xlink:label="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_413" xlink:to="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_415" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingAgreementMember" xlink:label="loc_blacu_UnderwritingAgreementMember_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_416" xlink:to="loc_blacu_UnderwritingAgreementMember_417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418" xlink:to="loc_us-gaap_RelatedPartyDomain_419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_419" xlink:to="loc_blacu_SponsorMember_420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_618" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_618" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_621" xlink:to="loc_us-gaap_IPOMember_655" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_us-gaap_StatementClassOfStockAxis_623" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_623" xlink:to="loc_us-gaap_ClassOfStockDomain_624" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_CommitmentsContingenciesLineItems" xlink:label="loc_blacu_CommitmentsContingenciesLineItems_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMITMENTSCONTINGENCIESDetailsTable_414" xlink:to="loc_blacu_CommitmentsContingenciesLineItems_421" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities_422" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_423" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingCashDiscountPerUnit" xlink:label="loc_blacu_UnderwritingCashDiscountPerUnit_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnderwritingCashDiscountPerUnit_424" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscount" xlink:label="loc_blacu_AggregateUnderwriterCashDiscount_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_AggregateUnderwriterCashDiscount_425" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering" xlink:label="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering_426" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnderwritingExpensePricePerShare" xlink:label="loc_blacu_UnderwritingExpensePricePerShare_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_UnderwritingExpensePricePerShare_427" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_428" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_CommonStockSharesIssued_429" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EffectiveExciseTaxRate" xlink:label="loc_blacu_EffectiveExciseTaxRate_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_blacu_EffectiveExciseTaxRate_626" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_658" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_CommitmentsContingenciesLineItems_421" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1220" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract" xlink:label="loc_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract_275" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract_275" xlink:to="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" xlink:to="loc_us-gaap_StatementClassOfStockAxis_277" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_277" xlink:to="loc_us-gaap_ClassOfStockDomain_628" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_628" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_629" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems" xlink:label="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable_276" xlink:to="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_280" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_281" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_DeferredOfferingCosts_282" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders" xlink:label="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders_627" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AccretionForCommonStockToRedemptionValue" xlink:label="loc_blacu_AccretionForCommonStockToRedemptionValue_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_blacu_AccretionForCommonStockToRedemptionValue_283" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems_279" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1238" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_431" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_STOCKHOLDERSDEFICITDetailsTable" xlink:label="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_431" xlink:to="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_433" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_433" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_434" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SubjectToForfeitureMember" xlink:label="loc_blacu_SubjectToForfeitureMember_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_434" xlink:to="loc_blacu_SubjectToForfeitureMember_435" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoLongerSubjectToForfeitureMember" xlink:label="loc_blacu_NoLongerSubjectToForfeitureMember_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_434" xlink:to="loc_blacu_NoLongerSubjectToForfeitureMember_436" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_437" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_437" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_438" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_438" xlink:to="loc_us-gaap_IPOMember_439" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_PublicWarrantsMember" xlink:label="loc_blacu_PublicWarrantsMember_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_438" xlink:to="loc_blacu_PublicWarrantsMember_440" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_StatementClassOfStockAxis_441" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FounderSharesMember" xlink:label="loc_blacu_FounderSharesMember_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_blacu_FounderSharesMember_443" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_445" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_EquityParticipationMember" xlink:label="loc_blacu_EquityParticipationMember_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_blacu_EquityParticipationMember_446" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_442" xlink:to="loc_us-gaap_PrivatePlacementMember_677" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_447" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_447" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" xlink:to="loc_us-gaap_PrivatePlacementMember_449" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_962" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_962" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1226" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1226" xlink:to="loc_us-gaap_SubsequentEventMember_1227" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_StockholdersDeficitLineItems" xlink:label="loc_blacu_StockholdersDeficitLineItems_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_STOCKHOLDERSDEFICITDetailsTable_432" xlink:to="loc_blacu_StockholdersDeficitLineItems_450" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_451" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_452" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_453" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_PreferredStockSharesIssued_454" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_455" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_456" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesIssued_457" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_459" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_460" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_CommonStockVotingRights_461" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_462" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_463" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination" xlink:label="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination_464" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_465" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_466" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NoticePeriodForWarrantRedemption" xlink:label="loc_blacu_NoticePeriodForWarrantRedemption_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_NoticePeriodForWarrantRedemption_467" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_blacu_WarrantRedemptionConditionMinimumSharePrice_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantRedemptionConditionMinimumSharePrice_468" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_469" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_470" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds" xlink:label="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds_471" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WarrantExercisePriceAdjustmentPercentage" xlink:label="loc_blacu_WarrantExercisePriceAdjustmentPercentage_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_WarrantExercisePriceAdjustmentPercentage_472" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_RedemptionTriggerPriceAdjustmentPercentage" xlink:label="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_RedemptionTriggerPriceAdjustmentPercentage_473" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_StockholdersDeficitLineItems_450" xlink:to="loc_blacu_UnitsIssuedDuringPeriodSharesNewIssues_474" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails">
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_ScheduleOfFairValueOfAssetsAbstract" xlink:label="loc_blacu_ScheduleOfFairValueOfAssetsAbstract_286" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_ScheduleOfFairValueOfAssetsAbstract_286" xlink:to="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_288" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_291" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_292" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems" xlink:label="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable_287" xlink:to="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems_293" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_294" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_631" xlink:to="loc_us-gaap_SubsequentEventTable_633" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_DebtInstrumentAxis_635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JcwPromissoryNoteMember" xlink:label="loc_blacu_JcwPromissoryNoteMember_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_JcwPromissoryNoteMember_648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_AprilSponsorNoteMember" xlink:label="loc_blacu_AprilSponsorNoteMember_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_AprilSponsorNoteMember_1176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember" xlink:label="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_636" xlink:to="loc_blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember_1222" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_645" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_645" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_646" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_646" xlink:to="loc_us-gaap_SubsequentEventMember_647" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_649" xlink:to="loc_us-gaap_RelatedPartyDomain_650" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_JoshPanMember" xlink:label="loc_blacu_JoshPanMember_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_650" xlink:to="loc_blacu_JoshPanMember_651" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_SponsorMember" xlink:label="loc_blacu_SponsorMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_650" xlink:to="loc_blacu_SponsorMember_652" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_633" xlink:to="loc_us-gaap_SubsequentEventLineItems_634" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_638" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_639" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_AssetsHeldInTrust_640" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_641" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_642" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_WorkingCapitalFundAndOtherExpenses" xlink:label="loc_blacu_WorkingCapitalFundAndOtherExpenses_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_blacu_WorkingCapitalFundAndOtherExpenses_643" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_InterestIncomeOther_644" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1210" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_1223" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="blacu-20240331.xsd#blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled" xlink:label="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_634" xlink:to="loc_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled_1224" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g476668g00d20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00d20.jpg
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MD;0S-%-6@H23!PA$1F-R<Z&QPR22HK)#8F2#A:/!_\0 %P$! 0$!
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M .-H!VD.QL*Q[A14UQI'TU;$V6!^,M/$0<@@C:"#@@C:",A2&F[6;O7,DO%
M.![2!51CS@X;(/."'>9QVJ^IXOHI]LO5ON3W1T=4QT[!E\#P62L_O1NPYOM
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M;/FM).PEN?LQ7>\;*@NL]">&.-X=52#D+QEL?[)<>1S2J]!1T]OI(Z:BA9#
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MQ:17DM*1-ZUK?^=QU%<.-E;52U##^P]Q;_DJU+304D#8:6&."%NQL<;0UH]
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M]VFZ"(G1B<Y.ZCH?Y8]VFZ"F:2_RB:+7"Q5M'1W3=*F=FYQL['E&LXG &2W
M1$CX,8.<O1UYUH[_ "AZ+VVU,HJVZ;E4P22,D9V/*[5(D=LR&X1%Q^+",[B6
MLII1[J.A_ECW:;H)W4=#_+'NTW01%VZ,6><G=1T/\L>[3=!.ZCH?Y8]VFZ"(
MG1B<Y.ZCH?Y8]VFZ"=U'0_RQ[M-T$1.C$YR=U'0_RQ[M-T$[J.A_ECW:;H(B
M=&)SD[J.A_ECW:;H+R?^7G3.P7KM'VLK]WW'=]?Y&1N,[GCYS1R%$6L/AQQF
&TRSF8?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g476668g00m05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00m05.jpg
M_]C_X1;H17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP-CHR-2 Q
M-SHU-#HQ,P!R<C,Y,3,S-@       Z !  ,    !__\  * "  0    !   "
MEJ #  0    !   !^P         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MGN'_ !/:QJT[_@DKQ#6W;9U#%M=).]USFF#]%NVMS6^U2]!G_<S#_P#8A_\
MY-"^Q]%K:'_M'):VL%P/Z> /IO\ ['M5HNP.?MKM?"A\?+V*S8[_ ((OQ_!%
MZ#/^YF'_ .Q#_P#R:7H,_P"YF'_[$/\ _)HF_I__ '-?_P"P[_\ R"6_I_\
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M[TMNOK8K7TDAE7TFU.]>BW=N_P""LM]6W^;>KGIT?NX__L#9_P"324D]*_\
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M !+_ %WUDG;[X9]GNV_I/Y:B[)^L)+VLP<9I !;8[)<6DQ.W:W&:_P"G[/\
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MI]2OZ.[\[=_.?X/_ *VDI__9_^T?!E!H;W1O<VAO<" S+C  .$))300$
M  !2' %:  ,;)4<< 5H  QLE1QP"   "   < E  "')R,SDQ,S,V' (% "E-
M:6-R;W-O9G0@5V]R9" M($9A:7)N97-S($]P:6YI;VX@06YN97@@2#A"24T$
M)0      $)#J</TJBI==FYPIUB_!1F4X0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M<L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 !
M 2P    !  $X0DE-!"8       X             /X   #A"24T#\@
M"@  ________   X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M       !^P   I8    & &< ,  P &T ,  U     0
M       !              *6   !^P                     !
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M;&]N9P   ?L     4F=H=&QO;F<   *6     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    %.$))300,     !6V     0   *
M  ![   !X   YJ   !6: !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" ![ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M?^30WU]/MMW9W5"ZQH::Q7391 !<Z7;7?I?=_83L67F)3 R888X=91R>X?\
M$]K&K3O^"2O$-;=MG4,6UTD[W7.:8/T6[:W-;[5+T&?]S,/_ -B'_P#DT+['
MT6MH?^T<EK:P7 _IX ^F_P#L>U6B[ Y^VNU\*'Q\O8K-CO\ @B_'\$7H,_[F
M8?\ [$/_ /)I>@S_ +F8?_L0_P#\FB;^G_\ <U__ +#O_P#();^G_P#<U_\
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MMBM?22&5?2;4[UZ+=V[_ (*RWU;?YMZN>G1^[C_^P-G_ )-)23TK_P#0W_\
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M$>/T]K/;_64*>J9-MK&#$L:UP!>^&D5DASMMC&6^I^9MWUM>Q)+II*OZUO\
MK6]0PLN_(LR&V4/I92_978\;?4$ NL8P^[T]WL_EI(?_TNV'5;\<9-;;L.MN
M.ZUQ%SWM> 7V"MUC-OT/4V_I&*W3D=9O8;L=V'=CO$T/#K/<-S=I=#7;/T?J
M?1W^]/B8>0_=<,VYE;WV?H *MH&^P#TW.J=:W][^<4V].S0&_P"4KS'/MIU$
M_1_F?^G_ #B25 ]>$2W$=!&Z'6"1[MSA['[7?S?M4,>S*KS,BSJ'HL+*&NW5
M%Q;M#KB7/]0-4_V;ER#^TLC0RX15!]SG_P"A]K=K_2]G_GQ% !ZG8#J#0R1_
M;M24XN7UC,LQ7TONPWFVEQ=73ZI>X%KM_I;]K6NV?1W_ .C5ZKJ69<]M5-V%
M9<X M:'O]T#])#=OM3]1P,AN)E6_;;M@98\4Q6&Q#G>D[]%O]/9^B^EO5G]H
M.W1]BR.8G:R->_\ .)*;&.<DL/VEK&OW&/3)(+?S3[@WW(JH_M-VPO.'D@-B
M1L!.IV^UK7[G)?M-_N_4LGV@Q+6ZP=OM_2?G?FI(9YWTL7_CV_D>K:S[KS?]
MG)JLIVY#0!8 "1M<=S=I<M!)2ES?5&TGJESKFU.'Z,#U;',.@:[V;3L_[<;]
M-=(N=Z@;1U>XU^L-&2:JZ[!JS\_U_P [^JDD)\7J%UV2_'?8'. #JF46UFP@
M_I9?5;M_[3V8S]]?[ZNQD?NY7^=1_P"3630;#EM%A?Z88=+L=C:OH5$Q?5^D
MQW[OYRG\^_UO\'L5V<;QQ?O<DILQD?NY7^=1_P"32C(_=RO\ZC_R:K?JWCB_
M>Y*<;QQ?O<DIH]2#2QAO:S0Y);]L>T1]/?Z?H.^CM_I'_!?S*N?5T5@9'I"M
MK/9I226\'][W;_\ J_YQ5+G$ &AT&;Y^S-W&9=Z>Y]CAL?N_H_[]BN] WS?Z
MAL+HKUN:UKXAW^B]FS_SA)71UTDDDD/_T^L^QLR\G(JJ9B79!?D.+'6W"P#<
M:IL96=K?YS])M72X]?I45UAH;L:&[020($0'.]SEFXW4!275?8\A[O5L;ZS*
MP6&;/I>IN^A[_P#H+6225*JW_E2S_B&?]7:K2IEVSJ-SX+MN.PPT23#K=&A)
M#B=<RJLBYS'V83O0%C:0;7B\'Z%FQC?T?J^I7L]__%_X9=+76RJMM58AC &M
M', :#E9.9GMMP\AGV+(J]2BPFQ]8:ULL<_\ 2.W?O>W^NMA))4DDDDAJYWTL
M7_CV_D>K2J9WTL7_ (]OY'JVDI2Q<ZOHEF47969Z5KR *G/:P%S2ZENQCV^]
MV^M[%M+FNKWV5]3O]^T!C=A-;;6@[-T[7-=8W:X;ME;_ 'I)"1KOJ[ZM)9U2
M+0X"G;<R2=[]C W;^E8Z_P!39]-6J^J]+L!+.LM<&C<8?1QM]7</T7N_1^]9
M#;7 ^IZXD!K6[JFG0^_2MM88_P"A_.;/T7T%)N39+BY[-CF@,BJL.8[VV/\
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M$AKF^DZ-[7_X/]Y2/0JBT,^T7;1]%H= '(]O[OTEJ))*MJ-P\AK0UN98&M$
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M['-(8_\ :&3[7$>U_P#-_FN6Y6'-8UKCN<  X^)\4D-!]W7F/AF+C6L $O\
M7?62=OOAGV>[;^D_EJ+LGZPDO:S!QFD %MCLEQ:3$[=K<9K_ *?L_P"FJYZ?
MU 66E]/K[K;'ML^W7U^QSW/J;Z+&;*_3K<VO8Q"R.F]7L:!C,&,X&2XYE]LB
M/H[7AGYR277P[,]X?]MHKH(/Z/TK#9(/[VZJG;M5E<_1TSJ["[[0P9 /T ,R
M^O;S/T&N]3\U%'3^H&RLLI] MLK<ZS[=?9#6O:^P>D]FRS?6US-CTD/_U?54
MDDDE*22224I))))2DDDDE*22224I9.5U#+9GOQZY%3-@W-J=9&YN^3M/O]WY
MC%K+'R[.C?M)C;_5KS;B PM;:."ZAC][&^G6W\W>DI'DWY-UC,<Y5];7->_?
M5BW,>"W96!WW,_3._-_T::_,S/2%9LM#7N967_9[0^'':Y[7,]WJ+1/3*"\/
M-E^]H+0[U7R 8+A]+\[8U1/2,0D$FV6D.!]1\@CZ)^DDKLT&Y&5B5/;7=?:!
M+M]V/:XZ-;[1O]RVZW%S&N/) )^:J.Z5C.G<ZTSJ2;'\QMGZ7[JN- : T: "
M $E:N2>H9CLNVH%S*F.< ]M#[/HD-#=M?O=_QB%==DW7?TF]II#7-%>+<T.)
M<7%MC?HN;^AV_P#;BG6>CW=2=56;Z\VP;GB+:R-S6W;76%K6LW-_,W_F?\&K
MIZ9022;+B7"'?I7Z@3I]+^4DISK\G+O<VBRRZICB3ZE>/<UWM\/2._\ K*=.
M7ET"NL66/;ZC6S=39)#[-KMUK_H?2_L*Z.DXH=O:ZT.$^X6O!UY_.2'2<,6-
ML.]SFN#@7/<=0=X[_O(:HUTU_E]C_];U5))))2DDDDE*22224I))))2DDDDE
M*65D]3RJ\]^,S:*V%@W>D^PC<W=N=LMKW>[\QC5JK!SO1_;8G;O]D[?5]7Z+
M_P"9V_HMW]1)3+)RLF^RNC[6:@6O?ZE6->QTMVU[=;'[V?IO^H37]0R_2;3Z
MNCW-J+QCW-> 3Z?J-<+MV]&=]G^TU_TN=CXGUMT35.W\S9^__85>S[/ZE<^M
M_.]_7W3N,;-O^$_?_,WI*[,F9>3B4V"O(=?$NW746N.C>Q=:SV^SZ*VV.+F-
M<>2 ?O6'E_9]MD^MR)]7UOW3S'Y_[FQ;E<>FV.-HXXX\TE:]7*/4\LY5M(+6
M5L<YH?Z%EGT2 &_H[0Y_]?9L0[<C(OO .6ZOT@UP]/&O:';G;BVQGJ._T/\
MY\0V^A^V,CQ]\^CZWK3-?]CTOZG_  :LM]#UG_TR=K9_GIY?_9VI):S^H9F7
MLIML..'C<7UU6[@0T/V35<[][_B[%+'ZCFU>E5)M8; US[:G!T.>T?3=;_PG
M^C_1('3_ +-ZU<;I]$1]F]?=]&J=L^W[-_HO^M*+/LWVFB-O\\/I^ONGU*_H
M[OSMW\Y_@_\ K:2G_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M 0,1 001 /_=  0 4__$ :(    & @,!              <(!@4$"0,* @$
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MORQ1XXWS'QP228LL*-A.R5>5D0R.L:G<@9RJ*6(%[ 7]PS\;_@6J>5J'YQ)
M9&A%4^2^/RT33K&)6IA6M0"D-6D+!VB#^01G45T\^[?ZZTU ?H+2I\O&FU4X
M5T_3:J5QJI2N*UZJ-VVXBHL[DCS(9" ?0D"@)\@34\>N?B^6FK3_ !7XYZ@
MQ7^!]EZM)) -O[QWL2/? _'/X##ZQ?-8<@<Y[XZCDBX'_ 7ZD>]?ZZTYX;;;
M?\Y9_P#MEZ]^]]MI7Z2XI_IH^N_!\MO^=I\=/_/%V7_]D?OQ^.?P%%[Q?-86
M(!OGOCKP3] ?\EX)M[]_KK3G_EFVW_.6?_MEZ]^]]M'&TN/]ZCZ]X/EM_P [
M3XZ?^>+LO_[(_?C\<_@*"08_FL"HNP_CWQU](_)/^2\ 7]^_UUI\']VVV?\
MAL__ &R]>_>VVUI])<5_TT?7O!\MO^=I\=/_ #Q=E_\ V1^\L'QK^!]7/3TE
M'C_G'7UE9,E/1T6.R/0&1KZVHEN8Z>BH*''U%963R!3I2)'8@?3VY%[HW4[F
M.+;+8L 2?U9Q0#)))M0  .)) '6OWOMM ?I+C) '='DDT 'J2< <2<=8I_\
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M1LE5*X$4#*=; "_MJW]VC=V:[C;6MD^W%$<2^/,(RDA C8.UL%HY90@K5BP
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M_.T^.G_GB[+_ /LC]^_V7#X$?\</FQ_Y_/CO_P#4GOW^NQ+_ -&^U_YRS_\
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M_'#YL?\ G\^._P#]2>_?Z[$O_1OM?^<L_P#VR]>_>VW?\HEQ_O4?7O!\MO\
MG:?'3_SQ=E__ &1^_?[+A\"/^.'S8_\ /Y\=_P#ZD]^_UV)?^C?:_P#.6?\
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M_/CO_P#4GOW^NQ+_ -&^U_YRS_\ ;+U[][;=_P HEQ_O4?7O!\MO^=I\=/\
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M_P#VR]>_>VW?\HEQ_O4?7O!\MO\ G:?'3_SQ=E__ &1^_?[+A\"/^.'S8_\
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M+_T;[7_G+/\ ]LO7OWMMW_*)<?[U'U[P?+;_ )VGQT_\\79?_P!D?OW^RX?
MC_CA\V/_ #^?'?\ ^I/?O]=B7_HWVO\ SEG_ .V7KW[VV[_E$N/]ZCZ]X/EM
M_P [3XZ?^>+LO_[(_?O]EP^!'_'#YL?^?SX[_P#U)[]_KL2_]&^U_P"<L_\
MVR]>_>VW?\HEQ_O4?7O!\MO^=I\=/_/%V7_]D?OW^RX? C_CA\V/_/Y\=_\
MZD]^_P!=B7_HWVO_ #EG_P"V7KW[VV[_ )1+C_>H^O>#Y;?\[3XZ?^>+LO\
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M /U)[]_KL2_]&^U_YRS_ /;+U[][;=_RB7'^]1]>\'RV_P"=I\=/_/%V7_\
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M]@/G>586V*1Q(8O%N%<1C4YBDL[B*4*I!!)CD9<C%:U''HJYCMY+OEK<H(9
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M.B.Q=TU&^>WNLQAX:7/0;.V6N&JMY[4Q,M!C^R-W87L9Z_[/%8DYBIJ:.1I
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MWOW[OO\ _E!F_P!X;_-U[Q8O]^+^T=>]^_CF$_YW.)_\^-'_ -?O?OW??_\
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MN<3_ .?&C_Z_>_?N^_\ ^4&;_>&_S=>\6+_?B_M'7O?OXYA/^=SB?_/C1_\
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M# 4$4-/^:4?_ $!UP_V5?I'Z?W=W)];_ /,S^U/K_P"AK[]_PYO\UO\ G[&
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M:U[_ .EC W'].E>AA_\ ,QY][_J/R@ 5_JY:4/\ PM?\W5OJ&_WU#_SBC_Z
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M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)
M_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\
M]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^
M@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?
M_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOOW_#FWS6_
MY^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[ZA_]]0_\XH_^@.O?[*QTE_SS
MNX__ $9W:?\ ]FOOW_#FWS6_Y^OM_P#]$GT)_P#:P]^_J-R?_P!,Y:?\XQU[
MZA_]]0_\XH_^@.O?[*QTE_SSNX__ $9W:?\ ]FOO+!_,]^;=+/!54_;6 BJ*
M::*HIY5Z3Z#UPSP2)-!-&3U>=,L,T:LK#E6 (Y'OQY%Y/-/^0Y:<:_ /+K?U
M+_[ZA_YQ1_\ 0'6*H^*/1E53U-)4;9W%+35E-44=5"W9W:FB>EJX7@J8' WJ
M"8YH9&5A^03[(_N/<.:W=N'/;KW)D)\ON+<^9RFX<_EJHH:K*9O-5T^2RN1J
M3&J1FHK:ZIDE?2JC4QL![%8    QTRS,[,[&K$U/VGH>L1BL=@<5C,'AZ2''
MXG#8^BQ6+H*<%:>AQV.IHZ.AI(%)8K#34T*HH)-E4>V7W[JO3A[][]U[KWOW
MOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][
M_]+2V^-WP1^6WR]Q&Z,]\;NE=P]JXG9F3QV&W/683)[8H5Q.3RU)5U^/I)HL
M]G<1/,]11T,LFJ)9$54]1!(NGGNK>U75<3!%]3_(?:?(=*[>QNKM6:WA+ '.
M1_E(ZW,OE5_,$^%WP@JME47RS^177?1-7V-!G:K8]/OJOK:.3<M/MF3%0YZ;
M&K1T-;Y$Q<N;I%E+:;&=;7YL97_AD_\ FF?]X=]@_P#G]Z\_^S+VD_?.U_\
M*='^WI3^Y=S_ .40_M7_ #]%)_X?U_DW?]["?C[_ .?O,_\ UC]^_P"&3_YI
M?_>'?8/_ )_>O/\ [,O?OWSM?_*='^WKW[EW/_E$/[5_S]>_X?U_DW?]["?C
M[_Y^\S_]8_?O^&3_ .:7_P!X=]@_^?WKS_[,O?OWSM?_ "G1_MZ]^Y=S_P"4
M0_M7_/U[_A_7^3=_WL)^/O\ Y^\S_P#6/W[_ (9/_FE_]X=]@_\ G]Z\_P#L
MR]^_?.U_\IT?[>O?N7<_^40_M7_/U[_A_7^3=_WL)^/O_G[S/_UC]^_X9/\
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M^Y=S_P"40_M7_/U[_A_7^3=_WL)^/O\ Y^\S_P#6/W[_ (9/_FE_]X=]@_\
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M4=NO?[,U\>O^?T=;_P#H68C_ .J??O\ 9!/FU_WBGWU_Z++=7_UN]^^LL/\
MHYVG_.>'_H/KWT%Y_P H[=>_V9KX]?\ /Z.M_P#T+,1_]4^_?[()\VO^\4^^
MO_19;J_^MWOWUEA_T<[3_G/#_P!!]>^@O/\ E';KW^S-?'K_ )_1UO\ ^A9B
M/_JGW[_9!/FU_P!XI]]?^BRW5_\ 6[W[ZRP_Z.=I_P YX?\ H/KWT%Y_RCMU
M[_9FOCU_S^CK?_T+,1_]4^_?[()\VO\ O%/OK_T66ZO_ *W>_?66'_1SM/\
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MZZ_YX'97_H*X+_Z@]]_Z1>Q/^?@;Y_\ 0PW%_P#7+W[^J_*W_3+[9_V26_\
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M)46["0+)4NKB>%PZ"-B*Z?B(4-5"2%*#5W.2H4*_FM"AN!X$4$GC1 . :LU
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M/^;KW_#Q6Q_^\ OYM'_IOKM_W[_AMG=W_>6_P!_]*KV7_P!>??O^3M_W2/\
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MWQSG_P!R;_MZZ]_43??^4RQ_YR'_ #=>_P"'BMC_ /> 7\VC_P!-]=O^_?\
M#;.[O^\M_@#_ .E5[+_Z\^_?\G;_ +I'^^.<_P#N3?\ ;UU[^HF^_P#*98_\
MY#_FZ]_P\5L?_O +^;1_Z;Z[?]^_X;9W=_WEO\ ?_2J]E_\ 7GW[_D[?]TC_
M 'QSG_W)O^WKKW]1-]_Y3+'_ )R'_-U[_AXK8_\ W@%_-H_]-]=O^_?\-L[N
M_P"\M_@#_P"E5[+_ .O/OW_)V_[I'^^.<_\ N3?]O77OZB;[_P IEC_SD/\
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MHZ]^Z+_TA_YRIU[_ $F)_P \'V9_Z"%1_P#5/OW\+VK_ ,_W^,O_ *.O'?\
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MR_\ HZ\=_P#6+W[^HG,7_1IN?]YB_P"VCKW[HO\ TA_YRIU[_28G_/!]F?\
MH(5'_P!4^_?PO:O_ #_?XR_^CKQW_P!8O?OZB<Q?]&FY_P!YB_[:.O?NB_\
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MJ&DADL9IYO.A>NR6T5Q?W%M(\(EN(6C5"RB"V@DN9Q9Q]Q BEN;J2:<T&O\
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M+*!8K9*Z57@*DD_M)))XDFIZO?7UWN5U)>WTQDN6"@L0!A%"**   !5"B@X
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M]L?43?\ *$_[4_Z"Z4?2P?\ 1PB_9)_T!UZY_H?]X_XK[Y?Z-]E_\_PZ]_\
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M#\I/^@.O7/\ 0_[Q_P 5]]OUGLU$=SWGUNP16<K'C.R))&"@L5C1=BW=VM8
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MB74S$#CDKD@8R0,T%:#CTN&UVA4,)Y-)756BT(]0:Y'V=)S[WYA_\\U\:O\
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M/]_R?[R/\_7OO?F'_P \U\:O_0W[1_\ M?>^_P#93?A7_P _"^6W_HM.FO\
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M,.6$0JD2)GDC4N/WE)_RM4__ %/B_P"CO9GTQ4>O0M>_?>4G_*U3_P#4^/\
MZ.]^Z]4>O7O?OO*3_E:I_P#J?'_T=[]UZH]>O>_?>4G_ "M4_P#U/C_Z.]^Z
M]4>O7O?OO*3_ )6J?_J?'_T=[]UZH]>O>_?>4G_*U3_]3X_^CO?NO5'KU[W[
M[RD_Y6J?_J?'_P!'>_=>J/7KWOWWE)_RM4__ %/C_P"CO?NO5'KU[W[[RD_Y
M6J?_ *GQ_P#1WOW7JCUZ][]]Y2?\K5/_ -3X_P#H[W[KU1Z]>]Q,A64G\/K_
M /*J?_@%5_[OB_Y5Y/\ :O?NM$BASU[V7+^9&0WR8C8$,#T9\9B&!# @_'_K
MGD$7!!]NV_\ 9_F?\/1)NW^YK?Z1?^.CHN_Q@#+UOG@P(([L^17# @@?Z>>Q
M2.#R./9"O;_19T8CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]F;R7RK[#ROQ6VW\0ZC$[)CZXVSV5DNSJ/.T^VX(=^5
M.8R5)+3-C*_<PE,E3A*=ZF22.(QA@S :M*@>T^YVL>[;MR]O%TS"XVVPEM8@
MN%*2S&9G<?B<$Z :@::5!8:NEEM>O:[;N&VQH#%<SB5BU6*D+$E(ZDB,$1)J
MT %_Q$@"B3I-F8>CWEEM]0R94YO,X;'X*KBER]?-ATHL;-+/!)1X22=L;1UT
MK2VFGCC669416)"BUN/0WR1^+L'Q*^/71.>[!Z^V+O' ["AW]N3=LE#445=B
M-X[:^9&+W3E=G5];1;*J<I@>U<ST_"<AMO=^,KSD<?#3-0"2)*BR$W,D%S)S
MA<;S:>(]A >7T"HK:GC_ '=?P7;VKK(O@/:WD\+;C$R^%N-L663Q&C3JVPW!
ML-FN+><J9KR?=U8-W: 4L6LVE2CK-%)X,\=N&H;.X9;A!354&,EL#>'^E#<.
M]:=9\CB\M6UN)APU5+3FFIZ.3K2CQE%E-39)(LEMR?/4\L%7B:N!HQ52K5HN
MI"[SNH]V?RUMO9S%;V[![$QN$VIV[L7O#JKO3K[;.X=][NWOV#BZ[LK;V8VI
MW-N;?DE&F;VF-[Y*.E.3V<L$.4AQ6*K:JCKM=7#H*[1>:!ROO'*FV1VUMN4W
M+VS2V[W$9^AL=SAN+<_2,D1!O(XUCENI9XR@MBZVKQSK&I*O=KVT;>+O>'\:
M=[?>MW+2QM6XN[.XM[H5C2;LCEC5TMK9W,J73S"9F5A+3EO*C[DK#G:?;=#A
M:N7;F]MI;BVC6UE+)1I+MYL57#=.V*:FEG6@?-8FCUPXW)D-1RUE;"*BGTT\
MQ<IOQDWW\?MD/\A^F.WMT]3IUUV=\N/BUM[>5;LVN['H=O;K^/6V.VM[93M.
M386YL=/'N>EZSI,538VI45J2Y)J:6GE\4E7$K1&:0'==B]N[RXM9UW&T3=;I
MX[@1^*MU^X9X]O%X(_TI&%^X5%B*QK.S=RPNU6-S1+6_YVDVF]53-MS06K15
M"#Q;RV:L2R$NK" ,665F!$>B75W:A%W9B,SE!C<_A1E*3-8O9V\%PT<L>&E:
M@W#F\?BHL94U=%6K-32Y>C,,J):3[<!I4DU(X]PZ=O@MF.D>V]UC8.QZK?U1
MV-VM1-MVG[DS'768Z_V**W;D/3F?Z2V]N##;@JNU(L=B/XB]915M;%55]2H%
M8R@Q/[WMGURVGMK;;O>7*R36]BVYW A61X[GZ\-?(T$91%CEL*1*4;PX&=GB
M?7%I*Z[^A:[YV-C;VA2&>1+!&DD1);9+)UBD:0^(WC/>*LKD*"P 0(L<ITQZ
MZ3?L>\,3BJ:N:+ Q4V)JUR!V[+DES"TE+F(]Q8K.Y6+)4E'M^KR-4U!+33QT
M<WC6.555O):.!\K\-\%Z+O/H?"=#X3:%)T55;YQK[F[$P_<6X=W9;=?4N0S6
MTE0=D[$J]M8O.]3;QV[C/XDM6JU%755@E+6'AC+O<HR[P^^W'];5$<4<K++"
MJA[<TN[IHY;>Y0@R(]F;:-D !5X]9(>5P"OF$6R\JG]P*6W=K96CD9@)1+]'
M&9$E@8%0?K#(R,6T!?TP&15;J)L:?LNMVKG:O=54D>ZGQL=-2XJ';7\'I<3N
M2CQ+0Y*;&5E=G,Q'G\-D<S::DE?PQK%92MB0HWX;&?RVJ#:GR2[,_CO6;[DH
M.W>T:OI#KR&HWQ2G8^W]@=D["CZ4I]L8_*G)9GM_!=F[!.7JLA492IIH*=J8
MQ5,8GGC94>R3[_;;;[?3WVL[V5VF>[9E4CQ9MQ9-VMY8T'A11VECHGB/?K+F
M.)I'B96:1$OYN9K>ZMXH[&.SN+>&CE3,1M<S6MXC:M2RON*1PRQKIIK\4@0,
MJ(G<M4]O29G8FUZ6FK1C'HJ*FWMNE:>C$V7I:W8^ZX,Q7"OI*RCH-HY?$[RA
MQDD2TU+6--YCXD$(<+-[;?X!YVM^;>^FQ_2W9/9V2[]["W!L#$;0[0S/2_7T
MW0NYMBU>6Z[W)TS3R[4RM-DM\8C?=1')F=NO%1U)FC-(JQTSN4)HK7F';^5N
M3=NLFN([E;:[AO)9--S-%?K>6XMG6/Q 9K!K7ZD1N'_$#+0I%T+(9-HN]\O[
MK<(H7@>VVYX$5Q#&R&"07T<K@,8KM)! #V%"?$:+6"2>.VJSLZ*?K3'2IFZ'
M;,NRMMTN3JMQX0Y_>2;MPU9HW)!O+)4>7HL=219C!TXCBK5@G5ZR1YA]$1Z-
MVM<6_H/]O[D$FO0,Z,'[Z]ZZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]ONV=PUNU
M<[CMP8^*CGJ\;*\D=/D*<5=#4)+#+33T]73ED\L$]/,R, RM8\$&Q]MRQB5&
MC8D ^G'IR*5H9%D2FH>O#KWL2MG=X;CZ[W)C=Y; P>V=E[OPIJ#AMS[<7<=!
MF<4U715&-JWH:H;D?Q25./JY87;22T<C?DW]IYK*.YMKJRN7:2TGC:.1&H5>
M-P5=&%,JZDJPX%21Y]6DD@F$8EL(&".CK52:/&P>-@"WQ(ZJZGR90?+J+645
M'D:>2CR%)35U)*8VEI:R"*IIY##*D\1>&97C<Q31JZW'I901R![37]_**R#_
M $=]>V1M0O0;A9B?^;CMN9GE'_!RWMWP&_Y2)/VC_!3ITW08L6M8B2:DT;C_
M +UU*]\AO^C%_P#C'77?J.HWQ>=//^ .XR%'^ L/>OIS_P I$G[1_FZU]2O_
M "B1?L;_ *"Z][,U!@^LW^+U=VH\_P <4[5@[!I(*?KI]R;D7?<W7KTCXRID
MBV2*LXZ2K3<92H,C5@JA0W<+X_=;\P68V*VB:[EO+F2;Q60*T44813#XK4!1
MBZ3 A=1[HM= PZ>VV3ZH;[)<06T<421> '+*[N#(;C2 3J4HT CU:1J64+5N
MDY_&Y_[U';_\'SWVPPO\2_CG\/@_NV:C[KP_PX9+[O[K^*B+U^+P>+Q\^35Z
M?99_](%)_P ^YZZ_\]6;_P#LB]V^G/\ RD2?M'^;IGZE?^42+]C?]!=*/W[_
M $@4G_/NNN?_ #U9O_[(O?OIS_RD2?M'^;KWU*_\HD7[&_Z"Z][]_I I/^?=
M=<_^>K-__9%[]].?^4B3]H_S=>^I7_E$B_8W_077O?O](%)_S[KKG_SU9O\
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M-1!2CY$=U&HGIU"EIX81V)Y)(0&!+*"O(Y]H;_AR+Y,_TZ2_])NZ'_\ M?\
MM_Z>/^E^T_Y^F/WM>_Q+_O*_YNIG^RQ=9_\ .T[?_P#1_P#>/_VP??O^'(OD
MS_3I+_TF[H?_ .U_[]]/'_2_:?\ /U[][7O\2_[RO^;KW^RQ=9_\[3M__P!'
M_P!X_P#VP??O^'(ODS_3I+_TF[H?_P"U_P"_?3Q_TOVG_/U[][7O\2_[RO\
MFZ]_LL76?_.T[?\ _1_]X_\ VP??O^'(ODS_ $Z2_P#2;NA__M?^_?3Q_P!+
M]I_S]>_>U[_$O^\K_FZ]_LL76?\ SM.W_P#T?_>/_P!L'W[_ (<B^3/].DO_
M $F[H?\ ^U_[]]/'_2_:?\_7OWM>_P 2_P"\K_FZ]_LL76?_ #M.W_\ T?\
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MW^^XO^<:?YNO?Z ]H_\ /4]Q?^CO[8_^R_W[_9X.U?\ GW_Q@_\ 24/CW_\
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M_P"<:?YNO?Z ]H_\]3W%_P"CO[8_^R_W[_9X.U?^??\ Q@_])0^/?_VO/?O
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M\1DD\4LC(&8+<A_E39Y-BV9+&60M*]S<SM4*"INKF:Y*'0 A\/Q?#JH"MIU
M"M.G'AV^UAVZPVI)5V^UL[:!!(0S_HP1QL20!74ZLRX%%(%!2G0D[?Q?\%PN
M-QE[M24R)(0YD7S,3+/ID9(V=/,[:254D?@>RT>Q'TUT\>_>_=>Z][][]U[K
MWOWOW7NO>SC=_?\ 9-'P1_\ $7]U_P#P2G:'MI/[2;[1_@'2ZY_W&V__ $C?
M\?;H!^LO^9M?)/\ \/;8'_OG]C>R<^W>D/0\>Q,Z>WEMCK_L?;&[]X[5S&\]
MOX2KFJ:O![<WQE>MMR&<T=1%CLGMW?&%I,A7;<SF#R+Q5E+/]M4Q>6 +)$Z,
MP]J;:YDMA<M;W$L%TT+K'-$VF6%V%!(E:JQI565U961F% :,&Y(Q(8M4<<D8
M=2R2*6210:E&"LK"HX,K JP5L@%2G=VXG(Y[;.<PN(R&-Q>1RF-J:&FKLS@8
MMT8B$U*&.1<IMV:NQD6:Q\T3-'-3FHA\L;$:U//LW>Y/G=5#N+,=X]?=>4>+
MWUDMG4W4]35]I5VW.Z8=W=52]<+U]N9.U#N/8N/J=]=L;XCU3Y/=228^8HPA
M@IH;>0E=A;FWBOX)[>T-K>S/)/#%$8H% GM)[:.UC#DVR0FUK* SFZ>61I**
M\B.HE8O>;;>_43O=V)5[:61]<JRTN%>25B-,H"7'AVZ%%6"..,#655E0AZGA
MK^OZ/8.9W'F::"F>AK5RFPJS+]<UN.RF/R<>4I1M@X',O)M_;M&\2P08OR5$
M"TJ^*1I5)NO<G_,:PFY8)LUN;XW;'BW_ +/R7=]?T1D=DYZ39.PNMAWUMRGV
M_N2+<?7M#@*F+?<NUZJ)\IA9DK\6R9&4FL^[A"Q!5<-="YO=SVW<;B+?;JWE
MM))Y7,Y%G+>75WHA#T\.X1+Z\LTFJT:PRI(L G@60K8+V%9+=;BT4V4$UI<1
M1QTC'U5K:6]L7D-&\2&X-G9RSQT5RT!1)D25QU H.J=Q8-=FX;!=F9X[1P6(
MV]B=SP[FI9-T[\WH=K(JXS(5?8E3E:.MI,EDQ&B9:>6CK)JV)+1-32,TA2.\
M_G[5[VZ2[$Z6S'6%-D,?N# [,VYL+.[AW:^[\SLVBP,6%?<>4SF4W'MRMS^Z
M=T;DS6(.3AKJ2NPWV-34O 8YZ".GHX6=PMXKZV6*,&&;]]RWVM,$0LH6&S6E
M#HA"G6[,QN6FN9IE,\HE1G;;R:PMWLY)'FM1MZ6Z!FRD@8M)+P*&-P0D<(1?
MIHX;>."14219E$.NJ:'=&R\_15-%1T6T*;=4,6'I\9/1PM+N3PJLV-7%9;&X
MJB2FB5XY4JJ+("52K1&GE#RRB%MKL_ =;?$3X]T.Z9*REV]VOUK\\NJ,ADL?
M0')UF*JL_GNJ\QMZMBH/NJ+[B)MT;?HH)_W!XZ>:22SE C$N_P"SVV\6,XD@
M>6_M;FSNK50X1#<6UPC#Q6*L='@-.*!22Y3A\0>&E6Y<FED9;2.6X$FD L8Y
M8)(#IU8JIE5SYD*5!!(/2 V1$\GR#[^*2&,Q8KI"5O2C:T&&WHKQG6K:=2O]
M18\?7V%O5?RDZBV1D^ALS0=?;GVGF?CUUUW#24V2K-XG>])V9O;?6 S@PM-+
MA8=O[678V,BW5N*HE>=*FO"T82-TD==96<X64G,NT<P;-J*;?=;8EE"JZ?$A
M+7'B27$DK=LH"R2GPA&AJ$",#4E#8I91)M46X6TDX7=([J=ED$=5C$9T1II;
M):W@ )D&D&0DM50!FIL;FTJ\W)D<K1Y*@R.0HIL30PXI<9+A:""&%*BFJ*X5
M=:V:GEGB,JR-'!IU: + 'VG^G_F3'U3T9D.I#L3,Y[(V[;CQE6.QZ_%];Y6+
MN#:&,V?E&[+ZH3 U>/[!J=JT^/-7AWDKZ1(*LHTB2+$JES>;%]TMQ;),J(]N
ML#ET\4JJW2W(EMB2OTUR&72LRZBA(D \1%(=V6<;3>[E>D.[3W$$P"MX=6@C
MDC$4] WCVLFNLL)"EE#QZPDK@P,IM1LEN7'9[[C&11T,$$3:L%!+GE-/43U
M3';E^[CJ<9157FT5$ AD$L98!EUM[>-M?-ZFPFWZZFJNL:JKW1A-P;TW3U?E
MZ/L/(T&W]OYKL+8& Z]W,>P-H2X&NH^S*%,?MZ*II(VFQSK)(\%0]32D0A5)
M'.+Z#<;6:-+P1RPL60.GTTNX2;AH5,:95DFEC\4LRE3%*(EG@CE"F2_6>VN+
M*YB)LV^ED4(WAR+/:VBV88R %FB=(XW\''AD2+&ZK/)5PR&&K*O)XZK@KZ."
MB@9#DJ.?$15E36BG9Y*3[+(FIA;%O'*WK/CFU*++XV]7MQWW\\6W#A-RXS:'
M767V?5=AS;TW%V)D*SM;<.Y'JM\;XP&U-MY2NV6),5C:G:6T(\;MI@,5+-D*
MB850BEK7@IZ>)"Z':$M[KEP1S:MJVK<(KJ"-T5I7T7PO3'<7% TJDJD8HJ('
M4W3QO<NTG3K[M++!=M-&IW&[MHH;AQVQ,+>VGMH6A@ TP$?4.\@!8. L*A(A
MI.'%;>FI*JOJ,E6462$[QQ4,4&(BQR4M#"[30QU:K4U,>0KUF=B:@+"+6"QK
MR6553_,7_O75=K4W9?5.9W-MWMG=FY-T9&#!]Q[EVWN?;J9[?/6F^DQ6W]T3
MX3.&.EI*WK:.%_-32)4)5M(R":&)PEMN78+2\Y=W"*<_5[;/XZ&@!EE62^EC
M,Q&657OG)_'5-<3PN[-TFNKOZO<I;QX]-I+ L+1*2 (QMJ;<=#<%8K&LN59&
M/Z,B218ZPUFUV&.CHL'4X[#R4].L%,9<#15^/CT4-10*SXU9*+A8IQ81RQ<(
M%)*$J9F2_F<;YRG]RZR;;FX<=4;*[BR79U-M3 =BMB.M<U25&<W+N3#)G\''
MM.3=V0[#VWE]R.T&YFSOEF$0>:E>H9IC9=EF_P 4,UY&[KMTEO(PA5/U'AF@
M\:W2,K' A2YF#P:'0AM"%$ 7J]W>BXM-ULHE:*">: J 0Q\&&2SD\&X9U+7&
MHV<9,@,3:J&A"A>HD>Q,2F9KLPT-#+/78&'!S5$M'++D6A2.FIYT>>6N?&_8
MU5-0PJT"4<?J4L7(;3[C;D^2O3^8^ N&Z;I=][]H>X/"<?NG;U#MY(*;>,0[
M@W%V)28[>V]:G[D9[K_ _P 7;)4%*DJ5JYR76Z&-;^TFX[)JYHVR_L[!&V^,
M6K*2P5(9+?;WLY9?! %9F1D@MV4E$@\76H9DH8VNY6DUKN\FY>(-RF>[8."7
M<F>2%T5'<DI$X3_' 2'E>.)A7NKU3XG+_P!^ZW)STL9PL>+ABQ]1/5"I6"8Q
MQ1S18RA,H;$U,I5ON9%3141+&OU4^ZPS[%?0>Z77OWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>SC_.'_ )FOL'_Q6+XI?_ ^=>>V
M8?A;_3'_  ]+MP_MH_\ FE'_ ,<'0%_'S_CSMU_^)J[[_P#?R[W]DX]O=(>A
MT]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O9@?B8ZQ_*CXT2.P1(_D#TT[N02$5.QMN,S$ ,2% O]#[;E($4A*DC2<#B
M<<!D9_,?:.E%I_N5;?\ -1?\(Z";OLA>B^Z69E15ZF[&+,X)10-GYDEF"JS%
M0.38$V_'N[[JZ7NOIC/0[)RWQJWW6X/#?).K[(WCNZ/N[8&ZJ7'_ -U][[^K
MSGNC.M:_,86OZ?[%WMC<_38;.93'[@>GJL=2Z_LO(5*(MX==QMA##&I@&W30
M*KEEG!FLY;=X4NUJ\-I<2S-<W5NR2HTXB/PQLDNKK:KDVF]Q16>N\NF"U9QX
M10W-K.9983J62\MUMO"L[E?"DBC>1"7+LQ*!@>U.FLS1X/=:]IX2G7(=-X#;
MN&HH.J][PU>O+;>PLCUF[,PU+446],12BG2?'T-3C(7H97D*S?N,! VUV5\H
M=J?P#$XSX891]J=5X[K2IZ-H*KY0[9?<6 WCUEL_?6T\=E>TMTT=71-VKMC(
MMV'7U+X6*EP<%)XH:>DD@IVJTJ7+]OK9MSW))HX]YE6Z@A;P87MX[.ZLX-O:
M.6U:/P[FZ2UMHO\ '9*223%S*KP>#;PFL=K!"[VJ;?<'9);CZF5/J2+E[A=Q
M;<HW6[H9(X1*WAM;4=&0*X87*+/T]5_9/4^4Q>!H:_NW$R5(R>5J-[5,?2>Z
M$@SV)R^5ILQ/C-J4DE//)L:JIZK'TXBJVFRC:0[R)).T<T)%/D#\=?D]WG/U
M?FD^/.5VSNK9_4^S^MMY5]1W-UWN+"[MKMCT(PN)W-@,)/E<;)L>*MP<$ J\
M<E374[5BR31-$LGA2H2*+==XO()--A<F!DC(9Y(W2WBAEU3,2TJR/%XB!E#Q
M!O#9Y:!RF%O?/M]K:SPAKJ.XO'+J55"EU>37BHL0)5/":=XZJ=,BA&T(P;4*
M^W/D9T;@4S44G8E/50Y+<>8SE(M)U[N_%-1P9>=:R6DK&@P4JY2L6NDF=JME
MB>574,I9"[E[_P!D(^6?_/IV_P#0XZW_ /LP]J?'B_B_D?\ -TQ^[[O_ 'U_
M-?\ /TH_]FIZ'_Y[B3_T$][?_8W[]_LA'RS_ .?3M_Z''6__ -F'OWCQ?Q?R
M/^;KW[ON_P#?7\U_S]>_V:GH?_GN)/\ T$][?_8W[]_LA'RS_P"?3M_Z''6_
M_P!F'OWCQ?Q?R/\ FZ]^[[O_ 'U_-?\ /U[_ &:GH?\ Y[B3_P!!/>W_ -C?
MOW^R$?+/_GT[?^AQUO\ _9A[]X\7\7\C_FZ]^[[O_?7\U_S]>_V:GH?_ )[B
M3_T$][?_ &-^_?[(1\L_^?3M_P"AQUO_ /9A[]X\7\7\C_FZ]^[[O_?7\U_S
M]>_V:GH?_GN)/_03WM_]C?OW^R$?+/\ Y].W_H<=;_\ V8>_>/%_%_(_YNO?
MN^[_ -]?S7_/U[_9J>A_^>XD_P#03WM_]C?OW^R$?+/_ )].W_H<=;__ &8>
M_>/%_%_(_P";KW[ON_\ ?7\U_P _7O\ 9J>A_P#GN)/_ $$][?\ V-^_?[(1
M\L_^?3M_Z''6_P#]F'OWCQ?Q?R/^;KW[ON_]]?S7_/U[_9J>A_\ GN)/_03W
MM_\ 8W[]_LA'RS_Y].W_ *''6_\ ]F'OWCQ?Q?R/^;KW[ON_]]?S7_/U[_9J
M>A_^>XD_]!/>W_V-^_?[(1\L_P#GT[?^AQUO_P#9A[]X\7\7\C_FZ]^[[O\
MWU_-?\_7O]FIZ'_Y[B3_ -!/>W_V-^_?[(1\L_\ GT[?^AQUO_\ 9A[]X\7\
M7\C_ )NO?N^[_P!]?S7_ #]>_P!FIZ'_ .>XD_\ 03WM_P#8W[]_LA'RS_Y]
M.W_H<=;_ /V8>_>/%_%_(_YNO?N^[_WU_-?\_7O]FIZ'_P">XD_]!/>W_P!C
M?OW^R$?+/_GT[?\ H<=;_P#V8>_>/%_%_(_YNO?N^[_WU_-?\_7O]FIZ'_Y[
MB3_T$][?_8W[]_LA'RS_ .?3M_Z''6__ -F'OWCQ?Q?R/^;KW[ON_P#?7\U_
MS]>_V:GH?_GN)/\ T$][?_8W[]_LA'RS_P"?3M_Z''6__P!F'OWCQ?Q?R/\
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MS8&3:^<VY"J=7T#YZ%,JCX7/+>?*U=.7J;D01HFEQ':[3;2;GRQ'/XO[MOT
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MJT53/]S4)(\C>$6C4SYONOZM;!S#OU':VM]M2\@4:0[Z+@Q2+*S_ *:)*(Y
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M=[M=+&!<W=R9YW_%-.Z(CS2'BTC)'&I8Y*HH/#IVZ8_1[6E>Q(F51Y*OB.U
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M1LA:)4+N6)H^$^$<KM))VE\HF=V9W8])=6W9F8LQ/_&=1R6-_:E?%50JQJ%
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M\H?[IY.>L_N;)M;#8'.T&;CIZ6.2D7<%5D9Y#33+4F,"G:*2,OU/LGX_]_\
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MR16LQH5EM(+D4-2L5Q'')&7_ (321%:N YTU)IUS$\1T7D56EUF-'8([B/\
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MZDJZ.IN"."/;=[>Z9ZY^_>_=>Z][./\ .'_F:^P?_%8OBE_\#YUY[9A^%O\
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M[ZUO^4>'_>%Z]_LNN#_Y^?\ (+_T>?8G_P!>O?O]G'W!_P ^!^('_I,G6?\
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MNNIJZ_8->NWZ/^"1+18/(;;PU/O&+)8O=V"IX_NJ6MJ*^LIAD)9':E,(ABA
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M</?O&C_C'7OW?>_\HS=>_P!./4W_ #W6%_Y*J?\ ZG]^_P!D@^6'_/CMY_\
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MN5BFDH3V/):3H FN0#PI&4)**)3&%VF+=G:D4L,SQK0ZG>WM([Z2('X-8M9
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M.J/<0VTEC/)XQC0-#+9 ?JW<*,JNDL--Y>[?<NVU11-.6D0H\=N;1;J&292
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MO[6/_3#_  ]-^68KBLFRDAEQ]8P(X((II""/\0?:N^02A>^^[U4!57M[LI5
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M1A-P'8VWJ2BUXJAQM%7Y=XYIJBI*T6.FJYRW=+ZZVNYO9;A81L7]8WL8YRQ
M%O)#$VWK(0&4WMY)/"Y0%([:!D\?1-<V\;(MHM&W.TL9XGC-U]&S2*'J3<)(
M%D"@J%2./3-$8VDDF>>$B$2*6,:QDWE7QT,.#W13)1[AW!#O:*ABQ&-SE70I
M3XH9*;'K6UL5+64>&E;$PJ'GK9Z:GJ:O]NF+R.(EK[^3A!^2?R$*D$'O'M@@
MCZ$'?N?L1_@1[-HQ2- >-!TQ>$&[NB.'B-_A/2@ZN-^L^NR;DG8NT22?J?\
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M-HY9(KFWNXWI<17#SJ?266)(9'IP/B11QHX8%6"+4$@'J1N/KW9N[**+'Y[
MTU920Y7"YN)(I:O'R)E-NE/X-5K48VHHZ@-0H@15UZ&BO&P9"5(4;;[*W]L^
M#,TNU=V9[;M-N+)[<S69@PM?-CH\CE=H9C^\.ULA4+2F,&JV_G!]U2.+&"8:
MEL?:B)C EI&GP03)-&" P66-)(D<!J@L(YI4J:U61U-0QZI<'ZEKY[A0S7,+
MQ2X UQR/'))&: =C211N5%!5%]!TJYZ2FJA:IIX9QXYH1Y8U<B*H3QSQ@D$J
MLT?I8#ZCZ^Q(W'\J?D)NNH[3J,SVEN0_Z;\'MG;7;E-B3C]NXWL+![,SF+W-
MM;';GQ.WJ'%XO(Q83<6%I:Z%FA\@JX%E+%[DHXK*UA5$BA 1+Y;Q>/9=(DD:
M3(:U1UCFE1=&D*KD  =/RW<\]U;WTLFJZBM);96(%1!-_:QG&1(,.6JQ%030
MGI&XCK+8.#IMF4N/VMB@G7<N2GV-/6Q/E:_:L^8H:_%Y2HPN3RLE;D:*HK\7
ME*FFED676U-.\1/C8K[;^R?DIWCV^T\G9'8V=W5-68#%[8RE36+CJ6KSF'PN
M8?<.*AW)5XVAHZG<M71YR5JI:JO:IJS.Q9I23[4JJ)=W5[$@CGFF25M "*)(
MU9$=(THD95791X:H &..FQ-*+6QLM?\ BUM$T48.2L;>$"FH]S+2&( ,Q T+
M2E.G#;.R=K;.IZNDVWB(<;3UV;RFXIXEGJZI1E\R0V2JJ8UM14M1)4E?\S"8
MX$'"HH]B50?/7Y?XK<5#N_&]];VH=U8_:=-LA-QTS8B+-5VW:'*4F=QT&<R2
MXL5>X\GB<WCX*RBR.0>IR-%50I+!/'(H8-SP07$>^1/"HAW+1]0J 1JQC#!2
MBQZ5A;2[JS0B-G1Y$<LKN#6W;Z6/:8X40)8Q310 JK!(KB,130]P.J&2,*C1
M/JCTJHT]JT3DG3?64U/)23[1Q]32R;RJ=_FEJIJ^IIDW964[4E;DH8)ZN2*G
MAKJ21X9Z2,+1S0NZ/$RNP*0ZX^7?R8ZCS6^MQ]<=U;]VKG>S<U#N;L#*T68:
MHK-W;GI:G,5M%N?-2Y".K-7N;&U^?K:FER!M64M34O-#(DIU^VOHK/\ <_\
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M\7P@A&5,+3RO$?\ 0W<LN3T7W&NYL?W?)*PM=,H !II$T"VTFGT+VZK$WK&
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MO&R1AD!HK-&[<6[F=XHB[M5W\.,,Q"+14[4VIN'8^$.W-K=(]?8K"&KRM<U
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MKUTE-!&TP&F*%(XHPOI47-RK_P!Q?B-_WD3V]_Z3?AO_ +?'LVU3?[[7]O\
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M_P!!]>_CW;?_ #[?:'_HSJW_ .UU[]_<7XC?]Y$]O?\ I-^&_P#M\>_:IO\
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M\QMW.X_=%7\8MDS5&+R&TL17X'; P]&_<9Q>'Q^ Q64GBI*.E@BHX/)J2(.
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M*4Z@.TY/ 8XGY=*+/_<NUI_OQ?\ CPZ"COD7Z-[G%B;]4=BBPL";[0S' )N
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MR4'_ 'CU\:/_ $6V2_\ LK]^\/\ X8W[>O?5C_E%A_WG_9Z]_HY7_GN>Q_\
MT*I/_J3W[_9DH/\ O'KXT?\ HMLE_P#97[]X?_#&_;U[ZL?\HL/^\_[/7O\
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M/=V^J"EA4)!1X[.PXZAIT'TCIJ*AQU/24T=^=*(HO^/</_9DH/\ O'KXT?\
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ML^M'C*N#<D.;QRXF&2;*MEXH(\1.N16JAFHI]OZ9 K*KFHCETMIT*0D=F?S
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MB,;BMDYW<U7'C\)F<?@JS=&53:U+FUP>W'K<M3-%+6-!-+!*91%HBF,?+?\
M_+F[0ZUVEG]T[D[-Z7EJ=KIF*',;2Q6Y-S5.YEWIMSKC;O<.X>O:2.?9U/BZ
MK<>)ZOW)%DY*E*DX@S0S4*UC5R"G8NL]UL-R7;)-LD:YCNWG\/0!5TM-P7;+
MR4:B L=O>R1QU<J\R/XT"2Q)(R5LHFW"Q^MA;0M(:AE;!N8;B>U!TA@3,EM-
MA2?"(03>'XJ$O=!V/'7YH88;0WG3!I:;_<K5X_&1XC[&MR&4Q-)D_N4S$DII
MI\EBC&(A&:H1S0S&(0/Y0T[U^!?9F.S6\)=L/AH-K[=S/>>(IX]S;GHJK/\
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M3]'YGK;9OQ*Q&Q>GZ.MWELV;IY-^X'XP89-M8+9^<[)Q>7ZUVAD\?V%5U%-
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MJM<"L[V8]$W1V/?O?NO=>]__U]*[K'_LDCY6?^'U\9O_ '-[<]M-_:Q?8?\
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MU7ZI?^42+]C?]!==_P!Q\A_S\3?_ /YU[9_^Q;W[_9@<-_WC?\<O_08W[_\
M;*]^T'_?C?R_S=>^J7_E$B_8?^@NO?W'R'_/Q-__ /G7MG_[%O?O]F"PW_>-
M_P <O_08W]_]LKW[0?\ ?C?R_P W7OJE_P"42']C?]!=>_N/D/\ GXF__P#S
MKVS_ /8M[]_LP.%_[QO^.7_H,;^_^V5[]H/^_&_E_FZ]]4O_ "B0_L/_ $%U
M[^X^0_Y^)O\ _P#.O;/_ -BWOW^S X7_ +QO^.7_ *#&_O\ [97OV@_[\;^7
M^;KWU2_\HD/[&_Z"Z]_<?(?\_$W_ /\ G7MG_P"Q;W[_ &8'"_\ >-_QR_\
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M&=__ /VR_?M!_P!^-_+_ #=>^J7_ )1(?V-_T%U[^X^0_P"?B;__ /.O;/\
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M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][./\X?^9K[!_\
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M0_\ 0EPW_P!6^_?[+SW]_P ^.[@_]%GO3_ZR>_>(G\8_;U[Z6Z_Y1I/]Y/\
MFZ]_I!V%_P ]OM#_ -"7#?\ U;[]_LO/?W_/CNX/_19[T_\ K)[]XB?QC]O7
MOI;K_E&D_P!Y/^;KW^D'87_/;[0_]"7#?_5OOW^R\]_?\^.[@_\ 19[T_P#K
M)[]XB?QC]O7OI;K_ )1I/]Y/^;KW^D'87_/;[0_]"7#?_5OOW^R\]_?\^.[@
M_P#19[T_^LGOWB)_&/V]>^ENO^4:3_>3_FZ]_I!V%_SV^T/_ $)<-_\ 5OOW
M^R\]_?\ /CNX/_19[T_^LGOWB)_&/V]>^ENO^4:3_>3_ )NO?Z0=A?\ /;[0
M_P#0EPW_ -6^_?[+SW]_SX[N#_T6>]/_ *R>_>(G\8_;U[Z6Z_Y1I/\ >3_F
MZ]_I!V%_SV^T/_0EPW_U;[]_LO/?W_/CNX/_ $6>]/\ ZR>_>(G\8_;U[Z6Z
M_P"4:3_>3_FZ]_I!V%_SV^T/_0EPW_U;[]_LO/?W_/CNX/\ T6>]/_K)[]XB
M?QC]O7OI;K_E&D_WD_YNO?Z0=A?\]OM#_P!"7#?_ %;[]_LO/?W_ #X[N#_T
M6>]/_K)[]XB?QC]O7OI;K_E&D_WD_P";KW^D'87_ #V^T/\ T)<-_P#5OOW^
MR\]_?\^.[@_]%GO3_P"LGOWB)_&/V]>^ENO^4:3_ 'D_YNO?Z0=A?\]OM#_T
M)<-_]6^U9L+X_P#?-/OK94\_27;L,,6[=MR2RR];;RCCC1<S1%G=WPH5%4#D
MDV]Z:1-)[QP]>G([6Y$D9-N]-0_"?7[.F[+]@[!_A&5)WQL\!<9D'9FW-A55
M$2DF=W=C6@*B(I+$\ "YX]JOOGH3O2O[R[GKJ+I;MJKHZSMCL:II:JFZXWA/
M3U%//O#,2PS0318=XI8I8V#*RDJP-P;>](Z:$[QP'GU>YMKDW$Y%NY!=OPGU
M/RZ8>ONPM@-L'8[KOG9SH^SML21NFY\(Z21R82A>.2-UKBKQR(P96!(8$$<>
MSE]0[KSO4W4?1^W]M](_.K:G;_6?;NX.PLWO_;>R,#D-OO@-_P"U3L+?^U-M
M[7W/U_D!/1Y#:-)#"L&4DJ:"K%76PU4#12)9;N]S9;J-DVN2WB?ER+;[Z"ZC
ME2.4W+7JV[,K1N#"T"RVT0T2H[,G<"LB+TGL;2[M['?%FBG_ 'A<W]C<1-$7
MB$/T#S&)@Z_J>*PN)&+*459$C%'0N"A-SY:OW!N#?L$O871E3U_EMB4N,V?B
MJC,YJ@W72;WI*EZV/*;@W#B-W4T,>#6JE#0G&04F3I9(4E2H+VT+G-=[[MSG
M;]%GZOX<_(2GZDQ'QPJ_AWCMKX'KEMI[H_T+[GP.[X-Z[[@?;^RZ796WNW*O
M=FY_XG24N-Q<&W5@$E'+ RRO,Q)#:)>P\WMO=T1=;S/%(PB;7':"Q;;7VV&
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MH?1"JF3045(S*VH!'+M7(18@;QNMC%/**G3%),CSM&R:28UM8$9Y6+.6C0R
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M$6U<L=VYO#;3VUFZF>KA2>6JJC3Q-<()"\88\V[<H;O;K7<6N("+E+72ZO\
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MUIO;J'-];X&HW])%V1G>R*#;&T\,^S]YU.SJ79&[-P[HQ>VZ/'=A9:N-*E+
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MCMX<:,>D^VK+N&S[5O'B!;>^FF6%@Q9&C$,\]J=: CQ+U+.[-O%Q)C5&TNU
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M .J??J#TZ]K?^(_MZ]_!L/\ \ZK&_P#G#2_]>O?O[U[I_P">ES__ )^<C_\
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MN?MS^>/9G'B- >-!TGO*?5W5.'B-_P >/2NZN%NLNN@  !L3:(    MM_'\
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M(M"0I=T626]K=[)R#;Q2.EO]*(K]E8K>06HO;N))V>3-S?/;I#W$AJLL[C0
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M*KO?7#3Z4;SS+_I@U10Z9%.MK+9ASS[>T,I:LQH&H:TP:TIPP:XI^73"W$;
M:;*,U%1\>12M1W<*9KZ=*0[.S0TW[0WP-3:5O#L4:FY.E?\ ?F<M8'C_  ]O
MFRNP,1V/O#:W7^Q?AKTQNG>F]=P8C:VU-M8>J[SJLKG]Q9VOAQN'Q&/IU[D!
MEJ\A75,<2+< LPN0.?:JRVV_W&X^FV^*::Z*NVA%U-IC1I'(4*31$1G;T4$G
M'2>ZW2RLH);N[MX([=!5F)< #_>O7 'F30"IZ;\Q@ZC;V(RN?SG;V[\3A,'C
M:[,9C*UXV'34.,Q>,I9:W(9"MJ9=F+'3TE'20/)([$*B*2>![S;G[+H.L=[[
MBV=N?XA=1[)[!Z^W/EMN;BP]3D>_,/N7:.[]JY6?&Y;'SF'N6*LQ>:P.8H)(
MW*LKPS1&Q!'LHV3=;3>MNVGF#E_=_&VV[@CGMYX6&F2*55DBD1P,JZLI4CBI
MIY]+KV(VTUUM^X;1$LT99)$<,>%0P8:R"/Y$?+/62BVQ59O&4F1H.UMW97$9
M>AIZVBJH(M@UE!DL;7TZ3T]1$XV7)!54=92RAE/J1T;\@^XVZ_DM0[MS%1GM
M_?'KK3=^Y*I((ZO.[WW?\B]P[@J8::&."EAGRF=[MJ\A)#30*JQH7THO 'M^
M&RAM1(MLHC#.S,%5%JY/<2 HJQ(R>./EU62]>0QF>W#410NHR&B =H6KX7-1
M3C6OG7KO'==5.(HJ;&X;?FZ,1C*2/Q4>-Q&*Z[QN-I(M3.8Z6AH=C04E.A=R
M2$0 L23R?:;_ -.?7G_>*?1'_GS[T_\ MR>W?#;_ '\W\O\ -TW]3%_RA1?\
M;_Z"ZF_W+SG_ #\[?7_4C8W_ -A?OW^G/KS_ +Q3Z(_\^?>G_P!N3W[PV_W\
MW\O\W7OJ8O\ E"B_XW_T%U[^Y><_Y^=OK_J1L;_["_?O].?7G_>*?1'_ )\^
M]/\ [<GOWAM_OYOY?YNO?4Q?\H47_&_^@NO?W+SG_/SM]?\ 4C8W_P!A?OW^
MG/KS_O%/HC_SY]Z?_;D]^\-O]_-_+_-U[ZF+_E"B_P"-_P#077O[EYS_ )^=
MOK_J1L;_ .POW[_3GUY_WBGT1_Y\^]/_ +<GOWAM_OYOY?YNO?4Q?\H47_&_
M^@NO?W+SG_/SM]?]2-C?_87[]_ISZ\_[Q3Z(_P#/GWI_]N3W[PV_W\W\O\W7
MOJ8O^4*+_C?_ $%U[^Y><_Y^=OK_ *D;&_\ L+]^_P!.?7G_ 'BGT1_Y\^]/
M_MR>_>&W^_F_E_FZ]]3%_P H47_&_P#H+KW]R\Y_S\[?7_4C8W_V%^_?Z<^O
M/^\4^B/_ #Y]Z?\ VY/?O#;_ '\W\O\ -U[ZF+_E"B_XW_T%U[^Y><_Y^=OK
M_J1L;_["_?O].?7G_>*?1'_GS[T_^W)[]X;?[^;^7^;KWU,7_*%%_P ;_P"@
MNO?W+SG_ #\[?7_4C8W_ -A?OW^G/KS_ +Q3Z(_\^?>G_P!N3W[PV_W\W\O\
MW7OJ8O\ E"B_XW_T%U[^Y><_Y^=OK_J1L;_["_?O].?7G_>*?1'_ )\^]/\
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M=5T] J)A8J*FI:9*A8ED"?=-HW+>;3>;B^E@&[;CN<]Q<Q(76VD@?;K;:[:
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M_P#GL]J?^A%B/_JSW[_9>N_O^?'=P?\ HL]Z?_63W[6G\8_;U[Z6Y_Y1Y/\
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M]_V31\$?_$7]U_\ P2G:'MI/[2;[1_@'2ZY_W&V__2-_Q]N@'ZR_YFU\D_\
MP]M@?^^?V-[)S[=Z0]#Q[][]U[KWOWOW7NO>_>_=>Z][][]U[KWNR6NZXB[,
M^(/Q3QTV;_@2;6V]\Z.P?N/X>V1^^;9-9U]FQB!$M32FG.3-/XA-=A%JU:6^
MGML@I;;S>BA-O'"P7AJ\2Y@MZ5\J>-KX&NFF*U!E&JW$_+&VNVE+J>X0O2N@
M);RW&K3^*O@Z:5%-5?*A+WL1M/R"^0?%[X7I)?K:VK$;Q%_\;>V##?R]=]0Y
M>;&]B=I]-=?TL?76^=Y3YBIWBN>QN W)M+KS"]FT/7>\9L)251P&Y<]M/<-+
M5H$%4D,9D5SYXI( 'I^:MK6#=Y+%S=7=I"TGA1TUS>'?_NZ6.'517DCN 1IJ
MJN"I1V5@>D&WJ-P_JI*L\4=IN=Q%&6D<*UM'-#--%/<)EDC=86H:$@9(!*AA
M1JMY+ L30;9W?D%EW!A\"#1X0C0N6K#1/G9$K*FDD7;^(93)65%M44(UJCJ1
M=*Y3X!]Z;<J,!#O3(]5[&7,]69KM_)R;G[(P5,^Q]K82/"5$E'OS'8\Y+,[<
MW/DZ+<V-GH,:U-)4UT==&(0T@D2,RN]WM+2XWJV<.TEBPC?2I(>;Q# ]O$?Q
MS17*M;RK@)*K$MX8\3I5:V,MY'R_+&Z+%N4Q2,LVD(@A>X6XE)^"W>W0SI+W
M!D*B@=E0Y*?>^%K?O!CDR>1>BS5-@I5HL952K)55,K1+4P3LB4TV,B:.3R5(
M?Q1B-M1%A=P3^7AWW%F.O,'F<MU'MO(]B;,S>^*:DS?9^ CR6V,;@\!C-U2X
MK=F QYR&YJ+=>3VWFJ2LQ^*I:*LKJ^.<+#&\J2QQI[SF#;;)-[E=G>.QB#,4
M0L)'\3P7@B(XS13@PS!]$<;@LT@B4R#?[NG$&VW):,175P(EJZKI#JSQ2R:B
M-,4T:F2)LEET@J&95/HM[8BH&6-+!EJDX;)TV+JEBQE0%D:JJ32+74L\HBI:
MC%Q31R^2H$GCC6%V8@:2S)D?B#68RD^/^=I-\X#?>#[5VO@MZ;^Q>QY)9=W=
M38#)=E2=>3G<.-R5-#&&J*D)]I*-9:H,D<D2"+4Z]+LON>XV'T[BW@2TI/CP
M7DNX/&2$/7$JFH=3@+I<,0<(I(IFVK<+RVDA?<8)MQ3P 3K*;>!KN"I52(FK
MBM&P0!7J7CMR1Y"IS-+)BLSB&Q69DPM+/F*)*:FS[QXJ#*G)8!X:BH>OQ)BF
M:,2LL;&:"1=/ )%/._RU>ULKV9OS;G5&[NJ=T]>[5SV_<<.P<KVAMS%X/;K[
M4WG+M+%[/[!SE9#C,7@>Q\Y--1^&C5?M:AJC7'-X4E>,CVWF"5^7-EW?=;1E
MN;O;[>>(1*QCNY)8@\L5BSZ3.T!UB16TLBH&;MDB,AI'MGU4MNEI=Q.K4,O<
M3]*&C216N=*GPPVL(NG63(&C%61J-E9OW#8RE%1E:;,T!;(KCHH9<16/4U0^
MT2NER5)2TZSU$N)@IBS22Z;Q^-E90X"D*,7\$.]<SM#JG>N-;8<^)[:W[CNM
M\9!-O/'X_)[4W)F9\_!A)-]4.2BHWP.W<X-KY"2CRZ&HQE3%2.R3D6N;_O6S
M&XVVW2.4,UI+<I(PI&8X(8KBX4GXEE@AGB>2%U64!QI1JBI=<PSVEANU_) 2
MME=K;R(I5W,CSBV4QZ25D0SD1ZT8JK'NH*GIPFW9C:>MSN/D@RAJMOXZ+*U,
M<6-JIQ64DT;N@Q;PI(E?4ZT\9A4^42$#3R#[X8CX;[JW1/1T.W=Z==&EI,1V
MIN7<G8V:WIB,5U+'M?JW<>"VYE]P[?W(X?-Y3'&LW!#&@?'1SU4IM2QS+R:-
MN]K%^ZVNM4"78M1&) 5?7>7-S;0*RYT^(]L: ]R*=<HC2K!5=68M;B.R,R27
M+7\UJ61@T0:"UBNI"7P-*1R&KBJ,5"QEV-.IE;G(Z''C(/C\M4ET@:/'4..G
MJLIY)X#.M/)31@QQ2KI*L6=8T;AF''OCF/@UW-MSJGLCM_<N1ZZV[MOK+,;A
MPN4Q^8WA'29[<%5MG>.+V)D/[F4WV+X_<LDVX\O$M/3150K9Z57JE@^U1IO:
M(\T;08=AE@E>5MP, 1$4F1!<)<21-*N"J&.UG=W76D80"1E9XU;<&W2SS;G$
M)HE6V!)<L-$@$23#PW%1W)(GAA]!D9PD>IPP6"V[*,;AQ6VUQ^9EK,ICY,BU
M1#0B6BQ,20O-''G94F,V)DJO&R0F6,1RRC0K%^/8K]?_ ,NO?^\^M:^O;,[<
M7N3+5W3E5M/K"GW9AX,CM79?96)WANNNWKW/2Y"EB;9FWZ?9.WZ?*T\Z5,AC
MIJE1/&))(X_>]XWV#;-[VG;/J8%L1+N27UQ(6$-LVWPP,\6M0:S+/-].ZZ64
MR*R(Q=&Z3VEK<7D.WSP)K^L0FWB%?&E!ECCCE5*:3;R R,LFKX5$I B.L\:W
M=U!CFRS5=%F(J3$0)*U?_#9Y*/)2220P1TF(EBUFMK&JIA$(]*EI/I=03[8\
M_P#!#/XCK3(9:/>VPG[-VGV'V;MS<^V!O_;>0PNZ-F[$VWUQN<;QZCK\0E;'
MO6CQF%WC55^6(J4D@HZ=5CA-0DL0466XW%[N]O;BSDCVSZ.&2=FCD\6T=[ZZ
MLY7ND ;P[:(PQ:I@& +N^HPJ75YK":.[W2Q\6&6X2.&2V\-JK=B:&69(H6:E
M9Y/"81QOX?DK$,R \Z?=E!5MA334F5FI<[3BHIJT8VHBI:35'*T,.4DJ!":*
MHJ9(C%&C DR6!MJ4E/=X_!_<G4%)W!N3&=L]0=B;'ZDWC0[+ES.T]R5M=G=R
M92KH\+6U"T>U:3$U==A8L/'G84JZC*/141G5XJ>>HD0K[+[;FFWGEV^VEL;B
M.[N;BXB52N MO))%X[.2%\.9HF\( F9AW&)4HYO#8"Y@MYX+R$H^W07=-7</
M'A$OA:::FD05U4&@"A9P:@8L!NU,Y!A))<!N3 3YK%'*"AW#004%7C6#LG\,
MR2QUE3$F6*(TGAB>4B)2Q(%O;G@OB;LB'K[%=H]@[VW-MW9FW.F-I=O=I3[<
MPF+W/N&>3M/L?-;%ZNV?UY@JO(8"C>OKJ?$FJR=7E*^"EI%5])9S%%(])S'8
MI?7EK%-XM;^.P@"HP/UOT/U]PL[-VI##""P=:M)A%0L2536L(NA9 ED9H[J>
M8D#3%;V\\=M'IH2TDUQ.X55TJB!PTCJJ,6<<G7Y2.(PXF@IYLC--+#1KDZHT
M5#IAB$LE543015E48#^E1'$[EB+A5NP<H_AWL+ ;YWNN^NS\Y!TS0;,Z=W'L
M;L7 [2:3<.5J_D;#BZSJ6FSVQZJIFGIZW$X:JK\CGL?354DK4^%J4H9YC)3O
M(KDO-R6.?;ELXEYI7=VV]86?]*22!?&N)(Y"%+1B P@'2'AEO+83QJ-:APK9
M^%%NJM,VP_02W;MI F5(I6M3$$J8S,;H%5'B:9(4DF1M(H.J'*U59CX)_L--
M<36PU-$M2CQ15>/>6GJ8HZS2(Y(WJHM,;D+<,"P6Q 3?<OQ!BZ*R7;'6^\=S
MSY#N?J;KC:N_]T8C"04QV7BILUOB@PU9@:3/.]0^[/\ ?E[GPV4BK*3P01U%
M1/3'R-"S!R'<XKBWO+N-BD-MND=BZLH9S.891<H=#E$%K>PR6XE#2I<JHEBT
MQ/&[OS;9-#<64(D5XKFSENHG *U@ 22V8JPU*]Q!XDKQ.JO;D)#(!+XBQX=M
M[EH=UXC&[@PQ>7#997EH*FH@JJ.>HI0&$4YHJR"GK*5GEC93',B.MKD>R.GZ
MG_7/LSZ+>E'[.-\X?^9K[!_\5B^*7_P/G7GMF'X6_P!,?\/2[</[:/\ YI1_
M\<'0%_'S_CSMU_\ B:N^_P#W\N]_9./;W2'H=/?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V8+XE!6^57QF#@%#\@NF0
MP(N"I['VV&!'Y!'X]TD_LY/]*?\ !TIL\W=J!Q\1?^/#H)^^P#T9W0"-0/4_
M8H*E0VH?W/S%QI-PU_Z?GW9/5_%+L_L#%P[SQO<W<=7V'W?O/?V^-E;-VGF*
M#(8'8/3^*^0V5ZCSO9/:5/7]D8SLA,)!DL?D:E)L#M_*T4<<$2U%3$\SB%//
M<6<%_%MZGMM#:MN$I \.!;RV:XM8HRNH&XD3P:?4-;0:[F&$2^(P#.PBXNAN
M4JRAI&NI[:SC62CW%S"J,X[@/TPTFEA")IHTAGF>)8D#$*=F[BPM*=K;:.Q]
MI4^W,#L3;N.R&7RF*KJ&MK]T_P!Q,-N/%X#;C)M2;:E13)@YU\GFRD%4KC1%
M3.J%BFO]DX[1[=3:6XOB9\F]X[UV-N7'[BHZBN[UW3/TEFL;OO!]ET/56"V;
M21_WSW3@\_7]H;CS6..WOMJPD-6&&N^U,#R%IY+R"?:?JMO5;;=;=9[ !T::
M5!%=37,4D=:)+9)8WCSNKM T$(E60%Q&-W\EG9L\0W*3Q(-TEL+AF5O#26&"
MWN&G5D+M].8[J%:L@E$AIH*G5TH(MTTVU\'6U?:/5.%H\O09R&AF@ZPQ%1V1
MCOX+6TC9.'/RF/;6&SU#2XK'1R&O6>@2TD)%,:G7&&#6C^'7S$K=Q0;>B[UV
M@B9C#;4J=E;BF[_RD>U.Q=W[SJL_C,-U/LG/:C25_:"9S:>4H*G'5/VD-+54
M#^6H6.6GDG66RM?Q[FVV6<MU)!.T<4<43F2\1;:.\%Q91E5:>![6:&6-P%9S
M(L*H;@-$MIH);29X[[<8H(XF=+B1W/A6LL<YMWAN'4,%D609T:U\/];5X09P
MZ5N]^O<?B<5EZGK+/K!7Y_)83)TPZ^I37[3I<35R4U?NC==(;28S:L$/AJ35
M)YF-+4Q2".Q<(!_QPV5WO\@/D#M/HL=D=L;?FK<QEO[^92@JM[;KRVQMG[-I
M*[-=B[C.U,1D/XGFJW:NW</63)01%)*NIB2!65I 0JVE=JW"SN=WN=Q$/+\-
MF;F2Y6-IE2(A5A<I'WE)9I(8BZ@^&)?$(*HW1?N[;KM=ZNS"W9N8)+U;..W:
M149[EG\/PZLP!T$,[A=3:(W**Q 4J??U3L?8FS<WNRJP6Q1]A0DXF#.UNV=I
MXG,9RM*TNW<'+N7,0KC,4V?S%1!21SR:PKS A7-E)ANU?A3\T-@;[W3@L-O_
M '=G-E46;W32[,WKN#?67V)4[IP^.WCLS:VRCEMKYW.');*WEV13]E[=KL9@
ML@RU<E/E X+1P32(&MDW22]BM+/>[..RYF BCN;=7-Q'#>-<W5G<VL5RB".Z
M-I/8WC2O$/\ <>'QM(\6)'7W?@Q_4W%CN?C;:BR2"0U0B%+-;Z.653_8B>!@
ML.L@//6(&HKTT;,W3U5O;:F$W7C<;LRKH<KB,=E9JK"+M_<^"I!5T%=5UIIM
MTX6*HP>7QV*JL364LM932O3_ '%)(EPPT^P ^4/6/R1^)._<1UQV7W,,QN;+
M;0QF\FI]@]M;@W/'A:'+5V3H:7%;E5GQU9M_<BOBGEDH*F&.H2GDAE(\<T;,
M_MF\;;N]SO,&WDR165R(3*%_2E+0Q3AH7_&GAS)4T4H^N)U62-U6LL-W!:;?
M=2R%?J$+!"6$B:6*$.II3N4Z675'(HUQNZ%6,GK'.[![5VLF[L+L*IPN.ERF
M6QE/#NO9U!AZNM7$UTM%_%\7I6KHLOMW*B/ST&0I)IZ6LIW62-R#P6S_ $K=
MH_\ /R=_?^ACN+_ZX^S;0O\ ".DOC2_[];]IZ$+^ZFUO^>;P'_GGQW_U-[]_
MI6[1_P"?D[^_]#'<7_UQ]^T+_".O>-+_ +];]IZ]_=3:W_/-X#_SSX[_ .IO
M?O\ 2MVC_P _)W]_Z&.XO_KC[]H7^$=>\:7_ 'ZW[3U[^ZFUO^>;P'_GGQW_
M -3>_?Z5NT?^?D[^_P#0QW%_]<??M"_PCKWC2_[];]IZ]_=3:W_/-X#_ ,\^
M._\ J;W[_2MVC_S\G?W_ *&.XO\ ZX^_:%_A'7O&E_WZW[3U[^ZFUO\ GF\!
M_P">?'?_ %-[]_I6[1_Y^3O[_P!#'<7_ -<??M"_PCKWC2_[];]IZ]_=3:W_
M #S> _\ //CO_J;W[_2MVC_S\G?W_H8[B_\ KC[]H7^$=>\:7_?K?M/7O[J;
M6_YYO ?^>?'?_4WOW^E;M'_GY._O_0QW%_\ 7'W[0O\ ".O>-+_OUOVGKW]U
M-K?\\W@/_//CO_J;W[_2MVC_ ,_)W]_Z&.XO_KC[]H7^$=>\:7_?K?M/7O[J
M;6_YYO ?^>?'?_4WOW^E;M'_ )^3O[_T,=Q?_7'W[0O\(Z]XTO\ OUOVGKW]
MU-K?\\W@/_//CO\ ZF]^_P!*W:/_ #\G?W_H8[B_^N/OVA?X1U[QI?\ ?K?M
M/7O[J;6_YYO ?^>?'?\ U-[]_I6[1_Y^3O[_ -#'<7_UQ]^T+_".O>-+_OUO
MVGKW]U-K?\\W@/\ SSX[_P"IO?O]*W:/_/R=_?\ H8[B_P#KC[]H7^$=>\:7
M_?K?M/7O[J;6_P">;P'_ )Y\=_\ 4WM6[![1[-GWWLF&;L7?<L4F[]M+)')N
M_<#HZG-45PRMD""/>F5:'M'#J\4LOB1UD;XAYGUZ;\OM7:XQ.4_W[6WS?&UZ
MD-A<:RLK4LJLK*U,5='4D$$$$&QX]JSOOLWLFB[T[II*3L/?5-2TW;78\%/3
MP[NW D4,,>\LRD<<:+D;*J*  />D1="=HX#IRYEE%S< 2-36WF?4],6P-J[6
M.P]D?[]K;R@;0VRJJF$QD:(JX6B542-*54CC10 JJ J@6  ]C/1[6IEZ>Z*[
M<RORP[7^V[%[/W=U_P!F8/"X?>&0K^MQMG$8/.4L6 ^YW?0R[^SV8HLS&JI%
M%1T,4TT:&H-I"AC=V!M)^7&BM)KFSO[:X8")5\9KBW>!3!$CD(P?ZB-0[NAU
MAZ(5TLR:&XDFVK?KPW BN[&[MHR'<B/P;A+EA,\@!*E!:R,456["M65B0/'&
M129G=.)BZ[VC%!C<-BJ[:^4J7H3%N#(5Z95*VDR5'!@GFP-)BZNB@0S!ZMYT
MG9EB7Q@2"+E.H</@_F%B>@=R?,_?6R.K<EM&EWAE.PM]Y5MM;QV'75G6=1OM
M>I^PMNUW8D>S=M=K46?B3;M5!)GCCZ?(3(9)T.N)"G;R7AYQ&X/;R7.T_5"-
MK1Q+#N+P:="64C^'4REC$Q<42>*9%,J*DDBG=#+;?U7>T,PCW%[;6)PR26<4
M]R86FN(U#L%6 "\10 S6\L1<1DMI1N3K<G1]23;QHNI-G9C?L=)!''M/$M59
M+ 5>0DS,.(EKJ'-X_955N*NVY%!(V062+#-624:66GUD#V+"_#OL8X/?6Y7[
M0^4D3Y3,5NWOCKUH:W9DO:O9AH>F,1W1-V!D,='W.<!G>L9-N9ZDFI:K957N
MNNKJ.1YXH/VPDA0-V1&O-FF\%>:+26X>[6DO@6-I:7GTUP]T%C>Z6:)=4LJ+
M;&.&.&29Y?IRLO2M(DDNEN4NG/+QCMECE\2+7<W%T94CAMSXGTY/C0M" TXD
M:5TB6,RB1$9?[Z85Z[8]'!L_8#4V0I,;6[\W!+C<['M_!&OR-;MT8O"UJ[(D
M'\:3<U!)3O#FSA?"H <^4F-6_=_Q<WYL#!8GN#KSY(]I=U[%Q^-Z:W/C<OM*
MFW)6XFLR.1W#'!VCE<W74.[\B-M=:=?38\QP9:IC%76557%#+1TKT]::=1?W
MD]A?7T-U:11;:F^S6"2O(HUPK$C6LYP8UEOWE3Z2!9)#)"&EU@- )F]OAN;^
MTLKNWD+/]*TDB!P[>,DD8D2-5JYBB1V$TCJC12QE&BHZMTJ)JK:TF-3$[BVE
MM3!YW<M/O:DQ&*./@G:O@PT.2D6"-*W!T$DU=+@H145,)C\**6"231Z'>N7Y
M.6_V9/Y"V-Q_IQ[9L0;@C^_N?L0?S[-8_P"SC^P?X.DMY3ZNZIP\1O\ CQZ6
MO5H5>LNNE5555V)M$*J*J(JC;^/ 544!54#Z   #V!WN_2?I=^_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_
M_]?2NZQ_[)(^5G_A]?&;_P!S>W/;3?VL7V'_ "=+8?\ <*\_TT?_ #]UO+;L
M_P"9S=/?]J'M7_W%V=[*C;_?7]N](NAB]^TG_#_;C_7]^Z]U[WU[]U[KWONQ
M_P /]N/^*^_=>Z][Z]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]G&[^_[)H^"/_B+^Z_\ X)3M#VTG]I-]H_P#
MI=<_[C;?_I&_X^W0#]9?\S:^2?\ X>VP/_?/[&]DY]N](>AX]^]^Z]U[W[W[
MKW7O?O?NO=>]]V/^^(^G]?\ 6]^IU[KWL_._-X[FV7\-OAW5[6RT^(J<Y-\R
M-I966".GD-;MS<N<ZYQF=Q<@J89E6'(T$S1NRZ9%!NK*>?;:DD7]JV8)EC5Q
M_$$D291_M98HWQ3*@&HJ"8,QABV:\C-+F"29D;S4LAB8BN,QR.N0?B-,T(+Y
ML-0WR#^0EQ>V$Z38?X$8C>1!_P!A[!"#Y8=_0[@?<M1OQLID:G(9#)Y"+.;>
MVKF\1F)\ML"DZLRD6:P64PE5A<O09#8%!#C9J:H@DIWBB5RGE'D]E%OR[LUK
M'?1VED(OJ+:XMW9697\.ZG^JFT.&U1N;G]=)8RLL4@#1.E!T7V1_=SV$EF C
MVLEN\6 =+6@808-00BNZE6JKHS)(&4D=#O44%+50?;31MX0\$@$4T].ZR4TZ
M5,+I-!)%,A29 >&%_H;@D>V;/_([M[<U*U/E]QT4M15; DZNS>:IMK[5H-S;
MMV,U5A:J#"[UW/186#/[Q;'G;E!%2U62J*FMI:>ECABF6(:/9@UC;-+<RF.G
MC21R,H)"&6-BPE$8.@2N[,\L@4/,Y+REV))=69T2R1*#Z?Q?#-!5%FC>)T!X
M^'X<CHD9)2)32-4H*8J?%T=-)42Q_<NU36_Q!EJ:ZNJXH:DPB FBAJJB:''P
M%!?Q0+'%K9FTZF8E1XSY;=U8G=.Q=]4V0V3+OKKC&4N-VIO>NZJZPR&\*5\9
M'BX<#G,CN6MVC/F,[NS;$6%I5Q68KIJC)XT0+]O/'S?WT5N!N:QJ8TNXM$BH
MS(M"S.Y15(6-Y6=S,\85Y=3"1F#$&ZW3B"QMGCCD@MZZ!(B2#30J(WU@^)$H
M-%BDU(M%TJ-*T;ZK;&)K8,C2U1RDU+EJN.LKJ9\[G#3R-&J*U+% <CXJ7%U*
M):>CB"4DX9A)&VIKH;<'>G:&ZJ/8E+N#<@RE1UKF<WGMG9NIQ&#.Z,;D=P[B
M?=V3-5NE,:NX,U1G<\TM=#3UM344]+43RM"B>60-:UM+>QNK:\LD,4T-K#;I
MH)55BMRW@ ("$UQABJR:?$T!$+%8T"UO)Y=QM=PL[XB6WNKF:>4$"K2SJJ3-
MJIJ D"+K52%+#53422YQXVBB:M*0V&06):J(RS- ZPTRTB+'3/(U/3K]L@4B
M-4# "]S[%W,_.;Y*;DRE5DMR;PVYN*+)TNX(<_M_-]8=7Y+9NZJW=6X(=U9_
M<.[=DU.SGVGN?=V0W'315AR];1S9*.:%#',@4#VA78=HCB\"&R5(5MHH(@I8
M?3Q0JRHEJ0:VV'D+M 4:0R2&1F+'I6-UO0;5O$&J*N=*UD_26#]8TK.%A1$0
M3%P@12H!%>F>/:&#AI9*.FCR-)%)6TE>7I,[G:6I26ABA@I8(:R#)1U<&-AI
MX%C%&CK2>,LICLS IZ+Y@_(FGVULS:=-V'+3XGK_ "6V<KM>2+;^U?XS25&R
M*3<..V/!6[C?"/G\UB]E8S=F1IL115M344>.IZMXX(D4*%576W6=Y<F\G@'C
MF.=6*DH)#=1107,LBH562XGA@@BEN7#3O'$BF2B])'G=[26Q(46SS"0@*!0K
M.+E44@56%+FLZ0*1"DI9E0%C6:F Q4>0K<F()6J\A"(*CR5E;+3"(-&[K34,
MM0]#0F>2)7E,,<;3.H9RS<^P]QG>':F&VU)L_%[PKJ/;4NU]V;+DQ,=-C6@;
M:^^<WB=R;LPYDDHGJ/!FLW@J2HD;7Y$> !&12P.[NPL[^2QFO+=9)+9K=HB?
MP-:2RS6Y%/.*2>5E)K4N0U0 !IYY9#J=JMX\TW ?VL\*V\S_ &O"BQGR & #
MGIU,49;65]6I7O<@ZE4HI-CS921_3V93<WSAS&]OCC7]%[SZOVAN?<E?ELUF
MG[7RE97296/+;AW'3Y_*;FBVRD"8FGWO+!3#')DX)(53'LT?@+,7)=<;#!]7
MM$FV2"TL;6VMH/"1:U2U\<H$D8EXQ*T[-<CO\;2H[ .C#;=VEV^RO;)H4FCF
M\3XQ@>)''&I8"@=K<1 VS&AB8L3KKTFUVV1NJ3<W\0FL]#'1_8)$L:DHK)>:
MJC=9*FE ;6L,BLJ3$N#<V]A]0_-?Y,8W!;6VW1]D/%BMIIM>"EC.U]G2UF=H
M-E8O-8':6(WQE)=OOD]_X/;VW=Q5V-IJ'-35U(F/J6IO&8=* PN]NV^_W7]\
MW]E%/>D3 ^(H:-FN$B2XE:$UB>>98(?%G9#,[1(Y?6H;HMBDD@L[6Q@D9(8&
MK&5)#H!,+A8UD'Z@A2<&1(=7A(68*@5F4RUVWB$;+.D-3&^:>:2M>/)9)'22
MH2))Y,>ZU8;#O*85=C2& F4>3_.7;VTQ_+;O.DVEOK86)W'@-O;-["R.Y<GF
M]N;9Z^Z]V[C<;4;TQN$PV\8MEIA]KT<NP*#=>&V[14F1IL(U!3U=- (Y$*LX
M9EMHLI(K"*4S/],L:HSS2L^B*=[J.-I&<N\27+F<1NS)X@1B#H2BB*]F@O+W
M<($B2[N$57(C0#L1XU=%TZ(Y?#DD0S(JRE78%\]<?[L88UV,R<E/435^(IHZ
M2DJ9\EDIGDBA2:. Y 2U;IEIX/N)&CDJA-)'([.K!R6]R<[\PN_=Q8#?FWJ[
M=6&I8>TL)A]M=EYG [$V'MG=F_MO8-L7+183=V[MO;;QFX\]C)*K"TM1415%
M2ZU53 LTVN6[&UQM5A=.&F@J@O6O-&IA&+ER6,HC!T JS,R*%"1EF,:KJ-?6
MM[-9PV\-LL8\&S%K&Q1&D2 1^%H25@9%U1?I.P;4\?8Y*XZ[CVUAXJV@R IY
MWJ,7%4QXY9Z_(5--1&KDG>>HIZ*HJI:..M9*F2,3A/,L#&(,(_3[S87Y9]F[
M5QNQZ7:IPV/K-K=9Y'J#<;YG$8O>NW^R^OY]V5^[<+M[?.Q=Z8_.[,RM%MBL
MK]-&KT3%&ABF!$R!_>WV^.6ZW*670;6X:VD$2HJB*>VC$:W*.H#_ %# "LI;
M4HJBD(S*6(G6!+ 0QJLUM).R2+42%+DAI8I&K^I$S:B8V["K:2I"K3)D=OXO
M*P24]9%.4>J-8DM+6UN.K*:I*"-I:3(8ZHI*^E>1 0WCD74K%3=21[ZSGRX[
M?S5%MN>3-F+>6%[5JNYJ_?3+%69G-[XI\1A]O;-JY:*LIY<-B\;US@,.M'A*
M&E@CHZ&%R(HD"H%\FUV<0M$AC*0PVMS %5G&KZV0R7<TAU=]Q<'2))S^JP1:
MN34]/M>S2?7F98WEN)K=RVA%TI:H5@@"H%0P(S/(J,A 9V [3IZE08RBIXA3
MQ01K3K3+1I"%]*TXU%HRQN\GE9B6+$ECR>2?:7E^0F]\GL#-['W/*-T35NS\
M1U[M_<^4F=,[M79%%V!4]E93;D-72QPS9^CSFZ)UE+9)ZJ2CC3QT[1QL4]J9
M(%:BQ1PI$TELTBB->[Z.V>UM=%*"(QQ/I9D%952,2$Z%/39O+YI5D>\=E'U)
MHW=5[MT>=]1J=3LK$YIJEE>@>1B<R4D<4K2PEHO)-)43HIND\TD20ZW#!BI"
M1CA=()Y-R?8#'DGV_P!,=2O9Q_G#_P S7V#_ .*Q?%+_ .!\Z\]LP_"W^F/^
M'I=N']M'_P TH_\ C@Z OX^?\>=NO_Q-7??_ +^7>_LG'M[I#T.GOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][,!\32R
M_*CXT,JEV7Y =-%4!"EV'8VW"%#$@ L>+^Z2&D;D<:'I1:?[E6W_ #47_".@
MD[^_YD3W78%C_HD['LJN(BW^_.S/ D;B,G_5'@?7V>C=O<>0V;4;^ZIVY\YM
MM[6VQB^RM[OBHJ+HK?#;PVWCG[4DW[4;4PO8:[!DWMB=FU>]\53Y>IPM-D4Q
M4^1C\SPN[.S[FN);I]MFFME+VQB*X0"3P!,+=9U&+A+<7$X@2<2)&)** $CT
M*#%;1#=8$NU5;EY2QTMK1I8UAF:&3XX'FAC2*5X6C:2-0C$J2"&6R,')6XG8
MN\ZGJ'<U1G)NMMKXZICE[ Q1PK_=;6H*:JEJMLINT;5KL[34LKT(RK4C5II
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MV92O9:]VJ@14,TI9]@=G&C,FP*3YS[?FVMOYNN-D9W"GI+L(&/:FUCCMN8W
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M?NO=>]G&[^_[)H^"/_B+^Z__ ()3M#VTG]I-]H_P#I=<_P"XVW_Z1O\ C[=
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M ,6$Z7_]^/MOW27^SD_TI_P=*;/_ '+M?^:B_P#'AT$_?7_,C.Z/_$3]B_\
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MV?\ W=47O3?"?LZ<B_M8_P#3#_#TW9?_ (M.4_[5U;_[C2^U?\A/^9^=X?\
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MSJDKE@ DC(TBQD5J9&C1W6, N45F"D GI/&K2WMAMJ*3?708Q)YN$!+LO]!
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M_P"C:^0?_P!LKWO1)_OX_L'^;K7U%M_R@)_O3_\ 073C_<#LW_G_ #NC_P!
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M7ZWZIR+8S(0BT-?CS5;2D-'70GE)H]+K^#[1![LZ ))_V3/K?DD_\S:^0?\
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M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O9QN_O\
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M4-2Q DZII?&7\8=U0,2G9+>^M-NLK3<[OZC<HX5667AK>K&O < 0M: MIUD
ML1TKW:2VE$<EFA6T,DF@$:30:14KJ<(6(+% [*A.E6*@=)SK.*>#O7OF&JD,
MU5%MGHR*IF+F3S3QX+=Z32ZS'$6UR F^E;WO8?3W7G[-^B;HQGOWOW7NO>_>
M_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][./\X?^9K[!_P#%8OBE_P#
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MSI<H\+EQ+'$8W-DJ[B^SV4P?<H-SMK*;Q2L,6NX9SXT4A9B88XH;EW,J1%/
M8N!&Z2=/NV-\;VJ<;DX][[$H=M[EHQ@'H*7 [LAW/MW.)N5FBHH\;FJW%;8R
M:5F-J8I(ZV.IQU.JZ-<#SQMJ4)OEE\8]D?'+$].2X3?>Z=VY_MCKG9_:\F.R
MNW=H8K$;>VOV%M+#[RV]ADKL1V#G=U5FX\+1YR*DR+9+ X.FGJ(VEHO/ 0PT
M9[Z#F'?>7[F*)CMDSVL\JEAXEU"565H4HZBV=B_AZIS.H4>+$I8=,VXLKW8;
M??;9Y!'<W,XA1M%? BGN($>0AJ^*_@K(0D;0@/I69BI)S];;_P IONLW^*O#
M8W$X[:>^,WL[$RTF2SM;D,FNWZR?'UF1RM/E=I;=QU U5/#Y($QU7F*<PN-5
M2)0\:DJ]F/27H4O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]G&[^_P"R:/@C_P"(O[K_ /@E.T/;
M2?VDWVC_  #I=<_[C;?_ *1O^/MT _67_,VODG_X>VP/_?/[&]DY]N](>AX]
M^]^Z]U[V?'?_ ,-L'LSHG.;_ (.T*NM[:Z]VKT?O_M#JNOV5)C<)C=E_(.GF
MJ]DU.SM^PY_(?WBSF!IZG%G,TE7C<;$ARJ_9S50IYC[?W:SO]NW-K.&U\6UA
MW/\ =MRVH*\-XULUU%I0DB6WF$5U")582)+;@O$(YT<*=NCAO]OAN2[K=S[?
M)?P  -%)9QW4=H6,FH,DQ:6.18S&5\,L"XD72P;XW>.XJG>]5@ZS;%!!M&J3
M(P;;W51[B%=D:S+8!XX<[0YW;CXFDCPT!F=_L9H*VO,ZP2>=*9O&L@X8_P#E
MO;(RV.W36XWO_*3S=!PTV0^6E+)U3+&>N\))U;7=E5&8ZMF.\R.SH:?)8Z3;
M/BK%P$S99XI](Q[/4QEMS>I9QIO-Q:S?U5:ZN[,2 )]3]=:3PVPA\ R!#'</
M,98Y3,!'#$_BA93&COVVVW5VT.UP*O\ 61H+2Y:)R%@6UNM3EQ< L6EM[=1-
M)$(J2:Q'$[.IZ3_^D3>R2YM)=D8!8,@%7JRN3?#O2;LJGK)*"/'[L+;7CJ-G
M5A;15'[2/-1_9LUG-0G@=XA_E@[0S-!DJW:7R7Q^X7:7KC>^ Q]-UY42;@_T
M#]@87$9Q=Y;HV91[KK-[8K?U-3Y5HJ/"4&.RF-R=12M%'ED>6(%G>)-[V*\3
M:KK9O'W6&?<8;E8'UJLEJGB620,5&N3<8F@FCCF^G:**>IUM!.JVBLHKR&&[
ML96^DNK9);?QA'"]-<D<[7 ,IC2**2*6%7@DN&:2/OCB22)FFX_L?+B>E3<N
MVJ';E/#LVLSNXIY,_-5PX?/8W+_PG(XV#(_P*EV_6[?I6@FD:OEKJ6L$8C9J
M!4>1H2Z?(O#5.V_BE\2-MUM%F<97;>[$^7V%K<7N3%2X'<F-J<?O7KBGDH=P
MX&>2:?"9J#0!4TCNS02W0DVN;;=<?5V\-WJB82Q1O6-_$C-1DQR47Q$K4*^D
M:@*T'#IS<H/I8X;?OHDDH&M=#TJI4LA)*$J0=-32O$\>DGUW-%4=^_("H@DC
MF@GV]TA-#-$ZR0S12X7>+QR12(2LD;H001P0;^R(^U_13T8?W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]G'^</_,U]@_^*Q?%+_X'SKSV
MS#\+?Z8_X>EVX?VT?_-*/_C@Z OX^?\ 'G;K_P#$U=]_^_EWO[)Q[>Z0]#I[
M][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO
M>S:Y7H[IJB^'.U^^J+OC"5_>.8[6RNS,S\>T_A:YS!;+I**>6BWM+_N2_BST
M]94Q*O%.5 D%PHTNZ3=;B2QWOEG;K.$W%E=[=-//**D6\R3F-(6*U +QC71R
M":U'ITOM+:WGVO<KR>;PKN&X"1H2I\="D1+* =2:&=P2X"N%_3U%7THNBW)G
MJG?>:VO/M#(4>W<;@L;DZ#>TE5$V-S.2K)WCK,'348C$\-3BXE21Y&;1()0$
MN4DTBF_P<HL1TA\>-W;D[%S1[Y^8&.RN>^-71>T^OI-RTVY<)0=B'K'"1[VW
MT^YL5'M7.]@[FI*Y,-3TN/R<,<5('KYJ,3)9=N,%U;\Q6W*NWPB?>4LK&\N@
MQ\.**VW!&EA,<G<'DBMD-W=>((8HH:!97DU(I;M<]I=[+N_,NX7 M]ABO+JT
M@D ,C33V,2M=:T&DQQ),\=HA!=Y)F9P@A36P>8GNB3-[[[2Q%'MZEI.N>EIA
MA-_]B9;/_:SINY=H8K?E?BMO;6I,3D)\EB=O[9SU"U?75570L*BJ$=-!4K'+
M(N7=?\L?Y,[0Q^XMR9"3J?(=?[8Z_P YV-6]F[=[6VON38E=B=J;[INM-Y8G
M Y3#35E=N#<FQ]Z5:4N:I:.EF&+A(JZEXZ-XZARN/=;)Q*S2%%"[?)'K!7Q[
M?=/%%A=PD\;6X,$ZK,^@+)"\$@6?3$QDVW3IN$&U.R"_)O4D74/\7GV^%+BZ
MMK@\([A8Y(FCBJ3.)5:#Q%61DC;8^2O6^Z9\%CZ>+=V'SV=WX>NAMG<^TLOM
MW/87<<FTJS?F/&Y*/)PP1X*@SFSZ,UV.FGD49!'6*G$E0'B63W'_ "X.S-A_
M+FE^(?66]-D=W;JJ^OMM]EU&[=O9.EV_M?:NU<AUO3=E[KR_8%=EJZ2AV5A]
MB[>-165E955)BDQ<<-6MON8X@OADC>;GPS-X&V<O7=[%<W,H98O"LKGZ4SB@
M9_U9C'"L*JT@N9!;*'DI4LM9H[S9O;[=('5[OF.WM7MK9&#S>-=?!;$"@9\%
MM0H/"5I6THK$-_7?R7VSO?HVA[TS>S>P^M<9D,QFMOTFRM];:FH.P:W,X_>N
M0V)A,9B]MTDE9/E:_>V8I(3AHH"[5B5D-K%CI5W9?\NR;H?X=]K=^=O[KQQ[
M'Q7;W2&R.G]O[.WQM.NV+O\ ZV[9V%G>Q*?M_;V5^QR-?V/A<OBL9'!04N,D
MH):3155%81]N:=B'<]_^BYCY:Y2CVV8;Y<76Y1W:,*O:"PBL62.2)<HUU]?!
M-#<%W@>!HE0,\ZE#2PLDGCWN_ENHI-ICL+>6UDB;$\\MW<6TR:F7_B(UK/'/
M#I683*:T1"6:]B_(^/L[N#;.QMH;:S]-M&KZHWGOS<NXMQ;5S>.J<1N[;/8>
M,ZZJ.K\BT\U+3;7WIM_)"NFR%#5QSSS0I&U.!$KRLM1_*0[B;I3K:L5 /DYV
M#W94[2KNHCN;:<F'ZTZGIN@,?WS5;P[=K(9WR/6^X\5MG(Q9"KHL@R/'BIHF
M\7G81D^WMX]JWRWVL7$7T-IM6[76YW1:MM:2[7N%CM\ENDR5226*XNS;W4:A
MVCN?"C4MJ;23['=1;Y:7%U9_JO/-M,=C&G]M<_O0;DZ/X34/A21V22V\@(#1
M&61P$56Z:J;Y>;#J=V[V@C2L_P!'FSMN8&:FWF^+S$*;WWIN/L?-]9X;;/7;
MST<>*WNF9W-A_P"'T<E!42--D)$C T21NV6;^4SO^I^.<^\L)N;;E5\A=O=\
M]M]=;AZTJNP-A0[2W7UYUMT_L_N ;PZ<W!'D&?L/*P[7S5;D\E3T\I^TQ=/&
MQC%07A"'==P2SO>53:1NVTS[-N%UN+.C"2PFL-[7:)3(@!/T<6M'EN%#K76\
M1>!&?HVMK&1I.9K2\:-;NUN-N6V97!BNEW"TN;B*-7/:+F9X%CMXF9-3.%?0
M[*#SB^6>V(^TL3M#(X'=%'LC='7W5N[,!O\ .TMT?PK$YWLK?&^-B46V>P:N
M3&I1;+JY\[MNCI*45+ O5U;+*8U579IH_P"6IMG!_P Q';WP?W5WO@-U[>SO
M7>4WP.U^O_L*"GQTDGQ[SG<N"I]QT.?J*^GVM1TN2H((\C)4R.R8:3[Y0OD1
M%0[MO$MERS[N;K%;JFX\M?O)$\5J6\\NWWHM*M(,JDE&U*H+1S@V]692QWL]
MK%N*>W-T[ZK??HMOE,<1#S0+?>'5"*4\1!)J4D:732_:&H.--\J3EOC'2?)"
MCZG[0P'W.=Q>)?J_=NTLA#V9#'/VU1]9UH3:N)-?65==50RO78^.)F6HB>(N
M45F*AA-_*P^7U/3;WRDNU]D)MK9^S]L[YQ6])NR]GTNQ^T<#O#9%9V3MZ3J'
M=U9DJ?![\J\AL7&U61\-/.KQI3/"^FI*0N97M['MMGN]WN*- ^W[A<V=S$U/
M'ADL_I3=R/"I9S#!'?6<[2(&#P744D0D&K3;;]MDW;<+7;=LN(9YIH(Y$96_
M3;QIIK:*,N0!'-)<VUQ;A)-!$D+AM*@,5C1_*+J2MEV)1QY'/197?M;6T%/@
M:C;&:AW!M:?&;SBZWR,F_,(U)_$MH45!V+4PX.6IJXUITR,R*7\9,@,3WG_*
M!WUA=P[$VS\=-R8#LV:KZ3Z>W'N'+;D[*V1A9NQ^^.S^JJGNVMZ;Z1V>U)C<
MU6YW$==-!6T>.JYZJMR5%+3U@DB_B%+2 OW;?;;:M^]TK.='7;>7]UW*WC73
MXES/9;)#;G=MU"QDA[2UDE9Y]"ZK:,&)O&EBF*H=B7]\;!R7N,CQP7NZV\$C
MZW"P0RW][<6NW6;.P&F>?P-(+D(\@D(\.) [!;L'YF;>R.V*3='96W-U[%AW
M!V5V1MJ@HJS9>:HY=A;*V=VCE>I=O[O[6K)JNNH\#A]W;BPQDI,HK+CYH:I"
MG[<$\X+CLS^5W\J-]9C&83#T76U//4]2]>=S;@K\SV5M[$X7KW:G;TM'%U/C
MNQ\W52C%[/WAV-_$(7QN(J916^%S+.D$2NZB&[@GL[S=[*6*LEIN,.WZ@R>'
M/?SV\ETMG;2%@DTJ6\4DLI4B*,#2TH<A3NS3ZZ':YH6 ^JCO9=+5$D-OM]Q]
M+=7%Q'37% EQ^FKE:R,1X:L"*B?N7Y2]2[4HIZO*U>Y14)O+?FR<?A(=I9YM
MR;BK^K8Y9^Q\OM7;TE'#EMS;7V924L\U9D:**:F,5.[0M+=-:?ZS^!F[^PND
MOEGVG5;^V9M?=WQ4W[UKUQD>I*RJCR^Y=];HW_O7(;'EQVW\CA*RKH/+196A
M9<?X%K5S<J31TS#Q:G*+K=+:':.2=YMSXMOOFZK91*:QR1AK*6\$SQNH?2%C
M"NA"-&OBR/00LIW%$3S!OO+]RRPO8;5<7K3NRB!A;SPP&))*T+MXNI6^$DPI
M_HX97C<?>N'P'9'2^P8=J;RS>-[GV[V!N>D[&Q6'9M@;)Q6P]OX?<0FWWFJJ
M2G.!.YZ7,+'C@Z$R31.KZ./:ZSO\ISY=X#);OH*O&=724FP^L<+W7NO/Q=N;
M,AP>'ZAS%;NO#5'8U34Y'(4-5'MK;6Z=GU&%S#&$5&,R]124T\2O50ZM[AN4
M>T[;NNZW]K<)9V=W%;2$1/)^I<VD5[8,IB5PT>YPRJ-ND!*7<P:WC/C+HZ?M
MK*:[NMFLX-)NK^.=H5)T$FSF6&_1M>G2]AJ\:[5J>%;*]Q5HE9@CL1\Q^@\O
M#M@G=59B<AO#M/.]'X#"9S!97&9BO[@V[#%D<AUQ3TTU-XJG=,NW&DS-+!#)
M(*S"TM370-)3TT[Q\-@_R]<]W)\(MN?)3J#)5>Z>U6[*[WPNY^H:K)[>Q^0R
M_7/36R>NMWU^X^J,'-(FY^P-QX.FW=55.=H:19I*3'Q031QMJ?29<QI<;)<\
MGO#;M/M=_LZ7-PZ@L]K-/OIV.TUHN4M)KA[:(7+]HN9O#8HBZB7;1<0;@>9H
M+F>."XL[N**$NVE)@UA/?2IJ(I]0L=O*Z1U&N-"15J N.7^1>(VQ\A&Z/W-@
M\Y14F5VQUYD]L;XH<%FLCM4[DWQE^P\5!M'=6XJ>D;#;:S60?9"'%P32:ZPS
M$$J3"),>3_E1_+K!;B;;6X\7UCMFIQG76?[.WO7YWMO9-!BNK]O;2K=J46[*
M/LFJ;)/)M?/;<;>V,DGI'CD>1*G]@S-'*J,I<V<MW=VEO>Q2&*ZMK8.K5CEN
M+R_FVJWAB?@SR;E!+94QID D8BW99B8?0W2V^Q7#Q%?WBCO$A!$BHED=Q+R)
M35&AL5-R"1F.@_M#HZQTORRZ?R.W%W/AZG=N=H,AN6BVKM2'!;*W)EZS?V0R
M^ S.YL!5[(CH:":#.83<6%V]6S4=<)(Z5_MRKNC,@?)E/Y3_ ,O-JT&Y<OO_
M &_LC8&,VCOG*;/RAW-V)M2CR63QNW-SX#:NZ^P-F8PY#S;WV)MVNW)2N]9C
MFFDJH7+TT4RI(5=V*XL-WON4K::9[=-SNK2&0.I6:R%Y?S[;"]W":20AKVUN
M+?(.B2(M)HB9)&3W$%T-OW_<-MC2\CLK>61#&PT73162;@8[:0]KO]')%.0:
M4614S-^EUGHOE5U'F<EB\1MFOS>ZZ[,[8QNXZ(;?P-?6T\=3G]FUV_\ :VTL
MM4E(XMO[SW7M/&SU>/Q]?]O).$T$K*\:.:WO/^4GL';E9W2O6?:]7MW ]%]>
M?)[>S[P[,WGUMO+;_>%5\<=W[0V768;K =?C#97:]1/E\[-#F#G:;1ALC+2T
M"O5NTDX#$&_SW'+^W<RBQ$4=W9[3-':2-IN0-UWV_P!G21GIX)A MHWBRLL\
M@EJD43Q/TO6UM7W#E_:$NHC<7=W>6\D_B 10/9[+!NSI+$5\5)&\5@%!=1;Z
M9=1<-%T%>U_EQDF7K>+<>S,QN/+=F[QZ,V=)MS8>SMS4FX^H)^Z>L<OV3!EN
MY,?N.H>FP^#P4&*-+4U-!4UGVTK*M0L4C>-:J?D3\:>R_B]NC;NRNU4VY3;F
MW%LK;N^XZ#;6X*3=-+08?=%%'D,5!59S$K/MZMKFI)5:3^'U==3QL2AE\BNJ
MB$SQ?O'=]L1M4]E.892. D4D,HK1L$&C%0KKI>,O&RN4<=O))LNP[\ !9;C"
M980?C\,-I!D7C&6X^&])$X2(CU4&AZT[.VKVUMZJW3LV:NJ,+3;BW%MD5&1H
M9L74S9#:^5J,+E&.,K/'DZ&)<A22*BU<-/.R .8PC(S%]]O=,]"%[][]U[KW
MOWOW7NO>_>_=>Z][][]U[KWNQ[X';4V]OOL#XZ=<;HP_W^T>U?E%3[.[&CPV
M+VX-[9O8U-@-J5N0V_MG<^:P>;J=OY&:GK*H4DL"@1U4ZNP:PLG4;5XV[W&^
M/,NUVFSW]RSQDZHC;VEQ,LV@?VHA:-96A_T94,0(+U"??=SW#9^6GO=HC@;<
MFNXXT\5048O)#&%<T)5#XA#,M2@.H D $-^X,QNG;W5W8&;V-4X&DWQC]I9N
M39E3NN&KJ=K0;K:BEBVY+N2GH*BDKI<"N9D@^\$$B3?;Z]!U6]GH/Q6QN3Z^
MSDFV<KFLUO7-?*G8N.ZRWA@-B=59_"'X3[\ZW[3WK@M^5>S*S;V#HLWO2K_T
M>U-3/-45=-54]-B:P+$Y.EB3;K:0-R%8;_=VUO<36VZ?O><.[)!<V<>U/;^$
MD4D@%M,E]]271F?P[NTC*5H6%VX368WOFVRV.X%W$?"&V0M''&]1N7T5P9)0
M)1(Y9_IEADT!)K:21G!<A _RW8&_</N2KKIZWKT[,Q74N<JJ[%5=3DL3EG[C
MPVX\1C9*([EJ9ZC'T>SYH<BE-$IHY*IZF9&UD60I?<'PHWEMC=V&V;6_(?;&
M7S>5[%^36,_ANV_C'UW7Y";JGXQ[*PF]\WNS;=%7'&UN[.S-_4>XJ:GP6T*:
M%)9)HYFFK8T"%W;00222QW>WS(]IM!O+U4>65X)GW6?:(+:-8ZK,OC6SW%U=
M%XXK2U8.ZL4E"$(WN">_N+"SNE8R;MM]E:LT I*M[:+>//,$C=K<0*Z0I%22
M2XG<(@49ZCXKOV7+[1;>J[17"8"KVGUIF\-D=T;B&(IOXSV%+7056*W7]MB<
MI)L_$[2F@@6LR,PG20S$1QDIZWW=GPNR&Q,KO.@WQW[M[ [4ZIJ^[\AO/?\
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MYE\%E#6];ETEN93;D&$SSS113R3E#*9HHY P91UL3S+$B0OX4RR0,)8Z)/\
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M]TM_Z!_?_P#]J#W[6_\ OH_R_P _5?IH/^4Z/]C_ /0/4_\ OIO+_GT&\/\
MT(.MO_LV]B3LC&4?6U.]+L'Y\]=;0B;))FD; X'Y"XZ>ES$=-]FF6Q]7!U"M
M5C<F*3]K[BG>.7Q^G5;CVS+#'/J,UIJJI4UIE6PRL*T96&&4U5A4$$'I3"Y@
M1HHMS01D@D:6(J.!H5.10$'B" >('6*?=FZZF)X:GIK==1#*NB2*?.=9RQ2)
M>^EXY-Z,KK<?0BWM:X_>V],1)2RX;^9;@,++055-78^7"Q?)/#RXZNH5J4H*
M['28WJ>E>@K<='6SI32PE)*=*B98RJRR!M+#&DGC);,LP4KJ!HP5D6-@&#5
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M X2.2K>)&H"/J;4IU-5H;IN"B4"Z8+)HU#%&\-0L6H4HWA* L=0?#4*J:0H
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M5=5/NW$8-% HJ3(FIIJ,#]E$]T;:]N=%C>RB:);DW(4J"HN6%&N0#@7)&#<
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M,NZMNQP5?^S =Q3FFE?,48280RUOCE,;&]FX/Y]Z9)-)_5\O0=7CGM?$2ED
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M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V<;O[_LFCX(_^(O[K_\
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MO>_>_=>Z][./\X?^9K[!_P#%8OBE_P# ^=>>V8?A;_3'_#TNW#^VC_YI1_\
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M[-_Y]SOO_P!!#<'_ -;_ '[6O\0Z]X,O^^F_8>O?WNVI_P ]/M[_ ,_6-_\
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M7O?O?NO=>]G&[^_[)H^"/_B+^Z__ ()3M#VTG]I-]H_P#I=<_P"XVW_Z1O\
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M9T<(S9*FI89YJ*!2Z$NX "RHQX-_=>-1&L-1-$I9EBFEC4NNER$D9 67^RQ
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M8<>^/^S7?*3_ +R4[^_]''V)_P#9'[WX47^^U_8.O?5W7_*3)_O1_P _7/\
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MZN[_ .4J3_>C_GZ]_H$Z+_Y\MU-_Z+G9_P#]9O?O]FN^4G_>2G?W_HX^Q/\
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MKWU=U_RDR?[T?\_74?0'0\4:11=)]1QQ1(D44<?6^S4CCCC4)'&B+A@J(B*
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M&Q3I2C?LHR.$S'^@+Y'_ ,7PE"N,3*"#8RUV5QJ$R+0;@F7LU3FZ5:DF95J
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M6_Z!Z]_IOSG_ 'CYWW_YY>O/_ME>_?[*-MG_ +S/^&O_ *&W;G_VD_?O%/\
MOI_Y?Y^O?1+_ ,IT'[6_Z!Z]_IOSG_>/G??_ )Y>O/\ [97OW^RC;9_[S/\
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M_P#SR]>?_;*]^_V4;;/_ 'F?\-?_ $-NW/\ [2?OWBG_ 'T_\O\ /U[Z)?\
ME.@_:W_0/7O]-^<_[Q\[[_\ /+UY_P#;*]^_V4;;/_>9_P -?_0V[<_^TG[]
MXI_WT_\ +_/U[Z)?^4Z#]K?] ]>_TWYS_O'SOO\ \\O7G_VRO?O]E&VS_P!Y
MG_#7_P!#;MS_ .TG[]XI_P!]/_+_ #]>^B7_ )3H/VM_T#U[_3?G/^\?.^__
M #R]>?\ VRO?O]E&VS_WF?\ #7_T-NW/_M)^_>*?]]/_ "_S]>^B7_E.@_:W
M_0/7O]-^<_[Q\[[_ //+UY_]LKW[_91ML_\ >9_PU/\ A_?;ML7_ -B>DP!_
ML??O%/\ OI_Y?Y^O?1+_ ,IT'^]-_P! ]=CN[-D@'X^]] $\DX7KX@?XG3V2
M38?X GVT_-+<>S]P]S8V#8^\\%V#A]H=.=#=>5.[]K)EUVSF,_L#I_9NU-R2
MX"7/8O"Y6LQ,&<Q4\44\M) 9@FL+I()]""$-5H22?VGK5^R-./#D# (@J.%0
MH!IPZF?'W&[BH.OJJHW1MK*;/R>X>PNV-W1;;SD^)J,YB\1NWLS=>X<"F8."
MR.7Q,.1J<+D()I(8:JH$!D\;-K5E!2_;O2+H;O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[WW8_6WXO_ +#^OOW7O3KW
MOKW[KW7O?=B?]O;_ &/OW7NO>^B".#[]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MNQ_I_C_L/Z_ZWOW7NO>_$$?7WXBG'KW7O?7OW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][[L
M?^)]^H>O=>]]>_=>Z][[L3_O7^Q]^Z]U[WT1;@^_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][[TG^GXO_ +#^OOW7NO>^O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?__2^?\ ^_=>ZW^/?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O9N,KW5TA6?#;:O1-#T7CZ#O
MO$=L97>>;[_#8QLAG=DUM%-!1;*9/MAE(8Z&H=6OY=#!!?Z !-NL$U]O7+6X
M6<W@V%IMLL$\7 3SO<&1)B!@Z(R$U-5A2@QTNM)X(=LW.TN(O%NYKC7$Y 7P
M$"0@H".Z36R2$ZL)J[/B>J,H\!N*GWSFMQU&ZZFKVSD,'C<=C=FM2Q)28?)T
MDTDE=FHJU6\U1-E(F2-HW&B(1 IR[WM1Z%^-'Q/W9\:OCSWGN+9O5]9LC"?#
MCYF8GY);WK=[S4E;@/DW%OC/83H"#<>"_O+3Y>E[%-!N7 -MRBIJ/[;*12)*
M8YXX:IHW.88F7FOF;:K.Y,-GNVQ\HVVSLJZT.[76Y00[PT1X&2*WCNY+X3,(
M;:!&E8Q(T;L1[5+N,B<MS> )WL.:-RDW)" *;.NU&>S\8\? >Y1EB:*LK3?H
M9>B$IVZ.VNP*+N'<'55-F-Q46X:[OKI_(;-Q(VQ324^2Z%_NGM'*]F9#%Y63
M&/15.VZ?*8S.T^1K)9?NZ.K84\;))+2*Z_D^!OPVZ>I/DGC]J=S;?R]#34_R
M&^*V>W5W?FNJ-UP;=S^R]S?&_,8+Y&=:T>T)8JW%XUL7O7)T:Q1-6U!%)*\%
M:4:HCA4;),-[CV;:KLI:;;O\=E<QS $W%B;/F_\ =%Q!+(_AHPO[-8KI5TP>
M'$\PE:6W"3LJW(7.U16&XPV,MUN=G:*\T"&J7#WW*MYN)C12E8VL;L>%WF4N
MZPZ1'<TB+;@>V>_=TXO;&5W7L\8[)T^"ZI[CQVWNO*+=^+;.TF].N>W:^NZ:
MW#5[LBIXY<[1[IV930232I101-DJ+[FG@=0947)_*J^(N3[^W#TJG=G<_5<>
MR-O9CLO([M[I'4NWMB=J].]4=B+C>W-T]%]@8S+9'%[JW+N3JZ89G:V/JJ2E
MIWK8C"]34Q3*\8)/-%]!L&Z<U7^RRQV6WV,=Q>V2ACN5J\T-]#':_3&C7!7<
MX]NMY)HJL([JX?Z8+;"1Q#N.S 7&R;/LER+C<MRD>WM+E@5LI9O#M)TGD8=\
M%N()+O6KU;5%#^HK2F(,R_,??-%U?M#L&JV+BMWS]B=C[7ZBVWB>K,7O_>=?
MMCL7LC XP;1P_:F*I<$:W8N V;OVM?%;HS<[?P^BH47(2?: M3(C]F?RU?A[
MNRN^%T([N[F7:_R;W)A<IN3MBGI^HX>J=H[,SN$[0W%ENL:[=N1W! -I?(7K
M:GV7CZ*OHLC32X[)UE7,T9I(U@\I]NU]<;!N',=KN<"R1[/RU>7TGAZE.Y7%
MKL=MN22[465M=G/N$L^W^%(#<QK").^<FW!-=^'<<LR[ULBR_53[PEK"DJ%Q
M;H^[C;PM\(]+*[69&XK/%JAHR0Z2C&=5+E/DCW+._P B,=MKK_9,>Y.JFK\)
ML_:FXLCNT[LR667/X;"[4WGN';V!PN1:KZR[!H,I-E:.HQU0U714M)X95EED
MD:F=_CU_*N^.GR)ZLZQ[%P_9/8>VJOL[N7;U)@MO0[PZTW?5R]-YG=':>!S&
M$R#18/;]?C.X=AT77U+7YZ>*BJL/B\=E8:J2%D=%]^W*YOMBM=CEW$6\MT;2
M[DO%0M% /"V9]VAN()V$I6T25/W=<M-%J%V1&A$A\,J;E+>\??WV6TNH;+ZQ
M;>R:Y"%VD7=++;Y(Y4C*J\LT%U)?VB1NOBQ1$5T R=<>P_E7N_8?8W8&SAMW
M 9C%;&Z9W9NZMK4H-RT&=H=^[=J.NH,'%68V:6;"56S>Q?[^R)A%3)PY"HK,
M544PU@//"S[H_EM?%'#[+[GWI%NOY4T/]S]Z/LBAV9)L_8V9[!ZAQ%-T]@=]
MXWY =P[7KSL?);A^._8^Z<I5+M_,8F&D>;;F/DK1YJETI1M9[SP>7HI;FVCF
MW"XOP;EL6=HUMO5MM\.V;BP9Y+3<OH)7W"ZJ&2)FAB2*1%F=3.?;+>*^WV&*
MWN)EL[2W>*.,JTE\9K>\EDN;)RJI-;0S6\=HH.EI9FDJ\:F,GEMWY*]E5FYN
MI]H9.AZBK:K=NU,'N+([HQ>>SE'M?L3)U^ZMTX#=6R>GZE1N"AI][=<8_ T]
M3D:'+UY6>LKTI%EA1)*Q1%^3?Q@^/7QDZK^)O7&RX=G[KJ(OYB552Y+M'>>>
MZEW;F>XNK9M@=(U.-W[03[*6.OQWQTWA65E;4XC'9=IFB4S^29YC.$$O+-]!
M<^^WM-:;E:+9[!#:7JW=G<KFW\/F1X(SNLA"6TT\EE")(V5%06[2:#);-#-(
M$=R@GB]JN?=QCN6FW"ZLMHN+>6'4%,DVSW\MU'8JR^*OT]TR03Y8F5(0X253
M&J:ZG[?[4[=C[TW+E):^BIH>@\#-MK ;.P._MO2;)WU45_<"[AV=6R;I@>ER
MO;NU9*#'4M=/BBH22.'7!&CTQD%_Y$?RS?AOO?Y'=Q;TQ.\MZ[4_C6XODMOW
M!_%KJ3/]);CWGV'M?:'<FUMK[3WQ\<OX"E-M#%]5[BPVZLE6XO UWER_VF#D
M\#S4RR3Q13R=>;IM>Q\G[?NBWERK[1M$EX[1NUWM4E[?WMK,NXB0QBZDAM+>
MTO"81"*7T7C-$C122CS=H;>_W!KQXH[:%I'6%@0L.X"':;>[_P 4 4M;EKAI
M+>1Y?%76C! TZO B%ZT^5?=6'Z;VZ-Y4.R\EFL5'U-M'*]N;BQ78NTMC8K<F
M=Z/;>VXL1V+1YYLKN^'=6/WKCX,'65<3/!!5YN!JM(*N":A<LFV?@C\7NV]K
M?'C;^SX=UX0;>W1\UZ'N#=6=WKL;9O=/:,?3FY<'/L7KB@ZNJ'WAB]M=VU.V
M,NE;C\.U8]+58VEK2M54,GEBDO:42_?DJ?<I$AMK_8K*2;Z9A,JW$^]/MTUX
MCR>%_BMI%-#=W:.B-#9A&UL8WDF!4R7-MN/-NW6UA>32Q\RI:VSS*L4<<+[-
M]<L$H4%B\UQ;S6L%Q&S127+!="-*L48I[I[Z[?Z\R_=^4W5)M5<1_!N@I>J,
M8NU=U9+:/7N1WYM[<-'NS.]B=AXYZ*?=G71WUAC3?Q/'XVDGQR&(34Q,Z 55
M?,CI;9_QU^4G>?2'7V]#V'LCK3L',[9VKO1JK"ULV?P=*\<N/JZJLVY4U>!J
MJV."<13R4CFG>:-B@4'2 MRINU[O>R07^XP)'>>-<1-H#A'^GN)8!-&).\1S
MK&)H]53HD7N;XB>[U96UC>0Q6K2>%):6LVEZ:XVN+:&=X7IC7 \C0O@'4AJ%
M-0#7=.;URW9'4O6/86?V]-M+.[XV#M'=F:VO4+6++M[*[@P-!E,CAB,C28_(
ME,=5U3Q(:BGIYV109(HW)12T>Q'T4]"1[][]U[KWOWOW7NO>_>_=>Z][][]U
M[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>SE87O3H.A^&.[>B*_X_8ZO[_S&
M_<5N3"?(1GQ/\1PVV:.K::LVP(I*,Y/14TY,89)?HQ%POI*;>HI[^3DUMOF\
M!+%KHW0X?4B4+X([:$F(@_'44I0>85;3-'91\P+?)XXN6C\ 4 \#3$Z.VHU9
MB[,IT?V8IK \2AZ0S[<W(W846Z!NZK3:D>WCBWV.(%-'-FC4O*NXWKB_F6:.
ME;[<4P A8?NGUA;6"?$[XY_'/L?XJ= =PYK9'7.YY.L-T_.^I^7F9R6[ZC&9
M3;6U\5T!0;@^-4N]\$-QX[)#&56^(ZG^ S8RF9LAD4:C8RRZ83?F6[M=JGMY
MFE\+;KGDB9(W'<K;ZV\7]O%&M U+T6TVVE(&HK0,L^DQI.Z)M@E^J;<+"9->
MY1<V;.X5EX;,R1?O!]6!],#'<"=R0\;4"LIDC#%OWGVINW;/<V^>O,GG\[B1
MO->BDZ/HZ3:\62BR+UFX\K0=KR8C(Q8NKI9Y,=0PQ2Y-,A*G\.H]%0/''('(
M[; ^#OP\ZAQ/;^Z<'V5C=Z[DV1T%G]J[TH.Y\SU%N#:&1SW>GP4G[GQ6\NLL
M/A9%S.-SO2N_ZR3'L6?(54T\48B:FKE,+(>;GNK!]VV>V=?W;=[]N^SQSIK,
MUO\ N+F/8XEW)BBE5MMQV^ZGI&FHTAF,<UQ"\@B,N2YDN[CE7<KBQE;<(]ML
M-SDB)403C<8-XC-@5D%5DA-M;REY6H&E4R11TC9D%1=R=V;]RVQJ/-[;K-FX
MC,;SVGN;'3[1Q.^J.NH\-M[O_-]=YO:F]ZS+44,.0H-U[1CQN5++3T"11/5)
M)'-3"*K9(U7\I_XF97M?$?'K;OR"[+VYOO>FT*W)=/=Z]CKU=AOB9W/D-K4'
M7&]=SYK:O8M!EZW+4>*RVP=P9P8VAEIF>GR%#3"HK&US0JN^I W#F*ZO+2:V
MV?8[B2;<;272-R7:[7<[FSN;BS6IBN[B2R2VW"VA05EU2PQB4-'*"JX,J;/R
MA<6%N]Y>;K L:R1*_@)N%WM_U%G#,&&N"&.^!LKR20ZE5A*J*RF-V*;YM[\P
M'4N?[KW-U?!EL!M7<>W,%O7K;K+'[[W_ -V==Y3>=7D=H8G:6Y=B8O;HK,GE
MMM=@5.'7,9&@62DCP]965JP)3X]IY@P'\O?X8[CPO4>XM@=P]]9G9W=_R0P/
M7. [(DQ75<^PNK=C9GY#5?4+;6[WSHS6-.R.U/[B4D>Z:6OCIZC#5$5=31M!
M' YJ@]LZ327G(.W;]X,%U>[5!>WC*X6)O&VN]W"6VL)'KJNMON((-ON8)PID
MG-P5:/1"LJG>H_W?L7/MW9PO-N>U_5QQ!074SVOTJ1O*J9:UOI)I9(&C;Q8H
MEB5DED9P@I9#O_M^BW7VMM'^Y&P5S?676.8W#!@JK/;ICW!O;<./ZWP&[,?N
MO96.H=O9(9_K#+;URU5MLQJ\>9I:C&R3-&[2+3*OMA_RH_CAVAL;?>Z]J=N;
MW@:L[HS^T>EJ>EWEU;O3*U>U-H?(;;?2N4V?V7M_&XS U5'W1N?;-96[KP]'
MB)*NC;"B*I820*S.2;3?;AN>R>VVZ-:B._W4[3)<P,'6,V^[6^ZSL;:<@LC[
M2=OBCW4SPZ(/J$8A2ZH'-\2WV^\Y[@L@[6.U?501SO32UW9V]E*"]"%-M?R7
M,L=D58.\D#P@NZ-5*[A^6'8&T>RMH==9G9V!J:JGZPW#N3M2OBQV],51XW/X
M;IVN[0@W3L6LJZ.MH,KU7+F<5-MZHFR4N/K:?*.D8,D@:,Q=]?RR?B=MNE^0
M&:I-R_+&GBZDVOUU_"^O_P"[&P<[V9F'W=M3?>=W'\A-L8C)TW7H[-^+6VMR
M;9IL##E,9'2U%7.*J=I8A]O#(BN=ZO8MDNMRM4@DDEW>]MX3)JB6R@M[#;[N
MQ_?"J9I+2;=GNYWMF"%%LH%F"32N8E.=NVJSGYF&Q7HE'A6*3/X)63ZJ1]PF
MM)4L9"J1R/811QM>Q.=2W4IMU?1&\HP[)^4W9V9J>F,'FL9U,]?V-7;G&9W;
MC\QF*'9M-E<-OO&X&FZ8I((*W=64PG=]'M#)R9/)4E=))1T]9CIJ*,RZS/3M
M'RJ^*_0'QK_EZ2P;%RNWNQ=U;N[^^*&Z,1W9E<YUEF*WL?;F[OCSV%N;?$W2
M^.P44._]I]4X#>-?'B<I29DS2OD\?$U1X9U^WC'32+;>ZGMWR\8XX]MM>8=Y
MAECD(D>>V@DV..SO;F5/\6:QO4-Q<62@N!'+)260B;2%.6O&O-AY@WZZ@F'U
MG+VWRKJH(8+H[A?">SCC:LJW]K$L*7C=M?)!$86D<ND.YNRNU/D5GH,W!/@]
MF8/879.,?946V][XJIVCNG;W;^.VYC:/?V7R$M;LC+;NRNU*),E1&AD@D_A]
M<[PI/2-'52FV^67\NKX?]M?*O.[JPV^:;JJBW51]A9G =-=59SJ"IQWR CZK
MZ$ZPW%1M\6J3!T]-@]EIGMZY3(8FHQ^<>MJJS)4-3]HSS^:"$';0)MKL.<;F
MXM=PNO!O]TN4MSI>ZAMI>;7L8)F(8AK)=LN'W"V1$5TLK,:5DMJ3A?8EKZ'V
M]M[Q/!CO+#:X9+L@^$93LTD\RM&U)%N/J;:*TF=V*"ZO$,IC8A) 1Z2^3G>.
MV>B**3?L.(W;N' Y/KK;VX]V;AV_V/M^IZLH]\[HW]CZS/=TKN:63*;BJ-K8
M;!XFHJ3C_L/(,I&T@I:9HJARVP? CXM=@=<]3]?;"QF[MK[LI/FO\@.O.P^Q
M.X=Y['ZN[5@Z[VKTQM7L;9O5.\>O(JW>V+Q_86\ZZDKL9L:II2*+-Y5*A)&4
MU,-/1OQ3W4E_LVY2$S;(G+FZSO'9J97W">QW66%/I%*_IWJ6;P3W5E++V0!S
M$\HB>8JS;PPP\RVJPSB[;=^7XHFF "V4>ZVVF5Y9%4"6Q2Y5U:ZTQ^$QC:18
MP5CE&*/Y!=I;8W=V%F=]Y79<NT?]EYZ.W_M#:.T-I[LW-3X7=&Z]Y[KVCOK>
MP['27#TV[>LL2U7AZS(0#'TF4Q>.C>H8>-E,E3?S1Z6V1\>/DSVGT]UQN++;
MJV3M#(X)=OY?<-3@*O<8I<YM3!;DEQ.XI]K2S8!L_MZKS$E!6BE.A:FF=2%8
M%086YD#[G;RW<%P;:_N[<30AA#.EM=301SQ:B3HF2-9%()4AJJ2I!*6XB:);
M)WMI()I;6"5X9/[2&26)'DA? [HW+)D5H,YKT:/HO?>?[-ZDV+OO=&(Q^"W!
MN/#?=Y7'8A\K)ATJHJNIHVJ\.^<H,9EWP^36F%32&H@CE-/,FJ_ZB5OVHZ3=
M"Q[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__3^?\ ^_=>ZW^/?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]]W_ ,!_OO\
M8^_=>Z][]?Z<#C_7_P"*^_=>Z][]?_ ?[S_M_K[]U[KWOU_\!_O/_%;>_=>Z
M][6&P>PM\=6;NPN_NM]UY[8V]=N5$E5@]T;8R=7A\UC)IJ>:CJ?M:ZCEBF6.
MKHJF2":,DQS02/&X9&92ZDTD<=U$&K#/"\4BD!DDBD&EXY%(*NCC#*P(/ICJ
MCQI(8F=>Y)$D4\"KQL'1U(RKHZAE8$%6 (((Z:<[@<-N?$5^ W#C*/,X7*0&
MFK\;D($J*6IBU+(HDC<$!XY45T86>.1592& (R]A=D[][9W;DM]]F;NSV^=X
M9=:./(;AW)D:C)Y*>GQU'!CL;1B:H=O!08S'4L5/2T\82"GIXTCC1455"*WM
M+:T65+:!4#R-(U.+R.Q9W8\6=V)+,Q+,34DGI7<75S=F(W$S/X:!%!X(B\%4
M<%45)"@ 5)-*D]8MN;;P&S\'CMM;6P^/P& Q,!I\;B<7314E#21-(\T@BAB5
M5USSRO)(YN\DKL[$LQ)15_\ >?:CI/7I[]^_'T_V/OW7NO>_7^G _P"*_P"O
MS[]U[KWOKW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]]@_X#_8^_=>Z][]?_ >]UZ]U[WZ_
M^ ]ZZ]^?7O?K\WX_WKC^GOW7NO>W[:^Z=R;)W'A-W[/SN6VONK;63H\UM[<6
M!R%5BLUA<OCYDJ*')8S(T4L-51UM+.@=)$8,K#Z^U%M=W%G-]1:S-'-I9:@T
M[74HZGU5T9D=34,K%6!4D=,W%O;W<1@N85DA)!*L 152&4T/FK ,#Q! (R.H
M>1QU!EZ"MQ64HZ7(XS)4E109#'UL$=31UU%5Q/!54E533*\4]/402,CHP*LI
M((M[5/:7<':/=NYDWCVWOS<W8>YH<70X.ER^Z<K4Y.HH,)C!(,=A<:DS^#&8
MBA,TABI:=(X$:1V"AF8DNM[.UM&N&MH%1YGUN0,NVE4!8\3I1$C6IHL:(BT5
M5 73W=S=",7$Q8+JI7RU,SN?M=V9W;B[LS,2Q)+)M#9>T]@X6+;NS-OXO;6$
MBJ:RM&/Q-+'2PR5V1J'J\AD*DJ/)5Y"OJI6EGGE9YII&+.Q)O[#B_-P /]]_
MMO:GI/TI_?K_ . _WG_BOOW7NO>_7_P']/S_ ,5]^Z]U[WU[]U[KWOWOW7NO
M>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO_]3Y_P#[]U[K?X]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]\E5G9416=V(554%F8G@!
M5%R2??NO<>'7O<S^%Y+_ )UU=_YR5'_7OWJH]>K:'_A/[.O>_?PO)_\ .NKO
M_.2H_P"O?OU1Z]>T/_"?V=>]^_A>3_YUU=_YR5'_ %[]^J/7KVA_X3^SKWOW
M\+R?_.NKO_.2H_Z]^_5'KU[0_P#"?V=>]^_A>3_YUU=_YR5'_7OWZH]>O:'_
M (3^SKWOW\+R?_.NKO\ SDJ/^O?OU1Z]>T/_  G]G7O?OX7D_P#G75W_ )R5
M'_7OWZH]>O:'_A/[.O>_?PO)_P#.NKO_ #DJ/^O?OU1Z]>T/_"?V=>]^_A>3
M_P"==7?^<E1_U[]^J/7KVA_X3^SKWOW\+R?_ #KJ[_SDJ/\ KW[]4>O7M#_P
MG]G7O?OX7D_^==7?^<E1_P!>_?JCUZ]H?^$_LZ][]_"\G_SKJ[_SDJ/^O?OU
M1Z]>T/\ PG]G7O?OX7D_^==7?^<E1_U[]^J/7KVA_P"$_LZ][]_"\G_SKJ[_
M ,Y*C_KW[]4>O7M#_P )_9U[W[^&9(?7'UW_ )R5'_7OWZH]>O:'_A/[.O>X
M)!!L>"."#]0?>^J]>]^]^Z]U[W[W[KW7O?O?NO=>]]@$D  DD@  7))X  'U
M)]^Z]U[W-_A>2_YUU=_YR5'_ %[]ZJ/7JVA_X3^SKWOW\+R?_.NKO_.2H_Z]
M^_5'KU[0_P#"?V=>]^_A>3_YUU=_YR5'_7OWZH]>O:'_ (3^SKWOW\+R?_.N
MKO\ SDJ/^O?OU1Z]>T/_  G]G7O?OX7D_P#G75W_ )R5'_7OWZH]>O:'_A/[
M.O>_?PO)_P#.NKO_ #DJ/^O?OU1Z]>T/_"?V=>]^_A>3_P"==7?^<E1_U[]^
MJ/7KVA_X3^SKWOW\+R?_ #KJ[_SDJ/\ KW[]4>O7M#_PG]G7O?OX7D_^==7?
M^<E1_P!>_?JCUZ]H?^$_LZ][]_"\G_SKJ[_SDJ/^O?OU1Z]>T/\ PG]G7O?O
MX7D_^==7?^<E1_U[]^J/7KVA_P"$_LZ][]_"\G_SKJ[_ ,Y*C_KW[]4>O7M#
M_P )_9U[W[^%Y/\ YUU=_P"<E1_U[]^J/7KVA_X3^SKWOW\+R?\ SKJ[_P Y
M*C_KW[]4>O7M#_PG]G7O?OX7D_\ G75W_G)4?]>_?JCUZ]H?^$_LZ][AZ&U:
M-+:]6G18ZM5[:=/UU7XM_7WOJOG3SZ][_]7Y_P#[]U[K?X]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]V*?RDH8:C^93\-(:B"GJ8).[=N+)
M!54\-53R*8JWB6GJ8Y8)5OS9E(N/I[8N?["7[.C':<[C:#^E_D/5?'\V"HJJ
M7^6O\W)J*MR&.J5^.?9*QUN+R%=B<C!Y<%/%(U)DL;44F0HIC&Y DAECD6]U
M8'GWRWK_ #+_ )[XS>>[\=1?*KMJ"CH=T[AI*2!<W!HAIJ?+UD4$,:BB"I%%
M&H554!54 *  ![TMO#I6L8K3JTFYWZR2*+IJ!C_AZ5&&_EX_"&3#XAF^,?4Y
M;^%8U23MY2QT44" N[3EY)"%NSL2[M=F)8DE,_\ #GO\P'_O*[MO_P _<'_U
M%[M]/!_OH=4_>NX?\I3?R_S=./\ PW=\'_\ O&+J?_T'5_Z_>_?\.>_S ?\
MO*[MO_S]P?\ U%[]]/!_OH=>_>NX?\I3?R_S=>_X;N^#_P#WC%U/_P"@ZO\
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M_P#J+W[Z>#_?0Z]^]=P_Y2F_E_FZ]_PW=\'_ /O&+J?_ -!U?^OWOW_#GO\
M,!_[RN[;_P#/W!_]1>_?3P?[Z'7OWKN'_*4W\O\ -U[_ (;N^#__ 'C%U/\
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MC#_]N/V[]1%_$?V'_-TU^Z[W_?0_WI/^@NA8_P"'/?AE_P ]UV=_Z2]\J?\
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M;L_"=;OW]-ULV6QV)V[!1T6Y*O&5&X8(VDF:K>L85*E,EE;2[*FQ/<O])-N
MO;LA0&N9UOOWD"A"TLT:ZH7CLQ#&T"K;!5@U(ZNWMI[6^V.^AVZ/5M%HEO8
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ME9D,!A3MWX]X;R;?HYT_R45GW58BDB2HDXL4O_AJ[YN_\^XZ]_\ 2E?C#_\
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M/%:_?PMQ'AQE3>+:VSV<D<-P56&XM+MH#65BZS9O!2&\FO6"27TLL K5S%#
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M2*T#4\E3)J<F50K64*73YVUW3^/Z_P"BNO.IZWIC[?9N]_DA6/B^F-[9G?\
M0)L[<>ZMF'K;<&Z,_FLCFIH]R[DVUB?)-2I5@P&(^6EHIC)3JGY?3>Y>9-SW
M'>;9H[I]HVZ*4#_<=;N)[YKJ.V/!XD,L?ZJM(KU&F5Z&C-Y#;02W8LVC:Q=X
MVA<5$DL(MX@LMRA9O"N2VL31@1Z7!'AJBQL[SLYZV:EJJFKGW).M3)'-"NY\
M;0XVNI6;R?<4D<=)3T<LE/3U 8(98@=%M#R(0YK7]CCI%TL??O?NO=>]^]^Z
M]U[W_]+Y_P#[]U[K?X]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]C9\:=OX3=GR-Z VMN7&TV:VYN7NSJK;^?P]:)&H\MA,SOK X[*XVK6*2
M*5J:NH:F2*0*RL4<V(//NDA(1R.-#T_:JKW-NC"JF101\B1T&W<V4R6#Z?[6
MS>&R%3B<QA^MM]93%96C$!J\9DL?M?*5=#D*45,-33&IHZJ%)$\D<B:E&I6%
MP;!MP;W[ER5=O3<.P?B/\(,SLO'=L9'8.,IJ#HWI>IW%C_XEOK(;+VE)D]JM
MESNW&8#)YV!,7392LI4HYJT+$T[2N-2"6XMH)K>WFN) \BMW=VA65'DT/)3P
MXY6CCD>.-V5Y51C&K4Z,5FDF-Z8;>VTP$E@0BMI!C5G56(9XXS+$)9$!6/Q%
MUE:] 7LSI?'5^V]H)7]U_(^;+UFQ]N9FKJ9^U=TJE:TV*I15UCURTL>-DKZB
MH#2S0QLK+KU"-(RH"/J>Q_D/0[9V9O*O^%?Q"H-K=@T?:=?L_-UWQLZKI*+,
M4O21T]J.C5%7&]%)LYRJU$=2L,DC.@A60NH-'O+!+BYM#=N;F';[.^91K)%G
MN$KP65P  =45Q+&Z1LM<J2:#/5E%Z\PMQMT(E-W);4**!X\,8EECJ<=D;!V:
MNF@;NJC *>'HK!5%774,/=?R%>KQLE+'6PCM[<H,#UT(J*4%C$$?S0L&!4D#
M\V/L$#\U\U?_ +)K^%O_ *3%L'_KS[7F #_1'_WKI']>W_*+!_SC'4__ &7:
MA_Y_%\A__1P;A_Z-]]?[.OFO^\:_A;_Z3'L'_KS[]X(_WX_^]'KWU[?\HL'^
M\#KW^R[4/_/XOD/_ .C@W#_T;[$WI/Y5OOWN;J+8V?\ C1\-),#O/M#8&U,Y
M%3?&K8U)438?<.[,1B,I##50)'44LLU#5R*LL;)+&3J1E8!A5XM*,PE>H!\^
MG8+OQ9X8VM8-+. >P<":=(GLOHS^ ];]AYO&=T_(JFR>(V)N_)8VKB[?S9FH
M\A0[>R-315L"U$%12M44=5&LD8FBEA+J!)&Z70Q.W?EA-LKMCM'9N#^-/PU3
M";4[&WQMO#1U7QJV)55$.)P>Y\IC,;#-52Q&:ID@HJ5$,DA:20C4[,Q+'RQ5
M529'K0>9ZU->>'-*BVL&D,0.P< >I6P>B5S6P]CY?(=S_(F?(9/9NUJZOJ7[
M?SHEJZZJP5!-65DPABAIQ45E0[2R")(X@[G0B)90AJ;YQ[LIEJ*>@Z!^(^/A
MR$0I,A2XSX][4QM+E:8R*XH\K2T,M/3Y2D,@!\50LD=_Q[<6U$S)%0N2PTJ:
M,-7X64&H#@GM89'D1TV=P8 D6T -"*A #0\149H?,5H?/I6GX[4-B/\ 3#\A
M+FWJ/;N>9Q;_ %#LC-&6^A*V)''M3Y3Y-]BXC.8K;==\4_AFN<S=+C*S%8ZG
M^-'6];-74^9 ..:$T35$6N>]M!8,A!#!2#[$UYR)S/8<Q6_*=UMDPY@E6)DB
M$B/J6>-9HF#H[1Z&B<.SE]*+J+E=+4%6[<K\U[)NFR[+N'+T8W;<889;:)%C
ME>5+ABL.D1,_>[@J(S20-VE0<==?[+M0_P#/XOD/_P"C@W#_ -&^U7#W3VU/
MEJ;"P_&'X'25^0B63$JG2?2;T^;?[J6AFI<'6KE319>OHJV!HJB"GDDEIW%I
M%6XN((/:#G6ZOQM=K;V\EZ\0EA"WUH1=1E9&+VC^/X=T$\*02^ TGA,A270V
M.A='[1>X$V\6>Q1[9LYW&Y \ ?7;=HG?QOIVA@E^I\.6XCF_3EMT<RQ,09$5
M64GW^R[4/_/XOD/_ .C@W#_T;[>^LN\-W;FW7URV>^,7PBJ-D9_L_8FR]ROB
M^ANJ'R=)#N3=5-AJC'5-)05CYC&5==2QU C<1I(J#R(R^E_8:ON3=ZL>5[/G
M!VB;8)Y%B66.Z@E(E:-IEBDCCD:6.0Q*9-#HI"BI J*D3\C\U0\OW7-,NV;>
MVR6UPD-P4GM'E@D>:2!%E@29IXR\D4@0F/N52XJE&*5WUT.N'V/O7*X_N?Y$
M4^0QVT-S5M!4KV]G6>DKJ;"5TU'61++%) TU)4(LB"1)(BZ@.CK=2ENZ_E4^
MP>YNW=C;?^-/PU3 [,[0W_M3!Q57QKV-5U$.&V]NS+8C%PS550DE152PT-)&
MK22L\LA&IV9B6(:2+4B,9'J0/Q= F:\\.:6-;6#2K$? IX'UZ;>J^CVW'U?U
MKN#+=U?(FKRV;Z]V5E<I6OV[FXY*[)5^VL955]?-'3P04L<]=5RO+(L4<4(=
MR(T1-* ,Q\ULVQ 'QJ^%Q/X ^,>P?];_ (X^[K;EV5%=RQ- *GB>'3)OR,FU
M@_W@=+S_ &7:A_Y_%\A__1P;A_Z-]JS*_)[L3"Y;"X/(?%/X:)EMPT>-K\-0
MP?&?KBNFKZ;+N8\<810FI7RU+C3XR1(K<,H/L3W_ "+S-MN_V?*]YMDPWZX2
M%XXE=9"Z7"+)"RLC,A5T8-751177I*L *-XY;YHV&[V.PW/E^-;W<K>*:VC1
M8Y7F2=S'$%6)G/B.ZE!$:2AJ H"0#[_9=J'_ )_%\A__ $<&X?\ HWVK(N[.
MUYLQ3X*/XQ? YLE71HV,B'2?2AI\M,U:^.EH,37#*FAR64HZ^,Q5%+#(\].]
MO(B@@D_MO:'G.\W2/9K2*UEW"6-7A5=PLR+E6UYM7%QX=SH,4BRB%G,3*5D"
MF@(M7VGY^;>;;81MFT?O*<?I WNWZ)9!,+=K>*7ZCPI+J.8B.6U1S/$Q4R(J
ML"??[+M0_P#/XOD/_P"C@W#_ -&^^>S?D7O&HW1UT^XOBQ\+5VMN;LO#[+GG
M7XW=:RK53Q9Z@HLWCRE+*]5$IIYG7R@(&!)BDN P!U[RWNUAL>S\Q7,+KLVX
M&<6THD5ED-N46445BR%#(A_4"ZE8,FI37H-W_*G-&S[:F][KL4$>T?O*2Q+@
MP-_C,-?%CTH[-1=+ 2:?#8J=#M0],VX_C]3TFW<_4T_<WR*AJ(,'EY:>>+N'
M/B6GG3'U+0U$)>-X_-3R@.FM734HU*RW4D?[LQ&,P'<W;F!PM#!C,-A.SM^X
MC$XVE#K2X_&8W=66HZ"AIED>218*2EA2- S,0JBY/U]EJ&J(3QH.@/<*%GG5
M110Y _:>AXV145-9LO:%76U,];656U\!45=95&-JFKJ9\522SU-0T,<,33SR
ML7<JBJ6)L ./88^[=,]*CW[W[KW7O?O?NO=>]J39M!297=^U,77Q&>AR6Y,%
M05L(=XS-25F4I:>IB$D95XS)#(PU*01>X]Z;@:<:=7C ,B \"1_AZAY"9Z>@
MKIXCID@HZF:-B 0KQPNZ$A@0;,OT/'NU'<F^.U\AN3N&?K7XF_"'*;+ZW[,W
M+LRGHYND^F1NN'#8O>D6S\?D_P"[F5R\&[\Q@\;4Y+'T^0S"TTU+32U"O53J
M2[A&[1Q/81/+*9;AU1=(=@K.2L?BLH*PB5P8XC*4$DE(T)=E!,C<EYMPCBM[
M?_%P[$%5!*1JTCE :&0QQ(TD@0,4C5G>B@GHJ>V>FL?6X/:,N4[I^1K9;<.V
MZ'-2S#M'="4DU3/CZ:NKO\HIJ-<512&2H9HZ?5%^V"(DT(=+929WY45M'3Y"
M+X+_ !(CQ]3V?OWIA:ZK^-_4M!1P]G=8;>;=>_MI5M36U]/#CZW;6W$>KFDG
M,=,T4;^.1V1P"Z?>=FM8-ON;C<66&[V:3=H3W_J;=%-]/)=J--3&D](F%-8<
MA=-2.G$-Y+-<6\.WPR317D-JP5%;_&)P3%&M*ARX%0R%D"E69@&4E_'1VWVJ
MI:->[?D&U3!1T60DB7M[<C$4>1FJ*>BG#+&4=*B:E=1I)(T\@ BY<#\U\T"1
M_LM?PM-OS_LL>P?^O/LX\ ?[\?\ WH])?KF%1]+!_O Z<O\ 9=J'_G\7R'_]
M'!N'_HWWU_LZ^:_[QK^%O_I,>P?^O/OW@C_?C_[T>M?7M_RBP?[P.O?[+M0_
M\_B^0_\ Z.#</_1OM^VK\QLCF=T;:Q%9\:_AB:/*;@PN/K%B^,NP8Y'I:S)4
MU/4QI((=4;20R,NI;,M[J00"-&$ $^(_^]'JR7I9U4VL%"1^ =-^6^/E+38G
M*U$7<GR)26'&9"2)T[@S^N.5:28QRQZXY(_+$]F74K+J NK"X*N[K^5C[$[E
M[<V1M_XS_#2+ [-[.W[M7"0U'QKV/5SPX?;VZLKB,;%-55*RU-5+'1T:!I)7
M>1R"68DD^])%J16,CU('F>G+B[\*>>);6#2KL!V#@"1TP]?]#+EMA;'RF0[J
M^1E7D,CL_;-=7UD_;^;$]96U>%HJBJJZ@4]/34PGJ9Y&=_'%%'J8Z45;* \I
M/G+NR@>1\9T%\1L1)4034=3)AOCWM3#R55'4J$J**LDQDM+)5T4Z@!X9"\3C
MZJ??I+6*5#'-5XB02&HRU4U!*L"I((J"14'((/30W!U(=;>%7' A "*X-",B
MHP:<1QZ5Z_'>A!_YG#\A&N"/7V[GGM?\KJ0E&'X9;,/Z^U!E_E'O_!C;_P#$
MOBO\,H6W1009/ QQ?&?KBKER-)45#TL+)%1FHDBF>="OB<)*#;TBXN(]RY,Y
M@V?<MIVC<+"=-RO[>&>WC5UD:6*Y9DA*>&SBKNC($)#JRE64'H1;OL',>PVG
M+U[NFQQ1V^ZP>+:D+&YE0/H^&-F9&U8\-PLF5.FC GQ^.U$;?\9B^0W MQV_
MN#_>?3]?:M;N[MM,O0X1OBO\'16Y&*I>E8]"]/\ V+5-'414E9BGR0KSCX<[
M1UDZ134+RK5Q2. T8O[$4?M+SI/O4.P06<4FXRQ%XM%Y:M'+27P&CAG68PRS
MK/\ HO DC2I)1705'0ME]J?<*#<MMVJXV"QCNKI9-!:XLQ&LD142V\LOC>'#
M=Q,Z+):2LMPC.H:,5ZZ_V7:A_P"?Q?(?_P!'!N'_ *-]P:7Y$=@1QTN3S?Q;
M^%6,P_\ >.'!5 K/CKUA15]9+#F(L5DX\5023)D<G%2U):&2:E21$=6 <,IL
M07?)F^6&P0\R7L8BVV64I&'FC6:0JQ1F2W+^,T:NK*9!&4#*PU=K4)KSDGF_
M;-IW7>]UV.VM=OL[J2W?Q6MXY'EAD$,RV\3.)+GPI#HD:W615:HU5!I#R/Q[
MI8,=D)HNY/D.LL=!6/$_^E_<!\<BTTICD *V+1O9A>XN.01Q[=.__E&O7'>G
M<6P-M?&?X:P[<V5V;O?:N!@JOC9LFMJ(,/@-QY#%XZ*>LJQ-5U<R4M*NJ25W
MD=KEF)/L,)%J1&,CU(]>@=<W7A7$T26L.A7(%4%: ^?21ZOZ*;-]9]=9G*]V
M_(VORF6V+M/*9.OJ.WLRM179#(X*AK:RKJ%I*:DI%FGJ)V9A%%%&+V5%%A["
M,?-7-L;#XU?"XGZ6'QCV%<\V%@(?K?VZELTCK'&TC2,0  222<  >9/D.F3?
MD9-M!3_2#I=?[+M0_P#/XOD/_P"C@W#_ -&^UUG?D=V7MNGQ=3E?BM\+$&6J
M(:&GIZ3XX=99*OILE44\-73XG*8['255;A\O44LZ2QTM5'#4.AN$-C87;S[>
M<T[%+M<%]8.UQ>2F&-(9H[E_'4H#;.MN\K17(,B#Z>0+-5A1.-!IOO)?-_+6
MW;;NF\;#!';W3(@53#)+%+)&)8H;F"-VFM9I8B)(X;A(Y'3N530T]_LNU#_S
M^+Y#_P#HX-P_]&^W5N]^TH\G1XFH^,/P4I*NOCJ#2FLZ+Z;I:26MI*F"CK<)
M]_-D%H4W)05=5''/C6D%;"[ /$+^S&'VIYNGWBWV*..V.Y3HIA'UUIHF9I1!
MX4,OC^%+.DQ$4D$;M-&]%D1214VE]L^>+;<++;;[:MLMKB=9=)FN;*.-9861
M9K625YQ'%?0M(@DLI&6Z0L-40Z]_LNU#_P _B^0__HX-P_\ 1OMMJ_DEV/AH
M:[)Y7XJ_"RFQV#W<FT,O,?C;U?4I39Z*1S-CWA@EEEGC @=6EC#0D@@/JM[#
M^X\F[_M.U?OO<+.2/:_WA+8^)XJ-_C4*LTD6E79L*C$/I\-M+:':AZ*]TY)Y
MRV2TYAO]SY>@CL]IW+Z"Z:L#>%==WZ=%D9G *D&2,-&&HI>IIU'J_CK1&DJP
M.Y?D5&6I:A5DC[BW"DD;-"ZB6)POIEC)U*>0& X/T]R_]&W7O_#I'^C#^Y6
M_P!&G^S8?P/^X'V\_P#=;^[O]]]7]V/L?N?/_=WP_P"3_;>7_@+^WJMS[#FI
MOIM=>[3QZ!WA1_O;PM \+Q:4\J5X?9TE_P"]N[O]D>_OE_>?+_WW_P!EN_C'
M]\]=)_>#^\7^C_R_WF\OVGV'\<^^_P JU_;^'[CU>/3Z/?\ _]/Y_P#[]U[K
M?X]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]F ^)LB1?*?XT
M2R,$2/Y =-2.Q%PJ)V+MQF8CFX %_=)#2-SG@>!H?V^7V]*+,TN[4GAXB_\
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M/)'4.)$")I#,BWWV^VO;N4-WW2WO[D[UMMOM<USK1?II(]VA$L2PLO?&T&M
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MTU562ITN'J)X,?2QP([DLL4:J#90 #W^CCX-?]Y2=X?^DMX7_P"W][7:IO\
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MJL+B*/&SU=#%6],_>1T=1+3%XUE_<52 UR"?8??Z.?@V/^YI.\/_ $ES"_\
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M"TSZ41D8LP1684LT-^9A:$-X=W%:MD#_ !J>/Q8;<:B-4TL9#1QK5GJ H+$
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M2QO8FR5VVD\>S.I:7.S;?7M?&Y&"M=\EC,+D,55IE8JB.F6G:2F*NRNY5M)
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M 'R/]Z_V.O>!8?\ *<W_ #C/_077O[[_ "!_Y\+MC_T==)_]@'OW^B/X5_\
M>9>_O_23\K_]N7W[7-_OD?[U_L=>\"P_Y3F_YQG_ *"Z]_??Y _\^%VQ_P"C
MKI/_ + /:CV=\>/B%OO=^U-C[?\ F1O9\]O/<V!VEA16?%7+T]%_%]R96DPV
M--;41]P5$L%&M96(972.618P2J.P"G1DF ),(H/Z7^QU9+:R=T1+UB[$ ?I^
M9X?BZ8]T=J]\[6VQN7=%5\?]NU5-MK;N<W%/24_=N-2IK8L)BZK)O0TKU6Q8
M*2.JK5I3%$TTD4*R,#(Z)J8"[G?]$_76YALFM_F']N4&1Z?Q.]^D,?C\;\8,
ME+@<1MN:KW+@-W[?Q='_ *78J&JP^<FR^0=Y)J<5$_W/EDTR@:&)X5O&OII[
M-6DNDMQ*U:,ZVIA-L&8 -^@8(3'GM,:TZO'';6:VUM#N+HMM-+(@6,C3)*[-
M*P(:I+LS:JUJIT?!1>L&W]_]U[DPF!W3!\=-IP_WBQ&#W'&L_<V+DKJ5LGC*
M2OAIZFH@V%-$]70),(7:*22$LA\;O'I8B;C?DOU1'!W$N[_F95=LY3O:#;=+
MV#N7M/X45.Y\[5Q;1VO+L_;7VVKN6''31X;#/'X(:B&2)*FFAGMY8PQ0W6RV
MMSMEGM,<!MK:&\O+I3"VE_'OBK7#:J$J6==2LFEHBS>'0&@5;3=P;1=)<0WO
MB(MK!;K'+&7B$-OJ$:%"V5TL5D!KXH^.N2<,<_<=.N#CH_CQMNAI]N232X>D
MHN]8Z6D@>>3RS%XHMB#R"1[W#:@P=@?22"3,]1_"LV_YS,W^>+<_$[*<<FP_
MYG,?Q[-M<_\ O@?[U_L>O[>D AL?^4YO^<9_Z"Z5/]]_D#8?\8%VQ^>/]-=)
MQR;?\P!_3WU_HC^%?_>9>_O_ $D_*_\ VY??M<W^^1_O7^QU[P+#_E.;_G&?
M^@NO?WW^0/\ SX7;'_HZZ3_[ /;YM?H#X?;PW-MS:.$^9&^'S.ZL_A=M8E:K
MXJ96GI/XEGLE2XJA:KG7N*9X:1*FK4RNJ2.L8)5':RG1DF ),(I_IO\ 8ZLM
MM9.RHM\VHF@_3\S_ +;IIS_9W?6W\!GMP5/0.W)X,#A,OFYJ:#NRA%15QXC'
M5.0:CIC-L*.!:JL^V\49E>.(.X+NB78#151=4])5^\>GJ7^8;VSMY-JXCM7H
M+<6)P7Q>R)Q51M/<NZ#_ *2MJ05#=M05-9MO=&X,,M0XE2.20*I*Q$E S(AN
M4E66W#12M:.P+FCM8W O+,L.#?3W*K/$#4+( PZ\EK96EPDD=\R7$4TS@B,@
MK)/;&RG8'5QDM28&]8S2G3#@]]]O=A;:V3O-_C;M.2'+XW;&_L-#DNYL9-78
M:OR>!CJZ)V>#8E12QY;&4F5DII)*>62(DN(Y'C8,TNH[<ZTK&K)ZS^8MV;69
M.KW_  ]HQ;AK/AIBZK=F&WY%6XW(ON':N\*CLF3=&SIZVMQ%-)5PXFLHJ:M,
M0\\<@+ I[/;K;;QM8LMNCC2S618P#VZ)?$UQRJ12>(^-+^E.)(QXLFE1K:OI
M8[*:SNK"6_8VDT44;+X7X8$6.$J=54=(T11(A62B)5CI6CY/F>[*FH^YF^/N
MW&<XR;#O$O>S1T<N.J+"2GGQ\>R$H:@V%E=XVD0$A6 )]H;MG)_'WO++8G-=
MI?/?L7<];@,7+A,!$/AY#@\5@<//E<AG)\7A,#MSM/$8/$4$V9RU35-%34\:
M-/.[D:F)]UL=MMMNDNY;.P5)9V0R-K+,WAQK%&"S5.F.)$CC4'2B*%4 "G2N
M\N4OSJNMT9N]GQ$%!=].N0A2 9)-(,DA!>1AJ=F:IZD8O<7>.&HXJ#&_'W:]
M/31*H"GN^*>5RD:0K)/4U.Q)JFIF\42J7D=W(47)M["G_1'\*_\ O,O?W_I)
M^5_^W+[,=<W^^1_O7^QTB\"P_P"4YO\ G&?^@NG#^^_R!_Y\+MC_ -'72?\
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M;MFGBR5/N*:.6*:6KI_+/3A%955514=Y90;FMU]98I(+BU2W>K9:!'DD2(D
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MM%'610+'WFL5,8Z\ 525-'%L9*2M62UQYDDT,25L23[@=P;KZ0[\DP<G;?\
M,#[+W>-M29R?!T\OP^@Q%#CJS=%52U^Y\E%C]O\ :6)H7RVY<C1QU.1K'C:J
MKJE?+/(\A9BQ;;=:V=U=7MKMR1W$RHK%6H D9<QQHM-,<49D?PXHPL::B%4
M]/S207"Q+/N;MH15J8^YM"*@9VU:I)-"JIDD+2,JJ&8A13'A\WW9@*44>)^/
M6UZ6  +ZN\(ZF9E4N8TDJ:O8L]3)' '*QJSE8TLB@*  "W^B/X5_]YE[^_\
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MWN"Z!F9/[M^0/1"[4W0W^FCJDA-NYR1@O8&U9&TQXRJ=K1QY5Y'.E3PH+'Z
M$^Z^/D$ROWUW<Z-&Z/V]V4R/$ZR1.K;SS15HY$9D>-@;@@D$<@^X:CPB4K2@
MX\>L=[G_ '(N,U[V_P )Z$WKV19=@['E6^F39^V9%NCQG2^%HF%XY%21#8_1
M@&'Y /L(?=^F>EA[][]U[KWOWOW7NO>U;L&6*#?6RIIY8X((=V[<EFFF=8H8
M8H\Q1O)++(Y"1QQH"68D  7/O3?"?LZO%_:1_P"F'^'J!E4>3%Y)$5G=Z"L1
M$16=W=J>0*J(@+.S$V  ))]W:Q;6^0NP:#Y/;-R/QB^7_9\6^>U>WJW9^P*K
MK,U_Q[@3=NZ:=J#M2@J)\%6;LIM[8BFQZ5^,JL3)!3U4\-([S/3^1)2?=!=7
MTG+B07$206TT#R2$L)XTAN!<M%;%>W1.5$4JRDQZ)IF,;MIZ5G;;Y)]^98I4
MCN!(-"*-%QK@F@ N@RL&1/%#J4'B40!7C)#J5+:O:G1E13];YR;MOIFCJ,+L
M;!T,U7+OW!TFYH:M,;%%-B*J"3+Q4ZX]1+(DT-3&9X92X 1[D3]Q[O\ E%GM
MK;]Q)^!_R@7<O8>W.\^O-R[PJ]O;PJZW-=5[GHJ^7X_;(KL>VU%HX:;IW<&X
M*^HJI(K')01442B'[:[$>]\N)NL6RK!N"Q/!):7$]0K"XOK>Y77=DA5D!?;X
MUMA&SNIN&DO'+2, IG8M?6[K)<V+RS1,B0L$"F.T-H$N(":'69;T?4+)5=$#
M-;:2I!"YH.YNF*7*9"JJ.^^G9\;-_#)L9CX=W;1I9\=71QSIG:F6O7<+FN7,
ML8BJM&C0:'&J0266K(_"#YC?]XN=^?\ HJMY_P#UG]C'QHO]^#]O13^[[[_E
M$D_WD]*;_9@.B/\ G]/5'_HP]I?_ %V]^_V2#YC_ />+G??_ **K>?\ ]9_?
MO&B_WXO[>M_N^^_Y1)/]Y/7O]F Z(_Y_3U1_Z,/:7_UV]J;97PJ^7U#O/9]7
M5_&'OBGI:?=6W9:BHEZKWFL4$*9BB,DTTAP^F*")?4[M9$4%F(4$BK31%6_4
M'#UZLEA>AT)M9*5'X3TUYSY =$G"9JW='5)MB,DQT]@;5=M*44[,0D>4>1R%
M!X4$G\ GVO/D3\-?EKG/D%WMF</\:>\<GB<KW)V=DL9DJ#K+=U709#'UV]LW
M5T5=0UE/BI::LHZNFF62*6)WCD1@RL00?>HY8A&@,@K0>?3MU97CW5RZVSE3
M(Q!H<@D])GJ_Y =$_P"C+KDGN?JQ-6P]H-IFW[MBGE4-M_'D"6GJ<E#402#^
MTDB(Z'A@""/8._[)!\Q_^\7.^_\ T56\_P#ZS^[^-%_OQ?V],?N^^_Y1)/\
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M?]E#_P"9F_SW^9_S3_Y[_FS_ *O_ &F_OW^\]:/_ #>ZS4_^?@_YEQ_GX?\
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K_P#(G_P)/T_Z;O\ KI[<Z2_C\^/Y_P#%]"5_8_L_I_Y ^G_0O_$>_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g476668g00m06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00m06.jpg
M_]C_X1=O17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP-CHR-2 Q
M-SHU-#HR-P!R<C,Y,3,S-@       Z !  ,    !__\  * "  0    !   "
MIJ #  0    !   "!@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M!W_I5#=C85MDYW56N>UH-8KQWT0 2YSG;7EUG_4(X\O,&8&3%"$.LHY/</\
MB>U!6G?_ )K8KQ+F5AMF?C6O'TK#?8V9.GL8_8U/Z!_[F8O_ +$V_P#DT!O3
M.E-+2WJ-P()+1MN[GW?G?11J:^GBFL,Z@'5AH#7?9]" (_=5FQW_  1?C^"_
MV<_]S,7_ -B;?_)I_LY_[F8O_L3;_P"32V87_<[_ -EC_P"12V87_<[_ -EC
M_P"12L=_P5?C^"FXSG.#6Y>,7.(#0,FTDD\ >]6/V-U']ZO_ +>O_O5<T]/L
MBM^=[7N:#%!:=7-_PFW]'_76P_I..]SGFR\.?MDMNL;]':6QL>W_ $?N_?\
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MKZMUQ::;Z:V$M?8YC6-L<VYGJ/&Q.\=7!,8N>YS6[26Y./M=X/9)#MWL;O\
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MMVTR1^<Z6^Y_\M:R22K:-72JJ:Q53==56W1K&.  [Z#:I_8#_P!R;_\ /_\
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M /@U.SZ#O^3N!]/CZ0Y_[Y_PB25.IOZ4XC!:[&J?M]3UW5DQN(TV>KM9[_\
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M3_.-_H'TF<?UA]+_ -%I*?_9_^T?>%!H;W1O<VAO<" S+C  .$))300$
M  !2' %:  ,;)4<< 5H  QLE1QP"   "   < E  "')R,SDQ,S,V' (% "E-
M:6-R;W-O9G0@5V]R9" M($9A:7)N97-S($]P:6YI;VX@06YN97@@2#A"24T$
M)0      $)#J</TJBI==FYPIUB_!1F4X0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M<L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 !
M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    %HX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      T$    &              (&   "I@    8 9P P #
M;0 P #8    !                          $              J8   (&
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (&
M     %)G:'1L;VYG   "I@    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "!@    !29VAT;&]N9P
M J8    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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MS(<XM.PUN#/4<Y_\WD;_ /MFS_1H<11;5_8W4?WJ_P#MZ_\ O2_8W4?WJ_\
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MTO>H6<M_Y.^D>>?HGZ'\O_T4IT_SC?Z!])G']8?2_P#1:2G_V0 X0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M P,# P,# P,# P,# P,# P,#_\  % @"!@*F! $1  (1 0,1 001 /_=  0
M5?_$ :(    & @,!              <(!@4$"0,* @$ "P$   8# 0$!
M        !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'
M$R( "#$403(C%0E10A9A)#,74G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B
M1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H
M:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7
MV-G:Y.7FY^CIZO3U]O?X^?H1  (! P($! ,%! 0$!@8%;0$" Q$$(1(%,08
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M_;H]^_UW+;_IG6_[*HO^M?7OWIM/\%S^Q/\ H+KWWWRI_P">7^/W_H>=C?\
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MRS))%2NI;F-A2E0:K$05(R"#0C(QUM]SVF.HECND(-#J5%H?0U84/RZYBO\
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M5/\ SR_Q^_\ 0\[&/^\_Z.!?WW_LIGPC_P"?U?*O_P!$+UM_]NCW[_7<MO\
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M?]:^O?O/:?X+G]B?]!=>^^^5/_/+_'[_ -#SL;_[7'OW^RF?"/\ Y_5\J_\
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M\_J^5?\ Z(7K;_[='OW^NY;?],Z__95%_P!:^O?O/:?X+G]B?]!=>^^^5/\
MSR_Q^_\ 0\[&_P#M<>_?[*9\(_\ G]7RK_\ 1"];?_;H]^_UW+;_ *9U_P#L
MJB_ZU]>_>>T_P7/[$_Z"Z]]]\J?^>7^/W_H>=C?_ &N/?O\ 93/A'_S^KY5_
M^B%ZV_\ MT>_?Z[EM_TSK_\ 95%_UKZ]^\]I_@N?V)_T%U[[[Y4_\\O\?O\
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M^5/_ #R_Q^_]#SL;_P"UQ[]_LIGPC_Y_5\J__1"];?\ VZ/?O]=RV_Z9U_\
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MWRI_YY?X_?\ H>=C?_:X]^_V4SX1_P#/ZOE7_P"B%ZV_^W1[]_KN6W_3.O\
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MQ99 R072SH]T?$5C&C30=MK.Q:.)%E@U%G4DPW8LU3CQUM6[_P!L;Y[!Q?\
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M #O,=[TP(ANS0_[CS?\ 5I^M$CMS^)?^/#K!5?\  :H_Y82_]:V]E _F ?\
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M"#+8HI^@^@]V'(G+(H1:7 -:_P"Y=WQ]?[?CU0Q61X[9;?[Q_L]</]EII_\
MG^OR6_\ 1OY+_P"H/?8_F.=@!M0^.OPL#6"ZA\9]F@A0+!0?-P /I;Z>_?U$
MY8(I])<4_P">N[_ZW];\*RK7]V6U?])_L]>_V6FG_P"?Z_);_P!&_DO_ *@]
M]_\ #CW85M/^R[?"W2#J _V6C9UM7/JMYOKR>?\ 'WK^H?+%:_1SU_YZKO\
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M/(?+!U5M+C/'_&[O/V_K]>\*QH -LMZ?Z3_9Z]_LM-/_ ,_U^2W_ *-_)?\
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M[_9::?\ Y_K\EO\ T;^2_P#J#W[_ (<?[#_[QX^%_P#Z35M#_K_[]_4+E?\
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M_);_ -&_DO\ Z@]^_P"''^P_^\>/A?\ ^DU;0_Z_^_?U"Y7_ .4.?_LJN_\
MK?U[P[+_ *-EO_O'^SU[_9::?_G^OR6_]&_DO_J#W[_AQ_L/_O'CX7_^DU;0
M_P"O_OW]0N5_^4.?_LJN_P#K?U[P[+_HV6_^\?[/7O\ 9::?_G^OR6_]&_DO
M_J#W[_AQ_L/_ +QX^%__ *35M#_K_P"_?U"Y7_Y0Y_\ LJN_^M_7O#LO^C9;
M_P"\?[/7O]EII_\ G^OR6_\ 1OY+_P"H/?O^''^P_P#O'CX7_P#I-6T/^O\
M[]_4+E?_ )0Y_P#LJN_^M_7O#LO^C9;_ .\?[/7O]EII_P#G^OR6_P#1OY+_
M .H/?O\ AQ_L/_O'CX7_ /I-6T/^O_OW]0N5_P#E#G_[*KO_ *W]>\.R_P"C
M9;_[Q_L]>_V6FG_Y_K\EO_1OY+_Z@]^_X<?[#_[QX^%__I-6T/\ K_[]_4+E
M?_E#G_[*KO\ ZW]>\.R_Z-EO_O'^SU[_ &6FG_Y_K\EO_1OY+_Z@]^_X<?[#
M_P"\>/A?_P"DU;0_Z_\ OW]0N5_^4.?_ +*KO_K?U[P[+_HV6_\ O'^SU[_9
M::?_ )_K\EO_ $;^2_\ J#W[_AQ_L/\ [QX^%_\ Z35M#_K_ ._?U"Y7_P"4
M.?\ [*KO_K?U[P[+_HV6_P#O'^SU[_9::?\ Y_K\EO\ T;^2_P#J#W[_ (<?
M[#_[QX^%_P#Z35M#_K_[]_4+E?\ Y0Y_^RJ[_P"M_7O#LO\ HV6_^\?[/7O]
MEII_^?Z_);_T;^2_^H/?O^''^P_^\>/A?_Z35M#_ *_^_?U"Y7_Y0Y_^RJ[_
M .M_7O#LO^C9;_[Q_L]>_P!EII_^?Z_);_T;^2_^H/?O^''^P_\ O'CX7_\
MI-6T/^O_ +]_4+E?_E#G_P"RJ[_ZW]>\.R_Z-EO_ +Q_L]>_V6FG_P"?Z_);
M_P!&_DO_ *@]^_X<?[#_ .\>/A?_ .DU;0_Z_P#OW]0N5_\ E#G_ .RJ[_ZW
M]>\.R_Z-EO\ [Q_L]>_V6FG_ .?Z_);_ -&_DO\ Z@]^_P"''^P_^\>/A?\
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M +*KO_K?U[P[+_HV6_\ O'^SU[_9::?_ )_K\EO_ $;^2_\ J#W[_AQ_L/\
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M )_K\EO_ $;^2_\ J#W[_AQ_L/\ [QX^%_\ Z35M#_K_ ._?U"Y7_P"4.?\
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M[R9^/O\ Z.;KG_[)/?O]DX^7/_>+?R(_]$MV/_\ 8Y[]XT7^_5_:.M_0WO\
MRBR?[R>O?[-I\5?^\F?C[_Z.;KG_ .R3W[_9./ES_P!XM_(C_P!$MV/_ /8Y
M[]XT7^_5_:.O?0WO_*+)_O)Z]_LVGQ5_[R9^/O\ Z.;KG_[)/?O]DX^7/_>+
M?R(_]$MV/_\ 8Y[]XT7^_5_:.O?0WO\ RBR?[R>O?[-I\5?^\F?C[_Z.;KG_
M .R3W[_9./ES_P!XM_(C_P!$MV/_ /8Y[]XT7^_5_:.O?0WO_*+)_O)Z]_LV
MGQ5_[R9^/O\ Z.;KG_[)/?O]DX^7/_>+?R(_]$MV/_\ 8Y[]XT7^_5_:.O?0
MWO\ RBR?[R>O?[-I\5?^\F?C[_Z.;KG_ .R3W[_9./ES_P!XM_(C_P!$MV/_
M /8Y[]XT7^_5_:.O?0WO_*+)_O)Z]_LVGQ5_[R9^/O\ Z.;KG_[)/?O]DX^7
M/_>+?R(_]$MV/_\ 8Y[]XT7^_5_:.O?0WO\ RBR?[R>O?[-I\5?^\F?C[_Z.
M;KG_ .R3W[_9./ES_P!XM_(C_P!$MV/_ /8Y[]XT7^_5_:.O?0WO_*+)_O)Z
M]_LVGQ5_[R9^/O\ Z.;KG_[)/?O]DX^7/_>+?R(_]$MV/_\ 8Y[]XT7^_5_:
M.O?0WO\ RBR?[R>O?[-I\5?^\F?C[_Z.;KG_ .R3W[_9./ES_P!XM_(C_P!$
MMV/_ /8Y[]XT7^_5_:.O?0WO_*+)_O)Z]_LVGQ5_[R9^/O\ Z.;KG_[)/?O]
MDX^7/_>+?R(_]$MV/_\ 8Y[]XT7^_5_:.O?0WO\ RBR?[R>O?[-I\5?^\F?C
M[_Z.;KG_ .R3W[_9./ES_P!XM_(C_P!$MV/_ /8Y[]XT7^_5_:.O?0WO_*+)
M_O)Z]_LVGQ5_[R9^/O\ Z.;KG_[)/;7G/BI\G]L8>OW#N3XY]Z[?P.*B6?)Y
MK-=2[]Q>*QT#S1TZ35V0K<!#24L33S(@9W4:F ^I'NR.LC!(V#.?(9/[!U5K
M.[0%FMG ']$].V!^2OQRW3F:#;NV._\ I/<>X,K*\&+P6![5V+F,SDIHX9*B
M2&@QF/SU16UDL=/"[LL:,0BECP"?84_W*WE_SR6YO_/#E?\ ZD]O^!-_OEOV
M'IKPI?\ ?3?L/0K_ ,=PG_.YQ7_GPI/^OWOW]RMY?\\EN;_SPY7_ .I/?O F
M_P!\M^P]>\*7_?3?L/7OX[A/^=SBO_/A2?\ 7[W[^Y6\O^>2W-_YX<K_ /4G
MOW@3?[Y;]AZ]X4O^^F_8>O?QW"?\[G%?^?"D_P"OWOW]RMY?\\EN;_SPY7_Z
MD]^\";_?+?L/7O"E_P!]-^P]>_CN$_YW.*_\^%)_U^]^_N5O+_GDMS?^>'*_
M_4GOW@3?[Y;]AZ]X4O\ OIOV'KW\=PG_ #N<5_Y\*3_K][]_<K>7_/);F_\
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M )X<K_\ 4GOW@3?[Y;]AZ]X4O^^F_8>O?QW"?\[G%?\ GPI/^OWOW]RMY?\
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MW_#HG\P?_O*_M/\ \[<5_P#6OW[_ (!#[FG_ ++9RO\ \X)?^MW7OZS\T?\
M1^E_WB+_ *U]>_X8U_E!?]Z[/BS_ .BRQ/OW_#HG\P?_ +RO[3_\[<5_]:_?
MO^ 0^YI_[+9RO_S@E_ZW=>_K/S1_T?I?]XB_ZU]>_P"&-?Y07_>NSXL_^BRQ
M/OW_  Z)_,'_ .\K^T__ #MQ7_UK]^_X!#[FG_LMG*__ #@E_P"MW7OZS\T?
M]'Z7_>(O^M?7O^&-?Y07_>NSXL_^BRQ/OW_#HG\P?_O*_M/_ ,[<5_\ 6OW[
M_@$/N:?^RV<K_P#."7_K=U[^L_-'_1^E_P!XB_ZU]>_X8U_E!?\ >NSXL_\
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M_P!&7N3_ .J_:;Q?Z)_YR3?];.DW[PW+_HXS_P"]M_GZ,#_LO/07_/D.HO\
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M_DQL:NV/L':.SZC(]']M4V4EVAMW&X"?)TE#O7J*JHZ6M@PU-21Y%:6>IE>
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MD\B1"K:@N2+>>+DWEE-D-29JGR.+P.'W V4JL/6P;9KJ?,9&OQB8_&;B>/\
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M-)15VUJ"DH8\;!1SUN0R#[EW)@)ZR*)*^(+2XR/(9*8L3'3.J.RB]LK^6/\
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M^S+<J_\ 91)_UJZ]_57FK_IGY?\ >X?^MO7O^'Q/Y0G_ 'L5^*G_ *-3!_\
M7SW[_AKC^87_ -XE=M_^>O'_ /UR]^_X.[[F?_LRW*O_ &42?]:NO?U5YJ_Z
M9^7_ 'N'_K;U[_A\3^4)_P![%?BI_P"C4P?_ %\]^_X:X_F%_P#>)7;?_GKQ
M_P#]<O?O^#N^YG_[,MRK_P!E$G_6KKW]5>:O^F?E_P![A_ZV]>_X?$_E"?\
M>Q7XJ?\ HU,'_P!?/?O^&N/YA?\ WB5VW_YZ\?\ _7+W[_@[ON9_^S+<J_\
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MI4G^]'_/U[QY_P#?S_M/7O[M[=_YT&%_\]=#_P!>/?O[];V_Y['=7_H0Y?\
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MSV.ZO_0AR_\ ]5^_?5W?_*5)_O1_S]>\>?\ W\_[3U[^[>W?^=!A?_/70_\
M7CW[^_6]O^>QW5_Z$.7_ /JOW[ZN[_Y2I/\ >C_GZ]X\_P#OY_VGKW]V]N_\
MZ#"_^>NA_P"O'OW]^M[?\]CNK_T(<O\ _5?OWU=W_P I4G^]'_/U[QY_]_/^
MT]>_NWMW_G087_SUT/\ UX]^_OUO;_GL=U?^A#E__JOW[ZN[_P"4J3_>C_GZ
M]X\_^_G_ &GKW]V]N_\ .@PO_GKH?^O'OW]^M[?\]CNK_P!"'+__ %7[]]7=
M_P#*5)_O1_S]>\>?_?S_ +3U[^[>W?\ G087_P ]=#_UX]^_OUO;_GL=U?\
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MC_\ JKW[ZRU_W^O7OW9?_P#*,W\O\_7M:_U_W@_\4]^_T =R?\^_SG^VH_\
MZJ]^^LM?]_KU[]V7_P#RC-_+_/U[6O\ 7_>#_P 4]^_T =R?\^_SG^VH_P#Z
MJ]^^LM?]_KU[]V7_ /RC-_+_ #]>UK_7_>#_ ,4]^_T =R?\^_SG^VH__JKW
M[ZRU_P!_KU[]V7__ "C-_+_/U[6O]?\ >#_Q3W[_ $ =R?\ /O\ .?[:C_\
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M_HN*G_ZX>_?[(5O3_G_'Q2_]';0?_6;W[QU_@;]G7OW1<?[]B_WKKW^G2/\
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MZ]^Z;C_?L7^]=>_TZ1_\^B[U_P#1<5/_ -</?O\ 9"MZ?\_X^*7_ *.V@_\
MK-[]XZ_P-^P]>_=-Q_OV+_>NO?Z=(_\ GT7>O_HN*G_ZX>_?[(5O3_G_ !\4
MO_1VT'_UF]^\=?X&_8>O?NFX_P!^Q?[UU[_3I'_SZ+O7_P!%Q4__ %P]^_V0
MK>G_ #_CXI?^CMH/_K-[]XZ_P-^P]>_=-Q_OV+_>NO?Z=(_^?1=Z_P#HN*G_
M .N'OW^R%;T_Y_Q\4O\ T=M!_P#6;W[QU_@;]AZ]^Z;C_?L7^]=>_P!.D?\
MSZ+O7_T7%3_]</?O]D*WI_S_ (^*7_H[:#_ZS>_>.O\  W[#U[]TW'^_8O\
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M)U,T<IB8H9</+B=MUTU!)7R4R#^!R+3"5JR$LX[.^$74<^UMB;6SM7M/<GR
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MYR_MG,%!%'=7+@(0TK1P+XU8V2*K-N4'@@7-M'J(+_HQL$)* S/R\[ 3;/R
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M_0_[Q_Q7W[^X^Q_^?R[1_P#0<[%_^Q'W[QY?^41_VK_T%U[Z:V_Z."?[R_\
MT#UZY_H?]X_XK[]_<?8__/Y=H_\ H.=B_P#V(^_>/+_RB/\ M7_H+KWTUM_T
M<$_WE_\ H'KUS_0_[Q_Q7W[^X^Q_^?R[1_\ 0<[%_P#L1]^\>7_E$?\ :O\
MT%U[Z:V_Z."?[R__ $#UZY_H?]X_XK[4.T]@]2U&Y\#3[O[\PN VK/E*2+<6
M<P>PM^[CS.*P[R!:ZNQ6 JL-@Z?,9"&$GQ4[UE,CO;5(@N?>FFFH=-FY/VH/
M^?NK+;6FI=>X*$\Z*Y/Y"@_P]-&?J\Q0X/,5NW\/#G\[28RNJ,-@ZK*1X2FS
M&4AII)*#&5&8>EKTQ4%;4JL;U!@F$*L7T/;23K/U_P#RUOX;4X*/YY?)D8"I
MRM)FYL*?C!IQ%1F,=1UN.QN9JL2G9XQ\^8H,?D9X8:ED,T44\B(P5VNUXUY6
MIL<_Z9?\_2[P]GII_>DV@FM-!I7A6G"H]>BKCLKYAO)%52_$3K 5<<$D*R_[
M--%)+#'4-!)401U!Z*600RRT\98"P<QJ2+@61OSZ[FZ&[(V]\1.O.@=Z[K[
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MM1UXHQTT#C^'XOETT39'L6 YL3=E=/QMMJE6MW$C[0S0DP-')2RUT=5F(_\
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MQ&KH-!!7CVXT+,YD=E:4BFIE#,0."EC5BE<Z"2NK-*YZ9_?":0@MV"5J 'H
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M,[1_]'OA/_M->_>"_P#&/V?[/7OWM%_RC-_O?_0O7OX=W+_SU_6W_HO]R_\
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M$CU)<\3J! $%[N5KN@W6[MC03;YN,NGPC%B1H1K"'@DLB2.N36I-36O1C\0
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MD19I9;C;EME:.:>L(;QP299%U1"LB5/:1%<W+OSCS)N6WWUO$\TB/;7$JS>
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MAG%D%>XO92VF[1[4/!M6MIXPCC5<O=-=1?3W=O,2XM[:.V\5I+=W+4*Q!99
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MSV3RL-/!CZZ%Y5EJ4.IJ:G99) %="U[*,[C^[#9LKB\$I@R 9/ 37+I!(/8
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M"]Q#&K&0NB6MHYKVTGN;&%YYTW&&R\%!JG:6X0O$RQ_[Z*K(3(Q4*L4DC4B
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MD,\2PRRGQ/#0":V>&_N(Y^VVNX(I58%)(XKF62&"[=6HJVKF&9M9?4L<+N4
MTZTR-]T8SVZMOS83<E'4;6H,?E#7UV.BI<-G\;6PB2JK=N922K\%=%A9"8JU
M9/!)%(.%965B37-8?);>S&6P&9I)L?F,'DJ[#Y:@J!IGHLEC*J6BKZ29?[,M
M-50.C#\%?;-E>6NXV5IN%E,)+.>))(W'!D=0RL/D5((Z5WEK-8W=U97  N(9
M&1J$$:D8JU",$5&",'B.ENK!@&4AE8!E92"&!%P01P01[;/:KI-UW[][]U[K
MWOLDGZF_OW7NO>^B2>3R??NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[V<O9G_9!7?O_ (LQ\<O_ '@/D![9;^WB_P!*W^3I
M?'_R3;K_ )JI_@?H#<[_ -E&]:?^(A[>_P#>KZ?]DT]O=(.AR]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]V
M"?'C-=BT7Q_7;76>Y-K;5SF_?E)L_;,N7WGC]L5FW*6-NMMSR0563JMT8+/Q
M8REHC+([R4T)GD4Z LK>-/?HH$N+E8Y) BB-F)(D:@4:CVQ*\C&@[51&9CA0
M3TI>[DL=KFN(HV=A*HTJ%+&H- -9"C/F2 !4D@#H!MY;<VYF>T/XAGL-79IL
M)U7DZFDIL=69.&ND5MQTTU12T=-0Y&@IZJJK&I(U3RFX90%9%9]0G;ZV;_,'
MV?OC<.TMNT.*[@J-O;*V=OG,[HZ;Z:V9O#!TFV-[86JW'M<95I^J</N';^8K
ML=2U4B8C*4%#E/\ )YF6F*+K*))E(N(Y8)(Q'<>$ 2&$CT@[HC&SK*NFX@+L
MA)B#@3B-D=562RW:S6-O'<1RRSPO(@5*-I25X6JKQHP'BQE%--,I,?A%Q)&6
M3^!;HS+;7P6YLUCJK8*9YJF*GPN_]RUVW\U2U-)4_9U-/4Q+NFMQTFB<H!-3
M5-13/Y8],C%U!0%'DOYA^0K]\8NAZZWE69'K6GIZK?E#3?'W8DU5M>*KQHS5
M'_$X4Z]+)+684_>PQIKDEHPTZJ8E9A:62R@L9]TEG1=MCFDB>4OV+)$VF52U
M:#P6Q*>$55UE=2UK#)N=Q=)8PQ,UXT*RA-"ZC&_P-I*U[SVH#EW!106!'3]4
MX;H2C_N^*O)8:F.ZIC3[<$V\<Q&<Q,/("E$'S0,MGB9+\#R62^H@%)=+=P?*
M+O;MG8'3FS]]]=8O<O8NY\9M;$Y?>FS^G=J;.Q%1DIA&V7W7N?);)7'[=VYB
MH=4];6SD14M/&\C^E3[5I9O-'>O;P/(\-M--H4DNXAB>7PXUKWS2Z?"@C'=-
M,\<25=U!22;E=1A30L2ZK0(I(U,%+'&%2NIV.%0,QP#TZ;IV'UIM+;F;W/6[
M6W!DJ/ XRKRM50[>GWAGLY54]%"T\T6*PN-R,^0RE:T:'1!"CRR'A038>W/.
M[Y^<FW]Q9#:]5@\A69*AR>Z,7')A^D>O<MC\M-LS=HV)N.HP.1H>OI:7-T.-
MW=)%0/-3M(OW$\2?JD0,5[7?6&[P;3-;,4>]M[>:..2L<WAW1=8"\;D,FMXY
M8QK _4BE0YC?297:[E9S;C&[HT=K),DDB!6C!MT664A](!5(7CF)\HI$D(TN
MI+A#UKU=/%YHJ &,1Q2L6W%N"-HDFI16QF:.3+K) 6I#Y;.%(3DBWMG[/[5^
M:?2V2P^([8Q=7U]DMPX==PX"DW5TSUGB9,W@'K:S&IF\0:C8RQY+$OD<?40+
M40EX6F@D0-J1@'H;BPN+B]M()U:ZMG594#'5&S*)%#BM5+1LKK7XD97%5924
M[S;C'#%<.M('9E5M*T+(0)%K3XHR0'7XD;M8 XZ:]L[0Z6WI03Y3:4E!N+'T
MN0K,355>'W9FZZ*DRN.D$5?C*LP9IS2Y"BD($L,@62,D:E%Q[#/_ &;OOW_G
MK,!_Z+#JG_["/:KPH_0_M/\ GZ9^ONOXQ_O*_P";I1?Z(NOO^='/_P"?[<7_
M -=O?O\ 9N^_?^>LP'_HL.J?_L(]^\*/T/[3_GZ]]?=?QC_>5_S=>_T1=??\
MZ.?_ ,_VXO\ Z[>_?[-WW[_SUF _]%AU3_\ 81[]X4?H?VG_ #]>^ONOXQ_O
M*_YNO?Z(NOO^='/_ .?[<7_UV]^_V;OOW_GK,!_Z+#JG_P"PCW[PH_0_M/\
MGZ]]?=?QC_>5_P W7O\ 1%U]_P Z.?\ \_VXO_KM[]_LW??O_/68#_T6'5/_
M -A'OWA1^A_:?\_7OK[K^,?[RO\ FZ]_HBZ^_P"='/\ ^?[<7_UV]^_V;OOW
M_GK,!_Z+#JG_ .PCW[PH_0_M/^?KWU]U_&/]Y7_-U[_1%U]_SHY__/\ ;B_^
MNWOW^S=]^_\ /68#_P!%AU3_ /81[]X4?H?VG_/U[Z^Z_C'^\K_FZ]_HBZ^_
MYT<__G^W%_\ 7;W[_9N^_?\ GK,!_P"BPZI_^PCW[PH_0_M/^?KWU]U_&/\
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M:3I1Y9J-JLQZ*!88&D-$NI8T6*7_ '8K6%A,I_YB&SZ;KW';3SO5N>WZ=W=
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M(9C-;Q:)-2L4+,)9V)FG+%V=7JQ,QN4<G-L'-5Y:>,R6<L!AU%4/U$;0SN&
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M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V<O9G_ &05W[_XLQ\<O_>
M^0'MEO[>+_2M_DZ7Q_\ )-NO^:J?X'Z W._]E&]:?^(A[>_]ZOI_V33V]T@Z
M'+W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W8M\8]JYO<'1*YC%]?;4[2QNROD_M3.;FV/O'LC%=68K/8JJZ
MQW71K21;IK-X;*R]'D-:O)!/C*HU5%-&DQ6P4-J*98+D2,TBGPG"M&Q21'([
M)$;2VEXVHZU5E)6C*5J.E?T\]SM[I;"+Q1,I_4570BF5=&*AU<55A4&AP0<]
M%V[%W1B,%V++C:S/Y+;65S_4V7IL)EL=M/*;L>@J(MPTT;5[45)A\OC)?LIJ
MR)O!5A5J 2%#*LA4ZI[T^6&+WAM3/;0Z'Z=PF!V%V3TEV)M/"Y?Y4; W/N$S
M](;0[2VQA*/>._ZKMNBW'O>ORM5VS7U<F3JRM91I34M)1M!2P+'[)DLF:YN+
MVZO2;F7;=YL6$<8AB$6\6%KMK.L2#2LT%M:1UDR;J5I9;KQ"Y'53M/\ C=I.
MD+&"*2UDTR3B8L;;<H]TTL[L28FGC6-(0!%!$ (E#C64G@LAUA1;3&W=Q[JS
MVZ:ZIQU;0Y?+S]29S'T]8V1J,34UBX_ 0[+GQ.$Q3OAH;4,*FFU!I'#RGR>T
M_P!;]H?)S9&WMHX?._'OI'?&0ZHJ=H;IZ3S=?\GNO\-/L'LS9^P4Z_IMYY:E
MP_;\4>^J"MH*2DJY,36M'3I5TJB.1:>2>"5;;I'8&*^VR5K?F"&WN[:"Y55/
M@VU^L0NHQ Z- \C-%KBED1BA=ED251&$6RVS7T$VW[K9BYVB6>.XDA,P4O<P
M7EQ=P2^*K>,H7ZAH7C5]+HJN"DVJ1L^\MQ[3W-4X]<7V9O#;.%J*JLCWMAH>
MILUF!O' 5LM5/)@UR.6V7/7;=825;**FD;R>(D "0)*@!=5;/[^Z/W?V#O?K
M3H[HR+.[VZDKNK\9+OSN[H;LJBV;6;GQN'Q6_M[XO"[IW]/M_*YW=5%39"*.
M#(TE518Z+*R"*)FBB=3#ZUH;'=K#;KB:TBN;J!U:(T=+:"Y2Y6S)96#Q.T4*
MR2%1,1$I1T):J=[&XN=SVC=]PB2>^MO%E)UJBR7<B2(MR51P!X7BL5@[H6('
MB*XJ"H]W;RZIWUA*?;^X\_OG^'1Y6CRM0-O8'M?:%96/C*MJ[&TSY;;&*Q>9
MIZ2FJTA=TAJ8Q/X0LFJ-G1CE87Y#?)K<V]=J93N7IWK"/#Q?(/HOOG>6[^M.
M\^CZ+L*ERG6N#P%#VC#L3&U/:]+MG#T??>Y]EX#<F?QL4<%$,SA8&I%ID9A[
M3;39<O6]ZPOK9AM)&^+X2('7P]V6ZEM[5Q)J:2UVZ]OKZ:W5F:18;^Z@+.FE
M>J3VVZ_1S01PPR/)9V=NX+K&'^C=8UG/ALM+@[<B6.H45A&DKCQ"S=!ND/7&
MV]OC"]?[UWM04>+ZPW#US@ML[AVOV)F=OU@K98O[JY;=.=K]J5^^\KD=FXY9
ML?25+Y)Y7I*N9J@5$_CD0 ?G;L#*_(GL.GW1U/LZOJX(-O;7PU)E^PN^NA=N
MXS:E!AGW)+5;&ZTZUQ_8[T&UMA!\S3RI'),\@R$53-$J)4M<.[%M]YMTETUQ
MX2B0QEV&J26X=+:WMVGFD8#3W0$6\2K^A:^# S-X0TB/>&L[U(_H[(++JG)H
M8HD'B7+RHX13W3-&]+J5B?&G+2\2257T[OG;NQ-C8W;NZ,Q-/EZ:6JDJ&PNQ
MNPJJ,QRM&*85^9JMM?=[ARR01@5%?,JRU+F[ E=3$*_V3+Y _P#.AV'_ .CS
MZ(_^V5[$?C)ZG]A_S=!WZ"Z_@7_>T_Z"Z%+_ $U]=_\ .QSW_H"[]_\ L9]^
M_P!DR^0/_.@V'_Z//HC_ .V5[]XR>I_8?\W7OH+K^%?][3_H+KW^FOKO_G8Y
M[_T!=^__ &,^_?[)E\@?^=!L/_T>?1'_ -LKW[QD]3^P_P";KWT%U_"O^]I_
MT%U[_37UW_SL<]_Z N_?_L9]^_V3+Y _\Z#8?_H\^B/_ +97OWC)ZG]A_P W
M7OH+K^%?][3_ *"Z]_IKZ[_YV.>_] 7?O_V,^_?[)E\@?^=!L/\ ]'GT1_\
M;*]^\9/4_L/^;KWT%U_"O^]I_P!!=>_TU]=_\['/?^@+OW_[&??O]DR^0/\
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M'/3RQ-(KII-3>2IH*.OK*:DJOOZ.&JJ(Z.O%/+2K7TB3.E-7)33?NP)5PJ)
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MCCJ/#YV+%KG\1##/6-2!-P18.B->""]=]I"TYD,:$4N+2VN=PNMVN+:-]QN
MH>0J-3+'(TR+6GPQRR/*JCM221W #.254=Q<1VEC:1R,+2T0I$HX1JZ,A4?Z
M:,M'G)CJ@[,=-6V.OMB[*7(IM#9VV=LKE\K-G,K_  /"8[&'(Y>>2:1\C6M2
M4\35-6#4.$=R3&K:5LO'MMVU\B>]]G9W!;GVQV_V)A,]ME,3%M_)T.[,S'48
MB# [7.R,/2T.JK:.&CQVS?\ <3'"%\0QP%/I\0"!5%+) +H0L5$\ES))3_1)
M+PH;J1_XGN#'&TKGN=HT8G4BD)="Z($TC3%)$Z4QI>%Y)(F6G!HWFF=",JTL
MA'QM67N/9VU-WX?*;?W1MS"Y_"9JC;'Y;%Y7'4M;1Y"B><U1IJJ&:)EEB%4?
M* ?TR^L6;GWG3Y%=R35^UZO-[YS&ZJ+:/:];W;B=O;JJ9,UMH=EY>OQ>1W!N
M6HPM0XI9*K<L^&IQD H052Q@/SS[216MO;RV,\$02>UM#;0L*AHH&=I/#C8&
MJJ)&:1:&JN=0H>G-R>;=K/=[&]N':WOVUSYIXC^%X D;UD$7Z88BND &H ZD
M0[9P%,E:E)B:"D_B&*HL'6O34T4,M3B<;!54V.H9I44/)3T$%;*L*L2(UD('
MU]NW<?RF[\[XWCO7>W9?9^[<[DM^QY"ASN/.=RL> 7;N0W9)OC^YV.PS5LE)
M1;/H=T.M938\ P13QI)8R*']I[#;8+"RAL@[RZ8[56DE.N24V<"VUO)*]!KD
MBA70KD54%M--1JIFOKJ8V)>8@6L#0P@8$,3J$>./^%7C C8#XD4(Q*BG43;.
MRMH[,QT>)VGMK![=QT-5/7QT>'QE'00"NJ8O!45NBFAC!JYX (VD_48P%OI
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M)(-35'<3!''"=5:PHL1J@"]-.3)%%"^8HXS&H_A0SBZ*KZ*;D"X(%/U@)?C
M/3U5X/"U]-54==B,764E:E5'64M504M13U<==)%+6I4PRQ/'.E7+"C2A@1(R
M*6N0/:BR7RD^1F9K.RJ_+]U]D92J[BPF.VUV@^1W5E*U-\8##TL=#AL1GX*F
M>6"KH,+01"GHH](6DI[Q0Z(R5*<6T LY+#PP;-[\7K*<ZKP.9/J6)R9S(Q=I
M"2S-1F)(%%C[E?R7J[B]TYOA;&V#UR(& U0_\TS2I7AJ[OBSTG:+K;K_ !L&
MSZ;'[+VS0P=?RU,VR(Z/#T-,NU9:VDJ:&NDP?AA0X]ZZEK)4G,=O-K)?4>?8
MP=(_.WO[IG&]L4F$AVAV#7]JR#,;JW+VEMB?L#<=#EH-NYG:J;CI\C7Y!8ZV
M>GQ6X)0(\M'D:!9UBE\&M 3[=(8]RY>?ER9O!VYI9V+1T20_5A$N$UT-/'6,
M*6 $H+,T3H[:NJ;-=OL>YV^Z6:J9XX[:-$:IC"V;:[9= (&F+X0GP-&!&ZL@
MT],^\.I]M[TS.Q<SD:K-X\; R;Y7%XK"5T..P^1E+TD\$&9I%I)9)J:CK*&*
M>(024[B1+,S(60DH8$L?H2>?P/K]>!8#V^!P Z3,222W&O0G>^-N+\<?X\_[
M;WNG6NO>_ 7O_AR?>NO=>]Y33SK"M289!3R.T<<YC<0O*@5I(TE*Z&D17!90
M;@$7^OOV*Z2>ZE:>=.%?LJ"*^O7N->O>\/OW7NO>^RI'^PX/^O\ T]^^77NO
M>^O?NO=>]^]^Z]U[V<O9G_9!7?O_ (LQ\<O_ '@/D![9;^WB_P!*W^3I?'_R
M3;K_ )JI_@?H#<[_ -E&]:?^(A[>_P#>KZ?]DT]O=(.AR]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]GZZ)S
M'7>V_C97[FW_ +O[7V14[<^3>SLSLK.=1;<VON/.TNY*'KO<E0*NL7=.[-HP
M8Y* 11/32P33.TA?4@"JQW!=75E>PW=C(8[I 2K D$?81TK-O9W6V36]^I:V
M:45% :T!.02,=%S[#C[%J>TJ2@V'A.O,Y2U_6.4I=R4^_LYN+#QFCGW#30T\
M&.BP.W=P1UL56DDZU0G\6@",)JU/I&:'YJ8"#/[CW3'\U?YB7]X-X4>V\?NS
M*2;9ZYFJ-RTFSH,A2[2ASHF[TDBRO]V:?*U*8]IU=J19G$14'V73V,5UMMSL
M]S:0R;7-)+(\359&DGB$$TA!!_4EA'A22?&\=48E205GUD8NX;\7D_UD</A*
M^E=2Q>*)A$#JQ&)@)1&.P. P%0*!;2="[HH,;L[$4'QX^']#C.O,AD<IL*BH
MJW<])!LROS%73U^8J-KK3]71_P ".7K:2*6J6F\:U,D2-(&*J0#E'VC\=<='
M30T/R,^=E'#1UNULC20TVS>NH8J:OV/BZ[![,K((D[Y5(JC:>&RE328UP :*
MFGDCAT([ OI&\<?AQQ($USO0$_%=1K%<MP^*XC1(YCQE1%5R0H 3R-92K.DD
MTS)*$#@JM&$<[7,8(U9"7#-.HX+*2X ;/0M2_P"S)3ZO-LSX]S:XY(F\N\]^
MR:HI95GEC;7UN;QR3('8'@L 3R/:DROR!Z:SNWMD[2S?RC^>N8VQUO25M!L7
M Y39G6M?BMKTE?B*C;]1#BJ*K[UE@@48&JDH8C8F"C<P1E(O3[W>(^XW$]W?
M11RW4ELT#,V6,+A!(E:8$OA1^*10R^''XA;0M';:Y@L[6&RM;NXCM(YO%5%
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M $.^PO\ [77OW\)^#'_/??+#_P!%'U!_]NWWZL_\*?M/^;KVG;_]^3?[RO\
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MG;_]^3?[RO\ T%U[[[Y/_P#/,="_^AWV%_\ :Z]^_A/P8_Y[[Y8?^BCZ@_\
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M!@8AX"EFDUWGU$5N\%NKF-I;[=/;S&*138FTB6*2=EBNCN!N525985=D6T$
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MT8V!O)9:3,5T4NV\O3R4NW\16[@S,J5-%-3M_#\%C:BDR.9J$675]K!*DU0
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MR:I6YJ%4>;#TCFE"U.5B216:G35,JL"5L?= I,T%N!_C$JED7\3JKF-F5>+
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M*D7<'H50O(NESVLIU*2.FR/<^ GQ\V6@RM#48NGK(J&7(P5,,U"L\LM/"/\
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MQ&/I-LU"[H:LSV.^TJHLOEFRHH/M\55+Y89(*<3522>.73X@\BJ^/7\POJK
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MP1&X6"[DM)OT5D&BUNM5DEM<W5N$DN[.XFCG+-%;E"O91-LNU<O;:@BN!8^
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M=SXA(2IDB.5C0\N[B&>ZN91<SF-+Z.YA8!(Y)A^[AMQM[TH=$D-LBB2TTKJ
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M3@PF/KML_'.CKLW54]554N&HZGY&[(AJ<K54]#%/6STU!"[2ND*/*ZKI12Q
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MM)<-8^).8A_9^$\4I2<QQ.ZR10;CN&VWUU';RVL\\<KOJ:-5MKF&TN)B\2R
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M0+RR%0 S:1[,!DOA%LK;^0VYG=U?([N;#]2]H;XZTZ@Z6WUMS$;'[1;>N_\
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M\Y8/^O?OW]\-V_\ /4[C_P#/WD__ *J]^H/0=>\23_?C?M/7OX;CO^5"B_\
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MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]GV^+^_=AX+KMJ&O\
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M\;NJA@H=D!8*&[@ U:!NX#CGI[<[>&TW"]MK9F-NDC!"Q!;37MU$  M2FJ@
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M"&4D&_NMO=6UV)#;7"2!'*-I8'2XI56I\+"HJIH145'35Q;7-JRI<P/&S*&
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MDDMX>D@'Q!A_$#@ =H4UZ:/X95?QXYG^.97[(X@8S^[>G%_P050K#5?QP/\
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M66037RW&G*NZ J\82-09WMY>27W.5S/<B^GOX[QT=@((Y9YKS;;B%)X@DE8
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M470_>.TND5Q-'G,VM=V7+O2NVC0X'L38M77[?H<2.NJIM]8PBOR,]"VJ25-
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M7NO>_>_=>Z][.7LS_L@KOW_Q9CXY?^\!\@/;+?V\7^E;_)TOC_Y)MU_S53_
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MQJ-'7;>QF*@FK7>:HIY0V@'5[86=VO.<"0RQ6.^727,T8[O"G7>+??96MI9
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M%_X6_P"SKWT)_P"4N#_>QU[_ &9*C_Y\I\D/_1.YW_K][]_LDV2_[R@^%/\
MZ4GM/_ZF]^\7_A;_ +.O?0G_ )2X/]['7O\ 9DJ/_GRGR0_]$[G?^OWOW^R3
M9+_O*#X4_P#I2>T__J;W[Q?^%O\ LZ]]"?\ E+@_WL=>_P!F2H_^?*?)#_T3
MN=_Z_>_?[)-DO^\H/A3_ .E)[3_^IO?O%_X6_P"SKWT)_P"4N#_>QU[_ &9*
MC_Y\I\D/_1.YW_K][]_LDV2_[R@^%/\ Z4GM/_ZF]^\7_A;_ +.O?0G_ )2X
M/]['7O\ 9DJ/_GRGR0_]$[G?^OWOW^R39+_O*#X4_P#I2>T__J;W[Q?^%O\
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M>Q_Y0#_SD/\ T#U[G^H_VQ_XK[]_>WIC_GSF=_\ 1JU?_P!A_OWA7G_*6O\
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M?5;4Z1LOYKU=953?0=E=)U%34U$SW^@ZF>6::61O\68G^OMM4FC1401JBC
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M\_7J[;_!/^U?^@>O?:_*[_G>_'K_ -!/LC_[,_?OXE_+P_YXWYH?^C+Z/_\
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MGLR&#8N1J.K::NQ6)P%)2Y3%4&3B1R(RE+.2SER,6MK!MN]6:MO%M]&NX7C
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M-MO>U7B7G(IJ)(*"BJ-$<?@(&ACP>\?@;%O6F.>?X429NEV_UN/E#E1UEO\
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M<'W=> ^SI/+_ &DG^F/^'H0=M*R[<P"L"K+A,4K*P(96%# ""#R"#[&7X?\
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M]U[W[W[KW7O9R]F?]D%=^_\ BS'QR_\ > ^0'MEO[>+_ $K?Y.E\?_)-NO\
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M"/\ I?[T?\_7OWC<^D?^\)_T#U[_ &77J_\ XY]@_P#HZ>Y__L_]^_V?'O\
M_P"5?HS_ -)<^-G_ -JKW[P(_P"E_O1_S]>_>-SZ1_[PG_0/7O\ 9=>K_P#C
MGV#_ .CI[G_^S_W[_9\>_P#_ )5^C/\ TESXV?\ VJO?O C_ *7^]'_/U[]X
MW/I'_O"?] ]>_P!EUZO_ ..?8/\ Z.GN?_[/_?O]GQ[_ /\ E7Z,_P#27/C9
M_P#:J]^\"/\ I?[T?\_7OWC<^D?^\)_T#U[_ &77J_\ XY]@_P#HZ>Y__L_]
M^_V?'O\ _P"5?HS_ -)<^-G_ -JKW[P(_P"E_O1_S]>_>-SZ1_[PG_0/7O\
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MQ539"EJT3^-)DLE7U&5AT;;J:W%00-/*8J:J!,KM$NH!:/YV4>=VID=F]O\
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MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V<O9G_9!7?O_BS'QR_]X#Y
M>V6_MXO]*W^3I?'_ ,DVZ_YJI_@?H#<[_P!E&]:?^(A[>_\ >KZ?]DT]O=(.
MAR]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]V#_'SI+?_=_QJS.,V+UYD^RJ;:WR6V;F]Y8#$;HV]L^N?;]5
MUYN:F$$&=W%+]O13Y(T\L<<L=/5F%EU/&1I#>AFMH+N%[R-I+>F4#:"WRU:6
MI]ND]+/IKN[VV:*R8"X\0$$C4!VG)&I:_9J'1:NRNV-@=7]JX[^^FZZ7:]7G
MNLLK'@'J<-G,SYY:#<=%]W4>'#4-2#!025U.9(Y)8&E\@"$V<I83+MKN]^U.
M\NW*?^7KNS$[P[?V9MW96!W+B?EELQ-W=28Z';3;3[!GV+G*_"9"ABKNR,!#
M#0R54M :W$T+54-',OW3.B;?[R[WZPYD@DO8XK[=-RN+J=UB[)(IBTJV4D>J
MK6PNF$\P61'NHT6UE;P6E\17MUC)MMQRZ\>WN]KMFUPVD*-("5E@5(H[P-2@
MF2V4I&NDI%<,+Q )HXM  8[NS:\6*ZUQN:^56U<T-JUF;J]^(GQ[W-B\9V*U
M3D:.OVP\&-I,HS;0FVKX92/%-60UDTBRRQ#Q*I@[4K_Y@FU<+MC!0?%W)5%%
MMC-_%;*01KWMB*."HH_BWU=O?K+$X8T<&[S24]!O"#>\U=5JB>.FGC*1HRRN
M?;,"6<<$T$L<,J2;GO5ZP>-61WWBRMK,HZ$$.MJELOAZJET8PM2, =)KO;+R
MYV[=-NCA:(7%C;6H=&421QV^[MNQHPH:RN1&U-(4J)U'B="-D.]OBU6Y!\K'
MOC"4F0..SV/2NAZ]SGWL9W#G,3G\C.E;_=9:H-4UV%@>8!P)YHTE>\D:,&CN
M';7R[[?V#N[9U=\,,OA*_MG.=4[F[DRM+\A=L9/$Y_-=+]=Y;8>Q_P#1_M7+
MY*JH.M,7YLI][60K+DY7CC%#334E':,,2VMJD-K8V,Q3;H+^_OXQ*/'G%[?B
MCNUPU)# FN<F!0AG+P&XEE:T@936(WVN>YNK!6OYK&&Q<IX<,7TD-REP%2%%
MTI,?!@0RU9!IFD2)7NIJM.V>]^C\)N>OSV1[KP^4HX8,C0;3QM%U3GL!483&
MYG*0Y;+PYC*4.)D?<=5//2Q".58J%%LTDL<TSF08^E,-\TNE.FL%T;C?@OU]
MN#:CXWNV+L/<.7WAL(]C[RSW<&WJ7;5'N';V^?[R2Y/K2?85!@\2]!%BU/GG
MH&>9SYV".\PZ]Z-E-:7YL[VQL[5+&5%!DM+NUW)=T%Z&&@S-)<Q6X:&8M$L4
M)C2GBN>D&UV5[MHN@]I]1'<WHDGCE8-%);?2O9FT5-0\-7AN+LM(I):6>.1E
M/T\:F#NGMKXZ[KWOBM\5/R([&QDF#JL)-0;2P=7V)B-@5<&(.0::EW)M&@P4
M%!NI,LV7J/N?O3(KA:;T@TL1!SNK^S^_Z[<>]=U=W_&;M7K?+Y#9W5[[1RG2
M&3Z?[(FH.]\!FMS[Q[<^1%#2;YW]BZ'9/;/:F_MQ2YNEJHHJJ@Q-;42(%\,<
M8]D6Z\O;1+%O";+$ML)I+J*UMH]4"6VUSV4]FFV072AGCMX_J'6Y8 27%F7@
M%)=+E9M=MX,>WVF][8+NV2WTS&2C_5R+<6[I-=Q@CQY(K6U@AB9V<K/"D[5\
M64=!SNSLKKNNHMJXO%=U[>W5B,9O3<N3SE)N_;^^=LXV;8&0J"FU-@9'![7V
M>])V%A-HX)(J%8\FZU%?+315,LWD,@-)6[?Y?/RLR>42IVW\?MS8JD^RIXZP
MYSLWK;/9'*95#)]_FY:B+.XR.C_BDC"0TH680,2!+(#?V(+:54CTNR*H"!41
M6"I2-%95)RRZP[(:+1&5""5U,Q?6E[=7EW<TED,DTKZY2OB.'E=T:2A(\3PV
M59""0[AG% VD&DC^6_Q]4,)NR:>0M([QE-K;RBTPLY\2$' R:V118MQJ(O8?
M3VE_^&Z/F;_SY.O_ /0QZZ_^R_VH\>+^/_#TD_=M[_OC^8_S]9/]FY^/'_/Q
M8?\ T&MY?_8[[]_PW1\S?^?)U_\ Z&/77_V7^_>/%_'_ (>O?NV]_P!\?S'^
M?KW^S<_'C_GXL/\ Z#6\O_L=]^_X;H^9O_/DZ_\ ]#'KK_[+_?O'B_C_ ,/7
MOW;>_P"^/YC_ #]>_P!FY^/'_/Q8?_0:WE_]COOW_#='S-_Y\G7_ /H8]=?_
M &7^_>/%_'_AZ]^[;W_?'\Q_GZ]_LW/QX_Y^+#_Z#6\O_L=]^_X;H^9O_/DZ
M_P#]#'KK_P"R_P!^\>+^/_#U[]VWO^^/YC_/U[_9N?CQ_P _%A_]!K>7_P!C
MOOW_  W1\S?^?)U__H8]=?\ V7^_>/%_'_AZ]^[;W_?'\Q_GZ]_LW/QX_P"?
MBP_^@UO+_P"QWW[_ (;H^9O_ #Y.O_\ 0QZZ_P#LO]^\>+^/_#U[]VWO^^/Y
MC_/U[_9N?CQ_S\6'_P!!K>7_ -COOW_#='S-_P"?)U__ *&/77_V7^_>/%_'
M_AZ]^[;W_?'\Q_GZ]_LW/QX_Y^+#_P"@UO+_ .QWW[_ANCYF_P#/DZ__ -#'
MKK_[+_?O'B_C_P /7OW;>_[X_F/\_7O]FY^/'_/Q8?\ T&MY?_8[[]_PW1\S
M?^?)U_\ Z&/77_V7^_>/%_'_ (>O?NV]_P!\?S'^?KW^S<_'C_GXL/\ Z#6\
MO_L=]^_X;H^9O_/DZ_\ ]#'KK_[+_?O'B_C_ ,/7OW;>_P"^/YC_ #]>_P!F
MY^/'_/Q8?_0:WE_]COOW_#='S-_Y\G7_ /H8]=?_ &7^_>/%_'_AZ]^[;W_?
M'\Q_GZ]_LW/QX_Y^+#_Z#6\O_L=]^_X;H^9O_/DZ_P#]#'KK_P"R_P!^\>+^
M/_#U[]VWO^^/YC_/U[_9N?CQ_P _%A_]!K>7_P!COL?_ (H_ OY;;0^4'QUW
M3N#IVOHL%MWN_J[-9FM_O9U_.*+%XS>F&K<A6-#3[LEJ)EI:2!Y"L:O(P6RJ
MS$ TEFB,;@-FA]>E-G87<5U;R/"0@<$Y'"OV]!)W_P#+?X[/T/W8K=DTL2OU
M+V+&99=M[T$<?EVCEXE>0IMMW"*SB]E) _'L)MZ?R]?F-D=Y;NKZ;I7(-3UN
MZ-P54#-O#KI6,4^6JY(R5.[^"5;W83PT'?\ R/3,FW7I=R(#0D^8_P _0A[=
M^6WQWCV]@4'9--*JX3$Z98]M;T\<J''T[))'Y-MQR!)$((U*K 'D W'L5?C'
M\9?G7\8>\-B]W;;^/K9W)[,GS2-B*W?FQ,:*[&;EVYE]I9R&BR]#N\UV!S0P
MN<G;'Y& --CJY8JE%9H@IO*^W7FV;[LNXB9MKW&REMIA%*T$NB0 JR2JI9&2
M5(Y.!5PIC<&-V4IIMIW)FM)H$"W$%S#,A94D0M#*DH5T8T>-].B1334C, 5-
M"&S?'R-^-&^MJ9K:F3[!QDM%F*589(\EL?<F;QKR03PU=,N3PN2VU)09C&FI
MIT^XI)AXZF'5&Q :X-1N3%?,'=G;&:['S_PTSF7H=P])4'QFSF+S'R!V/EMT
M9WH^'K\[+R";A[!K"V7SO;];7P4N2CW3/ 8H32I2MCI:>RJEM1;1_P!8VNUC
M9]VN6GN/"3P094FL9K5T4:@KI)8H]Y(_B/?R33S2&*65G*N>PO'GV6:&*8BP
M+F/QI3,["=KSZI9)&()1XKV6"V10@LXDA5-?ACI X3N'H;;77F-V;M_NG#87
M*8B=\OC<IC.K-T46W,?N*2MEKV;'[)IZ..CH-J*]1)&F*BJE,<+66I#C7[26
M\^JOD1OJ+N2'+_!++XZ#?74_7G3'6='MWY%[,QU%U;LWJZBV\NUYLLE:,K5=
MD9VKS.V:>NR=1438Z*KDEG2**G5X_$KEW&[FLN9-=W'^^MVW:.]N)Q%^F$AT
MI#;0P:J1K' B0"5I'D(02-JD+EU-K:RVU]L3M92OM.W;5-91Q&11*_U#R333
M2SJH!8S2,ZQI"B*I\,@H!T]4_P B^M*.787V_P B,9/386ORV1["7*=3;IK:
MS?DN3HZE(X\/6014,>Q(<=D*HR1".&O/VR)3L2 TCJ=L?\Z\QU+NGI+/?$R3
M<^"W%UOLWK3;64W=VWL;>^;VUD:!\:=R;\GRF[LYDL]D]SY')X^GJ,(E%DL)
M1[=2EIZ6-9Z*(P,6[Y:V6\/--'/+;W+;]#N(D1CX@B@0*+/4 H>.<ZWO)75I
M+III2]/T?!=VE+S;;&WL?HBZQV3P EE"AI&).E*%$@5#H2W4 H5$B2B1IFFX
MUG>WQAHLUMK<U+V/A,51;,_OSDWH:78N^J&!GW13U$M=54\6%H<9C$D5I9I:
MDU=#DFJGD9U$4Y,IJ^^>=A\T?E&MR3'WAV)"]_J)(-QUT,JM^"R2(02+@D<$
MCGV80_V4?V=%5_\ [FW.?QGH;?C#/%5_'+HJL@<2TU;U-L&MI9E#JLU)6;9Q
MM52SHLBI*B3T\JN ZJX!LP!N 4OV[TCZ'3W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W_]737^/%+45OQ=^=
M='20RU%75[.^/=+2T\*-+-45-1\A]EQ000QH&>2661@%4 DG@>W+6SN-QW+;
M-OM$UW=Q,(T7S9W[5 ^TD#\^E2S16VV[O<3R*D$<:LS$@!55@2Q)P !DG@.M
MW3M&1(NY_C9++(D446>[1DDDD8(B1IU=G6=W=B%1$4$DG@ >[:=W?RA>ANF^
M[NBZ+?NY.VEZDK^L?E/0]P3;XV]D*>#(?(OXK=+UO:VXL;M*LV'0PYX]-;GQ
M%;2Y2AJ(E?)UE%B\A303?<-$Z$=SO<=VON==[-9.NV0<L_O795G=%NY(_P!Z
MG89FOX_[..2"\C>\CB4A3:W.WB:GB.S;M+2]:'D:.]VYEOI-\VRSW,K(HBCC
MW*W@OH&M@1XA+QR26+_%IN(9''P%.BO[%^9&Z^S]H]EP;$K^J>R.PL+V9T[-
MM["]4;D@IY=L]"=][PQ6-V'F]ZU&_:E\14]EX; 0Y;^)P4K#'5-;2+'2@,WC
M!=MX?RH-BYGL#;&*ZL^1^!V[UM2?$WX\_(CM[LCN;%S;1P.Q,Q\@HL-1[-I*
M)\A)B3)M'=63S<-;3-/*]7AL466L>HJHBDAL\-Q'OWN9MHN(!M>Q\QP;/;S2
MN(C-<36;W2K<<5B*K!.TLRKX:@QJL=0Q#<$FWWEMRE*LNG<-RL]RO)(8D>01
M6VWWTEJ[0U),KD^'$L)<.\P<A@CI02*+Y;;JPFQZG/=G='[AP.\Z_M_M_K_8
M_76P\Y3=K9[>NU>J,KN"2JW70ML['5L=!FZ[:^W:F5,-.%GDR4:4:R!ZB(^R
ML[P_EU;^VILGIS<V([/Z=[ W+W">[,WAMF[?W]M_ 8E.N^B^PLQUIGM_4G:N
M^\AM?KG/8K=VXL),<#!CJRKK:^C(G6&PTDN_?=G;W1^KL;M+:VY?VS=[Q)(V
MAGMH=T4O!:- 0TSW81',R0QRB+L;N#8?7;WFFW.SANX6N8]\DVN!E8/#<2PV
MT-S-.DP81)!&+B&.LS1ZI"ZBFBI&W;_>&-S>=W;C:S9F^]N8?:^4Z\V]!N/-
M8)I(<_N;L+;N'W+#A:' X6;+[HQ3[8I=PT4&6GRE%04])52NA<I#)(IHZ+^7
MATYWY6?&C;/0M)V;U/5]P= T7R)[)[+[3W/CNR.N>L<)G.V\]T9M[;.4CVUL
MG9-5B:#)[TPL$D>9JJF1YY<C'104<LP4N*)N7MVDYBO-LVZ2)K?1MD=NLH*-
M/?;M9QWEM:>*"5#D-)%$JQ-)*(VE*HJL.@Y;\Q[2VQ+>W<+1WR[AN,+A75C]
M-M*:KNY2(@%J*5E>LBQPIAI#J!Z+_DODUO#I_:G?F]^Z,EL;=]#UQV/G=J;#
MVEUGMC<>W]Y[FP.U]CXSL3. 4.7W+O)]S[WI-LUM5,:2AAI*0Q8XN702GQ%Q
M^2'\M/L#XQ?'S%_(C?/:?7&4V[N/L[.]+[7P&W*?=]3G<OVAL'=&]ML]K[<J
M#6[?H<?AJ7K[^Z,%6:ZIE2GRL&6IQ1&22.J2G >V<S1[G=\E6<=A+'/OVVQ;
ME;!V0?[K98("MY(02J@7LK[>8:^/XL$TYC%J8II1;<;/);R<V(UPA79KZ2QN
M" U/K5=6C@CQ5Q-9L;Q9@!$@5K=W%Q2,BAU)\M.L.ZNU]\]-[*@W,^\.MMC]
M<=C;R&5Q'\-QN-VAW)B'SW4^3I*Z>HT9EMYXNAR+>&D$TN,EQ<\5>M,TE)]R
M,G<WP"Z=VYWUE/A]L'+=EXKLOH[KC'=N_(_Y$]@56.J^HX>O*+I?%]P=G;EV
MMUCMK;#[TIL3M*#*PTFWC%D\G4;F\B$I3&:,@064C;Q<<Y;I82^!RYLMQ?VL
MD<JZKF62QW(;4DRD,BI)=7A*_1LC?30&.1[EF2;HE@GM;3:.3(MXDKS'OT=G
M+;^$0+9?K86O$@+M5G$%@/$FN.W5<Q3Q)"%$9*8ZT^1NY=R=,4W>^XL;MZIQ
M/9&>I\/TYUUM=:B+<)K\QNJMV?M';6Z]X9?*M@YMP;AR4<!K911XZCPTCRPL
M:D0^:14[-_D\5M%V-L:@[.[UVWD.O-R]U_&;9TG^B7!Y[<78-5T]\GL?MW/=
M9]PYK;^0QL51U+MK?E+N2FP^*J\]2O#'N*1J:H0!$,YGMT%=_DY;WN&2WW6#
M?-TVBY1&22.&_P!K5F>#QU+1M)<*OU-HE%:XM$FE6C03)&6;ON20<N[[S%LT
ML<UG;[%;[G;&8&(W,4SO'-HB)#F/;VC=;Z1&*QNT"*S?41N&W-_,53M:NJ-I
M]8YRJWW)TCW'V7MO:F\<Y@]H8G/[]Z<RN8VSN'I^AWE+45^W:_<F-W+@:D9&
M>GFDIZ+&&&O!EIYM49;,?\#]N[N[Q^8VW]O]WXK:WQQ^'F8KQOSO7>FT=TUE
M?38;(=H8_J;9./CZ]VWCZG=&:W/F=Y9B"CF6GABIHT@GJF9(E16(?;R>^YVY
M0Y,WR4P)N^]W&VV=K$FKP[B]W..:6W"LY)@MF@MKBX>24LT,:+&5DF8*13S%
M:VFU<Z7W*6VRO</#!?7+$@*R6^WHK7-=117E222*W4*5666164K'5E%#<'>.
M;VWL[J66KZSR60[@[<QM,^%Z?Q.Z=MR24N<HMIMO#>>)FWY7U%!M22EVKC*6
MH1:P.(ZZ9(UB73+J08/DU\!^O/C#UW\<>LMY9DU7R;WC\N.[NF^YZW#3;EK,
M32;1Z]W'L#:^!EZ_GJ:*EVC-C9*7<XR$LE5&V5EJ*^*,QPQ4\B.HY$N4YY]T
M^0^48!+%R[?[?9?5. @EAO;C>MPVRYAHS.LGT_T$BP2PDV\A1Y&9A)%0HY@E
M7E[E;G'>%>*YG@\.XLFI(B2V4FT6VY0NRX*-,+N/Q8Y=,D5%1142-TG.O>\]
MS;\F[6WS3[;FH>K,-U;UCOOJRIR60P4==NE-U[%RN^<XV;Q-'+5;BVMD,8\M
M)0R158-/(J>6F,G[I]F4[2_D]=;[_P!U;IPGQ6WGN_9E'TY\K/DI\8^WZGOK
M/[;SE#4[?^.VQ5[.R/=NS\IMO![263_?JP5--E]N/%*V.R#49-:L-2[0AO;-
M]O&VS8.;-\>"#E?=.6+O=P$20RVALMTLMJ:#6[!;N&\FW2P-K.HBI(E\C*XB
MB+'5Q8H;\;!9(S;V;O9[>*II'.V[65U>58Z3].;46-R6!,@F@,3J5=75@IV=
M\M=W[6VMCZSO"BVAF<YN3K#HKL/:LO6&+W%B:>MS_?\ N.?96U.N*[;F7R6[
MLW121[QC6*',^5H9Z RS2TT!I)M8<5/\KKJRM^+K9';_ '?L+)]]XGO_ .1&
MVMO[]VIG\QV+T_WMUCTU\?\ 9O>N0QFR*S:.-R6)VGNK:FUZK*5%:V1J1Y\A
MHQHTR1-(1%N-Q<I><I36]L]OMJ\M;I?[HDJG4HV_F,;0U]:.^@7-H8&\2W6(
M#ZJ*-Y@5+)&6+*R$LO-%F9UG=;_:(;&1.T:]SL[J6*SN4))AGDN(HED9JBVU
M4?4*L%7@/DYO7+=L8W%GJ+>D'6.?Z[Z/S]96YR#![/WGU=N?M7?_ &3L.'&[
MVV3N3,4.[:Y*W);>QQ_R6D'V5,SS$3:]"$1_F$?&_JKXJ_)#+=1=/]@;E["V
MK0[#ZIW5)7;PV_)@-QXG);_ZXVQO>?%9!/M*&DKDDBSZ5=/)!$HAI:J*GE+5
M$,S&XDN%WGG';)H56+;=]W&QC8,&UK97DUKW4QXD9B,<I%$DD1I(@(V4 MV^
M6WO^5N1]^2Y5KO<]GM;N:-58)%)/$KE49B=<;5UH:DJ#H8E@21H^.W8^_.V>
MI\#OKLGKFCZJW9E<AN>EJ]FT&],+V!1TE%A=SY?"XG(T^Y\ J8ZK7-XO'Q5;
M1 "2E>8POZT)]D?]J>K=#=[.O\,/^ OR]_\ %*.Z/_=QL/VS-_H7^G'2ZQX7
MO_-!O\*]%P^17^=Z#_\ %C^M_P#W#W+[)1[>Z0]&/]^]^Z]U[WV/J/I_L?I[
M]U[KWL\60ZAZ>J_A?1]WT>R^V-M=E93MG ]0;!K)]Y[>W+L_M+-8C;M7N?M_
M*0;3CV9A]QX"BV?0Y' 0TO@KJ]):K+>-WO$1[+]W?<;/>^6[:U6/Z"^@NKAT
MD5_$CMK810K*DB]C^-=O*@#*H2.WEXL*]*-LDL;NWY@CEUFZLDMU#H>QKFYE
MD9(66ATZ;2)Y&!;7K:$@:)*=(6#+9QNP:G +E,!5X6FVZ<Q7XZ/%Y&'/XJ>O
MKH:3;Y?)+DJC&5%'7+C\D71X(IB8D*>D/<R.Y_A%\<L)\<^N.]<%V;E-VXNG
MWIT+M;L7<E)OS9,&S]T9+N;8>X]V[MVG34F/P^<W9T9N'HW/[;?%9C^\-'D)
M*ZAE.2IJ<*JPN_N-R++FVPV>*:%MON;G<H(6=F59(["WLIX-P\=59#;WCW;P
MFVC5IK:6.&&23Q)&97MIMEW#8KZ]G8Q[I:V4-U/&M&D@,NX36;63P-I)D6*.
M.ZBNED,,JF8!*(I*-PO96:R&_L_LZMQC4,E-MK<>>QV-?;^?BS%&FW-RKMVG
MJGR%5XMN;GQV[(*F&MH/LYX)8E$D,H)]:BA-_+J^,&?S/;VQ-M=L;YPG8E'0
M=4=E]40Y*HH\]LNJZ4W7MC9VX]U[VH=RTNSL52=E;2J*K.9/&;?ROFVW5UU?
M2XZ(XUI,@RPD<.ZW[S[*B6,KJN^75C>QLBQ72J-1VZ,0&1EBO;Z-K>:./Q)X
MQ',S.T<<+RA9#8V]Q);PZXXI;W;R]NQ=F@^I1YHW(E"!I;:.>WDBN6:. VP2
M5]4I18Y<^W]Z;QK(MOU60HL954,F+W!%N"?'8NKI9H]SXS+?84^*-/-GJZ?
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M7NO>_>_=>Z][.7LS_L@KOW_Q9CXY?^\!\@/;+?V\7^E;_)TOC_Y)MU_S53_
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MU53LW<-9EL#DJ7>>-QKT5/EJU*'$UU77[>>EJZ^(1PUJH]1"VM;$.BKSXZ?
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MWOW7NO>^2JS&R@L>38 DV ))L 38 7]^\J^77NO>_!6.H@$A1=B 2 +@7/'
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MU8%:Z@RBJD%64J5(!# U!X=%I[.J-[_Z3:;&;3ZVV_V+CLQU?E*+<=+G=_\
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MEUG/!WY\+)^RXL/L7IRAK<7UMM?!KD?D+"*?;FU\;6?;Q8R7S8Z2"*.-X65
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M?(S_ )\#LO\ ]'LO_P!J_P!^_P!%7PB_[R_[3_\ 23C_ /;W]^U3?[['[?\
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MG_Z2<?\ [>_OVJ;_ 'V/V_['7O"L/^4Q_P#G'_T-U[^_'R,_Y\#LO_T>R_\
MVK_?O]%7PB_[R_[3_P#23C_]O?W[5-_OL?M_V.O>%8?\IC_\X_\ H;KW]^/D
M9_SX'9?_ */9?_M7^_?Z*OA%_P!Y?]I_^DG'_P"WO[]JF_WV/V_['7O"L/\
ME,?_ )Q_]#=>_OQ\C/\ GP.R_P#T>R__ &K_ '[_ $5?"+_O+_M/_P!)./\
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M1T8$$,KHS(ZD%65BI!!(Z33V6U7,?A3W#,E5-#'P96#*P[L,K ,K"A5@&!!
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M=EUQHI&-BU(*0)XC^4M[]L!E;8MF,X/BFUBK6E:Z%XTQ7UIBO#'2[=@!N=\
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M!L[*Y4-#)XCQ[A ;FT$<0!EEEE@'B"&)'D *U6K =/7%K):7GT%P\:7'U-U
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M26D8(B@ $EF=@H !)) '39F<QC=O8K(9S,U:4.+Q5)-6UU4ZR2"&G@0N[+%
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M(W6*JC@J8ED19 P5U#"Q /NK(CLC.@+*:@D5H:$5'H:$BOH2//K5!K62@\0
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M[PG^(7_GC[Q_^WK[]X1_WZ_[1_FZK];'_P!&^#]C?]!=9O\ 0MN#_O(3O?\
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M9_Z-7?7_ -?O?O"C_P!]K^P=>^JN?^4B3_>C_GZ]_HCZI_Y]CU[_ .@7MO\
M^MOOW^S+?(W_ )__ -V?^C5WU_\ 7[W[PH_]]K^P=>^JN?\ E(D_WH_Y^O?Z
M(^J?^?8]>_\ H%[;_P#K;[]_LRWR-_Y__P!V?^C5WU_]?O?O"C_WVO[!U[ZJ
MY_Y2)/\ >C_GZ]_HCZI_Y]CU[_Z!>V__ *V^_?[,M\C?^?\ _=G_ *-7?7_U
M^]^\*/\ WVO[!U[ZJY_Y2)/]Z/\ GZ]_HCZI_P"?8]>_^@7MO_ZV^_?[,M\C
M?^?_ /=G_HU=]?\ U^]^\*/_ 'VO[!U[ZJY_Y2)/]Z/^?KW^B/JG_GV/7O\
MZ!>V_P#ZV^_?[,M\C?\ G_\ W9_Z-7?7_P!?O?O"C_WVO[!U[ZJY_P"4B3_>
MC_GZ]_HCZI_Y]CU[_P"@7MO_ .MOOW^S+?(W_G__ '9_Z-7?7_U^]^\*/_?:
M_L'7OJKG_E(D_P!Z/^?KW^B/JG_GV/7O_H%[;_\ K;[]_LRWR-_Y_P#]V?\
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MG=S]H]FX+KW+XE:*IW:_2/4.*SV4V9G<IN".LS?0C]E3[GH=J1U+/-%14VE
MB:7F+;&YOFYPV*_F@FEY;V^/<ELA<IW?3R[Q*UJM^@"EKJ:QAMF=FTR-:B$2
MMXFH()H+:XMHN=8IOH5W+<EV?6UO(I4^!!?F58&+$1K$\L+7$:_H"\EE, ,8
M72I^J=BY.#?-?VAF<MV=/59_J/KG:=%A=[9I'Q>,H,-G-\Y6*MFVJM#",%VA
MD\;EJ$;IGCE,-54PP(D:" >QWS<?PN^0O9^Z-[=G;G^+6!FVKW-MNNDFK=[/
MLK:&XOC;MWXG)M#;VP^J\!ALW415DN%[BQ$:S4,"T]1'5M%(7-,TNBFX6>[P
M_OG?+.^9UF;F;7" 6NY;RYN8I-FN%0II$ A$D<1+A(E%)05T4(4LM[NH-IVA
M+B&WMK':M@2)I'0)X=O<2#=HRREB]R8YE>1: RA7,1#@ZD0C;\Z6P.S=DX#&
M=T=ATF6QLN,QV7GCQ6^=Q4&Z*K?=5F,WG.Q]V5T6'@HJ.?#9>T53*A1H89$5
M?.B"4-,3UM\*.Q?D9L_%9_%?#W:OQ.ZEZ_V!1[D^U^0V3ZE[,[GW3O'IS9AW
MOF<=O>:IW95;@W'LCMBAR,DE/)2T6)H_/+3()8VB919->PW&U[C>&$1[D>8=
MUCBCC5NW;(YZ;8?#H=2-#J(N78SS$_K!:*JF6QV5+#9/WDZB460\<22IK-PT
MTS,3HX,J-''H!\-41:=Q9F#KY"Y?Y!=?]2;DAZLW;W(W>?9^7R$6T-Z0=#T?
MR(V'U*-N;DJZRG?-]7[?S_7#1;>W#M>I6@1ER@JY9!'4$M)%*LA?OYHFZ>L,
MEBOA?L7K'>_56[*3J7X[Y?96:PW3O8%9V;L[8-;-VYOW<..VE3;SR-+19'/3
MT^#S---+53Q+)/+*[?2WLKL0YN;Z5D8*^BA*E:T6AP?0XZ,-W:$P[='%)&=*
M,"$;4%S@5X_MZ>?@OB]X^#Y+[UWAL;L'9$O9?R(_O5B7[/VSCME[NWC1XSHO
MI#8V4WO4;2QV6S*;=QN;W7M#(K1TKRHZ4\*D1JC*6J=]F?1'T>[W[W[KW7O?
M_]730Z"O_LJGSTY(!V/T#<7X/_.0FS;7'YM[9<#QH#I%<Y\QCR^WSZ7VU/H]
MQQ^%/^/CK=W[-_YG5\:>3;^\/9YM<V_YE?G?J/H;7]E2V_O#=&U(-R4NVL]D
M\'3[PV]4;2W1%C*N6D7/;8K*['9.KP.3\3 U.+JJ_$TTLD+>AVA2X-O;L@\6
M%K>3,!='*^1:-M2$CST-1EKP8!AD A O9+%.N)DUZ6\QXB-$]/35&[HWJK,O
M GH?)8()S$9H8I3!*)X#(BN89U1XUFCU Z)521@&'(!/M.7^O^/_ !/O?7NL
MOOKW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]G7^&'_  %^7O\ XI1W1_[N-A^V9O\ 0O\
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M_P ;-_\ 1'#_ .V;[[_TM?";_O#CLK_TK2J_^T;[]IG_ -^C_>?]GKWC;?\
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MDD@#)Z]_<KY#?\_XV;_Z(X?_ &S?<'_2S\)O^\.>RO\ TK2J_P#M&^[:)_\
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M> W[6[RSNY*C;FVJ/>XW5@]LMM#=577[8SE7DJ*KDI$SE7')E:%80CS31L+
MYE?F=\5J;?V%H<CU-L;>G6&:^7M?VMWE'M3J3%[9K^Q^J\3MKKBDV;C-M[AW
M0]5O?:^%DW9A<KE\IMJ!Z"DJJJ5AK$,_C0TVD,D^QEZVD%M#N+1J&)2WOK@S
M1V%TX76]TNWI(KI&[E6 DC>-RZLBO?IGE_KC)8,LLU['M,*FFCQ;:V$TFXQ@
M,"EI<7CM'&UQ H8:4=6 C(=ZP_5.^WV125'][MS;>[%H^HDV9MNKRN>CW#1;
M4SM<^2J:^OK]M8Y:+8^XLO0K)14D.0F@GE:GI%%Q>5IE[N/YG?%DT7R;R>!D
MZ]VGN'<.\MF;TZQJNI/C@U'N#L'+[3PNV*4XG<.3[1EW#B-A;%W%EZ6?(Y*/
M%P8W)4^4IC+2.U/520$OVV.\VQ^3]S@>47%CODD[6RLHA6,74#QW+,Q>24I%
M%,UM!XA4-<-%<(Z!#$LWP6&['F"U@E2.&ZV4VWCNC-*S/%<J45 ?"4C7!$Y9
M-+)$)4=9@6=,X;K7LMO]"^.SV.S&?CQ6T<_B-ZYW='8-/1?W6I\_'5T63Q=%
MAMBTV+AW9N+^#5B4%!6S%J6F@I5F8BK_ 'F+UVU\P-CU_P N_E3\B\+FL'VI
M7=L]:[EINJ-P[PZ V-11[/WGO6HVHT4=;L')0UFV(=S;%VVN2QB;D,-9/5UJ
M"OTO+.74JM-CEV_8MZY?V\O"DNYRJ91*VJXLWNG>>52VM[7ZR(_V$;*]NCM#
M'(E W2J#<X7O>4]SNP&EL=KA41Z 5BNH+!H(4882Y6&X".'D4HX"LT9TB/H3
M]F]38_&=4=7];R46>VGA^O8]MTT."Q?8^[<K4O0[-CEIL-C\IO2IK!N?=6,J
M7IJ>HJ(JZH9JL 1U)D4.KFDZZ^<_Q$ZIQWPZR/7V4W'@NP^L)Z[![M[(S'26
MS]P[OV'MG?'0^Y>O=]+F*%?X?M'L[#XWL[)T.6QM#'3FJJ,)1M#450J9YED/
M]^M;G=-VWBSL]P2VY?O]AW.TF94+"0RI:G;T=&_42X4Q3QW,\#1PI),7@#1G
M2 W"-.P<OM<VXEWVUY@LK]UU::&WW![FY:&0 A8IX)%2*%RQUP@R".D94'=P
M='[QWK5=_8[>6&_BNRMZ5>T<K@]JT/8NX-L0[ES.SMQT&ZL=64.X,!-'NC98
MJQBJ:EJE%0L$E1&_[#4K%6*+\OOD%\9^R_CST'U_TQLG9^*WKLB>H'8FY?[A
M9C;N_<YN>.CK:?>&\_[QT]:FV*[9W;>>FCS,.':D^[P+QI2QF.%&5T[P2/O5
MK?6UH+79C8HL5N)'E:SC$=ND>W32N3]4UI*EU.EX@!F-Y)XK-IC5!"UW;C;=
M[MIIA<7\FYR.)2@02AI9G^KC1%46_B0M;6SVI+(@ME>, L[,+_7&T>Q\+V3V
MUGMY;HRN:V_N'(8RIV=1,NVJ;!T6-=:IDH*;'XVA3-PY+;E(D-#-4U-0T=>H
M68('UGW6;[,NB3H=/?O?NO=>]^]^Z]U[V9CX7.D?R_\ BVTC*B_[,)T\NIB%
M%WW_ (!%%SQ=F8 ?XGVW-_92?Z4]*[ TO;2O^_%_P]!'W^CR=#]V1QJSR2=1
M]D(B("SN[;-S*JJJ+EF9C8 ?4^P6[!97W[O=T8,C[OW*RLI!5E;,UI5@1P00
M?=UX#[.D\O\ :2?Z8_X>A"VVCQ[=P,<B-')'A<6CHZE71UH8%9'5@&5E86(/
M(/L??A=W)LWHGO\ V[O[?@SU+MT[;[$VA-N7:L$=7NG8-9V#L'<6R,=V+MVA
MEJ:%<CE=D5F>3()3K44TTRPLL4L<I1P[-;P;CL/-FPS7 @DW+;FMTF*LPA?Q
M89@65*.8Y5B:VET'4(IW-' ,;MP3-9[MR_NQLTNK>ROXIY+=](6X1-54)974
M,I(FB)4CQ8HP2H)8-^]<?7Y/;=?38S'X[,5B-25D>$RTJP8W.+05M/6RX6LJ
M7IJR.EBRD5.8?*\,R1LX9D=05)V*[Y0_':J[<H\U5=L]CYJCPWQ>@^%^/[BR
M>PZY=^F*NZ_SFWY?DI!CH\\V1@QFUZBJAPE-@),@V=FP#:Q4I*GVWMNV*WTW
M-DUU E@=X>-VT=QC:P;:&26;P]/BS[L;&X:Y96(AFFK,]R&=G43!;4\KVL-V
M;J';7N',K*P,IOKC<Y2J*[$I^[?K87B+&DDL'Z7A*4*!;#M[=M#UGX\?UMM*
MBSC2S;QFZPH<[3KMRHRE14'(U&R7S=3BWQJ5-542%I*]*-*'[P%UB$9U^QTK
MOYB?Q^>+;V3Q_9/>E-G?C[@]V8+'R_W8I/N?FW7[@Z!P'1^$W1V9/+GZG'[&
MDVY+@5$D6;@W%++MGQPJS5OEC9%N?CWDW,F_VNV6R7NYF]C2R:AALVN;H7,>
MXEO#,<LXE"7T\21HS;C# 4F,?^,1'&TR[78Q[3LMTZ-9V,VWSFY1&#W,=G)+
M)+MN@TDCMW65H;=VD9%66<O"@*HS7!L?<L%9LZE7J_K\8G(_9UN1T92)8.GI
M\;7S[@?';=AAQ%+6[BCR=;5&*.2CDQT<-6&D:,4[+$H*=B_-+HOO'I7?&S>S
MZK=]=VECME=:OL#<^U,76[#P6^.U8,S+F,A+N_;D.<S.#.R^OLCE\BX_B+2G
M)RY*LK:.GQLTD4$1?NVSHEY-?;!# +IN9#.6E4D?0RQ*M[*O<72YN6C"P1!B
MMJ@13)*)+@%O:MPB7;C:[H"UR]B2[**,UP/!CAC9A348XHXVD91';RM"H,.N
M.*5U;3[2W3MS.;.H\!65<^THZG?M7N\UTN%KJV=<JDU7MVC^XEQU'D4AI*RI
MT0_:6=(H(XZAIE4.23_/._\ LZ'R@U6O_ILW^3;Z&^?JS<?X'\?X>SB'^RCI
MPH.D&X5^MNJ\=9ZA_&D6^/?2@L5*]8;+4JP(92N!H00P/(8$<C\'V4KV[TCZ
M&_W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W_]?3J^+N%.Y/CO\ -/;JU]!BFW!@_C7A!E<I))%C,8<K\D=C
MT0R.2EABGGCH*,S>29HXY'$:DA21;WN"W>\W';;*(?JS2A <T!; K0'%3_J)
MIT^;B.TVK>;F4GPXX@YQY*P)SP&/7'6[GVE(D/<WQMFD8A(L]VE(]E+$HG5N
M>=B+<W 7\?7VY3_R[.X:#96T-_YC=G6.'V[NCN/OSIBN>NW!DQ7[/S'QXVQ-
MN[=NYMU8Z+"255%L_/8B@KOX-5QK*U;+CZA"D>BY*;G=D@AV6:.RN9OK^6)=
M\B")4_30WDUE);L20HOEFA#&UU%Q%-#(:!QTHBV^66\W&QU*DUOO%OMP\3L$
MDERJ,LJ5SX">)&)&8*0SJ%5J]"12]AXBLW/G=JQX[/)783!;4W%%65&/2GQ>
M?QN[:O(T5,VW*N:I0Y.;$U..T5Z:$-,U1 /4TH'N-M?^7QVUNO9O1.]Z/=W5
MU)C>Z,?V1N7-4%;N:K7,]&]>]:;7DWY6]C]TX^'%S-MG:NZM@X_(Y?!&G:LJ
MLK3XRHCAA,X2)UE]?[?M&[O8;Q>I!MR[=%=-=C]2#Q'G6W?;U"5E?=(7FL/$
MLUC+ ;IMY#$3,8TEG;W6Y;>;W;K9I)6W$6<<3?IO([:PLXUZ56U\2*X1KARL
M:_33/4QJ':)6=D14>0WKC3L[?4DNT%V['158P*1XG?-?N5)EI,;L?*2UJ4N4
MJL=6Q"GR!G-+%0NX>5A#>4-$7Q VG-C]W;O'REZ6INJJ"NI-L=<=H9'$]IT.
M#[5[#J-K+NRLV'CL,^QGW1LZOV[12PQ92MSE'18ZCEK*7]YTG#*Q+>7-M9Z[
MG;77=W,CPVVN,M/;1,GBW$<NOP:*LB 1,XD:X+6P7Q$:BR*SMY;NVA3<8OHV
MCC,DM'I;R322111RIIU59H99"R!D6W43,:,H/"'?>?E;9=&_6^YH<SN&.&JW
M5B6RNT'?KK'2)41O79VNBW"^.S*#(PB!(\3+732@M(JZ$8^R2.NAW2ZG0S+=
M&#J=)(NKKPRFW!'!'M>#J (! (\\'\^D4B>&[H6!*DBH-0:>8(XCT/F.A+]\
M?>^J=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O9U_AA_P%^7O_ (I1W1_[N-A^V9O]"_TXZ76/"]_YH-_A7HN'R*_S
MO0?_ (L?UO\ ^X>Y?9*/;W2'HQ_OWOW7NO>SV=5? K?G;];\6Z#:G975%35?
M*?<6^-MX*FI<ON#+5'7U?L+$T>=RM%O^#$[=JW@SU7BZKR4V,QW\0K78QQE%
MDFC4F<VUW%O)%XF;5MINK\2*"P9+))I+B*-1WR2JD0TZ08WDD\-7U))I2SWD
M$&SWN[EP1!NEG8-'55827S*EO(S,0B1%B=;.RE$7Q"-++4)MZ=N8W8V&[+SF
M8VSNA*#K3%8O*U%9*F"QV.W-#EH97B.WLIE,[14,=-05,1AK:K(O04M*P9VD
M,2.ZP=G_  EW)V#\L:?XG;0WSCI=P28S-9:IW1N?8';&RA1P;;V+D=_9RD/7
MNXMETO:-5F(L7C)(J2CAP\D^0G:/[<.DBO[)=MF>_P!JYEWB2$Q6FUV]Q/(
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M8X$<*KJIIJH)(+'5Y+/:;=#+6;<X(CX:"1],LT$;A$)RY5R%XT.:&E"!._\
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M(9IC2;DRM3F*+8&Y&C@K)L4DN(ZYR-/5Y',[W^[A!RF#IY*=:"02JDC,(89
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M0H\LF7(MMIYCWO;+[7-MMCN%O9>-;HTP:ZEO)+-EF6BF&VUPS2Q7(\7QH?!
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M$@$@ ]#W@*Z;)X+#9*H6-)\ABZ&NF2&I@K88Y*NFBJ'CAK:55IJV*-I++-&
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M^DZVNKJNH<RU%565E3VA)45-3/(Q9W=F9F-R2?;$43011000Q) BA551I55
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M $^_4/ARRD?IQKJ8^2K4#4QX**D"IH*D#B>MJ"\D,*"LTC:5499FH3I4<6-
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M)(S'PY'B$GZ<SR(?<HRFWN>0I-Y2+]Y;9?6$YN6PQ:2PO4OS,$&EECN3!HT
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M28*GVWFL/MS;TV!I,%/G,9!%E-JYW<.0RE,N^J3!1Y0YBGJ<2:9Y9Z62GMX
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MDHMGUM4U;3TE8U35[>2GD<RQ12EF.I%:ZA#RM+O<_+'+D_,L*Q\QO86[72*
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M /*))_O)Z]_LZ_PT_P"\MOC)_P"CZZK_ /LK]M.>^$7S)VMALIN/<OQ4^1.
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M^>C9^N:GN&#N?J>;J.BJEHJSM.+L7:$G7-)6-F:?;BTE3O=,P=LP53;AJXJ
M1M5!S6R)!;RL%/\ _];Y_P#[]U[K?X]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O=DD>\-W;1_E===3[4W5N7:\U3\[>X
M(JJ3;N>RN$:JC7H7IID6J_AE72BI$;7T:]6C4VFVIKIZ W#U /8/\)Z,R[IM
M4)1B#X[<#3\*]5]56S=G[K_F4;S.Z=H[6W*])\'.JA22[@V[A\U/1I)WUW/Y
M8Z2HR5%4STL,Y ,B1LJ2%%+ E%()3_IL[F_Y^YV=_P"A[NK_ .NOM[0G\ _9
MTA\>?_?S_M/1OO\ 0[U%_P ^LZX_] ?;/_UK]^_TV=S?\_<[._\ 0]W5_P#7
M7W[0G\ _9U[QY_\ ?S_M/7O]#O47_/K.N/\ T!]L_P#UK]^_TV=S?\_<[._]
M#W=7_P!=??M"?P#]G7O'G_W\_P"T]>_T.]1?\^LZX_\ 0'VS_P#6OW[_ $V=
MS?\ /W.SO_0]W5_]=??M"?P#]G7O'G_W\_[3U[_0[U%_SZSKC_T!]L__ %K]
M^_TV=S?\_;[._P#0]W5_]=??M"?PC]G7O'G_ -_-^T_Y^O?Z'>HO^?6=<?\
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M_E.MO][_ -CKW_#BD/\ W@[_ #%__26Z[_[+/?O^&YY_^\Y/Y<G_ *51C?\
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MW!LW8WQ9SV)[%ZHVAC<-UE69*FW+MGY*]65V;V.N=S$LVX5W(U'4UB01P:W
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MV>Q7;4V:Q,'?'9(Q^8FQ&'VS)BI<DLV<GK7?%2U4KT_@GIU#R,9!(-(4M?\
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M3CO/2U%#5++%(X#::/HA.TI<K/#<WES- D4@=)4>UG6VNO&C8!H5M9V6.=Y
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M96"S=Y=IRJ&1@Z.$DW2RAT=05-K@BX]F8[/W!\NNG-G1;VWQ\>/AU0X2ESF
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M'_G&G^;H7_\ 0%MO_GNN\O\ T>W:W_V5^Q6SW>?R)VQU=LWN?-=$?$.DZ[[
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MA\BMU[8Z!W]EMOY_M_?&3P^3IZ3'M3Y#'5F;JIZ.M@/\1),%53R+(E['2PN
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MQX^JJ,DGW3U%6C1P3TT\ GCFNI9OFC\5<+\4LOT5@,9O>OWKE>R?C_M3L_?
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MALF0#AP5.&!7X2:&E5-"I!%>E(BM+JSDM+N9D4R*V V=/#*E2,T\\\#CHO\
MVE1]B4VZ(,GM'KBE[&P>>V/F-GY^F3L2+8&5Q)GKX:E)8*B7&RRU$.1I9Y$6
M>FJH*FDDB! .L/&:1N^]N+OO#]E4'\TC?6"WCMS=W6N^MLY#:_Q"R6U:+:VY
MNG\?FL7UM7;7P&W,]B]O;<IMJ46XZ]8*2BI8*.1JV=YHI))79F+$W&V^,;,.
MDD@NPS>*S.PO[<6EV"[$L1+:@6]*TCA58X@B*H'KZPVC<HYH;R6-X9(5B9?
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M_P"\:Z/_ -'7M7_ZP^QNV71_"7:'2/>/3[_,3<]?4]QY7J7)4V>A^,.\(J+
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M$VQW4O;F=I<]\DY,_45D]7BMRTV:?$UN>Q.Z*TY"MR6:CF6D>:DH@HE8/&Q
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M5!@\+39:MS]/B<=#G,E3TU)D,Q'1TZ9.MI*,'[2DJJY8Q4S4M+<F.-F*(6)
M!)N>OXY_(SHWJS9&P=US;I[/H>_-B=5]]=)[=VA0[?P^*ZNKQWN=Y82EWOOG
MLA-PU^<J-E;3PG8=949';R[=J7R4U)'$L\<4TCJWN2S;A'N>RQ&%=KWS;H-N
MO99M3+;6XN5>:9($5FN91$H>V[HC;78BN5UO;(LCEK<06O[KW"\A9Y=GW?\
M><$<:J[W+QQ6_AP!G9!;EIH"LC]P>W9X^TR$J&>Y<%O?.[J&,;!;,EV",KM;
M=9W!D,C79/<D62VY4TU4^*QFU),138['Y.6IQT#TV6&38TZ%O\G,BHWL5\?\
MM?C_ (3:_P JNB8>Q]ZX_9VZ*CX^[-Z<[(K.A^O^]<5ENM?C[L'?FPZJ@JMC
M]H9W"G8]?O7([I.7H,I0**_'-45  B:1@2W?;<;SM5G<V&TQV=RF\;M?-::@
MK2"[M[:WLD^OB59$EAAM(HKAQ&1(N@DNT2@O;3-<V&_6-QN.Y1SVT6PI8B6.
M*HCF:[@O;B06\M%FC:43*!*Q93HTDKD)K=^P]X97>G4&\J? XW,3;6JMQKN"
M&C[2WYUR,0VYLCM^K?+18K;E'6XGLJBIJ?$O'-B,X4I2_C>-KZK4X-:YM]+\
M?ZWLVZ1M2IT_#T8;WU[]UKKWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>
MZ][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO__2
M^?\ ^_=>ZW^/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?KG^OOW7NO>_>_=>Z][][]U[KWOWOW7NO>^<<4DT
MB10QO++*Z1QQQJ7>221@J(BJ"S.[$  <D^WK:VN+RX@M+2%I+J5U1$459F8A
M550,DL2  ,DGJKND:/)(P6-022<  9))\@!QZ][L$[5_ET]M;,S&*PO767Q7
M<]13;9ZG_P!(S;<I9-NCKOM;LW?/^BZNZCGBW-54DNZ*_8O9-708;)Y?'"3&
MQ5>3IM;1B0'V7M?;?^];VT3<K8[0=TCM+2[,@6.[22SN+L711PLMI HL=RC8
MW2QE?H)G/:R5W*);3:;?<]R@:VE;;9;V2%Q6:***2 ,I5=1>;P;JTN##'J?P
MYZJ&6-V ?[?WS+7)D3N7!3[1FCSFY:/!0560HLPVXMN8)4JJ+=5.V'-2N/BS
M>*<54=%4:*V- 0R$@^PS[-^$G=_4G3C]Y[P/7J;)I]Y8'85?3X;LG:&>W3C=
MR[JQNX<[MBEK=L8O)5&42FSVW=L561IIT1X6H?%*S*)8PR([YMWU6P6<<C22
M;C#<21%%9E4VHMS<Q3&GZ,L(N[;6CT),R!=7=0P?;KB*;=[69HTO+(!GC+KK
M:)IGMTFC%?U(GFCD1'4FOAN::5)ZXXKLS;^8W]FNN*>AW53Y["X.FW$U?D-I
M;@H-K97%U%3'0R/@MV5- FW\O54-;*(JBFBJ#40M<E-(U>RB>S?I!T(7OWOW
M7NO>_?U]^Z]U[W;E@_Y466SOR&HNE(/D'LBFVM)\98?D'E.VJO:F=BPN(STV
MR\CF5Z:EV[]^<M4;V;>N-?!(R2!&3_<AXQ3 K[+>:]RBY3Y>]U>8KE?'M^7/
M#$*Q'4=R:4Q-&D)^&%C ;R9_%PG[ON8ZL^D'VP"7>[7VUNI('MAS"A=M>19Q
MK<M;L\C#ME%3:E-!&M[VWA%'+4 9NWMW'9U+N&GZCSM5GJGM"+8_]TH]Q8)*
MB+:#[\3;TO9YR\S1XZ3!P;+E3<!I$O5D.M  :LA?9?$_EO\ RICQG6NX<OM+
M ;8VGV7L3+]D4^\MV[OP>U]I;+VK@\?@<O7U79.?S=114.R:LXK=F(J((*IO
M)4KE*98@\CLBG$T1L=YO=DW;_%+N"2.,^,1&))9)UM? AU4,LZW1^F:)1J$R
MN*:59@]!;RW5MMEW;J7BN[DP*0"0A"2R^)*0"L4/@P33^,Y""*-F8@E0SP>]
M.O)J?>SX>OKMTY#8.7AP>=V_L[&U.[-ROD*DU:4T6.P6 &0R%<)Y,;6("$!#
M4-1J $3$ 1\GNG(/CU\@NW.CZ;/2[HAZMWMF-FC<,U##C7S$F'E$$U<M)35N
M1IDAEF#>-HYY8Y(]+JQ##V%.4.8&YIY;VKF![3P&N4+>'4DI1V4 U"G51>X$
M J:KY=.WEI)92012D>(UO!(:$,H,T,<M%8891KHK#XEHU!6@$S!96+.X7$9N
M".2*#+XVAR<,<J2Q2QPUU-'51)+%/'#/%*J2@,CHKJ;A@""/8#^Q+TDZ=??O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[V<'H[XC9/NKI+NWN%-^X?:E7UK03_Z/-C5V"S6
M5S'=NY=O4$6[^P]K[:R&,5J#;]1L#JJ*MW-5U-=^Q)243Q*0[ AC<Y6L;3:)
MH DMU<;A#%)&SK#]/8RRQVC[F\DNF)K>'<KO;+&2-7,H:_6;3X4$Q%]OBGO]
MPNK1;=UM8K9G,M-2F<K*]O:JH[FEN$M[@I2M#&JT9I5'2-S^Y\EAMQ;3Q--M
MJJRV(SE954FX-QPY3%4=-LX-22G 5%?CZZHAKLK%N',1B@C%(LCQ3R*SKH-P
MK=M_RX/E-N+>#[)DVUM#;.4BW'F]JRUN[NQMEX'!IF,/NO:.PX ,Q49=Z.3'
M[DWMOK%8K$5:%J7)5E4%AD95=E<6>T<JB7T)N'1RD>H:W='NU,"KQ^H*6%[.
MD+:7>VM9IT!C2O3$DT$=K]<UPAL 5U2@ZHT1K..^\9F%1X*P31!Y%U!)I%@>
MDU4#+N_MC:NS=IU6\ZF#<V?Q%'3T-9)!LW:6XMVYF2AKX9JI:RFPF#QU7DZN
M"EHJ:6:H\<;/!'&VM0UE)+=S;>R.TMR;@VIF%IUR^V<WE=OY5:2J@KJ1<EA:
M^HQM<M+6TKRTU93K54S!)8V:.1;,I((/M/87MON5C9;C:$FUN(DD0D%24=0R
MDJ0"IH14$ C@<]*[FWDM+FXM9:>+$[(:$$54D&A&"*C!&#QZ$:GGBJJ>"IA)
M:&HABGB9D>-FBF19(R4D59$)5APP!'Y'MC]J^F.LWOWOW7NO>SA=)_$7)]V_
M'?Y$]YX;?^"P^8Z&CV_74/6N2QM6<MV3BJF#)9+>4^V\XM3'04V4V5@*#^(-
M0O%+/74JS-%I\#W8W>8[5M6V[JL9F2;<XK21$KKA2;3''=4H=<(NI+>UEI0Q
M/=0,=2N:5VHMNF_;AL@7PQ!M4EV)35E>1)%5;72H+*\D*W,R2$>&/IF1BI=3
MT'FX][Y#;^^-B;73:M?DL%NZ+<*9;>%-6TXI-I9/'IC&VWC\AB?')D:V/=DE
M35QQU,0$%&]':=E\T5S$;L_E-?(6GK]O8_JZNPG;,K_&/K;Y$=ASXZ*?;=%U
MUF.Q8]X24_2]15Y:>6+<786..R:Y *73#4RQ.BZ64!DWUDHW+G6Q>QET;1OK
M;7&P!+7LT5I;7D[6L= S"WCN&:9"=:1PO+325!5V$,6Y0\N/;W<8DW&V>?NJ
MJ0(+CZ:/QI3VJTSO %'\<Z+D!G"!3Y![=P<#2]H44'6,V1[(W;LG:%+F=R8&
MOGW3M[;F6@QE#V%$E)4QOCL#FEKJ20PR!JBB-=3QS /*H]@_V=\&=\]+_&*L
M[Z[)SV Q.Z%[8ZTZX'56,SFW<_NC;M+V)UENOLZGJ^Q\=C,O-F.O\_'AL/0/
M3XZNIA)/%7.6,<E.\937N\06W,&P;':O'=17EON#M/$XDACDL);*&2 2)5'F
M62Z=)D#5C,7XM1TLV,9O8KRXUHL<=I'.J$TGI)</ C2P,%>*&98WEMY342J
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MW+EI6M[NZA=F29AT?->WK;A9;A]?:CZ;<$NX8A_8Q.D1@:*./31;:6#PH98
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M]"-[-!\]/^RT?E#_ .)N[!_]Z"L]MP_V4?V=*MP_W.NO].>@7^-/_9/?2?\
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M@*3=,V]N]XL?6X'$[A#G:U-GY,]\<H9\5CLXM,QQZ5)CBJ1&?"&TFR*&XMY
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MO\T;=.;F,TS-@=HK3&GE_P!++BG%/+ZI 6'D7TC_  *G_?GX'?\ >._R-_\
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M797_ -S[[]2;_?B_L_V>O>)M_P#RC2_[V/\ H#KW\ ^1'_/S^J/_ $3^YO\
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MDR,M53QT,=#\D]GM6R5DDJI2QTB0?'TSO5/.5$:H"Y<@#GV_$MV9$6%ZRDT
M534DXH*&M3PZ123;6B.\L$@C ))+B@ XDDK0#U)Z&J3 _(01N9>T.I1$$8R&
M3I_<@C$8!+ERW<&D(%^M^+>Q<W%DNEL)O*GVCNSXK_/3$=@YK;YH*/:^XOD
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M([RHP;4_]JX_I<E;_OS\#O\ O'?Y&_\ I2NRO_N??;M)O]^+^S_9Z2>)M_\
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MWE^W]>OWK_%/G7_;=;'[YS333_FU3Y5_R=)?)?\ #;_][=H?Q?5_??[3=?\
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MW?\ ?M/_ &1;W[_%?G_QKKW^[?\ H?\ 5+KW_."/_9R?^S$^RV;A_P"' /\
M9NMB_P!X_M_]F>_T;5G]PON_]!?]V?\ 1=_H^WC]Y_"]/_&%O[N?W&_C6K5Z
M/)Y?^4NWNX^G\)J?V=<\>-1^?&G25OWA]7'JI]5IQ\%--#_M>%?^+Z%3$_[*
MA_H&W/\ P?Q?Z%O[]T_]ZOMO](G\2_T@?WUV]]O_ !#_ )C_ /C7][_X;I_V
'GQ?\H_O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g476668g00t01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00t01.jpg
M_]C_X0DZ17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ ,(7@   G$  PA>
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP-CHR-2 Q
M-SHT.3HQ- !R<C,Y,3,S-@       Z !  ,    !__\  * "  0    !   "
M$Z #  0    !    ,          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M>"!(.$))300E       0D.IP_2J*EUV;G"G6+\%&93A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M 3X    !  $!/@    $  3A"24T$)@      #@             _@   .$))
M30/R       *  #_______\  #A"24T$#0      !    '@X0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T$
M   &               P   "$P    8 9P P #  =  P #$    !
M                  $              A,    P
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<    P     %)G:'1L;VYG   "
M$P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    ,     !29VAT;&]N9P   A,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     @X0DE-! P     " @
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M\Q[ZO40<;ZW],R14ZNN_;;Z0)+6PQV0ZRO#KMBSVNR7U>S\QGJT^OZ6]2/\
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MH;O2QOL>Z=OI_I/V9Z>_]']+U_L7\OU/12U5J__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-! 8
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M_>&[=[=<_*W#]0[=V/2]R3X:*HZRKJY8\WFLEE<A2PJ^X-N8M9*@R)>.0KQ
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MW1B'%!D-<$C4LP#.'TM[(^6N4?;CF/<>:=BW%)=JNEFCM[2=K@RQK=$2*8V
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MJLU.S1110A%D"M'%HT)(#(VH#0M=.FO=YL23OF/W4W#F:?DV:_V&Q7]R(D<
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MM\EC;K(CZ8;:4U= %=2Q8476Y+:5 X8Z@YKJO9>:IZV#^&MB&RF]<#V#EZK
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M %E7H9\V\G^WO)G-VU\N[U[:W:\A,T:MN@N)_%8L 'E9A^BJHQ[XBJD*&*\
M""W1_;N]^^>C:7LG96^NOZKL7+XFHRZ[(-#]QMC:>9>.1J/96Y!!6P;L04[A
M(IZYI(FE8F>*+Q%$+9\ ?A[\,?D?\G?DYT#NG9N9WMM'KW);EW/U;VCM7M#,
M4/WVS,?G8\3BL35TV/4XW,PUU).E1'7IID)NK @@BGM3[>^VG.?/'/?*LNW-
M>[5:3M+9W<=S( UMXPB1"J%0^I75Q)Q%&4C((3^UGMW[9<V\[\]<J7>U->;?
M9SM):W4-W(%: R!%3M[7H#42<3FO7?RN[C[0Z6ZBVCV%M6/;-/GZO=FQML;E
MP.<QM7E<>&WA54^.K7Q]51Y/'SQ3X:LD+1EBZ3("#8V/LLN+PGPYR.$^0]5O
MCXL[WZ\V9LNKW?UWU[W;M?M3?.Y\7B.WH%R;;&V_N_ 91)(,@F=AQK2S24X"
MTP%W0(X90$;7V[:'GC]X\CWEGMUL\\%K>17$TJQW:B3Z>&97[#XA4,["I558
M:!J#*"DLO;9H^=OWKR+=6>UV<DUM;WL5S/(JW2EA#'*C5!,@6I(!"^8H0>C$
M9:CWRN0VJ,%NG Z(,G!-NS&9G#%ILSMM8V@R3X.:AK89L7DX*J>&2-Y$J(#_
M )MP-0<&G^)W0?\ +A^47RHV]\;ME]2;SS6TJ#IBDW)NCMP]M;NHLEG>QL9B
ML'/N:GPVWO#'CZ7;4>1R4L$9($C/$66R:;COV_Y5]G^=^<H>4=LV">>TAVHS
M279N9XS+<+X6L"*HTHNMEP5JXJ!H U#OD+E/V5YWYUAY1VOENYGL(=J$TUV;
MN9&DN (_$5(\!8PSE0>)(.*4Z+U\B.RNY.C^ANRNU5R>S,EN3 9]ZW;N%;!5
MO\"I]J5^XZ7%8;%96H_BL5=69F+&5*S5-4C11&H)1(] !)1>^\'\%L)MWY7=
M;8+K+<757>W3W9"8#J'+R=D;HW?A.PMM8S=DN$S]/E<;E(6I<?N*EQM,:DD%
M8760!+-&=0"YJMO:NT@]Q=DAV6>PYHV^^:.Q83RSI.D<PC=9-7:K!%=ZT[BZ
MA2N@ZH_YKM?:6ULO<+9(-AFV_FO;KH)9O]3+,DZ+($<,K=H<"K'RH<&JGH=-
MM2=@5\^RLY49C UNV<KL^.?<V-_A$U'DX-PU=)05U!DL+71ULL1Q;%YX9:6:
M-I%O&ZRFS#VX_P I[HKX[_*7OBLZ#[VZTS6Y3G=NYO=&!WKM[?V<VK7[<.W8
M*5IL7/AZ%'Q^7H\G]P3Y6*S0N!;4I-M^P_*G*O._,U]RWS+L[SAK5YHY5FDB
M,?A%=2E4(#APW$FJD>8)HW[!\K<G\\<RWG+'-6RR3EK=YHYDGDB*>'I!0JN'
M5]5:_$I&*@]!G\NNS=\],=%[N[4V!4[?&9V6N/KY<;N7&5.1Q>8HZO)T6+FH
MRU%78^JHJA/O1)'(KL+II92#<"[U3U1\%=R_/_L;XQ;]Z W)@.K,-F]Y;3PV
M[*+N?=S97;51UZN3J:_=FY'E4T]?C,W38QS-%&(_L@RE=0#GV)]KY=]L']XM
M^Y$W7E=XMBAEG@CD^KF_3>W#%I9#J%4ET$4U 1:@26"D]"K9.7O:J[]V]\Y%
MW+DZ:/98I)8XY1>S QF $M)*<U1@IK2A3''-'3>>6[K_ - ]'NGK:KVSFNV%
MVUB-P4^+RN$D3 ;IKZVDIZB?;]/"N7I)\.:EJK12S-42:'51+=69@V?.7X$;
M ^&';W7'<VW]I9+O/X2=F5F.J,73TV\*['UN/;(TJRMMBMWSAE:>,5M*YK</
MD2#'5QJ8Y!JC8NF]T_:?:_;;?]EYCM;%]S]M[N1#I68@J6&HQ>.E>V1.^WER
M&%5)8IJ=)[F>U.S>W?,&R\SVNU2;E[:WDB@QB=@T;,/[,SIDJZG7!+P>A5B"
M,I;XU_(:K[UVMN3;NY\;%USWOU_/-M_LG8T\9J)-O9@JZT&?QM)4S:\AM_(\
M21_N,$D#1,Y'CED&W9W1_P#+5S_SYJ?ASN#H3?FV-K9>DP^-V1V%-W9NJ7,U
M>\\IM>@W1#C,UC3$<9%CLD*QJ*F>-ED6HC0MJ$OI$EARQ[.7GNO/[<2<K3QV
MKHB0W!NY]33F(2E#'J( D#>&E6)#J*BDG8*;+E?V4N/=:?VZN.3[F.U>-1#/
M]=-J:<QK)H9?ATL"57((8>8.(G9FX?DALOX\Y;?VW,KL7=G9^T\=D]PY?#+M
M7(4VV\_A\9/4O6T>&IQGAE*'(TV)A\Z-)/,)98VCT@,I4IO=OQEV/U=_,KI?
MC31= 5-9U_/NW;FV<'L6H[*W.M5NK;&X8XY:??C[V##)8Z48Z=ZJ6-%^V@:E
M>,J0&)C_ )FY*VO8O>J/DV'EEY=C-W$B0F>0--!( ?%\:I9#H)8TJ$*E36AK
M'O,7)6S[3[UV_)MKRBS;')/''' ;F75+%)GQ_&KJ4A:L1P&@CH5>J.Q8>S^C
M]G]EXS.TU6VZ=ET^<_C--C!#3PY.2E<5\:8B6HD*_P -RD4D!A:5F+1%2Y)O
M[-'\6.BOY=_RE^<&_P#XS[8Z WI1]7X+%[KDVGV&O=F[9=QY6JV76TM%6Y2O
MQSH<8<5G9II#2I%ZXHE1F9B[!1SR/RK[3\\^Y._\I;=RI,-DMX)&BG^KGU.8
M'5&<KJ^"4L2@U$J ":U(4><D\J>SO/'N5S!R?M_)]PNQVL4K1S_6S%Y#"RHQ
M(X:7))2F0 "3GH&OD-V+W9T=\9\KVC'G=EYCL+:,&+R.>I*C:M=#M?+1Y'(T
MF/J,9CJ2/.+D\>]%]\K1SO42ZS$=2@, H'KLSX28?MOY'[/["^*>_L%TOTUG
M-U[&G[OVEVUOK-5VS-S?>97"]?5NZL!6H]#F8]RYO'"%J>D"R0F0-I:-6/L,
M?0^V-OS%SE8;OR%>0\K[;<36YO(;BXF:&0.\<'BJ2$)E9"HI\+$$JRAN@VFU
M^UEOS#SCM^^>W]Y!RMMLLD!OH;J>0PRU9;?Q8SAA*ZZ:+4J2"05KT.:OV%E=
ML[&R>$W1MVES=8NV\OGJ'+X)I<?G,5-#25&XL=B_M<C!6XBK--.[4L]ZI8I%
M02(RL6 G]5? C9VS?Y>FVOF .ALY\N.U.P\K/50[$H=P;EQFUNLM@TM?DJ";
M.5&$V3-3;EWAEQ)CE%0JRA*0U"G1:-V81\L>U.W[;[36WN%)RB_,>^WA!2V6
M294@A+R(9"D!625T\+N4$T,HP!$Y<ZY:]J]GVOVHMN?6Y3?F+F2[HZVPDD6*
M"W+,NO1"5DE=0HU &JEN% 209KOD1%4_*C*?'RIW)@-AT>V]CX'<T53E_M6S
M?86<W++4&+#;?DR3QXVBHL)01+)( L]95SNRQA$A<N&%+MG^6!54_2G:>[-J
M[ZZ_Q51B.YJ?O[H(=C9G(;LQ/8>UL/2U'7^!VO534:9_&;<W7D)6--458U*K
M&.9M4;>P^UG[(&QY6WV]M+BUF9;T7U@)Y7D2:)$^F1:@.B2N7TM4472KG4K,
M2B+;O8=K;EK?]VLKJS4QW@OK 7#M,MQ&@,"+4>(D4C'L8T-"0V0>A:FA[P-+
MOS$TV2V*E6M;M[_1ONJIQ.2=1B:QJ<;E;=V"BR<<55F<1XZC[84DM/3U"O 6
M"'R #AM#XU?"G=?\N;?OSC_V73-4.YMJ[JRN$Q_7R]V[ZJ-N3T=#N/'XB"6L
MRK*F5,YI*TM)H"!I$X"JU@*MHY*]M]V]F]^]ROZE2)>VC2JL0O;@J2LL2*Q:
MH- )<C34E.(#8$&U\F>V.Y^S^\>Y0Y&E6^MWD"PB^G*%5D" D_%@&K>9(QCH
M*\QVMV'C/E?L?HF*NP<VTMQ=39G?^1RLF&9=P1Y/$9.?$I14KK7_ ,/6AJG1
M96+0,ZV*@\@^TMT7L7^5IW/W#MO;-'T]O^EZ^S70:=D;UK_]+^Z_XYU1V)A\
MM_#]R[2K1+304>=VWX)8I8:P,LNF56L!J52_E/;/8OFGF/:]NCV*>#;)-I-Q
M=2/=3_XI<(YUQC(\6+05'B5KJ.K2%.E47*FS^P_-7,>W[?:\OW2[;)M'U$[-
M=S*;6X1M+Q$D4DC-00P(-"#TM=V4?R-I]C9%-I[GZTD["I-T5_\  I\WMW*I
MMO<&U9I;XJCRE/39=*O$;BAIY"))8I9*>26+A K^E!_,+^7)M7J;YW]9=-==
M'*8SHGMW$83?F&RV6RKY6HV_LC%T\E9V0T^;E0--_!*#&SSQ2R<A:B($GBY5
M[@^S=GRW[J;'R[MWB?U3OPDP?5K,<,9I=]^2?#",ZDU(1XZD\24<]^S6W[-[
MJ\O\O;2DL?*6XJLP9F+F.&+NNP)#EM"J2K'^)>FWXT]WY+NCIBFWIG<;246^
M<'E=Q;,WO@<;%4TU'2[WVMDIL76T5%'625%3%3US"&6/6S:1/:Y O[$G^:+\
M6?AI\2]A=!YGH[J?<V5E[DDEW,NYMT]F[FJXXMJX$XFH?%T^(C,<1EW72Y&[
M5);52IS&-1!!W[]>W_M][=[9RT>6]D:2;<',@G-S,R^$B1/I",QJ91*O>::0
MIH*M@Y]].1/;?V_VGEZ;EOEJ4S7\K,)'NIF B32:!">,@;)_#Y=(SXJ=M=P=
MGYKN[$]MKLNAR/5?8#["BQNRJ*N6C>>.AARD]7/D<AD*R:I:%*M:<!4C4F-G
M/U "B^5'QG^%G1WQ$^,?R6V9\:-Q[@W#\AJG;T4VQ,UW7ON>CP+YK;53FGH\
M758A8Z_*535=.(8=5B5:Y!;CV[S[R5[=\M>W?)W.6U<ERR7F[&W'AO=SD1^+
M TQ44)+FHTK33BIT^07<]\D>VO*_('*'.&V<BS37FZ-"O@O>W!"F6+Q**5RQ
MJ-*CY_+KETUVWV9O?OSY$]5[DR.WFV_T_6;7IL!D<3@)J+*Y,;IH),LAR[5.
M1K*0OC8%$/[,:"9@7X_3[+Q4;,^#=-\F_COUED_C?VCMZ7=E'%U[\BNE,MV?
MN2/<75_9^7SE%38;<.V-XF #/XU<17)5&B< &(E)-$XM[!L.V^VTO/G*6Q3<
MHWL N=-M?6CS2A[6YD<*LD<E:RJH8.4)6J@K1&Z"8VGVI'/G*&P2\F7\3748
MM]PLI+J17M+IF&AXI@/U$*D,5/D:884Z&F6#M0;-WNU)O#9U9N U.1R/7>X4
MV[4-BTQ"T5/4X[';GQ<>7T5D\=;'/#+54E1&LD#I(J(X*$8_YBO\M;K#H+!;
M0^4OQ:I*OM/XR09.FQ/9>UO[T5^:FV_78[*MCJJJ_O31_P"Y:/;F9JH'H:J3
M_@1BJZP;TNN@4^\GLGMO*5G8\Z<DQ&[Y24@7,8E,OAD2:-8D4EO"9P8I.XF*
M4#-&TQGGN][+[)RK;V/.W)=HUWRE$X%U;^,TA4*VGQ%E'?X3GLD_%"]*X-0
M7QC^3.[>P,_N/ICOO:]#UE\@=K4J9H[:@D*X[=>TJP*]+N';@FJJOSM0EPE7
M"DLND%9 ;&18DEO#"?RO]F9_9E7NGX_]B[9VCN7XITW?-'1'NK=61SNY.RMP
MR>#;75&'GCIFI*7%-)#*\N2ELXC&H@6LQ9N">QVUWFVM?<H7J6,^Q+>@?53:
MWN9"/#M10D:-(?\ 7JM6H?#HI#)-QM/8C:[G;FO^4[R*QGV 7RUO)6>2Z?\
ML[5*4 7C60G(%>AJI:#O$XC+4HWELBMS3[[BI:#*/M.MI:/%; CJXGK'J<:F
M9=LINXXYF1")8:/S:25"A@1%R7QO^%F._ENXGYT_[+=F9MTY#>%/MV;KT]X;
M[CVS'1S;PGVZ]5%E0C9?S?90B15-P)38W46]G<O)7MS#[+6ON>>3Y#N!=5,/
MUD_AL3=F G574%T9H!4-YTQT=S<B>VD?LQ%[HCDZ0[CJ6MO];.(R&G\(]WQ"
MB]P^>.@YI^TNPY_ECDNC#E,&FT*'J*G[#BKQ@V.XI<G49B/"_825!K_X>*")
MB9KBG#GA+_4^ZK/EM'\9G[%V[E/BA29_$=:9_K?9^:R6V=SYFMS^;VEOJMIZ
MK^]FVJW*UT<<E8<95(BK(EXW4ZE-C80+STW)LF\PS\C12Q;-):Q.T<C,S13$
M'Q(@SDLP3 U$D$U(Q3K'_P!PUY&_?5I/[?K*FQS64+M'(S.\4[ ^+&6;)"F@
M!\^(X]&*V9#O&FP:4V^ZW"Y/<$%=DXGR> HJC&8_(8X5]0V'JOX;4U5=)0UC
M8MHEJ(Q-(@G5RATD>S;_ ,I_X@=3?*+N?*2_()W7J/ 4"8.EQ29RKVU5;V[)
MW+',FV=K8?*T4D-4]=245-4U\D$1UND"@^EC>0O8GVYV3GW?[L<SS!-FBCTH
MI?P_'N7RD2L&4DB,22%4.HE5P5)Z'_L+[=;%SQOM]<<V*6V&WCT+&)#&T]R^
M4B1@0250,Y49/;ZY!GY6]E]B]3]+[HWCU3ME-T[RQ,<.02EG@6JH<5@,;*F0
MW-G<E2_=44D]%0X>GD2T<@=99D< A6'LI?R9Z0'Q1^4_8/4>Z\(^YL#U_OAC
M28RLK*[$C=6R*J6+*8(-E*(K74O\3P-5$CU$)UI+J*\BWN/^>>5VY%YWWGER
MZB,MO:7/9JJOB0-22(U%#WQ,M2.!)IPZ ///+"\A<^;ML-[:^-96USJ5"S+X
MD#4>,:USE"%+#\0/V="YUWO?$]F;!VAO_ 2JV)WEMS%;@H2KI,8$R='%4M32
M.HT-/12NT4GXUH1[MF^:/QL^"GQ9Z,^,'=^&^->Z]U0=^04&2S^V<KWKO.A;
M;=!5;;H<_/283*4=-,:JM0U31Q2SQ/'9064WM[R&]S^1_;+D/ECDSFBWY+DF
MCW1XV>(WTX,:- DY17[JOWZ0Y6@*U*&M!D+[G<D>U?(7*_*/,MMR3-,NXR('
MC:^G!1&A$K:6SW>0)!'J.BY=&]H]H]C]C_)'8NY,UMJGI>GMZ8S:>V<CA=NR
MPU>0@RN,J,K'D,[!69:K@>IID"1&.#Q(Y5F!%P $7?7P7Z!ZRZ>Z9^?G3F/W
MAV]\3-YU>&/8W2F]MQMMOL'9C9N6?&MCJ??.V(+5-+09F)J0SF$R1U"QEO+%
M*2@9YF]K^5MCV'E?W7V.SN=QY N'C:YLI9=$R([%"!<1 %0LH,3=I*/H(:5&
M)4@YI]J^2]EV/E_W7Y<MKK<.0IC&]S8S2&.>*.0Z*K<14KID[345!H22K8>N
MM^]L[N'M/L?X\;_QN,VOVQLS$1;DP><P7GK]I[SV9EM"8K<^+H\BZ5N/R>/F
MJ$CK\9-+,(Y%8QSO&;JHOYD_P\^+W3/QBZ$[]^*_6VX9MF=U24%=6;_SO8>?
MW+/M=,CAXLOB-OG#.!BBV35:F&6IE):*>E**+M?VK]YO;GDKEWD?E7FWD;:9
M#M]_(I>=II'T+)$)(4*,S*&>D@8U)5DT')KT[[T>W/(G+O)'+O-/(>RS&PO9
M$)N'N))-"2)KC70>WNRI;R9:>?2?^-7<W9&].P^]>J>X*G;,.^.HMQ8VAH:/
M;>%K,-2Y[:&6I6J\1O2%,CE,E4R0Y12%:-2J0-878M< /O\ QOPSZHZ6^,&6
MW%\5LOE^Y>X\$-Y;MPH[WWK1X/&]?#,S87 9REIX%-=C]P;]CI9:N&&4M34<
M2WLX90 ENT/MSL/+'(]Q><F22\S[@@GGC^KF5%MM;(C"G![D#4@I2/2Q.H,H
M 9W6V]LMAY;Y$FN^19).9MSC$TT?ULP1+<OX<;^HDN*%U7@@'V5,#00;[K=W
M[MF?=.)39D%-14&WL;!MS_<S29PTYFRU37Y>7(O39#'TWEA6")*:)_)Y0[G2
MMS0_S$_A!\6ND-U?%?ISHWKK,[6W1\FLC@II>R-X]D[@W#3[*HLAG-O8@XR#
M;\S08[(&09PO)/*P($06.Q:X'?O#[7\F<M;GR-RQRMM#6^Y;S<Z?J)9Y76-?
M$BC"^&S%3F74S5J *#B2!M[N>UO(O+NX<B<M\K[,]O?;W,JFXEN)9!"/$C4@
M(3I8GQ./RH./1>_BUW1V-VAA^YLWV)4;?JTZT[%W9L#'4.T=OUN.?(P;0199
M\Q**[*Y*6:MRPE"QTZ%$C*VN2W#A\OOBE\;/A%V/L/K;=?PW[([)^/LN(P0W
MY\IHM][TAWAE,I42+%N;*8.# 1OL7:DNVV!=,75TQ^\3C4 0_M3[@\A\E^V]
M_LFU7WMO=W7*LD2-<;H)YVE!8Z7*B,B!&C%'\-U DK1:"C=*>?>1^0_;G=-I
MVBX]M;R]Y/,:"ZW/QY_'62I65E$7Z4/AT#:)$(:M%X5ZZ^.W>N;^2'665WQM
MG>^S\3O>IJ\TE-UN]#'70[ EH*NKI<+A]Y(:F#<F4DR%-%!45E9 :6(F9UIE
MM'<A;T!_+=Z8^3OS(^0>(V#OZNI/A;T1-2;BGWO@LG!N+/[HV[7X>#*XG;N"
MS4T+41RE;'!5-653HPHTA9 A=D(#')?LYL7/7N!S1;;5NI_UN]M=2;A'U-(L
MBZHT20H1D+(SN4)54IHU,M YRA[+\L\Z^Y'-=KMF[2?ZV^VNK":-@\DR.@=8
MXW((K0,78@E5'"I%%#W%W_N+IGK+KJHS6VL1D^[>S,MMG86WMFT>0GI]LOV#
MFHH8LI5S9%_N*]-FX&H+SNZAZJ6#QQK9Y-2L/QTQ7P ^6OR,G^+H^.><Z8VS
MOJ?/[<Z8[BVSVCNS<'8.)SV+I:V?!Y'?.)W'+6;6S\&X:>B9YH(J> 4TK*B%
MQ=Q3E&W]J_<#F]N1H>3_ -WV<XE2TO([J=KAGC1G4RK*7B8S!"5711&*QU(.
ML4Y0M_:'W YTGY$_J<^V[=-XL=G>17,KW = 2K3K(3')XBJ2%"@*2!D9Z>NV
M,[V_U9U7D>Q\;F<%OC,[#Q<VYMX[6J\)'@\7NK"8^,5>XJ+;5?23SY#;V3HL
M<DTF/>H:NCDDC6.=2',BKKX.? ;J'-_,[N?X0?*WKC*;GW1L>DS><P_8NTM_
M9W:L<>.PG\,>C6/"TJO2Y+&[HQN5BJHY&(GIF)C8G\+_ &U]KN79_<?F?VWY
MVVMKB[M49XYXY9(@50II.A2.V6.19 2=2GM-:X7>V7M7RQ-[B<S^VG/.R/=7
MMH&DCN8KB2$&-2FD: :$2(X>N2AJM3QZ0?R*^0V<VI\:<9\A^FLA@\A05D6S
M\S0TFXL3/74N:P6[ZS'T,<3_ &>2H9\9D*'^(B1B'D4-&T; \$"O\;_@W\*?
ME_N/Y?=18KK'L'HW<OQUS.>H<!VQBNSLKO+;5=08_*9W%4<^YL3N>E^QI:ZG
MFP335<<4J(U,S:&C9"2)^4/:_P!M.?MQ]Q>7(=EN-KN=HO6BCNUNVEC">))&
MAD$HT:E\)F<4 93AHRA)$O*'M9[8\_7_ +A\N0\N7>W7NT7#1I=1W;S(5!=0
MSK*"M5,9:08 0X->L?>O>7971W^@_/4U-M[?N)[,WGM;8&=VB**JQ6ZQD=PT
MPJ#FMF34E34QUD=)XI3-2U,#A$T'RB[$!7_+)^/7P%^5N;W/\?\ MWKS/P][
M;0I,WD-L[OP':NY<=M?MW%XBJG@K)HL0H9,)D<<HBF:.F9TJ*)FD0!HW'L-^
MR7*'M9SU<WO*W,>W/_62V+NDJ7,JI=Q*U&**#17C%&HH;5&2] $?H,^S/*/M
M+SO-N7*G,&T2?UIM-929+J58KN-6*LX0? R=K%5-&C)89!'6;Y>]I=T=&;<Q
M/:>Q7VQD^N<3F,/0]H8S*[>K<AGMN;=KLC#35.[\'54>4HXJR*D2;QS4\\?H
M9HY%8IY "^=9=#]-=;=E_+S,?+KHC)T?5'0E35;?BVQ@>RMS8'.4_95=D)Z?
M8?7^T,U(99=V?WLI8FJYZFJ#&DQ<9J[*&4$);/REL6Q[Y[@3>X'++KLFT]GA
MQW$@(N&<""&)P091,E6#D]L=).&"&]GY+Y;V3??<>Z]P^57CY=V=M'AQW,BO
M]0Q_Q>WA>OZOC+^H7;X(^\@ ]&!SN5SFZMJ[=JNKMTX>BK-S#"Y?%[DK\(^X
ML1-M>=::NKZ_["&OQ99JS%3@4K>9%%3+'J!34/9+.I^H\E\H?D/M?J?J7;]-
ML]^S]Y#&;=PU3D\CGJ'9V%G>2IJ9Z[+UBC)92DP&)ADFEE<+),(B+ L![CGE
M[EZ?GGF^PY?V&V6W:^N2J*69UACRS%F/<RQ1AF8_$P4T%2!U%O+W+LG/O.=E
MR_R]9K:+?7!$:%VD6"/+,6=J,XC0$DFA:E,5Z4VZ]T8?8VU,_N_<M8*7";6P
MF0SN9K"JADH<51R5=7)'&616F>.$A$!&IR%'U]V)?+K9GPE^"_;.-^-=#T#D
M/D5G-JX;!U'<G:6]NR=V;2RF4RF;I(ZZ?%; P>T9Z7#[77'4,ZO'/4)6NTCJ
MKA@A9IAY[V_VR]KMYAY-_J@V]7L<2-=W,]S-"X,@#JD"0,(XV5"&+,LE"P0Z
MM!=YDY^L/:OVMWJSY-3E!]YN$A1KRYFN98G)?.FV6(A(R%S5E;) -<GH#^A]
M[]B]V]<4';&4JJ'8N,WY!/E=B[3H,?39:MP>V&JYH\+7;IRE==<GG\K21K//
M#3+3TU.LBQJ796D(G=;_ ,MOX[?*WY>46!^/>\-Q[=^).&Z.Z][BWYN&LRU)
MN?>N,K=ST]2]9U_'5N@HJ'=9K('259D9:.&!Y"C%D!.-G]FN4^?.?8;7E#<6
M3D=-KM[J9Q)XDJO,7"VQ9@1%,=-9 P;PE5S1SI5CW;O9;DKG?W @CY2OI8?;
MQ-KM[N9_$\:8/-J_Q;411)<=]0="@FAJ.DSVK\@-X]#],TNX^P]N8#-]M9O>
M$G7^SMM;7J:^BVUNC<&6SE70[3R)J*]J[)XK"R880UF0OYI(6$D:7)3V'/3%
M#_+Y^0WRF'Q33XVY[KK8&\<_F]@=8=T8'M;=64[-Q^XL>E=#A=S[IQ^;EJMG
MYBBW#/1W>B6DC6F::-59@"?95R[#[2<X<ZGV_@Y,DM-NGD>"UOH[J=KEI4#:
M))5D+0Z9RIH@BI$70'4%9B4<N1>SW-_/<OMZO)$MGM4TDD%K>QW4KW0E0-ID
ME#DQ,LA4]F@!>T>M%MV'DNX]@]49??6/S&W-V;RV;@:W=6=VO-AFQ>V=RT^+
MI&R&;P.$K8)9<WA9$I(IACJJ9ZHF5(_N(V5GL0?YD_%W<_P]^0&].C]RY"+.
M)@I*7([;W+3P&F@W-M3+QFIPF96F+R&EJ)808JB+4WBJ(I%!( )B7W"Y)O\
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MV[T'Q8^9/36'[+ZNCI\OCMU]Y9C;N-Q^U*/:V*HJOQ;WS6\54]:[WVOFHZ=
MQ=$J9EJ+W\BLGLQ]O^=O=?\ K3)R#[C<K)=;:D,OBWGA^&HBCC++(SBEO+')
MI44"H[,PU58,I4\@\X>[;\U2\B^X/+2W.W)X@EW#0JQ:$4TFF<5MIXGH*F@:
MC9R".D3WY\3>DX]BY[O/X\U^Z^INTX:*7<FU:;K.LSN-JMS[FGC6HH-LOL>"
MV1H<KE:V1(13P14WVTK7FC\:N/8>?RQ]L=98W^8U\V-W=$4./H/C=!C,QMC9
M6YJ*6.CV)_%)<OB*N;![;R%;+##44/WD=5)1QQ%E6C5"+1Z+E'L79;8ON_[G
M;KRO:?\ (/"^'%)&/T=1GA9DBI@K59#&$JHC"TP5J4^S6U;6/=WW-O\ EFT0
M<F5$44D1I;E@Z,Z1-@%0VH@+4!>';3I4?-&EWQF?A[U?B]Z8G*9GL.NW1TO5
M;TQ&W\95Y/(/7T,U'6;PF^UP4-08XJ$B5IY(@(4(]!L5N4&NVC\X?EQ/O_X>
M=K[4FVQUCC.\=T]P'NK=FW,1M/#=>[9VQ1[E&0@CEQ-#A,9NZ'/4<D/V6J:>
MH,S@JYC+%(^NME]U.>I^8?;G>-N^GV!=ZGO&O9HQ'';Z/&!U-&JK(DGB+0]Q
M756OA@E0/<;+[H\^MOWMWO6U-!R\-WFO!?21I&D$4?B5 T*BS>(-&DEF8'-2
M*T.%DH.K^N:R+M:GI,G+E,OA-N; HEPS9K/5F8H*W,TD>WZ"FPOEJV$L%;5A
MI*C1&8X2[U#Z4NJ9_D1;4RU-\U,WO*"BJ7V#MG86]\%D=YU8BH,#2UU;58L8
MFCJJ^JDCIDR&2@@,D<"LSZ03:PO[+_NM[;>GW#W:_AA9MM@V^9'D QJ:2$(H
M_I-2M!4T!/#/11]UK:KQ?<+>+^*!FV>&RFB:; 367C*+J)IJ<*2 *X'0,?S"
MJ:JR7Q/[+PV.H<CE<MF!MVCQ>*Q.,KLODLA4KN3%53P4M!CH*BID*4U.[LVG
M2B*23[KG^=^S]T[.^6_?E/NK Y#!39CL_>6X,0*Z(+'E,#E\]756*S&.J(VD
MIZW'9"E=9(I8V96!_!! B+W8VN_VCW'YRMMQLW@E;<)Y%#4S')*S1NI%05=2
M""#P/KU#7NSM>X;5[A\U1;A9O"TEY+(FH?%&[DHZG@589!!_GT:C8%1!5;%V
M;/3.7A?:^!"%DDB<:,72HR213*DT,L;J59'565@00""/9^OY#FV<])\U*??7
M\,J(MF;=Z^WIC<YNJH,=)@L5D<K38_\ AM!5Y*I>*E2MKO&?%$&,C $VL"?<
MI?=8MKI_<2]NX[9VM8MLF#L!4)K:,+7_ $Q% !4^? $]2K]U?;[V3W!NMS2
MC;H;"97E.$5G,>E2Q(%6H:#CT6#^8'3U5?\ $SM?$X^AK\KE,M182BQN*Q>.
MK<MD<A4_WCQ$[04M!CX:BJF*P0N[$+9$4DD6]K;K3H#M[,_S6?D \>Q,I!C7
MR/?V:?+Y+[:BV\^%WAM_=5'M6O7-5,RXN>DW+4U\,=)HE8S&6UN&L;P<E\S;
MG]X+G2VMMHE8M/?25- ICF601-J)"TD+J%SYYI0T$&U\G<S7/O[S>Z[1*L#&
M]?6P 0I+&XC.HG2=9("T).>''H85W=@MM=+;0S^6J*JGQPP&Q*7]C'9"KKA/
M/_!Z7PG&4U-+D!)!)J\ZF/5 J.SA0C66G\N+Y.X!L7NK^5O\],/)#L#=%;)M
MC8K[X<T4VR-S-7)70[$R.2J'U8BBJLL$J<'6A]-%7$1HWBFC"F'LWSM:>#?>
MR'NG9$[;*6B@$]5,4E=7TSG!6KT>V<,"DH"@G5'H5>S_ #HGA7OL9[H6E+9B
M8H!<'2$:NKZ61C\ +=]M(#^F_:I"L!T7;Y7=-[VHLQB?E;\=8XAW=UWB9X\Q
MM](GFQW;>PC3DUNW,I0T[1/E,I0TRB2BLRS2+&(HV\BT^BO;^83F,CU=_,/[
M:RVSLI)'DNM>P-IS;6RHJ(ZJ>*HV?A-MMAYYJBF?QU$T+T""0@^L@W^I]PW[
MIS2\N^[G,-QM%PR365[$T+U)93''$R$DY)4@ DY)!KFO4/>[-Q<<M>\&]W.W
M3D7%C=0M&U:T,:1E:D'/"A]1QZ-5U-E*S=O4VQ,WN#%Q4&0W1LW#9;-X9Z2H
MIH*6LSF-BK<ECS0UZK50PQ3U3Q^*8:U7AN;^[GOGIVGT[N3XX]+_ ,R_;F9I
M*/N[>_3=;TML;#43T3U WAN^BJZ3=69JU4O44^3ZRI)LND5P #4H";Z/>2WN
MQO?+E]R;RY[RV%\(^9I]M^D@C4)37< F3-2X>TK<#5FFH E2R5R8]T-^Y=FY
M.V?WFL[A%YAGVTVEJH*U\2Y!\0X-1): R4&*!O7HG?Q.PV\^KNR>[_C#6[6R
MTG6.R]UMV+L'>52LJ8>GVIO>ICRF)V32RR1>/(55-7Q5#MXGM (95D%W0>R&
M?R%MMYN7YDUN]7QLZ;.P76V[L7G=TU3QTF#QF1RS8HXZ@JLC4R0P"NKQ"YCB
M#%R%)M;GW%WW5;&^?G_<=SAMI&L(-NE61P*JK.\80$^K$&@ )P32@)ZB;[JF
MW7LO/.Y[D+9OW5'M\J22\$5W9-"%B1W-0T S0=+[^8-!4UWQ-[1Q6/HLGE,K
ME8,%1XS%X;'5N6R=?5#<>*G,-+08^"IJ9BD$+NQ"V5$)/L9.U<3\Z/D5VK\D
M?A?F-DR?Z(NS^]ANS#=I;CP6(VYM;K;;VS\_6Y0[J_O-AZ"@I-TXBOVU'$J1
M5%7+-(ZIH;R,P]BGF#;?=SG?F/G/VNN]G?\ <MYO3W"7#PQQI;QQRES+KC51
M*CQ+'169F) T=[,",-\V_P!V.=-[YO\ :^]V@KRW?;NLJ7;QI'';1Q.3XA=
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M'E1IHX;6%!4B"&B1*H%/P+J/H2<TZ/\ TT*T5*$>35H$DT\[V77([--/,_T
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MW'!+K L875P4G3Q8=3=][*'=TNN61%$W]6Q&Y+H!X9N"Q ULOQ2+&**6R%)
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M?4@2Q&-9A)&8F5764.IC97MH97OI*O<6-[&_N%5;U[-W91X_95=NW?>Y,?\
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M%ZL*2P7$2-'<1+5F610P:.1'),$B/VD!F!X=)N2.?]A]OMQYAAVU[B\V&Z:
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3W[KW7O?O?NO=>]^]^Z]U[W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g476668g00t02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00t02.jpg
M_]C_X1S&17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ ,(7@   G$  PA>
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP-CHR-2 Q
M-SHT.3HT-@!R<C,Y,3,S-@       Z !  ,    !__\  * "  0    !   "
M#* #  0    !   !)          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M!OJO=8TO]1]/JVUN]3Z%VSW._G$E./5D/O+*\;JO3;<K(].O%J:UUH+VL?\
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M!KS6G^K;'&_/N]+/I998-M>>Z0#ONLL^R5?X.K?;^^_U*_16E9_RKC_\1?\
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MTI'I]OI[]NU8_2\!C\W$Q*J>L8E>*Y]SKKWAE;CZC'>A=Z?J,O8]^-_VP_\
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M)[[(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! !/@    $  0$^     0 !.$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           !)    @P    & &< ,  P '0 ,  R     0
M           !              (,   !)                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !)     !29VAT;&]N9P   @P    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   20     4F=H=&QO;F<   (,     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    (.$))300,     !N4     0
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MCVO6QB,L90!;(L)<7 O]3DDZ/AGM_=]B(/I'X_P4D$/_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
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M3VZ/_M=^_>'<?\I _P!Y'^?KWB6__*.?]Z_V.O?Z.?DI_P!Y+8#_ -$-@_\
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MX;;E_P#2GMT?_:[]^\.X_P"4@?[R/\_7O$M_^4<_[U_L=>_T<_)3_O); ?\
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MDM@/_1#8/_[-_?O]+WP]_P"\-MR_^E/;H_\ M=^_>'<?\I _WD?Y^O>);_\
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MGIWL\:5"$CU#V'_^EWX>_P#>&VY?_2G]T?\ VN_=O#N/^4@?[R/\_3?B6_\
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M* ]%8$32PT[P1SS1Q'?.MXH'J8U=@"%,B@VU"\3_ $O?#W_O#;<O_I3VZ/\
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M -X;;E_]*>W1_P#:[]V\.X_Y2!_O(_S],>);_P#*.?\ >O\ 8Z77^CGY*?\
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MA(^BL"[T\S0Q5"Q3*N^28I&IYT<*UB4=6^A!]P_]+WP]_P"\-MR_^E/;H_\
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M)W_W\V[/94/;_3'1IO?O?NO=>]G_ -W?RU/DQLSK+%=KY)>KZ_;M5M7J'?\
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M.[.Z.J\+1U%3V3@]P8VJGDPE'65%#2F:@J SR1R2(2R2V>>ZG![82$S3)I7
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MM-]X&_:%*/LPZ+.KJ_?O?NO=>]FX^)W_  '^4/\ XJ/VS_[M-F>V9?\ 0O\
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MWILE79#;+T]35&:@AC\,93/;3-X9%NE/#*Z21VFOQ T\_.F>'3HNH!+7ZE]
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M4.R<Y@,!NC<5'M[9^Z^T.R]Q4M;N.6.@7']>]3[!S>:G2S25DM)#10_Y15P
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M^_V0#Y=?\^AG_P#0TZZ_^R_W[ZB'^/\ D?\ -U[]W7G^^?YK_GZ]_LXOQO\
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MOJ(?X_Y'_-U[]W7O^^?YK_GZ]_LXOQO_ .?E0?\ H,[T_P#L<]]?[(!\NO\
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M77_/H9__ $-.NO\ [+_;WU$/\?\ (_YND_[NO/\ ?/\ -?\ /T87_9Q?C?\
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MY;OCK;XR;5W$N7V_UOV36T>"HMJ;TH9,!0XC/Y$8_,PT]-E?)!305OCF4GF
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M^RZ-=U2XZJWAF5K,_7X>BH:.6?Q4HUHCY<1HFZ>F61%5I?BE\89)"J@&1_\
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MC1+9JW*5<%-1P3ULY]3LD4:7_2JBP]F/^)W_  '^4/\ XJ/VS_[M-F>VY?\
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M%_Q?N@__ !43XT_^^UQGMB#A)_IV_P /2R]^*W_YHI_QT=%D^+O_ !8^Y?\
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M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]FO\
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MZM%HVO\ +[?8TS$+$W_&,^G.)200(S_:/]/;)_M7_P!(/\)Z5C_<6'_FL?\
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MBGEE@G^'$,$\$CPSP3=^=K13031,4EAFBDA62*6*12K*P#*P((O[=7[EO)3
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M_P#WD!4_^BOV7_Q7W[_31\6/^\+L=_Z4#VO_ ,5]^\.;_?\ _P 9'7O&M?\
ME"_XVW7O[@=S_P#>0%3_ .BPV7_Q7W,':_QG- V5'P@B.+6K7'MDAWQV[]@M
M>\+5"T1K-/VXJVIT,@BU:R@+6L+^_:)O^4C^0ZWXMM35]#VUI74W6#^Y/;WW
M(H_]F(;[PP&J%)_HUV/]R:82"(U @U^4P"5@I>VG4;7O[?,1O#HS<&6Q^!P/
M\O\ S&;SF7QYRV*PN([A[MR66R>+$$M4<EC\=14LU96X\4T$DGFC1H]",U[
MD:(D4$M<@#[!U8/ 2%&WDL>'<W3=D,#V/B:"KRF4^3E!C<905 I*[(Y#8?7M
M'0456TL<"TM765$\=/35#3S(@1V5B[@6N1[3#=S?%I&*M\+*!64E65OD!VP&
M4@V(()!!!'/O?AS?[_\ ^,CJOC6O_*%_QMNGC^X'<_\ WD!4_P#HL-E_\5]]
M?Z:/BQ_WA=CO_2@>U_\ BOOWAS?[_P#^,CK7C6O_ "A?\;;KW]P.Y_\ G_\
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M^VF:VGEMI>QVMGU TS1*KD5X\: \>.>CN]WT?7W<NU.G>P\+AO[[3;*^2'6
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MQX7>F:RNUJO;JF6ICFI*5&I56.CD$-*WM;T1=6N>QF^./_90W0__ (F;J_\
M][?!^TUY_N)=?\TV_P".GIN7^RD_TI_P= M\DO\ LG;OO_Q"W:7_ +PV=][B
MF[/^/NW?_P"'=NG_ -W^1]]B+/\ W VS_GD@_P"K*=?0C8_\DW9_^>&V_P"K
M$?26Z,_YD=TG_P"(=ZM_]X3 >UUUR'FPFZJ+&8NNS&X*W,;2CEHL1N@;/RIV
MFDE><G409E6CJC14F3:"2HB@=1PCSZH5(]QUSX1%O'+5YN.XP6NQQ6E\4DFM
M&O85OM,)A#VX##7)")DA>0$$EUBI*1U%/N2XM]]Y6OMUW2WL^6X+'<"LMQ8G
M<8%W$B'P%>VH4+RVXF2%I%)J9$MRLS ]$0^?D9I^T.A=P[[WEMKKWIO;G7W=
MU5C=X;VZ5SO?NRJ#Y!U%;U\-D8W,]?XZ3^#MN#-=>0;BAP]37QR3NOWE'C&C
MKZN-BKJ1(,>N/DQN:.4ZRVQB.W,/N^N.1IXZ/(5=55YT4DN7Q@G4Y++[A27'
M&AF$$IG,0:)E"FP6NGN;]MR&X;2+?W(W*YV.XL4\)F>*-$M3*+>705AM[4B\
M6XC+IH,A656)'00O&N=R?=%W/8_I?=+=KOEVXVZ/PG,D21QVAD6VG*$6\%D5
MOENXS)&(A(4G#-(*EGW)4S;LS>[&W[U!6;)^<?=>^_Y?W8?Q_P 1_<;<%5E]
MG8#;NW^EJK?F,Z]W?-AZI=C[/ZBS&%WXVYZ62JHDH*:JJ8:X2'(1BJ:-BXS=
M&*QVW\523-B\IA.R<#N7?<$6:H:01[/JMN8JHH\KF)(ZU(<CMZ*B-:DL9:94
MGGTO&'<>S7G6\Y>O]QW[<[J 7.WW?+EW:;:S6\KUOTNYU>"W!C+17;O],RO2
M-GCBJLA1,G'/FY<J[K?\Q;O=0?6;1?\ *MY9;6QMII"VX1WEPDEM;(8B\-X9
M1:NDFF-FCB#1R-'&3T(7S"WET=V%O3LC?NYMNY'L79_9OPG[*Z9^+F3EZZW;
MGQ6_)' ]L]D;>WEL?KS%S[>ER>V.V<KNFFVT<;6+!15%;%B4JJ.H>GHGGC>M
MN;@P&0HJ(4])D(I8,ME,%L6B.3I:6"6LQ>!W,M'6[=2QGV]/68?)04[3RJ%.
M3J8=&IHK@MWK8=ZL+NX::2%X);6&?<7\)B1')<V>N.Y(Q=B*XC>4Q1G4+.&7
M4564#HKW[EK?=OOKXW%U XELX;C<Y3 \K+'-=V1EBNV!"WBQ7,,DRQ1MJ^C@
MF\0HDNED5V]TMV9L[=.X&W'4[--%EME;1[*^26\AUIN7>&1QVV-Z]G=.U6XL
M-W%D*&2' ]MX+;6[]F9C(4^&H9HY(=DX3)Q530TV01*D#MQ8ZBQ&?S&*QLKR
MT&/K%@I6DF6IDB4TU/--1R52>FJEQM3+)3-*/\XT)8\D^Y?V.^O=TV3:MRW)
M%7<)XBT@52BDAV42*C9195"RA#\ ?2, =3ARWN-_O'+^S[MND(CW&XB+2 *4
M!(D=5D5&[D69%68(?@$@48 ZMQZ%WKNKL;IGKO?.]\6F(W3N7!25V3ABQU?A
MJ?(1Q93(46*W)283*%LCA*+=^%I:;+04<S,]+%6K%J8*"2H?-G_LBWY._P#A
MD;._]^[U_P"X+^]#_P!.KB_Z7=G_ ,=FZQJ^^E_TXZ7_ *7EC_UEZ;^U_P#C
M^_BS_P")_P C_P"^&[G]ZG7O #KDQT:OW[W[KW7O=R_7W;N6WEOC^7-O'>O8
M& &]Z?IGY&;-VKN'.9+;N(QFR-Y0YWN[:G15*:>".EPFP8,-NNHP\F-D:&B@
MHYVCKM2>J?VA9=(NE"G1J7'RP3]OGT<13O)+8/+("P1@O 4/<%] *&E.'KU5
MAO[K),'MSYVX#:^Q,X-K93MWX][JW!A\/A<S4U.^-GIBNFLWW5-3,L,V1WW-
MEMG4.6I*Z.)ZN>JC1J'DJD($%Z#NUNL).F*+<F:_V?;_ &6C;V,RU(G8="_<
M$NSJ;Y8[GWM'U_\ WR7<+5HW70=?U.,S$V+_ (@*^/;"11O&((/#'K](MK('
MT^KTQ73Q_;_/I]EF,/TY;_'_  A7N&JGB$TK7B!0TK73TE'AZ]_TJ4'9<NV:
M&/X>P=^;JR4)?8F0BZZ.ZZGXT[8VDF^!M5\$:6;;53O*ER.*@R:TBT)W 9R&
M:>H69ZW_ )WYG;>X/EGW+E=K93!9RBJ,UA(LOG-LR4L^#S>]Z+:&W:'L?-8^
MMH?\AR<66[!ILG4-60%H*V21IXV9) Q4VX(A0$4_S>7\NBS<&1KR<H014<.%
M:"M/SK]O1Y/A[BL[A?C=U?C=P8K-X*I@QV;?$X/<D5539S";/J=U9VKV%A\G
M1USO78ZIQ>QY\= :6:TU*(Q"ZJR%04?V]TCZ,M[O"^ O_9'F>_\ %FL[_P"^
MJV9[Q5^\O_SJ/V7/^&#K#7[X'^X'(/\ S4OO\%IT6.B_[+,W-_XK'L?_ -^I
MV'[,X&T,LA6-Q&Z2&.8%H9!&P<QS*.6AD"V8?723;WBJAHP-*]8.PN$D1] :
MA&.C,2Q^6*6(221&2-XQ+$0LL>M2ODB9E8+(E[J2" 1]/=I@W?129K:^X-XU
M>[=J9S?O:F.W7L#:_:&Z=M5^)Z\K&ZUWQCZ"LZ]IL=/-4;6V!0[FR^%I:.NK
MUQ\3K'2!8B:&699CBW&,M:WEY,T,T]TDD(E=2(QX-P"572 B"5X KD* $4D-
MX19<P(M_MY[C:]RW2ZFM;N_W..>UBNIXF2U8VEX ;=0!X5NEQ+:QQR.(ETQQ
M45C;LZT19?JK.4&'W7LG9.'VSOS:?4_1^[.NNY]P]+]?[LP6<[;QZ]T]*91*
M#?N5JZMVWGVO4;+VOO2MRV,QTN5E,N2JSYD_BL5+,7W<6 S\4_1*]K02Y?</
M5%#'N3N]<]FJ#.9O;_6M9W#CH<%1[GEDR%95Y6H%+E)I4HD>JJH\?5QGQK%]
M"3<HBO\ 5H[H5DN;8EKFI#,(GN/TU?-6)#DA/B576M%X />;.[$WMV>9P)[_
M &NLNXZV65X[-[\"&.6K%I.V0E8AJ=(I4JJIP-#U_GL>:CY=CIUZC;VR.\*Z
MFVG\88]O8;)[7V]N/M[#?'7(U6]\OLJGBQ&/H]OTIKMO01RY>3[:@J<IC)D2
M5JE&\@NUVY-V['W#C:OLG,Y',[CWAWUOU^M*G'[[Q(W!1=?;RQ%/0MO3:VY9
M*NMH=L;(RV57&)32.T%))31U/BC7QN09W5Z]J4-_<%[V2^E,)\1!IBE327$E
M2$#/H()["HDI3)Z%E]NE]M%U"_,&X&;=+K?;DV92XC\1;6YB">/#/5DBA=_
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M1'_H"]@?_;$]]?Q+X/\ _/&?*S_T9O47_P!J7WZES_$G[#_GZ]6Q_AF_:O\
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MV9[Z/P]^&X87R?R>U#0!?.=1<7_0+_W7XO\ CW8?WN'N'0T]C]@I_P!+&_\
M+_J&\OY=;_X)_:B5?^IMP2.!^K3R]/\ $?+KWV'RC_YZOH+_ -%]V)_]LSWV
M?A]\-U 4Y/Y/@7N <YU']0;WM_=?BQ_/O7_)W#W":I/L=R^?^IC??]LW6Q]Z
M#:Z:1R=<:1G_ ',3[?\ E"Z]]A\H_P#GJ^@O_1?=B?\ VS/?1^'WPW)8-E/D
M\3I.J^=ZB)T#DW_WZ_*_GW[_ ).W^X1'_3C>7Z''_)1OO^V;K9^]!MC=QY.N
M344_W+7]G^X/7OL/E'_SU?07_HONQ/\ [9GOFOP\^'0 TY+Y0!;< 9SJ,"QY
M^G]U_P#'WK_D[C[@C'^L?R__ -S&^_[9NJC[TFUH-(Y0N !_R^)_VP]>^P^4
M?_/5]!?^B^[$_P#MF>U-1?'WXJ]9=:?)#=N)E^1F2@I/CUO*ES5!DL_U?#)5
M83(;@V=0UL6-JZ3:TJT6362>.2.26*:+2C*4)(LBW#^\ YP^\1;#VPW3VPVC
M:[.ZD69KB"\NII$-K_C"A8Y88T(<QZ&)8$!J@'J4O9_WOL>?^<DY>AY?FMV>
MSN'UM<"2@CC,AHHMHN.G375@D&AZ+SW_ $7R&6LZ$_CVY^E9$/R(Z_&(&+V+
MOJ!ES?\ "MU_:-7M5=A50;&^/R:Q&$DU:;,!?W4'_$O@_P#\\9\K/_1F=1?_
M &I?952Y_B3]A_S]9. V-,K+7[5_S=&,^Q^3G_/3]$?^@+V!_P#;$]^_B7P?
M_P">,^5G_HS>HO\ [4OOU+G^)/V'_/UNMC_#-^U?\W7OL?DW_P ]-T1_Z O8
M'_VQ/??\2^$''^_,^5G^'_&3>HOI_P"BE^GOU+G^)/V'_/UZMA_#+^U?\W7O
ML?DW_P ]-T1_Z O8'_VQ/?CD?A!>QV9\K+_T_P!)O47U/_E)?J??J7'\2?L/
M^?KU;#^&;]J_YNO?8_)O_GINB/\ T!>P/_MB>^OXE\'_ /GC/E9_Z,WJ+_[4
MOOU+G^)/V'_/UZMC_#-^U?\ -U[['Y-_\]-T1_Z O8'_ -L3W[^)?!__ )XS
MY6?^C,ZB_P#M2^_4N?XD_8?\_7JV/\,O[5_S=>^Q^3?_ #TW1'_H"]@?_;$]
MV:_'WJ?XG]O?$?'&G@^1N!VM@ODGO\0TC;JZQR>?GSF1ZMZP-;4S5IV5B\<F
M*2@H:9(8E@,HF:9G<J8U5=MWWM.8_NM3W,FS<C;?O7[[C74;BYGMA";0M0+X
M*2E_$%R2=04#0*')K"'O;[GV/MO;<L.=EFNHKM[C/C+$4,0@!']C+J#"4'X1
M30<YZ+?1T7R%/RYW2L&YNE5W%_LN/7YJGFV/OM\6<+_I-[-^T%+#'O\ CJ5K
MQ7>;S,\I0QF/0H(<E1?[)Y\._I_$_E!SQ_Q?.H__ +%_9I_R=Q]P?_"'\O\
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M'L<_\FD.6?\ PN.Y?]RNW_[;>H6_X%?V_P#^FJW[_G%9=&#^P^4__/6?'_\
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M+<_7_DEV_P"W_<W_ %?EU7_@7O;L@L><-^H#_ONR\_S\^O?8?*?_ )ZSX_\
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MM56$DTUC&E34 L,C()%*\#BF?Y]*I$>:3Q)5DE(C)5&&EJU%>&2H!J*4K2@
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MO/\ PQMI?^Z#'^S"_%#![;&[\;O*MW#U^-Y8?>^R\'L;9N]<C%3_ '%5E\I
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M4#A_]](#4,HZ$^T3<M[EH@L+=CM5ENKI:CPT9#.9+N2%XV9AX_B1/%XD4B@
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M%5N3<.=W-E*BLS'3'36;RE3)DL_6UU0D=3D\C-(L$!BHZ<-HABC46]DH]O\
M2'HU7N\_X&?]D5UO_BTV]/\ WTG67O%;[R_#E+[+G_#!UAQ]\'_DF>W_ /S4
MOO\ !9]%:QW_ &6QO#_Q5KK?_P!^SVK[,> 6(4 L6(4*H+,S,=*JJ@$LS,;
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MHIL?CL/FW2L62 RZ<@8Q&\%2J%%3W 4I^#5Y:C0=&6W-,CNT8E\/%="AC6N
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MIQLDM%7U>-?(8>IJ(:>>JP66-']W0RN@:2CFC8WO<@MW5_V2G\L__$3[7_\
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M.2D4^6OPYB=9(\[\EXI(V62.6/J[KN.2-T(99(Y$[:5TD1@"&!!!%P;^[_\
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M"R.1<>TKD@W1!SH'^ ]&* -#MJL*@S-CURG6W_O/,Y7;F[_YA.X<%D:G#YO
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MJ3_@53?]1$/_ %L7W6;_ -UT_P#R3/\ YS+WS/\ _8A?_&R_[6NN/G_L8?\
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MF;UK_P"BF^0G_P!K+W[7)_O@_M'^?KW@6W_*:O\ O+_YNO?Z0>R_^?"[N_\
M0TZN_P#LP]^_T)] ?]YF]:_^BF^0G_VLO?M<G^^#^T?Y^O>!;?\ *:O^\O\
MYNO?Z0>R_P#GPN[O_0TZN_\ LP]^_P!"?0'_ 'F;UK_Z*;Y"?_:R]^UR?[X/
M[1_GZ]X%M_RFK_O+_P";KW^D'LO_ )\+N[_T-.KO_LP]^_T)] ?]YF]:_P#H
MIOD)_P#:R]^UR?[X/[1_GZ]X%M_RFK_O+_YNO?Z0>R_^?"[N_P#0TZN_^S#W
M[_0GT!_WF;UK_P"BF^0G_P!K+W[7)_O@_M'^?KW@6W_*:O\ O+_YNO?Z0>R_
M^?"[N_\ 0TZN_P#LP]^_T)] ?]YF]:_^BF^0G_VLO?M<G^^#^T?Y^O>!;?\
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MK!7P+;_E-7_>7_S=&>_T@]E_\^%W<?\ '^^G5_\ Q.\ ??O]"?0'_>9G6O\
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M,QN"'8NS,AN*DP=/N1\F,)!DJZ)X*:*NKXL1/*L*L[+$ S6#+=__ -E&K_\
MO(GXD?\ H_-N?_4WO7C#_?;_ +#U?Z,_\I,/^]CIL_V8"G_Y\Y\@/_169+_Z
MK]^_V4:O_P"\B?B1_P"C\VY_]3>_>,/]]O\ L/7OHS_RDP_[V.O?[,!3_P#/
MG/D!_P"BLR7_ -5^_?[*-7_]Y$_$C_T?FW/_ *F]^\8?[[?]AZ]]&?\ E)A_
MWL=>_P!F I_^?.?(#_T5F2_^J_?O]E&K_P#O(GXD?^C\VY_]3>_>,/\ ?;_L
M/7OHS_RDP_[V.O?[,!3_ //G/D!_Z*S)?_5?OW^RC5__ 'D3\2/_ $?FW/\
MZF]^\8?[[?\ 8>O?1G_E)A_WL=>_V8"G_P"?.?(#_P!%9DO_ *K]^_V4:O\
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M5F2_^J_?O]E&K_\ O(GXD?\ H_-N?_4WOWC#_?;_ +#U[Z,_\I,/^]CKW^S
M4_\ SYSY ?\ HK,E_P#5?OW^RC5__>1/Q(_]'YMS_P"IO?O&'^^W_8>O?1G_
M )28?]['7O\ 9@*?_GSGR _]%9DO_JOW[_91J_\ [R)^)'_H_-N?_4WOWC#_
M 'V_[#U[Z,_\I,/^]CKW^S 4_P#SYSY ?^BLR7_U7[]_LHU?_P!Y$_$C_P!'
MYMS_ .IO?O&'^^W_ &'KWT9_Y28?]['7O]F I_\ GSGR _\ 169+_P"J_?O]
ME&K_ /O(GXD?^C\VW_\ 4WOWC#_?;_LZ]]&?^4F'_>QUR7O^!F5?]#W?RZF"
MZFZMR2JMR!=B:OA1?G_#W[_91Z__ +R)^)'_ */S;G_U-[]XP_WV_P"SKWT9
M_P"4F'_>QUT?D! "1_H=[_-B1<=6Y(@V)%P15V(-N/\ #W[_ &4:O_[R)^)'
M_H_-N?\ U-[]XP_WV_[#U[Z,_P#*3#_O8ZZ_V8"G_P"?.?(#_P!%9DO_ *K]
M^_V4:O\ ^\B?B1_Z/S;G_P!3>_>,/]]O^P]>^C/_ "DP_P"]CKW^S 4__/G/
MD!_Z*S)?_5?OW^RC5_\ WD3\2/\ T?FW/_J;W[QA_OM_V'KWT9_Y28?]['7O
M]F I_P#GSGR _P#169+_ .J_?O\ 91J__O(GXD?^C\VY_P#4WOWC#_?;_L/7
MOHS_ ,I,/^]CKW^S 4__ #YSY ?^BLR7_P!5^_?[*-7_ />1/Q(_]'YMS_ZF
M]^\8?[[?]AZ]]&?^4F'_ 'L=>_V8"G_Y\Y\@/_169+_ZK]O6&^$6\=QC,-M[
MN[XLYI=NX.NW/GVQ_?&V)!A]MXR2GBR.;K?)'&5H:*2LB5]&N2\@TJ>;>,ZB
ME4?CZ=66PD;5IGA-!4]XP/7IJROR>VY@CC!FNL>]<6<WEJ7 X9:OJ[+ZLGG*
MY)Y*+%4HAFE)JZJ.FD9=>E+(;L.+LO\ LHU?_P!Y$_$C_P!'YMS_ .IO?O&'
M^^W_ &'JOT1_Y28?]['3J?D! "1_H<^0''].K<D0?]:U7[]_LHU?_P!Y$_$C
M_P!'YMS_ .IO?O&'^^W_ &'KWT9_Y28?]['7O]F I_\ GSGR _\ 169+_P"J
M_?O]E&K_ /O(GXD?^C\VY_\ 4WOWC#_?;_L/7OHS_P I,/\ O8Z]_LP%/_SY
MSY ?^BLR7_U7[]_LHU?_ -Y$_$C_ -'YMS_ZF]^\8?[[?]AZ]]&?^4F'_>QU
M[_9@*?\ Y\Y\@/\ T5F2_P#JOW[_ &4:O_[R)^)'_H_-N?\ U-[]XP_WV_[#
MU[Z,_P#*3#_O8Z]_LP%/_P ^<^0'_HK,E_\ 5?OW^RC5_P#WD3\2/_1^;<_^
MIO?O&'^^W_8>O?1G_E)A_P!['7O]F I_^?.?(#_T5F2_^J_?7^RCU_\ WD3\
M2?\ T?FV_P#ZF]^\8?[[?]G7OHS_ ,I,/^]CKE_I^@T:_P#0]W]^HKI_T79'
M7PJMJTFL_2=5@?Z@^^_]E&K_ /O(GXD?^C\VY_\ 4WOWC#_?;_L/7OHS_P I
M,/\ O8ZX_P"S 4__ #YSY ?^BLR7_P!5^_?[*-7_ />1/Q(_]'YMS_ZF]^\8
M?[[?]AZ]]&?^4F'_ 'L=>_V8"G_Y\Y\@/_169+_ZK]^_V4:O_P"\B?B1_P"C
M\VY_]3>_>,/]]O\ L/7OHS_RDP_[V.O?[,!3_P#/G/D!_P"BLR7_ -5^_?[*
M-7_]Y$_$C_T?FW/_ *F]^\8?[[?]AZ]]&?\ E)A_WL=>_P!F I_^?.?(#_T5
MF2_^J_?O]E&K_P#O(GXD?^C\VY_]3>_>,/\ ?;_L/7OHS_RDP_[V.O?[,!3_
M //G/D!_Z*S)?_5?OW^RCU__ 'D3\2/_ $?FW/\ ZF]^\8?[[?\ 8>O?1G_E
M)A_WL=>_V8"G_P"?.?(#_P!%9DO_ *K]O>=^$.\=KS8VGW)W;\6<%/F<%AMT
M8F+(]\[71\CMO<5$F1P&;IA%'*#0Y?'RK/#J*R&-@65;V]Z6X5JT1\&G \1U
M[Z)QAIXA]K#(]1\CY'IHP_R@VWN**NGP'67>N7AQF7RNW\E+1]6YG10Y[!5D
MF.S6(G\\L)-7C*^%X9=&J/6I"LUK^V3_ &4:O_[R)^)'_H_-N?\ U-[WXP_W
MV_[#U[Z,_P#*3#_O8Z=_]F I_P#GSGR _P#169+_ .J_?O\ 91J__O(GXD?^
MC\VY_P#4WOWC#_?;_L/7OHS_ ,I,/^]CKW^S 4__ #YSY ?^BLR7_P!5^_?[
M*-7_ />1/Q(_]'YMS_ZF]^\8?[[?]AZ]]&?^4F'_ 'L=>_V8"G_Y\Y\@/_16
M9+_ZK]^_V4:O_P"\B?B1_P"C\VY_]3>_>,/]]O\ L/7OHS_RDP_[V.O?[,!3
M_P#/G/D!_P"BLR7_ -5^_?[*-7_]Y$_$C_T?FW/_ *F]^\8?[[?]AZ]]&?\
ME)A_WL=>_P!F I_^?.?(#_T5F2_^J_?O]E'K_P#O(GXD?^C\VW_]3>_>,/\
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MK_\ O(GXD?\ H_-N?_4WOWC#_?;_ +#U[Z,_\I,/^]CKW^S 4_\ SYSY ?\
MHK,E_P#5?OW^RC5__>1/Q(_]'YMS_P"IO?O&'^^W_8>O?1G_ )28?]['7O\
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MG;,?!Q;CW!N+M/LK:/5>U,?03[DRN$P=,LNY]Z4GFEJ:J*.* .]R0%)SZ/\
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M_BJ-3Q-*6C:2B7EN\8E$E$K3/KT[^[[HND:1ZBPJ*'!\CQIP./MX5Z!?K_\
MF=?"+L7H5/DKB^\<+ANI9=Z2=>4^8W7C,YM_+5^]/N*Q:';N&VS5XX[@W%EL
MQC*)\E2P8ZGJYI,7>J*K$DIC)-O[8.]NK-Z;EZZ['VMG-D[ZV=EJK!;HVIN7
M'5&*SF#RU$^BHHLA0U2)-#(O#*;%9(V5T+*RDOJRNH=&!4\".DCHT;,CK1@<
M]'-V+OK9?9VSMM]A==;JV_OC8N\</19_:F[]JY:BSFW=PX7(Q">BR>(RV.FJ
M**NHZB)KJ\;L/J/J"/:1]VZKTJ_?O?NO=>]FX^)W_ ?Y0_\ BH_;/_NTV9[9
ME_T+_3C_ "]++/A=_P#-%O\ )T6GY(?\"/CW_P"++=;_ /NMW7[*/[>Z1]&6
M]^]^Z]U[VX8G'OELKC,5%(D,F3R%%CXYI QCB>MJ8Z9)) @+E$:2YL";#CWH
MF@)ZVHJP%>)ZBUU6E!0UE=(K/'14M15R(FG6Z4T+S,J:RJZF5+"Y O[N4S?\
MF_/8/MW9?6T?R=ZLW+B)_EALKX<]R[FVQM'L%LCTEVMV#@\QN3:QR&VMSXK:
M\>]\)D</MZN/W.)KY4BGIS%(4+ ^T OPR,W@L.PL*THP'V5I^SHQ_=_ZJH)P
M8]6DL <>F#QJ.J<-M_SDME[BZ8WAVW-\9^Z]K3Q_"WL3YY=-[8W5FNKHQW?T
M3UG7[<Q&Y9L3G]L[SW31[&W1197>6'62@SL5(PILG#/&TJK.(20;]^!'RPZ]
M[+V!U9G^E]XT&Y>W:G<*=219.#%XN+?U'MB>J3+U5#65&6;%8RHQ=-2^:NI:
MRJAGH(W4S!0REE2W$+*SB04%*_*O3#V5S'*D1C[FX9&1Z\<8SGH]>ROG!\5=
M_P"Q.RNQ-K]W;$S>W>F/X5'V[+A<K)F*K8%1FZ"ER.'7+XV@I9<M/1YVGJU;
M&5=/3RTV54,:1Y@K6SXG^7K\S\YV-N;J?&?'_><^^=GX#;&Z=Q8^:7 46(H=
MN[WEC@V3F8=W5V9I]GY*@WI4R>+$/2U\PR<RM'3>5T=1KZF *'\4:2:?LX_/
M'GZ=>6QNFD:(1=XI7(\^&:T/Y'J%E/GO\.<-U_MKM#(?(/KZ+9N\-P;HVGMV
MKAKJRMS&1W/L6.JFWYM\;1HJ*HW?2Y?84%'))GJ>>@BEPL2ZZT0*02C,7\-_
MD_FNL=V]RXOI?>5;UKL>KW12;CW-%348C@_N/5046]Z[&XMZU,UN'"[+JZA8
M\QD,=355#BVO]S+%I:UC/"'$9D&LT_GP_;U46ER8WD$1T*37AY<<5J:>H'2T
MRWRS^-F"[2VQTKF.Y]B8_M'>,.W9=O[/J,PBU]4^\:>KJMF4%74!#CL1F-ZP
M4$S86AK)J>LR_B84<4Q%O:Y^/?PMW1\A.M)^S,+OO:NVJ"G^3?QY^,C8K-4>
M;GKVSOR&JMR4F&W8LF.HZBE_@&VFVVYK8]7W4@E7PH]FM66=8B05)[&;_>>M
MQ6IEA:;Q  '5:?Z;S_+H.?D1\U]B?''?T_7VY]G;UW#DJ?XK?)'Y8O7;<3 -
M0'9WQH79#;IVNO\ %<UC:D[LW'_?FG&,'C^R/@E\\\/HU1>O?@YW5W!\I>RO
MB;U/%@]X;]ZRSG;>+S.:DKWP6UY,?U!7Y?&YC.FNR4(J**BS5=C(Z:@26(22
M55;3Q.$ULRZ>YBC@2X<D(P'\^'55MV>9XD8=I.3@<:?S- /F>I78WSEZ&Z:^
M*_7WR^[?RV8V%U7V+A^G<EB8:O$3YO<M-6]V_P!WUVG@Y\/MTY1ZK)TK;A0U
MOVS31PPT\\BLZ)<P:#X%?,/+;2[0WUBOC]O_ ">T^F<_N[;'8^9H**BK(<%G
M=@*C[[H*6&GKY:O<9V7#(LF6DQ<=;%CHB)*AHT]7NQN( 5!E%32GY\/V^7KU
M;Z*ZTROX)TH:-PP1Q'S_ "Z?<I\W/B7@][]:=;YKO[KG$;Z[?PFT]Q=>[9R>
M;6AR6;P^_BZ; JZE*F**+;S;^JHGIL%%DVHYLS61O3T:3SHT8*+[>Z2]&F]^
M]^Z]U[W[W[KW7O9N_F%_Q?N@_P#Q43XT_P#OM<9[8@X2?Z=O\/2R]^*W_P":
M*?\ '1T63XN_\6/N7_Q9OY _^_#RGLHGM_I'T9OW[W[KW7O=G/Q__EF[D^0O
M3?5?8>WN]^KMM]A=\YGO+;W2'2NY\7ON/</8F:^/V"QFY=\8Z#=>*VYD]F[=
MFDPV5B>D?)55-!+*PC:1";A'+>+%)(C1G2@!)Q@-P^9Z60V@EC#^.%8UH"#F
ME?,8ZK,^0'\S?8GQU[9[AV-NWICMK-==?'3"?'S/]^=V[9J>O*G;'6^+^36Y
ML]L_K6N.T<EO7%]B;MI*;.[?E_C!Q&,K)L?2,)UBGL4]HSMO^7'WSL'I/KGY
M$[*P.XNU>G-T?'SK_O3?N^,%MG^&XKJZ7>^4RN+K-IY**;,5N3ST&U9*.E-=
MF*:F2AA-?$LHA/UM'=1M(\3$*X<J!7C05_U#KTEE*L*SH"T6D$G H2*TXU-
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M6%%E5D<5##ACC4<<?S\NGK&_S$.I#TS\D^SMW;0[&ZZWI\2<RNSN\>A]X8[
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MG\_C]S[UVW@:W"8+>^YYMD[+S.7ILKDJ6;&XK=V\J>3$XRHF5(J_)(U+ SS
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M'1PQ-+*ZM(Q5/;W2?HT_OWOW7NO>S;_$[BG^4/\ XJ1VS_[M-F>V9?\ 0O\
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M^@?\W/\ G_HV_P")G_4/_P!8>B16/^R^?3_N:75]1^G_ &=2^KZVM;G^OO\
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M"_XOW0?_ (J)\:/_ 'VN,]L0<)/].W^'I9>_%;_\T4_XZ.BR?%W_ (L?<O\
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M]_YI?\_IT!_<?_%_Z!_\3A0_^^S[/]E>]N](^AP]^]^Z]U[W[W[KW7O=OO\
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M^2KU6-K<G!'5TRU?;NYJVF$\8+>-IJ.ICE )N%<7L;@ '_LCORY_[Q^[)_\
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M??3?![Y<*"Q^/W9("@L3_ VX %R>)?Z>]_4P?[]7KWT%Y_RCMU[_ &8/I(D
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M3:-5VR^_<]@-F[QJ\?L3([_A%=M>(U>8D K:!)6+355'31D3-\?+#J'>&?\
ME334?<M#1=7=E[9ZXJIGQ]#WAU]W-O;L3:WQJH^O,IF]H9W;]%GJ;=.VMP[Y
M6JH<Q@>P\A/2Y:"K;)RRI5&6H]T2&15B!6K@GT( U5_P<".K-=1-]6/J!X3
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M*0YR:A,3-#435443",Q:=^"?!,.H4KC[*UI_DZK]8AO%NF0U*]U*"K%2"1Z
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M:[_VO7[CHLS2KN*E@Q.3_9JT@>7RQQHT84Z@6#&_B.1IT-2O&O"G2\7%O]/
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MITE/\/R;TJ)*\+ERVUP0L1"BI^($\ #0T_/AT[^[QKN@68J@&F@R2PU+7T%
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M9;BM_9J)(8(XW4/<(K49 &&I"4(K0JQ!' @PVK<+^2]=);R1T\%VH:<1IIP
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MBZ=VS&YBRT>/[#RM'21LQS9),5+"B?BX4?FY)7/^'"/F/_S_ !SO_GAV9_\
M8W[COZ6#_??\S_GZO]?>?[_/\O\ -T8[_94_C]_S[B@_\_&Y?_KU[&7IOY-?
M.CNS)Y/&8/Y.;+V?_#$QR'(=I;LZBZZQV0R>9J9*3#8+#R[CQ-+-ELMDZB%P
M%@C:&F1#)4R01>OW1X;>,5,1/V5/3\-Q?3ZM-TJ@?Q%1QX 5XGH/.Q.G/C3U
MKCJ7)97IK=6X(ZEJMFIMBX'L?>M;1T>/IFK,ADJ^FP%96-1T=)3CC61+42$1
MP)+*0GM>8WLO^9-D<1O^I;O3;V,W;US7=A4.;ZDRVZNFZ'N&M;J6"MJ^SY\'
MUXV/;-Y*#8U!BJRIJO2CU%/0U+TBU(@DTT*6@TGPSI-,YIGAGY]6\7</#>0W
M !!/;5=6.-!QH/\ BJ](K(8/X7X\;*R#["RE5L[?M+LBKP79=%B>QJGK-4[+
MJ**CZ_7([U6K&'H6W979.D@IRSE(IJRG6H:'SQ:H>\>V?YC^Q^J:3MW+]X8Z
MIPZT&S,QNG:V&R?668["ZWP/9=#'E.LL_P!D;-HL#)DMJ8GL+%SPU&-DEU$)
M4TZU*T\E53)+M8[5G*",U]<T-.-#YTZ\\FXI%XIFP*$C%0&RI(I@$</M%:=9
M]M;:^&>ZM_/UWC-B5D67J*_>&(V[ELG2;\QFU=[9CKNM;&=A8G9.Y*S(Q8W<
M60V5DHI(*Y(6Y>"<PF9*>H:(M7_#A'S'_P"?XYW_ ,\.S/\ [&_;OTL'^^_Y
MG_/TF^OO/]_G^7^;H<?]E3^/W_/N*#_S\;E_^O7L5.BOGC\M]P=W]-X++=TY
MRKQ>9[6Z[Q61I3A-GQBHH<AN_#TE7#Y(MNI(GE@E9=2D,+W!!]L75O"EM<.J
M481L1Q]#TW)N%X(Y")S72?3T^SH)._\ XR]%X?H;N[*X[KZAIZ['=0=EUM'.
M,MN-C%4TVR\W-#( V9*DI(@/(][..Y\Y6P[HW5!%2;76*#=.Y((5;8/7\K)#
M#G*^.)#+-M:2:4I&H&IV9VM<DGGWU/M?:;VL:RV]V]NMI+M;0L3X/$F)"2>[
MB223\^NW%G[)^S+;?M;M[5;$7:SMV)^G%2S0HS$]W$DDGYGI =-?$CXZY/IW
MJ+)U_7'W%=DNJ^N<C6SMOCLM#-5UVS,)55,I6/>B(NN:5C8#W[$?QW,T^0K(
M9>M\70XN3'0UN0W'M?K+!T*5&6DJ(L=31U%3M%UFJ*EZ62R@7 6_T]E^Y>W_
M +/[7<6-G+[76MQ>W*RM'%:V3SR,L(5I6*HW:J!TJ21DTZ*]W]LO8S9KC;[.
M;V:L;J^NUF:*&SVYKF5EMPC3.41AI1!(E6) )8 9Z8NU^K?B#U!D-G83+]&=
MG;TW+OR+=%7MK:_5-/W3V%GZC&;*I\5/N?,5U'A]Z"/%XG%OGZ"#S3R():FM
MBBCU.X'OCC?[SYBGW%68['[1FH]J8V7+YVK?8O6\5-!0QSBG7[65]J#[VLJG
MNT$*7>6)6DL%4GWO<.0/9?:I]DM;_D#:DNMQN5@MT%N69I675W@,?#1?ADD:
MB(Y5"=3 =6W/VT]@-GNN7+#<O;+8X[[=[H6]K'])J>271K(95)\-$7$DCT1'
M98ZEV ,O?_5OP<ZNSW3FU=][0J,%NCOW><.P.K-MMN+N"LS><W-)A:K/5$.1
MHL?NZJ_N_B\114GCKZ^L:*CI*R:"F:0SSPQR2\#1;JW)#+/C8-@PQBOBQ%%_
M%MH]9XMLSG:BF>MAP&$2?:9.1S$M)&7$8T* R@L"R@IMXY*]E-AE6+</;>Q9
M_ :=_!LWF\"W1Q&US/I;]. .P76:\&(!"L0BW[D+[OG+4Z6VY^U&V--]*]U(
M(-O><6]I'(L3WET4/Z-LLC!/$.HDAR$*HQ"3[DV[\$.B<[C-N;YZWWC692HV
MMD^P]QQ[(D[KWM'USU5@\A'BL[VSV2^#W=,=J=>XG(2&.2L<2S.(:B2.%XJ6
MI>+)'C-Y34^$J4QNRPF??32Q2;+ZUCJ,>C45;DXJK/Q/M-3A**HQF,J:A))3
M;Q4[DV( /I.3?8V*?=8'Y%VK59#]0BV8JY\2.$K P8B=Q--%$5CJ=<J  UJ-
M2<B?=VBN-YMG]L]F+V"UD*V3,DI$L4#):L&(N9$GGAA9(\^)-&!4&HQ5V(_E
M_8S+]BX:MV7N-)NM*99LC6T\O>5=B=W5*9[;^T:_"]99"BW-41=@[AQ&]=WX
M?"U-%0!YURF6I8$#F2X2J[CKW4.D&U'1AJ21>ONN],B'E9$/]T^4=>0?R#[$
M#^T7M;&S1R>V^TJZFA!AR".(/=Q!P?GT*6]D/9I&9']IMB#@T(-L*@^8/=Q'
M _/HQC?#GXUJ2#UAI86U*=]=FZD:WJ1].]R Z'A@";$'V!WRJ[0WUU_\5/D+
MO39.7QNU=U8#9VUIL3G<'LW8F.R%(:SM'8V.K8A+3;7C\U/64%5+#)'(&4J]
MP X5E@G[Q/('(G+WMQ'N6P<GV%EN/[WM8_%AC*/H99=2U#?"U!4>=!7K&W[U
M_MW[>\G^T$F]<I\C[9MN\#=[.,36\(23PW\76FJI[7H-0\Z#TZ"KL#XK_'W!
M;]^-IQG7$,0S'=N0Q.02?=W85=#/1+TIVYDXT:GKMW5,!>'(T$$R,5)5XE_!
M8-KD?\.$?,?_ )_CG?\ SP[,_P#L;]X2_2P?[[_F?\_7-3Z^\_W^?Y?YNC3?
M[*G\?O\ GW%!_P"?C<O_ ->O?O\ APCYC_\ /\<[_P">+9G_ -C?OWTL'^^_
MYG_/U[Z^\_W^?Y?YNO?[*G\?O^?<4'_GXW+_ /7KV9[(=B?S1\7O#IG8%=V!
MDX-X=[X!MT;$P?W/4\U1#@XJW*TU97;OGI\?+1['_A5'A:BOKHLK+2S8_')]
MQ4I$G/MH)9D2$+A30\?Y>O2G7N?B10^(?$<8&/Y^F,FO = /'BO@S+M_M3=0
MP5.F Z:S,.W]\9&:F[(@2++55!B:Z@IMO032QU>[QE'S5/2T<F+CJXZVN8T\
M#23*5]J*+>'\QR3>=7MS_9F>O$V=1[$I>S).\I-X]7+T4^QZ[=$NP:#-Q=A#
M;30O)6=BT\NWEH?MAD5R\,L3TZ)%+(FBEJ!7PCJK2F:UI7A7TSU<G<!)H-TF
MC3JUU&BG#C3UQ2E:^73:]#\-TPL%;_HIW:VYJC>55U]'U@NW^P3VA_>^AVS!
MOBMQ#;1_B8G1*78M5%FFJS)]BV-FBD29FEB1RW]@_,GY[=6;UW-UWOWM?<NW
MMX;0R]5A,_B*G"[%F:DKJ1@&,-528"HHJ^BJ8F66GJ:>26GJ8)$EB=XW5BXM
MO;.H94P1\^DLEY?1.T;RD../#_-T,>S.A?BQV'M7 [WV9L_$9[:VYL;3Y;"9
M:ERVZXXJRBJ%)5F@JLK!5TE1$X:.:":..>"56CD1'5E"/_X<(^8__/\ '._^
M>'9G_P!C?NWTL'^^_P"9_P _5?K[S_?Y_E_FZ4_^RI_'[_GW%!_Y^-R__7KW
M;E\,_D_WKOWXN9C=.\=]_P!X\[3_ "!S. @K\OM79%>\.(BZXVID4HHHJG;,
ML$4?WM4\C%%5V) 8D  8Y>_N^;SRX_*[[%NMQ:F07&H12,@8J8=).D@DJ&8#
M-!J.*YZQ6^\]SYSERG;<E3\M<R7=E),]X'\&0QZ] M2A;32I74X7T#M\J%SI
M_C-T3/\ +/<>!DZ\H3CH_CELK))&N:W5&RU,G9^_H)#JCSR!D=($X8$C3P0"
M01\_TZ]H< 9K#$D@ +U]UR68DV"JHVC=F8FP ^I/O'4>X_/I( YNW&O_ #T3
M?]!]8D+[[>\;L%7W$W8L?^7B3_H+HP+?$CXZJI9NN*-54%F9MP;L"JH%R23G
M[  >QOR..^4&/K,%BTK=C9;,9K<-+M&KQ&#P_3N3R6T-V5E!4Y6+;N_::+;:
MC:&17%4514R?=-X(8Z:</(KP2H@BEY@]THYK>W'--\T\D@32MV[%7(J%?3*0
MIH&/=2FEZTT/ID.XYH^\;;W&WVB\][A+=SW"P-''?:W@G8,PBG D/A.%5V.O
M2JB.0,P,4@0KV-K?@#D,1N;<4^U<K@MM[=VC6=@4FX-QXCMG"8G>VQ*')4.%
MGW=US45L\;[ZQ#9K*T=+%_#UFGGEKZ,Q1/'6TCS(W>&[^\MFY;"8N?<&S-R0
M[HIH:O:.=V7M/K3<VWMVP2Y&7"DX#)4>S8S55$&=IY**6!XXYHZA-)2S*S(;
M[G+W'LIH(6YMOY/%4%&2YE=6R00"KFI!!5E^($$$<*D>]^Y?OOLE[96C>XFX
MW"70K!)!=O+%,-;1GPV5NXK(K1LM ZNI!6E"1,V%U9\0NP,)NC,TO7=7M>78
MM;/0;]P&_*K>VS]Q[(J(<12;B1MS8S+9Z(T%%5[;R%/D(*H.]+-23!UD)5PB
M\J\-\EZ7.X;;Z;BZPKZG*U6>Q=9D,=2=/5>"VKN+:M/3U6YMJ[RS*;56BV]N
M#"1UD EBD+Q2/,JQ2R'5I7S<P>Z$,T,+<W7M7+J2+MRJ.@!=';Q=*LNI:U(!
M)&FO1[/S3]X>"\LK/_7%O',S2HS+?ZHX985#30S2>)H22,,E:G2VM=#-F@:8
M:7X*9S 9G<-+UUNJ"+&8O:VY,;B:[ =JTNY-X[-WS65U%LO>VQ]O-7'*[GVS
MN:;%U7@E@B,\2P,:B*'5'K"S/]C]W;7I<34Y_(X#&R9J3.I18Z;975YRRQ[<
MS$VWLE65>-CVHU51T#9RDJ:6GFD 2IEI)_&2(R?95=\[^Y%C'#)=<T[B@D+
M#ZF2O8Q5J@2$BC!ER!W*P%:'H*[K[L>^NRQ6LFY<_;I$TS2!5-TQ?])S&Y9
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MK+&[^[$S>X-O;/J>H.Q=T;YDP==15\]5,1N&FSD-$\] U*R)$YY!4+IK93H
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M/'_B<NI?_>^V_P"VYR!#,2<:3_@ZO;_V\/\ IQ_A'0<]W"_2_;P')/5^_P
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MTR&"R&/H>R*ALVU:4@%5CHQ2M4I/KAK*]JNBSH_GL9OCCQ\A>A__ !,W5_\
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MY/+4\&,'6U;3UB?;FIAJ)H5\14R-%YEC! U.:@G#'RI\_GUZ.:XDU@PP*RL
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M%ECT2J"0K $WHT_V<+=__/FOB?\ ^DM]+_\ V*>YV\%?XG_WH_Y^LVOKY?\
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M0U[23]G]G4KPS5\696MFI46G5HXFD,4;L[*H9V)%[^)[%_[QZ^,/_HB=F?\
MU/[BK_@W/O9_^%\W_P#;:?\ ;+UBE_P1WNE_T>8/^R.S_P"M'1B_]EUV]_S\
MGY _^CZ[0_\ LC]B!L_KVJ[ Q^7RNS?B=\<L_081O%73TO1O7T&NK^SGR/\
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M?F<>KV:_+BUL!]@KGRKTWL?O+[W<R2W$6SWMO*\0!:MOMZ :F"J-4D*K4L0
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M[ F,%'\C>Z:*D@5]IX@I3TE'2;U@I:6F@2R1QQHB(@   'MYV/V;\B^R?O\
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MHM'B-<D?[X\Z&GK0G@">K1_?<^_I-%MDT/O5S$T=X^B*@M#J/S'TU5!H2"P
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M2O\ PB&U_P#.6_\ ^VSH"GVW]M5!8^W&P4'_ "Z#_H/HPW^RZ[>_Y^3\@?\
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MCA\E5147VM;6.%CDLP=IHV ;!R#33PXCSKZ?GTG3P8K2?5+&=:XTD^)6H(#
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M-?=2E./G7RIU$O/@V8;O;C:/I]0MT$_T^OP/&%0?"\3NTZ-%2>+ZSPIT=SH
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M50?\H$7[7_Z"ZG?Z,=T?\_T[9_ZD=5?_ &L??O\ 9@.KO^\/>@?_ #^=^_\
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M<AC>M9X$K:&?T3PL5EB?AE'OE2;%V+7OCXZ#H3;M:^7EJH<2M-7=ARG*34)
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MI (H/(3HC1;**_O]F ZN_P"\/>@?_/YW[_\ ;G]DOAO_ +^;^7^;H(_50?\
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M,[CVUG_C1VYN'>F"Q^U^V/E!N'XX[DPNR:+N_;W:U#CJ?K/;^XJ;-;XVQL/
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M9%ADDA 7PI)(E21TTJ 6J%4&@ESEF\W'<-CLKS=6=KMVEH[Q"!Y8A/*MO,\
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M+C_?Z_[S_P!#=>\6S_Y1&_WO_H7KW]ROD%_S_?:/_HDH_P#[9'OW^E'X;?\
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MI"%5Y)"-11'^E'X;?]XE=E?^E4R?_:-][T7'^_U_WG_H;JOBV?\ RB-_O?\
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M7^^_^E?^XNW[?WP_TT?Z;_OO]'WW7\ _@W]XO\E^P\^G[+T^37Z_?__6^?\
M^_=>ZW^/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^M?Z>_=>Z][]:WOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>_?7W[KW7O?O?NO=>]^_P!]_OO]O[]U[KWOWOW7
MNO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOUO]Y]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?=C_O%_P#87M_O
M?OW7NO>_6-[6-_?NO=>]^L?K^/Z_4>_=>Z][Z]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?=C_OO]]Q[]U[KWOJWOW7NO>_6]^Z]U[WW8^_=>Z][Z]^Z
M]U[W[W[KW7O?O?NO=>]^(M[]U[KWONQ]^Z]U[WU[]U[KWOWOW7NO>_>_=>Z]
M[[L?]XO_ +#^OOW7NO>^O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
MM[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>__U_G_ /OW7NM_CW[W[KW7
MO9QOC+OGH'977?R*3M[;N&W#O7<FW^O,%U%_$MJ4>Y:S$5D^]8Y=]YC&5&8Q
M.8PV%:EVG&RRS&..O=7"T<J2!C[(MWMMSN+K:S8RE;=&<R=Q4'M[ :$$]WY?
MQ#HPLY;6*&\\= TK*H2HK0ZLG((&/S].D%NW'[LK<WL^;;]2T&*H*G-U6XHA
M6&E2L7^$2Q8>F=(WBGJ <FZM;5X@%)<'TV/KV5\>/@I3;#VIV)/EL-L_;W;N
M2[5KMO=D3=AYFJ7%5]1G-Q9/K''5O4FU,%D\]C]LY+;&%D:HDIZ'5@*J:CQ^
M019ZE9(PY:[IS(;A[/PM=S%X>I- II 02D2E@I8,>T&AD74ZX7)Q-9[0(8Y2
MX7Q=9#5.#6J]H%:$ ^7;@')Z#+#;J[7G:.B:@6LR^,@PU/F,3'AFIJ,RTU#0
M)N.:DW%D:^.BGJ(\M7>*&-I+5,,,D\+.JV(+T=!_*XFR6Z*,IV)5T.,ZOW3E
M]K5?][MS;<DW1OVN[/WE3XW#5==D]I92GP-9M3J.CPM9CHFHYZ7+9*HJ(JJ=
M',<41B&YP"PZO #&4!C0&B"-#4 ,*AI=:MG4JA2HX]) NQZI0-141DJ26%6U
M&@X'@M"/(GCT\T\O>[QXPU,>UJ-ZK(T<.484PKABJ./;&&:2>"G@R4)R5/6[
MNDKHYSY8I8*58FC5K,S /0[WZ5K?BWMO8&6P/4%?VP,AV5N.JW'/M/<&T-W;
M5P>W]ORX[K[;DV^-JX"HGW[N[>>Z-P5V02EKWDQ<--BJ"&IJ8 [",S:#<!N\
MLZR2BQTHH&H,&8FKMI)[%50%J.XEF(!H*I1-;&P2%DC-Q5C6A!  [1J [BQ)
M-#B@%3TJIL?ND;[JLI%/F:?;D='AJ&"DAKJ&OHLE5UE;Y\S728RLJ8_X52XN
MCQ\$*R1_ONU5.RQMP?;K+GOC$-BT/\9QNR\Q1TVU]IU6R]M8#%[AV_V-_?3!
M['RDO8%#VSO&CQ\<U5A-T[Z:.*D,%34AXI8&I#0115 7RINIF&ER#XCZR<KH
M+]GAKPJ$P20,UKJ-.K:[+P5UA"-(H "&J%.K6:<"W#/I2@KT[Q1;I66 /+&7
M^^R'W\H,1I6H)LA%_#314[DNLU-C;ZKE?6K7UW4>^5/@_AE49F@DHLC#_=ZH
MH=Q3N-Q;AWWCLC#GVRN"GK<1DEQV"J&@VUM_9U17/M>K@26JS&9A6+)!8SX_
M=PV[B(AZ>-4< *4H:$5/$M377@*Z>MA-M++0C3GB6&<8-!P KH/%F^+K)#-N
MHT>J>F@2N!"F*,P/#H6FF,4B2>6Q>>L5%F!-HXR2G]?:UVWLWX?=G;LPN*QM
M8T?\2S%#0KXILSMG.O2;=VUCXZ7R[8I<>FWY\#E,!AZO(9V>GJQG*O<C&DQZ
MZ*B)F2RR[S;6[.0I< D_B J36C<:@D: 1I" ZN'3D<6W3R(H/%AZ@T 'EPH0
M*L:ZBV!QZQ+/N>EC)D@BD+5!+!W69!'532DK#+&XE#PU$L<<0=1&L%V8W4^T
MAV=UG\?>O]V];/D\#44,6[=_3KN78%-VK!D<=MWKC:DTF#?-P]AT6&RYJ*+M
M+(UGWE).:=I<6,54TS(2XE#MI<[E<0W(U#MC&ERA!9F%:&,D4*<"*]U00>FY
MX+2&6$,E SY75@*,5U4/Q\1Z4(ZET55EZEJZ#R*%I::/PULV.D@-155 \@3[
M9J@$-1QH0Z\:C(I_!'MVP^!^'>WLMG'I]T[*WE2[GP7\%P6.W--V5A\)B*Z#
M&4,^X,KD<A2[9R.X-IR?WBIG7"SPS5\L\"E9M,4YMYWWIQ&!&4"O5B-!)6I
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M-145  _8,'K1&V]PU#2/, UIG@#@_,G/"AZY12;K:IJ)9*:"* T@%)2O-3R
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M5VZ,*ZXZ#%TQI8\8\7\1JI*N"01I=#NJR@2,&02+6B@ J5R 2211NXL:U^$
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M#'@&[JZ 2=5:@@"E.G=&V=N1J[ZY- <Z:"E2!BF03FO7J=MT!%>H^U/C2FO
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MM>>6FVY6;Z/7$FWA25%'G(6_B%1D&EIZI%C(>/<C;OJ8IB&BCX1KH:5;B%U
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M-&TC21U04>%WB\Z0ZJ=9I5X@1Y.+L0#_ %]FF?KCXF/F:]M]9W8_7U!+_?\
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M]$:7P21!ZF!_:JXNKR.6,PQAK=HP:A6-"6RV#4A5H=/$UP<'I+!!;NC"1B)
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MM4,W @B@)KU5[2T2)F%Q601ZN(I6O#A7(X"E>-3UEILKD)GC>3$U,%-))31
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M)6.G8>U5I-N#P3R74!6X520N"&KW* :#*_ ?F*^=>FITLEEA6!@T1*U-3BE
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MOM\##D\5C:45-/BMNY7!RQSXN;(5<M1,$D>HB@6.S[%_>"SOIWM:3QQZE%"
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M?0[1PV9IH\4J9:6LJ*>&GFFB$?D657]^AWJ1XR\EH55= 9B?-M-:+\1'=VD
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MFI,6)!6M)/&9!&I9E87>[=TUB%Z4/I2H74PX\ .)X8Z=.UR"3PC,FK5\^%:
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M1YT/[*BH^?6>JW%C:846F45;5_@%-'1/'/+)]U'4RTKJFM"89UHI@'^ET/\
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M)ZN17AKIT@>,$E@LDW2*.."22,H)%)&J@ 8?@XY8Y(\B!QZ3)M[.\Z^(#X;
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M/K6G5X/K-8\'774M>-*_AU5Q^W'6*L_A_C?[S[?3XY+Z]/D\?/DT:?W;WO\
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M[B_WA_A7]XOLO[H^0:/XS]I^Q_=SR_3S_P"3:O\ 'W9O JNK175BM./R^?\
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MJU6M^;^\5%_I*^UVC_#O[\?9?Q%O[A_9?Q[[7^+?Q"IU?W1\'[7\1_BOFO\
M9?N_<:_[>KW=O!K)JT5IW5I\N/\ +C\NM#QZ1:==*]O'C7\/SKZ>?7$_:_Y1
MJ^W_ .FJ_C^FA?\ @1?_ )MV_5_9M^/;A3?Z7O[S?Y'_ *2/[Y?=M_P&_O/_
M 'F^^^[EU?YK_<K]W]]KO_;\NK^U?W4_3:#7P_#I\J4_P<.K#ZGQ#3Q/%_.O
M^?CUTWV?B]7VW@TM^KQ>+3;U_7T:;?7W#3_2=_#T\?\ ?S^%?QNC\>C^\'\/
M_O':A_A^BW^3?QO3]MX;?OV\6G^S[]_BU3\%:?+AG^7'^?SZK^OIQKTU'K2O
ME^?IUV?M-7/VVO3^?%JT>NW^.G]7^'U_Q]S3_I?_ +X/?_23_?\ _C-9Y;_W
MG_OA_>'[VC_B&O\ Y?7\9_B'V_FO^_YO'J]6GWH_2^$*^'X%,<--*'\J4K^5
M>K?XSXO^B>-7YZJ^?SKU[_)?$O\ P'\'C73_ )OQ>+2VG3_8\>F]OQ:_OK%?
MZ7_#DOX'_I(^W_O/2_QC^$_WG\/]\_/_ )%_$OL_1_>?[G_->7_*M?Z>??C]
M+^G7P_A[>'P_+Y4],4ZTOU'=HU_%FE?B\OS_ )]<3]EJ75]KK\7HOXM7@]7Z
M;\^+Z_3CZ^\.,_TK?WG_ -P_^D+^^?\ >";_ (MG]Y/[S_WJ^UJON/\ @+_N
M5_O!]EY]?_*3XM=_3J][;Z;PN[1X.GSIII_@I_+K:_4^)V:_%U>5:ZO\-?Y]
M<V^V\?K\'BT#]7C\>C4+?7TZ-5K?B_MBF_OA]]F/N/[R_P 2_BM7_>#S_P 4
M^^_CGAROWW\8\G[_ /%?M_OO-Y_WM'GU<>3W?]'2OPZ:8X4ICA\N'#Y=-GQ*
MO75JKGCQSQ^?'^?7,>*R:?';2OCMIMHNNG1;C3>UK<?3V[9O_2;Y(?[Q_P!^
M_+_"J/[?^-_W@\G\$_@_^X_P_?\ J_A7]W_\SI_9^S_3^W[JGT]6\/1JS6E/
M7-:?.E?GU9_'QXFOAYUX4Q^5/Y=<!]M86\&GS<6\=ON-9^GX\WDO_M6K_'VX
MS_Z8_L:+[G_29_#?X3N3^'>?^]/V/\"NW][_ ++R?Y/_  F]_P")>/\ 9^OF
M]U'TM<>'6H]./E^?IU8_4T6OB::&G'A^*GR]?Y]<!]CK-OM/)Y5O;PZ_-_8O
M_:\M_I^?<F7_ $W_ -Y<GY_]*O\ >_\ A^3_ (SY?[W?WE_A7\ H_P",_P 3
MU_[E/X?_ '6^W^Z\O[?\/\>O]G3[T/I-"Z?#\/R^&G'%/+C7\^M_XUXC?VGB
MT->-:4S7SI2E?E\NNA]CXQ;[3Q:UM;P^/R>1M%O[.ORWM^=5_P ^QG[9_P!F
ME^\ZU_O;_&/XIK;^XG]Q?MOXA_'?X9@_N?M_[F?Y1_'_ .$?P_1X?V?%_P !
MN?/[16?[K_QKP*4_'JX4JU/BQIU:OSK7I3<?O"L'B5U?AT^N/X?/A_D\^HE)
M_"=,WV_AT^&+S>2_^9\DWC\GFYMY==]7JO\ 7\>P SG^E#[6A_O+_?W[+[&D
M_AO\<_O#]K_#?OF^P^Q^_P#VOL?XE?P^/]OSWT^OVO3Z:I\/1JJ>%.-,_G3C
MTD?QZ#Q-=*8K7A^?SZGQ_:ZF\7V^O6VKQ^/5Y.=>K3SK^M_S[==Q_P"FS[3(
M_P![O]*7V'\7R/\ %O[Q_P![?M/X]]C_ +EOXC_$_P!G^+_PS_@1Y?WO!^OT
M>]1_2U7PO#KBE*?E2G\OY=6D^KTMXOB::YKJI6GG7SI_+KC%]GJ7P_;:M"Z?
M%XM7C_LZ='.BWT_'OCCO]-'AQW\)_P!*'@^YW9_"?X=_>OP_>?PRG_OU_#OM
MO1]S_!O%_%O%ZOMM'W'HM[\?I*'5X=.WT]>W^?P_/AUY?JJ+I\2E32E>-.ZG
MY<?EQZY'[:[ZO!JM#Y+^.]M1^WUWYMKOHO\ GZ>V.H_TB?W=RGW?]]/[I?Q>
M@_C7W'\<_N[_ ![[%/X7_%/+_N,_B_\ #=/V_E_>\%M'IM[V/I?%CT^'XVDZ
M>&JE<T\Z5XT\^J'Q]#5U^%45XTKY5\JTX=<AX-::?#KTMHMHUZ;G7HMSIO\
M6WY]J>O_ -.]L_\ Q3_2W;^ZF._O3]__ 'QM_<?][^$?Q_[CC^ZG^<^V^X_R
M/]6C\^ZK]'V:?"KJ-*:?B\Z?/A6F>KM]7WZO$^$5KJ^'RK\O3RZP#["T>G[.
MVL^*WAMY+I?QV_MZM/TYO;_#VFLG_I&_BU;_ !G^^W\=^]A_B/\ $_X[_%_X
MC_"G\'WOW7^6?>_P/5HU_N?:7M^W?W<>!H73HT4QPI2OE\JTZHWC:CKU:Z^=
M:\/\W\NN:_9Z%T?;:/&=&GQ:/%K%]-N/'Y+?3B_MQRG^ES^._P"YK_2-_>;^
M,;;_ .+I_>;^._W@\>0_NA_P+_W(?QCQ?=?PW_=^GR^'C7[J/I?#[?#\+2>%
M*:<:OE3A7RX5ZVWU&OOUZZCC6M?P_GQI_+KBGV-E\?VEO%-IT>&WAO#Y].G_
M '5?QZ[<?IO^/?'_ (RUIW3?_2+I_C<']]O^/ET_WC\E1]M_>G\?QOS>7Q_=
M_OZM=N;^]_XMIC^#33MX4I\OE]G6_P#&?U*Z_B[N/'Y_/CQSUD/VUX;^"^G_
M ">_COIL/\S_ +3IM^G\>V>/^_?E;Q?WM\]YM?C_ (SY;^9/N-6GUW^XTZ[_
M -NU^;>[?HT%=-/R_+J@\;--5?SZYCQ7-O'J].JVF_T.B_Y_3>W^'MPRO^D_
M^ T'\<_O[_=CPY#^%_Q7^\/\!^W^\3^*?8?>?[C_  _Q#3]QX_3YK:_5[JOT
MWB-H\/Q<5I2ORKY_9UMO'T+JUZ,TK6GSI^?'K&OVFLZ/MO)K&K3XM>NW%[>K
M7;_8^W?&_P"FW[:B_A'^E3[/^YU?_#OX;_>W[;_1_P#=C^)_9?:_M?W.^^MY
M_'_D7E_7ZO=6^CU-K\+5JS73753%?G3\Z?+JZ_54&GQ*:32E?A\_]KZ^77&3
M[*_[OVNKR#_.>*_ETFWZN?)I_P!C;WP'^FK[2*W^E'[#^'[(\-O[V?:?POSM
M_HW\7^Z?X?\ =7_@=OV_)?[7GWL_25-?#KW>G^V_Z&_GU[_&J"GB::+Z\/P_
ME_#_ "ZY#[6YT_;WUS7MX[Z_^4B]N=?^K_/]?<U_]/?DF\G^E[R^3=?W&O\
MOGY/+H7^_'FU>KR>.W\5U<Z;?<<>Z#Z&B:?!T]M/A_VM/^??Y=;_ ,<S_:5S
M_%_MO]G^?71^SMS]M:T7U\5K7_8_PM?]'^\>TOA/](WVV2_NW_?;[/\ NU4?
MQC^!_P =^V_N=]W/]U_$OL/VO[L_?>7R>7_)?+JOZK^WG\"J^)HKJQ6GQ?+Y
M\/GTVGC4/AZJ:<TK\/S^7\NN4GVUU\O@OK.GR>._DTB^G5SKTV^G-O:GI?\
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MMS?[>_B2]_'?P:CX[WY\6O\ 3^+_ $]X,=_I<\.Y_P"$_P"D;[?^[M%_?/\
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&=>Z][__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g476668g00y12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00y12.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 'L L0,!$0 "$0$#$0'_Q  >  $  04  P$             " ,$!08'
M 0()"O_$ $H0   & @$! @@*!P4&!P    $" P0%!@ '"!$2$Q05%A@A5EC7
M"1DB(S$X09>8UA=XE:>VM]0D,C5"<R4V4G>UTS-#1%%457;_Q  7 0$! 0$
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MQ5(L9R546385"N#* J9<I^Z[0+&5*50RH"!Q4*!Q,)@ < 6(BB" EC(\H@!
M 2LFP" )D*F0 Z)!T A"E(0 ]!2%*4.@   'DL5%E[/9C6!>R?O"]EFW#LG[
M3<_;+T3#H?M-&ANT'0>TU;CUZHIB4+M)))!)-%!)-%%(H$222(5-),A0Z%(F
MF0"E(4H>@"E   /0 8$=.4=PE8;6#RATMZ9OMG>"SC3VIB(=E1VQM5NBY!&0
MO!VXF(*L)J>J(V#:EG %$CJP-/>Q[(ZDP_BVCHL=K9=RJ];AZ=6J[4*\T*P@
M*K!1%;@V)!$2,H>#CV\9&-""/I$K9DU01*(^D0( X3FSN P&!%3C&\)227KC
M9+"#2=TG89%Q3VAQ!,DQH.]ST[/:9FH1(QC**0]7B/&.F7ZJ@E6\J]56!P+=
M"-?PZCLLW3=,=8LGS]I5X19KQ[!TH95RQ9N%3(':F57;(JJ&:J"(G;&.H0QA
M0.(B)T1'NS"(B)1$1P*(PL.*)FPQ,8+<Q5"&;BP:BB8BR)&RQ#)=UW8E5;II
MH*%$H@HB0B1@$A2E +DS)F<QS&:-C&5%L*AC()"906:G>M!.(D$3BU5^<;=H
M1[A3Y:79-Z<"@,1%"(",9'B( 4 $6381 "K Y* #W77H5P ."A] + "H=#@!
ML"HE'L$% 508LT52B82JI-D4U $X& X@<A , G YP,(#U,!C=>O:'J%Y@<&Y
M';%E]?ZT?-*4=!;;>Q79-9:4BE2@L,CM&ULWJ,$^<-"G*X7KM*9MI/8M\<-B
MJ+1&OJ?:IL$E"QIDS%CG;ROT]L?.;XCCA=_\.X?M@O\ V<+\I]GB_P!/H_M[
M4+^ZOZ[L'7UC1H.ZJ$A(MZ9<UX]67A)*%EU&:\]KS8M>;O8Q6UZYM"T;'+R4
M8C)1LQ"S$=%6BJR\1/Q3=RH2)VO_ +2:,)1^142]L,;K3<$&KI'<S]0S..IU
MGD2.JML!VW2%1P[TGL@[2,K^TXXZ2:KXL.S1A]F0<5W#R]ZYIBCI!L<4OBV.
MVN';"92.PA@,!@,#@6Q>0U2IT^KKNIQ\KMO=!VS9RVU%KT6<C88QN_ 183>P
MY=PX0K>IZ@N0BRZ5HV%*03673:.X^HM[3918UY\6GU&,^UGZJM]5:ELK&SO]
MR;FEXFT;IG(=:OLT*^+XU"U#27CIC).=;:P3E$6L@Z:/Y&-C)&_;"EF$;9]I
MST3$R,E%UBJUVAZ]HXG".7?.?;-YF0N$,!@,#B6X-0+; 4KEPIUD'7VX]>FD
MEM>;"3CAF&K5M,"P-8J5=:\5]%>6>L+J$5%)7"H*2D6Y5<Q4'9ZQ-UB]5>IV
MN#'9J],Y%,23\3K3><$32.WI-P6-AHB:DQ?:ZV;( 03=[I39[AE$PU[,Z*FY
M<ITM^VK>VXIBV5D+%KJ)BCL).0'7\)*X# 8# 8'"-D\@Z70IP*%#-9C:&XW;
M-![%:;UPDSFKN9H\,8C*9M)W#QE7M:4]PH14A;QLN;J=4661/'1\I(3:S*)>
M%B*Y1C/+^Y1:Q>L-46PUN6W7N^1AIS;KR(>0%;K]:7?N]?:4ILHX9/9*F4%>
M4:Q[^?F)MU'1B^P-GRL3"S5[=Q,4BU@*A5(B$J,6)R_OOYFV4B\(8&LW"E4[
M8==DJA?JI7+M5)A(J,M6;;"1MB@)-(BA54TW\1+MG;!T5-8A%DP7;G[M4A%2
M=DY"F .!DXY3]-^5I#?&U-;LD1[QM1[:_;;PUD98  B:)XS: 2VR8.%;(@"#
M*LZZVS0*\P1(FDSCD$TR$ M<8KG?X^YB58%>9E>^;%CQCV[U_P#6!*[4XZ=W
MU'K_ (;XFY2=]V0Z%_Q5OVQ 3_(Z]V LSB-_#2(C=W*N9V!==:M>/>@B6&B0
M-(L4P[5Y5; +!K,;\M;$(5./=EXAFD5G*!Z;*C)$7B&R:!56(MEG8K+@V%F,
M[1Y;N+WF9/=6X5OC'JO[ F!NNU-_=.O^8:WY <:NO9^GL>51>WUZ=XGTZB+,
MYVCS[UHGT#?[IZ=S\B]D69BMT%[2-0IH\>J"L<GI24;R-,?R>^4"@83 X8.-
M^OH=^CV6[^,<)"J585PB.^]W1VZA:XH&K*^G5=;TVM4:NIN7#X8BKP[&&9N)
M)Z8%'\L^(R11&0F))8/")28?&<2<FZ,=T_=N'"AU3$;I@,!@,!@,#7[54JK>
MJ_*5*[5JOW&JSC8S*:K-IAHZP5^79F,4YFLI#2S9W'/VQCD(84';95(3%*82
M]2@(!'PG&N1IO0VC=W[5U0S2Z'0H\K),]Q:M,H3Y#=J6M[5;V.VU:OM$.B#2
MKZIV'K.":I)I%;LTBD[)BURC7^6;Q57 W,RN_(%'C)M_M?\ G^$[4XY"D ^D
M.K8&?*4'(E#H41!TT!0>IP*D'S0"S.-I\-'-N_E639B6J#<>M!C9EJ*OL$CQ
M/E5L T $*WGVU<.@=XIQ#2D@DA?.2* @6'.W%J4RGA?>=$1+2*5K/.G+]Y-X
M%_S+G/[*%3XQZOZ^CQV.P=J;W['7_-Y+AK+CEWG8^GL>6"7>?W>\2_O82S.?
MJGYE2/H;95SZ_IDY'[ FV"WH?4K2C!OQXI#H"=#)*)35<D[+O^/5*;KWJ;#?
MZ$>[3Z(NX]9/M@<5PC>W]='9]?:QUYJB#-6];4RN4F%6>+R;QG7HMK'#*2[O
MLB^G)MRBF#N<GY(Y 6E)Z8</IB4<"9S(/7+@YU3$F:MZP& P& P&!&.@_6PY
M(_\ *WC3_P!0WU@2<P& P& P& P& P& P&!&%7ZY[+]6&3_FM$X6Z=8[<23V
M$,!@,!@,!@,!@0FD-B1NHN3^Z)BX5+<CJ%NFL=#H5N;H.@-Z;;A'[JKR6Y"S
M[%68U1KJZQD;(1GCR(47CY1TR>BC(-G"3=1!3O +2N&\1WEOWG;:K]5.3?X*
M.9?N%P4G+>/)YVVJ_53DW^"CF7[A<%)RWCR>=MJOU4Y-_@HYE^X7!2<MX\GG
M;:K]5.3?X*.9?N%P4G+>/)YVVJ_53DW^"CF7[A<%)RWCRHN>7^I&;=P[=5KD
MP@V:HJN7"ZO"KF45-%! AE5E5##H7H4B:93'.8?0!2B(_1@I.6\>5E"\T-+6
M.&B;# PG)&6@YZ,83,-*L>%O,A=E)Q4HU2?1T@S7)H82+-7K-=%RW5((E414
M(<HB!@P4G+>/+)^=MJOU4Y-_@HYE^X7!2<MX\GG;:K]5.3?X*.9?N%P4G+>/
M)YVVJ_53DW^"CF7[A<%)RWCR>=MJOU4Y-_@HYE^X7!2<MX\GG;:K]5.3?X*.
M9?N%P4G+>/+3]?7%KM+E*YN]9JVU8VJPN@5JJ]FMB:5W!J!JI8'^Q&4NVBXP
MNVJ-25YMQXM:+NW!H5&029IE3!XH@== J@Y1=SB^)Y5PU3+PA@,!@,!@,!@,
M!@,!@,!@,#6+M_N9;O\ \Q/_ /2G>!S+B]]6?CM_R+U)_ %?P.Z8# 8# 8#
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MVYH)NX!H@_TNO'&N+AG99A$)H) NOVP0R3>;BHEU&HM"7&7%Q//#03B0<PD
M6.C&9IBPC(.'3069\LN?CVQU/5*.YRE='W M5E72U;KHG1JA5O$Z5L-.7=2R
MDC1>F-(*0R5>6H;!BL]*U4>.6,E('CF+EXZ2$CL8        !T  ]   ?0 !
M]@!@,",=4^N9OO\ 5CXC_P U>;.2^=([\2W1K/;A2<RH8# 8# 8# 8# 8# 8
M# C#M/ZRG%3_ $]Z_P #1.%NG6.W$D]A# 8# 8# 8# C'5/KF;[_ %8^(_\
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.._A][,,& P& P& P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g476668g00y13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g00y13.jpg
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M 0$! 0$! ?_  !$( (X 20,!$0 "$0$#$0'_Q  >  $  @$% 0$
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M)1#JW<:&OT^6#3H*LY4ZK3]YEZS"5EO.J;&W%ZE+?KY_OG6^YO"*O]+F</\
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&'J%PYO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g476668g04j81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g04j81.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[18V4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !8< @   @  ' )0  I3=7)A:B!3;VYI.$))300E       0;P'\W+,%
M-//50I_5\T2A)CA"24T$.@     !'@   !     !       +<')I;G1/=71P
M=70    &     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$58
M5     @ 0P!) $4 ( !2 $< 0@       $EN=&5E;G5M     $EN=&4
M04-L<@    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    & $$ 4 !$ "T ,@      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64LX0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M     0 ".$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -!    !@              ]P   <8    & &0 <P!P #$
M,@ Y     0                         !              '&    ]P
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    ]P
M  !29VAT;&]N9P   <8    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   /<     4F=H=&QO;F<   '&
M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%
M6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-
M3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N
M=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y
M<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T
M<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U
M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    &
M.$))300,      NL     0   &P    [   !1   2JP   N0 !@  ?_8_^T
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M%I\A/'CB1FJ]/F''^]_>9<N'F3AQ"/%QQX^/UZZR]/JXG!_;?6?^YUW^</\
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MT]/YGVC]"'I&ST>F1^PH^VOV_9=\3Z;/Z%N]WV[]_P!3_ ?9T'%]/]C=0_\
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MW_\ UF?^\_\ HW_M/^C_ .V7_?$K'8(N/8?AV?_9.$))300A      !7
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #$    ! #A"24T$
M(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!
M.P "    "P   +&':0 $     0   +P   #H   !+     $   $L     4%D
M;V)E(%!H;W1O<VAO<" R,BXQ("A7:6YD;W=S*0 R,#(T.C V.C$Y(# P.C$W
M.C4W %-U<F%J(%-O;FD   .@ 0 #     ?__  "@ @ $     0   <:@ P $
M     0   /<         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%.17AI
M9@  34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (
M   +    L8=I  0    !    O    .@   $L     0   2P    !061O8F4@
M4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I #(P,C0Z,#8Z,3D@,# Z,3<Z-3<
M4W5R86H@4V]N:0   Z !  ,    !__\  * "  0    !   !QJ #  0    !
M    ]P         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M*"@H*"@H*/_  !$( %( EP,!(@ "$0$#$0'_Q  <  $  @,! 0$
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MXX//G3'+<94-D6PTVAIM+;20A"1@) X"E86G[DB\6:'<6D*;1(;#@2KF,TK
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MI.YDP1BTG^FVZ]MK4]FW2[A";NBTC^[=,-[)'(#G7IF^VIZX]7LW&(Y.RH=
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%2E* _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g476668g19a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g19a08.jpg
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M%S)A<2,V-X&1&$)25G-T@[,()#-B@J&QLG)UP24T0Y+A)D5&4V.$HL+P_\0
M&0$! 0$! 0$               $# @0%_\0 +1$! 0 ! @4# 0<%
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MX[N+EL8EFWQ,R8=NFLHZ57JIDNALI4<;D9!R![<>S)ZT<6W1$I+,B-"P9DF
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M5<==R@QI2XZBMDO-A103SQGEFM#EALR94V<Y;H:9$ILHDOEM(4XC&"%'VC
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MFFS3Y#4+U=,A]M3!0G&-1.%*V!S@;>W(2R3:K?*B2XLF%'=C2SJD-+;!2Z<
M94/:< ;_ ("M9M5J%M%G,2)YD4'$30-)2""3I_,@Y]Y]]+.&KH_-O%QC"4BX
M6YN/'D,3$!(RIS7J;.G8X"$*]^'!GV&H YQ:I5SMG$'G#*IJK-+#\;"<PO\
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M:]PQ=&I<F+;YTY:6XRTH;4M(BN$(7J3G)<0<#/M'MQ@)C&L=KC/H>C0(S3J
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MLS%R;F>9W$]$^AW0'^;.O7L,GEG W-!.[APY'G3WI+TB5T;Z4H>C92IMP $
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M2BL]&2, YU<LC!K?PQPE*LLRU*<N;4F-;8+MO81YL4++2E-E.I6L@J2&DC(
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M6]Z[:%Z4H;=*"5 C*0DX"E' !S[*B,2P2K;Q$S%@1<PH:HJ&42(CB@ZEII*
M[TR7 @* *AZR"KU1L?5PYM_"$^VRF9,"\M(>U24OZX94E;;TA3WJC7ZJTE1
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MJDJ"FUL[*3IQG((4"",[4H:X'FL1(K<:]H:=CQ%10XF*1JR^ATD_I,@$(TD
M@X42"#BNBV\&R(+L52;C'*6'IKR4)B%(_P!8458^_L$DG\Q@;<Z#KC<9VQ*
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M0>G=9U:VT^M][U%XS@'2<'EG:CBJ([!8F1X\I^,\VRXEQ&C2 XDJ 4HJ 3@
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0Z/!6V@#9Q)]BS[J*+'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g476668g72a58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g72a58.jpg
M_]C_X1VO17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@ ,(7@   G$  PA>
M "<0061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C0Z,#8Z,C4@
M,3<Z-3 Z-3@ <G(S.3$S,S8      Z !  ,    !__\  * "  0    !   "
M+J #  0    !   "#          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M]+9,8<9KCECZ\4)<!_N^ES>@]/ZDSJ--MQ%]-5A98VBUK7-)K?L86A]+N_\
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M'%N9]H<V75"YN@)#@_C:W^9V;_\ K?\ A??F=6Z[@T7Y&%DXA?>RXD%[*[6
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M:*R][K Q@ !WG?M=^E]_\A.G#C %U1O:UF(Q!/$>'3M:'I6TOIW!KHL</UR
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!SX           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 3X    !  $!/@    $  3A"24T$)@      #@
M   _@   .$))30/R       *  #_______\  #A"24T$#0      !    %HX
M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      S\    &              (,   "+@    4 <P!P #, ,  T
M 0                         !              (N   "#
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "#     !29VAT
M;&]N9P   BX    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#T$CI>+TP9V:QC:V5A]MI9N.OYWM:Y[W.<
MY5V]9^J#FDMR,5Q##:6-@OVM8Z]_Z%H]7V4L=8]FS>C4=8PZ*::+3%@; :7,
M!):W<[8UUFYVUK?];%<;D;VAS<6QS7B08KU!'_&))<UW6?J<P2[*P@/'<R/'
ME6LJCIS::;FUU"IUE9WAH@M=Y_NN5CUC_P!P[/NK_P#2J%E7V$4_J]K8M9'T
M/_2J2',S'7#))P&=,?B[0&LO%C+-WY[W6ULL9L_<J]+_ *ZFK?DN%6ZKI>[>
M!D-:;##9=O\ 1?Z7OM]/TOT;ZV(K?5KRC0,W*^T/:2*7&ASH)]3=L<]S?\%8
MVOV?S7J*GU/J. VRRC)9MR&9)-9N!(!<VMT4FBZMWK.]NRQK_P!&@2!NNC&4
MC409==-6^W[(W'Q?MC<9N47M&1Z+2*R8=N]/U!O]/^NJMS\P7V^A7TJS'+OT
M(?ZE;PS_ (5S:[FV/=_)]/8A](ZG@/-=&,Q[LA]X+PPN+?:UVUOZU<_TW>DK
ME+,BK(]$9>6^V ?3=Z+G0',M=,NV>[^;_P"*L_TB0(.RI1E$U(&/75"QV27,
M_1]++=P%@!LD#8SU=A]/](]F1Z_M_1_H?2_/1JOL[:,3[>W%;E&W].,=I%1&
MVW;M]4;]OT/I?GK-ZIUSI3'G%R&.;EX]]NUUC'. WN]3;19CVU[;G?H?TN[]
M&I=%ZYTNZS&Q,-MC[W7.>_9O+#LKL VNRKG[/T.SV[TK"SW(77$+NJOJRZP*
MJLEMN"_)L9<-I9BUX[ZJ@PM^E5DLW>M?N?\ I?\ @_3_ $:J,MOL):69['FM
MK&V>CBEH>ZW]*]U5;-GJXE6]EOYEN/\ S?Z:VI;=%635<:ADYEEC6->:WFES
MMNYOO,O_ ,)Z=E7M_,_[<?E=3Z]TCU/LU['#+Q[KF@O8XD![G.L9191;6YEK
MOT/Z7\Q%,I1C\Q \R[+V]+K.*QQJ>X.BUY8UNZ*[9<YK&M9[GC=[5C]9]/'R
M_6Q;LNRFWW"K#HHM946BL>D67-:_;?L?;_V]_-^NB=%ZYTV]V/AX3;'9!LLM
M?M#MI(KLK]OVJU[F>STOT6]:./7D59!K;DY=KZQ6Y]3S2YVS<=IL]_\ A_2N
MKW-;6DH2!U!!\G$I]4O]('J!#WEK;+*<1VSU'L.^UX=9NJPV-V?S?_<C_K6Y
M;3@BFFAEK!>6EC\@5L#B?3<WUW5;/1=^FV6[-GI>HL;J77NC[SC7L<W*Q[KF
MDV,>2 ^Q[GLHLQ[J_3L=[/TJ&/K#T9_3C15NW5O]:\D6[)EM(C]-]H_/I_0^
MJA81[D+KB%[;O__0ZDW$7%K+\>HM #J['#U)VM][W.S*G;MGN8QG^"]+^;4V
M9U_J-G-I<PN:"P6P8=M_15$9_O\ 4]3]$_\ XM1=>66%IRJ:B&@"FP@$2UH;
MO=NW.9^=^9_W&5PY_2F[@YK&%A]P=D%I!:[T@?<?])[*_P#P-)+,]4Z2" ;+
M))( ^V-Y;],3]LV^U.;L?*KJMQJ\BVOU6C>W(#A(_-'ZV?<B5,JOJ;91B>K4
M9V/;?+>==ON_>36X[F"L-PWU@W-=#;R 23JZ _Z22FLZ^H]6%,D%HV'&-OZS
MZA;ZNUMYR_H^E^D]-JP.M=.ZE9U*^VDBBFVX,K;D7,DN#*V.K][[?>YW_"+H
M7,R/VBVMH<)&]V/N)<6P6_TD.]ON9N][U0S*<[[6_8XT,LO+6L?:YVX[&2S=
M+MF[\YR9D-1W$=?TMDQAQFN.6/KQ0EP'^[Z7-Z#T_J3.HTVW$7TU6%EC:+6M
M<TFM^QA:'TN[_P#;:Z'UP.J^@?4U86C$]7]8W0VS?ZOVK^9]-9W2VY=MS'FT
MYE;;6@AMKF.;+';6N!]/=^]6]:;1:>H.JV/<&MW?9O4.YI(;^D^T;OHN_K_R
M/ZBQG3<'7]%4H<)KC.3KQ2EQG^ZX^?TW%?DBRS&8U]^0]I.0\.=9[PP4UGU_
MY[\U2Z/T_&9?3=7CMML9:6>IBN%9$U/FMS?M7M?_ .BU<R'^C97Z@-+;+[6
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MF[<EU;6?9\\6V#TV6&[':\$OKLL]HH]UN-Z?I>RF[]&^^I=!<.FM.*T4[HL
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M,Z/M3!6\#TGNV?S#=U/^$W_V%9KIK^VN!QZG-=(;4X 4LC:'/GTO=N=7]/\
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M &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ',
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M P,# P,# P,# P/_P  4" (, BX$ 1$  A$! Q$!!!$ _]T ! !&_\0!H@
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M?L_V>F_&L_\ E"/^]G_-TM/]''R2_P"\F,)_Z(C ?_9E[]_I:^(7_>'^Z/\
MTIK<?_VN/?M,O^_1^S_9Z]XUG_RA'_>S_FZ]_HX^27_>3&$_]$1@/_LR]^_T
MM?$+_O#_ '1_Z4UN/_[7'OVF7_?H_9_L]>\:S_Y0C_O9_P W7O\ 1Q\DO^\F
M,)_Z(C ?_9E[]_I:^(7_ 'A_NC_TIK<?_P!KCW[3+_OT?L_V>O>-9_\ *$?]
M[/\ FZ]_HX^27_>3&$_]$1@/_LR]^_TM?$+_ +P_W1_Z4UN/_P"UQ[]IE_WZ
M/V?[/7O&L_\ E"/^]G_-U[_1Q\DO^\F,)_Z(C ?_ &9>_?Z6OB%_WA_NC_TI
MK<?_ -KCW[3+_OT?L_V>O>-9_P#*$?\ >S_FZ]_HX^27_>3&$_\ 1$8#_P"S
M+WW_ *6OB%_WA]NCZ_7_ &9O<GTXX_YEQ[]HF_W\/]Y_V>M>+9_\H9_WL_\
M0/7)NN?D@0H'R5PBD* Q_P!!6 .IA>[6.\O3>XX_%O?7^EKXA?\ >'^Z/_2F
MMQ__ &N/?M,O^_1^S_9ZWXUG_P H1_WL_P";KC_HX^27_>3&$_\ 1$8#_P"S
M+W[_ $M?$+_O#_='_I36X_\ [7'OVF7_ 'Z/V?[/7O&L_P#E"/\ O9_S=>_T
M<?)+_O)C"?\ HB,!_P#9E[]_I:^(7_>'^Z/_ $IK<?\ ]KCW[3+_ +]'[/\
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M_9E[]_I:^(7_ 'A]N@<?]Y-;C_V_/7'Y]^T2_P"_1^S_ &>M"6S\[,_[V?\
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M*:W'_P#:X]^TR_[]'[/]GKWC6?\ RA'_ 'L_YNO?Z./DE_WDQA/_ $1& _\
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M%_WA_NC_ -*:W'_]KCW;3+_OT?L_V>J>-9_\H1_WL_YNE9_HX^27_>3&$_\
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M )NLO^CCY)?]Y,83_P!$1@/_ +,O?O\ 2U\0O^\/]T?^E-;C_P#M<>_:9?\
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M<F\-IMCH=T;<ADS/:%$LV?VI/F*1<E1+>>B:IB6=8RZW#NKJNBZ# [FW37_
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M-9T1N_MS$?(G!;N^+6U>SS_+PZ![!W;U;B]O?%?;NU.Q.ZMR[NK<-V]44/\
MIDQ63Z8Z>WCL39^%@R>:HZ7$OFYZ5Y(J*D#U#GW4B58S&0Y3Q6%>XD+Y<,D>
M0\NKQE3()JKXAC!([!6I-:5%!04Q2M.D=03_ "CV5U]E/C[O#K;Y3]@]:Y#^
M8O\ (?8&T>W]X;U^4=7N;JWXY[;VLNYNDJ_-93H_-X?Y =Q];[YWAD9MNX'(
MU>:7#TLAII<G6M#21 B?!#\2VWE_,#VKUP?AUUAU3G]^9_=6Q/DM]W\;^R</
MA<7)\?\  Y>#J:FZ+[-^ZWS5]4;VWMEYS@,UL-(\CBMP.T;1Z:9(8Z_KZ;5F
M$C.!E>X>?&HQ6G$'RZNH4+<%!& <U)7^'@5/EZ4/KY]!5BF^<>)ZY_E^=@=B
MR_,'MKMC!=:;*V5VS\4*VG[]ZSS6Y,Y5=^SXFI[SJ._.I7H.M*;N;KG9%!%-
MN+ ]CU=3M_/;2$QCE2HK'J*D!.S<M\28_P"7=B:;K[KSI+>6#K/BKUU35N5A
M[*^.FSNT^L_EU#GL3)OW=N0V[F<?%\K-[[ZJ*[[FCDH*>HEVI5[8J8Y*>.-(
M P<03_5'4S ZSY$@KY"OP@?SKTVW@FS*JJE--:U4$-C_ &U:^7 CHPO3^W?F
M%D?G=N^K[.[/[LV%D,+\P^ULMA,1/U?W]OGJ'M+X:/LK,0=6[!QVZ,'FO]E*
MV%M88^JH*]LG4T<.]Z#>>/FIYWF_B#B3%\ ^U>MMK]5?RM*#<?:&P]MUFROY
MH/9>]-VT.<WI@\-4[.VE5[#ZFI:;>&Y:>NKX)-O[;K*BAFCCR%2(J>1X74.2
MC >N4<R7A5#0P  TXFIZ;MO[.U[P/U#YCT/^JO2-_F"]&]O;X["_FX5VT.F.
MP]YTG:'\J3J#K7KZKV]LG*9JF[(W[BMZ_)NKR/7FT*BEI94W+NS&TNX:*6;&
MP%YXTKX&*VE4DFOS1WKM'<7P^^$6 P6\MM[@S>W.R/G769[!8C<&/RF6V]2;
MF[RQ&2V]69G&4E3-58JGW)CT:IHGF1%JX5,D991?V_;*PGN"5(4JG_'>D\Y'
M@1 4KJ;S^?1U?ASUWOC:OS8_F$;NW'L+=&V=L[YVS\%J?:.ZLSM^LQ>$WG-L
MWH/,83=,&WLK/#'3YJ7:66E6CKUB9S1U#"-]+&WNSVM['Z:[/W=\$=V[\W#\
M+LKU]3?!G([3Z7H=P1]2T>(V7\W]N]/9"AV[M/OS;,7^_LVITW@-_&+^%T.?
M1=IQ9F8S!2LM2[) LB+<A5DU^)4\<IJ_#Y$T],TZ7:U<P.Q33I[:Z?C]*>2C
MR!Q7Y]5KT'5??W5NT/GAMWKK;7SJQ&_<M_,&Q^]^U,EMJL[:KLKOSX0;K[XP
M>:W9NCXJ;AR-9-L?/=O9;JJ2LIZV7;+KO*/'TAI$TU<./7W57_,S;JU][=$G
M;LG3$W? Z)PH^6LWQW&TQTY)W3_>G='VQP/]P O7[;E&P_X4,\<$/X8<F'\?
M[GE]K;/7IDKJ\/5VZN-*?//'A7RZ17I0M&:#QM/=2E*U^6.'5I?\M]>W!LSO
ML[S3O2+IAOD/N0_$R#Y-?WE_TY0]%?W,V**A-SC?+-V,FV/]*PW+_=A=S'^.
MKM[[03_L_;CW6?[5](NK&O?O?NO=>]F@^8?_ #.^7_Q$_P =?_@>>KO;4/\
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M%L#%[ME;PT-4^N25:1VJ'MJ(3VQ61H22R&M*FK<03Z<:=7E$5V!&LO>&%:T
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M7W2>:WEC]UU&0[#3;==UUM7,U>-V545E%29.OIC/Y8H=8=A[;>]5'93$=*D
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M?^[-#19*ODJ),C/2SP00S13-%.OM/]:**62G>5/G2@KBG'I6+*,^)20GLJO
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MG]\!@^V]]5NW)5JTQN GKZA4=4D"221H^VNH5"EF(J*\#@>I]!]O7A8W!9E
M6H-/B&216@-<GISW9_,#^+&Q<7M3+;MWQN7 Q[IZ^KNVZG'9'JCMFGW!L#J?
M%9K^[>7[/[AVT^R1G^FM@8G<5Z*HRNYZ;%4<<T<IUF.GJ)(DM4_ [Y-4?7G7
M?8U9LO"T=-VUD-K4/6^R*W?VPZ+MS>46]MVS;#VGE<#U'5[CA["R&$S>\::3
M'QU4>/:*.9"TI2.SG8N82S)JR!DT-!05X\.J_23: ]!DC%1JR:#''CTIZ;YJ
M_'"LWIVELFEWSD*B;I/^]4';.\(-C;^EZIZ_S&QMFXOL7>.V=T]O1[8;K+$;
MKVWL+.467J<;-E5JUH:J-U1CJ54!\AOC#VI\7]Q8W:O;"['ASN2CRP:@V;V7
ML'L2;#9' 9)\-G\!NB/8^XL]+M7<6%RD;0ST.16FJ+C4BNGJ]VBFCF!:.M/L
M(_P\?RZI- \!4.1GT(/^#I==$?(CK#Y([5.]^J*O=N2VM+#AZ_%YC<_6_8G7
M=+N/!;DQ--G]L;KVD>P=K[9;=>T=S8*LAJZ')XX5-'-#(!Y X9%+W[=Z9Z&_
MW[W[KW7O9P/C7MG<F\.J?E_MW:.W<]NO<%;T_L.2CP6VL/D<]F:J*D^0'4U3
M62T^+Q5-5ULT-)31M)*ZH5CC4LQ %_;$I > L0!J/^ ]*[96>.[5%)8H,#)^
M)>@![BSN#VQO;H+.;ES6(V[A:7L#=,%1E\[DZ'#XR&>LZFW_ $]'!)7Y&>FI
M5J*J9M,<>K6YOI!L;!7_ ++5\C?^? =V?^BJWU_]8?;GB1_[\7]HZ;^FN?\
ME'?_ 'D_YNE?_INZ8_Y^[UA_Z'VU/_KM[]_LM7R-_P"? =V?^BJWU_\ 6'W[
MQ(_]^+^T=>^FN?\ E'?_ 'D_YNO?Z;NF/^?N]8?^A]M3_P"NWOW^RU?(W_GP
M'=G_ **K?7_UA]^\2/\ WXO[1U[Z:Y_Y1W_WD_YNO?Z;NF/^?N]8?^A]M3_Z
M[>_?[+5\C?\ GP'=G_HJM]?_ %A]^\2/_?B_M'7OIKG_ )1W_P!Y/^;KW^F[
MIC_G[O6'_H?;4_\ KM[]_LM7R-_Y\#W9_P"BKWU_]8??O$C_ -^+^T=>^FN?
M^4=_]Y/^;KW^F[IC_G[O6'_H?;4_^NWOW^RU?(W_ )\#W9_Z*O?7_P!8??O$
MC_WXO[1U[Z:Y_P"4=_\ >3_FZ]_INZ8_Y^[UA_Z'VU/_ *[>^*_&SY%OJT]!
M]U-I8HVGJS?+:7 #%6M@C9@&!M];'WKQ8O\ ?B_M'6OIKC_?#_[R?\W79[LZ
M:6VKMOK%=2AEOOW:HU*20&%\KRI(//\ A[Y?[+5\C?\ GP/=G_HJ]]?_ %A]
M[\2/_?B_M'6_IKG_ )1W_P!Y/^;KK_3=TQ_S]WK#_P!#[:G_ -=O?O\ 9:OD
M;_SX'NS_ -%7OK_ZP^_>)'_OQ?VCKWTUS_RCO_O)_P W7O\ 3=TQ_P _=ZP_
M]#[:G_UV]^_V6KY&_P#/@.[/_15;Z_\ K#[]XD?^_%_:.O?37/\ RCO_ +R?
M\W7O]-W3'_/W>L/_ $/MJ?\ UV]^_P!EJ^1O_/@.[/\ T56^O_K#[]XD?^_%
M_:.O?37/_*._^\G_ #=>_P!-W3'_ #]WK#_T/MJ?_7;W[_9:OD;_ ,^ [L_]
M%5OK_P"L/OWB1_[\7]HZ]]-<_P#*._\ O)_S=>_TW=,?\_=ZP_\ 0^VI_P#7
M;V87XR=!=\X/L?.5F7Z.[CQ]++TO\A:".>JZOWQ#$];D.C.P:/'T:.^""M55
M]=/'!!&/5-/*D: NZJ6II(R@'B+\2^8]1T_;V\ZR,6A<#0W$'^$] AW]V[U-
MDMH[4CH.U.M*N2E[JZ#R-1'#OW:;/'0T/<NR*BMJBO\ %PQAI*9&ED(OHC1F
M-E4D%Z_V6KY&?\^![L_!_P"95;Z_/_D"]N^)'_OQ?VCICZ:Y_P"4=_\ >3_F
MZ&__ $W=,?\ /W>L/_0^VI_]=O?O]EJ^1O\ SX#NS_T56^O_ *P^_>)'_OQ?
MVCKWTUS_ ,H[_P"\G_-U[_3=TQ_S]WK#_P!#[:G_ -=O?O\ 9:OD;_SX#NS_
M -%5OK_ZP^_>)'_OQ?VCKWTUS_RCO_O)_P W7O\ 3=TQ_P _=ZP_]#[:G_UV
M]^_V6KY&_P#/@>[/_15[Z_\ K#[]XD?^_%_:.O?37/\ RCO_ +R?\W7O]-W3
M'_/W>L/_ $/MJ?\ UV]^_P!EJ^1H^G0/=G_HJ]]?_6'W[Q(_]^+^T=>^FN?^
M4=_]Y/\ FZ]_INZ8_P"?N]8?^A]M3_Z[>_?[+5\C?^? ]V?^BKWU_P#6'W[Q
M(_\ ?B_M'7OIKG_E'?\ WD_YNO?Z;NF/^?N]8?\ H?;4_P#KM[XCXU_(LLRC
MH+NHL@4NHZKWT64-?26'\"NH;2;7^MO>O%BX>(M?M'6OI[@D@0/7_2G_ #==
M_P"FSIFP/^ESK&QO8_W]VK8VM>Q_BW-KC_;^^7^RU?(W_GP'=G_HJM]?_6'W
MOQ(_]^+^T=;^FN?^4=_]Y/\ FZZ_TW=,?\_=ZP_]#[:G_P!=O?O]EJ^1O_/@
M>[/_ $5>^O\ ZP^_>)'_ +\7]HZ]]-<_\H[_ .\G_-U[_3=TQ_S]WK#_ -#[
M:G_UV]^_V6KY&_\ /@.[/_15;Z_^L/OWB1_[\7]HZ]]-<_\ *._^\G_-U[_3
M=TQ_S]WK#_T/MJ?_ %V]^_V6KY&_\^ [L_\ 15;Z_P#K#[]XD?\ OQ?VCKWT
MUS_RCO\ [R?\W7O]-W3'_/W>L/\ T/MJ?_7;W[_9:OD;_P ^ [L_]%5OK_ZP
M^_>)'_OQ?VCKWTUS_P H[_[R?\W7O]-W3'_/W>L/_0^VI_\ 7;V(G4/QV^06
M/[9ZNKZ[HGN6DHJ+L79%55U51U?O>&GIJ:#<V,EFGFEDP:I'%%&I9F)  'NK
MR1E''B+P/F.G(;>X$T1,#@:A^$^OV=(WL;N7I^LZ]WW24O;'6<]35;,W134\
M,>_=JL\T\^$KHXHD'\6Y>21@!_B?;W\A/CQ\@,KWYWAE,9T7W'D,;DNX.S*[
M'U]%UCO:JHZVCJMZYN>FJJ2IAPCPU%//"X9'1BK*00;>ZQ21".,>(M0H\QZ=
M>FMYVFF*PN06/ 'UZ9.E>XNHL?TWU+05W:O6M)6T766PZ2LI:C?>UHIZ:JIM
MJXJ&HIYHVRH:.:&5"K*>001["#_9:OD;_P ^ [L_]%5OK_ZP^W/$C_WXO[1T
MW]-<_P#*._\ O)_S=";_ *;NF/\ G[O6'_H?;4_^NWOW^RU?(W_GP'=G_HJM
M]?\ UA]^\2/_ 'XO[1U[Z:Y_Y1W_ -Y/^;KW^F[IC_G[O6'_ *'VU/\ Z[>S
MX_$S?/R7^*/6'<%#L[XY_(J#N/<7:?QB[1ZKW;1=8[M_NUMO)=#;MWAN#-4>
M[*"7#1UV6Q^Z,=N447VT=X9H&FCG!1Q[2SQQS/&6D7PPK BO&M.'V=*85N(8
MW MY/$U CM-,>O1$/EGTST+\M.SNH*W??=?2]9TMM[J3Y5=1=N["J][X1<YO
M7 _(K:.Q-MT$FW,Q2YI8,#6[7J]HM6K5%?N8*G[>:F>.6+5[/5NWY';&WKV?
MVG?X&?-CKGH'M'X.;8^)Z;&V!L43[GV%E:+N"+MS.U^TJO/X";#2;0@KVFI<
M=#4H:A(64.B@ !A8'5$_QA#*LFJIX'%,_/I0Q9W-;68(8].%SQ)/^']OET1S
M;'Q/[EV=U_U1DIOF[\0.U?D1U7\\MY_+>IWWO^IJ,!M+LK 97HK/= ;<Q^[L
M7L_<J9'&[_\ [L5U)D<K649:CJLI#*X0B5B4IC?E7NG9>3R4W7_\O_Y"OMKI
M_P"(63^)'Q(V1V5L/<&^,'!B^R-\5>>[S[ ^0E12;7VY4[GRW8.W<[EZ%<;A
MEI**"+(>#4(T+OOP-0HUPM6?4U#3@,!<XH:'\NO!W75HLY:!-*@@^9SJ_P %
M!Y5Z6>8^%M!OF@HF["^=752;Q[B^9FVOF/\ +CL3JW/X?KO<-;D>G^N\?M[X
MX]4_'FFJ]U;MIMG;0ZFW9LS:U8:[/29?(9%<1/-+^]6Z:=+=B?([>^]>O\QN
M_$?!_P"0.P/E9N#X:Q?"MJ[9G5.?Q71FV-@#L!16;DV3A9J"NWEA\HW0,4>R
M8:1I98:>GJ)7$S((T][2%4<+XZF'7KH3DFGG_ML]:9WTL4M)%N#'I^$Z:$^7
MF,8'2IZR^)FV>O-Y8C9V0^8W6/8/QHP/S>J/G%2T&^^Q:#+=W[@WI-UF)XMJ
M;QW+0Y/$[1R^'I?E)43]AK41T,+F2*FI3%>-YG%GI_Y?;CZT^+W4/467^)WS
MRW+G>K^@>WNFMP]11;:?&_%GNW(=H97?%90Y_MS;D^T,GNK-4^TX=U4\E/'!
MX)FGQ\062-=3-1[8-,\@FC 9P:_B% .!KY^?5HW:.)5^EFU::$:<$TIGS_V,
M=!+WC\':7MGY5]N=QX7Y&_"G9V%[0[X^/O=6W^\+297Y?]'TO2.UNM,'E=E]
M0;K7=^/VCA8.P#L.LI:BLEUI!CMP5R24M6715+[OD].=R[1^*51VU\1?YB3]
MB?'GIGI#I3/XW;&P,">LMY;:ZXW34Y?=<JTN6VS_ 'IAJ=P8;-5]+3?Y3$L;
MF!I!97#.JLJ&;PYH]+,3FM03P\^J%!(L DMI]2*!A<8_P_RZ,#UKMOO[I#?/
MRU@ZP^3'P/EZS^0O<O>G?.S\ON?<.YV[.V-OCL?KW$X79=#E*6AW#)L[-X3;
MN]-MT-37%5CEJ,<98XP)=+^UE\B/E9VU\I^M/E[UQV3\!>R-H1]M;\V?VKT7
MN;J_I/=V,W/@]];#SE3@MO5'=F2S$=?%NY%Z6R=3@FJ<7#1213!2D1A.A*Q6
MZPO ZW .D$&I]?3TSGKTC33+,LEI(*Y!"FM1P+5^6,?9T@/C-\(MA_$KL;X?
M=@];?.S%[S7IGK#?/2_>&U>U>T-LYO;&[=@]AX'%;FW$>GL?C):"?8F0?O\
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M )1W_P!Y/^;H8?\ 3=TQ_P _=ZP_]#[:G_UV]^_V6KY&_P#/@.[/_15;Z_\
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M[<V+\T-I'N]JFDW@>VZC:^9K,MTAE'V&E=UA+@-W[>DRD,61&>2H%1]H^B%
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MVMV+G]L[P[R[JJ,KFOXICLKV[O':.QNO<1N?(;0H ,=CZJ3'M7RT^IZF>5V
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M^N7OVE?X1U[Q9?\ ?C?M/7O]&/6W_/O=C_\ H)X'_P"H/?O]+G:W_/SNPO\
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M^H/?O]+G:W_/SNPO_0TW)_\ 7+W[2O\ ".O>++_OQOVGKW^C'K;_ )][L?\
M]!/ _P#U![]_I<[6_P"?G=A?^AIN3_ZY>_:5_A'7O%E_WXW[3U[_ $8];?\
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MT!UE55,S#^)>J:IJ9GDD8W9Y'9F)8DEJ%%T?".)_PGI3>.ZS45R!H3S/\"]
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MT8];?\^]V/\ ^@G@?_J#V8+NK>&[CU7\.-TMNK<C;G7JCL]$W&V=RC9Z./\
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M_P"(,^2'_OA.Q?>I_@'^F7_CPZ];?VC?Z1O^.GIG^1?_ !YVS/\ Q.WQY_\
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M?$T]3#E^P\OB<YNB66NK*FGJ\EA-LX?:%!/2T<\TE-CE3!8&EB=8%C61H];
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M$32DAG)(!]@+_K>W.F>AE]FI['_[)&^+O_B2ODY_UKZ.]LI_;S?8O^7I2_\
MN);_ .G?_ G0%;-_YG]WC_X:'2O^]=D^RK>WNDW0Z^[1?A_'L;;OQMWCV%NG
M)="[1%!\H.IMO;CW7WAU >X(LSUW4=>]D9C<>P=MX"DVEN?+2U64FQL53+!3
MSX9ZCP(!D(&4,$<^II@@U? 30&F:C/1E::!;2NS1K1QEEU5%#VC!-3^7V]$'
M^2;[LSG=>"V3M^A[CW')5_'SLG.;>P'4G9Z]6OB=\P[RV/BL)NS.9NIW%A,9
M$U-!7R04U154N:AID:?50S!_'+-[#WO@>F>L>G-^_&#IO9"[/^0_9WR"SE94
M]B=:;1[AS&0P^ [BR.V-A?'.N;>6-W;_  ;'[?ZSBPU974&/EAR.2ESRSRU$
MJ_:M'I%,DDBS2'4H7@:>52V*>?G\NM-(8$CD@B71(6X@-BM-.0< 4X<:],O7
M.WMT]D;][:V3\A^VMS3;LZ6ZUZ.P+0;#WEGNL,#393.]6T6?WQWOC8=O5&W)
M*^LW!V&<O2T-=61O0XZGPIIX8(7^\$HUR[4Z8VGWEW?\5>HJ/K7JSO/<W>^(
MH.N9>V.JL-W=L'<T&\]H;9QT_P 3)=Q9_#[SR/5=3LSM/-5=%#E103+72>*/
M*UU']BDTE-4C11S.28@N:&AQ^+RK4>7[.GJ1)+/#'I24OBJA@:@=E:&E#BOG
MYD4Z"+ [T[HSG3?3WR@[9.]M\=08'I3-5G8>*V!O[(=8[QP4FT=S[@RM/\F8
M<1@J_:V/[,I=U=:82CK9L7'70&FCE>3&4-8*QH$I1RF/K<3D\CBLE *7(XRN
MJ\?7TP>*04]915$E-50"2!Y87$,\3+=&9#;@D<^UX-0".'12002#QZMDH*ZE
MR=#19*AE\]%D*2FKJ.<))'YJ6KA2HIY?'*D<J>2&0&S*K"]B ?:^Z5_YG)U+
M_P")-V'_ .]5BO=9/[-_L/3D']O#_IQ_AZ2/9_\ S+7L/_PQMV_^Z#(>WWY*
M?]E%]^_^)J[4_P#>ZSOO4/\ 91?Z4?X.O3_V\W^G/^'ICZ)_YDATW_XBKKS_
M -Y'$>TLG9FZH^JZGIM:BB_N15]@479DM(<;2')'=>/V[D-K4]0F7,?WT=",
M/DY5:F#^)Y-+D:E!%M"Z_$_%2GY<>J^(WAF+\&JOYTITICL;;IW]'V6::H_O
M;'M"78RU@KJL4G]W9LU#GWIFQHE^Q:H_B=.K"<Q^95N@;22"+/6?RM[%ZUV?
MBMB';_5_8NVMJYO);FZ]HNV^N=O=B'K/<6;^T?-Y38TF<A=L?!F:K'4M35XV
MH^[P]35TL<\E(TI=WHT2LQ:I!/&AI7[>GHKJ2)532C*#4:@#0_*O^ X^70:;
MX^.FP][[JRF]!D]^;*W#N;#XS;V^*WK?>^=V,=_X+"M5_P 'Q^[A@ZB UM1B
MJ?(U-/39" TV5@I:AH4JEB$:I-V=\P.V-EU^[]U4=%L#-=K[OW3N'>K]Y[HV
M3BL]W+M[=&ZZ<T^=S&V-Z5EY<;65 DED@9X9C0U$[STG@F(D&F@1M().@>5<
M?F.MK=RJ7>BF4DG415JGCG_53RZQ[F^-G7&Z<=MC:U7)NG'=:[7VSB-GP]0X
M'<E=A>KLQMS 2Q28C%9_:U#XTR5%2)3Q0O%Y4BJJ:)8*A9H2T; GC.QMS8GK
MK=G5M'44B;0WIN?9^[\[3/CZ66NFS>Q:'=>.V]+39)T-91T\--O.O$L4;!)B
MZ%P3&MG"BEU<_$ 1^W_BNF [!&0?"2#^RM/\/0JU>S<!6[SP>_ZBFF;<VW=N
M;CVKBZM:NI2GAPNZ\AMK*9JGEH5E%'42SUFTJ%DE=&DB$;!" [@\>S.Q-S]M
M[^W7V5O.HI*O=6],Q4YW/5-!04N+HYLC5E3.]/CJ)(Z2CB)7A(U"C\#WY$6-
M51?A'7I)&E=I'^(FIZQ;!V-MSK/9FVM@;1I9Z';.TL3387"4E36U61GI\?2+
MI@BEKJZ6>KJG4'EY'9C^3[&+9G_9)'?7_B:/CM_[S???MIO]R(O]*W^%>G5_
MW&E_TR_Y>@ZW5_V4-TQ_XC;O3_W;]*^RR>W^D_0Y^ST_!;$XBNRWR.RN1GZR
MQ&0VG\:-Q[BVSN[MW:--O;9>RL^.TNI,,F?J<'5;8WFKY&?%YBJQ]+*N+JVC
MDKOT@$L$]P2/" KEZ4&"<'[.EUCIK<%M-1'@L*@'4N>!^SAT4GY;Y*OH\;T;
MCJ6'L+(X_<G?^VL%N#;_ %GN:IVGN7<N%?8W8N3?$'*TFY=H3G%ID<735=3$
M,A3^1*7^W;0QC=^;KZLVYUSW?\EOC+LOK'.;IQO8/QVZCS.\8>I,?-LS8K5_
M5&X,KV7VCUYU#O?&93!==X?N3M+;IH<;/7XU314E+-!2P4$F0^WA:57+1Q3,
M:48TKQR* D<:#_4>E#R1HDUS;JADU*M=(H.TU8*10:B/,?LKT >P\1VI6]D]
M/]#]^[MWWB\!6;*[Z[2PN$E['*;CWF:3L_$XOKWK/>O8.UZC'9S?.6Z@ZNW!
M%69)*2N>.OJZN*:IFKEH?N)GU]Q=(['K=F[J[ VQU[\?NXOD=\8NMM]4>_:W
MI3&=F=<]6[ZI.R.P,379[(=)3XG,8W:.#^1G6&VL/E'K,1AZ^?%M4RS8_'"B
MR/[6J2MJ"$M&KD4K0D4&*_T37B<^O6]<:%)'"1RR1@UTA@#4BNFG;K !P#3R
M%#TWTF,[FW;%NW&;*W+N_NSK'HGY(=B;)KMCP]IU>P]]]C;/JM@[#R5)BJ3M
M^"OQ=3N/,=&]A[DS.-2CRF5H(\B*)(J_(_?8[]ZLKO[8N].LNZNT-A=B8W;>
M'WMMC>V>QVY,=LV#&TNT:?)"MDFD.UZ/#P4F-HMO3I,LE'!## L-.Z)XHBIC
M57&RO&C*3I(\^BZX1XYI4D #AC6G#\J>71^^G][;7['ZLZ_WULJJS5;M3=&T
ML)E<#4[D:N?<3X^>AA$*Y^7)35-=/FHM)2JDEEF:2=6;R27UL$/N_3/0C^S0
M?,/_ )G?+_XB?XZ__ \]7>VH?[/\S_A/2N]_MQ_S33_CB] E\>O^98P_^'WW
M#_[^#??L&MH=C;FV1A.Q-OX*:A3%]I;/@V/NZ*LQM)7R5. IMV;9WM!'0354
M<DF,K8]P;1HI!40E90B,E]+L#=D5BA/%34?LI_EZ3I(R+(J\&%#]E0?\(Z$G
M.[3PNY,AM+*92*HDK-D;ADW1MZ2GK:JD%/F)MNY_:TLM0E-+$E=3OA=S5D1A
MF#Q$R!BNI5(7'4/R"WKT[C=U;:QN*V3O;8>]Y</6;JZX[-VGC]Z;)R^7VY_$
M!MS<2XVM,-7B-RX&/+5<=-D*"HI:M:>KG@9V@FDC:KQ+(5))##@0:'_BNKQ3
MO$&4 ,AX@BH-.'^'RZ178_36T^R\CMW<.0K-S[8WCM&+*4FV]\[%W%7;6W7B
M\7GGQTF?P1R%$S4^3V_G'Q%(]305L-32O-2P3!%GABD1<1?+K?E9O/<&]]Y[
M$Z3[.KLOB-J;>PF'[$ZJV]G=I]<[<V/3O1;2VSUGM>F&.Q&S=L83',M.,;3Q
MFAJHT!J8IY"SM7P5TA59A]AR:^OKTY]6Y=G>-&) %"HH .  Q0#TX>O25_V6
M[9U#M3$;0VINGM#85!C\ON3<&7R6R]_YG%;DWMG]WS/5;FSV^]QSFNR^YL[E
MJ^5Z@ULTHJH)6_8>)515#^+Y!]JG>/;?8&1W(,YO'O#;6\MJ]D9W-8W'5]5F
ML7ORII:K<AIXVITI<35U$M'&('I8XA2QKHA"( HMX::46F%(I^73?CREY9&:
MKN""3\^E54=']:3;5ZSV1!M[^&[6Z?W!L_<NP,/C,ADJ*#"Y/8D4L.VC)+'5
M?<Y*GI$F;R1U3S"I8ZI=;$DI/??9>ZNQJ?8=+N>HHZB'K?8.)ZTVL*3'4F/:
MGVIA,GF\O04]8U*B'(5J5VX*DM42ZI75E4FRJ!94"ZJ>9KU5Y&D$8;\*T'V5
M)_R]*O:FQ]N[*DW5+M^EGIGWGN[)[XSYGK*JL%3N++TN/HZZJ@%3+**."2#%
MP@0Q:8D*DA06-QO^)?\ Q>N]_P#Q5'Y$?^\#6>VYN$?^G7_#T[;<9O\ FFW^
M#H'?DK_Q:NG/_%D.C_\ WLJ;V5'V]TFZ,A[-9\'\#A-S?*OIO";CQ>W\SAJO
M/Y)ZNBW9C(,UM<-1;:S=?2U^X<14TU;!DL-B:RECJZF!H)Q)% P\<E]#,7+%
M8)"":_[/3]M3QH]5*?/(X>8Z+!\T-PYS:OQ=[DS^V\SFL!F\=M>)Z'*[;R$F
M*W!3M/F,72S1X7)134TE#E*RFG>""5982DD@(DC_ %J=L9?IW-8#L3M7KC;7
M37;O?WQZ^*U)F=TY?:?44N&ZIS_8&X>^\)MG(=L8OJ#*;?V[@]S5_2W46Y%2
MMR=3@*7$396>+)344R4!J:E@B12B,Q$3/3CFFFM*_,CUK3'GTO+1UDDB$;S1
MQY(7M)U :@I KI'F12N:8Z+)-0=J8+<VR>O][[H[.ZUZ5[M^21QNUL=G^QX,
MGV'AMF[>Z:R^X:#J^M[*I,IF,[MRA[<[+V[Y:2A@S-3E:?&T\V/CK8GR"4U(
MF\'O3K%MK?&+Y,_(?K+:N)W'O;*?)GK;(;HVWU5MJHQN=H]O;9V?1]4?)#)]
M'T_]U^N-_P _5W9&]\C15\ AHJ+<"8=(9?+5T<IDV5?5/#&Y(&D\3YUJM>(J
M!^5>FA(A\&XG0:SK%0H].UBN :$^F:>HZ?\ /8+LZ;>WR!Z+Z1[!W!EL-M+$
M?'KL:GP>=[!RE-5[?R.8W)NF?L7H.A[2\&?W[LJG['Z[V?CZ^DJ&>KJ\$V6,
ML/CI*N!8RB?+W:&[=L=EX#*[FS/6VZ\=V'USM/L'86^>J]D8WK?;6_=@Y<Y'
M&8/==9L?'[:VA)MO<]9586IARE/4XZGJ/O:=VU31M'42OPLI4@ @@T()K0^E
M<],7:N)0S,I#*""HH"/6E!0XSCHS?QNWIM[=^Q,K283";VVKD=C[UW'L7>>S
MM_[EJ=Y9[:&],2]+7YC;\.[)L]N>#<&"IXLM!+CJBGKIH/LIHT"P,CT\15_;
MW27HP'LT7=/_ #(WX<_^(J[/_P#@A.V/;,?QS_Z8?X!TJG_W&L?]*W_'VZ!'
MK;_F:'R(_P##XV1_[Z'8?O\ _];3TQ^+Z?R7P\Z1';&\NPMHF'N_Y## +L38
M."WQ%D8GVOT.<E)EFS6^=DMBIZ2585@2(U(G21RV@H+IR9!.^A01I'$T\S\C
MTO B-I;^,[*-3TH*_P /S%.MT*6I[%IODYVV>O\ "[&S:2=0=$_QD;PW3N#;
M%11SKN;O04 QPPVS]V0Y"FJ(FD,K2&G>)T  <-=0I_NM\/?I_ID[_O\ T_T"
M['_^WO[O6;^!?VG_ #=-:+/_ '^_^\#_ *"Z$O\ BGR+_P">'Z6_]&GOC_[3
M_OK^Z_P]_P"?R=__ /HAMC__ &]_?JS?P+^T_P";KVBS_P!_O_O _P"@NO?Q
M3Y%_\\/TM_Z-/?'_ -I_W[^Z_P /?^?R=_\ _HAMC_\ V]_?JS?P+^T_YNO:
M+/\ W^_^\#_H+KW\4^1?_/#]+?\ HT]\?_:?]^_NO\/?^?R=_P#_ *(;8_\
M]O?WZLW\"_M/^;KVBS_W^_\ O _Z"Z]_%/D7_P \/TM_Z-/?'_VG_?O[K_#W
M_G\G?_\ Z(;8_P#]O?WZLW\"_M/^;KVBS_W^_P#O _Z"Z]_%/D7_ ,\/TM_Z
M-/?'_P!I_P!^_NO\//\ G\G?W_HAMC__ &]_?JS?P+^T_P";KVBS_P!_O_O
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M?_[>_OU9OX%_:?\ -U[19_[_ '_W@?\ 077OXI\B_P#GA^EO_1I[X_\ M/\
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M'4F.IJBHJ>J:>.AHI*FH'FG"SO'&"5BD:P]C>/Y0?7O'_.4.X[_G_C!(^O\
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MIMFY7&Y\U#E_<MUDV^S^GM#$;N25[B<SQ3W_ (#2M2.>"V_Q6,JZ?K2R=RD
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M)F:?^.T,F-Q\N)H8:6LKJ^D^QI\9.\DM)%CZG'RPH"S:XT5[W8@2QR[N O\
M; K0RQW%M(;>02R"5R\<<3ZVE4*LAE25)&(50&9E  4=39RIN?[RV@1O#/'=
MV<GTLHFD6:5I(XHG,KRH%21IDECE8JH"N[(!1.K3OCIOF7>/7"XO)8K=V'W/
MUCF/]%^[X-\[GQ.]]T5^<PFW-MY^GW#E]Y8..GQFY,CNG;>Z<?D:N>*&G6.M
MJIH!&JQ"]=_>W_;PGX2_^("[(_WKO_WCC-_XEI;?\\"_]VBXZQ&W+_Q.O8?^
ME7_WA;SIZZC_ .9A?*G_ ,35LK_WQ_2_O__0U <)U=C.ROAYTJ,CW#U#U2<-
MWA\A%@B[4R^[<7+N!:W;'1#R5&!3:VS-WB>FQAIPE29S3E7FC"!P6*IBY6>0
M:&/:O#[3TO\ #$EI;@RJE&?C7/P\* ];EF5[$J]A?)_M>.DZT[.["_BW3O1D
M\D_7N&P64I<1]GNCO*%*7+RYK<NWWAK:WSF2%(EF!B0LS*; B72[A[ZHML;8
MV?3_ ,RCX^IA-EI01;3U[Y[2GS.WZ;$T=?CL/0XS<\_1TFYJ;&X7'Y.:"BIA
M6?;T<+!(4140+6D52WTK5/' _P _3@DG"J@W%-(X?%C\]%>DKXNIOXON3-_[
M)#W$*W>#ULVZ85V%L5<1GJG)UM'DLK6Y3;Z]DC U60RV1H(JBKJ&IC/53J9)
M7=F8D+]A=;[HZOCKXNO?GK\:=H1Y3)87,UZ8/??;U&M5EMN4^;I,#DI O2Y
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M]E9VU_WE]\2/_0L[:_\ M,>_>,?]\O\ L'^?KWTZ?\I<7_&O^@>O?[,)E_\
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M/^4N+_C7_0/7O]F$R_\ WCA\C_\ T$]C_P#VQO?O]E9VU_WE]\2/_0L[:_\
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MS":W[CJO?E*T,$D?8;HM1&)?+I?2K11R$-J4*Q>_]E9VU_WE]\2/_0L[:_\
MM,>W?&/^^7_8/\_2;Z=/^4N+_C7_ $#T*_\ LPF7_P"\</D?_P"@GL?_ .V-
M[]_LK.VO^\OOB1_Z%G;7_P!ICW[QC_OE_P!@_P _7OIT_P"4N+_C7_0/7O\
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MC>=)*=$\=5"49]3!,IONV<TVG+^V\]I=[7?3>/=VI4P1HX&F%P0VJ5"":U%
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M#+!&JQ(BJUU6%^^JX\A7=I[!K*Z&.AAAJZC)YN26*#%PQ4^,@0?W;$2P4%/
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MK_O+[XD?^A9VU_\ :8]^\8_[Y?\ 8/\ /U[Z=/\ E+B_XU_T#U[_ &83+_\
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MZFHDEC<MZ97+_JL09'>4+V\C>WF\EH8GBC_Q>VI'%(JK)&B_4T5'151@!0H
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M/6WP3^6>S=J8^IK:REPF%V!U8E.*S(SM4UU9/-4=UU%965=3*PU2S2R.(T1
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MOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][-+T;_ ,R0^9/_ (B+KO\
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M,U-#%314]=.'AIXZ::%FKR]J>B[HXOOWOW7NO>[POY/_ /QYWRI_QKNA[_\
MG?V5[R.^Z^:<^[W3_HT2?]7H>LRON1_]/)YL_P"E$W_:1#T6;L?_ +*4^/\
M_P"(V^1O^]]/'W;>%9VCBB"F6:2."$/?1YIY%ABUZ06T>1Q>W-O><A=8TDEE
M8B)%+-3CI4%FI^0/73$ND:O+*Q$**68CB%4%F(KBM :5Z%2IJZ>AI*S(5LCQ
MT6.HZO(5CIZG6DH*:6LJC&I(!<00-IO87M[&RNZOIFW1C-HX^GC2FIMS-MS<
M>[(-S4>8R8JJ?%5F2JXLAMJ,18[:CUJXVH^P$DC@A0)W#:U$56WN%*G+&X<T
M7LNJXDL%NK:S-L\$1CDECBC,=R=4MW3QHO'*J-)+>$A723"=E[I3)REN?..X
MW :ZEVP7MG8M:2V\!CDGC@B:*\:LU\J&>#ZLJB%2S&",KH8U+;;_ )@6XJ+I
M#L3Y![TR:RYC.]-T';O2O1]3U!O/96QFV]FMT[9VO@<K@>W\C02[E[FI=NU'
M8. CW;+CJ2)UFK?)C:,PRTK2!YN?&TN/J<35T>&I:#!Y.GDGH&Q^[/[W4F8C
MH:W[?( 9V."".GR5,Q$%3#'&%AE(9 5*DCC8[^>[BW"SN=U>?>+9PLVNT^C:
M$R+JB_Q8DDQ.M7A=G)D048A@P$B\M[E/?0;K8W>\27&^V<BI.)+'Z!X&ECUP
M_P"*LS,T,BUE@D=RTL8*N0ZL =SXZ=B93?&![ VUN/LZOWCVIL;<CXS=T.=Z
M4JND,SL9\_B1D-HL.LLO75U=6[2R]+&^1Q%;45M2U=3:H)IS-#,$65#@MF92
M@VS4KMK)8G);DRFXY,+B!O&LK%S^&VSAZXBC:JKJ*E.-GW%NV.+'4TZ$FT4Q
M'J*V"UWN_-%AN&^P?OR&YVZQMK83R_1*C6\]U<1=X6)V\1+6Q+W,J$9+Q FF
MKH'7N^\X;9N/,UJ>8X+O;=MM+,7$YV^.,VMQ>W$?>$BE?QTM-O+WDZ$4!>$,
M0NJI7MP=L?)?K[=O?NWZKNW:F_=H]+]==3TN_>PIOC[!@Y>KNQ.X-_[6CGW!
M3X7;NX\C%N^BZBZ&J<CO#-8V4>("MQ9>41&=!'W=UW_ <969''1/51C(39)-
M>5I99\9M&*DQZC51*PFR\L>3R-ZBLC]-/2I"6!:8D.\L\[-O%[:V6X.L4IA6
M*@C<"6\9Y3B3X80T47Z<+]TDOBA32++_ "C[A?O_ '"TL-P=8I? 6%J0R!);
MXO*320C3 K01 10/W33M,J&D&57\=?F56=H;XP&T-]5^.PC/MC&[,D-%L/<E
M'1[J[WJLKNBKJEJ]RS//B>O:.IV=M)3B<)7::C+9:IR4,$FG%#SA/.!X9N/]
MU2?]"'W(L1/B1Y_$/\/4JP_VL7^F'^'JQ&D)^ZIN3_P(A_/_ #<7WKF?S/O^
MRX^[/^"=9?\ OH-@>^6G/O\ RO?._P#TN+W_ +29.N(?NY_T]3W&_P"EW>?]
M7WZ"?XF_\R-P/_AW]O?^_BW[[(-["G4>=&/]^'^//OW7NO>["=N=(=5[U^'?
M8/;,'6F?VGF^M]N8.LQ_9E'W7M??>;WWOV?>6&V_F\!G>@L9B:/<VP>L1B<I
M5SQ;@J!'#0U=%212U=6V02$)3(ZSJFL$$\*$4%/XO,_+[?3I>L,3VLDGA$%5
M!KJJ2:@$:?(<<^5.)KT43<G9O86U?DAL'8*[QP6=P>^\KE(<ELNNZYSFU:+:
MVT:;:V8R./S6%[;K,K48#=F_7W#CJ6%L#&KU570U53/%34\=#)/[KV]JND'1
MN_?O?NO=>]V4?RHO^RMH/_$.]Y?^^TS_ +'GM1_T];VV_P"EQ%_QR3J7ON_?
M]/R]J?\ I<1_\<DZ+#\I_P#CW^G?_%GOCM_[\[!^]@V!J))8I,DU6F.C;R5[
M8Z."7(_;1HTCK0I4O'2FIDTZ5,AT+?4;VL>FKBZ=3'9",WK4$8D+",L<#Q--
M6T"M3I&K%!QZ[-2K=R))'8+$;]A2(2EA%K) 'BE 7T"M3H&HTH*5J!)W&=S_
M ,$S*[+I\!5;M:CGCVU!NJKR-%MDYB3]JD;/3XBGJLJN+A9O)(M,AED":%*Z
MM:BAE]N;5V[G>SJRJQ>2RNV]B1[:_AVWVSDM'6UTVZ6H$@3(YZFI3.$QD,T\
MC&.)?-*(U]*7]QWM&_<Q[]LWMS:V^XV]MOV]-=>+<_3B2.,68D+>%;2/I)F9
M40:W(1"["KZ:1CLW,/-G,&R>UUC!N5K;<R[\;SQ[H6VN*);$2ES#:224K.RQ
M(!)(PC0R-W/II7GLWY ]^]H]4_#7:F+W9L?9W='R6J>VDWGVU2=>#,[9VUCN
MD:7<M7F*G9W5^7W(8#6;RRF/QM+''79*=:#'RU3ZI*D1,'V7KW:N*W#B-JY!
M,KDIMY[JS^"P>:BR7V4FVL70T^,_@M=+C88)*7-9.HK\O&*M)62,01MXP&8$
M%"<]<P[CL.[<R60M8$VK;+6XGMVC+K<S2O+]1&LQ8/!"D4+^"0&<R,NLZ0>@
M]'[A\U;KRYO'->W&TMH-EVJTNKFV:+Q5O9Y7F^HB6=G5[6!(K=_ 9%=VED7Q
M"40@AHOS&^0_8766[N[]EU77.RL5\<N@^L.W>U.MJK:D^X:3N3=FZ*O?4G8V
MV,3O&MS465Z]VEA<!U]+_=Z:E@JJQ\AD0]8\D--X)PZP-'A:;;^X=T;DQE1G
M(<+E<#@(</1967"Q2UF5.2FR5?+D:>&>H*T-!BW^VC4!))Y%+DJMB/=XNMTN
M-]V/EO8K^.TEN[>YG,TD0F.B$Q)"@C+*HURS*96-2L:D)W$$2/OU[O5SS%R]
MRKRSN<5E->6MW<M<2P+<D)!X*0Q+"S(M99IT,S$ZEB1EBH[!@<[N_<_;V;[4
MZBZ-Z/WOMSK#*;^V-V=VOGNQ-S;&C["J<=MSKZJV#A\%MC$[2K\KA<;+4;DW
M!V##)DJF:99:?'T,D5/HGJ$GA%!^H<;)/DL)1555/7T6Y*JCDW"]; (Z'&T^
M<QT4>)J\$FD29*7:-?\ ?+,MM=2$06C;W'L/N;>FWV[=KFV1+2?;T=;?0P,D
MC6\A:9;@U58UO8C;M&Q!6'5)EEZC6'W8W+P]NWB]M8H[&?;(Y%M1&Q,DS6TK
M-.ET300KN$7TGA&K"#6_=*O1*:/^8+V'#1[.[%S]!M2BP^Y>GL#FX.H*3:^>
M89[<V8ZZW-EZS?V%[2:JFCI-MXWNW;0VB<9)'),N*FEKFU3PZ?8/;CQ3X?,5
M=*:-:*EE8UF*A7)09A3B)YIXZ%SE::\%;,HIWCG9;::A'2WI]R;LVY)NFW6]
MRMT)9P-,I$;0_JA5+TB?NC4Z@\:M4^&R$G/4M\O;M%O.TVUVEUXMRGZ<Y\)X
M*7"*AE7P9.^->]7C#5)B>-JG5U8WTAV/2=G=<X;.+N"+<.X<4$VQOVJCVIG-
MAM!OW%4&/J-P0G9.Y88<[MBBJER,%;04]2'D?&5=--KD$NLU]=[?]O"?A-_X
M@'LC\_X=_P#O&F;_ ,2UMC_RX+_W:+CK#S<O_$[-A_Z5?_>%O.N'4?\ S,+Y
M4_\ B:ME?^^/Z7]__]+41VGT1VUW5\0ND:KJW9])NU-H=\=^?QV.NW%M/ TD
M$N2VUT34X^DGBW/N# RY"*NAQ\VO[;R*JJ0[(64%,9$2=P[4JH]?GT8K!+-:
MV_A("5=ZY _A]2.MS#)=H[!ZY^3O;M'O3<3X*ISW2_1E3C5AQ>;R,\M+1[H[
MTHZFJ1\1B\C%3&&HJ451*59FY"D GV/.X]H_._*[-DZYVY\<NI=@=?MM'LK:
M<.TML[[VWD,?C5[;R>Q\MOC*X:KWKWCNW,8>>KJNO<<M)1P5*8FA02M%2">>
M:9VQX .HRL6J#6GI6G #U^WIUX[UD\,6Z+'0X!'XJ5XL?08X#TZ"^DC^*AW;
M0[]W#VYOO=V\Z#=VQ-WIN'+X+(8RIJJOK7#;YP6T:+*4FTNMMM8S+4]'0]AY
M(SSU,$E?5N\0EJ#%3P11X*O;'\Q/(;E["W-D.GNMJZ?L3LGJ[M^KQE5N/JR;
M#;8[)ZCKZ>HVSNW9=&W9ODP&3K\6M3B\H1)*F1QM?/%*I<4\D&ZVX"@.< CS
MX'UQU;3N!:1C"AU,K<5PR\".['H?4$_*G"GQOPVH\%LK 4>_]ZTE/L?8/8_5
MU'6TZ;[CRF<V#VC220[CVSNFL_NL3F\?2Y 4]?CM:J]!74<,D3!3*DO+8VVO
MYBNQ<7V?MZGZ@ZWW)M7MCMS:'=^X]J;NW#U/G,#0=@;-WQ2;\I:[;=,_9$$^
M%Q^>K\?3T69I4E:+*XRGAIZC5X87CTWTS%#K.H*1Y\"*9QU1([]-?Z*E6<,0
M2M*@U_BX>OKUAW7A_AKNS*=99R3L/?F SG5?6>Z>H\%F=JOO_!9#,;'W5L?(
M;$?';MEIML,FXJG;M'E)Z_#5$RB;%96:6HIRAFG66-L+;/\ ,MV+F-ZYZ?96
M"W]E=ZYNDWDU3V5O[K3=@VKV-BJW.9# =F;*AF[+IH-N[VV[5;FR#4<Z*],H
MJW#P2 )IVWTS!0&(IC (QZ''#JT:[C&S-H#$FN64T.:$=V"*FG3SNZ/X4;MQ
MFU\.,Q5;5QNU-OY#9U+2[*P&\MMKE-C9>DPU%F-CY]Z3:[2Y?;.5I]O4(FAD
M;R$TJ%9%.K4B.N>E?Y@/5.)ZYQ>RNMMM8UNKNX\AW?MC*2;UZGJ<H^Z\M@=K
M[:RV*S$TO8)ILML[*X;:=/!58R2+PU44L\<Q>.4H+,\#EB6.5IP/S^7'/5(X
M;^)8U2-1I?4#5:UH!Z\*#ATJ=][Q^)O9$^_)=V[NRV0@[&ZTI.JMR4"8C?-/
M1';F/R>XLQCJ_&1P[;67%[GQN2W/434V1A=:BFE2)XBCQ*WM68'8?\PK:&^>
ME-^;*Z@Z]V=D.@-R[SW!UUA\'N?JL[:@H]^[UR^]=Q;-SN(RO9637<.R*LYR
MJQ+8^I=UEPLK4LS2AF<U)MV616<D,!7CY"E>''_+UOP[\-"RQ*-!-*%:9-2/
MBX>7V=)?<4_Q$WAL;M;86[.P=X[@Q_<^W-NX#>^9K8-\T^Z)*G:FUL;M?!;M
MP><QFU:"HV[O7&G$4V3@R5&(IJ?,0I5P^.1%TY,QM'^93D-W[ WAB=F8G9D_
M6^Z\YOC 8'9O8O7.&VO5;KW-V9F.U<]FL_A6[-JHL]4Y/<&66ED%2SHV)HJ2
MC(\< OX&V"LI)-13(/"E/3_4>ME=Q+QNJA2IKAA2M=1)[LU/\J#K'B8OA7CM
MJ[RVID<]7;KAW[M3 ;*W)F]V;?W;F-S5&W-L]=XGK3$4%'FFVE#48T087%O5
MWIQ'_N5KJNK73).U@H[9^,/S4[AKMJ5>>Z6V7@:?9.TVV3MK$;0WIU?B,1CM
MN_WNW9O."B2EJ.R,C(119+>55##^Y:.DCABM^WJ-TDA0-1R:FN:_9Z?+IJ6U
MO)2FJ%0%%!0KPJ3_ !?/H3.ONV_C?UO29^FPO8>?R,NY\]'N;.9#<&(WIE,C
MD,XNV]N[7GKYJD[7@'FKZ+;,$T]E'DJWEE^LA "?_9 ?EI_SZZC_ /1D]4?_
M &<^[^/%_%_(_P";IKZ"Z_WV/]Z7_/T('^S1=%_\]N__ *"V\_\ ['??O]D!
M^6G_ #ZZC_\ 1D]4?_9S[]X\7\7\C_FZ]]!=?[['^]+_ )^O?[-%T7_SV[_^
M@MO/_P"QWW[_ &0'Y:?\^NH__1D]4?\ V<^_>/%_%_(_YNO?077^^Q_O2_Y^
MO?[-%T7_ ,]N_P#Z"V\__L=]^_V0'Y:?\^NH_P#T9/5'_P!G/OWCQ?Q?R/\
MFZ]]!=?[['^]+_GZ]_LT71?_ #V[_P#H+;S_ /L=]^_V0'Y:?\^NH_\ T9/5
M'_V<^_>/%_%_(_YNO?077^^Q_O2_Y^O?[-%T7_SV[_\ H+;S_P#L=]^_V0'Y
M:?\ /KJ/_P!&3U1_]G/OWCQ?Q?R/^;KWT%U_OL?[TO\ GZ]_LT71?_/;O_Z"
MV\__ +'??O\ 9 ?EI_SZZC_]&3U1_P#9S[]X\7\7\C_FZ]]!=?[['^]+_GZ]
M_LT71?\ SV[_ /H+;S_^QWV87J/X4?)S"]3?*;"Y#K6"+(;KZOV/CL)&F_\
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M4I:20K<1,VE=(KI52Q] ">IO<_RKZ"S&W]BT6/WQD)*B+OKX^Y-A4]==J8Z
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M"XW]LEA-I<\S7MQMZ6<EK;Q2"\(L[>5TD9+=EME<.KQ1>%-(SR1)$D2G0""
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MW?\ ]!;>?_V.^_?[(#\M/^?74?\ Z,GJC_[.??O'B_B_D?\ -U[Z"Z_WV/\
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MXS<6,W;6T=125>-FA\/@D0+4T\$Z3:?>&YHIZFNJ<IU/D\N<OEMP8G-5^_\
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MGV<U)41LDI+!?>/M?X^UW4'6>$S.[QE\3V='W;W!U#O?:%5_#9\9@)NM-O\
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M D$2O.H4,SV;3I,\\X;^.6=K@O8[6)Y9;J"!=;%(U,TJ1ZY'5'*H@8L3IX@
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MDBX+/9[;4U+D9,?(3+1K5B%V9T9C,^/U-32[TW8DM/#(AZ)^1WIDB1UYZ*[
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M*T7F 6T^X%M<66]7%_;QR"SN8X$EM9!/!>22K'ICM7 75*DL@MYD('A3 AG
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MN5S9X<C*?W$_ D?\2(?3HM?8DTT7R3Z"6*66-9.M?D4)%CD9!((Y.G94#A2
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M>.X]N;FQ5-FL/_$J9X!6T4AJPK-&6]<9(6:,M&2 Q(.37?(K-3+A-F2_'OY
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M:1V?P2*G@%H/\'1L-HY/9&T-J;:VI!OS%Y6';6!Q&!BR>9W50Y#+9&/$4$%
ME;DZZIKI9ZNOJE@URR.S,[L23[1W^B[LS_GW6^O_ $$=P?\ UO\ =M:_Q#JG
M@R_[Z;]AZ47]]=F_\];MG_S_ &*_^JO9[>[-F;RDVA\6(DV?NQY:/XO[4I*N
M)=M9LRTM5'V/VI(T%1']CKBE$<JM9@"58,."#[Z4_= =1[/R"O\ RW+[R/\
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M&S5?BX:O,UM+@L%":NL>.'[NL>6811!Q&KT>E%"EP3Z_,YZ2SB6:0N(&5:
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MWA;_ (]'=7T_YYS-?_4/OKU^]MLK7]X0_P"]@= \7EMI'ZHX?/HQ7]]=G?\
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MJNO^4F3_ 'H_Y^O?Z'NI/^?6]<_^@1MG_P"MGOW^S1?)G_O(GO7_ -&YO_\
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M65K'WMN.2KR>0?LGL.E:MKZF3(M/659I:6*+R2,SB.)%OI4 8:^_%[>6G/\
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MDDJ:ZK>I804\2*69K$_@ D@>^D<VQ\NPQR2_U7M)-(PD=K$\CG@%1=(U,QP
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M'4,V^>Q&D\4'5&_*H1HQW995>H@C9C:_HL" 6!+U_L_WRN_Y^)@?_11=+?\
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M7?MWZ:'^$_M/^?I/]=<_[\'[%_S=#!_LJ_1?_/(Y/_T/>Q/_ ++/?O\ 9_\
MY7?\_$P/_HH>EO\ [7?OWTT/\)_:?\_7OK;G_?@_8O\ FZ]_LJ_1?_/(Y/\
M]#WL3_[+/9NJWYB_(H?&7HG= WSB/XWG^Q>^\?DZK_1GU089:/!4W4IQD4-
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MIFM*&@SN.>_O"V^X6&SMS;=/O%S(J) DUM)-J958!XXV9H\,"2X4+0ZBNEJ
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M=<_[\'[%_P W0R?[*OT7_P \CD__ $/>Q/\ [+/?8^?WRN_Y^+@?_10]+?\
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M#_"?VG_/TQ]=<_[\'[%_S="O_LJ_1?\ SR.3_P#0][$_^RSW[_9_OE=_S\3
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MJ?RS=MU.S(\A'D:O&[XVMLW?>.W3@=\_)+<6R<%L7L;*G;_7F]-_;QPV\JS
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M.]P=M1)69G*&)S(\<D31@,7\8GZGZAFXZHAJ?2I6E]<V]U'$\:HLP*@ #O4
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MN'S&9C["DHZB''2RU%-'1R5$<_,.I3>[E96@O)K._65[R[\73I8:8BLZ,CU
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M^-NV,I#2Y#%]HM386*7L'LRG_A6'6E[3I98\8KTK3 5#U$_FGD)E92JKT/\
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M5JJNJFBIJ:FIMN=VSU%143R+%#!!#%W>TDTTTKA55069B !?W[PB,^._\O\
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M_P#/5T\#HO<0(/\ LQ_R"-C]#E>KK'_ VZH!L?96/FS\C,!B?DAO"ER?Q?\
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M_9G]H_\ >'OQ._\ /#W3_P#;P][\)O\ ?S_R_P W6OJT_P"4*']C?]!=._\
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M[,;Y:4PK"=I4%5U1%49Z*=ZB)(Y*</'+)-&B,SNBGCC,N<Y4FBPG4.S<Q6)
M]2U+B\1N:MF2G2VN=XZ?-OHBN0 3;4Q %V('O=]M?[K@%UNGN3NMM;:M.N6X
MM8U+?P@O  3QP. J309ZWN.U)LUL+W>/=3=K2T+A=<UQ91*6/!0SVP!/$T'
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M?U+6T-92S*\-325=-*T<D;@JZ,000?=B>Z:SJ[?^:ZSH-D=B]:[3RG\PSL_
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MMRR&8U5;N*75-( H0"_CW_Q^VZ__ !!'R-_]\;OWV&?O*_\ 3C/</_GGM_\
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M_P!ZO$^Y&W?_ ))6Y?\ //)_QT](T_M;?_FJG_'UZ-KV?_S+7L/_ ,,;=O\
M[H,A["/Y)?\ 91/?G_B:>T__ 'N<[[X=V?\ N):_\TU_XZ.A7-_;2_Z8_P"'
MICZ)_P"9(=-_^(JZ\_\ >1Q'L%O:GIOH5?9QOA[N'IS9&?WIOS?W91ZU[/VU
MB,0O0F;K^N,WV-MS!;SRF3:FS._Z['X*KCJ8]R]?X"-ZG;J2P3TPSD]/5R?\
M A'*Q.'8*JI5#QS3'I^?G\NE=H859WDET.!VG3JSZT]0.'SSY=%T^0^![%W?
MCMK;/VQM&+=?7V<R.3?M^CIMZ46T,]E-MX['BHQ.RZ%LACJBGJL%O;,LE-G'
M6IIIEQ,<U.@;[HO%9CL6G&,^9/R9[1PN^$W7TU#VGVJ8?D3)VSB-L;+Z-WSN
M/:V7H]X=B[FZ>W;FZJK[S$%!G8J)"RK3[KD@TTDM6THIPD)/T\*%:24';3)]
M!7R_R=&,6I+B:0,3&&/=J "M0ZB5)[O+/!J8KT0W=%-55/P\^/NP,KUS58_M
M"#JGJ>7(_'J'95;7;I[#P.W,CA9,+UWB>R-L8BEHNI)8,QB$K6DC ; 1*?/'
M3HC3K02; D W%S8_2X_!L?I?V9=$?5OOOKW[KW7O=B_P_P#^R?\ Y)?^)#^.
MG_N/W/[ESV3_ .5NW'_I7-_U?AZBOWD_Y5';_P#GO_[5Y>@+W7_V4/TO_P"(
MW[U_]VW2WL1FC$H\195\Q6'4Y"H#*PC!D9K*D=V]3&P4<GCWE0ATLK>A!ZQ<
MC)#J1Q!K^SH<V8*K,;V4%CI!8V N;*H+,?\  <GW:>NJ7MGK'N'LBBPG07;E
M9WIBZS&4*=RT'9NV>QMLS[ W')N/(TNW\UN3+X?K6.;*8S&8#'9C[ZCQGDSX
MTJIHO*L3%6CVC==AVYIK_:5V]EU> \3QN)45!XD:*TQ*/-,R:'E"P9)6:AGM
MI"VX;=NU_)%9[KXXQXB,)$*,[5[F*C4L<:-XF@>*:4$1(I1J\?+CNGNV.BNL
MAN7Y'=(470V3Q]66Z6R_7&Z^O=X8[L#:.-VE0U&Y-O;7P$G:4KX3.9G<.8Q,
M>(K,N1MC]WRG++#* 7R*VK59S"=<4NWMM0]=476?4>],]G^C,_V7@M_;DZDV
M]_I,429&H[#JLF<IOZJ[#RFZ$KJ+%,&RN/I89-%/]K:9Q#RW<-;3;FU]=&YF
MGNHU%R(6A2YD\#X5@4,D7@I&%9U;PG8Y;Q#H >YXM9+\60LI8HTMH68P!T)B
M7Q?BUMH+%VE#: NI0:Z2@#DR7Q"W+'M/,]J3;TR.0WWD.S>V-CX+!_(+#]7;
MHV)MWNK<#=8-XL=%UQC\;7XO8477.&V;)C:S->1<+DJCQ!JM:UFI(HVY>W,I
M++\6MY;GR>5[%S59TSV=L;=,5'N6AHMWPXW>V^.S-B14.'RLZU%#M'/XO;V=
MADQ G@CI*95A+1B!F)>M=H19>9;:"(6\ O()4)C[&DCBMY=;K0:UDDC82'47
M:I%0U.DC[X\DO+5W=W!FG>WDB<Z^] TES&!4ABNB)JH*&@"X/ JO;_26/I'^
M66S]I[>P_7>#7N#J3L':<E5LN679V7RVRM@=-;ZGR&1Q='_#)MX8W,;MVU+3
M9FHAJ#6S,9U\XJ$!48.[Y.M-_=<]F55--2>;KC-[KJ\GN2D["CJXY^[8,/U?
M@\=30[=5X!V!0=@T<.0PM)F_!(M/%MN:6G:**9S*2[*-RV^^VQ!&?#N(HU"&
M'3IMB\[,"YS$T#:':&IU>,JO5P-)SNW[KW/:=TCGN-"PN22) WZM$RHK5U<Z
MEJ 0?#,@Q74!/0]'VMUKVIU?#_!LA]OV#@L!18W%938%5#6_Z%JG.]H9JJ3)
MYM5DAZWS775;+CLQ6XII_P!^3=<-%.DDU-"8*TJG_@//_P L9?\ H1O<E'@>
MH8A_M8O],/\ #U;1[+9\]_\ LJ#>'_AD=%_^^%ZR]X-\U?\ *T\S_P#2QN?^
MKS]9R;)_R0.7?^E?;_\ 5I>@)^-W_,IZ/_P^.X/_ '\._/9.?9#T9=#M[''X
MW=>;X[5[HV5L+KO>N*ZYW/N"IR5-%OG.;Q@V'B=LXB/#9&HW)DZ[<LU?CF@A
M3;T54GVT4AJ<@7%)#'++,D;-S,J1LSKJ4>5*UZ>MXWEE5(WTL?.M*#SS]G[>
M'05]V;WVSUSU?NO>6[]L9?>F#PM-0O+M3 [5K=Z97/9"KRU!083'TFWZ"@R4
MLQES=53ZZB2(4U @:JJ)(H(9)4/WV!M:?._)CJ#9?8U7NGKGX[=.='TPR.<W
M3V)M^?LGL'H;J2LW;O?=55GYMI[XS:T.^^S=S5^0Q6 V[3UE1-A!D,?00":*
MD^XD3J2(G*T,I;A3 )_+@!Q/GT8/$_U$<<A*VZ)YL*E5J36A.6-0!Y5 '#HH
M>T:ZNV?T)VONKKRAQ&]>[^VNW<ADH,3M;:F8.R-G=R=E4^U=FX5L:F=VOC9*
MC977F"I*#)9O-U-)3Q94T5=72B&6J,"5O]S=J[F[P[5W[VWO"9I=P[^W+DMP
MUL7GGJ8,;#52Z<9@Z"6I=YQB=OXJ."AHT8GQTM/&GT4>U*((T5%X =%LLC32
M/*W%C7_8_+AT=#JKK?;O4'7&S.LMJ0)!@MEX&APM(ZT]-2RU\T":\CF:Z*DC
MAIVRN=R<DU;62*H\M542.>6/L,_=^F^A ]V3_P J+_LK:#_Q#O>7_OM,_P"Q
M[[4?]/6]MO\ I;Q?\<DZE_[OW_3\O:G_ *7$?_').BP_*?\ X]_IW_Q9[X[?
M^_.P?O8,CK:W&NN1QM1+29&B62>AJX-/GIJD0NL<T&I743)J])L2IY%B ??3
M4V]K=UM+Z%9+&4JLB-\+IJ!*M3BIID>8P<$CKLX;2SO_ /$=Q@27;YF59$?X
M'0L*JU".T_B%:$8.*CH3,]MK;^\L5D]I[KQ-'GML[AB.,SN$R*M)C\KC9IHV
MGH:^%705%'-H DB8F.5+HX9&92..<-5GMS]UXC;V1CDW+N6DV2V#J%S-/1R9
M:/&28.NSM+3YJHJX8&J;".HE#3AI13L/4R6]Q)L<4.Q[![1WV^[>R[%MTFXB
MY0P,X@,RW$=LS6Z1LVGC&A6.B>(I% U>H.V"*UV+EOV1W3?]K=.6=KEW/ZJ,
MV[R"W,ZW45J[VJ1LVBI>)*1TC,Z$45^JB>O\12=7]+?RZ]_=G;*R^*Z5Z9W)
M\BJ;L;!KUYG<K3=>U^]<=V3MCJS/97K3 [?K\M2857J:G#44T&,:*B?-TZ 1
MPSZPK9<C2Y;>&#W!@\Q0+MO:/86],MOJK&7I:.D:GK<?AUJ,]+2RU%/+F*+<
M--0U=) T<<YEE?18:^0O'MUWM_*F][/N^V3G?MSV+;X=O3P7DD#1RS:8%=48
M6[VS/#+(&>/2BZS71@&P;5>;9R;S!L.^;'<GF7=^7MM@VR,P/)+JCFN2MHLB
MJRVTMF\L%Q*KO&(T DJ?#P R;%SNP^A=^=6]J]4;VJ>X>^/A[\<^N?C!MJ38
M><SV=QVX-K[A[/K,3UE#N&CQM=BNNMQ=-9O<N"S63AKJZ@7%PE*Q6844K0!5
M@,%FIMI9_;V&>GH-Q;AJ=@[PPM)#GL?CZFIVC%49OQ,]<U=314T^"KI8*JII
M9)%GA1!(4]/N2]YW3:TYFV3>]U1Y=@LTW*SG9K:615O&$!8"/PV9UGB$D,4Z
M*8I&;0'&JO4M\P;QLT?.'+W,6]))<<N;>F[6%Q(;6:9([YEM=0\+PF9UNHEE
MMX9T1HIF<PB0!CT?;NWM+J:#OGJ/MWL?![AW;T_U1A?DWT#O;,S].[YW+BMJ
M=Y9I.ISJDVV-IUV4RN.WUM;%YC"X[,X^CK<96R5#X^*H)K/'()8WIM:JW!NJ
MHJDBDP..W?3T^/R2Y" 8G+SYO>.-S<5>N(>+S3/0YS'U&0FK!>%:&)=0+2 $
M IRIS';;#R['&9!O<NV,TL9C)EA$%C+;^&UP#0>) \5M';_$T[L0:(6$:P\E
M\U67+?*T=NDB\PW&SL9HC&QGMUMMNFMO!-P&HOBVTL-G';?&UR[ ,%B)!.A\
M:^\,#TYT7B<=A\E3]B[NZ%GR.Y-G0['KJSL7KZ@ZX^/V[NM)=M578M-D$IL&
M<[L;=.(VK2;=,?WTFY*YIX:E8*&9X@9WW04^.W$\4,34U3544.2S%$^7_CTE
M'F:VKKVJEDRWDF-5)64Z0U;AG<H]01<"RB4N4[JXO-EC>< PQRF.%A#],'@1
M(]%("!H",7B6@ *QC!(),Q\C7]WN/+ZRW)5K>*=H;=UM_I5DMXXXA&1;T'AB
M-S) M% *P@T)JQLP^(>[]P[QZA:?+&EKMO[=W7DMH=:;CH>NINI:+<_7&$PF
MW#B*JBZ\FIZ)=N4&VLW5Y';U-''3P1R4^%1PI+%WKE[V_P"WA/PE_P#$!=D?
M[UW_ .\>9O\ Q+2V_P">!?\ NT7'6*.Y?^)U[#_TJ_\ O"WG0B=1_P#,POE3
M_P")JV5_[X_I?W__T]/?&UO3%'\/.DAV]MKM#<)D[P^0IVZ_6^\]K;1CHXDV
MOT0,E'FTW-LG>39">HE:%J9J<4XB1) ^HLMDQ$AG?0P TCB*^9^8Z7@PBTM_
M&5B-3TH0/X:UJ#UNC-3]@3_)OMS^X69V;B@G4/1(S$>[]LYK/M/,=S=Z&AEQ
M<V%W7MO[6%(?(LT<RS%GT,C* RD*OXU\+C].M_DW_P"CCZO_ /M(>[TG_C7]
MA_S]-ZK'_?4O^]+_ - ]"=_#_D'_ ,]=TW_Z+O>W_P!M#W[^-?"W_GV_R:_]
M')U?_P#:0]^I/_&O[#_GZ]JL?]]2_P"]+_T#U[^'_(/_ )Z[IO\ ]%WO;_[:
M'OW\:^%W_/M_DU_Z.3J[\_\ E$/?J3_QK^P_Y^O:K'_?4O\ O2_] ]>_A_R#
M_P">NZ;_ /1=[V_^VA[]_&OA=_S[?Y-_^CCZO_\ M(?X^_4G_C7]A_S]>U6/
M^^I?]Z7_ *!Z]_#_ )!_\]=TW_Z+O>W_ -M#W[^-?"W_ )]O\FO_ $<G5_\
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M?"W_ )]O\FO_ $<G5_\ ]I#WZD_\:_L/^?KVJQ_WU+_O2_\ 0/7OX?\ (/\
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M?OXU\+?^?;_)K_T<G5__ -I#WZD_\:_L/^?KVJQ_WU+_ +TO_0/7OX?\@_\
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M;_)K_P!')U?_ /:0]N4G_C7]A_S]4U6/^^I?]Z7_ *!Z$W^'_(/_ )Z[IO\
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MHWQ_V1S\>O\ Q-WR2_\ >:^/_MI?[:3_ $H_R]*I/]P[;_3O_P ^=;NNTO\
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M%)X>9%,T/0"[%W3-E]D= ;.JEI=N=28+8?R<RV'E^4N^]Z[0P^YM_=>]VXG
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M,VQN$UF1_O+L#"Y"ADHMN9'[B9JW T])*[:V8 G7M_I'T9?V>FM_[)%^-_\
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MN_ K_F:O9'_BMGR#_P#?<Y;V)^1O^5YY-_Z6"?\ '7Z(N:O^55YE_P">-O\
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MO"L_^4MO]X_Z&Z]_?;O'_GQ>(_\ 1N8G_P"Q;W[_ $4?$G_O+K<G_I->Y/\
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M30J$BIZ:F@VG'#!!$@ 5$4*H%@/;=_HH^)/_ 'EUN3_TFO<G_P!L+WOQ)_\
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M+M602/VWA@R3R]J[TDJZ8M'M=HYA1U;O$)5LLH36  U@6G_11\2?^\NMR?\
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MJRD$&WM$>[=4Z4_NP/N__CS/B?\ ^*K[2_\ ?E=K^^E/W/\ _ISTO_2\O_\
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M1P E$"M,SRTD>AJ&D6(QJJ@H'60N59D *=ZY9@>PN7VJTB,VHRFCN6":5(4
M]M5#ZFU48HRL-15ZB#T/\E=U9K>V$V]V95;G$28[$]9*T6!P$6)F[(KMQ;^2
M+<6\:RG>'+15>?I]B287'_PV&7%1Y/&9,U/@:HI$0BU3_P !Y_\ EC+_ -"-
M[&YX'J,(?[:+_3#_  ]6(>RV_/?_ +*@WA_X9'1?_OA>LO>#?-7_ "M/,_\
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M>KZ>VMONIV1AJ[,)\J:O<>7[+H<;4=E4,4U<=G-T%F-B5'^0T0@.0C-3!4/
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ME3[D+ACJ(G1HW>-AW*2#]HP>K-/<?N__ (^OX8?^(7[,_P#?F=T^X)E_Z?\
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M?O3:VV:+;U#M[#[EV9E]M5.V<E#A4VGCI:65J85%/4TB3QR+-=SXNA4+X$@
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M9Y1P0?I[P4BGI%&##)4*!\)].LR9K:LTI^HBRQ_%\_LZQ]+=]4F/Z<ZEH/\
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M[\]W93QS[R%(*6*73%]OI,1/W;+%]6!$+2;@Y]\H;O\ =]R&%FJ^'X3>*?\
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M7E)MH[WR<J305,BTE+04$E355YA34J%@S<FH+56"@<2<X_:.GH/"+D21LY-
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M[EWV3)_K;N2U.D[<W_5^'J+/>0G^J-@*X_>'_:O+T!>ZQ_SD/TL?R.M^]?\
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M-7_*T\S_ /2QN?\ J\_6<>R?\D#EW_I7V_\ U:3H"?C=_P RHH__  ^.X/\
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MGU:M)(TKW$)U6SG/F)V#A/D'O#JM,-M_,YC;&Y]V4U+TSBL'N"7=6XNK=O\
M4M;OW%=E8+M-:J39N1WKN#=$=-C%V;%229:"GJ@[QVC:I*6[_P"AL-UWM&HW
MC@=G=E[$IL%W%N'I>IQG9F2Q.8JM]0XK"U>=P?9NV*C%XS$"AH,U2XZ5:FE1
M*O'_ +]/)1U<R>2RO8>89=QO8;*YGMY9)+!+NL*N E717C<,S]RNRE6JKBC"
M6,=(^:.5K/;MO:_LUDC6*Z,!#D'70 B045*"F3AERNEV!.E;_&GY/[@[+[#Q
M/7.Z-R]<;WK]W=!8/OZCRG6F+SV(HMC25FXJ;;.Y.M-Q19K)9@UU;ALEDX!2
M5$DE!E#X*I*_'4CK#Y7>OZ&V3+MCJFNPF%S$^'W(W1L797=-)VUL?<&WMCU?
M9=;1T>Y*/,]6T% FX=F4^-K:XX^EK<I5)3I64Y\K'R*ONHWV]2ZWA)Y$6ZB-
MV8+8P2J\RP@F-A*6*2:@-;"-:Z6P**3U=N7=MDL]L>WMW>!Q 99Q/$?#,@J]
M8PE5"$Z29'4$H0,N (=%\F-]8_<W<6-W=6X?%[MV[+W_ /Z'NBZSJ[?NW,YV
M=B^IX:JLVQD]O=DYG(28/>==N;#4"Y&6CPU'/**.L#QH%IY6+GOSXH5&+V[N
MC=FU]G[TI)Y<1MR?:O7><W!@:C<VV<C329ZL[-3/5<\.)J-WG;^$P$2T&/H:
M9,C45.0E=HS#02,]+#FE9+B&VNKRW,*LP>4!PK!BBPZ:UTF1Y*EG.A53# R*
M!O<N4;?Z.[O+.&=;C0&$1:,E*:BX8T740%J1& U#A2(WKPZ^^8!R&ZMK[2W9
MNGKNLQJ9O<M!N/L7#8G=-%A-PX^9<%1=:U> QXER]-MA=SY7.2-55N0K9\7!
M!11JL_ER-.L9(ET.JNFEE=5966Q!5A<$'^A'L:4(-#QZC1PR,R&M0:='^]Q>
M[P/[U_# 6X_T+]F"WXM_I,[I%O\ 6M[@J8#_ %_;<>7T*_\ =OGZG^I_UAAG
M_B2__:?%T!/5_P#S-+Y*_P#B1MD_^^1ZR]__T=/K$=/=K=J_$/HJHZRZUW-V
M/%MCO?Y _P ?AV_B*S+TM!)6[:Z&J,?199:%TJ($RD-#,5L5+1QO9@0/:<NB
MS2!F )4?X3T8"&::UMO!B+4=ZT%?X>/6Y_/V)L787R;[?@WKN_#;3ES?3G14
MN)_BU;%12UL-'N7O:GJZFA-0K13"DGJ$5OU:69;BQ%S!XVL^6^RJ/$X/J#X&
MUO5VTJ;<NXM[Y[;%%ANV]V4VYMYY_J[?'45/E:G(;QW7E\EBL=MG:?863_AU
M%1R0I]S/KJGJ@D2QM%(6):2?4U*>0Q4'R^8Z4:+Q<1;<56I)'<:DJ5\R:4#&
M@_;7H)\U@/CKO>NRF:[,^3<F^-Q5FWL9L_&YHY+8NV),%M;&[^VKV3)CZ*CV
MUMK'T5369G<VS* UM34I,33P".G2GU2&0*,)LCYO8'%==XBE^+^[YH.MNH.Y
M^F</+4[%W(\U=M[N]NQ6W'D\IIJEBFS6*/959]BR*D"B"$2QRV?7<^ VJLG%
M@W'S%*?X.FA#?!85^C;L5@,'\1)J?V_9T).5SOQ@S&0W3D:KN/%+-N[LSK#M
M7(I#NG&)#!N+J9MD-MNEH4:C<PX>K;8-']["Q=YO)-IDCUKH,#NKLOYZ[EK]
MKY=/AGD<9F,1VAT=W+N#(+MCM+)KN7??0:92FVE!18K*[KJ\%L78M919:5*K
M!8*EH*02$-"8DCABC;$=N-0\;&DCB.#<?M/S/3Q%\2A-BU0RG\62OYX!]!3Y
M= CMGJOXD[=Q51@Y?D1D,OB(NNNWNJ,#25NZ]JPS879G=+X&?=CU61HMO4^3
MW7O""HP$7VN;S$U=7+&S"4RN\LDA4MQ=,?,[<K=1O6?&C?L!Z<QU=C=OBEV5
MN%1DXJ_L_=_:LKYHR32&61,YO*HIU,/A'VD48(UAG9X-"-?Z@[OG\J?Y.D[6
MU\WA'Z1NSY'/<6S^VG1B<#OSXV[>F[(GHNW\!(_:.4HLMN#[G<F/D6DJ:#K_
M &KUQ F("4\9I83@]H4TK"0RDU3R/<*P11(R.&^<^2KMRU\WQ9W1'+N?Y4T7
MRUK$BV+NH1P;ZH9MQS1;<I0U>S+L]FW+-JB8M5VC3]_@WK2"@'BX":>/E_GZ
M=,=^=0^B:AE\3@>.<?9G[>D-1Q_%.BQ6(Q$?<]&]-AN@)OCC3-)NW%-++L>>
MFQ5*^2J&&/57W3X\1':I 6$%F_9Y%E\F<^;.FLSM1\)ZBI[2QO\ I;HNLNU_
M[D;]@W'U;M[NO/;SW%N_!8;%P9Q-N;B7"Y3L',R[=JLQ2UM7A)<C*\;R,E/X
M*%(3CQ^S%149I2GS' 5IQZL5OB&)L*OW:30U4,22!G-*FE:TKTC*G9OQ9GBF
MP2?(>=.O\[+UQ6[_ .NY-S[:JL#O_+]5XK:6%VSE,O65&%?.XN3*8S8V+@SD
M..JJ2GS$5%&DB*&G\\#:]1\SL73YC ;K^&6[=Y;#S.'Z:I)-GQT_<&QC0YWH
MSJVCZ?VCNC'[GV%NS;^YHZS+;)IFILS225$M!7F7R+##-%3RP[9830K, V<X
M/$U/'Y]:5+X5#6+%***=P^$:0:@@Y''RZFY+;_QC_B>'W/M?Y 8W:^]\/-VC
M$=V-4;#W149; ]O]E5/;&Z]MYG%[IVUE,/58VBWG4"IQ<D<,-30F,+Y9$>=)
MDC1;5^7$.QMH;9K_ (5YW(;JZFS=;F.B^S?[M=B4N[.JZ?);^/9-3@5@CSCX
M/?V%H=TSU51CTW!39":D;(55Y)1(@CM^EJ8^-VD9&,XI^7Y=5$5YX81K EEK
MI-&JM37USGA6O$]*>NK/CS5[KWMG8OD/30;?[6P\.*[;V&^=V[4[:WU/2[.7
M8D.:C:7&#*[1S%7MJ&GIJV3$5%)'5I14W[:-&S.+T^^_FK19_!YW97P.H]BF
M@[QKOD=GJ3$[+[0R2;K[7S>U,SM3.560J<]NS)56.VA)!G9YZ'#43008^5WT
M.P=O=/#@((:>O;IXC _U>?3W^/ J5VZE'UF@;)H1Z\,\!PZ#6'KKXP56,J\;
MNOY0[AW>C=1X[HS%RY'>.U*$8CKS"[HQVZ<4(J7$[<HJ*LW?Y\334]9F)HWG
MKJ>%0Z@@$ IO;9GS%[%Z;VIU;O'XD;\R>?V/@-O;)VQV9!1=IXO+TNP]K5E5
M58';^2V7CMQT_6F;R&-IZQJ"/*5&(:M_AR1QNSRQ).+KX*NSK**$UICC]O'I
MAX;UX5C>Q8L  &HP-!\@=)/E4CA^WH5=EY7XZ=>]@[KWEM+O3;V,PF]<_N#>
M>X-B--LVKQ$F]MTI1#<.X,?GJG"R;QQD.9JZ(5E10QY#[1Z^624(HD:,EA_V
M3'Y7_P#>/?:W_H'Y7_KQ[>\:+_?@Z3?07O\ RC/^SH<_]F*Z,_Y^KLK_ ,_=
M+_T=[]_LF/RO_P"\>^UO_0/RO_7CW[QHO]^#KWT%[_RC/^SKW^S%=&?\_5V5
M_P"?NE_Z.]^_V3'Y7_\ >/?:W_H'Y7_KQ[]XT7^_!U[Z"]_Y1G_9U[_9BNC/
M^?J[*_\ /W2_]'>_?[)C\K_^\>^UO_0/RO\ UX]^\:+_ 'X.O?07O_*,_P"S
MKW^S%=&?\_5V5_Y^Z7_H[W[_ &3'Y7_]X]]K?^@?E?\ KQ[]XT7^_!U[Z"]_
MY1G_ &=>_P!F*Z,_Y^KLK_S]TO\ T=[,;T]\4?DOBNH?E?BLAT7V929#<75>
MQ*+"4D^UZ^*?)UE'WOU?EJFFHXI$22IFAQ>/J*AE0,1% ['Z<LR2Q>)!^H/B
M/^ ]/PVETL=RK0,&9 !CB=2G'Y9Z"'L#OSI6I["Z(JH>S]G208_>^[):R1,O
M"R4\4_5&_*2*69U!CBC:IF2,%RH+NH%R?9<O]DQ^5_\ WCWVM_Z!^5_Z\>WO
M&B_WX.F/H+W_ )1G_9T+W^S%=&?\_5V5_P"?NE_Z.]FGZ*V-\G.E]B=D["K/
M@IGM_P!)VI)B:+=>X\ICNU]J[RGV;C&:HJ>N*;<6Q=R[>JZ38NXLHL%9E:.,
M*V1FHZ99I&AB$19D\.1D;ZBFGRQ2OKGS].E,,%Y"DB?0,=7$]P-/3!&#Y^O0
M"=K9KI7LW=NR-XP?)ZDVI5]?P9:;;V#I)=A[AVG!N;)FE2EW[+@MU;>RZ2[W
MV]CXIZ/&UC2&.CILA5Z(O+*)4R[2V)\C.OL#FAL/^7]D-M]CY/;78NQZ'M08
MWM[*YK";.[-Q>X=LY^DH]MY3==3L^IW##LK=%7A:?)U%%)(M(XE:-JL"I&F\
M-R-=Q5*@TQQ%#_A%:=;$%TJL%VTB2A /=@&OE6A-#2O^7KGO#.],]@Y#$Q;R
M^4<.6V3C,[L+=DVP8*G8F,Q>5W1UWFL+N?!5M?FJ';T>Y?X4^Z\!2Y.:BBJX
MT>IB"!Q3%J=EW'N7YZ8Q=MYS;'Q%RVW.SJ;<G36YNPNTH=B[UR6?[9J_C\^/
MDZOI-SXC*Y>KVWB:".HQ5)59Q<52T3Y_(4D%34L)$.O12W:H:6JT( J,:N/^
MQZ=787Y"%;$B6JU:AJVGA7-/MI2IH>D!4;#^(^3BS&$SW>D>8V'-MWM[;6TM
MA/NK"T&(V%1=[+7IV3/@LAC<?2YRNK*FGRE338I\A4U0PU'5304P$;@($/;O
M5_RJ[%V=MGK;:/PRW;U+UOMK=FZNPDVIMO#=C;E;([_WMC=N8;<6X*K.[\S.
MY,U!3-A]I8^EI:&"6*F@CA+N)IW>9K1F)&+&8,U /+@/LZ9EM[R141+%D0$F
M@J<FE34U]!T*>P]T]"[2WIG^R,]\@L3OS?V?VKMS8<VXLUD-KXA:;9FT\GN#
M-83#P8?:N+PF'>I_B^Z:ZJJ*N2%II99]*>*!4A4NW^R8_*__ +Q[[6_] _*_
M]>/;WC1?[\'3'T%[_P HS_LZ&3_9BNC/^?J[*_\ /W2_]'>SL]Q?&CY!9+:?
MQDIL?TWV!6U&#^-6UL-F8*;;]7)+B\K#V#V;6/CZY +T]8M'70RF-K.$E4D"
M_OHG]TWF+9=L]I9+;<-PCAG_ 'U?-I=@I*DQT8"M=+>1X'\NB3=;&^:]C,=G
M(P$"@T P0SFAJ1ZCHL/Q[[ZZ6P>X_E <OVALO'C,?);<.:QAJ\U3TWWN+J.L
M>IZ2*MION/$9J9JJAFC#K="\3 $V/L/MB_'7O/;&=_B.ZOB;N[LO"24%;0U.
MV-P8W>&$IF>JC58,G1Y7:F4Q&5HLIC9$#PL7D@-V62)U-O>0VZ<S[#>V9@L^
M:HK:<,&#*8G!H1AED5U((J. XFA!H>D L+X,3)M$DB$$:3C\P0:@CR^T]#9O
M'OWIO<&#GQVV_DCM38F7:>EFIMQ8G(;1S%1 ()E>:FDQNY:'+8NII:V -'(#
M&LBAM4;HX!]F@H]P_*=/[YTF4^$[9'";GV%L_J'"XJBQW9^VZKK_ *;V>*YC
MUAM+<F#W;3;D7 ;TK*]ZG<LU54SUN;E+I-,*>6:&0#_NKDV)K*:SYU9+B.\F
MNY-1MW2>ZFT?XQ-$\+(SP! +;0J)"M**61&52J;F!*'V,LK($I4KIC'^AA@V
MH@\6-06/RQT5JKV;\: VT:W"_+;^%YG;N_=Z]MYRMK<EUIN/';^[>WK)C6_T
MF;MVYG-K56#;<>RX<:(-MI10TE#A8GO% 98J>6$--J;-^0NRJI1M[X4ST^$R
ME+V5MO?N!JL)O[(0=B===B9##5]'L3/9"JW%)DL=%UW+@X),!D\?)392GJXX
MZB>:HDC7V=;E/RUNL9%WSLQN$>WD@<- OT\\"NIFC414/CAV$T<@DC,;-&B1
MJQZ3K:;FC$IM#!2&5A_&C$'034$!: *1F@ST)^[MQ]#[XIHCN+Y915.8PV0Z
M]W/L;,TN:V!02; W_L*ARU#4[TP%)2;=BIJR;?5/FIX<WC\C][C9Z.62G@AI
MXY'ORSN%^7^6WG5;QQ_QGW#MQL?U,_2?7&'Q.UMRM0]5;%_@\NW(9-KU=9DZ
MC*Y'=4>"K\@ARF2GJJAJS)U%8-,XA:+5F.1K7;6VX\R:UFOOJ[AC*H,\VL2:
MI !HT"18]$**D:I&B4TZ@UFMMU:4R_NQU;PO#4#@B@4%"6JS 5[B>)KY#KA@
M:[XJ8?:2[6J^_P#$YILKVDO<>_\ ,5V[=OQ5W96]OXK!G)/[T4])10XZ';1R
M6/H%3&4,-)3)18VGI/5 )4E8^WMB?*_N"DVO29/XT;GVX,#-E\UE)=O;7SRM
MNO>NXL;M?";@WCDX\A6U<&/J<EAMD8F 45$L%#3FF9XXPTKW6[%>\F[!)=O;
M<Q1N)%2-0TBD1PQM*\<:X!(5YI35B[G70L0JTM/!NUSX?B[8XTU. .YC0%CW
M<:*  ,#U/2CZNWO\:NK:C/U%!\@,!GOXO!B\3CX\[N? R#;^U\'D-R9C#[<H
M9*&EHI:V*BRV\<G,:NL:HK9A4*DDK+%&!'Z+^,OR(Q6\-RU%?TIV-315'2_?
MN,@>;;U1$)<AENF=[XW%T<;2LBM45^1JHH(D!N\LJ@?6XCG[Q/,_+]][*\^6
M=KN\#W$D$ 4!JEB+NW:@ J:Z06^P'I3M=C?)N$<LEE(J>'(*D#B5P,$\>H'?
M?R$Z-RFT]HPX_M;9%7+!W9T)6R1TV;IZB1:6A[CV55ULY2#R,L-)21/+(Q 5
M(T+$@#V30?#+Y7$ CX^=K$$ @_W/RO((N#_F/R/?+[QHO]^#H\^@O/\ E&?]
MAZ'<_(GHP&W^E795Q_U>Z7_H[V8WXX=:_*_XZY[=FY*/X:;JWSFMS;0R&SL=
MF<_@.PL+N#8E)FGCASV9V!N#:&9P.2VUN?,X3SXN3(1LU3#CZNH2!HGE,@:E
M,4H \8 5^7\Z]*;:&]MB["Q)8BE2#45XTI2A(Q7C3AT"_=>YNB.Z,5MK"UGR
M(QFV,7M_<U+N>NPV*KMHY3;^\YL=2U2XG$;WPNY<-F*;.X#%9>:'*14@,,3Y
M&BIGF\L4;1.)^QX_E+L#^'4F"^ 60. V)VP.\^D,!5T7<LL'47:1Q.T<=/F:
M;)1[OAS.^</656Q<7628_.5%8BU%(%BDC@DGBFHPB8U-QDBAX9&?V<?+IQ$O
M(Z:=N.E6U*.[M:@SQJ> -#_@Z1&[:/HG>JY6?.?*4-EMY]9_Z'NT,G23]?P'
M?^P/O]SURT$M"^VIJ';.6ACWAD*=*S&)3GP5+:T>5(980\H]C?,#$; WOMW!
M_$/>6/[![23=5!V1W%+MS>M=N?-X#>.=@SFX,+M[;<U:NP]C_P <6CAH:^LQ
MN-CK:K&QFF$L<,M0DUCX)9291I7@,>7\STWX-Z(W5;)A(U:M0U-34T' 5X&@
MX=+:OS_QVR^Y=FY+*]ZX:JVEUU4;>R6R>O(LUAJ7;]!G-LXVKQN&S&;R4=,V
MYMTOB!5FHHZ>LK7I*>M5:@Q231PO$H.U\9\T.TME;JVROPXR^R<]VKG]K[L[
MXWSM/9&](LUW%N;9<.33 97+8S)Y3(;<VK]Q7YFIRF4BPU)11Y3-2FKE "QQ
M)I!"A!\:H' 5&*_X?SX#JTD=])&R"Q*EB"Q /<1PKY#U-!DYZ3O7D/QKZ]W'
MMK,0_(--QX?KK#;BV[U+M+<.YL%/B.M\%NN;&R9>@QU71XVCS6?--2XJ&@QT
MN5J:R3'8M?MHCZY)'*-_LF/RO_[Q[[6_] _*_P#7CV_XT7^_!TD^@O?^49_V
M=&+_ -F*Z,_Y^KLK_P _=+_T=[LMZP^-/R'IOBQU%M^3I+LQLUB>T>]*S)XV
M+:U?)64%)E:'J5,94U<"KY*>*ODQE2L)<#6:=[<"_N<O9CF/ES9[3FF/>>8M
MOLI)+B!D%Q<0P%U6)@S()774%) )6H!(!R>H0]Z=JOKP\KQ0PGQ%BGJ#\V2G
M^#H#-L?(3HZ@[Y[FKJSM39=-29#9G3,='439B&*&IDHI>S/NHX)I-,4STXJ(
MRX1FT!UO:X]K'8_17R%V9O+;.[JWXM[RWW3;;R]+F'V=O+9&X*C:FX9*,M)3
MT.X*7'S4=75XQ:G1*\*RJLIC"/JC+*TOW_.7(M[975HGN/M-N\D9421;A9B1
M*XU(S2,%8#X6TFAS3J'-GVC==KW&UOI=KCG2-JZ'J5/V@%:_,5I2M>E=V7W3
MT1V'L#=NQZ#Y+8_KJKW3A*S"Q;XV%NS!4&\]L_>IXI,GMNORM!EZ&ART4181
M3/3R-$6U)I<*P&+)XKY$Y?<6^,UD/AANVLHNV=OUNWNXL+D!VQE).QXZC<>'
MW7C\G5;CR&=J,YMK*8#,X"E-*,<\=$:=/!)3O$%12>/>N08[:R@3W.V=7M9-
M<#+>6 \(^&\5- 95<%)''<-53KU!NA4;W=C>2W+[,'69:2ZGE)<B1)58'Q*J
MP=%;M*BHR"":@#BZ'X]XG;>QL'0_++ XZLZBW$FX>F<EA,?U9@J/KH2;1S^Q
M\KA8-MX[;4>!W'A\WM[=%=%4'(PSUBR3F:&HBF D]QY*#Y8#=V,W]0_%/<%!
MN_;F3V7#M/*_W(WAD8\!UQLC8=;UQ1]./29'*U"9_96=VS6:<G4U[2Y>IE0,
MM3&#I&VWGVXDM;BPD]Q-I-E,)#(!N%D"TTTPG:XJ&&B5) 3'I'A@,1X9H*,&
M^YB6XANX=JB6XB:,(:N:1)&8_#(+D%672'K5F"TUBK5F)B?BE-L;.=<9;Y-'
M*[0W91;YR&[,<=U;.QE1F>SM^=C4_:=9W'3Y#$;?H:S ;WP&\(GGQ,&/:FPU
M&);&AD*(RLU;L_Y*MN;K#,8'XC;CVSM?IN#(?Z.^MX-J;TS>V<;DLIDJO/UV
M<S>0SF2JMP;HRE1N>>&N?[NH,$@H::G,9IXV1U*<Q<@"WW2*;W*VE[F\(\68
M7]DC$!0@"*CA4 C!50 2"[L#4@AJZGY@FN;!X=MC2TM:F)#J8*Y);6=3,2VH
M^;$:0$(T@#IWPM1\9Z/;/;..SWR>I=R[Q[RDQL?9W93;@VA@-T9C#XC"T6UL
M=MW#TNW\-08#;&'I-JTLM&@HZ1)UEK:JK$HJYC,&O<^Q/E=NS86%V1E?CGV"
MU702X%L_O?\ NGN6?=.]J?:,6YX=G4V>^YJ)<53O@%WGDVDGIH8YLC+4(]0S
M&)?=[7F3VZM;^:^CY_V8:]9"?7VFA#+X?B::2!CK\*,4.$"D( K4Z2[BN_[C
MMJ6,FWHK:PS,"U3H#!!DD44.XX D$:BQ4'I1;.W%\5=D]C9CL'%]Z[9D2LIL
M_%@MJ3;@P";>VE-O&7:<V\IL+]K1P9)X<X=AX=8Z>HGF@QR4C)2I$DTBE+=?
M_&_Y#478/7U;6='=I4M'1;_V/65E5/M#)1P4M)2[JQ$]54SR%+1PT\$;.['@
M*"?9C/SUR*\$R)SSLK.4:@%_:DGM. /%R?0#)\NBC:N7=U@W&TEE@ C5^-:>
M5!QH,G&3TNNS/DGT%5];]@TM/V[L26>IV/NR"&*//4LCR2RX&O2-$1&9W=F8
M   DGZ#W7MWW\1/D_FN].ZLOBNA^SLAC,GVWV17X^OI-JY*>EK*.JWGFIJ:J
MIIXXFCF@GB<,K*2&4W'O"*WGB:"!@XH4''!X=9LRV5V\LKI;N5+$@TXBO'J+
MTEW[TMC>F>HL?7=G;.IJVAZPV!25=--F((Y:>II]IXF*:&6.32\<D<BD$, 0
M1R/83CX8_*[\_'OM?_8;/RO_ %X]O>-%_OP=-_07O_*,_P"SH3O]F*Z,_P"?
MJ[*_\_=+_P!'>S*9'9?SBRGR6Q7RCF^+V[DWKBMV;0WA!@8MD;E&U9*_9M!A
ML?CJ::F:M;)FCJ8L+&TX%2'+,VEE%@&:V_A&'Q1I(/GZ]*6BOC<_5?1MJJ#2
MAIC^?0,0Y7XN0=)9;H5>Y,2=G9G;FZ=L5=<V[,5_>-<?NZHRM1DY(,@*,4L=
M7$^7E$#FG94 6ZM8W"O:OQP^8NTQO]:'XW]BU([$V=E-EY;[O9V;8T6/RN<P
MF>FJL;XFBT5L55@HD0R>1/&[@J201<R0G3^H,&O'IE;2\7Q/\5;N%.!]0?\
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M]ZMH=6TOBXV1]+!O'(OW0+1O:S $$J3R/>3/[XVW'^,G_>)/^@>L<%Y+YI#
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M(X/LJW^R7?+'_O'OM7_T$LG_ ->O9%XT7^_!^WHS^AO/^49_V=#9_LQ71?\
MS];9'_G]I/\ H_V;[J'%?,OJG:NQ,!/\,\]OG+=-[OW/O_HW=&X=N=@XZNZW
MW=O*/;XW!73XW;&=PF%WQCY:S:F.JX:7,05"13TY1C)2R24S,2>"Y8^/0, #
MPR!_@X^72J*.\C1%-B6*DE20<$\>!%> X_X.BV]C4/QF["SO8&6;O^AVY0]P
M[.P6P>W\'A\[MJHI-\;5VVFX8,31PU>:QF3R&TZP4&Z:^DFJ<9+3R24\^I?'
M4I%4IR@S7\T9NKNQNHLUU_W1N?:?8^R=N]>UJY_:-?6UV#VIMO)8NKH\5@:D
M4\34U(^,Q28SQ2>6.''L8X5C*HR[(M2Z/J74IKQ\^K5W4Q/$\3L"M!4<!\OM
M&/LX=2IMO?!9NP-C=F46<ZXP^Z^OMS[GWE@JG#;@AQ])+N7=^-R>.SV7R=##
M-]O6UM><Q45,DA"O+5R-+(79FNA.SNJOECO;86WNJMH?#O>/5W76%S4&[<AA
M,)A=];ERVZ]ZP8&+;5-N#<FZ-YY+-9B6FPV'\\&*QE*U+C<:E;5-'"9:B:5[
M(T*L7:8%Z4\N'Y=-RP7CH(TLF2,&M!4U-*5))/#R' =*[:6\N@\!O?,]D9WO
MW";RWGE,,^UZ&MR>8P&,Q6V]JMF9<Y)A<!@<'2X_'PRY&N\#U]=.*BOKC1TR
MR3>."*-"]?[)=\L?^\>^U?\ T$LG_P!>O;GC1?[\'[>D_P!#>?\ *,_[.A:_
MV8KHO_GZVR/_ #^TG_1_LWOPK^*WR2VKV;ONJW!T=V5BX,C\?^],+0/5;7KX
M?O,ME=@Y*CQN.IA(B^:LKZR5(HHUNSNP 'U($7)U]8VG./*MY>WL,%E#>J\D
MDCK'&BA7JSNY"J/*K$"I'1#S5970Y6YB#0LH-JPJ1099>B[_ ".[YZ8R&'ZG
M:C[-V?4B@^0W2>3K#!EH9A3T%%O6BEJZN;Q!_%3T\0+.[615%R1['3_99/D=
M:QZ&[7^EB/[FY0?]$ CWEW_7SD,?\[YLGY7]H?V?K4/^#K#G^K&\@U^F_G_L
M=#X?DW\?02#W#L$$&Q!W!1 @CZ@C7]?8^/A?E0^UVQ)^*>ZAN^7J"G^/]5V7
M_=;>AS=3TU3M&@VI)MDY([.7*2X^):-LJM(*C[<%U1:HFH]D WSVZ%SX@]QM
MI^D^M^L\+Z^R"?4_[\U:]>FO?X98J&H*E0%Z'/[RYF_=WTHL$%UX AUBO]F
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M8^7&]Z8=^7F+;SL*V84W0N83;!OH94H;C7X(.ME3+_$P'$CJ;1MUU_K)C;]
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M %-D_P"CO?J#TZ]J;^(]>]^^ZJ?^5B?_ *FR?]'>_4'IU[4W\1Z][]]U4_\
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M$/'H)&6P[XF_6(OX*HA8T4R!G"\8V=0>SQ(RDH1NY0X#9KTEFADMYC!([ZP
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MC3Q4C4<9G8BOW53_ ,K$_P#U-D_Z.]J*#TZ1ZF_B/1N_?ONJG_E8G_ZFR?\
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M!UV.NP?J[K!_M&_PGIDZ'97Z.Z9=2&5NJ.NV5@;AE;:&'((/Y!!]@W]M4_\
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M&B_Z]^_?[.Q\M_\ O(CM?_T+LG_U]]^\"'_?2_LZ]]=>?\I+_M/7O] 72O\
MSZ_97_GAHO\ KW[]_L['RW_[R([7_P#0NR?_ %]]^\"'_?2_LZ]]=>?\I+_M
M/7O] 72O_/K]E?\ GAHO^O?OW^SL?+?_ +R([7_]"[)_]???O A_WTO[.O?7
M7G_*2_[3U[_0%TK_ ,^OV5_YX:+_ *]^_?[.Q\M_^\B.U_\ T+LG_P!???O
MA_WTO[.O?77G_*2_[3U[_0%TK_SZ_97_ )X:+_KW[\/FU\N1<+\C.W$5A:14
MWGET250;A)T2=4GC5@&"N&4, 0+@'WKP(?\ ?0Z]]=>?\I+_ +>NO] /21(+
M=5;$=EOXWDVWC9)(2059H)'@:2G=T)5F0J61BI.DD'W^SL?+?_O(CM?_ -"[
M)_\ 7WWOP(?]]+^SKWUUY_RDO^T]=_Z NE?^?7[*_P#/#1?]>_?O]G8^6_\
MWD1VO_Z%V3_Z^^_>!#_OI?V=>^NO/^4E_P!IZ]_H"Z5_Y]?LK_SPT7_7OW[_
M &=CY;_]Y$=K_P#H79/_ *^^_>!#_OI?V=>^NO/^4E_VGKW^@+I7_GU^RO\
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M_9V/EO\ ]Y$=K_\ H79/_K[[WX$/^^E_9U[ZZ\_Y27_:>O?Z NE?^?7[*_\
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M $!U[_0#TG_SZS8__H/8_P#Z\^_?[/-\R?\ O)_O+_T9.Z?_ *X^_?NS:_\
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MH%Z7_P"?8[,_\\='_P!>_?O]G7^6W_>1':__ *%V3_Z^^_?30?[Z'7OK;O\
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M?[T>J_6'_E&A_P!Y'2Q_T"4W_/W>^O\ T:.5_P#J?W[_ &<?)_\ >-_P[_\
M2=MI?]???O '^_9/]Z/7OK#_ ,HT/^\CKW^@2F_Y^[WU_P"C1RO_ -3^_?[.
M/D_^\;_AW_Z3MM+_ *^^_> /]^R?[T>O?6'_ )1H?]Y'7O\ 0)3?\_=[Z_\
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M_=[Z_P#1HY7_ .I_?O\ 9Q\G_P!XW_#O_P!)VVE_U]]^\ ?[]D_WH]>^L/\
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M][ALE/#K4++&7#QNKJ#[!S_9QLG_ -XX?#L_X_[+MM+G_'_.6]W^G'^_9/\
M>CTT+LC_ (C0_P"\CH63T+3$W_TN=]#_  ':.5M_[C^_?[./D_\ O&_X=_\
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M_>^M=3?8F]*_\SDZE_\ $F[#_P#>JQ7NDG]F_P!AZ=@_MX?]./\ #TANS_\
MF6O8?_AC;M_]T&0]OOR4_P"RB^_?_$U=J?\ O=9WWJ'^RB_TH_P=>G_MYO\
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MJD"(:64:"6^OMZ&)TFF=OA(6GY"AZ:FE1XHT4Y#,?VG'1I?C+\>.S.J_E/\
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MHK3%:@5]:?GUKZ'N(^H3P](.K-*5H?+R_GTK:3^9AUI5XK;U.O2OR(7M'/\
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M.^%[PHI>G%Z_WI49^NW_ +:W/393<%?N[=:[[R>Y:NJR536922HDF\11D$*
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MH6?L[>&>RE?7;XQ@H]AX#KO TW66[Y93G>JZ3:F$VW33XJ/!340HLGY*U/\
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M4;+KJ"6DRZ8@5D?AJHYXX?-HU'.X2/Q ,H2#7TIQQBM>FI[>)YI/!KK$E"H
MIDGX<YI2F:?;U+^/WR0[!I^LNFJSNS&8#%T&^>@<QV1C^P<]OF UL-9L2'9U
M/EINUC3[<I,+M]=U?WQIJJGJ<:]?'3,)*:6/RF'RQ)?@9UHG9&P\2W;&X*/9
MO8W5^[]Z[1V]DAU#3]J;HWKLGL9>MLGU/M_)4W;%;TK5;HKSY,Y2&3<L;R4-
M/+0B%LCX89[?4/I;L[@P!XTH16O"M/+A\^'5OH8_&5/$.DJ2!VZB0::1W::^
M?'Y<>G7_ &;O=HVYOT?Z/<94;EZZWWMK;&Z<_CYM]5W76"VIN_8%1V#B>Q<O
M#'L5.R(<#0JD6'KDBPDHIZ^>.I:5:$3S4[;LOX"[7S>SZ[<F^NU:SI^?=&\.
MYMJ]:0=HTG7VQEVP.F&I8*^H[]QFY^R\7N7:E=N/.5T>'2DV]1[ADQM8KS5!
M:/Q1S;:X(-%350 FE3Q],?X:=:6P0H[-*5.I@NK2M-)IWU;%3B@K3SZD[J^9
M%9C]T5V V'L ]KILS;?4>Y-[#K^JW)N:LW+3]P&M;$KTW-A=I9# [MIL+BJ"
M3*35&1K<3%4T>E(K,7DBK*]JNBSH]/LT7=('^@WX<_\ B*^SS_L?]F%[8/\
MO?MF/XY_],/\ Z53_P"XUC_I6_X^W0(];?\ ,T/D1_X?&R/_ 'T.P_?_T]*C
M?'_9'/QZ_P#$W?)+_P!YKX_^VE_MI/\ 2C_+TJD_W#MO].__ #YUNZ[2_P"R
MG.[O_$2?'[_WHN^O95O;O27HP?OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_
M=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOW
MOW7NO>_>_=>Z][-+T;_S)#YD_P#B(>N__@A^H_;,G]I!_IC_ (#TJ@_L;S_2
M#_CR] MV/_S,KX]_^'WO+_WT'8'LK7M[I+T-/NV?']2[.W)\W/B'A-];'HH>
ML-Q]1_$?^*T=7AVVWLS=NX\KT+L_(83"YO*T]/C\?/#V!O7[:BKY_,DE6U7+
MKF$A9PAULMO.5;O#-\\5_P @Z-#$#>6P9/TBJ>6#VB@],G'SZK\WKV/O#"?%
M/Y,Y[9F[*V??.W=^?(B"AR5#7QY_<VT-O8CM_<N+S&6PV/D;(SBMZ_V<)ZN@
MI&A=(320H(BFE#U00_(?Y3=2_(+:O=W6\-7O/:V\>G=G]"/6]8[=ZMS^S.]=
M\]N;>V5-TELZ+$[?VL\&*SO7]9EZJMVW(DM/0)@8:P10-3L\ECX<+Q&,]A!+
M9J* 5J?SIGY]:I<7$4RS1=P90N--&+4TC P17'RKCIKSN7Z?Z [%Z,W+UIV%
M61;3W!MGM'<W;R0;YS78F$W5TUM+JW.;M7MS<M9DLMN0RY/"[UQ^'IZ/.1R1
MSU[YN:F,DWG"KA^=?5G5U?U=M?>_1NX.H=XX/XX[FB^-6Z<IT\N2J:K*]?M0
MRY;J+M7M263;6WZ*7>F^=VX_=]-59&,U,<T46/I_,0D/DU;NP=ED# N-6?7S
M ^0%/Y]>O8XC&KP%2J'2:>GX2V.)(;^77/XF=C=@4/8>2V?VYANT-LYGOG9X
M^0& QO:-71?:X/? R"8SL_JGK^"7<^=R%%@-D[:KMKU,.,18H89):^H1;O4+
M% E^.?QX;K['[.@V/V)'VEF/@8_R[;M&3?44F)QN[,#C]P;AJ]JT6P!MN.EJ
MMD9_!89()JB:M-=35TIEB?P1^*3WC2Z]6H:/%T4IY>M?7K1A@T*@B;Q3#KU5
M\Z5X4X8ZEK\@^Y&W=6YJ;*]>1[*Q/S1C^,";/I\)D'R&4VEEH-OTM+N:OW/+
MFFDH-^XK-9.9TIH:8X^>A5(WC$SF9*KO:WHMZL)]FT^4W_%@^)/_ (J7LO\
M]^7VY[:BXR_Z<_X!TKNOAM/^:(_PMT5?XS_\?)\L/_%J-S?^^IZ>]E]V5O\
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M;@ZHW'UE@<[M':7<W1^R^X:;9>>SC[HFV?79_*[GV[E<'CMS34.-K,[A/O\
M:CU5+-40BH2*I$,C2-$9'M"S,&#&K*Q%?7JEU'&C0M$I5'0-2M:9(I7TQ7\^
MA"^/>^-X[PQ'8V)WUD\%GL]UGVWN[K0[BP.-DPD6X*#!4F$R6.RF2PK5F0@Q
M6;:ESBPU4<$IIWDA\L:QK((DS_$O_B]=[_\ BJ/R(_\ >!K/?IN$?^G7_#UJ
MVXS?\TV_P=-WR5_XM73G_BR'1_\ [V5-[*B..?;W2;HR'L1,QO7L#LB;8&)K
MZBMW)5]?[2HMA[$H*#%PR5F-VMA\OGMT4N*IZ?&4:U&0^UR>>KJ@RS":;3(0
MS%$4+4*JZB/,UZ=,DLIB'$J*"@\@2?\ *>DIBMN[2V0=UY;'4E!@%W7N*7>&
M[*Z6J>*'([AJ<7A\#+EJR6LJ&AIY9<9@Z."R>..T*^G422-W6_?/ROS_ &AN
MG<?5-=N[=':6_M_8?N+<L.R]D4FYLUG-W[0.YY*3.2[>Q6W\@K8NG@WME(JR
MD2F&.J::N>*IB>(A0VT4(0!P @%,GR/_ !73L4MRTCF$%I&;4:"M2*GA3ADU
M' ^?03[QZ8^.E!U[AMJ;[V[M#$]<[9V=6]98:DW'G)\1AL5M/.U6VJJ; 09*
MNRU*T<LV1V;BYZ>8S&L@J:"&6"1)$U>YV:^27R%DW_A,'NW9NQZ_-[+Q^<ZQ
MVMTUN?X]]<3;8V=1;HW>NZZS:&"ZBKMD+B\1DVWE+]S#IHAD143.GD99I$?0
MBB"DJQH<DZCG%*UKZ=6-Q.):-&NH54*4%!4UH%I@U_/K)B>F>G:/;^X<_MS)
M9G'T^]JC [QW9V3@NT-WT^?W9-M?:U-MG%;@S?8-)N;^)9.FI]IT$=,TCU1I
MVIXE8BZ*RIRH^6W>U13[[Q>\,MMK?DF]]V;KWKF9.T.M]@;]R6"WYO*CI\5N
M[=.T9]W;9R<^Q\]F*.@IXJ@XW[5+T=.PC$E- T6Q#&-.D$4 &"1@<*^O51=S
MJ'#:6J2>Y5:A/$BH-/RZ<<3\?.I,)-M6MVA@:O9@VKMK;^T<2NQ-T;GVC0UN
MSMLU%97;<VWFZ7;F9Q])N7"XNJR=1+ E<M05-3, VB>=9"Q'_;>WNDO0W>S1
M=T_\R-^'/_B*NS__ ((3MCVS'\<_^F'^ =*I_P#<:Q_TK?\ 'VZ!'K;_ )FA
M\B/_  ^-D?\ OH=A^__4TJ-\?]D<_'K_ ,3=\DO_ 'FOC_[:7^VD_P!*/\O2
MJ3_<.V_T[_\ /G6[KM+_ +*<[N_\1)\?O_>B[Z]E6]N])>C!^_>_=>Z][][]
MU[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>
M_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWLTO1O_,D/F3_ .(AZ[_^"'ZC
M]LR?VD'^F/\ @/2J#^QO/](/^/+T"W8__,ROCW_X?>\O_?0=@>RM>WNDO0T^
MQ)RG<W;^;V=2]=YKM7LC+]?T,&,I:+8V4WQN?(;/HZ;"<X:GI=M5>4FPM/!B
M#_P%1(0M/_NL+[KH0'4%&KUITZ9YV3PVF<Q^E33'#'#'2.Q_7?7^(W#5[NQ.
MQMG8S=>0EKIZ_<^/VSA:+<-;/DS$V2FJ\U34462J9<@T"&=GE8RE%U7L/;EG
MN_>]-TU.W*S<O<W:FX*S9[S2[3J\UV!NO)U6VIZBG6DJ*G U%9EIIL353TBK
M$\L!21HE5"2J@#0CC%0$%#\NK-<W#Z=<[DKPJ3C[,]1,7U9UCA(<M38;KG8F
M(I\_'%#G:?&;1P%!!F88)7J((<K#2X^*/(10U$C2(LH=5=BP%R3[#FCSN;Q^
M-R^'H,QE*'$;@BHH<_BZ/(5=+CLY#C:Q,CCHLQ102QTV3CH,A$L\*SJXBF4.
MMF /NU 2"1D=,AF 90Q"GB/7[>E=48O&5=9C\C5XZAJLAB'J7Q5=44E/-68Q
MZVG:DK'Q]5)&T]$]72L8I3&RF2,E6N./;E_?;>6J-_[V[GUQ;8?9,3_Q[*ZH
M]FRPRT\FTHV^[NFV)()W1J ?Y*4=@8[$CW[2O\(XU_/UZMXDG\9X4X^7I]GR
MX=1/[N;?LP_@6&L^97<;C^%T5GW A1DSK?L>K,HT:D51_?!4>K@>TQ[WU3IY
M]FT^4W_%@^)/_BI>R_\ WY?;GMJ+C+_IS_@'2NZ^&T_YHC_"W15_C/\ \?)\
ML/\ Q:C<W_OJ>GO92_;O23HU'NQ?,=2=D=L_"3XS9?86WI]XX3K#<ORAR&^U
MQF:PBS[4HILEUWG&DR..JLG#7T7WN)QTL\3" B=(SHUE2 F#JD\@8T)"T^?'
MHQ\"6:SMVC34JEZY&.!_R=$FVOO/:>Q?E_\ (6@W56G 9'?^ ^.5+M-JW$96
M*'<\L%!O_$F+&95,>V/KVI,C4""15F)IW<>0('4L=C+/V##\J-\_(G-[THJ_
M^7SE>L-WTE%74F]\1'U3FN@LEU'E-M[%Z&P_7W\<A+;UH<H]!@H-M+CQDL9N
M6F%=)%$:=JU$V/ 6)5_QG4/MK7+5]/.OITI83^,]P7_Q'3ZC3II0+2O'RI3!
MS\^BDTN*QDOQ;VATS@=J9#%?-/']B;1J:T9':.4FW[CNZ<;VKAMP[[[?R.]6
MQE9$NU\EB#79<Y]ZYL?7X"J%+&THG6A<,L=@^I_]E[3X%R=D52]KY;J&7O*3
M9XVWMM>OC\LI::'MC;IE[8JM[)#2;GI_CPC;!>F6@--_&:^2 SK(#I<)D\7Q
MPG96E:YT\.%/7/V=5"IX'T&K]4KJIBFOXOBKQT=M.%?GT)U=5=B#N)_F&FPH
MVVGC.W8>FX<NU;GSOL?%H1GKO<%1#L6CV7)D:K#U'?CKO15:K);!4$56JFX5
MJ7?:[HGZM!]F8^)__,S]P?\ B#/DA_[X3L7VS/\  /\ 3+_QX=*+;^T;_2-_
MQT] '\B_^/.V9_XG;X\_^_KV-[+/[>Z3]#Y[$K'=S=P8?9=3UOB>UNR,7UW6
MTV0HZS86.WQN:BV754F7F^XRU+4;7ILG'@YJ;*5!\E3&T!2=_4X8\^Z&.,L'
M*#7ZTS^WIP2RJN@2,%I2E32AXC\^D=4]=]?5FYDWI5[%V=5;QBDI)H]V5.V,
M)/N:.6@@>EH)4SLM"V422BII&CA82WCC8JM@2/?.N[J[BRFU,+L3)]K=CY'9
M&VY<=-M_9]=O;<E7MC"28:W\';%8*?)28R@.'Y^T\42BFN?'IU&^PB E@HJ?
MEULSSLBQF9C&. J:"G#'R\NNJ3KGKZ@SV0W30[%V=1;FRRUJ93<5)MG"T^<R
M2Y)E;)+7Y6&B2NJQD&4&?R2-YBHUWL/:43=V[(\IG,Y'N?<,>;W/!FZ7<N83
M-9),KN&EW*)EW'39W(+4BKR\&X%J)!6I4/(M4)&\H;4;[TB@%!0=4UOJ9M9U
M&M37C7C7UKY]/C8'!O18S&OA<2^.PLN-GP^/;'4;46)GPYC;$38RE,)@H)<4
MT*&F:)4,!4:--A[YT.]-X8O^[YQFZ]RXX[2JJVMVJ:#.Y2C.V:W)/%+D:O;W
MV]5'_!:K(20(T\E-XGE9%+DD#WXJIK4#/7@[C31R*<,\/L].L<^V]O539AZG
M X6H?<,-+3Y]Y\70S-G(*&-X:*#,-) QR4-'%(RQ+-K6-6(4 'VFO>^J]/7L
MU/8__9(WQ=_\25\G/^M?1WME/[>;[%_R]*7_ -Q+?_3O_@3H"MF_\S^[Q_\
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MSL;%?&;$OBZO<&,I>P-^="]>UE%ELI.N0E_A;;=IZ*HG,U,L#-$$JZ(E4=\
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MW^?I4_W%[/\ ^?X9K_T!=A?_ %H]^_TU_&[_ +POV;_Z.OO+_P"RWW[PY?\
ME(/[!_FZ]X]M_P H2_[TW^?KW]Q>S_\ G^&:_P#0%V%_]:/?O]-?QN_[POV;
M_P"CK[R_^RWW[PY?^4@_L'^;KWCVW_*$O^]-_GZ]_<7L_P#Y_AFO_0%V%_\
M6CW[_37\;O\ O"_9O_HZ^\O_ ++??O#E_P"4@_L'^;KWCVW_ "A+_O3?Y^O?
MW%[/_P"?X9K_ - 787_UH]^_TU_&[_O"_9O_ *.OO+_[+??O#E_Y2#^P?YNO
M>/;?\H2_[TW^?KW]Q>S_ /G^&:_] 787_P!:/?O]-?QN_P"\+]F_^CK[R_\
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M_O"_9O\ Z.OO+_[+??O#E_Y2#^P?YNM^/;?\H2_[TW^?KW]Q>S_^?X9K_P!
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M_P#0%V%_]:/>2+N;XY3RQP0?"K:,TTTB10PQ=T=Z22RRR,$CCCC3=A=Y'<@
M $DFP]^\.7_E(/[!_FZV)K8X%B*_Z9_\_73;'[-52S=Y9E54%F9MC;""JH%R
M23B+  >UCN7</6FS*5*[>'\O"3:E%+.*6.LW+V#\C\%2R515V%,E1E,]2Q/.
M5C8Z =5E/'!]U"N30753]B]7=HH_CVW3]I<?Y>D]AJ7<6XIY*;;_ ,F*?.U,
M4)J):?#8#K#)SQ0!TC,TD5%0SR)"))%740!=@+W/M%?Z:_C=_P!X7[-_]'7W
ME_\ 9;[MX<O_ "D']@_S=-^/;?\ *$O^]-_GZ47]Q>S_ /G^&:_] 787_P!:
M/?O]-?QN_P"\+]F_^CK[R_\ LM]^\.7_ )2#^P?YNO>/;?\ *$O^]-_GZ]_<
M7L__ )_AFO\ T!=A?_6CW9/\%MK_ !B^2_6OR#VSG?C11;5VYM[<G2>>GQNW
M.X^U&DS66D7L_%8Z>KK<QELK+30XFDK:O3'"$$[5-Y+^*/3+'LW[>[9[B<T;
MAM&];G<PV\-@\RF$1AM0DC2AUJP*D,?*H('4]_=Z]L.7/=_FO>N7=^N;NTLK
M;;C<@VS+J:194C ;Q5<::.V  :TR>BZ=C[6[<@[ZZ4QF,[VKL?6Y/KWO5_XK
M4=8;!RTU/38VKZDJYZ6FADIJ*.G-9*8F>3U/: (-*NY]FK_V0;X-_P#/@,W_
M .CO[!_Z,]Y(_P# O\D_]-)NW_9O_P!:NLM_^ I]K_\ IIM\_;;?]:NEY_<?
MO[_O*/(_^B3ZX_\ JKWED_E_?"6*EAKIOCKN>&@J6=*:OF[D[)BH:IXQ>1*6
MLDIUIJEXP/4$9B/S[;7[LO(3SR6T?->Y-=)34BM:LZUX:D6,LM?*H%?+II/N
M8>T\MS+91<W[N]['37&LEFTB:OAUQB,NFK\.H"OETTTN&[>K\]E-JT'S#H:_
M=.#@HZG-[8H>K>I:S<>%ILB@DH*G,8*FRDN4Q=/6H08GGBC5[\$^\D_\OGX4
MTCQ15?QQW51S5$<<M/#6=P]ETDU1%*=,4D$-3312S1RMPA4$,>!<^ZQ?=G]O
MYU=[?F[<)(U)!9'M'4$<065"H(\ZG'G3JL/W-/:2Y226UYRW:6%"0S1RV;JI
M'Q!F2,J"O%@2"!QIUAPV/[6W'15N2V[\RL9N'&XRMK,=D\E@NLNHLQCL9D,<
MH?(4.1K\;EJFDH*R@0ZIXI71X5Y< <^\TO\ +P^&<#0I/\9M[4[U$R4].E1V
MMVK U14RG3%2TZS4*&HJI6%EC34[6X'MN/[MWMQ+XG@\[WCZ%+-IFLFTJ.+-
MI4Z5%15FHHJ,],1?<]]F9UE>#G[<)$12SE+FP8(HR7<JIT(/-VHH\STSXS);
MTS5/DJO#?.K9V7I<+C*G-YFJQ6R^D,C38?"T4?FK,SE9Z//S18W$TD5FDJ9B
MD* C4PN/<(_ +X0*)"WQZW"@AE\$Q?NGL9!!4'7_ )/.6A AJ?VV_;:S^D\<
M&RD?=AY&(4KS1N9#+J%#:FJX[E CJ5R.X57(SD=+!]RWVK.C3S7O)++J6CVA
MU+CN6D7<N1W"JY&<BJKBVIWA/]I]O\LFJ#D*(Y.@6GZ@ZNG>OQ@%*3E*)(:]
MVJ\9_EL/^41AH?WD]7K6^*7X$?!Q(Y&'0&;NJ.P_XS?V#]0I(^L9'X]W3[KW
M)#.JGF3=J$C_ )1_^M73B?<H]KV=%/,V^4) XVW_ %IZFP[%[^DFBC_V:+(G
M7(B6/2G7*@ZF"V+"H8K>_P!;&WNN;YS[R^//6?R?[ V!5_%;;V\/[HX3JO T
M6>RW;_;]#D:K%8_J/8L.'AJX,1N.BH&FQV)$%*9$B0S>#R/>1W)POYEV>+8^
M8^8=DLKJ1K6SO[B!&<*798I70,U !J(6IH *G&.N>W/>U[=RUSIS7R[:Q--:
MV&X3VZ/(QULD+F-"^G2NHJH+$  D])'XT[:[1S?4&)RDO=61@FJMV]JFH6DZ
M\V%1T\M3%VQO>"IJHZ,8^J2D%;/$TQB61DC+Z5]('LI/^FOXW?\ >%^S?_1U
M]Y?_ &6^R3PY?^4@_L'^;H*>/;?\H2_[TW^?H>?[B]G_ //\,U_Z NPO_K1[
M]_IK^-W_ 'A?LW_T=?>7_P!EOOWAR_\ *0?V#_-U[Q[;_E"7_>F_S]>_N+V?
M_P _PS7_ * NPO\ ZT>YD';7Q]J:6MKJ;X0[9J*+&I!)D:R#N+OB6EH$JIA3
M4SUM1'NIHJ1:FI81QF0J'<A1<\>_>'+_ ,I!_8O^;K?C6Y!(L10?TG_S]8)-
MG]BPS4]-+WQDXJBK,JTD$FR^ODFJ3#&99A3Q-B@\QBB&IM(.E>3Q[A_Z:_C=
M_P!X7[-_]'7WE_\ 9;[]X<O_ "D']@_S=:\>V_Y0E_WIO\_6?^XO9_\ S_#-
M?^@+L+_ZT>_?Z:_C=_WA?LW_ -'7WE_]EOOWAR_\I!_8/\W7O'MO^4)?]Z;_
M #]>_N+V?_S_  S7_H"["_\ K1[.I\"MQ_'GMWO',=<P?%O ;-H-U=,]T8_/
M93#]O=M5V1J,"FP,O69'%4RYO.9.BIVRL=*(&G\1E@20O&0ZK[$W).PP<S<Z
M\I<M;A=RI8W]\D+M'I#J&#'4M002"HPP((K7H>>UVP;7SK[B\F<G;@LD&W[G
M?+;RR1-^HJ,KDE->I:]H'<"*$]%S^2^U.S*#;?61'<U?/5UGR#Z,QF/J*OK_
M &-41XRMR6_\70Q9-:=*&E$TU&M0712VG4!>XN"?QO@3\&574_0.:4 7)/>'
M8( ^GU)2WU/O,4?=<Y*8A4YBW<D_*W_ZU=9[C[E'M@S!5YDWTL?G;$_]6>A!
M&P_D"[E(_D_DV;40$3I+KISQ<VXJ;FP'^\>Y</\ +Y^%515+04_QPW949!M>
MG'0=P=FS9']M/+)>@CI6K!HB]373A>3Q[3R?=H]OX;<W<W.%^EGC]5I+-8LF
M@_4*!,G [LG STFE^YI[1V]LU[<<Z;K'8BE97FLEBR:#]5HPF3@=V3@9Z3V2
MH>T\-@)=V9CYFXG$;3@6G>;=64ZTZ@Q^V(UJZN.@I"^X*O+PX@?<U\JP1_O>
MN8Z!=N/?"'^7[\)JF"JJJ;XZ;HJ:6@19*^JINX^RIZ:@C=BBO7U$5.\-$K,"
M/W2GT/\ 3W>3[L?(<,T%O-S7N*7$IHB,]HKR$9I&K(&?'\ /5Y?N8^TT$UM;
M7'..[1W,[%8D>6S5Y6 J1$K1AI" 0:(&XCU'6;*8CMO!Y3 X/-_,;'8;-[KJ
M:JCVKALMUAU'C<MNBKH88ZBLIMMXVMRL%9GIZ:GF1W6D28JC G@CWRI?Y?7P
MHKYOM\?\<MTY&H\4D_V^.[B[*KZ@00C5+.8*2GFE$,8/J:VD?D^ZS_=GY M8
M_%N^;=QABU :I'M(UU'@H+HH)/D :_+JMQ]S/VELXOJ+WG'=H+?4%URRV<:Z
MFPJZGC5=3'X5K4^0ZX;AQO;&T,<,QN[YCX_:>'-928X9;='5_4FWL6V1KY##
M08]<AF,I14C5U;*-,,(?R2-PH/O#_L@7P@-/]V/CUN+[,2BG-9_IH[&^S6I,
M9E%,U7X?MUJO&"WC+:["]O;G_ P\C>*(/ZS[I]1I+:*VVO2#0MI\/5I!QJI3
MY].G[EGM6)_I3S7O/U6G5X>NT\32#IUZ/"U:-1 U4TUQ6O3@=K=VC,C;A^6@
M&XCC7S*[?_T1]6?QU\-'6IC9,PF'_B/\1?$ID)%@-2(S )B$U:C;WY_@'\'X
MG:.7X^9^*1#IDBF[K[$BEC;@Z9(I(EDC:Q^A /O2_=AY&=0R<S[HR'@1],0?
MF"(B#^77E^Y9[62*'CYIWIHR,%6M2#\P1$01\P2.LE-M#O2LIX:NB^5E16TE
M3&)::LH^F^LZNDJ8FOIEIJJGK9()XF(X9&*FWU]EF[S^/W1$7RW^%71<?7E<
MO2L_1G960FV)_?K<35TE8^<[UW29!O1E_CL8_O-0Q56@#3I4P_H8^X7?VFV"
M/WPC]LEW2\_<KVPE,WZ?CZC8R7- -'ATUQA?A^$D\>L>[WV+Y3B^\CM'LP-U
MOSRO)9F4S$Q?4@FPN+R@.CPZ>)&%^#X"?.G3#U1B.R)Y?E!MZ;M:9]]T?<&R
MZ"E[-78>V(JB+'?Z+NH,NM%)LY)?[O5#K0UU10_<,?(8Y1+;7&B^_P#_UM+;
M<;4"_$SXTME8YY<6O?GR';)14K!:F3'C!?'LUL=.Q("S/3:@IOPUO;(_MI:<
M=(_R]*WI]):UX:W_ .?.MVK K6M\CN^UQLE/%D6Z9Z&6@EJT>6EBK3G._12R
M5,<;)))3I/I+JI#%00#?V=7Y(]1_*7N?Y"Y#"XK=.>'P\[4["V;@.I=U;:W<
MM-\:\)T345BS]714&.I,K2[-Q,'7NQL4):S&RT\>0H,ECZG[F,5OD9TT4D,<
M08J/' SCNKY_/)Z53PW4LQHQ^D9@ 0>P+^'Y8'$<13UZ+)T%O[IKJ[X]4F?J
M]I2R?(GKS9&YLQV?MG<>W*JJ[US?<\%+$O8QR%?44%?N3+S[WWKD52DR,,LV
M/JZ"MIFIG^R$00S>S]\=+=S?(+XZ=W]5=EU^6Q?Q[[1W+T<T%5M"'J;<FR?C
MAG>MMZU'QFQ.WWK]U9FERE?L6+:F>QAR[O3F'(UV.^X1?+&6;82)')&Z ,XK
MZ@M4:OVU&/MZ51R1S7%K-"P_38KPTT6AT^9X4(KZTKT 6<V1VMUCU!W-U)O'
MK7'T^0[JZKV_W!534V8G[)VMN?Y#8W?&WJ?Y#5&XJ?$[7Q613'[Q?<F#R*TQ
M65ZVCI<CX0! Z@F7R6KNI>S^IOC5E\EV_P!EOU=A^L.TAL7L;>N$QO<7=&8[
MB7=..K-Y=%=H&EWKMC^X^V-FF2AK=NU"FNIY,5G/O8XC+4U--2J(M:O*- UU
M&!@4\B/M\_LZ2W'A2Q6[/._A:6TD]S5KE6R*4P1QP:^?1I_C]B=[[)[/^147
M]P=OT>_,QV-U]_>79VVZS)['ZDI.LO[O9"FVAVUUY)6;9KZ?<>Y=TTD=53;B
MIP8:A,OB&I7D\%/2U54%7=G;?9F9^%'Q1QF4[3WOF8,]N[Y,4>YL37[]SF43
M)T&,S74382DS^+J,O4>>@HS&6HXZF/Q*59HA<,?>XT47,[:!6BTQ]O3,\LK6
MEJ6E8DEP<G(!6@/J!Y=+OJ[K_:6+^5_R/S%%L+;V*F@VAT!+BLW3;/QV.=JN
M:C[83*28[,Q8R#[FKT5(6I,4KR(L@62P< U]>U72#HXGOWOW7NO>_>_=>Z][
M][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO
M>S2]&_\ ,D/F3_XB'KO_ ."'ZC]LR?VD'^F/^ ]*H/[&\_T@_P"/+T"W8_\
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M9()X)(YH9X9&BEAEB8/'+%*A#QR1NH*L"""+CW[KU:9''KIE5U9'561E*LK
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MAPU+5M22T5%#[+K/_F9O^64G_0A]S3%_:1_Z8?X>LA(?[6+_ $P_P]73TG_
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M&A)($;,T!->YHBW%CU-'(>Y/N?+J-H@^EMIC;0M!&8H9((8XO#:*-BQ54+M
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M+0T\QGI1]*I\AXNF^I8L8>E),;'UCL&.@DJCOM:EZ--J8E:=ZA8PT:S/$ 6
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M/Z'\^@'_ (AZS?L7_/T82_R5_P!3T;_R5O[_ *,]]Z/@9_QW^7?_ )R=-?\
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MDGB<^_?B)U_V70]']==&;DZ?S>9Z7[1V?\5^RMP]2PUN2S=9M/=ZS9A^\>Z
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MEY=X=L9S8FYLQ39++Y]VRM+C]H*M+4T\%8*[)RJK8ZF+HKN0@%:L  #45SG
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M(S[UU-M:3K6JV!@*K9<&V_MEAVUBJ'#;ZQ,D,BS335V4.3DJ1$QA\I5>H/\
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M $];VV_Z6\7_ !R3J7_N_?\ 3\O:G_I<1_\ ').BP_*?_CW^G?\ Q9[XZ_\
MOSL'[V#(JI:%XZYJ.DR"T8>I-!D%E>@JS%$S1PUL<$L,LM,9 "RAUU 6)L2/
M?3;P#=-]*)Y(C*536A =-3 %E)! :E:&AH37RZ[.&U-]6R6YEA:8A/$B($B:
MB 6C+!@K@5TL5-":@5 Z$O<&%GW)A\OMVFW!GMJ3YREEQ:;EVO-0TVY,(M8P
MAFKL%5Y&AR5'191(&989WIY?"S:U76JD#EN&6HPVZ>[L]M['T4>X\%2;-FV_
M34V$HJN#$Q9V7!0YZKQV":DGHHT9)8X/3"?%'4M:Q:_N(>7@FZ<O>T.T[U>S
M/LEW+?K=2-/)&\QMQ<&V66Y#J]00ST+C6T2U!"TZ@_ESP=XY<]C-EWW<IFY=
MOY=R6[=KF5&N#:I=-:1S78D64FJ/*:R5D> 5!"$=5&];5 W]TG_+DZM[,WGN
M_(=/=D9_Y XWLK*Y?L;=U'F-_9+J_#=CY'J[;F]>TZ;/X[=N3DBDQ-3EV63(
MI+D*[!QR2%UA9"K9<=1XK>&!VY@L+0_W=WCV)O7%;XHCB*6M@2GI,?AGEP,M
M=-!42X:BV]25U560)%) 8G37<Z. U#N5[?\ *V]<P;QN<W[^VO8K&:PD$SQL
MS-+< 7 B#*)Y+EXXK>5G236KE:+J!Z"$&[;ANW)N^\R[WO5P.8]IY>VZXVV3
MQFC8O)-<@72Q(Z)=27CQP6TID259$?0%4R5Z F'L'<&_>@]^]R]F=M;YH^V>
MB/AY\<^Q_C/N63>^8P.0R.>W-N+LV@H.REVY09*DPO8N<[NSVW,)@\G+74-=
M'DX&CHXU05DBS _M:?)[?VCNS<&"I'GW'3Y?9-%C:NJPD66G_NSEY\P35T='
MD*.JB>DW+74--223K$1*C&-7!<^Y/Y@AL-WYIY8V7=;G1L3V^X22*LYA7ZJ$
M0+X;R1NAUVD;RSI&6&E@'93IZF#F>';M\YPY3Y>WN\$?+LMIN<DT:7#0*;RV
M%M^G)+%+&RR6,,LURL9<:& D=2(QU8M\AX=@=K]^=#=3=E[VDQ'45?L+Y%;J
MW1A]N=F9#9./RW</7,75[46"W%N3:F;PV2BR'6.U-R9O-T] :N$T\L!KWC/V
M*O$+9P^R:O+[HV6%I*+'X+>1EK\>N+(5LGD-X8=\1!1Y\*6B@J8ZJ7 I1>74
M(Q)ICLA<1Q%NO-\.T<M<ULTLE[?;4-+F7_0X[&<2LUN:"JLJ;B]R%TARFICK
M"=11'O'.UMLO+/.#SRSW]_LP$4IESX46W7'U#O9D@:D*)NC7)307,6M_U G1
M!(NQ_D3@^MNC^_JC<&Y\CO;L_P"/D(VEOW)=AK3O5;2VWT-OJHWS4Y+J.JJ%
MI,I64E=AZ+LN7<CT9I&K31TS5 ^[2C<#=YX\T.=>H%2U5%G:1-PP.^-BPTD"
MUU?D:22D.+IY):>CBIJG'2+"D;%?M_&?U7]RURQN"7^TB,0Z'M)3;&DAF#&.
M.)]8E8!I"RRKK9@"9 ]1PZF[D[<AN&RK#]/X<EE*;5OU3.',<4,@D\9@K2,Z
M3(9&(!\7Q!P ZM9^,.^5WCUBV%?$R8JOZISS=49(MO>7LB/+2X';&U=P8_.C
M?5518VOW+793 [KHWR%1401S?Q452G6JJ[5U][?]O"?A+_X@+LC_ 'KO_P!X
MZS?^):6W_/ O_=HN.L2MR_\ $Z]A_P"E7_WA;SI5]1_\S"^5/_B:ME?^^/Z7
M]__1U!-O;-Z^W9\0>D9]\]Z;>Z5GP_>GR!?!G-[.['W54Y]I=L]#RU%=CI^O
MMOYX8K^#301*PJO%)(\ZM$2$>R8LPG<+&6&D>8]3Z]& 2-[2WUS!*,]#0G^'
MT!X=;F61W/O';OR=[;AVIU9F>RH<ATYT6V4EQ>Y-EX"##O%N?O2*GHZF'=N:
MQ,U<U?#*\@>!9(D5-+D,0#+W?-M[L"I:LWQ_,X?=M4^WJK:<D^X=F_*?*R2[
M8KZJDK\C@9FK-E2^7%9*OH8*BI@:Z5,\*22!G4,/*-.%M:"O]'_/UY]#_'N=
M<4R'X>G#J7A!F=M(D>W?A)#@TCS,6X8UQ6?Z'H!%GJ>GJJ.ES,7VVXHS'DZ2
MBKIH(9UM)#!*T:%4)7VP+MSKI,CG\NO\QV@7+;K;$/NC*#8?RB&1W')M_*XW
M.8&3.5O]R/N<K+A,UAJ.KHVG9VIJFEBDC*O&A&ZM@?38'S7_ #]:TQZF;]Y#
M4>)H^:<*X^73DV7W<]'BL<WPUG;'X),E'A*%MS]%FCP\>9H:S&9A,53'<IAQ
MZ97&Y&HIZD0J@G@GDC?4KL#UA-M=<;:K,SD-N_S&\=@:[<>1QV8W#68;8/RA
MQE5GLOB,N-PXC+9F>CV1#)D\GB<^HKJ6HF+RT]8!-&RR -[\2QH#;</FO^?K
MRK&C%EW$!B:U ?CZ\.N&4RFZ\VF%CS7PRER\>VZ/(X_;R9/<O15>F!H,QAY=
MO9>APJU6Y)1BZ/*8"=Z&IB@\:3T;M"X:,E?<+;>R.I]FMG&VA_,+P.UFW/B*
MO;^Y&V]UO\FL,V?P5>RM6X?,G'[$ISDL95L@,L$VN-S]0?>R6:FJVK3YK_GZ
MTJ0IJT;@!44-%?(/D<=.>6W;V'G_ +#^._$C+YK^%5:5^+_BV\^E,E_#:Z-2
MD=;0?>;IF^SJXU-EDCTN!]#[AT?6_3&/H,;BZ#Y_[7H<9A\\=U8C'T?6/R6I
MJ+%[H:&BISN3'4L.PD@HL\:?&TR?>1*M1HIXQJLBV\6<UK;G]J_Y^O>'"%"C
M<!I!K32_'UX<>LM3O3LFLGK:JK^)V<JJK)8O^!Y&IJ=[]+SSU^$#U,G\'K9I
M=U-)58OR5LS?;N6AU2N=-V:[K7[5ZSRN8Q6X<E_,6Q5?GL%FJ[<N#S57U]\G
MY\KA-Q93.R;HR6>P^0DV,U7C,S7[EF?(S5,#I-)7,9V8RDM[T"P! ML$4XKP
MX>O7BD3$%MP!(->#\>/IZY^WINBSN\X,5D<#!\.JN'!YC%0X++8:+=71T>*R
MF#IL4N"I\-D<<FYA1UN*@P:+1I3RHT*T@$(41C3[AYG8G4NX\M09_<'\PK 9
MO.8HEL7F<MUM\FLAE,:S9BOW"S8^OJ]B2U5$S9_*55<3&ZDUM3+.?W9'9M@L
MHH+:@^U?\_7C'"Q!;< 2.':^//&.I&,W/O["8R;"X;XAY/$X>I@@IJC$XW>/
M25#C9Z:FQ-%@::GFH:7=$5++!38/&TU%&C*52DIXH5 CC11@W+UWTWO.MBR6
M[_Y@.V-TY&""6E@KMP]8?);,UD%+/D*[+34T-1D=A5$L5/+E<G4U+(I"M45$
MLA&N1R?!G446W('VK_GZ\\<+D%]P!/S5S\_3J3B=Z=DX"G>DP7Q.SF%I)'BD
M>EQ.]^E\=3O)3T5)CH'>&CW5#&SPX^@@@0D76&&-!944!._Z#/CA_P!YN==?
M^B9^0W_VNO>_$D_WP?VC_/U3P+;_ )3E_P!Y?_-TZ?Z4.Y/^\9MX?^C'ZB_^
MS#W[_09\</\ O-SKK_T3/R&_^UU[]XDG^^#^T?Y^O>!;?\IR_P"\O_FZ]_I0
M[D_[QFWA_P"C'ZB_^S#W[_09\</^\W.NO_1,_(;_ .UU[]XDG^^#^T?Y^O>!
M;?\ *<O^\O\ YNO?Z4.Y/^\9MX?^C'ZB_P#LP]^_T&?'#_O-SKK_ -$S\AO_
M +77OWB2?[X/[1_GZ]X%M_RG+_O+_P";KW^E#N3_ +QFWA_Z,?J+_P"S#W[_
M $&?'#_O-SKK_P!$S\AO_M=>_>))_O@_M'^?KW@6W_*<O^\O_FZ]_I0[D_[Q
MFWA_Z,?J+_[,/?O]!GQP_P"\W.NO_1,_(;_[77OWB2?[X/[1_GZ]X%M_RG+_
M +R_^;KW^E#N3_O&;>'_ *,?J+_[,/?O]!GQP_[S<ZZ_]$S\AO\ [77OWB2?
M[X/[1_GZ]X%M_P IR_[R_P#FZ]_I0[D_[QFWA_Z,?J+_ .S#V87J/I_HBBZE
M^5%)0?+_ &!D\=D^KMBTV9R<?4G>M/'MZFB[VZNJZ6OJ(*O8U/65L57D*>*B
M$=+%/*LE4LC!8HY&#4COKAK :U/F/0_/I1#% ([D"Z4@H*FC8[ESD9],>9Z"
M3?W9/;4N_P#HJ:;XX;N@J*??&ZFI(#V+U*QK'DZIWY%+$FC=C!#% [2EF*J!
M'IN6902]?Z#/CA_WFYUU_P"B9^0W_P!KKV[XDG^^#^T?Y^D_@6W_ "G+_O+_
M .;H6_\ 2AW)_P!XS;P_]&/U%_\ 9A[]_H,^.'_>;G77_HF?D-_]KKW[Q)/]
M\']H_P _7O MO^4Y?]Y?_-U[_2AW)_WC-O#_ -&/U%_]F'L2L50[+P6Q<IUC
MA?YE%+BNN<VU0<ML;'[$^4-)M3("M,;5Z5."@V.F.DBR+0QFI3QZ*DQ(90^A
M--#4L'-KW^O;7_#TZ!&L9B&Y4C/E1Z?X.DC6Y'=61W)2;QR'PTJ*[=E L"T>
MY:O=71U1G:;[3R?9M#E)=SO6I)0B:00,'U0"60(5$CZD?F>L.D=Q#$KG_GQM
M'-)@,-1[<P*97JKY)9!,)M_'R5$U#@L2E7L"5<=B*.:KE>.FAT0H\KL%U.Q-
M@SBM+<Y^:_Y^J&*!J:K\&@H.U^'IPZ?<?OGL[$MD'Q?Q2S^-?+9&;+Y5L?OK
MIFC;)Y:IB@@J,ID&I]UQFLR,\--&CSR:I&6-06(469?]!GQP_P"\W.NO_1,_
M(;_[77O?B2?[X/[1_GZKX%M_RG+_ +R_^;IQ_P!*'<G_ 'C-O#_T8_47_P!F
M'OW^@SXX?]YN==?^B9^0W_VNO?O$D_WP?VC_ #]>\"V_Y3E_WE_\W7O]*'<G
M_>,V\/\ T8_47_V8>SH=P]5=+U.U/C1%6?*K8F+AQ_QOVS08NKGZP[JJ4S^-
MC[ [+GBS5+#1;+GFH*>2>HDI_%5"*HUT[.8PCH3T,^ZCNF]V?M1)%9<MRW5N
M=YO3K66V0!BT=4*RS1M5?XM)4^1Z(]VBM?K8R^X+&? 4 %':HU/G'"M3@YQP
MX=%E^/W8_;%#N3Y/?PSXZ;LS'WGR4W!6Y 0=B=44YQ.1DZQZHBEQ,YJ]V0K4
MSQ001S&2$O$!.$U%T< %(.INCZ6>"JI?F1L*FJJ6:*IIJFGZI[\AJ*:H@D66
M"H@FCV*LD,\,J!D92&5@".?>23;YS&ZLC\CW!0C(,]E_VT]%WAV>/]VZ5'_"
MI./D>C&S=G]RU,,M/4?%;=\]//%)#/!-V3TS+#-#*I26*6)]Y,DD4B,0RD$$
M&Q]B-MBIQ.RJC<57L[^8N=K5>[JU\GNFJP.U?DMBZG<66DDJ)FS&8GI-HQR5
MV9\M9,PK')J5:5R'&MKE=X;N_%NMY[8B581I0,VW,$4@ JH,Y"J0 "J@*:#&
M!U9#'%XGA<P:"_Q4CD&H^I^?S%#_ "Z06Y(\SO&EPM#NSX*0[EH=MTWV6WZ/
M.;BZ RE)A:#Q00MC\73UFY9H:+'/#2Q(U/&%A98D!4A%MCV^^#VH<&=L_P Q
M&/ #;!W(=NIBMH?).CBPO]\I:.?=ZXZ*+9ZQ4R;JGQU.^14#36O!&90Q1;>N
M?J;LW)N?; .TVCQ"S[>2_AU\,N3<58QZF"$UT!F"TJ>O1^%$4,6_Z2M=-(Y,
M:OBXU^(Y-:YSUWF5S6X?XV<[\%(,N^Y4V_'N&;(;A^/]549Q=II51[5&6J)M
MRM/7G;"5TXQQE9C0B9_#HUM=.U^T^NLKD]QYO*?/#!Y+-[QIY:/=^8K]A_(V
MLRNZJ.>HHZJ>CW%D*C9LE5F:2>JQ]/(\=0\B,\$9(]"V5Q7^[0P6]K#[=.EM
M$:H@DL J&A *+]1I2@9@-(% S#@2.J-':L9&;>E+O\1,4E6^T^F!CAY<,=/U
M#N??^+QF"PN,^&>1QV'VO-%4[:Q-#O+HFDQFW:B"&IIX)\%04^ZHZ7$S0T]9
M,B-3I&RI*Z@V9@>.X-H=;;MBP<&ZOG5MS<D.V,1#M_;<6=Z\^0^5CP."IW>2
MGP^(2MV5,*#&PO(2L4>E1Q_06];;AO%FUP]G[>R1-+(7<I+8+K<BA9M-R-1(
MXDU)\SULI:G3KWI6TB@K%*:#T'R_F?,GK)A=V=B[;ER\^W?ASE\#-G\B^8SL
MN&WOT;C),SEI8TBDR>4>BW9"U?7R1Q@--+JD8#D^U[TAU3TM1[MW)+C_ )8[
M R4TO3??5'-#'U5W=":6AK>FM[TM?E7-9LVCCEAPU)*]7)$CF::.!HXE:5T'
MN)/O"[SOMQ[,<]P7G*5Q#:M;P:I#/:D(!=VY!(2>1S4@+14)J03@'HPVJ&U^
MOC:/<D>3PY!3PW7!7)J<8X_/@.@T[W[+[>K-J;42O^-6[\=%%W1T-4132=E=
M0R>6J@[CV1+24:QP[NE=GKZE5@4\+&9/(Y"*Q]D^'1OQQ(!/S;ZZ!MR/]#7R
M&-C_ $O_ *.N;>^8OB2?[X/[1_GZ/? MO^4Y?]Y?_-T.9[0[C_'QFW@?_*C]
M1#_Y<#[[_P!!GQP_[S<ZZ_\ 1,_(;_[77OWB2?[X/[1_GZ]X%M_RG+_O+_YN
MNO\ 2AW)_P!XS;P_]&/U%_\ 9A[=<+U1T5MO)TF;V[\\]FX'-4#O)0Y?#=4?
M)'%Y.B>2*2"1Z2OHNOX*JG:2"5D8HP)1B#P3[\7D(H;<T^U?\_5EC@1@R7X#
M#S"O7_!U$K^P>U<I234&3^+&Y<C0U 5:BBK]_=.5=).J.LB":FJ-VR0RA9$#
M#4#9@#]1[R5G5_1^0PV'V[7?/;9]9M_;LN4J,!@ZGJGY(SXC"5&<DI9LU48G
M&R=?M1X^HS$E# :J2)%>H\$>LMXTMK7("3].:_:O^?KQBA*JAW %16@TO05X
MTQY]8H-]=GTN1R&7IOBGN"GRV6AH:?*92#??3,61R4&,%2,;!D*V/=BU-9#C
MA63"!9&98?*^@#4UV;_09\</^\W.NO\ T3/R&_\ M=>]^))_O@_M'^?JO@6W
M_*<O^\O_ )NG#_2AW)_WC-O#_P!&/U%_]F'OW^@SXX?]YN==?^B9^0W_ -KK
MW[Q)/]\']H_S]>\"V_Y3E_WE_P#-U[_2AW)_WC-O#_T8_47_ -F'LW==U/TE
M_LL70^-_V;#88Q-#V1W]-C=PGJSNW[7+3UE-U&*^ABH1LHY2GEQ I86DDFAB
MCE%6HB+F.0C-K[GVY;O9[5[CC;^7I;M6O[0L5EMTTD6\@"TEEC))%6J*K04)
M!Z*MZBM=.W:]P5 #)0Z'-?@K@"HI\Z5J*>?0)[9[*[=@[S[BJ*;XV;PJZJIV
MAT^M71KV-U'&]$D#]C"FE:23=JPR"K\CV569E\=V #+<(ST_T.18_,'KP@\$
M'J3OFQ']/^/$]YB_O[F;_IB;G_LHLO\ MJZ)S%9$$'=HZ?\ -*3H8_\ 2MW7
M_P!XM[S_ /1F=-__ &9^UQ@\9L[;.YO[Z;?^?V*P^\?X:N&&ZZ#8?R*@W$N)
M3'08B+')EUV5]ZE'3XJDAIXD#@10PHJ6"+9%<7FZW5K]%<>W;M9ZM6@R6&BN
MK625^HTFK=S5!J:DU)/6P(%?Q5WT":E-7A25IY#[!04^P=)+)YC>>:V^^T\M
M\+*[(;7DKGR4NW*K>714N#FKY<E+F9ZN;%-NLT,L]3EIY*F5FC)EGD9WU,S$
MY\-3;:VX[2[?_F%P8263=T>_Y9<7M'Y*T4LV^XJ+)XQ-YSR0;11Y]T#&YJLI
MS7.6J#!5S(6*RN"Q.]Y= K<>V0<&W\ ZFVYOT:J?"S<'].J(='P513IJJT\B
MP1C3'OND:M6(Y?BSW'U-"0:X-3CJ-DZO<N;54S/P=&55-L2[)09'<G0%;HV9
M-58^OFVE&:G<LA3;,M=B*29J 6I3-2POHU1H5Q9O';2W)NA=[[@_F!4&9WDE
M#)BX=TY#9/R/J<_38N:DJZ"3&4>4?9IJJ+&O05\\!IXF2'Q3.FFS,#>WGW"U
MLVV^V]MF2Q9M119-O"EJ@ZBHN-):H!+$5J >(KUIEMW<ROO@,U*:C%)4#A0>
M@H2,4X^O67$9+=NW]OOM/!_"2?$;7EK%R$VWL=NOH6DPM1D5J*>L&1J<9#NA
M*.HR'WE)%,9W1I3+&KEM2@AHK=H=:Y/;>$V;D?G5MROVAMFJR%=MS:];UY\A
MZG;^!K,L4;)U.(Q,VRGHL?/7,@,C1(I8W_J;OQ[AO$-U/?0^WCI>2@!W66P#
ML%X!F%SJ:E<5)IP%!CK0BM0JQ_OI3$I)"^%+0$\2!ZG_ &!0=.E)N[L:@SN4
MW/0_#O,T6Y,Y3T=)FL_2[YZ.I\SEJ7'Z_L:?)9.+=B5E=#2"0B-9'8(#86X]
MNO6/4_2-+V7US547RTV!DZRFW]LRHI,=%U7WC32U]3#N3&204<=15[(@I(9*
MF10@:5TC!-V91<C6X;YS%)87J2\F7*Q&)P3X]G@:3Z7)-?(4!R:T(ZND=IXD
M.G<T9O$6@\.05(88J<#\\=-78W:7<TO7N^XY_C!O*""39NYTFF/9G3I$,3X2
MN624A=XNQ$:$MP">. ?I[#[O?ICX_P"0[Q[GK\I\Q^O\'DJWMCL:JK\-/U'W
MU6S8FLJ-XYF6IQTU7C]@5-!52T4S&-I(9)(G*W1F4@GC+;LZ00HL+%0H -1D
M 4!I7%>-.A=)#;F1R;U0:G\+?YNF_I;LOMR#ISJ6"D^.&[JZEAZRV%%3UJ=A
M]3PI5P1[5Q2Q5*13[MCGB2= &"NJN >0#Q["G_09\</^\W.NO_1,_(;_ .UU
M[>\23_?!_:/\_5/ MO\ E.7_ 'E_\W0E_P"E#N3_ +QFWA_Z,?J+_P"S#W[_
M $&?'#_O-SKK_P!$S\AO_M=>_>))_O@_M'^?KW@6W_*<O^\O_FZ]_I0[D_[Q
MFWA_Z,?J+_[,/:]WUM_KKLZ3#2]B_P QC#[W;;N.CQ&WUW1UQ\F<U%@L7&D,
M8H,/!7;"FAQE*RTZ%TA5 [*&:YY]U4LE=-M2OH5_S].2+'+0R;B&(X55_P#-
MTG-O[@WQM-LF^V/B#E,!)FJV3(YF;$;TZ5H)\M7R22RM69.>FW5'-7U(>=]+
MRL[*&L+#CV@O]!GQP_[S<ZZ_]$S\AO\ [77NWB2?[X/[1_GZ;\"V_P"4Y?\
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M4*RAE1P+-3MK:9!![2V\018@[3WH00?J"/X?R"/>9W[YYG&1[>7H/_/;M_\
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M":M\)1'=1&&Y9E%S[L9_V<?X9LI5OD.64@J0>F.TRK BQ%CC.58?U]]+A_7
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M.M-$KJRQJ!EK_FQ\1,I52U^3^2U=DJZ81K+65W4':U342+$@CB5I9,:6TQH
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M#W+]UD*-7DK7D79M)"+2O3E*<21JIE>ZKQ'P(S>X.M.N]^4.[-R;?R&Z]_\
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M>./P]5O3=FWMKQ>5$JZ/#TF/HU4'[LR2S>:63Q%5!4ZB*5 _"#QI\^MI';M
MYDHH"KW4)/QL.%>)%/E0>O3+N3Y"]BOWQM78FP,=F,\L7<?;W7.XMK9VMVC@
M\%DI=J_'3879^*GI]T4N"KLSB=JX[,;E6-':GJ\K/7U#ZU-&J)$AJOX2;0V=
MD=RU7:WR)P6T-@KV'LCKOK7>VWNO=Q;TDW]/V)UYM[MC;^Z\EMG^);?RFR]I
MXSK_ 'EAZO+-(U;D:6JKOM:>DJWBE==BX9J:(B6H216E*&G'SR#TW])&K-XM
MP FH $ FM16M,4%"*\3\NECC?EKE=VOB,%U]TSN#<?8<>P]U;]WUL3*[KV_M
MNIV=!L[?FXNKLIMNES93+8G<^YLGO[9V7HL8L308^IAH6J)ZNE22$.+71'PD
MV)M#MK8.W/D-O?;^5WMN'._(/'8/H[';?W#E\'N^CZ3@["V;439GLG'Y3!#;
M%3NGL?95;3X%(Z.L25:)9ZUZ6*:-7I-<,8W,2]H"]U?6GE]AS_+IR&T2.0"X
M:K]U%&0=-1QJ*5(Q]GSZ1/8ORUW/N/KS>6Y^F-D[BBVSM[#]*UE?V97U& @R
M6&K^W/[@[JCI,;L'(PY!\_%M/KO?%'7YMY*BE,7W!@HUJIXWT%9WW\4ZC8FS
MNQ>P:[L#$5&SML;2^/VY-@90X:MI)NV*SY"X5]RX' X2DDJI?X17;5V_@]PR
M98S/+X*G 34^G5*C!]9=3*H7))K\J8_GBGV],R6GAK+)XG8 A4T^+7D#Y4 -
M?LZ'7:/R+Q^\-T[-V50[/S<>Y,[N;NS;V[*+[S'S1=>P](96'!9K,9NH1U^\
MH=PY;-X-<:(%+S4^:@F;2J. 4;V]TCZ,?[-+T;_S)#YD_P#B(>N__@A^H_;,
MG]I!_IC_ ,=/2J#^QO/](/\ CR] MV/_ ,S*^/?_ (?>\O\ WT'8'LK7M[I+
MT-/LYWPOVYUQO[L*EZ_WYT;1=F8S*Y2@S>^=_P"7['W7L/$=,=,8&.>;L[?U
M34;?JL;B*"3;V(F%:F1RTE;2)+3QTJ4-5-51QNQ.65=2O0^0I6I\ATNLECD<
MQO;ZZY+$D!%'$X]/4_92IZ+5\G-Q;PV5L.NW?M'LN?9>9HL=7XK9^U*/9N#W
M?6]E]G9@0P[ V=3T.3BGR5=_&,M$:9J3'FDJ'BG>9JNGB@>5)5#L#X_9CXS?
M)/=&T\)O3,;\ZP[)ZZ7;/8NX<\F/QTFP-W;MWA@<3BJ78>-H(X/XIF,+CJ>M
MR-975<KP5,:P4T,:>6231:42Q!B-)!Q\Z>O6A';M:W+(K&16%"?0DCA]@S7\
MNH-9O+M_&=W] [>W#E-LXO;F_=A[^?=NRL-A6KY5WEMW;VT<M45\>\ZVO%2,
M?A\I5U--1TT%'&M33SM+/(72) 8[97QNZ3[VZ;ZSR6"V5M+K[=&\.\_CMU1C
MLMU5W!DNV-Y8'#=D9;([2WMN/Y&[.W#F7QO74&2RL$,VW)X*;$Q39&84+J\1
M656WE>-V%20%8Y%.&0%/G\^/2GP+>6",K$JL64=K%FH:@ZQY?+ SCH$^R.^^
MS.DNPM\C+;ER.[=J[/Z;[L[/R^*WUL&GV7CLU5;*PL&[=K8CH_.;<Q4F3W]4
M83'&:#<D#'(S4U&J52E)?VI"X_+?JO:VUZ;:F]>I]I=78[I^MSN[=BXG<_67
M:>ZNV*RNW'MI\=7U&&[.S6Y#14,&_*?!Y6EJS)AL=0X*NIZK71"1(V\;L+EJ
MJ['70'(IQ]/ETGO(T01M$L?AY%58MD?Q5\_L !\NC =$]AY+,5>8V%O[<6Y:
M[MG$8/ ;OSN)W+LG';$I/X'N(UE'39C8V+H?N9Y]GG,XRJI%6NK*O*TLT&BK
M*,\>LD_M_I#T8_W8'W?_ ,>9\3__ !5?:7_ORNU_?2K[GQI[/RT_Z/E__ABZ
M)=V_W.A_YYD_X_)T57XR_P#'R?++_P 6JW1_[ZGIWVB>FJ;8U;VGL.B[)PF>
MW-LVNW/AZ'+[=VYG(-M9+."MKZ>EI\6VX)J#*/A\=65$RI53PT\E2D!;PZ9-
M+KD1S'+N<6Q;K+M-TD.X+ Y21T\0(P4T;PRR!]/Q!2P!(%:BH**,1-+$LVKP
M2P!"X)J0 *^0KQIGTIQZ&;MJ;>5/UKO6HV!G,3MG=M/MW*5&(W%F\')N6APD
MM/22S2Y3^[Z9'$)F*NB@1I*>GEJ8H))U02DQZE)G-A=>; 7Y6]H])CH^C[0P
M=%W#N[;E!+G^Q-W[1Q'6'5.Q]W9^GWENK,YO"55$8H<!L^C%3+F<K/+28^.D
M:62GJ&?3[!6[[YNR\@;-S(>8?I+V3;X9.R&.0SW,\,9BC2)PVHR3-I2*.CR%
MQ&LB<>G88HS?S69MA(HF915BH1$8@L<^2_B8U%!2I/1;=][_ -\I\8.O.W1W
M%4]>;@J^JMM9JH&(V!M?=>2[$[*WAM3#/M/;>(VYEXJG[BKSF[:SP08G&B&J
MKI:E(8JB +K]@QU]A^EJCY*XS;63I=V]A=+5/:[[>V]2T69AV?N+>&U:S=W\
M*V@^<S+8NLGP--F,7+!)D'IJ3[M$9U@$4A#H(=WO.9$Y*N;Z.2"TYE7;];G2
M9HX9O"U2:%+IXJQMJ$>IP'T@M4%E+,?T[7*QNS/:^+3!HS*6HE2<@,*5_%_/
MH5M[YKN.#XUY/<<=5M;K[NFGZD.=W!4C$R[RV[L[>=/M Y'<O\#Q$F7H(]PQ
MX3,),M E36"GF\:&9G0L&,CL#X_=3;KS'R-V-%18JHW9@>T^QMC;1DR^^ZC!
M5W7&VL%B=Y2[$W7B,++705&_(\GOK$T.*S.N')/0XDRU#10EONHPE?\ -G,E
MM9\J;F2XLIK"WFDT0!O'E=H/&BU4(@9(7DEBS&))=,89P/#97:VL-Q)>PG$J
MRLBDG^S4:M+ 5&JK#2W$Z*GUZ+[G^]^X,1@/C[OBI::#:&X.J>LM[[OK<5L\
M9BGWGNG<63VD-[;6K*I(GIMF)0['R5?E,2_GH5J<FD5/Y9E'VLH#_)_IBDZB
MW=01[:CQ4FQ:R*3;&(R>/W.FYLC7[GV5B\#'O"JW8J:4V[N7.OFZ/.#%Q!J>
MBQV7I84DD>.4^Q5R9S'-OUC(UY(?WB )&7PVC58Y6?PM&H594*/ 7)J\D$K$
M*"!TW>6IM)S&/['X0:U)90"Q:O!FU!@.&DBG#H??CMVS6=G[8JSN,UT&]*)H
M<[E\=4;=J<!CJ'"[LK\U+MREV]/4:CN'"X4XFKPS9(E)*VNQ-3*8HD>-2E_C
MW_Q^V[/_ !!/R-_]\;OWW'_WE23[&>X1K_Q'M_\ M,M^GMI_Y*<7_-*7_CO4
MGY%_\>=LS_Q.WQY_]_7L;V0SWRDZ.^A\]F@^'&V>IM[?(GK+9/<NU-Q[UVKO
M3<^$VA3;?VYNA=G_ '&<W-FL9A*&LSV<CH:_)Q;?Q-/6SU4T-"(JNIEACB6:
M)7=PS.SI$[(0& KTIM!"T\:SH60FE :9)ID\:?9GH"ODKF^P-L=(=C;IZTW)
MA]I[EVMM7/;G7.9C;@W4M/1[>PV0R\]/C\--D<90S9.OEHXX(Y*EWIX%D>1H
MY"JJ1U^$_6737:N]LQU;V%U[U[G?+NWP5^Y]T=VY[K[LQ]IUD53C8=L_'_86
M/R-%B>QNX/XA2-/BZ"JAR*9.OEI:"2*&*9IO;=P[HGB*Q&.%*C\SY#U]./2B
MTBAD9HWC7#9):C4]$'F<?.M:=!I\I]\]D]?;-AWWL;=FX\-41X63['%T/7.*
MW9U]1YVF*YAMQ]S[LK('R&Q>J:7'P/#ELG#/1''47FJED>2-(S.ZXZBZ@WY\
M9>ZLSD.L=MXK>_4O7VXLE2Y3 =L9S+?)');YV]N[&K)GMP]"U>67!XCIS%[=
MR+P[@JDQRR8F&F>K6K=U:(Z9Y%FC&LZ6/IVTI_%Z^GKUJ.*)[:0F,!U4\&[Z
M@^:^2TX_97IJ[&[&[/VAW3T]C,+O9JO:W8V^,'2Y:FW-LO'8WINEV5EL'64S
MX/;O;%%0MDZOMO*9Z"&? 4,U6T65,OVY@52LJH;N7:?44_QCV5VIC.EXNA=Y
M;J[#AP_5^)@[!W=O')=M=4XC;F7I>P>P]R8K=SRC'TF"["HJ&AQ>7QJ8_'Y2
MHJ\C1QTK'%R2):-I/&9->I0,X H?("GRXUX8]>J3)%].DHA\-BW;DG4M#4FO
MH>!X'(\NE7UUN?L7_3[NCKZI[$/:>S]N;"ER.^<B^S]O;?I^O>R<CN+'5.S=
MF8K+;?>'[^IS&QJVMJ\ACJQ:NMQT-+CZEZA5R,<;$5]J>D71JO9Z:W_LD7XW
M_P#B4?DE_P"XO2GO/+[E!_W4^YW_ $L++_M&EZ+-Z^':_P#F[_SYT!.S?^R@
M.\?_  S>D_\ >^S?8:;8R. Q.X<-E-U;??=FW*#(4]5FML1YJJVXV>H(FU2X
MLYVAIZJNQ:51LK2PH90MPA#$$9I7J74UK<1VMUX-PR$*^D/I)% VDX:AR >/
M#HG8H@#R"L8-2*E:CTJ,BORSY>?0N;DH<SD\#E\?M[._W9SE;05%-B]P_P ,
MI<U_!JV6,I!D5Q-:\='D'I6.H12GQL19@1<$[F^MC]>;7[$Z9V_B_C3_ !SM
M[L+KB(;K^,%)O?L&IQFT.QMS;GJ#UN]0])F:CL&'-Y_KXTN0K]LU.3CDH)JV
M)YY8;R4<48[5O6]7>V<R7MUS0B<O6EU^A?&.%3-#'$/J%8%/ *)<:T2Y6.CA
M&HK4$KJI%A6:U6.Q#SNG=#J;2KL>P8.HDKED) !R:=$JV+V!V'N79/=&XLQW
M[1X7J#K_ '\&V;\C:C:&S*.OW7L?;>VZ=^R0U+7X:+8%3@,%OD56/H-Q4M T
M-?#22K%%*$CK*@!N\\!T[LWY#;LV[M&7)5_4V$SF'AKZ3:NZ*+<571U"83%3
M;^VULO>V3H'HMPXG ;Q?(8W$YF>GF6KHJ>&I83%[N*N5K[F*_P"4[*]W9%7?
MW20_J1F*JB200/)"')CDDB$4DT6L>%(S1J5TX8NEMX;J>*-S]*A_"U30 :PK
M'B U0&-?SH*CIT;N#MG=W0>U-P[V@H,=VAF,'EZBGFSNW:K PU4#97*Q;'W!
MNC9])D?O,!D\[M9,?D,IB8ZB)Z*LJ)J8&(I9#=471WQW?Y1]M[$J=J+0[3I,
M!T[D]B==9GLJOH9\3A.P<1U]ENQLUCMWU]5A*_=^[^O=N;DK*_%4#W.2J5 %
M%4J@I6 :\S<YMR7R]N45XLUXSW0GN%@4!G@EN8[=&A'B+%'.\<:22 CPQDRI
MJ+A>+2U.YW=J4_24QZ$U$8<)K.HFI9 Q(J>)P.'181V_\@1\;.J]WQ;C_BVZ
MZG(=F4&]^P<7US22T^1S.S*_>N+V-1U^SZ)LS1;2VSOG<.$HZ+(UHD9,;!(2
M:N O]T@ _(WXZIT[M?8U=AY<#EX\908O!=D9V@W.V2S59OK=7\?SV(K*G;#*
MB;;VDV-PU9B,4Z%Y:VIP=9/4"(S0Q^Q5RAS=)OU[N,-TSHSN[VZ&/2%AC*1E
M3)3]24$I-+FBBYB1=6EFZ8N[)K/1WA@*!S7NU-722. 6@TJ1Q-:\>ASZ&[\3
MM/<>[,?E6R>,JLC79?+;%V_7;>?'4M)M';#X/"92F7/,6&X-QI59BARN04:(
MJ2GSU'!"9O%/)[ ?J#GMOJL'Z'LK8?\ [U>)]B[>&/[JW+/^@2?\=/3"?VMO
M_P U4_X^O0V]G_\ ,M.P_P#PQMV_^Z#(>PC^2/\ V43WW_XFGM+_ -[G.^^'
M=H2;6V).?#7_  #H5S?VTO\ IC_AZ8^B?^9(=-_^(JZ\_P#>1Q'L%O:CIOH5
M?=E7^A#IC>'QPVGENI\7U3NO=V#ZQP>^^_\ <T/9'8]1WQUU'3]@Y.F[ S^/
MZ<J*S$;#S>TMG;6DQZ3BCBKZI:29JQK 220)?$=9&#DA2:+@4.,9]2>C,PP&
MU5HQ&SZ06.IM8SGMX&@_EGHDLO;/9.SNW]U4'9-5O/$87/[^R>T.BL"^T=HT
MG56\I9MB8:JV=@LEV720YK<V)W/NK<\62,,E>]!3&H04BHS"):@3.\.A>BNO
M=OUW9>$Z*VUE]G=>]Y[:ZZV'B-K_ ")K]]-\INL^P=I]@5.R=];E;:N5S.<V
M=FYLGLBER@_A7\$2O@RL^.2AI9J/S"B2NY">(0Q6IJM-)%/7_5Y]7GA@11(+
M<:0]  Y.L$&A-*T-0#BE02*8Z0O5O;G<NZ,YM?8FYNPLQBMQ]B]([K[$W9D<
MMT[2;43X_P"_=@;EZXI-T[-QQSD%-B]Q8R2D[$GHHOXA_$9*=L.*PU=3#4B,
M$Y^8NP=A=;]G;>VYL_;4&P=R?Z,]G9'N3JZAW%E-UXKJON"N&1?<NP\=FLW-
M6YH2XW$ICJC(T%75UM3A<Q55F-DG=J,A7X69T))JM<'U'K_JX\>DEXD<<JJB
M!6TC4H)(5O,9_*HJ:&H\NC&_&G>>\M^;(W!G]SYE=UX!NP-T4?5F_),'1[<K
M^P.L*4T*X/=M?B<:4Q86LRS9""@K*6"EI\MB::DR$<$:U5B4_P!O=).C#^[P
MOY/_ /QY_P J?^H[H?\ ]S^RO>1WW8/^5]WO_I42?]7H>LRON1_]/)YL_P"E
M$W_:1#T6;L?_ +*4^/\ _P"(V^1O_P Q[W;@J/(\4,9 DGFAIXV8%E66HE2&
M-G5>60/("0/Q[SC9TBCEGE)\.-&=J<=* L:5Q6@-*]=,&>.*.6:6OA1HSM3C
MI12S4KBM :?/H4JNLIL=15^3K"XI,905N3J_&!Y#2XZDFK:D1ZF1!(88&"W(
M%_K[&/<G74LN6.V=E4.!R4F&W(NU\MEZ3.Y#+9VGKS25#2UV\*+QIC<1BV-!
M55"BA644ZP&%G:7@QGL7/<";3%OW-5U=0B[V_P"MAB>!(8&BU)2.Q>OB7$U)
M84(N"C.TH=0L1%(?Y=]Q8(MFCYFYSOKVW2\VP7T,#VT<%J8?$0+%82D^-<7'
MZUO$1=,C2O*)418N%8/2/S?AH=AU'<OR7W3V5M:#??3B]X;"V)G>KML[!ZOK
M=K567P,6.VGTAN.J=-W;YWS!/OC!8F7^\M?13YB;)PUU+204;$0)G?&"P.&K
M=GC$PYS&8/,X#&SU64SE%5P5U7.N:R&.RN;%!5QI]K)-1THJTH5N886C#"[&
MYYRIO&\[G:\T'<I[2ZW>TOID6*!T,:#P(I8;<R(3JHTG@M.U-;AV7 P)>2M\
MWS>++G [I<6-UO=EN,Z)#;21F*-?IH9H+4RHQ\33)(8&NFIXCARITJ*#S\5.
MX.U>S=E?(:JWGG>MNQ.T=@=M[LQ^W-F]<YC!#;FV<+D.M=E;WV)U;4[EQ555
M?QR3"9C/3X:LW%5+$:^N@J9$584C15[6[*VTDDE;_!,9CL?C=U5."P446\UR
M5%V!056W,[DMIU68K?O2<"^8RF)@$DR/2HT52T02,IK]A*UYKY@*P6;;G--?
M7.VI<SDV/A/MTB7=M#>I"FC_ !@6\4\@16$C:XA)J<.%Z EESKS.WT]@V[W%
MQN-UM"7=S7;O EVN6.\M(+]((BG^-"WAN9-$3K.P> 2^)()/#Z*!LWY3_(>K
M@_NO7]B[VW%NW=/1&-[1[+J*GXPU.U-R_%7=&V^XNJ-E=V8#8>UY=MQR=E4V
MQ=E]F9*:#&U5)N.OIZO;L=4U3D(ZW[=F+>/7U-AL769#$?8S7K*K/^-\QYJ[
M'[1IZ'%*:6@I0&7*1TU=E/N:FI=A)%2M3JH?4[>S;ECG.YW*_MK'<_$23PUM
MC2&D<EZTDQUR2',):*'PXHE&AYA/D:5'1]R?S]<[QN-I8[QXL9\-+2HM],<M
M^\DY#R2<8#)%!X,, 71).MR24T1KT-'QV^8NYM]]B;:V=V?4Y2AAEV]C.M'J
M:;KM,5A<YWK49_=Y.9W=G%F$NRZC/8#9;X[$8N& 4=5FXLNLO@,%)&0<G_S,
MW_+*3_H0^Y+B_M(_],/\/4NP_P!K%_IA_AZLKI/^!5-_U$0_];%]ZYG\S[_L
MN/NS_EGUE_[Z#8'OEKS[_P KWSO_ -+B]_[29.N(?NY_T]/W&_Z7=Y_U??H*
M/B;_ ,R-P/\ X=_;W_OXM_>R#>PIU'G1C_9Z_B%M/IWL.DWAM_M3IH5NT-L;
M>WCO+M7Y%R;_ -VX*IZ?V?%MUJ/:$NW,%CY(=GUVZ*W?2T]+CZ')4V5GW'75
ML5!!%!=I@FG,BZ2DG<30+0&I^?G2GV4Z6VJQ2!EDA[0"6>I[1Y8X5KCSKPZ*
M=\F]U]G;'I<!E>KM^4B[YW!F=M;7ZWZ9KMM87(X_LS<\V>AJMP4^:RTD,FY\
M9@*3: J)ZZOH9J2+"4=-)6S-,%$+#SF/C)TO2_#6G[.I-DQR[NCZ$VKV3,T6
M]\T_R*I=]93L^GPF5W3N;IELD-N8KXFUVT?+_#=S1T/W3--CYS.QJGC]MB63
MQ]!;MU$?T:4X5_BKQ'3YMX?I XC&H(&J"=5=5,KP"TX&GH:]!'A^_NTZOY)U
M?75?G*2CP,?<>>V?354FUZ9>E\ILF#9-3D,5M;;G:0A.2R7R6H,]2B7([=>H
M6*.*.MC6 )3K-[ 'Y!;1Z@A^/_5/96&Z?7X_]A[]WIN*79NQ*;?6[-YS;YZ%
MHL32P47:6Y:;>5379'#5,N^8JC'8ROIOX?09^..M>"BCCHEED=B,@D=6DU*!
MQH!0^F/E^SIBX2,012"+PW8X%225_B-?G@'%<XQT+W4^ZNSJKO'?^QJO?5+V
MOUOL_9N(CW-N^;;>&VY4[3[HJ<O---U[AIMNT]-C<S2#9D\5=D:>;[BMPLK4
MB2U$AK"D)&?:CI%T:_V;_P"&G_'V]S_^*M_(+_WA*OW(_LS_ -/C]K?^EPG_
M %9FZ:N?]PMP_P":#_\ '>BW?);_ (M/3O\ XLCT9_[VU'[0'XX_I]/I^/Z_
MCWV'+$>?09'PB@\NC(^[,\'\=NF]T=)Q93"X7!STV.^.B=R9GO2#M(5>\(>S
MMN9G$5'9G5>0ZABRZBEP.WL7E'H(U7%QUJB*'*"NFAG%,\*7?.'--AS 8KQG
M56WL6:6OT](S;S+(+:Y^J*G,AC\61O%\)26MS$KH9.C&*UMY+57"<(/$:75W
M!@1KCT5^%>'PX.:U.:X,YW]W1M3MB.'/UV5IX<U\E5Z3PO4=5UE)1[:;KO<F
M$RZ=>]G479W@>IKJ[-Y7#+633_>O0*9IL6:**H@^Z4(?E=U?LK;U'2;]Z9VM
MU6G2K[_W;LK$;\ZN[,WOV%-75=-_N1VW@^PJ3?-8*W;&YJK:U.<A *>CIZ:L
M5YPC.8&2,0\C\PWUS(^S\QW]P.9UM(IWAFBBB ! 65H#$@5XDE.@G6Y4Z:FC
M*6:O8[>)1/;QQK9^(RAT=GJ0*A6U9KI[JBM>%>A9^+O:>[,\YV'W+G>P:?O#
M^XFU][9S9'8.PMH[*@H::2./&[IR>P*S9D$^*W-M>AW96"AF:3(5M51LM/Y=
M*U,<DXK;?^(VS]J=.193N;;'8&)WW_I ^..XM_;FFI\]@-J]1]+]I9?+P5N
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MD^SRXWN<7D)U?&R^:*GFEDIQXS*$\L>K.7[F^[6FW[1[D&X6;]2_LR-$,TE
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M5]^B,4.%,A'H0Q_R=:F2YN*ETAU5K4%0>%*<>'RZ=.HHNH.E<=1X3:6X>_\
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M5XW;LYFILCB*Z05#AJ.*H2FY:D)T@%A6A\\\!_ASZCI?'80L;@-(W8Q%13M
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MMS2H5G&4K,I5FG00H8$CIVDDT^2,>S7EOGB+?[N"Q:6.&Y-J"RZFK)<:GU)
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M#*& OUEN!3:X/U5B/]8^Q[[3DCW7]M2"01O$7_').I?^[Z2/?/VH(.1O,?\
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MXJ?<F6J<O4X/:.W:/+-0;2V;BYZEDQ^+IV:"CA]"$CV W^RR_)'_ +Q\[O\
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MWJZ*2<,5IJA8TJZ2FGC("_QG^24CN[?'SN[4[,[:>IM]JMV))TJNWPJBYX
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M_P#0TW)_]<O?O#C_ (!^SKWBR_[\;]IZ]_<C9?\ SR&U_P#SP8G_ .I/?O\
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M5G_2[VO_ ,_.[#_]#3<G_P!<O;OAQ_P#]G23Q9?]^-^T]#Q_<C9?_/(;7_\
M/!B?_J3W[_2[VO\ \_.[#_\ 0TW)_P#7+W[PX_X!^SKWBR_[\;]IZ]_<C9?_
M #R&U_\ SP8G_P"I/9__ (I;]WYF>A?D3497?6]:^HHNP?CTE'456[-P2STJ
M5-/W%]RE/*V1+PI4^"/R!2 _C75?2MI;]EH8).:]SCE@1HSMS8*@BOCPT.1Y
M9_:?4]13[R,3RIMSMW,+_&KN'^X\WD:CS_;0^0Z!#=6S=GCO_IVE_NEM<TU1
MUSW>\T#;?Q#1224^7Z9,$I1J,@2P^1PK"S .PO9B"MY-W;OC1W_OCO-M*E@H
MW;N$%B!PH)R5@6/'O)\;;MQ( VZ"I_X6G^;K&!)G=E73&*GCX:8_XST-7]P=
MB?\ /%;2_P#0<P__ -1^S2[CZ0WGA^T]L],8WO?=&4WYE\U6XS<"YK#]M;(V
MMM3&8;;S[EW+NJ#=&=K9(-YX#;U!2U/F;&0NTOVY,>H2("%K?=MKDVBXWY^7
MD&W*@*%!!(\A9M")H%/#=R4H':@U]Q&DTD.^Y,^FW*SVN+<(C<,6\0M$JJ@0
M5<GLU44!FKI-56J!JK4DFTOD?UOG^F-U]_Y3H;;./ZVQ.(QN2VJ^W,SUMOW=
M6\*W<.=7 [5V[)M_;B20;7W#N"IKL>$@K:P"FDK1'4-$892H9;YV]N?;Z[ R
MVQNV]V]E[-[5AKUV#N&GKMY;0R62S.'W"FU<UMK+[8S.<JZK!Y>@S=33:":B
M:&HI:R"97%W1#*PFVZY^NCO]F@MKRUH9DTQR*BLNM'614 D5E#$T52K(RD8!
M8GW?EZ>REV[Z":*XMKHE481H"'4T92*<1\6"1I*G55B%%[K+>W7V[_\ 2;A]
M]=1;9ZOWOTY+C9>P]MUM+MK<N-QV$SNW_P"]. W-B=SXK%P4F8PN1PZ3ASX8
M9Z>KHZB%X[(DDHJY3H[<='7U]-C/D?6YZAV+NS<>R>[LK2OV32Q]79O:&R]R
M;[S]7BZ&JRBU78^W!B]FY>CHZRC^T:KRE T/CCCEBF8LAWFPD6#Q>65C>XA2
M6V#+#^NLDL<* D B&0F:)VC8OIB?5J+*Z*;S<FJLQCBW>W=8799R(U_3**[-
M3LJP_3ET&@UZ!@!D9@>P'R,V;EZ"FJ<C\7Y-OUN^MD[<[#Z*QE>O7DTW:6U]
MX;UV=L';HRE13:Z3KS/+F^Q<!-D**M>H-#09,2AYI8*F"(-^Q-B=E]:XRKRF
M7['W/74_]^*O:>"./S.^1'G\/18:@S#[Y-7/5+28+#5,N8I:"GI:MQ5U-?\
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MJ.BW;N"FIHWGZ+ZWJ9W6&+(*@>>HF>1S:[R.S&Y)/O"3FJ./^M/,PT"@W"X
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M/I$TEI*FMJC5/X*>*-2Q.EB;6 )('OI;+:;=#%+*-EADTBH2.WA:1SP"QKI
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M#W3LC=%%@ZJ7)[_^2#Y[*[.6EK<G!F:O!XG=SRS8"OKM1>HI)):P++(T@/\
M?7:M=C/B!LS$;KQ&%P'>G>>2S5/4T6 SN*S?V?P_I=_5'>W76,RF,Q^0R-5L
MV;+=S[UR*4%+4O%5283;U*DD$<45.TCL:_K,0:QK3C_%2A_D/VGK4\CI:*DB
M@3O\Z_IUU#APJQQ7-!T,'4?5#Q_)W<L^%ES&2Z@ZDPV!R5#D,_B\UB:VO^2^
M2V1%T]O;(T5=68['XS>-!0]2;0QTE764ZRQ1YK.5;)-)+)41P5:^.3_CF_\
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M D+QKX3,H9I6+:F+J$ 8J*E5)0W?,FQR"QA@AF$5HC/&>PDS.ZZM2ER GAU
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M>74;PH?&BR/B'F/7H_WLMWSU1V^4&\"$?_CR.BO[# _\R%ZS_! (]X-\U?\
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M#K;K"OI:5IXL;M^JQM=A:[L?=>4I$;-Y<U4(DHHX:2G6*&*05!%_%)_QS?\
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M_H[W[_9Z?F%_WD7VG_Z$M3_Q3W[Z>#_?2_LZ]]9=?[_;KW^RI?''_GS6Q?\
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M\[_&,G@,=B)=P31SR97*Y_*8:K6@I*"GJJNIAIIYUB$$$\L>V6V 0B('4*@
M9/5$>]=Y$-QI"&A):@!K3C\_+I59SK_X=X7%;$R"=,87.Y#LW&#,[%VMMS8]
M;EMUY_%QXR@S%?D8\/&J/CL?A\=DZ=ZRHK'IZ>GDGBA9_--#'(7ZM^<'S"HJ
MVKH_]F3[)J_M*JHIONJ+=53/1U/@E>+[BDGT)YJ6;1JC>PU(0;#V[]/!_OH?
MLZ8-W= D>.W[>A:C^*OQQDCCD_T,;(C\B*^B3"QK(FI0VB1=9TNM[$?@^XO^
MST_,+_O(OM/_ -"6I_XI[]]/!_OI?V=:^LNO]_MUS_V5+XX_\^:V+_YYX_\
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MOM,   #^\M3P!P!]/?,(VUN<F)>CLWET<F=OV]#K_LJ?QQ_Y\WL7_P \\?\
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MW=E1;W8@ GWF!/R+R/;037$W+EF(HU+,?"4T"@DF@'D 3T4?7;A4 7LA8F@
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M?[S[HP.&[_[,QV(PW;79&+Q=!3;BJ(Z>BQ]#O+-4U)201JH6.&G@C5%46 4
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MO5G9><I:F?(-UY28W=T$&6J]V/EZ7>)SN9VGF=G-!MEY@=NYG:=1'N9\E/\
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M:L_^HO?O]FXJ/^\;?B-_Z(W&_P#UV]^\'_AK_MZ]]6?^4>+_ 'D=>_T'1?\
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MO]FXJ/\ O&WXC?\ HC<;_P#7;W[P?^&O^WKWU9_Y1XO]Y'7O]!T7_/V>\?\
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M6PF;Q%?"E10Y3$Y2AIYZ+(8^MIY%DBFB=XY$8,I((/M,?[-Q4?\ >-OQ&_\
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M1CQTMC ?H?H?XF;'VM;E$!6/]8]UX>=R_5'N"J,WT5I@$_V7_0W2F_T 1_\
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MRL=A+-;NKU-N\CM="*)#':+*@1+@PH29 E'I&\B2:VB#*L7AQLJ5F"-J  8
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M +F#W&/Q_3^Y)M[S)%EO?EOR?]DJ_L_M<_;UB4=ZY8)-.6//_?O_ $)T-O\
M<'Y"_P#>0V!_]$EB/_LT]\SNOH-:<Y-OC;NY:$5+8\Y5N^=TB@%:L7F;'G)'
M8GVGWJP^HP>3R!>=-O>OI=XU:/ZQ1:J5_P!Q5^&M-7]K\-<5Z4#<=B-N)ARH
MQMRU*^)BM*_P>F?LSU%_N=WQ][_#?]F2VO\ Q'[7[[[#_0U@_O?LO+]O]Y]K
M_??S_:^?T>33HU\7O[]-NCH2D%/'4_&K>%$M7315](E7WONJC%913L3#D*1:
MC8<:U5%*R^F:/5&Q'!)]^6TWA]6GF&,@$@_XJ*5%*K_:_$*\#GKTVY[% 4>?
ME9@64$$R\5/ _!P(K3U%>O4NS^^*[[G[+Y);7K/LZJ6AJ_M>FL'4?:UL&DST
M=3XM[OX*J$.NN-K.MQ<<^\?]]?CX [_[+ON<*KL))?\ 9@MR",2(BNZ-+_<@
M1F5(R"RWU $7%B/>_HM[/_+?3_LE7[/]^\2<4Z:_>O+NA'/*QT,:#]3^0[/G
MU*_N#\A?I_LP^!O];?Z$L1_]FOO++NGH2"66GG^->\*>HI&U5%/4=\;J@J*,
MVC]=33S;$2:DOYDYD5>77_5"^A:;RRAQS#&5(J/\57/V?JY_+RSU>3<]@B:1
M9.5RK 9'B^5:9[,YZP0;*[\JH8:BF^1VVJB"H&J">#I?"2PSBS&\,D>]F206
M4GTD\ ^^']]/C]_WCQN?_P!*$W'_ /81[W]%O?\ T?T_[)5_ZV],?OKE?_IF
M?^JO_0G6?^X/R%_[R&P/_HDL1_\ 9I[#[O'-]=GM_P"%N87KC)IL1>D>S%?8
M/^D;*/DI9?[\]VT_D_OX<&*^)?XJRU6D4=M">&]F+B%);>^'OG#";\?5_1J?
M$\-?A^@F-/#U4KIJ/BXFM<=3-]9MG^LXMV-M_P!UWU+_ *6K_E]C%=6G^*C4
M \OGTANK=N]D#(_)? MV902]A-VALN5.P3L&@CQ\%&>J^JZQ:$;*3.&EG88=
M):0SM6AR\WET_MJA_]72HWQ_V1S\>O\ Q-WR2_\ >:^/_MI?[:3_ $H_R]*I
M/]P[;_3O_P ^=;NNTO\ LISN[_Q$GQ^_]Z+OKW;1WOV1TSV;\I,W\0.T]]]D
M;LP'8_RFZBJMSY+L67 XCK_H; [6PDU!EMJ](Y?^\>9R6,G[ DS$6&J,BPPF
M-@QT43R4LLNB:F0Q)(D(G50&"'AQ)]3]G'SZ,IY$DN#:RR,=4BUKP6@X*:US
MPK@4ZKCZWV#VQL#X];7^3G7.TMI[;W)UK\;^S8<3M;9"YO(;E[FSNXZV.KQ>
M7[6Q\F!Q,&2@V='BSF(:-8LGE)\I+*D54D321U84Y#H3JO([FW;+@/AMO2;M
MW9/QK[$W\>GMT[#[9Z@V#NC=FU^X.K=M[2W!LG9N<[,W9V'OF7:^T\[EZ?/8
M^GR_V><GI(F@3SO4%KB1U"UG&@N!6H)H0>. !FE,=4:&-7-+,F8(3I(90<BA
M K4T\Q7N\NA-KNXNU< O7L=;\C]G3=4]D?(G8VP:/L'$9+978>^L5M?<73/;
M>[-S8G<6X<!LS;FQ]IQYG=VW<+/@\A+CFFQM/4SQU%X?MPL3?'56SMF]7_*K
M#[)^/6RWWY)L#X;=D]A;$EH=S[HW9\9\OO?![SJ.W,?MF9MR2[GVK@MJY.;%
MUU5'D&JY-OR92&@R<DA@ &P[%X2TITU8 ^34X5_U9\NO-&$6Y5+<:J(Q7)*5
M!KYU%./RK0]9.N^T>P-U]O?'"7=':>['V(N^/E_L7:^Z8'QFV]L=_4&S\QL6
MGZFR>YH*;#P8'<.9K,3!FHL?+CQ109H8^IR%%&(I-(&OJGI[!87Y-;8W9LCH
M>3N_+5G\Q3L7:/9O8N;WGOJOSG0&S^N-Y;'K.L\P=UQ[H@H,!79ZFR-;N"3<
M.XQ709DT'V,1U15(D:DD8PLK2:?T@1PR2#7_ #4'V].1H?'UI!JD,Y!8ZJI0
MBAK7\ZFM>'02[L[<W?N#X\[DQN[.V8NIZ:G^!VQ-Y[.VMB.M]MC$]K[M[!V=
MO:B[#A&S4V^^0S5#M^KI:+$1[?P!HIL6]6M7,&6>D\97MS]-]#8WXGP;XR/5
MW8&^,OO/I7<'8]9W3L'KG>>77:'R$?LC<>);;N\.Q(]^P]<[+Z_VS0T%/C,K
MMZOVZ<L6KHJ^*H=ZBD*OK)(9BNH !J4)XBG$"E37UK3IAHH?I68PDDJ3K )[
MJ^;5H!Y$$5\ZYZ,5M?LKN_.=_9K:E%O#9^R\=L7N^CV%3]9[UW/@:5-X= T^
MP<%E*?=>UMLQ[4;>VX-[[GKJR>NQN5@RYQ48HI:26)?#4CW4+[6]%/5CWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWLTO1O_ #)#YD_^(AZ[_P#@A^H_;,G]I!_IC_@/2J#^QO/](/\ CR]
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M/_?I=M>\IO9'_E1F_P"EE=?]8^L:O>__ )6JQ_YX(?\ G[HK/QI_X^3Y7_\
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M1M'KO:NX=WXE,1F<;1/!EL_"N2JIESE+#4"1EE6.GJ?^8.RDZ_\ D1V#MO\
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ME*AKJ0?ILZ@*5%P?"J26&F^W?TT<#.9 JW3JQH,O(LJ![0]I$$;5=%!TK2V
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M\/TO_P"C1WQ_]J#W[^[?P>_Y^]\G/_1#]9__ &_??JS_ ,"_M/\ FZ]IL?\
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M=*=>5KTE'"28:2E:I^0,IIZ:(L=*)95OP/>AXXX1I^T_YNMGZ,TK/-C^B/\
MH/J-35'?U&)5H^O>CJ45$\E5.*;LO>< FJ9=(EJ)1%T\HDGD"C4YNQL+GW,$
MGQ$&7DW ._\ Y<C/2KHES@Z=V$,Q(GVZTFB3)CY"?>NOVJ".Q<CQ@+]!;W[]
M:E/"2GV_['6ZVFK5]1-J]=(K_P ?ZP%>]31+C#UKT.<<I!7'GL7=YHE(E,P*
MTAZ<\ (F.O\ 3^KGZ^V,[<^#Y^O;WR=/_E!^L_S]?^:^\W][K/\ P+^T_P";
MJNFQ_P!_2_[RO_0?3A_%/D5_SP_2_P#Z-'?'_P!J#WU_=OX/?\_>^3G_ *(?
MK/\ ^W[[]6?^!?VG_-U[38_[^E_WE?\ H/KW\4^17_/#]+_^C1WQ_P#:@]V-
M]<8;XP)\7>HH<?V1WQ)MQ.SN\GQ=;-U'L6++3U\E!U,,O!6XY.T:RDIJ.FCC
MI6IY8ZN9YFEF#K$(UUSY[(/NZV7-?T5K;.OU5OJURNA!\)Z4"Q."/4FAKY$9
MZACWDCV5OZL?73SB/PY].E$)/<E:UFCI_P :_+H!-OY;Y')WWW*<5L+I6HJV
MV5TQ_$%KNU=[4M/&@?LO[0TDL'4=9-.[DRB0210A0JE2^HZ>_P"#_&'_ )^7
MWV?\#T_L0@_X6_TG\^YR\3F3_E LO^RB3_MFZA'Z?D[_ )3+S_G%'_VU=##_
M !KY4_\ /N>@_P#T<78'_P!I+W(IZ/XW4<Z5=%VU\BZ.KC!6.LH^KMGTM8BE
M/&RI5T_:L52BF/TD!@-/'TX]T;^L+KH?;;$IZ&=Z?]HW3\9Y6AD$L6X7JR <
M1%%_VU=1:VL^3F2II*/(=6_'FOI)=/EI:WMK?=532Z'5T\D$_1[Q/H=01<&Q
M /N/_"/C&87ISV=W^:>27SR4YZDV08))[L142P_Z4?%)4KK:TC N 3SR?=_%
MYDU:OH++52G]O)_+_%L?E^76C_54@UW"]XU_LH_2G_*5Z=9_XM\IM8E_T;=
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MQ>9?^4"R_P"<\G_;-UCM]/R?Y7EY_P XH_\ MJZ%O^-?*G_GW/0?_HXNP/\
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M[BAVAO/8B?S'_CP=L=@9'>&4W312[A[8GJJRJ["J5J]_I09F;H.3-X"@WQ4
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MA?$__P _W<__ -I'W[QV_P"4=_Y?Y^O?3)_REQ?\:_Z!Z]_I?SG_ #XKNO\
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MQWXY4>0WYN>HWON2MGS':&3J9-[U=+/0U.]\/-E/C]6OM;><])4&-LMBS19
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MXG_^?[N?_P"TC[=\=O\ E'?^7^?I/],G_*7%_P :_P"@>A4_TOYS_GQ7=?\
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MW_30[G_W+[C_ #=8_KN/*"D,O.EF&!QV77_;+T,7^F_<?_>.??W_ )[NJ_\
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MNP_5-!E=QQX*GXI!D)ZGPMZQZP&]NQ?>V^[A#?2;DF\[E]<[,2YL;IC5S5B
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M#CUKWFCH6KO"_P!HM8].DDZ4AGT^0HK.$O8$V'NS6A^+/1^[/D;D:';-)N7
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M;&9.26!)P )50-87]I;W;JM3Z]*/WL2=<?\ 9.'Q0_\ $%)_[]#LOWA1[_\
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M238^NIJ['U=1C,MCLECJA(ZC'97$Y:BGI:NGD4/!4PO&PNI]N_6G_,R>NO\
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M1ZLR.TMW[SINQ<Q1Y"#.]PY;>PJ8]^XZCR]!/3YNGEQ5;11-1&G4R+)6MO\
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M_LB'RI_Y]I1?^C&ZK_\ LW]^^IA_C_D?\W7OH+K_ 'W_ ,:7_/U[_9D>FO\
MGJZS_P!!#>__ -CGOW^R(?*G_GVE%_Z,;JO_ .S?W[ZF'^/^1_S=>^@NO]]_
M\:7_ #]>_P!F1Z:_YZNL_P#00WO_ /8Y[]_LB'RI_P"?:47_ *,;JO\ ^S?W
M[ZF'^/\ D?\ -U[Z"Z_WW_QI?\_7O]F1Z:_YZNL_]!#>_P#]CGOW^R(?*G_G
MVE%_Z,;JO_[-_?OJ8?X_Y'_-U[Z"Z_WW_P :7_/U[_9D>FO^>KK/_00WO_\
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MY>5<EDZ&2MJ&S63BCJLA)4S+J]T/TQT_K-4$FN>)\SCCZ>GETZ/KN\&UC*D
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M^C&ZK_\ LW]N?4P_Q_R/^;ICZ"Z_WW_QI?\ /T)W^S(]-?\ /5UG_H(;W_\
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MXZ>DKJ*CRF4P.+K:R26JQ&(CR=+//.[Q_M3@QJY5@*1;Q:R*K,KK7CBH6H)
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MV1ML8Z=,CG-WT67V91154%//%'25=)1U3LYCI69/<76S2+_9G6%4&@*E$9@
MQJ*!2&)!I4@L!^+IZ"+<8I*B9"*Z@"P(9@/A'F6J!6AP0#Z=0JRNVO5PQS>
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MD@2;Z_M(SQP%R:&F67)-!4Y-3U!>IP=+5U5*, 3(DT%)-XX*5S*];"T-)'5
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M5&?0 =5:WO7EI+, ?B)U8JII3'XE+</4]<_XGA:>@J)*.D,\,4#O+#%2E/\
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M-1-GZM:X8ZBQ&\\Y7XA,:LM1#45=1)3S*D:*)E:>YV9K:0Z-,3Z14*034-0
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MQ!2WMJJMC_+#-M@ZN3L[;]37;:W=4U>VZ>AWAAZ3()W(JY')5O6]%#04%/\
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MU*";-UE9V ]378F6EDE&+H:&HJ(9X4E,9UXVV0RF$V16(("I"X/Z9J-(X40
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MSS[DDR-7+MJCJ*BG2@CI:LT\ 5ZJJ0(NI)=M6YE26S0")T4'CQ4NIT@4%-9
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M--)S7UQUP7)[:'VQ6D/F:GEEIX#CY1/''+2UU3/$L;1@1-]NDVN.X*EM)%V
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MH:RMK-MYO/4^(R]51J\TU?7*KO40&296XY=IDDBC2T_5T @:,A6-1^VFH \
M*X/3LD6YI%)(]T!'JTGO'$<:?830D>9\QUA@GVM+.E-3X^EDGG@IQXTQJL?M
MY(Y:FABF_:TQPS4]&\L*O90L? #6!F2]=_(C?>W-N[JPW<>Y=T[A[(VMC-Y9
MS;U/D9,8E!24DF9P^#FR5:N;AIH'H\=0UL\T]334-D:66F^\M4R1MB[VZ"26
M&2T5(XV**:5)."0*KYFF 6'D:8ZWX%]+''*ETS/(M2*T]0*Y^1R0/.E<]8Y<
MC@:"LDCFQM+3F"1<<E5]M%<I5&#_ "= (?*8II2BA4U1W #%3I4R]P[$^36X
M3L/<%;O_ *[P8V:^X-T[$W)!O^GHI-YR[UW7AH-R=KT%15O4U&8AWQN_<F-Q
M4\KQ4T4TFF%J5$AJW7:76V1F<+!(=0 ?L/;H4T0^A558^?VY'5I(-PD\&1IH
MUTU93JIJJ0"_SU,0OE7A3CUQAK-MTTF1*05#O4F"GKXS1SR14_\ #:.H>"A*
MB/P1?94U'*X5;Z3^;L@+)7?'7Y+S[DB_TG;ZH]H2;DQN7H,SD<]O6FJZZFR>
MZZ:LS]=UI7X*AJS6Q[LW/CZ$U:8QECI9X +2@H46PW3;1#6UB+JI%*+04&->
MHXT@FA;UZHUAN!=?'E"ZAYMYM4Z:?Q$"M.'SZSKG,&M.]1CJ4U7IBJ$^UI"B
MS0QO]M%5K,T:H88G)35>ZD'CVV9+J_Y([DBV_P!<'MC ;DQ Q6Z=L[=Q./[!
MD;#5&)V338.FR6,F0T=(::F_B=-1X*B.26$55=2K20,T<:GVXEQMT0FNOI60
MDAF)0UJU<_LJQIP!J>/56MK]PD!N59:$ !L44"H_P**\2*#KG2U>!ABGKX<<
M:5O37U#&@$<VNMDFJ))0P!664EY)Y1&S%=19N2?8@;*V7\O-M4]-G=M;W;<.
MX<3V[M_;.7V?5YA<O0X;LW?NU8Y,#C-SY&KK(:27>-:N(;R8W5-&*K"--4,7
MI0 DNI]EEK'-'2-H&8, 1^FC=Q%/P@GCZ. ./3T4.YQ4:.:L@D (K6C,, G^
M+Y>JU/#K#45&V"A6H@IJ6*2CJ*A)'@6&66BQD]IY8H_'YOM(6JK:K :9K#AN
M9-+U[\H-[5VSNJ-Q]N[6P%+E=U[N_@%;B=UTN5JMW9&OK%@DW/65&$J"7VED
MJS,18VCGJY:*AIE41F&-HS[N+G;(A/=1VSEJ*6!4]M!4  X#4!8@9/'JZV^X
M3,EM)=JH+&E#6I/GCR-:#@!Z=<1-MJG.3KVI&_R-:5J\S4#D4C!52.*-'B&N
M=2@9Q'K()O?GV$=!M7Y*[FRNY=D;6[&R6:BZTVD=LXZ.+<]?MZ+.[-W'-BI&
MP.!&13'M6R5>.I:6>>BJI$J%H*! -45+&%5R2;;$D<\T 'B.&X5HP!HQ K3S
M%>%3ZGI*(+^1Y88YR?"6G&E5-,"M/*AH?(?+IQJUP<21U-700VDG6J9C2I(\
M4L1E"5$R(&D"B25E# $:Y/ZMR_;BZ_\ D/E)]S;IWQW=B9%VU@-Z;OV[EJ;?
M@S"[XRVT,'DH-Y8[8--CF@%;D\.CU%+F9]$*1&:5R9_(Q=J*XV^(1PV]F:EE
M4C131J(TEZ\ <$#[.'5I+>]/B2378HJLP(:NH@4.FGIP8^7SZP)7X:G^WIJ?
M'/&*B:@A,24!B6&.=A#CZB== T0-]IIB)''BMQIX4>Y^@.V=W[,P%-D^^L=E
MI5V%UOD,5LC=]?/MR"KI=QQ[8DVE28J6:OJJ3(T0J=YICZ7)UL=+-45]-+"4
M6"))_;4>XV<4SE+$@&20%U%0"FK57S!HE:"H (/5Y+*YEB0-> ]B$*QI6M--
M/7XJ FF<<,]1%S>.I*Y8EQ#)Y)\D@JJ2%)BGV*3M4!ECC643.L!/C35P1S<V
M]IZ;KGY;;C'7&>RW8HA=O[M5&PIMP=A08FLQFYZ;)9B@HL$:"O--68_?&(DI
M*ZIKS41!UI]<\TSK)=[&ZVBW-VJV_=0ZZ(22M!4XXJ05 I\@!CJIM]S?P)'N
M ":::M3.:"G\0R37RR3U(^YVS3U%73"B@CG>"05(BQVHU%%##!Z]<$3_ '%(
M(YD2,7/^I4<&PCA?EGDL5@-GXW<O6>Y\E-4U^]<#ON@S&/S>9IL]3XG;^^\+
M3T>=K89,1MK=NY=J9'&+AB(*2IJ,6D&.65!3&FC8KM"M-*Z.J@:64@@4U%#C
MB5#AM62 26/&O3_^[)TCA62-CE@P()KAAG@&((TX!I05Q3J(M9MF)YJH">E$
M".:B'QS4\1I9:JKH*EIJ5=(J*2*O69Y+JP65C)_:#$&H.D?DI6U-/0XW?=!E
MJJMW+0XV 8[M&&KGG[/JMRG-5FTDF6K\\G86!S"MF<A8D4JJ:IIR2"5HOMN(
M):$@:"<QD=@%-7#X2.T>O"G206=^QTB<$Z@/C_&373_I@>X^G&O4R?.;;I4J
M?NUBI8Z6!6JON*%HHX*,Q"""2;5%I2GG2811@_JU:0/K[>]P=2_)[,93)YC/
M]J[8JL]35<J4</\ I8Q'WF8ACS-%/@*C:U)03BC;%[DW3LRE7%QQ"%6KZ*-G
MCA,>I6UOMLC1%%JWAE<_IF@&G(;'$*QK7UZM):7Y+,]RI>O#6*G(I0>A(%/F
M/*G7<>1V_$ZPI2&-Y7G5A_#I%/EH@RU@E9HAJDHXZER[7/I+6)ORX[7Z&^1>
MZJS;>U(^RI,9M?(=G5N#QU7DLU4P5.-WMD$CW'B\E6XE)FJZ6AW3DFDFHJ[S
MOCONHYYI)HGULVI;[;H5EF^GU2>#4@"M5';0'@2.!''('ITY%8WTACC-QIA\
M0BM3AN-:<<G@:TK4U'7&/-[?(:M$<89J"HKFF2E+EJ6@ECHJL!Q&&,M(SQK)
M'8.%9>"/HG,!NCM[:G>&R-F5O;>4R*8K,9+([1SJX/(;OIGR^Z<!6;4CW')M
M2>IQM5DLTE#_ ).DU=*WVT$(*N],%$CK0V4EG+(MJJK0 BH7"G534. KG'$_
M/IM'N8KV* W1.ECI-"<D4KIQGRSPIZ=3:RGH),;/4+CXYE2G1O#I2!WAIY%K
M5@#LA"IY5U:?TZO\?:FIMG]C8W<5/N.H^3&2_CM?708O=69P>/W#GL701;GQ
M>X]_;,K*BKEJ:'&[@ZYR^V\979;)U7C%#AJ4%F@G4<-"XM'C\%; :0"54T&5
M(1A\G#$ ?Q'S'5Q#.L@<WYUG!(!(S5AG *D DG@H]>F[[ZBDIY4&WRT<"&LI
MZ9XZ/RR5%+44T<T<<(9VBR4564$?^KD4>M3;VC^XJWNKJW&X?[ONNNWG!D*O
M=FU]T4L25#XVFW978?;.XMR0U#9>*6#>\64P6[<;-#FI8_N"RE%$0AA=W;)[
M*Z/Z=KHTA67UTU8+P^&A5@5_S],W+7=LJCZLL,@^E2 3Q^*H(HW']@ZE8JHQ
ME;/XX\:E'/!3055.ICB#I123U5/"5:$:*5Q-32!HE;T_GZGV6Z3M/L:3;>,V
M@^]=Q?W8P]'E,=C\*N3J$H8<=FHS%DL>\:.IJ*">)F5892\42R.(U42/J,?I
M;82-+X"^(2#6@K4>?V_/I#]1/X8B\5O# (I7UX]/@I*82-,*>'RN5+2>--9*
ML'!+6OJ#J#?ZW _H/;E/W3VI58>BV]6;XSE=@L=@,AMBBQ%?/'7X^#"9.D@H
M*ND6EK(IXGD:@I8J>.=@:B&"&..-T2- M19VJR-*L"B0D$D8-16G^$XX9/KU
M8W=R5"&8E0M*'A3A_J\^N"4%%%*T\5)3Q3,;M+%$D<C>MY2&= K%3+*S$$V+
M,3]23[Q'N7M5XZ])M_[HJCDY-OS5<]=E:BNK//M7$4N V]/35U8T];0U&*P-
M#!112021O]G#'"28T51OZ2V&FD"BE> IQ-3PXU)KGSSQZU]3<4(\9LT\_04&
M>(H,?9UU#CJ"G71!1TT*6E&F*%$6TT[U4H(4 $25,C2$?36Q/U/M4P?)/NNG
MP&5V\G8&<:FS&,P>#J:V2H9\M3X/ 4V;IJ7$T&0/[U%!6+G9#5S1VJZDQQ!Y
M=*E69;;;)I(Y# *J20/*I(-2/.E,>0SCIP7UV$:/QC0@#YT%<?SSYG'45\'B
MY*F"J:DBUTZ5")&$40-]RU*S-+"%T2,AHTT7_1S;VB\?VMV5BJZ#(X_?&Y::
MLIZK[Q)$RM4T<D[9BKW#(*FGD=Z:L@J,W7SU4L4R/%+-,[.K:FN\;6V92I@2
MA^0\A0?L  'H!TT+B=2&$S5^WYU_PYZF&BHRN@TT&D*B@>-.!&JI'IXNIC1
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MA@PA4''E_#\..%1Y'B.O&YG*E#*VG/\ /!SQSYCAUG%)3*;K3PJ;Q'B-0-4
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MF*\:5' ]1OX/0?=BM$1$RF.P5V6+1$L@2)H5(C>)))/(%8$"4!Q8@'VV[/\
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MZ8YBJ2!8*RJJ*ZO>2*)T2>KR=;5R35=1(&GJY7+S.[<^["TM0Q86Z:L9H/(
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MT/G_ /OW7NM_CW[W[KW7O?O?NO=>]KKK/_2#_?W:G^BC^\G^DC^-4?\ <O\
MN?\ >?WG_C^H_9?P3[#_ "S[_5?1X_5[9N/I_ E^JT^!3NU4TT\ZUQ3IV'QO
M&C^GU>-7MTUK7Y4SU"R7\/\ L*S^*_;?PW[>3[W[S1]K]OI/D\_D]'CT_6_L
MP8_V<?\ NMB_^9F_W1_N+5?8>33_  O^Z'\*Q?B^Y\OI_B?\&^P_AGW'^Y3P
M?:_9>GP>R_\ W3>,U/"\?7Y?%74:T\].JNK\-:ZO/I</WIX:T\3P]&/2E/\
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M_2/_ !3_ $=2?Q;_ (#_ -XO[B_<9/Q?QO7_ +G?XMI^]^S^Z_W+_9>?[?\
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M (5_%,W_ '@\GF_RG[/^)???Q7[7TVO]WZ-/O4G[L\>'7X7U&H:>%:_A_/\
MAK^755_>/T\NG7]/3/I2IK_.M:?GURG_ (-]S2?<_8?=:H/M/+XO)JU'[7QW
M_MZK^+\WOIYO[1,'^FO^)9GP?WY_BGVO7'\>\?\ $/N_M->W_P#19_$+>KPZ
M_P"&?PK5Q?P>/^S[>;Z*BZO#T=].'S\2GSXZOSKY],_XWK/Q:Z)7U\M'_/M/
MRZD/_#]=/Y/M/)JJ?M=?BUZM#_=^"_-]&KR:?Q>_L4MZ_P"SB?Q/;?\ ??\
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<=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g476668g75c17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g75c17.jpg
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M87&1T5)B<H$C)3-#4X.2L28U1&.")%2AP?#A_\0 %P$! 0$!
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M&1G.[;O[H9^D+0>JAPX2QUA:\=;?!-(_W06ID8)!&7M#R,AN=Y'X+]+@" 2
M2<#/6OCUWJ)SH3IS><'QQ27N0T\GVV>!E8R%K3U M W<#KN_:.>R_:46ZKTW
MT5GDK7,;3W2:%L!8\:K?DT[2]PQO+G8QQP,<,N0?5EX,FC?]21CM^KN<#O\
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MW3D3I1\FNEGJJJ]TY$;!T6^3713U52^Z:J=3'1;Y-=%/55+[IJIT8(B("(B
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M=^?PR/O69]-Z*_<])5^O?<F^F$=842+ TPOE38[?X:EH)*DGC)]B/[W8W_\
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MO]L9-#$^K:U\S@QFLUP&L2X $XP,EKL9XXW96?=['JZ(PV*A@EF86,IV2^%
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CN/3#IU=;?4V^OOSIJ.KC=!-'\E@;KL<"'#(8",@G@B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g476668g79s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g79s64.jpg
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M8G*"L;33)$1%5I.RPL,'""5E0V-D@X2BP?#_Q  8 0$! 0$!
M     0(#!/_$ "$1 0 " 00" P$            !$3$"$R%A%$$#$E$B_]H
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M R#_ /VW(6TBE7^Y/HH64]$ULMTJLLI8CNSRO=S,;D$GP ;2 418A,FDI/\
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>0U_2O^7WOZF^(R?YV*3\/UB9M8UWP^C$1%YW1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g476668g82m88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g82m88.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1)Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !8< @   @  ' )0  I3=7)A:B!3;VYI.$))300E       0;P'\W+,%
M-//50I_5\T2A)CA"24T$.@     !'@   !     !       +<')I;G1/=71P
M=70    &     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$58
M5     @ 0P!) $4 ( !2 $< 0@       $EN=&5E;G5M     $EN=&4
M04-L<@    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    & $$ 4 !$ "T ,@      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64LX0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  @$L
M     0 ".$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -#    !@              BP   ]0    ' &0 <P!P #$ ,@ Y
M &(    !                          $              ]0   "+
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "+
M %)G:'1L;VYG   #U     9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    BP    !29VAT;&]N9P   ]0
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M>W:_<K"^54DE/U4DOE5))3__V3A"24T$(0      5P    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  (  R #  ,@ Q     0 X0DE-!"(      49-30 J
M    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    L   "Q
MAVD !     $   "\    Z    2P    !   !+     %!9&]B92!0:&]T;W-H
M;W @,C(N,2 H5VEN9&]W<RD ,C R-#HP-CHQ.2 P,#HR-#HS-P!3=7)A:B!3
M;VYI   #H $  P    '__P  H ( !     $   /4H , !     $   "+
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0              2     $
M  !(     3A"24T#_0      "           _^$!3D5X:68  $U- "H    (
M  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    'P   'X!,@ "    %    )T!.P "    "P   +&':0 $
M     0   +P   #H   !+     $   $L     4%D;V)E(%!H;W1O<VAO<" R
M,BXQ("A7:6YD;W=S*0 R,#(T.C V.C$Y(# P.C(T.C,W %-U<F%J(%-O;FD
M  .@ 0 #     ?__  "@ @ $     0   ]2@ P $     0   (L
M!@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !
M  (   (!  0    !   !1@("  0    !              !(     0   $@
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M(R8G*2HI&1\M,"TH,"4H*2C_P  +"  N 4<! 1$ _\0 '  !  (# 0$!
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IL8GWZ1*Q6UNB1"LRF4I#:TG: IP=UH1[ CXV372Z4I2E*4I2E*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g476668g96m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476668g96m02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M'X6>.?B1=VOV\>$M N]0L]-W^6=5U=REEH6DB3JAOM:NK"T#*&8&YRJLP"D
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M@ H :Z)(C1R*KHRE71U#(RL,,K*P(*D<$&@!2=OKU X!/4X' '3W[=3Q0 M
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MM4TK7]5ETVYBM+'6?%GB_P *:QX=TR*^NK5(KNZ?2]!U>Z'V26<1*S"3RFD
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7?(^DJ "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFE4>#^:U7@(4V2RLR3%))3V0,E71<4 UX(,!4R/6,8TAP2H;01B9M0#05'2
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M;:2LP8BAHA;*ACH,]NOPP;)+WXVV!N^ "G&=++@7;C-;H#J@G4_2E^[/YHY
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M-G1#$7U*"J0@1,7H8(2!6$3)4,:! 4UR*35_"6J?&4P *%MRT6*%)%&@AD@
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MSM.8\WT7C2U<ZP'*.Y6&4WQ+<7BTG6%Y4['T(VN*X)T2*- 3VJI<\@HA0%<
M!=U&+*434+>0L&UN8; '5%Q+#7!0T#_;,L^-+[B)T!P,L'B]=@W@6*I$3LDP
MIQ'=RU"B419"^4ZIG#NRD_-!.Z?]5"W #&R[=#+RY=>B@LBD02*01U]37-/J
M<@R3C^%T(-(O#:3%/-^TH3&& =GWJ5*9>P9DQ8NE\Y)5%AW'%?3[XP4+MEY$
MN+6AQ.DW:O(<):V2,SG,E2]%##+@,B$'UXAU3/(_Z(SC1S+."B41UV2+Z.Q,
M#&=8ZT&!$EOG1Q**.X,!_BX#"=9VQB8^X9<;>RHIW+(F]4[I#!\U($B1;K(
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M*_'YOY3#_W9VOGDI9/-2R/_[2R$7FY="_M0OA6Q> (DO@!P<_9#\</3]NO=
M%M/E8/,JR.95D,VK(/];KX+$VOGIXOU==,GF!9'-"R*;%T3^DR^(;&_>$-F\
M(?([OR$R57_DBR$K&OS-FR*KWA3Q/S2PT_O1BT+!=_1;(,[#KO_]BW@U_MS(
M*?_*QDXWW/]6R25<CR1%PH[PZ.[@^Z,MOU'3?JE-Q3^A,31U;0K^.$%R*TL#
M<']DT(B&+[1 _!&6DW\#4$L#!!0    ( *"%W%A?Q1L*(@0  $H.   9
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M_(UMY-DYZ70)8PYPE<;3"[*R\W;%ILV,1^,)2Q!IKU<R.$0C)P1AMJV^FR0
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MYSUB@H/>Y>T5X!J?3,8GM]]^>S)A([J]OA*WEZ_%1U,!W*>7HS7 B7'><0&
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MD^VU!*5U-A NCM;M05?OO:9JJ_*C#KJA[PLTL,<L-DIPF66:!EZPC7S5: 6
MNP[@+NSG$HO<R]+&QJ XQNXQJD[CRVP%5K::%I':)M!(_&"ZE2,'05!MM/)0
M*CQ64K/MR X0>\38E'AKH?IY[Z#R<8]J0I*(!/OM.-I;U%SS-AQ'7AOI,N3K
M/%Q)\)ZCYEK Q&J'\&\=AK2::VYH3*^+.G[05JF2;Y-1QP%CFG$R_]1W4(G
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M<('7"G15EDP]G&$AMV,O]!X7;O@J-W;!GXS6;(4+-'?K:T4SOV5)>8E"<RE
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MK!2:QI(H:4H@(DV>R4ER*Q:Y,7J2*)8K<N'Z<L-5)&N6*XU8HR)ZT%-966.
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M-O.41=+5[73<CG^V]7PW%?NW(!V+]EFC,F<;U?^5_9U4]MN3VC[7FKV3\:%
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M<#6Z7OKTWO*#^EZ@-!>4AD%I!(I6;Y+*_#)'?[V?:H+:9: T!Y3F@M(P*(U
MT>J=53EUIMZJ2^V<TM]Q$I$:=&H"Z//U43%[/%(SQ)<\(FYL(U"GKJ#M7EM,
M#./PE.(T!9XV!+I= S'HAA H6EW7RL$SX2T\/;*WDJ FGMGNXK6'8- Q$2A:
M7>+*R3-_A)6G+]J["4#-/+.CF]<Q#H..CD#1ZNU0^7ZFWOBK]OC?J1 TDMWV
M>5!##Y3FF(=6W8'2K2$8=$P$BE87N;+R3+V75XF<W6O436)0,P^4YI@-MMJ^
MQ*TA&'1,!(I6OXFE\@,MO1^X%/ZS.H:C9:!JI#:!=GJHA_45%Y3F@-)<4!H&
MI1$H6KUE*A/2,O_ZZ:$%ZD""TAQ0F@M*PZ T D6K=U;E:UIZ7_,CTX@"J3E@
MS_55>W<#),T%I6%0&H&BU;NA\BHMO5?Y?68<1=&VJ_6Y?G"]FR:GG>Q4/3T>
M[UU[= G"H.,B4+2ZQ)73:.GOL_O8+** :G=Y4'\0E.:"TC HC4#1ZOU0^8.6
MWA_\R(3#.G3<#KH!](X\4)H+2L.@- )%JW=#Y2I:>E>Q. &DPA\5G=#8 (=.
MW*CA%INYOEKO+NA6U>T8AT%'1Z!H=>4JL]#J;A:B5?+P;^9))#FZIM&:2BZ^
MH3NV9N$V^_^U=L()Z@^"TAQ0F@M*PZ T D6K=U/E-5HG/V#""6I%@M(<4)H+
M2L.@- )%JW=697!:\#<KZI&]&P?4X+2:[B^<3$_'H_VS4L= ##H^TE#VG7OB
M[,K!M/4.YERIMJ81FM.M+VF@SC'B*TOOB+NZFI?G%O3?[ D1^2V=1TK?\[>T
M]=RCK]O[$3!0LQ.4YH+2,"B-0-'JW569G?8/,#MM4+,3E.: TEQ0&@:E$2A:
MO;,JL]/6FYW__[TP^@*]VPC4);4/;5E[-#Z8'74+PZ!C(U"TNO [3RNW^)H=
M3UBWSTS\<A$$7&;_E[NMSY8^=$:#?:@9]JEFV,>:89]KAGVP^7MXKG;EN=H_
MX.Y.&_3N3E": TIS06D8E$:@:/7.JMQ;^WO?W:DOT+N-0&U?^]!G;CJA=8G"
MH",C4+1<]N'.6V%")IZR%_[$R.-))/,7Q)1KRY<*762OTAE6X?D;B=29[<F/
M8A2P1Y5J'$_50$7^DI]\0?)M]HZ9!RXE#[./&T;73*0!ZN^/G,NWA;1 ^:JE
MV?\ 4$L#!!0    ( *"%W%C>\51_^P(  (<(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;*U676^;,!3]*U=LVE9I*P1(^K$$*86VB[2V49-NFJ8]
MN'"36 .;V4[2_?O9AK*D)5D?]@*V.>?XW&NXE_Z:BY]R@:C@H<B9'#@+I<I3
MUY7I @LB#WF)3#^9<5$0I:=B[LI2(,DLJ<A=W_-Z;D$H<Z*^71N+J,^7*J<,
MQP+DLBB(^'V&.5\/G([SN'!+YPME%MRH7Y(Y3E#=E6.A9VZCDM$"F:2<@<#9
MP!EV3I.>P5O %XIKN3$&$\D]YS_-9)0-',\8PAQ3912(OJTPQCPW0MK&KUK3
M:;8TQ,WQH_J%C5W'<D\DQCS_2C.U&#C'#F0X(\M<W?+U)ZSCZ1J]E.?27F%=
M8ST'TJ54O*C)VD%!674G#W4>-@A:IYW@UP3_*2'<00AJ0O"4T-M!"&M":#-3
MA6+SD!!%HK[@:Q &K=7,P";3LG7XE)ECGRBAGU+-4]'D[NIJ>/L-;BY@,KJ\
M'EV,XN'U%(9Q?'-W/1U=7\+XYO,H'IU/X -,JG<#^ RF"X28%R5AO]]*B)="
M(%- 6 8)SE#/,IB2!Q@+OJ+V%7F7H"(TEP=:YVZ2P+O7!WU7Z0B,#S>MW9Y5
M;OT=;@.XXDPM))RS#+,6?K*?W_'W"+@Z=4W^_,?\G?E[%:^(.(2@\QY\SP];
M#,4OIP=M\>RG)YCNHF]%$S1O0V#U@AUZPS3E2Z8HF\.8YS2E*.'[\%XJH;_/
M'VWG5>F%[7JF9IW*DJ0X<'11DBA6Z$1O7G5ZWL>V7/U/L>0_B6WE,6SR&.Y3
MCRXP0T'RMH15Q*XEFIJ\BDZ\\$@?WFHS$\]1_DG@=[91R7-4-_2..W]A6^:[
MC?GN7O,3112V6:]HO8WMO">V_XE(]B&VW/8:M[V];J=<D1S*IL[H3@B4I;Q
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MPX?@\#M+.]2*\):!*^+_Z)"V-6IHN1=AX*7!\@H\QT]>Z4N:B), ;+X3@-,
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MH$A5@3)/!>L]E;BT_3*D0@HBQ8JF4/*-Y8!SZF^26_C%*SIME\Y!-#A0+F\
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MF*4=Y/<5I6+?2!V4%\JCOP%02P,$%     @ H(7<6 W<)P5^#@  3[\  !D
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M*V]HP%2 _+ZF5#Q/U!V@N/-Y?P!02P,$%     @ H(7<6#LI26OR"   BG0
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MR]#4)?52%MOC?>'QKO/M#U!+ P04    " "@A=Q8CWJT85T!   D$P  &@
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MG8^?EL_-Q4N8<-;P4^SX"U!+ P04    " "@A=Q8[UO*"88!  #5$P  $P
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M^YLW^P102P$"% ,4    " "@A=Q8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *"%W%B=D\TU[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( *"%W%B97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ H(7<6,;_!AN]!   !A4  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( *"%W%A9[9)*-08  " @   8              " @0$-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "@A=Q8]OPV_G(#  "C
M#@  &               @(%L$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ H(7<6(J^1#*^!   U1,  !@              ("!%!<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *"%W%B4C7L&
M9@<  ,<_   8              " @0@<  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "@A=Q8A;]/*&$"   )!@  &
M@(&D(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ H(7<
M6!(^Q0W."0  (D$  !@              ("!.R8  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( *"%W%AB!&EAW2   ,^[   8
M      " @3\P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "@A=Q822D<.M86  #;>   &               @(%240  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ H(7<6$<::R;; P  (PT  !D
M             ("!7F@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "@A=Q88?]I%1D.   B30  &0              @(%P;   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *"%W%B!A) [C@X
M )!%   9              " @<!Z  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ H(7<6%_%&PHB!   2@X  !D              ("!
MA8D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "@A=Q8
MP/>7]&X,  #6/   &0              @('>C0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( *"%W%CQ7VT_=P,  #4+   9
M      " @8.:  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ H(7<6*6SLEKT"   J"0  !D              ("!,9X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "@A=Q8&>'B6SX8  ",@P
M&0              @(%<IP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( *"%W%A1L;S[U0,  .0+   9              " @=&_  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ H(7<6!Q8HB*)
M P  V@H  !D              ("!W<,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "@A=Q8X -S=U(#  "%"@  &0
M@(&=QP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *"%
MW%B!5TOCGQ   ,7    9              " @2;+  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ H(7<6$"VB<LG"   =DD  !D
M         ("!_-L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "@A=Q8WO%4?_L"  "'"   &0              @(%:Y   >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *"%W%@#?QMJ70,   L+
M   9              " @8SG  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ H(7<6 X8,0J/!   >Q@  !D              ("!(.L
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "@A=Q8E;TL
MX$\9   !JP$ &0              @('F[P  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( *"%W%@>>&!_R 8  +XS   9
M  " @6P) 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MH(7<6*?H59BD!   7!8  !D              ("!:Q ! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "@A=Q8#=PG!7X.  !/OP  &0
M            @(%&%0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( *"%W%A8Y.1!!0,  /\-   9              " @?LC 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ H(7<6#LI26OR"
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M2P$"% ,4    " "@A=Q8CWJT85T!   D$P  &@              @ % . $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "@A=Q8[UO*
M"88!  #5$P  $P              @ '5.0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     )P G (@*  ",.P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>166</ContextCount>
  <ElementCount>201</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - INITIAL PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering</Role>
      <ShortName>INITIAL PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption</Role>
      <ShortName>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - STOCKHOLDER'S DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDER'S DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables</Role>
      <ShortName>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - INITIAL PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails</Role>
      <ShortName>INITIAL PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails</Role>
      <ShortName>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - STOCKHOLDER'S DEFICIT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails</Role>
      <ShortName>STOCKHOLDER'S DEFICIT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d476668ds4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>blacu-20240331.xsd</File>
    <File>blacu-20240331_cal.xml</File>
    <File>blacu-20240331_def.xml</File>
    <File>blacu-20240331_lab.xml</File>
    <File>blacu-20240331_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="d476668ds4.htm">d476668ds4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g476668g00d20.jpg</File>
    <File>g476668g00m05.jpg</File>
    <File>g476668g00m06.jpg</File>
    <File>g476668g00t01.jpg</File>
    <File>g476668g00t02.jpg</File>
    <File>g476668g00y12.jpg</File>
    <File>g476668g00y13.jpg</File>
    <File>g476668g04j81.jpg</File>
    <File>g476668g19a08.jpg</File>
    <File>g476668g72a58.jpg</File>
    <File>g476668g75c17.jpg</File>
    <File>g476668g79s64.jpg</File>
    <File>g476668g82m88.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="609">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d476668ds4.htm": {
   "nsprefix": "blacu",
   "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "blacu-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "blacu-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "blacu-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "blacu-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "blacu-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d476668ds4.htm"
     ]
    }
   },
   "keyStandard": 147,
   "keyCustom": 54,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 17,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 3,
    "http://BellevueLifeSciencesAcquisitionCorp.com/20240331": 1
   },
   "contextCount": 166,
   "entityCount": 1,
   "segmentCount": 37,
   "elementCount": 302,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 609,
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
     "longName": "1002 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
     "longName": "1003 - Statement - CONDENSED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONDENSED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis",
      "name": "blacu:CommonStockRedemptionValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations",
     "longName": "1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
     "longName": "1005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical",
     "longName": "1006 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis",
      "name": "us-gaap:CommonUnitIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "blacu:RightsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
     "longName": "1007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation",
     "longName": "1008 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION",
     "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering",
     "longName": "1010 - Disclosure - INITIAL PUBLIC OFFERING",
     "shortName": "INITIAL PUBLIC OFFERING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:InitialPublicOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions",
     "longName": "1011 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies",
     "longName": "1012 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption",
     "longName": "1013 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION",
     "shortName": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:CommonStockSubjectToPossibleRedemptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:CommonStockSubjectToPossibleRedemptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit",
     "longName": "1014 - Disclosure - STOCKHOLDER'S DEFICIT",
     "shortName": "STOCKHOLDER'S DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements",
     "longName": "1015 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents",
     "longName": "1016 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables",
     "longName": "1019 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)",
     "shortName": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "blacu:CommonStockSubjectToPossibleRedemptionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "blacu:CommonStockSubjectToPossibleRedemptionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables",
     "longName": "1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
     "longName": "1021 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)",
     "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "1022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails",
     "longName": "1023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails",
     "longName": "1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
     "longName": "1025 - Disclosure - INITIAL PUBLIC OFFERING (Details)",
     "shortName": "INITIAL PUBLIC OFFERING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "blacu:NumberOfSharesIssuedPerUnit",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "blacu:RightsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "blacu:InitialPublicOfferingTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
     "longName": "1026 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShorttermDebtAverageOutstandingAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
     "longName": "1027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "blacu:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "blacu:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
     "longName": "1028 - Disclosure - COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details)",
     "shortName": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock",
       "blacu:CommonStockSubjectToPossibleRedemptionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
     "longName": "1029 - Disclosure - STOCKHOLDER'S DEFICIT (Details)",
     "shortName": "STOCKHOLDER'S DEFICIT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2023",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails",
     "longName": "1030 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "name": "us-gaap:AssetsHeldInTrustNoncurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails",
     "longName": "1031 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:AssetsHeldInTrust",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d476668ds4.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "blacu_AccretionForCommonStockToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "AccretionForCommonStockToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion For Common Stock To Redemption Value",
        "terseLabel": "Accretion of common stock to redemption value",
        "verboseLabel": "Plus: Accretion on common stock subject to possible redemption"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r83"
     ]
    },
    "blacu_AccruedOfferingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "AccruedOfferingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Offering Costs Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r420",
      "r473"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r321",
      "r447",
      "r448",
      "r449",
      "r463",
      "r475"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Excise tax payable attributable to redemption\u00a0of common stock",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdministrativeServiceMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative Service [Member]",
        "terseLabel": "Administrative Service [Member]",
        "documentation": "Administrative assistance, including, but not limited to, accounting, tax, legal, regulatory filing, and share registration of managed fund and investment account of independent third party, and related and affiliated entity."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r362",
      "r404",
      "r424",
      "r457",
      "r466",
      "r467",
      "r468"
     ]
    },
    "blacu_AggregateUnderwriterCashDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "AggregateUnderwriterCashDiscount",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Underwriter Cash Discount",
        "terseLabel": "Aggregate Underwriter Cash Discount (in Dollars)"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Underwriter Cash Discount Percent Of Initial Public Offering",
        "terseLabel": "Aggregate Underwriter Cash Discount Percent Of Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_AprilSponsorNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "AprilSponsorNoteMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Sponsor Note [Member]",
        "terseLabel": "Jcw Promissory Note [Member]",
        "documentation": "April sponsor note member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r104",
      "r123",
      "r153",
      "r156",
      "r158",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r235",
      "r239",
      "r253",
      "r290",
      "r355",
      "r420",
      "r431",
      "r454",
      "r455",
      "r469"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r123",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r235",
      "r239",
      "r253",
      "r420",
      "r454",
      "r455",
      "r469"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrust",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-in-Trust",
        "terseLabel": "Asset, Held-in-Trust",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrustNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-in-Trust, Noncurrent",
        "terseLabel": "Investments held in Trust Account",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "blacu_BcmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "BcmMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BCM [Member]",
        "documentation": "Bcm member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434"
     ]
    },
    "blacu_COMMITMENTSCONTINGENCIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "COMMITMENTSCONTINGENCIESDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS &amp; CONTINGENCIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash",
        "verboseLabel": "Cash (in Dollars)",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r292",
      "r332",
      "r350",
      "r420",
      "r431",
      "r438"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r103",
      "r405"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH, END OF PERIOD",
        "periodStartLabel": "CASH, BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r66",
      "r120"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r66"
     ]
    },
    "blacu_CashDepositedInTheTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CashDepositedInTheTrustAccount",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Deposited In The Trust Account",
        "negatedLabel": "Cash deposited in Trust Account",
        "terseLabel": "Cash deposited in Trust Account",
        "documentation": "Cash deposited in the trust account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash Equivalents, at Carrying Value (in Dollars)",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r471"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_CashFlowsFromFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CashFlowsFromFinancingActivitiesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities Abstract",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_CashFlowsFromInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CashFlowsFromInvestingActivitiesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities Abstract",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_CashFlowsFromOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CashFlowsFromOperatingActivitiesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities Abstract",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Operating Assets And Liabilities Abstract",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ChardanCapitalMarketsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ChardanCapitalMarketsLLCMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chardan Capital Markets LLCMember",
        "terseLabel": "Chardan Capital Markets, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r107",
      "r108",
      "r123",
      "r143",
      "r144",
      "r146",
      "r148",
      "r151",
      "r152",
      "r160",
      "r167",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r193",
      "r194",
      "r196",
      "r199",
      "r205",
      "r253",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r342",
      "r364",
      "r386",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r436",
      "r443",
      "r450"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Number Of Rights To Call One Security",
        "terseLabel": "Class of Warrant or Right, Number of Rights to Call One Security"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights",
        "terseLabel": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r47",
      "r291",
      "r341"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r165",
      "r166",
      "r403",
      "r453"
     ]
    },
    "blacu_CommitmentsContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommitmentsContingenciesLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS CONTINGENCIES [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r447",
      "r448",
      "r463",
      "r472",
      "r475"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in Dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "blacu_CommonStockRedemptionValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommonStockRedemptionValue",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Redemption Value",
        "terseLabel": "Common stock, redemption value (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r342"
     ]
    },
    "blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share",
        "terseLabel": "Common Stock Shares Excluded From Calculation of Net Income(Loss) Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "definitionGuidance": "Common Stock, Shares, Issued (in Shares)",
        "verboseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r342",
      "r361",
      "r475",
      "r476"
     ]
    },
    "us-gaap_CommonStockSubjectToMandatoryRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSubjectToMandatoryRedemptionMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject to Mandatory Redemption [Member]",
        "terseLabel": "Common Stock Subject to Mandatory Redemption [Member]",
        "documentation": "Shares that embody an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur, that represent equity ownership in a corporation, provide voting rights, entitle the holder to a share of the company's success through dividends and/or capital appreciation and, in the event of liquidation, provide rights to a company's assets only after bondholders, other debt holders, and preferred stockholders have been satisfied."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r6"
     ]
    },
    "blacu_CommonStockSubjectToPossibleRedemptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommonStockSubjectToPossibleRedemptionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject To Possible Redemption Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommonStockSubjectToPossibleRedemptionTableTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject To Possible Redemption Table Text Block",
        "terseLabel": "Summary of common stock subject to possible redemption"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_CommonStockSubjectToPossibleRedemptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "CommonStockSubjectToPossibleRedemptionTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject To Possible Redemption Text Block",
        "terseLabel": "COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued (in Dollars)",
        "terseLabel": "Common stock",
        "definitionGuidance": "Common stock, shares issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r294",
      "r420"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r342"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonUnitIssuanceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssuanceValue",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Unit, Issuance Value",
        "verboseLabel": "Common Unit, Issuance Value",
        "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssued",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Unit, Issued",
        "terseLabel": "Common Unit, Issued (in Shares)",
        "verboseLabel": "Common Unit, Issued",
        "documentation": "Number of common units issued of limited liability company (LLC)."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r91"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum": {
     "xbrltype": "integerItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condition For Future Business Combination Number Of Businesses Minimum",
        "terseLabel": "Condition For Future Business Combination Number Of Businesses Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current",
        "terseLabel": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r51",
      "r82",
      "r84",
      "r127",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r261",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r444"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in Dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r178"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r176",
      "r261",
      "r411",
      "r412"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r410",
      "r464"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, End",
        "terseLabel": "Debt Instrument, Maturity Date Range, End",
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, Start",
        "terseLabel": "Debt Instrument, Maturity Date Range, Start",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r127",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r261",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r444"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Description",
        "terseLabel": "Debt Instrument, Redemption, Description",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r439"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "negatedLabel": "Offering costs allocated to common stock subject to possible redemption",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "DeferredOfferingCostsIncludedInAccruedOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs Included In Accrued Offering Costs",
        "terseLabel": "Deferred offering costs included in accrued offering costs",
        "documentation": "Deferred offering costs included in accrued offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_DeferredUnderwritingCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "DeferredUnderwritingCommissions",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Underwriting Commissions",
        "terseLabel": "Deferred underwriting commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r40",
      "r41",
      "r42",
      "r126"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information Line Items",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "BASIC NET INCOME (LOSS) PER SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r141",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r249",
      "r250",
      "r288",
      "r300",
      "r407"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "DILUTED NET INCOME (LOSS) PER SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r249",
      "r250",
      "r288",
      "r300",
      "r407"
     ]
    },
    "blacu_EffectiveExciseTaxRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "EffectiveExciseTaxRate",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Excise Tax Rate",
        "terseLabel": "Effective Excise Tax Rate",
        "documentation": "Effective excise tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "totalLabel": "Total income tax expense",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Provision/(benefit) at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r224",
      "r233"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r462"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences Change In Fv Of Warrant Liability",
        "terseLabel": "Change in fair value of Warrants",
        "documentation": "Effective income tax rate reconciliation permanent differences change in fv of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfTheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax provision/(benefit) net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r462"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r99",
      "r114",
      "r115",
      "r116",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r150",
      "r161",
      "r162",
      "r207",
      "r216",
      "r217",
      "r218",
      "r230",
      "r231",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r303",
      "r304",
      "r305",
      "r321",
      "r386"
     ]
    },
    "blacu_EquityParticipationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "EquityParticipationMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Participation Member",
        "terseLabel": "Equity Participation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_EquityParticipationSharesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "EquityParticipationSharesPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Participation Shares Policy Policy Text Block",
        "terseLabel": "Equity Participation Shares"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ExpensesAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses Abstract",
        "terseLabel": "EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r79"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r252",
      "r272",
      "r273",
      "r274",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r208",
      "r213",
      "r252",
      "r272",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r208",
      "r213",
      "r252",
      "r273",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r252",
      "r274",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r272",
      "r273",
      "r274",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations, Total",
        "terseLabel": "Federal",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r223"
     ]
    },
    "blacu_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares Member",
        "terseLabel": "Founder Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_GainLossFromTrustAccountToPayExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "GainLossFromTrustAccountToPayExpenses",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss from Trust Account to Pay Expenses",
        "terseLabel": "Withdrawal of interest from Trust Account",
        "documentation": "Gain (loss) from trust account to pay expenses."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_INITIALPUBLICOFFERINGDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "INITIALPUBLICOFFERINGDetailsLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INITIAL PUBLIC OFFERING (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_INITIALPUBLICOFFERINGDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "INITIALPUBLICOFFERINGDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INITIAL PUBLIC OFFERING (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r116"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Loss from operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r61",
      "r68",
      "r133",
      "r134",
      "r135",
      "r136",
      "r145",
      "r148"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r94",
      "r139",
      "r140",
      "r154",
      "r223",
      "r232",
      "r302"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r221",
      "r222",
      "r226",
      "r227",
      "r228",
      "r229",
      "r311"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net, Total",
        "terseLabel": "Income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "blacu_InitialPublicOfferingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "InitialPublicOfferingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_InitialPublicOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "InitialPublicOfferingTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering Text Block",
        "terseLabel": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_InterestIncomeHeldInTheTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "InterestIncomeHeldInTheTrustAccount",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income Held in The Trust Account",
        "terseLabel": "Interest Income Held in The Trust Account",
        "documentation": "Interest income held in the trust account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeInterestEarningAssetIncreaseDecrease",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlowsAlternate1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Interest-Earning Asset, Increase (Decrease)",
        "negatedLabel": "Interest earned on investments held in the Trust Account",
        "documentation": "Amount of increase (decrease) in interest income on interest-earning asset."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r437"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest earned on investments held in the Trust Account",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "blacu_InvestmentOfCashInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "InvestmentOfCashInTrustAccount",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment of Cash in Trust Account",
        "documentation": "Investment of cash in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "InvestmentsHeldInTrustAccountPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Held In Trust Account Policy Policy Text Block",
        "terseLabel": "Investments Held in Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_JcwPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "JcwPromissoryNoteMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jcw Promissory Note [Member]",
        "terseLabel": "Jcw Promissory Note [Member]",
        "documentation": "Jcw promissory note member."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_JoshPanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "JoshPanMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Josh Pan [Member]",
        "terseLabel": "Josh Pan [Member]",
        "documentation": "Josh pan member."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_JunChulWhangMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "JunChulWhangMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jun Chul Whang [Member]",
        "documentation": "Jun chul whang."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r123",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r236",
      "r239",
      "r240",
      "r253",
      "r340",
      "r408",
      "r431",
      "r454",
      "r469",
      "r470"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r85",
      "r297",
      "r420",
      "r445",
      "r451",
      "r465"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r102",
      "r123",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r236",
      "r239",
      "r240",
      "r253",
      "r420",
      "r454",
      "r469",
      "r470"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_MaximumAllowedDissolutionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "MaximumAllowedDissolutionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Allowed Dissolution Expenses",
        "terseLabel": "Maximum Allowed Dissolution Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_MaximumNumberOfDemandsForRegistrationOfSecurities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Number Of Demands For Registration Of Securities",
        "terseLabel": "Maximum Number of Demands for Registration of Securities"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "MayTwoThousandAndTwentyFourPromissoryNoteMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Two Thousand And Twenty Four promissory Note [Member]",
        "terseLabel": "May 2024 [Member]",
        "documentation": "May Two Thousand And Twenty Four promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_MonthlyAdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "MonthlyAdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Administrative Fees Expense",
        "terseLabel": "Administrative Fees Expense, Monthly"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 16.0
      },
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlowsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "NET INCOME (LOSS)",
        "terseLabel": "Net loss (income)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r68",
      "r86",
      "r100",
      "r111",
      "r112",
      "r116",
      "r123",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r145",
      "r153",
      "r155",
      "r157",
      "r159",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r250",
      "r253",
      "r299",
      "r363",
      "r384",
      "r385",
      "r409",
      "r429",
      "r454"
     ]
    },
    "blacu_NetLossPerCommonSharePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NetLossPerCommonSharePolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share Policy Policy Text Block",
        "terseLabel": "Net Income (Loss) per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NetTangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NetTangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Tangible Assets",
        "terseLabel": "Net Tangible Assets",
        "documentation": "Net tangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NoLongerSubjectToForfeitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NoLongerSubjectToForfeitureMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Longer Subject To Forfeiture Member",
        "terseLabel": "No Longer Subject to Forfeiture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable - related party",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "blacu_NoticePeriodForWarrantRedemption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NoticePeriodForWarrantRedemption",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notice Period For Warrant Redemption",
        "terseLabel": "Notice Period for Warrant Redemption"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Days After The Due Date Within Which The Loan Shall Be Settled",
        "terseLabel": "Number of days after the due date within which the loan shall be settled",
        "documentation": "Number Of Days After The Due Date Within Which The Loan Shall Be Settled."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NumberOfRightsIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NumberOfRightsIssuedPerUnit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Rights Issued Per Unit",
        "terseLabel": "Number of Rights Issued Per Unit (in Shares)",
        "verboseLabel": "Number of Rights Issued Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NumberOfSharesIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NumberOfSharesIssuedPerUnit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Shares Issued Per Unit",
        "terseLabel": "Number of Shares Issued Per Unit (in Shares)",
        "verboseLabel": "Number of Shares Issued Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_NumberOfWarrantsIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Warrants Issued Per Unit",
        "terseLabel": "Number of Warrants Issued Per Unit (in Shares)",
        "verboseLabel": "Number of Warrants Issued Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_OfferingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "OfferingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Policy Policy Text Block",
        "terseLabel": "Offering Costs Associated with the Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r78",
      "r308",
      "r309"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r474"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "totalLabel": "Total other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r365",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_OtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Due to affiliate",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r420"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Advance to Affiliate",
        "negatedLabel": "Repayments to affiliate",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Redemption of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Deferred underwriters' discount payable charged to additional paid-in capital",
        "verboseLabel": "Payments for Underwriting Expense (in Dollars)",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Investment of cash in Trust Account",
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination",
        "terseLabel": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_PercentageOfTrustAccountRequiredForBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "PercentageOfTrustAccountRequiredForBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Trust Account Required For Business Combination",
        "terseLabel": "Percentage Of Trust Account Required For Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_PeriodToConsummateBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "PeriodToConsummateBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period to Consummate Business Combination",
        "terseLabel": "Period To Consummate Business Combination",
        "documentation": "Period to consummate business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "verboseLabel": "Preferred Stock, Par or Stated Value Per Share (in Dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r342",
      "r361",
      "r475",
      "r476"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r293",
      "r420"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r163",
      "r164",
      "r406"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Proceeds from affiliate",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Initial Public Offering, net of underwriters' fees",
        "definitionGuidance": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Gross proceeds from Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonLimitedPartnersUnits",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Limited Partners Units",
        "terseLabel": "Proceeds from private placement",
        "verboseLabel": "Proceeds from Issuance of Common Limited Partners Units",
        "documentation": "The cash inflow from the issuance of common limited partners units during the period."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from over-allotment option",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from note payable - related party",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ProceedsFromTrustAccountForPaymentToRedeemingStockholders",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Trust Account for Payment to Redeeming Stockholders",
        "terseLabel": "Cash withdrawn from Trust Account for payment to redeeming stockholders",
        "verboseLabel": "Less: Redemption of common stock in connection with Trust extension",
        "documentation": "Proceeds from trust account for payment to redeeming stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r111",
      "r112",
      "r118",
      "r123",
      "r131",
      "r139",
      "r140",
      "r153",
      "r155",
      "r157",
      "r159",
      "r160",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r234",
      "r237",
      "r238",
      "r250",
      "r253",
      "r289",
      "r298",
      "r320",
      "r363",
      "r384",
      "r385",
      "r409",
      "r418",
      "r419",
      "r430",
      "r440",
      "r454"
     ]
    },
    "blacu_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Notes Member",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Member",
        "terseLabel": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "RELATEDPARTYTRANSACTIONSDetailsLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_RELATEDPARTYTRANSACTIONSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "RELATEDPARTYTRANSACTIONSDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_RedemptionLimitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "RedemptionLimitPercentage",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption Limit Percentage",
        "terseLabel": "Redemption Limit Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_RedemptionTriggerPriceAdjustmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "RedemptionTriggerPriceAdjustmentPercentage",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption Trigger Price Adjustment Percentage",
        "terseLabel": "Redemption Trigger Price Adjustment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r266",
      "r267",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r360",
      "r362",
      "r393"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r468"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r266",
      "r267",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r360",
      "r362",
      "r393",
      "r468"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r317",
      "r318",
      "r319",
      "r368",
      "r369",
      "r370",
      "r390",
      "r392"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayments to note payable - Sponsor",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r74",
      "r296",
      "r306",
      "r307",
      "r316",
      "r343",
      "r420"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r161",
      "r162",
      "r216",
      "r217",
      "r218",
      "r230",
      "r231",
      "r241",
      "r243",
      "r244",
      "r246",
      "r248",
      "r303",
      "r305",
      "r321",
      "r475"
     ]
    },
    "blacu_RightsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "RightsPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Policy Policy Text Block",
        "terseLabel": "Rights"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_STOCKHOLDERSDEFICITDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "STOCKHOLDERSDEFICITDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDER'S DEFICIT (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Excise tax payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of the Company's Current and Deferred Tax Provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "blacu_ScheduleOfFairValueOfAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ScheduleOfFairValueOfAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ScheduleOfReconciliationOfCommonStockSubjectToPossibleRedemptionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reconciliation Of Common Stock Subject To Possible Redemption Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share Price (in Dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "blacu_SharesOutstandingHoldingTermAfterBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "SharesOutstandingHoldingTermAfterBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Outstanding Holding Term After Business Combination",
        "terseLabel": "Shares Outstanding, Holding Term After Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]",
        "terseLabel": "Common Stock Subject to Possible Redemption",
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "terseLabel": "Short term debt bearing fixed interest percentage",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Average Outstanding Amount",
        "terseLabel": "Short-Term Debt, Average Outstanding Amount",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r371"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r121"
     ]
    },
    "blacu_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "SponsorMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Member",
        "terseLabel": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheCompanySCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations, Total",
        "terseLabel": "State",
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r458",
      "r461"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CoverPage",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r107",
      "r108",
      "r123",
      "r143",
      "r144",
      "r146",
      "r148",
      "r151",
      "r152",
      "r160",
      "r167",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r193",
      "r194",
      "r196",
      "r199",
      "r205",
      "r253",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r342",
      "r364",
      "r386",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r436",
      "r443",
      "r450"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21",
      "r99",
      "r114",
      "r115",
      "r116",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r150",
      "r161",
      "r162",
      "r207",
      "r216",
      "r217",
      "r218",
      "r230",
      "r231",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r303",
      "r304",
      "r305",
      "r321",
      "r386"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r150",
      "r275",
      "r310",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r366",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r424"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheetsParentheticals",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r150",
      "r275",
      "r310",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r366",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r424"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment",
        "negatedLabel": "Less: Proceeds allocated to public warrants and rights",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of 430,000 Private Placement Units (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues (in Shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r54",
      "r74",
      "r312",
      "r386",
      "r398"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r54",
      "r74",
      "r215"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "terseLabel": "Stock Issued During Period, Shares, Stock Splits (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, Stock Splits",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r54",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of 430,000 Private Placement Units",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r54",
      "r74",
      "r321",
      "r386",
      "r398",
      "r430"
     ]
    },
    "blacu_StockholdersDeficitLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "StockholdersDeficitLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS DEFICIT [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' deficit",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r70",
      "r344",
      "r361",
      "r387",
      "r388",
      "r420",
      "r431",
      "r445",
      "r451",
      "r465",
      "r475"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS' DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r122",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r247",
      "r389",
      "r391",
      "r402"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Stockholders' Equity Note, Stock Split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "blacu_SubjectToForfeitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "SubjectToForfeitureMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subject To Forfeiture Member",
        "terseLabel": "Subject to Forfeiture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r270"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r270"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r270"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r270"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r270"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficit",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommonStockSubjectToPossibleRedemptionSummaryOfCommonStockSubjectToPossibleRedemptionDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Common stock subject to possible redemption",
        "verboseLabel": "Balance as of Ending",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r219",
      "r295"
     ]
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Temporary Equity, Redemption Price Per Share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par Value",
        "terseLabel": "Temporary Equity, Par Value",
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34"
     ]
    },
    "blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination",
        "terseLabel": "Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences",
        "terseLabel": "Threshold Period After Business Combination in Which Specified Trading Days Within Any Specified Trading Day Period Commences"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Consecutive Trading Days",
        "terseLabel": "Transfer, Assign, or Sell Any Shares or Warrants After Completion of Initial Business Combination Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Percentage Of Total Equity Proceeds",
        "terseLabel": "Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Percentage Of Total Equity Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Trading Days",
        "terseLabel": "Transfer, Assign, or Sell Any Shares or Warrants after Completion of Initial Business Combination Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement Member",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_UnderwritingCashDiscountPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "UnderwritingCashDiscountPerUnit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Cash Discount Per Unit",
        "terseLabel": "Underwriting Cash Discount Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_UnderwritingExpensePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "UnderwritingExpensePricePerShare",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Expense Price Per Share",
        "terseLabel": "Underwriting Expense, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_UnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CommitmentsAndContingenciesDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Units Issued During Period Shares New Issues",
        "terseLabel": "Units Issued During Period, Shares, New Issues (in Shares)",
        "verboseLabel": "Units Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits (in Dollars)",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r225"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties Accrued (in Dollars)",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_UnsecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "UnsecuredPromissoryNoteMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Promissory Note [Member]",
        "documentation": "Unsecured promissory note member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r89",
      "r90",
      "r92",
      "r93"
     ]
    },
    "blacu_WarrantExercisePriceAdjustmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WarrantExercisePriceAdjustmentPercentage",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Adjustment Percentage",
        "terseLabel": "Warrant Exercise Price Adjustment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_WarrantInstrumentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WarrantInstrumentsPolicyPolicyTextBlock",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Instruments Policy Policy Text Block",
        "terseLabel": "Warrant Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "blacu_WarrantRedemptionConditionMinimumSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Redemption Condition Minimum Share Price",
        "terseLabel": "Warrant Redemption Condition Minimum Share Price (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/InitialPublicOfferingDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails",
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Or Rights Outstanding Exercisable Term After Business Combination",
        "terseLabel": "Warrants or Rights Outstanding, Exercisable Term After Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING, DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r148"
     ]
    },
    "blacu_WorkingCapitalFundAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WorkingCapitalFundAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Fund And Other Expenses",
        "terseLabel": "Working Capital Fund And Other Expenses",
        "documentation": "Working capital fund and other expenses."
       }
      }
     },
     "auth_ref": []
    },
    "blacu_WorkingCapitalLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240331",
     "localname": "WorkingCapitalLoansMember",
     "presentation": [
      "http://BellevueLifeSciencesAcquisitionCorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loans Member",
        "terseLabel": "Working Capital Loans [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(i)",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001193125-24-172392-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-172392-xbrl.zip
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MAQQL?D!/50PV/KR L14_8*U)'$?@JTI$B7FVV5E./^?W8BD^YU,OEM7)W $
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M]#GY;:5];*?02)^ *172QV'WJ;1E8C9\2VL/ )'V?H-4E7@47E)9[N;W_J^
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M,Z:@'7B/S<#JTN>:Y\E.U_J7&HXI1'#!T804F5[:4W&5@\F;['057YF<8T
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M>S:\?(_)-H:P#H"UNK-6,X,D'.V!OV5&SF.<HD1ZM%!* Q:KMS[E1@@3B/9
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M(9>H_,:.;P2&Y221.7'E4(,-G=G\F3.F:!=8^RU%\ +SS"CT9OED(US0Z!4
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M$*A1@PG=]Q)7MJ7(2URO#T67D[AK*#1*GY.XR[YEXV%R)Z#C*VA5DHKBK2B
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M<N5"TJ2UA'DK2LXJIO]AO 9Y8\R\8:24@C7":E@?JW?3SOX4P<U%R2<X+0P
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M0$W8\[>)^UY(*+,&4=];!ZD7RG<(J>9 &S_*%KB\>IQ@I"U,:[GHRFO":2W
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MOCBU *)5JD36"*&;2 C$6*Q7@M."?>!?;[:!?TQ[\WD0!@3)]FEVIDG8A0&
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M"!;+UB"CF$>&DZ",QD;4FHZ<?][,5]OYUE[XF6S JT%GLM&&>2*&6;:+3SC
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M888&H<:=;2.U'5"J:L2%QU,8T$M:LOU(E[4LD3)S_K;3*.OIL"Y!UVJ!.P5
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M3OT)'Z*,? ]4@3]=^Q'N['&#E0=P7?7ZV4N>W<CY[/AT(>YE28]$)>W9N!$
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M/\FCE779 3.@:NHCYM[TBJ $SHK2\[KT@I)P\[];"7B^@&*35+-)237[H25
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MU4J.VBR16=:RK?HV7T1GP%8.&<!"Q/HB Y@'B(-X""*\#Y\"[[^PNW->KW&
M#UYCKKA6#D"CEDLMWM 7E(B0HHS6C@$.(/AHEL<MT*G;1 MN;**=3]+D%QL<
M.#Z-F)KN]]$9N^9FH&C*OGVH]-3&WR1;]=)?Y@VAM*51F16 OF.WQE9H:YII
M*ZY![/<6NSBB4V<J3)HP-162S+J)%YS)5GM]PGSN54UD71H#M.%.NM91G392
MAG#:#GJ7MO3U!!6-H:*U"=J%B>/;,>@AE;=IE=T!6[?+[FB%>0V;. F>!NZ2
MM#Z0?79O$O*E;7>]A3L(VA1R A>QQKXXFQVZ*ZR^\^T)9^%5<$\L@]CP_'#
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M7KP];O7'2BY OZR6O@Z<*C5*R2W[Z8NJ .FW-9!4]]\:,.KEQZ_WQQ:_7:(
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MR7@A&V5BTF6E]3+Y?F.YQW]CH_&;2%*NZ9G $I=KNJ5>CCZ5+WL#;[YBTF\
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M[,XI6G7"J9Q!:<OQU95C7S-M4 )^SVPZT>5WY+WVIB"*[$J1C?DAE>S_I6T
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MT61V"A 3J6P#8D(^_9A1J G(5K  THQ]"!,2:\]2SM,@!62#8;F9*81B*V0
MB=!^,B>1T59+T *DX>22*X5C*Y0 B5PC7GDR:"";#JN>E'($MJ(.RIU_A1_,
MC;WL6P#C^1[1)/M@+!8T9BF[>48)K7: &2E9@!EK!F!LQ2/@3T.]^<>2I[E
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M,V:H',]7-HC"&4T4#G*[AP SDCFH##>B578?C>/9R0I^GLP3>!(&$^J3/;?
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M#+<4LJ[&S0M4GS_TG85:. +U,C:7EE4O<4CO^LR5;Z_SSR%LN-G0A4<621M
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MA,-']:?-R5Y'(%]B9WM1$F;$<Q$55@IBX<K]C>55^,[N!N$P_QP1>1H"91M
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MPU_$)*S);P_"$#0^@%PE=YI7(#O0,I"[R7\J7CW+\C((HLT_8 &R4T?]JO>
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M6#)K!&!TUSG]_L1E^^A%X881ZRF"PJ3Y)3I6D0-587AIX*+3L,5A61/>@0N
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M-9PZ^E[)CP&&Z&7G:02&H1+T0J?DP19Z)Q$T]4!$FP^2-LG*"RU:NI<$8F5
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MN>TIJ'(BG35),>TUK,,PX'4YX4V@E2K!UY+ >:"=\#OB>C HW;2%L2SA<&,
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M\5UCS!Z*;A,+S1ID(^-IN; AC&,W13N=5!]KX+Q$.Z%A$O&:TI]%=8)$.?5
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MM=;U#;PEP-_%5XP[$\/85UCL1;OZ%8 !R*G! ZV+1K7YCG6^=;KU:T -)YX
MLS#=IT:S2AAI=%BSQ=]P5>_6+W(XE$@+T"<6^K5Q=04( 41V;]M-CC:$7TO
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MOC\Y-0Y/F.=PP6GDT^MX)U_[Q_>X-;Y%^;TB3IBDHY]I]XZILZ6 N7<^:X5
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MR>'124Z*X^0O@',U@/L:3\7^R?'QXO,<JO/ :I!6:3G?O1%PO?^KR6W0TO-
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MO[,=4&9]V _Z:ALC2HWGH4LHQ\&!*)X>'^44;^W6;;C1[J1N]C;?P;1.])T
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M&4<M8;G-$QE^PRC%D*BT<+7JAG62]T;07[J5U3R21DRSZ)/2^RJ)8;/'4O'
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MQQP!>< :GH,!]F]5I&3 H=HQ@+/FDHNGJW..!"F<12/#0%@E,YN!P3^";9Z
M81X9,?!K,*F:1M*3P:_P?I#[3\%/21[\"T2K1O;#TW\$.V(Q_/K3O^2LWC7&
M)M<*N#X)/W2H&!FH0]%YD;!I#O-]71?Y7 U@'%>(-4"0C,K\D>'CX74!JV?=
MT@X)7#:2^V8Y#:Z&-RPOFY/+9VK]2C#>?^8(V=%XOS8>&@?YUSY]WNUD,EWA
MX4&CFJA\ F[8=),V?;?M8(#6.87U2!%_>K1R;=G7HGXD>9K'P2D!3L\L(L^4
M'[W,!V'P:S4:A&TKB]DYT!UV%RA8N5 66XL<OT-+'>UOQ:>Z\C;(>LVPJD#8
M55.NYA@$[[/@ESI3P<%A*"LCLZ9)J-&JA7+WH0L@D/V]K%"UUNWD0\(_2H<7
M?'@H7$M,<T[P*72G-79,M/*?=+EPJ95E/9NSH*+>"+FH>40[G4&;F"S2Q7I.
M'WN'\"AV,*XM[,N%P@7G/%(5?5)H995QD0SY,Q/@SYP@-Z+Q.[[=:3 JHG%E
M&.;:%"JOG7S3Q/].B#V]1&)WS7J)RR!\<\'/_.)E!/,@>(-0*TO.Z91,AD2H
M\< ]1O/\-WJMWFOQ'&^QYU<[=W>@SFQ]%E6AZKHD!OWHXB4=F&"T YLP!#*G
MB%E"]76(\1-/0BPR4?>"LG30$7 +1SLL=$#D]PIQ$ 6!QZF2CI*UB4>HZB1S
MA3U-A$[;1D@M9H?%>SW^-"ERV&NX$2;LP!A^ N=B0X &\LVQ'0J68# /PVH*
M*1M9F\T,Q@D?8:B0X'51NB@E.*;/5]GYA9K H;:Z9RT<+CDEBME3(TS&L*X"
MM!XPB .'9$-96>,S;%&67/WVM>PELC<+)IT0.^F4%C0I6T(S]SY<W/K!6[ %
M89?_"T1?N;5ZMD+/Z/PU8XEDJF9G\$K830*_7S+_M+I&18#CP"V(0H$A1WIQ
MFR'FAG$U]<DWPW[QO,<.]-B!'COP("-17W&LU9"NMRE4 5+J4 J=R537CGY@
M763F?.G.+.'AT =#^V"HD;@W'HU_&XW7.16UOC9%K6)F".-_\"K"EM66#(<"
MF5A@:CMVT!_1$H%;S[GM72[T'0V1;MH>9&US ED%'[":C )H^%Z'DR;X!=S0
MD2X!TG6ALAD2=R3>P[T1[9 O[ ^'O94VLY:6<:1B"4"^( <;,^[?_>B/4AN8
M+H..[XWM@G,,%XP+#OXB+IL6O'W=2#]05,M2EDKK0!WDI8FL'853%DHWP)>G
MX@ML&#[%5A/8ZP&=&>(&HA*)_,I$9S(5$?G(%3Q,K1@PS*WRI"4?2U^+[M#*
MM/FEV]:094UK0/@PT62"G@]'APU5W?Y1>/+T)'QZ\&RE..[ ]$[V3"NY4_.L
MER[9A5WEX4)(#A IA9"+5<E7DQW89=B%^T2ML#>14"W8ID0TSNNB5.W;E&NF
M=:@G&N:7"N/5VVZYM4V%WN79$^]K:1:>UNUY8YOL^N/:8$.R;#%A>DU;2A-\
M;:A+6ENCK&;=;;C;Z-&7AL[G9K_"0Z"TQ;"<(9DA4$=Y,_$XL]F,^WQ.E%)U
M83;*A<VTE4U&SA[VT)OB8AC]G%^)0<,IRB'G641]#'5E[ZBQV]NP6;W!W1O<
M6Z(/WK0=(9HM!6/)<4<6.6'330LG6"I+;+\$&64FBQ$3F=ENMU<HY"9P1ZF:
MYOV#X,-69H_P($I27[,D&EI"^?U/BS2Z$F.@I9-(RSB"G6L8#DL/(?Q0EP&
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M>;S0Y$7N+PI$%J8BNHQ2<48.#NA_*Q4ILGF!78$TEQ,ZC1D@^_WS 5I_&D;
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MD$&ZBKFIUZW.O>5!_$ G0;_?[F2_/7P3Y3WE2N)IE$U4*5X^2I=R='L,@XQ
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M";G=&6_4R /#>[L4BT8C8*Q#L1GK9T];JP[IN]!JN ("%A4!_!-\&N%!X-/
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M8XT2T,8DQN1<4G#&8 -0S>\P9D%K<2_%O]O(\1,U;NF/@4]9Y.'5\3(R5-G
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MEC(/6RI?+"^^4I<82$[&;.YJ:QOL:0I;)ID.Q905&,E5D$4SI:,A,&:Z:5C
M;. APRC[Y*96LGP&CH!8UC1*RA+%5?MMWDV4'V"3B2[FY>QM[-[&WC#B,@:;
MVE@25$+@!-VE%*RC5**WN7N;>TN;6R(86NA(Z6X@::9TKBMFXE;.+?&6K;K1
MR78[D8TA9DU4(^=$J6I.>CI5PK@D+@S$1&EN?(Z83=/S]*(P"%. L2(4*^01
MAV:@@B3A\(P=-495EXZUK8?LC )1#G %19'@C-5I>2K<<W* +1&K#L!&=S:O
M/]SZPZW[<),LXAD6P= !)^8>\R]2*!8!.>B?PSX 2<>MI\L4>TZF_DC;]DA;
MBB!M)7!NPGQ6IU4R)]#D/%'E)A O@HSIVVQ\2E-QL+L%+DG-VI7^-L"RWD!]
MCC"O8'0_]6AW?1O0R_X,V \!6=&)>.\0XCG#B:GF48%YCH[76_KZI>=9>*<9
MD"[LEC.5BN2=8TS3VV>C);>L4!/D:>7ZU\9,T#EK&;Q_D5U- QS0J1B."(:<
MSR&XM*KJ(C-]7W644/S;UF6@:" .0;_=98Z/N<"_]1P6QBIWONTL3?U9V9^5
M*\[*G(4?XVQQPN!"!+DQ80&38LO?F.\L_XPZJ2,_VI^;_;EI9,M23%Q?H :Z
MWPJBLR:PT".D7@&/!L^+#]P[)#)'(S\6GK33!HBB 8[PJ" OX@47U(!W0?T=
MW6?Z,*9=4K=EF7 ! (V2WQ3IXO[-9V$IEG!1&N]%&F;%N.+]@_!X;X_Q>W(Z
M);-A791JZ::QH/210B#/:(>LY>I8>T%>5T_R\9,Y'"&J\GL069 ]@PM':I8E
MXY;)+!,W:&*T6!!F<1HE,S!^X,]#N(9)X=*\)+3T*)K!P_@M^I4N<0G%A^VR
M8%P4[F)SPN42BFMPAD=)E,%?)5S*?QXGHQH^4X%?SK#<H% V6;WH:%V%1;*H
M:[<  7Y[)?1WCL0;FX^!'5N^2?"<^1#7+^'>\PW#0FBVF$62GSK8N$:(%E4?
M!EJLD48(7/CY% RB$'\:1W&9@!;@GS ?'VJ*%<(\9JJ22FP.\5-=]4*'""C\
M+K#_A0L0Y*(/J5A8TA&]*=.;,BM-&:P+B6%R9]B/8:33.2A!7.M5=J"T>JNE
MMUJN@1>$ P.9(+*H6#3E3*+'H-\RT&CQ"GI@QTC"<&@YI5XBZ6:"RRU";H"O
M"YU+.K!JI\)K%"U<(.&&*+YO F9RT,-,>IA)#S-YD"?)UVRAY&2?3%4ZAZ.A
MO,("KT7P5ZU*LMM[.Z2W0ZZ72"=8M)&C(!KF]8KB O3,^#YJL.HX8&[&0343
M#IH24V5$[.D!8?%ADG(3T-*+&Z'+_\*#W! <_)J,57 >)XKX4D^1MKQDAK"7
M>3%?51YZ2R;&_M[SO;W@W>O@J)J":X]@L3 XK\%*"PX.]_;N?D!ZJ<+@]]/@
M^;.]O:.['\-I564OFHCJ.Q_%:XQGO @F15[/_W,HRQ+/!G$^N_O!_!E?X2IL
M/H[]@]NH9_X#(8DZ/*1AB52ESL0N)K34C,1&H@CN=-LOA8C/LO@>]OB'P7LA
M*O@I_QS@CK^'/?5']"F91;BK>2C/GSW?>WY?6_N?$7BJP?D,<YEW/H2+'+SL
M-TA(L-8UOM#1SA="9?/LZ5-AC7CV=._)L^.38^TZW_DTWF+@?/L9'.R=/)09
MK!W\ZR>D@GFXGTH4E_^,])XF#8-*</WX;T\7&FPZ!^([JMS%$&-B%HS)CS3]
M&+&NCRS,[?SU2XJK@XCF5YHUP8OIZ\Q3H]7H#97\\U)+UHPCJ3C-EW#3&XRE
MOD5,Q)E3OR^Y,9,IP]L[T!F-RE0&:3C]\$JE/KD\ZQK5X-WG8@PE@392:7*I
MRU^YE03FE8C!#Y--.RJA_,]\NBC1E$^)?HR@B$6>\6\HMX=!$+"20;K2!N6;
M*;$%N2/R,#[T='47UW1Y]0/-*-EF9OR:JX233H.+N#3 (6Z#+1&K45U(!G*S
M-@E:HD"FL7$-T\@/T1\8YI?*SNJ_S#>F$H\U0_WO,'@=(> F"W#C4%IHVR=L
MMBC;+!US"%97>2.ZV5T+O6N!.#:Y9[F83(<3-1JT[8&&0V;[8%$:W$BI)^ZY
M>"1$"$^BO? 1/IYXA\%<HY$<?^M.S2QGWTAV\D+VBZB3:#;_0>BWQ$Z\!T<+
MAH;X+.UC'>Z!RGV3YK#*=SX6_.,?.?9"U/\"J_!>/*UWU&'EQ0T !0[V#YX<
M[SU_<@03:> $'JQAH0<8EQ7^_)^Q%63"S1L7ZYM(9ASVR8P^F?'@DAFWM@56
MQ>'EJP?)Z']_!_;XT=.3DY-G_]_)=S^>__86EN6/X/V;X.+GU\&'C^__[Q_!
M^<7IQ>NWK]]=_!U^/O_P^N7%;^?7\39H (B3RJ[A;:PG(4,R *Q=*IBS.F7.
MYE)WT'/]$0$&K0>34_MJH0%E!\<TR/4>2/!ES2T\P_QSQ'R'8+4,@@LTE)#
MCLFKB3ZUP21GNUL)'=X-$,J%A@XN+V@2:)'-4Z81[JY(AMM44!=<0LNV<S3B
MU1(>X69 O,'0?0J&]&?DY([!6!O7*;;<]:]H>F^Z6MCME63*A17($4&\L$<@
M!K..][@!$SF?JQZWA0-G.C(],+'^C9F(+*4L?:QQ@C5O*(ML$&O &,J5F,A1
M&M?"6/?"MN>(2M@BU(C1=).DNH%&*TGTP5W7T^.CMCSVHYS$2O<&V8GT6\#
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M&:-B&,%G>?+^<ZH6]I/L7>^3+#]NZ>/ )&JL&04;'RLM:G3V8/4F41-,9$,
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M^@#3_8C/;8/H.C9.UR VGPQ1,L"3KC/*ESB$UF&*.1((63ECZ:B8*=UB<PF
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M<#E2_,69!X3*BMC-0?];G%PC[*J%SEF'E+7<1W#>""$CV!LI:;IE3W%!I-9
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M4V&=OF]6O31O@U^[$0M?7GDQ$=2PV4MG4O6%*: T0%+7D,@K[3C16YC+I2%
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MA[C1SK:+&[FXT<;%C1X0V /+N<<(.1WH9@R-O4@? 6O*0CLS[2OF=\.IM+S
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M2:E1L*J?1$EY+L2T>BK"4\E$F0RR)*9Q"[$28'UAVB_&<$GAT@IY+MXD'_A
MV!_1J%/FUJ8((Y%%OJ90L*7"3 AT,*![6[M5/85IY%FY_[0?*7FO?"_,\=I%
MX3<%1Y1K/LALK$)!I$(/0M !4Y);TQ;,C$W%D^2W /5D(05']7MX/(6L5=:#
MBF(*2V_5CIJ^$I)6.8](@$:OPH&BRVKH@NT)9"C"7FB.L!RA_"R\C,,AL$Q@
MYZSD9@LOQ4KL6E^*"N&;ZP#\&*YR<,GRA'8&33VXZ2UQ*CX#!^R^<\ Z!^S&
M.6!_^(6S-?HJBM#6@:O[]U?;K^CW"?)3^;VZE\=G'S\>?;DX^5G_L%I.@45^
M'*OY>5O.\>=M<X046^09#JK;L-/Y$6EU<>A(7D2/T]/U?]P8ZQ_C'A)1#A:E
M2ZTK@PT8)NH8?W_5Z9C8O(X6R% 27#2WK>&J+Q-NGV:G'\00_3?ZHD[F^*)F
MIAT\2B[;PY_-WH,?S1%J7*C4?$Y^Z:4_O3M7 R4:V!T.XZGN L]I=_M'MQ>7
MWJ?@>S@NQFO<BF=Q1Q^>?7[1+A<R*ND\CDHC[-%(<R,V0MO5+WL7'#DX<G#D
M<"_D\)1EUMS'YQQ5PTY7?9U;?UQX[Y,H"M+7#TU@;DUN3?RR9[BPYWA8:U@3
M)RW_\'Q*@.ZQA.T<$W2*VY3\//MRQZ>Y%5U_I]WV]]IWZAGSY'?!$80C"$<0
M#T,0KBR\)E./,9\H&7I9$*G;("ML$K&X>V-UNM[=[OC;KM.U(PA'$(X@'H @
M'KJR?+/JD#=A#JZFW.WC)LW![:/;QTV:@]M'A]K[>(;V;VF249[_,+P-MNHF
MJ8Y.BS9;<;A]Z.]M[[WH/7#DX,C!D</]DX/S7=?3>0?C, Y-H2UBJ,29\V(_
MG_NSU=[QM[M=__!N\9^'QZ-T-.%HPM'$4Z8)Y\Y^[#DX=XW;QTV:@]M'MX^;
M- >WC\Z=_7BV]YD!V,+.#,[H?D[*=-=O=W;\[MU20YR!Y6C"T82CB;L9W2_<
MP[U4KSR#=5EVRK,:L-^F6]>RC[^</EUN=FYVCS&[9V:0K*\_'&.-*N%USOIX
M+EI%^]!O[[@B!4<-CAH<-=PG-3Q-6V/] I1PYYW\?"YW9*N[O^NWV_O.3>,(
MPA&$(XC[)PAGHLZ0L*>((X5]P+"+N6ZD<*5T8XJ1BDR7CJ]I <\=<2>*)RZ,
M]W9V_>[.G5I</_D[UO5W.MO^7G?G1>^"8[J.(!Q!/ Q!O'1S]HPZ>#IO\/.Z
M)>U.UV'6.')PY.#(X=[)P=FQ<T6K\Q,_J[NSM=O9];</[V2F.[>@(PA'$(X@
M7$7ETZMT<?OH]O&QY^#VT>WC)LW![>.3J:A<;#S?355PX=/'W(..O[?7\7?W
M7;3,V2*.(!Q!W#]!../TL>?@E"^WCYLT![>/;A\W:0YN'Y^,<?H,X7Z^$&Z]
M0 IX/35,4EU[Z^7!]R<>%W8V-\)Y;/L[>VU_O^MP59V5Y6C"T<2#T<2C^8@W
M5=J>&L&J0>V?N(!U]Z=,6O2W#]O^SO;VB]X%1Q".(!Q!/ Q!.-_V8\_!^6[<
M/F[2'-P^NGW<I#FX?72^[<>SMC^K7/JR:O_V,$D)EN-&!>D3M[R=:_O5NZU#
MO[N_[7>=%]/96(XD'$D\%$D\3;_V^@J'C_(\#7M%'O0BY>6)0Z)WLW.S>ZJS
M>V;VQ/JXW,E?19C?>".P)52:><F03(=)D*HG#^7GM .G,#J2<"3A2,+9$(\D
M79?J@-6'$=(DBBH]L!A\UT$6/9O+Y;;";87;"K<5C[85S\P$OL_NT (9.)ZD
M:J1@9ZZ4ZTKI9N=F]SQF]]*-D@])"MPN]OI%FJJX?^/E:1!G49"'2>PA?W-&
MQW-1)+:Z>UU_U[4]=P3A",(1Q$,0Q#.S,M8G=7\+PAB;: WG2=]D:/Z>3%1*
M'SIQ_&PN6[MSZ.^T70<(1PZ.'!PYW"\Y3 MB5S?WL'-P=2%N'S=I#FX?W3YN
MTAS</CZ9NKFG&\O[FN1!Y"6+(GK.QGXN6O16I[OC;Q_>"7[">3@=03B"< 1Q
M6Y>WL[2=)NGVT>VCVT>WCYLP![>/3\;2?H;IM&R"SS&^";'&H=4\#^7ZT-_;
MWO%W.JZLT-E;CB0<23P023Q'([S+BLD@*1""YI&THQ4FL;EJIMM)MY-N)]U.
M;L8DW$[>QTX^S="WPZMSLW.S<[.K/?3,O(L.K\[Y!YS+R)&$(PE'$IM,$B_=
MAG!X=>YRN:UP6^&VPFW%8V_%,S.![S'!YB1(8Q#&.IMFHF#'1F 1>T'5)4BF
MLFHTH+^0 >U\AFYV;G9/=78OW7CY-<C"OJ>FF6&2#L(X2&^8*SH3Y;FH'5O;
MK;ME6SIOT#.C!H=KYZBAI(9]EUSX/%,]W$ZZG=R$2;B==#OI=O(E["1I #_
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M,"=)\NY,(L95J(#?\$90[EO1R]1?!2X/]X3GCM\H\Y$H12T/OBGZ0M*+-,&
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M@,[Y;$-?,U.&=RN^L27_$(L4YT=RC,ORB.'CE87;4TQ*8YP' O$!QT3,?U*
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MDR#&JE?,H4"6-8:ELKI8BT6R'8),%-6!F#8(U1(X5')67BEQS$E@L?FUI&C
MO6QB\EL41*6*-&3U@?=7D:3%V NS\AKRC:.Y7#3([D]\%5^+9$4V0%]XNO&+
MW6T7OWCZ\0L8NYE1G*#^!8LGWF48F^%=^(MP-V)A1<P_ -.,#6,#SBL)FWPG
M*XH V$N4=Z0M)ORC2J]"=-2*)H?9"_"<ZA=TBQ-FT^1\G>*0]%(*SK-1( .0
MK".'-0/CB/.9!73YYL#XF6ZMMVR@QB9>J:/!GZ![LOO?Z"1UKQ3I$2%KPIBF
MDA6ZZ,LR='!G1,WK*;1YS.%6N=JQ]F+"^T"4#^PW9WY=":=SH#.$86CP6,%!
M '&$G!R3*5;4@<FB@9=[?]M%TPW^U^;,$AS0P'?@:^?JEV*A?PKC< Q<_,BD
MX1R#<6O-77L.:*ECE?LEB_\U 0V5E']\@.9<*VT.>-.7D@KTO(=NTI2]'W 8
M/EOVR _YO:"]P4HPR*5]-)F9 .B6^BC\QB\WZJ?6MTOLD\%CJM%-E,K6Z2"9
M2%R1-K/JTB3A'Z"Q63^ANQY$PO^R+T&EXS WYC08L' _<D-OI/ZHC#D.,(V)
MV-%+W ?V"%?UF'N_![>^!B9&N11?$6=)PZG-N$QH)TG/E#L=G2BP.MX5P/4U
M67CD30IZ!4<FB*O)E3&H<1;_8ZXG&A[Y/&5;+9?!V)J%,,*&P&134#C(V<\@
M(SQ!:A!'">VTJ.,-ARF5&X;W9V$NA@@?:,G6?..I69%M;9CX;; Y3XPR(S8G
M6T6QTK&:4J\)YW_G>!2@>5,>*ETB^*4:^^/LU$%A@0Z /=/6CFS0NG/:QB',
MF,G).$.U!6BELJ$[!G,'"J[K)I=@1\;"8[$]<*-P;'LAJ:(LSK3BM0BC0W#F
M, UNB%QU1+D/,Z8Y4#GR9@H!Z*1,.]A:<>Z'&?M&$O0E#ZZ". ?[(RF6B9/>
MB]Q;E4HPR&:H1+3OZP 9QSHH9D$DS=>;5)EU#ENB.,*"JK8.@31KR1<4XZD2
M).&&4LJB4 WQNYGG+21)F3>&'/%K:/7)-"@Q$][?5Z5Y4,EN0$;/^X@FO83S
MA>9C=9GD80F=.9-*37RZY7U@O8!.A&\$'0M'LB:,[$'W >O66$N8RK@H$XYU
M*&T!U^;4>.WGIV2 RD63]>!ND<<#>?DDN#&%H3_!4<W+^Q@FEE5&R)X<[N54
MK.GZT957P!D]<* 8/8@XJ<'XY4QK4QRAMJT,$#F,"O)+(1F,X<BNS++-$<YA
M,BWO/>AIH0#^F="G3!=YRI*GWQQW1XXP4<06++Z^M4ALA"VEX\*6DO3I/X$9
MOCTBAUV8YTJ]]CV#,3KCJF0YZ@^X4PICI6P96-GJ_I+KM*5Y5F&:.CC3Y#4+
MB-'>",WT!%\T)VN\<;ZMDIG5;PTCYO4Y?1ISL=M=?[N]X[<[7<NA1^(* 1]L
M?J^Y$A5,<&::M[?]H^_M=7]D36-O[T?#L^+$CE-E?14':9CXWN[VC\U_X$K4
M[Z0T-3X@I@"Y23=02?E:.LZG$QE*JB4!I/TOQ)W+R\FBFMBIY+7S1>44@M23
MO'0^<>)\_'?R#=M7O/+N:@240HXZ.]&DVAD&H-U+ 3"1FRPL7<>V.M!(V\2(
M*RP,ODVL8)*&9(MGU7G-RQP0Z58NJDRT%_-!;S5I]I31@_(<;S'EM^E\.>1@
M=.W#Q8E%)K'AL328?V'XF],![=1.A?YU8'_&]JAL(VL?MF.MSG^;G3=6ONXW
MI28X B@"0ABW(-ZPEGOUA!WR;>>0?Q8.^6DSR.:M%._T)4G9RM/W=<ZMIFP2
M]!87U<;@%'?R,7$'@UO"*9$+.E1M5]2[<E$OYM%/BSKT&$G@&L55GN@\M6HT
M=CK4KT.RG$)63V"HT+;$;$KG6R"^-DH?G)/JMU41RN+;NL3$ HJ)W-0B1ESG
M@N+ZBE^'ZWK 9<V2BZ\=#(2[P?=V@R=!.*"B!Y/I"83]MPZYFZGVZV_;+;#&
MRH2WUV1/M?U]>6;.=?#M.B*IG[&*CL#<&X'@Q:L01(5J\L(W6_:G0Z^(4<RE
M83^7^.80+BL,F*?! ,G99[^U3([-5)K!**@M5TIE> JX]C+)CV,*I;\=='K*
M -55-4WY@,U\P6 8XT^UE!>_]%FBNR?&"#<<E00?*-Y12<.:!R/ L  ;N+QS
MA5D]WGM*!<7<Y\L0TZK8F."#9(=<7,E\ @I2GO22J:9$T6%2'B$MS?%(QR/7
MRB,-?RS2_H@NRDZ7D\JG\QX1#'<J5]MJLE0Z75]+;9!U0?4+K'NWXW<E@9T8
M<!LX\#9=07S1Z[+2!E_3E'4LNO^<3$V>L?'>F=1DBL?/C*VP1\*$Y5#1>9AZ
M#_*\S%K%0HY>35^\/0,41RB^]<$8NEW_N)"W/\Y"+=;NN+#CP@]A:\+%N0ZH
M$A>;_3'3@\]F5L&4>>35.J-Z/L\B\VY+NU'@&E;J@%Y7+#_YZC (HXR[3[$7
ME[/OYA>G:8;*IW6/7-7=57=7UWI7K6P%_!'K+"Y99@V'8112JIV8=>65)IMP
M.BJ,%%U-=JF$#RGO[H2K40+O?:UX@S,BY,]+94:8K&:>-$:)IDI""% *KY]_
MFY5BY<O2JR6GL/9%P?8/*DQD^7"7N^+NBM^;.,[![,BDIJBS;;N"L)#<5!AD
MII8 *PWHEDBA@;YTO!%<D<5V#9*_KLPBWPY73C%"H(G\E1G^/;K3DLM2UEYA
MB0)GJV7ZCQ@XZ5,>57D+)7K(V2HF7"[!%TI*:%CJ%S%&OAACQ-2L59;/!19-
MT]"Y.]S2M\*C>II'6;E@[_5&T6XN,Z#)9 6;E"+)G%MRV_UQS,0QDWMC)E/9
M*2:DCW\I[WR96L$W?W9R!94,Z11KPMX,Q[TBS>0RHJ:_$#-AX0-)D;])AF\F
M8!NHO(;WH<$%= 6^_#O? '@\)\N,!+)5#\A"RC)904MD]$XEZ<25/!VS5[06
M<7XE M!44"9/\WY*&B26I*&7I$P97)@8Y]B=8W?WXE!&-P;S*]40>-OQNSKV
M1M%ITRQ3A^1T,N,P8: ,'2=)TKK[KQ:W8[EO^98-FDVS7Y6&K/F>?>H3GS7S
M;P+R:.8*5!>.-W9,B,X5Y$&8\S#48+^A#2PG:9WHHS;9L(S&D2#.RP(!0&7[
MDF*'4<'2X3GC8C_-Q+".2PQ[N,2P9\"V#^>P[0?FF+"CC5Y63-6!_\>2SR"K
M<[4.\".>?QF3+C$<*BG>S(5L/C#-ZIK"9X$-UO-:%ZQQR2UQ.0-&,D<)0O4O
M#:F (9!J&-"*4N'SJ<JQ^+&!Z?EFP@LA]"JO,."4BU_A5!NGVCRZ);=5XC,8
MI^EKNCFD(_PK20G5^3B88#6#]S$)3!@'\X,P="K_:G0!!)4K81SE>Q4\L"T!
ME6X<7$"C,=JLKW?C.J331FXPQRI+$# ?"[@N@L%!TP/VIF[,=+?*Z&\F&Z>!
M$LP+N2Z&X_T5/5&@^% I[/J'VZP7Z@T0U$)Q2)/G*NA7T.Z:,A/+ F;5C-;J
MX[MV10<U -%<\)95H']6[G?B;<52_BCXH8P^CO]BX1[.D1GS:UV1(S12^NAH
MDZ=Z>BSQ:JJ!H^0"AG1<#-)=-\^)Y#DL.,^B+[&1+91O? _/W*K"2I6DY W*
M_ R8)N=+"1"ED X9_+E5W,ZXBF7O&4UN>#Y8NZNKW^P@J),&3AJL4QH@TGH^
M2HK+$6ICE8I5W1 *:WI0R=.U4CW%::@: 43(NYD/-V &520+F\*QAMX+4ZM*
MK\*H*_6O7/9J(]YII/AI1EFM?EW@TJ-;+I#H5R'61EOM@![))8FQQ8*B&4U)
MZKA37"&<Q'6)- JBH2 GPRA84A8.*<6M+%>5@G&]%P(4;95U8T^A 9S"I9*F
M0ED1,I-HVC]NY+-J!ZW<PONH2*<'VN AA7QUCI[6C>H2OAGT"F<=7 <A"7%#
M(TYQ=ZQZ[8I[V* /H,9B8'L'-N!F!76'*U@1KE=K&K?)<KK/B$8U@%'-'L-R
MV'$,O,L('+BW16H5\THG0E-$6@.H%B0AX*%%W_0V06]I>W^W=$_8.6(DEVAU
MN$Z5>O4'M%X?4 2D\;62OVGRW!!NF3/J;R2Q4R,C:V9(M4Q3'-D*HQ@<=7*9
MT593(AR\DX%\*(QBP! J\,LHL8 5IP/J$'(S0Z(FU/@-]@D;"";10&NE7 =
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M%5;8IEY#4BJ,":RI'%LP L3'MWMT365658")-A1)X+O4&;)6@J+$ ZGPY.!
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MC[ 6EIL"\GM!C9!QB#/\4QG%L^VJA%U;%(XK.Y]%B*?,JCUEW2A$,R;@#SJ
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MB!&]BZ Y8P.O-\PH+_,;_E<]TGS!R+6XV$TO@(#8XI,0E(70EUPDB*D'=ZM
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M5UB3#X/;DM:<REOLK/-A5'>3*]A_D/#F'V*]?ZYF_[FM1"7FZ5<9404\$]D
M0@\OR_"(,GJ1(U"2ZU&-$KBR=,>/2-S/OOCR\1</Y@\?/'WXX/G#V0.:>_$<
MDJV"-PH>GT !OV4.OS! G_V[OYSL%_$P'G(>76G-61:TE?,U'SZ@>(!SVJA
M:BZB>3L'BS@L&SWNYP\??/]0U[9_@K.9IQ@[ZBLRMJ3U'"*G<L56. ^OQX2
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ML/!5)7T.#AXGGY#2B24F!NGY$.3G=JI)!)@BD)'KJ6K. @BQ>S\1,)'LT8P
MCRREI7^(_9*2<K3KL,8&:S/*W;G[ZQ-FT/KBU#+Q\5HF_JB9#==F$\&D,'Z!
MAZV'_V^0*F.-=,G>V9:(A0?''M)NVR%YR$R2/+K=#U/KU(_D"8Q4'GM36SF)
MPXZ8:(SL:0?^JF#WC')PM1MML(T"X&%W(IVH5F<JKTM91])-?D1YI<./SHJ.
MC[8;?7"1!4/2V@@H4MU',4^CM $HCDDIZ&SV"BG86/QQ=#K7K)4]>&,I1G">
MKX>.XP3MWC/GB K5QT]UIM.<BL6H_>6.7>&R28RQ/P;0[R_"V^Z4\RVTU@/L
M\I0B>D,#7<[+C= (5&.7(KRL<-3T:@ T^M9I#&ZZU\4YK<!?^*.6:WWV^>/O
M]?M*!6E/52\[.GJD_*-*0TVAAR;Z_&0[U^<K\8Q4@I1EL*((N;*&$6RWNN F
MX.O"FJ_MB&817QR1DHY/F,HY.=;UGI1EZU:[R'39\ M37S@)K6W=>,E>67/K
MMB37A>+%+U+W3G2=\^1UPF3EX%2+?DL;CGHI0GWL9?L"8\ILFTQCL]IY..DJ
MOVY5ZJ_C#;DL%E3F\L6D?DNW,1#".->@YD@8@,3VDJ6G/SA:5E35>>C"'Y*:
M% ^6N^URR_Q']D=H/',O>J3S;7N%UWZEQ$OE'5^K5?8.69US64&R@@GZ0UMJ
M2#N 8I:II>.\NI<8 F5=NQ;ZJ#4=RF$?I_P#H]4[VF=]T3U8K;!!MBR?38CF
M@HO-TF 2655Z]1Y2[PJ/Q"R$RESXCDV>DR]-B&-Q)Q+59&L8YF[DQ.#%+%9$
M&"/!(%*E?+/P]8DN0?;LE&J;K'>P^SK:DO"-N*PZ9G.BJ.2"7K!HF$:KO*QK
M-,[<,6'&;_W93MBR7"F:J#,&1(W@>\ZXJKWTZG/<0,E'W037;U2RHLOWE\]
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M?KRNQ_Q<GXX>3P-)1D1S)GS#7*'ILCR&Z,4(CI/ GQN #,IT-OM9O)HP'PN
M3F*NU?"N"A_'+C/GC)+:#2>?%B7*<D2!+>GJJ0)D@GGMX1#C'9!OCDK#!D?;
M^X*TC7B4@8ZI50%TSW!>$AP5M$)&7.#TC=GO;^'/407C;/8C)U3H^MF>59J,
MIZ:XD<R*BX,%7!MH#2/V",_._%2<PH_[17-L-,\.9R0)-,=6A)3\IFPL9R_?
M4_/1]I"37"B4.%KP03JIYLP6DH6O)M\L'*LDF-[_8O2"XX+EYN (MXV#G>P
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M[E8"WK?^BO&WS*Q%9:R5Z_# $]]X,N1AQ?%O.M)-D,)SIN/OFG$L.!&T [\
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M[$SL%G2,7>="S=**WD.FX9"DY&A(;" 8,ENEKW/0/0K+-YSH;6$^*8Y:XT[
M\:IKDB.R/8:GLW9-YMRA!J.\+WM():$]]BVB\Q.3A,1.L%7UZHK3FO;BLB<
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M_$8F72EA4B^%PL!C89WD<T_H>0_VEYO^J;\C H 9KN,'NB96A[QMZSEKK/%
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MS5F";61/1 %3[T% ?,,<"Y$+^=U%6SQPWEH/IECC-N@DVG@:8XFF.CS3VZ,
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M@V?22[&/3 G1%JT-5LE_:E"E@%P?FK)EG!VRJY1$* A$_LX'V/^DAT !):U
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MF65BNNU=HEX?+)]'GK:V7+_A$;AMVM/.$QMXV=)^PPSV1?IA*EN07& \@'0
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M4\:996;+%;$&D^ 658PL:;')3P4A#*>)$KD3/7HU5R@_W1PW<>AMX[0<$[7
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M88/AV? :Z\+OZHMR36YKN3^G.=V-3+S;T?XA#\[2-_@X_OF<".D4EY)COD(
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MSLM4=#+K=7;Z#^$;.OB%]I';5NMFM[DFIS3Z0EQX)L($H=!6_5GKA K1>&[
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M*4"IJ?PU32Y0:GS=<<QT&FSW@V"^_XBCZ4Y8A*H2\NT:_OJNN"C;G:2<FN0
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M2POXTDEJA/"%W9%=HR(%MAB#<TQHBP6!;A'!>XJ@C3*@[RCH]*#+6DZ;L0E
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M#P_Q[3@G)D:C/2A(-=F>".X!]#4%D_LK?6$Y&,O!N-?!4$(^@($<"%?3H#(
M'N/JKCPVQ.TT4^1O@MSUGC@W[]M?[=FZI$O5Z%9P+ 7G6B>QMPK=%0^YX7W*
M8#Q-$>OQ'8X6<@M[!&"F1A!83$5OSUS/5'=)><563_A)9G$%YAE WMCH&Q#D
M0^QSWL=&+0S(*?4 <N6Y35[+7 Y!8>?G!"!*L':/#JDA85=((+9;?B77.A_+
MKMJ-+)A -+^U9V#59!Q9Q2&;0A*YB4/T/7.L/H[I@[B$0;S!+B5MI[:@XT'O
M$?$FTQ_A4@S8IWU# CN0 ]>RX)(/82;!G5Q&$!;3]6ZFR[6T(0X/_E37FPN&
M#-%Y#1#\NZ)XOWSUS1#$FU1.=TD=I=3H5G9=(0!99&0B=&/?ZC#.5%Y@NN?.
MPPZ,_@9X \5FH>;V6Z2Y/LG1Q7"<EME%+YH?=G9QT9#_#32DZYATM'I*$3C)
M>PW>WK+-+YI"*X^CS@III/2N\C!PW3"6V(Y\J];XX  M+FW]Q,A0C2KIB8<U
MFG]4*$COI$Q,"-ACAY>Z('#"W5%83RFWY=Y@22PM1^R>1^SZA"_=$">)!B.*
MFH%?9BL<,(XY$I0,\IE%@J>MOB&:VM^T:!"AI^KF(J]D]IJ'K)^]^C["FK*C
M[O#FPTL)08)CES7$'#"@IS2M3!1%*!F$5MCA\AP&Q^=<#M=RN.YYN @UM.I!
MFSWL5#56\^W4=.1V-4,)+]!DN_"@VM9%] O6V05KX^\#.]34!P(,CLFBB9FT
M>+Z[OJEX5+1NN[,(,GACX8212<_Z@U5..D";7* HSM!:PP=>3MERRNYYRDX5
MN$G\5;)O6=B^13D[7*R_H:B-?[(3>%6">8H<OU%X3*QP];I&#.V/::[C;-&;
M5$!')<<,PA;,W?54 \FXL+\<L^68O1]/L2JXP!XVP? 4!1J-( R*IC(T6VH.
MD>X[(?5IF')M> P6Z5RD\T/%,<QQ$,(288BRJE52D-*YCO5E7E;0W=?*R]/V
MH&J:"8ODOG>/CKS%&E'$KH!E%PS&-24Z=L?E@"P'Y#WDTJCZF%2!'4+,=/.T
MQ!O)',GBOR^2^3XEDU"06Z&/!#I>0I;A:_[#/"GK7JD]+9*X2.)[<B)VG%?,
M&/)*J[39ZN6K;\+_/Z>^(G(K7K/;^UU=E>'O)*_?H%Z;S5=;AT'<5+$U\[Q!
MUH,P@=!/?^:3 )X@(;T;=R:LJN"8#_AE3P3 .?5Z2)=@SGQX24J)X,K/"_I[
M\+8 ;D'Q<.7<'"929>C@Y5@NQ_(]19[:#@<Z;FM'BO04^57PPK5)BBDF!#29
MN^<@R5*V<P"N-WA&IS.QBV>T"/X']=DG 0=FO/63H ,.K_'._G_8RQ[TMPAI
MR5X9($*XK)2S"]=Q1UU"%R71Q0XS/70BEX.Q'(P/UA@RU=H]:!!)63\9]"XA
M1R(/CUF,6P#WGY$;%C[[MESS)(.@L#( .""^;/;3.5/"E\1DU@AH^(YV8(:)
MT$?2>\Z)+]!81J()38!-#*T2RQ^[K*/&V?-C>.=,V_#)@9YVC@4VW75!.NYW
M;,50:44WU-A:,@'7'(G'M"P\6;W&'@^D8]+['KWSIF?>*U?@G6C!3YA,6?F.
M(7I125JO@XZYE7\^T="D923<VT:-94V'W9JQKUL#"!2-[K!PTB;.<Q=3LT3Q
MGI?U+FR+(RF16H%$^A1N<!]Z KR:^85+>%I6PGPO)*J74P1HF9^1BF2M<;))
M7U[[NH3D3NG>B58H7[_AJ2@Q<]N^4DADJ@J61%8V7MR/3[[S75A7>L.,Z LJ
M\CQW@];=[:3(B*@7S15X2UJ8=FJ0H?TH6VE*#J]*&XVPCXN>O.Q$#4=#EI$B
MC@G? /E1M=Q_@X&&X&RS,$*J<9 EVQV.WT_4LFQC*NNR6?=[H@!:8U+!B-BL
M5P()]D/==*N6V'6LG8'S1>%9+\M#J].?\U"+<]K@Q[M^ZZCY)V9ZYK)7$IK$
MYPHOTEW3 >BY)I'/;!B8#->(*C;@QJJVNY*G6%'&*-HN';_.<62*S6 $2D\_
M6:KC.[\;W86-V+]Z>L1:CGNXU85B*6,(A2RFXUYD-??I$M%\^<672S?WQ^OF
M_H 4] )"3"\[T2EALV_!Y=@Y>1X:Z*XM=EO51[\4]8'P6?]=;(2BEAVFR#6>
M2^]O63G61R03?V%UF&G,M8\4<!XM^4:XV*D3FPD#53"%K2K/S-H@W309X?M'
M(NH*7L$V?10E9UG5%>*Z?1W1)!X#]Z,G#!JQUC//FS';,PV7*PTG/*A:UO7,
M!4E/7F0Q2."JQ\N5<)4F/*]N*&_<[ W^5R2K6DU/"66W]EK !@8WI1?2/TQ:
M,VVLQML;*AFWZ\MBTRM]*/J0GJQ>;AW[+%6NBZLBV4:_?!<U/9,X=3#OVR:G
MI4=JJZI[+!]QG[XE+Y,G$!/FNTGBT-/9!3=R)YWRX0=R1ZCT'9STV+H[;N3G
M&C]%*E*M#T<AJ#/.VH7]KC>& ,6QA+@5ED@LWAKM!N;<A^1#<\^NQRJGGD?>
M6>"=E3HO=8Z;&@]D^ U+C&/1W=1NJE8&,<M&QP(<E%K""7?KQR,N9;V840P*
MH^]XRO/)ZFEU=.<A$58O(\;@S>O8[),;9%.3HO-W31NS'^$D[W!,],8NV/"J
M[+1XWC'^C60-K#TV2 %(IIFX,<A@AC-W!K=[CQ834,=ZTG,! 4=;"QU]F^ .
M3F2]NZ(Y876HZ[XC%LI(:AR#><^UZ>:/1R3&3<)U://' EOJTGU#M7;C,M7-
M+5=)7$Y6.*0/J>-2\"RVIN4>9A+Y087C=K*1*>J&4:Z"HS)OD@F*H/OJAJN'
MDWD'"R!((BF-<V.*P&9+XR261.M<,\R#]3VV)9L\EXJ0=S"(W-NFJN6HL*I'
M4R+%FCQ'RW1[Y08A;O"$*A,F3_<ZZ&(<3W(EM@YI#B/%>!J=MSM/Z_[S^=/!
MM&YXE]4W0@^]^D>(E:NP;?>YQ3?_&-X"+RQ@&,[SC($BV[9@5ZD8'"O!DGZ9
MKXS!YZV.*^=W4S59'ES<D*"9H(3!M,H,L_":N8UZY8H-03:#L9GC#F3U%)]0
M1(,E;,)F4::2[I_>@$HLE%3(O4\G(]$R2A17*#- BD2<W3LB'D".OS'WK:O)
M(:CS$##$C,UMLVVV%2%\HP,<<\ZJZ>$=*H>MD,('YXGK_;3LG-#&:ZI'<(MW
M)6^*6R##.< U9")1^]F-C*SOD+ZKE0MS5US1IOT2CF,KY+H@/J;V2(0G]/86
M.,7C->EPJ,87% :N*XT$[Q'Z#ARDW#TMA\V^8VZ.KI60N8M/(-3<B3J;826-
M6OI6R?.',;D_+&G.J33GZ:WZ\0Z:YK&D,R?SC.-LYNS[O(\$YJ\A>32_0!\D
M7W02?^@1ZNA_*@NGA:?F"9(C*NF0.<VRS]\$8>J<&Z[&N2TE6@I*H^G+3A0(
M5, AW+$00IV)*S^4:J7XOYI8#IHR&RR):"U14^/0\8:DSWM8-B[[CSN"\\9X
M-8)H4O8(3NXN2/OHW?CQN4H]S.#DYS2*QW. 1,TX? 6]&$V30V7IX^F3PW69
MV^"GP<)GLRX8-:*Y1T$ZCFKL^9Z42]XRO!WX(A'8(&V$&WW*%9>OEHK+KZ/B
M$O.6S"/F#ZYXJJ-,$TR>I-E]2E02PM([P_Q.$=3-'[7I6H4>N.=#[DG.^4LW
MJ!Y=?MZ]=+D%M4.W#@>2=9T::"TL;+C:D%ET&0DN25P,KP+V'0GG'/G2;;^3
M1@>-U=R22> SF^6 N\H. ]S*;=] %?J *6K21VAP?[QTQF6Z)J*Y(PW,D[ ^
M*,!R'_W]F36:2!<@,K:)[?.<DD]N7CNB8-JSA8._*RD?X7C@!X]X#L)AA+A7
M$#J956'73Z[U4 ;=+_7-"=GM;3.35/XABWI'HS^Y7(,5)_SN)@A,4.%CH_G#
M),<ROK+"5U*(4[=3.I[97M;7XL6V"+7$K<$K:2JP"^%Q>)KPD0,Y^>'@2B'G
M@@:>PY=N7,KNLJG[B\NY]0QWT[7D3L#=^%U?5E:ES%)"^ ^7:?>MD:I6B$N[
ME\27Z6AFZGW;\:K#&?$@I(V'CT5(L/KG\Z>__>8?3V>SCD_UW#CB@E'+'970
M")SAQC<.VQ=?F=KA0L1?2.(]:,U#7<+Z\EM?0YONRC>D%3A#SEV:2E _%\I8
MN6PE(\,ISW V7^Z-^:Y3"R4X\N/EFHO])>EVX_+$=@)>DJJNSGYZ\OH)_Q0U
MIQUXER$([Y^YT# ;FJ_;%">Y< .M3*5NH)1+Y&V?AMGO:9E?4+:OG#84[.QK
M!3RIGU-46XG*T=2+IFW+"'2+_?!VQID7PX<20"DI2;#IIB0DU5-CN'@BZM5\
M!25#DM);V0970M-(K L!_(F4BD;5@L!LD;GAVUG.V^=W6;^Y1X\V\]H2U@,%
M4U<4QJS:?4[>6M@_:I?DDSVAS%%82(Y\](W>6:B]3 ,S&A_\T+(,AH;5MKBF
M)HVF,*ED6*9A*\,C]*9N7*"7%#^4^XP7)#SI&:72^:>ZT64Y4+6 E%?PER!,
M,#531\[@9[0;A!SV_GQ7MI<365,D%-&,2Z<3CKGZV@S/7E"%VDUN0?#3VF0>
MC!3G :["FVQ57G J-O#D\4S#-)K.P/AF8)T<XQ;_AW++OATNDV6!L9#K'8[X
M>D<5'K\QM[;TZ2[3J^H^SVVKQBK!)3Y'9 -7V=_<ZK7A2-_" 2JJ,]O4N8?*
MO$?I'4'.^3"7B\RB"O<%<M,M@Y*G4B)2QAAD2*FLJ%TF>6[2;A"[ 5%,)*70
M-NZ?"R["(%&5MVV_/P@8(261]XI,&!9P;0WEHP=LN>XN=H$?I#!J C9\P]E&
M*3&@&>HRYV6IH=?[2DPL=P'A;CE5!.DG<=,*>\7@GH0GD!7-I%9Y!U&R1H5T
MVV2'=.-4&4@>D(T3X%(@:.+3.?\>YH'26*[#),(P^M63L@Q5465]Z>J8@=M:
M<1_7)?,U:.JC/<9RGE.)PM84./98KQO?7Q=T(Y;DQ]DC)979/3D8=]=::68A
MU4\RWJ**;'=T2X7UO<TYO$DCP"<(3D?=M[NC:G*J323R\SYDQ]]5"LO!-R-W
M)VP-ZF;!^\8B]<%OV0T7 ^995<J3U;P2Q8:8 BW9_IVV:N0.#3\V9_BX1J93
MCJD2@A(KVS?BF:7IJ*0TI+U9D@ZW'8[&<B(GI9,GX@K>:$W#)LIPC0H.C4EK
MY>[&?72;?H/[D"RRLD7(ODE?9H*_.NH:-$#8QU@B^KGP^0OM@MN6X;\O__D<
MJBK\=Q746K6Q*2W7LST,W0Q)?Y0_B7VWZ'#3MF5JM#5GE;N9<1KX2>[62$)O
MP0.)$N9"(]&!?U RC\G%M3HRJW7KMKHS'\(_GP_;GY(]F1HC33XPGVP\L6=!
M1X'H)2==D3FT#T!_K12L,O+8M$,(LQ2B+&:7:\GXXF=HSIO#@'\^/RN(029<
MR92P=N\TMY8>30\Y8^O[YO6*JBO#(G$3H*$B^/ZG)$9O>X5%&86/=+ANV"*.
MXU-#>IMW^I3K9;];ZF6_CGJ91BPCCT-03*SE4#S=\,N>V NT:8LF16H%W,01
M2IM)UB4.4QS%/L4U@S&738%A;O(^AI/:=YRQYO[*4W!&&@G$H>D\>IX3T\3D
MU*CRH02D&L7;/,R@&7FJ7SH9GASN2%MT9 O"U]'EJIII6B=Y!7?1Y]3%JCD[
MM&#;QHG/IXG)=-J;;4GDT857C+@*:<6V&(9)<']S@(:$M1\C!%OSAN(>M-YS
M 9I^R1-/ZMSPF'NXT"T4,:?%W?1VXB:=MK+SIE2>@H>OIFM[:J)=U6=(N^$*
MQU.9K4'&3S]F$SRCZN%@ .%Q>JV)R 0!+MZ$%ST06A&Z6O@(L-"?*JF>]YUK
M58Q<=+(E<Y=$N<"YK?)Q;BB.G\M\'L2Y@<$H<1V!>MU"D)'+V_@N]/&UHB:)
ME(6QU48'ODY"Z20EBH=RC5]-*S%:/PKS?'/UB-SUIZJD!-?KSJ;!%!GHEUH;
M!]M,AAMX[8HHZI%M)L2TU+P91[E:3MFTU #12NL3MV+LM!]*R@@2F1[J0TR1
MM5Y2K#66'OA[_CU/4W"#Z)=?__EW,;A)'S5G62-;I(,2XU$$4FVI;(9=#2JO
MG'K#8'(HJ))74U(S*9!8=C32W6Z"!%9<=9(2<3[QSF@)0'D!"&%???%%]L47
M7V!<X*K<]&[:,MDQGN"<NEX".!8O-['IU]3ZR@VP//<@T( X7,ZLQ&D&14&3
MTH[*DBZLSIP&AY\<>$K.8@@ =)U3C_!$=W6D%_9]VVG/<XCQJ 6/NW39*'%/
MW'1_*TI7DPLV?2M2 !T]82XA%XR2]C2'4T,?"(&F ?[$="N=-E**/($2(4"N
MX2D-JM/2"]3E;ZFW/*^X(0%P5S<%9WU;-&?;PAC'K_.2TC;!EFX[.1YT O 8
M[=R+\DF!?(;#P,-.KK]Y>%K@](2K114IUZ4"N!P$9- VL2H1W;[YG=W4!<_8
MA--S18-FU3&NAU;*=4H73]8WL63>I32T)ZJA'W_D_&]Z]-DX3.@;.);YO#64
M1'0KJ<VF[:::J'7TS8T4T:]$!7521!X:/7]0PVD7J6>H?IF$3INVG1U4_890
MOM_( XI#?0.>%O-:X-EY\D[MS,31E0$>?4PIVTDP(G=%=0 K![6L.@B_'JR(
M?Z\63L9G?_J<P_%CB$&I6/.6,$G1)53NH2T&TQ=ZYG.T!L'E<QU$;8\;-%)X
M274A<;2Y?4[<BB8J7Y?$"<M2MLYWHKH25)X-H^G5_]7G.+WI,?.WL)F1J_H-
MC9]QX_V0SIJL%(=<FI3A P:ERST.3CROJ43KB@V%]#D@)MS>^67T)50%V;;7
MQK$"A(.6R9&D1=2"LUEK_/%/OKC2-SK/.JY#/J4XW!,90X,U,],<+!WUQ''#
MZR[ON0F>.Q15&_2MFP121\TFNZ=\<FX7$:_Y SOH#^.4?UPI>#%:I;GSGZHY
M>X&,C^#P&-.26D\16I[# JV[Y,Q$&V.1+$T'(*TC8]VQ-LB3 4*3EW2TF":-
MR S3?AO>-8?W,?2@6]>ZY7USZFLBQ<($>_P1,P?XZMP3;.TZ.GOFE%509YU>
M0*9W4S-10Q&ISJ;P0[3V2CN^V.,G!5_)."YU;#495]!LZ3G*? -/D<,D\#\I
M,SV52L0=I[K[DT\Z=_S[)7?\Z>>.WRTI%,QWD30A.F62\HUI#AE'N$5 0'$?
M<$E<B#B1-[-$@D1U6@5/<&PZCC8>LCG>]S#.@A=1YA.:)J9'6K :,A8/K]U5
M8;88"^PU])!<> 917(MF<#/\)$BZOL4@I0>#P/KJ0'7U</>>V3209ZT 4XLF
MZ'P7+,[\9V@!0G@8;,]EQ2BW]L?5==WL-N$LA+?\P<QW,BY'6>=2)H?S=;XI
M]A2%.CC7;$7)6/!XY >21XJ ]N'7E\7F@@$VPP\1KI,]6'LRMB,<B@J%;'E%
M!G&:-=:""^DFYL]DO+A4B&1ON].)6I376T+;I4;&6)4%+FC34(*>$^1;#)?H
MY9P 96FY-IL6J(_OMOP(+Q/] @ZK%@RB0V$X)0'"Z19VKV\:-O*'OFE[#="2
M"0!K&Y9$UBY8B(V ;KDDHX04Y 1FYAU8;I$T3R5XRURBV??\6#0_&2+0_@)P
M7N?%#IAFU@T-YR-?7Q;<).C0TOJJ#!Y*EB3%$+@ *&-0FDEP9V-&AVHR *#(
M$1?F%SE)N=<$\16YWR@6/6@E;U+13S0+]-&A9#U*'6]R,HWGSWN(&4J\5KZ3
M+B>-VTHR^+1F2,GF35<5]'%L?=H$I)G,22H'@9AKNA(]7/&4 ^7GQ*GS[0@"
MW9>Y@> )C"M#])NJ*^D\?)JE*38.V$V8'S;U Z#_%L0#+ @,ZW_U95LFA<(;
MSW>X<4_0,=;>H38?(@Z;'3?%T+;)41*<!!!IR^1 V,NH8 ;SU$]6K^4C='YH
M>DRGO$S#6.\>AP[BJ7OP/R]_L6<7K@0&KD[I;<@G:[U$UQ>;^ BQHCHP;/P+
M2?#UP@*(T5/%X>(1=?J)6U1+&BYS:",0HBKGIZ&\54N8(;OT6<;RZ2G3;;S\
M0B"K)>LPDNB<*J?4^LRH2B073,*I^TZKS<505+Q!#I'QI+^R180+9QJ& ^WO
MR>K[WCLB25?R6KLYFR(<"NY>EM[!CK-3P_%Z=6Z&1K)(#A9;G,EH37Y&EKDJ
MH0G"37?42VB(:7PVG;N5=G'*,SQ9?<O#;G3!+'XT&KHDAF9U'E.1;7Q[]9 -
M]BG&ED:CW>KVI./!!&K$61.[OQ=]KYI,'U$Q&O+GC--5,5?#M0U,19L60M(9
MLQT4@\QTZ8KBK"*"0[=1CUX65Y-0_KM$ )N^M@LR!@^7'(J<;$IMH*LK YN/
M6)JN(7*%.,XY%\.6D5C2;])#(1(QC0C!"A(%2ZRPV<7)$:DB2&:]5S39^KRM
MN6$X[?D_]S$13ZV8I9F.$E+9';D?4+44VD@3L '33/HG:YE]I#X0=N+V2 CJ
M0$;PL=>CU5U?DA9EA^VFLS4^WX^P4T+GBG>EKM<NOPZ>+9U56=Y>U\H/B(9P
MIT^A-/4*.EWFUW<RMKPA%$RTU(/UYR*@S2E5>,D)1K2XN]G N'!@A..9CV3"
MQD"4)P<*@]Q?]N%N$VWY6]=$E60/J#I!82%Q2N^NBKA5,NOH\0 G>)*0<$=9
M!#M*4&G43R&(7+QO)_?WR>I5<9$W&U@<*JP5(1S0X( 9X[G%/W/+(\^6N%I_
M&6SHPGVT<!^=XC[:%(H^PMIZJ(=G!7U"J2P<=8LXWE,<H3>/BD#9%(>^L\IB
MXL(:^A9)9+ZBL@[ =1897&3PO@2A(2S?-/DU(Q .N;$<=^TB:XNLW5/6TH14
MRRWSXHQR<PT[ON0E\N3:(G2+T-U7Z%P,LJ^K CF[G-M0T< \5'1(W$M+U2)_
MB_S=4_YV-0>Y@LJTL/@N4O6>6'S+RH&'W0QPTW=G.^;#,'J8$T#3$]+YB?9K
M_6'IUWJD_5KW0]QV;0P\D<0\8=*T.\ZO$A$[FA5\0RUJ3OE%,54-C%U%A[IJ
MJ:A7=DDCK^-QQW6 (.3SV#YMA(PHHR/91+]](*&L,_(].I_VU/%1402+2!@.
M3V"4 _[1ZCAXP8F+89X+]PO+L4LHD[22P:XZ6 =&7T_9 FD"R$^'&MU9Y!,,
M.@J5C&GL"MN^J=?&G%D<P_K_V7O3YC:.+&WT>_\*A-_Q#2FBQ,;"U>YV!$W)
MW9K7EA22/([[Z481*)!E RAT58$4Y]??/%OFR5H 4"0%@,B)&+=( E6YG#QY
MUN>ACJN<VXGC*=!S>7L")!/%F-IHG!A8Z"#L^=Y 2N4C<O9\=$%^^/#[3Q\[
M_S9_!K@NN+=Z)S_"1RP+S6?$O?@ 9JI +WR[/,8ZL,0./ PS',SG#;0[A)UC
M\7THNV.9UI@3>\+M*IDX@G;F#O$#/GEYYRT59T0C]7KJ/<\*3IG CS\+4LY%
M-KU,;54^%S:M?&%U?R!]81&!+, \DYB8&3#"RFT2,62*_&91V-_ &O!OS8F1
MW^)JP2/TZR"32#W<:TZ-#FY=KK@HG9^P1JU4FS ]>9VM*Q\ =B0LH8F8E$<4
MO6,2S_2'IE &P"4T4E)P%S5R(TEYDL:)&1NY5#"Q1A!>4>,C]FB-DAKG#50&
MT,M9]HI$/03;S70I L@_UV0N<MWJ3P4N_  Z)A7B2LBJJ0XCIGYW% H^D60C
M861D\:4J').;2I"^US!6TVR4(%$.'+O%G!$-;.^..I2N]\RX5*,LM_B!LBN1
M1[6XX!8()0_-E6[58J"&HE2XX:G((R;,+2]JJJ3+W'#7 -]0I1/SM0OBEQ2"
M)K7( 5\6+N'I?)(Y5%E7&0;"\ J1V^@CB:)!JERENBV&I0OE#L6&M)X_%IOU
MM3M"4":\&5Q]@<6(F+C%#H]LXNIF%#/I2 [FDLG+"JDRU*PN#W[=(]5(4:W.
M-3#K@!'@K8#NJDJXGVZ8)HR@"!TXKK)-X8&Y#K"&=?/7B3KZ8*AV#RJ/<(=9
MKPF"XCOMI G'J@@$E8)@6S=$QA15<#<C)2N5XND/B]*>5O2J&R$4&EG-E7$I
ML+E[B,>H=4XU\K2G5U5;5@/S!]H/=_73K900T$KDH)NTWB#_NPX!AMJLH9R#
M;@?_'<P*Z5\61L9QBUER\*2"'@,5M2 -BFVDELMS9,X2X<8P),_D3EHO&CE-
MVY1..\H,SK?:C8&I]R6U8!LLW"'=)_?0$^UJQ'C@B*VD:FTO/KXW?[OX#?[K
M*L)]O#O;V$&=K SV4[&,9LE5ACCFYKR-KI+2WI0H#X6BW*M<L$V]3 R:QWJ]
MB652F!,]CI>-]!PSIAW@92;Q3=IT.O'>(O\6"J'NO754[:>17M$KYTL14.$%
M.U\)!QW(&"Z85"[!9 8]0G\ASSIU OA;H2_=D3F!P]*_>VD.*)&1K6NEVD'$
M;-(\\FO-S7K^JNR:D9=5F:<4CJ_[4*IPE7K?4KCSZ Y&L\\QU].Y0Z/B%E2O
MN3@.S Y#V/4ZF>"UP1<W](8!B!<H( AQ)! XH'L4^H7UA5MGHE&$9UC&9C9F
MF.4C-%=L,[TB,H2NI\P<P\ALQA4W!;1H2*KA<%7LD(,:0=+)F?_M9J$% LG9
M,%I8S>*]CJ=NR^K^L+R*M7N"ULJQ9&HE_Z^+#[1C__KM0U7-HQZ@+U]Y<-U7
M"^,/T:%/9F;EAU3Y*^W((H ,5K8*"2-K+#;4Y'B>;=T"[\0#X05HG9837<3
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MW^FLBD0A@0/^')ZDRR0Q\S"#F,D[M*LM!9D21VHBW,%ME^6[3. 1LSC/S6%
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M$M(^S&*"\=PQ+H)C=_T+BL<H-\'%_W>6Z95XPEV5(M)[)-S(,T[SHI0\;37
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M2DTI\;5H)M0$G2=VD8D!AUO2/<^_K.PH05F[^\^B;:0S]K,))]<8MNX7D<S
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MP<8::(D_T1VT[%[G2<-AMN]+,+FR.5=#,FHF,[$E]XPLN763X'Y'#D^"^3Q
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MFA(HH_62XN_$C>\:'C/K=/MVIQ;3J^LM.'9X0_V!/>B,['9OOZMP#MHMNSW
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M[;\W![\1 ^ #3D\444S+O\7$"GQP]&^$&GYMS80W@5]8\4Q8EV$"GSL>C^'
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M'7%BPE0 EX"1&(>769[K7+F>&[M"_HQ_!OS&08@*Q5@?(BD#4W8@23R)776
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M0/>6#][[@87C3H *7RDL'*H"0UUG^![PE>.',@I2 5*0SH"X)#T&_HWH*EG
M%T^\("+!#L>Y2]D7!<>U#PR 2(<3.IYW1Y?ERTMP(BHE,,%1 @,O.)DG$L6
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M'9^SBP&"3QKJ]+RSQJ=B+.97(I2G[+;M7Z["G]]V6IUNHQ/LK:V@Z@EQD+5
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M138P*!I_+7"6!"H<N4USZQCH%VYTX=SITM4?A\#W1U6,F9\%F@ZE1&EW1VC
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M&_A5\0TPY OZHN=&L3YI-5$!KMW8DZ0G'U')*3L@L'\%A+C/P:T(WUA?Q#@
MYB:JVS)E_2=(4DHJH0NN44H;^C%2DF0,%+1,YKA3ZPZ>&-PB%63K"HD83^3.
M0KID_?TQN!/$8%=)!/<:1944*4D.! M^Q4062L#*"\5C84C$/!(0HSP6?DLX
M2,04-JF$+YX!A-E1G$C+ZTJ("W =6A\(#Z%& ;Z&^-3U:4-CI_4FBD, UO*=
MN:#?M-^0 (0/PF<<=<_$BR[<'/AGSG@,+F9L$U31+$@\S&[XL3..Y;NNPN"K
M"-$A\[_B%R7_TE9<09PK_"@)A3R: HR N@)]"G(#$.C=H=ZY4\A#9!'(^.IP
MXOAC ;02S^3KP&&.PV2,>@M8][R$!%NJ#.L6_Y-)H55$82RRM/$3\MX-":;1
M6%2.JLF=1(0\M@.2T'/-9G<;(!Y["6W)'(/][KA^27J(;V*<Q.Z-EJ2J;3Y5
MN;N1%$1N'WPW1A(W9.2V9<4''PG.%W3GDA)RV',5B LYQP=0*$*Z2KII,C2)
MGH 4G6N@?K0<HHKGJ-NT*Z[#IBX1I4?&21BB:9)91*2GP&<(+: QM$?PNRDI
M@-F2A%'BH#6C]1A\^DY"8V@),(56DBF)!*!!^/(<^6/JW""_20'Q3LL%^,X5
M+J1&9'U62N[0^A@>2G?N/T%@Y\]],G/%U'H/W_%)FIW+0]OZ6*O/KD UR?PT
M/ 2.1!5,_PJN@.PC^</)+,&; 6BLLV1&C\1_?W;"K\!Z5\@=0N-2X0(.*KZ-
M9XY_G0I>_*,(;\CF #U^XTZDK*S@HU27&+#2:TD^^$&</8 H B]!LK*V'20F
MLS>G-)1>7!'<>^]E)3\O<UZ>Q$/'J2(APXK^O=*>MM?)&P8KH BQ,3WN23;Q
M[H#.%N1]S.$#H GZW</N3QI:<\?P"MXXM(Y)5\#'\('T=S(O\()](4F*P CA
M+0C]C9)O=-_*):I><ZPEOQ(O.4L/10H"?R.^[ZXW([O_-PG"9+YM,7UL_2W?
MJ^VZ!6 3:6&YS8;VQE]!Z,85=[!234NC_&%F-AIPH5# B-1G2=W5D"X7&0&H
M"(R.JPA#,L3S83#')Y,R49!5/*GD &=/!&LM)AJ4-@UZFS[9M_,@-%P0,L&L
M7"U'.?KWXJVTM*08]P/_%3Y4_A0%JK;#\@+$CC19#5*U9O"[:R!\:2_))Y6M
M-7G8G(V%0,-!/8'F-T*OH49)5R5$;$D 9.F2Z4BA!T4+VG(&C0@/D3<M(HQ6
MJM"&HZ@(;%D)*MP'UOP0KZJ_V=(BGCG(S7Y*.H5K($=.NH;5QGHF$TW;_F$F
MXRW9P4#DH?@[<4-)A'!B5Z#F3\\@PYC-#,(..0C[#(.P+]Y^T13[+^V4?D[E
MD&;/&L2=5MJSFNVDG),J&'ZKV+E*S^/OTZ#?8S7/[0QL9AE73)7:PQ60_=U!
MH(V8@HC<$S@LT/$#\<EXTW@[GMRX8 ;?6;^"R1?Z%)K(N$<A\?$XW /,??!1
M=")'?O8<9N0UQ46H;EC%1P5Z5-(/=E+_"W^:B&@<NE<RIH:0G^H_GGDJJ**O
M WRQU!:<)V#PP0<%!3.LA9>$H-@DGATP\/!),CY+D5DP>8UKN>\BEB%81D?F
MPO$C&3#$3RF(5,R&C/<@TL%A"K?*H^]*)F39JWO(FFGZW@47Z#4\)*(E?8"B
M'I._729K=#QK%?V#/S,.P,?$7TN/+7>#%,V8! N=-A4&O-*5.M'?AH<"\TQ,
MLH@PC7F?%M%05M*5HX)6!1BSJ-4BC?CM\.HBT[<%C)*W.TTPSE\01O?$H*0X
MD$D3PYEU,<<&OB6.Z"$"!^]B F((K'MZ":(0'H\Y<"2$4,3@VW^(\7ON?!&$
ML:-<44PYP-=]&<4#)G ?0'KX&+P#%?DIIP7,$!'E-=VI<4.K".11CZ9CIO',
MW$:8"9W)NG7<F]0<\=RQ[+/S@HB2$2D<B4]:9-FYCW7 D[C++T37,$R:S#%V
MMR($]D$)KDD@HH=^BTXU=5Q/)G+G"T]0D#R-]Z>9L+'Q)4#8)\ <UA):[9[,
MY%D'B>_A!RE[3 %0I*!OL6R/J,@T(4SIKAW)I138#L8)90]>FC'&0A1@XD91
MX-W(Q+'GPA]DR#4!%(>H4U5&#4$%RDSDH_&-A-U0S!W7ER4,_H3BR02V_A:\
M00902M'('40:,7 R!XQ,TCJ2U)Q]1X4C.ZB5656Z<B4\C- 8ML5J3M>R."];
M=4;ZWDB@2JM2Q$W S;N4BXKB?"9B-8,GH!_<>9!$'I*+0K<ZP/)ODE)7*=][
M>L3>GW]1P4.=$#:5FE$FL6V%\F]D!Y30:14' A262.Z^2S<S,D4/XQX;P\AY
M?Q5B@8\"4W12@?TT09*^U\XG<U7RR,B$.#?"H A%)Y4 T>N0F"8N)C<ID(JQ
M:50M(+PF2HX#51[ KY0-[=PAXJ8@)6(2:B]U_ER_D1P%@VH.K0LAQ7&DS*+4
MAEQ*2?3OUVX,GL%X1=R&T-1Y Y99@0%2_)WF$D9G:9;I7.-P!7X*Y(N*7>.$
MPM0TX<_(Q30T('O$ =EG&9!])Y,Q]Z9_/@7^*XS91CK7@YQRG*:KHFTKVS]3
MLS%,/.F=WCBA"ZK*DGRI%&@HKN4/(%82\&JQS%1G]*/J&B(=@Q@[OLZ>Y0J;
MR$A3M18H]N[%':;+P# ;@\&%L(1W&H=SK/4#\:(L1!3XJB"@E 6;!;>I,[W$
M9C1D#1T='@46?A*:=0KP"'R++'A:>O1#:1\8!HOI4V66AZINS6M_;9;>BQ:M
M6<4DRRI6HDEIL)#DQ???&9;9%JNX=-6:=EHJT2^1%M++[&7I2_#>8])[$\#:
M#58D*.=RC#:!^(980S,*"!Y\H5B:W>CTD6?XZ?Q2YS\-L-]()U5_)57&)4CT
M\94'5WZ2S$.#^M;9PN@A.5^E>:M2OX=*X>D[VGI-R8Z2Y12#>4JV'-E#(^W)
M:6I3 "-DWP579"O(9JXG-&@9<SX>+MMTT-7AC&#MLEA@6LAXZT9"/H+,5#^P
M!%B>XYB"3;*T<9Q@>>B#XDT;+6;^#[+8A22XG<2\'EC.BSJ#Q '6WFK3.M(A
MJ+1*&,WN*O_K7F_S4&+"D'A +/B_$;HPMS*2GE!@!)Z]*J)L0DT12VSR#M$M
MN*$&&#064TUH2KBJI[W>^J5@$38HH3)X5W<ZCB2%%!B%](^)U 725C$#,L*G
MLNN)B53EAV"? =K1"\?%6/N-\(*%2)5\JM-0(^>50%4EMJU=%S/]45G(#1@.
M9;$*',9977N=<U^G@><I(L@IUD>:)<5Z;BE3]'XO%9M20-/CS!IO9 )'B7(1
M4CS#(&K5H5$LT$I12=>9Z@J\"UN"JO!)OS<PB?7RQ&J@=[%G(XOFFT\@&5>B
M%$="KS%5_F(*%1*103F%CY%*4W8-5E^MM"D- .Q[V2JU\13.HBPP(L/&=(FE
M8,BA=5[Y>S.TI$P7A=;WYU\T3A\0,*G^4CE-4_VYE8F195]:DNU9]O'ER1^Z
MQF6 E7,Q-E4FD_G@1&A[3O-F>:6(_I?B%\JJ8F%L3&:J]$*H2.]*"%]=*O4J
M+;&;4O6.G3&HX7>1_M225O9+51=?^MBT'RE_B.A<8!6BZM@AZP+0=N/*"*<\
M.)!OE%S-W5C*9<50N52V<P4D(AMN-"=0^  -:[-[*\?5 (%\+EA)8#81$X)W
MIL5]Z;9^"VY1Y=D*VM4,:3;;D*YU9 _?_4TR4E!3OOU:H&_AB6NYG ).379U
M5K.YY!$[B?W?!%]3 ^PS ?OX"(09CWE\!80DHFM5H4 *0.+20>4"\ ET[E2;
M*742RHC7,E<$.Y3,#D,@Q$D@;8,[Z8U(JTQJ4_A#R;I9QR1,]:CU3+I,QUMF
M(;OR;,W"[,T'32LIC!E)!TPNGZU G^C^5!QC@!-)]$0$I /E] Z6/J)=^8CR
M>\UGKG,:RF/07X@_OGBKR3-"B>GX:69)6PRR"\5"@TIVP;ZQTLDF--TA'>[
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M,[+),)^.A]7S^Q#$)%UY&AN1E.0*?5ZZ"S 4,<J+LT3HGP2]!,4''L?*#'/
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MD8!I]EL0D*Q",:5T*1V(2E53X;,M\;N>6[L0_AU."7YD4/I23"9WQ1CTR2R
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M])B"96L7S4J'=%;;*^FDRZ%P$7K&P#UX2\9N3ZG!MA_"W24'_/9$#LA%7=-
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M/;[+$]\,)B_.,BBT !N+&0[2>KK"-$<97Y%.$/$TB)E#ZSW2:I4HPEEE:BM
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M2N!HY EH2:N"\JHL(PNEZ%,9'VXQVHT#C$3@J2+(U46;^X0)-U.UXSQB!ZG
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M/&,S%.,50FBR9\C(J&W*B6\XD!V:-5#@CAJ E7N.3$_!&F\1,]HL!45D#Y9
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MZI><L'9$9L1F< #]\<$,RDK/8/G7_MDTFF0""JV%* VS5OOEW%DP="(Q'C>
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MFXA%'"Y*W"+P:"GF@WALN$52YXI%P\X1Y>_L)?'7B%EE.<8F>WYB8%?@:Q@
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MS\,X,=8/EVGP "5ARV&O&LHQ"$=<UK*O6$Q\'H^8K6*3D ?BM!-Z[036*W5
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MH/CP2&03AD,V)?;.AWFQ"'O"(W>1THPH105&FT; X+/P*U^"C,Z!HDZ47H6
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MB7"_=900*$;,U5#C(!+]15WKN6M+)?&1%HT<;8M&[JYH9*MHGI2B\1&#X;_
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M(RXU1&3\,,< _-B9K$B_+:*[ASK>7\#3 Y4.-ER%R:D35@D[OYR<W)4ZJHT
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MI"->G]LW^=N.@=FC;/ ?"2IQN :]_!E:_63Q<[9. ZYDR4LC8[.'76T_8J#
M'8K3BD/:G$FWM@_8HU-0D^:9M,X$5,U1-NI(R+-J0H%Q@X_G@>6Y'KKF&;V
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MU*VSZ?"K8O)'X?R@!U*AMH%C1S$9=QL".!YX"3C^#8C#- 3U-(BBEO=.DFP
M3YS"E,KI$$ER^>XA24,-%TTR>*? (6=TN_@+08\Q S!7UCR>1^A-L%LB+DLW
M>%?E.*896#(=&.Q(3BM&CD!5P]*CTUJ4>34L$0V8=J&H!F"*QR&'B]Q%==G
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M?:!\0$!"^)VHN\\AG"T2X'/H3;2>HQ=X77#%LLDN26I"OO5<S09":7PA8+&
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M E##7_+N'ISRWO4X_JK>5#$-X167A+RZIXL>WQ!/H$, 'B&(&O$&T/ CCMQ
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MV$OQA!M30&RTP;R5EO?)2M2TQYK:X_F8\UI9SV7=S+ZF?,?HM/LX3C5.QH*
M][L"ON@"X8L^('P1X6_M2LP[2)\HTFUTN=4.!R8.M*\?%+X[086]<MY=?+"
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M3Z*K+9_ 7)D_#%3?$D7)ULF7OEC[U$DW&F]>L^G/<DOY;&XI?^H;6HD0+29
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MF*?2RBI#V I_]B;.N'= ZHIX*!N(&0[/\5D[%\_<.X+_[> BCD_P'K!3PFL
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M 9A@H=0D4&/E>-0<72RG;MM. 3\3FD=H_-UPHF-7,_DW-J^(AZ1HKYS$:I'
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MG3 ^SA",8J:TF>OW1UNRM[\ZB^C!0!0E\H11'>OVSU/;,S#7:?*/DC)FY%"
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M-D8G<C]Q1+TVC(=[):+D33%QD$K-KUK1%M<6N20@!D!X!X[VWX^.CC9C:6]
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MIV>G%[WC/:\X\IF&K7[IPE;//VQ5FX:&M0Z2T?_^=[ $7O_TYLV;G__?BY_
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MP.]'D7ZA!!2EU)!6M>$^PU.,4:1(03G"ZBP-4]^H#/35=NRA;ZA8DIP*XSC
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M\YF(H@;\*H%%O[8XHN8\LWA:D+_<G='=MGG ;8/(KAVW+-W(\AS$?T 9\=T
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MK_9?>F1&F'2L>!\CBKXRQJSY$3X?4E/K$,\UDV:9FW], U5JY>&&Y\KY C"
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M,%8:R^:!8)I?.$Y9_*F=8/UCW9PZ[+KK9$"\;FP<LQ6!.>I<R"6%XQECP%R
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M22$?Q9;,DFB/?+M2?)5.G0FUI0B1AEB/7K0ND2:Y[I%K^L2_Y08)ONB.1NY
MZN?HE" _PW0F_'L:?)<( H@D6X7/(6P#6<J1/2;]9W"@!SHNBRC"Q'O[W0N&
M&J_6+/4B6=$#6827A[+O'@C"[.'5O]:"LVA/GL)T.:!%XDGC#!S4W!%+D,4?
M'JN5<0)LER2H@![T G'5R@.N892-N2H$*L;\TUKC">411_5<56DH ($'<G/<
MM$"M$/9='=9)@1ZE.8QZI?94) NFL;&T$%$+4Z5]LV4O,<&@TIICJ7H4B%T#
MMN(X6IK91%M . F3B3M$R>7/19D?5RZFA&-J,7\L< N9^!==3!5^49<HO3M:
M)0I%+>,P3:MW;D&D4W\__GWZ?*Y&BF\;)Z3QC"79:% AZXZ6<^9EO]3W"(8+
M([6YVC8=&1^2"">E4*$S(*G%7=7H0WM[E<,0=AV&>!%AB$V@9AS(:*1$CB[^
MQ!O)"/]#1;IO4@ .G9TNY)]<&+:,=^8#G[K.MY!W:CCB:4%HD2_LG59P3CH:
MAYF**H G,R).4K<*BL>3.$[P<'::C.;HIJ$JA/4*6: %*U$5+8<#3H61Q10%
M"9]N0)FR*#;CQJ4/Q9:P @)W)I&N^I0>M#0$!AZ2A*J16-XI3Z[_DK'K#I!U
M*Y"U6H%\+--<BK> <2F*&8YZLE=:<<EQ8)F16]!@-B ]3$[4T*[C0W$VB6]0
M[G54TB/-)B/6SKY*?E-)GB0Y(!<)"%6U+W!NN*^] !1'D- 0[9!1CC-(H&!5
M^H"PP&_K_C\/7WK;6GKK&Z_\UI](.+61!_81E1ZV)2P3J-%93A /QNXP074&
M[=]D,DE=2@NX MW%O"FG7TZ]:E.WG3(0.8%JE8[E69GO1IS^IG+'RI>!P#]S
MHQ3H2AIN0QE2!0NQ=!#Y$GD%5=0IY4WY7<DI&D7U0:T,*[A(TT(%D=(L],U@
MRZ;X"K)KP]&1\0TUEE7/I.#NE%Q0/Q<$D$N"%,6D<(@T;0TJAOTG:?ORK //
M>;#<5N(UQ-AC)@5M>"<=_36;J]G<T]A<,9#@(G23N8#R3 ;^IU1ZBAD5M?O4
M1V6*'/R56Q>)1AB<)284 ?9,4JL!SEE7239245"*O[!/Q>6G.!?#3FAA4.67
MS\88.:YXL.0VHK(!/X?A;D-,-';@2K]1KBJ)WK7Z<LULB!+UM<1W&#?L!YKW
M.;<;+1UU+9GE7ZQ&T9&#R_D<)S#EYERHF\A,#,PO!"(L6O[%K.=!4<'+EUG
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M( D_V)6KM0RSLHR_F\C*N=")='L<2^?JLKWR#7%+RI&5YHTH]_%B\KQPQFH
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M;C.ZWM2;@JH=E#0DV8XT6B![[+YC]1Z6/9VCIM5N=U+98Q]UF[U6HUSV/',
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M-F TK<9@CU\1A_SSOS];-F-'V2!7&:[RH+$='MDZMJQVI]<TC;.+$^-/9S!
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MGN8\1J KY,O3R"-8S_L4MU-P-)!S*&]B66FK 8@2D)E$B*)>9""[N =K:+(
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M937;?:M]M&XQT3[M>M,ZMJUMPL,_9==/+[+[?K)%Z\BV6FV[W[=JT5;;1Y5
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MEM7M=JSV2963>U^9%)NZ 8( UU+LT5+L?^OB_2JNNE)2#%U]QU:OU:RR0=B
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M9K<;M23;+TF68G7]M!C_JB!=C(+XDI/<,HQ6H]7BGI\_P4*&WMVO_']_@M7
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M&6IZ5,S;?1<;<.F&QMF)-A4G<@T/+\X0YC$+C1O\\U_N *<U]"+XAS_''X3
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MX#@S=QJ_S5-@2DZ=QP*(BY&>#!!.]*Q@P5,/41&2/ =9OE*0*1<WXN%;?W_
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M7KMT^ E;RR-97]TD2^+GKAPL'Q(E%BU8<@N7)@Z\_^6*N5=]!2HA.!"&S/%
MHGS<//AEA>#\=?)/ZIQU0*DXBATB=P-:I5-$4@W+6[/9#,; =GKXD-=G;Y(7
ML*PP>BL?8034.?S2-2F-N.P:!.<1 >6;_\P6RU\.N8I%J089A>?\OQ<P/+,/
MXM<+Q(75(,+P1KO)ORW?9(,,KB!L!R>O^;,,9-%W)I!//=J7G"=FGAE-"#Y
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M"ZJ;GE=U6<_7AA 99C\]K^'XT(LLLB#T"^RI!>8^*H8&#E#6T+[ +.P)H-0
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MZ"%$?MVAX-73=VR?MF1/&IL$AX;AJ& O&'T\H":,+J1,@*<!6H0-,+87J7(
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MC\' I/C!E\B]5VNT/F]O=$7QU26X_EBXQM95J":XMUW&7K2J=5 :6=%B_-'
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M##]',,=D"<IEI1,J:)VTE#5W6<X57VH?<!M"K17H*6;SL/;K#L0_V@;BO]!
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M#-,W60FBD*\Y-VBLCEE$PD.<)5'D/KPAWBUX#,,::IH&M?)<22?$NHK7R3H
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MUD1S3:JAFE/(GQG!N1,AP2P,-0.1NTM,7K^/5TKO_7:35T+"B>L3@S&PO(D
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MF<@7V?JIHN7?SEAD#?F6G+1<BJ%L*1;Y[\RJSVVQXT?&93OJXX;/7.7KFK:
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M&<6SZY=WL_G^PED;^^7+W:=J3%?ONG?F0*>B4B0$Q%%8_B:<-OCB28 V&S4
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M?1'VZ5J=7H%.=Y%.+[Q.CSG2D>H/GS&=-IW+/^K^^H1E'#F4AVXF#.05][[
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M4BO+%^%=3,+&E;+[_?W>LQ==TGSC^2$)5VWWQM#+ELT#\GZ5T"C&8V#CTR,
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MB$D)R(S9+",!!@JDMQO0$E"<\7QF"^O=2Q=%G6D%^@4-S8,P6.FL3,\AIMP
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MJ2(-#(P;VUPGKS^V@Z!3,Y\4(\=!.PFO%RVQCF7%=M5]EG@W\UO_0HR^]^(
MHQ?D2V;4K;)>'5'VJBIXOLWQ@((2]L%^! &_EZ'*?]^T>+24A+!1E$C&XD[I
MKL8[)A9IV>)RWH(V=E>0%&)<,TXQT:JT]A9O1IS[G=)24@9@"DAF(^V97BR^
M45O TMTV/,#5N<(QL\EDMPXYKCVL-_*P?K)J1R65JIPA%@)UN6QQN032#>&/
M&7A6C"MQI2-V38%K"KR, I?0+VQ6#9>* D#Y!N1)!(DAN Z.\Q6#^@!6XY.%
MYB)J*F0PE%8ZL4\;Q6L.Y6QDLH3Q.Y(@@].::H++T#_X848?W5*%UC+P(+_G
M!\E&U=K_1$ON+UT\5*-YDL.:11U*EJF14'VV%8<77!"KBKNJZRCI'ZP:/M<)
MA)_)V;N(JI@O_N:@GB_-OE5@(^=SH[#-G5B"ORU935]&<TG>)+E&AQBH$9X:
M0C(@<VH>5LR.M6JE(/&-K'$@F<A#&-0=R\I#*"YR4U:3=-:+>&7ZXA><LTUJ
MON*H\Z*\\IC;_A;%0K#[J45=+J'-)A?;[%!6^WDC,&HZ=R-PI:&40XIN_CJ7
MQ#RQ3)N9;P!-<1^K]+R*8<K*E,L=%4?V\C1<<G;'.Y*1;TT53N*72EB>2VG&
M,$DK;]&K)AZ #"S7YH:G??_ND>/._=4ZU>2SIO%SW:]HOW5".S8WQI<8+&]A
MV@P@<!U"<2%E\_A'09N3(C/?50A[S!C/,3QDR!^,G.^?X<JPD1:4=FRIE ,/
MFBF;7"+S .;/:^_*>- .5^Q&064WDRV=*.[X5E84GX/"?+F 6FT_I)U+720J
MN ]2=<'NG58XQ(:4.RQ^Y!UW^G_D(@8>'['. 1*Y$!.- R\S&R(E:T<X'-MP
MSE'6K))VC1T!_2#K '_KT89<P,47.V_ILN7,O;G"O[89#,]);@89@?0/MNG5
MJ<!@"L)\!$ND<S?=[:$%IZ7%5P@0#3H2S5WQB9O8DXX6/=]>1XL>:;3HZ[$=
MK_#8:QO<1E:\VXZNKG!T<+.SA;O;U;6JQD2A<=K U>A#.UM36M[$^8-77."2
M:^NX.-P]XEBE1M^1'LY56AP+ &P#EYA5$G?G,IE+_#9/JH,=7YTO:6&WNWNS
M%G8[W[5A^N7O!_OXX5ZZV'UI&[D?NNCMVC>SWV2ZS[^@] +$]Q6;1WQY.[U[
M7/0;Q2 4J,RF&7H7G?+NN)7(3E<KD9TO:272[_WW?SWO'^[_ )_%=O^'=\5U
M-"C%-NS03^Z^-_;7XMT;*_ZN5AQ#4P8H0B,S3O G %/,;0"YNQ[2%8O-:,04
MK%CKP?H[$<^L<MB0814Q_/R;CZ?#U34TA+LAR9T629[>EAZ_CC?Z1LSJ;G9F
MM[4SQ[P#6S:(>'=W;YJ.1IDA-KJD['SAG8+'R=V.]M7J@BWHNFC!9;FJO<R=
MN$U"PO3S P!9.J3U!*U58"(CX@CTH!S1[B'C+KB0-F*+)=%V.D-(+RSF)_N9
M04CS:%=Y1VS+XT=I14:H24H!PF'XZT1BY5I?*E7/R7PIECDPPP0U_XU08F/B
MG!JN'A:D(G.ZBWPFC([?NR/%IQ6$V'$W]ZG<TIW350&.IAP/6,O:N3'-HM4X
M2CJKU^-F^7H+5O+*.H*8_F^B21*D#99<#4M_)4)6STE12E\&F\C?S FJ7)>7
MT(O$'6&"_ \\8P34%AW%Z;YP!?1]^TJ/&@74[;UN)(:DUKW>V$,&L[5-F!*Y
MA%W[Q__T6X@J"^"/$:,?SGG0>9D.:C'UPL)PAJ"Y*I\DG+?#RV$_F,\:\=_N
MG)Y];9#DGYEGCTJ2PHI[&=1L=''N.\] >4P5YK.Z!#JZ())<66V^^O8RT5P4
MZPKS5<'VO2N#[?M?%&R_T[CYS7VG[=JXF[+K=<[&FHRN)J-V0FF7#%A9G7N'
M?+U9=OE%M'\S_A^:<N#_=Z&E76?F5MYVBXIV[G\+XB=\-%"]ZA45$ZQE76-2
MO55'T11<2<?\TK'40R1EB.6MIHV*3 FC:;-TT0_YYQS-)%#"T*X9Y:A_5^%H
MIQ+23-IH@Y U\*BOI:ZRAJK [V0Z3=)9%;8CHP\PWOQA+SH5Q'H85M.!&8W,
MJ*$<,S@:EG+%'M:Y=KO0?6S.LJDZM^9K$YM]ETNN.[V,H&Y:=[B*.*Y%?]<M
M7V[6%H1!4XN$W[1S&#8=X2.M?"A3SO+"<N1P)!><#J+"MO>6TS3:Y("NE1V@
M9->[/G>M!3>+:2]G\??>-(QNKG:@=!=8FXUDYEQA%,/M[T5'J]Q\OLYV:T#,
M@9,9 DMJ9:'!\B[XTH.3UQ\UG'_#*H"G'([OK\/QCS0<?Z/+]9=F)4I;-C?*
M$8BG70 6CG$ZA4U9\M>[(2E67$L&IG74*D&! ,Z&M<![ N%.ND%(*J0@ZS.;
M!&2K9&\QB.XTK:><AX0FLI5WHHV-1-8%2]=W01)_Z5G)+E)?O$;SE.2AI0FG
M 3"_<W 9'??F@!0!)KS-_2F6V4Z7GGSW?/[1E-=X =BJ>_+$&*1D^\8CS?>(
M4"8T2:F1&N+4LDS^(;4'E::[<L/'M&HU]FV,1?ICE@R%,)-<ZZ$\!/X4S>6D
M?#]O9<5*)Q$')._\[@(K;]M-ZM>;V:'-@6S!EQ9/)@'V WOX1XWBW+E"EBIL
M;@,K82EW,OBLZ^O3>#KA5HVM?%>[LJ&K3Z4MG:FRV$K'K!1KX29ZW[U'!=Z/
MQY69\T$T0AII S+W@>L?5QID"?=X&H?IKO#V:JJKT+#T:K)NXQL4AJFF6THK
MR:!)A$'3E:%A>9B9,^A37'^,INXRF8"<&N#.,D<=4;AR;BLL< P0L#E3WMRE
ME"+UED&B?6ZOC*0OM*54E4[KC*Z0*>HJ>XB,W>-FU7RB>:X>:_B>Z>DEOLXU
M),L%ULOFMN;_=].;1&/<.$OP[WR_A8,-70#6HCL#.#[LN.U(UN,95.T"RB:7
M O]KK^$1 F^_SFG]9QR@/A)R_6+0[=L&&]U$[+T9:D9[I7Z$[-[)<7E23#I,
M @9X\N,:Y^[:70G>^_*T0P@R5'(P2C9[-8@J!1-(6(]7Z[3O@OMQ"2_)::A.
MIC:AE!/:I#+!#F^A.%RK-VS: =GLMF'!J+$0D9T=OXTE:M:8I"TN9S/Q/#47
MWD%Q6:)J[&^@N&]$SUB$ &NN&<7 L)@6#=MAJ:/Z2'M,09PKXL:*\\+QW]&9
M=1S+76O!RU>Z?9&X%T2VT)N\=<4+HO$'L!!7/)^Z3;[F"W(4UWR8H[C]'Z[Y
MM&UA>-V9Y-==9- .\9IO<">(40I<=??&_7*K$S\#026U+72")B0-+J&-P:6%
MA56[-)?< :*D<S4QV7E-7"=W74BRQ98CGBAMW3VZ0"E[F=@."=M+;A2!<=+H
M.SG13('$?P/7'(@5FVT-?=SP<\9A>9\'*W=-^K0O+I?/C,RT@$S&M-?!Y74E
M]XVQ!.9F.)%N2F-#@L<VZ/#-=-2WNG0EJD)D#MVIBY3H=1"VO;8M:FS[OW4
M>TVJMR;5AMEJFV9U$R>XJ:4_>$K3:U2RKTEP38)7D:"UBHD 0_+JI,$UP:T)
M[E8$]U-QT4U9+&^MM@JE<B!"5]K#D5Z9%]-TZ-$%UY2XIL3;LSY1[IQ^F(S,
MOU$B[#7(1@LFEY1,IINT?U^2VJ&YI)@J:Z:Z)N5[E>*:5X(,EI3A1RV4AG4^
M-+/VBVZJ'-4<219L#4_4JSJA/,U$DYUUHLDC332Y=1-W&[AT!3"!<PJF_+6<
M9"XWK*JGKOEN<)-\SJCSET%\N"R#I5LU3LMJSO#;51C9E)H9FP:HG3>207%N
M.,> \S^OZ=8#L/@@#)G&C?O;F'T[IKZ4['LMC^-]%S\%136<^[(J#^_JPY7
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M"CW6UBQIT=FIF<U=V7N_%U2C%P7[Y;G49&=?0/"YM-'7W'$"B,T<%V>[L2$
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M*X2*+2NQ H+^'VNDBF MB?[0I'F3%(-OR$LHRI&TPN6+!LX7<)I')S]:8?%
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M</S[QZ_TDZ//!U_V\ OZBZ(3UV"W-[/5C\[QQL(/[MDZ!T,:G1U1<#*.TF_
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M0)N3?-.<(8'=0=T+3DUE43VTF=/7I6@*^.L;;1%<D@_-6Y1D\=]2.$"$3D?
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M0+<NTV[1:1EA%6HL/Z2X099+.:B!%&3W@WT*E74IHAHNMP2LMC#GJHM@JGX
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M:]H'<(4>QGK;1QK!(-J>K64]D-2K>U?3N-@H!HYF^'&CWT@2E\B>P1J*<<9
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MB3EXB,@VBSA/6DJ#/^>*P'*,"%DA_?X<%+-T<*GHP"U;SEP7"& $>Q\+Q+S
MCK4\P@U%9_HK%Y7,G1U(1O+I#.(U4*DN+0G'8ZZ.!F$:$899I.)5?$/Q(&9@
M0]3(\#N>)+Y#44=5Q6*\HZ'5V D0&0$8] /S6GR$53G\6'<'54I$$1-PB6P@
MF#8,<CF#:TI0B3J*Q8@L!X,8H:)U<HA^2":O+@]',.K-0T %Z<*MTV%P[_!\
MGZ)B&/TGR,LQ?"[-OD@U8&!.8O)-?*X()HA;A=[#/*&&R627B(X9!>.$\/0&
ME?ZL)VJOF7'62"$57%*W\AVG$-,@W% A'5H8::!LJN>'#[ +F2WD=^OE41V%
M3ZC1L<D("H-X,AUGET:75+A=1K>R=EB3C@2F1LR$Y+3OI2U2=('WN"#4GTGU
M-/$["=<R,P2)8B.ZH89QP^#__->?=[=W=M_^7_Z]^3.@L G>-6+IWD:W\?/:
MQA2AD202#W9.U2"EJ%3'ZYD@O.6(EFA5!X=U,LDXZK@:J.3 /]@W?!5) 6?N
M-GCEYV@$7 41X9JW13<7NH<(-_K- @WKF>E96_\!:2FPQ)@G++$0(;F$<"!=
M3=F>^%(=)9G@8A-W-K-&LYVX:@U&!AD6.XE&T4!VZRF[V+<Z%_O3=['#V(,D
M'Y03;"@XB OG @G>)UR3^!SQEQ/;X%SN7Y([-Q>U5,MIR8<-D@?T!HP+9Q>I
MA+&J65&*3VV@5V]^!T/#I1R'><&@]N<RN0FLI1CDR4ELPF,&KXJA9)?,L-D7
M+!G?$<"M#[AC^E=G$AIU6%0(M]S/-$^3HK]W,;1[4DTI0O>+ZI[Q=63JQ"U/
MBF_!D7%M?T8XSN)!D-[G65:D6E@/&E,A1WB%\*QW'E:7XZ*<*' N5#0/G,RZ
M"M"+=P$JNW<7\2=B4UZ&]L=@.)-BQO:EN89Y.9B5Z!!V)E&0>DTH40,WF]:Z
MPAU[)(C34Y-R,3!1 %!XRIE 3<7I.895\"?1&![.D$GPM3W%W4C). &=$=B-
M:%KQC'&4[/1SO%,#Q2&>=P38WQSLOU,T0'*,;\%&(5@4Z2FX.RWQD83X(6<X
M\"9*T]6!9A$;1[4@*P>P=:CE8J\%M2];9B9V-JFCIU$^M#P5UW5.;Q> ;$K
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M%ZZG05J%2,0\'F.9*+&FEJOA)EM4+T9D6#H2H>W4F69.1Q)NOH")-AQ<-U)
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MN*7E5SCQ$SUQV*<<_PTD1'> 2:F('6&5^H(,B"&:!?W>;J\7?#H(-F=G</A
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M#CC)W?FM,/T_VZ_D2]L!Y?Y;^V&,->0=?"GM5KO4WA4#^9?F@)U"ENSVE_
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MRZ.O3?NEX*-QK*P56)DQ5C9.+FYLCU=IS+<MHJAY0"A6SPS%(L<SA2K".=>
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MKI>FCV'375Z:CG/3GYX<]B2*/LMJ$YY<*I44L3HYQT@.ZHR\+9S:Q8=WJO@
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M2O>.YSG&H^]A^ON#?:<MS(C)&AW?[Z-KE:EU7+.!K8S3&$;A?=TM,FV/MVT
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M\C^%2I"P=N*72(*/$+#X1=@(%(&8-BJVY&=:F2M?VPZ9#!YH7$P9P_4C5V'
M]75BJO%RI"6<.MFB4T$2[R6)2D$2BT@"@PP[Q_0MOZG CY7PH[IS_"@2]780
ML^[^GSNTW_I%^]R<M\\]!G0]N?B560Q=OY@XH>ECPS)<S]%P$H#"7B?H]MWE
M:-2Y2__;+#-N-]5L?6;"=4\"H!U+[\3 V>703 192^7O)9Z2\&!GG9Y0/[FH
MU4MJLY76G.J=T=4MUS$>#UY4(WB141 >B].;+;5<*@:SKA/B/*Z,QGR%OX\+
M]H6^O@-]_8OMNLK0L<>*/6'(LFWKF(;%+ZB>Z%D#>\P01M< (C[?U =I=QO
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MRW;DZ8"//)T>;_K> ::U9G* Z:J">88?C3^^NNS\S_>]]> ?58"U .O^/*H
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MGB_PJ:%BJ#/+A4]#P]*L 18&NM*T<,^5N,]-3[0B21Y;ZME.M<"-'6WD:1%
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M3N&0V?]E[255QC6AW5+E#,.C7"H=@*>TZ/E3]/PYKJT>LB%_1,=X1%O=4O[
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M3WY\L&.7)1>*X1F0Z-@S4.?9BD[ W430@T*+I@:K&V(@"&D +K =#<0].OZ
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MG:SD\FJM"<NS>Q/F)B^YO%JWPG)U]A$6F<E9!1+**S;\G-?/</-YPO$,FA(
M9I>9)IO4-\*ICZ!/!$Z20<2S21IT7">1P^?1^D@=2U_CU;"!<B#2B7EL_<F0
M[:FHJPU@\U403XAJ*_1SD&='3A;?&_%^(E/=G\CS@/8[US-&8,,Q4<KKR6\7
MZ"-+@F+&AN%57[7$E^1L3,LUEHK6UC3Y0*5;=38GA3"XXSC2V7[&%+%::CK
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M799'"+9>O5%6V_5F[LXOV?$IYJ/FZ8L@=Y8Z =DA^79XJ;DC,94B'?A(-W@
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MUXL_!'%PFYPW4:YSL1ZGRJ"801/:VR#!!I=2XP3KIB>\24J\C'H>XVJB8MK
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M$5#5B2$:,7B>J)/@Y12\J\RXCF;\IH$5S G>TU_G<('R0(3V%MGKI^O9ZWD
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MY"C3&)N6+4&1@1,33RB;V6@&7[AMU%VA/7.,-6@CX@PI$<:$*K,WC2?7AD=
M#Y7PDJ,_[TWG+R^8SH:O!@M>Z4_QQ>).%2E0>08*)(K+K5.H7J 5A&,IS89>
M7W]7HY-/E]#)Y=>XOV>SE8X;\_Y)*3;K=2U,UM[/]HED>==_O#:=';56>^V]
MLZ-ZMH:LBI.P39L/>,$ 9HA;>PO24M+FF^/KTDV^V"DT-F'R7;\SB^^:H.N6
MLO>JM/4R@LO;M?6N=\#4VS4S3X^3;\S46T?O5:/+.DOHLHJMO/E*GHPP)D%N
MQ&M6X'K[LN[*P6>W_[@WAW\]> A+O,\U6-34&Z[!2%5F=:P76JY&+0TP>6,
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MDQP\**+8?51\LN#2;%>FWY6O)2PLH]+J)JC'.]EAE+6;R/"X/\H=0LYM*7P
M&ZWY]&XH&IVW58..;E!%X&XU[ JY17*':(.V$7A '&6TU:J//:Q"?^DGC,'E
M Q<BG:OC7706^^)P4%;&Q8Z3_CRZ+K]$;Y,ZNA:@"I:QP66V=?5Z&X',7GV;
MH^8R%&$2'E")O[ENQ@RLL /C@CUW52:*C1\/+B'Z4%@"O"[R@K,Y2KGH+9PC
MP3KU7@C0'0)_;#DR7@'R&P=,SH0,-G!?N("-G+%9 .)Q*L,4=#.;Y;/BVA$5
M"9[#YHY,A^V#<)2?QXX:]MOYKKXB*GGC%<US?(2E-C_+- 1*(]C:\+84Q)J_
M(=\''[\X5G&)3NW&)F;GPMSV#K&GNJZG!>P_-_ 0:C7!:PRE9]Z#H3DC4%;)
M)_(#-GZ+\TNL"I)OK9="\COS]9!;X9M-Z=1\MNEOL*BP'D]\E'%0U@S_K'XX
M,NQ?+.+6@HY;0PE,:4Y;"S9P, *UA)BN)@Y(,VZ#*7HPQD"II7<+(_A)P&HX
M1A_+@<:JMI7_QQ-Y54#]T_FWUIS+SMDD?\Y[-^%7R&>+3$R&'?V&4&/V:WS7
MO@CA7S!H8?+H]Z*C'[W^&?_YK?">P":M4QSX>._LN-7?3A@XLB@)UXVL00Z@
M&(3!" [I#!4D&40@V\!--3W,IJ%!9,:/D\_'Z<#XP8ZR!D#Z%CO<]?9=I<5C
MW;$+(Y1-Z_OBUO>CA:WO9?1N'RX5Z.]G]VY7UG"?G9U9_FG[2SWM4?U;[X^6
M>J#CIO5^\ZFTX[W,<Y)E$*UA.!JQYVC#@RZPKC*!HN)-M*'?%QO=&8O<8T!@
MB-%WM(XD$CO\,6%;QA@+=!4_!U0:LX9PIA@-C;RG*_L&%XBD].#-&7#,3W(@
MO$)]3H$46K(%[ K#Y7\7#KAI]L 9Q<VN#(LMW3VMN\5VB#AVW8(F6X;)A3NS
M79KW-)K7WTH^[!2WDN>(V%)Q'W@T^[5%>9M4VY6.IT(T]X2A#P=Y8#*G6;X:
MB#H=M#7.-9:ZTRFE1)J+VH'P?%5 S]=/+SP'3JXE,;0H !7VXL8^RFG(S0 :
MVV1CZ(Z)A2Z.@5@U0624(Q%*C)G5GMZ8J%FY=2TA$Z)@L4>%EC[AN6/P5\4U
M#C*C0[L6!OO,3S8((S;O->QUY1AZK7'GF&1B)UZ1$H6[Y'"-F+U'^?KR"_9/
M?G:.\11V?H:[-+K (7VO=3J B$E3SVK\ V.N!UGN;C=NK\O:CD(;>",DD(E_
M-<;-3(K1KMRT+JBM\'6M-[!?VPV4]=4Q1'#:U,'44W.KNB?ZCBYQ7I4)'E:\
MF?**I9_CPY_=D_JSP5%MV6!NRT^+;7EL;\L7S["MI_7?5DHLU'-7[R@H(G>+
MYZ2BO06;LH&DQTA,R(G#_Z=BT'ELJ#!$@VR&0VXXOK*QC$P&<%+(\&K,5]F<
MK9O_->;LDVQTLFWS=NB9ITY@HYJB"DR/# ^NQEMX"EMX6,\M/##6R(<72X4W
MF? 4GNBWWWXF/'LD1269AG?;RW]7(*JYL4!:?<5PO[/) &Z-Z=#=.^MG&<O;
M$D9F5F]P;CP_-X:97SEAY(ZH!,$SL6BBO3]P1N?TPP?A#$$B?K9\;!0*/(%9
MX$^V._RK$$OL&0(V:XH"R0M$7A9?II)[X-1HLR9/<'3'+H=BOU_=71A]$O:=
M/\ZOOGV[O/MV\?WN5@(A?/_,+\ZOOM]=?O_[Q??SRXO;6+C6R'KZ"K+J93_\
M#5A9K#-!ZO!D\>QG>^NQ:%18CT F:2O*TGZ#:_M;66T<QH=HY'OJN'<\42;U
M8LQX\/M';FQ8]=?<-2A[B20:CFJ,DTT_N/R,PF()1(PM*C-;]>EI3. Q$TP#
MSP],;A$T4[\1=I(8OO7@$ B/AJDAQF-.[$B4D-Q9K"W9VJF\?65?A6N#7:"^
M%(TN:!S"MH":X28<;>/P$A/S7RY!1O#?8)1IO\60@TZ B?F7T,.2!;P!\\6:
M!!.0TB#^T1_$<(;_Q?7T W4UO@WOF=N E=2G0'RQ=JE[O[=W-GLNTA12D>[D
M&(]/ "62P_U'RO##$QCAIW-@+EE;3KVS*J38DKNJMIWZGU1;LFP/GEH/#Z^(
MA"!;@E/9.-F3$OM.E/,W0'UC$4!P[P.K2B1UB3U2Q+7  R_O2#>A3N9,9H^8
M>X[O]8-Y$\ 7#CM]@P45.;?1-P=#V9\6<U<PNB:!8@J.G4?#A<<IXT5H/1E$
M.@B;M5 Z8>^7>!'>T()]0E&G!?V6V2%S3"1!68(_];%UF@*"?K*HA+^9+7[2
MEXV?*@@C1$GR7+IF0#)F@MWB4S!\Z=YYCR57"U>>N+2UV"KGP+V'0Q-ELC+\
M[KW?TI3K!K JYF\Z7P+1P&=4-:>G]%%#-7S@'RB'L-44!49&3T^6=;GXF8Q:
MV*25F)U*1#^ WSUC6X^%.A(3]=LJ6ILP?V@9\!W'??;,Z=*+,UF7'_;W1Z;,
MXKM3E)\;,"-X0@:K(,PA:I*9FH#)7'3S#$N*" ?@MV.(;BD#CXSS2S*N.0UU
M#1=T1^P+ $/11TFK+B/HHI^*\% 4B+RDA5I\6D )T9;#O;/3+"R%#<15HLPP
MNT'4_/N$*(3PS[YIVRZ'.:)^<FDE9NTT R?8:'?%#@]^AN@>/&8%%36BQ8';
M1 6;<6FT-?%2[8UK&QV.23AJ>=6],D)X3=G%@@D;_=2=F_[C9_ES.,C(<OF(
M&&4>V9+!,?K]O;/V0;=^.;LX- ;A1!78IL$#D!=!H'Y$S*!OUT;WJ02YBH4\
MK>XF4&I6WB)9(F\JRH.'_N^ X$J*:L=%FP9G#-N>KL926K.P5K)Z<UN:#*1$
M)VZ_N\RF'N^==6NWF;\JM_8!["(_,0TN6U%^6'0N8P/A[Q'$#*U3 70F,GL>
M#CC$3?GT&GWEFFLC!L_@_U^1@>A?L).,_727S@SN[5O#?YIVL B-Z/+Z*@:D
M$MS[UL@RO==;V#D-2*6&AQ^+8EJ]6I?%) \_VE=);T-FOA.VF,&&/R))J_C'
M2&%)?VR%Z-(4BJ;(F.WZ,G"4PX]_1,C+% G$T)<PAX^D1$+C?80 1);S)'Q"
M$F3</+ 7?!>^P)_&4 XH2I5N/6#ZV1.C8,A61M66A%S2RFCO&[!#>JLQ^RG:
M(9UNOZ:,K@P1'?9\"+N7"",ON?^RVH=0U:XE[M/.FI)';=S"7EU%5<R4-*<@
M)UXLA':W7Y<H%9>*"7,S*?NX>0>^%$5SU$%%<U)S*S,":(^T3>VMC_KM=1>,
MSU;[>&LXY7G;:8W#=_E%83-"7C7-E@B3U$IRRR!?+%R =L)(@ V!F:N8IM?C
M.Y3_"K\V%N$D7OC2@NNKV*.<"9.->^N[-H@D]5G&A(K%X,/:J(@8^N-<-"M,
MO,\G1../ *<C/]J^H[ _60"[\P&T!MYG,;S/\2)X'V.32#N&DG"R &Y)H!V]
M1JT@'@U\]V>GW@ [O,1E'JC; .QL%F"'B;[,%O6RRR:SA,TFX7CB!6)#824
M=G.MRUS+#HM878?".)Q.XS3;YLRRLG)H1X?KH$TP-7DM?!R0+ ;1!<WDDJA-
MU\M*9-*'<8-Y;B-V**EYU(<-.5P/%4ANR**HF%$L+!:9D6%HBDN-0A,7BTGI
M^SCCPWV&.\XL6U:6)>8<1(/4TBS( ^.62L5X_=37EF;78M3,4P8Q9MDX7RH+
MLB[^'6#1)&Z:A?.YZ-[,*P>J1NLR:^2"FC\7#6$;L56:<]60$)Z8!9X3#<P(
M&\[O%ER *O\DZCDP(>5W0W\1 X-?:$ *DNW2&8'A[KT:-^(A .[$&6J#8/;(
ME:)JJLB7R^\W@W!&I&I1I>I;M%]T0SVF<LJKML#B_?U@RG_ /:4=9B+F.9Q=
M9(;.29NGI%D3>&:+HB+:C+:E:^ 4JOJ">@J]^I#HQ#6(_4ZG_4%\_-#Y>  _
M6? 55;JI%37J6/%X>T5B67/X*$8/5";,]:-8%]F"W:9Z; OGX4QQ#(MG#'$P
MG3X'A]PP-<G%#^Q9Z*4!C[H3>#+< M>W]/I-;5WWKW1_AIHGE[/"/? +;D(+
M*.51*2)\B8K P0/%DX8/S@>[!<>:J[*!-J#$'^"B\)O'UZD+OQG236KR--KX
M0@*'B&25K/9$^PFN,A*PZQZ58DH1 +^5NYEU:;P 0\G?NXYIC'GRH9Q-Y/+%
M''B]B;I5J5U*+UXMJ2PUI<"LZD:>-5M7+E[H4>_,EW<+GG1'O#^V9?L.)K7H
MU0!$I])FES?X9ZC.@)D0- ,..8@]C$853?E?**9DN@/9;X %"[:8K=;>L,#8
MPTJ+;<1#?S4TUI.Y3D^$989 834%%B0S6?.H1D!'H7 "F0IG&+.=/PYN#PQ]
M7FPD:U/["KL'QA>468''.R?%0K26%C7JA.L@G2H1$RD\26XUIC[%A"W^EK;0
M^X#D&5?(N31V2U.D!*L8C?G55VT.J97!)YG#CTLVK\F6*/=GD'W[,L0A[S3F
MAA)Q/(<7T1-GKZWXI%S4"'1;CO(:V-H] >LRMB2JY9,='YYPO0?3L?XC@1C?
M;=/UP"<N0%LG1M.04&"+^:T$YS"OF-.I_:KT<,0FS+W(K7 6P63B/AA07*AQ
M)3<R%T@S2J)GAA+H]GIP'LJ?F4E-:>3V2)67SNTM(VJ,TW@VFBL,R](X+'7:
M(?D1\N[4R;^)L1[21]M$?706B &.$7-?7HTG' JN1D]S4;EMC<'J,$-C%\G3
MTL8I U7QK= !QC_T\=J<Q2A"R!7\H7GB9WE((['/&TO)IT@J;(+J<F(UBWTY
MD9)&B/N"RE> \>!C%(=J1C;::2-W&,B*9AZDKBB>PK=;HVZ8Q@,U- H]4!"T
MFZ"K!K.A<Z<</QXZ\6@U UTM.34*-015^VCB#+X"IKX?"0$=^R<17 "M(C-\
MJM%_%VVAXV*VT*8+%,$0V02:6.[%E[P619)TT&D.5@2.";IH1N$EA0@=\:36
M IG5Z_2^K) 9]U*B6 1%/B-&2$XF#'/D[** :?#"M8"4NN>X'L8\X>A&:?$D
M-L_8PN-"N!NX:YC5CUU'QC?!\Z7^ MV2D#6#;)>SZ:K9$M_=)X9_PTO_@9>)
M[*IXM[+$^BA6U0)'&Z$[0L%QS24(Y]B!NZ#8O9KJDI.]LU[_M'7:/]Y>;8E@
MT8T;9UMJ'* 90:F'J"LI_<PJXT9]_"[0Q>7VZ6"*P9,D^EO(-_?*=#)M%RQ,
MTA0/J'X0H4B"*J2,*PQYU8TX&72Q((>)-,SH7X'/K4N,;"C$:&X*=+B*.*M2
MTF &"D%&Y?SYEN$%@VB6*(9(RY<:G# U]*]3RM28SY F,HKTUDI9T]Y26=/#
MTJHF5FA13EZC +Z*Y4N?^H<C73 ,+"^8GI10&]$_89T)7'U?5B,X>-3M/]![
M?_ 0LF2?*Q/(0@Q79*0*_CIFT8L/@L)O]W>Q *<^ #L%'R4IY?,ZP,E(HNFW
MS/@/MGL/&AJ6\I>00A&A)SP+<:M ]#ZY&+]DD0]?ARMZP301$*,N%^%.743_
M0WUO@6.E% 5K9?Q:F&P%D8YSE(V;P/<M<__'7QY"Z"!?C4'7ST(_  L;P/)'
M!"P[YGA<^IXI[/U_F!/3#W]&]7;2_0B+!A?<BHV%[^05#F:VB9.AC3M/F+#P
M*RUD%49+O@_NKL)HR4A,;?<5@<2B?MD)/K7ID><S9 4G3$0-<8R+ ,-IK?#Q
M8IO1TM_Z/[#DD3N1@2#Z&9A:\*&$*N$((-4W>I8(C3$'WL!T]9,)^BGP#1_4
M912,0_1>S^+,11BD>S!QKR1Y6L8G89M>H+[/"2+@+.O)&@5@QM#[5'I"((]1
M"(AW:^(^,6"G"F=%)KC%KK8,&X99=W=H">DE_NEZ]N@9<T"7*.KN3><O+3=\
MAR+&G4S QAKRCDBX5\-_!>I.#HQS><^0*LGU)<C--+-]-^IP4<D:W6B1'T;[
MBIE[1+YDFP+(AD!_0_JNXB[:8%=R*2T#.(J:;6*G9 9^"N_"!(T<TW (KP@)
MZ*B)-6A06<Z3J6"CU"W .N8]"[FIX"G1#I<ZEQ-87( Q8C+YHX3]S/Q+."W9
ME"VGI]-[*K''YE +%X/GHK4Z5[?D8L,QX@YJSWN7\H0^2ZNF6+8IEEU0+'NR
MN%BVC&+/XN,A\=O)\9 5E^BF@58N5:2;\@#+/&YR>&0-BW67JSX^:8IU-^]F
MG%3B2&96[BXHORW=#L\TXM!20%TIS7)9[$0F"1A5CM31K([9@C%L,"^IVH8C
M<5CA(A[8&-4,?%E2A3A] WOVZ 8/''NWA?, QB_I77F!<<QR5H8#^P:/L*\V
MU@%-/3&"=Y$!6USIQ(NRA2E!&]&AT/R%F#V&U4_6&*P@,. T#X/,M\G$'>$?
M!!F#67"\$]LM0PF6*;T5K*,RG@4F1WV"%(>5#1_1"*1I%>K&_'!LA&&$^/4>
M)P+..)\N#6"9[L?X#],HM.BI^,?1_9C(K.9'-D>(ZXGU6"9E'M@?TLG.OE-D
M#8?>EA,13/>9Z'U8'^X%YUT4=>($R$RD[X;RWH2C73  7_H)'S@*W-0P[UTX
MJ.BL --@8@).F>MQIA$YBP6!@RU[Z)M%YWB>CUI)#HA<D9AK@5D0BWDTQ?]F
MS\%)<RQ:2_L2&N9F=# (()/=1^EJMO(.2S+PZ@N**U,-9%16'0:%APGD3L+G
MA!T&>1-^AZ+#44V,"DJC>X?DX$9EK19ZT8T.,KFU.6O;/FMWA)<:)BD2Z4&5
M%%"U=<@"(\':@#Y_PKYCQ>CSK*AA&JN %WJH><S2 CU)F*_X1274"4.M*+NQ
MVQU;9I@'EX-SS"?3LLD I#(LK#ZU[H.93%4DBQ9,/8&_$LH])]?U]B"N7[IS
MKUV0)["0FS!]MQ[(?01??XHP%CM4]?H=T>J/-+3ZJ^_&[=W5^?\Q;G]\^N^+
M\SOC[LJXOKJ]O?ST]<*XN?A\\>WZ[A*^U$B7NH;,[U*$PI";P60])5CL%#Z+
MJAW#XCR%*:T <5  6" 8..=XSQ-8N.X]5?K@X?%<6RE:52[H#@D3&L..\,/
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MJKJT*AP2[/V, _2#J+M%7H,GM\FY9"U#:YF9HS_NL;#(Z'DE.J/YQE=,L?^
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MR]EDG"F0FN,QPC[)[WS -XD/VG_<XF?TNO/'QT@AC5H@AU#V(CP4R'-//%E
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MB!73$9S26.-8B&?>![[)IG(BQUI.Y+A>.9&CO;/.ZF6A1OGI$-+*VTF*-#F
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M=43W $D'(AJ.2, #D".D:!TGS&2.C*OX)[5F&O\!<>O-'A^)I<\Y]("G+58
M4#1[?<\#_?V<AFI>TSS- >HM'IP\?93(1*S_K#6E81#^_K-_??6=6.C,0_-D
M,+OSK)$%6\)VB%?C 2HZW1?+BVL&I"1Y:\A:;!R<'F-I]KSR[)UA(I\([MP+
M^#=!7V(-RWD2U "-J13JDLT^$N:BHJ@G/^.'] C@ZGSL</YBQ#@C7R%1@P]4
M(6A%<5JI#0"G#C@+L)]_SL.;H$A??N$".!!B"=B70N(COU-AXV:19SWYKDW
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M;LR%'G5I6_LR#WEY9>QDN1+MZ@?3QC!X)K-5*BKGA1&/:_40#><EAS!=P]6
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M.,,D^H:*H:KO@D3N*?>)#TU.F1:%"F&\C"@L&1/1$;N1[/N@$UU%5K#IE7V
M;$P>Z?"^?0"4G<C:*6T.)BI#KPFN%P<-4+4[HAV]4IT=YW2B\X'9DLS*T&US
M>'Z42STZ.']U7N\_E?<.H,2E$>7)Q\/B!>:N#@75"L+GLAC34EN(KCHLLX]K
MEXCCC[961!/AN8N:=\H$?)5V/ F+T73S4+NLK43+4 L3TQJ9B6G1V\-"MN^.
M*QP6J%%^C9:P'1Y-"#ET2@0$,K,U0 8;BAQQE,2BA9,>7K4T$I/$)/.I0PP;
M*^^_CCM\.BG34*E,E[VE"J^9O_+# A8;610)2"P/XB.5P<<H4HUF[-U*L1(
MLQ'JF%0D??PL<>')S K@3"4C4!8'FEXQUU4:?J%RC$!1#?4 ^'*LK1D618XM
M]Q',RWDL0VBE,4+-7<Y@(R2CU1<K"@U"GI%,YR8,X<ZIKTRK</"H.55"TU@9
M6.I\_X;M2;6,4ASGDW1F^EQ$O>]D!<830BIW)'ZN9: G2E">1$*8]1"G59G
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MCH1XY,;3Z4P5N^F\1,+?2<#+.+,&;AF:CO>FTR;MK!!@5FE;S-0&S+=OG>^
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M#$NB3!9C),K.B3#JU2;H;8T._&BU/B]@1,EYDQ'Q=DC):5O-2:$WOI.9C_W
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MD^H[JAAW,Y_N?!5^6-%7T4<,T) 7$VR*BF&--6W:'#E3GYJWD[+\8#[AH,-
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M>FB5D:<^*&2R8[K6;\8GZW-TSIDA1YPU T']R;)R9M?)Y 3,KYO?6(G*L]6
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ME,V$GC!3O(U<IO8S.+=1#SL-OA:(P9Q4,4I1R&#4D0%G&\M*:Z?IF3),F>L
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M?K\7S&:1QOD2UGWU]5>!C=>W7[]_^OK;S=?K3S?WZQ#OPI#7X0!W!R8F-QA
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MQJU785QS"M992*KI[\L4#TFLD(DEFG22OY70  .]SI@[MI@D=WI34F]Y.EY
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MR\HVM79!B2@'[X;/K<C%:GMJ>Y7<'I6ERK7>:[,+TA;G*\,U*@V_.%E66)U
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MB A/$(V^V;DA-G>\P3;.0WG^+D7A/SS+WU0IWM,R%RH,Z\9[  P:P"$?Z?D
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MZWC,"G8TS<@V&":NPE[XTZH;84&@"87/_%8"R$)'8YFQX"H![YL3XJN ;%(
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M$W.2"(L:CE.GX3@H2QKZQ2F<5"P&4PS>+<ZP:6V88+,[LCBYO)^.QQS'@04
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MHOJ;AO(+_:;PF"R$G^ TI[<U-D8Y,;,L2/)*,*V/,!^F,)<S CP7MC- =@F
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M94E2@N1NE I/Q#G/F!&#K.^9C!\\+P C?F+P(?:T<WTT+$1+CI[P.O)NZIS
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MV/R898%)'<0)Q66H"VY7Z,0F_GQ>6>P)O#&MC<,1_1^("R6U;Z[SG&-?;^6
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MX1A) 5VX<[Y!^]-@#,U1\WZJ$!X#?,#$YYX:X$C&.&\K XL $B!K#Y4UC8+
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MN,(Q)BNAG[+\;>K]\#$9JZ?'0=TC*$W<,/?<\,'5"X7W ^YI_JJ9[\D)Q),
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M@!/B::+,P]L^@HI_[57J_5# RJR_3BPJ0/3!K[(-A.K9+S8@G%&I"W 2A2Q
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M, >-;;U\!TSUZUT"7.4#SEW6T9A9DX>9-\'418GJ^+%20@8>?^"-;&4="&;
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M<1Z\YDW+I+7FF$UE>['M@0 $*.WRDMI\^*87@>8HO4QX^T4UJ,N"*ISAHJ!
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MN^LQ-UM++]//=W5+LK^Z!#O-O%UWIDYR.$$YXS]*Y[)G"F1?T+SH>&; HLP
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MGJA^@F;;ZWR>XA'GC7_]\YOQ#_XG0*+SS=\PXTLZN<&!EC">-%G=)L$D\.*
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MN4C52)0.,QL>!,GJWAB?O$!B+P^+7:U]NVGD(TF0E--\-=%4 ^-Q\4OCU39
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M?J19+;?^E'NBK[WY@_>8@#G!7_#B[2PS<*0],L)_WLR$064O?^A0I?&<NWO
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MY![TGQ=+=)^(+ATV$'];_PR*OS47?^NW-OQV49#*-KG6'S3E>G&QE(_B(J'
MPB$""[IDZ5<UA1J>9'V=*OU-[M).2*L>=Y?L >L-CXSG.7Q?E\XHF@+QJC1_
M^>Y+]/#JWINOE*+GMG[B<U=!Z"-?70)GT"=SP"RWQ]S17K"_$YW\MM.B>LS.
MI0] =UM:$36;I.:!+I+NF[+8(*P0AR++=1?;R&4F]^\'9A=0Z)?''M-ESG#
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MHNG8Q4TEMKE2ZXXZYMHUAK.4W)X=EY7]A,S/"1I2_,(-%C?]2 BM3K$B0#%
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M"[HY'2)X^''S=(((X!J !0%P!7)&R5C<YN:@?W4[/RXXR;[O@?J=LH-+."!
M^\;YT/G)'BU-=.Y@&/@]=.3[(1PP*ME9 /9 3'.G*QH1X\UZ+FKD@$)@_PQ=
M5C,=<="ZP8*',GHSYBZPY -FB4R\$+\#NS#-.1UBX #T!S=$%@F0[@(AT73B
M:)BYP%8#& J+"2@8E,DKRZ3RW)3;)*41K*(?@\&%QCL[RP%&O0%& UC\OR,
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M!QVBDW*KM@B[H$L&5(@$;/C89Z OE.,9T 9B8ZEI*)<8N%][ !EPX6R?\.B
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M?SJ_)N>Y,&1*'XV&+O(.5&6!QTQE8%C,6U+-,.NF70G5'W((+Y#C"XUAX2S
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M8V$<I'+<67X!J'.M*,49R %/^3O4O/98[J'0P&'\K00)4AWX:?/HY.SLZ/(
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M^A?2!5=@!U%EH+;#@HL9&)-G'U,F4<\85;B^*ANF8HYFUR410O#8X@FUEDK
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M;@'*4G$+&'$"L&! (TF'LK^I3K2?N9$\(1=;ACOG4GO2C@3FFJ=%;4C.%:;
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M#+M]#D.;Y[@'@QUGI ?/>&?#=:FB!FP$.=:HJ 12(B BC#ZB>,VZZ3%CK58
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M7>=XA6R1'9<\8T_QXC=*S,2Z#!<.PD%UB?8*VN1:%;P50)LLI(V5NX,SS/7
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M%WR$%@A.Q]2J6R[IE/W*77*4 3?.B(VS%Z04CPE=\W#RMGB?&D*E9[,/!*
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MWB6[;NI:*,1M.O#^S";NW?^A-I !9I,5S%B/N&J&$+-Z#B!F5DCGB,2]4;M
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MF38]]R^;2IO $?C)5/*,4SC2U/9]:]ZJ,(++T?IZD1(P-!62 4HE3S;%H[<
MMZ74220+C1]#FAG1L*LN*.3MHWR+F]Z":@J%E0U#L5F?G)VF:]?[%3G(H;*3
M3@+'-YMI"@51-))Y@J#;\L8)1(=V8_P*3$1BP%=>*EJ\!%E;?MB(N,W!Q8*Z
M+IWM-:AG.&G@<[LT)1%->4I48JMRR\DQ4;Y''6FPN3?!ZLC&A!7/#6,"YOP&
M[X+@EDVN90VGG4G\X7DPKDWU0AAJHJJKSYMB-&IJ6JD;&$:K^"/[I#4+=HC_
M;,!T'QUI1%RD%1G(;N?=OSQ:WS7K8/VU,PZ\>.HGU9O]<V3=U^3F"&"YW>,8
MI\QN:39-W1K CVT>1[-YQLGU*P?E=8O.VK-I(2%CD^8O\1MTD+.4T0^V/1KL
M[*L!'2U &Q I&-=1$_#C-5(THA?X54=ZXP[:08<R H>WG#.XA=,&;N6SL8&\
M_VS:R$\<]X,.#SS]'A[X)L,#_V;"0+/[T)70K0T_:M )&0*K5N*5[H/F3P;3
M-'RN<%EIO-D;)]N>R;ZL4-P,BZ7ODG]HUA)/#SCK< TLO-/1OI"0&G(B.-U;
MT2/.LVBFY/Z5GS^.QTG!.X RALG@9, J:;('_O-6!7;NKS8*+&GZ^OWLTK:A
MK"[C(OM?P= $/X$&"V(;291(@"*+).Z+FAI,2!]T.7.30?5:Z/,SX9UDSC/4
MQ^7IG0?2:3M%(T>O=-9H?\SCN\#=:0#!5_X!76"@U^=XS>/?H$RVP@2^C!<2
M2-.:7D4*LS*6+63,'>UZ-,/XFM#(6=-",A=<EDAQS?ZVB.$, H0)\DK#XC9[
MYEH*]K$G=-X[3K;J6,,J$\A+MW"-*I0Q(!T52AF]C=91Z(N2;S@$[;U23#V_
M'U,Z?&IR-J_SSRG=LW4XC+,7=_UQ.GB3_'+W,P;WO5;KN]K/]5?/V&\;=KR\
M>N=2(1$]X%%J0U>02Q'&>]EH8(0Q#!'! FZ5[0Y7Q$A>Y$C [?ZGJKGK5#5?
M>ZI>%;UYL+54O"=D.>5X_B(,+3C!00K=8'[S_4]JV\_Q7L?( RF,(I&4U$*%
MIZQNF6Z[J!4GZ^_,Z@!'OHYIK9MXNV9/E956C2O0[QX+ U_PK,(19FZHFQ&4
M%O\:H0"E9HQ7L+JPA"EY8Z%GREM)YT2/BV^DSV6U2Y<'#HC[7RS7PX0 >&8J
M@DJKL.HG/N\7/EN.K#$X%H4C5)C9Z,/E)8+]^4,#T^20="!D\KCR> JRAC0;
M\ &R [*;/,FXFHDD EV"Q;TVYJ<FU5K[8'(*SH7+/GQK;^\JVYW\]2_:<0_]
M$U=[.CTLS GQ3B*%,93 [N7*92R_H.V#\)S!V);[=:C<$NV$,A]3?NY_;=]L
M9H8;26X(,DPTI879$C *11';)%T5V1*3-]-E6G#1P9+J.%:K7 NE,TAR,+]=
M(L7+SU$V1V+AVU$>]S\QGZ3T]D":4R_'"6%T)59ORXJP%*0,J4-C28W*A6PM
M+E^Q:,E+X#DTB-*RD_H]E@3,_+;KRE6'U#SRN*+ 95K;9PK;;0@5A<%^ZW4_
M7]E:GV&*\4D.D^) ,7,IKFX-#-#2% 3\ S316A]C$,,335[TG1PN'I0RJ*83
M2^:4@SLP'KK#>(]]7<12!X]<.X6-26*(7-_B/84>2S'A)>*,&KGRH ,D/WX/
MD'R3 1*_?#T$G8M7A86DR@Z%@!3YF_$D;@"?1QNI;-^ITWS(XS_D><>=&F)A
MU?"ZXWN&)/PV\NBP >DZ@],W6SC^&/)_HMYUO.E@.WOX)U5J?TK,JC],MJO?
MIURS; */YI_6AQ^I#X\G]^%#_"FM]ZFZ?#<+R!:.' )4_=5B)K .82M<,L(-
MSWOTJ(D_,BT!KO<%UO-H!&7:(-VHU/Y"]*< Z 5"5M(#N%PY(I]7O!'"F-8,
M1G'V/FW:JC!V]YPX: 0Z&H@*UM173O&@6!)?89\45ZGWL-"U"[!OT= 84ZB>
M!1 ')/WG04 G MU!TSW21+KHZ.8JI;Z!"*$<JRMBZ&43W#?NF#PZZ;HO3/@-
M9!T1U"T5R@GDJ&3 ^&59)B@"B&2?P["V+)E-.D=7C6!D$F@S_ESQIJM--4%X
M<DS)G/Q\G-XJ\:RK_P2Y&\]>_?+^@M>%-NVSZ)O1E_9XI\KH3NMQLP9'0YPS
MDI"J'E>7@@],VCZW%CZ=,HO1,^FY/OV4=(D#W(KKH^B"1<AGEAQ/^):7KF0$
M;M"@"EOO.9-WQ<361#RMN/*D3(=X%[#*'%[D3Y=Z9.FAMHQ^)!]<']SB00.H
MJ9[JA(U]IN):W-H2:TE);:-&XK/]59&Y7S3:B(D4<*O$GIH@8%' ]&+]V]L3
M5E6V=68B=DQQNZ$SKL/8?!CV!E-F?%7AVE.%X/92],%P=4T43:.:"<$-Z"U(
MT@';UP-L1^:&[C#<,166[,3,.&A>IX 3TZ YF%MOHV_>TIHD6=8-F4(%E^,N
M\RQASCL8^()PBM:9TXF_*9S"+MT^P%<H[&1],CJ/O+.#,C-6%R7NYIX O?^S
M=KZSB\4#I GOJD1>LJLY'FMQI\)8(OVN0<"1B>B+I^'7ZI'12NF=GT'"E-U?
M" LKWD-U -"V1[O\LEO6A&U2_]2Q.QS;N"?9D!:C=&;-'TN!@83-V!^8$\G!
ML>O\;%TVDC2H&;'L) B@N#9XB3>)EYN3"[JH=DX=[3<^"IHN>%QV?MB(55SL
M>G- AS;!H4$.@2I;X<^4+L._LWQP+/^<,^%D]/TO_L5Q$#NT"N>8HLDQB7E(
MT,.K+ V%1]:DXB&DDU' [QP!&[DT2968"N%HT:R)/Y&=+8]0^:1?BQ0^PA43
MTLP>S\3>[,4\.6^[L^3@H4:!!AT$5@75P@"!5G(Z$2O+NB_B;AOD=7Q\C>>+
MLRRX8&PYO^V''\]P'MP4P-@<23\IQEBO2ZVZZ+:[LQB)&;.AVK4H('*)^*28
M52N#AN(CCV^DU*]"=Q;2*K<O)%@P(Y9!YBJG@S%HZ].SAV=?OZ6^_-N6X7P6
M4C+"X_.<MJ_R/^(Q:P-N0;DQ0E5,>,.U>P$LI84>@N:A,@9H"8 H0''H;*M@
M*#\@CU%;8>[_I52(JL,5,3M[?/KPZP[P:QK@#MLC,[E,&&]$C^MXK*N4#2J*
M1'H'[+8]@)5$0<?9)E/O7SHFXN3?)24?3T#4S:[2G$F@:(AD&*Q]1Z>Z8UP(
MS-A1Z]3;>OU7#+&0<XB8T[A T5VB3/?:R+L\+B*^&;?*C4EC&H\?1_WT]$B4
M 8PAH*Z08B I-27+PMI,"8T1&?296*J#01%7*L3$(W(BLZVH;I#4JW,;B2/5
MW ?VSWNJ 1HN:)4H+_;T/50'^T_?'>P'XF#_[%JVGO8 UW#-FZRV)7_@WQ7\
M? $C]]%[=B9A?C7;&H=;O3C,M>Y9A6S=5.9#A7?#6EF"X:0$Z&J IG$ANRS0
M''Y\%!QK7=>#>+>$/"\5;L,A=>G'1VBRV6<%;.KBZ<.S_?X/D.7=P&F/X<8=
MP&D(.F->%"E[J%Z$83:9$:L6BR3'Q+LI7(N8Z D2^KJ?9L".-5$D0:/ZHX59
M6[(PU_!PK?KDT83%\?#'T[_9*3T^&3)+QBH[J/[ET(K=7N,"<1!:.19JA0LK
M:B49R@^MY2)O[[N3DP-.WH;FHTZ.60N+"084H_'0<WZ; \QDS?#+S5-X@:N!
MA*)Q8&]TQY%1'XH>LX<BV3RHL6)L#DR93O1NR$P!F6^???^[Z_+N91-=Z#*&
M-:D5!M!+H$LH89R6>IGCP)D6!06PVB(C1J1_G5R<S)8IEDG.HRF:N/BKCZRC
M0E[K7 >V!S=2,F/!PAY6)(S;QI#AGU9U[W/F ;_T?B)U.CG/HUF51\,@Y(T*
M^;&LY0';:_OY&&R LQ,TSAX\4<FLEME.AAB:MQ%['_3@Y=*G=4O95:A#SV^-
MB\JBX.Y_JK.[3W60THV_*AR-W2F@TTM1MYYCWT,'FALZXB?!"_6H"^PL)4<Q
M30E,84:V=3PC$5<Z0'AWVE Q%6ZKH7E+Z-@%40(G>Y'$UC[OEJSOM>G^9_7W
M/H*V4S].$P0V0-\7Y=J0@0S&O":[&$D(P!,([#=[>/KP-,+_G]'_']*]\,>C
M^Q^YCY\G^@32C=TT,5[Q%*C-.Q)9LI&DH/I?348 2<Y>T7%\Z57,(\_7V3M)
M!PCOH4IDUM?%*DE<&U(HR7LL$A=SY>Q&":QUZ%7Q+8%<??3X,?X<?O?D;+]T
MC7SK1(\NY@[=.+K  Y&CBC0SW/-V\P.N:O2P%OTE3K4GIV=G#WX H^KHX?&)
M'F[W/=ZK<+Q?O;_P8TW?_@NT+AC"BT:):R89NWR72XOAFT'2D+P7@9QI\#PM
M%DY'T1BRB12;TMMC&8W#D/0.$3M70G.Q:&;%A+>Y-+^IYYT-PY-3E^"D&C-Q
M07+'1L2A$G;6.@A&Z$:D2W#IW?\.+(ZE(AO3'G.P /I:S]JUA)65G6K7.5 ,
M#P[5N[1:82V(9/8:'W[__2['0W13S)MPG\ JRY6ZZW:F'E$ELE3'\397SD]/
MCQ8H+0)3T\#V;7DQCHX)LGT@HB0/._O_V7O7YK:-;&OXK["FYCPE5<$:2;[%
M\5NI4FQE1G,2VX_M3,[[$21!"3$%< !2LLZO?WI?>W>C08*R8E$95YU+3)%
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MC$X#,\D3C@?K$2(JA 2-?_*RXVT)8#+AC3 CF/0:H!0</FGO^73#X8LD_^D
M$OWI5;N@IM/,SW/HPYCG10(B@?P,FIO!MJ%?)!I+X4%!+BKJ$B I%)KP6F_*
MJX;-LJS7..PB2',=/I5OBL6+:!V'FZ:F,J/XGP'R$NXN2I#XPM#N3,I%+O3
M#?;?+N;4/@MCLXBUT47A8GR(3HF0XKS)D8KF8N7\.C] M3N$BPQ PH$C5E:P
M*&XZ?;X1QT[(@19@##;X(C[VP.?6C ]/R22Q FN5YN)_N=5S5>(%)<O>H/!5
M8\]/ZKZ1>.IV(V,0VO$1SOFK@Q%D3)Z_'#U^_#3GSD/WOLBG\.9Z6^5Q NU
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M20TY2&B"?,T3%RB5K <Q+C&8@']=%_F"2<7!06_<H0RNL;E$;<BW8" 9/3
MSA;L74RAM1+&03@)KB9[!W^'3_*K+UX!L:NESOCMW"LXQ $3XG;/9?ZW7V[R
MRCUQ-GJU&N?N_P*[K/O_9^Z>V>@-]K:@+E_F7-HI?/;AQL73<)%_.0_@?U?%
M/%<P#WGJD(LF,0#JJ&&)/.K:17PD5J[ #_9<<*C7:]JY<?M#C-<4%\!E>H4)
M:_=6BTM LH(:'/EQ8*1"?G#J(\*HZ60*I2;M%'X?<MP3+DZ"J8Z6<2/=O1"G
M0UOU_2\FMY9,_\"4/>49>K[(I3PO(HG(I)L+3@W\\03"Y6!2O*-E5!3#\ XL
MK/1X0T]&,R4'G;2?\)W'0^)WRS1(Q!W &T*N1+U%U-==-(42OL'R'FDOOT;Z
MKYG%FOEK7O,-:>.S;^8>)W&(X%.@QOJ]OTQW-FB*5KG6 GI$3X@8K%:!(E="
M(YQY+NNZ\4!27,+\WTA%XD&CE(QU%[BJYVZ#*HC>_]/+3R6HL_W G$&>L# $
MQL%(A8(E3*%"L8EP=_0T=74^93HKQ>?WV>_[C_,G6RMERI^$:9TY"YB//4U7
MNK:W(1MM*DJ,]KJ[WLTN0(>7O7.[GYDE%2*N<3C8! +G-*2Z^O0LUI9Z/+M0
M$ T.">+ +8Q*KGJQB/4#-WFKX5S.-K_@#"8<$-NRE&.NAMZ?\++JOWAZYW'Z
M&5THN-S,'4QTOLSK'(F4T&EA ?O@F:*2",E9P,_EV;KSFD5X>T;G^\0'&8<L
MQ5B!: I3]A6X?=!)'5)CNM<]8'YM8H"]1_CEJIKGUY#YO0&"V9SZ0A"+K-Y?
ME#](O>0LG+-H>-GP-; #M9^G6/LYWJ+VPW*.NU2]N4VO\_%VK<:88\'.ZJR3
M(<?ZJNI<NG/&>6Y"4;-M"T!%%X)-FH^J_!+-)WX0+CIJY@&(W@)JO)C[FDC?
M*B!5@:6ZMX\=/X*KZ]_I)DT675CNK?Q;X9 (@ML.>[[[/SK'^U@VZ[P[-'/Q
M"XQ*:/Q6W<-:U$.FD ><(2+&1=.9J"5 @$$5H3US8L#%WQ<@6>1&>XILW-H0
M&6@+X0A*8<#"8T%8<#2#7#9\!SX4W/V=G6N(^QK@?00.V%C\NBL4A53J(T03
M3GCW6_'&BKHXG4-P6:XNE4+]O+QB+75R.O<9 >+>*AQ&6/ '95E,4W#"GM(&
M3'S<\,&YH-.!NCT(M@0 I66)<1?5[KK#)6@K]N18N0L"W$^-G(K/[],B"NMY
MFZ /[G%X<XJGPDM1V1>EI@7? ZH4:NC%TMF4I&G1IV<Z?(20-5>HE@,==-@H
MZ'SU*8XVKMV9N\/]8+%/\F58730.8=]C>,N5L=%8:LZ'<#!S+F"ZYUA-J#&<
MC-A.')//\)A\//BD^;&&,/2$*Z))85;\"FJ>(</-BAP%=]@X?W!:+QCWMG)>
M2GD)I%17]9)G%9P9]R_<3$#0>UE0ESW^%G2MV&!?%/,I[XAE&.ZZ.TY@=J9^
ML7K=GNN<HK;@[L+4KXQHL!KPALH*VQ1790'MM.KHBT%H:15*: [KXD?IV'+3
M,5;Z.EQ[PC%*]60NX*6^KWXS-UJLQP^NN8;?0(!/F%ZI!/;!Z$T-F"&\/KV
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M[D558MZSDO3<Q][0P&V!D8.Y13L)64QG%7&B2_B('&F E@AZ?)1?,V?&7FD
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M&5Z'!;<9(/LQ]'O3EZ$WF.D>=&IJ0Z>42I[VO1$LA'TJBH4]_9%A@5DHA&*
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M!Z829_)3H02N&!]>U9\B\A/H:D:=&,IST-F>(I&CDQWD?Z4XX,P-!I7V<J%
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M2/7B'<EO1(D;%EQ6#PX&'[W*Z)F#!)XP9Z;F1FMA(&<-KF@;MKQN4PJGP.[
MW<-D1@K=N5.V/\GA&O]UB5F2^5PB(?88M8Q'&FIQ(P55%O!0@ZO:FO$\OTZZ
MKP^Z#O?=MSK< ZG#;4>B9D%FB!U:ISD8=&62Z\'"F#6Q]EB6_-@'LU8W1-)9
M3^1@F$,<VQ5@G$6-.#9I6.\/S)JU9MG(IP'"8\G8A<N<>QKB>]'S16Z >=B#
MT2E?/7GB##XR2R4-,%8\P)ES!SJY#N LW*3LCHF#6QW-D /SOJ.C\?[H3<T]
M:)APEAY5I9K1>$(AF;&AQT39N!B)*!V^$@MI5U<Y6@U[-&WR5V*I70-A#[A=
M:T_I>B"WG)/F>$@#GIFU+HO[1HY@N"EHE'.*4 D'L1Z 7L966X&.\4N%IE,Z
M16<PF%R]"/HQ>F=K*0CJ5R^(HT*_TJY:* *:=<5>[Z2K=1H(%7^)/4EZA4&
M \%?[7R#AC$_ *>5"L7O[N1NI^5$\93\=.)S\C:#^9N%2S"Y<1B?P.W8^.XJ
M<;> B*QHQ8&C<@G>I.W<94K+*13.&V1;).2GP.5RM22^*"R$$ \?+VZ=G0VK
MVZYG$<RA1V&GEM?43)\ WA^*E>6S65(**9XS$1TR;![!!F_9H^;,.=V;9O'^
M#=6$U=Q5KJ7U>5EKW)EDW2NKSC %BQIBM3+CQ%-C.;67/@!12Y#ZC:2P_5IE
M(Q*;39I"($1V$]Q 9C\OYQ[[D$JDV+!#!V&WM<V%<)9#\A<<^);!!>+^/R[M
MX .XL+M9%08;B>1E&CG-F.]"FI/)&0]0"O@5]>8Y5T3I"GQZ9-GI8=W!"BK-
M ]^_E1^A-S0'OTV>?5(VD]4EI=Y$>EE9\V](7!>.(:PBCR[+UOFNE(X^FV5#
M:[VT_2CC#7;&W#-01)/:#BH/LSB!12L Y?\%$GZ-2;L0DO9F9=+ _5<"ODXD
MA#3G<#[D)#:NE9YYM#FL"7/^W]RPA=,^$N7:B,E17(,@RNY)$"0S))P0Y'KM
M<,PUG>8<S.>8%^ ^KZEH4DR*#5$^^QX24 :AOAA2'U.*/#Q\W*SFA:@2GZ^X
MCD[+4F)5;A.,Q>6'_/K^K>DTE/?9QJ@&M<]OMO6;;?U#;*M=9?5:$OY.G+BE
M*;9WNGN+W/4<8\,,2RYID0/G^YMAOF_#_-4*K\=8>!U._#&H-K867]1;)%OS
M*[&([2X5>HW_ ZU(^*9A4@;9]CBOG\Z*4<J[,EI-\=E%_$&M29-+572Q:K@S
M=715XRW;>@Z5,25N#\M"!I$7"GBM*9YL];AM75=?\JC;I01'>^.5TG73$5 !
ME=-2FO0>'[I[WK1;#0'UM^7(3QWWDAT:/(/U&$_O5.(J?#TC-M(/NNCPXEO1
MX4]9=-CLR7IV%G?&M]A^AW8!MRQEEKJ_!B *EY #6UFWY)FXC3/+K^HFO6,L
M^-K7!-$#X9*@]V/KB-H,JW_DS:HW[*QH(8T7[%S' Z=:NL$ET-T!0G=)32MU
MYS?J?]VP!2B2NU\?A66014^8KZS$GELF_K^:H_$8'8WAL/Y?RJJ\7%T29&)2
M+N@!Q\8S[SHA*2B#V.#8\/IROS'ABI-U;\39!/>+9T3=;]WCGU:0?'U=SE?8
MF0;UM=$)R6D D .1784=-Q()ZV!'_ZQA6INV6RO#M\R,@.'O4P\]$ABDB7\8
M2,.1XWA_!/;M=@^P9IBI6^[$(GN"B^S)X$5V@E@?>)(SGX!X"=9[!@0Y % J
MES>[Y'3^M)&Q+0Z!UU1$]Q)ZMC$:*A"UW?\>6]48V2XKP("9Z9+1AYY"6$55
M3:BLXAJ9[7+.I+^-_D'P&?AK6X .[WDAA&3<_!_*L6>C$"HU#"85:;K'T#Q+
M5D[K)E_:#Y?XOM"[I@TBU3Z>)7UX&KW2*6$?.OW5/M(LGT!W26G85&B*D8 .
M#I&$J"S<:%S7GR3N!%)0J5G-7DH^2<#T7++6LS7Q/IG,H1<"YGG8[=-(.PT\
M+$OD2+<,==UC6T)5S,WSYARS#WG8MC-.SHQ'K[ '=-9M2('+&31\591+;OG1
MO5,);9*BY&V>3+9$KA:E9M;7N@W3F]?P,LCAI^_Z+X++0:(=FKC\O:C= TZ%
M/HA95J4?TQF:IBIN'DWF)=OE*Q>=G(N;XMZ!"WR*F)/@+D1FL?^R#!5M>1(P
MW.-I -?&O$WS*J8%-5<4;9@<W'I(0[J_^QXCX^F.9MEH+[3YK%C>2 '9*\ $
MBW2OA$!<>TVG/J6V8,!G#$@<((I-%KFS_R@G*[U%72IU>B!(FG)CGS1.\#/>
M!&L#R8+NOT+@')63"#=#@;'/FLI,=I!&.]@^!SZ(+#6U%I^ 4&!B/(L4#3^F
MQD/OPU?U,\Q03$>_Y,WD@N[T^# ;'1\>/]X&WAYY-]ZOBPX\SUR9@B;LA+_W
M%/V]IX/7P.EG+!]=/1"G#FFSZ8#BE)VAXPUJ6P*@9]6:J.:TGC^T6S5(RGVG
MCE>1^NYC)51)9-_&GDGT#V8?6@ TJ':!CJ@$NN-PU;;2_5>Y8QF^6(IV?<;<
M>/6JR44*A=#2W"9?5G @>>47#J+'5,19:&BEB*'T+?10KVXB&QP1-7B CNF1
M[DAT^39([#Z$?_../6_JU4(XIN!W',A?%GG%G2ULOF@ZCQXCDZ%(V_GB0V;]
M,^T-P3>;4V8J+5!; *8+9N_I?V&CN7.%^G1 / >=^SJE2C?_J($,[(K>AUO#
M%1+58P_2DGA'B84KZ$OQV+0.(5[WAM";*LY<2(6XQ\)GK; ;DL,F3QY UE 2
M;=^_*$F<^_*0!AKP>7<8S/(YE5\NZNN.LA:15SPV[X8&UB):+2(#%(Y (73!
M#XG29:4L.LSS'_29PHMQ6VQFX/=3<7>\9[!^=>*R9((.]E7JZ^J+GGRI)'EX
MWNG)DK(N+I8<>*2=@'Y*E5/4ZV>A<Z#M_=AAU+ L,4 :@/Z_6J-@ER?LAK54
MYO=0,>7@BF_#DQQ;D@A)EY$I3!@3X]OY 84PXN+S@MJ40+*BR*<J]M8S.[0.
M16Q1VHS#AT>U,7K2%=2RG9M>4,45!19)<-4_^;K;O1Q\2HMSRZ_/M,UKVR0R
M3)>H*('B$[;9O)>6W@S&<#K+7SVSN0>U;NI5";FPH:L+&L/B1NN==5*?>MG"
M1.HT[0+D,\ "4+M[->WL65ASM@UO@GQ"EA]#>7DVG?)VWWB&?L+@0*R>Y)WN
M67P1 \R\K0,=A)*!!IH)$:0PMA4(B8)E^'S@E;BGA]\J<7_*2IR$R8Q'9^,6
M)G6C/;M/>^ "JVS]0JE<%Y@2!V8Z0DUA@DK(_H$-K$'4LM&>9L\JAG2M<4\I
M,D^(4.'4[<6F)IDB&[[:M+V<N%R<7_F-.R;">O<?A3-F,RK<P9@N,QG4F@<'
MQ%D*(<;EO]@ <JM':^*0&QN%)*Q6G]'JA[EIF6=Y$=$L1;"O/58KJ6K&0!@
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MRLA@3$/C>,$]FAKWU?80U"T1YQ?@.@*4\5C0_<F"<(!6M\7$H)8R(1!D<&#
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M@-Q.#?B6VF#ZB&&4\G%'?6 0T4T7>C6J6]E/]XPX\+V2_L"T4./I-ISKW?O
MSYK[P,*\$IP0!%TG'BJU>\X12H3G(EQV<O?JG"L6-@'JE3CS;6'WK.P-NAK,
M =LK<*9C5&AP$ J&?PR#"_#>T"%+>QBZ(91SN8@Y/3",R]]F9[OT]9QA$\*Y
M*VB U,><S; ]1&YJ3RR8 "&68?"Z+TE*8! ];)!O^"YR6Z^!;/0R&1,0D-J^
M4+OW-4^X>Y%^WERD?XY3A# ]BY4)SXB>X/ #3.&<J(YSOUG8C/J^=1-A<6#%
M2]&^D0R#((K6'A;7[C(?]*<8+"UFW2[C:"9(@<@-@LD>M13% --ID"6STFD4
MS,F=^^&26# J5AZ#IPK:KS<&89,<S9>314E'RJWTLQAU.^X7_ +\-X"]50=+
M/3F_B&OJ#P13*9EH@$_WJH,@W1#H00JT- ##$6\[SK>$"^["T-R$??!M"N68
MPT?H9;DR=V 66\JA'-(+";:E:72<1;0O2!OEN+L&H12R)L3:5*,99D4!HU.7
M(\!NP&^8) FSGT(Z!2M$L" CL11C%&%4%Y1K8B@R#%RQ&0X' <V+:8K_M)!H
M/ X!0HV  0M7<RYPH!E56X#Q%UU$$/JRS)&@/'$;G:QTQWM-PQM))>H_:."9
M<NC54QUD/_>-#BI9"P$2>I'!JT1N48@MP+7:P?/N3+5E4E8(ZT->^^F@N9X]
M4O\<I42:QCY-C3S[M*W)K/%C9B&!R' 64VV)$IY\A$1(7I'AP^'*%QP,<QC@
MF0BO ]=I09<RG1B[P@#^5'#(#H!E,6 3J07-TWBF<8L&,=\+2B=UU8;1D=I&
MU&&P'%'Z@-BLC]5>@-\*>LX=]TR\<4S)@+#@*4%/?\Z#$F_%0SF[D'G2]Y7R
M2+P%K#L%#BB^'JH 0H2$'L8,O8-T8@P=J)2/,$*)?O6I=W!F0HJP -P.&A-B
M%*,BZPL2LCHO/0Z&IS'H9>#S@3137"2YY*9*\%#U8='*/'T4((O,5[*'ODW4
M?>F3^&(9(]Z#=-@B1GM?I*$IXJ'4/;@XAOK>%?Q=^5L-;F$%>M!B5*08P55L
M_DCNEBFWL:TN&P&1:\1\<[S[O7K9?*].$ O:VB;R0N%WH !'& RTXQ66Z^\W
MV/2J%[&Y0H2<M%EU^4/&@'S[9-,K=U\S"#<Z5*^:'ZI?E9N@W/DHC;.I.5J?
M4C0>3.&# VQ8:B$HIR8>!+C@GJ;1600@YZJ=[?"^SNAIXQEY6$#O[[0.&D_+
MQ_;#G0SW=&XO&\^M!(:][<E<$- U=\50NMN 6UO5XY7"66(5TB5-EL6S:%2C
M*=C34(.%^</B)D'+VX6=D&J:AXPC\?;)ID7V45[//GA';X3(JB"W,S)S 1HK
MA\\:VG>%2Z@D=;V @HO ?:"UMOV.Z"]N"UOKWH)F'0TJ&=T(Z"F5A"7]:31\
M_?A70,^U6<&J!'E,B(;Z$O3IY^\]@I5;'^29H^W6"@M&:&5K'D.+8A]UPW@(
MLM0>1<EPW>L(F,$/>1%74N9MR)<]!G74 %:P"J?ET^*T(E@*- $_2YG-Q4:9
MKU.9;Q9P<QLV'@.A;VZNY,=X)3?"2-U_^O*;1ZL^,DCJXMN$_?^''=)ZM@EI
M?2\A+2R=VX2Q-O0:*]-K!,"L$0BI1F#Q:03?%Y7&V]DC@YJ_EY;F+2_O.@7&
M,ET?T:R,#?=M)M7(*'Q^\(V,H^_7*'R^,0KOJ5&XS-:6E^$FL-D60DPQ]=B
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M]A#I7BAU?+J!(&7P%M/NG]QN$HW'>3;.$V2Q[O\YI99RPCT8#+&W03V_(%S
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MU 5=Z*S$.?"68ZN:3;5NL:[Z4I&AY62ZYQV&A>1\_:F2T1KVMBZK'IH))I/
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M(:QR.'?4.C '<KS2\;NA*USM>,=_O\;&OEZ%*;D(WF.8_ \'+?2!!@&>;8(
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M=BV,45[D$5*)%ZZAR-6%+".\=RN<Z++T/N <QK--#N.>YC"^I?H].5K%_NG
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MZ@Y71QCEN6FZ'HXOHVZ,CZ(XIQ109M>R4%&_CU'@;%!-SDI;A6&)XLH@I7\
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M:]*%["ECN18<=.I"P4\*;7TIV3Y_W[P[P#7O^F.A#D*"MH9GZX+Y?E+TE U
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MT33B:NTGXE8IXT"XU>@%90>A?(186171():^KZS0@:<WQEHQL\9*(NK,(PI
M(AO6N&<<?)KW6D_8W#5<#DOM2V!F $>\121+-ZJ @/3UC2J-G"[3*I>^K"0'
M6L6P)?;&6&?"E"[+HM:,PH)S%UTC>>']X1;' "(<))5LY^V-:WZ5MD(_",T(
MCFXX/73T3'6VNS.S3REUE\P]G#4Z'^OPP 'N)Y(&'E'DPM2E.58A1U %PM/2
M&KQ4S;3%#90M#AAO7N[]<G4O.0VPRD@J#GI1V]U:]:BG+[BVKR-<;_@/=<*
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M-^0%H3U@M3F\55TD&H.VW$G>63*,%:HT!M##*6O:"J.U1&%7^NC8X83-Y3?
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M)Q^/\*T5SPP 78V; I2/X;&4&[OG/?>S;\&2'$CON[Y[L)I:QC#NE%:<"6/
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M'N\J(N/_3'=-E/^@^T<<;;D%XS*&MAG$UQ?M!ER7C1;5R+[:W)>"_)RK.;J
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MW+FE *LZ^K)]2]F(CL'[G5J1<F?)@%!UY\"TI38RY 6(<PA#9V.<Y\,ODD)
M6@>Y&]CN&$A[,VQ53NH1=-#DQD=64U##5N8<CN.A&5CT 7X/0E&"-9?Q9&PA
M#,MZN)R"8(*Y%*PN'<$8?;]UZ8B^0(</E;NJQ3T0R)\I0(6I.D,PG]S+-7Y,
M/7T2%%>^=TD14%:EVPCX6)(W&;T/1#<DE95B=Q3T/D:0QY"2TAU!DHKD<V2
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M(GB(4-2.H,V?,S(YJ4J&XHBZHH44:4[NH6>9=CLSY<OVE6@I<JE'*:2L4^)
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M2VF&"[KJ_> ;-I:_,&.!WU2AFM-J3Z-H5Z&V4_V J]MQD,;) [WN&5[#1 ]
M=84THCZEX&S["0R7V:AZ-JEXD"C9B]Y1LC-?1=DX9>/TZ-L*SC=X+3ZM388Q
MB DX,W5U/QB"+>#,=2LGT0:%!2C\DDY%LZROW,EW0N(;^)#A7-47^4S-YFE1
M7Q!,&0YL-2E' 1MZP')JJZZ,CBOE;C.QIE6[DIG(?KK"+.AN"AV*\I( K[,1
MAYE%-P<GU1<'#<+FDMT(HF3RCF.%)F4K/717F"_IA<U:*\L,++VO9H'>KK^:
M]?IIJ1CYF+7;^A@T"RUO\U:CM;WZ/J?J8FF8Y@35CRRB*!MB,[+=G8QZ2G9
M>LU6BKLVW>WK1.YBF5]T5NAQ_&TEHR-]B1:+)!6;,4TF\C83&>MSXYB'6OX_
M:UI'M'Z;K<5)P@BZI8I >F"^A-"V>LBRY1=J/!AMT]B5U>I33=AQ@JFV,)#;
M<&-:UVHG!"^9<\VBGN"X[) JK>ZUG,RQ:[8+9SRG5.@*18F>R-V49-.M)0WQ
MU,8*,R&CVV>V]"Z9B:\^GTLUSCG<F$=-LW0K=<]]66_'>*' 'HH5%9SC3]SL
M?GHI2YFG>E[@:: )\W9CFSM.D7@QT<Q2$VC44 SC6 'F>1(/_],=0[FO-Q6C
MG7QW<)*ZK=I+B=-)V$EP[2&=//C FKFC7GNL@;^+8N/6F\EH<I(V"SX>UIIZ
M.  J#*GOSA-U2+!K4(;:H782U/GP2F;] #1I!;;J.!(F\1Z\(9-_*69WE8J#
MYQN+1;D[.%H,)@4T;#MX.1CE-U%[ZF9X68R6H$A!$2ZGTQ"@E[*GW8Q:66^[
M71'EOJS!L)J&*MJ"5WSJE.RTX(\4[G_4F;V?GC)[CS^SYYX]YZ918SE-%/3M
M!*V!2Z'MIV(;-9G<?[GG'BNQ*'Z=JI$$M"D^MM$%V[XV_5$[-\ HXJ!/Q+=;
M[V 8&%-6]-4: 8@F5O 0@+2!Z99ZH?$*$+-@MY;Y.B"(&$8.=]8PA86?3M @
M/62LQ5WE.V6YRU_;):8=+AU(L.VD>7W2M#0-9 <M&[,%GXCZ1=].HI]Y -M>
M4.\X@O$VT.2(6O"T]HL(4!:V^1TUVEF8))?X<A>(*N9A+7R=%T[+Q+_O;)S?
MYOYT%VBXD@BE@:!G-Z42XEF=+$U:$1+?!(^7+./L2B?5'(7/N<("31"*\A!>
MMB*F1FX:(":*6JGL<\F:^JHTP\,1.FO.7J(< )6K[:P1/K!SL!6W,]V<GAKG
M[O#L:K9CV$5V6@EG<4#%"6;@<I+#7\?E5TP58J)+@U%$D5#9[BVK8-]I542L
M?-$(6]FN8&#.-1@MAXO-?=<XV>>FMRB=:O9+2?OABSDU"[QS8(A![V5E+%D@
M6/E0:K]S:-[:'6)+1 VBJ=[YK&[N 9WO0G7Q=_-1AHNX\2;0&6"-F/<9].3D
ME*^C#P2-V*JOY11^R;(FU3*I:STARRN/9[>&HB10#I[!E5-3T107E\O@N=Z+
M,0E3;HJ2CI&&'F=R[/NX6S$CW!QB.:.P U\YSL+=6<D=F]B8DBXDK>0XEZX*
ML9-GY@=&@]#(.$DM%L$3E;5%EL&9@1BYYI/AQ_:P<<GG[E38W(V)3N8UV*N(
MWK_%H)5T[X4^/NDV2R&#]PF-[@CPQ0]L<H4L'-]3;PUW5[#7Z4)2+:8_Y,0I
MV+;WM[ZOW8O>C!'] IK_(L',=8',H$!AC7&9>=.R6_(D69J,YLC+91$$)#&S
MGR<1]=0:NF1! JB]%#'-4KXPFH);T%LVRD0)7H?I)P45N(SJH_-D0A?V6RQA
M57LFON4Y):E+9C/_=B\9#V;N]#&44QY(/T+RIAB6-#.B@<PTJP@7.[TE_HW;
M0[ :/'J2ZF[VZ!+.Z;V6<[Z=]$$I=W.$PH'*PI-RX'C"[:]Q4<H1TB&SBR+Y
M:I-T\EFLAG--21M\QQD%Q)(LZ:_0R1>.$ZY.F6)]KAOI+L5S)7Z#AC65*QB?
MMG,UMU&]]FT#=N07]GX:?YF-$Z5P"\."!(VB^9V5GBWA:V/^!/;;-I*OL>%8
M6.=;LL0(L+)O%>^'RIE4Y%3E/MF0 )WK QD6'-8KMV"DOOQ>'M]PJ 9&059<
M GSJXWP0_IKEW&O3YWG<:M3. \6YC*KKF53 XADK<D37NO69,)YB37O1U?<A
M.T$*)R!B8U"&'LEOLG VJZP(">![ T@#/:B*[N-^-F0S.$#<-N3M\7^UF K6
MN(?]HK;BV:T$VF-0,289BJ,B/\5+7>C]27F0B1/3&16WH;LB/JI<!]V)F-;M
M*Y!CND#QAJ0_EK.K:G(E,-:@/I)5:,*$V49=V+=7FSNV[S4^C/3;/.E[(P::
MYE^X"=ZJBM-6-:&3 !(:1M@!UP9\FIIP@4.-;</CRM:*&VQ[E=RN8<%?690$
M*JXAU_]  8-3Y%(Y IE/I_*PG-H9#\LAD5:C\X_8BLP *]P/[G9V/UP5- %G
M3M"O&5'%C!08D1I[-DBL065&2'BYOK%* IS;7X(U2'R)+<]3;WZHAE8*HET>
M6S&[4)26@*UMY(S+4*_<47WDQ8>OGU*4CS]%F2H^?+D_^'3T^>C-7WX_.QZ\
M/_GMY.R(.E9\YW+#$SIV B4L&ZSA:YC "&]PK!^ \!T&-L<8?<0;QMU^7"A_
M^-.S7W>&N^CUSH#H*:R[\*>TLWJ]LM3ZWCIAO:L(S9QR9:VG_T)UR8.CN@;5
M:.":I(/#[I1BSXF'D?EPM')&UE+KW 6=<(IYM!R2WV\L.=^PK.TQ$^I-6C/V
M>GL&*!5RJ&'07 .):G7A^PAD0<=9+=*F$DUQ=V7R<8T=8D?"=6\T(YQ86&@A
M28QRF._JOY"2ED@/Q+8H(;9)=$N=5;S$AF_TN!TCA,Y.;@GA^>[.X>YN2#D)
ML>H((TOH1$4BMMZ31<CFM1 !Q$CO+?*O:K9B$JGI!.VVNN+=>5MX5]P:,E%4
M+G&@K^5T.;WU'$AVA_+PK@EIUC]?-G(L>7%3DK!VJ[^_Z>HCB[9)HA6Q%\]>
M'PT\3LN>[=;'B%0AYA-LY_\1#:?FHF9!V\Y'*J4-!'\76#! CM=*=7!W"6-,
M@A>%E ;T^..KJAQ)]MKKOJ[A]9"(D!.%K,J6</G:$U05!$D'\I-BUEARL7C'
MLIAEJOV!8DWL.9]95]MW\3DO%M>8F?*8?8X*=W#FIMCC2C>M(J?"7#?(LKD4
M&#4DPKDX;US6S8)^A:Z,WQD-P0'&0#=@Q_>!DE_1X<2X#'6K:;0\=+Q$EX+B
MWK+[^$J^^S%VL>+E0"(W@?"?^QY?%=\1PWJ'$;; "'=XULIVT6L?RO>^5LZT
MCLGJ .@]<1"_VA_\>OSA^//1^\&GSQ__>G+Z$,;LNMC#J]X4Q&^=FIWD[OEH
MF7Y&M74O88</E<VCS*QV]L2I 16>(4@W"$3P]R/KT_T6_'8FFC5VO(]-8)T&
M0GOYU<(!'M-OQ-K)M\BMJ.(?0H4V_J$T?62Z4_Y?/7J-C#C7Z[*J#0M3%X>X
MM'2LTH08Y"08%:^OLFH-'LQTEX80&-?7>2_>;!=((T4D9$ET\ 4S"T.+3M7L
MYM&K57M$[I#R9M)>4N0+);J8(KEIKR3HW7K-(95O6+[9Y23E4JU_?D/BH#0I
MHR55S$-XK"D79K;Z>F=)3"K,L(:.@V0Z&QN(Y7VB:#CS7:8(Y2J$[L$_U?)8
M$>8[9T:+N3.Z&&03BK1_$3\9,;MDC8D/H"8"<6"HC9?,T*8;[](W:7*:5@[P
M")[G-QHS'G)B98T6PL?VX++BP<(Y@:Q0/=J#D)W[8 V5;$4H#(QK"[X)LX+/
MXJWE!EY=4W<F-M'X !H26MM[-4Y16U:VGKITZV+=KWJ7MW^H9DCVT&#0TD[^
M?FX=TR$W'U7S1:QKI%NNL\BF9=.EBF(B#"M>F!>!E/$5Y=SBF\J=)-#=:M9,
MPE"_OZ/0(8FOB0[*!Q QF Y3IRR80 DRW5?1!9%;OV:'J\;M[YCAQVA17C3F
MP*8DF*V(Q] ]A^7UMD4-QZU*AJEOP2$KA\M)7MMO[:XAMR -4M86=^<;G"KO
M^_;E?U[UKIW\FVFN<0;MH>Z](43+S&DSW61)KYU<<<0C8US'^[<4UB2&$56>
M(VHZ8KU!;6N0#;@#]:0:DLD$X7KGY'.++/M$&Z:(V3')B\,&)=!L-<5C;EP2
M-6ZH23I&R#KKW'T/@]JCJ2SY<Y*C/4T.'Y;E9%T$_'$FWA"([4,QW4**&232
MJ_YC<D*9&85U*,GM?LP9H\-G3QFCQY\Q<L\6U< 4*/F-UH>$K%3]E)8WTP;*
M_V$>0#!A=;:(ZE[Q\*9Q-BH53SUKV&7Q$;8?DK>,A9>RYOS2>M+%?%K8BCOJ
M=+.RM,/W?; Q:;]X*X;GFW<BSZ1I$WJ[@6+3KNE\4F /Z=.0V(30^&H8K?.S
M:3!LBJ@RCQD<XPU,RT!G9919,"VDZKFU&6%D*^Y$1)TNL6)&T@"K)0T(>_C!
M;2"9]SRE4<"BU0_&-]6TL,?.][4H32=.SD?ND]>S5D:#G*V6S%5^'VQ]E[4+
MP#W3U%&[6:S6,:T\,_#R1*/9-)$.]7WIM67)4IAU$F5@8E0,8SL"L&*!O^=?
M8\.C%%/$O\W=V#YK!.6*.>.'H?9QPI#AT"=_R(H-WPX4CT>PQ#P-S=%T:AC)
M*20;V DQ1A/R$M6%]%K*3!=ZB/N,EQ.W,1,;5E8XH_.CP)>P3-\D3)('7---
M+U8VBF/43ARR GVMUF!5 @;REE&8K3'<HOA_;)?>>,/4=J!=5W7'-T?$I@D+
M ;M"=7CTR>ZUTR+-%><=8S[E#'<!UFN)37KX^%AC/CJ+<33/JD^[54KK:/&J
M?78(1ZX^=I*?O^\.A2;\JGW8'_RENBZP>!;!]S[8=T0P!R0XA+@H1KE^GX]Z
M9>(/GQV\VGOV6HXLPMOU4 "7/T6\#:782A9+4$[NN$TB=O[A954U"I;+@6/$
M^'. [J!R9'O!Y49\N.>\2,WJ"T- GA=8"F?JMXU0M.5*!:I#*>T@76Q\44S)
MTK0MC4JJ16WT"A!-HF_P+VUWQ&RT;CU6EK5;HRL\ATY'V$XRN]L8MNA=(953
MJO#;1BO.^'-N]9=TZ(;\'ILUZLH4.=D94U&-V]-22IZ0KXU^F#'I<[)3QK3(
M9QPG6-F!Q%#5;7&MVZO>Q1AO*%BY@5VQ8>SI=]_2#7(*;M;&Z.7#Q=1+NE?A
M?COU L?I\-G/BKG%GP]^YJV$O6M]),&_L2]?V[[MZHL7)RC+)RU6N)_JPUQE
MO"/U!0H4=C,7M<?X9,QJ<&F*[>X(O5##%L_ZJ%RCT+<H*-_&D_=CWW2()V?^
M%7M/W\M>_BVR<ZXKL#/0E0HR\>APN6.#,7ILSAV2K*-?/UE"3UKXJU3RPSW9
M#)<3")Q<%-2FM/6]<0$7MW[">^ZL#T0+;.-N_M1S-T_!R&, S[ULY,F:BZGC
M2C2'B@QI<*DNR#A>SHJ9V\QA(5VE",NPI!J&27XM8 =KMY"H&&B.+YRR(]+4
M;0K+T=!B,?V:'42"$HE20*A:,D7NM4@3A;TM>I:&T>T4ME'.7O?M&X[E^+#P
M[_/K>TL6!47=)5H(Y,QR"U8)>JT@"\CD'I!<Z&P49.S;.TV2):T7$:FS8%*2
MM\4$JG_!%^&<;CX3Y,W8>0<++AFJ&-<#LHM^$#AGM=-%Y7S"+L:48#G&! %P
MP-"8013EXY'FK;3QFF4Q3!>20882[)S2LS*[QR.8!\]Z2N8[=K7_TTRHKWVB
MLA=ACL-6!]+&W(?W@<"F+O.)E/P[;[+-4X;-4-6FH!ZS4(,FUU.$J0R>&]/$
M2#VCW36J?2SY:;_/2@(]ND<T:]#0/AR!??[2K?$ 9.,-*UN2R46W9&CI(D3F
M5QZW4[;K&*8ZLJ#^O;*MU;DN8^I&!7^3NEDVU2G<XF0[&\PK=QPQH#-<-DY&
M.7@PSH=P-5)=/5@#OOVI[4QX=AD7^1+40=,)/6(C[KCMS=W3&FUGY;[J# ^J
MKX=5F\\G@O6N"'CH?AII=:*VS\://^I$Z<%3HO0/D2BUQ=?<?B@RMVSW@'%E
M>Y^+"N-4#Z!T ET!G[S3H<KLD<I6'J;4/++!I81(?61&>SM9D]<TETH[E"U4
M7; NF6TOCW\=1MSN.'2RE+76@[2L>=_P1D,+5#I@4IUA6#O93&DK[_@#9TU2
M6P@Q%J7-HG4ON+=?-42KQ_)C^*NQ(<#EA$&ZB #2EA/&>#N>74!U!UF)W-S%
M?%-Z;($'HQP-6D[&7Y9/9<$O]6WR#.9PA3IT8GF#>VM_\ O5+LP7N6&+,_GU
M3XA9*^<0O 4SLP39XEAVC34J FEUVUN132AKTV:IH4@6MF@&C( MJ-&E6$,>
MV[) $[T[1H/K'%E-*;?F6[^/?=!?,BX03]$T2P S=A]L[&0"3TK6=RL%N2\6
M%<N>^F=(?_RYIP\%)53WZY5A1].%ZJE5M5Q1"9]F7@&E I8/$I*:%HA*WRJY
MC[A#M9'!-'(<KA,V[XK:AQQF-,S2._7Q4(G-6B&%(\6$!X%@T?Z +83'\!\;
M9T0O]D#Y<RT<T3 "@;6II$T7Q'4VYNNJJL,;) 8B"O9<W4J:#T9/D]3<233^
MBJV%SW"$FSBAJ,I0 MJ^-37JR/;JQET"-ZC "(7(-F&CVD=; +;(OS+R>(8_
MN&UPC@G60'35(RHDOZ-]O;2;A"?ZHN^N#XM:3:ZO\J'W\2+*KWM3MP:7$2-Z
MNM6+0=3HI7]:0-6:WQ2IL0D+'95&F8L/L;31S;FN(!V+_I)VK-U\T/EL!L@=
M:J$^WFB8.V%%O7Y^Y$[()7)Z.AM^4A;UW1.9&U-7OB.["Z#ER>(BT P7<0XI
ME.J(AUGAOI*&'EY"R2%$ ?ZY6A]T2/4LE$$&W!E4!SC\A*O2K1%F[!400'_M
MHZ557ER@GM4:T60C.IOJYA8S"8["=OL2)H^DMM<V$H(F\8K)=$W$VGE,8R.T
M3A.HJ!85Y^FAX.. 6ZNQ$ UJ;K1O@#!'56/1@I%]PP^S;%/1XX@KD*-S<&GX
MOK08GA'6GM0+0@9DDH,S )0NW1I\+B"1@L]BL5C??V$?)&?O^4ZYN_-26&&I
M=)F:E5XP,@E?;OPHO-]*WR$!A[*+>%25ZCM)L^R14.J:W6:A\UW+,4T4WRLI
M;F6\MSLDB&04I4_TX@SR1$CK* ]*?Y6/!':$]!T&$)&+5DS38)_>UL?2,T=:
MO6@Z[EF@,-W5/K_T56E2$FH0!2&O7P?[:GRR!.IFF_-]$Y7T_97TFL;$,U.>
M)6=JUD(F!8#3FZ@2$5TZJD'7XL1:MIV.;]-HF052N& Y!!@FL.YHF]Q(\7#(
MV))6Z:E!QU6\,HD.K%4T(_<=S[=GAZ$!WG"T6^EU]:UV\E1WL.CO9>J;EY-/
M"\&8K5UIH(HI?3<G+RT8W[9'5.A]?4>)9$515+G>D7N]D\F=$+,L09V!\XY3
M##.AHN-";6J4 <09A5N/<83&[WSL^N5LE[J*I] L.']@:U^K<>+C/JK@NS2J
MWHLP)^=2KR&/4L>#UQ-B=--"]L/F1=P)BEI4HM<*I!_4@YJ=E-T,E4;-M=S^
M=:B[\G*"7(/66O1 8<J*&]PO1J55B8@J.3R$ 9)&"5X1*)S7KU^'I<@ZK)1$
M<M!*G)],\F,/"R@_4$1Y"W"'VTZK2GXL3E9U.R7RW'%=7/8AG#%>RGI>@EMH
MSSNF8=KKA?_^$]!9EL,?_OS_?D;H DO_)XA<GF R X77N9GOB_%B\(L[ E_^
M/]6SCSDI=?B4E'K\2:G6,M@1XAA^^//1S)GM@[_$9\Z\Y=#+:J?H]A/5]FP2
MB_L_W/*74^<]U,/_^.'BQ8^O7KWZZ>+9L\6S@_V_SR]^ +?J/WYX__'7CS^$
M6_!B__#%R\.?W#:PZ#S;?_[3\U<O?BQG("O?7ZD,RM%__%!74YK"_WYY^,.?
M_W,Y*VBA#I]G@\-GAR_N>5@__/FW_S.?SG\^,C8"*_5[U2H__)D-E/'@K;ML
MAXN*B!GN^Z7%9%)<+0MGMHZ+P>FP)/3#T=!=^4SM\J:JY_=]P_SPY[=.30U.
MR[JY35?7C=[TQAEEU1 :G;CK^&0&OBE>O$<C9\1"(<2;:C\;O%^,]@<['&Q9
MVUD%GLB7&$=5=GU3HRG4P2P\5D<$;!@+6$("=DR(?,TH6G(;#\@]N/=V]YSY
M+^^/WD2OR6S*#6%%HP)RZNBPSLN9>+G)A4CT'D%34"MLWH1=*'S#O@Y>DX^G
MGP=_H:*69O.-==\.9R?^0T^Y"$C/=1\D2 OWZ'1.F6'J.^<\>8JEV%BB&(2P
MUFH)IN:Y@:R<^>??98*_"!FXF^DY.YSQ;..<Q1&C$6 FGPOFO4H]R$!LZ?C\
MEM\,]!8HOA;#)1ZJ>'DV7(K5KXYFLR^M,3!81< ,1)U#018U1:.TG-!%*2B.
M*W$ N0:\GPHPF(HXK!['_2O@,^-?8&3QLG"&P^40Y%+*PH;\=_>GT3^6>4WI
M4#>!TVKICNI_.6LU'RP7SBOY)U54KHT/K_T ;^)?EN=[;G/W3N?5EX)W0[T&
M\L>4F7[J?,X)*0\P+&K>+0B#CZM)">3]L_R"6:J+?#K88=PEM]+A6>ZZW]78
MM8[2',1/"DPQ[L3-604U^B'WWZ*P/7C U\$<H3 4N?,-7/[8H;>L%@7\TLGK
MM!CAO^FU)6$/[8*Z>^0:*/T)]7/J)O;/HG:.T^@!V")C+^"^+^L##%8+'IKB
M(1SCN&?+Z'#?W8]NG^5RAMI.%*^/?(G=\_N?$[+-:.HX8_:]1_1B'W5K=,X(
MF#N%[ &(AI?B>Q[-R_WV G28#\;(>U.7B(&^[]&]ZC^Z@!VBR]+I=C9_VM39
M_!__UP)WBA_UR\?/;X\_[[WY^/[]T:?3XS_)/U9KAG@USJO:C?5/STSHX0>G
M?2>3.40L9Q?_\<,S^AFT._^,0]%@AHE[E#CS/R$0@SXUBCS7?_OYJ@ <6SYA
M#])-'1Q=]\__^ &B!^L#_!J>__?%B-]AOR_?3+S';L0@7/K!O08@:&*K]"%.
MQOU/#?\#N_P='"GP<V:8HVJ8.""P;+7H0 ?*!D^BDXQ"H1948(+:3O*3=0$W
M..H;?"6 :SVE/1,73C%1;Q.'"/\ O<6OG>?-8I^.P]\*LL]@])A7L*.$0'^9
M-\G0M S-S6TA"1L_0C:AD1T0;W/H_@3<*2?M,C W_NIB1O9)78T+)&QTPRC<
M X=<:!'\8<Q)-'QAPZ@6;<2'S N8^05Z#MH@Q;A(8S6*S%-'\DJ92UOMD<W-
M$Z8)>=\E)</=A&##JYL"F1$P,>WE0>%?T.UM-HR% 2SW#+?(/W&!Y7&\[( '
M4,.*F6=SA7CN/^G&;ZP;#Q^M;EQOL7U7#7EF@APA+PGDU)SX%XR#X".E81-(
MR]'8.T(F_FG4L.'ZLH"SF<5L3]('M&<4A77D60AE@L$PF9 YPJ RY70*1=KR
MW%U+K>"$NN9N<'-.?J9LLJ!#3#&IKG=-I_)J60^^.*]P4HPN=(L!K'>SURP@
MO32!D%8C(:TILK#L#_XFM9#"AB,+2AZZ%)*QFQF+#'N:W\?[;AN,4"90$PDW
M<5-W" &#GL]O",_JJP<TZ1W$E/U^C$9.Q2)(AZBO"R-XK5M@M0AT[^_C3>O]
M9>^IU.P/D-5SSQ8=<W>%TG52B0:O::M>.!BLW]E.LVCS)7%CH3G7>BPI<R@U
M C.3>CPJ$#ANL,;,)1I\C"'$#Z3$1E5!L_8Y@9O!5>F^!>@(/U'/LDD=&VKI
M-L ]I $:K[R%J,$8APOUM&X%1A'-_7FA)/F$L/!M(P9T!,F,7'"=_ KS]^'4
M/Q9*D:" N(Y+Y*X<.S4_!]NK(;7KEQ@PE[4TZ5K?-6PRV2NEV;)A7:,.)$B#
M@Y!56I!RADUY!)*[\K*'/<$R:^KA7/D9N9'CE4/P:W*@V/&3<A-D\L@$?XNP
MRD7^-:.CN  R]@S]APGPM $_'U1W%S6W&*)*4/2H=)7@\XA!%>K3RA[]\^*F
MFK$A1N7=SLMPUR%[-"-NSC1MN'OIJ.W! B,78%W@7()CQ9)$T[Y=<>0W/'E\
MS>.8$7XVN<$@M Q_Y):L4:AIA9R)&IX*W$!V%Z=NI@LU$9*9B[SAJ&"1A'?;
M;K=.K5V411.*LF\%AMW_($580!J5AXD<B8"4%<G#X'C W$\-/X#8_^'.KZ]@
M (:V,'S;H*]"9I/3/O,8(R8&*K+%3]#MG06',#\'"#WXS:08^<PB81SB^"95
MA0TH?;5R%KP+:6K<*D^Q4C(5Z'#2\'>R/Z5_F.P;IT(8:>C[=5$NTM<(6[>=
MYPJ1'E;E4AK;4%&M/SHUM4D..%:%T0'.)NSUD$0);DC2 QC2H+XT3NS*H?R9
MQTX])/'O],G]P1%]4?YR74[@*?6-+\KE%=#U(HKZ',@D\'?,\B51+E1W=<'!
M#_X,3$#- UK8',H \N&-KSLQ>^3W!*>B T#CH^9PS^!BF0MGY65NT8=-$>PJ
M=_,A.I#5.:-O=!92I@RXD<MZ5C:7K/I1&35J>+4=VQTF1QOF$!99W$@OH=VN
M0'IP8Y]H;W6Z#"%+FPV&90W].K#H\Q_+"O\+NP77R2AJFE1+'8)[P Z'OGA(
M< W5Q8(97BG_!SR;]7S!9!S3*8K\;@=K@2^%)E9QZ,[DS&_4>HSL)Y/Q_K?K
M)+68B1UT0^9P*8HR]R\$0PX)K/+)3<-'O)S!/8X'OM$O<1&6)Z!'96"(64P;
M)=BD:8,5['!&I\ M*T7VD$/7H;2P0G[FK_X%0W\O_\W/2 -WP2>>]P@.8LSC
M5><C#I*/:+_W7@.&/9>_%1_\C );$(8&XAAH/.*5M_36*\%-WA7GM5.Q-S2S
MUX@[>;X)LN23/CG&Q  Q<3FQ5M;OG)(XW1^<%NYJ(.0 G)%CP02A9N2&3K-H
M= <"B]EYYYZ[WO+_4/'[GC]_OG?XZL7+US_N"IYB?9CTZ90]G;)5IZR64W;T
M3@W!=FS7&)=8WK9DWL2OD+LK!%ZP4W_X]%>^7TJ^3_\*1 [3GY\$]4E0O[V@
MWEHJW^;@W#J7[4DPGP3S6PGFKY?EQ#D=IJT"XK-56M^^>:=BB(+J76B25)#,
MS[^] >SS1M!G]YW(:GD2ZR>Q_E9B;0"#'$8F%M#R"CEH]K GBJ"-5;Z5!R<J
MI-"8P9.(/HGHG46T*?)Z>"F\7R![_T1C8(B5"(5S&2'&=%4RN(LR 64UO\SK
M:<XIFIURO]BGLNM%!EV$R@5P3B'D>P@1D,Q)]V22N]WGC(0[ V!@X N<0>$Q
MX[[52F7H6S(#M$4.J1"42U'8I^/P=!SNZ3A(O)M0A<S=#CT4&_Q,=8'1%,J9
MNX^/ZJ7[C?12?A+E)U%^0.,C$.11OL@'=55-&X(MSQ:<JKG*RXETD' "F$EZ
MC7E'D'E)3)0,?T!QAI1?V61!HLY0RMH<]LFG+!)V.@H%U TAJ_YLU SS>9$-
M/J.E\Q:'[N%7<2YO*+5IG"850A.(9SX=H*<#=,<#A)AM,>#=8  ?0I1%IKV<
M5M9Q42HQO E3EHA[9BKH,B/1EN&?V@)@!%U+7#&]M C3RD^2_239=Y3L(>.A
MD6(5W%'HJ:<7@!=/96(7\3=UVD+?:ODFS[WY_C/*[I.D/DGJ72458#?2U%8:
MU#4+3<*741(^XRS\[1/P'4+[2!'=3SQ-?PA$M]3N(31N1/5NBJ4#+(\ ;"S_
M"/2:'R-N3 HD!(>567Y$*6F>.-]5\)TY$5?GF2]HU,;=UM97D%.$)HJ<"D!^
MNZ,)S9&6B(9%) # GL5+<6X'? *95.,K*6.L)*$[<<;<&J&9PU7&W)O);M#A
M).A)K6E0K2)S#2+<AM^B/:KLG+%12DEC;EN ^H+& ^/ "[,K7HS'C%L6COP^
M*,+[!T=]$RG+%T\XI:=K?J-KGF@W(Q0IMD&I ?-9%JJ3I,J80VIKB'2DT:1$
M)'PS%+(9?.\_K,*N.?L]K&HH'WORM)X$^XZ"74 39I#9FYX2B_CE\7+"7<ZA
M?&=R(XAS6YXRK*X*YZ>Q*"N?:A-46T&=*WV5;BN\$7$X3[+])-MWE&T01A/
M\O5YJVK+%*!/C,LEFX)@4V#/*_3(H)#P24"?!/0;6!4IT5,1Y0;&HF7=0V=4
M])#H7KU&<3^)ZY.X?B]Q93FE DYLR4;(#+)T.8. <HM=@CSK^K@ $@SB,"-Z
M?_C?);8XAD;;W)J]UKXWS5,8]TFTOY&I0%WE05="&(9EK*IO;$B&Z\$:'ZR]
M LR%#^)*)5U?*Z,Z9XZ 7"J>9Q!SF>0WF>G*R3UN:^X$GC&IEU@V\C#N0=YJ
M-HU-OCD @O5P9,DP1X+I<L?]8J3#;]5FGZFP5Q*$D<S7SFV+=*J,UP(TH<:*
MR]<ZP]CW7EH'\7K*?Y9204Y]3:^5?FQ!1-&&% A(2K]PG$\_!,M'/5KFES<-
M"#"X[/-"E\I&H4!:\K*A.&5ABM+'ME&%0'"XA![S!>[STK\'%.G.N/R*M9.5
ML(ME RAUO\+RVVQ]L5$U'N^=YQ.P'O::RZ)8&*H!#9#N2KB06[BV^+Y\#26X
M:QG2CV'3V6O3()&4_(P=NZXE@%+-^8)Z34E'SOS<'4>D"\+EQF0(U)=CD[E@
M727+P@LYK["K!;V$"Y%AY81JP!_L@531NU-##;N6,^V ,ISDY;3Q,67#Y68V
M(_-=][K6*B=BB_^?O7=K;AM)V@;O_2L0ZG:'_"Y$$^!9ZE:$+$MN?V-;6MG=
M,Q,;>P&1D(@Q17  T++>B_WM6YE5!8 G'0D0(!Y'1TOB <AZD)65YU1UR8XR
MMHFVF3=4,;KT4LN5I 72;,.$9*W/)7S==&?O^OU+SD15_2KB"EVQ#SU9YC[V
MQZGYK]2K*9X>QVEL7!:<I&U&:OA)4MN[U*^>:L&\9, LG1LC&LTZIY8L/D)&
M[IKG>E._:9;'R@&8SBCU9IH9+Z":0@R]])[52Z]1VEYZ]W8?7E;BOY'V>C.]
M1F?(30];>H2CT>-R=3G\]MXA%.OK&+*J(9_6K[@E7^B/7&YX8=A-L]FV3-MJ
MID:04F,46BU/(M4%S-S>8D MCWZUZK5ZG=,3^3LUGH:@,K:$Y22>'(W$%G^T
MZZ_GIJAQ786XMIQRRD2Q6Y4X()E4P(TZ%3VRZ^C(#SE)\FHYY$^IH-;#ZEF!
M^IKJ-+104:WF(J0:$7&^F50[7KPPJ5[)9E'_QQFG"J^Y[KJ=Z@)/4QS<@"<R
M4O.J:?2VSUYJE:?)E2W:\SPWP&&&K"? ](AR[_'>)(VEUL >@E2V9DW:L([N
M5-WX"?GQY="*9<1K#M9H)BT_S@6"7_E[,SQOZB;[X;VM*KG!3U( I)_G*<<'
MWGLCG@@A+W_$$[AEO[95EY.MMU5:>M+7Z0%)$;A7(W8IT&<?Q%ZH#WN+XS9T
M^UVE\UY)X^XG-VT12_G5;C9K;0FUD!\C-F#N6XD7IMMX)C(C$10L&&8>DMHS
M<4,94C;\L8K<ZV''"TI=?^:^#L^-C9:8G+52]WUL($LHORPA:(KTA)JEU11)
MA+U;G IQG!1Y'L],A<A5263YRA:.= J78R2-DJ?S@W?D(>G?ZH(/G^=MA\\=
M+",^-#-.YMMP9H)-0IXZIUCVAS(=?[8[:G*/@2O4!.I\*(D1IX<S<:>"8Y43
MD\ABUY7X(%G2G#QV1V/ Z;A2#>TU<-F;^4?AW$KF()>-Z96#*9QY>D(6D]XT
M]";*K []:="7OHY9UT8_\&7[18T%.34<\N8(ZMTH[F:GTWSHL8W%<4!M$;.'
M@#/MK&[]()2\Y\G'&7C<N_ J5=RJJI<XVYB H REL3L-Z$^>QR541-56,)X&
MP$R?I-#+DD!3-OG4;*I<F8-I&-'@)&K;*9]&/IT;I=''/EIY#@V%"2B4J)O8
M<+CQ0VY@*^PEVJ*J9CVI8@^3L.C+Y<M0"9:0!,N\1%'[6PD4%@>WKG2$ZL12
M;\ E9NDFAHM%#9I7=T.7$KYUDAFWYN'O,!1OLL>?J;'VR=2Q>JV#S\P?B]!F
M#.N,H%Z8791:T9-GNVKE9D[56%!%UJK\I%3&6 ^29.[7M=K%>E<@U:_YV%KG
M-4^ 3;\SIW;(U>H;T<>77:>QINO8):5G/60T[UT.*U*/45R-1_,0VUZ/6-W*
M*.]C/Z[T6SW_5WU;LJS>4%:M3GJLL&G%$GZI\[]Y95O?X-%6HC4KJ+HO48*U
M673A>^16CS7<QR.RW;B\"[S!M?O.\Y^!S+9B<DP_P] !)#$DI\+:H% ;]L\<
M,%^\F\LI8)F'Y7P:N-^$+CSK45!JS=J.0JO^T%F8=O3$'K+[73VG_I1'<AB[
M?_[?;Q:]/FLY<Y>19=>MYN^7P=O#W7=.2.TF4M;_FY<RUY/(:$DRSIV1;QR-
M(M\TCL6'KOQ@[#E/I>29--AU8_?8N;GDT\DT/CM"'/>'T]"-HC G$NIM"0-Q
MWK_]X+MIZ-]R?1KUWOJ0>!DA+6/WG3"U*1ZTA(I%33>U3Q>VJ?*@M\4;;U>^
M0VVX:/O]L6.7_E,9& +92#_I#(JCD'GLM7/V@.3'R\^ZWS;>Z27WD^T@-_+0
M(&JV0]3H&O4<1<T#)!W+"((FZ/X/&X_[F X/79%>Z0X.XE0.6L25%X11.JRS
M>_33)T?%&SW0\</7?QA._[]3+_0D5GEMN,U#I1W E%Y5MSK2UQQ2X^^9$$X>
M?//9#:[E,&FKKEOAQO[^.+Z6!R6GLCZ6N>/8#_RQ,_"-=YZO8V2F'% [BMLE
M)2&B*O+.Y9WQ][%Q%(V<T/A;W)9F3<ER>B/T!#H^M[_4@5'*?^H/ Y_L/S<H
M&E[&BC7RON &<&/9>)"&>(D%JD6I4NU(%E./.9L,I^BVG*(G]"F.!XL[]>-Q
M-@4X3-]S71$G[SV/J.Q(NW "5U[]VAV[%/,?" "=T-TB] I)%$A+2(, W@H!
M/)M<E^%>?3B+XN-X3[6JU\< SYR?50OF$Z ^"2TA<&B@IVPWZ$9DA[!B2WGA
M4CWR0FKA0O6OEU-/YF M7(G=I=]8(19D7KJZ;?[ H(89W"LMZ ]YZ"J/?U7Y
M9-EM4W)2W,B1I ]"YRU")^"X#IR;4%EB?6?@WGB.P"O.+ O<@4NI5*'N[BR+
MU=648S+L(N?JBL!R>$[B EKQ"-JTJC9VW4$FIL3A46)'\FQ30=G(W9.ML<7S
MV9LXT?#6N4LE#!Y1*CT]+6XSX8XH55-\DAAC1.EQE+8TC?RQ?^-/YVH&SY/!
MLWMRG3%(HY'?5QWY"-ITWMZ5T&RS6?PI:4<2[<=S0ZH<0VT@O@Q=A*<>!_2D
M!0A<DBHK>QY1=#OR;_?Z?AB9^MI#(4_VK@/_-AKNQ36KIM$?>6->AIQYKR@X
M$5MZ3%/!8WU>\*+D)UF'J#F5*QVS-_X.*8%X*I/4R$@9BIMSKN"LZ)!5%%2:
M\G6^M%3F&]*J([TSN.:2TCTYWXUSTCEWT]';,L/U/$=8Q'+6=8+1W>P#6YN$
M-?X4P/H!T3NZ,V.C=9"R^69+L\>CNP-#4&T,6>).O(DK6(H*7F7JH0"?2H'I
M.DORODM:'M)$>8BZ<H[E(:7*H.P5+&.Q:)F8+\R@?"(9*S,H[3B#<LUY(TBA
M1 HE4BB10HD4RB( @Q3*)Z10EL A=IPRY^.ZN]S\8HOT?$[*-U,CNL@I$X^*
MU%;<N_>RP"VB<(J>ZT5%D-0 _TRWXA%6GGHM+R/T18M:0K=QD32^>MY2BOYD
M2K?"1T;!TSB4@?L>N:RR[JW[V!)!GNT)\L0NRSOV3O[/>$JC]7(,S%K-_,*9
M_Y_=RF5)]4+>Y27 M?[G?_*[6Q<"9HL$3$1-4*Z]/LN7O#-YOAV%)M_XQA\X
MJBFH'_ KU+V/XGCAKC?NCVK\VH,!DC'U-%-A)[D(^IHS^(_XD#A*W3PK5SZH
M#!^UGH "3BK;1X::Q!G//\6G5%N/7;=V79. <*.)/@4Q@WP*C_ZD4"!'$F4\
M_8C;MQ+5_+>FG!/Z^)7I^,:50>.<."6_1W?L3$-G)..!W(R%0ES\)P5,1_(L
MG@34/5A\0[XQ%;MU!JG\R'T7.-YX[W$[Q+NYF8[=O>MIE-XAN^\^?GC#OW$Z
MYY7XAERC$PT5;T+H;X_0/[M5T?L<1?UG[Z?L?<GE-$K^Z93VHM</%?U6I08W
MTW7+,-[OV;>4V_W*#L=]XU/MI/8/[L0Y'7&+6M4:[MM:^D#--)B;:UCTF1(!
M]XVCL7&B6[^]B]MT?0O<\2#NXUJE9MQITRC]QGV>FBQ[)RZT2OPH%-PI-9)3
M>56I/#@>TTRMB,5/<1*/N/D]=^WE]"__=LQ3GU.Y-ZL&,U?D61?^89^$D2?'
M%,5)F-&0^DS//,6Q'ZG^R#)*11\[]H-(8*EF>4>W?CR,EYV7"]^F7$&5R!?1
M6)2P=NW_V&+^L!_!'W\?__%#5F,5G4]4TJIIO'O_1]R)+I6N:QK?COZ8[Q[Y
MI$ZJ:TB$HR[BD3CSSJ:!:N*8:M*7FHHBI_50,J <GW+C_(?'6E^Y@6RP&7<E
MI.FV3D #..E,IYG95$K'9VHM=:CFT@!3=;B>^M.0\HU#8=21!<P]Y%WJ_:C2
MEFF;\@Q3H8K0[(RD16I*D,<#JDT2YG):]MC_(=.1.;=47SUI&B],3+V#96M7
M_4<Z;5M\EP8_L9IAV0>&QZ>)'"XD+Y64Z U^D$=!LD\ZB=<TPHD R[^Z$K]^
MYG#"D1$%-)E)&,*N'"/D\4 ;5=PI/NH&XB:AL?OQ_"Q\DT]3SCP;/NK^M@)/
M/Q"/E'L%R^<>4$ F9ELE4&9R\2^]:T,I7BRL[R8R>39I&GOICMTKXA;=!%\F
MQ9I+AN!0V2B[(&CZCD^-59-GC!GB,QK"0S/F6H\X(ZPW13\;OJI*C_]5_?8%
M@\CR ,P@O)<_K/J##/(8)6*;AQ *)=,U3N+0\JZP-]_L<P]P52UC" DZ,X>$
M9L?T_=BRY!""JRI52"J*(]"-I/==36 3/W7409QD?2\43+QWXWSG 3'C.)PM
MY9V<UZVLGC&?.:EX^.PHM:LKQPO4?,Y8:*OY5W3P43-S4I]YG(_LI2X6$_GZ
M/!4_W4DJL,Z=J!UQ?%(;<G+]"L+%:TXP"-58$/&A?N!%\H2F]MV/&"F(/8@]
M>.\>U!5C<7**4++8WQ.*K2A_X5)'7?#WORY7X,B)-:J-?+S58IU1VH F3168
M7M%,0MI*/.HO_N:29O1.W 5]Z-[P8$TY-D'H2&)SNU?B:]3^G?1CZO#.,SOE
M3"!LA#R4%;OPRLJ%2L44[!QY-UIG 7- 2KY,2IYHV6/$''84%_CNQR^F)*'V
MJ @)%OKC,?4ZG1FL<:<+R%6AL!#!6LHE4NV;TAKD<):T*I/,^A"&)[&?E-17
MNG#73^4:JLD8]XP@+FD19 M%D.K*F)$%0;<FDRR,]DZT#"('U;[Q[B[I7D#:
M&1?R4VD_-3*0 ]ICN:?L*6VRL/3B:?+3B 46FUT!66+I*\H9?\G5J"1<"C3R
M=NJJ<^U$C&]V?'$6FBF_)TG4P!U,:=ZF0'+H.F2:A7IZ/2=#T/O"JAKWH33F
MHS0V"J\TGH[<GQ[/"9>&Q5=!C*/^!HM HKY,HAX-G$FDV$DZM]2 0ND8NN+$
MQXF03 Y_D T6(?]X;"W)QCC4-9;QUUDW%#7.#X6RZ89S^J7T$B4QF+"6MN9)
M[QP,J(^+((:;=K%Q'K@W0G ...^2^AD-O#"83B)EDG/S$IJW&UP+>2MM*PA1
M[)"7[I"4O-TWCJ2O5'<!I7Y!Q-JIY(,9+G9#XA 9NQ6[1FR:@>"7L;CY)/#_
MPT.2284@E9A?E;LI[6NB#1@R!>*+LCU1S/^D1=P.W=&-W@$IOS0X/Q?UH5EX
M]>'""[\;J7(ZL 4$XLL$(G-4W%!3.YF$&19.!,:#V:B4'NYZ0\DJD]@59,Z(
M49*6-^+C/+@]$)<7ZL#',)S*D;S^6'W+&/B4SR4D)65YR*Z"#AN#J\Y_4XT
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M(YDKP1?@M;NLILA$5E7]:ZI?;+Z _+VAYG<;TH2BA*.0';C+=HL"\*^OZ1W
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M_9'?EPD=@>[@-CMD#?P+_ETK_Y[\E$/15/:7;#Q,5'$FOPH3<';#7U_?F]H
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M$1Z$?3&&@KX^C_AX)>N3@"-PW#0-P!$X%HD&X @<BT0#< 2.1:(!. +'(M$
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MTUE05!H(+$!@ X(&(&@"@A8@: ."#B#H H(>(+#6JAYF8^L_LT+]N1Z/3/P
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MO=7G64&SW<L.>M?L--!*)^>ZCJ8I;@O0<P?]'NL H&<%N@U.SQWT>B^'SHL
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M@&\)49--ZOV#P)<RK2>[$L2S\Y-_P:U9]"0X9.\#\"T'/!L%"("O!#P;9PX
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MCB+Q_#&'WI*S<EY?W>8<B&>!> N YPSX1L[.;&(C6U]I0C$4U)F4)_R(8#M
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MU,=Z#X--<@>]T06GYPYZNP-.SQWT7AM3'W,&O6=:$"_Y@][$?-.\06^:G3I
MS]DXZIG='L:RY6Z1UAN8^I@SZ'6SWH;*F"_H&V-TY(W!KXWX ' $CL 1. )'
MX @<-[V&(M  '(%CD6@ CL"Q2#0 Q[+DC6VJ>=G:^G+_]DO/:A]\<2/CU@^^
M>^-KH^],J!2R BEEH [4@3I0!^I ':@K,W6E+ K(K0'MEW\>OZY.[UE0!^I
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M:-OMJD/0:E9=+Z@W.U77#NO->N5/A$9K77K!HK6+#/NB1-^+0 ,R*8!CD6@
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M1N4T4>(1<^_#W;&[P>9:%Z6";V1D97D)YL<GA__!-W+OE-(@#IEL!^ #'_C
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M#G>XPQWN<(=[V[FS?F>_:A+W!J9KMX"[JBNM>]T"2MJL+B&U.F@@/!J..FF
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M6OR>C*_2P?8U,*/,2B^9=:L8*[NG5D][WNV5<DL]:7"@!SWH00]ZT(.^'O1
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M^T[KAEUO<X8?W,OB[KA=NYRXCP>YK_L';_QK]=?YUL5AMN'C1O9%@2,<Z]8
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M:3YD&=3C?L/'7]C%ZU$3_Z%S*+]K-Z]3&D !"E"  A2@  4H0 $*4( "%*
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MFW(H"DDW'>;( NF2B&K*Z#]ZV;%6*42ASKAD/4TC\> <(ZGC^9H"NWZ\?;I
MJ8>A!]]X5SD<&)AA2==V9D;G>&(\5H3"0.>I<$04?YCNRL271+.4O:#XYOA(
M#,8%V^&6_<C'+F F0=(/4O3%Q 4\R3--.NDKZ?;0<1G/VT_"+P$<? \ND.&/
MQX)$2-;LC"(M VRQR'J6LNC9,5RQ)S69'I<F4V?(L95&B'3F0^WEC\6HLY_/
M[U'*9IP:%?(.008\@5W=>/ ?LL4,Z21CZQOU7M054A)P+Y%"DF'T,/80>,H
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ME]B]5)1;QIX>V2_ *R*L>>D4"^S.!V5P9/@^)A;%ZRYLF[_+MUV$&A&4S?M
M5,X)XCZ''D<@@A/H/X=5*J:G:G24B1C=@UTWC44.LMEM_BL#_Z7+?5W?[Y]^
M_OSV]E;T>*OXXKQ^OG!;7?#-O,^\_6*XGX&SC,]:HU*JZ-7/(+HTK5G6]*I>
M+E5*NM;\W*[4:J5FM<W?RUJQZ_>F,/#E<##I=B@D=Q3'EJ2S&L5LD:>4W&:
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MP]](&_[OQCN;-@7[/0-::?EDT<:=>JVD@EAA3O..BXZ5D9& [1GL%ZG61<<
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M&0A,RB,Y]\Q;1@!..DHFTY;NHJF$D^G"!;[0?5AS 5_*>F.7@T@U/68[/C-
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M?1G,!=;J@  RI!G+6MBU@X<W)#5&K"+4EY,)+^)&3O1[,<DK&D/CM5AT\^+
M7P6!%? "2 !/Z)0V5[_#8U\=*^@)9+QXRL7:  8Y,B5@OH.$MAW+,ESV:EC!
MM!O>G,!J"RW&WUL<=5W7\-6">S/"%8.7'LL.P4!9F[^:<D0=U^F)]UG.&]+9
M!77" /!PWL"T-WM"\?6,=[,7].1[<<3"1H2/!ZA:%=>$6P %%J*V-,$_$_;[
M)!V41U#KK*)7P%IB9J<P83J%,A93YR5PQ$'U7;/%$]-M.\!2+AH$8-'JI<.1
M&0_'$CT['I5\TA@;H%K52V<CH<VAXYIN.!=7:6=,ZB1U:\S*DWGI3(P@^]4^
M+K!PHETT;9(K0LP7P(J3&.T%%8Y"A[5Q.";XC7@ALF _#N/!=RW+\6*.F"("
MT-](OEO-%+S)"UK=(5)F/FA,8))5,<^J^)I_JP)D60%7HF2[P 7E( 1AFP.[
MX'$3RM2P3./9M/!\$V%G3E"H!<8-X"?!5%-5C-<U9/RCC?MH0[_!8#:0.(5_
M76[)?IUJ;4P0T<K;D!W6\9I(VJ!(1X(2-QF^E. @=_D4>J32@LMAN3P[-N@V
MK%:.'JKT)+GN:U@BE_E?(FBR]1Q@8Z'+A[@4K,T>-VRQI7.&<8T+2.G[!"-*
MRSPV'Y1- 2_#8&2 /G%;<BMPI%B,D5Y,\OCTR."6UFO7J%X[^WKM'1<S5_D7
M,XMHXOE:&#68\(W5<7JN4LMC;L(TSP \FK[A^E*B+:"2A:$J)5&!.:@:I5,P
M^59TEZR!T,RV>FVY]!5MU,2M,:T\I-;$!\+HL> W<>=%88H&CX: Q\PGMGG/
ML)/E4<9X@?"K31_CE!W3!<<Y0"M;>N"1>+>YYQ5Q9Q]XR+Q=8%WG#5QVMR"-
M"_"/XB=C\ 5?/A5/&'YB?L0#S'@:9MOV\</;JH**#36=$+ZQ0&9Z+PK35K;5
MNNG#;%<!D45&B7E2^CR&-,'@"7'"I",B5^@DXD)0+DHT"05,EG$79D/X_#VG
M;78&@MWC5TKO'%X9 K/<N-Z,I8''UR.9,?X]@!O\?^#TD9&$$9MH1&1#KD&X
M7^^:<!_A/6"IA<5]''.3[LM0!&',!E722H@/X-0>=K@=\IV2OI:X=TH.(JE-
M9L21"^JD-PN$Y] 3W_ M&*?F?M=I2X&+BP;8:-1L#D,DL8(SQTQKD;M2SB%&
MP]&2#M=@#-60]1Z;Z!W'LIPWI*;E]'J!K8Z@\PJS  CS^H:@F;MC9 I5%%Z%
M&2_@>Y4Y$Y0*.G&XH_[J&-TY"<9?B @\*&5T3-RA:/RP7)W-.:/N?1S^',XM
M3K=:-A/)Q^%W7,Y9R+I#V8@I8P*\0+E(]8LV#WB0'.R7SAR,X%*Q(N"G4-HA
M*H,9-VT"%8QX(L\[;BANQ+(2EMW26*FZ8YF]FA W-9Z=P)^#&E;M))927UEK
MR\&_H?CQJ^0QB=Z0)(HLL-#V#H5^A)VP36:RQYA\FIE.7TO)P4V1H1Z,32*I
MN)XML\4PGA:KG1%IG@B18.0MU(6N$[QT<6&HZ$O,4S*0@@ E;+D92NEY$*93
M/4<4Z.!= WB,@P\9#E7:L<)2AFR8\P!5HNA'R23-,*U2/6H=2\TA&I"ZB3R]
MG$<AW!/C3XX#U85:!V.9-+!G4"*B4:%F.E%E,312D2H:33/$;_3P?CEV3XQ9
MI9S4N!/#]432",T\R8;. D1)_H6[>Y$F2-")=Z;/>3\KSN.B-U\"8-!C<I["
M%36N98 5C!?7Z'?9T8VZ>-B^YRW>ELZORU S)!XH##W7%SJ\Q[FOK#JAUU1A
M2V<L72WOGYBSENZL)Y4!S 2PAJWNEAZ5/<UZ\X+GO]7$Q\Q9P5,]HX)$,7(C
MN6;@<2,% M.=Y]"XP205/$U0B%VBE#T3/P?(CWSH,& ?&L?*,/8H ;%$ B+-
MA?-+$?=9.QW#1<XP1\YDQBD+IT5:W;)68:JSH@1+'R=6U)7!:-NP%EKRR%L8
MG]G" I9PVY$+EK@0B4HXC?M%PWY'HD) ZGI/VNUA>.G-]%26.UD^97BRJ-?
M%D%A?C_4J'V8AMASPI2ZRIH.0X&ZY@6DM.>'&JTO.X#"P_D[9LT3B=J)B[H@
M9Q4'4  $.0K5%D<AB7,@$]VO48##8"W+,'MB"D9I"0D1A";GYR@18Q.ZWQ@(
M!E>2.FDZ=9!J;GNB$* 5N,J1ZANFK&V/IBV:-5GL.CIG$Z9,@0#4M0"53@ ^
M*MBTME+CL-(-(=$PUF.&(1JLNX"''@N< 4I7A;!D4&5!4B8(S#D9F3%>D?&L
MP!;^ZSB+H+F)S?' CU-E$.*<\XC#/.[[:G? $'U"APA+!.0T+ T9+H,G*3G<
M!PC :L+@T=] J]<V6\H.Y$Q4AXL!=;F8WHG\"6^4 <V5N#34%2^XH]"6 Q&K
M#CQ "];/WT$[?&$H]X31HP35MB:DZI20RBXAE=;<PDP6V3)5M-)(]OJ.W9:_
MBI7F*9$;F[RAZ;A >#UA>8[N'%$660'-P&=P&/  %0?/<(N<%WQC(70X'!O\
MNP"T+0JBMB%B5RA%S+X?+3U%L3)*,)BFC),A2L.HM? "9%P:5(N'\7,PWJ+$
M##Q+E '"$'KP#A$W0SSEP#&_X@T[ LE=P_$[I)4)4LY#XF*]O5118^CZ1;D:
M,7@Q4PDS;6CC3)I&TG^*6.<EMO$,%JX(L*Q1N$!Q26.7(4-ZH18,+<J6;!2M
M=)314L$QTWYUK->D"1JE,= 4EYI6VO[+I<- G=BH,[#TOY>8H"V7Y0V2Y=LO
MRQ=IR<7,]D\'HF/NT^W/WRZ^__YX_?0142">C.:4_8$HWL.(>S+J^T^PL^!3
MK5DN3W13V@%(&+$3ISTKH!7NQI$Z#BU?E.XRTCD>%%2.1X!*2KP 9J_KN#!"
M^$H9F7KC"\BW<9ZL5P&12=DUO_OE,]QQ'NHF/'%6'EHS)H\3@.I+)CB17^,L
MYP9:#E;&.P[*53&IZ>#PRM)T;!^X>!M";5H;PGK<AG#-?0@7:I,Q2M4ZFI;.
M[DCX]?KN[OJ/WZ_9W>W--7NZO+W^=@EK^^+R?_U^^W3[_?;^&[N\?WQ0;0I7
MZ%*"_#BE38GX*A]]2@"0P>DXL$SQ^=?[[]_O?SLM%>O513LI3INKY9\HR/OL
M?6:_!O^P7P;@&K-?W@S[9<J<9 78-[!H)D"V&NO.:+&9K]%_-WTKT^%CPR=3
MQC<NNR;OL.MWT'G"(KY7$1LT3*]4'&="YQIIIDW6W'HE&X/B_.'^S^M'=G_#
M+H#_'[]=_Y6Y.?$G'Z]!B.*G L,HA HZ=^$3RY3KZV%Z1#AY6)[@FW[@R\T_
M1K_O@ \[NHA%H Y_@*OL!O)2RWC#B-Z0!)_$$H8ZO "@.,$M;Y+)X E*:C-8
M"\@O(DH'3[3 E5+G'J#S*(@3L4X;G?CD1S*3(), ,NXGG1Z&]A)NP(*GV+#^
M"[C)IB6I]GQNM MA,9<8,B;>##0F5)F,(\PI:74-[4J*MW.'YS$]G53D<-3!
M# (C'('+8U\P&O"(CZ@^#QU%3XUP<BWEY)H(%4JHZ?*7*!HO_YQL;AY'40)\
MIG0;!4@RKP341UTP?+G]6MX@@P.Q?S\<8_7#[C6%Q*ZT1"($'G#]KO8C73H]
M/,-1S. +6KPRDX# 8]!Y31R5Y"4QS]+6]47?C;8C][IQ5V1,139)-  1:4-#
M!4$Q_J*J4V 520:" 7//PRH8:7JW,3YC2M:+ZQ2  6"(HKV()P@1E\M0@!]-
M=I0$@XLPAHPR24:T<1]B&W>4*<XNA"L7.:,SD)DRD3GIF)@Z>TDDF->V(L4>
MQF@E12M/%&3&?\$8,=DCQ0%N5G/$$&03@1@BH/W5='T0'BMDM-+VT&:MF\),
MB1 '_J6L#L/E48%9F-@*&R%$$D?LO6UA@$Z()<&*+;'5U1:^%'ADTIV:L==_
M:7=JDY[44//VV9Y3N;F<YZ1/\9RJL>>T7CNL,<\,4Z;52 OT>7[/DZF.]5E3
M _9UTB9LRB1='VQ^OBTNUW*AK7FM$Y<361/]J24BJ=K2$>X);TNO ^8HYV4:
M(1YG<_'[J>G#=:V$*R,T[6+>C%H4*<[01T9R]."">6KV#6M\ ,<)HG<_?++I
MM7QEO,+]_RFROQPGY84\^JH]7<5RW<8MN13;;\%2':-9R)KX^\3AC+26-["6
MGS N\LL -.6O9B_EQ3SVKNQ6\SR.'5-^Q'?I\MU#U[38SQP;ZG.>,M^-O8OX
M;F_Y[C^FS?[$>M('P_TG9;X;>Q?QW?[R'6B]RVY@"89(V_T=?]D6<%Y\ZL-H
MJ=.7S\].>X!%07[/.O__4$L#!!0    ( )R%W%@"^3'0RD@  *UV   1
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M<W*AR+KAW&^'35\WKW:[/;N-S-:M*@CC. Y"'M#CF>7VF-7L:C;?F:4U9PQ
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M6L]EG72JP@H-#^,1#)'&BG&?2;->HU/V= V<\Y)R#$I$RMZV(:@Q3+>ZC-E
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M8+<B&&53]56:,%HRBGFZ6V$T)9QB-3Q;Q],>FX:$Y* *X"),W,VVW##/L*4
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M8 (J'$=4)!IN."#7;.4ILBFJ/I/MD"5(E<MT+F0E]7",T4-=@J^RI=I@5R0
M%0IVQ.^T^;*5\H>;$,'&X[XLD<UV$E$Y2)**&/"2W2:+DAR1#O9<=MB6WZF
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MIP><[G]Y*C/M37 O]<0[CNI.67GC4]EG7GQOQC57G?:+AQY^^?931EUT)7Z
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MVNDLV3,6J@6'S.F5U4U8I@J;===3$351]H*_4CI*SO?Z \A?*TMPJ?:<#S2
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MF5CI8^%9WG/[A/:;XDKDB]]^??IHY=&_$@?2^N*''>Z.XZNB=3_<'(@9%R@
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MK(TKT3B5N%:L-3XK_Q&IW'K\$G6=O2S+O=-"\RXESJ9]QDL^]]DE*7_KU(8
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M-26D7M:%YB?" EPAZ&'JVVR\(WD8>Y7ZOKZ<JT:2)D0NMW2#@$@;92B*\FT
M!+[MHGP& 35-80IO]ZH">NAM@"H5%R\# EWK.\[OZ5.@Z.5 _]O4E_"A*A"8
M:<)BKN/0\XF\N&ELN;?:JH9:,;JU&S-,1D=ZDV>$1_&4@ 4ULMTR?L4>!,9B
M0<#'NT=ME3S=2OE83?HU=C4I%@D"4>HDTS6RW_]C(S^FCNSY:V3\<OW_R<A#
M_W?H_/^MM=='IFR.W"6S]+_8>^NXMJ)O7_#4D5**MGC1%B_>HL6]N%N+6Z 4
MU[10*"YI<7=W"5)(*6ZE:(  *5;<G9!DTM_<F;GOWOO>FSMOWLQ[,_>O?-AG
MY^PEW_5=:X=USO[7"T_\RX7?\F P!EA@^%%%W4FSQ-(A;_-FG5[*Z: T/8T+
MT<+K9XN^[).C\7,4+^<#6163F%&D@U]"Z^W'OR=_<4=83Z@/SI,9.R:2I_E^
M&.:0M*(-)%;K0 32W/9W+XFEN'=]+U]G#'=ON]]] ]SY$&0@P]&7$G\R!TN1
MVPB3IVE=>SX.O_/FR4\\6O#=OG0EQC'HUT=2SQ3>Z]5*Z+R-DL4"=?C'3IA#
MC0[8B9%+-0;J[[W-);6QCJ/BETM8(.>J>@^%O%1P"6,XL^V0 (]N;(/1A'P,
M:)U]Y$YPP!P6^*:S7XVF]"_& I6+Z-,DAA/WOS_K'F"!7X'^YX'[U_DB.SB2
M'PGPPUE\;!H+7%%:2ET5(V&SMR\;<=8L1EI<<4%QQC%I1_VG"Y__,@</BGGN
M_U]>UQP+V#JMP*\QL5#<:#T)%IB21&/ZGXY4HWHDK[# F$TK[&IA'VGT%@LH
MBFE<CA*C[\$[@H\Q6HAJ<+W0X38&K&B"!3:,PK' 5C8./-9D?^#HY>Q \$;=
M@@7:Y7R_H@8+Y&<67Z]_QH1L(Z5]L<"S73AL-NWB%$=R^958X(2K&WRJ 0/_
M2QN?3QN"QWY.8-R[L(#TZ7X.#HE?O?X[FLFD_-\RTP:OU!I=ZSE*P((>MG[B
M"<.$IL1A2L_WSZ0E0>!%]G,X)HH;1]?3^T%70\17+^? /WW &Y+M)X^RCV(7
M_-&IU7$6QU>B2"P@,XS+N+JH<]23;&'8/CEJ&PO()VUA@6UO6*#-9S3MKM2Z
MN-0)@_D5X>BEHDL[9AC>5WV)IG/% KFVS%B@+!"%CM=(MSB/#,09+F_($WS:
MANRHZ\+$>F4?9S%<$5<'WEF_SH?^AT/_?^#0:\D;UPB6&SC;5JE_OK:2F#B5
MNGQPON(/_:"\P W@*HQ_KNI.0,K%63?'N8BI "F@M^ #418'@%(62&"R&0J.
MV"X7L36Q]'K]:]Z?V.]-5I;XS^F%%+^=!_Z/ISSB#<8)YLU5J/U:W?1D]6C'
MDC19(N4]6VLD%V*5UF)8P^1]4G3YXP>[)I^7,/\*EMX43/BFIBW/V$HA_',#
M83)Q3[JE*>QWETM,RU>C;)I,Q*6H> =3LX[NB+S>60L!?G%A:JF30T&89H6:
MN\+&=_X:/"S@O94IB?KW%7O_GQS&3L YE^A563]C=*5$CQY'QP0]920>L(AR
MH/#BKRMF,*)6E6U/TE4I4WZ;J2V/5J'N_8$+J7U)<-O=\9^H_<Q!+_CTNU%G
M7SM_5E;Y!(XG89]5PXSCF%6B)R(V8RXS7XIYV:_:N-+?+^5P9[H5+]TON&WK
M^L5G)\CD$I<EN;9HJR1#V.6P?\^*28EJI%>)3>M(Z>?$\'2M/=3K$73B#;-3
M?W/WL'\[D.M[8MQ)S$SV\8'(*"84%84%JLPQ*3AL7U?C]C$=LSCV2,("I]4E
MT%/P&@?X<H@7?6^J"D<?YJU8(.N>#7B#,QA',\0XFE%:B,#1QZT '/58-,.N
MUO:14T&XR"^R<,9E7U7P%1P.,\!HXS)91MT_L(VF/H5?'XAQXO0V?80%-/W/
MKQ1V-"XO:-9QD8GNP0)PWB!,^1$,S8^R0T-PC#;=T7X%.TJ4NEY+_LM;&_ J
MV/K'68LK@M^PJQ D;%S$$CSZ'2EU]6B/%]/B?WYJD8@%-I,14CL0)*;Q=!]'
M"5]+<<4*%PP7TKA]6+LG%A!_,(B3Q> .%IBD1V,2VL@P07<O<2,P-_ IKF;Z
MEU:H#JJ^+M3 49C-/RCL2FB[^O*WEP$FN)D7DW..O)+_W^27)?K?Y8?^,_F;
MQ'5P/ODOF(!/UT3$W[I#>!UU%-?N/;[JU;'5N;M3-)#-W,*J,N=\JJ"=)3JO
MX$31\M[SZ_@2#751>]W)XS(V5 DDMJCLU58M=Y_ >W3Q-W_%1AU_FZ;&0@S<
MW2NYG*[DP+KI0..C."FBFV%+7QLT-^@T0-;Y=5'6,4S$G5.]I>IL=_!21"Q?
MJ+'E:XFW34[6,V.!JSR]!+D.3B4F?QMYCJ/\NKOXV];;6_3+G9ZJ)YB?I9^E
M&H[%DNB&5,.^LQBVU-3_DIN9;Y)B_=0G*V!C565;@*$R@)0QN'+JXG:#I'8\
MV9LTM5+KOUVST83G.$U-VX>D_@4ZQNQPS#NHBP6.DRRNB'.M_D_ P_]_*GCL
M_\LX0Z,-UL!7-F>C*!9<8J@,]/\_0@P.&ZLV X_>JH.=4'2"3^_!P 4NW;@4
M^[$#?/)\W@+]_GQ_"X8SS01O$WB6%89VVD;B4B6[SM^'CO_F.DR,WS;&APZG
M84X5(18HD9@IFD'H> LO7MRH.>=!(WV,.[[/H3N;V-U3[@N[UYS+ZUNQ']VL
MIHN)I+U-56'=..FS4> WN)46F;*<TZL]RHUFU.B'G7<X3UOM7^ZI)X8F(4$W
MCY(Y6QSDO,YJRG;/]XY^7CF0F^4:Y>L[QJLTLO_*=1&GBWO;G%GD0:):KLRO
MUCU/H;2L[<12U<WE!F\^(R#-2:XL-9&&T\2M+5JY@KX]#7%U64A."7'5;GP
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M&IFRM&DOCE*T?1@<)>=_7,Y4<\>&E"7\M]?4.Z7-*(1<0YPS6L;%IB'2Z-$
MM::9GE(7,5[OTK=3WW</4J+#AZQ*WS-!ZD(=QPI53$,%OWK6*JYZQNTYV!)R
MBU=$/LXGC#K>N75F-4Z?$?CO>WKY__9A["0<>NF\&P-#@(=6_AC(%[N>?#9R
M74 N8@$&;V%D\9[+*"+333:A&\1E?E R/#D^DEI"(<3Y:)[E;5Z8W-%S?0ZE
M#NW 0?3N:G8;;%'@[;G!O-P\,0?"N2VS'$T!FQQ=7NBCEE5J+-0N\VRJ&I.5
MG8"W>:!@/"YBH((QUN$O<HKA<_KA6[T-I;_YI/LJH[! BO#Q(AW1]0 62%X?
M.#Q<647ZG&I8>-P;D6Q?;(11MZIZGMO:.>V9CU1=H(6'/XN$S8V)GPBV>,P)
M7;%8<KUEFY/E+Y%::O+V1J_!OC.@.=J3L8!YX)DKYC7R7 D+!+AGHP=@N]LY
M<:=D@5C@ZQ##93]XY!=N$C%%+1;8!V#IBICT;2@:A:&Q\P8OFES?P +CY;/@
MTW4D;'47"WC$G?>]Q +SZ9C%UO-_?@\X;&FY20K]^]&Q/1:8"/3" C!PE_/>
M/FH(_$'J2L^?%_/W<=),V%X"YF)="O4%C(";8_)<84>I5EC@)?%EZ_FUN#Z.
M.;[=Q( 8KERKD.?[%Z#,!2S@ZWIP#PNH5-M@ ?C?[ITO4/2X%))V'0N\=T7Y
M;2,GU<\Q.ES@=<:_[QS  I\C9[# ^0>+D7PLH'Z*P*"Q %%]&VR?&P-@@4V]
M'=C5\3[R""=>JR)J)0,+[*EC 5<S_ZN(#BPP:!-WO2KU9QMY<&C"@#D@O&P
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MGWPE,@L^OA8]QP(2$G%88$81%BB'/ I]NFMQ15@=R,5P\B[J3/GOF[JVLS?
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M#:HFH7?V0THP$;'69COTV(4[9XV4R^B[+R'[^I&()=\Q[8901<N=.3T2D=*
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MB^B-=6R&>F47#(J30[7<-7-L1]^677$&DN#E!&1RR>]DB\G>-7ZT+O4,=MB
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M2I_: P![^7*X#)Y15# XH9$U(T<BIQA^;1&A$]5*5]G27%.'D?DS1A/\JH:
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M:U8V9',@ F#L?*"LJ()B B5&S*2&PX]/U)4D(:ZJA)QREL9%C&B%! P 8"4
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MH5[K9AEC357$;U64W:8UL(UTPH;6O,;\S+D\A5V&5*+[S*W/ZS2S@MJ",B>
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MMJ7UTYU=BGR5@5EHVHA!>/'FA&3,?<,-4;*4ZAGXR\I]J6=Y42Q^B13*I:-
MAZ;MP Z'MZ;4V;#43=-0!'5#A"_T-,SLN!2B+?*+%_!Y;9W8> YI<T9['TVE
M>\,&=Q6D"CRQE%S(K:]M>"?7^,WF*4-C."UW-_87THR&^O^)O;>*:@/X^D73
M(FTIT.+%BQ8+%&_1X@0I&MS=$HH%"=+B3@D.Q=T]00H4]U+<DE"T18M+L=/_
M>;D/=]VU[O>=M<[3]SHS:\_LF35[[]_(;\=3(2Q?5=FW+@//^W3.&-O7VN-G
M7_Q^2C\W?_VUYSM%>L685#E=N%O9M_YUW:G=^C9GU[,YAA#H_F(%+7350^M
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M@[,KIHI'S_\NHB2'V>,EM\!MP92'EG"?O8.JG\M+;R%&TL1;VT!(P3V 'H$
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M5[,9Z1?:6,+3"BJ=P>+^8!=6G? 1:"\;?K!_K'9E_HB>59VGYQ5?UN^AIF>
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M=QE%N)$JK=BX^2-CD=HVGIV;>*@VG<5=X8NCWF^!5@GV$;Q@2ST(]WR-N;9
ME&KH5CF]?/35I[N;F-: ,%PU)#XLF*N2]+1YA76E<;&D!+KRG4-E-F">-U5!
MF(]F8+?0?N+7*[;E]B"1JW[.WSZ=,MM"7I$0KSN<'5R^>'AF (BRDMGJV.D8
M'LT:_8VS#;CHO7V1;4>N\J.T1TE%3#6N<#(IJ4#:1CYCE>.&U-0:QF^V]LIY
MZY^ %U,GW=:? 0-#FE_J>>44S+GT<9]HXH3M,&8RB5;029U'R"^^U('52F3;
M3[<JL>H_7Y]%OHU1+_^AY06)6%3A:$:KQSN<LCFT66=$8P421)/'S+,I-ETQ
M)^8J^GG/FU;&1CEISZU]/AMJO*T(")-\G7L0O53["Z+T?_'O ZAGM$\CC=N,
M3VR,2L^ DT%8T#[GM7MPL?C&ODK>?;KC?WKA/HD(H=X?/EF[?'E1B_'(['&'
MAV(R+2@//>,6OKP$C;T_,P*!'E F0CJ\%DB]=\ ZA,[SB,%56+;#,5ON6?X3
M2@(\.]G>LF$YBJ1T<&Z4)48:GZ=?B9OZVILMS:RM]?6JJIY7X(3G&3X0G'8A
MF9*UFQ8FD0OP[ZN!6@II,E8*V-!5"[2<JJ'E=%11G<Y'Z&5M,:\H$*RV$A-,
M:'CP H_/Z0TE5+^IU+>6GV876L_6C"*.QJV[R-WF!P6_]]DX^DV5D#._E D?
MYX<SBV&7\.@4*^I23.6&.4E-_@H9[9A,BM[@,%COCL=,0,9:QPM_P5OK@CYY
MQK$V00_KRKP6<"&TE2>?O/*\O$%^T44?EZ+8*Z%>+_7AO.YH6/\.LXP,!5I:
M: 689"7,7IZDY^0 $OW-871V:6D=Y#[,/712052P5&L7V=RH@CO>>EQG0#KX
M-6(C]T"?]K/!WG[.X4U'E4B7HV.+E)<EN'6>(]75QC_:"D](7*:_N$A+!;_.
MC6R6CI,5&HM=I=HY>*R86S' :#2XU&&FP@OKY9(">T_,.@APP++:\/GED)H/
MF2"=6K3:]EQW*_T. 5K#F,KE=%AJ2()RZFJU_(SGUVL&U94I-7DE_,5XMXA"
M,UBVM\]+);_IND31TG<2M_3[Y &BIY>5R=.J>C'B[,2_6%/<)W#VZ><"[UP3
M1_(X$O-XC"5FH6O[.D<-'2::\M;*IZ<*8MN5:KASE87E,'=_:W9"S^ZZW+X$
M;P^28SAOFWZ>&QSAI<]^U>_OC50Z)S_JPMYN]-T1XX;'41?C6M6C@6A!)LY
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M@:[K+?N&D1JMSU@N461?UKO\H/,5E790E^$^69JZDDB%/@%6_Z9CYNODK8$
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MT<I%_(1/3$:$>US4:\X):]7C$]#)4UEG9H>^1)'I[$).TP9K*$[*>*_W^!D
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M6C2T&EL4A/X:58D;FI)/7D6.</!Z14Z<T@%OTC(U&A6J6C@;I,N/%?GTAZ3
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MCT\38AO/@+PW9V^> 0K)5<^ ?XLG:X27L.NKDVJ7.[D?CYM^-_<<+>)W=\\
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M1GZLX7WQJJ:*MIFYY:NDA.\$]<F0N7Z]E>?H/M-]DV3Y>&#A[RA0+??DFGS
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M63>S74"L1A\5M_A:KR.%2K&Y>J]!##35"-2.PTGJBSN=FNR9"RH:5%0 E]+
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MEE)\1)_>^ RPS!85D@ >? ]*$^K*:'M;K*E4,ZN$*SLU*.];@24$K9]A"GW
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ME.$;612?X4NH=5Y:4>\>7U4U)#A&8J]/\PZ:653IZOAL^G/:]")%BQ&TIX4
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MG3-]S.7Y,EJZ?.XOB(&HWOQ5"%M!04E0/7\SN TL=#K@\F[2R( XB20UOX7
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M?H9UB;NR?%TYE7:A_D?474 UHC#+]H2\-NZC5BQU:G@]JI*?3M#=AV"$O4D
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M^->V;JH6-G:L? ?=K_XQ9,T+LZKS_A[Q6;Q8S9,W5_$ )I>;TAV"%0>02 _
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MFCSFVFT5[?2JRCW?=G:A5OR*U"QD'.7;13QN\(K9C\)AU[@MECCDQ*.VV4Q
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MJ,23=73FU/'$W_9/T%>42Z[&<!/U,BE.,VB-_A%5(&<[LX;)ZTAOO_Y8^;8
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MMVAT<)3P5J%DG $T29Z"])R</W\'5P<)3ZY1"XA]WG[7)9@QI#&/J.#QU>4
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M#8<UF^2?TE-C*>:9V3-9-LLC6/AV'R^WZ]4X*#,CU0(65]^>%2:?,*M7O?@
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MG/LQ[1+BIYAI_UE3\X]000>7PQ]'>4MH\>!<>OJF\XYH$3<W[:/K&6XNF.^
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MZO+I"W_/U3[60;< ,:KVM/D(UO1\K%SD/AG.8*IE"./VY6U>\$]:(H5FA],
MVL&E3*FVA!6*S4S4$O=]WS$WKX2W95\))A3MT\+;5E+R;1-K7_>8P]@0X5&!
MGA[WP!I .3_1V6444V2G88[0<]6KM8"\\N0'\ W5F)E0F&&U:GP5=/JV6TVF
M@7^67,_9F< ]I/PL'U+\8;9&B[W^NC)MB<K%5S6\LY30D/^W4R GRKC\S&<[
MEZI.+@7\I#B0<P)1GJA)4F ^R(BH[(;27]C7=>W<^JS=!P2]>@#4NGG_B7T
M;.%HHO(NZ(W_<(7]$9.[H;__L/=UYP_]5=)U3?OL';#A@"T*$M=VR0*R5:^;
MF9Z: AU/PBLKRK/FV3G*'2T6DZ0TY,]K]>3U[:P 6'F^1L<4DX:JFJ.R-_ZB
MR<._?8H<70M+O:+RK!\ D[3>WTC51&%Z9'96!< W+<S06D#0]SO+^D(_L-G%
MP2XL(8L9_)[<;I#9M>0;1!%-(>3)A$&IC$5D?5RXKX\W:K>EO(%'])LVX'$%
M-?MCVA'.V[X/22G8?(''?UWUL%69C<[KL"*IA > S&9UU\_1I;"[B)NKV8D'
M +M Z.P_70$7IM /@*D1^L4'P,5CLY;[Z+O->ZZ3M=T)Z[")ZX.:V_-+\P>
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M=]G6SX_\$/2X*!UU:9^;/TRO*AI:;=<$DS4.XQBA)MXP>HU:T,QAD'R664,
M@ESM=&-?I.D/67?020PP;*S#2&K^F'4T2L;;U$9*@M@MZ-7+03_4"[+PH,+Z
MC(7C!=KOL2'D/:%OOP\S]O[4$38W![<BO64:_3(>8^R,67=7)UQMJ?)1K<$
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MC!ENA:-R6#<0W;<,]J!M(G%P(> ]G\.4@^W%& 9AIEP48:[(T\-FGR#U%O*
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MUL)/%1,>Y;9D_F)FQE25O6\GP/U93XT\7/F(B/.3;!Y^?4S>]%6GP1,9F&%
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MR%3I8S#K0G[SUSDA!O2U>LAP9K7.N]&/,29(H=%[YNB(TM!PUD 3QW8D9F!
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M>,J =09E3G?8GSG'AQ4[UZX2)KEY"@9F6/^./Z(;C)-]L'A'PZ?OSNA#:#2
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MT,#([,%GX<Y[4>!JU13VA.7GP30\;+9*Q@4\PZH+:%Z65@E(;[_VSLNPG\@
M/\^S#ZKU$K>65A-Q0HV-TIX,31DQS^E(D:^UTO,/QMFUTI]\YQ1\O/58+C,(
MF+;1_NV4KN[ 9+2R&=6Q<GRRS4BVAI3D&:F:QS!(AYSLV*_[S *9]1+ZECP:
M]K5N#B1.SNI,SDRITYFPZNW,0M4]/=NZ:J7:L@YA%4#-5-\WS!0<AK8)1%03
MRU\?E5 0EW,S<2'$^Q;Z-UQSFZ*)'C?81I875,71\95YYPMZWS"EXADA]7]U
M$;B0%G,R+\=1=YJV_UAO15K:'ES9&SJB&_ER=AY+NY"\Y701MC"B^+A17]!"
M_75:P;=!51T#53;O^];I9XT^!(M)LAC!^M ]D17ST3,&\J"B55SRULB<;F P
M3O8W"NB4XV@#%5"OW3J?<K:!:O@ C"HUI8D:]^+'5R*RZXIRUQ%E4U,CJ$,J
M3]EUOY#D*OCIT_/,@1,F&/JO:8KX18O7]NS#DK>IWH\DQ=QZ&3M$]HEDR7#B
M,3!<:!O-/[UPIW(Q^J/%E]/AVPF]%-^II$9<;'QX:OLJ9NQX"HG:X.;.SC,N
M7VJ!9GAZC=$V(82]C,6%5>;C3".J^/P!*?NK!5/_LFAT=):,S/."3THJ)<(-
M7VH?=ME=G6I]1N70UF?UOFX_$ N*FR6XKL#.<3)9\>@&K\Q7+CM)\Q?M>I4A
M38B4'&Z]Q,%?QY?\=YZ/R@.5-6Z)68K6#33L5 =@CW[TCU #]8]_S]9#IG#)
M)&^C_.XN9$8)F3KNTK/RJ7G[?C3^P%VDDT<P$R?$SLG\^C+L>:AKKAR9+T_]
M$^&<[V:;-+ E3/]X]XC7T4WL3=].:3GTRU\R3$][5N5:&^:=3LLXKU@O]&SG
M=*U/J,35PDR]/W";.\V(UBORICRJ\0+FLB8;[6<LUN $HV<>GP5MZ'4$Z'E"
MA@0VT/)5PKR?-B[K&X^?S.'*OLW2N <A&<[;,RM/Z!),_7VM(P-;2>65^=]^
MB%P\J8Q8/X7)N]%872*/A,UJIM@\%9O%Y[QIIO01BDP37Y1E7OFN4K8HDK*)
M B5S4NX>EE>[9YRC:)^:A4<>$]DUQJ^RO&F-># T4947KV-\^E?OI%0.HH3'
M UOZIM[E<\'\/+8<""\+Z4@2-$I-]1:P9U) ()ZD[?LP,1+R'[ SB4ZIZ_WZ
M(EI1FR1$T#4,X8UMU#C!7EJJ[S]PNP84R&;B#]'[+M_B3,3EO%?;Y;[_-7J5
M6/;\X-?MQXAZMTD(CV=8/[M^T_E0W+S_?!3-*VR<"!Z.5N:%S!*>851]4@>A
MC!3EEV)'#:EN:&1!]",[YPC^UP(*EBQ)(Y'+-(9B;<B?<,P):9TTEJ7B9W.]
MGW(89\3/C\N.)DK%CPITAS6>MK35L^62C,_,@7V2SG#-L),H[25-U(^C65[H
M8'*7W3J&=F=%;$]1SR3FC[;?*U7-Z+9^MY]H^('S*T_=U :$-G-E_9;/X6(_
M'HZ3NER9,Z[*2?Q5M8*E196!JK\L/FZ4)H<>?7H$-JO%-K>*3Z%-6M(WEU37
MRLI$]\2ZB![TT1Y ,+D(="64NNE]5%+CY.8U(+_,+_]32PHQ/C[59_*Q"HIX
M0Z]<#82B! ?5_3?VWBHHSJ!K%YTD) %"! U.@CO!@P<(#L%U(+@S$-PA@> ^
M$#1 @MM D)G!">ZNHSC!!H([['Q[WYQS[O[_YIRS:]^\%T^]U=UK5:^GU^JJ
M]31.^[&1;6N6L/(/\2[&P(B4L-IW']_V/H]9]HT\(+2)RB2"R>4TW<K:B-Q(
M2<M5U#R96(F>44C-3NHUC,7T[VW$D2J8I?CI4,S:)&TK#,7EV^[\NB4M>1ZT
M%_RE013*H@,RZV\7R/K0@]V^\K2=\II#+[2%MO.;Q9@_8XUSM\TFW 8=T"J[
M#X.I[D] F3VXPO=@P.)!5&$;%J(07TMEV1BK8;+:8C8(.[=XH/QZCY*I0+Q<
M]I6 0$7ZEB42X@I9RG'**@66P,&/'E))YP%%6[*0[UE%U"QISE.9'%[3<J87
MI!(U[9_=;RHJ+!^46>C7OI9Y42YEJV$TESHQ66S:X&"OLLI18A==CB<-QL<?
MR>_,0_1JS>OI[85  B[C#9;0P8&?2S#>)U1Y:TB@^3V-9L] >)7^&X;NRE\S
MC80I6G%IY3US>F1@=@NP'_:5-<M(BH:[/4O\J@?\9]/7,A*@XI2?L]!O6 JI
MW;O)AJA.7?[[XORRSC#H9GTZ<H^BH3G%"@:N(MFP8UA0T'^ZPK45<ZV00&&H
M/+S]MJ>E@%0[.GJE7NV9P0/FV7&U#PU^)G%5[EIV^7O7,[/U,Z(Q[QT%G.E+
M".7)-^9NS5OZU/>&R]!F$;/^$$C:^.HKM-'HE[9%IG:9KROPDAGD367\;RT;
M&(Y7'#0[=]S2G%@ 94G%%:E&.(EQ!>D6*02FG\/2?4GE05QB"=FLTY>VA.JU
MIDUE7 [S6BHN4R]HQ04W_ZJJ]_K*%B+7.R*-XHMMC2;R_N1)Z+52+(5PF"!Z
M?G"P QPP4R#^?-8-%4YLW+ETP$L5+D;';?X=<L:;-K&RDHPA)SYN8Q8#(TG+
M'!/R9$75[4'#ZQ8)OD]N4HLJ<SFH,L]@MR]EBU,*""KLP \4C2;1E8S_S.ZV
M64J+Z+/-7ERSI*^E;64"I\YO1C+A#H^Z;BV+N<W9ZC,ATS;K5M=T2 60QODK
M/\>D]ZK\BEC=,_F!% 'UNL?X!YG&1OH%!\\4$72]EPAC\]]W@.K)IIG%E5TF
M%3W3Y 8-%6X+\KGF!8AB^O3]FF"K@P:M.5MVP1GZH!X_!T<@L3;0C!O<QZIZ
M7-#[_>L=H.OZI4]:7$%XN2S%Z;>=CL]F30A_L^*(SGW>@L*!O80HN 1].VWU
MSLC7A4"@ORLU77W#CN_-!SYG6\=/:MD#:\1(96Q!/IWB4_V@M+1U%MOYEKE%
M>'\PST@1,_$V<P+G^)+4Y!?CX[(L4$HQYSK9=*>2,_CU9AM/L7?89[]QJ9F/
ME/O)3U2H.5@FLN/Z#BN96:7<>)Y4^)G=^&9A9QI-)"-L,C6Z@:=BR@<O="8F
M=: ^=I ETHZ_XB85ERH"*B08937)Q'@F0R:$$/JM':II=^[AX=NJEF6!"TF)
M]4_"E>#.-1054)C4YDT3N?+\ZQB(0U#:480V-S?$,M2IBG?^TZ^Z#F66&/L(
M9@+.M!3A,I# ZR'QN?A2SMG'3! ,*D>M,L?@&UUA2G(=G3)2A=S@6M51*Z@O
MP+A\IF*.2>O1"'?7RJGE.=,1+@?9GGJR^/_I9Y#MGJ]H=0QUQ!?,=PQ(9U+<
MPG>#X?U7#%X!9)_\M(Y+QE_Z%/T]>'DK*4YPM9,8O^<),M@.Z3U.";P#=,CP
M]R8]NAT;"OK4>V8WO9^ FF^#=VQ+'#F=]LFYE)H$C^'CQ(-8]_8;=MY70/)R
M_*3/NBP_U32Y([@3_U3WR<*W1JTF6PL\Z#(QI7$N=8BS1X0Y01G\G=S@-QP5
M#M4VB@;Q K_U4.=6-&%UZ(P#GF[.9%^:GL/]<I]# L9(_Q_$"1ILGVM;%)9K
M#5,PU/["\I#7B9AL'4ZOU[ 29Z:8C!I^X2MK9[4ZKLN:Q\(L07I9!AB^QEJ4
MC_C^<L/,?CB-)Q/>0@4!!;6XT_Q >?3@RM_#*G*&8?C:<9TU(XIN<(;FT&78
MRKEV8O=V951_6'JL"A,89V4O05PXM'3P]-'0PM6XD^'JX9%*21UK^!['5H4#
M5CS#;L>C%C5% ^E3A"-'.(0R2)BB0;@-Z"5*[(]%<:':CE-;G:/@]GVJE3#?
M1-%@;CY6,':.NGU+K%$9-*^=[H]C4:[&+9--3 &SB#'0:&J!<;(I_/6)G]T^
MBG/#U$49$'@BB9,JT:SZS 4F/_%G;MU;\_I,'-)+]?*+X??!U<J5BB*CN.G!
M)^2.8(>U&,(D[Y,D!Z\(Q>$<KH5,# X:R.3$>[)S<S-_5>]N*Y*.0VU]&UCB
MVF9_YLD %Z67KB'-Z]'7GM6UX9_Q)M8@$"=R21Q"Y-&@<IOWII3YF)2+[OV^
MKVRO,S%.<U^^EYV(;.[GY.2L&94"*YP#1(=K.S:D $E.O$R(>2+59$Y-,4.V
M(\OLID4HH)R8V-ELY/(=]B1@:76X>JP:11XC.+5V.K;3;57F2T_81"+6/LRE
MF5@QM/IU2D>3;&#F1)]84J?\F<9OL9LOU\WM"J#JJBW,(JS>+"5C46*\W%?&
MSNTFH>E-8(:]?.2 M?M5:,B2"(.!G8<PF'X)<_$L$Y,&C(6!P_"Q2=W&']J-
M.79GT45);ANYBQD&>J%%:D*6*9_@.MA^V")7UP-.Q(*YJ<G[^17=!_TRB5A:
MA_ZB*Z?A1I<K@X.5A_#V;-N(< K%>'G)TU*3^Y)J,_4M(@?NK,**4[AW88B;
MROFK#F\W2,>[@+/72E#11TP$\F8P444,)HM@KIEZ-]C;8*?+RL(I(=$!GO><
M)2:!LRAUG.55L/*8U;O\.FGRZXCMO&PL9K$ET!FRBI)@\M;=W:JEO)T>-=B3
MFL[.\+,3$=:7[DIPYU_R35VNOW)C%B#6MF$N^U'R,R!F-9&* VO5)'H#L5VP
M"E/,.B,H4NYBTM=^[1S1F/Q6#C;5Q>10<B^MX6_/):M=@GYQ N*RGH._2(O[
MZR\GDF%7=6%".=/7C7H.MA/KA=_[(:]]GS68130(T&4Q&$WNQF,4_)$[S9QP
M;DI:.L69'N9R)1Z1ES*ZFJD9PI_'#*<-JAIJY[2Z'YHPYQ$4.13I,[%YNZ:<
MH',^AZY9,]T!9J7'MC1YDYU#5V3@/X'G(@RWWD:+U\O_R*SFX^7MR5[^Q9;G
M'>#B8N .<*+9IA7@C7.[5CH]V5]:"+V8M0X]BLRX;0L\.ZOQN@.,J^7_^XS]
M8[R*X,OPZ9K_.69-Z*/N.\!8)<T=X+M0Q\G.8D=;8.EM@.D=X#;$0^9&=W^&
M/C<0> <@OFD+_+_/?G.S@Y$YFOIS!S@Z2KD#;.>'_#C>02Z>)^%V%CM__4,K
M^NX ?Y[RW02<[>]_W+H#Y&7(W 'ROR?= ?2N3AZ7?IR[ _2$NGV\?1IU!\@U
M$+T#O'4,W9GO" TXT[P^;KH#7%^OA5Z6+I9)B9_";YFN L[^NLA<;]=V7'2K
MW0$^MEU=S3>'_BD>_S?)G__IJ!O9K7EHQP$#:KXCW/(?JI_PSS!J\\N3_45L
MV_0=0(HW] X@(\9P6WZV_?Q#&^0.$'V+;;NF>7X'$*]RN_TT=0>8KPGY?_JT
MXW\#GT)=?Z.OTLTNZI@R/OVQ28!'+LPD90P(Y-AM&ID*R[XDNL<P<35]KVAU
MN+('M]*/#GE]2Y]SN! DMU)G8U7;<>!:?0=(H];]Y&B+]\+J5=C3:$EB''"Q
M)=5]VK?#1U:S43"Y^Z7KJ8X2F;]+&",[UK_RH;86X*SH@9SU@-?Z\)NF1NJD
MOL5E*7X76D46&.N@7>^JBH02R/0FXA6MI</G>^_?<7[F!BP]>UP/FF(@U1P@
M8NNCA#$,T VUS+=<6?\*./O%CZCZJ$D#OX33_1*)E E9%V@PEME_J!&"2\]W
M5)%2KSD]UHMC2^1COZ]"CCL%E:9#3F_V_1J]UMTPAO ,4H"D@C,I03I[<G*I
M5F,BLR.=,V]A:1=ULV+]*.]\\^"S$JPENHK'.A&J2!.N2?MA5&O6^#7W%G7M
MWX6'/"QDO_:"NW(4?-N5.&IK9]_RM$1V&N*VW*7%K^?6:X;TYK7FK(M[XM]K
M6S\5D76T_EITHO.A7H)R6JXJ,4V&O-Q7=+"Z;ON:]68/ IEN2YVE"EGJ/'VT
M/[3+/:?KCM.H^8*EXF[7?9Z)D#ABFWM+1*_)7V_?QZLDEOFCL'.\6KTJ[4!N
MK:3!$10E/#@B$H*7XV5E&V72-4ZT@D;.K:PI@2[C/E77,S6(DKU "64(]!,8
M^B_'B) A]Z4+D/ON%#R?OJ7S48M=<Z72?MKY=IN+G[(\O?I*O)B 4@"O_VRH
M(K5"X*JDT@U$"SOOTINS]#!*:/F,@1HU2_T6(-#44'T#QM4<AX/)TO33CH;5
M5.*SVZM(.%ZGFOJ2')D3B$A)G^Q5__KMN^B^<?7RWO0Y]L]6_$,6UNFAW/6H
MBJU+>F09"D>/W26"VCO,]$#,Y 1I[@F>:\+Z!\&DK7B]5()[OB(H/OZ]EW\5
MW%C'6]! C I;#*T5DF:!Y_VAW$%<)8_6Z$FD6H_R?<Z^.IDXLJIV"0<[# RE
MO.%6U K5I6.)0;A2FG+V,"M>.N>3^%F&O5U*&UU!1Z^]3Z=BVNIXVEYW(6EN
ML/<8V?*,EGZEO*)G_V(]W&.UXDV3-X12W#)6O7WFIZG,U?>I)/E&F4B;.%6.
MKXSEU#*@G/SEKRA=%RU?<SU?!BM?D=X>2W$WWPF#Y4^[,_OF(JNE4;"S9W[]
M31]KGLY=/3/A$?*.TQ"1*PDH)IV>[E<""CGY<B%@P[@NB8$EC7+?"V[&S*%'
M92;,SAP,\'>-:&J]-^^J9Z(I4E+6X2J92-P&>O?TJM+ND:?-U$!VIQNUJ":Q
MMN)[]]?>J3U%PY(*> I&;_1G_APX*BB$H1>X>9D^[2&#SS2B?Y;TZ\\HZ%(\
M(DI0_?TQZ+TT=<GOOE3-/P>Z+>E&S)GD;0'7WVLOV Y?),KNTR-JV_9D.IJN
M/"]6$=_]$NZMRDX%#@6;S;[U^\>/]%)<S8W JN9- ("&U.$S / $=!T*> :X
M SRW\&TYSB_^+V;<_PN^ ]Q-_6/3$D&QX*:#J+7J%=2%9"2I#/Q*=*7/[6'.
MOPK8NF[!98R/!T6>B:[F>JW"K.]%11MLRL4M^'Z'68?=]M7GX#VJ=6AK0].7
M<DE0N<:]GV2O)L*>C[R0I7P5/A5.9"CQ<1TD:8E;FZ@NTO_/*W+=(\0]WJTA
MI\4E$!RVI !2&E:=6 _RF>4Q8]'3GM'5U]73!N&7EI:%Z?N5ACED5A;>KRH*
MPS\]#,V$CX3N"QOL?<#&$F&\7L3^*=K)*ROLG5MWK#]RK9!:-8:7BW!+A-34
M;HJRR,]-N\9P -UU]9K\*K7R'5_50:&PM@;H5P4W\8@"_2"6%X./XG3P11PF
MAIE=TR/)4VBCGLY.W6YIE/L':1)0R6@1!"EXDHJC_;ZT%PG*DS*4'3@-T"2H
M)&,(9C7A[E<:I^LNF;0&/F;=LBJ\.UB!44VSM^_+BF]?LRZYI+6$%%#.<?!K
M"EIA\8RRO_=5_&3Z?-%RF.2T>DK/Y7H*L6.BFZ=99$( ?1*37'8SEZIWB?JX
M6+Z,N/'\C0*)7FJB_5TH[.HB*VH\[@ 4Z06)%4;,/&2)$8A7\'\[QH]4'6C3
M$N1 AE]8GT<6YE#X]1XAE56BL+\V7I6UDH"S@D6>,;W?'Y7O#6"L@M<A[=A1
MIUC3E[REVQ9NP51N?J%(]H5<_$(Z=L[+&DO#-;B(%=RM^*.AKS7_@NF<7.'K
M].RJY5K>U-4#RBQL6Q'*K\*I@?Q^/K7C:Z?*L2$[EN%G?1?.AS00']@1 OBR
M=OL4N["8Q=.9/;I2]DE"&QPNV/(&"G3V7#_5U_CP*  +&W*E@QJSBM05N@[&
MI1?2*PC6?M$1+II+-MT]S7DZ1"4R8/&&L\G.TW6<+,'UL%90S8WY5R]WLAI3
M+W/<BG+\;F^:?+#GH]7@YO=+']%U#5&JWW@C%1-EJ1X)IS-Q91:_-V;DN71I
M(,MH%/]CMY?0#8=_\'SA+)ACHLU+#_$P=GJK#];6OK]6>RQ\O(#>%=*W'M>@
M"Q+FG]8+V95E/@G4M+Q5]%5\TL"V9QIR42658!R;<P\\;N.>R3TJXGQ/&UZ(
M]'Y+>XL9L:H\[0M]K ^W5#5VV'$H+0$+Z0P8RS^P;OH('=OQ<WT^^[$U2="J
M^G" U7<9>?N&E*DZ/5%?A8E]NX@IFENF*4CXP=FGKT"K]A=PK92'$"?RQY'R
M>N(4*L)<;WBI(+FPLT</3\=T:=:ZA16$3::G].>MV4JKBFJ2.#2,%9)[9[77
MRKA>#2BR&%MFBSTPSR$AO!(^\ERG7ZL9W!!]Z;(&?^3+AE@(6:=)$ON,N "-
M?MV])@6MRK:*A*P-@+;C-WH'Q7&25GK5% 5AU MEKQ)_LBC/RK)$8NRA"%RZ
MA(LTG@B((R:Y;DC26E"UYHVT4&T+6I,CT9A>AMJ_E) U!;V]K+,][U/;F/"Q
M[W*6IR3ZRW(#/Y,2-;?7Y,LH&LK) OP=.B8B8KU'_3N@M#N 2WXGA3BG67TJ
M8C"JM&9(!X> S9EK+J[LP&:%78"AS(GWB >U-;@GN,'<'\)4'JAA9<2E]7SP
M:$J2_$Z+LD9<CQ<NJEO1"R:YN?,'%@) -_=]PKS.<;7K^QE.NLL.<$5@D/[P
MMWPI33PQ!->:8X)=?:AWA@MJ/7)E 5'0R9S^_#T]I28F9GF!65SH_ 6JSY@"
M2_="8) =+$HR"''O:':NE)A+IAE@:E0(YBI/WQ.*7.UQ,K!+9R^0FW:V8(Q3
MT:4F3X 'U%CBE!U>_;9 ?N'/&O2E>_(O"D=G-1\9N'"!NA:]@>"R<G 8-P%9
MBG8+E%9HBUJ))'J5<#SL(NO0T\7E:<T<C2?LJ)$GI^Y0PIH-YG @1!,0SA.?
M8>L:GWZ*]%)KWOIUL(>LHEC$4L5^S^45"=AR/S!4G\:73+>P]%!8'T/Y^L5Q
MSX&=DTPJ.=Q*+]_9RA%^H)B!UE7M,!8]9U;%\QBHB@%HU']"3+Y#[7TM4+B?
M<(FCT2C0Q#$>F+!G:Q*D A7C9SGQTV[<ZHHP5$_7SH4DXCABJKH,#8/WE.5Y
M'LF)LSL/62LX].JN<3D>-!RH&9,1&#*_*0)Q*#S9PPOE:9?3V4O#&H5TISK_
ML=H5_S#_>1=27^\C0I_SR^'T"B?;Y.@S-HYJE*I7TP7";<'@.O;-N>QVJF)R
M_B';Y/KT::GB*A'^"&=*Y'JZ&+EM?+ 5LR]'@=:V5?K;22)FRC#&BH*R!Y7F
MNA[IVRL'^M5L:K8IOPEQQV 5GOIT#9Z5;N;J'>$@,XVRIE>Z0L&A#=-N";6\
M B;7[W[#$)890W:"_AR_JGMOITJE,FH@8[/*=<9SCIPF7I^H3 7")-#YO.U*
M>R-(5]I^9_L,+LTV'S[+59MN'4N14=;'OMZ)Q+#%CS8^?7P@J]JWD$J-NK^\
MCOP-1IN.#HZOQ:V_!FJZ49L,KQ:;6 OW5$V1<H#5?H2M%Q^HG6/%^U(&ZG8,
M$@P8)?E+(>9?FG*Z?7Z<G\8X+;^+]R,>.&)\E?0N,56-&5E(N&'O:!P?#ZQ:
MX$F ^F"IP^]%]111MOJP%C[6H-/0]U$M6G5FO<I><#HT%J\829=SNBRPS0N(
M*<[S5_&G^PZV5#I,;7%L"<MHYT=E//BZ>VE"W6HY L(V[O# (VKZUVJA"T%M
M]&[6%CXA$I:N^(*-([GOQ1Y6]^F%OC &[@45+:(^H63='%M!!Z\I1/\.$PT:
M<%IEX;E&$T@3;C[H?G$>\N2AGY=XY'.S<9Z3/H2_5V?U[D:L4=&/9W7=;'&T
MQ;^)#A\/^G*/<58;J]!91EG@HGV^![Z:MMD^W=6@Z7^DZ[ZGWJ[RD0ALN[5V
M^W?=XR0GHJAX0+%.KJ\L4XZS)$U?JZKFHO>PAB4.=9Z=MSR*#VLEU[*L$\I,
MJ$Q"?X(J]E7O4')QB=K)/-!H%K@PY3.SL>M<J>3B8JOL7LG4U1K4)*FHSIN:
MW:OF"WKX4@>E@A=?J (6*X9E+[5G.Z=O ]5\6W(KI5!*MX+,S6NS#4W?&",?
M3B_ULZ>\5$TN5H\4UI)]0LMJ3(U]K0Q!Q'QA$I+Z5+C3EB^?@A93=M=1T6]V
M*G,6Y#!+&['9M,EA,+J@]O[1:^.\7>MG8C<P-"LHK_!44IB<R/;;1SD@FJ?^
M2&:M;V+7[ AYSCM6%A5\ZLKV.&Q7'>*S@#!NYL'%HKP#?5]'%J&O/$5A_^)<
MH*&)IS2QPCXO82VO^IO]MSR=L7&3BH7*XH+H"6S;$L '@D[XM+$BO$P[<*;;
M2J)(#L%J&&R(Z'%^?WX :3\9#&P!^H2)>IBU4D1MY8GR&@TD/=Y29N:E>W.R
M3;^TW1;>[+,GX?1'Y%C82%T&'8H?1HTN$:\A/?.[W-70_-L*$VE.XDN\BC?X
M4)!U+5A2X9\MN"ERUE>S83]H^M6(;X4N1]L<C+S*%VZ!;6Q5HVAXZT,L#J]B
M:]P--U9Z?>@4T:E!$[CK!!_<X"@KHV3L2A"T[E<)T?RI.>LD;-36#3[L '&D
MRT%N"=\H,VL23'F:&;)UW\/+>&2LK:]/)P>A]2<J;^QEK%3P]F#SYBPB2.N3
M[\$O;JKBGWG'I%OZ:K9B5?,7#,IJ .?7E-4E5Y1_GO![9C*^SV7I@^B+R>\>
MW3 :1I1K>EV6U7MR;1T6W?=Q-,K:<E^8UEEWT8'#JS6'UP-[\5!%NQ:"B=R$
MVEIA837"0?D&G]"!O)F?J+?LK<3OJ5.)-02+7):+7K>IHXW5^95HS_;BE++=
MB,><ILC><SMOZ+\(T%;ZT/ "96RL@&>IW:KTRK]^H#<'Q_8CO.07I5D'RISS
M#A!F[>B>CZ6?0>24BIU6#%]KNJ^)JT'XH4VQR2._Y_16_\ZDB 'O-VR# L&*
M4N5;,HHR"ZM3#,P2.:N)\IZV ?:^O?4>P'XW QS/H*E(WSB:7$RC)JVXXN<(
M",&,,2):CGJ2\[,*3'CIT/II7@[)9OR"G0#.)6&VZM2T</:6 E1BKP1FI:N>
M_.4W[ ^/8JR*)BA0KF3\O%U%"TU7D]C1&$(T++Y#%H:PT)RG47^>*9M5W>*&
M3HT0&GKOYM:VK71W-AV4LM OCEO[*M(2[B80_!A?7G-T]U?.IS-6Q.G*,Z4G
M:=OBW4A!?,9'0]. $C1S1@GUJ*SX#S*E\&<R7B>[;RQ/&Y(B1BVM1V3A]I"R
MLM^CNDV.(L4B2]513U6^!2#5A<AU^A7(\->#H<$PA"O(;_YOED;O]],Z)SOQ
MGTU0(-=GQ0H"5NC[,)4(5H=)V=0&[65_\<)^*KV$TD0=8N)'9=4::Q8.VLK@
MS9PO^$72HMN4)_95PH$/' QG[2HY_R9K:#<ZDD1QCTI9%6MPCI/K]M)RZ/R:
MO!E5)QZ4>%<+E>^#<'A46DRUM <FL=3!^DWG3J6W\FU<VO:_[R:4PVE8&"<L
M1,?6PNG4<M"-DY0JY8?D$U86.O*;&G@%Y;[<%92%<#0L886R:R^=(FP.:]Y+
MWIC1_Z)<>/<@<$"X'$ = =!QSOH3Y0-/E[-H;R0=:\4#?_7KSM;YRISX@_#9
M:FSV\3X]YK="RO#Z:M?*-$=^4<&/,1N*R$P#VTWWKE]:VFL5DB&J2"?^Y.^*
M8 J](ZFH,G3/"=O >%I;/79A6_^")181N B7"'<[?;2TFX<:6CD(Y&-"9)J*
M:#Z&PA_;V56(8'W22XEE9<%YD=EYS>!28G5GRE;^0I57_[8$Z L,4H#A 8$8
MT_>[!')?_$8E/%QKCF84E'H<\X8Z32_2I':3:8]/<GB0MG#D^L2[UA75,6'T
M>\H$]XNG]_JOL2.QO-L]OU:WAP!/@/M*E5PE5Y63A5+=*52:.M]-Q]*1_]Q$
MD@/5\/;:/N/E,XDG#N_Z5S](JSKR3[*A^G_\GFRFG"FG5DB2&9>J/(0OT6//
MX4F["3LPI\#]0(7#EH#]MNYH4P9KT"CJ,PZS7/]J4,>5^NDBU-QMXY'E+W!V
MK$KME&X!?H/)$-E^T%K@F%PZKV$'_ O/+9B4N@_+&/TU8I51/==*N2>[<_[C
M2D]M&<-"4JL;4_"6V!.WLU!49V,URKG-S*32[#>LGF6V2N0R5H$6_"K"LDFY
M4$ON,S4_I3[=2TRJTF=T[M4A$#0SK3>H&=YW3$;:!Q5.8^7\BLK)89%G(0<]
M52<OLXSTNW%FA/V0;;R<+18=<KTI6=3U4=Z-+_[PMV+ E2@!%*+&\&58R^;#
M=J<UK'VISU9D3Y?4&':8X\P&.R!+>QY35I1!T> U*9>V'5V!7P"%A2&JIL@O
M/:KP70][_UR6^-C/C'(T%=WRLVJ_(7G\[-ZV2W#?P1H\HQ=_4H.V=E,_7O%O
MGU5\7VU%Q<.8;"GV^V1VBCI5O[,X_E)FQ\MVJJB44CB"DV7Q3H3JE(BL3T>$
MTZ;E@7B;&CWEC$,TLQ775P$U%TF'AAS1BV\EHQQMM@\P<=(&P2/URS[U<YSV
MM6EOU7&/$$.A]V\Y:C\A6EEYLR/KPA^+B,=6Q.:)^UOY:6L)7S4/%#=3WOM;
M?'"O?&;TY/[^B4ESB;:7] _FX@D-X_N1=JR3KK[IAX-"SVKK.7G(B?4EW^:1
M\9=IU8KW['Y9Q5_6[/VB/ C]Q#^SO#T5\76!T%(E[@[ 7<TO3]@SJ6A?*LR:
MU^Z7DED$?<)=-C)2117#D:V92K<OJZMBJ(#(B4PO">OP7MO<^#RI>(QX>I#V
MVPYN:\KBT!?CZ:\!2<K6D4Y2S?:*"]LQ =8I425!>>8>_GQ5I2($)_P<KD7A
MOYZL-2,4[SSIDM+/TS&E_!EUGL":S^/F!%-?=(3J1]V\.AG7)-&>&F$AZ20+
M\SH8H9,GT.IE?FA*$ZE+5%5Z&<F$A L>B:XEKHZI-8H^MYBVK]@6N5U&Z6=>
MS_7N?*^>'["&VP6 9ANW!0(%.AQF0$1YH7Q-?\0XZF;)!&R?^JE^T6)][ZW$
M.@P=)/L;3%WE(8^GI]I?(*'W%S?%&*'^A(1"_T4:&=ADOC?5^">F!E%%5_H0
MDI5%H,^<H9 0_\U\CH>:D8'&W.G5-9>BDUEE^,]2<'IB>H"#[:#\-_=G:ART
M)77?Y7Z9>%>10IBUIXN<U2EUHS,4$UZ:.[LEA8J<E2IOP"ETW7'JSS]-V3<O
M.IV86(LFZ-N2K(KX# Y.KOG<8DO*>CDABAB'S5X6$-F!,C3-IF>LPSP #6O<
MK_H326%40[WE^CX"K[#/R.:S8-^)\:,8@BE';-ELF; F'*,&-Y45(M*W3M33
M*BJ7%5K4PM$\_])J-8*/]]0% (BU0DO8<1\+:<4.EI%D,#81/!0_T$&:?=RM
M(?NE]S2@,(M24G.@H\[_^Q MUIXG2^CMB/&PS2&58'S7)*O$\P3A$YU9:J(/
MT@*3$ZOLU^WB?GK?8EGT:9\[@WAZBR&0']DJ>-H5SBEQ+8X )Q\Q>Z%*_D%A
MMIJ/IL&VF-G%+[0?N>,OF<SX2TIXBE_^+9B+E?S\8+A8!M;A)*[Q7VW$_Q[Z
M7>9(^/3Y+=?+7K[;QV.MIR,R3T)+9):W?)9O&D*/5&7.ES:?G%_< >A]=NX
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MAA.0L%>EN;)!7I'&?6:GDL#*G!Q<J7NNM^D"2M,-OXRX2I2=J2EFA2Q6+Q=
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MXX^\>?YWNV,#ME&#:?.M;Q;=,#=?]6CB_,YC<-D#PA2WB"/-$B(7A ,_%]C
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MINYD=K#.WE<5>$C:LTR_4?&%D#,B,P98=V"?@XXNAMO5QKE&K H7WLA]&!4
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MX&1R[0P<J\H3MKAF.#703+<W*O,1,NB#L8 QKY)N32C/QJJ]3%"ZDP/C,Z5
M3_N%Q%]Z[X'3P145A6&ZNH P+0X%*"#LUA=(HB;6JXS!-WLM4;F_,/A!WEWS
MX"?2]^]Z7F#BVTX__ ]S==H4KJ403\]+_J7IV(Y=!Z(K*V?.:;:1U!Z-/-EF
M378_2GI<'^[\_A2@E![WT_F%M7FP@_LKY<"^>UP056-HS51/<E2.7I%#ZJLP
M+B[S^O804'."0B!;4E1'K*$FHXVV&K-<G'ZA_:]#,I'G\AHQ%3K23A(CA7/8
MPSUHS-DSZ4F!!L.H.8WX'OGH[I+PM7A"6*MGCU)3C< "!-6BDER<)1#[66?6
M:KHQ4]1]Y\5@:*)5J2)3XG,S2JG0)>!)_1NV*#P@DI;137^Y=L1&--W-ZNU-
M#^.STV4]>C=^8>3TC'X$G(A?('7&X$&9]S24TMUS0+Y)-\^NMP;RLD12W3\,
M.QLX:%),F2*6Q)Y,+0=6FF5])_ZXC[V/).*A9YKBFLUSQ2A'V%1;%%J)7-!P
M0H!P2RV(G/W0/KDKH?"KKPN#>\5['N+594J7_(*/6M*I88Z5U0#(Z%0/J6KR
MA/:W7<87'"H/_1O["U-= 2E^#-8WYM5P)1SII]IBD4+('ZZ^DBP7;!Q#D8=.
M_6^F,#CM(CD> ,4];BC*2TRKF+7N"10)LY8O=-,D?KZH?\IP<]'P"MO4[MNS
M:EHT]7XQE-KYDUE%GKAD"@+Y,$2C=_Q#I0SA%U>![)[F9?[2VT9=A,,RK/?8
M@X/)&<P54VUX%0J[C8D9[;Y&&)'>.UOTD__QZOJ4P')3<,UE_]/T$7\*-,!%
MR2),O 'HF.OHD&/X%>#TQ+6C1M#4!TI@RK**Z3(V^?3^T;4M]L(IOO*K$N$>
MD0G-X9Z_?\37<?&&XP=;,;&*P[%.P7+Q?T7YLZ4WS?! #14*WN]1Y9S2(P]*
M7V^%%V6%MF+=9.R\R%6^%650JY/:F).K#S^3_L,R+X75 -.!40J3N5<ERV;Q
MU75RI7A ^)4%RFPHORKF9;NC>*#PY4>IM9Q_)1\9HV'7S><[-]M[_\J^]?\O
M@IMH(S_#!W-C=JEZC3:>J@'V"E-8:F'S3^[<T]+;ZV=88L2-JI_\DY[;\$]Z
M+G@K'P_XZOG\[#=+?DLA>X.S?WIM<'^F%YV8&)^=B?)0F3K][VB<Q/<G XN(
M24A6?4L7[8%1V?&- :T3AM *8V@,_Z@WP'AZDYR^."T %1;E.DS^*!U5O22%
MYJ+ U,53,RM<I[$\7WR-H(LSJ5LH\G#S[D]DFXA,3)./$YQ\&LY81A)/XO['
MSTK>M^L-Y^07<>WL1464!;LM]19C7:K<P5#;X^ !VMB7$7\>*:QQU4&I[V<'
M:L>_0D76%*%C_V0U2U8O-O7V#DDWT#G&V @^)5>3\*T2>R2N"E7% ]KXB8<V
MY3Q88JUJL63>G1N74GS1B*6"@_(\;*\/7V2RD%(D974#7^J$AHPV4$ZK23D0
MOB(2_LOZ#:2T*"X_#H[:8UUXFL1T)LT!"FR<9QHMSU)XS)7)>[OC[=3K>R(D
MP6(%WH;89,.X*MG@QV*PQ0G+[]2 <$+/SXH\Z4^^WKL7!PDR]C="R88'K#,-
MHX*65_S$K44HKK6!5*:S>;J5O:,.D$F2_GT*$;LO-C21B8;D:2.4=0F!H>T[
M6=:[:5)8K68QXV<WW7_86E:,^2\U6X^Y+\UG2$2MM2LK8!9CDLOC@X;U%/?R
M*M\Z*7_\5<5ZX=F)E.]PJ(N9UOGD1U*IX//(]F<VZY/1$2(A%-&!@&!JJQB)
MH\N'5#P@R([3W!</>.J:Q5[#0QW?*@@WVS<+:^-I]BD^1;Z*K80*SM*4M^[6
M-=WT9%>'4X9W6^W,-=U*JZ8ST:92A /J'R?\\R,9J!WI(IGE&N50%=5B+S>]
M^%<*]6L43A"3(R:D6:A9FI<X*GZDH='+#U#CP&_I@*=GU<:WMM0 93OM/"&E
MB/F8*K ( M'^XNNO=:=Z\IA*WWG/:>%A4]XT0V387^UN\JUV:E)S\MV1XO[[
M?%:6+QC![?WF)[7+5]%V+N ($X6Z@/O5<$DC%Q<.B0\*[6^OTNW1-^6IN91I
M?:,6:/UR'K^*)Y;!BLAR]BY^^6[B_0+K)9!098O#UA.SI6L0#/U@&YY#1F$=
M!32@3Z0B+"]GU1(N*\E5J;84G#(!785-/!\AMTZDXEG5^!56]P G^ZE^5IFS
M%IC5JV5M+V;D8^-&[D_AO\A62C\OD$+^=W6(JJMKOHA-9R35\4JI"]/>59"_
M#D$+[EUPRK1XD)*C;@[W*H6"-B"*#.6CF,"5(^Z/Z$??'/+B'NG;#=H%P*KI
M&/G'V2KLS92Y 0%!E&] LM'.^6]'AW\!R:K4W5Z_*7_.Z[N^.6/=YD=H&_!Q
M6NYQ:;_]9^_0\E4/S0\"U=G^&.HYH' 4F[,+99!+C#QODA0IC1!QU%ZKBV 2
MI^J6J"$%=2P!D^A+=T590"WC46 Q'C"5:PI>9CU1P'VZFL(#X"SP3X)X /A?
M_JK:C:K94>C+:U=<\*[K&;<('B E%@B>CHW% ^;-VL$EDJUX0*OVG_CKB[,2
M/,!%/>@ <7/]'X:J)1Z0\J9]'?P/*W9S6VI[V[7Z,K&V_>KQ&>9D>R[W+"J0
M^._Y6/($#T -8)8IP>U9_Y)B_UM[>RO(UNWK:]0I'J E*(0'6 3=X+Y?'N,.
MU?.ECK>7<V^:)*ZZ7,^._R6GED7C-/[N7'^[]0\G-OW[WYJS?[;ORO?B ?O<
M*^W__0C;?4$XW'\PL3S@01*SP_9_0+CNQ[G'Q_"Y&\7YE9O0J[-+C[VQJQ[)
M"#Q@+-<?C-TXPQ"UKXS\B\$MYKYX'XT3^@\@UM0#%^1]B0>445+B 37M07C
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M=5.CX5JD$M_@&(?BOG*L!'70\6>,6M,-6U&K'F4((A] \P8#PQ3P9#PQ4IU
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M[C>,0;/)3M,7>C&8*^;X8*GSZ*MJ/"!8NT&B(7=1#1M_\"3=& ]H1( OY?&
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M,)@;0I^7>(!QX-4_EMQ;YF_'S-Z45(.]!.'7Q[Y/KX_7VR^S5MHGX7\=WMC
MRLKE*S0WKO$*&XHCGFMU *]47JF;_F]E==U]FHG]A;/E@3"7GA7W'F8,0H71
MW>6FX\^NAXX>867"ZWA_&T.:B:[R'HZ?C%Z)/^FV OU=AU F53PBZF<HT/$G
MD'_"O+$3.[O68$5%I2IP8CI!^NXS9U]L!>;GR'XFUPDZ4_E#UXK.=,,2=/Y
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MMRXZ<1(D">XZN 6"A& )/DAP'2RX#1I<)H'@[A8@N$.PP26X$YQA9B"XNS/
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M]R\?5GH0MQ^GB2^ _U+?IULP@(W9]?93('SQUNOBX!3T"WJ1)*R- 4@S.V(
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M-"XMVG'&UKR1=!#EEU978"U%#YBC Z.@0)M*8]OU^>S;K3+[')#44@-P69M
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M(0]55D_JK,XP;)H8YO[Q@GK1P-[5'PT^0=HTTHE(EYE)8Z=I?I4N<$H6A:2
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M4^'7.+RB570U-/G6N:(IER!B(]^:<IJ<K?!?4,KZ;TJ_?RM5==E1#V]^6\<
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M&U)4[C$F0[21K7LP/.R!@X,/3</7=T=!16.%QDT/BSD^3>Y]&BX Q5.E>9+
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MZU]*PR$<.L@,5"P=U!]FAS^1G!H.D-_%E2%GD"QL"_2Q<*S 9+LD6#U?TQ@
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MDD<FT5.+&SYM%6B,*"PN3KEUK$#:XF#/[P);"%=B8LS]K_[]])1\GL\'R,<
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MQG#?2^7H=\?*T$)%,>722G&S9V?N'97N!3S> \O"A#@9P.)?69KY1\9X;<0
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M#JX:V_VAHM?7^GR'8K)$IJ):&"E[<41>.^^;_HKVM=#'][-8$@L!IY&IF2%
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M(H=5,$8JR/[W ,K-+*,QW0\9"OR><?H,# LMP-PW=LFJ."M!^=GUKW-]:B8
M%^"C-V=_\<(MKH1-U*^^5M ,V &\IT/?;(J[2*9RW#U83^C;$ *=-E4&/D5D
MMV%SUW#W?="_J/57/6@$DPH/R @ 3:M461Q*M"JI\CW8?KVLVL6)E_HN?;F]
M@"[ </8U %.H*OIT]^(^ZVQ)UKRVD*N0L>2/XA^!QSOQUF?I$*;H>O>3-U5=
MRWG-[WRG+8+H$B.H/XM64;JO119YZBJ>EHDSWC@$B4DM"\?NC0WP7MAY:$3P
M-D.I'*9WKSX^]0BXFLEYWRI\I$P%IG$<B]'W,IH<M2(>2AG0)%VYQJL]:1EJ
M_W5)E6:.^L";_L%?HL0FIJ_)@*IJS26B.C?8WWU-'@ZRIOH(W^&H%U@DVB%-
MHB/_D"5OO.90]5?7BB6?U[<O_N*A4*3!U"'QF_CTQH<&[AK^<E:^TQ)&_B6H
M@WT+.ZHFT2#2V>>ESVR==G>.9^]3)O/P1?Z5RLYK^M06[B^A<Z2X5SV.-PLB
M2^ZT+^DWG':/(0# F%AJ4&?\\_)YTWU[:4/FM11)]Q?ZFAKV4;Y>,2IL".E[
MMW=\9=.6_3C;H[9V%JD_3KWA_IT36/A!2@@$2/6W1HRH=?33.%D$%R^<[JQF
M\K*)Q )J'<I$;ZC50W_7US<1)P@?:'8AI;<\UZ&6/R]\;Z\B,YT*LYDS!OR?
M6L[H&A3J#1,AV$F)VQ_U[3P1(HTK,KYY%WUL$3V?T3&Z )-@NZK!*%+O[;C=
M N\<C'<8(G.PY&95X$.QNN.-9V9+D2C-YN,9GU_.2:H\']1JI+BE,NX'DVH6
MS9ZW$ "/(E;DV7XZJYK:>M35G=@^%[ZQ>;[3X16J&9M[>'QF!,++<%<UJ=^?
MQEE%TU99R*6$*A65_H;ME<@JE@R"92T%73=WY!P/+BO%SRL+!_?;.X"69P;G
MXXM65LHF"7GY2+%C4)/ F^KF]\RZ,KI3[37L0BJ[Q 4/L*KJ<S!F\,K68NZH
M K#Q20\!D%]UE#KD (-T<NW48K7KGK6TB ML5*<5&X3G,K1ME1I\2QRB(J=E
ML8G[BRS 0Z"&CWR=&8Y<DBU,G/4O&F%3^RT"SS>(5:_7*\\OO '/SYJ=ZEGE
MF^GU]CQ[6.NCT+W&9\DUT;TF4EQ-GZF\1K5ETB!=\JRY@>IY;AJO&=$\;E3A
MEN%3G;-Q/>)]&R/;"KBH".U6-DU"B7_2LX&6$2@-6K53:QF7"4R 2@!W!IL]
M(&5X_-8A9!YKQHQV1M__[=>_A4WWMY1C@PS&*TP85$;.+KHEC3BF@LE_F#P5
M5KZ1I8B<7SG)L,&5:L0(%H7R!I/+OELZF@I+_[<FO0AST\'K'N<3_I\4,1!'
M=[5$Q;:V=9@<JV='G:F.*CKXO<NAUM38FDN(&[%*'4B/F\>#UOSQ?:@[9P0)
M5E7 AL(TH+(N@<X^0E%XG*0"W.[3-\%08&A!6W&S,.[+5Y2E&ZP_6](PT_ >
M4;C8[:'7"MQW6,I([Y:RG+5;XO**1\!0D"VOSK!B$J*C0]Z$ C9@7U0Q>$#[
M-$;&WH)D8,/\@?*,[SX*X_B'8COVH YK5"DU^#K@=O]\4^R[>=PMY911][$B
M(T._(Q<[+FCZ&,K_1=&POK()3-JJ5LB//^;G^$OA,"<7(D]6]EIC,Y25VVAK
M6:Y'%)K!N; <9_ZEHTG#?AZ\_&# \%=#8M:OPN255H??BVNL5&>H&LT&*VU*
M_K&NMN(4D5UUWZ[#AQD2ZEVD%*/044_VGPC$S0FWXB<U*K-_:?7O+0WW.X#Q
MD,!9?W\/4(/'AOW^5<0LLO7*$'RX?&Y:SFAEZL"U6R\9$BT?WK,_S/NM*J+4
M8%;,5K]1I%*7TCYN%6_/3",!?QJX;_HCYD"N&A$4U[4,I&^VW%T([I H/ESH
MHI,0H+$W6-GAZ#U<[(WOG3G\HH7;,Z5'[&M)A8"8V91SQU]Q1JCJ;CQ%B6OV
M!F>9C8\&^W6VI?%FYT>7B[?4H3A@R&\QDL]([E9YV",1=W+:11L16W'%/Q6F
MF^<2W&O=J:G!86(1B#;WJY=EK)<5)NX2W,8\(NQ_Z&ZA?)2*ZS/SO-AROCP]
MEE5%FMG(;.IX5A4MF"#:T31OUNJ0,*?7:"V*;#]=Y<1!^_60B"'D]$:F3T;,
M!QO2''-)GEW)[3QWB@JI<%B7W(LKJV4FIKD<XP7F)%H-Z$!I<,V-:1,^ 4';
MGU-H])W&9]&MPIEATRF>]SCV+$85DDJ_QG-?B9 -/U8@(>/@2I+X,#+ $.4Q
MARU>'>MDP>VU&)LLC'N</$.^3/,9>C4)C:@1_LI-@OH^_"#IG"%1I**>Y. /
MPJ2I_[VJ$!*TO:C(]T9O90B=@&S7XC%@]_2D@V9(BX(/?]-&&OAPVOS&?8I;
MZNJ'?#K#'AQ,QO7.>O)\J!Y7;/6ZN-)ZND]&?@?7W<2Y_5U3A#5<K;4N6?<]
M[]TBD9VX9NT9 J!F?_[4Y&?-4<W_^8V&A8&C(RQG?#CP/!I;0P"$ZS?*-N8B
M--'QO\G3S0F %B3D4HD B(>^ )I QA 73PF 3\W?"8!E8%U'<N+9/U?0(!Q?
M7O7L>,27G'^$<=8<+F*[VGBE$2G(KAM?D4@%;/I[!%-K0SV#7EY;UU.+3I'9
MV0O-]S([5HHQP[:E=2:2F>L9TP62_MDSM4?2[H,"-DQM6S9MC6G;3YJFS#7V
MV+49-8V7;DV?3J4GJ,%_]5F+<2E5/1$V-J=#&IX<@:!UK^[]C@%/T#DMJ54F
MJC_]M%98Q_W;/M0@,4'XID1QWQ)L5=K*':3GSL<YC<J(K8:I2T,#!+;[/6.*
MS:@W&_AO'V8S?\QC"$O<"J=W44.YNUO8&>P?ZDCE!ZOH7\7NA-:=D) A<A3;
M)(XTY=4;UO?(AEO%YP8.$T<XT<B+Q^4U".GKJNA7&R]KIWXYEX]%?&;U&[4#
M*&E5;#3CA"$FR1"F?,#?>$09?'4?8 'UCO/+0IJIQ3Y,FEW_I/\6)&G)[<'X
MI!RAPAJU:"EL8!2ZJAW:N%08AP%+Z* 4Y%@3U!K&\)P9;RW DZ*Z;!3+(,,E
MS[MUU5)Q[8N2<MGI]H[.S@T,GWNI_)GX<F#S,_&QHWJ.-F,VSL[22<FW<](8
M;K^.S1NCU[5B^P:*M&4/-AD^25ZK9KMSHNY]]E@0=BG=A*7N\CK E^8CGS,5
MY.Z.Y\VVDI(C\<+1 ZOE 8?T!342)5Z>H9VI"VVH$#H>65CLM$+DNU.^I>&U
M3P'U"+"KJUG+K_8D7\X5>Z8)QN"DI7E3>3'&IHZ(U-0L8[C9Z.<"(Z$>S&.>
MPM V"_C:)1H0PN"G#E+YJ>?8D#1ULFNL]'GVD$(YBBLQZ[GMUP!/:MW[GWBR
M/<#M9NG6Z_7<=0%W+%::X2+F2^H<N:B*^;_"KFLKK=F$.\C4^8[A=T5]HQ1]
M9V*B8@V&C<D:IMT,S$$AB[ODYSM5?^HP:4-+)DQ[BNKU#)4![,:XIJ92W^#\
M>!I-39C$UNLU-,CJ#O18,B1,JT%@/DO*W!*46"H2KQ4&SRNI*NT8F/-(^YU3
M>%>0)AB6\9IVJL?W%JNB6.%TJ%2HO 77IVX56GE71OX]V1X%=V_/-F:JI2EQ
MD5N/V=.+OOR8:E(0];.;Y)4>%4ULG.,ZF2BGXGSJM.5%%UI +=+DB'S>#@Y+
M?G:E+9LQM,6T]47[O;Q1>N$8_)!6?V2/S<!(3_5&)''FS.>U&[!L_!!T5:QK
MJ^S"A #HL#+%FG8A-2\@Z>43^)7YT'K(QS>*;LQ8+F!"%[I@1QLW?21HUX!<
M9-WN_K]]]YP#S9I4PU75^<#GRA\$ .L;"T-#]6?/P$H(XO)O%&.J*^3:;:WY
MDB6).XJYV/3KIDF,!B\C=4_Z8CT^/[A:U2Z.-KE,FFDCS<@X/TIL82'I1)TM
M565=D<:!'7!K F:.[!)PD:HAN6_HD1N?L]"Q)T42@ ;:GA89"E"5H?%C%\XT
M0Q9_T@?0"OHS:[]JAMV"I"I\Z4WW39PL-7LC\W*U/B3&>IJC)IH\P WG9K/Y
M2%,%6<IV:?-]+8PK\U]KYE2JE7:<:1AMT1^T5"_[TC2&.^8UR:OJT9LG0>O$
MRI'/&Z'Q;BFUSUV#,Y@$8*I?!ZQNJ8EP;[-VN^\_UB=I\*7M6(#/S"^N-H$[
M>1NV]S9**M.#_7O/PG76A9WYY2R)'Z45H2CZ^0S]'\SV<]+G%V=PG0P^D?'(
MS60*;@77@-=WPX!7:2./9X\L#I!5C1*>9NX=<S'9DBUR6@=RJ]V>,TMG?P:_
M+,#>T\V>1QW K#Y^RRO/&YZ#RQHT==(5O:7PJ89+NKY&3SC?1*@VBR(>W(JE
M8HGK%H"C:2/OG^E89:[]SLMD,7L5,V"Z]GE1NF/0O]WDS\4QN^8$N"F+98."
MP[GYG-\VR4)*@\(4I<@Q,LH<S=</C_70KU&MW_EDYWXPKM@B-<$<T[/O@& >
MJ&- \G\8'XR7!L'(83[\93%Q_%WZL<43P[=?9G7LZ;TQ7O\]J$$'@KAJ, ]E
M,?TY[MW\L86"):7;8.*#T'*8=*HZ*/#5S*SGEQIEU??=MLU&)NZ,6C3.\DU.
M#J5Y)=DT,=4#1/$NEM4E*MAW@DU&Z(?RK@<%$WRPG*KF=3+\ED=]K83T!X:F
MHN]9H 2*@AT]U24=#7T%XH.8=P[3DTV5Q8<$0.A7I6#))\A;<4O[W(S@M9%=
M(2)O@/U-4!PS47-3VJLN#@29HJ1^@_C TX8P.5OOEB$1)$.Y^.9+#8^U3X$&
MG,]<#\M*]YQX?#+YO_OZ;IZDMA)S+W+DC<B<7@14FFPX?$UX8+[;:;#6U=:Q
M/&=@12,MD%LE'=2I9E^$<)W-UKI=LB@;;P:?M6#+I/N U+;Z5+[K>>CO'*XF
M0AWN,G5:VY*69^>")_MQN&7S\%!*?$]VU+.5EZ%11*AY2>#(XVWJ#6N.@64?
M/@7Z6-[5%J%R@(D,,NL0(P%SI:TLB:#]%9OPW"_>T>PVJ%1,'RQ7JE/A0B*0
M)T1$9FC,]-$,)GZ(K5PTIL^9:^;F]CYO+\RN_Z:H^.K\$L&'>F@;X7CN%IWQ
MYON?O<_M2\]'FTOS[4 AL1=&==+<ALW,@_$)SBFEYWLG?Q658[2V]C2H'_G.
MZ(-!A\B+'T5(6#(O='-8N_,X5 %:U_1\H2$U@C3-<.L//[]4+@5[O,?B[:T?
MT^9'#\>=6Y!N(UF/NF,/P;CO%HN+#"^F.,K:/C[YK$S90'',*Y,B2N*V2=T<
MDN?&OW$/6K395%S?9=C8\3F2X_5C [,TURJM4BI[/Y5W5'XU>J^YP4H2SY13
M41W^,1%=8:IM9<)FP0%SCMY#392ZRFE#'$J!M@X#AH<:T+36X]^O9E)NZ].K
MZWCRWF%R7\[0S)L$TK>=E!1+3] !M<"4P=G-;5WW9XS-:\P"?GDO2^8,QAR$
M]K;[-/G!ZM-KQ;7NLZDJQO?.KM<_5XM?%>*5>3 J\E#V*AHH=,#0+D$*3YP7
M:_=NT<88"3=D+1SNOR"%WI<YX3^-!GZ8U"[3 RE^D@];:D#LAW0WJY.$:HZ?
MC!G?Y@VZV=%0537N]%KE@UY?E:?.]NIB""@UF].(1-EJ7GK/EW'0Q$"A1?PO
M]]".UEV)-"7^N<^J'VXW.,U8%\2%, :#FIMI*L1.4Q_849ADDFH9VJ,YKZT[
M]3D?#NCWL[/W0CA5&O,-C#%U""B$,*/)1P_B+O87H;>/*Y =\?-FV'N)(P;^
M2B0D:2A*R@52<1ZR/FS)H^@XF8]Z$VMI3_;.LXS#2EP?(@X?>C3/";VL8FU6
MAL;-/C[Q&MM<<\ZBXS1C24 @?XS*:*[+]B5]9NE\M0C&5K0>5NO1'J:,';^"
MWB;)S(3W,+'UADL'[M!;O#UY<)BKO5(H7 YT<3,&XY^5.:U7[UP9SV.[!+^:
MNW/BQC=K0WW#A[J91&$!UE-VWJ=D,)<*)TU%&?\+P55(#QYMPKWB?_/F:/:%
MO46[G+4#7N6P(_/$D4W\]_EJ_.Z5$KIR9[$J;=\J+B<%9D45@3_S!Y/G-^>Z
M'86 %BH&#17E]4T,PT>&%=(R*J9F>AGC?N542H<.RI!5XP[84 $%P4P]'X.J
M;5P_5SN$'XK+45J!J X<A,[+V5268NHU;]S?[PGM\D2O3>''S/%;M7$(E7&0
MJ+"RC.ZH&^#&F-OQ(GL U_$Y8O*=893BQ!UCMYR.GW5^S5.?RO*0YVZ=+J9D
MT>*8'^OBH/7O&U!+6R GKW1ZB5OQ:C^$5M)7'Y3/^(7$R.\>'Q'@SE7UQ;UY
MBVEU3OB>7-4A67IM:? /6$N=L12^O=^6I1IEA9)-;&*H=:W#.GHJ*D<NFW7)
MOAMQ\)E)<;_BE(I),(8K@5)3%-AML&D874]&FFRW[/CI?%7V2$?/8 C3/CA!
MM-)D[<- <3T\3NU[ O+#1RJ4XJ-]+/SG@;<?9G*^:NQ$J:YC'8'4]&3'D# (
MF=A1E-^,U:=4LW-(JWSUM?6[6VB64X,A\KVC=CN#K7M.<NK8Y-95L8868LB#
M-.WI/<K9B]MOQBQO:_;SB3:,TU9E"9>#^5Z6I2_E"H@S>_RZ+M+0@R^NXG^@
M[84NY)7ALY#M&ML-9PDYYJXPV96V>(<I<)A+<5P$C/Z-J^_K.*6/I<X^(IJW
M;$5%] SZV%-*LL P]Q^8#(QL8CM#+/Q$/.LIV'A-Y2(V(-G[$8?QA&PVRL3\
MY<N"H5I@[(IH[>D/)&-BV&:T3Y)#(W)M(41,!5X)WF-S][W'F?4DR^)1/^LQ
M><+Q\$,'538UMX,F5;CQ8F+MFV7965KR:N1,X.=RX4]>]I9=#[R1G]@RAZ?<
M1R1%J+B-M%L*AHW'C<RKE/F4CF<&650"7\NY_-SXDV%>C#__@YQ9J,K37T)"
MRK#,KJ?5P[E^IQ"K(SQLC[\#GGA UN:-#?8\=.OL0R$5GDGK;Q096\=[&1CJ
MS?";#5E8?$:Q+'D$?%K:B%I3Y_7S?9PT/>S>@?+@7-)\G6]F<7!2O, ^4B7;
MKA))K^H63GU6U_K!3;R>31QISU]0Z&>]JLJ4 I\V5S),S9+W@F/*2+K>>XNU
M-5[:3?/TH3H\ZP9F%HWY\S(74G4]99J71SW&./>7L6_7,"$SL_K*+>1&8MHI
M(P["LW2D9M_U3 .SA_DI=4>*GY7I ]G#=->#1ZLZ35?*VF ;Q2*P#NS@,Z2%
M;[US6X7K@9L6LF;<8[P@9<@A^'U]+8E^"RQX]!U23P!(-!]%S'<K5*N<IP9Z
MFX)A0=(9'&>&/G*\SY@=,?F7TAA=VEW=S:[,-2CT\-C..H 18L:F*!S'$L_
M4\K[+=/&=<N3.FFAER27+$3]4\32W23E%*K?;!2#[)N+%(8VIP)T60J"G@=9
M&N2X>;KS &:3F+#9O3;-U!P4E73!TTS40I2I3/#TU &N(W+48%2QL4[G5QK]
M;DRTG0_5!?.#\, CEWC_._CH8 E\Z \L ?!3P0MRUC7?:TH /-BNZ$['G2[7
MGK[NZD#JX]^$=A  N96>!( !%G/)O[]\@9&^+H7ER:YK9S@!$ ;OZI/"O!?$
M[G19[RTO'901 +)R2P3 !%R" "@/Q>*HT9Y7V!P, ? M8H4 V(-TN5JM,07_
M\XBSHR/P=:/_-=<3LK7'0 #,RN'^,T_+337'Y!TKH_A+S_DW& S,!3*A#>WZ
M<Q9+ .SFAA$ BAW9!(#<5B@!L,W: KQ</D+,G7^R_&U_7>A([,L&8Q>;@%LE
MR.6+RP$"X$R["Y*_-'X-Q[>3 #A]@&+&>6(.7*\4:@)%_GZ;!?IQ!^X0D?MG
M^N#H"F<+N2Q9[IKT=+C&TKH,N;SK<1\/Q:*;\*QS[72094WL?4L\QEW[8@>-
MP8?5=>'T#\QJI0;K\Y>SGZB^P80,TA^1U94M.SO.*O[Q8S'_$LB8;(W3[GA6
MG8QZ[A^8G]X??XI<>ZP\5WS5>8#X]"BE<QM9?EN\(S-;(L;@E:EJYN)B>7C^
MDYLFD8 ;OH--GF%G);:S 5"P@?X9^CSK'BR@WI+;%F'V+G$2^M4IO.0<<N46
M/"6UK;7ZW>_7F%YV=CB;BZLGV^X;ZSW<8B,!T!+,$CO=O&CF>)"N'"\=G23)
M%L)!,LBN-PB:'*7\W)V:DFK/$BZ/>0UD#IYP.=TRO@H;/&1*/KEVUZ7J?;FQ
M44<OU;G3EL7<#]<]*MQ$H )ET&'?MBNAI.!E U7J+\KB6V*U&]#_:60T*OJ,
MV-HE.<PI;C!3'.9AGE 9;(X57W?T]3$0W>'8:71:XG)='2<%*B7(^(PSJ)+&
M?QO4) NSRCJR9XC=0[(MA9W5PB(H/G[C?8TA*JST2W5]YW=H\K!/3^E#91.'
M#MWNXG#2(G+]/,RLL!0<"YY%NC?5-WAD[<8NI"UE,#;\8L];RK#K5_CTR5F;
MA-BOM+BJO"J6#MGG3V00YMMVG&WT)B1DW/]( ?/4V29,\$QG=S$*-UT/Y5P:
M.<Q"'5QK&B49U^LLSKE35;X7$F]UJ+E,FJU HVZ2&1'G FE/*Q@AX@^&U2S1
MA P'>1,KG*$?NJ^\VH^G:NIH!.UYKT4%I@>HK_=+"I<KNDSVT@4HI@KPN_'S
MB8=6]SND#4SXMZ!$U4G?/$W:]$^M<HBAOKU(Y'2XJX!2LX.7,:2*; ^HL]7[
MIM"1]\TS!7= E2PU?GEHOS9<D: &WM''//_>*,RT_CD\%TR,<I#H-3$QC"](
MLWX6N/:Y7"16TBH[0PHW<2):TB,'QV]AJH=KOI55I > AY8O%C<7E2/G:3.#
M!46;:N3;T'&"?KJ:.>%?^C&B9]/MNP?/<B10CFDG'AXMT,6-B-W5&BW4WJT6
MZI>[AS_LGK#<O,<*O8ZAB<^5+F_^;'US,"U;-<&-LCRH\N)?:8@Z%6V@;C$+
M-FMQ4"F2W:$:12G9*_7>9?-%17V3'/!OWLH;\!LG4QX)H;+K<$WI!1U>]]E*
M.<\T(Y=/6\9^Z#7GTS-J4*I(;;$E]FSHT[O\GAKX*7\W,-$NZ>4852Z'[:'%
M6ZD_4"G>=@GQJ_S!,SF)ZH /TJ *C^Z68"!C='3ELFP"S,5<C%'!R?X/E?[J
M:SQS-O;2>2NBZ'5%=6D-A_3B-UCD(1@Y^1A]-2RVIS)9_,[1AU\3P>[_6J#F
M\6*[XRT]L336>P9-QK\";).WJVR1GOS1)M%BNGFWNTJ-\BM&YX\H7K#&VMG8
M"0*2G+;@%7=S4K+I/B5%:,@=(J*;2H6E=S5[R<!G9 EQ4@C3D3$;?5F_(/G$
M0?T9M2657Q5YE-'THI[L3BQ4[T^"V.,W:H:<?I'6#RY9-";QYL7"7RTOG'E-
MUI+&T#*\'Y()MDSA2J']ML.T&%:]VQZB1 #<VPF=]5$6-#IKKU-)ZN?L63A1
MYM-*&F3WA-:-)2FSVQ<D,FGV<K.\]QZLE5ALTY["_#N#6!#"SVG,&HV%7L =
M$_ G7:/#+/Y8902$18[I[!0YQZ$@I\_0B 1[",![IQU%GN^:E.VZ<CGM\=B>
ME*O$/$CK>HRA?!G\[G$;\)TT2Q['1AQ-TO.W5%+%_L;ZDXNJ@Y:P=HLNNT7/
M'/F(1X]DC;F,SZ9,[CTOU$U+B>][I,*2\&81VW R_G9?JWV"@W+A:8];W.9H
ML7CF>E3)D_E]R^ER+'V0 R^1_LSGJ +)N[0G+]#<1A#>G$4H6.['LO1R,Q@_
MF3_L=I0N/5A[? 8SDM!/V,WRC#[3C$&>TIV#JFFJ*X_<1I5O+]^M ]1'WD^]
M46L:9F_<C.OUBEJP>[4 5M^^\_E&UOJ;UC@BI&4%7C#(G7'2?"S)L?O-1TK9
MQ]JUB\BCJB852)\2QMOZC%XK\593PZ+XRN25J\L>Y3 SQ1&=(6=!62/3K';2
M$JS 46^_"KGVW4%JCR9J\5&WPFW$DI<GRN["9?_K=)5+ Z=2LNVTOM2OZJA)
M#2+GLO@'9A=FX"\F!$!,ANGXP8>>:<R@V9'<X+)D57\S5(Z9:9*RP[O>^B#T
MS_M%^AW';#_[8UGEE &'/ T?1+E&E%XL>9(*V=9B)7^ I]?^QB/5YI/9))3Y
M!#%?+(N)8@["[+O%8U 3JLGXF:%MT@L.Y=^1KPW=G?U;#D*J II>.'8M"28A
MEE@1;=4\:(\_#_/TUA;LVE8L6".Q%M\5>'$BUF9,L KG'>LA W=<]^?OUM[S
M8VCRM@(_]5;7LM]F-N5/(VKZ/WQZUB:W^PY46S PHS<D;W;S(0%0GPL7751O
ME<8*GE"$ +6,T(_5RZ6TGQG.9 8%!#AYFC_^4;"(_;S5'"JPGR77B4"Z^S2*
M&F82#3G8B?E_YM[94DR<@LX%H!^Z-4^[YQ[^\0I?6Z-MEU_)-G.&+ZF:KK!.
MLPVMLG[H+UNP$YA\%<U;!6U$'M9 /S:CKC23>G<*LC9>S;>V48B"]AZR1C[H
MY>^+&RMG_7VZEZ5]BW+RB&<GP /HH!RN*E)WT,8_WE:BT>C(#"T]\4_-0+G+
M\E4II9J4C^SN6UB^6RV6)WLF+=+ [J;TN8[MDD(V\]0([;43_/_70XAY"7.(
MX.(@\N'5BY+Y'-@<W=C<R%BND^Z<[:JD$Y>47G:YL]!%1U\ 'MR<EA11(?@8
M/D)_P<W5RTZO1_UE^&E>;,\N?_6?T+A=23-W)/@NQC5R3=/EM4.KR9-W8KR:
MHIS+O?;TE#_6A! /B_9^*GL'0)6][0')OMD!FIT,[B[L0?:_X31@*N,D4$("
M><F#FA@C5BEBZ'WG:7>IL+[A0XN.C-X5<0;W^9UGR1U,FG('H?U4?-YR]-',
M8@YZ65_CGQFGB,AJ/'RF4;U=]8!\C,%J]<<S[Y!<('-]3O27O4I2+)M$YV_D
M5D/S8Q*GS0#Q9S2U%9AJSG1W=TF87(7;K_* OAF@?7ABP//BFJ "7SXW4XX7
MV=GBO6.PB:F]-N1'S4KWZB!:5#<@6E616Z1P+8AM"F&KS/.CS;P"594TZ+>
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M@YU=!3Z/%+999Q8&^[>)KU';C/LS*M6_R,IX<'-W)NO3/(9#8G&-BX?K1,C
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M48^%MOGZGAPL-N1\*F5]*FC'/T/1\/:NZDJTD@Z;#"M'2ITO-1=CQL<X+;6
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M!GN9'R)^X^>(B>%S,EYBX5DEBT_Z@WCG9VGU&'>O(N9<8C<%].=F^1]XN/,
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M  \;7:0&Z;JQ?+$RDK<V4<A6(+[WY(XRBT7GA@Y*#3AU].H@6H9O3<K!WCG
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MRR>X# UFQIXG@D><#+@52/@)P0K"W<@ !7?(,0,\6)8=FS6E$(!A/_BZ.$!
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MIP=;5BK+,:[QW5EZ5P"!3L)+#SYV"SX?;ZR7.4K5-\T?9XS;&-/!H_:HE\+
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M$.*_5@[$F6//-B$M?,0KYP'?2 @39,1G;O&/^J( Y$SM#$>0  \MGN)8 \F
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M>GB B7@=PC(NUOQKQ#]4\EN4VG5JP/M1SPB+==>LGH8#-P/QL#;7JQMF"<Z
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MG)4>^%D<73HAKVGTKSK25Q<?A.[[+%%7>&6Z']3%*1;M0)>9*3[2+#C'-"3
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M%!I0>(T/N(#=R>K]C03)8@:YKI@0-J/V7O[C@"!1#?+@?O-KW-\0RLXFR=5
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M* IK/C'<.UJHXA!3N+5AI)36_4&FQT__"O>=]FL3NJ)@+UCP,%\PU]EYTSW
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M/<Z>$<A"AN_XHN;OFR/W4[R_>J/B/;#LM=R><R)D9:\U*K3N]*IE81YOO7S
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M?#K>[K@EW>\XU\<"?A<OW]GD0<?5'6,J8P'=8NN0YHZEG'W((80CX^Z;2 @
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M,W@NZ;90:_[6KTG"S-;+PEZ$<@0JJT4\CQRSYL,E>-;T2=K+;<T@(A3<@R8
MW1.03HUN_?B#$H6L1"T+N2E-NCDPP^LI^)ZR4N$O&G6Y#V\8IZ2O6P/)K":
M7Y@+RS,X4>\]0?V;'FW9N%PE#P4+<"HI[[\MI8Z1MM(D;*#5I_0/-E!+WJSL
MGOG@8)GU)R4$IB99H!M)\YC4%S^]V3XW3JXPR'SG$8X?=V"W#./V[/]#TSCW
M\F58V51OO**!2J>4U7NO?$"2UW_P9+.1L+ Z09+"Q6"E0AGY-672 MX3-9$?
MP"-MM3SOBJBA$;5_*Q_?"U<(/9]>$VOK$WA7<:@HMKY2(-(12FWL/3[?,"XX
M,_%6P(DO#I3TZG=DN+]:-TFU7;0KLJ7"F=6@)F;NLP^UEVI1A SY0^TNL+1(
MIL-ADJ%.GI9 BXM1U"8#GD[RS]?&"=9$,97#$^.;A6JU>D_X:HV:M%*9'87)
M*HFJ@K[JU^K*5, ,CS?W GKFR&4"FEL8*J^.ZR),E^9I9]SW%XJ(B<.0-)VF
MR0JM)],@/[!50>?9_G;_^-24CBV'X@\R$M;C9M[#79:639"TDVG;ID!1H] O
MF_H&3:H8;13M<:0NZT3>5M\#76:["6%YFAXPD\.<R!BAW:9*82/7,Z5*CNCG
MH4Z['O@_!-B:KI((?RGT4BC'DS^%F_Z5T/?V#Q!SIQS<:YF>^:TSJ:VC%5E<
M5>:PR,<QSZ[%])K(6I&6K2 !)W&X/S;7J)1^=[6*<GNG['U(GE3CAVR[O/)P
M4XNR&$DJTCRV> /%& _M04I<P+' WCF'/7.$<E1^W5?]B3*54CVUB!C<;S$)
M"]U\^_R,Q@F*RM9/OB6_+XA64\%3U\W[0>WS)#EP[=KM?]+J*!;PUO]-4+,O
M14N-^.AQ25##RMZV("6FM?37@"P+U\QW![JZZY/ OLR\E#S8X^9CS5E-TZ3@
M[6\D'V;4OC!9<:'H5P)PY[UJ D#V"!O+,]>45V!+BR&<7Z:_5>H&R&KLIPK>
M?G@WH:U4T:J>._S:LK*G0?M6]$,*7*3?RC:H+5X[+-F,O3SM4;S[Y^#F#Z4#
MAA,VN44IZ8D7K*< MO>EUM5415G=HGSJK"Z3 5!-8<QDN$:T1/XK^FI+ 4<(
M7T6V!-/<957BWAX%>M?_R>9N0,[4V?5Q_KT:B6I/6S1L:$ZZFD.Y ;9WB1A4
M2GSJ=294'+MO]N[*E5KL&.^5<MT!6B(.7-IB_$A"NAS5*T3M&$"1(G%B%-DD
M_:"$CSIM];?9L]7LT[ F\0"8D+.'!]UJQ@M>R[0-F=K6 ]H$&N_P5<2'1 4Q
M\K%O/W:2E34N;A';>L&=?TMU4UVLA$ZLA,DN"@:L7(RFE,N-AC;,Z;0>1R@H
M<N\D]MB\54PC "RS8<10LL&[^X5#'UH8:.9IBCWV]_<1TOO53K_2"Q 7A+/Z
MF^=%A'^.IJX3G5 WP]"I,Q_?1!GM9SK3RBN^7I-E5_.7T5YMFSLT3RMKQ:<M
M?9P%<).=E@XI>'1UW)&]0".\?8M/K_1)D6T-U\$5QZ6M\&26%!G>:F>)K[&L
MI YDMDI@J35V86!GO?V4V>'\N]:<Q=LE^I8G4\=YO<F5BIRE(4!A13V<4S$/
M%RFI=SL(>O'F^$O6R;GB(E^__SCCZK\''?Q3N%JJWD+_/-;68\Q8Q\J^ECPK
MLD,\I+M@R$!!3)&=O]C+B3!P.8@%J*7I&[Y=4MC_V)3EK*Z48(!^9Z30N.VA
MKROGC;%%&#7%>SG[8E7P23/S/ V/M[/JEH-K')BHLE'BS1Q"DFNEO+_G<_?T
M1D%N87J=D3US:;F: K5H57RY(.\OIX#TK+[?6 #1>>_J&*HB=KCMW/%\TTW@
M2Z5=.Z=UE#!PI8Z<$A'^GF\A8C/;V#Y2N11X2E(*K,K-9>V^ST0F-X$%6!9&
M.UM4##JG_YB\EKNB^6'[<#[K.NO7BDB\.RZR.%8BI,>&--T,E>M3BJO[-;ME
M[Z\WC*#SC"S'92T^WS8Z2U7)NI["^53YL!IS(@"!;'-L0*Y=KY>:.I99;G=O
M8\K_&$$&W2"C(EC :_?M6_3E RQ ]OE'R-9N 1:P]V"Y8YRAL^-ZN.T6"RC(
M2<8"4$,'B$TLP#\677TNA?[R 0O@&L$"7HS]8RIE.Q; "/G;B8J]I7//N?WL
MA[YBN3#$ GQ2.SI.$X\[;IL"KDV6#^(Q9Y@^LT->N0W)CK]46,"/9C1Z>9WX
MYL*T%@O(KTK$ FJ('62RCM96*:X7K_4L45A &LW\"7+,[;UG"IF!/W!H<ASR
M?"'MG8:XZ,R4\@(YZ2\E:'*8M7N,,86@6GX-OKO5]_L:S$%7YGL>5K ZKS?J
M,_S=]ZX";4-7MV/=/:O]4>#:)B]%P[[;%J F#+;OYJ*EJK78.%5:&?DXLFR@
MC8AG^J,1%TM9Y3L],DW1>/DZ06$I]J+[^UZWS\YF-FG8X9>AYQNXRL5'TLL%
M0A<WSKV$28VT2LCT:M<_$H'+/>-80.%<B4/-Y4#=)9X/>S'YL]NQ%$WA+[GA
M*Z#>]G0_,7O^A 6UZ7PIQ'?-&AN Q!8ED]#?AMZ&G:,^L ULYO<^?R18M([1
MJ'^2M6J$YSYU08N(0Z5#L?(OQ5W<Y>7;V2;![W23>'V:Q<3H2)*@!9>*VY'(
MA.;D.N]!M0O['0?&.;TW9^Z/!8,17*S?ZAAH6GV-PAN7$VYU:.FZ6SHVK0T_
M;D@CB.#J<]*I#1@R_7U_E E(V7&H_GP6Z;!OY#*I'-+U,O"1 U,":VE1B)^/
M):'VXD<87-HZ>Y(6%X&@&1HJ%(2E'AU$0+L<<KF-9W7K[.TB)4)?V9&#)3Z!
MGZNZ$!V$13H^;.[CM5Y]BMPAR96?-^4U>.6X&AO3Q$'HAJ:3^K.6?W$$V[(_
M7T]4#RW(.S#:MF?T63\>-N.$,1X_ID<3E0AZXDVHL Z?,736.U\.CV"\X7+/
MZC)=/\IMNC'TU8/=L(!VO.O9:_H.>,%]&H;+M\Z7O9 M_F2Y94B<.,/1%\^^
MO[&GLZI][,LG (A6 "1/+AB"3O.[Q@)4Y7BP &3J,G0$<\EP<">/@_M=&+T,
MC$O.%4$U) #S"@L8"T8R7$EMRUT#SB^A5P]6S@\7D&YV*[)6SJ'#^Q68YV +
M@_+5(H/LQ(L4/S;UB%R'IMG&(F][TJ)*C:I2EHKWR<J.7.,)[Q\+1D"*[E*W
MG ^:6)>W+)YG)Z<UC 7 MHOEYA?/X(=4J%]ZOZ5=O05?:+0[.=A)UWW3!_:%
M]>FO4\=\'ZG)_^)0+HOLH4I>"Y/^NA_N^4!1WU1O GC=5UP*^>[\$;6.:(R9
MWN+K"?_E;]:?"52:7&CY<9>>E:4/%3RGR,4RG-V="(6G7B2S)+PJ4^M6?34<
MYJ0+3%D0U87FU_#;H2P_"? ./2$Z17/7=Q/)]S]XTIH",TA]S.HUG$JB*?*5
MA;$B$4G#-4=G8@5EQSV+FL@2_(->=O:D0,Q+CV#$49),0VN>O9@NA83]CU;3
M<PXWV;A2S1RV01;ZNGTIO;K65D4):CY680FKDO3BA!,[TFZ5/-1UOF.;?//0
M-*DV+(#8KJ?149;:8@=N0Q.H"(KN;U]!M'3FUUDMTDCY(A8419,_K3IREI9K
M*(S1?J[AVCO?!;>"+8:<8D3K[Q*<V"G<7]-EL$#7.S9:8/LM:Y1WG;U.9?FV
M95WZZ$XGZ%P\49'L8_OSE2\4+]2R@,HJXV0JP59Y;$;;[V2UTO8'TV.;,M;V
M%VQ?#-0<D*+KE97YI?(ZU7R.CO:^Y9:(4QAZ(][@!+]_?!Z"RLSI6SH>LG S
M+3Q9KO62<7KPG/_9O:<7/D^(R;]TC27WVW+TK A*NS4<4;Y4Q)G/A&KJ*6IJ
M48N>M,27AJ-!=#"D4\(^2/JAJJV5L'C=\!*M(]G[>OWM&%:5-6WW/$X@ -^]
MZGA#8+2\<CRC+8?DX</EMTV/=.\E:#(.,#U<_U ZGUY<2MG6L_3"X46)4 >#
M9YN,J-H/KOV+XN1!I;B*Q*FI/=4R!YNC-V5FREY,B@/PFN);DIL[>;<.+2]?
MJ5Z:8Q;:ASW^A\[=(W_68 %)=[:=:8OYNMUU?7",A_'GG\,"QF=5L8 Y/'AT
MRS@#D1?_GY^H08:T#)2CUQ-'\J\%/K(<&ZTZT]:[VT>'ZN(QZ_8O2=2UJ4YY
M9#^[EXLE;0T(XGQ7ODM$.F-PA6DRQ264%._<=NP6KNT:$+E\,6RCSKKX &9#
MN>?A^>IGVZ("S51 ,B]4/EV2;8Z'T'6*LH%'TFCZ.X4U*$X'OC2=87$0O5''
M[<C4/_41-=L(J[C$]RX,R6X&MZ56=*L;XX@$G@I.RU!Y&)YQU^#E.'--Y;8I
MJQ1H/5%E82\TBIVS_[T!/^Z2^=)I^U T24$DK'<CF+9.0;0AB$61R!:I+B;]
MDG0 +T-!F#1*\1?STD0V>EK*ZY]IP<G;Q.1RN)>#0.U(&?A]X+?%=K8G%[Y6
M7%E$PO.T:=,4MH3W1I]5&((.WOQ^-C/M(5RRJBG5I2.LIS>FPVB1=#@D$@RH
M58G/^AK"3?"TU>3+WJY3S.>+@'HT_PI"LB-->E$$!)),1J8%%UR4II;DF\">
M-/O;J-KM,#2^3\B+=K0W463I>S9 EQ;_F)N*5.,5,XG"K<"YE-GYC,IPM#_B
M"R,F;54.Z6[F0I>\+%EA("&D_AOD*64"?<BOELPM7?;%@2*EF:RTB)S@24\V
M6<FA6O,T:SSY/OD<H"?R7U2!KG)&]V,!OG?N5'9!P7"<N7P2A07\-GV!!?PG
M!T0?_&=J./]W:FC[)VKP.#CHZ&>X/&RQQ *433FP@/?TMY@P##D6L&1]<'#+
M>E.-!3B9!\Y*7*]#VB"ULZT$Q/_NV6W_PAL+>[:J_J)#ZT>-Z0)ITJARX29\
M7C!CXFJ*[HOVS?8B;A7""4B1$A?^@"#_*QM\HN3H+^,^_V--,+X]H^#G([J0
MY3N1[\B8O_<ZHZ.S!IW2SWL4%)25"55[:I>KG_]6%0RFUOP6SS*LIV)K_4IS
M[HLK[EZ[7(E4I+3F],%-IY_A<P%%)_X^Q M_)9;535W3MN#!36$J0H[W,*ET
MI_GB2#:MQJ(8HZ*4JIPAF1>*UD"@HK*/->XFW-S8(H$@4A_N"WN'X\.J$@Z@
MXS[NW\'#<^V2W'XCSX-+HM#4ZDPWG@%])"M(4M0<4BIEH9C;FUS(.6(@TS9G
MNMSTJ9%OEJ%/IE+C.I0@>)35PW0R/+TYVK&$L;JX,+LHU4)_4D;Q:<GO=U16
M835L=$DAS$K]ES13?G(L*0.;@;:SY\.7,;5S,A*LIDV',+B'SMK5;(5=*GD=
M+(N<<]_!CJ/+0BBNAT!/G[46J$SZ&!I?OEQ5H;N/]/G\:T4]H%'53[1$.0*M
MV\6J)6:L%O*!)_->D:8(&ZO.= 4[#+E9DTXP"3+2T.&*"M:W[^GBIR2M9)3Z
MPJ$KK>1'A"M9)AVC8E$4N3:SD/^5=\1LY6CM>M[N95/$SGQY.4]10H8%ZXB,
MHOX!R]/.O?6 Q_2#1,KZ_KPEV?;(S;=72NG&;%QXW9G1+Q]9>;K&_7KNRJO=
M#:_+^USVXGX7XGNKW5J,''ZN/F';6[PTYH*K1%WO[+1,8Q--OBY3'%N+'@,^
M;BCKN+X8N7(<Y8,'A:^6&1C!8_*HSSY80/JL"H3]'W\PPIORZ_I703HY9MP>
MRRUUS&U7_U]0 )HYL2B0<A8XH:-W,[!<*0,&RK RW9$[T!\JPDJ2*K>=%!=Q
M?'\&!W&.,\?P[U?<M2 @??5\Q/RRZ$[C-?H'&$QA46E9X#<D;]+4-#EO^:)^
M^L)K@I$U]3V V$"^VL(7MX'[?^?6XI%T$K^-;\>F]'.&GT'%I\U^C7FV#PV-
M@V.CC)-Z(T:V@[$ I;9"366C1:@BR#ABL<6/LH'\OMW:,SUF#((^8&J =_QM
M]",AK8^,GT#$Q%&I]\7)<LWI15-RNO.+F>$-R/WNWTM)K1&;DEV/ZNI_UO61
ME7E\6%,M!'Z0IU"B#V [_VOI97.+: %YC!S!'7NT&FNN'3W&M=>OBXD-#6/L
M<XM'5W&.=??>-3.L4@XXD'^+4V?F_9$4'QR^ X>XGZL3I" OY3;)YWU>VEB8
MQNLQ#OB_R.TW7"UO7GL<A 0)<$'=R+,R9,VM;00S_,"66REP8ADB_:F&>&71
M!.XOJ&\PHZH/K1'CNL?2\U7=$5.)?8W)?[/2?A)N\TZ\K"9X1J#2,^Q;XNM$
M*7[!5U"GWCS?EH[XCGBZ]5[3^IE"BMD8R6DC]930O<\RL@.-TIUJZ6I%%[>P
M;PTZ,XKW^Y8<R85B6N_I)XNZ?+0JJ#3F<]E4%15B^Z@J^\<+=W?[R4TB'@<8
M"Q"4'5I< ZMFYN!I"71M"9&]V!D9!ZJ;-QWK_..LOKV%G3E?DZNHR]2Z([UX
M656I.>_QR^#OM6#XN_E%4S,$:H"N>S"BY]UG5NMAE[Q)#1<E*\@3SL[>]# @
MX/1FXO6G6M[K#-@W8&EL4P/S#UOPNX)$^;(T5CX6[A(;)D6AE9. ^<^%9-XY
ML2"S%,#]JY9.J;0T_:9HUM+RN?JI =I[@[T5&Y;JS)]_  C^%6GG0_[=F1/_
MV=.E_T7."?0Y%X:\OWLPH[;OB7G'%4L#V3=,2A(4Y:_PW.Y?/3#K2G221*/<
M(.W_5MC]?M;^']RP2W9]L$XFJ"5\2C\;G_O57E=DL<%^PWO-U@B:W<%$6)'K
M0?]PW_L\!@NPSNZXS<@YUY=K-^JX SY-AJVH@X,58X85,^(#AD.M \-#.O.>
ME^:V&.#YNU9$AZU9M6';1?ZO(_N-=QY:A7+&I[XGU9KV)VM:Q^X'F#0N+& ^
M  O0@BQFY@3=DD'NZL2^\]):1Z0#9O??#N^WR'7?='0&HH<PZF@I#-)PWURY
MX[^;U/^'%F):X;0WE1?]<M7];U-OS#$.LLB;P "X4(%PSE:.E(_O9@Z82$K'
M%K.!F(P-ZQ#H?GF%+[UNGN^726!R)F?Q!5(LK2!TMNZ"Z?:3O?3U!:=-W 9W
MP,WD"OQH'IH>*]4+A,U_6I<*D!:H_@02:-NU6:(I#]29GM$[A^GQS<5KW=P/
M>E(+G%3]?#SS-IQ0D(*S+7U>PLRDSLV5?Y,INO,BY,5JPM*J0 &U@CQKW,R^
M;1;7QR.0/83^4SQO"$$*?-,G+PL 3! -_F;5NO,^=:=LPXCU41&G@7C!L;IP
M@WMTJPJ=3V)!91[".\QR5'O]B,X'QI*0ET^54_S+*J\:.;<3!J(R.RQ:'K@-
M2F"S*[3/2ST?:3K/WZ]XWH/*FKZ-AHN_W;@X:H3C]60JK?2!*Z>A.1_7Z[$
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M:S_:.K<^[@+M^?YE4Q(>KS\!0MH_.Z+/6%__8+3P5]# U__M;C_DZ(O$C+:
M"PNNOS1J/9&N)MC.VD747^S%7;RY"63AUEL5W=(^M[LK[E$+M[M 6E./Q)]]
M6B93-$X9?#5LDJ4B24#7U=V:Y F#XGD+\=7R&;G#6=4>^1Z _)AU\KZX/@+5
M=NENFK+V$30T5_E']1P=]WC=!U5=N2ZP"FU+AE+CU/-:-<;SS0LQ:M0G6H7T
MY;1MM$3P@QHWSAJ.* 8X$&K+8M.MD:1(M0ENY"]'1K^FD?P^*54RP3P1M=P
M%--LDJE?Y)S?<:C;7_%-.1^K\QDE6':.V&>3:]78D R2!&1#BZ.8@JF8.(]
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M?0(@NW^QEL^')3*SN$AR83$XM/:FTB$/,KLL>9'6C6O#4G<[?7DK0%;X0%4
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MS^!(NWVH[AQI0"S0;8?H((RVBQ%N_'.P;K+IYK!:N8%26;'=0A3J5TFM]&A
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M?D  _%O_)+Y_R!Z#/M<)PN$/QA&KLN;_'(C#$]O6EN4(/T"$^0*O\-=#//Q
MA"COK4!@QWD  +:\ IR#75PE #KA%U1 T#F4 "A)GUX77SQ8)!+<=L@+L\8"
M\_"/SV&#B+T_@_;D_P)02P,$%     @ G(7<6&"J&ET$KP0 #'T% !$   !G
M-#<V-C8X9S P;3 V+FIP9^R["3R4;_<P?HM2"2U2D26TR)8]Q"2$A+*&$&/L
M9F3&$C'M2J%4A"0E^Y)U+#&A2))]-R;[;BS#,&/F?@>IOL_S?9[G]_O]W\_[
M_WS>U\4]]W6=ZUSG.N=<YYSKGOM< [:#O?L0&CY.]@"@JPL<!P!@*["583?
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M=E.XJ*59?/JVLCRG\-:I3YY$/OIQ_L3 +7[T'9Q._B0M.]\U),ZE@[WK42/
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MUP-FZ*MG!/5U@2K8"4!4^$_Y*/JXN;O!4#;\/FZN<*2BC[+ *G%%>GT%+"'
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M<[#H!#%>I,E[A^;,D]ONPBZ@O2R,ME_GFY@G+)@[@< P>3D<!!JP82 PQA[
M]\W[O>G96#H]YD>[>$JE)WI?R^_8W>3+R)Z>CO8]%5C#;.PF+EVU#"= $./S
MA.V5-UA_\O9WRP5Y0;BRZ=N*76[^X@"9R'4=+^3,0@X5[T+48=$7EJ[<4 GS
M9>/K]_8!@10JHCQ;]JAK?B99?\&7]$^"RL\=G-AWW+H?4]YZS/,0XA%%(4B>
M_.Y#E0[[F/*B!Y\H<#KW)>,*7S0,G:TO,UW_THC((!#(/<&82KO:U>LCKJ:@
M'^QW5LZ#+56KH5E$49*<7/3^QVT"](D"E*\/&>6>WM*1V$%>7.(5K,GT\5(
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M^K<S8\IZ6I2<[H]4](JUH@L*-5P&1+^]Q#ME#3&ASO5QU]%Z1F,5O@%[^9H
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MW0H,CZ+G&_<L6&]$1]6[C+V.%@+JN$"UR7,NX"H?LE;P\E7-$DY[$>BH)IZ
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M1D/*X?2:EI)"[ =3%_,Y*,@0NJ1Y%4H C$W,,>/BL44?[V+7Y:QV" !]'P*
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M'%.#BT[?)<"RO)J)CQQ@Q-= G.%FOYSG)RJ0U"]Q!NU+3<I7@ )%0K8=]ZS
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M1R9B'H=[;\0\4?:1O; [2(-LL.GS-C?9.J\Q(;16Q);F.O5&0Y9?YG5A1G;
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MAN:S=E!Q,Z<X59.%M"[J>6R<)++NRZY4S9?=]/&@!5<XFSIHX^1XG:&\W?:
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M4L45+]L\U>'*,X\KH@Q0[TPD!?ZMC63"EX,]GHRRRC7VE$M^9&;Z#?D:#=^
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MPU,'\1BE9B0\?7OG*L8!)Y>Z5E30,V4TH_FZ/(SF,_.IR/AK?V^9$1C_+CI
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MWB;2+;'L<,-QZN@@*HWK.NA.FLA^^%"/IN:AC4KRIO"#H?JNBN&[@Y[V=SB
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MH'!<.9P>(3+R>OA9W"71L,BM)*6-J\CL^>74#(9/4H0AE14H+Z.56-*SLY6
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M7:=B0T>]5+QGXG]>5/2]+?T>8$6YTG%9S_BBX^+SWP='*7?+?&>5=^JI??<
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MUXX%[A)V!%[37!S_+U""_S<HMQNORV[#;I9@_S )^6],#E;VJJON 3N6V?>
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M)K<^:3A:JC1?K5<\W3"!1BDZ-X'.2ZPS7]&^Q<2M L0SXL2'Q?(,]YBD%]:
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M 2J\2\2,63=N^\V\7A\XBCWO'<'$C39<T RHT@CO!,0(PI2Y]=6T7.X!@_<
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M:8C_5"L<IRHON'"] "^97AO[_ B+S0W:LOG"8FU(05+'6?M@^LU3RL^E3Q\
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MJYXJVG13?JE==ZDF\SRQUN/$-IZ&V:Y@F>=E1J5")8]-]L9/ N5;V\9L+F#
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M1IL(K ?XLP\.KN,09?/RG@+SH/#V%Z<IO-NZFBR[-:/:'>EEJ@]WZX#+C))
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M!!J3<X5RH3:K;!2#'9_V,M$-F;E:&?I7G@@WJ+X[:BQS8,R0(\GX:XMTK;(
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M8^*H_9_A8@+,(0Y[@G!G.YHJE!Y/_:FQ%$A/[/7WE8LBVJ*?^N\ $>_#55I
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M@<38N*ZZ+-0N6RXIN>W,@";<F^E#R?:VGM@[^Q)XN-6XK2:+^FI_!CB;03-
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M]X#\&O_0TX*5-K_0E8KK@//_:R\/SFP"".Y"+?7N 3NA39U7NP<KF/B@D7M
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M%;+QK1DL<9W6'RMO[>7"V6"JGF)D'F^8PH^BPG8[UZN8^FJW]UN($0);Z:2
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M/M4B8%C,@,N\H5 F-LP.,&Q2E: (_S[RO?2Q%:$:Z:E!FHP_B?(3P%4)??Y
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MWJOG\;_CI=G;8@],O@6KL$1XJS]V$$IO$7^K/ED)33]=5&V"=]M*7=8SKW8
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M(@+RHJ'0R4$2(#"H#E\M3U >GAMDKNRE_-I6B F*1+MMG'^PR7MRTF#5[U@
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M(%+="/M*EQ@>Q#+LY$G+IK)$?+7N%O1+1'.EQ:BLU"08M2ZD':"LJ'><1RK
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MV/#3?\ =$1VXY:O/VT_W9,97=4A?KLE^!)LLA"6>^UR3T9'V_@]K]I85P1>
MJ_],Q5\&R\NMH OUJ_W\OP\MZZ[)GIYL7?'O+>.[_#,N\/ZU5[&"]==D>)GE
M]DCT*>B2<$WV1[#M?.SH-.5R1>$/>YO-E0)A_,)XN6/Q"T'H;(%@=4EO87=-
MMA#0$4H%WX>?HZ_))BR@I-RM@Y?G76$3<L'=%V'H_-/:CK!&BB6KH_JECG\"
MR/YKLKJ]#_]8/%8\2/#_9$>2_E?G.(XZO2:#*QQ8.4+7R)?/V Y1_ILP(7./
MIXF9;-WP$XC/ASGVA9_;[(C^64(;K%J_I<(+$3_8;%-0F^^QRI'>7G+;YL7[
MZ5'A!_7-.<ES4\),2=O=#[:N/FP[%(^M^)MRI#_Z98S@8#RZD#?7^3'^N@,:
MT#YP2FCT0N^&K9%.5.^FXJ"J-GJ]\Z$!;5 9("HQU/$9&F4FG=M1+[R(&>46
MXVCAY_V#0ZK1QZ2[9HXJU:OT=N5O;4XMM;"77EFA,BC@_IO\WB<*O9CT [Q6
MYZ?.U?V&O5 ,MGO!Q!AC^CBZ\$=AE6YLS_2T[D#],W'A7IM!KLK'!7M>7TU;
MA0=?JXM7;*95\WFKUH*PC>!F!.4JK>LWLO+9?C+CC<,_"J<;'9(?CI<[A.K/
M"X%G9M1M9X)H&H?):)>?I;_ TI#X;;FAS+('C_HY\6>$<2M#@>2F9"97)@B=
MH;(S5/Q/8J'^_Q)=N)Z?#E^S!'%]/)T]"I.+J"[O<ZR#.JWEV3U,*4SM-HX?
MLON@XIZ-9-XQI75-*$DOX0I<,*GDD<<VM;>B)>4:O>IRNEOA60[Q39^-U 9\
M;<QB*LF\[\G>VR8UP3J6)%&4 TKI/ET<23KDJF"!TO4A-3D(&FU@$"2(.]U.
MJ"U)J(E!B2S-^/E.!_\L*Z[8R>W4T=<1]V]*TGD05Z7P\X1/\D@:%]\FPQ"8
MF!#&-"FSQF2J<VCLUM\$_PYUZO"1D*GTV%N0)-\M2OS !9E/86L_:>.VO<\&
MEW_*0L(9)5,\T;J/ZSKR_O4(K]]*#R31!P!%;IH*" EPI;MIME"F!]E'E*0_
MR]#Q>MSL#Q/)'-<RE\UHQ)-(C3)[_G/SP"GLYR>;.W.'L^Y$ZZS)UU;,=XQ<
M;$Q*_D4PW.A)J[U[BHU)<0*/%F&SE@I*;3>+AX['CM[!YEG0UE.:\ :H\G[@
MNTH"0\' ?Z! 9B%' C-X-;_5[(]P2I"7O"I5-KIUUA/RHVLCW\>8@"O$GG<(
M'?*AUM/_8G*&W1R.4B#8:2L87'NX<FE_M0CS[?<)]^@ GK!B'#?P!E9>=VPJ
MK<8S5U-@5!3_E:Y#"*P+EE'I%&<']KLT0V#D+U\:;+>IV&&X\ARFQ=1Y'7,?
MVVLZUV01]6YPT,QZA/4+"@FFWN.$YC:8]"B4LMYRSF.)Y9F2+8S.QKVZ,/V2
M0;YL3@ZF#G8=N5#=94W34G;DYVB%6;CZ]M$4"@=1I607=6X -R?10=^YH1[V
M/(?Q,94U8Q"+CF1T*CBQ?%1>3_HV3?]MW6(_[YF/3UG;_3SRXYI1=?B\YIWO
M5[?$EE /VX"14[B%T<GL+K\P3S]ERXVR'<)1$W.&GYVW7YJ,*-4B2#LURS4N
MC<J=NJ""-TL1*A<)&@"B*=5JBRR&IF2*(_$N!VO_T%:%*!OT"GWV8Y:;DX]I
M][MEWS#QC.$H6=!$Z]R3@?\4:&TB6)WR/D:- P%J^4%5-I)4-/1FDJ^QF[,.
M]>C8D.3L6_.TV?IG.  9D$XF2"G6!+]%<,6KR)$B1S!1S.@45Z?V<XH4$Z_%
MPIAHV;\W8Y_?;/J<5_"4PVIF60$UQ'YR.G@H6)!B9X_B7VTCYTYQ,%KWOS3X
MRU)3R;!POM:T,7+"QAID I)+'X;4= Y(&'Q35XFGB'_\J*0$-OOW7 97G1O'
M;R<_DJ/[\>8+$.>BW<)MKX^*_)>W-62US%J#A_OA1="FI^VK& ;O/-6\7;]\
MK_3WAO9NY<2YXU'#M]%S#LP<]^GLF.5#[4;^JHR.XN47=A&[< G@0_B.Z+'I
M3HQ 5V]JYV@:N@7<^)2D46*F_J-;,>K'+[TV5BW: U71)T,[(T6C?Q./K&MV
M'USX!H7%7:I^V\'[;Q$!UV2-_I#Y@;T0^;!*F8>M2!_^F=QXI/1R, 0\VNK&
MLX;U,G@_;SBQ83,TI0B4?Z[4%#6/ET.X.UZ3)=<BM"1EOJ L(O><&Y'2S)I0
M_O(5!/VAX,<,D7[Q=X8+7).@G*9_N30N^O6(\)':$5%3Y14+#ZCC=BC9W LD
M$OTRV63S-%:)P%I+<2^$6>"=K6WN@!;V(-MBU#!ZK!MCD9. G4FU\(K%( JY
MYURI^_O]HNSZ%\XA;$<?^\ C$K=&V0QF9X2X.5=#9J1X5W,=M>[_O-J_<F,[
M: 76*+H;'.^IV'%A6B[6H4?>=D"(GR3U)88E?&TDGW&7Y!\<G(O630P7;G,=
M.E!6U=)49#<T*WMSGJS2GR'2#3C9\@'?@S4A8GVL2N/R[TM)QO?U^V)>:ID5
M'3BBZJ+>!+'9?&P5*;/@TL0SN8?YC:Z<HB+JT9^RAAG2Y8H].-"KWV[2*(E8
M#K/\,7!)LQ45L2_/:KSBQP.RDH/_:?4O!*GQCE'G>]@<R63SQ0E.=X/')E/@
M(HRL='>X1;]^Z,OQE>YRJI P/%Q['I.N$:4V<^X9?E;L'Z%S#@P:R1M%FXRN
M'':O4?>>;K3N &5F":/-H*1%57?KGT16W-WG\E#+JYQ:3S^3;R+)=CP]65([
MMUTU.9K;EKI;":W=UOP026I7^/(]#9=( T3ZOQT<E5F1B1 $:^GKPBH>_--Z
M\M2&:>,/6,H?HI$\-VN"!]T9FZ6LMQ.HUP+_K1L4HRDN@46KV*7IVL]Z4#&%
MZ>8SG/.S"'2HA>+" C;[WYS4X ERB: 6,2&+K)(4WQ7)/B9_"Q6-&%GK0?<J
M3M#R14(V4GKPL8BO]'I0^5JN(7KZ#.GO8'F!E2FU]O/O[")HXWZY,WYXX_>!
M%-,8XDY<&@-?DR4DA7CA9J0"MYW0AOQU 37<=S"TIYL BPB,)IT%P#DX,&<)
MO 6)#8[Z#APN+[H<1$!0V+^\NJM+H^V6ID0//DV-4*/%EB4!E.$4)_B!8:1]
MMI23.LOBBHQ<*=^]8D>L/]JBYF[&#0C'DGP%SXO A@X='SM/@3W"H#.1XZUJ
MI-H4&G[%@0^!S"Y!H?Q9H^NB%M!OE?FU\,A7[U=(*A.%EGV5RZ>^W>M:0!4S
M@3C:60[*Y&SZA <X3O4[YE2THX]<%YZ.Z@2\0><SH@(0R,:'BU+79+$F<7>H
MT?E4;23B9"A)TO1X#F3GB\"=?ZCTA,@W)H1FZ.LJZH-2^L!+ F-FTFPTAD'<
MZ8Z&R%@T81@#L:MO UXLCAC)9*N+Z JH0U%FU6D;I"^7PS6W.//5;]>!0A7)
M3::X'E-=2C3B6Q%#O6;RYNB]:DZ3-=LXF'] OZ<FK<)BYH7^[ZKDHN1^*C)'
M&Z,-PP,Q)SV"Y=P2BZ:(/NQ KCFS9LCA]Q61<+^TJQ\I685&UY75+;JRTC_U
M,^IL]9:ZO\7!GSP(H%(V#:2S4_IHJ*+YW#A]8'Z#?T-LWKZ2KX&N\6G5K%_*
MH+XN[S49$_>W_!/Y8[ '56YS<VZ#"SQ&0ID]Y@?/TSI?NY9E#"0GXF3+_PT*
MD;7A?>=&$"/J?=#]E#<;D]4D2O0EQ__FE^1_1'5"KX[%5KI0FID.MD8LU?3B
M5=N.UEDN/H:"KPB?S3:,@&OO==L)@\; H]][3NY0MI&O%Z!/N_[^]9H"B*<^
M;B(7/HP20J'!Q+.$Y2QLKD?!4D= Q:U_;S%:@*Y<\J(A.,TP3ZC!'H_!#\II
MF"@@(GW%@59C. #*-E(U*W"H5,TL>._&;<#*HSMJ-YK=B#S.L'=-YSE^Q)C0
M9>1:.=;DNQ'_*6CT2S[%IRLJ4IC3MU\3HU]<K&N_S6LX23R9Z1?AT#,UN"OX
MZZPRE5!U"51L"A8K"DA8[K*1[G? AY8#)4-M?N_6-.T &G/0,JK5_HYK71X5
M5%CUYAW]5\>+3A4UE;5#]C8QIJXW?[Z=D;'_*CX_SY([<MXZ+RE),[8A@='T
M8JMZ?#H472_N;W22],;A20&G2);$:<U2>!VFNKFZ!GNGR:WY%](N^G/G+8Q.
M@)2QK?V\CY<79XJ47?\[6W'FX)6(!<;+YL3J O29^9BH>=I_;W!2K;HSGRM_
MX]E%LH/W>4+%_:J0%M+PG"&_=UVUK L'GU+!G+G"$3?A! \>Q[C4!2?GP"J!
M2FTV\RP[&7=:[*JV(8T?X-H%I8LL+-3G!18=F;VV2()99(Q%OV9.U6=U^S(Q
M64*5Z+EX"B&D&VY!G!?3:AOT1!<1WX^V *;YM9._?7I.K4LK4?&&TTLH@H5G
MH+EXA%XUG0-6%VWJ'HF%G284 .R;TS8CNET/N(K&ID6U#U4.LU.G#0#Q,VB7
MNE?QE20F+]@!HAB3EIED?#?1TVG:AVI3- O9T73U;+I]MPU:+=XTJ2Y95!L=
M>%GDGS&.^[,H9]?Z+_9&]()!#K^?GX2DCMW!X)>!;O8)].'T>CG)R(I"4S.[
MM&\]0,%Z,+NR8M30H?R07_=;8(5M I.+RSM!#Q;VY7;0.!C*XI+A\_DXVE'
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MZA!S*GIOKC)#VG)J=K JH]]RC'S@OD]=0ZFT6*'3:7'"+\I010\ O6"CC0?
MSS647W^QS%D6]NWR7[\'@*-J,B:D<@S__DW7VLW]\=KA5_O^8S9IH@? G@I2
M!E.!/B;%D#P 6AM#7SP TCME$".6_[_0_SN%D- G)XS^[G4[E!^0R:DR+]%8
MV[ <\S!L#VNO(D;4YRXNA ^O$3$6)T%RDG%QDNIAAN_I $YKE0L5;OSM3#9
M)7$/Y=<.A2]SP'X:YP,V62MZ=L?AD [/G,2QHGW:U&48R=K0TLZY">D><$8_
M^TZ3)],4EN@SI\UM$?I>5_?=&5$$NX-U&8. ,<E-<N1*C7CL'@=&_8ZKHJ8\
MU]2U)C!,&<G'+:4AF4ATHOQ,S,)+-4HC]FG2"ZK;M?@' &[XRF)BY!,YOV?A
M<TGY]->\R85LE3'E8<IM D-4,P*^O]9C<\7TQ4GB7!AS63@4%A9,PCX_\3I<
ML>O@^(/&NH-+A(/[Z/X(A):V"EB$+A-N2G\ 1BH5K-S64BLDP9=%7;PI^?O4
M_6C\V-+AS"[6V*I2O5\M@&MF0 \GT#:2L2OZ#V^,UD)'#@]W;G'GD*0S)KE2
M[2531/<&+B4DVWTW^HUG@C&!%)NI<&RB8"';D;1I#3^VL:OT^XU]S-I1M\R6
MVW!FA?BX][U(X7U-=ON7"@NA)_-Q6_B7]XDYK^:/N*(OI3)(@T)PH:&QTJ^^
M AW '</7+^9N)3R/)EED&%M:KE8UCDUB#S(L%E@$F)=$5=C+JMY9FW(_?ZQ&
MYR&]A N=<BG/_*72XQA+5*<83K(13J54]8D^\VB]H+9Z,/?%[RJL1F '<OS7
MZL^;681:@'8)+=F+QY1Z#NM7G_S(,!D)0=(47^E*<R\^_3B>2HXHJ1MF5;UK
MF=RL:1&P+RF!FW$VBYB35;OR7796NS05(?!VWJMK2C5?DV_>!IC8MGU>14FO
M>E*>=X)ZS2^OM-+6"&P;\NQ&E@0O#=9XN@_8A?'=]9Q$I'>&'$"UAGX'#P 0
MY W0"=SG&J*X73Z3-910_EYO_ N*!MA"NNK_,BHR; <BC)&T8=^HKT\#SBB:
M4]LRVE"83),!1=X:L.)7%392&:8>I7A\H%+R3=IP6<CU''7HS'%W ,6F#V_N
MZTI\F9DO\U%X4X/)O91A73$CY6:F:I=Z=F9*6@)S\K.,K$4G"1INE\6QN3).
M<&/I%GA?!<UHO*@:F;]V=J4I9$EC<?[]F4< O^MTQ83?++P?PX;,WY&K?QM*
MS^/Q(61A14+O;1#D!0E//&6[W<0?U+-G#HSSLQLNZZ/V!HM@1OQ4UW*_7 O5
M-%*UT-6%)(C9[>A1 _'F/,T&.8FQ!4>XL@*35X\+33K>QSU!(N^UO?K=MLXH
MN]-BDYD7^4(D6Z..5RD+RU/L*B\M^2_?X]33\EOLM1]4L52.WX5<XV85)U6?
MOY2SFB7O:=.R(DHT;"?065#3;M$?$5HE-NB6:@.\0V&C*B<UKPZX%_+WI!X
MT@^ <ABU# SBXZM_7^2A8]^23OUCEFP%Q3*&>-%;A?)3<-^LA1H;/Q6\)-02
M]'-.5=U>T8^J95F_O#4\)MX/!:9"/GC;R%$Y><;-4M[\#%?)/*.D-&Y@M.=D
M4%S_=%JQ:"'6G,2]! P%:_0NM)& <5IH%Z(7@VOS[.WD[A/08%U&O$B&Y&BV
MG[&WK!Z7/*C5*VIT6\<B-^CHZJ"& \]V)*;ZNYQ.$YI3I<MV<![9Q5AL;J>A
MEYGF8IN9RY'ME*D0RET5K.S?/UWS $A-;R/#_-RW:$T:&FH-0CMOO^T--HI9
M7E8OO2P/NQE'WET*BU"V.L:[V7/RAZ9F58_.;6B\$N\N*;8/\IRA?W0K;=@*
M/>;AY79*(>D28"!Q5/[@\L%A71%7?[ #Y5GFPB@3H\BF6#I;#7:N?+%I)J%2
M8GWH()0.,X_O*DLAIIMB&J\[JS)TI;C3,&KH.Z#N6NR\Z0%AE7H:<3OZR!05
M0GR.N(9W)R;,.O==:CXL5G)GU]8T-L31*^'I8_PSUB.8$TT'TAKOD7O)U^<Y
M:_<4[>'W,;>2)XTRV]SA")F_[JD!*)FSC^&[]/]9G7Y]C2F];WX Q-VBT> *
MF=U?3N$7K@L/ !3M,8)X]ZZ\\7;D_N523S#M]3N9\Y0'P&^IX*)]&2CM?U;
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MIYR7YH?5#:AGB+7]Y/GE@ LB]H%_/TY1A;T$"%RC95HD]&\VU'['@/?"#!X
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MH]W2K6C]\71RZ^._E*>>+1_Z&GC.RSX])@-./#&WO(UTIF/-\! .ONKH//K
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M!>(^0:>]>+9E7#\I'IXJ/#?) H^EU.C/OV>TL4HUD=#'IM=G],I2N$RJU%9
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M_']ZI)_X7C\+^6&5VG%6R#AZ VB)C<"E=_SN&(>EFGG\T_H,LFOJS<; J!N
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MW0!N ,G!,3> L7=GLS> N;+%UOLW@,+KHY"1Z8[_7?M_U_[_0.TTYLA%,<*
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M<PA.+H<Q_=,/W&Q=C=Y*C5F)UV32\1FBM5 <:C#5;:DE8SCQ:I?(8ZVF3CG
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MJ1 4I2A6BU=:E*Y.M,:1SYFG"Z[^O73HG@HK5@=TE/E_71B&.SK)SQX>G-X
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MDMW-M'#48ID64[*)6S35C99>6J&.O'D>N9R %'6'\L#^Q%#(/YD?L0S3^NC
MM56D$L7IUM9 '6\'U^*N,=$+%-\(4V1Y_?XXRRYJ95RN:BM^B*"W<]KF%G!W
M!<@LHT^Y\@-PZO_T5&M^PB/9Y4U'*W-$P[1S7U5>?""',L_H'"UO9E2+C1,A
MD1"I+TNR^WZ)OW=Q(,E_2^?<SDT7K=]?'3U@@'6^\;99')Q=%>6;^W8%Q?I[
MB\:GY@^8-S2;)=$ROXH>FE#O*.>VX_ZH;.$ZU!J&K^)),%G$RC*S',&MK5D$
MZU]P*<C2?[!Z&?NG:.='^Q(J1K597Q5DH>OQD=H$5#[T[4?57=D']VCH4<X'
MT2K&D2X![OFU91&UT2BAI<;4E-3GU3,GPDU2>GD1A;D^7P55B2<&AH9DB8O#
M]DG[KLHN7GWIP;^D%&WW%T]_WB8JO;F<G4R?W2WXYR('@Q;I\+?"7_<;(_3$
MT@5:O2*V!RS=R%8&0?(@'NUT!122)*>B$5'_FG\2O#0*(0TB1[4X&N12T&NI
MG(K =GXU@-_WZ-W9S95< 7DV4S_JR'7TM4J.D43&LZ0A!-9,EY5+?,"Q$.;4
MTJ*)=B^V0:<<$<?+(F2$13Q)+*8Q4[[+4N<5\%.7=?ZXN4O"'*O@.#W[T^Q2
ME2$5EV4:A]1CA<HS:9S "O^-N@7&F0:ZMZ*CV-2Z&U;NDM(BF;55;O^WC2PA
MGCM\@>+M5<^;/V+ LI!!N9?G?[F:?X:&*DU,5UM3#O%]Z\SS:&VG9^W=3QB4
M$%%#8-C#[XT%DQ\IJ-D+7&M^+D6SA)6S^-N)[('=2)<G:XFY '=EJH))-]A>
M-PRH)=5UX543RY.G)=' N2GYA,].6%9Q:V^(_E6= XUE?%K@IAGY:RMOCMSP
MG9^1 LG1 *Y2!?V*-FK/=,?P;%2C/UF0N9<79EEB6*;Y]-!TZN>V%]L#SH2L
M(I*&<F_]M3H<)CK2:?T1N:$*3]_6D*Z!!HFX(NV,VKACGM,U#X/A94@L[6D3
M"FFO;F7'^ZS?D4RL2E"6ECQ*^15YPML39)8"**&).6E--4(3H"/<]28-R'BG
M9HZCF\:*"?98'#2Y!L_X^S7'^HDT#%;W1H_"R[0R*XO#03"U7G/*\E75 )"&
M)S55P++\8XCI^Q&F*-*_N@ 6I_$T,];6XS(2/41;)QRYG^UOKNWI12-.,FC,
M*7#M'8_3H]VC;3 O2-TL?$ML>E(9@.:54!A436:JY"4C=+%PKB-JS]-CC[9&
MINL7OE"U9@BWYT+U)&'D_[HH%4NZIGWX6/VM*'1N#MMCWA3G09LDH1M_-#OI
M\Y Q%*5R=ZRTBNO3R]<$Q:9;N^KP9=TWS;AQN$B'30QK6O6XU:NJ'FV&]I$-
MES+(!L)3L/^E.Q"4C(EU/>$; <H3O6"9?<[AMR+#$Z3FY34_M@_K.50?6[Z4
M<9N!5(YL+>)H4=Q975;<7N&F7IV0>>6XNO*L-/$K/:^?@VK)?17<JF::8R/6
M;M_W3,*L$9%05 /F5321<I:AGNX=\CAH6GC"TP@D7)[P_CVMOD]:E!$:P;XL
M*!WT<&99>&%B57I<+>$T<RX/S>:'OJ;J, /Z'+@_@>6JH(=OM<@$QN=KAPR#
MR9>"P767&7*]F>;J9 NC-FI"H/#S47KIXA\<GN^?PF9<8HQ8&I8"9B[,7M**
M//USN:A-$J(8WP<!E6')9N8TS8_>5KB\K28Q"7R7UB:*<LV@SHW(HS-C!1*3
MJWU42F,N6FP(85MU;WU[_\9G4YGA^IS]80/U@Z[#US 92H7[BASA&:GWF$+D
M:\)SYYUU,0=EH()84DIJBHU4(_ZSY4S6Q!FV5!+F!(DX(XM=]<;0>+?UG5/]
MN^D,;7LL WB>0%Y2[0DK0>T9*:=%F88R@6EMJZT!I5D-G;N]$K/PK_",=-Z3
M8/X;+0-@RVYEV\^&C=KE["*(L]1TLLE\4@Q_%A8LTD:;LO2FR=?'.I[]Q](%
M#R^%@G2JM9&*V';%1C2+#Q/GGM8??M2PG9K;$@X]8T6FY<ZL-.ZB0963!0*5
M!&I3INE4(J3K3(O]8ZF\TB>*D<F+,8IQJ0%"#N3LT]4>$PDI=XCM*%0 GRD
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M 79*Z(^_\>L0R76*K3AMA'%:&.18;^)FS$C@)D+ >5NR&;88VZO, Z[V<?L
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M4L4)F!E9M M,'2S<:5D!<"R_FN%\1X_^<>=3P2[5Q@,YF$ FO/G4@N@-";,
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M4BNT8SG*5.B;$3L4,EOO/=]0Q/=< FYM^Q H$MO+^-V?\)65E[I!GY2[;"9
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MJ'X)6)+'11%C0_&7@&FJL$/.*^ GC&8)WA;J6&?4Q:40O=K^S8VHO=J+E$M
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MF+&5!PU)!GX*$[&9F1JLWWL:]KYD_X:Q:K>C(Z%9'@(G7F0.*L\M*O4";CL
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M'-3_J0)OJ(RB9%-<;$6-",AZO,WK5:(<6OYD*DOI]=6F44ND]J38;40$Y^_
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M2W[VH!4/69"4O],C>G?MBV4#-,X@CH%:3Y"8#*EW!^4*K,2Z^X'M 4BS7<>
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M/6X "W=6'\" >-^V"?BYA#G#99)KVWIIR,>+.YYM)UHMCC> +Y_A;:=EFS<
MFTD4YL4?C__0\H_^ 65-W2D^);I:O.*:R]IMX@J0I*H1&9F8RXK4JUZDBLZ?
M0\7[N]).5:^(D%_T;Q09!QJGWA:SS"\,-:*MQT5N)'6H%/JE2OKF.M)E9&B1
M9V1%ON#D"?B6\7@U+L;EM\HS+I=#=99!:LXD[>%?@%O<0PYDBBI+8ZRM6Y*B
M7*WN >96NT$U-35[(./F:_U:P9J-!3TD9[^GT+<F:F,K'[/YO![M2:55'N]L
MH]4$[O>,1&5AHOL1I0^W'%MO^]2K"Z',$($*6@_Z>;J%GN^4F^JI$VGZ*@D%
MW1YOG>G5'Q\F. >HLPAT_3FXKW]GEIZUL,;;+>&I]8/W3^1$?MRED]?IGLFF
MP!\:_ZG,,59RAPTP.Y1C4C#CRHE-V:^,Y4E-ZIP>>5.]>60!V$S&9I\1Z%Y^
MFI,--QXCD^:[GV,R7CXHKW3QOJ',P?!5_''*B_F%^9<^LUU2V:*"WWH#&;!;
MEQJ8J+C :XWX-5[M(H:PS\RZ=4(DMF6,?SX7]2H C3LHC>UD6?*9,+$M<P4=
M15%VMX3#*[\[673KUY]]T7_ASFAX3E\9;\U<YSZG//$0V4>L_4PUPDKHDM-4
M5NJ6I1ES"6%MJRP7DVC03H&?L.]XD\(=E9].H,<!$M@"/Y$+8K 0LBU:&$'!
MCYQJNX?W"/KX 4/)DY*.<3[HR#O3D/'&N=AY"G[X-37B+R6P*M!046LN]?+6
M-!U+Q/4/%W6W%PTU=1E8\O4U.X?DF ;X7J!5XQ+%E%SQN6_)]K35#]<,M6++
M6D@J9:H*((F#IBVB4O$[E\H\<96)3)/I-><]QEU,TBG/$]V',F.AY^\>;M.H
MDERQF_= Q2BNB^:#$36M-,NVA9_Y]O)@[E4&"G))15&(-0W%1.,8,XT,B:%@
MU52)[,@OPRKF"@+#FJ^:M7L&MHPT^;3]H9$SI;^>:= ^>B#&PB#UP5FCSJ[&
M(:S7[LAB7C-R7C55[LSC3HE^3C'GX/M.JKB!<T([>*#+8(I%_I';"_$'<D\E
MQ<CU7)4;&I97MG>V3\$F(9PM>?MIY:]5O<@[=J\7POS 6]>-._1-BUG['Y"9
MF<4^=&PH]5XUN;3K76]]M;,,.R8C=3(7RV+G%Y%'KS(X<K\8M;@@>&"]=6!)
M>KS4KKM0@CKI6*X0T9<XP,LNY7+ZTA5J T9S[1C[DWA,F_]Y&>:'AW3=J>=<
M;*WEO(ATZ\S6K#>*KXJW0E0(D>U@/>&:=/3EJ;@OY:/EA("/D7D^M@7SBRPZ
M+/R-# G2]L(Z8](N0H8W@'CON8O""([EHHR*C*HF:#^KA IG98H>XW?3BG9F
MADW[)=&KI5[;D$UCO9"3F!/221G\64CS#:!VYMT9*N0R1^9R]0:0X^]_O188
M<0/XL5\;<J1$?(ULO;I.;24)6: ],;A.*3"X 3B,!D^*WP 4R6X :M>C9ONP
MW?.W(>?]?TWS\2[.H ]\?@.@$;T!R+O= +"9NVU']7N9UWLKT+:C"LXVO"+^
M)/T&L)AWM7&5W;("N@$<?+H!'"9=AV\OHJN^+AY>BX"OORS= %"BBVT3LQU@
M?&?<P U@HJ[T+S&:W7G[&T!P%7X4+PWN1=T UA[= #;8KY[,MC6:,[9M7+HL
M7CWKO ' P'"&H_"]PS/ET1L 5!UE_FM$?OF^_57&][2]VE32CKH5F2\A/W_4
M7[]XV9?66=6_(E'A&G16\>OQNU_W*_A[U85UQ L+J@ISMB3V4G]]MK18TT^Y
MTJ"N=ZQR%79T\M\4^NV_C4\_(-&//SJ$'F].%UT]_"LH6(7,IL0%^/QT?$?F
MLS5Y8\^9.DJFW:8JB30][*"(]9+G($&GVX!76(#A#SN6AI&,I9_K+>U 38.5
MT->@J;.<%((MVM WA<JD)06!I5R;6MLSG_">%+?[MYJ<+[X+.TV:H9TFIJKH
M>#0>5-X _@VWL-VCVO]YC6'_6..RZ\/_LWBXI4OVH+D.)9O75"=>AZ-,"@1/
M+VO*$XT*4D*52+6*% 7[6>+>Z $2U3^WE/L0O"W_4--]>_\Z2 \'Z1O/5M,W
MG'JNDOCA5E>B_@=B ?_34ZY5T<L;0&SF#2!7+.1D^/0'(U*&T%WXN*&YJJ-U
MIF=U?UJ/5)P (K=F]C:N*126J!]:&@=+S,NU+BXH+<RB8HF=-J5]^N8%/C?=
M5L^[45^;\R'97;_WLV7ID/V>[IY;UY-]JPR?AVR\_Q><9(O6!-.N.\TR?#[3
M1%$9GS.6%:O2@@>^IW@#)\>TU<U-!2:UC][5"@GI"D'5N6XY+,=F?=%C\?M4
M6I#M_?B>"C/ +UO:N0<5J7#!/C54^B R<>AM:1PZU8KT5J+R'?:J$(]6N9#1
M,V3;!?/G&X#+HEO(Q.@_U#/[OZLG;I[]OZEG0 ^J[7^KG:UM__93JG]I=OSI
MCQ/_T]B_H&. Y 8PHGE!\>^&_0L"U&0>M>T2!7#= %0GRFX =?9MCC^N+F06
M0I#;P2*8&\!+OAN N,P?LY:KOW;N!B"S\A>L_(ECN*H-PE]Q7[+= )K%=ZJN
MN%2KKL>SKPI#3O_< /QN /95OBB?RY]M_S("_TZ2)^Q>V9I+%&X^#'K>4HND
MDFI@.6169"V$%+DEDT*84-:A@/"Y=__1P=04F2F[NCKPM;AS\R!I7 FC.DOT
M(L:\1\%N7_;G-<.)O\<=^*C0^VC1>]\>;U=P7<_F*]E-!";-M8#F)%$TF)8@
M\T0DBMD;5QY$I).WI2@ A8,MRJ!'4^D,-5@)_\6:DHP8EE:JY^]C5*N= ^1Q
M])UGZA]'-]RLEQ_8Z1'PVG-$&J>=6TH)Z/)*-/D+9RLGY;,HKZ9;3@V4Z_*+
MK"QTC+QY_?)?[)8*(?QK.:"!U"%_ =/;H^)N$#B!BM9,D)'=?R<Y$<&@8,2D
M,#[$I,+I:)6A\$4%N?OBBV068_HWGH\L!^Y+/J==A/VI/;\ANQV\F%%[3^&Z
M,[0BQ9.#-([DP34/88]RH61*-(A8;A1H"M03_!3W,@$S]^'6Z\70F8LMO= I
M*G;AW%)RZS>&8[<U "P7 )7-]"J13-]Y1VS46[%:5=+'&8\3Z\A8;AUN"[O.
M[I9[T^G+,1X\L7K__OWDL-%?DA-C$^/C$SJ*D[IZ>KJC\X\(I:6>YMC[6)3^
M3'Q#/UW[U^H=JL_)E7"&I(7T^0=/N7RG5-A6N99S_08_M..T5(UR,=XY?_VZ
M<DG\T>:JT7,&^,Q^M<7CKT&%4'MT,FS1(ZE8X+8U]1\K;M8'*D+\I.XOQ-_&
M4&>HDV$*6C[E/L&6.MA+O*SLICQ+WOM#=4OBF#<JT#B<2VOR31&V%J9XS,#>
M5+VS$D75CE#2M29"BLD]0,?\&@TI "_9DSK&)^&D6NGH*_0W4-%+%V_%$+?]
M9%)G^_,_E\RQ.[Z[PK8\YZV'V"FH7S$'^CRJ14.?WI>?3+*^DJYV7:8)@NWX
M/%2<%?X5*E[:2C)B^"*<9;J@8.:MKT7:U-N)_#N>8,KF)E3<J,QL.W$LBW%F
MEW*).5F28D%,%01Z>Z*P;M3P"-+XPV62.-E4YU1R(MNX)4OS.FK?+ BI1OC<
M9KT$Q1]2$,+FG\WM$OU^5)55[^.G3YLO\.TI82NMLU6A:7XAO#> !*#Z?79G
M5_\9=,B+4_V'$UC"-:"F',SG71'/_D&"Q2]7E2UM*6_/^52HDA9)HXBH8"[:
MQ)CF3VLE5YCK9JRC1$["3^]IO73K>_-,=S[=B_KP:%- S6+?&,T3G>FWM)\'
M)H$IRYW9Z8*$?+M^%%6HF ;53\<5:EDBVH1EI5V?K,:;V/PV\O!2 <9MEKXK
M8/&C-3D<-YB4U#JI4>'D]WOL$Y7[=)O%0W&\1O%^=]@:!1 [DGU.A6DQJF,=
MT*R'/+#;):R VPR/:NI]$S-1M"M-HTV7:#+V5_5O^E.BI:^B_3)5\5XHSU&X
M5HW#>/QS"4V?YW*>4BJFC[L>'[%ZS6"'P L%V^K;#7D]G3\P 33.&X?N2SFE
M15V\YEP1>>5]-X#'114EY>5%O=2-)IVTM>HL[E\KF*NYWP3< %JK3X.3CEC_
M:[G.XF[KCWT9\W_K?IR&'#?> (A/9_[Y=/RO^A[\;M&EYNR_KP6>F93YV;:3
M\OKO9EZ*'Y.Y?)HIBN*[*F?XNYT?J&';T-*]5YPAO;U Q GX<J0M5N;,[23D
M^N)R%VK^CU8;%D'_*?Y95D@$PQ[%VNXUAY)7"&[%$F\'/N([6BF8D>(+60\+
M"??G96!J&SEBN.8. =X </1K)ZK2+1/T,2'_A^;,UM>8W=D?9PV8MK]+!\R_
M@LK P4=AE^P%V!L RUS(>FU(KT'NE=P-P%:GL6W?',9W?>G:=:+^ES91#/'_
M!TU-<+^N!4_9E%8VC(YO ![+0^MYEI?=\U3^ TY6N7FL</-R4389[^6GDIP2
M=B)8;P7F"(F'V<-N00L+*/O6C V7]2>&ZW-5%>QUC0;QW>9%B-B?W[[5LW_1
M,N_2Y<W)(B6G5?"YY0\Q8D$99\:(\@\3VO@FC]XB>4NMO/4G0EX/\L:0$23^
MAP$MIC=Z0J]$Q=3'5+9USDC",BV42]VV^U93_@;@K3P^]69;ZE:[(J&-R"5>
M!(,XC%XV,;5O@!&_GSC5MPIST;6XYCVV90OB@'C;*?WV! \I>4/H7J\-61ZF
MLQ4LMH3/Z2)I7>8JR$A)Y]"9JDGDQ#1DP,$6UX!1/E>3==CI24AS^:+;IYX,
M5^Z3>R(( LO0$K4?!?S20_MW\V%?'GZ%]D57VBN7BSKS?+DB[  E]=LSW?56
MG_37EVSPQ0@ZVAJ$@1,+UWWM*MIU*.^E@;"O.TW*A:DJVF8E@Z46,-'^KN6I
MBX.VGM.ZIEA>WA\@#;>Y\E9DC[:!RX44"Q>W'Y5]4;^Z% ?-9+EM?'-0VX'!
MDH_':7T0;S_2U+W&'Q]H?2T%XJG1NOK5[Q)4#ZM&^#3_\7F]^A-'W#PXK1V%
MK9K1N@'<+QE<?N'ODB)D(695&&+?7&$IB".T;0:_SVP4Q4M&\E&21AGF5*.?
M;WD;>=>!W+W=7987%)Z1?S3,)92=QU3QS#K!+VA4R$@L$!_D*W>%?$A,#"D9
M>86X$U"]A/UQOX.K]X%:5@//X&40N,-.=EU9T0+R$K>+:9@?QG[-<!Q9$/:#
M^!LET9X]EFZ4C<LKS!NQ872)(4TAFB;UF*F[K_[P2P2P]=HZT'4KZ!@XX\=Q
MH0.7F W $<>S^_1.7YE/9V9_YI@,D+NUV%#9EQG8.O7Y'M2][86/*>2\<[,"
M-<]6V*$SV9.2[/VL+U$>%1LOA(-=MN-S/<%-:N#&X+P(63K,S&*=DC-AK41M
M[[T6;/(L12%K'(?/[8D.-GB^Q<'^*A(,PU]57CP:,^ZG9OF22$:(Z)8J$2@>
MYVE.U:+<:39_;HC]5IYCE]2]^60R2 >8,$>CR9&<NQ.4D])M"X<L]V);>I%T
M8>_KJ- SJUVVCD[4/Z3-=1J<1$:DK-:NJ:*&I,;?=^H)\6BR>'"]8(\^7]F/
M=]^QY'.:P([T[5COC59*R-DKS+6\B(;[M\(KJ_VN:EO\EU5;/NK$#KCV!S@5
M[#?&O-XB)E-$J[K+#WSYU!PV-!9]NJ&&H#$-R%YK-#8;%H'&0EY'4>H_M,;&
MC:A78JE7E644S\Z,5UYF$RM\+SQ!*;1Q@ [[?V-ASUT=F"=8=8&Q_;BE5$5;
M 1,EZ>^QMCR(5PXJB<J+)MDOAO4F,@?OI'05F>IO0%S1Q></$)+,@5K6HC8!
M&0A(X7G9SV%]W'C"#LNP>CV_+S*_\F>:JS698XS>?6.M9X:AJ2%I,JROQ4_8
M>RL^3[?0IAB^,V7#;0>AXK?-CU1@(BD&.EJ@X!]!\2VO@&$P]Q1P%FZG9WM1
M9\K.HF^VVS<Q5Y&-/?VWZC#(FT\<Z1H0CC<#[04YD.3R(()XAJ>;89!HI_P.
MZ)SQ+Y[\AKP@N7@2+:+._!//80;>;GON"UO^'@)JN;L-*KS4ZQM;KW;)EE)8
MHNZ7P&+UB9XRBY7,X)7<EWWBKM$!841G)8=&'#GX/OP#:80[/O?A:D0>5>9/
M5*/#\R3K;A4YOKD,3LCMH]/7"H^XJ#3:S[4N8:+A]@H@:DQ14RT-%V,-GJ$$
MCX R%)YXBX)W<&WH!OK:BFW0])>H.,2=>E$9M^,0"^SW[K>#<O?NW5,499I:
MS]7B"G>ZD.X_C\^HS+.YFF5;M!=Z0D(:!1KH=&ML,?R2PI+-!>H8:X>Y$I=3
M2_83!),^XS*>V4$>S'(:=SX-FEBP8E-ZHA :X,B-FS2E>6]$)_J$^2*>IJ-T
M!]K/>@>3"45,NNI 6E6I]CHYS-L,/';H2I+1Q^:8*)2LCLIWU<MA$1K1[UV@
MEL'39U,*=Z.-=%2T'CQ3;-*%]1\Z_\995TJ !\=,;6$"9_0W@%\08F<7AXN,
M(M&O985=)^3KPR++2*/B \.K/"",Z^+:19&$$08=_U::5Y2FNO7H_8#EU:8S
MPJ-G0WK95$HDD5R"U%>4T)DO)I[F%D&"F2LO/'J)XT(W8N'E44^BXE1;U(29
MZ08H"9QAF^TG)>EG:UWJ<&>>6] IOG5^_8E#47Q]73_+H?+:_'OK%%%#2(&!
MPPD92/$*(V=KWX0+O#_M3U!(0GR?U[C9B[+8/85,-YD$+(\V)(BL')Q8STE_
ME,:\$F253:J/BSN7V=OUO@Q>" I82)YKKO(\I3]$4]&&N8Z4S?O2MR(Q'QLD
M-2UM3N*.4< TJS'LZER69112#/V)JLG../*W7T%<8AJ6(9P?Y,PZ"I>T0WF2
MZI]DIJ+MLO79Y&%Q?FOH"3\V'MHRB;Y[#;IE)(5+T];JG'QP:6W/ZUVF&>=/
M"8P1+Y.YJS/-;Z,5HQP)3B8^\EOTZRD?"0Y-\._*5.,9Z-"2.I[8\.)H2Q!A
M@L&7LJ>NG%&7A2L]DQ8>4W4H#SA#1B*LM,V]TN_/UN9V8,(C[>><G$\2*\$(
M_.J/CM?5.]*3L?WO TVP428_WNU*MTVAXIU=>!H1_'6D5/3]"^?O%@9P[WQ4
M9.'[FBD8% 1!'#\O'D6=][73POU5QB+M81TTE,<*XWKB:BG*X<XN;"('$VY/
M,2--R(4FDBL7]S\W[PSN]&W-( -R15X^T9WZ.DBLM$F/@2T>#'8WY,PM9_QQ
MS)7L4AHO%:.F6D/A>/)2%\0*K#WB>88*2ONVB+Q/S4YZP/8N\SL2$!E#J:P>
M?%D0Z#+U=\7P*J=CF7N#A$3, JH8>RZ(Q-3":@ZU]#)BF!2?5Q;""OW?%^\E
M:,J0X+?S_,/PB*2=EM@8#!*$0."3O"96//$D)&V0YH.-5DE<5N;TN*U;^E"*
M-+E5V@.4=\/%^8LL*L8H!C$!@;,Y@S:ZZ4:/K<4T5WFIOA<)EM_#"6D33;&N
MK(JVWD;,<'C+'C+/VXA%-8]+Y&M'$/>LQJS;1#M<&F9-G5KT$20\E,8?^"8Y
M@25"(*--[PY7]>W\[5V>*C9LY_02D;ED>&%EX)ML.&B#"X*S$WOIZ27.V><H
M<':$'Y#OT]:NEUI@4TI\9/:JO\RP6CKGLOV:S48$]^O7B0:*9"?&Q^HH!'PJ
M^MY:0M)F^63#%7)IRB;RP.:$5Y(YU%=Q3!((==>5C*BE4J(C(]HN(-9@*CB6
MW[1&5?:L",\O<)I4;K;%PE3[\QS"W".0.U52KX!;VH]6&B-=*%6.%H2T.]:8
M#,>Y*2A6=P]Q"FS."'68> K9L\JE:C1N+4 $].+-P1RZ)]*//JV<F+9>@,JP
MQ34X;'!";TV0SML\K6-7Y2) <-J7$ ]LKD4DYKF"2J5QHOK$+K QC)XWWEK<
M(#&W+#%!,,6]/R7'\*W4I&+'KW6#=9]N)]!5>$[?L4C/0I9EQGF ^3QFC7YJ
MZYT9LFHGN*P+6]F0CVP8AC?XR$V#@ZK"DR"6'HV!A?,?_W!PEA98ELO)Q!**
M?.U_W6,&^PJ4:ZASHDR&MS8(*EEZ+7FW3& WF9H4<7H?$D5C!\N86B[LTRY6
M6,.X:\UZZSH*,Z2 SI9"F3$6KS@<W7VQM"#WVQ'46M,?8C[[=QYKX(,25+2N
M<&A40(W#1:2(':IL8",/+034D30YY\RXN+BJCS/FB6^ 'G&QDK&(/_J9K5^4
MK^7N9VR+6SG/VK<9#\SL_VVSC2EJ\"$Z0&9.ECLU):V$:>&(V@>Q4KQS!6)9
MG4E8*A\B9DL7T^ZT@A_,B?$4]T59-9,+!28D=:95;O&AK)M1#$FG8O1:[M:M
M*I) KI?AUA3OI7RXA\Q45!5(AT$/ON@*=RJXQ7TD4!-MMT306]2'ZL;15"2C
M?'$Q$[52!IQ:[QD>*<_>U3 2@LJS*AE]M'^WU#0+15T]6:F=V^D)EM(?'UT6
MK?3Q@A!*4YP:_Y"A,R77I%"(F*N;:_"Q6[XF-$PF):LE+R@,3;&SXKP!^$7/
M@@)_S?W%\KS7NI?1'>O5026F*&GG1L>F/+==H@]S4UH[5QLM3B)Y"G2N[?UR
M1C!&-(H"5*E&F?FUTTC:U.GQ%1_WVE3II'4:> Y>:8X:[$C$>90DJ\Y7<B]L
M+OCIPN#U%WWQ)\^@+4V2<K21;S"<89[ANWZ:GHA;!37S2UKT'_2YBKFI'VI%
M/%^S;'BXM*H==[M6T>O+!<D)6,=Z/TMK^@K,2A[@N'1Q(@U7)WI",8>'<VD?
M28J(.U;/718>E933_/"VYC3+R,[-Y=R*<*J^Z\VF0%3I*+&](=.E4=(;*-%W
M?*+C_AM!7,Y>V8Y;Z!OR2AU%2[998K/VQ_!I53X3ZR\-SH+'=W9>B]9"O<1=
M0 1>ZZ5YCQ3'IO0>IZ\;$9]N [,F(0O<.Z=W86OXJ\^>=>DI3QX1E#A!CKS
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M4Q9I1&NWX$$^CM8P ^/67VB\#@6P>@^X4F\Q-/BM3PUQLBH^-$*PT]K:MW;
M*_.EKHB=5Q4*B_M!(Y0@^RP86YMKIAY4+0=H<K413$U189#C5H5#J]R]&AL=
M.MJ?6L&*G[U+C.2]!79",YDVS.,^U _.)>[DQLS>:8^C1(8+4R['B20D*X&Y
MWO[LK!0K\ :]GL!(>HK7%N^1I7AB7V[Y8,UVA2>6G,OL34K5#> .U\LFWO0*
MC/GE)>/$\T83+YGC<@KUB%1D1B5O +4Y!V%Z5=>9HN<B%S0;6\.]9PR]9P%B
MG_$O-SO"\FG"@V%;S=[9.9>.Y&>G$Z'=JL<1@]KE#VVY/N;<?245<==#Y@'R
MGY>@TOS'+D&=G2Q;QI'B-.-N $(G6[-C5IEN%M?"2_<-.%@2K/D_<QTH68\3
MQ*D:6F7[_GDYM*"2(;;J3IU(F@ .",7LBM+!!A@O:E6?THZ1_ZJXU:UY$5FD
MF?D%*U*QOJX=*+9,Y+Y:_FCT5KR)-^*'H_+74]$>9+[5<^Y31^43[:Y<;U>_
MN6A/-XK]XY,UF8,='#5A2IWHM37$.X[!%1>WLCORK=(?VYY$AI?AWU]Q44?
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MQ7%PWU.-[$F#GZ&<GYR\^5.1[W-7&$3O@%EJX5;IXRWUFEFZG(2NDRPBXOH
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MK[A*W^C8J [Q/L9I3SB3G7+A0*K9U7F-V6>CQ.=39(BN'X+T9KC-X:SQN./
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MPZ X1<Y*14_>%<'3U[!"&QY17Z*8745.#_$,B[*XPJR^:6C\L],7BD/Y9+<
MG(SH_(W' M[?>%_ML.,6T!"#.-_>6CI@N5I@OEYPN=*X!;057?S1#ZPEG:4[
M*D*;_&%$(&X!]6<=@34,BTO'#5M$U^R!47]Y>9W_9;^:W"W 6V)C=PE1(1$A
M<5;WCSSA+<"*HT)B7:VNXT36T_,68'\0< NPD&[KV(3\I/NC?0N@N@5<VER>
M16=&W1P%CLYV>'X() D\L/U'>7Q$]T/@4)9MX%;$_L'-[.+US4"8;^#8?+;$
M2<F-T%_C)\X.:,2HKM=N >F5 ?M--ZQ_2?;D/RKI*15-MX D<>0M8()T8>FZ
MLNWR.HX0=PO(:)0,W-:Z<KH%8/,.%D5\A"X'_\DB_$\M/;OD,7*Y!;#[%]P"
M<CD0'9<FOF>7C#1_(P]1QT^W &31^=(M8%Y^J=7]Q.DLX<:Q[;)E]3SO%N"K
M=GQZ@#-K6;W1OE2Z!<CH>@;BVL\._G7_=GC]M_[U/8/V'\K?X+(V=Y?V>J']
M5R6XY)OPBOV_MOGON9P/'[ZL^[.TYOD>]^ WYA9 QT.E9''VTG"_?"(Y??UE
M?^I*+V3OP7[/.M];"OJ<O8@AU,PW&B5@&F,$B+H8?"_+/1YLLR!I%^L7<]&B
M86O)+_1&$4L;XJSFX_Q0W/^!V/PB@D]LDJ8YN/.C:)A0^LAI]%7/KZJFBB_[
M\,A"$XYX-,J ,X"/1HV[NRC:9V>G&2F<E"_+W;67N_: JN,7D8?EF>/VT,^-
M=HE1V02,]T@(=??ZZ_Y7^B4<O$E@DDGZY-K<1.#/@;*6)(.>#W?[$8^103D=
MBVH7+9:X"]1"L/Q[M3^,@5D%?0_77IIH?JQ*K"??GPG*S7H>&>K%O)6YIY^3
M)D).IF E,T?,KO(BJ*)11.]Y@-AW;.(2<\NNM;O5#*K-]'<PJ1&2H^UPNX5=
M7 TJI\N!HC*L?W.A_-+>H;TW>^ JI'C^@J"MH_I"T."S-$@*+&,N+2_P]B6N
M\,Q9-/Z;6$\KX@5$K7'0[B[0=?YO< DN'DC,L([>!??P]K/;N.+IR()W=7S=
MY_WP'?R$SZ2:^YODW5888%0I$PP/WH!BNGUMD(MZJ>0B#X"['F:T[1=S8(KV
M'\,S3DOQ2=J7Z\ZO8SI!2*,P0J:*4H\UQ92KZ"X[XZ1@%A6PP'LN6<6U'=?8
M<>'U>Q9]6J+I+XYV7R'8SAH&^ZZ4=B"=G^;_#MXY30>UA Q\&\'7*N8>%;IV
MVJ=<A"SNGG*K??MB;<VVQR^FK3CX--9<FRD'\VW9_5Q;+;_Y#A=;(9HS<?K[
M%?E<KF/!RCN%D]LYK'!B80?8T".L)GV(AGPX4IAH,IG**WUK-1JYR&%H)(<B
M^V X#&Q\H<;+XXKE/#)2_C P J=25J+\=#=#PA1*,J]#4-1L)]KOC=PI*AVT
M:'RH?&;A'=ENE]9.G>B-VGWC[Q)*OC.PRS:=&_'9EHU>]C&)0@0)Z[%HX\6W
M3=XVA)%^^PT7-UWSK\4BE[T!1/^*]9GHTX0EA-;SZC.R7VAR?02AY?Q\:*G=
M<HE-^[Z0K3%K\H"%I0X^ABMC2K2\%;>>BXC_A6YGSO]3WBGT%O:68X5= &/W
M2^D9B;K%;(&@M,O\/FYW'L0 *B^'?#3>BFA!Z0TWHNLB0+I>V6DZ6I+OY,U5
M@#EF.17GO=&0R!-?^2;&Y HVYT1#1;>96P#KJ^+<O/F$-;NJ.A1[:L-5PKZ"
MC1WO-.%+YNG/:$T3<$B>Z=*&)9'>071"Z.NO[M?><U0L5J>YYG1KLS+3LC6_
MR=GA;&[-?L\&SZP4'S<*'I?D*X[ Y)EH_.I.;6K5N2@B2*,R%A?'O7.:HZ9#
M#QXL/WE)2(E2-)P/*PDL"*?;*]5_[,8W8)G8UM!1CB[/K?L,09&-*;GJ=P*'
M?JVE$P(\AK;4J[X\N@>.4E!?1W 4L9^1S2T2R<ZSQ:(>(^ N55I^?M@2F'<C
MF&C>@OKU'VZ?M1*]Z2]F,#U*JSB8"7<E=/78Y&T09HF[76$3U^?TLED0I]LL
MA#6FDP@N__8J=/CG8!.''P6^L6)&9A:#E&:>ME:?P5OU,$WM8*R#P.^\XIPB
M6<]>@Z.U4C#T^PGKE6?_.H_1TTFOO44.IJ#AB=/,X6"FD!%-D%1RSPSW4O;Q
M:DWBBX#3!XI1@]%>=+/X\ %,"4[WNAFI&OIOU&3_'TF)B<GAE42$!V'018+X
M[SSX /813R!%X4(*FK(VIF( 6WRCY" WICYAH<.V1*,+CB(&NH6O\;PER$<O
MSD TL,=.Z22&=2&"12U1UA]MAA]_!'($L1/G:T=HC8<9(X2Z33?H%M("O:]Y
M?D,M_4PZB\U**Y)(Z9P,:\_(!X7L_7S)K8MBN%V-&GB<="E@<;PL)8W/<GSR
M]1FM"Q5STZ9X889'XNW[TG]G-):EJ RC^B-$L,?DP15.J1#QNDY<[BQTIL>)
M)7_P[P3']:YB<0DJ02-*=%<4@F+;8F_,7$:1U)4G0=R4+[;P"@SI/Y)MMCBN
M.B9LI;$*04JMFM"-<6PJ9'Y8SS_IM.B@@GR^7LX[-B\,OI(F]-Z++X21X0Q#
M=V9PLQKUF=L"T>OU@O#\[VU4AH6G3&]$,C=01;'9R&QY6[ZTGR>*@M;'>.-.
MCOT_S _3PXKEM3QUZ&RA=/T$NWXK&V?)(Q4="[[]=$<=Q6[D%'!&.Y-]LKO$
MP/ZN)T*89;X@4(:M%$/?_(W:@F@F.HM$D'9GV"F@?G\08;*J([2A:E#D#E$<
M:&CON?",&K?R$$=W.2ANOV"K0CRMM*\F+T?H,D-MB^%NAC4A>OHJ_2^S"L9T
MU?717IC*!@,G0;Z^F!45[XX]A-J!&PE?'[YZ=[-R>NBP+7$9LFUFT@UH.I<B
MJ>B_J+9CNK :/</5[:SGM+<>+_?[(]H:,^OP)W45ZQFZN&AOM./]6>V0HK28
M36[;.^,B)ZM+Q]-JNW/- W>#%DA_6,UW"Z!IF)&PV+^R_UXIN?%@$JL<[1O(
M'Q.\I]+1Q.'VS-J&H5O^OJ4XT=-8K_9#Q5%RNK#SV@G22]V_E,)GVH_XXJ$T
MG>S&'T298'(O>_3 XN%^U*#@GR7$DH.U:#?4FLJ:^;JH#^*./FD"E?"XUZ[T
M[0Q*4B"ID+&?%JR3;=9+\MHB#*/-VE@M@LH$PT.^MFG=J1'!7&MHPN3.^]X)
M5U*,(!^!Y<\0*AF-;QQ]/\C)UJ/+'8%:;*0+([J"N-)?O,^*/^JG'9U"6M60
M]J94,J$@/9WRO8Q5:2.D(5N '!3ZP7?0$[8V=G8/87[WP6L?YNE!"$O>;M2W
MZ*(%*)5!,$=R+N9H$!BO,Z-3(1BR^&@]85B#@,VQ]6.W(Z0SG+RL'=^<SUL1
M+V0\\2U&,K\\#2]RE'Q[^]FZS1TO.!>)]%#YEDFV>'7Z#F<YRY_P]5G*#)<K
M(G71!"XT1K=I^?"=SRN,N8+3 6/TC *3/OFCM9%PCM]O<Z>3/XM( 2T(:6@T
M3NBD^Z?\)>8"PQJ([%KD9P/^;:]7CW5T$YT_/3J[!9#DM4B<N51=UPK]>?G'
M!;E+^[+C6*JCJ^TE49S)I@_1+8!,HOP6<$;D>OF*=G&;2$[B7SR))]/L+8#T
MADGZI\0]W]UJP8X!8<$86T\U]].. ?]>C9CA*7/>6H>%D#I/6J1J2]=>5'/*
M"!(B-[JO<7>Z]Y659OLC]DQ6C6S6SW^]D1N&RQM]"X#AOH3]"%"@"DE35/O*
MO'JJV[#G^"1-WF'\SCUM34W&^*'3Y)>U7P_>6KLB9#P6RB^"9AY: !C1JG?K
M7![PQUM\I4B=5[%R(V9[]!BOQA#AW^[;['$C)#$[33H?^*+6U9?N>60:7K.S
M-H6/SURM0/H*YYBK" 4'<UDNS.[N:DX>_PW0T_-(HJY/:T7NQZX)3-0GIMVG
MD:GQ1LC"9];NX$F)3P2BQ1.WU&_IJU1R)KB];4"SFP!'03!49 @?ZZIM+:.0
M\AZI[P4YT3DYGW.E7K<9+(UXC$&KE=;3T^G3-A8'A(*7!ST=9S1'\5V[L*0]
M'C.S)J6,;WF4!VE^1$L.X+_^%;%^X>F"_OC0--,FLE<@E6S.6,6>SR95(U[.
M!J@'QW<-(99$<I3P92\E7097; Y@?2Y>N")UM<WAZ<Y:'UV@*YRT6]\>-KLF
MUM5:OG28F>R],S"5]&8&%%W,1:%O"&Z+%'5:)C(.+""*RU!#+>B<^\]*37KO
M#^^(B%?MT?8/_%2?GG '"]EA#=ZI8I<NA:AJ>8@1(_6&151S]4V<;00<UQDT
MPN4VTCD+0M]V'34V"/KM$*&KKFA/-J9F,S/66,/]Y[+>W,7Y-H[8Y3I>X%TG
M[TJ6EI\4 'VF)Q"&NO8%;S!VKQ/E&=*@9V>MX^:RTA<>H=77T.JM+G1^)&]-
M'0@WRA'Y8UZ!I6Q^8V3>7.W]M?J\M7"KJ',_\(!V*9=4GWQ>]'H"7O!!1Y39
M[?FLMC71!8$Q,V>T6!O?T"W@H_(-TK_RMV\^;QM=ZCY=Y+QUH!-+X?G%K.$8
MPG$?.TTX.PR]1&JN\1G%+8@F$*7W:\Q:_+[LH M.(ZC^$J'PJRR".EKN<5%A
M:(1(6"-DYM(6T[C9B@CE"A6W$9Q0(/U>7A?[PV%/@4)(,SUEG]O"<MJ6Z#/U
MMXK-#[HHW)P0ATI.?'E36^*/+FF&-&>D;;,NBT+H<Y*J)DESV+8&L0%P^ED5
M(IV#U)+PM:L8K\X:W]L_"K1IY :/_4@%)E>WV-:"6ORMPJCN>*];$E0H3"19
M''W!O^%S,"I!F="VB^V-'D?FC4+>Q8QTQ'KCSW"\:MGQ8&9N3W>\LMKEZJ<1
M]/29F+" XS(7XHN(LWI<>:0X$]V-]<$@C3U=*D8U*'_..V$L2P#N9Y+"PE2M
M^6=J]I:20OAC^NKIM5HTY.>P?J,PHSCE8SKE6BFJ+^]=US^$K$JG4:I_%KT%
M<,"ZSW1M9Y=?#6E9LP7P[FWS@(6YFFE_CTD;7'^;<Y8\SR@7,,)_>Q4Q2/\&
M65=<"[)D[NMQ7I(8VK1PXMINV_W3[;'9,@\!A>^F0>(:Z/#B]HTJ1)]Z^05D
MM;M!CW -A"TA-C=<2K)1)07SHC>YF<TUU=5)RSQ(\%C.O-'0$4&'7_P5';RQ
M?5$Y0*0\MP V(="BV#BIJ$D%&9-MD:NOXS?,?[2BT)Y+K_O4EV,XHTRNA3Z5
M,\_-P6!/H/=T;4:=_WF$\LQA2FFSHJ\#]SM['\5!R;QOS;6B3B]F25+#J])K
M&=+,0<V\]6\CN#XW4PIS,/<"FZ*;!R:GU]Q$E_9_/60++HK/L $2PQ5&&$(E
MF?Z&MIQ&@T9MAW-&XR@WB%BP28-@Q6_5Z812(5431]UEOL#GGFK##EC5V="(
M9J:%24@D[50Z_K:L^HI/*EF>ML8#]9M?(V27-(6G@>USF/E.<VA3UR'OE^;
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M8?'^U9'9-&Z@F/F$U55X:) # :F$2Z]*&"R"'04C*](;4>(+H><SCJ$:Y/L
M(H$X:X',8>S:; ;(%L5/=;_R\10!(JYO.4TCI4EFGSZ+%8_+)S"M?YAM9T>
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MQSHEGF.'6ZV#&8+ZH3<K"Q1&>3^[2O=S!]]IUT%)@T3<7JFP:EY_;]0\YBI
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M$%EJ_:9"_7UM 2UYC1-+B/#3+$32B9ZNN'FZ?T-MP8+XK7!#1?J>)+NG2@3
M>YCXYT-_S[%0C:\$0$1%A^ZWTY4M'^G6QBA][P O%'.AX"^R>KL4FYIK(UOT
MM=Q G$^OQC5R =JM<SJ:VY2"GO),_<C%G[V@#@WEYI,I0>7FYS!Z)\QO#4X_
M[[/F3K*&PY<//+2L.I+Q#-TNE%P3DP_B.MV>4[YS'[D\%9YKD*92M 77YGR=
MRP!/->$;%F"B3F87U[-\F&LPY\V1G5KMGB=,X5XN.HU2%4,/@J<&QL:4#1OM
MS,O"\O+=HUY."P4(GRQ[^_(,08%2\)%/MRF"<AO2B/QHWD&I"0 ="K"&XXJ
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MF#QOA%O,:L4,6@HD4C3N@HC%[K?4*<5FK\7N]D=_SGI%RG+5O;G2^W=.% D
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M>_DR7QK[M7W(F !0=H 1 +6C5^HA>#,+?QA_Y@+>TC8#7U!B]YCQ% 1 754
M1OH@ X3'XGNO!$$(10C^C^=9! &PQ3L+/M'?6_RS<#4=4"Y@/G4<U_<K\6_:
MAKL2);^RKH0'LA>O5=&.NGJ,G<4_*S%7MY$0 "_ .+;F/?R@Y 6>/A-\,:*^
MWD\ %&A$$@"[>HLMX%,M_$CK?VBG+YY!D_FB8W&#GP#(AQI>U5=6=8I0,=<:
MR&)O/UZX]V#T3-;BA -;QM]6XUV^Z80V0!, 7U#>*=53=0[V1OMJ->JQR9PR
M4;_8>(G**9W')M6U&.X&YH)L,%.&&/K;VQ)>4.+ZJL"MS^_5C_D90N%YL>PQ
MC[,TJ=)>YH3-]=(]\X$/&70T(8C*,^D[]6]4L^=2!:E N]KH8/6V=[5CTUXW
M]YLRM0_MZN\:'\5E/20 TA*$)S[95">*&TF%+X283'<J- D75L1;J;:P=74D
MJJ_44A5_^11G&<7"5_? 1ZYI2WS"_W Z?<RO :]67\_X0F1CR'W3P Q&;6HF
M%GVGS3-OA0V)2VOUC(8+S7%>W'$>A>ZC-3X.O+]WSRWJV6JPD![$^W8O#.68
M[N92N<E6BE! EPQ7U$K4*MZJK$51V+!BR9]A0)Z/!%_P/(O:M(HZ&!&G+QNT
M^E(9M[':PMG:J-2ERKOZ6$OP[B_^98UL#1FKF;3B,V5(T3RPW9*CJWUC6)']
MV%OZNV,X23JR/B.16'11':@8W;57#(T9,;5VYM1BDWPJ^S3-QYM1>]O2-,,P
M&O[BV,BLR.1,^C*5$Q(E6RM*;;^,RJKQD'M5D=$&95)GCO&KG!LHG"+G>:EB
M[[*Z[S:]8ZP6V3,H+'0W3*)Y\NYG?,D+NZ1TRV^R]U_PF$?T"*HD/YZV.@^>
M@))LFR>]S EM"QV7B>]E&1T23$]_COBQ8O,9]%BI.N5AURV)Q^$COT/?\(P<
M!,UT'>VH'6!)5=O,%DOV1<]J5($X> _(IZ)=:^*BLLAR=F*EQ"6A?IXKLDKJ
MP,^>]@P<H<PF#Q+HD-0>_W5(_;R[P/@^MI7I?,=P*_S,^#+5*063*S[+,HO\
M%+3+&!&YA6MM@=&8Y:%PT>JS;@B-YW%[Z$ZUX)RBI.;7@Y2\Q$+/>QG>*X2C
MPT!0IW8D+VLS]:2^/[F@>!.T%J<)XHVH$W*J^V@H'E[7DJQ'+ICL\RT>A)(@
MDQ%&EC #*=>*WNLVP8+>=#H[:9.2*]7G?#<5>G8O>^I\\O R%?'(_CM^2#W<
M>+@GJLA579$="%YMCO9Z[_$]X70A89['4BP+K+GWK"[!:\&Y..YN;MC8/1M6
MV;+^)Z9JL+:;TQC<>*/HVW9!Z21V5+S3!O<AN<E)4?_;=Z3V*\9/M-A4S?Z\
MM/;HBEG9%ZI@#^4<2PQ_3N$D"36CFX,#YTL:8\W>Y^2S+7SY6?>CYNQ'EE0B
MAJR_$:7NR]L=I_JDA"PFS "@]/Z9,-/*K5O*V3<8B86,A_CHN,147OR)/XO1
MN:=BS1FDYMC#$"1OH1C(&C&J]QY13KMM.5ZJ^)C*5'T3[OE7/(!7_0L&Y8-A
MT9=%0' K 5 SE77JK 3>NP-.:<?'(3T) (M,' % /"J-V^0X6", )HI["( 3
M[CV4]"4G 6!EA%L KXLA<'NXJ"MO$DY2W-+>(?75;<#*JPAUB^W+35>E2\L:
M_F/6N0[-(K[;_Z*7  B2WMU9_!\Q9]O_CX*MY<XR5G87'*8_&B.9/-<NT$:*
MX7GGNHSM'ZGO-#E'K%'>_H,\\U]L;Q[D#H:?#AG=EB!^D!BGMZ[_9.6UC'/'
MN:^MGL!-G;"=8H;H+%6>;%7%-'W^QX^[5KYT"+/0_*ZZS-YK11_ <$E2]3N+
MP>VB'AA5XD/P"K75)I;#PNW-+B@6XL'_P=-H'B6^Z(SA'8Q'@H@I29@=5C83
M6)U'-81R6*+8I_2MR^ CH<TP\%]Y]#.8F_BBYKSS[,NER6)K/*R:GM0,U'JF
MI]<(#=BJ>FN$^CD^VN!)3*&3:O\MO%]1Q78[[\W:!VJF^4;-L;Y2+IL)7,6$
M^(55[*]L]OPE)\F'_!OILPAL S@9.C#\9?I"5'+.EP!P/G8WE)J;IS?B>H5E
MVNS3M*AY]2BT8W*-VWE*AU8ES>?5S1?]$BI[%E/\8-N6]H/#9);$ 7.6L^[+
M)DVQW4B0*;=?<>_U$BTMGH&[XMH/W[1O]"+EYIBO5&%=$;/CU-"O<]0W H#Y
M@E$@>H.3Z!YXGA%O=GV[7.84:NC.DYW@B#T!:CXRLXN((F*X</PK-[;_2UZ6
MXO^[<6,[N-/UJKCW[K]LDCXJ?=&."[_ 1A, 5PV<;?=D/GL'(0"N.M>L"MP9
M+DL >(E?=A, 1TD[[1<\)WQ'BMV,._N+#2>>+O;2:5D#LRRP$UYW!77'SC9?
MK.V>?Q/5&Y][I7=W;"$;OE8ZIMO;Q53EPZHLA<VV^5'6 _UTSS4H+V,Z&G_&
M- ++]'GGBV7+7?G"'KR[ZY5OSA/X8=Y<QW)L0.E)JH?7IIT9[WH3F3I#MM=7
M5:%WK.]W5,1L-4I%;S%X-">R4@3CSCK#=R5S?LRGJ@<;#UT0R6061J7E<=>)
MW7!!$P_+U>C(Z,:M>#+=]QE??U%'RSG]L?<QN9R!Z(.H ?D%HX$S[@;18 (
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M+[+#(V^% ]7R=H+B:-4G8([/1S78JKT2[0D 63-_9YB#I3&)36ZM%*E?S=Q
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M[C@T6]1",Q>8RKSF4S)YTRA%TL]Q^I 333GF7#DVY[QOH%Z)0<,' #=W!LO
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MT&BPT7#?O[QM7#2IKC_V]\AIQF:54AJG(3_4GN;DXAE81QQ(@S?PA!78%1+
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M>)-]7G)FYCS#6\46J@ MUT-R,:M]M'O>X+]?B4RP<R\K6:XOXSC@[&5A[V#
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M-8PV%IKJ7B_*@RI TQWZ')@*T@T80R:4J-)D2/K;RBBBGK2+ROP).CO0GLG
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M(N;E9+I#W+>YW621%!I</CG-EY(DFI%A&.I YG3%K#9R<H>!<-*\*IE5_./
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M8NO:V.PZKO)_3^:(&TY[Y[MZ?R/Y9^=K9M0QV6J\)-(AK[EG^]'^,"PG60O
M>;?DGI/0/S%S/7<G'IEY%W*ICKY#S:/;U4Z8/4 #IOU+&0F^VA\=[[E=R)MV
MQ27\&<4#A+8'8.+G4TE$_/9O8];"-[U,I'_. 7'Z(MM>\=-TW_>J&V.3_4EV
M*:?7)E![3G1[+066MUPK,CL+,W-RRNX5XS15MW-"-]?SOM-O.T)-DPZD[TIP
MI0?#\JC$G2>Z9_IEQ,9(HH;5<3Z3/C,*5I3[OR2Z78;OKV3_TK3:?:_J_['2
MTL__R8G(["5T9[6H F@/G3=',S3JN5_>BL :E)-*O 3I,1^I?C52W57FV#\L
MC7M'Y76[<)F9!0D;6^=SM^+E)UR+],UE2##XW- .&E 1ZD;J 8IE=8YL8GW3
MA<9UA19]<V-5(NB!4/>\'ELB*A:XO[\H)F(0U,69SD9+C<FYW&/<2Z#H2"_S
M.GY(HS8UE_ETW(Z%!N3 U8\TB.G.0DGB;_*DF4P:4#F;YGMO<)6#>^F&6-UT
MX*=$.AG^A--8C'X< 9YU[BHW,:_=C>93P %1R)L=7U#6S\6_2L>,I,4[=CPG
MA>3KB'/<^GC5R32V%!,)=GW)UG'5VM$9?T8$CSZH6>&9Y.57L )YU6+BK]$W
M-JHT^Z.^B\3/3$9=;7W7#,C(UJ%>C;ZAT*?>N'PI@J^_IL:PF$FSQ2B<5L_M
M^3OLTZSHVI/+%G)*68;RX;CA*W'C]W0','.2511J(;<XZQ'$A_/^*O35B*5N
MCBP*QW4^E>R27HW;\N%N#E^>Q!3>T;C^NZU!"Y8_?5-BT(D)=5R&#B2U@+3>
MG*2 8U%1WWFRH=F&RSROE7]%'*/4/!SO:+2Z?>E,(;E/P^J8$/E7]K07LJX4
MPWK><\":WD1+([ZFCI:#)@9M[SI =L]&=9CHYA/K/#A_-7+J<J\6IWV''G":
M(%.AQO9Y@5W.O9[TKMAT8:_M)VJZQD1R#-G>A,S3PA[#-#58@#G9F@W^D35Y
MV'I&1X*@&> >4G8.:V!D#DF4E*H4(E:7[18!*T&YZVCH!)8=D/FDD>;5)-@(
M_EDB/?AZ-]EZY-^6O2&PAAJW])LM_OO57P::=0\OB]6HSU!9P_VN*UGB%-JM
M0ECY@$:@'=K8Z^50<,R=G1(89QN31P>JWKWMN#7-A?%UOX(;ZQ.L;@R"^61V
M)#M%*:AJ,"!QKMFB\GG\Y>K7XN+BQ<RX1LL %]^];9AUSJ+_ \!]?]=:+$'7
MZ59G":(0.]R-J_'J,D369=670.65Y=V+6\Z_>F]U^ &PQ>Y2>3\2N&2\=!!_
M?W;?JW2+37.E+GD2_0#(_H'W3V$XP>SA!-YIK9SF?0#PB0^;5"'B+IPI/^"Q
M'P[D<3GP&/'6--/7(GI6!];YB'S+EVL063+T_)<+U*:YS7AR/+JA:3ANA!6K
ME>"&Z](;L'\P=1FFUBAC(]Q^2='$6U)5%=OSNH(^#B&L0S"97&IO[7#NE1$:
MCEUKP;5^Q*2T+NNNTDM82]?/SS)(./0BGD);1[2H]UR<ZWCPX!H2X:GI/(0F
MS:WLYX981K.3564%!#$6QU+@QE=B8?RE33$BH .G&/2E>--XP->?JV[B@2$Y
M]_:B*\D)9>RNX(P/N31ATX.IB+G.M?/]^9[]@ ? 4?MJQH7+WEYS>FFOIB7?
M-!E'()=$H;+^LCY%[Y[.18JWGKNIB10E5$Q;?KN#7%BN2U/&=5):IYM_4@%'
MA>,X;VC]75W(($].<+?3<K7:S[+7'YABPSORP)D5*;^^O?6)=R8=J)8?Q&_%
ME"IX_^G&(Z _ 7WE?1DA/8W:_K3J34'SC=\,Q,@NF:X=UGM7>7A7J:>M0YSK
M$&VL R:8IE.GK^N+I=R\5UL]0F:.-O \ (;9O2V/_4LI/G4-,^+].E%10Q2?
M5RSV[W'6W\<<C5E-4DV=^8C#TTIS"TM0KRT<+()__/2'WR4O&"J [9L,C.=?
MT+7Z&BZGE7*T"4F)B"W-IQ;HYRF]F7ECEQ=+EX7/]N0U1"7*,;ZAL$%ZTZPP
MKA/#FJ_4QS" GO9[VM<0G"QV_G0X'\%3IU;TK:C5BGH7N6TO^,PIC:I>C;NO
M+O6=U;SJB;,P8\S&8D^A_HR!/*@&FV&[IHH7\#/_P.F@M^S"]>S95.^%C>N9
MQ. F3K;^']&LH)RA;EU!*MTG=;RO=33!.0O'MFQV#X#8_7DQW^\S^9_2V&[]
M-.0'@,;TYU991,<_BY#JW*J>D4H?'8M)C0625%MQP1<",%WXE*/A3..F?4>[
MH\:N^&H#[+J>LOD/7_N6]TN^"O/= $_897&-J!$5HYSI*:B1F"V]SK(:2/9(
MN>[XS2/6@.6%H>S_=&;\?VD8\I^>'/\8/J^8,\+V\0H]_.F$^_E3)5IT%*S7
M&XEJ]B:N;I/AAB:9K.3F*5E%4/M*4['IX\N%#(?!B1$I)#67Q-4D*4K\A.6$
M^!\" 96JHVX894'OAOHI11*)+8BD;+#8>@'X[TMH\7B?JUTY(?B>1%<,;3B6
M5*=^M^: -U+&6)7B,A)18EEEP6"V-3+J3S_6-K^"Y4#?4\\(4P?OB^FY"?;.
M+S8O#*+M&W.1<3/_'WMO%197M&X+5A)B! D$2/#@P1V"A^"NA09(<*LJW"6!
M ,'= P1WARJ<0(#"M= 2W-T=.KOO/:=W]][WOO2Y;^>UUC?7G+76^,<8<W[K
M^T>,>MC0N*#R8"@5KK5U7A&A;I*CJXZP)YM,=!TY<++M'$2\-LF5-CF&XEFP
MB>"5[ZG[):/#I@( Q/\I/'=PPR?:-UGJ8"[5S^?G MX#O$T?W@.(=56DL'^+
ME(+]W:*.[OBC0"7<[)EW!^S*D#![GHFT]B7'R6)N)6E$;F\-,\N&I&& 6!%/
M%DG;AT41)GM7/).2<U61:L$"H5H1-8CVA-8OU!OYG-X1_<P>BZG\ ^![-O/W
MME-EY0;Q*K+OMD3W28-5^)2VA6A1ZX9!!/H?)E3U-@^6Y'U\0249Y<14/*Q+
MP1HD-?W8Z0.LS<_M=_?*9ZTR78+YEPQL&/0(:=1.I'C+O%2P:W$_Z!9=^WN!
MC":#R0,AZXZ7HG*H-,:R ,U27.ND]W[#.:1)+&&V/7'6G=VT;!'T'Q_@Y16(
MO,YMUBVV%MA3JSX#R]EH[C7);U=1=S/!?2=]Z4^(A R\@N$3.B,Q.<&5I/&%
MQ4$EM.%#6+V;Q7K4X)9#.5^!N97RF\_)'Y]9Y!)]GGQCX?INRSOVFPX@0'BL
M[J<!PX6Z_=S'L(5B'8MREQ@56=PW;K!8,<O??YUUXSQ;"L5/(=[ /K4?_7S/
MWT>ETRD/QD\\-P][7\@M3,Q.ZH)XU@JORD*V,FY*_9],?]G1Z3OQMUN\RGJ
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MN,VP3XZ'V%Z.\HU*Z_;1F)/GYQ><VS7,[JDK\"=.3;-_^ZB:&&#&6BO-[Y>
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M(#PYU**%0JE1=K<XMD1TN%://Z=G5XRSYM:TM='*C%"\^5:)_>#B'G#$_@-
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M"1^M\3M&72%UKF8 YNZ#^(%P 88%NB^7_II@F4,LYCX4T+0KG"G-:?M._3_
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M^N<TOK2)FQZG#(9TEH<?/87<%/=8"&HW5S(=Z;JX03E!:H@ZXFHKQIG4!OH
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M;L# =K)Z/$0P0O[&!*G#OBF14=18UOJ\6IH"^:8T#VVC581BFE@'"TN4Z-8
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M:4P0=9*"H;KED'/XZ?DTYO3_ %!+ P04    " "<A=Q84C&:2P/9  #?]@
M$0   &<T-S8V-CAG,#!T,#$N:G!G[+EW/)Q;MP \0K0@$42+$BW1HP=!$#UZ
M)R+*&&4*4]3@I)&H0?0@>N]E=$D$T:+7&43OA"A!\ TI)^>][WO?^[O?O?>/
M[SN+9YZ]5]MKK5V>M?<^'CZ>))%2<G>P P T-0$\  " &$",=Q& CROAX?X
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MF!3U8Q+/7+I>(:'C[;_+[%.'E11H"?-%F:F4F5O03P,OTC].\*P9^<#S0)G
M(5]TOMR>><R[I79,DJOQ18/+B%*I&;9L0YCDIF%8ZR"J[,F%M\_8M4D]*1*Y
M=^XQ1'O-2I]AMSS\U+[:8320=]Z<UZ;AR60)_>4$8G]F7SN>M)QV+3/=)907
M,Z#$O]0'#/TXG#2="H46+\5DRPI-?<9XW;<ICJEKU%0*Q]S@7LRU%S]:49.@
M7HU.HR?5%0WQ([E<F@WA4RFO.094Q2<)J;7VWEN]Q%/#IOR"A^^AV8TR>S7Y
M%TN6?6:+?;G55=:>Y@T'^54(*KANW;#K=J"UH3E2Z05W,&E)"ZOPQ?9L>5'6
M5W-/MAMAX%?*P_'N!M:9;7DU&.>!M0<U!K:<V9^!N2Y;-UIMF_*2HUG.]$Y;
MG;LX1A.^4R5A,N4;LXO\M.O:TC6UTV*N!ZDO7Y-IF8AGS+=Y-]O<],8U9 Z7
M/&-G##02Z'D"S!RXHAP=57*NR_-UM$GN6-'6WNVD.7SZSLRT8,RIJMV7)J>Y
M_0Q6_?+%,Y41"N[A=$,6%VIH6A>:6;RJ,LC;'6M#VCK!8#2WX&0%\11!U8L+
M=P'[6=4Q.4LIX:I=FB-KQ:/F$8Q5U^!E^FJF-3O:^S)8<S^23H&95@CLDK)<
M4;2@5EA'$"._WF0W]\4['7P0>\7YG:T(T+='PV*'&GU[3.F;"&_%X83<X"3:
M:O:X7)?>&;G GDZTTR?LAL'JDN?-BIR8*+:.<.D+V -(W2"6!3:OF;_G!=V7
MV9_11IYIHRB:TIVDO$9\26N6&L)13N$)]GKK?8".K_"?]2[.<VL/D^E.&Q#(
MS[.7Y;?!J_F#&93G7R"^OI'P,&'@)<T8Y%G;I/A B7Z ;U''=/%P]79KWU'0
MJT+-0'^-5GA(]=/GLMT'0[.SKEO#&/3]Q)>+FL5!V*]C@0'I'R"0AH1FNXI.
M.0L5/B_X TX$E.?1""W-Q;C1N/2LN/(T+N5]DTS4_-"8>,U8[GYIQ9L(/E+F
M:V.V\M!K3TT^>,5038D0"K[?,J[QBA18+K,$'P,&("7C]%%GSU]4+5'9^O2L
MK?C%P"9*9(G_;F*DK@V9OK[F-Y6K5S'B\G'<CH\;#9QF3/GU69XYF?%+.;R+
MI,QF3W*7IIJ+=MXE_+( V<60HW=W/GT]0']F='(:F+-W,H*TAF#HY:8JC2=H
M1*N('4O+NPUX2+B,G\ZKOO$*[Q@?K_LPIV6+];!$3"0RY@9GW.CE5].TEM@@
M"E:XJ6S77G&N/RKW$F?^_!B%[9Q,RTL)V?LFT#57^]X;@=G,;*G+^D)&9S$Z
M-(Z/^KN2[GA96JW*1"@EMJQ>EA$?3\'&/Q:K+BFKK#/XK%8I<8ZC*B_AIH1]
M]M4/AE<2Y>D,1&IDRH6J66;F/R3T;::B2P^'ZL6/>C$'[2CY$(OW\<)^#?3/
M6@=MKB6W*$8X,GP+T?R4%^47=VVFAU5YXW$:([8PP:/Z(-$C8#?63=KD2EV"
MCO![NJN+KX,UZ1-RTPTNFH0KN6_I=MV=]^WZUNK1R9B>=F'B(ZW)L^MZ!@[D
MRG9BK #$[*!F<*GSH5=9D9<@+&[Z*:;?^C'C-_4*<#"\C\0V\F)*A5>GS@<@
MJ\C%T5NTTR,^.S0+++V%__MGF;^CCWL&_/>\'IP;/EP=.FS9C)B1M93S_SK?
M7?DJ':I!5#83$HK<$?>B?/9@S(CP,:].N))?4V]O3+CG4Z/8V:S;0<E&,$1A
MV=$0Y%M7V1?:FXB[)9E75W5KI%1T.5:I?7A3RJ4-J30=E.U0AK8,"7#\D6.
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M_<;8VGF7CD:CV5N005L&[$%.X2*>N:2)I6)GBB\11"V? 'X>_#'Y'_)WY.=
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M$FB1/ID6H#HDKE]+5%%TJYU*S$HBV[V':VY:W_=K*ZLU,=X+ZP%P[3+<1H#
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M[D7<S/"X8JCA!ADK\0/K48%.BN_'[M/NWO/IK/;S@R6R</O7&=D[IVQC*.3
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MXM>:I?JA!%(1&TCS1*H0:M(U)+& XK4(^NA1'*A;V9O+3=/;WG;V@W*5;+G
M"Y$44Q$9D,B#M!:@+)(M&7CI(85'2D^16Q,_A?DG\<?DA0XK)Y_9^RESFP]_
MQ8:EFR-=M?#[IBJEQN]),?2)-6UF#QU;6NN0:%':GATRE2BL5##^4/T3OWXZ
M_(C?OR,^2.%KNA^J.E=@[OPNY-S]H4\NT:6KW'F/MJ6'!X*/*K3S;CKEIZ>:
M311+/J.@*274$A^[[RING*?-N^<W\W6K;9LVUVDL<DER#$OBR$+I4M351%D)
M*A@3I1:NZ*P>^[]R;NW*G-/,/-?.5NVU;/MMG+$\ES2)?$<J"J%R-9"@GMU
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MUH?315Q$:-XIHPIA[-\[6G@WWLA[IV1.VREHH!/53%)75],YP5J]'MG# I*
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MJJSO&$!/JQ!H "<$TH">HF^ZIMU[+SSN>Y"V;]U1[?*DDO!%=V30A8D=S4-
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MJ+3;_8(%3ZZ]0)7PD[, *X7:$=G]F]FTVZRIE8*&A5Q'>,'F,G&K645-H)]
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M\'WTQ+FOO("/9+MJ"HN8O,83%FAS<, (<&-A5_]4(EY90H)W9(T-$T?:G;]
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MN](GZA![2XLJ#% 9.DZHYN!\B@%5X1Y MT.+&"?"&2$M_OO>/W^#78QT"YK
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MOP;,4L-YJ^EK&;B6^-A1\*TK\79.'CXZ.#<L.O^<>T9@O&USVHF>YQJ#V6N
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M*>&+<"G+6I-N\7=2PLC UL1PYLKS'J#MV%W6EGX7+L3\JR('@AU,$%JF/$=
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M,Y!769="K'?,"AM.'KMCMOX:'\$@#ID)%!^KQT6WQ*[Q%I=T4R-LE0G7K,^
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M:G!G[+P'6%-;LS"\ 045 1M(D2)%% 0$! 0$5 1$JG2I0@@U!4@H$B''BH*
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M:&+UZ@+[5ZH)"_D]#= P6(NF <L1Z)&Z_FE=:D3P1?2(WA4-O.85&D!66EW
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M6@X )2=&M/$W%PR$D[5OK<HVC2?F'N XCFA.<;_/Z.'FXWY]LA.-\O>W]UT
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MF'IO"]3@1;A'Z\*SO)=Y2BG/KNKI6Z$X<:J8-)ODH@#PO&&ULBM5$V6:NO^
M4O#IO@^8$JP4#:CAY+_PY*4=M"Z3.$E^>,UH8X>UQDA7>A+2*F7?/N,NG.[H
M>'KDP,J,V]1A+V?.1;5K,_5SZ\C+)]"'R!_9EQM<P5/#9&8!P37C&-"U.S'2
M:[O.:B>(/%J33^HO41OLVE4T4^A9?ONBX]?\\JCL0SK)NCVSC&MQF#@GP?&X
MY>0TFV D>]_0W#"&*6A^+FG &&)K3YTUO&=PLT96];.O@=]<0X]N)=F2XVF@
M!+3VB9RTZ_Y5@O:]+YP(+C]G>,YU?*6!J)G%]:QCUE<#UWUM+H=TMNP%LUH_
M<).HO1:0))9V=O0B'J9^T==B'#UQ;XFO*JM,_+U:>\'7M94A.X?KPQ2'6&Q4
M$+1W&&LW$*1;68:DM)7_/]R\=U13;[<N&L7V4Y"?"J)@0$7I1:0I@41%1$1
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MMB3$AC;MVQS!,_-&'):=&^KBK.1N$!? KZ\8+HMD?LU>'QQTWD%S 6?!BUQ
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M$U@\I:P,R8R052E9->KN#$NF_%56IO1\PBE5E0_DFL*395VUE).?3Q[MB$\
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M<1;:Z\IB$\$/W7Q"7Y"Z>JL,8O![II/SCCJWC6P/AQ[)D,QLUQ$Q/Y[@".#
MN "YS)9U8B5:7&D<L5RNG,G_BGE;$1>BT<3I;5N&+YLL* \M>-(/V7,!1A]:
MG*10=?NR8CZ_I"@A6>9TTO##Q"LF4O?\IM9=[XY\NV]J>9R'9)C8ZW9/4:3B
MM1WOY[+G'C_8>QI \%](Y;#&C=P*C90H!)F/60<BA;!U\5R ]/+/)[OC@?,:
M^!I?8YV7;72!;-$:='1U,3K$*2AK:SK :F6N-,2C*ZG#>.2.1'ZF&[TCN\MT
MH<YA;Y(%.M$4XN3[&UYA3D_U<V3IGD+#E;UNJ$$>+!0]T\HPM]2%5DN!@!L@
M#^REAX?EU8B%Z2CA3\MY9UK*S>K'?@I^BCQT32#?XWGP,,3'%A3P]5;6Y4>O
M/$T7'\PE;PJTWPL)*^%X99]3$M$.=JM7$*]'Y5,F"&W#&+[T-4UZ5[OV!'15
M$;O^9U$CXI2@_=GE<I)-"'#Q[M!44\4S4^/Y-6G7_(J$E"*+LVXDGT7K#?WZ
M=7R$[%@C)V?FW I\:8=D6%/^DZ999B_4P;<X#G+EPZ.?8=3M1<=4K(5M>'7L
M9 5AL(>"@N9>)7J'JLV/OE-C?/QR?/3(B^R/-P2Y $=,L-JJL\)9JTZ^VXG3
MNOD0F70WH&80<O/!3O?P>5Z8;*T4VM1E06IWLYQE62^M;"NJ$9(="Q*JJP^\
MUS[1F+65?SZE$+^QI'[UL+.W7O3#7F]Y58'1Q#;@N0=1<7]X9K,=V 4%-'+S
M7C?\K"/Z&QTU.7VC[_W.,@H526*>F RP_CP* P7 ^.+K&,WPPSJ9O[:#-%Z8
M+ZX4MAD^<"E^XWC7WD\>5F[#\[>Y@-.ZTM>X6^ZDQ<7AH %=Q;<N_/B'\K*X
M98YA)1=P#9NN]6[]<L$\7<294I[_:QZ-#:9FYF4P#VQH!\(H\>LU!7[/-?DD
M3-V]^[H(>%DOF%<DH8_.L2A;WQ$NGM5^&VLCG*VE]WEH:/2*KU@W%U"'%O</
M\%:T&J>TX\6D_+.O/%Z9BFWI-:$8=+./SIM-OJL/V,N.S'LO:U"M7'?NN]ZU
MH6_;[^3UE$I3#L3TCGA<'6\[.):VTV Z7G;B#O6]2(Q\<7KET[KY#V=69(>6
MX<AK"O%KTY!PK&MO@WL]?]M#-YP0[:V:X<AT1L4!G33FM8DF^2A^!Q=#D)AI
M\SI_4F=AUE?AY]^^Y=<FXLXWO4TB=A/1,B&,_'H/JN&7N/#0R$1'HR$L\ KY
MF%%'; L>DX9>4S/LF+'*?'-6S2Y,8JQO2?IJPLV2ZV;#\KS>9H/'Y):1IJ)%
M.B>3RFPRO[[Z9CD2..NZI(H\I:HJ54>]F,[SP'3)_^5().<QX21Z\SL=]X?:
M#^*9UQ3A@)G,\WL_RXUB"6X-(?6N@S[4'Y-IY2TIQ1K%A/ZZH/9[YSV&(L2L
M]8#ZJN<+61T++X7^WN<%!T)'D"&95%8_C12&E]J[5?EE;#:JT]O('ZA_)K34
M]=[-G/(ZCZ*S.A\'Z<!@!K/6:+?8E$2Q*-SBMQ)=UMMN4[G$J^'E6L<7SYD-
M')0RE(W-%$'4K%C/7SR>\-=%UZ0;99X_ &$A#_B7C$>N!3:WDA_2S-@?)[>U
ML-CUL.#!O6>8IJ:,IW2? &<_EG!!]>HF0@SF!M<2!$J,?YMHV/W^QL75KX:/
M?C#62L9$)O?":80O4M8G'BT"8\R0*!?VZ6K;\.C\$H,+T 7%B3>KMSFKH$N"
MS0.W@'GU52(*H4<(_:W7?>3CH;KFD<5=*)G$2_(! H.=#+EUR3<+<HYF10HR
MTJLV8A//MRL(&T,F&^U?/'^MYY0K<80#S[@B59 ?@+E-NT==MG:#W+RIBO'
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MPZ&[BM +'',V\N<3M/EUX'NC$PO-VO!8U^1[4S,?;"(DL=?-5?Q4483DO()
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MZ?!G+\=M;!LE002;E6;]Q+J702^87S[_7 :+>/?%3F3^&-G3;I+XR49-B%W
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M.T=^%VO,YUGS>;+6FM-99,SPE.MT];I%[-9T/&W;"/6/S=I=LZWJ4CDZ[V*
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M^7\+=X5; ="@L7BBXM\AI.FN=-T[A, !_EJTB9TG]&&^G#^_'AP:OPU$MN
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MF^.#)U98-9]@R%Y1ZY+B_((S6@&,CRY5W"GN);R"S0Y4OD4^DM.ED.*G:7@
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M8=:O"IHD?*G/-*//5J"ZT1:>/A?<$S4JQP^SA;3>/'L[KI'(G"!%R[<@)=N
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M_.*/PT_&@!_;.W>];?>MHIM59+/5^7+?*\CS(>>E.V5?WYY+R:Z0Q&;7,2]
MO;VP>I/HA8@*T)W/<RE6[_1O-+&LWF[:J\GN=4(.R^G4"$_2-19Q9,Y];X,Y
MW)'A+?CC*0+E3)=YJ)^J.(FS6NY"S./X<BH1U71-7F8"6SA*GNG8*1=TBJG\
MH<>2"!.NR1NWQZBO8;<[V#M1_^JZ%-T=JFG&!F/C!78+XRIP2'3>HYQ<2O+E
MY$!Z'7:6=/622\Y44P YP%02C8,#9SWU0X!EQI$@\]BN?[Z7C2L#K"[1P4Y\
M:K7WIB0FW6U%81)YUS90*B*!+[\BQ>+$5@'J TIMF)N%B-:&)QDY1DDZ. O_
M4;QW9976Y-T'I#WJ#/5MF[EHM^]FT_ :#9F?EZVC&/Y\P50H B'3I",W62.E
M4L[3I US67*3XN\P54XQ/(P%21;-_5@M^#%V8^S@N<##Z!Y)_:"/SX;_'![N
MZ.1OS?]P'@UN$!,2X[W4*:(%E9Z63>5OE IT&=A[O[LKZ+%'@:Z8@A:>7^$8
M1TC0!:OGUH%EX1^.?^KABZ/GCR:DG.WY1'Y$[JQE)-Y:RX#>5%?68/>H)$]G
MCSM#N[Q&&G']\Q]H!B']Y:=GYR9$ ,VK%4K".44M.AP2K'%6L+ D P0^A(\)
MGDKR >]#5B;11,"%L4LL''<&LZO*1!-^;(Z#JX?7BM.VT%]G34S\26F,;+H%
MJS??8EIUCO1^,H&<K&'0L;5UCRMOQ9XL()^IB9M?"]EEC'LL  ]/9S^*J_<S
M/M\-4JE65.6_"0JJ$O["(9J\\>V0Q2Y=H<GB$[L1O29,<H*;=5]:B>T2M)WO
M!:]&_NM;&WF4-=[E)BX"J:';NWE$P+;A.;@:*[Z?]<O.:]D:F[??C=[>#DB<
M]E6O_%'6/;UZ$C*O<N;P.T?LWFI102%WA/K5^)O<'35U$EZ[E*3@]+B)ZU(S
M#.AZ1$#_\H_<D<W80:8WO?5TYAPH'%SCD=)HE2!T#=K9.XCG\=VBGQBLK:Q]
MUCFPYK[/^=JGL-*UUM$F.N<;^99K3HS/=(_!\,::FN_1D>N\0.U V, ^S8<B
MRO<TDDF?GN6]Y]%V_V5#U> N YYM:1E#7(<[K?C]J:A[X)X%OE(#ZUI%W!_W
MNH(IDE:_OC3#)%'I'<])5XA5!VEGKH1XK')7B5B^?UJM'F'%?_9</UKL<#OQ
M.9SP3,?+Q6518E@>M'N[A>GK=FIXS-[KW;):S 7K3G( +'G8B;G.G1T/P?<C
M?-YZ@@U&AV7Y.<U4R$:E7E!D/K(9^2*\GA?')M;[IURO18"CPC=^M$WS4H *
MLJ;]3%.'C2Y? \AD#2UO2DLOD=P3^8(1*(P/JG</2&RE-)0=7 BP2XV%Z(&D
M.>[L+8C&3?P(6&]*%$@K[\ZEWI>+M8I4F13^S6NH"ZQ-O>]I%=@M&,%RH@UG
M!AX\]Q0D8!$0A#O$1O!<AW G-0CG QF'[A_18B$7O2 4$?#;'$X$8./ZP=12
M&@3;$!LB8/D5Z6/<^)H,UI&436.<$R_&F:YH=$M<3$!.#[8V2HB =9-C+(&.
M08<(\!!E'@*V-<,MRH"U)UXC.TQ[</&3HWY/(Y01IG[OZF8ILC(#D40Q^@3(
MWA2C3,$XP_MU0$-,<:'+]8/NJ$Z_5-E7+!TNTZZV:5<J%W- 48LLFC]5%LN?
M4A2*MIJ0%LM)_AC!O?]#:6E5GL+8HPDDXI-(U7FE65O4H@\>W)N70W_ &BRV
MR"OLQPL1J@2+\9TC_$!/NF9Q?,^K*YG2FC0HX(T.;[80#&4PJ0A$M-Y+A%<P
M5;V.@(+0Z"MJGV_+??ICT[KC[8P]'LFIV=1@\,T:ZUE\JF)S*[OG]5OKJ(&]
MDC',@.D=-M_IC6K37/5J$:D-!_$WSV'Z:VCGAN@Y99@M]7&IGM%5EO=]1V]&
MNAE2>GU]_;"(VW6!BQC!JG[KTOM2<IE.<VNLB<I4'"7% <=J*GJW(UGYGD[5
ML1;4#=+T!I0]<JM*7BHN5G8]#?\<UU9VX_(/;JE?UM[J('3Q/%XG;I8($)"R
MDME/]_5\(*[>%-MK[17YA(UJ<I9IY],LN'-_LJ;)D6R2(8BI^<V2K,JSS-PT
M'=UDQ^]OU /%^V<"!.%-0242G H4B7>.3N&(>)..>VX(V]?S#TORN]']+>*<
MPMD?M'7U[U]7LBTH@@>/3V9/Z)UF%G[-"WU=E2A1-CO0I,&W]T K):\.Y32@
MD6?<-;K0>7OH;E%RWC?-OM[7IJ"(NSL<./OD.5_GW%VONH 7XZ(J9?(^!QG2
M/AO93<BC@(#Y)IU\,.6M8 ).O:I5R?/C7)+1AX;U1.>U_8"U3[--""'5D-+<
M_'V-L(<.YU8QR4D)Y.;\$X<EVKX_^ORMT<[0U.TWA=V@1J<$!HY*;,+,SA \
M+\7;^9RIB1!_,&&:W5"7:+%;(N8>,(2:/_JP!WN+4BGCS/;/6E)S9L]_S=KJ
M../-($ $>($IIZ.VR9*MEI2482YY829&J8'/4MJN/_P>0I7R74GS%@_BB:4C
MV"?_)9T*KVZD) ZA'6:Q^>N!K-^+4F&3P->>MIA?7BXVMG7+W0U"N&%[$,5*
M"V'!V6YC2&.J@7ZHN@V$:IK'A3/W,^M<T<8]OOET9EM1):>K-\7HLJ)=6I,4
M$6!O<0($89"U7U2VC1UL$&?T%^(Z0-7&JA0--Q!%9? \ \S*1D*,45.NWLV$
MUGV-]^#^U'O%@H3(9/E[M)<MUTQZ]^H8&,)CZ'8>D]VPNJ?("&74N3&3("?J
M$'N-_3MSO.C6U8,<B7N==)+78V.U2_KHOD<'\_[^K,@,W5  ^;<>;".KTP=E
M.-357]F]+SBLOZ#PFN[&O+U#ZV;[-,7*9\1Y(")6SX+;.P_1K6V3F2?X^!63
M90EH]*MEQB;TM,(_A0CHU$-3XN>=AC\ 42N$GV5;1( J PM.Y4W"+A%PJ DY
MVX@E!&Q*G0D2 9=;GT.6ASUAA"UL2.,)MO]-U+D(ZO#E-_9*]IA0*U\JZZ3X
MGR^_?O1587VR+-90]5F]?F.A<7]E^@$['XVI$W6\R=>)%TL@'UI@NG>U":$W
M4&<E;6R&)IW]J1C+@\;LU;+Q?JL3-)GYB1=#H-?U91F>1CM4TN *-/RR^]'9
M&Q0R3G0B_CFONYYR[<FQ@!@38]7$R^@)5KRKD 75 1WECXR>_%V"7?:?(X4;
M*^<?G;1?^#QEWQ(KR'7H'K#0U8'J\<B3]:G('@SM_?"[SZ6\$/#I /=A>0?[
MU?9PQC<ROJHRO]ZK!FQ@B^[#EE&+32"M:MT:;J<*,!YHU2T/B.D>JY+K.N2;
M8E#M_2XR!S#Q]1Z4";3&.]WS0F!+R<%[K[.HZ$T)TE0L?'NHK5_/.;5:7OQ"
M2I&BIC$!=E?HM*^/I:5;=WGS($Z,YEUH&F\R+Z#$%*#W?:F*0K&O@0BPRV=,
MLAZ[Z15#,^!Q[>5/UPQR'RI-^4M T=:Q'6-_9C:1)HFH\9 2<:C6137Z?*52
MJB[L31L"W\MEN]M,P>D>J#ONA)U_3M$VHVWK4.5Y) 95-XZ/GYP<50BK5F07
M$_R3XKG+M'<XWBRA:#@YLEIGJ^'-FC&PPI%7E#7_7/*VN"!#HX3T<W)Z%7+&
MWGE<412,]7A?[C8=6:&84-<WW@(C4$F%0OF!3I;CM&)C4O:I(\[UI>.&CHZY
MK(PAUV\!6$M=8E=K#@+_3<- OHE;?#ZXFM;T]L2DCYJGK0F'.4P<+T^C;JN0
MS\")0NCI>IC;\_]15CXAT'I9L\<1 2X>B=ELN\?H/=QC@6@B(-P( <=M2FJ@
MW/&]\/D%-^!Z:LBIBR0_"EZ)@*SG_/7,.=-NR*R#"\N%'JJ."%BHG$.U5>2&
M%15Z>>F^!MS##-!0F[7O_K[C@TUO36NYQ\S(=W@L^^KDZ#V4,3T#ZX \KI/5
M]DS7/K8S!=W&6NPQ]PQY<R*1\?AJK5F/)#7QSH646-L)M'/2.%ZO)0-9JUW\
M4]S,#FFD8E3H*FAZ3>:V?%9G<G(H;0+H3,1W'62QL/@919$F4+GT '6%3_WR
M&_8$S#;E3<-T&AKGZ&S[UP+L&5<\E[KLO1^LN3C>?C(TGA1$.[G_G/[U^[9B
M%0E?35KJA]L5DB(\!WM58+M*7*S+HE?4Z$Z)]QN,3$K(CA^HN=?"/67/VA+6
M;)+HZP6SVY6,+(PJI.2$4#*:F-/JJ6HEJ 7(FSH6M9JC,V[CLHK=O;P]T?A$
M&.R( 5I*8-'<-?V6@H[$UELCP5XQOF @9>0N9JE7&\/?JL/6Z)7GW2CQ5?WE
MV B'T;,;6R&A<O<;?QY.>*4H"J! TSB35W#WFPF>M6%"U+\%JFMKDZMXB]1I
MXLB_YKTG KJN3';4,W$V"KJ[5;)M?T:HT%II2G4UT.?7TY:^*'<X9TXT?27_
M=49&H$EB:&O&\Y2Y_\S5J 760F;@=,$(UO%65R<S7"N6'"[@X3M99Z-X,(_$
MN>?6R0NP31HHJXUN$-;'?7/DN2"M3>0R30TGG@$*$E4GF%<^6 V_W0@0LA@]
M6)B*CIA2K:]@\+[1<C"2@C).7PIPF8S4B<K-R>R85)OI4RBS#>=Y>S5&6X$Q
MNT;5W09\N>3>G)R%W0?K<WOM6?TQ93HGEW>WA\5^W4;SAUV-X0^8&OE>*)2[
MNG1;E5'[NJ_UB\8V-\-+RPJ_O;@NO?ID/#%^=3BC$<N6U('Q9W2N^E/#X)@K
M^<I[ A3&G(], 9>ZBIIJ_9RG,Y2\TB*N%MUJ7H63I'=JD=<+M(PA]X_T\ BK
M7A8J7PZKJ?>OZ3Y..-\6F&P5KWWKNE*G0 2@W)=%?$S7@A+?@P)GD"UM>J]F
M?JB8QMYFXY(U=T<WZ+AJK05]%#]A#KOZC76L0'+UN;=ZOC_":R?<>]K3F;PB
MAD?:$)U9<YW3]^DGRQ\,[C2W?/XHK7V;,(H<,6Y6%ZN58A?-;+,\M^XN-M#^
MZ57^0X:.U&?',D%535+7:JI/SZ'+#/#W3JL#ENXIJA]>-=1A#=!I1;FQ[PSJ
M=NS7VK57Q,N6/JO1@)YVE>&"!$RE5-EA@KHAFY IV0W0M^$KDTG@NZV.D.Z-
M,2+@M"B=$8Z=7PDX*%^@//<G;$'&EC7.8;0O>X#S%.4$WVPB@$S>>[G\PE"*
MI#P/PE<-"!<#PU4N&,%M)+V@7?Z9]\F#Q5D6MLIGS6;K^7.G,L?531).+O1)
M>;]7#+A@"R7>J19MPVD]"O'/YKWT&V]D%023AUYSB[[:^MKY6OA7"B:EPJM4
M.#_SNIY>-QKCL%]!)_;/RL^+1V7.QJLVO:'=D>UCZ*+(\41$4V*9.\(A.)'!
M-*4P>V#4Z\W(^VIJ'S_N(G7UP,<4[AU"P0K9UB*9"NKO_$X+*V45+&2%7=(0
MOVTD3HYW+M:']YBKMS'?$%([M)Q#I3V@R"1SF)1.+=C*3M]N*IRBVDOV/O^D
M8<]ZAE/PXOR$1^#EFOKS;_$-QD :S8_T&;$:,V3G%9(Z=DPCM3'R_*,T'PKN
M"',/M#>3)? :4CX:<3V\ IS (5K$\[4'PQ!@;T_GU-%Q_*>95%CRG%&80&]4
M=CNH1T+"Q!-K"-KVE[ZW#GNS/V QE\(A( #6?O=!3.QE1L!@@.@;-O^0LD%(
M%4G%R5RG0>=J(5TM^ DBX Z)-7\/R-ABNFP.W$!X*-G;,1 Y14@-6\_$E'-
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M@7P#6A !0+-2Z'X_SN ""=X-5"<"AM5'6<XOGY"^[J01^+\,YO?_=[ 3:X=
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M\+&_L)Z%,$.0G>949V1QSMQ8Z0-UZ[3G;#&&>>$JPG'LX8_G@<U7?LH>/.A
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MKN[77RI-V9:5.[]"P ?*8??.I"#U),:\ZBVXP7*HU4IRLZ!FN"^^4.Y6+PS
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M^]#8L0/R*/>4],VQA)O?FG:8NZ4C=E4[>W<&9L[(;9$Q)1O0.A>+K>RLPO1
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M#IK$F)4W/ZWGK ^10\7)-4$2^_=^%0R0I/=#^QRP@\T-YW]W4]"1/5&T%'B
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M!L**BT/A_8(R*A\P*QN%&3;/:EIJ^'F98_T)P-F,AE]2IV-GU_^L34'OHJ-
M29A$_Z7&1(4-]&0B@Y7I4,_"=:Q"$?,L\Z^X#1^D$@SW<6Q2<US]&KR=*B8F
M\C(O-S?ODE]/345)18VF^XZD!(4;I<SMAQ^^JC^^ P(  .=!^ZC"G0<E1P=K
M=1X&U>(/5XK%@*+O4@MS=@VYSN:N'511\QQG4X_Y#HIU7=P5M%Z\NS6ER:Y
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M3=%_&/A=PND9O,$Q(!-6*<GPCO#$U_'00,);G*;JER_5CVMNVK'ZI'8&;ZO
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MS Y\K(E&LKUQ^^JX/;#[2!BF:7 I/^<4[!1@LN=FC8 O'?A>Z.,.#9O?O['
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MS@P>L(9HWU:8Q_K.N49=Q&SB 4(^R>D1QV5+C[!)D1EGU16,;-7V_A_(J'P
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M(/./*I^F;8@EQBE)@JY?;X]C_L<*_Y"1AJ*\*I]);=F06B=;L:%:SL/'IJ"
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M?GQ=K;XB,M_/0'%?R$<<3)U?EJJBW*=Q4ZZM_SX*TW-L'GB8.4=3&[&_BEE
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M'Y7G3E-JJ&E1_]BPU--<)L@7>:Y!J_W.S>$+^3W%1$ (X(3#FR121:!=GXF
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M>6ME(@"*Q^'C24H0UPT)93X#BJP1 5I^V @@VAE'97PF2'*WI#LCHA"$_LO
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M4O$&,I3,XP5%-#((S#FX7+[4%$XU=:L* PPW-_9-8A\.G*2Z0AD8Q9JE:P;
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M:",&H<]$KK\=81.^(6YJZ(GI<K:FJZ^GY^BX]4"RB*3S!K)+M6W5*3XF'SN
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M@M=&'M:]]Y%$-<LLZX!-"#>WES)K,]WUP6P.H _0(CL\=6%9'W=1I&Q@H=E
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M*N[BP=MU1&LHI1P+SNH,O!E2_H*EHF;60C6U,J#.R8<P@B++LS9+R*+[$\O
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M>'U6?XQ%TDETI;CJVC^=O<>G!?PSD#VJ?2>/G*BGGQ>>HW8GJ*LAF.$WE<.
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MHZG)],2FD#JP\ ^XWK&G^9$V]A6[M?-4#R.ZLE*/>QS9\S$V=1#(I=Y_BWW
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MD1)_V6H1*K)T[_=>\N-XVU#S?<ZM4*T57<,7IY>8^@@?V;1#?OXG>\<O5I7
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MFAE_%#*'F&+$NUX O,ZG)/%+H%/"SIP&">'(!S<T"^D1<]\Y-A55)/K[#UT
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M?@II@T@!H6BU/*!!RT-W:@ETO69OUBJ&W&W(Y[U&_A=PP)O*=NI0UY(U_0M
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M_\>F<JG<[1> *=JM+%?0L3TX[;/K!U750\$N@^G5MLQRIDGF;<5+5\B\ .0
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M+98*DZB,-.34KC.I<XKT"QI^WTPVT^4RRRO2>!A!]4*.7CF*Z5PMQO H^R>
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M3\J<\H(_KM*\8OL*H(A+3T(E&/"[82(;IU/9N";]@A VL/M6C(%974,?]NB
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MVQB)<W.[ +AYL'FDMS?ZC#H,?WR1'C>I&=8HE*%CZU!\WCZD-Q"!(?\&VQ.
ME]#WHK2:/B<-;HMJE164%+=_Y.-O(3?B2!L9K;OOPOS<Y^UQQNK,*(Y'2*X&
MSIR-4T$68[ZZ2K*]9&1&I@=JH4Z *^2TVA9;>:V^89OH@FF&)P'-F3S*P9'9
M<:#EEV2J?V4R\IB_'VV)>_.I*:M$93I&P6HW5L+7?S9=./JDO3G7Z^<7VY]!
MFINE]VO<;[\:_8S7^3$>MP1QEJL^SIAD]*,_TC'TE"!S&L:(IAC'%V!FNR;O
M'0DM32%'/;2%,E*Y1E-W7-Q73WN6]E^=AFY^M76MJ1M/@9"[:,CS:)UE8:RP
M9:<8_[9$A.E*WDRR+4=!GWL&B;M#:5)JX8_6CWN"#_JTV7ROSU[Q'1LCUS+0
MB-7Z65:>:)O\VN8KZ:+1W>*AI8GS<#<-3[8P5^X$#8UV*<!2!(7_])[(9HLH
M0_G&:761D'%;+A%?^OQ*<*U-$?BJ</",00GM#3G>F-[V+^4]#JV3-W)_Y7EE
M9P5\2TF,#+AILVCY+CYA[O?.">5^R 6 AAD*P=E4 \=-#GD/E\Z:C >#YLZ&
M0?MNP?A'MPI/<!^4FQ7=ZX6N34+(T;ZI?B3_*J80)I94M,\ *A+-@;+VO==1
M\^B 5.W2G=$( C]T+ZQMR1]_H8F;4&9]$YLMWN9XTB_:VM<[[_?!"/3ZR%/?
MJ>!@8^W+SQ?]Q5F]I#XV!2=V0PXP B]#G9APE6CK;4O9U*?C=<:(_F676G+Y
M,_ZG)*9R#>8_0IA8TC?'[9VFJ\X[$U^-X36D0%KA_L<G-B%30Z#T.$HO!VS[
MOE@)U%$:?,RKL.CA[[OH%&\ HA!^=@% >0V,QA:<4'B"CSK0]\8LUL<CZ9_&
MAI:1ZO<D9VDEY*5!$_EB'@B0X&_[GC6\/[;]/#0@422C\!YO_FGFUE56C:[0
MC,\\)?O%//TWNF9=W0= CH<P2Q ]8UR%&"\PM5W=G!]/WA)#O%ZYOX]Y%)76
MX=#\:R HD$H@-@4:G)WB$VKKM6IV1W%*DAZGH^]6KNHIJRK\N5O-HW@"*FV[
M9%R$8],_;Q52_5"&#]55CXV :UC+/ ?=>!RK*B%$ZSG4I@J[]WY[_2\LT;^&
M\(HI)1:Y! N>KW@\2"EX0',!4'HI(9U%9HH;0,^A2Z?.M:+:5JTY&U8*$\-<
M=!Y"=AD)"UQ2C9$C D=Q.EVB.ZZ*3&P\N!>CZV4)VKQ/?)K:?IUIXLGJ&UJ-
M5UO<C9>ZCM*\@"WUIN@[%P"*=U5@L(TY9R48+OBY0]GHOIVSF5"$ W4;C^!U
M006S>T*QN>UTR)T.Z[83BP[$P>YYLY&WPW-C%M&W2A^H#)T>6K]*\1XR&RQ0
M@D$.FRG]Y,:]C;NF#U.Q!Z^,X!(S@K/Z?980U_=2<=,GAIAHUII4,$>#=7&V
MKR'-B$9WS,OLT5M&2'F_XS7Y!CI@ZL/.\^A.(\CB)$Z2>$H1<OSK N!B<GX9
M/)*Y%2%F7ET 5G,@GWUX7LU#IMIG;W3,86K<?S5%E!/CP1IAY[R8HK<M%M^^
M)Y ]X;,X5[AZY=WI/@GL5.%59#@,;CLK*2HD 5I5X1*#58*9+7W=<O"@:O"2
M\S:VJ(*_AC!8E3M9[[TRC1JM^#%@SJ_75^IX)9,KIB201I&&AF36W);55M93
MO3"H^B9IK%(#:6@:Z:F;C>",NM%QT'WBHZ>%MF/S!H.KKZ]B-BM)VGC&$7>%
MA<:[D=N,"W,)%P!:8=P[;+CVZFS=.,J '30C'^*,+4TW"6DW=9[T4>X$TEP'
MJJAH%981].GNJ- P&$#TSK*FQ'!_C1\Q[LTQ'$O,3S[@C1=13F^J]FX>_JV^
M9"M\+%RXN'5>VPBF_<G!)2;).%[_H AGO_0 =@&8%_0M>8BPD]/C)U3+]ABT
M22U$UW4FV+UV-G[HTZAC]RBBH![TP'THMBTRY4IO-.(^20;Y7QNN30U</O;I
M@Y.4HT#%2EL?5$7.R04@=%;L8TJ2C9:FN3.#0@X45<%_0I[4:%N)HD#XOZE%
M:5/I),4BQ^[V_.[7D%/Z8GH9;'$WJ((GSF(Z$-[=(9L1!T$MY@NI-F9PF*GG
M  ;+#>KPRYI UO\$*M\64:Z<1$.:A(ESB8$B01CNG/ZG-#(J*J+?2S@M?4*Y
MU7E#IK1)EE_3E"^_7E"MSKMG_'IUV4_YL:W3>)G*IUHFI5O4CP=)4\8.Z;#,
M$>D%5>P-<L*A6_KZD0/3#PRAG-DAP.];:/0( 5RZ;_+(,^,HKT-1U82)RPD3
ML55[?'^5:NEEJO#]K[7O6R)2.-:+YN]<G6/WU[;/Z#XY1?&6"U-JM]=X,EU=
M.B(75EEV\EO3FFQ2KA,MMU1?\+R'^=*/U#Q\UM.N::E>6^SRG9+<<26KYZK6
M%:U2-0,9,M:&-,8W]>WDJIG)9R=N*9L;3VLUY:GD205P2&M^A6/*&F<2D?(W
MM)V9$> "L^,(IDT,-8:S=*N&_WSM/3HYJO<HXOX MK]I"CX"%X0-$$+(556G
MX*DL7ULTU63DHWJ_<;S0\H(2O#-N%" U)<;=-) A8&&3%XC%\R'(22&"'H*;
M7@)6DMR2'(6=^.B!]PPN /W4%X#(R##>]GE9JOKG-R\ ::EX@/<U)S 9A]G@
M?)0IL[0[DW03P<KJ2()7. *50&C.85-53>EMT=.(S+*WI&1+\RP*". H8=7[
MV"%@ER5/,9_Q%\[;_*[LR-WWHJK4_MS?Z 3*WYBX>D0*YYV.NGDXFM#$#IA!
M:UYM%#M[>>0H1>AV6SI/6K?SFW-R6+>$VH?"[6+\2!U</V@U\0SK^K=-HW#5
M8E15E>G28TWN>E GD0B4#LPEM4TL?39UV%4#ZQ!3)>3_/(?Y.43,(!*E1W^:
MF%(5&AO"+,U=U<?X(]1!_K&VIM;86F^P>/=&UR.]J]W<#8_5_Q(H*BH%T!6U
MB,N*6F":T<53X!*SHU7DE(A_&X;G7+GN@*Z/\<:;0)*OK0[ C)-WGD+;:'C<
MDZ>!Y%]S2F?J3D7=(DF+&Z8W)Y="J>@'N:] N19DI271:.>)5\;HK;7-@;')
M48^R*3Q-4J!8\%::JN[PF!6?7D0_@CTON[ ?LXDN;X >J=!R27,J'":_U91_
M%JQKE9COQ.(QY%Z4)[ZU+MDJZJ6[F?)JQ/U%U29E-/NKB;[W\U'&@;ZPGO]&
MVGM%-?FU:[]1%$0I(J#257I7>DU$!*1+;]*E$Y#>B8* TB(@77KO/0%"D=X[
M 4((':D!::&$LOFO]QU[K?6MO;Z3?9*#.<;S/)ESS'E?UV^V>]"3O%CTZKS7
M(_\LX'(*WR<Q+3HN=O(;N=?48Z$];G90G]90O675KVGF]=8H$;PK(07C*^)Z
M85CJWH9Y'L\:*H#YNNDT.8>IX)?'-D>EC^#FC*"@VNCV3LV J\4X%VQH;[D?
MQ5T6DFN BU[4%87FA^=.SQU,T2&C[-^,JN,K%!.(39P+WOY#-$G+H$39<O5:
MWSWBZ4I<MYL/=N>)X=#7CEWA>=1@Y%,P@I'\TWW*D#[MCZY@95)6$873>+'(
M@<R$>-VVJ.8#K$D\EBQFP.)E<U9MB4B=TV*[3,/+1XIZ$?W+A_42X2G%%+'M
MZR]U4"ILNNDD(21'$Z=<+/;VA2RA[V.[-Z1B63[_M!\]WLQ,('S ]3[F #1H
M66Y$7B/";SUF58+C6\D9Z?@\. G>V7G?HZ=H&C(T(:.NPR;*&]$[,;9:A130
MT)75>)A"13FA2C^6$/[64^/"^!I0G72*O09\GRZ\!IRTHJ^.17$"-W "6MSV
MO &1MTR;TQ?,N:V]T8&@D[1R]7.&G7DBEFM *[?H$<%60!ZBY,J&'0Q95EG(
MP$^N!:" =_%$VG%X1= $T]^C]?'7T4E;+V7N>(2VW:&P(#_1HFPC^A&09!J=
M=EPEX973\M8,3C:.8@A!G,"V-NC3^V>:8V#PQTNH!@Y/$>4J!U$V"\0IH8-S
MKG"]K9M[51>ICF)0.6W?CRX.(F7-[A&>MX^H"/^#;6:]ET(7!;C%N>7,W@DA
MM8+$M'W.CFB\%-X[#?=CG1*'EN#R6ZA49SLSOS"F1B_"_N&EO^AP&M%H;KOW
M2QQ%W48/4GV*MEB[)Y6L\O5M\E/N_7H'_#KB83-B4.AJRG!@M%YWPG!_%7\-
M6!6U\:_H6*GT>8K[L]/MF?>XO6-,MAYV]2+&1;+'>>VEF&$C_^*8+"_K70&[
M=Y9\Q%;8*-;1[$9M_O[XS8V*#U*.3O>0S$^HA(8(7R_?*\Q<&M.;S[AOGUMT
M]ERQMA'OK/B]:',ARN_!BH>QR3*!(%Q 6DYCQN/XT.+ (Q:H;/OG5;+J",/[
M 9^6D^<:&LS*W)MP^*!-[W (BNE)T?FVK1>KM;JX"/\*H=M';,OO'L]U2V '
MEB$&=:JZC38P[JF%LPHU\];" F][]?=\RT%3Z1PG#TK]D>B[J*,6.O#NX59Z
MFL^%S+LK<X<\S5NWB5P](ND1TE(Y);W]UM3D\V)[<EL",1-F;('Z6?D/+.9L
MOA8_X'V<STT7FCMP\0.-R/BT,[<[AO)A&)O$PZW6<&':*Y5^84Z39+U#N_[=
M8I;K_0/)I5T=7P?EQS6XNTAYMCB0%XA-2@3^ ?L3]_<#<\9IDZ>E[I?Y:.C:
M!PSO-+Z$?&[<F2=_8"MMFJ;3/V$+DX="?^@Q-9639=#EIDGX]CXT)=1.59KD
M$0-#1GY!&%B-4^M4D6GQ[&@%TVE=V$ H_R&E+Y-!)_N71'#GE\\N'9FSB2NB
M;KSDQBM_4&08R2GIN%]%8:6KG4?O=M1^SZ:&%87.9&$"TKZZF([CU[T\8'MZ
MX>'Y!HOE Y8%]GU2.I7===04!W00LO$]LO$=T,E*C3/I6M*PLL84PDV\UI/O
MC6]C$)(&#(>+OI*,H)1)_"6L$8U0U8BUMM,Q#@^I*O\I-TR4KB[W1--[FE)9
M9]<>%T2T2@9QUI6=D*1EK-U*"ZXLVCJ)MP).HI\.2DLU!Z=GS>&'.3BS;M,R
MM*5W09>2)>8<53@O?IX$OU6JBLU\A#C=O 8P>@V87NA*+%T#JA"Y-Q#S[PL]
M)!TNT_8NQJ\!&=.YZRZ0KFM 9DOKH10'Y 2%@TR?^_T[F7A5B<M1NA=1I02[
M_]CT^'K^7EM3#CK5AD;Q RH2;#TZ?^#H(J-K]=UNV[[&YXX!9Y>D=$Q[72K4
MG>R!Q#6 _*QD8H^ Q_. 0(O55JJ+%)0AHT8$?VE0MCEG)&$O,0@Z?PPN]GKL
MQ<I+:\%M=R(_%N%=9O5 08/UK=!,DW\>%\DF0YJBL?)(#7D3\,GB2X?95$'[
MB\\H_%ZK!#_8275B-DU5ILZ+D9U<7;&2V<=/G;I2DIN9H],9VS7UODL*1>NB
M*'-75?CNQ_JS[<=W#H78V66?]D;5,\%#%.(AR^<:K+'\W[Z[EDG<-K!]W?.0
M;I]B_<OO\68"/^<U'7G#N%*O4+_"$\_Q+;7UN:<,B&FCJU;.K^45L3G^3XD,
M5N$)_9D)*MW#'9[,(_3: E+QPE3QPNY5>FWRAV)?Z7>@47XE91+J!?@"]E^_
M5PL1>J=?>L$J;DB1M6T-"9BR&23P>0)57NXU0 FA1'RH#WHPL-ZCA6@)I0W
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ME2291PW=/38BS"HH5E2T_RW%6.TI^_ZW:#N:P,?,C.YBFW9U6L*E7#W'U(K
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M%IL+?:UFASM:5]]W*H>N."FO6 '7>]3K]E-;@@*;B@=67),W/QF#@W?F@-<
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MO,7M>PEA^__G7E10][U5*-$<VSO,G0PVR:MW R7\L8(SR3J/V#*%GW.]9HZ
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M_XA3\OETN+3]QW>F=52O#18% +\EE2^]->ZJ1I7RI;W)88+/;3GP@;]"S#5
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M"R4^E%V+=A/\WE[@0Z^U=B#D/=FW7H5X0!G<(_QQ$U V:,4^VTWB*9)A4E0
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M%2H*N5FV/)RK:"0B'6MV^YYW##T>\#5700K*QKQ4OTO',RX?/O#IVXT([>Z
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M-R-9SDJ2UW@Z!PB(0OGW'#YL=Y)ZC"G=8XCG^K@^_W3G:CUS#J-L7'V.=O%
MWF54KQ*IL'&R#VB<I%/XY%A,'R\4']-K%2HC<5E;\^-<5J0I]<034=. @**5
M 5N532ZP^1+>3B^6LMJ$#0O2%\/]_3][7T0_RJY(AB,_9325[.L$%[WE3G@D
M$CU^B[&98$;D5+C^DP_//*C<ZYV]/6]!\N_%K;]I&7(-)[NS"\?Q29?!C9Z$
MMTN8&67=S+SBK26R)42_ZWZT59]3(,R=>N!L&M,JX;L5%(OP\S11=Z[SW)Q/
M!:;2Z45N%PP,)&[/18H9HR4LBW!'$_1\HI+,H[Q>%X2%907I' :SQ.[$GO\/
M6^\9UD3TM7O'BB)%I2A=I4E5BB!=1+J $'J77H-T)$!4I/?>>^^= "%$I/=>
M0T":4I+0"1!(7O[GG.>\YSK/^3(?YIH],]?>:ZW[_NV9V3-F+Q6XS)[,!XT5
M,4A[$2Y7/,M])TU2*>JCY;J*E/2SRJ DN3P;9B+ )_R'T;GVCG61;I-9!'W
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M=B]S3OGX&"]^_]JTK;^27[U@@-6W8#OR2JK[/$FL9R=&!9%1D3K"R%>BPH*
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M[3^5:;E6V"Z(%P0&@:3A(5@B "\A8W_)<Q9S(+/>P=)TA>!$G1]?<[^,-!%
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M"L?;$VZ$?]F-_G>F62]TQI< K2MP1"\Z<2IXY2B!VJ/'Y\^,^2U=+24D:K[
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M)WVZ]H&CD"("5/SDR>-!$ONW>$ N0>YP:]3/;2=]-'Y;+7!63++>5A#O0F?
MX<)#?4[:PB.T@.Y5=;,U36[@8VLU7'Q[>!X63[>C5)K.KA?+4_?)] HV&1 \
M9EOA$BO]R"DB5N8?CX3WCO/Q#D4" N\8<THXRL&J1:RX\?QC"CES$>=9[G_H
M7)CI$P_I4Y3W9B("K$O:(0=ZOD@B(*#/$7RWJ>2BB @ R:QU'.&8X8]]XHB
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MN 2>,W749O5$C*Z=)DL\".WY7.9593JQ&Q[RPWDHMG=21.?@-^WWG![)(HF
MSA$>J+O"Q!M87R,V7I518,"-G_RGALU$PTX<JDB97UL0J<C*:RKT]DM;@:)-
M:X.0H3J4=.H#=</M<0XKW_)O@ <?J&<5?#Q^+#)]1L4[$5;GOT;!4CM/]KY:
M>TO/+B(U7+WDF:^&+_T7Z4P+AS[7(XL14F9Q [,@![65>>&)H;NHW'Y=Q5#C
M[\GB0:%#&NKY2TQ74S!2@1\[47BU#GL)Q0W=0XP)/GD9]3DIQ0D]6KW"$.!<
MC*=T=T)GJ;&;XI8T)VQYN _KUFVI.3[ZOYC4&<0:"F)@">?A!(^.%5ZMNPT+
MN4U!+S))XO_2^;DPBVD'A)-$T3Z>CO6)IV/5?(<7;9[@C3-2KXXW%JJS$G\O
M.*4,?-^MVV@8'JXGQ2&"D/7J/1X8:@7+V18/E.WN12.%2KVB66WWAE5L1&TM
MG+)&:(_4\$U0+_'@O&;I9>-LBN@,&EQM>F]T?5[Y]G/])(Z@PP<;"$UO&5V7
M>[,?).J-U]>\1!;ZT>)O1:7Y&2'6NB!>/<O94U[2@5,#Z9::RCZ]U<DO#**Q
MZ:[JEMJ9=&Y]+_?P%$?FW($N#ZHM&EC(9E$6=EHW 3/KY2KQP(<*K*^J*Z;F
M8$5%&V015\W5B]$ *3F'DG1MP;DU28')C((+DL:+BKKFKB%KI,4/WN6C,4O1
M*GOD@GC;:%LA,LTD@;:G7-<W/)WI0%[5)&:@W6Y\=>O%MU$KVY]S AYU)Z_&
MB0 [2(__D X3;1IKWAX+M.  +7=>+KOL+V!!WL%]Z79W)9 0[1K<=_4=USOF
M)[-]A+].-M4PF9TEDP>Y1, 7+\3YWYA+)IJ5<,2!.=;ETO!5G!G^2,ATH*\%
M4>%A!\^4"9F\]/D%\N^9ST)U'*0RC=7F=6[ZFMF"LH+:17-,0?!S?@6%CWM6
M(B,_&K@X9G;/[('/7N??8EZM=O U#'O\4Z>R<F3M(0UM[L&H_2'>WZ_-R/IX
M$,/>_4UP2NE9K$8%L-^U)*VSQY?/C"T/Z_>7Y49=&\QASJIY]-@/*]$$#4 M
M&X$=7;(J&E?[>M:ZT4K>+,@)D3\K0M-2]P?#0S=_358VO6:=2;>)=%XTREDG
M/+'&!1_E;)QR<AT&-A_!^Z#N3(&PB\"&W>TMWQ57X%Q7RHCG4NH2WT</5,0A
MD]M,HAA9L"XI$%JK YQ29,EN-@S7'>S_Z+@:$#Y%PZA8TP\1FMIRUN&T]"(?
MHJ7A7J(L&3FS_7:^3^X.TVL\8NBJ;+;?)JU4[ NH[?$T=71Q=FZ8!_/GG'6<
M=#5))CZMVHLNKRC,9DJ8$+)\N;-E5\I1:8PU?&IKHV\73U\)'UB1>M1RL0*'
M-L\MBT6FV/IE[J[$@&\]GY:SLW;51JEJSKPQ\4]:H?-KWBMG!6$_2FOPS$Q/
M8,Y<BY5'F-72Z[BLBB9$"Z+?35103+/-S3:5G+G/%J8C?V7%O[=.^F1?)+R=
M)_9'X277AKN*1\^T%!/22-3]>+1WR'Q_PO/?.Y=HS'(B/('_3T'E@!>[C)4<
MXN5IM!!#<QG7U/,?_99;X!=Y#<Z&6C=THB.UFE0TJND'3ROR1V/^U66LQ[ \
M]V4A JA$]8B /9? T_2CJ^[K8ICN3 0P28F^.M6"%,G\V:(]9R<"K# K.6=!
M, TBP,=I#]X-M2S!P;POY@C2F*FK/") XC+F#(_62:]#GM933VT_(P(JN.;&
MDT)E8")^D&X&EXLZ%N7J\&#=K>4$'NJ?D+SEZ@W61[W=OV[UL_R0ZG#RV[&@
M;Y<^Z,64<Y>W:[=*>JG:BV"+EH2%!4=8?S<2 <[ VS2?^GCC\ELC]!,7Y0'X
M!T=>H\A,KRH6'K46LT(@FV /^%C0L+T<X/K<PT;76L'YYOLVDL_"3+=:5ZPD
M&KWBY0>IL$:1GY9XJ>0"1,[YV-)TY'S2)\)AO*">#^ED[\Z<[,1O$DP]=8%U
MI5Y)"E3KS6BLR<JW7Z<T=X>6C5XA$ N^2_Z:Z4O'+2]U\[R%&0)O)2<\R2SO
MF9Q6U52E,-@J[E58"[:=+%)60S2S>="AM27,!")ZAD)6=B,*\I9X&.DDD_^5
MQIS9]P/I20M4@1H1P?0OK00':&@DV=])*UBPM&YD?TG&F2]9_54%5_WF&:DK
M_EH59I=;'_5S[8D!E5Z$D++[LY?,]CF:N?(  ?=^XQ-V'!_(_<BY:'F;YG0<
M]UC9%L5(>R\@]_VNH*,R/[U1V4.%>.,1[H9'J]S')J)Z793))Q(9Q?B;ZH0%
M>$*'JW_"@4)#_2Y.U$B-^HP\9M+'R_E HU%HJ/WU@8U &@:O%[\$!%;SA\-X
MX@85)L7[9#5(?W5N-#M3O_5S#D G C%\!U$KB0ND?G? $)\U)P76L^R5@F(#
M^H]>A@D\$?J6V7E!O!,2;ZUK[]B<-+O+;_8>M2RX[>RBO,2\>J.J+5A4>K]>
M\J2X%?2%Y:7">AX>:'XSI(^GW4.:O5T9@V-U&2MS-&&'EWC@;UPL$1"&F#8^
M>^*F7/)Q7_E.E\K!![*)MDJG2F7S&FQ'^[D>O($I$"Z2\_X/),R;".A!;1X
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M?.1'N,S!WV?*>(WDLI_^T6K6'2_''Y/"^FR!A$I1U&SW4N[LL2,1\7TZOLI
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M,=U@_9$X@ <H[.\ZYF9]]&8U^. K#O#Y0:_K/YO]P1AJ1/(5-O\6LGH2U;=
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M:FY6KA[TH&.NRI+#V-]EU;5FUB<E=Y]+?=Q+I!SA^6\&"W8]_T&(7Y/GY'"
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M&DF#6MN2?5[J?>"R;'L-?UR;9AJT,9A8>X2F-?(J2U $XL5;VSQ[/UM725V
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MVR@VW,AQQY).,28KG-LA'^0JO!5E!!2U .-A$D8'QX,?JV;:WX,]!8?'>DD
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M-F4RS)I0G#4(Y@=WS6EK5+\)=EZ:IIX,4 W=CAQ:0'_9_\:]UJ]E,+Y6K]#
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MT,Q[QD(@U [QD 20]T0P#A.UF E[Q$_;4)S ZIUS$B @EP3(40$19]D(Q,1
M9N@BEY<!,>DUC) ;@%?LP1.@B]!-E];E61*@GP/:2@*,M/KADPZN$Z%MHR3
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MUGWAF/)"T/+8[T)L86AAQS2B <H!W6.7@!'#2C2(,T0R@&N@Z)\#_-5W 0#
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MNVS&X9>7F@2I?Y'/N\,&'X\;HHV8?I8O"V^X;WP^0TM%I,!+]2/04D%JE/(
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MA;KI)"<GZ^5+>@IP*4G*RT%F=OH)\)[NFUJQ)74;YC0?<]H$%"$CJS9Z1\O
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MQ4UMC.;3I&. @V?FM]['E#+NNY.IDGRF]L#Y7EQ<97K20;#BT<-]0N5\U+,
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MAQYL*2K4=5O'?4N)!R5T=2Z03+'E11<REAP&>_B)NFR'3!;K0FZDX;:*B%(
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M2C#IDT9P1U8%XZ^S"P33\G9#Q$"B4# O4%G>';#C.I6\91I_$>=:K6IU_:8
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M!Q_9E5UL\NUIL?F3D<YF<7D\C@&K<=/!2U)CST4T'DAB<^WI]T>WN+B)[<%
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M?OJV**ZQNU9 @  )U4J12OD//@3@5ZW^ZY=6@RJ&TEO.E, &M/,GAQ49-.L
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M236[=306SV]XL:%'/=)Q %!2E,DL* $ \ #BG3=O'-.LEHTCU7X4X5-:\30
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M=W'MW>NX52G3)1T-1FZ-/[F-!3FF:)*U*C[F*;Q1VDM>[F;3Z9O"_3?56OD
M5'Y?%GCZ4ZI;6*S>.&EHR@4IYD@G\^'Y\:]9,AN):$TC-3E(IZ6JJY7J7\/V
MT5-4X^G(J JR&%B*^Y!!92FDK<\3:KX7[MIH*O*5F[=M87#8O'5NY<]-D(MP
M5\F#VD[5D6!R*SXC!STFX\OEZC&SQ38[&F:KQS!#5+&K.8ZC>;<Z0(V+L=(
MIEJ5(R10#U- ?*OGL[:X&HR@**D\30>1P,D^8&1Y]99-QT<<IA\%7))Y)X0L
M<2$F2DC66IU7D BCB1P0S$!^=-_S*_V1W?T]%F*[&;YZ^KJ*@W!1[,QM5-D<
MOAZ;.[V?<.6VKE]O47\8Q=#44[X_-;>K(H*B>*.')M$BTQ>1P@T-ZMJH&ADJ
M4U\ :)0$,:'A1@32ND<:=6&URE9&69" 0/,5))! J/4'/GY=18]W8Z2&"84^
M0 J*2FKQ&*5GDCHJN&*>&HF$;.L2!)AY+D>*Q+V4:O?6[_B!!@L10YC%=DP3
MTB[%J-[Y9\[LS>6$"4=!MW$YBH3'QS8@U2U^5R>=I,?C:&KBIZFH8O42>*G
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M#E>?/ML[-/S@07[NR%LSV1G/7'BMLN25?_43E[;]^.FQUWY[S'8A>^V+ANU
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MARV7L;P!AV&H>U+R^1E'B>E8CLUV+">V@RO5_,4 GC7M(F$VW#_:FC4QWZ^
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MB:/%TB$&IU@\E6Q1]1D-IC)L]_+RNBUNN6[(E:!^'^BN"KP'D<&4B/XU813
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M;1"#[KC>FY,:O2&5C&$2#$J(Y7X!RP9,J#*CCUHAS)E&!<H0XC,J6,!4#5C
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MH&$IGUD2ZAB,J,4Y1.^G22X1A$!A,@_0#M*&.85Y,8%#651OUG!R5N@,$-6
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M@5)(<9O%&Q/!$CJCB *D*4EZ"EI,EA>D(#%!@DI088&R'B^0HL)Y'&'":F6
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M*:>7I4BIC5+K"$?6'.2+TE0D:51D63C#V>R<-);6@PS$N'QY$2+6H[(8ZO-
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MG][<!NY\=;OX'OA=W_7N1O&]G4PJG EAS(UWVYU:?0L2#S(HDV\A!+N PF[
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M=\=E7()F_I.O-C@(#:C_-P%02P,$%     @ G(7<6#+&)_Q[-   2,P  !$
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M&DTR.9L28FA(#H6CWH(Q8XE*3BN>MQF\WIH;C>=I+^*#+#*_'"ZC1AB-\+&
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MXLBT/,>3DH^EH9S.6;"#M1@[F$6RD40R;V;2N!&.)$TF)6>QN_THYBKZ]5A
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MPLN[OG6%9]AW)X_87O?H5V7'/2,@[YI^FU_K]/Y;3ZT<SZU]>M M%YS3_.R
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M_\M@_*C*I)4FT,H/Z5LL .;(?($8><4":O;1G[FR $HB\SIBZ-QF%J#.]!]
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MR$@-(D5ITLBTG748"HJ,XUR!0]EE9 ")1C555!2!SDJ30*'HP,@9I#D19'/
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M[/%VR!-P?P&>4-AK%>OM_P!02P,$%     @ G(7<6'+G:IC'A   W;D  !$
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M,R)@B"Z0<J3]9$!(!VMJ*>_VYI!85@PF^P$SB%7"/?%PA@%Q7555O<KF6OZ
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M+'0_LY35C6*)4<U$P_;;^0CCD-QBI)9D23;$$T3(V2HG\G LD[22,I\$*ZQ
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M"8=O#*<#UBH0EK'N<,!G5!)]%"7-%79*F3(A>]UQL"0Z.*/[B]?M8) 51:!
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MTZ;.MK;X/FO&W$@TL2+:-ZGD*>BE3KC[7X ,LO?NY*7K4"S14U#L0D*I#?8
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M*J*KUZQ2L AQUM?V=?&!^48#M?QL ) =7=,=-G 9JW.EO#$W/Z8,6)7=\@0
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MF!]S8RQ^W66$@SHC/W&*,\AY?,T-KN&(IU!##5!]R02QL@U,UEXD34[]0 _
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MRD]NX#/"N$]7'AX58:5'UC[8?I%@L\-@8:F1V:Q$IN%EO)%@$H8_9!^9W&[
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M7RC?2_4_6J:(1^$@>J;(P2EZ/$+*/7+VPUD^_.>/O!V]<AM9WM<9^B0+-^;
M@719)E%5-HZ&K)<=HYRJ+N,F$F8*Y[EHO])KSM+";P-8QD@GL ZG #<3TY3D
M84@![BGE3Z+QKY2U_6F(YT\>543\R72&(HI.QP^"90 O(\:K)7C$R"72>147
M*:7%&UE-4>@WO)7. 3?OE]A>91.OU?[VO'/J6B-R]ARA3:*Q?0 RI5FN<?,*
M8!7_U3'_R'([ZP%RW^@CE*J<(#PRV=Z[J#Z\OW]+4YWG2;;@("C8^]BC,YH=
MGP>3=5XVDE5&GTX/ :$!T@]NIE*.NB?U4;+"5AC8$Y"UD7OZ9 V6Q3+1P5$]
MR.\FI>INGT+.!0;$\(>ADM)#(AJZD=^;AB$)^^RV4]'%W:P8E5..*9:8B1\;
M(XI^0U'9C(O)Q5C&6H.H<[ !I^QENH0U6<MH:,P5LT!-BM6XCZOX2RQMYI;0
M 1EA$I5&<%M,Q'!)I9:G6649A9==B?<&K$EO%_1X@2Z;A31@!A!!7!16?)V
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M5/>6'4VQDP<A)X:O_GD$KT!'%]D/W+7F[]@5RW"*BR(\W4X3!/$"># !/%F
M(XC&0I:/"]N^_E84@SV#O<)^CW40[411N+4<5[OHS:]:7H#"JW#LP]!UA6"#
MC=ZX9K$,YA=ETJ59XHS5-LD=S+Y5:$HW?$0$7M%.=!]C_!L7*Z,*]1^&B*DV
ML' M&FSK C4M >B103B 1+YE\0O4W>HS-Y%<1L-U@TMJDN75Y.9RY%M1M"%%
M..[7LT)OB!MDR)>IM@8R@02V6.80J &$*NON EF,RJ,E)6&Y\6DHN)<RW2*D
M]ZFYZ87\XJ="Q%1%KR\^, VUE@16GR%$!H#6PM8\$Z:Y3L@U?'5,&A;MF\D3
MF&'Y(N(WD >] ;^R'E_(,>^[)K^ 6+]<;R\$[ZP&R1N,:GB5?JH4$"3KI58E
MW'RC8$J^IN-2PB63-TI5HC">\5MCDV<6N)'B>^S'J7C1WD'"I^0EJP<23#0R
M%'%-E;ZI4X;4(S%-R/M(NGZ<@AW3I0U@OS TD?J,?0K=U/RQ2#8*5,0 JH1R
MP\--Y?+EVCL4>\ !J<+#B^.BW056UE*Z>/RJIE%-65-B'T_PBV_:ZE>.;!/]
MLMGV$OV@MKT%ZL]JD#C7F4S*I,C\%-+^N4VXGQ=5\Q-PAOCZ."-K4M2!%HNS
M!T]G^'XP?5J$-P*K2Z*1(IK*MA)]X]<!!#8=M8Q3,4B6+1FY1T:O;9:]!0&T
M0IIZ'])_'E-D>8F3-_!_$>6+784!NUH8@7B ,!@\?S S[?MV4\T?9?_LGH0F
M;=\Z9 QR:!?QSUN$SD37O\^K>(Y0YTAM":@YZZB=.-/_)+W.KN/9_TIQ*!X6
M%V+K@0VQIF< !-K;V"10>BC"^]\X-&=M:>5Q/SX0D8T*"Y)$9Z#3$0=)P#S6
MAZNSY!=,ZY5"S3T>@SF+I# K 'C6-,R+N#U4]@8 F'U4[$78!^(UWLR\WZ\-
M24>=MQ.%HS9OI]+2$4E4V)KYUW*,NEFK'H^@;BI&.LF<Y'@S4W.=QM22&4D1
MI!P1_D6I%DVS1?6/6RN-')YX&'^O'X*(%&>AJ^NWP!S\84C1O PT[O$\X3.N
ME\;OQ'+B'XV8H\HKG:*(\%FHB6Y/FN!&D2<&<V84BG1DL;F!\9?2A3JIU1[8
M4W@9_"R?:ZR*C]DO74M42X^TC/1SM\<9[^Z$<?S'VK?[EGH=8% $B=#)Z.W4
M33F]^:M2Q8/_L=2UA;-WG-=WZ_C<7^)QK>''5Y%'00[LM]8JM/3^#&/OU_5,
M.1%=-%%@X7+I25N6ZNR8+KY4/3),^(R,MN=!T6V7#T[(]3L8(EE\RR=CS>'@
MQ(O+G'/3%[]DFWNJN*<G):?(;,W;/\I2+*8NO7:/E)C;(J([HR3S:[9,6#(A
M<)_!V@@&!E?F%_D_K[C)\Z[=-Y4SKO5Q4)%Q<Y-;O5)V;E'DVXMOQ79L^^&I
MV2NYX7*F^@31ZP[08T%(I1P%D5HL2,MRN_DLX#V)]-*'OVWO/K$NW>HXZY7P
M4NT)AV) 9P2L?B?]:65*[^%MVV2ZB[2SM#T"O3...3'<OK[,/CM,OV7GGVW_
M=@G=O*;*]V$ZOZWDC'<WWG8GSOGBN\J(*W#RY,;>S<XRJH?7:"XU3-IFMFSZ
MVDTS5K!R?>_=9LW5_7=MQ#ZAYY]N_WKQ.VICC>KYI]N_7JSX]'97N1Z+9\%U
MH9 PN:Z]4TYW<#EM/_?@[;D=;V.LT[;8;%\;ML)@;E3)RL(;7IPR'SQD5BE^
MVYKTPWO^Z?S7B]]F'?TPW7[:_>LN]]YNJC;2%DZVE$O6W2][<&GNK@E+5E1W
MV+R>^]MVZ^_B OGM1XJX*SCZM@5%^UDF6APXZK3OVIIXSN*?N7]+:N'NZGSU
MR"WJ\<H<DZ7NEBE3^"_.2;[Z/<?C]LVHY%L/W#_7F[=*KC>_(GGAAJS<^KW+
M<S>_/6[54HOIJ0N^E[,;IJIZMDJ(V*2HM!T[-^=I\M_'D_?;OCZN*_9<08][
M@M(JX2ZM:*Y,52Z5)Y/F)%O>_[S"_];5[H=Z];K[U_5O72U^*.9?='TLRYVH
MM2][DI?Q),KLD-5MFR2\1L!I8T^* %\]U]>P$UIYP5GM,MLUH^Y[YB1>3>!9
M?:],YN^A!?\9X+%D!_>B\,RP&T'W^[ZL*+Q79;75:+LT5W#ZO4F5=:\.ALTN
M6C:SJU'DM*J6_K3):Z9\LMHX=Y4PEB!VM!)0XNP[+1CQ>7F =/1=B6M;^CS5
M9\JW9D_,W'ZBH<-(X6B9$ -G8JZJ!S" 59*S6K!$]P7_<"&KPXPY)@L.-<UB
M9?Z2PL3HOSO)[=XO)==^WJWF@FTS<[V#3D5[>&@%GK2N]K0T94*D%+B3%FQX
ML>HSW%GN\'!K.KQH]7EXV,G#0X$S'[H'T6S5^G:;59'*$0LV/8F>&"3EY<F[
M6/[[97FX'M9VU_#Y6$)/3%8T#EL\1Y2$5F(+J<2+H<^Q1.>H\:/&0XTW12J=
M5]A/B=><5CV=/4;)4.K!=)D7'\)N,=P\,C_I_*XNG?K_-P%02P,$%     @
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M]K&H_;2/1>=7^S:Q?)?!HK_IAVQAEV_R3GVS:^.;T<N8 ;@WK''6A0";&+,
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M!6QAT-SBDL>$"GAP FXJ.2G&4?$JP!+^C!.P^P">W%:LR$6JL_3&&;7.%^B
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ME $%0 7XL97^4GZAK8_X 2_Y)X8?Y6?B !!HG_4 7$?(<+@BT0@WU+_L6VB
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M.G.\Y:LFO2#OVW17!K"/S-$V0QNN"37KFD7DKXR5DXMG$3&%+3 ML'K$*LL
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M+S37FE*RGVKIIAC.&;N(QDJVF84!U5N%)@'W+WY63,):QSV8Z,SAV[*9%QG
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MV?MM*06OE&#IZ$]9FB(K-[D;O+8K752H*8:SOSP0% B3SZUYN__3#V,GS7H
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M3%\K2T%1!$BY;JWC9GK\^,3P;4.KL#)HD/F;B'RC \DNUF?VUC#<A].4:70
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MB:Q1:N_V!H7>%)-*V6,T8E6J5;R>F%]/!PF%^1Z=-F)5WJLL?^8>?N3R4$)
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MX'<NI0F W$$D 7#QI$66 ' 'A50AOT.;_FY!^V__C#G42@ =]YR \;'2AP0
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M?,*>V!P(\Y$ >.6#6LEE(0 V(K;<<72!JP0 ,3%0D ^>D9C'-10QT_?@3 0
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M.[>)<-VSG9,=,K6RE'Q8>W0"Y? Z33%>.F[B<2QGW[JO1*5_ H^FYQ4Y,B
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MGX3-P:F0MW9E[QRN6?YKQE;."SI:<Z%>AN3JEKD?B'Z8)-0?A8-<_@@,"0M
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M2>V>S]0/2Q-;.RO7-_E/!NC"I4,0J3!>=P98T[NZF#J9Y%**XQ.C+GFU=L'
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M%!GO8M_54T?[Y=SLIST86E19X2DONBLPQ+@W;T'GN=28W8?:"IR"AHC6^OB
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M8@NX$FELGRPJ#1=VB0O<FL+KKA  L:!QZ4!<NCJ1'B*(=2;N&IKX7!?W$ +
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M6Z1-#4O!];[LP -8+EE@__UVH?M&W6) Z8R&;4]MW75G4*3MT_H444B&[EG
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M]_[OBDT>N6'::Y_O#!8?&!R=!'Z\5B4MB#D4]1/W]WO/"&D9I1?,?Z2"2RQ
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M^B+NKL6'E=T"SM]<QJ%X VR!_TSD=ZDH9-YT'EV_O@5$<7^ W<GQ_M[SLUO
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M"XMH#X5X>#%]"&0 R+91'29]EJ#ZA>ZKVLC?D6!D*8/MXP]DLYXU0%]T4]F
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M5@I88MXNOU[>OVG-<#J>DNJJ/V_TD#5ACFP?^2'@K7 IZL$2G1 ^KCTNIPP
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ML3J'!FGM6^Q%@">6"=3-O) %.MI"H]11\C-HMZ!!KH4PYUTJ5>7*9KL<9/)
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M&#R15FKY\ #CV+G\P&"P&&<RAW+L2G_%6EI#_)DP&TJL89T2C+5=F5X?CM!
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ME"4T%T  &6B?Z4_U.__Y\^L9A,!RQ9XT>+/V#L!=HY@';WUU%4+2(?M;\>>
M^3_4FF7+#;I]5M -(6E<(V!\%5\\R$S@%^-=Z9[929%E(1J@[1"EYUL<$MR(
MC<S-IM,:$*3HQ1,4UJA34/E(\">1S2]=.0>O^/]76;A$#Z%)@@K)-]>W$ ?B
MG>R7C3.>F&30<H()J.C#G96=[(JK2HYG9!)Z)%+(E7IT/9[&WM09J1=-"%B@
M@;L.K)5M.D^[WV&WO!.3EE,7S<3:M'UUE298E,D_P61>?<UW=R)L:Q+)7(:
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MB)AC,34_W<N?QB^1XT**(<]"U&5?<LSU%3S;>^0D[E080J),.9"CG+DSK&;
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MY:8ZNS<WQJP.1;]KYT=SQ^0.]5'<-F]4%T65/K]@+#26D=[ 0E>NYC6")^X
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M]\M.A-MMOG )U>J:3>0VNP%VG?7=W2E(>EM8,*0[,TM[#51:_YB&Q25Y6]]
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MY9R@4&:);IJ%D*;SL'D5V$'7YS"%^.6W'%N::'CXCY.A 47=>S>F#93]J7>
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MC# QC9Q"<M?^O<=0J+?!])R*B%WJTV^?;O@&F<X.2.&P#\>X5671O_HS>'/
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M_-#$6II(8H(XZ=W97[-XE=3U'"SSZQSLVR1UBK?12*';H*7+.\"HHLS_I+K
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MW@GAD?V'B&,$7X^[=Q/8N.M>>T!#M@CB*ZH3K(4?RN->^#/+@25;J'?0>AI
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MGXP7]H5?=>D\C=],-"7KO]*W2J@V5GZB)5RH0O#(D1S5UH$Z&^JR; T/;!1
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M(\I(?Y3%Z?5[G2'M,)2^H73%_$4S%AC@IGJM+9#=:\W-[7%Z/"+RFI?)MXK
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M4BIA[N+=L&TCH8]@6*8_&(<79"+G\'9RCCR.H\"HM4Z,]-=3>/.CPL\1T]C
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M!!F)=U!JIBQ+=+BPS?1/8QX1>GU.VWW$ZZZF+3PJRV1V+V?QPI$GVTI@7J+
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M(1?[3<$?Q4#?T0)QZL(,Y4>[ ]HE!7;P%F@^PG0,991=L>:JANYOO:6(Y#1
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MF2HN#CD8(=(Y\U&&,5&K0HK:EK-H=UB\]JFFWK H%M=@KT_P+@S1V>SMO;H
MXS_"JXGN]=(Y>=ZR?\4"&['>.R45@;DZX[SNFHLZ=G55Q9-9(4TBO)!':Q<!
M,(T; E">H/O^!5@-6]:PKK40_-W=EHIX\@:8BGGAG5 9FB!CO,C)74LR!G9J
M55(JMSNB_"[LI3T!K#%\*9/S=/MY)BK]3FK#P8$+D#!3H1:&!5%4T[QV+$R<
MK!Z=R,S*WAD+R%X3^ DQY:C6MB^JIH: U\+5U=K%B#\G$.;@91::7%]WUWO
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M<#9D3JTJ-3!0\B)[0N-Z(4#61,9%9*G-H;>T? ="SI";OQ>WO;MW,C%NP"2
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MI;!$V4M=#YRO]JCDC!5P=#+PV/LB_.-D&X(9M5V".N?Y0)T77Q"H9M $UMR
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M3O4):)_]J-Z?'C<+H-M^7/AINCAD#=HW7A$Q>J0\VL $@WD\DE9/&K?U$)N
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MW&C_DNDK_/'2)2^8!@@EI>/3Y]*T]-NJ0A"/OW6WE*G<8+ZW]R), H>8\B"
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M2-<ET/8S&D.O:%N^^9I1?D77&*-Y.=NFRA%[GF_V-#$J"CVK[(CBK]F:S#M
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M%NS-]T<"=CI;?D%64ZO?Y35II:AM M1L:)XJVQW-J1T.IJ,/-N<SO9]$._4
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MF_W6I3YU/ZP?S0]4(6!9A?-N@+FI7.VJ^!8IW&J,<8;E^:T:/-2?"!*]J-A
MBJL*M+=L[OD?<'.GFP/5AK.-V*_$6D_$TU_H/J+]J&N*G_62-<H_3:7NJ7D6
MQ7I$+W45(W%[^(_UCU5CUT .X$V3<%EK._*\RCB(6/19CY.8Q*IUSF)*M6;Q
MJL%ZK)EV@0S.M"^>\;&=B'-'WIA$,40 87H(X<H!1[X8<-E'/4<][//6$B@P
ML(Q;5R5)+ Y6C%W3)=!)T*8[&ES7-SQ--_=\'R!OV 6F&_['QD3YV9HV892W
MT^0/,?T@2R=QANP?;I*)F4,VKX])X(HVYI![E#<F(.&P3OZ9J5EM.6H/05KS
M/1JUT&K894V987L+BK_(#>I\L$(38'9$VK=F5T+1_G%@=EBG5U&PZGNOEG6:
MSXW]WXG>MV\L)>,/;1%<;<D.FZHN4<>K3YB[&NW3>X^*GYK[ !FT&2K .85_
M<ZMI<#A'BVF+:T;6?!HW.].SG=ML,;OS0+5?/06R>*VI'^'*+@'X@I7=:FY,
MCRB>\ \3)QQ2R$M2U_8NF52$H^*Z#K^S#@;.(Q?NZ <].;A4.S.@NR\J@EP;
M1$5A*B>= [<6+NZ 5S6F9L&X4:">:5!W6-]0+K%0)6+7KH3D2&7DU2#,QZ,5
M+&SDZ*O,9^>N%=M<&U7A_6257Q2&OU3BG\C9[41#QFME/13JAM8PE-!DPS'Z
MZ75^Z*X6GB[<ER6/>/CUJI!)V[6Q'\C^+H6C)A=(ZN(5LL+< 61DY#,M6CZK
M05AM=.DO6F3.NU,YYQF\JSH-]CFPB7H9JM]GES'6DO65EZM#:V1$]36S:=6?
M0<>>F1RV>9^KF%8$$*I[[$U#^'0;?HK0B%NF4JT"LT!AV:Y)A65T+*O#KER3
M4L>EL'%=@N4>?1>KJEW;TA/E>T-DAZ*\TYN%_APK)3&6]LG,4LBO.Y]T*2PD
MW=(^.A/+X^#SC:LD\Q=6J==^=GDW)%%#>T VSX]:_:/D6LR'!_^X2L/WA=G<
MN'6$Q>9AM(]S:GX^<3PK"YIVDO^PRK,Q0">,M-T<S>&J]ZI*@,VB:N!% ^&[
MB"R^KS)$>?VPP/&R/?^"_04(69)*[%E.Y<+%!')DS<.D(&IA>DWX(B[Z\[J;
M5^9KVA)PDFU9@4)EN<^1@%9MB4QBB9<W^+:#=84'\XI[" OP/<0"? [XZ/X:
M&=/QY)M=-WWTBLQ.Q[#^ ]95NJ]_(3WK=Z4O,\S8@XZ$G.MNCVYY#K%34 %'
M8*MP>%]76%^9PEFZMZTW,,A[0AI7MOLO_% TK:#6I?-WD\Y%0(E\/3AWJCSW
MXZV)LZ62M5&;3>Z;;[)JO2P<AL52]!](/I55G.$6D23+U_SX2_;6Y.>#%[E(
M$L9XXTP;4.]6H#*:6TM]'!D C(4C.*9?K&_"+FDJH@=TM&+[D;.I%"8]VFTM
M<_Z*-_RYF<$C#=K]U,RC8;>R]SJ/WA^Y4LS\V1HH"[&/F-C/!-GY"QJ;JR6'
MX^$M:3W=8?MVO.G(6&S6QN=8F6A)VX+OLO(]$&*WCP6(Z%PE(C#T9&]6ZC=R
M]^UH'K/6T)@]?^&?='#$\F>.ER]G<([^)%",PMT]Z+'<O&^#J80SSP<D#>@K
MI=S.@VMK+,#6S\$("]C/O=$ WY;[E6$!X/#."S4,)F@#X]I\YH %O/Z &< "
M\ML]L  YT<E++"!G PO(4X=@ 0<N*'FZ82Y(8G7)X&]_P8LJ0Q,3[8<TI#3<
M"-3PKN/N;HD!6T5%03P$IER6:X<?E=_(!_ X1%)0'"U?!F77/2EAPK$A#/RW
MF_=J0D6-5#[O5G;)>ML(<0GR0W6@4%O?54I?7Q_-XJS/F\DU<V\*HH0XQ_K8
MRYFR_1(S+HG"X)?.I??%_S:N;M*)A S-6PJ\B<E=0%UQIG%PQ%:D13/&#FE"
MO3V]2%*;A#YU:/7MUE%'Z7YY%1_X/ GG1;,TSXE72YLNL]' JY^_5[JWN>L_
M>*F!],*BV:(O7RQ=<MJJ)&5UTR3F3YS5V! &$%JS:2H;R^MKS/-KSVKI:@\U
M*#(Y#VWWI"3(GB]CQLZGL8 .R8L\C#0*MSWHVL</_6WY< MCMKEGII=W'$JT
M#[QZ4A&T;7='5M(G'=TG._-!MS6=9Y@QS-2__Q +R*7=N8OHRB'R15!WWEUX
M:@*,@D9(I.OO_EDG)LPC[\Y'BM^5<JD<;RP !E_N7LR#2:/#NU]TG_0BI&\[
M)*]_ =%W8^YFU5VE<?DV_%SD]N%\]^\)#TS0UN>@K9E:+.#:V"\+"^#\D;16
M\>/X1N,"PD(9U0)AE8]()D74Q!0.;[P:G-[@%VRRZ_#_H&^]XT;BIJ.4+U@_
M_;;&C1*.?+ZVVAS@AG$%GU45\TS)R01088)WQ4Y=?'4G$]11*)TAZ,ST%'1=
MJZQZAE%;7H[Y(U10B'1TCJ'6EYWMF)18[@E$D225N %@[3[Q^<X=AX (&%!U
M,<O4(IQ^=CCQL&Q;ZE/)@^0RN)\QL9VS*?RGM@ZZ:F:5MXE0FU%1XU[AH\2,
MX+X\7P/!N:06-?_N\?E85*53<\3O#_J:^=0 U I4PFRP)T14Y)<WKO-*\?B&
MHT=;6[U<Y=$L137"^I.<;L885//,66##W:-'E<36-RS)C-K^R\Z'>T&WF;=%
M=WKB=R2.!4A(SF !\%[D#0L6$"1]?)=>1E=-6$#*ZR"KH-\F8D$%W[=NL(")
MNR\FRTRP@/,6].&YW7G\[<IAW^'-7[0&%@ D"OR;?7LW:/0&X;<[@_E0<!N+
M!<AZ'9X*?+]+FTNDV>7I7C=F#GG[K\7/^:^+7_?_>_$/_X?%1U\+7"MB_J)7
MO3$^_Y[IW3[_S/3._YCIZ"N*B:#)FT.>FRNO92S "7AGG6V#[+$ ).V-^MW4
MB3SOIOX7?8C7O3QY<[<27372&_AT"\NGY*;_C4;L]WH1#:G5).V:I8HR750=
M)=-F2-4L-&M;E?,BFE(HAG8A\*JCU6C!9I-.0WUF&LYF5<-GI5EI&I#2;XU-
M%D6VQ;$AOR3LAJ5RPS=FCCY6*;K+5\L\> GXC>9^&B2AS9@?_4,L683(PE->
M]-!T/V7V,'8A6-D](-#T>_\LU7D0)Z78#LG[7Y+DG_;6O"E=Y=@^_W=S.3_\
M9[[NQ/\K?K\A_X?(F_TC\EC _Z?0/SM"A+:[7W>EUQT%C0X6-5"A6H*3N90;
MMJ]ZUW45=LO[YM?,QZ9L+.%'WO=MS"CTPROC:L6^DH?N6!O*^0P!O:;9JG:-
M-6KT;Q!O&B"ML:"%L?!15?USQQU&J47XZ0*>B(G&*'=?B).\F794NKM:EU@<
MYX//*IPI%XYC3IMT%MR2[B1M40YL3-^&UU4R8"PXT/+,"*3XUB=7R?'&OV:C
MT:4GXF ;.6W-CI8NGHHNI7D43<E#1I_=DJ56(]>E=,9@):8&OLHX#M$G5Q&T
M-SH O#9'NCLIR:ZI&AK;AEB2FS*J0@.*],1Z3$)@"QW"+]RL,2; )=#R4@W^
MP=@!"+.S^UXXH))!8*;V!9MF/6/A2--?-L]G$ED)'S_Z$4C_YZ<9_K]"ZCD_
M6W93('=]IS0[3O_W\D!,L@?I9QONZ&^7JQ&#!= TJ*9=P%OX$Z;7^0(*H0L&
M)?NT8V48TG CTYF2- G+3H[W#^6@&INY;VULV*M^8P'M8?U<6$#3I(3?V=D/
MJMF_,\]#U F\!-.0VEKN]C]?_'P: 79*(4]D@__Q_5G6*LP^^57NIS;IA+I&
MHL7%)32SHW;]4K:H U)&?B.^WK4ZT#9@??[ CNG(*UX;&O1\Z';29!:/_VDS
M X/5<P7Z*%[BE<S@SC;XCT."?FX$C.X)1MJUIN<CJR,G&1QFLOA]3(^+DUA7
M5XA;A I.*I1<(L3)PQ3ZX5NLJM 75J0\PIG#XC["S&-B[6'#=!U3VNO"XM=5
M0AF:6C*DHDPX26(RC9PQ]?V-QAWA7_#[\D8ZB3YCZDTJ(BLG7>-3 D9;_GJR
MX!AG3:*Z*GM7[<=UWPMZ_JIB3-SS=13ST-37I-;<<ZM5U"6WQ#%<.[Y&<^5,
MNCB;'9_L$:1MP5)^ZZ%BV^1F\^@=&^^0M/*[[K3.5OV'<ZNY58OJ$@:E]]NY
M-J]*J^)MCN$NPN<MX,;K5/<T[2QYQH\N/4RO?D<LP4+="3\5)\IM^W95/.EP
M^O'61E/O0YQ*O!8N_N7GO%>^JO.6PNH\A.%+AM)9QF@:,/J%#O?RQ#Q(7T7+
MHC%6Z8!&:^78BPI?C#-;6ZG$^IGX]JL0JP.>9C^QLH#UC5_.0=],7G2<Z)QZ
MK+/S7NM;H^/^C&C_UAHF$=*=63LRJ=+5)V06G&%09GRE8P=(4#IO/[&*!G[Y
MB*(^:Y4%EG-7,-7+0WVX2QOO:Q;DUP2::+%].R@E3$,@4PNK7FAH<5QZYB\%
M>"LVU@]G()8YQ+V=+)DJ@B/YL^-]SH2)J,]2C;I@B1P- 5ZJ[V>%**D&7[IH
M6)F['.RQM8-M"5#,XS?W=M\+N!"8"HA#R#GF.K& >'$SO.STGM QU'/=Q2-J
M*1X^D=*TPJ)!DG4: N> XK!)YS9C6S":85<^!\$XXP86B=BY+2S-UJY)RMEM
MYKCXLC<N%;QR_H:D_&%E#8SHGL?/2[K)+Y*"5L+(V7%NYA_+?-=4G&TWI:JX
MP<YV%J?COIN-!I[\-G\ODE5_,%-PEK*1-*M)B&U\>=)>U^02Y&-QI*9*J[V*
M.TA@G;IP1=U)\IFP;:G)77?5_1.7G@#;^U2:-BJU^*$9WC2\E)>;,6%O=4+V
M1[B-D\PQ1*(H5]((,=.AWR%O"3G''S-\<ZO3O<JH-RE<T+G'_E*'%C?^_KK_
ME9[FZ5F@+$M2R'K>9WU%-7U=V0^G?B'5CEKXNQ3(K)8HV_ ::GE]16TJ14X7
MNUAH%4"^,TJ2'FELQ@I!,STY"ED+E.Z9,4&;3G]8]5.2?.>#R4*>)5LY2J&;
M]HJ< XU>&J65LU?7J D&BS*ZU](?=G#WN%GM=TN9T-HLV>(]P%7-#N RAKC)
MK< 5H'\6S+W8-U-I>&"U5N+?["&>C_U%A#[,_OH[7$)H'VB:<__V9&9Q+! *
MTP('>I>89[>W$R?WZZ;O#402ZKOO9\BK5)NXX F15*\:1#+KZ6B-_"1E.O7/
MA<G@8(;1?2?F#R=PVUV=N>[8FJ)W-^ $]U_*%_0?"S+-?Y&PPSMJ*?E/U++<
M\2]J,?T/U.)W2[ EO87Q3L<$B-T9IV8P>*S.?_I/^5_#.V.X'&O@2#@5ZSRW
M6#NR/W$Q.(7B%-.;M3+C"JZH0F58C*[I,\H+B>;F%$=H/"FM4?IIKZ FDU,I
M-7GB9>51S.;T^(OH2^?;'(2PU=74\2R%XWO]8:GEX=D__/=?Y)0,HJ3JJ\M_
M;1A%Q3/Q9=H[M*.4^1;OQPUI0Q_;XK$&^R!A)LJ&5B)I%^.HCYMCO4'<W-]'
M@83U&H2V&[ ,9,DEJTF;\!FS(IS2MWH3/[ME8WC588LT8=LWHDCON"02"I["
M!UBY>]Y685QK&Y3&AN[*$+5">OFU0K5G3C9>L\./E^/SFL>'@3W-C1Y9SL+K
MV4&>IP8$S2I9H8[^MA;G[&M56WK%*211BN:6@9(LPUQ32.7Z$UUQH.\-^<5R
M(YJ46%O5\"N"BJ[K'..8)#;B4[F]7M&_ <E-:G]069S)'--D+N%:#7Y YX=7
MKNOZ,OZ.]S1K!6EX+)X!W[X,FD1(_?'=$5'GSA-MD7H/FEO[-=NIH],6\W1K
M=[^+NU2%LFV;PZILR.KJN##)KJBV-(GB;1O?*!6C8<J7W/\6MKK_"5NS@?^"
M+0VZ_VPHLD=0:+CT?KVGL/V-Y<7J[PUQNNZ=HAYJ#4<"%KXC*.*==>W@N\Z:
M&UDG=R>#:"W;BAS\Z5^,!OM7)]XHO\;1-A?3=1^_V8T?:K_& B._.=9TA)7U
M!W]<S9C1#-F;4C_Q>FG2!?$GH.KK?91?FDMQ<E+C@Z^=+^=T]LB]K%,\*<%[
MT'LF2S)OIGJ6UT;LTM&Q:P?R,K3<06Q3Z;TGA@[^.$+6FZEY(&'^!:*U^EP]
MY$GPA=_1I$C6B$Z_?'3OROFDI_5Q&_LB_)U@QHT7N8N&H:&N !6G6Y$X73XZ
M0^!X#=;/W#\HYNKV\TN:K1^S[OU(3N>?@*=,6412D9A23IPF8S()@![3S1<*
M2?Q,TY**'BLG#]')9$EX6)\56TGUL(T[)+GJ:&$I@ G?U+$2MMO5'):6E$5"
M;I>8JN.NT:R@[XLB>(K*W[M9_HG,[@,N5?T>C%H4I>TXK%2#I_H7D0QP"P#5
M8!RI0]^C*Y[Y6 :Q/>#:#RB,=JW/^F4RQ_/IT-A9S:CTA<'+=(W!2EF'?(<;
M+XNR(^TJ"21U+@&$^HDDSF/-LV<^SQXZ$HUT!>:PEK>4+@T=?$\[&[SIV1^Y
MS0Y3V1ISA=UQQ4RJL1U)1FO?HLBP7?[>5O^'4K$7M1Z<Y?2FIKTP?O4;N)OZ
M:<.-RL4DC8Y',V=*73"*M#RNA(FW4^"GG_=(\Q/>UUJP9C>G:U[J.O'77EN$
MOPNHY0P3%.&G.F6Z5^4R%;":("NW%8V6UC+*M1++TQ:+ E*.8X$NRIS"%]5[
MV7O:3]YJ#[$0QS7\MF3;G?4SSK,D-5U!^MSLN?@>;EQ#H=FYDF#-#FMX*HW#
M\I1= 4PGDC/5+]=?#O1E2/9KB1+UL,Y1M7)^L"S9N3%-Z+>67U<\;CR48R.,
MQ'@MQV%O91Z_-/K0Q@3(AT*MJIIB8IZ?/W[WC6RF8*_8S='M_L%D*L<T=Q[0
M1:R#B2HM?5/12N=@Y'N?N&^V-*[%*;15Y?N9:K'.@HI_I?.C_#PN3::HBO<-
M%#D9@.(\>\>XP][I#VO\7D%$F#=::Q[*^MQ4]-I@\31\S@X=4C4Y$V[N2E.X
M@=-J88U"F%YDIE6JBE#&\P-?=[C2L2*Y*$J-@9*7R%HE2^?1O8FJX,<UO$Z]
ME4_*(PB$LTU8F@0=*=U*/51^WUSI]4!)9W5UH8+=S'X#I6"RO_+)12&?SF)F
M#7;8*Z9KT\1V?:ZF2HI]LPS)#/J^J@[TA/;@PNJJQ;><],^!'S_4]2_'MIY7
M+U_S)SH=7=3.J^P*ER]E#,GK4D'/^W7%9F7,M"@8$^_C5!A\)(&G<W[L!YL-
MWSHA7E9SR[!,I^([&!D&VWNH1$WG&');'='?=V[1LM;\0%E8_5#!!PNHDA![
M?RZBLN5PA0Y4#Y3U'OM%D]YNPSN>OI=,TL[K=;"6P&I8E.)DL/@5O+7@O4S'
MV%+*V $I(F7M.XR^_,S7V;APRI,Z:N$7_+%4><<[S?91W="P_!)4$&BLISW,
M%O78DGOP+<.BXLN#1"0,,3:N]>7R<]35I]-+3^ZD'3)%LZ*(WXE&0AIC:*_[
M);[A(OHS :HZG3L(SVCM.6-\KY*28:]C;6T\4"ES'\D>JXDJ0^\SX0\3XQ;#
MK'D6BO_%F8+_MP77_0_%#"_O/VO>9NDE5TL5^ZOBX@N7([W*VDK[BKM/RQ9H
M4E-34R*:A%>6P 0YK28XW:JK^S S F"VW,$@L-;]SRKYYNK?[VN57<X/_3VJ
MJ7F,"\DO"V9CR?W<2.-!PMM+G)YF:!,(UHE[/:5LRP1X.%E/F^U[:#1">)!2
M@OG8R:<9LV?4$8IK:4V_FY=$K.G\/HPI,34?*<0!+Z5I-HF95GLG%$OP@[W>
MZT-QU Y-]QI7+L5'+( [AUCI78QPWW0>N=/: 6I0Z>0K_(GP0BDP7?S24:29
MYJF<[4S.]<RJ"UPV^=EW%]!"Q+[:YUV)+^7Q/5RO4YGGVI5;6VW^FP8"ZG\U
M$$K_MR=7U?B_V'I8Q%S$'ZO2D:O[!T^:=PG??(*[_SZ4BAB 6AT9T(XE4Z7'
ML]$Y*26O%XR>IQF5H>K5XJ4=_ZK=^ZK-FVC=;O_LN+NY(QO5LL?*<]+?.3ZP
M",1IBY$7-_Z1PO\.SV>@U(2X];>;MFDACV\1[/"SOM/M5H/QQ[>0T+?@* "P
M+!W2\,Y2IC*J&6 [X/M !*AA%Q_@]9 2O?7YK:/O'H0.53CL-8]0:+H,S&%Y
MB51O\7DGT-3S_>5"6B2GSB,"KKRT2^:'\;(W'A_RDP:=@;\!]]:3_&A_XJ#>
M8@%?NE%8 !:@P#6/V=2^\[75=[6D5.E^,J>RM'C=M>.V*18@ZQ>-.99;I[NC
M*/ =12DVUUI!_)Q<^T/R/MU([RX1&&=5YH:[**?O3L '"?M-]$D$IJ?,N_;\
M^MQG4W7.GG>XR:XG3LU^H0]OTKS]'7AP<H%\F'IR89X^TSX$DV$B[G'4N?=8
MJ.2U4V^1Z&=CAY >XFOO>Q=AT17 1X4.7XT331E2SFB+BFFI@"Z2 P)E0/^Y
M??]MV.F94';&"H2HB#_$=5I3S5##4#='4-)-^F^4KTI,P%N5,UJAV#^)!L$Q
M]_4V+LF[SFWUWI/]O>B<-M80(7D&'8Y<\GO2\'>1M+2<P+R"I/GVJP;'C%I!
M\%!^ ;L\ZO%3>,!$(&H^,;(&5#.@I+&J-F%K!L.AFZ0-8($L7/K^DH\Z2>1B
M3/@B ZS2DOUC[RH[N3B#7-S+<MF+%:W)/EYN!;M2ZXPKN$/LO#V1?I0<;+\H
MH[1-HO8H*S6U 8E>@U5:N^3WUI8K,/+ W78$.+;DHGGZC()F@U12?7*P?SXG
M?Q;2D%5;ZBAFU-FL=GM[O,7&[KBS$2=:\2VQ<>"/2$E-$5K\NBT"Q7P+;_5Q
M(Z;&G*9%R#P(Q]S#>10K]U924?VIR0+,V$<??JTM^),$8)+T,^E1 K?C[*NO
M*M HMT$#FX4WVZ^]N;6 Z8BVIP*VNM /0.H8R&3)6@',"^KIF4G9SC6J=VO+
M]E?7L_7J@C5)K#1RFJ((A&.B'*I[[ &:4DQ(@ZSIOYN2CQP+\FZ8UG-V'2Z)
MIVCU]^+' G"&)&Y#**<V.P2UI6'#I0'/Q1VFBZ^] C>[O=.LW\%$&/:_?J'Z
M/E#IH$!"H:VYQ)?X/2XKW7ICX?EZ>L(!F9 +4R((X/PGKR+_S1O1<L8(P4^%
MNVW\_+_EXB_U$:DG-GR,DC%1T1YG#W7:J)_[V@\X!K\1:T/6$5M7AP9N\O[>
M37U4U8#(#4J[% JVI;E_-)9(\NU^,_HL-B&;"O1&^'SKYA&=]U'>DE_=[=B=
MVHJ\'[0846/@.1/KT_EZ9.)[1YWZ&O<+T<]>80&-=,>/%VZ?ZE=5!_V$5^+4
MG^M).=_$_+0,5 +B?\SKQP)BQ2N[U&IFSLY$QWN_'>B-Z"JG[N1VC[QDQA#"
M,SZZ:ZVE_=":X?3<UDI[W)O^:5I0U>^'RPTXJ-4=-;XJWV3P41EXCPRJ]]JD
M2&;B9V-+*F7&1JR&X>AH/-!IU+_M =FSZB<6KJ1^$;I_DU6BFNV+FO1*O^@D
M_U8^.JP0F.TT4_Z .$),-0+5%V,[/DMU4H[1-';NC$U6U7[,+.-S2HAF2XS$
MSP]]J/K?-'EAP'\B]=3DO[I,VT[_30/S8,\5C6 Y'+=J0<Y<2!\5>;IR]LL4
M]_T11HT?^L\!V?0TUTD6]O5$VAV=]BH)[,<+7R]6XX%I3ZVFGPCU O[AE9K;
MGKZM^28?GT!XIR.>B/0]-A!&N%$H]Y)^Z<U[*;$7F@FC-FAR0RNW)L'=MTUG
MJ6<YWH1<G/09]R9VP=)FEIP4$V.52Y 0V^D@+MKR*@1<'9^R<Z:%3<QCO5\O
MR%7+AM2,PO![G_;Y6.I%Y?LDL6:)QH'$B6I\L@=T7@?YP$HQC?&@\9F"$LXA
MX2;.-[$\\6!(<7$&(OLI'45KZ65HYRK\LKVRDEK8W;1WI_7OI>,N62:'_5&F
MR,*OJ/;:V)UBXL$7C0-6YC\=A(E$6/VUG9>0<LZ'1"%YE.>EZWW#U*)JW6W"
M9O[FC3Z+ML'LY85#ENXY,ZIFBDQ-,\51#0HEB;/A#^A SW<!-;W/_U&:LM;I
MV>>>/SJEORLQ*:VT[2:S$85+5%;KW2XHB:<J(NDTV3]1KK5CEARK<0YLZTG1
MS/%[(U%BY6NYY I\$,"N[/KS@_C_]TW[NP'_I6M_'H %I,U_/JC9. :EOU ]
MJEH;&,D4:VS=4P#:6?I)9?,21]=Y>!%/X0G<EK768P%V25'"9>5TP'7!XU9%
M!?K.N( Z<)*91T#W5Q[;R'4$XX>=(B-0&S0T,86W%$]+RD0E<"#9[U"D12^1
MKSE)#<;+'$X\X*F,H BP?_G948%B)#=:>D0]=X(;NL=N=GJ"Q#DV8_ EHB(U
M'_$Z1%AN5.W'<"HG#SZ?OT<Z-)4VCY?)\DT)QV>)D.6N1G5>Y./>6)EV8H8
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MK8;@HD.NV$/ME05E:WKV^.PR.%VB$8S7'3C:HH"A[&=C(4DB:3/Z4CEA!=(
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MG!^8>)2Q\RQFP>C!V&\+D!B3UL#-59B.#^3QP*:TKK7;.8ZO)I"E5%#:'8L
MF9XW99^-5-+B]A C5O&];X H>;L7\TKQ_>//>".3]KEU"CY_K:0N;#8$Y S]
MQ:J;HTIWE_#":T #GA=04PHJE<I]:J-'E?R,5>91D&IKF\,)G\M^57MNCX<E
M&E6%&+#]UH-R*TV3Y7+PX[,S1%EDAKHZ.X [@1HQR7-I AK4*1[2ANJZ]$83
M)B8:#U-*OB=W+2'*6]JZ&_W0;NCK&1;=73 13<_9WLWL(FI7*8/MOC=;/*5^
M7ZW!1($GCQPG(@XGI_IR5-BG\ZY-Z/M?FG"MDYR4J^R-@<[CFWU\9,HK,6@]
MW[[A7>%2"J4/"_[,K,)<E?)20HW'SS*.GF9LE7*%9=6U+'U-,IY]62;7"+KS
M=#VN9@QQX9%+B4@B 01$<8*.BH>TV%0B3HL$J$4W<IR<=C21 (7M5H>#,JE$
M-/($WU%*?NZ!DI^%%/E)@%7D-A)OBHY%XHYK0C#4L4TPYMV$OFE-]80\4[[<
M\H^ZV1D%SW=9QYU-],6=3S+O%"=87\).&7JX^)EK;AEK,FE4?$;>+/JFT?BD
MM$@M[<</KJI1%DU9$N"0K>]RJD=ZLJW:&=O-&^5ZL5-GH8ZJM (R=R7@+AYH
M(6-=I_UV;?8@UWW&6 G93P/EZG&_5NTS@-EAG?=][M_S=J1XF9:VKID?IFK'
M%>LYXP!3]%T!8E2?2HNL%RP(?RQY/2+/FNYXF/AFM[ZAX;PLLOF-<^:U'1Z:
M)TXJLG2&/!T]F:QZ>T%4#7[P_>6A6K=)=\YU:NH52O$E-=<1]X1ZIU7F^[$1
M*_SW:"R_H3X(6D2E$!(0TH3*J11PBY]B632\_</2*$S?K&VQP'51P)*[P"=Z
M]).^55G$+EZ%S^0$=K2+1&35U9U5)6]G#1X)9-;6N,RE+U5*6\ZA7_O9HF(K
MQNP"IRAANT?3::# C*]2]\9MF 7X1J:^W>Y6J*E,Y=),66:4__%Q6$\$OB@?
MVB$.WZFPVW;<9LZ&<82;19\TU$T;#J7E+4E.2_G$2WJ-VB6?O')9$V5'^,&.
MBK#U^SC;S9 EC' G6X<<0^*SB2%@VOT91O..>CGQ :;5R:B*.=5+-6XFF0Z\
MQU>[.UW]^-+]0BSA;^!<C^42=V)=$INB.,N%&YH\A!CNE+=;2U)HY- !Q%U?
M[W=O69S/=)3/L"P6-P>M_D'W*[2<_6@JF \8QOBQ-0,[_^Q=#.N:*C<['C;.
M5[4N64AE+C4+S>HP[^Q<Z?UI4&L:>J\2 /KKAWW1HBFA(RPPD*:WV1E,>_!S
M4CF[?W7'&1P-8NJZ*^]M8JBBK7"C]95 F9-M@D/HK9>&4_N:RW[:E4\S;9>Q
M1@'@FY)+%9OV32DJYGVWZ"D4:=)G_3_%]\KP1ZJZ7>HK.Q4^OGI8KS;*VC%L
M/JGN-909Z#[+<(?%M.@E.MW-E^[F3WO?U@@[6)B/:J2]][7XJ_(<[BB42-''
MSL X6! '5;.?A^ZI*L,:\AG:=9@@V^DG(NCLE^(D\W4GR2VFV.++KU78[&SO
MQN/FO5&%6!B3.8_RZDH);WW_@Q3IHMFR)9:RO%+.),I8Q,G)&3YQ[0'CU_;S
MCM68D5[+YO"H$8GQ3;%3INOE5_Z8,:;J"3^X3/&U=!@,IQ/I9XKW>(>*GNRS
MX7WU@EX<?N;F24,50=GKQM;5,]5VRS'TDPL=SS$H5?BH ;S->4S3-]KG&.WJ
M #-W:W7QN+QT->^L:;+;@0W6-R?R_?&KB,M;P2YH:CH='TL^MO!!0XS(_I;I
MD6R2@W+M;KDL0W6)S.HJ9G]7'3QC8CUE>R?SJG<;B\\*L)(7(48XR4QL*0XK
M?).;OG+5#W%%0=9+3J]G>D;*2&^M_IYN*E&>A]V^J:JC+$4+EF@#XK&343;^
MD_5+7HF!XA>/B&%K<_N"3<#WQ_W\L?2W"(_];W--O+S&3"'FG_(716WTG>L2
M'%Q6B'VYSKJE9!?_8D<WA!LQV186^^23K?FXO[6T^+,&O1L_::Z7LSP^"V_#
MTA[NT.<(.;DT$1&( .'<V<S8\*JB'3/AL3E&+=ZE)Y%E(NT9V1'@]:N+(S-K
MX%-)LGUG_7)FY%E0ZU=EB2$!8)_P9&O2<V6! VU! J#9[<D/#>2&EWV%!&A3
MZ7^5WP)=\=U3/"DG =J%-Y_SZ9, PS_/#4F B'([*#IN&PHE34TA6<RG[D'I
M9%Z",8LHFI^V:+KX8O<N<[1\98--?@2PZP7UEX"&)3A? /!Y8(09?9&SEP[G
MBWB%O"';GI<.$&K Y)/(\YRT;?_'49I0IE<QNAJW%,,:2^3=HZ<)[Q4'.Y>(
M?^S![H_X]$Y>#JNU849=%*:&_:0#F9F\O-_Z6<)QKPPX.$=8A\0<Q@=^4?+?
MZ(H)%E'4@9U+DP#Y<>1UXUX&=? 1I0CA>()T63_A5!0W20*,RU]'=A.52( Q
MBRGHA0@61@*XT840I0Y@1$C78#6!-<N*!%A41I8J'E;O*6[N+E9 D08D0(<H
M@7*N*QQ/%@;9;44DP(D%VH.XR$[ N_SQP^.@25873V7:R,;MR[\\$GKQY**+
M!&@(/\.=_F.U0: XW(X5MI $^!:()3N2>.CQG ^2&-6!(@'@RDARG,(D0(['
MD0L)H,9G0@)@XK$[NG@7'-WY!::< SO=A=8D 9Z=HO^0  _(1J5JNXO $$2V
M+$WA75#F,W,20 &Y-D>,U:DF 5 /T=,Y9W,8CN-3E+$BNA2ZG$I\O_N_>(<\
M_F.'_BW.+@/HJM4\=&RN\14)T$D.,M#J@JH:2G=.10+(^VF3 %MMRTA"@SSN
M;.XG\IQ<JKQ=)^]\H22 $UU( 0G0UU7S]]4VSK4D $23>-)U0F=)Y#BB(P;N
M9Y( $WX=73C'(.QA=6C7,8JH#=U:VR$[NDEV@CH)$ -]^_?U\S,VQ(M4PC9T
MB[T#K[C&@3]%D LF#QT$Q8QCT:M6-Z&;<'P&>:I!LE@D%,A?D.4!,[&;&-+Q
MGVHHZ PZH'B^VTK6C2K+Y"6B<M'(ODYZ\I[!SJ7(Y9?T[^7W_\6$#JOIK7?R
M*>KC*UR-OY_?IN>1J;<&KD;6-\FL!"Y&<IR@9W;5V#F+://RPL(J)>BTN>,D
MI;PZA-[UW;:85'&:];C#W#I;/'#!D:/;XQ8L6'G]@05%(V>!LR5;,WXW]H/(
M]WYL]8725DX+(NNE<U<GKO[,ZV,U[$,/'PGP H<==J'7&4Q1YR=.#0!B5J'\
MS]7U?FEV_5.V$?^]3HJD_E.1Y?K]EVEC@(XU_R-K7?]2TD3^+6GDR=0X_N6D
M69!SG?^/OO&OH0+Y$WV.Y> E)^3_)51@?&7#^0X3P#E]]H-[V><9&;HQ;18'
M8N-@#ZLI(X,_BI-4]MR2YP'.,IU%,OB<Y8I]^U#^E<?MS@^-C>VWBA%RW@\Q
MR22 KZXMF5XZJ\M7^KF:*O6G/]3W?6-_X,3MR7VBUBZ?T![^6D+BIF]1"BAO
M)]"$2:K*/S@\W>;L5&E9N[E3EP2XC$#HWZ5+A(=Z<_0&8OU 7!O0B7##="0#
M)BOUV;@U<?S[?=ZCD?4[8O'EG"7TYU818,+(QR-![?X=5$@#)PD05ZV?#5EK
MB@7+N6/*H"/7NU#5>>DL;E.FPGQ3QPF!XM#N$#7HF,.DU840%DD&2'6P8F3P
M2X%BW/LC#MT)=51(/6SZH.OP,PE0W7KV>L=1H=CI/.03$C,W(^7& XKYNNA/
M>T*&V?\X2:SNBL%'R/LC;M$"*9Q5Q??5T*L$-7>ZJ>7A8-3W)92EU=;=$*M#
MT?(<1&2%V:AG-F17R[/Z7 9[@$Q 'B^<I!*CY,DN%NZ"C+5:,16$A!X)K"&4
MP?UFRR2 YE^!B;]Q"SK^)96S<^7$@,UJ0N%I/G!>PW@Q,"ERH#WPGR=Q^7*6
M)EK\)CB2@<\X>VY7"4R5"2]]*HW]PR'[2+)UL7GSA'>5!+"#F)J[[?,[*;).
MJOQS2#8<:G8*8FS(%L5/>SHD@,;[*0O,C")D4=Y/GV4EJ0C6MO'P_9O=&_2Q
MG?F,=?V:7+)J-)I]1VJ<@ORAQ(/#8WV,30[M>@",P##57?U"O#SA%'SQO+8Y
MGK(LF8<%$'V'3C5(TS3D(*[[@UU2=]**+V>&]_D%-/6;;F<MX:S-T/%KT<'V
M-AE/VEE7.<W8FY>]M+'%+4"];P[.V>/ET9.%;V.*]7*7 3O1548?P!)6-_\"
MG/8/YKF*0*<X3&YFOG,C?GK2@AU:_ =0Y6?L_J/LPZW^ =3*?P<J 4UX=!.'
M)I,0^M](B(PWK]/_ 6^5._\SO"'_QAL9O/\Z#77]=QI"_FLL1&YG9!(:(Q!U
MJO[WTX'"R"G8<.7\K&L\$>J%P^):$0E'ESP;RA<(07A[YIFB':ZT5"[+P I]
MD/YHG$;#X'U)NKMJ_.!4,Z=1CI9?Z$TG+!=6"Q-%5'0J[XU5*X?(96AL90C<
M,+KERSS^X:J,P'+&D"JRBBDMI"A#_..9X&N'7U_YL^4I6,PYD'P=LE\,W)?S
MXAX PW6@MYQCVY8E]-M?8*07;KR(JG<JXTR&^OVR#0"]?Y;KNOB!_A=>:])W
MCR/!#"K39E,I?(I'E@J?8M.O/%T.@P6!^(EGF<3%"RXPO"$+G+1U/M"P94]D
M.9(E!BDDDI/@T$GF<[>@W^+(.\_C@70#\07) K)6E0 A-0$C7PXAM=5=]#*#
M;##%IO/EE1Q=H-?/').^; L@SV(RC;##A!G4\;]"H^A*UYV&7>)O?,14L4[U
M2>ULRO430>B)^@6T>_F7=P<E2T=) /2M]!X)\.ZBQJVBJJL@1X7?ZK9_("1'
MI ,OO>:'QT#(&CYO#$(FGT5L_UEU3WRASO?S._<R[\M7SO[ES)JE2?S<^[GQ
M'%M-E]4,T9E6W.A9MCIE6)_Q16D4L*C_G MK9#J/_2_F&K8+X76V!E(-5%JI
M<C5>D*OMHS5T@D\N"!/K5\J)=BXE 3Z1R]H-\H3%3:C'=*QZ[)2^*\?RGW?,
MXC1,=P6.\7C-*VV-_Q#%2>8_>^'+C8C".= ]_=FLH>A[U2:7V4#:<M-#"HD[
MB:K#L$M?CF[O:XXJ>W0>[F/&;OX(G+R^<S4I@2CIHB.96U*RW>/"0<\&G H[
MI$_VY6P-%9"(/(G><_48\#@)Z I!!_ATDVOU'59W25C1W,-_\S&4LNKHLVUJ
MHT,$CQA2W=:7:N?:ZKPOD@GZV<LOU4<E>Q>=D/RT&>=2.R6J'X7J;"KH&TNT
M6,^X7[>Z+=#JW%J4$K&CS)B?&%#PXH%$RY4XAEQQ.7TYU\MV2H#H\6@3.:?Q
MGZKUA]PS]S(:.7HZN[8#W;>UH,'0W*H"'-O<M),*,1K,L%!H985F*IM-Q95'
MXKQ PHIVADH\SR(7%[A>" <]8@VZ ?UG_8=9_X<*,?Q/*N0N])_4&(XH<=#V
M-VZ[=DD B;A_279:_:-7_">_]'^P8'6@S,/.];'5CT.VK6"!FYV%W=-@1>6)
M#7X)MNH:WJK$"INVD.+;"L"Z\#+'AT7%?RD9-*H+W97L<]20LY:>B8>"EU^U
M;\3Z(MT>+.7#4H0+.O/OJNNYOS$S[(FF??#!_*^W&@GCYE^;A//3FEY5BJRU
M1#+N@W9";]X9.)SJ\)F,UKTQFT4A6\V&=.B\^(MF=?KV&G1BTS<#*._57I@K
MV2TX];/%^2$)H'XXG9&'NA2::*0"BG]B/5BD>.%[MD".-Z<=>N+N&D><"3G6
M)#B0-:XSF07JR'[:S4(E9]?D5\Y15FO(D =9I$:=.0R*GJ,N%,E=W9U WJ!N
M-(5?>!_/'2$+9<3+*N%'<4U SHJ_**Y!Y WN?Z>*#\G>D\]='J2ZF+E=C&_C
M& W?Z?(XWNF'ZYC$?_"S6(@\&*DMGO=9K892__W/2/DN-3(=52*[",T03-:?
MPP10,$0%X?RYSV@"+GL?9 LH37";>48UY>4UTH$F./K57<UV# LG6I@3%UL/
M,4/):U=&MUOC5:Z3 /12[,E3/SN"_GFY\6AH]'*=3'X;)*14&![$,O==LZ.U
M?&9[-:>?_918#U]77'>*(@Z:DRFKQ4**V!3\[1D) ,Y,OR'O5IMSTCQV3$Z_
M@CITS&."!+@0]$.3 .X<(6R;AVEUCW<L]^:8G6+"W5PM]/M<"_6[)D 3=),_
MNY%=L]"@7*H,SF+\$8S0Z.N%BA-X;,N2O:5L&W?HNAF!&@V^P!Z,)5H=PT^@
MQ$@$CES'X<@BM&*,&W598'[[,T<$F9HU,[FB2AE(@'2CD.P=R+?E9]S'6B^@
M8_SDPJV"$1N7RCEV;A(FR[/IETV)9-J66$O%8P@<Y+8)"X%B_F!&CBD]\89E
MZ*\(^_U==+SAIB"83WUF&DC5V(KFB-8PBTW<'?3R5-&,W]'J?552U"MYVTC6
M2'S((/%E%+-XWK%NMNMFS6;(N]J+4&_:;9_0AH32%#_JZ2K*VWH"+Z]^RBZ6
ME0T29!&\>:NN3MGC#H7&!Y"-WG7FEY7\9M:-\I<AEZ+1MKLRMM\0B)=.J8'@
MYAF3N;8?A0$DP&3G*:Y/G\K.L"]>RB&^IU532$69_LVK%-U_-KNA_R#];=7_
M"\4GDO]+O?G!R+__E4;J>Q=^5*?J KKU?[#9'85]AZ .XUS\8KU]]D3:T6^_
MPB%\B):P<%],T8^!E;+#Z0Y(*I%'_4_/J<Z-*H'%##Z?#U82W(;W'6*F;^]9
MH=9[UU.;Y9+\*/M/;^\_&BR]*5(I>@C8T9ALOR95O#!1U3M&A\H^A.%B&MT&
MO9OW$J.:_V0-A!GKC-R1?"-32JLNF*!%.?'N7# *_;2&S80&C-[Q7TM:4U,%
M @,5VA$]2LD?0U8%O"9!/PP7#&Z47=*_=K<OCCJ&Z2&W:OW-2QS2K0, Z#CL
M#41TS!ZU JU>M6.';'[>(+Z3O 0>2]W6/H?FG\B3 $G%QX<_,*FI9 J0-T&>
MT#U?6$ ^B@"BV"-K^>).N-H[<Z:(#@[M?!LD $BJ=$S3XX.4TZWL$;BMRPW;
MR5M[Y2XW-,UWW2'PB\W1LN!GX''("^\Y#$&-+H<VBV,Y9U\@AS%(L^:C;M1.
M]9GG:G&HU_;ZG%BC@A&5>.S<UI^'].+07.WMBJA+ULCMNC53-9Q'B%4FP>2I
ML4X*TB#MPQ?!A4ROQ<?(;\6X(W6]V=]QE1TX\HM*KM$T_;6<,):#>Y*[>GZZ
M2M@FKKQ@TFV 4Y1[<8!"+A4S8S8W+=N!Q;_^8E-S\7&\<\>6L@#[C=8\3)0$
M8*J?*8%XG&*_XW_O!(@R;4/VL7[6,0MMCA\?7&Y+=DMV>\;?(G>(MOD:\.>E
M%ZZ=^9(5;0C[\R[][G/?MX3MY=7<.W1.X ?/W^O[0KL'*!C"_#UW:QM#C/BO
M!)GG@Y(O.W>3W_26<>T!5YO(+8[^J66[\Q\S8[FIA5CXSARK:T<FS/SD+UL5
M+CNOPF?3BAPYOL3FXV\E@DUQ,HS%'&16>*?H<+2=3W[1[ZIOD(+U0XV[1 GH
M.4<XAKV9)O_H"P65L\\;ZA_SM$G+*4)/J=4N7-??XPF0(ZO,+.O(VS*&(7E1
M\>4+0;Y&=P=K6!X!=+NDGWKGLVGC:F"C3\F0R:^6QI8<XYJ*,3FI0QP2OA K
M>'$U<.)< U6*,\QGBZD:FS2?2(-OW63?:Z%<\$#KG"Y6'PW]T?45&5AR@5EO
M5?TJ@F3 BUD7-GU'L4UPVLSX-V'R5,LS-Z*8)7 :-A?QW1QVR]+UV*B/8/M&
M NI$4SD7SZ;8YF#UL6?.XC)1,3(\3(9V#-NPH1GK6(\;4^1S^Q@2RCS_*J)*
M(;XDI@EA;]"I4,E (PPH:@2=J<MSR>13+L;/X;_U->W/OP-#3-SWVA/WE6J.
M]?=>\8\9^E+R,"UT(8M'1A[_T!N\G7KV*ZXMV?YZ+K4P:7HR/QBZP(H/) %Z
M$$?DGA)0'4=<M$*1^Y2&XM!DJ>*2K,<)F5L4?-NJR *W[NL^&O\BAZ,+FX>N
M!L\=\7F>>C@%IW_\,XM;8MJ?*$-R",G(TL7!?2!O/^U.'!:_L3FQD>6P\]T_
MC2D:V:QK6V5*+>COOF?D^3;>QKA527+DVHM;X:]>[$A.T&7Y<G"J#6%.;#P'
MA88<]TRC(_F+,J@H+JVX6-67+>\*L$_M0N.,D/Q@=\6[-:J]9PCX4ZT/]D$,
M\EU;LNA@6QNST0X$6^BG(V7-B!ZWX$HV'9T\4'GP'^*#$[%!ZN<V#[6WB=^V
M1L>^3WH@:@\Y@C!LO ?G##"B[. <7+E>NA?B8>B6!BY:*K7L&[0[+-5/J-IC
M'_IEM[N>E\.E2SM=D$IE'/%\:UG&]\[++5,SO4>MY3I/G^"H4&/::FSMR3YU
M0M3O'S&UJ3RYF,;C5)[X.,B:-P9956/#'-[:MXTYN-Y?E*=)VV^6WMA=8'QY
MF!71DN/K;L8<DZH24U+]00:2/\>X)$]WR/BH,%4>1/LNIG/_Z;V&56'%7LNP
M)4/\V]U'K1O,J'KUK^=1M%;MP&!X)^SIT5V^\;8N&,\"XAV#.^L&L/SI F-'
M:92CT^/QF<TPA6=I#:)R"JIX)ZKH]9@@1QI9WTLYO[H<JHU?/?"X*D'WQF'_
M?KE3)566KT$#T[>\$SJ5(Y<6,<_@OY8;X?%ZZ\YV9Q_9N2I@PL"%_%Z?JU2M
M8 ?CWJZ@.XWU4BQ047T8$.S@O6Y?4OIKB/:IB^,"G^U+9PK>THN[A75CBZ]$
M6OO E@MPEH_N>"D6LI7AMDAJP$2SE$/PZ5'6F[6XP/ &SQ-$>"M07F=9PVS/
MSE@%/YV>$?EY-</G@[C?RDM)YS?:9N&L%-/&:=750]77;-B%'%F4K^T\^F[4
M\9CV97%.-6WR^>@^"E5)NS#@7E;5L)0NYX-\)(@![MC"6_8V=-WV1***EOVI
MP]R+[=9U9N$L*31CPO:R?+I*50+#(,F[3L6)?B]$H(]DJO.V6F&UTM4&I_9!
MY647X>O+JV=;&UT0>VPKVJ*:E\[?X?$"9 +OG,(<;'S:K5[/_)16S.F1<VZY
M=*':7^I<->T9$Q:[I5*>A4^@0B<9*X^"J5*>1-Y/5;OC_$C'98-_?;SC$%F/
M\_!T)[;U@ME/X$&=<0T*PJ[+!QF9=QN^P:T0$(2A">R11(/YNT#79-L9G+20
M'T<B8]W5HM:$[3E\&>A+F8ENH\6#K?W_VQ-$_YL.%C62 $;C:'R.O2LKU.CW
M+DS4WMB=T*5;\YAQI$.S3?PI!"FBDPXF7*%?K,K]I>\@X"P>)J7A5+H9:7S2
M*KX45+X]N3A"GXZ3>7?[88K8G5FSR!LF"J^.M_FZQ,V5:>JD0\QKQ,]07;5B
M;2[2YNWUZ<$MWZUK6:QS6 Q%_+@21H5!-ZT?E1R6<R<:1>0]SDNE+7AM[N>(
MHK8_WZ.M6$3RP>SGJI$=5+.0A.P]A1X469"^F+=*D/\J#:%N\UL-F]VCSJ:D
MTVUKRC%:?R<VN2ZQK*G^8L&QUKM1W-H^^<Z=*"[58N7;S\2-#(5U!2X@R<=;
MDT977Q$K?]@:&G@RE7^J$KBT A'4%2F'51\MH,J;VFZ"?5(8O*?<:+>10524
M=4#@>$+0C?+\)FX6&UYOR';6HI?].RE9%R^,*C"AJ.!GW@!GQ6NM]!L^):D"
M"8PC?_XB[H'[!]E[BPN7%K(W$;CZ/QL,7(8'Q79[P@MM&/KAO=B(DH'-X@5)
MT>@DAMDVAW?H)8O+7HTTDB#?AEWEN/M?:M:X U/T:E_%)WRC.BM_KFS=V<"Q
MN3W.9)>A7-YG_>WLS9U+'/;WLMEM#27E 6T,/B.I"VR7ZLM24MU]>6^^Q7\=
M>KM^KMF)K1KOWG<CS'7 ([ZO/)(F^()5@_>QU?U[U&$Z34PN?"F7H<W5.*?%
M9/J4T+8VNY%9PN B F+84BJ=I3.X9['9Z"SM2W%M6UKRC*TWH4_[:QA/=ND;
M)G7^Z#XQH3S@N]PEFA>_@#/,4OQZ8A.2 S891L(&C)$7XX<[2)EZ?]J?NSJ=
MR*@/5?";[1C+!<1-F+@:"'S=N]E9+F.E[&NOCFW*7T9G0VFKHD7K]!?/K/8)
MTI/'B/=8*#X@YRX)< C"I!+Q57/8R9P6LA!_N@W=#H 2&5MY$%U+6]#-=,75
M(Q]0B#@)T#]X1*YD^G(?*+IT&^FA> =6=DH"N,ZX>^R[$Y?%>^<@45&%\F\C
M^S>D.\?+1E%E%?(*^)\&Z[4!T;8&J #!%S%RXZ&?% I]/"OX:(/AM@CP$]34
M.U@3Q0Z5!U.Z3;)-,NO/7E-M]K^\'AS8O7G)7UD,/$Y_H;/9[34O,%3VY2TQ
M%9]?R#"(R =B=\V$./<)F0V.JT@$-.U7# E@&M^/TIZ*^N$>'6)9;&_G(F;Z
ME2W8*<=9\H51\JSI;9M$?FN_Y]YB/DR$J",LSZ<!VX(]L^SSL\U6OQ2SMB8P
M_;+\1)VGJ>6'/>H1X.!2\^S'ATKUTC'RO+Q?C4%ZW""I5SE-&<#"^W2,,;9M
ML&7Y3@8Q\\:<_:QE1I/OR;T-U;1_**[_]GUD#^-!/DLLJPN/F55FKVMDRUWZ
M+O1:VZ.L*K\']*A?F\K1.795JY)?)R)V?:D913@4$2+0\X9T6J:<T]4UZ7#2
M-B%9(MFKEIGDZ 9BVW\VG2ZV:-SXJF*/7DB>D9J2$I:"IF2P_E7RP;;LEE"L
ME<*MO?JKZ*6.CRU G;U!:ETU3-_^MEFT_5CQTGUX4BW8"&X=SF<^]P35?QW.
M4N][ND\G:Y(H,#%';?1EUWCZ2/WRRY_5WGZJ+.YS3?/[8ISJK8O=@7)ZV6P-
MY?P4]@:VD4_77N9R+*2_B&&$"/4\A%\--KTWX8;(EZ0RK$I8I+VNIWZ<>[3E
M?Y[4Q03<&)J'>_NZ7?B_ZT#.R&JVY:;Z#\'FG$Z;CHN63AL<@M<\Q;-^-#9M
M8$=^EXK]E9+']&K',L&9*]:)V_#M55G7WS!1Q]-]+,+BHP4(+@]21I+Y3; 3
M&,;%W\6Y4X'4W-@N7,CJ3XXP8$MH"4P2XV'_W3U=**N66OUDVLS?>8=_14]M
MULIRP2VS\(N8VI70A?K0VPAKZ=L6Q;OF)91]D7^DE$3RLN\PQ7W>9:D5O_JH
M.(,E/*']54]<J6H^4T3;Z[A/N?N7O;BMB_.&T]V&FKTL(%V8*C['%;$LBP7O
M$]7^GV["B)3<^1E"S'O45[EQM$+Y1\R.=,HRBEH#Y-;>(93$95VJ&$%?FIV2
M'9!6& S?7;)<1+"X^+]ED([N<2CXM:>ELS#LM@1&]J\^ACC!FKA0&838^>WU
MU_M]%8NXGY$)XA*[995#J[N;*:9FYA7AJ.5M*43A>LP(^\:#Q(:,H5JGY3?;
M#P0Z63^\*HCON<(5^RK9,;\ _E60YJ=<8(.\$07@V[.&*1U!U4*(TND6/%@9
MV8B+<[?'5!F[@LUYWA?UN%>DK.8O@5KPL9JBG?7F(])7>/?"6C.RFHC;Q4N9
M9G45JV\;I6A%'RI?5F?NM[X>'$0"Q,%]28"5:^?D3'1*A^!N$-:AVWU!H22
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MLY1"%FBL>V3>.PEE49Z5X[+AMQE\XJY9(WNW!DAG;8^E<]_+0GXL@TN:=WN
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M,8+=ESVKU<.Q)IF'=7?'@+*>OVU^LMHFO(BZ]\&^]&Z*09XXDY@(7])SDX:
MJ>&3=FY=)ZH8_F=,VRJ5(1QIQ>8YTQO83H8UI"OT'5B*%RMEH3(1+N*,A;!/
M,H:'O\-&CO?>F5FIBTG";:TEIX_W/3P,?9#2K H<.!L_3VA&;E3A(#\%\JN8
M-LYP[2SB@GD"UA5,R@M7FT%]>DY)@Q6O7N&66TIUB^^1 %J*(S,^<.>YT^KJ
M.:5JU,SDWK[.;TGA*$4.X$)?@[#._.KB*Z[GT_O7_)F3<(68#?K+")]MZ8N@
M=_ TCCB<[%D_5FW3Q!YEA::5>:T*Q<$F@G:I\-YWY?%GP_T'HR.%1+ZX3/TY
MZHM5ER.ZCKN"AJ :R?.X8]]U<]NJJ,W[JR\XNPZK<NW%+7*;8^7VZ6+:9)]X
MW3]8%U,36V#QX/5*EX&>T27T9R"R%!=,?D!?3&PG0"\']:HT$>5MO"3]6?U&
MW0>__;#!WE= ?_LYX:-Z5M@SOO_KR15AWJW\?J6%A(DI=P$SN]O]9I\;'WU\
MZ?D$VV&09.@JJ+O"L;'[UNW[#=&OPB[:5''5O?V;<P+1Q8ZS)M/KSD1IUXN*
M0GMV[3:3Q)*]K!9YB#$RQ:$T]8JAJ<B8<\3!D9'&I)2@V%]M](+O=&%R"%%U
M]]>%QAY>>!RJXT=&I=9K4$LP4A-,;\)OPDY;Z/*X=L96$*<:V/KYX-21IY!V
MS7" 4JVP!?O-5E^E$0#)QR-<SZC5I?=U+PS7NP\#?.\R2%N_%3M8\>QB;!+A
M8M!QH5&09IB7->>(^VM-KS?^\<2DZT#IBM1$K6E#R5%I_>L@[6E7Q6B0SZE1
M,E12NA$D#%:OEVJ8X6#W<YT^30]3SW=M-!('2ZCI)SGN<!OJ_?X%FG>N9T&_
M1A[%*BZ'G[>6:AI<DZY\[G+ KM#%P)[]<(G0KW,P2-5/:*.<,A"^(MN]F/9D
M^<:]1T,J-WFG#.]SIDU_GAVX$?N$?9$$F%#KR<$-50Z2  5S+8JXMT'("$7<
M*E&27%3!@HKGFA[8N N64BC2_9 $R&'X3![0$D$"[)DCN_YI)/8_1LZU__>1
MU5!(6S\QV)*+!%#=X",!:O^^#5*%XPX4+0+C(R99KI$ J%#T,C?9Y\>=C?]]
MJ\9!!0FP+MRUK+CEWD' H#G.#_WC""QI.<3>#ASA7C!9\K6W+N5<: <ED0!-
M#%W^Y*].Q55E/"+H9ST)\*6)!/ G 7);L5AX.W2S=T7QQ-T:BJ/'HD_T#_F(
M1[OOH-M2^[K$>4O"BB[QC 2(H3OV1=\8(QK ":O$L%WD_Q_HOQRH_=V2"^2J
MO*@AOKB@+_C;$A.KO7(Y6,X4GX0/7/*)^Y 7WA'86I32)&#3R<LD7?9+Y<K#
M3W):408.T\;TJD[+%IZSK-/$AULA%H_"9-^RC9LG*BE9CK(-'8\5IU8K*> 1
MB%X1PM9Y6:L5@ZZ)=@=,V<9IKO'@J#)XTM<2'YF7K4Q84"M^5<JT<<<T=/6:
MRM(MR_^BJOUZ<@CD>)DY-K850QU( 'XW(OE1V4?HGZ)Q?Y+===;U?E#?WM-*
M E;%(!:3)5"[\%JW/P8>.Z@'4O7X;^R]951;[;<OFI;2%FUQEU**2X'B5DIQ
MEZ#%W3TX:6D+Q=V+0W!W38N[>Q)H<0L0W *7=\L]^^S_..?#'?OC_;366",C
M:SS/,^=/9D;FI%$A\:*SD 8JB=F<MO)6W]+Y<?,0"ZQF[SQDXD+TK#R[SZ^'
MUTJ>DFFP7TBZ6=F6HEK48F#>;Z*KBI*3V^A,EE)%AMB&]"?Z^?F-.&6GXK'#
M?>/":T623!WE&I[N]IZJ7BL[&JYL9=L?DA_MJ:?^N-"5/T1VI1:4'J&GUK2X
M%\\B/C1(.M'%RA1(1KD$,BP]E:G,4)?DN7-N''8^G0_8S"I6NT5/RSX.ZEG*
M]@,U]8E'-48KREL-_'QFBG241&'9S<D$*Z[\A?%F'!1\MS(-49&1IC+86M'[
MI/O1J;Q7=166+=:F]JB9W2WJ6_G87Q'IH-4Z?A^;X/0D%(F^(OY8<&L^^4R]
M:Y\=8D16*,YS4?L%$2NQP*^8>G!&1<PCO=J59G-6(Z;ZT\O6K:2R_9_()^3E
M*WV!":F]4_,R"9"^#7\B1TL6UF/U8<:C=?K\LL4ZK6XCXFG1\M(\&1M&J@0D
MW5VXQ$.6+!LYJZ&9.AY.$(:#:'](AA4Z5.Z=<\E?_7O D"&X'3R!D+P'_ _F
MW,_E/PM@VEV!HK[4O3L9&[>94Q-J@5E2RA(1;DD#C]0?-SAUC!$\;W@/GYN0
M,":YC[Z U23N?):G+O^BFT?G184^ARW9*.&%.9N)SJ(XUSBT&?N!N5%[:@9;
M,1]%VT$KA@2"WU]\S@G*$)<M&GL.<8@\6INTW.;\"_<T3%B?/Y)([MV4V%L/
M\JOC8D8&J$I>ZMBKUNX6[_*\K5DZPWB%^Z[Z]]N?MD_&+-A+>>6UFLX/99TX
M?NIWE)Q@!"$#9@A&B2FB6J9$QY\EA;!]X]&6(96F6"!N<.L7LU$J#N02HK\9
M&&Y;-H5^7EH^%B,R),32YWKM5?S'L_Y)T*1J1("HJQ?7]NYR&>[GNXE?IR);
M'IG=K3QU9DV"?31IS34D+W"3R,L/'9S:.P6\BY*LOVSF#CB&A^L;8\6*D&H"
M/S/T^/=+S&_;_^PP_E-RY=UISW>%Y<!<-38Z>3/T:=9SD;PP]!6GM8[*W>P9
M[[R4:,'(,9]B]-#\DQB0TIU9]).&F'@S0R#@B6$!-J 0H(''PL)Z[E6%O<)\
MD;\GIO:5J2H;5'K;?-2O;W=!YS%EOO,V$4IQ'B5 &DRIZ$<M(^GDM.#FJ7V*
M1Z3^6T&*=LA T<<V_0D/&[W>$%<LA_A@7I=GEN#ELZ/#5$1HS-W.W.QZ8]7"
M:>-%_MV^I<-&L/TNNNT<_97N2&1IL<3<M[ 0)59!F<Q87.=NY)(0J!LQD(Q<
M^\Q8T6/3@_T<")XXP,8"4'[&PGAR]A>OFDW7TU4.6YI^>@\2!3,1T>P,_%@V
M".KU':<\C!"EK#Y(9PMPWN(/S&W8Q5_KU^C64%.0RN)S]!;V8]-CVY!?+3YF
M8*PD!O20S[99Y!X#%R,A2AO+UP.6%P2Q!]1)WG*';*VW5^D0RD5HU)RVRQ6;
M>Y[]DNVFF:@\I=YD3(D4O@QXY*T,[LMC959<\..**4SU1P# JQP (0N N-^8
MQS!> 4%=(\Q$@>5RV@]4VS(NG#S@VNK7,$<UWP,B;V2_TGR3S^^:T#@?0Q3F
M]3 23VG\2FW5$]"4>A\[.8*B#U/G<-3V4Z"]M 1E2UD34=%:;'2>#\M][Y/Z
MWBV7N#WZ-U99EC)9H1#28SY5!U9NWC=ZUT#XSO/H6QC%PO<GV?X1KIM"E-9?
MX]=DXX9YR.3Y>59'KX7%^/HQ*BY!EY7;F\'!U0.VXIB&&.L\\QQ!&P<_E2SI
MR%!%=FLFG+$9G$D!8"?DKL"@E3TA2RFO[].B18WTD6^H7^$G"J6RVNH* '_"
M5C6S6_\"1%NRLLG [8&L]T[E=5%QU/4S]_>L-0WB_!U_ARQ35$^22AE[UI85
M"S\#9E5>?M$WD#%[B?YS07.WM1@=$'*30DJE]80R>U=[AT[7Y<.S;X\.\G:*
M?\\:L)9$3],4PU^;^1G="A(?I;GJ,A5DT68%B%UCMXW[7C@9SRX-)FV/R ID
M26QL^X7[_6B+P-&<TOT-]V=0Q!;XC!32*PQ4UZ.8A5HJ;+Q*HE"0H=% L7P!
MIXC&4N'$G!L*OJKYY^?X EJGPY2EK7M  +CO@3DD_PLTA4IWM/6C)E.#)5%<
M_\;I\5P5EYE/:D9?#"/'<2=:AXEK IS@DX/$<=66\8+&7;CQKP%23U[*]$,=
MLN\T[@'_+A+J_XM(V&DJ\FZM;9(Q6]0CL7*&]9!8,?3JT91*/:&5JWG&IS'C
M'YT5'///((K.G7%-\^/ZJWTK+IMB?V96M>@QC305)NM@[(/9+#:Q"M;,$2^"
M[VDXC<ED$MO\X7'V.=FI#\"J2@= P1F%J[I\KF\_^<FMLGA'KZ27YF.@E"J.
MDDB:KWB =:N"C6-]H[H1B7U6?;-*<K6O_"(#0MYPXB103'$)T:+:/$_;6CG_
M&5[Z]$!!</W!U]C@GR<4^=-<>+X+SE)4:XAP%[3[.>*Y8L<NLT:$B:HQU(,M
MWP.T5+,+*0/96._P.ZY%SNZ.$DPJ$TQ@9278;:BW+QJ(5E=,(//))F(93MZ;
MTY^>) 1VS?IFXPNH]XM!/8-59$6O "[%T'ICN<I.3FOV/?<6<)IH/VOB('!&
M=]U=GRZZK;+I56QE65)1:45E1<F^OKW][JZU^['":[XV0@7&FVK?SSE-_^'
M<$'E"@Y]#U3S_AXP8<1B)VCB,:$YK3YQ2OHX/#P\BU)11$1UKFMZ:DISNJ]Z
M>EI+J[M^BH7U3]CC/!;L4@#@T0'9-<OE@\3S]6J1/$V_>& S1^X@%/-_AL?\
M?Q$M7J]OD,N2)ZLHNFM!'DETA+^HSW+R=N8P*J9@NP;*6)O_*'2_\E)H?Q^-
MUZKC6.'\(:)XA5EVH=@;*#W9'R[/NFC-6SM#&5]*W-5;>WC0,G9\'#(_+B_
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MW]V.[N-LYK;K<7<7X^8Q)%Y+T_7P&UCU>2.M'>:[P A:0SQ@D[L/7@-'[&C
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MC;;+DQ4O1$JKH+6HIY:SF*J2Z[HWDXWE7U[R<BO:9S@-C5)+/LJ0Y=R*HI*
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MF6$,3@\_I?]?]7WLD++Y]S@YCV 9TU"6ZD!WZ(Z''XC&)"C OOLB:Z>HZX]
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M@-SG$%BX8O:]5O*]M7J*I9?6P)=F%)$<-Q(]Q2>O5Y\8._N+H3*%4(%CO-F
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M__68*?PY4U;&\3?QBTW81(PI9ZE9*^SH\)*:]G30,<>VF)M8XSZR"/+.V[T
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MX9^^H"W:A6<L?:9QP _=E96H5N9/#@U19Y8E9CX\)B%%2KSNLX:!)=:E%H1
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M5$;U9'MP7VK[56@] :Y5@4^RL[EN22G],]):FF#ENCZEC'#;R:+L0#6!5=<
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M! +8HR])[ %D:)O;*Y 8U\XCP/SP(2 H<DAE9 2.^&-JJQZ6RG+?(*-^RY<
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M^>>TKC08MUP&)YQ]N-2=XK28&*KA^#LMVXS1$7*F&((GHO&I.5 MQM=IJ$4
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M_/?C+BACM$K6@>-FO:C:TO^SIV7<^\5#T0+.QF7H?>GP!'ES_]VFE#+]P$'
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M]Q%0[_]Z%WDKUO&T8]L6K?# 8?(/?BXIG4P#Y!\!B0?Q4GM?LD[F=\/3.K:
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MS?\!@?#<A9N([5^N=RF^>CVW9O^2CYWH6KCQ3>7E7C8Z,S%N!;J[)%X^5"=
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M4G(M"".5T/)ZR(]R<\Y]?>)!RH"U0(!JV,)\FX=Y1DF_[>L.;2W%Y"%EIPT
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M@)'I.<:KVX)[0/YMYD%N5]# ;E9I-1_9C>"(VP^$VL'M2-NUJ#>0OG%6;/<
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MT*I\29=7H00CH9"PN_3Z\<<@@T$)CNMH*2+][CMZH]@%<70]BOF04,].M%+
MQ _N02^<_,G7C(!4"9D8Y6E?XKPU=2.B["*88?NA#"]JSN= NG30>_,/K2BW
M7G)Y:3AI= FL7RVB?Z5:."#UBUSCMF^7&NA!HWNFM6>'7L0=^^,K85<UPLIG
M1]O,ME6'$6V&49<<WPW'5+_^X*6:FV08>2Z0^ ]P@QC'KH4%0LV]R??QL R@
M5/I IY/'DWRUM;Y<@N]69\[P8'H^ LE?-V:]LRM <20;'50APY12V!TPB U$
M2*K(,N?\\C2) FHH)5/MC*"U=:8[DQZP%I+D,#ZEQS2U)UK? ZC8UBT96W@?
M>0/OJA^;MC-JW9+(:!V\P?;7W@/*[!N",1I%H8-_<[UMFXI(9,PP?TG)BE)G
MTN5G^P)P;[C_^>>A-X/_7%3V%+(H/2HY:(GR80[6126<,LV182'_1R[:H)=X
M^V\N8OCO94KW_RT0;MW2:7L\-VA)KTH_1K?#F-!649'5DMPB53?#,3?ZHF_S
MAOLZ=K6H+4\@3?; O(_AC=E,Q^C,S+JU,GN0D!#O:R19KG'&O+ ]:0C@#!HL
MQI""ZJ%;9U)?U?;7SLLNV*434!<C_F)VC0E>F3"1<7<;U._^=4C4AJA2J-Z!
M(5J J 7QK!&C3^DMC;7N5+TB^FO0LCY@V9 M/2Y=HNYO(EMCII>:GRIM+E.^
M2GUV*L%&O;QMC]^^'3MV=MV7*,_B9ICM]QZ>Z]NLZS!I-O"<TK>69)*L<:<P
M24VCX:_5+'SDJ,;B-*W*I.S?8WX.+BI5DO;!LG?TMYCLM$<GB!_543Y,'R<I
M=W?@5-;.]MF6+KI2TN/92A67N"DRLY8L<@OR&SFX1'P0W.1O*6UP^%.W8C&/
M"2^*1-JM(N"?T]PTS.KW]%A<8M[JQBA29WVO_&^E>3Z21#WA/]6A[7_PBO%_
MJ@-R\A+\=N]/;46&$P=YF[]?@E7M8 '*[1136=A#=P] L%WG^&=<)'YPW4L^
M4RBZ43![R7CJEF-H>]'RMYX$(X0HKDV6KEM(WID-VTG=+A(814)'=DPYE%[Y
M@ ORYA5'/]T&Q\TR%U0.KKVIS8RM=;.$.:U%L?TP=@FSK?:VVS1N.!+R(=6S
ML=7DJF9BA;[>+_7D'YY?'%9:C5TN<*<$P+_,*V9 .64AN@;AAJ$(>4<OD!ON
M[3*BUN[!^ECE^ROXU_>3I\65!+%23TTB$8*Q[;9[Y^>DHJR^B2'0(/6'J@54
M'X^OGJRQ0D)46W2%A2YG=UEJZH;H0OB4QJ>KZ3.+1?H+B3'T:8TD>D,SXL1]
MI8-*]05%2_%CUHC?9^/+CKX9"P)6')X!,5,<+!0&1Z\^G+8J&86^/\*2@?7*
MWO?XSCAP$96J*H6WAK@!>+Y\/(PO)EIU!*1:"5'L?GP;6O_ #<E@*3,%1V4?
MI:/&ESE,H_A??%U-GF'>^ "T)]V9W#?H\-Z&5O9++;%:\TX?G;$(7G _=EMN
M"HO#)[X-,6NL*!WR<6D9,FA2N$MSU;8UH*CW)6*>L-E.>S+WII1(^*U[D[[.
MI #HEM3&'E/&:SQZ2)Y#UE ].S01L7C&M[[C:&ZY(=*X6-JP6Y7GZ&Q9D8]*
M4+7+)1ZZ<*_C?/5(7+6Y*M%-!/O)LVM9.40^&1IOQ7]9> JI?Z^[W3=)$.*N
M9'5,5^L5MC0@@OJA,+S+G"V9^$T7]991VY8_^T\?<;G6T1%%/J'[AI%H'X2&
MX<M"\$3BG'AZ+5)',F-6/+LVMV]-@%H/\U;14E2W8C!O0;2P8W)L0Q0E1R2B
M]H\F#<T_,/]1IQC]=/7(7P>0:#/G!W/8+S[GJYW:TD_%4U#/%1O9$?J*0>-G
M4SR+"YF!X1YZ6J.C.O:<.[N[I3NPW0_^<V.IHC_2W_<V*C]-K4E<-+Q+7 &I
M*,#D,CY(?)Q\ER_ [ZH[.@7(7HSC;D%4+1CW'_<$0WM\GOU!+S^4%?Q4_C/R
MX[0^?B&:.8!2D>$IN[PC21AI1DZJ^%!9YH#; 4]E$;![;_ T&5GDMB):N8CI
M.V\V-8G'K#3"-[<JYR^;FK-,/\__GAG77K/KT1Z\4A9_KO0:.J'?SG.U=SLP
M<TJK[+)F;UF^8)C6.],A3*F<\R*\/-%:F'4I7)@I4A4.?,M<-U5?U8VCQ>VB
MU5:I%R%*GW;A:9)AI7U0;[DR^FJ5O)K<;EP/Z02PP)]\ LBVW(@:-D/,%R"G
MUC[)E_2$O>^<*O[>R&*F0=C#!+L'V+'H O_\(LER1/DSC)4O\B\3D79CFGN[
M5TM?",?!*A;29]><E+-&*(D?>E+%M+&NY_5:%T-+< Z7:(7&2/!CLMK*G3@T
M;'QFA?4^T&-K'^!!/9_<'5N+O>RSDBJH"2/S<R%D5[/^$W?BK5=#<TAK\5*G
M1^/5C5S1P0A+X$S5G!(ADM8W7K;ZD87 HV?@1XR!ES<1V=Y7N(NPVD&89%+M
M_J,*P#T W.KUAW9)X_&#<Y]9%-P-UG@@,R]ZJ:&:1:[B':<N^'P0;3!3F!'!
MU8GADF5.\E22R;'8^A^MCD9)V_=3#A##G=#IG4P;UL_5Y[-7W9&4GDHC!U-N
MP8)1M#K(<]+ SGFWQ,-?JN4+:I:9;,,KX$=]$#]L1$M>Z=%#H\UB^<C!A<J5
MW&"*(@U4UUHOD\"W6VC;2RFP/6I4;A&=D[(S7($.C@F?;>3I+)F_G"]KQOK1
M0WYC1OG3YXVC4TU8S#.'A^A9<(DE:14YLT@G)U5XON='S,O:DO14QDC6MGG2
M1X\>_/@\,-]B77,1NS$"')PM+BFH7*#B+FSR8YW:&VJ3)_RCDK8H>1Y<HD//
M]60-LUT"VRN\C522G:PILP0Y*>&<9\M8[$Z?C[B/ R;E\8JVWK]C*)BX81LH
MIF]#7YI!PVW:66E9&D]0>SZ8:$I!M]6"HI"**)P4M*2;VT'P22JDX-(!OM@'
M7:C2T.X^U-+AEJ)[-Z+W[-SP;K7H3G)DY :==!=[CGE<I.04'$@;?'8AS'BT
MZ'8-N0?\5Y_9E&/6LK_D@]/[EPZP&Q"C*&+4Y?D#0:5?8NJ'>!UZWPY'SJKN
M0A>-@H<STA;,',<[P4TR7.#. 3#_725J7*JW"I4=K;BG^"MA,_#AA4G33?B.
M-V$[8SEHQCCD/?Q'CS+%9-M[W5N9HJH[X6PCIC R':X))3J^+KI:H<0!SN^K
M$>0RO$Q5 +#.87Z,9%YMW3XY0?;:W>?0?>7(/? %]":<43J<FCF6:AWB^/Q-
MGD*BD8WMQ[48\MH^IFJ"[Y'XS/$ AJ$7OD'V0][GBLXN#4LU"'NKS=HC5^59
M]NL!F6][@[$8_V+'W?-P([>WL1_6)3E%PQ8H0AFU6*1%LE,#RDXKA5B8XU\,
M-!]D8K*F=X\[W.H+6&U9=XS-<1H3':VUH&B;[_BD9OH6PH]'^_MA/*X;]381
MB];N'Q_Y/>)2_!WM.8@/N+.QSEN9:'OM?EOY;8%VW.T .#$GMO#Z ,+8MO]6
M6A&DM;\C[V.+=[A/5"FG<FX*BABR<$QMA7#\^.>,?Z*:@OT1[.BU26N@;""O
MAPLW0FM6+&9+9']O7^1HV-9WWR?1XASN6>1QH%;>>![#(^L$8T*KU7J9F$$A
M>:U):G]C6)N+)D%?T:1_84I4<!YH$&$M52/K/_HS 5LH2Z?=(_V#*M5P0]^P
MX%;>F#+7]36"3\7Q]8<+W"@%FEQ(5&*!1ZEC;LG)\<X](!\$*6URIYUP%^D:
MW$_WW<3V8X(8)-WUQ^'V'IC9*DD_3TS,BD%,[!N[^3WD'U!J=@6AC^D>>\EZ
M]$B>@L.H8\ZJ^CBL8[]E)02#7A11!TG.BNW7ZQ_O1J<.H,^PH/+ #FZ4..9V
M"OF^TD^_]1XP7V\"QA>F4SW3)5%+AB1R)-%,<?YTE>I82#UT1_&(@"]L"37Y
M2-'4KXW8&DPL'QU?<EBFF(ZUXN/TK+X-;'[]]![P0>F?'A![1+V!I@VP4X!?
MGGM!*)(@<O>E?;@L'2,'@IDVQV_?I<UPQ0:=3J?PNS1/4K&V&HMPLKYX8>FK
MP%G&3TM2?2%DXD6#?>K7GC$T,0VQ5(K'EAGK#JAL)J9WKK2Y!=DN9"G6'V?"
M$/QIP]8_EXXQ0:JG)@;NVJ.Z&/[PO%Y-MYBN9(ABWKR]>&*?8LS/GN$1;E-3
M%G"L@K+F^(_C>\!;N<$7"4;R9)V;"Q^GLJ@BA)^-PD)A[W-]:BN=F#X8XKPD
M0 ^5G:<(]+VB.0W5AT*(-X7;F;_A .H#GP7FK ,?UY_,#A+AL?!-3+D4+/BT
M=2*(WTSU-*3Q&\54SHNY6&U7+&B$Y_W$7O?/ZKV&%I3G"KQNT4\?>!1])R[C
MZS9Z#SC8 4_FG+=9LR6:$EV/_+ICNON<J%(L_^J(<44FHD5Z,=JO/F>(W3:N
MK4:%KN9O:<F7B3O7XDIE//H2.+ M[.$U<KUY=SET8!;<=T&8+=/&"\:\5@_3
M3C(\N0MGO/$(?-3Z%BECJ%-;;2>YA3@85&)%M[5^6;\'O)-*D6DLO@?$GH G
M9_[5Q4+^9G-@T4PN8@GLH?6O /:_[O^KE^E>GQW:YS#]N98 UI4-6&,5F1(/
MZ-AZRBN/<]S/>F?GG$SSU290U553NOG4<[6;'\3IU[ZCD)'A3$:JLPT>G4/<
MY!3C,SKI+.JLI:,_\2O5G"%Q:=<M@2:G^;^M6*3%WJWKT*B1=)D)"1>R;QB?
MZK!_ULH_=*)S_=RO"C;=Q';(',W@MN3XK3IYU9OF("P&RHZF]XV=C#C>B&QJ
M\"+VBG=8A4?BZ_#UA,EUO;AVY>\V\^\DA^X!.N9_LVI>Z$2!GG3+OUH,).[R
M4/16#?Q?E>M,H]+LPF)I0-HQ<QWHD %M.I4)3I$V>J!S%R/X(X2*]!Y <8YS
MH:2+]1H&%#/M*-Z:1?UD:P*?[K5T5=[2V-X#XA3'W*XX#M*SLT?W(:T?O3U%
M4CE+: .UG12J7^@CF+:#Y]H6ICX[_379"0QT#Y@>"3K[DW</""K"_LWCHI_R
M*GL_M]\!H\.K%RNAM8:++2B3BII*D-Z67[T(31O0VAUEUEIJ9^V (':^%%F,
M OG2VZE'O?AGX$ @3EB8BU3WNQ5_<$?W^+86F><$2WUFIJ<;CQ"%UK-QBJ%G
M:<P$;2N:1,$*[Q*8UR6+15QA!QKT%Y+K,6L?EZ>>,X\[1'5G99$R.#E%D$L9
M*-EI=[);=]^DH0* OY=00'QXK*C]68SZ9N=!UD#6$KFW21'3C[GT)R?8;N[<
M&=W9W?UA\\>U*\6Q7-^"/TQ:]]=<OH:(=28*G5^8J$T)UXDI]A^ZI%JH)17T
MK=>@Y'CKSH$*E9061>7!WS+Z9Z05?5:+:S18)*?ZE#[6/#*R-J>+PH@<ULK6
M#[YTZ+-0KJ4*J2A\R6>\40<)<6C$H=YNRVPT$C=;Y62#!+ 9>"?,+_0\?6O#
M>?LV>A[ZP579O"/Z^8.',>/Y><@$;"FN7N,$+;S*_SHR2-K@:6CNDF'+7'.Q
MNTE(JDLL<5$5WVP@?]Q<0'0K6X<._4/]F1JNZ#B>AEF0-B:[<!ZUY#:Y#L^Q
M!X;UZVP%;CD4,JS-E7_OU#\XZ!B:6&6O$J)VXD:EPDIS&#7H@[TH"IN3O5DB
M\S_FSR.ES6H6N(8Z7_"7__+7D>LD%^R_]BX-=_LF]U'E)2P?P*D> Z]0GD<,
M51_ZHF_*]H0+:&P1I*4C/F_B.A2-"JUS']62K6R*F=?Q:XV"9]M>(XKTW(RY
M*/=W!]7E7/4PL<M+9^)9.;-DFWZ4+RHEXAPG#PC04^GS&?0)H= 806K(#P5*
M,:N^7JM>N]>U?72>?!U-@=IM) @_O)-VH-1  SR%E=%U4V1*X\)$4#%C0!Y2
M7/FI[2*<6L,HH6@^&?0^BHSK;$I;0P@P.=9-W!3"-+7$S=U2EE:2^Y.@T)G^
MJ5.YATX! )\Y49J!IHL6?85;!L<.+8ZX"\Z6:?6]V.9+Z!!\//T%$?+Z25=6
M1EK3*TU;C/\\([.C%Q8)W"?<7.AQ1:/,,]&7:CW/W8)X5![_4XSBLVX+JV#B
M%);F*?*> <[OY\G)R5-P4=@Z<A;:'(V3O0)C(957QJ7W@.&2>\#>5M76MQ?8
M#9E%Q:NF6!]&6>QC!:]9EL7CH;O!K=]&01,!X#GP?L+&<=\&XB*S37_1U$S%
M4:3^[@>HCU-LC=$W:^B1<_Y%. $!N.\]:B#<*('Q[M5D.N.!UST O;KT4[*L
M3RKW6.SY1]-[0,W[$"4"F=$94^'D8 #77\:M"+X'W$],,+1450697M;J-?$;
MJ4Y/%5V1+4T<J-K1%%WZJK!]#24[6E0=%J5/24RM(/151M QQ^)GBS_2YO.,
M)H]S(<$4 K8^W@-X5=2D(8--B=E,T]E9*7N^7#;B$I7Q.:\<W8T(/MEY A.V
M&SRH:?H%$PN[;=D&@[[&T9H;Q1A'*E040DN?,OUFB>HO-C!>7/:)NHIU"QYH
MOO!5K#O_1)MCI39/;X+*,JKC\Q\JA1_3FS0&F@>ME 8>Q\9YK<$+133<5X^D
M%(D5[?DK!=4G?3PT*OOPTMQVM-YO"SD]^^RS=G,RT69LNM05G5[_\*<F1?Y#
M0=4UZFVRWB# G*[D"WR$".7>H*O:<)8)2DJE!>%J<W7;AX=%H:?J/$^1YY6O
MX#7(;%4SP5=)&.IJ+/(FN3NDYMM.=SJ,.H5DRIP'7M%O>&2267:A;^]F*XE"
M(E]X05]XCEE[%EE?%*G8-1D(?VL?,$4<"WD<H.NC%\C6W\!VK5-CG;Z/LUN0
MUHHBW[+4T.$4D S2G!4?I"BD141F4/VX$D@Y7>74VA@-G36G.D%"WSA726(9
M(T>L)$I+ST5P:Y!6+JDLB,=ZOF%+&"Z@-2\N*XC>B)56RASQ.K>L(,2P*#9;
M/U'\)C(?-:-S4[L7'((."*U 2741#^Q)I<QFLKZU>XXL/ZZ[+?^R*#60O6_L
M6H[":@2[9/75BN)-I0$WIF.A.9C"/^OQT^_$/DY7/K!FTG6R(LE^PZXI6VD6
MYF_E4@8!O-11EW?">?B$:69K0O_BLJWQ@MO<WG['"R40/#)/.V/C)E9:T]""
MBLLI]43IE, O3$5 Y0CB*325ZY!<8UN$Q=TY1X*62D6J1EWJ'DS!P^T'%:0U
M;>!L6!!X7JFQ7N4MA?JR1VBN"0RN03[/L?43V4)C<^%F>ZXK=8*2FSFT\#30
MS*I=)D52B.HPZ7BV38AN8 1BF=ZRC\A8O]ECJSM')F%W]=2?B$I1\0!'B3R7
M>732@(+ID:Y/..D1!^+I[&%S3<!MY;P0JNC5I&14%:<D[X/4X"&=EJ8H)Q=T
MN7SS'V>$8 ,ZG^6SXSFKZ)OD,\,.!D[^IY._C[DB"!^8NO7M<_ON8A:V+LB\
MK8J1<L6M4F>FC'^D.HB(O1R(4\NV'?=.9EWR+3<,=X_9)SREA3]87P:="1UL
M6JI_R/RCGMZ=JV?U>7[W'B"C=&-;EA6-PT%(%R/AO''<LS$^X13D5HJBY2P[
M_Y'9%">!#I@S[9J=Z$M&I74#TS ?#BP92+AC/I5]?7-D#Z^;5*J0,Z%@JDB_
M6TX?M-48:0G5:-NKH0K^.B_3+IJF/>T3YWA>-Y5E&WWUH(U3I]KWPMI5#9,5
M9&_.4+M ?9LE/5O4V<<C1ROE"WHAM!1@6/\PU<GXJ>\X#E^QT]<LIH'I-IF$
ME?%<$%5B*]D.IP)PM'/ZYY_<(L+HV! )MW!:Y*6T@''6$9RI8IX^27XVRVV&
M=/7"QUQSW_#?$Q .]H)'ZOE>!\_A77=;^H7)^$_:/-29Z5$*[^W"+RQPP/T@
MK(==D@HU0&65-HG.]OLRK.3WP7FB2!/WYV_4K4%T#$^)8MLMBT\H,OU(0W_!
MUJIG9Y>A(8FI5.R.UK'DA$R3NMU-Y#R/YSH*1)]30P/P\AJ@,/TO.D* S^UC
M7;OH))49$!E.G2,?UN0A_T "K+1[OXE@ 3BO6N'&:YX]I+>V4Z/G,T>9Q);>
M-Z*G)?QA7$-'3RCIHX_X^;/@>HV;TI%[@/:_?TX&+T'?!).HW ,^8YURK@QR
M[@J5[@$*V NSW--_-U?GB^[TMNX!)=K@L=;;F>)@$K.+0_B_.Z@!]X!=W9Q3
MMS:?74:YF18L!@;>, -?I[#=TAZB \-'SP[__PT(D8XM*J9G.F$.;E&\Z6=H
M>BO+:0BN)9U\O]GKP@.6B;H'R&$R9.I";_G_TF]VRCN2T(#0/R27QZ<$Y[):
M_P][[QW5Y+JMC\:""()80$!*5$"D2Y>N(B!->F_2.Y'>B8J TD$Z4J3WWD.(
M2.^]DZ#TDH0B$" DN7'M=<X^>ZW]N^.6,\;OWC'.?^$+;][OG?.9S_/,&<;'
M')BYHO\:"+Y:0@:H!7]%?W=\)%E-_F'_A+E_8^'W\*.5 #CB5#L378"S$6^+
MTA1W/"5S4"F#4_J,C\*@H;*;?A@("1' *3Y2<5/^+)3I<]"H9&1FQ@[ZYS:Z
M+HP).AV1C[DRA?[:FLXO:G^$,V6NR>6(71#VQ[((\)#(21IT1H=G0E0\DE,E
M9/4LZ.PMR(ZZG@ '#C:[&>K"J:^P[\?I4QS'3IV$""IE,KZANOXIYG6 =AD<
M.Q*@:REZ9Z8#V3:+O%Z.1.%':J=-^[M=,HM4XU1C N.@Q0="R]%,/9$[Y\[<
M,7J7#Y9I'-AR(9/X?EN_\[+2W@#[@A,"H+&&::@Y;]&GHJ4'5-;C2 0%XAIH
MV6^]I)'OTUR@3D.U_B8#\'U@NQY% 81#Q\"(Y+IT4F@B1W'G,IC;K'29Z4%B
MOG00#.EIX!)AQ$UN]02P+7PQ4PGPT\PP#4"JS"W3DR:'GF>&]XTA5808Y!N#
M])P&>7OG4>&5E0/')'<D:-+AZ4L26EHL>C; FPI",HYR)#Q"M5-#.NI3M^DB
M68/_"U10"B^)Z)-W_[>X>,WTDT0!([CL?2JL0;K<-EY-/>$F,Z[G>"#%6'P.
M_(H97VI&:L)JQZD_I;XZ!<>2_1A[S[]Q@!5G03#('0J3XKI? ;*Z\1DT,I&1
MY<W2AB2B7 >U'ES7?4"'&A-1EN#C)%)<3 /Z':JX!>3EPHD,97%;%6D@NA74
MW)31.F5Y?)83^J0A^E=HHF/I<69@,1?'_BG2Q$LZK4 HD][>D25<R6"F0R).
MVMV64W4PR<BOS ^$K'P >=MJ/:I*Z1&FKKUE;:NJU+^?M$^]+;=U6>\!/=.A
MF%Y47-%5<<-$SI?Y<J2,KEN^2X%2^)2&X=F\W,IN2V\9T^.'8RB3SUI9G13X
M>>>96DX'UIR<Q28-#04I+UIV61,M599G0L)",0(Z3Q%V-VY3I9S*3$+@0/-C
M=FVO3%!A%=UP5K"U\!5,=G#]M@"4+PI^XD>.0C6[,3A KL7E+^D'HO3D#&BD
M!$3N)J6]>Y0Z'5OV8\?,Y337X9+K'$9_!;'F7_O(T49DNS&&XH/<W=XR"JJ+
MXK7"MK:I>5^3BHH;KUJ341R/U^?X^-E_NA!YX]I=>_'@&SZCFJF;E]O/35%2
M,3PBF!UTWZS/JZE^:\C[6H_P-FA)>KG=ID0E5XV[KZ'4UX9J;#!3;'[Q''U4
MF)R!@K#.BZQN!^L*OZFHG?J);+VV8[1RT]==SB*)VDK()0\0[S2<*35Y>Z@G
MI$"^!WV6LCZW8&NN85,5AJRF:^$H>>1.EIC6)ADEJ% @/-J_H=B77E[)FVEH
MY&]4WH"8GY<PE[QN9*R<OY:R;6WCP,4>QJ@233>91&(@&E<_,E7SJK;:8DT:
M?-4P7)U"6,'UZ\&W=W*CJ8.TZ@3 5TX[\<H I&II;<N,T]$P7]5QA44!:%G"
M-&4"7=[3QKGI?FMBQJK&DU_6*,+)A%=<Q5/?S00=Q;"NO*Y[7(*$[L*J#Q<P
M]#%]GJ8L90VO9@)78OMZ5+RB+S+55HG*V*QQ\5N\ZAYT?K+-):A<<5=_=412
M[@[G(_QD0=B"4(Q-W8+5"__: (S@P.$W4H'F>(^02U2%!B3W4+:@BU\C^@-,
MO^"V'C<E_?!Y2_>=<_3+A?QK:=XT-"#I;=_KV19M#U&+0=^_.9V50)OC^IDG
M![VB3^ LEBNN1_2&&0M-UHOI2Z0UU9.)+>($ &USI_:L+X6@]F"3/IS5MV0)
M_9UV5<%_'&/]L#^8J0$3Q!L@9;,.9PAU'DH+[*3UV*70[?N^]@;R-)]$J D:
M$AUFWJZC0"*KK.TH0*/*PE#\L+6P;^9+,^^/X4OR.XRN'SY^W5NVSS"5+0[N
M[_;2?4UM%\UY(6["6S3"S0)$,A6B?(NL]$8NW?>W]<.*PH7*O.%;=Q$YI?#:
MZ;4J,=:!\1^/Z>+>+Q  WZR221K<TGOXGR7#+^M,RL8CA'^![(NW"]_=*Q2:
M%&J_<>,;6Y!4A[IHPPX!\)#8JJ?>/A "?S/H([ZBA\6,RJNMX&#,WX"^=C9F
M%K@.GFOO#H]/[[W#KQN=9B8Z;9AN,%W ]YL]D*$:*0:S7&60L#%^%X0YV<M9
MO5;K;=.EH^%VP<;RM8QT+WA!&]Q#!OM#IMK4/?R),@$,_#?*9UFI?5QGHE>-
MA3%$+HB184GK&^1H]5]CXJ?RM"&"EC8'Q4;SKL\B/P.U>%P< \Q=ZV9?9-B\
MU;(H%;@J6_\\P7G&B$W-3ABKEHQ<P8H'<4@^VKA ]7$G#_C,='?P1V#BT28K
MTK0JN=I;36M50*RK<%X*U,J.I,B<H#M.0:.F(KJTQYPX' X<34CG++V"+.\_
M-'[V,QTM(%3GHL1-P1C4<UXZ5W44PK4J/N(Q??ZV(\!G^%R['9VW*/3FZ$N@
M919>+,9YS:B!]JHH:\;GB#G_Z,I+E^WCZ!HC98U[V3\MIU:2U/_L^6"D<529
M'\B5M3;Q_<?5GBT@XWVE4_49H17#NWZ^A]>F BR&^J!<ECF(IFWIO ',.M5J
MFY'+%QH=W</TJC>:/P4^-=@W4IQ:1A3,"2_T@#37X5WT%5'32FP/,W7B;]$?
M3P'_4&/PF>A\9ISZF<<;W+\)LW?Y'CZIN(WFJ#M-J;#1QSL^/F&BB1*'V)JP
MT!4<:57!]@E$[21T/"'=M%Y^2O0@IT>A9O[;U[*<V^\!\Z!_7 J;R6:Q$<B*
ME5I_EU"#1,?;&$4]%3U3(5="_.#7LCP4D9F8BYJ#P<\HI]Y5+/F;N;J89"C&
MA>:Z.B/95&8E"T ,- @5:Q$+)?%WT8;--)H&%VEO)%_5^6@>(W);7\X7Q'9V
MDO3NG;6>C@7IC;M1SWWT% N9J[G,LVP:X$A>T1W;IOE;3ZVCQ71%/>G'&4NW
M*LFW6*]3"]U[C@SPP@X@56<B=BB'/LQE!,=^GQYW9IIK.CZ$U)(UNFMU6^8-
MS*"::E)LAA2>Z[=\<[!0>--RQ#,9,S>\,$<_--!4XMC0:#_CK$H U%K,&37>
MYGDUWS6%<K*AX@L9='HI7I),]3:"-+C#:>MQW/.4LZ;\<!^F]M=(JV/.])3C
M8I>-F65HY!ZW)H=/QR-Y^6?,">0E!4)W/4:+6"Y/*GH;8P;TC!*WFAM:TVVA
M-7<F[L=??IRG*<?65*<=R6I_,X3ZQ3/-M*2OZ?J<3>"HP)"W\^E2(GC;\BH&
M3 F$@6,6RR!Q+NJ#UA>-5O-VA@\U8AF/\6HR&8%]38+^^Z+6VD26\ETI"BV_
MEZB1&X&:J_.^<C$]8$44166*#C9H6%]84'!Y7>JVKJ)P1M^)Y [MZ$>5=:D\
ML:I(]U\O+NG27/TYIJPFV$LBP1M"!BOS4@23G(M,VM7)?[36-0.\L+!F?VJ!
MY% HNJ;YG'F>!0]SJMI-,CJJ&,2S50:#J/G$Z?"A$O+U'FXL>H*]^?J#5W4L
M5E_X/V]N[.;Y:39E,%PX<"S/M(GQP%96>_/N]1 Y-K /&&0#\0MNW).H))75
M:':H2L %-KC?$'[2/L(XI2,T.E&J5WRK+D/+^[JHHVW+<OIK9T1'YQ$!8*SN
MPNG5HV=C&>:UV]SXZH7-KP3_1HZPK@F+E05?SGG.NQQV6S]YSL53PWLYV:83
M7,SKHAWIG*<( *^GC/8";\?)R&RN:P-H(#H)/.1%PI,.DHM$XV=@YG;4-N H
M[H9?_$S)(YZ'>>@E\+*V[]:CF[67(W,JCQ75$2P.!D($P%WOZ_Y4BZEMWQ:-
M>"'UD&3VVAV@8,3<Q*H7V.AAQ[>.!J]ZEYYVM&2]20 D][:R1FQO5WQ1D3P]
MYX\"0=6+72S2! "J?PA;M:]/$<K@H=BRVONZU%O>L.9KP8);VU0A7*BII;PR
M)#J$D]]SKJG1 ]8Y&$_7,_>MZFTC>9;K4O?/QAYGEL_2^=PJ;Z-'?]RH P@Z
MBG\40E$#;HGSK$O[$''[NFYA3?'ZLJE((D*'X^R!CGS4Q2BJ1RFIT3ED44)O
MR2X\F\IBO+^-'QU$G^LJ4]Z9-/;:RIT_4?&ZH\2]JMS&)2)G8QKA;A/E5&WC
M"O%L('G<.<^6=G2D)M&:9A \7)=71@ H2GGCY4P( "!ZD !($,\ZW7+-^N4X
M)_6YFX\'IA'$?Q)6N3 J8<4I&E66;(::& 3?.#T4\OIT;=HD7#]$HUK4E5OU
M[270*ADK'L!\M'=*JZH>] Q3GYU" '1;(PF /,T@T;8W0.(KLT!Q1E*3: CI
M-KH*7 ?:RTP59TH\DR@P>6GM4K33H'OE9V)#*.-[JM4;@<%@9RT"@/,7 3!9
M++.YY+\E157XO+':,D?TX)  </<$V\^\YJJ=# QL$UE'%W\?'SF7+N2Z0L5.
M$I!P0T]968^&M9[K>F)<3BR'*&=0YA8G/8O'$?76++ ]34SI%O5T!BFTMMJH
M]JRC2GQ-(*L=&(#$==3K/;8C #Z"KSFA!0H9N?"=DYKD(_7"=\^#](_FYT-V
MD?T!OJ>US>*"P&=U!TP*4[AWU:X&UY<7]<^8!JKM.!L?N 3-[K1 /VGIF#3S
M,)X:&POM:\AJJ*K'.W;SJ')3D<)?XN>3%A4S7H@\ <J:)K3[C &B+J:T6W8(
M/_@2^.2B%">_Z?OK/T\@P:CP[4&D5/ <A,'=RF+[C'PQ<Q0^=4@=%;9#>7K]
M+#LGI[/?-K=KQ$SWB(/[<%DD;BU:\4-W)INFJ'8]C?!M[<"XX"&A6A_[K;SP
M3"!W))[3IRQ 7:&DM_'G4V",@_B+9ZP94G=)[CZE??CM6G6SR)UFF?C GG]M
M40V_'N[ ;"\5_B@"TD$V Z%$&(YO]%3F2W:"NSY#ABINE"-A:I439S&^UABQ
M: 4,0UJ=_"#8]92< .@<"+IG^RM?7*Y%V[GB)?'38L[9LUF\!(@$3#L>X5IT
M5!CPV"@BMCDZGN+I66Q^" $P<_PAWV^;L\1PWL$OH3BGN+"LT"LWZ85AN$&\
MC\&*3_C+'/VNR8B;/6W1RM;<8ZUJSO?E+S-/_P@:#HZZQW*A5%W!?IE2(;E2
MUCF01D0IM);)@#XINBT^)[SDWBY]?%H)[7N?SC@!17J?/!;-V([MJ])(&8^
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M@<T%;E&='OFS$ "2U#)'NTNPN>E39P+ ]_:"V1F]-6R'>*! :P( QP0"(PO
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M+_OG@V"097:H,+#@R==0ZG"ZV#=%)30*@ O$0^^<-_R+>6Q+H\*,[BP9>1,
M''Q8OUW<Q4/8.98IE2BUXC)_*/I?5BS]907FC&0+?'HL0>0S20_P'_4S\P=W
M_=?Z"10"[GZ=:6O8_4T)1[N'U\8)@%](+UN\SR;Q_=_<7/F;FUGJ"8!#WM\/
M8EL*.K.369*M#'1>^BVZ1,FAS2>F8A8Y<KX_1GS_#VTS6VO\5VT[' 6WA9F>
M+<"(Y;9 M!I\RD0.KY[+.EW)_4W(6.(:V[7A^.!56Y<R)UE)1:@[&45DX]6#
MYXG7J./EZ;9L2!+XJVE%_9AT5^OK:EYL7.Y&,=S<-""/EWXQGGU7VS/7U\-G
MN <EO'/[/&B+C,GZ<XD7XV?YLCBUAPO=T!?\O=H#C,*4%]+H"AX5R,F3K^FI
MB^LN@O^D<IH%\!G]&O&T!$ ]4._?ZP=&$3Q2/B?S3V?TAWY4+!#U8X3O#_W8
MWOWW^A&TQ7=Z])N!_X/#_K8I+-#DWPH(G"CITHW$-&V$_B9G#%9\B0>V^P!"
M1*NL) P'QNR6_CMY)1:$-38/MC&-S/JGV3#ZG1 ]XL:;MLG$$^!Q1T20''I"
MB9T9$5 [1"8<R,+L[RPA81[)YV?PS_^TC3L!OT$6CH+A*(CU?$0 ++55$ #X
MZ$;8L98,SFEGR< =CR<:P60TT<ME&=6 _V3=XR"G\V9+[U/ZA9I&0)_TX:#:
M?0")G,"0^@%UU%,=VIHB@#Y *B^>-7%>4;Z8K)A;D?4T7I'U\[HBZY?/T_C?
M> 0>'PV)D^:MJ,<>F7861H'LBAL0 FGW]).\;FJU,YJONAG,SWBSI22Q_@X-
M ? [-A)F!,!S9!8N$*-6$(P[)(8$3@ 0:Q#1#,XV)1X\R[)6YE>/PI^J $Y:
M^A=1F'B&/V/RWW$A 'Z[*=!O9H$2DRO=8P/>B([Y1PK^NL_NO^X#Q;_S,\,'
M1@\2X<T$_(=%P?^V*/_IV9942;&;GKOED#_D"NK__[ZLG^!= EI#I@W!\4P=
MR@*+W(?^*Z(*XJ77Q,FV'')2%![L#90J7[_*@DB;GAO+C8??%>P4""5=?5;$
MLJJ@XU_ZB28W27,_DW/26N9!079,W&7/]K-+>=8 U2F)Z]D7Z74+G2VV=<6H
MWW]^44]]<+7D@;E'G-.FKR8546Z1AP%$<]KZ=5<&1V_TFZ=-YW S]>"QDIE_
M4/MAEHK,0=A_DBOF#+ E<WJ4#B0 GB'!.%]B;/RDK<$(=4P6/K)\@L@=?$'$
M]431^(\/.$(])H:5"7;^,P+_EL@TI'G$8IAV N-(JXE0W" 6T^8I4>M]91'@
M,X'&WVI)S)'I;[4L):HE+>[23%T' ?#(BTAIH7QGEXC6@)F(["P#XNI#YA[B
MAEF_:R-W70^W1N5+K(U^N S.C:@/_D1]* ?_EA<JTPFJ\Z\+?^HMT9+[J>$#
M;8A+1_V)QS -Q.(R8U+-, E2&\1*Y/(@WM7 $LP3!3YT()[C"S]X5,K_+S&X
M\+^(0>%_C<$_8^CY?QZ">0:V \=5$5LP"CTUX&UFLPKALK?8KDHW"YP!<:^]
MVEZ8]=L.*&=RX:-,2ZHNK9ZD\6CN[UT-9]?V+$FXN>/8PEWV@<>)^^N=SLG"
MT#2R<L><-$=U2GO#MSX;Y1FLEQ]W_:3J^"KD=W[70[>Y_,E&M)^ZYI&>X2BJ
M-6DX9Q:B&^-HXYC3;[TGU*1TE3_5.$%@=(@R2#[MD0Z7H\5G>M4" V'Q<)]O
M(G*7"%.G!  Q-3O@F" ,&CH#Q2ZU8$PQNT$[</\E*+;2<_=_+O_ON$P $*8G
M8 ['5]@+@K@]7;:Z#G?E=J/Z8/[!+?NIN/9YJ&WDTIQKU-R">Z$9:'G?T\#P
M'3,?@R+O1D7<2OACZR1G%42L5(&5@,JWWF\DC)1/9O+;IQGL&%]$#@X9AN]-
MJ.UE-JKVH<YAYN<A2&>8T2PTN6&/0;:TY3V,,GC.J/AX^K%5H^Y/U-JP-9=E
M7JY#&C+$2L(EG,>MOX]1'? QK]DJ"_OD5 ;;30"$@<]>+2@36;KQK<Q2#1C*
M7'H4AM<@=G.^3-S@43;1<QR"V/^-Y1+I8!O\NZJ!1,GU6=HCJK+B@CV8:%OV
M2+'':IC<F;8J8D$)R>RR$.E "72*A1(U+5>!Z/PG\41=EU;#[\-^+N$_-XS_
MHRFGPB"S=A4J \V)?&T'1BC\5H6$I5\8?Z)RRT?K$0#%1"GY$I"%6P%WP'#L
MSOG_F), =^=D$#&F9[_Y9Y1(DM%$9>" ;: Q,_@H1J+D:!'%Y*]'P_QY-.A_
M'HVH#EK@$?AN)>ZNF!F^D,@6K@=@3!0!<)W(8!D-R;\%" "&$3V"GY3_#M5Y
MKBS^@,@QEPN(+ =9,CL3<H/AU(B2LK)*[(T9\$P$P):$,]_OR0& V&7WX0^)
MG27P5#X,MTJTX62J!(",=QOLT&X-?)9%)-<>HM]#B)Y+$ #C7O-FOT=&%_"X
MS[C-H]TRF8,H*FPOD8]NI>.#=@/!FV-$)3B2(=K%&"+#MH).B&*5AZJ#_>[0
M+N&P[-BQG25]\-I=(":.Z/[^)UW_[>F:79@&W]_$V!H%?(3[@J*R;BQQ3 ?Z
MUS4RS]@%R:":'@3SI*'0;7.)M3JR),9O9I[/4G;ION>(?V%@P*I^E]\KDU/R
MJ2H;F<S'L]L3U8.LBHL+7=KJ"J##MR,59)LB"!,MO3!$H&S(5_0K;&B$EPN\
M*VI( ?^9,X_&@P[=C* _\_.RWZ_5ELWE^E28('GK.?Y]F0%]PGNSOYT$M?0?
MYQ?^SZB1R?RWH C$X+VFNPRG/V>>[SQW/G$Z->E(Z7Z]_TFF9RA+[=*JP%25
MN@;KU*W!:JW.*6%R^MF09WT__,="M.\(]#V5^7CTTTL18"2;M1F=5@N5^KB0
M(CG\LY]H', *D=^6:\2^1,8>VUCX:H;1*@A[&G5=]NA6S#/TH2MYQ-WS;@3"
M,')N?AK8*$%EY0FU[1E9RS!)0$@=9]&5_F+P=O&\L[D =T?<MMRIF83<KML^
M1KF\@EFMEKHVE31_M=]*X]!,,N$VN'J<:--H97MKX&E+4U71$<W*.%300>>Q
M47C:&V++K*HT$:8#;9#V/G^Q"+6'0N1=IDY'ZO89)%:^$ WIYANC)=(YK*6W
M%U^/N%>W+)^#IRDY[#KKDL^C4L&$&XHTK%G^%/6'.?HW'<QM6><00[OP1L@;
M!EJ>/;/L+6_375^9YB<<04P?W2#K&9QL!4JXY,CB[F?QBX<T L\1''8_$XVO
MR[#,OXVCX>9E>+D"[T!M!7/W]X=V2RF$;>UCI?RD9K_PJ6^(#/O[K 1I>E'*
MS\W+O\1$.TO@HZK3!4HRD\CG^RF7S)BTQIQ;0TB$E81?",>_V LE>7L9Z,N!
MI5UUMCDOV^Y7>VO"IS,WNRT;V^LY)/I]BU,43@F(%FL[J[3KB@C 2=&'6YES
M37S@W 99$-OZ^Y[I26,[E<#&2I_:,/YTNJ,8'OH=IE>B>9O'4J(V4^<-\$FH
ML]&3_%PD9U9<4Y.(E(EB45JLEI9+GZ/>)<GUBK27=6S/0*Q.#2VQ=SD@,:U<
MCR4&/#4#&#8YRRMG?,7VF8*;.=J LM*D%FM;)A;%72#&3@^JF 7ZN_;ZW+&Z
M?9>+N@>SL4MA3-J!LMI[Z!5\4-W#E-*FFABE'QET0%#AJWH&M5+[6B,M9YV
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M)J>$O1WUFFYC29>*;"RIS%SW;Z?P)$!"9@4_T#"^<0X>-H+CO_S)]$*\O03
MQS]"$/)YM*YS"<?K3?SIPKR8$1C][X( /?DS".#_"(+97R)7+9&/+:S&8AK$
ML?DM*RM\W_M1IW,+A;=KO1*9M7)$Y!F .AE#VCR\TN2MY9XO/#QN#$B\M8I[
MSW,JO<5J?U<HBCOM:3%:RI0#87]'J"%, _]Q4Q ="*LZNUTLP07Q9VC&OU!W
M8BZ88TBN:LQP$02C*8;EDYU0W*JZCH(:LI^R<Y,@;'HT) PI/T(,%?5)U!69
MAV4/^?JS=FU&%JA-+IPW"$[Z8QR]VU;FTV?LD</5" E:KMB3A?IM;Y S\EG&
M?,VZZ>?J-W1-EC>7V4/%MFU*WEFR*A;Q+S]['F#@0+Z<QXPFE39YI).:JFVT
ML,HXJE6G':DGPQMN0[L&ZFXMF$(81;#/98EZO=*K]#9[B@K<FEG 1U2+A%G\
M>'TJ ]ULP>8U)F#=N2(_$8W]P:*GX+U!+34IG@?JNH%]G[:LY1YQS67=SPH8
M/_(+N+KU$-FRZ&20)MT*I$C936M]<=A=PU@N,H&G/_<+L*I[VU];+O:Q6_C*
MQ$CCH5RAV61#C(D/#BJX/&RL<,A_$C;0,8+<7&244:D8+$):'G3X1D/SRI,9
M=&!4O5_LYA+FZ+A@(2//-%HH;?=>.IH30?*Y5?6)9]9Q[TQ/6U5@Q@&M.YII
MK*YAYEMF_*)$I659#-1KF.IGA'7C]=&7$9^,/,SM^!/I>=JJ4U+X2Z,9[$7/
M@$$<-RY$=9!(2ISM)7G9Z%0]'^CT\06"3-:KH*(->T8@#Q>^1.S$A0;OA(1J
M9\JNM-.;T5VO&[7K][D/^5&M4$]CNO/5Q-@G/B'<\:DWWC<RSW%@!YI*&D04
M:K>"J -\BG>,Y17?G+I\#UZ68EP TB?;/PAQ]:6<86)X;5?#([292<9Y1_55
MKNJL61"CW_M V>W#J<S2%>7LOD.-$\L1>1F0F@X#;<66=Y!,A4/;RV,3T==6
MU1/KU1#FH%_AE!OQG?+L@M:/CB?C>5UJZ0%?TW[U7'K1)L:+2*IJGTR$[L+3
MKTCWSV;1M5W3=O;UWRG&BY0UNV3OM J#S]30<8D2=V)72AU6BNDXWX5FH6M$
ML(82?(FA7U&--^7G[]H+V_-T[C'ZN8FQQ0L^6'A6J&[VP552AB_K:8_S[JOD
M+:D=Z6]+@5,'7EFN$X=4K@%)\=ROMN"I:3*'1F-:SCX2%\L=B^Q8"YR.A-*_
M1R#W9[ E/T:6=??K4QOPRZ>DK=)/78"1$EP_ESIY-A;3+3UWG3,2%])!7T5H
M/!E]7T%+^S70+0G#4 \ZT(]93,?P]^KUEVSJ+72UV<YQ-SZJ3/2RW".2SE%^
MO&YJMI&^\GOPU0+IH SQ-8SH<V=PS(+[VG7,J2"<@30/(S\Z"YD/]@&9#HV\
MM@R^-D<]ZY"1DTH1*$?6JVEUH""C3)_/G[J2V%\3Q6,5[P7N%;-<<NO:X\JS
MBB@UF*BU4@NU_ER1R6IOI7K80:=GU^IZWX:>JO'^,_:W:A ?5Z*ABQ3Q\=['
MBL]\$IO!W\MH!:N%+6R-;^T%2E"G/Z"7UMVU6T=^*RQ?!L>>''ZNDOU(GA''
MH!,*-P]1\<)>T  _( !*:,G5!IU2SL[_"V-!_F2LK<H_.Z/-%_]=?8>!YTA_
MJJB:.9*G.N$$OG^A.CW"S]GXCISYR5']U\1-@;EY<O+.:+O":#N3K1(Z4GD]
M(_C+>S?UWI)8L,5G@V]NCRV>Q,N'(CCO7"*7'%&,0DWPO)_SAXD^6V3ZQ>0%
M=$13Y%.'U=;<NKJ]R4^3*#1^LI&;1B;I+E]&,S8:MZU+2S+3A']5T8U"3,WI
M\T7!;GPFK9-@#W0.$/(T WI!35[X?+FRV;]<7:VF([DKI5(]-OZ@+E[PY:J#
MA7Z\)Z-XKKP ]"7PXYEGL\MSQ0<\=8:R-_=B6";T=#UI7FWM7&]</(U>WDV+
M;%N>E9"02"PR':@HI*'G;H#WZ,V\NI>?4Y@?-J2C/I3S:%P8FJCC!'#]6\.W
M^V?#5_*?#9_RR%\[H^)QIJXY\'U_4.69<GF0P#EGQ1(\O=E.)&DB=\!#M^>[
MI8.[V$.KO/!:GMBB\ C@M9K9/BX28)9'O%"X2-SZYY<T4CVE; ,OV^_,,RF<
ML62G0_=QGOL=!1"^-@G99KS\Z-&&EM/Y\"E")\7YJ.G7J:'3%?+$4H%;*WM-
M_1PU]$KU(=<_WI>/E_U&>VS?2*IQGMVNL\Q2<((Z;_&.9G?WG''W>C@*9W*O
M$A^I.I[>8R(AD81G5(N@@D:R^(7U;,R96]+8O@]0"]]6U+GQ7':;@O1#\%G-
M^ZM7\L+UWHTDC^0+I>PU-DKE_7Q6+EEMNILL5^IXGGZRU+3U*\Y*0FL]J!TN
MH5S=8E;NW6CFI;^$!08ZI2W%&I!'@C71\(&0(4OS\,\5WLKJNB\%JT=$I-/$
MR:LE>MB$-D-"(ZKQ<JL8A$*IZQ+@S!16ZTI= .&9T3:[EE^RI-]R(U;)T4U"
MGD)K8]/^LJ<&?[RAIZH !S3%!'73GNJ(IW#&5-Q*40Q,H:^P[.?CB\NX*SYH
MJV1Y+"U16XHW1)\Q-PP,,#[)_%YV2A]1,'NJ6)"4DTE7O5#C,/EM>H#[,#ZG
M3(?"8/F-F)9=RO69W:$9W"Y^Y_SF)K0/'Q/U<@GV39JAXC4R6&X#VP7O $87
M23@7DW 7:!C\Y/\X6U^7[M1#E^]"IQ<&9JZK&9X_G.WVV,=) T%:[A#'8B\8
M1@L[=) >Y+RTNUHWB@2OP.X550.7Q$JE1\?EZF4^:D\0 #[Y)31[/M,Q@V9#
MS.D[1G5#"#A,K:H8\@H<8L9DOD.^^/EG$9;9[!,U/U*IK-6M[]IR<:/_."5,
M6LXF9/1;_17UW@[5=@R,3-AN?\FLH P_7$^4"&6B1 2U\&-]/'[>Z=HIQB0J
MF,@>J-6R(>]*&JZ7'+.:[%"G]R=3LH?)FQ8Z<8>)7>%OW=\JLKNLT-L 4C]^
M??:9[$ 4\ECJ9K,(>Q<!\&Z*#A8'W4@_04V#$K<S&SK4=.;\P;<;?QEPJJQ)
M>3JYH<X?C*(=-%/)8Q/&Q:PI/1R%UND&WZW'%[5$JUVOB%?:CN3)SKU[?>SX
MT! 2#&F3.'2Q796^!O;V[@]W"NO:C<&ZK_8X\;*+0@75QXYLMOMVO\@_J 6-
M/(M*DAK*]$- ^C[QUZ5MYVA'I3IS&HLBH9@%N.J,B?F\4<<*7_N)5S+(!J)U
MH?9A]V%#>[^5;>\A8JMP#@MW\^E7*BSI[%!+*Y;+]WU?;J701S-I!H^S]+(R
MR)O,UF,?82F7'/Y8,3UJSQKSP??U(?M1FVP)Q*A.(JQ(),S]/#'+]]"$2GO5
M^YR>::6%WZ??SV5]7EABP?*+O&%-J#CWPN1K>Y.2I(R4L0&[M=H;4H.(YJR$
M0!]Q"'9ACS:;OQRNKR+O7VH9L1QZFYWW5\$P]_CRYN-]BZ3ZM45/ZFJR8;;W
MJ\N%:?16[S3M4L]S[LP4_,2^\H\6KX5^]_$KLT3_G#,;0)VZ[B3UCYR[(?60
MJW-FCS&9/UR2AVV]=IW(7YV3X6,.TJW#;4,WL;F KE%+5CU%+M9ZYJ8\#0Z[
M//*;+@1 ?&#8S$(82YWW;J=:!);=\^=J-&/#+'SI3A4$]&9Y+8FZ*%PRFI:?
MAEGIT]I['<];\OEQP=>O2B_J:[RU3NT_3SF<6%1DH(X?O]?16_B\8FX;_A7Z
M1A\U4>M/ #1ZN\P-/C^BB^II\,\Q/K[&I<8XKM5Z@FSC0N\?C>:_X*.WR[.^
M'@)ZHU W\[=IUM+?YJK2!,!?)VYG,OPU5C>DGP1(7G[/*RWAS!"S3QL;$;-/
M^O?18,=7>Z*.>8\1=:[N]U@+Z7AZZ>!A3+D$*TJU<;]VF=&G?E9*ILG P>^2
MB^[+.9.M27^@[\;:;5U=[>$JM<R1R58-1X[+*M7YB0H-*Q&&4_E^DWB^5"8I
MUR>A)M= -$+%)PII[\&IFP+;S"5E\(7[@KZ9J[LM)>OPC*B(6YF#)2%M/2 O
MWNV%V12#1ZYU'LC)V3)C_N2;8;$5A=QK*>]A?Q]-C?S':$KPGZ,IV%\:CUJ2
M_3 O;[Z!-GB'1YCJN>V)H Y,<';QV AX?7MKN'7N1$NA85^'_DNZMFUM8L+L
MO,&=Z,16!W2;0DVT6D/!S7;Z>,6\<6FK_:W>@GB;1TFCTXDG"G*8-69P<1O0
M(Q-Y>F$1VG$0S0N=<W]];ZAA8-%H),A%$QOSQM(+\<32JV"N6V_#K=-*H)I>
M-Y.>^8DL]*,6RB0R^Y0]/D]Q[>3S7B&E 7[H%>+$6N?#B$>EF87[+.)LL>Z4
M/#((T6>Q[3#MIR+)0BN@;95^'DU/S2539*;03HKUE:8T5KM>66$\/0^0W3I1
M /X*.%.V@9BM5-QI\S,[MI"6M=ZT/"EMDK;3<I&"0KVE08YK03*HOOTQ79<R
M>:_04"7)1&=C WWVO*^1:25IW@</$H^_[D*_'HBN# _T'_.NGZR=MWJW]2PP
M!>M,8G^Y>>"[MJ5'<W9>#1;06(NH6;;7']0;4*:G53S9SL_']EJ^+U RT!2C
MGU$L<Z8HNVF3P$]#P\TI)>=SM,5L-]$I,DI33@D0PKI'?Y9AAJQDMRFX&#/W
M+$!S?W%58!#HG2)(L+E3&S*0 )CR17=O?P+>I,@(GAEHVG==\78A!4H'A7#%
M1^<H+;J6O9UJ)U>[)J[0-M(+CC)BR/>GJL<_"F#K<FX[FT>U-"@OGUE6"C:3
MT]$RO!LB $@0*8O65D=&@IXBI!XKI=TB4/-2(<^X@9S.^;$3@=:/GU\:O'(#
M)U<:)BF:7QUQI&0X8\G/DO6BE0^(6S+9FLDP0P ?[GA3]4!7(7S^#2!W- [Z
M:4!;. A,AEN>I0\H$">GQ-:$;L[3?Q$;6#%UX%N>=9AW]OL!LKRSM)7U.34M
M8,W4+$<FR=M, V52.PI)]YCVLEG<PL4H-X3U!=;'P7$2C>[U]&4)CU<:7=87
M4J9+ MSC-!08JP._14*#K7]VL:7$JSY2K/@LBQ5OVO\$7#X^&J=\)'GBNW_J
M0>4"2I0!/J97+?_P;9<OTZ0P;4FB<-5T?-XG**_#B_WUJN# OJ4W"MV&ALY]
M*NBPA.^(>,TB($D4UB)*4AI6V^/:N;>W[@;S#G4$I&W!*Q'^E=5XU@"V!:$L
M)HD(1P\SNQ5./^_R$L&F(5SK/OT@&AY&&YG3JSV0\5UOV>O\5_B9%IM ;J=R
MT#*VA<ZXNU0HT;JH[X=X:>M860C*_"[EU7$NTP_X6A0!$)71U^+'Y^@)[B4
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M3IZ13"($0!3-8<^3DR*)F#QV%>*___-QM%N L@8.VX\ 7^27(MC[3[IH T<
MP!'  +T]/_K5DR1P* S%0!X >]#[NTU.;#%/&)AY0%.N&R:1$_= _PWOQ,G@
MRR2KF!&T+$C)G]O17OY*%6HS= Z7B7B_U$0#&53Y17C.[]2,+;G47IDJ+DJ
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MB^0N=!;.^Z4T67_\ON3]FM-0%56[RE8S[^#@W(V#:UU<8G4@(98[.:13WCS
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M192>4&Q+*]]U"^O2_K+6$;IT3]K/JWIIF!0OE,J'L5&#G@]6S<<Y.H+3 4>
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ML#D_SOLP-1U^^[E;H](9S.?P:[TUQTQ0286YD.!RRL8C^N<> FOC5]38ZW4
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M9I:1L0Z>4*IOAI+UTK@Z0BBNR/"7_OX9@!<"VQ7EG&:%Y?E7N<$[:_I[&I
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M3QMG]N%1K),97:@^/%#<VUGR!#P8O3TG8ZJ<\^T2ETU ?O>VHN)6'+:TNG;
MN0S&B?]N[.S;/*5G49+W$O5%XT:2Q WK&_?OWSY)C>R9\-.98!:I$*0*W27_
MO';0CK&Z2U]7/[Y4EY'[K2%Q);&0K308@MPTU/S[I@A3DS0(T2B9757TM>3-
MLRKW^W3A^N7]#MQ4_0M =D&+RBY-V,<+ /[J;,>FRG>5"7%J4(#GO[-3G];^
MA^Q4)0K"P;XAS_CWM4:9MQ4]7NTC4_CK&"".'FYYFP$0ED]X;.HHDS5BM(Q5
MQ YQ+B0_TS38:[^!9GWUYBXVP(%U*::MA8NHH9TOX5@O@GRO^X+3<EA?[;:G
M]^,#CI1]]9C;.2SS:+@43HX2T_1(H: M*4M0'#V<DOVE9_G5OAFW@=%:8R-+
MWL.;(GO#W'A#%[(/'!GH!E%>/DG\:9TV915Y?3>TO&VYPQ>HZMTUC0N%$!?R
M>P@Z?%#]1,I^S5&>,C=7>@&P_8C]GB*K3FS?).PP6>E^=J7R;WG[9^_>FO@M
MWWI\/+/T=P2^(4\XDJ6X+=K\+>Z;S!6!.P57:2=S7)!3^[5JD5[ZS1)(X*YV
M"TS?:=W/^@3#MO^MGE+ ;]CIB_D,=S/=82==RUIA&%\(=0G!4KW,B1G-6_NM
M5W>WU5[(%AT+3#]X(4BGQHM7X81&J"S%G K@, P5-3N,L4$<E5CK>#@9*1.@
M'\B"D!$4[- BC@SF)U_2C*OYX>^R78M-EW[@RUS*3"\&JOKF$1WO,X ".\E%
MKT5-<%WEVFRDMD&";E@>:Y>B/OSUY+AQ=PN=,D[+:G!0LB6V-S>%O^]SEI);
M2K#4^W8BE3>/]*GW!4:WQ7&6%,?7.%65;8@.UI<+[Q\R'U.S@HDYHOVVP%XU
M7:K)<'R2FMG;3WJ<5.CQT>YV$&$T7MZ:4H]@5.KH $%(.[.>[;^M2"*<4C7J
MZ'(<DY6V'_BL_ S3Q[<U]/3CD)ZO='.&NZ82CT_1,X6\$NU!D3B7\2?_7"J6
MGTG6Q:EY/^QA^X'2$!&B%]2C2>^GGIJ0._N4E[N]]3-N@E^NV]C#T"@Z6FW(
MZ4L;*\B*+T:7R$GN)HF,D'"40H'64P$H6=GR<<"C)4^!7Y0/0I9F91:+H-B*
ME=Q<BME8H"D+89*L<I8JUXNG:MKRJVS;:H0ZJ\!S";9[!\47@#GMR(.=\[\W
MKF$Z]U40Z L /4/&!2"$4& G]AV?6UEY5#-+4$I.E[?&-_I)6T5!G-^+<KBC
M5^O'8S>VWO,]RZ^(+NP5BOIF/L^XP@5Y%&-4!=37X6Z"U$0GT&L\R]S! OTB
MB&'G@_/'95*YMOX.E1+95"7M469E[;NVUY]::$BG-W09I(Q>S^#E,+=]J]1&
M&%Z>!3+$!ZZ3TYM;AEQ^XX)'JN>#_7\\!256=7LK/CH);SK,\ <Q^8.R+5EI
M_'>E [39=<8^7N8*<3858OL@PY558&H:0#<@\?3O"9:]S<8@K^KD3E?L ;#G
M;O+PE-?9Q'M">+4F""0-DJ\>;5[_: _GE6::DM 67MH2-J>W_S7%FZW[G>QX
M.MH68=_?*"6#N TAT5\ IG%6]D02<B0G/^L'U-:6^)G6QDGNS@$FH_5='X&P
MAD.1E-ZGS >S)ZD(FGEL/:_,W/O$\1$VUE7F<5]!9EGU,Y>*HG^)(.D@-;9"
MX@OGS^^7C(3?"@FY!1W<VF&H.EZ2@[*&#U BO: T&OXN1S8,)0613E"7O8$U
M>#/G=2_(.W1_\IQY%4J#I5U =NH*,_COD(VM81ZY^&%6Q>+U$[,]_E>+"&B;
MY9R-,3>&F:T$#D-H%521+0A:0Y'N)D_5VB4P>B/?<%=;)7)M0Z=2_CX0-+LB
MTNTNN R*"W8(/Y;\Z]/B=Y,)+C$.LZT:%N?OBI7E37%'/J3B)\H%67J_#^YJ
MV1=MZXC(@] .BJ?T]1K3P$MPTPC1K-B*[1QOV<F^11A/:\$OYNSY4DW:U&N%
MVJ+/;7BR/_4S^3Z\W=CQC*SRRK[>O.8[4$4J!=6AK#6_PVCCY:7O#,GJ68J^
M?@.'J_<QOZ:TB,!S?0"]DPE_N:/\/M5/9*#A.H_'N\UJ)2'W$T:QW-0E31/A
M]]+[XS)<S>7&E!!3@G(A1LE9U XCW9H@)E8TG6-=DUOH"_*:X]I]G(X)BR-6
M%UIEE.$04,6A#-4!H]1\GF3#%^]\4M\K_(]3XW9\_]O4N*VZ2&_&4Y]SSL\4
ME7/G6OL+P&(B(O+HZ4<R9<_X?$"\,W)7!EIZ?F2!#XFA"'2.)_\.V+P _-?#
M.D:=\-L7@$>J)1> 7>: ]?,]^61'95IW$U=E&HA()IN[K"M0?V_?S1$GGH##
M__#S/VYM<PV=[)!L2&_R<[J/,@%U-^3XW8_6=&0L:IB3U153T_>..;<I,!%U
M6#4J[64I/=!_2M+P@ZFLPH1IK5M98QA5T#H+((F X-IFE(G3(F&X4_U1>5Q.
MB:)[Y:^2@IZCOQYMLN?( '[=1C8) [7=R&;=RHE;$;6XD]$D)?1T'G/&PC'W
M=&ZH/W&$6!"F\:23._"N@_>U(3$-(5\V%>63,%U=_=UKIIBF3R\2Z)]/HJ!V
M[YWR-2*GC-SSF8[=5.Q/9HK+EWDR7_7>DU 4#7U*;QM7NIJ"AN6;;'PE"<*@
M@=41=E#8.2$/'4M:J,.?S<3A+"ZU-P*]Q2>UFXJJ]6)P."ZPD9EC_113:"U$
M-690];K!5&2(L)2QAD"EYKL'\-IS>8+9)FEBZRSQTQ;=].\3_3:*1V6A3^A6
M187-K^$ %;4UW_$#6>.2S\3@S;(])![SY]PQ99F6U,A=+1W?[OC[Z8*X >S8
M)XE_KKQ8-$:U[K&<!!3!D[LR>9RFN&5S=H6:Q\VX8M_0O@_):T/@_#B[,-8Q
MR V**RVL PA>*"DBYE1'N]MML[NZ'C'3TX4//L69I$*>GPO#VVSM77:#-3X8
MF.K'9_$>W91(O5LOLF%=.!YTGD(2(Y&46^;/"N1LH6:Z7EXT/[N\T=M#HB;6
M\1^((50J)4U*%]Z(<<J/5HJ_],72.9GZ]=,0SX=[@^--T<^39/_ZDC/>+G@>
M\?%[W8?B3//X36>F:OF9E7!%V?#R-H1Z*>QTN3P$[T>DS]5N5]QNAM>$^KO*
MKNH1YIB8V;ADIF:K6VDP?PJ:]8>#D$"E*YZ9G\]C4"):X!T]>\++OR\ ?"&=
M-\<[[P-#*UXQ!UL2&'[@@PDT#)6*'_G OP^:O69[AZZ9+Q:'%4D_4L]@9/)!
M\U0,E<4]BWG@Q_-B+8.[A,1M7IHIS5/F0(L9'UP^<IH)I-4,\'9=%=B=9-'=
M;:@+C1+4C,FTJ+^Q4NDV5HD2W>+)*3SVFZILNL[=__ YR!KSQJ$<4T#6Y#B\
M ,06+L//]\./2(G_?BQM$3GG'CDA?A+B-6]+-IB7O !\P"%5CKS'.P;YX:?Z
M/]<)7A< G?G! I+%^7/TI]I^,HI1)8&0,XS7?(W6D<SVHK=YQ!ZQ5(,R6F9@
MR$E-;14TR';OE7K15W4U] Y5_D<$,U!0R_\H7G@((M_'4#$QGEW*J!>EH(BH
M<E><.*,;AM?[GWFF=4\1FK&W34%H-8N8_J<F'G4?AWG=^@:/I'<D&W17Q^^]
M%?V>]C,\=Z\DS^,5!Q=<3MS>H6[?VPNUAOF47QG5!",_BVG:17A?1@H&CN"
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M2!^OVS0I0^0=HU9;Y(*,JB>ED:1^N=0)C^FVT.$.SXYY\2[1>ZAF4DV[23R
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M+#OY%96ET7B\@Q1DL7=_T3J,&M_?P9:=E?3Q-'U_<R!P[_1A;LNI1K3B841
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M57&[@D84&2;6.+CYN=J%<>UO$8]+2^#<K!EKJ_)ST).0UPF/?NZ8Y7\#$\;
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M6))! _EL ),TJ/."&5I:]:[;7E\X" 2"6)4:4 ^61]9:)'W!7+\#Q^9:L(5
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MC6@M,)Y0L_F8 I7"NRRAVFBR#XG!"]?O[S=M6.'-N6(![K"1DEW.85H!K8M
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MB_#Q&,]+EJ.\SE -N_?M+![SQLO6RSK_S-8 "^"N%R_$ A0R#D<N^@]B*L+
MN^#LN_;"57#F-!O9[:,G$7;:B2_&6AG?6CQY$"M?A<^NF +8AN*&?$=E)/S
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MDR!6[B.[;A%D-'S_B9X^\@_UT[;U T,J8H*8L,H*,3IO3/GI#@H+L(!CPF?
M^^4&#D=X*S,E*U,?PJ4Q6GE]&S<4)P>0-3 O"(8$/C]7I#!WJ( --C42KF9L
MU%<_'CU'+H+Y1B/>#7E-ML7B$-0C0TMG%2IIXY__T4XYM05"@WA.UZUZYN50
MAN4[UZUV6( G[67H,DSPIRI%6W(2%I#BZ_P<FM@D!G9!?._-G>J96YEWM8@*
M>-$D9%=<3$:.][BWC?$J[@9T!^<\P?OKA]C)!J_)*63CB[E1K7UAR SFPIW8
MUTS+J2IZ;LTM(^'B=C'3'>%#G^]+3'V([LB ^_1D_[AG1<+N9^SJE,$;*IH\
M&O9C4S.B)Z >U#?3].3&XRR%6"+]BN>4_7*=)[^D>?O/'CV(MJ[J%UCMQN"R
MDC42@<P>7+J<YSO,1Y?.HNUO(.QNU>A5PP/$17+7)!W<%7I>?H@Q_H* \.;2
M]^LAP@="B;1I&L"_65./.-^%9A167)R'7_4C#NI?+2?-/CJD17;+-7G)-7\^
MT6=,/+!IW*VH20,VGC0F%; M1,>S596&]_;3T,?+!,%I"#/J"W[&0'TCDV&M
MF3N&X1/VQ;MF(7<=B$#2&8@" ('^O'.7;O9:Z7V!7=9121^NT65:S94KG*/%
M8B4JWP[!:1%C)<:>%[]88+(RNE/JW!^T='R:[J&R*4[BQ9NK<Y9T@-0)="3N
M9S3*'"&]%T4S_3&A#4)>IAOA17RU3_>>Z ZE6[K12VU.$";?:S)_<,S7<7K3
MU/H#IC"I"]F>+6TM/TJ!;M"-87S-[OW;<!U/@/0;IO#(+MQX(<]A&(G(\G]M
MV1ZU_DNB+_=G]%9(COYG0N+[KT6R((&/!=Q*+/"J?Q*(-CSZ^TJ];Z1G'.8@
M.P>S5QR8_&SP9BD:"Y#UKB4.NA)&I&S4=Y<U9K?;9T09IMB"X#-PHT 6NUP/
M_0W^V"_4NJQ%NZ>O=.24\-T(&W8BO/3R/@Z^2ABA_HPPY&O;:W;@!<(DUFB2
M+H[QSPMB>I\\ >;'2*D1Q6K&35'FU>3>TXJLR?!,R3 5@EUTVF_=]_A0[_US
MF\5ZY=G/Q1ZS"3R;]KC.F7SZ$,?=9K-**,N^]U&]384.'9U97UW'7C+GT!L;
MB>&"_,=:>NYQND(&"I]/GLH-LT)5F35S=31%J1(NJB2'BC=^K9Y'^M+EWW31
MV)_?78?"N5?]Q;>BMD9\[I$>UF(!2K>3VM K/@'U1WB+OKRFCAX+&/VK^3-E
M>,&\C!_W=!#!%"J=W)+U=Z@_H/DA4;['6$ 0Y^7J':>9UC-<JI8 I_/6I5_9
MLSS'RRI.O:Q[O1!:X$X3SJ1=K!%!Z?2]^>N:C;V=&<CF:LHRV6C-!>7;]NN]
M OZM:U<*C*_[[=)]\,Y&@B?CD11I*M#N<VB/5&0W'0)"+<OWNRQ*X)?3$>32
M.2-"!'!;#_%C1IT*7$>WHJSR2T.*'!($$K*/E)A53["<[EV[54&2T.D@I+]#
M1Q6)]6&5+; L);+41Z*Q3'+['56I5<];MRN>"YH&!5_.Y. W$PKL770'8!_P
MVJ"$\*[P@2J27248@W#+2TEWA5Y:IMN?W:!FX<0^S$9&=HFGN;.7/L#Y]")P
M"Y4W+ 9MP\G[U:\)) F*:'J-!201]L'T$3%&'[]_DEI,4)?"P^'_&D'29G85
MY^,TU>66X+-/!T0>N]7.&@<W8"C:O8UNL^V-//?.N#^Y8==P,ND6J7:F-C^#
M!6RN&N[1TEU/?ACW:6NR\S+K1*<YV5D-Z<J$%V%XJYAK"G_#.O#+GKJD;;YD
M@4[<>.O:J6V+(VX70UN=A"3-C/$Z'UGSJ/6D&>;4T0TZCSY;#*".]2]O#WN"
M+DPMCY$BR;J@/X4);K>/(/17:B8..^APWG9Q3;^KXHN6U/IYMX6$^%Z0CB2X
M%+[&7.M@7:*M'/ZLO#2EOEN+MOSP,ER'UJ25 <6!?[*27R9*$-]6O2$F0.9-
M[C&AIZ06#HLO"(DH!FT6[N=\,Q0:F,@AY=4 R=?VSBYK(+_3W5^#EZV%.D[Y
M%+_9;5:KR!ZFUN%13[5":"\WNO6!200%;=4_M^U*AGX@R9HE1_9Y$O8\#WG*
MEJ,526!VY19X&/^X6M9$4WOB-Q>16(^7QEF13U!HWG4\YZ<]!=[*\XCV"'_%
M[+:9W-U)&U/=M/UGK\9+1A_A?V7"L7<YOR#_3\.A'OP/:)S]M[DVEO3/*-)V
M]B\Z!TE<$I;LK5M*VR?_?SYZ)O(;& '=FL4X_T_('OVO,%2S.T9O$%%B#X[&
M+6$^RI:UN39#=7B4T#C&L:_7@U/?=I119LFG:*>#F_CCJCQO/$1*HS+<)UN)
MW5=4)\\D]5!YBFBY\+4]1&:9*7RZ(]W(=FO& #URJ^<1X&V'_=D)JJ.ET1(3
MSPYQ.@V2#OO]ZP-%W$45'<%\F9C:E"W 45GH:YU+N,<])$G;CQ<[.3#\[E2'
MA,((C8!U,Z]O)CE2&WI:%#\'^QS3#WOE;BUGK\FM;ROTYL&TH8:N3W>.3XY@
M$"Q V)AD&LYZ[#R+G@(/3_SI/W4]-KW\9H8%J-#L8 %3;<??]]='GZ=4*;V(
MC>:E'6!^'#Y0XV>J01'>5X&7 7H"?Z[]*R:A(_H^$S0D'> O\R#OKNUD"6;;
M.GS^C8N"H);QP/=OB@&J]([#<IHFP#1*,X_(]5?O#E[(VXA.<?3G]6'4:G$4
M<+B^,45E7WO#[GUX91617Y6*BPHKK$K?>C;SJZ7G6N_8+P":Y-NA681P/F;]
MRG+C)/@G/^E =64+YYG\E2/I*Y(C!G_;,$?6R>"#1N:K,3KE2I_W^BS&=RA!
MI[INT6_EWZ.D!@?>T!O57Z+6J]STB;*J*W\"FN.HF+]J?G%^W].Q<W!DE[YN
M0[F^A39Z"?;4H]7./SD]L*=KK#5VOVG6^J;1J$=]5^[D(#]R1X'=)&9=?"1Q
M4KMU_\&$^,NO$WZ 59)N].F#&;R\)!3[M?3+#Q<:A+_G]<'>4]EZA*_)D9HK
MJT0&,0F!+EI^?#X1KY,=)=*T^^'R)(5?[ AV1!/HI"->KYT<A"J=)NF^0]S(
MW!\99+-)/\?MLQN)4.$A;I>RN$YY&'$/HIQFO9Z@O9SB0 55]N;1J4E9.%FX
M0.Z.2MHJ\G#K9M]VS<TRB 5)WAT1/"@X);F[=3#[G.FJ?2?H/?"1VQ>SR;SL
M%FF;&2Y[UV0>\$'O.5(&.,3@1Y^1@&[$1&U?L3<WJ_[!L OY2NKVUY=BPH2
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M/AUL%O^(Y3COF9Y+QP&FC'(:]R)1;DV-C3"XW<J1 1NLJE<E:/ZB9/=<AIL
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MX".;*0HB*ODBHI#E*%2=P?RU13F&WQCO--?.K=G70Q95\LNRV!E1VR'(O5B
MG)P"@T*>!KU+:^6W"E7@<*@1Y$O)E8M4-%U?OO%'UMT#GJOU+=\>(\X7 \X3
M&:\I,2^J;N3@]X#Z0?_,A8"-(O*;B>0[T%16;,#QMN/HC>HR;<#YV8&3%?\R
MFRAHQQ=K)TX#R2Q<6G[C/6AUSCVUZ#,+/E09_;Y @@R 0H/F[P$N/Q?GRVU>
M!M>)_8P*[F A6^Z>G!G5$1!XP]Z2:A[%E,;DZ3QTL/NJ]CD%P6GAV,?)GKH<
M*^8$O%3FU/?V6-MLCHU*IVJA7GF8T.Z^2G_(@D^R ^03=OO3EB64<*K^U,>'
M,&9P5"VZ2R6V1WTXOBHIZAU#7,%2)F[LAMT&>ZF<Z?=;ZTGCLK8ZH-&<L<]L
M\S(W^D@/XS>.:L:T'_0N>,1JKYLC)>BP9!(,,J$'T)4[>OG)M1WVG+Y"U79#
MPR=O@MG2G""+H-S/8=V60>P2_!MB?N].<R=8K6PBUS\)*8 %Q9Y[_?3=-W2G
M\BU:%HN?10H!SVO@-NM=VG)!\0<N[F)N8:@,/[F,0HX42._B=6TM?I^C24E!
M[Z^CS5KG46F7*1-P0>Q&) -_RWIQ2Z"_KS6F?$2J'+;$X7/&8PKE3.36>H"D
M'(+WTR1=(I$(JEI;./''Z<UD_!^[0R:HOE;0MQ+>069F*MLR0[B'753JAD$>
MU4B2>$9]T;'WE?=9\5HH.I_Y+5#["'H5N-6NI"IA[0T^@/8<W.:@Q,0B?A_:
ME"V@(MO?NC>#(<.UQW-+Z07S!HY :_X5[*&CAGJC:E7C2>H.?=8#*4$CF42^
MV^:OVN6EP1CCHBFM&\MYXY*(W<\MY%[0RJX0XNF+%!"^IQ--,L1#E0%JO>N#
M7WW.S.'Y/H].X=L!.SL5C8DI5<J-OV9N%8,<D(/F4QQ3GOU[&Q7OA&<K!'2O
MV4[632C.]N(9357C?O@*<2'C/+@(%:IR5C[31',G^GDT7Y/?BF.BVDL.I!9\
M)*".;*Z@[3?7$DZ0*_^V@Y]1:[W:!ZC4L$'(><CAGALU56-C%7U4N6'+HKM
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MX+X:7@ /WON<YW9:'/!4>^Q!.0?M:T%)2].1;WE%LABB>10*OT&8"/LM$+A
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M,"4M<5;CMY]Z,]IQT'1==V=PEGQW1?CU,*GUGY)P+(/^8RCP^=V$U?X/?TS
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M(O+DG+P=I"";55A&F]BP.'OLW1"%VRD@U +MIY"V!['3O?8H5;.*S'][OU=
M>,1C-BV\BXKP9$/@[1W /CN2/8\OX&U+5*R:U?'9XM")X.Q2"K:[VPJJ+W[K
MRQ$H_O+4RVMZV95WTZX'" YK?4AC&C=MF#JRH-MX6!GK/8=#TA(&&IT6MG2L
MNMA;087*C\C(J T=MJ!X-K-JK/"A@EW'9WK(M%?\@02BZOL"0+U\W2DJI2.1
M9;VX>SRHBWBG9'#[#_G1@N"^JW"(</$QMY;57$EY)&+@J53@<Z5OD_+,SX@
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M7O]20%J58WXK6$# ;F$J+#&MBR9FO?>F_Q6T"<V%@Q9S/0^B^/G^6CA3.F*
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M="I)M*K_'KE;SKW[0#MFSD@2^+TNCM7S\ K0+G.:1%\ [:AK*<1K^8L^C^I
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M$\L9HODQ0JQ97P!/+0DGOS:'F-6Y)0"QPX7VM "VQ)=*-YE7FOT[)0]&8Q^
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MJI(EA'9N#'[VZE180JYQ5FT_@:<>OC\^AXA-?-^R6H6D<QL&O]89O9B0D*+
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M5]\/*#+BF/]7/?7O?P:LXEO ?^GX^)=;@.HU\!8@;5$1>B*^\'>UU]G^?[>
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MP0Q:O =(#1ZRR:M/.P$.4*AM/RG!A([R(84)7XR"RK;/@RQB244)O*Z@COP
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M%4QQ++S2"#:57WQ\-YH]PJ;'6-S]S?+J]$=SD;O?'W)8*RT?O*OM8_&NS-%
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MQ.+$=DN=./CFD/3/GT>DLGY%TJ0*)%?%4"N+^U5VU:=(:O:RQ"#;:14M?E<
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M7N:UA4O  REQ-&&!WG1:JBY(K8Z[H@WGK2)\C_1W-P*^P9[\I@"_A%:Q]#N
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M4VP=J]6R 5^DM/X6+Q5%]E/&6((A+:A6IR&INQ/$+AW.._4#T-#:1A9#_*1
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MOHVY(*Y+'\%#!1J)J=8?GZ>0<EM*2C2A<.RGS99MG;<T*^?Y'B,Y3IMIL_M
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MD5^P#]EAH_GSZ]S/W6VM<5@@<QR)B?%'+2VIZ\]]CK0T=A(CG*TG__YFO(^
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M?Z/F9+,/.C _EST*=GD^S66SD$VZ+U$Q?YU)=\0&7G_$MADX]TW< 4Q$V^\
M=V-3[E50140C8R\H6DBQ$"'&/9/4EG(BAGCG15'B26)H_LPT,0-_C-P'Z+<^
M.&5;G)?;0UW_=9<>')Y%00?Y;<1@$544EWDO+^;DS"R&"[E0P&7+MO]^S(]2
M%WW>M(G:.RA=ZG@M-.0!2>[M.13T#1M;XC>6.]<S^([6""&F<6\_F;=3$A6,
MLBHOSZHHD61[WGNJRJ2M)O]@A1D:<14^60QNT(6@'=G:[K6\0X)J;(J6C^\
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M^%,%4\-!':9U\%KVHJDH9%+&S1?5A%U@CVN&__)KR:X[/E7?;^(#\]$XCC;
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MAMOA_J'^^=Z=W'9"0%>+]P5LB+C5*5*B"NV-_:N__TM 0JX-_2\&SV:G%^\
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M7[3N@-=M[,G:VSYT SVUH8:UIT\$??G!RRH#BZ?0EW#W:JZ,\G1[6SAU;])
M)XE6A?725\:;NO&B+R:,JIBVY;A)-&.NH=9A>!55OJ&!^MFT?9H/E$XLZQV?
M;2L](24?](EDUOYC;> =;&,49AY'I*OG4W_%G[2_W-1K(319R[+-)?07/,9T
M)D:RT_Z4%I0MSC6QO$K"?7X\1!S[XTB\9@V)B'GCYMN^ A4V0MC0R66&[%0]
M+[Z-B]QZ"&YH:^>2J/B\H13Z!-7/=N]WSCE933NCCT/!WM*5KNH$$E=@I]%J
M.XN"&"]T@.V]P@XMV )L:>GQ\+GX2S2-Y^B(6#*5?RLF_T'P(7:XS^S=4L,\
M>:OQ([[5DNBL")!D:YW65&*L#.SE>]O?4>I:>H\ A#[FC0$4[+_C5HT=OGSW
MBM.\N28= KO0QSY-_QJ3/5J$3;YL.]ZCG<Q4CJW8Q8]3US>>@1)45N89*0C7
M34TY&FG5*=/6)7O1Q0W0+<;[?@/MG]]T_;L)7OX7K*[\O[#*\)_.O,84AE6X
MZ4$)EF^PW(RIM&)QQ%5-[*"JC896&AO2TFI%/*D"5KGE BR7'.OQ](!RDTJ_
MK-TCPT*QGCTT05:P85H$8=DSU54[OU_Q5!TY?OPH7&_<P..)!'?_Y^4\9OBY
MM;UN>9&A=-D']FL*J8_8*8ZWB8AD&A^<[O>*$E[E%GE60^:N@+H,]F;6;Q;T
MKLD1Q:1L;;EM2 MSS)LJ<_ K"?_V##AQ[4G]>5)BV!^>"552VCA#89*).BR]
MM.CS7-(_/W221 /:1/*PM1Q348JW'*$3]:::*F)U,=)8]KZC^T8RTZ/^>>'O
M784R7O"M5U3 ]JA1=$)4=K*M7$*/LR'H%Z6%$9BRQEK##E(1>GJCEOC"-]XE
MY^K2O$H6[K=9':G^_U:!6(CYESR1PU9NW6)7X/FF_T.?W&)'38?%_IM[4G3&
M7IFTG7N*':)OV_Y'F2.=IO(J\"2#^7BMI>Z\[6I^8I/3.'=<BWP_=#'IJ;:\
M9%+7!4F:H%RQ-#&[B$_3@FX26#\]7?0]_\!A2\C;?<,M,7?ZHN-ZPR5#AD%]
M';V9#^1+R/ OO[_8JJNQ2KAW%0AE=J](_#*I6LUY^,WN@<'8NU<>3P^J(CJ
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M?2F%M8T(-%8HZN?ZR!]Q>[L+XA9D3ORJ.&6_F H)BW&$12WL,017*FM])R;
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MJ!M+Q;:Z/0+CM:Q9PS@U")+[*]VC@R"M7U%+2X6%^SY15G'*1')Y<B;\$[M
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M?/%%$I<9H^<=KD0-335WXQ/Y4.1M0E6,[AT@&WFB>@?PJHKYR_LF\Z:H@CN
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M'88\P[F0WX4C*U["9Z9G3?9%B*<W+D&LK"RGB2O7M0ZS-MF<<QM'^JLU8VH
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MD7!SO%GL!/-&0DL3BV[5#-6G[:-7_5H<19^*"P(Q]E+B]T0.U'O-4:B66!Q
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M8G.:F;'L#2+8OYGL0.AQTP]'':D@8M[@TD>&E'@?.\HRLB8>[^<'V ^#9G
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M.34T=K=BBSB,:IZB,6-]6&$"8=80;W]REG8#(OF5$,:E;_ ]M6]MRV'KX+&
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MX>?=.6"HP<_4'#PG6:'3V2LUO'E0!RL."+4)N-6NF%#-A8L0TU/5P)#'ESC
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M"\-#G[X,WF+^PMWDO_)AG<0,B@BNV+":-\/:L2'#5/+2>.H\']-N [VHS/$
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M'4Z$J_:VKRM9A(Z#NLV>/X\_4XPIB9EBE!INT4NM<<GTSOSAF)DH2Y,L^V=
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M;]/VQ=O;!'%T+_<,)'UGL0/<!9"S9JAH);SQ^R+QB%Y[QKC[ <KRF11M>T/
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M 9Z+&M>^LP1G:DX!@YP73MX:W!RG+?$ZL'@8T^_WP,OR=NM71';UNDJ'V-U
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M>*[P-1+2%%_ F=B,_1^I4/1+T8TLNJQ.@""N[?Y^A3L!C?D'$JG0W0 K/"#
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MUFDX@F5K%%0%#L4#4*IX &O[$=.5!QXP'[")Y@%=)Q!.KU4\0&$##R@Y/*/
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MKMXWNI*(E6=[<*!E2\D'^M]N)WV@&QQ]8RE!$=XGB;KST1U]%@[82JRM_;M
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MDM?_BJO@ZA-+M.)A Y40T8:78]8>!SYOR>?YP0;F!1\K$<@F1TLZ7K:][T%
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M0P5HAQ"/5Z(T53=-E*X[KIE&&;(IKUO)O>&^<\5F5=/RPN?DC2'J $Y@ J^
MCC#2'9;Y]!X,18VS?<L[>^.E-.&2[R5ZAQDH#D3$"Y4QPR/X;*#;/$ME1<M3
M>\U^1%!V%IJ 8^MB_D5+_31:0M(BE;&+<"7V"@F@*],Q8.OGO!_B[@5U'\Q
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M<N&?8# F1NI%HE*7UA>6W-#Q\9B[,VL-472(WV7*GQ*^>E]\ZMX3*3HN5,[
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M1 I53>7+I?'W.  UR-"H^+LA8U8RK^?0B-@%1"IA::<](FD48BUCZ:/6 D%
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MG\$$5,D847:B1(@C4[Z</8;G9"1 "S$%^W6YFP1HDOZS?05!GMA?!+7_/I,
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M:[V;RR,Z& :F%P88JNG!.1T+-Y]%Y=*G>>&O"E139C7HOLMT+3)^:A*H\_O
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M)U.&V&0)\D)"NSRCY^S/8/HJA6=)]X1W+]H.?:5XY^9GZ1.^^5QW(ZN%^1R
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M]N&/T0<H'Y8CQ>P"#S"CESEA7\RZ+K_^U?9W -L&GI!K!"-;5ZY0<FUF_7C
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M>EE51F 9=125JK:DAPNKRPN:R<D'-#(-:7UT(X=\G*-J>:VM8M_'E&X!Q]H
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M'1@B%_(1A,0"J"CEQ:YH7V9*/G]+>=#DEHT1F0X>,&<V+W.6;$:.!QQ?(_&
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M'Q/27*9+P&TNL$@#^]3<YP/S66LKR?0M3>(#@> ]FG2PD>>IRR=,@!<LWY>
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M'WPFT*51<3?10;<A0VLS3GG/Q./EU[OIBY6[B491/'+T<#1,1&_S3&^WQZR
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MR*DT\OJ)2JBQ;#*PGP01Q;3VI.J#EOYUO"'7UMQ"\77I9G71#/3A?]K$'W@
M]S)X+N*/F^*5N3.6CDP4#U!(&8PZC:ID;&)B=&YLS<,]C[ILH7ICYH$';,WX
MWDB92@IX9>S$*$ UEE]*S$+Q:C5)(?(A%>.BBFJ@2['T[L2BM/@:@8+J7*,4
M;9@I?#[:XM!;<N$<!==TV!]:<*@ JY*LSZ6!/&QS\D)A+J<: J\N6MJ^=@_?
M685RO8@MU(. OM_]3LI%,L)-FE<%BV2:F>@FZ@Z+G$P8*(^G+HQN^C79J9=]
M.S2EV[\I\.SIB+V]/1T"O596-S$PH;4<NFS"M63$ 56HVA2HV?;I^_C$(KS/
M<9PQ29T!#T #.QO=J=-)#4XCKW<7"CO00R"3J<EEF//>CE0:R=( 'N -UVC,
M#"'/_&-%5B\I12SX64M *U];9_"C#$(A>;^\KF/W9RZMQ*T@]99OJ"_7$;$+
M!@N]40'KU4:!3^DM"A=F?92V*N%\_$;JLCR>4B]H)&]ST#!*CLNRW*7KKBY'
MZ=77XP$4H:"@+,,:*CTF@G&[TG:#K_<>E%&'QHWQ-=!![:L4JH&T%A'5\T=&
MBFG;=ZN;JZH(7^J(,\=,B\3H4FG$#C#(D8N\E>G^<]3OY:%S@MWQU!UL/4LR
M0TLO=#HU-JV\K#PP*(MKV"RVC@7^BA\*&=PO)6%D22G*AI:7>D/O*2FSYN>K
M%%M@UNH_T\LV"1/:',/9\BK&80&>^Q\_P9SHOZ7T7:\[-,%IHW?IT I<_&JN
MHQ:8O3^DDHNS1=#^#U]5.!@6:^KGRNMC7$$.3/>]+<A"^L4#U;H-H046!%H4
MXR-/^E@]*NP18G*>:_E($>)D ZY%P_D7OS,BBW@C0"Q<4Y0L,"C_;\54QE^J
M)+'7WYJEW^PN; "KJF#7+VWK" R]-MR<22K+=L)-'N8BX@V<>JB*A3-(-COT
MM-=D(O=:AQ*?V1O*)T!=S]4R.I18P(X\&X?CL9(,?_^@K\N>/A*)S^Z0A=53
MFGUZOZJ!&%K1\&D+T%X1<*NM=FF.;T WQUA6#7+$-T]5;S^/%;)U:71CB_S(
MC48:B])8DI1".K4\9C0GK1]%L)(]FM03)^?90, 5*EM;$/4](:X)VAWUES^L
M?TUTV4]9L5Q].NE^]PZHJ-.3E4N94D\UT/P5Z<W3V"RBRZ8/7'+[<HJ2^M'B
MVO#J]?K!G"AFBM%HM=H[)%54^"E;-<RU7UCNI:1"#"5_%:2X3S"&[*L<X/?W
M9[<?7#Z6;V?\JU@I=I>,E"%[FL:@9%F\TLR\XI_W2VI7+VZ<X:TY,^S$V49S
MS#_MRQR1>,!&&^[H*<KF'?@\Y -XQ/'&D2PO9HN4MJW;747=7/*M&GPVY#G2
MAA^?-"L7[ZW&\JTH]E[!M-' DEEJZ;(+8B0\T!7=C%N9HYA\=;W DBL@$1#G
M#AP>;OSLV4AW?T64L'A.ETCHB9R@]50#)B6#S/Y.%:76SO%FC^AJ[,)L5TX*
M_:^[49OCV3&!&C!^)#;-$6AZL0>A/XY'PO6IVWQ4BRO/G7"T3YJZ)FC41D"C
MZZN_G;F?/F_*#)$(I!ZPOY]R3_ZU)E&3TT"7"L+(["(2V'(\B_KJE4DKDXRF
M[_^Y0)L;Z.Z263EH3N4)W!MIQZPOCBP=]%9F%W2N?DZ#W_Z>D#->]5Y'9_S;
M4J8\3V(=9QB4D/V5/\?6UE27[]=892+S1"&AYPGEI2!+F<%\TXVN*R&4$8N=
MY[6UAB;C]UFLI5C-*W)S#.ZJ:SUO'IM4_MI?/[-CVJ:D?K1/7VO-J]!+\U7"
M;(L3Q>F[BZUES[5*+]!(>7-)7ASMQ+5C<DY@G<@9T.H5/$EL2LQ8X>\ )K*S
M=$<*6_\Z?F<VOD;'J:RWNEJ7XH-6-^OK=VSVS)EB;YO0J7-!CS(!7RYHHFXB
MOUU2'^ Q,\V@5?@V!<OR7\4KLX]GX6:4H#+647T7]8LPB)1_[>5Z(!]L:==)
MS^A1V"P<QMA:GVA)KLV B!7W'_Z!,H X%&^C6(^>?5>)HK:RE]"WNAI#4*9Q
M?I$6. E8S=EA'6:H[G0F'JYK[:V NDMEF"!8..HA!R9S@2-L<I2-7/.$^I"R
M$K.ES6B5ZIC2S;K&*64#\MY(5[65B;)\D&LU;%S!OI/E?ETY3<,2QK-7.$#8
M1K^21GI\MUG(UE%WA=.7D?E7SQY8>B^0:L8 5Z'FK)#&4>GFW>1G;8KH43A6
M5-74,*RL'1@84FQ("['P^[M(JRA6!W^YLJ_NI>ZE^G+VPN_I.>JC:76([RY-
M^?2?59CI89B-E5>O+1JI\^P"Y&4#XY)7C<[MT[;DVK&-C17U*R_ZA)X*Y"X5
MM1047#+V\5R//)WJJN_KVNY_GJ=54O",A#7FO9VW9Q90]3#.TIE&;>_WKD;W
M'$5)Q&Q#:>MTN_;^7'WY9M%..IN$(]K^[+Z,1.VQD+;5W_ED'VX376LI>2%=
M?V*Z)Y/]?,$"I77T9L>M<*DVT'W%DOJG*LZ#<_1&,VF=]$:-/A!C#56'4[IK
MH# RQ_#=+OO"0P&NJ>39HP]<(="([7NCPYX8J /[M/Q#EBARLZ01B+=(G?M?
MOL_OY?7B#<&J?U).1[0K/Y*&&3DZ.PU7_4#YUG\/K#ASQBU@#7/X44&\;P-=
M,6_W#QNX&,K]81R02*K=]+BQ;LY:CXHE3AEK@JJGD+ -3WG3I]_Y(NFI%*>]
M@8&-EZ,>/FOU;(I0 0E5T+ZX<_>0UBK3GS,2(U_"Y+,]\2@^62EIYTQC72"%
M^CO[R;YJO1LAVI^>,9P1*N/8TGBV-!'DHFQV:'#U*M^^N.!A19I^%-'*8+Z?
MA.]RK=N:N^:<?QZ?N34L<WIQPBNTN\4.-$2;9@LT1$4$E1;%459786T[$'P\
M)J&EP6I6,5;%.X4J5?R'M=:6OE<B%XK-9QJ6[MHGIOUS[ZTA+*D\T&I0F_&*
M</E3T:VE0A4UH:>JU>[4#TI.?M.'GVH/'+U^+<;MWUS3D4WZ.*N6\=@C556B
MA#[]#=2,29Y@#NGS"@YJ%0>Y++F>VTN0NCM3LS/S2SNZ LL6C5+[:I2.:B\(
M4TWRY-19NUI"(I^-L@/8[\SK7\>0)L@<H]G;3BS_V7%@@SL[?84',![)K&]G
MR7KBL'A !-_%I<_-&<7"M@UH*1XP*G?#NABQ_<7=GWXE>$"6O3P>D$<+P0.P
M(F?[)2$WV2_FG__47SZJ.%N\L@>/S+3-Q6Q57&SOR)P\7L #KB-]S[#/&3G!
M&_-:X,V>[3;<\#5V^Q-.9A4\/-/Z?>?Z# ^@,3L^W<=8^3CB?)I&KN^*M.$!
MEIG7N+Z0@:P+3+S9)7]3!1Y0 PZX3 9'73 >>^YG-^$!_GA 3]+5M>]U"D,J
M'I!97H,'R!+OXP&S&VW@:N:C(IQ_ 14NW!F*!^PN+K86,J[@%*]0OIN\;8O@
MPX)_OE/^?WJ,5=@2'--5$*)%_\C=Q<9+@2V0O[5IPGJI/H/B.F%*5=B%*VSO
M3RVR[H1""=13XL!Q\,RGJ1Y@(*>V?C9.#<M\?A ]>W>&8/2J28NXH*/7K?3K
M:Z8[7'$EFA4%FFNC^JWP&>B1Q$Z!0*T8LD"79''!-[-&2.M^_V)U]TW(VJ%'
M_RJ$EB9*E8^.3PS&5Q05Z<7$"];DEO5C 'C ?Y][1)8VZ2$>P()SCKN^-X/=
MQPFV;6SJ_!\FO_CJ-(/QYL[2?U&UX7\U[P(&TO47*T&+!BU'U\HS%WG*DT;@
MW!I?58E&\?(::Q?3<@1<D[*F!+.PWRD_ZS%%N0ZE_Y%?'%N>F9M8S1TAJ>MQ
MU"[IVE1K.%L>O0K2:RR6=.PL>,[U=^F*\OQVC&X.0%MJ,0L1H_%U-P'4W1PY
MU0?40<$[GR:89*3N20;X4D;M<@('Z[%48HUNM) *&5AU++"Q^X%:HF&A4('W
M6IX/QVI!(@<3*")(7!D'DK]_T;/:RG?E/8(>/@W<&4[CG1F8V2UVE;AQ)"U%
MQ?,M9C7;GS,F0D:6A>^LK1DG:@2KS </6RU'0IE?J U"4:03]#*E4W=3-WX=
MBZYL;:U-Y.W V^O"2P ?<K^2 +0:OF1IQXU38:&'7C1H:&*OUYF;18V$/D\;
MZ*TU1YJW;G_&HDGDY*\&.*G;>QLO!NU'L0N3L]NV.=W39=QF[56GVA/O\Q\/
M:,_Q_;EBN5!-&UY_S>^!0;4K)@[HK^9UF,/OE'%4)GN40Q(+7+U]?/ZTET,#
MJ=Y4GY>,?UR/L9 GVI6U.&_X 9!\"[XI=4Q=PL1KD>_W- %Z@;LC"H&,1[1%
M[.SLQ6:^UD?$BLKJ*O^#O;<*BC/ZOD1)@@4)(4AP0I! (PGN%MR"=#<NP;5Q
MUP2"-=ZXNW3C[A#<O1MK)'CP0- @N?G-U,S<FO_<MUMU7^[KJ3H/9Y^]]EIK
M?[N^@[HE+.THKJZT\]8BT3'@$-7/H00<*-LGP/BTCA0UA A-_@]([/Z?2 3_
M3R0BN_]W3)V,F5ZR_!ZZ,!E2:S1$LR1*UO]).IZ8BBP[=BR+;<;/B*OQ6@-M
M'9J)HJ\.J"F32\J>[EWMJ2RN$&A>9R;YI*:UKD'ZS)>X'"L"8U<]AJAY#D ,
MH5*;A-+TVZ6Z)M>Q5U,YM^TKU $+*3YF!]>.1HAY1B9%/=F$\/ED"F0CV9TO
MEQ'9:J=+PS^H,NZN"(L] F@7SM\Y.V:WBFOW'+%N3$ .JEH/"2R$_1W"[6W+
MA[I42,"?F%4*5=3?8.YW-SM=J+</OYFJ_?XFJAKB(63J8E\>%! +D\0Y.V'[
MBV'P*:#G$?XO\R??_8N"QINK]ZO3TH]YCA27$1>?_VGC['W)VX-SDS_/_O/,
ML]G:('/5^L5BQ(>TRK@S-(Z<N#$*OIK;VQRGR]3^F&F],+O#W0)9O@S(UJT,
MJ1R940 :J7QD+:S(PH'M )5N=M1=7LV+"K7268:5&<<KJN;C,E@R92OK8EL:
MO8E_/@I_5KP=Y&M:8]2TL!R'A\HA^6"@(ZE5P],V) &GX'/X6;5/$6F4K )"
MQ!O;\]#3NK9G7P=ZM8M6BV?DY:V39M(9)G-=ZXH,U@=-;]<*Q_34LIT]^$@E
MH3-"\)-SPFE-XA\9)21BY:'D()C&^?;8Z6A,-O9@^>%Z++^0"$?*X81YHU-@
M=S$\;_QDZ8 ),<8P>(4BY+12(5'G<&_9MRO(FID%RKV*>=*WVFJP(H#.A(B%
MO_NB^HW8B?6SA=U\_A=F+#)\; "4E$J[.5#I.D,MP9-2O !H5BG*R6DA3R3Z
MRJ3.4MMF,&V#ASUM2TXZ1C_?;.?F+.(H(P=9=-IUF^INP9V)CY/XR(Q]-K9U
M6",>$!,<%HZ9=&O<6)E+'+X"CI)0X5>/38D5R]&NLH,K).7+0\H%;2&L E<2
ML2$EY]Z<G3'CTURK$TXGI?!^*X1;:X751N64(V;)$97(Z$-ONL,+_@*$7B%W
M7W3IM_>11K3\U:Q^<7:,LMN'(:_@6/JKT$9=?@,R)C)E*J2WC1 >:;L3P]U&
M$W-RAS%:]4JCL/K;U7+"V'#=ZT2&]$L%0FJ-O&"F&U*XUJEXSUF0'^J$H$DA
MT)-.TF7OO$4LX\2?2[">];<W;@VU%V^CS:]V,[VF8C#YZR<"K]UW87:Z/]B8
MEMJ6;G+ R<\ZJHU.[]=TV#+_E2W?\1)K9I/4$52SO0<3!)PP@E(Q,-(RC_(M
M<DD_*/6<S0.L?3=8,EQ;]0MQX4@<&VT>U&%*W!!7$E,:DK8_M7S867'BJCX5
MIG;U:RVR]N2FJN?FZ)\;ARG=7G!N!'Z\(%_M,_-\I':QL*FEX+#$IB>3;V>O
MM=17=>1) 0"H+%,"ZCEF.4AK &&>5@*M3+]/:-5U'%'+1N6R+(NG>EG[QIMH
M75_0<6PIKX4;.JJJF9P1)ZK$Y+1E 9PT"A[ E%JD9'K]QO!K;M-*W,2=H+CK
MY%[K^<ZVP,L5<B^;14 <GK26(@9>O,2L2*(X[*IP)5;_6C)9L/(TT0ER56:1
M-L*>!Y*:GWN;PB%%Y@FF%Z #O^$^.;D[F!AKO.JD(Q'.'$9I>N$H6@/8]CUQ
MS-4YO"MP( Y'78Z=\[3%[V)3R2(*,Q ^],H*F%S]OYX42E[)2OSCPZF&PK\8
M,S&HW(?,N_&I_UGJ](XO7IN<UCY>_&/-?Z[62J8D_'[ (_</KI/YXV6S^-U_
M$70/_T/0'9K\+T%W?<<CSO\70]S(^C&8>OTO1NV4>9#ZQ;MQ.ABL_7U#EZ2'
ME8P_7H1]4ZJY8^?8 G6XYV67=DZ&-UN]'SD@9U*M7"XK/P>,**JH'-11ES8@
M /-5$LR4AZTI,N7Q9$N8"]^YS)U)>^&*0.:,G/N#%996U;?=IJV71._RVK6#
M:>CVCB"_L5$IPG O\MD>L^:NU\\[N9/?/X?W.C87+<OP&H54A+$$E\"HVKSM
MV:Q2\$)3*"GQVHGGNWF;%DQVFC[-WBS,B@)%6YKH@!77@I --UJ_Q^1F[/$5
M;)MF>9%N?MAQ5MAZ:=6J;ELD]RU'* M7)B-8FK%W+A2FYOO^B?,$^TM"VPR=
MJZ#4\HA33$OR^0\#[BFD2(7<S6+U]&)?U3V>==KK3T?]CFHSRYV9+=Q^03YF
M7H\XU>>D?H/B(=!541_;(K3'C.G9'4M85UVFHR4;X["F%AB,U.Q)D"TC]F&,
MSC?[BV$ALZ.P5?'S^"]&)'6YY)W@U2FR[SYH^"]&9E'W?^[AT?XQ,/S]_WL"
ML-WM9F26-KS^D<.A,K*-K2D0WVM3U+[)K94 6Z%1I(0@5.*U\X9(+P&7EF+L
M%8,M#S^%\O 64[!^^DT3S*5OW5A__3;58V>DB39G\X05PJ1C,Y/&SM<6G$'P
MBO?*(TK2)]?I=BJ+R^?UG]JQ9L'>^>5C2VZN6DJ8+A0[O^=ST=>?(C@">_X>
MGKQMHO;B!EGC ^%3$..RDO[MH): ;T@/E)!,=YAV1D:Q)SS8YR>V?-9HV;@Y
M24DYB9-9\Q_6U;\89VCSH)]+!T'_E'*/R:'M5/?%R'K0?V,UW<;'VL"3OQAS
MSUK^\1SO=/WC^*G2/WCHP/Y)1>H:R3ORJP] 2U']3(C69_GWQ<5CY@*.ZE6_
MT(__8H4Z=^H0&!B'_JRCMJ>'T<:W% <K<U0: 4 C<LP6H$8>61@BP?QLC&XW
M2O<XCLV(7)'JS2[V/&. =$I#,5Y]I?O!;#]V,:M$>)+X3;A]E.,_PH4OVQQM
M-ZB$-;.X-R?J>B<WVLR.,-7:<:=CNHI$8N1AC19(1B:>C.=L&?U>;&B)WK/Z
MW)XJN=#@7=5?>GA_:G/<>D9V ]F"];.,/S)=NK=.M,:,-')XU&Z5C)AOE*5D
M;[\PFB)L%15\9F"@*5W?)4K%FSWDN-K\#;Z:#1:@-G7BL**+(B0_7$H*VF>C
MBF+6P19XCMB ^[8!$&GF*8KX\DV>+PRN65:S"[8C2>UU-"\JBVE!A(JX?.\4
M.9Y;FCVQY,,0MQX-O%E4X4OI0F%&KS#W:T;Q;J G$RH".=@KXL>)*?O2&;W
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M+^W+$XE]M_9 <G_8*NT4NCWU24VMCR'YQM'#7XRLWNU]/\9RNE3FR#''CL9
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M=9/X'H0:CIL%KE:_:REU^^;#/=6O38C2>S;KT1])C_CT"?NN_%)9+TFFKI7
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M9-"'N=7UIYNY43N^D60%\#J+UW[&F.Y50TX;*,,]]M!X9)G;0D+V*JO1QT:
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M1ON'S[6H+I(O-%DE&8X#G2^\"F;_GB ]G^C8$B\87A2?-]NEZG)?_XEO2L]
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MKJYIC?-KQT-V.WUQ?ER&&:.BZ]3]%*-,X^!VL)@=*Z0COX&)#B#KSW?+!6[
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M(S+/WE%(F*&"-U.BV.!!]GE5VS4N@%MEG0)^_F+!?"SD;;?B*E5TS*P;55!
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M!7@5.*4#.8PWN>BF/N27HP$PWJ+3H]+3,\BNO=.HRJ[EJ#\";L.)5U9C^><
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M>R&!-&;2K9&OW-BBNH_Y9+/[P^$@\@(#0;C+@1]30E>F!D YJ(14 MP;*$1
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MN!Z-A7N$_?"3M+2Q@#SKE6<WT,G]=T&L*%:VLUMF@CBFYN>#]*63DJJJ.+=
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MX%S%7N8-_/JBX/1R=;ZE76Z(*5]BF!@DC8T2%ZEQI'OUIBS3\DEY\=7[;KI
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MXWYN*U??O/-FM RY"@6G7-E$W'\[T1EN\V,V(<ZYI:(", &_=>WR*>@A &?
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M8I7SVD5O=#8/_1M]019&_)#-5=^CI\TJVQ(2+UA9\94<GP\!3). SX>'6Z!
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MS/R/P;;1^.F8UJ=?G#+6(=E3HO>3C<7>!YH?6<^@/B!9=JJE?C;6KGBD_#C
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M9PL5/QUFQ@M[A#)',679UYH76*-4QOXM;"\'5ZK,D 6H@ OYK&4,8Z4"WEZ
M6W)7<M:%Y-![?!'\PO)TQ,DV98L\0,Z"[U !_>V%%RCP9V;9_W>15(_*U5/(
MSX:=<=VU MN(?[OE<0Y,*JU^Z*&)C$$Q??]W5$!;I\+%:QCWSQ:Z87Q1 ^ZD
M3KX3BZ1S6?P_CT:R^4DW%^6O\$FDUQ(<+TGLHB1_/@IZ<R'ZOL-_><,@H92A
M61@?A0_73/Q$$<9A*&9[GL2\;CM[M@_+SA@[)A+1(4/%+A@6$A0%CEMVIP(^
MXD@-9Q.%X8'")X$[(B14=^? D.J,Q\$I$(4ZX93$CY3W5Q(Y)6'@[QFJVPOD
M7CZ'<QMB[9("ZAM1<IG/GP#K_KKP$Q5/!3"1]Y8ORD[I1I\LK%*8V AOB/OD
MH1?D1-%PD5\3<-'-I7AL-:P-I$,N=1<A(1S@C(I;GRY0FT>1Z.0#8K%+^V<=
M$>%*9$[)2K,.^8XS5!,GG. "ZSCPH%QD(Z@]#]-%4.U&O3V%Q6J1B42O)2I@
M;X3"0') G[2J]E'V-*B 0'#SA^$@S5P9I\[&,K'32MW1EO*!6EB;)#OD@FN\
M2U5+NYLR<*OV99CP&/BA%Q,^D@H "[6_V&DO!,^-+Y*56C#_<#,Q%Q;'K=O!
MA0H(@(V6S\&"*V"C%A_VJ(!X6)AG*M&ADUA[(D!>(H+;#L-19UI3P4#XRGG'
MIL-<1E3/?F5Y4\.ISYEQ0ZF//<=6/_%OLS409-U&]BB4'0S:/\0E%9O]#TKC
MO=J)?-\/5&>"PT)(O);^$!0OGTJ" Z9F8FT>YZPZ5419VJM=0N$%B%&DI_?(
M)U3 .[YN*B :QCQXD0M@H=<AO)XB=++0$X'%>) 7BL$=.L1Z] >'Z&/.F$*6
MVB42%1"#RC)SF%<%/RJ @?7/C<M0?QO+U[$B5$!4^*#P+/G#'#1J!]@I^:!:
M:R<LD#)?>8J2[RSTVKE[[=R#(I2S#XN Q8?7VL)X#ZB 6T14 [:9"AAY=7 S
MI/V"%F-@=.,])%[5;6)P9WQ"9??(@@&?ZAVXBA)*Z>S?T.E\_8%'D05V0(M$
M! \@F$BJ=JII.\!<9 36(<&^FNDDXN91.&=[+HP-]4TOY(*WXTA@3RH@G H8
M73B M:(O"@F+#3^Y:.8<1.ZLZ85N(FH^^1L1K@HG]^''U];F,5K$HN3BKD6/
M[B5T[=(2F9=').^D'!\T+^13OC-TA+->QY:=J^[NUA,<NH&Y#Z@ Z27L\J%D
M%JC#GDFHLS"YM*/I/SZ"!RKF%6ID_=R(<I?$Y07CIK"=P+LIW<1OS:HM)X<4
M] '?;OG^PB*%[W"A\8!<RW9R(1;\/<!\75CS4@A)RV(5V5J9:.LW?A%Z, 1V
MV3Z7#K/-3,+K!I_[_ZPDUJ]^N.@^[X.KA1,&"-,DF(]\WM90U&[C%JJX/_1H
MQW4&OCU+!93$,^UIG92?[AV0KIU($_-6*-LP9F)[UHD#L93TE-"YUW_""43M
MOD##6M<HTPUDS+^A1?S(BTJ+'K"R@V0];X&B/W$(S?NH.B1:Y&>C$@3\MS"B
M0ZL7%M"))L%WPNP5@1?!%>_*6 :K' UMC7A$U(*J7RO'!*L2G%63_N>HN4[X
M+RH@03CM5#CAU.M <D_.HYLD3$11%DFP^3W4 1F^35[/ ]<Z-(H04=W6[ABP
MBLSG:O]7T6(.HF_RR0$7A:[-J@;3.2<&!?_;5'T_7T@%0%9&)&?.W@0WA#?8
M>P3# JB 5\5V9P=X%"NAK@]6GT 2?D4%7-"F+NPGL!$V!UN. #-].%5Y-7""
M"MRD7"//4026_J=?\5WL<+]E,ERRR>1$LR5,]::9M&Y(/&:]$@0I,*V!8"[:
M^T0*#**;&]'M\#L#%V_QNT,=#0L@'<)N4EC6.S11]<1PZ_;A\)WV, \BG*]P
M]DQFZ]AF <A'E*,"%B3:R N4?Q<5D&S<X5N".Y.8B$L7<'&B G3@O8T7+.ZP
MM#"'XJ$027FGH,X%4IY%1S^QL@O&!L80S!LQU@23WXW_!H/6:X7WP!Q 90>3
M!7SE!_\(T^/>0O8M9.TBYV;$7C<%QK)^&$QR\%E1_=D.VX4+9_T[O1 2'D=>
MKT.]R 4.#;T76%<=9=M'[1).B'S7]H<6%^8<EDUA"^ 68O()!WF>"&?IQ)'R
M=B0)5,#*=,<$>/8<';>T-5'8./ZBK# $8<]1RWT<A HEG%KC-<OI3 ["$(3E
M?"GL#52;@V^G5QT1]3T!5'NBZE-FQSI"S*4"+NAGFM)9ZYCL#BOS6E(.IV2@
M.N _46UU5$#Q!:,^0+'MJ[8XM!)!]J@V5-3 "=\JW)/0BG+>Z:AJ/@>9A#\J
M\-\MKX%E>.@ZM;9OC8HE(S'7QC8QY4V=\$W2:;!)N9+DTO0F!;US?(;Z39)#
M9:*/;9*K*?G0\;/Q;3Y"9<D<^&0O8FLN=.%_C?'^_WL91IWZ?U!+ P04
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MGQ7*#-E==M 'I(3L-H<W,]0S-0J>"?U>V8U(38F2^*P]4\F5 RDJOBB%ZO2
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MD7P B/@8,3JC#X573DC_+L+_BVEY0!=@]J1F,\PV,$4 V,',#YCT7A<*3\H
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MTL=_ AP%_#M%?PYP%/"?6O"? ,>RS6>ZQE\!1P'_F07E?F((A!P9#ZI(,KV
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M$G,L?1$8*K6[JH'<-XP(TB"W]"#(_* ^A @#6H8*5$+^:6,)N)"CJX48!$[
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M8W59;U)C#"H"G4!#*M%XF\;/M01I/BN68#29]18 P%&L'X0)UDI6"(-,*"<
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M^WU\'\G@#^DP%!N*'S)ZE *C5^"5$?D 5&]"+*R#+5"*5&HN1<%3B.E^FEN
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M'<)PB5P[AF<-FA RDT^.(W)U;@X4:%#6C,WP@XS"=1EP(#&(I["<3+LD##@
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MO?35ZP/[17 "'Q@R9&#H^T/?'QCXZHTT5C5-=1H *,94EJL7^:FE>@UHLRH
M3G4" S..:ZML2>+-P2)?$929$S]>^>#$08&;.9%!8LZ8ZN>K0KBC\U0GGBEU
MI)*7FWC<K)$SVM/:-;7&F^Q@NR8KQK3VS(D]\&GV_[O%P,3!7A53FCD1ZSX8
MS,62@_ZZS@^ZISJGE)Q.:-#CG0JZ70CH/780<D).P(D"$#(%]$Q#7-.<SL'M
MU\19(^W[#)TK3TL'\.W=V7_-G+A]7JU6:VH+GEK7*P#H]7H!)P1 T!2[QA3#
M4DRV/44Q)O5!=N $>*.D"ZHIU)7![M]LL=XP9TZ<.')PIZO?D<J5VU_WM(L$
MNT]L$<+ [IK9,]]]JQUR_YY&(:)6^>&&%4"H57;;7-U))M\>Z?<.E"M]W49M
MZ')/BEP)X&6^QBNF8;<#OV^LF>2_&:H)J+L?J6$&A-H/MS4RELH#=C5>,6PU
MV1K<+0ZNF/\)#EY7S-TB=$7^[^2]NW:"+#<,4V?-NK[[YCM5^"%]QV(_W'NM
M]CT"3//?H^Q=)Y[FC7I#+_%V]>^18+#Y'TEP!U"PR7=%.>L;K!G=A3 -2V:B
M=# ]"[0-9JIS*@2!L'<PJ=>['ZY1ZBZU*3 T ]BE\DX@MBRF^76>-?F _9EE
M^P/7%*=["N3.@- TE_W/XW BTV#G#.!;-7>'4=<S];H\J^]WB&\T,0@A4YV#
M1S."PM5;QC$[86UO\2VP6)T3RM9_,J"=:GX;PW:&'&NR_Q'*SG6_A9.I-FI%
MA15D8]8N>NPY-$PV=RW=\4 6>@Y.976#[^IQYL0=BISXG0;;>^JZH&DM@3.K
MLR#$W1O83D4_U*C*"Y6J.0MTH]^TVE[V0\W*=;W&FK,BR6#HFW;;"W^HG5!C
M*_PLP"L"+@Q+45(ADJY@/JP2])%8T,"P .!)848V5&UR(6^'#7E;1"#6B&&8
M*R7)<<SAQ'J7#[/K=Z\@=N2D-C8=2W4;VU<*\P$.%Q:0<*D(160LE.DW* -%
MC+ ?5E)!'Y8-^BI9W%>10KY4/N)O54*^2H4,8/6HOU6/]@ #/BP6P%K=3RJ
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M!2J$FN4J-!%"6SF'F@M L.SV)]AH1 R7V&8I"-!!CG$9$J6EO"UWK9Z/6EK
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MAFRZ7M=<#EJKM<$0&@3;H3C9$/IA-"K7D11HMFL$@3$) R:"((14TQXD)*=
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MXT^$8)L-V\L5]ZKJ]FV6)FSGZBZM5MLY.OQ'MVB\!+C<9=D#F'6J[$WUMUE
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M,E('DF5+1DHQ&(0Z323M2Y:83@TOYD6EF&R5':@BNA5/5'%IV61())EHO>$
M$OTO"JUBWNWAW)&2X&:\9IIL1]MZ)!S+$W5$"6:%A"4YE+CEB"HIT$/3*5P&
M.E+!D97!(@6'W3FIRD2 3"%GDFHMV?\NP&CE_8E$QD49Q3"D-C,XDV8 1';0
MW7TY.9/SF1&H()EJI!/2,J$XA<J8;J I.N4/)+12*]U"[#6:<13+$M+?"/*X
M13(>"7/E'.3L5%(B1JEQTL\4G)PSG80#<;00*+%!W>XIBYIEATU12,!4H# 0
M<:-6+IV%K:\MKY^:_6BO91ML6E> < 9MVIYZ9^GW\^6>6\HF.3>G>EUH .9T
MO)1D+3\+L4P\%\L*WK!(8B@3%N(H3</I7+;N"D1;1(&*5BK>5%K0>;L'UG8B
M_9]IY5@9@#J> "!Y^:ZW+R+_QNG]P*V_!VL/SP3U# EYV99LZ+4HU"!#KGA+
MSZ3,A.BK1_)^E2X0_J3';?*YHM^OR5X:A6U636:ZW!&K 1XREK :CNV)3]'.
M2605 "A?W,ZFY%K"JK/I9MS-RC;35P,9*U(OJ(TR&"H6G3F!D9.Z4@;+K39$
M!P&Z'+=3$LMI [M3D?Z7_@ZK$R[DRKU'&%XRDT#WD1T6#;M)6>5EM^C3XG 9
M]L*!4B<7BP7]N@]S^C4C0#7\*=1 (A$E6>)B%-WGV)E_'RJ^N645PUL *8])
MD%J8ZKCI=L@PN(*KQ9-:".__,BW32D0U& 2ZZ94& JCL MQV6S?0C<$X"S@H
MM.R-T9RW#"K MRO0MF-)?%.A_^.3;JU6(,+;3$NUW9CN,.Q8TK3C!6ES:]_.
M4'8(23KL:.MHVMP+B]N5I&88R-B):,Y;L-V9WC<;P,J)@&KSR@X,&657Q1 =
M8E+ 5:Y"NMU%$2195<_XM7ROE=M.U'NPOMRN?_>ZV9Z:@5VCW+DONQ:*=;O!
MHCO-K>6WYX9B.U6RXT]O+/UIM0+]E:(#B#TWI\TZ_ZT<LT68X6B33/ >V6DX
MY&*[248H/J8(@BQFBJW^9EI4;>_>;?J!1%)6.JK&&VDX)+ UTN_$S$3>8>:"
MA4 J60IEA5 \)!8EPUG. N%VO1^D+%W0JD@:U7C>&T4[-5L169 KPFE$)YV,
MD6O8F:DK A82_G;-=H_I5#U>J&6I..SV1 W-]C]H'5%S0"Q<!/K,H29_9P>D
M2V_@3H1E%9X-E)F&3 GA;*%>8YPU-NU*256'U99$&L:3A8R@8Z1N^1P%L^WM
M$TXFV8EYM4@^)<4D#N%BEF6[[FRS74A$42EKFHQ<IF"QI74R&9>9$II<4  C
M=0CTQ6,*@[+!AC-="S!U*1HG^WNP*=W24V;3Y<(S\&Y6!^I!(3[3[&!@.!<A
M=<JD\:;:;E039'=# T>*<KVI>9LA9RX4ZG_C4ZF0+2OLRCA RVU 4:TF.7+E
M!"^XXX@6:KI;=B8E@[YD/)_P6&8\;%&I9CC=B+%IH>[RI7-&)DVW-"_62SI[
M@+N.B8FQ!37K4-LY'$EJ,A!"FB1$I%N=$@%2?H\LI*+UG"$$(I)3BP$M$X!,
MKYT&)R01J,']WW"V>:H!M#"R[-7+O=R8 !"S;0=P.A&VJK@O$ X$M(8:P8-U
M*NXK%;O[I)@C;,1XTJ*S7V.ZJ>3V3*H&AP54ICP=O%[RBD@93'A-;QXD,I"I
M)N/^3(G&^$2\QM1=#L+*%AB>,@S+W#$GJ5E+Q#IP0H!4>?NV<[511"3%ZV<9
M7XTN)EQ2EQ*EW25GUFGGH5E>TX%=:8^]Q+JTQYZ6J2H.P$P!'H$&;&=!]^V0
M)S15L<JJ3Z%*%@QH=9W0;<H':'A)8_!RSH/ZNOSF6T3+SDIWP[%Z@#MZU,*R
M(ZX7&:Y@T#5%,NN!HNDWVW&R%%,E(<**G9@G&PE3C5".B"I0:D=(-;)HDXTD
MRVZ?VJ?$WA+;UB(-L@%6E%JT@Z8[]B*HU;%&2RL9<E2TZ%@2W:XRAZU,+&):
M21R)JAT^2ZBN E$P:3#B4NDHU<_HBV)!SF>)9,O;%FV-:XH#;SK IF8G/&E;
M^Y +S4GVS.P<"&!AL)M)44E'L=35L8\UU:"CUH) V&=31T_?P?)0K$ QY9H8
M(?ET.J&3;=B7MF)$W(L7TA*^T_(6+1-H=[H!S*S;P;SE2Z,.2N[0<530 \U8
M$ND#.K)-LM:@V+3>Z;AY*RKJG)7&76&&IIR%G%.,1-"RVL&"=2P0!%DZ4],J
MQ23J2%I:0W<$,A+8(LMPT$D;LM'_X03>\D=4L4V'\NE:LF#6DJ2@NA6<*;LT
M.:R$;9FEPSG;:$T%S@$1V9##M9VSJFP=M.,+T4_0^HE/+TO[.D'+>Y$:BK))
MI 0&,B29Q26$K>>\43J MU-I*]4V&!H)2D7>E04:8-[IB[1I(NF@'64YU4_
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MQLBH/PH'U69!0AQ2)2.W'5J<,J-.K51C(S0.?#WH5J WZ#[[2OH,FS'F:AY
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MZ(/][@=[_?>C\$Z5?ABG9_'.G1OM=@W\'PCL>V0R8Z=C]3L.;E.-XNY/>\\
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M$Y,)QPGV*QW\29/+%^ND._W/"@BW_F7@(3@A5?T7AL>E_8,<8J'.\@MGZXB
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M]@*WYW' (&PNA,S5*3P,K9ZR]%S2&N^TF1SR$9%]R=%<4PHW-[@?U7\/_K(
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M71Y 2BW]XD>23SAI^+=\EX;]T?Y=ZA,^9DP9Z?,?[Y<? )<"HA?CSKP\;EB
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MG7)'+_C)YJ>8)N?L4UDCS<R;,&G9OO6>NO4CJY*^1@4MS5786_9+EU9\6/J
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M              "  0    !B;&%C=2TR,#(T,#,S,2YX<V102P$"% ,4
M" "<A=Q8>94V"D<)  #%<@  %@              @ $I$0  8FQA8W4M,C R
M-# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( )R%W%ALY3(ZC3   +7@ @ 6
M          "  :0:  !B;&%C=2TR,#(T,#,S,5]D968N>&UL4$L! A0#%
M  @ G(7<6!O !&#S10  5<,# !8              ( !94L  &)L86-U+3(P
M,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    " "<A=Q8PK5YE*\Y  #/GP, %@
M            @ &,D0  8FQA8W4M,C R-# S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( )R%W%@%9FPW:@(  ),%   1              "  6_+  !D-#<V-C8X
M9&5X,C,R+FAT;5!+ 0(4 Q0    ( )R%W%AUZXQX!P0  +,,   1
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M2P$"% ,4    " "<A=Q8)*<LS.(L#   'XX #@              @ '6X0
M9#0W-C8V.&1S-"YH=&U02P$"% ,4    " "<A=Q8 ODQT,I(  "M=@  $0
M            @ 'D#@T 9S0W-C8V.&<P,&0R,"YJ<&=02P$"% ,4    " "<
MA=Q811@-2@1V! "P.04 $0              @ '=5PT 9S0W-C8V.&<P,&TP
M-2YJ<&=02P$"% ,4    " "<A=Q88*H:702O!  ,?04 $0
M@ $0SA$ 9S0W-C8V.&<P,&TP-BYJ<&=02P$"% ,4    " "<A=Q84C&:2P/9
M  #?]@  $0              @ %#?18 9S0W-C8V.&<P,'0P,2YJ<&=02P$"
M% ,4    " "<A=Q8662AMQBK P"F$ 0 $0              @ %U5A< 9S0W
M-C8V.&<P,'0P,BYJ<&=02P$"% ,4    " "<A=Q8@_S2,WI#  "E:   $0
M            @ &\ 1L 9S0W-C8V.&<P,'DQ,BYJ<&=02P$"% ,4    " "<
MA=Q8,L8G_'LT  !(S   $0              @ %E11L 9S0W-C8V.&<P,'DQ
M,RYJ<&=02P$"% ,4    " "<A=Q8CQS$;:,A   *9   $0
M@ $/>AL 9S0W-C8V.&<P-&HX,2YJ<&=02P$"% ,4    " "<A=Q8<N=JF,>$
M  #=N0  $0              @ 'AFQL 9S0W-C8V.&<Q.6$P."YJ<&=02P$"
M% ,4    " "<A=Q8@SUEX 1/!P#AYP< $0              @ '7(!P 9S0W
M-C8V.&<W,F$U."YJ<&=02P$"% ,4    " "<A=Q8SNO5YATZ  !29P  $0
M            @ $*<", 9S0W-C8V.&<W-6,Q-RYJ<&=02P$"% ,4    " "<
MA=Q8*B$?'M-0  #A>   $0              @ %6JB, 9S0W-C8V.&<W.7,V
M-"YJ<&=02P$"% ,4    " "<A=Q82042EOX?  !>80  $0
M@ %8^R, 9S0W-C8V.&<X,FTX."YJ<&=02P4&     !@ &  !!@  A1LD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>d476668ds4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:blacu="http://BellevueLifeSciencesAcquisitionCorp.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="blacu-20240331.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="P11_14_2023To02_14_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="P11_01_2023To11_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_13_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="P04_09_2024To04_09_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="P03_12_2024To03_12_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2024-03-12</startDate>
            <endDate>2024-03-12</endDate>
        </period>
    </context>
    <context id="P02_09_2024To02_09_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis_NoLongerSubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:NoLongerSubjectToForfeitureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_IPOMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrivatePlacementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis_SubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:SubjectToForfeitureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EquityParticipationMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-14</startDate>
            <endDate>2023-02-14</endDate>
        </period>
    </context>
    <context id="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-30</instant>
        </period>
    </context>
    <context id="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-17</instant>
        </period>
    </context>
    <context id="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JunChulWhangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2024_JcwPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:JcwPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="P03_08_2024To03_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="PAsOn03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-12</instant>
        </period>
    </context>
    <context id="PAsOn03_12_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-12</instant>
        </period>
    </context>
    <context id="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-12</startDate>
            <endDate>2024-03-12</endDate>
        </period>
    </context>
    <context id="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="PAsOn04_08_2024_AprilSponsorNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:AprilSponsorNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="PAsOn04_08_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-09</instant>
        </period>
    </context>
    <context id="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="PAsOn05_14_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="PAsOn05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:MayTwoThousandAndTwentyFourPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-14</instant>
        </period>
    </context>
    <context id="P05_14_2024To05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:MayTwoThousandAndTwentyFourPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <context id="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="P04_17_2024To04_17_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-17</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="PAsOn04_17_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JoshPanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:JunChulWhangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:BcmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_EquityParticipationMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">blacu:EquityParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">blacu:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">blacu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_IPOMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">blacu:WorkingCapitalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">blacu:UnderwritingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2024To03_31_2024" id="ixv-114642">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To03_31_2024" id="ixv-114643">0001840425</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden117833403">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2024To03_31_2024" id="hidden117833404">WA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2024To03_31_2024" id="ixv-115917">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2024To03_31_2024" id="ixv-115918">BELLEVUE LIFE SCIENCES ACQUISITION CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2024To03_31_2024" id="ixv-115919">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2024To03_31_2024" id="ixv-115920">6770</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2024To03_31_2024" id="ixv-115921">84-5052822</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2024To03_31_2024" id="ixv-115922">10900 NE 4th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2024To03_31_2024" id="ixv-115923">Suite 2300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2024To03_31_2024" id="ixv-115924">Bellevue</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2024To03_31_2024" id="ixv-115925">98004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2024To03_31_2024" id="ixv-115926">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2024To03_31_2024" id="ixv-115927">635-7700</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115928">Kuk Hyoun Hwang</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115929">10900 NE 4th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115930">Suite 2300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115931">Bellevue</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115932">98004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115933">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-115934">635-7700</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2024To03_31_2024" id="ixv-115935">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2024To03_31_2024" id="ixv-115936">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2024To03_31_2024" id="ixv-115937">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2024To03_31_2024" id="ixv-115938">false</dei:EntityExTransitionPeriod>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="hidden117832660">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#x2019;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="hidden117832661">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#x2019;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1 contextRef="P04_09_2024To04_09_2024" id="hidden117833430">2024-05-14</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <blacu:NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled
      contextRef="P05_14_2024To05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="hidden117832595">P5D</blacu:NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115947"
      unitRef="Unit_USD">3637</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115948"
      unitRef="Unit_USD">15419</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115949"
      unitRef="Unit_USD">64543</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115950"
      unitRef="Unit_USD">7208</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115951"
      unitRef="Unit_USD">68180</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115952"
      unitRef="Unit_USD">22627</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115953"
      unitRef="Unit_USD">37205930</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115954"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115955"
      unitRef="Unit_USD">37274110</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115956"
      unitRef="Unit_USD">36627733</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115957"
      unitRef="Unit_USD">1548087</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115958"
      unitRef="Unit_USD">1081753</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115959"
      unitRef="Unit_USD">615035</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115960"
      unitRef="Unit_USD">524562</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115961"
      unitRef="Unit_USD">359957</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115962"
      unitRef="Unit_USD">359957</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115963"
      unitRef="Unit_USD">135000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115964"
      unitRef="Unit_USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115965"
      unitRef="Unit_USD">87000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115966"
      unitRef="Unit_USD">72000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115967"
      unitRef="Unit_USD">2745079</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115968"
      unitRef="Unit_USD">2038272</us-gaap:LiabilitiesCurrent>
    <blacu:DeferredUnderwritingCommissions
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115969"
      unitRef="Unit_USD">2070000</blacu:DeferredUnderwritingCommissions>
    <blacu:DeferredUnderwritingCommissions
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115970"
      unitRef="Unit_USD">2070000</blacu:DeferredUnderwritingCommissions>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115971"
      unitRef="Unit_USD">4815079</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115972"
      unitRef="Unit_USD">4108272</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2024"
      id="ixv-115973"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-115974"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-115975"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-115976"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <blacu:CommonStockRedemptionValue
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-115977"
      unitRef="Unit_USD_per_Share">10.6</blacu:CommonStockRedemptionValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-115978"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-115979"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <blacu:CommonStockRedemptionValue
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-115980"
      unitRef="Unit_USD_per_Share">10.5</blacu:CommonStockRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-115981"
      unitRef="Unit_USD">36766604</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-115982"
      unitRef="Unit_USD">36426253</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-115983"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="4"
      id="ixv-115984"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115985"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-115986"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115987"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-115988"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-115989"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115990"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-115991"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-115992"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-115993"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="4"
      id="ixv-115994"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115995"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-115996"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115997"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-115998"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-115999"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-116000"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116001"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116002"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116003"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116004"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116005"
      unitRef="Unit_USD">216</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116006"
      unitRef="Unit_USD">216</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116007"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116008"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116009"
      unitRef="Unit_USD">-4307789</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116010"
      unitRef="Unit_USD">-3907008</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116011"
      unitRef="Unit_USD">-4307573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116012"
      unitRef="Unit_USD">-3906792</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116013"
      unitRef="Unit_USD">37274110</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116014"
      unitRef="Unit_USD">36627733</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116015"
      unitRef="Unit_USD">450781</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116016"
      unitRef="Unit_USD">278102</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116017"
      unitRef="Unit_USD">-450781</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116018"
      unitRef="Unit_USD">-278102</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116019"
      unitRef="Unit_USD">480824</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116020"
      unitRef="Unit_USD">417728</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherIncome
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116021"
      unitRef="Unit_USD">480824</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116022"
      unitRef="Unit_USD">417728</us-gaap:OtherIncome>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116023"
      unitRef="Unit_USD">30043</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116024"
      unitRef="Unit_USD">139626</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116025"
      unitRef="Unit_USD">90473</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116026"
      unitRef="Unit_USD">29321</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116027"
      unitRef="Unit_USD">-60430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116028"
      unitRef="Unit_USD">110305</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116029"
      unitRef="Unit_shares">5622954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116030"
      unitRef="Unit_shares">5622954</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116031"
      unitRef="Unit_shares">5231461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116032"
      unitRef="Unit_shares">5231461</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116033"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116034"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      id="ixv-116035"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      id="ixv-116036"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116037"
      unitRef="Unit_shares">2155000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116038"
      unitRef="Unit_USD">216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116039"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116040"
      unitRef="Unit_USD">-3907008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116041"
      unitRef="Unit_USD">-3906792</us-gaap:StockholdersEquity>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116042"
      unitRef="Unit_USD">-340351</blacu:AccretionForCommonStockToRedemptionValue>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116043"
      unitRef="Unit_USD">-340351</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116044"
      unitRef="Unit_USD">-60430</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116045"
      unitRef="Unit_USD">-60430</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116046"
      unitRef="Unit_shares">2155000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116047"
      unitRef="Unit_USD">216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116048"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116049"
      unitRef="Unit_USD">-4307789</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116050"
      unitRef="Unit_USD">-4307573</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116051"
      unitRef="Unit_shares">1725000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116052"
      unitRef="Unit_USD">173</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116053"
      unitRef="Unit_USD">24827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116054"
      unitRef="Unit_USD">-62508</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116055"
      unitRef="Unit_USD">-37508</us-gaap:StockholdersEquity>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-116056"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116057"
      unitRef="Unit_shares">430000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116058"
      unitRef="Unit_USD">43</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116059"
      unitRef="Unit_USD">4299957</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116060"
      unitRef="Unit_USD">4300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116061"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116062"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116063"
      unitRef="Unit_USD">-5561311</blacu:AccretionForCommonStockToRedemptionValue>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116064"
      unitRef="Unit_USD">-1878249</blacu:AccretionForCommonStockToRedemptionValue>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116065"
      unitRef="Unit_USD">-7439560</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116066"
      unitRef="Unit_USD">110305</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116067"
      unitRef="Unit_USD">110305</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116068"
      unitRef="Unit_shares">2155000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116069"
      unitRef="Unit_USD">216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116070"
      unitRef="Unit_USD">-1830452</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="0"
      id="ixv-116071"
      unitRef="Unit_USD">-1830236</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116072"
      unitRef="Unit_USD">-60430</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116073"
      unitRef="Unit_USD">110305</us-gaap:ProfitLoss>
    <us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116074"
      unitRef="Unit_USD">480824</us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease>
    <us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116075"
      unitRef="Unit_USD">417728</us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116076"
      unitRef="Unit_USD">57335</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116077"
      unitRef="Unit_USD">81073</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116078"
      unitRef="Unit_USD">466334</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116079"
      unitRef="Unit_USD">340070</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116080"
      unitRef="Unit_USD">90473</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116081"
      unitRef="Unit_USD">-41782</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116082"
      unitRef="Unit_USD">-48426</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116083"
      unitRef="Unit_USD">120000</blacu:CashDepositedInTheTrustAccount>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116084"
      unitRef="Unit_USD">70207500</blacu:CashDepositedInTheTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116085"
      unitRef="Unit_USD">-120000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116086"
      unitRef="Unit_USD">-70207500</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116087"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116088"
      unitRef="Unit_USD">59670000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2024To03_31_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116089"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To03_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116090"
      unitRef="Unit_USD">9157500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116091"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2023To03_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116092"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116093"
      unitRef="Unit_USD">135000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116094"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116095"
      unitRef="Unit_USD">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116096"
      unitRef="Unit_USD">1447273</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2024To03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116097"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2023To03_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116098"
      unitRef="Unit_USD">1200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116099"
      unitRef="Unit_USD">15000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2023To03_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116100"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116101"
      unitRef="Unit_USD">150000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116102"
      unitRef="Unit_USD">70480227</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116103"
      unitRef="Unit_USD">-11782</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116104"
      unitRef="Unit_USD">224301</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116105"
      unitRef="Unit_USD">15419</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116106"
      unitRef="Unit_USD">124501</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116107"
      unitRef="Unit_USD">3637</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2023"
      decimals="0"
      id="ixv-116108"
      unitRef="Unit_USD">348802</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116109"
      unitRef="Unit_USD">0</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116110"
      unitRef="Unit_USD">2070000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-38461">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 1&#x2013;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Bellevue Life Sciences Acquisition Corp. (the &#x201c;Company&#x201d;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;or more businesses or entities (the &#x201c;Business Combination&#x201d;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of&#160;March 31, 2024, the Company had not commenced any operations. All activity since inception relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;generate&#160;non-operating&#160;income&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; in the form of interest income from the proceeds derived from the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering (the &#x201c;Registration Statement&#x201d;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;&lt;/div&gt;6,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;units (&#x201c;Units&#x201d; and, with respect to the common stock included in the Units being offered, the &#x201c;Public Shares&#x201d;), generating gross proceeds of $&lt;/div&gt;60,000,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;, which is described in Note 3.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#x201c;Over-Allotment Option Units&#x201d;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;&lt;/div&gt;900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Over-Allotment Option Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per unit generated total gross proceeds of $&lt;/div&gt;9,000,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#x201c;Private Placement&#x201d;) of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units (the &#x201c;Private Placement Units&#x201d;), to Bellevue Global Life Sciences Investors LLC (the &#x201c;Sponsor&#x201d;) at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Placement Unit, for an aggregate purchase price of $&lt;/div&gt;4,300,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Each Unit and Private Placement Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock, par value $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;(the &#x201c;Common Stock&#x201d;), a warrant to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock (the &#x201c;Public Warrants&#x201d; and &#x201c;Private Placement Warrants&#x201d; and collectively, the &#x201c;Warrants&#x201d;) and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of a share of common stock (the &#x201c;Public Rights&#x201d; and Private Placement Rights&#x201d; and collectively, the &#x201c;Rights&#x201d;), as described in Notes 3 and 4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;&lt;/div&gt;80&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;&lt;/div&gt;50&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of $&lt;/div&gt;70,207,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;was placed in a trust account (&#x201c;Trust&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Account&#x201d;) located in the United States with Continental Stock Transfer&#160;&amp;amp; Trust Company acting as trustee, and invested only in United States &#x201c;government securities&#x201d; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#x201c;Investment Company Act&#x201d;) having a maturity of 185 days or less or in money market funds meeting certain conditions under &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Rule&#160;2a-7&#160;promulgated&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.39in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#x201c;Public Stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &#x201c;Distinguishing Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;5,000,001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial&#160;Public Offering in favor of a Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;material&#160;non-public&#160;information&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and (ii)&#160;to clear all trades with the Company&#x2019;s legal counsel or compliance officer prior to execution. In addition, the Company&#x2019;s Sponsor and any other holders of the Company&#x2019;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#x201c;Initial Stockholders&#x201d;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#x2019;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;&lt;/div&gt;15&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s Initial Stockholders and Chardan Capital Markets, LLC (&#x201c;Chardan&#x201d;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;&lt;/div&gt;100&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of its Public Shares if the Company does not complete a Business Combination within&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;nine months&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#x201c;Combination Period&#x201d;) or (B)&#160;with respect to any other provision relating to&#160;stockholders&#x2019;&#160;rights &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;or&#160;pre-initial&#160;Business&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than &lt;/div&gt;ten&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; business days thereafter, redeem&#160;&lt;/div&gt;100&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $&lt;/div&gt;100,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#x2019;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $10.175 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed t&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;o&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#x2019;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Extension of Termination Date and Redemptions from the Trust Account &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#x201c;Special Meeting&#x201d;). At the Special Meeting, the Company&#x2019;s stockholders approved an extension of the date by which the Company must &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors (the &#x201c;Board&#x201d;) the authority in its discretion to amend the Charter to extend the date by which the Company must consummate a business combination from February&#160;14, 2024 to May&#160;14, 2024. In connection with the Special &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Meeting,&#160;&lt;/div&gt;3,432,046&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of common stock of the Company were tendered for redemption at a redemption price of approximately $&lt;/div&gt;10.49&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share for an aggregate redemption amount of $&lt;/div&gt;35,995,728&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, leaving $&lt;/div&gt;36,372,335&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $&lt;/div&gt;561,957&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Additionally, the Company deposited $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;into the Trust Account on November&#160;&lt;/div&gt;13&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2023&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; in connection with the extension of the date by which the Company must consummate a business combination from November&#160;&lt;/div&gt;14&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2023&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; to February&#160;&lt;/div&gt;14&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In &lt;/div&gt;February 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Board authorized and approved a second Certificate of Amendment to the Charter. The second Certificate of Amendment to the Charter was filed with the Delaware Secretary of State, with an effective date of February&#160;&lt;/div&gt;9&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, and extended the date by which the Company must consummate a business combination to the May&#160;&lt;/div&gt;14&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. In connection with the extension by which the Company must consummate a business combination to May&#160;&lt;/div&gt;14&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company deposited $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; into the Trust Account on each of February&#160;&lt;/div&gt;9&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and March&#160;&lt;/div&gt;12&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. In connection with the $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; deposited into the Trust Account on February&#160;&lt;/div&gt;9&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company issued an unsecured promissory note in the principal amount of $&lt;/div&gt;75,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; to Jun Chul Whang, a member of the Board. In connection with the $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; deposited into the Trust Account on March&#160;&lt;/div&gt;12&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company issued an unsecured promissory note in the principal amount of $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt; to Josh Pan, an individual member of Bellevue Capital Management, LLC, which wholly owns the Sponsor.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Franchise and Income Tax Withdrawal &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In &lt;/div&gt;November 2023&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company withdrew $&lt;/div&gt;561,957&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;of interest income earned in the Trust Account for payment of the Company&#x2019;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through March&#160;&lt;/div&gt;31&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#x2019;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#x2019;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of March&#160;&lt;/div&gt;31&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;, the Company&#x2019;s obligations for franchise and income tax purposes remain payable.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#x201c;GAAP&#x201d;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the &lt;/div&gt;three&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt; months ended &lt;/div&gt;March 31, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt; are not necessarily indicative of the results to be expected for the year ending &lt;/div&gt;December 31, 2024&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt; or for any future interim periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form &lt;/div&gt;10&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;-K as of and for the year ended &lt;/div&gt;December 31, 2023&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt; as filed with SEC on &lt;/div&gt;April 17, 2024&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of March&#160;&lt;/div&gt;31&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, &lt;/div&gt;2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, the Company had $&lt;/div&gt;3,637&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in its operating bank account and a working capital deficit of $&lt;/div&gt;2,676,899&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;.&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s liquidity needs prior to the consummation of the Initial Public Offering had been&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement Units held outside of the Trust Account and loans from the Sponsor, officers and directors and their affiliates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or 21 months from the Initial Public Offering (subject to extension by approval of the Company&#x2019;s stockholders). These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160;Over this time period, the Company has used and will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#x2019;s current operating cash balance may need to be funded through loans from the Company&#x2019;s Sponsor, officers and directors and their affiliates. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;If the Company is unable to complete a Business Combination by November 14, 2024 (subject to extension by approval of the Company&#x2019;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management will seek to complete a business combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Emerging Growth Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the&#160;Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"&gt;to&#160;non-emerging&#160;growth&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt; companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in&#160;accounting&#160;standards used.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Nasdaq Listing Rules Compliance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;As previously reported by the Company on Form&#160;8-K&#160;filed on June&#160;14, 2023, due to the resignation of a director effective on June&#160;21, 2023, the Company notified the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) on June&#160;27, 2023 that the Company was not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the &#x201c;Listing Rule&#x201d;), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Company has until the earlier of its next annual shareholders&#x2019; meeting or June&#160;21, 2024 to regain compliance.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Listing Rule requires the Audit Committee (the &#x201c;Audit Committee&#x201d;) of the Board be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of the director&#x2019;s resignation from the Company&#x2019;s Board and Audit Committee, the Company&#x2019;s Audit Committee has been comprised of two independent directors and one vacancy and, therefore, does not currently comply with Nasdaq&#x2019;s audit committee requirements as set forth in the Listing Rule. Pursuant to the Listing Rule&#x2019;s section (c)(4)(B), the Company is entitled to a cure period to regain compliance with the Listing Rule. The Company is evaluating the appropriate membership and composition of its Board and Board committees and intends to regain compliance with Listing Rule prior to the expiration of the applicable cure period.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On February&#160;15, 2024, the Company received a notification from the Listing Qualifications Department of Nasdaq notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the &#x201c;Minimum Public Holders Requirement&#x201d;). The notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of securities on the Nasdaq Capital Market. In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116111"
      unitRef="Unit_pure">1</blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116112"
      unitRef="Unit_shares">6000000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116113"
      unitRef="Unit_USD">60000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116114"
      unitRef="Unit_shares">900000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116115"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116116"
      unitRef="Unit_USD">9000000</us-gaap:CommonUnitIssuanceValue>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116117"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116118"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116119"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116120"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-116121"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116122"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116123"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <blacu:PercentageOfTrustAccountRequiredForBusinessCombination
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116124"
      unitRef="Unit_pure">0.80</blacu:PercentageOfTrustAccountRequiredForBusinessCombination>
    <blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116125"
      unitRef="Unit_pure">0.50</blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116126"
      unitRef="Unit_USD">70207500</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="P01_01_2024To03_31_2024" id="ixv-116128">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#x201c;Public Stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).</us-gaap:DebtInstrumentRedemptionDescription>
    <blacu:NetTangibleAssets
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116129"
      unitRef="Unit_USD">5000001</blacu:NetTangibleAssets>
    <blacu:RedemptionLimitPercentage
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116130"
      unitRef="Unit_pure">0.15</blacu:RedemptionLimitPercentage>
    <blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116132"
      unitRef="Unit_pure">1</blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <blacu:PeriodToConsummateBusinessCombination contextRef="P01_01_2024To03_31_2024" id="ixv-38583">P9M</blacu:PeriodToConsummateBusinessCombination>
    <blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-116133"
      unitRef="Unit_pure">1</blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <blacu:MaximumAllowedDissolutionExpenses
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116134"
      unitRef="Unit_USD">100000</blacu:MaximumAllowedDissolutionExpenses>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn02_14_2024"
      decimals="INF"
      id="ixv-116137"
      unitRef="Unit_shares">3432046</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn02_14_2024"
      decimals="2"
      id="ixv-116138"
      unitRef="Unit_USD_per_Share">10.49</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="PAsOn02_14_2024"
      decimals="0"
      id="ixv-116139"
      unitRef="Unit_USD">35995728</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:CommonStockValueOutstanding
      contextRef="PAsOn02_14_2024"
      decimals="0"
      id="ixv-116140"
      unitRef="Unit_USD">36372335</us-gaap:CommonStockValueOutstanding>
    <blacu:InterestIncomeHeldInTheTrustAccount
      contextRef="P11_14_2023To02_14_2024"
      decimals="0"
      id="ixv-116141"
      unitRef="Unit_USD">561957</blacu:InterestIncomeHeldInTheTrustAccount>
    <blacu:InvestmentOfCashInTrustAccount
      contextRef="PAsOn11_13_2023"
      decimals="0"
      id="ixv-116142"
      unitRef="Unit_USD">180000</blacu:InvestmentOfCashInTrustAccount>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P02_09_2024To02_09_2024"
      decimals="0"
      id="ixv-116143"
      unitRef="Unit_USD">60000</blacu:CashDepositedInTheTrustAccount>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P03_12_2024To03_12_2024"
      decimals="0"
      id="ixv-116144"
      unitRef="Unit_USD">60000</blacu:CashDepositedInTheTrustAccount>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P02_09_2024To02_09_2024"
      decimals="0"
      id="ixv-116145"
      unitRef="Unit_USD">60000</blacu:CashDepositedInTheTrustAccount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_09_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116146"
      unitRef="Unit_USD">75000</us-gaap:DebtInstrumentFaceAmount>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P03_12_2024To03_12_2024"
      decimals="0"
      id="ixv-116147"
      unitRef="Unit_USD">60000</blacu:CashDepositedInTheTrustAccount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_12_2024_UnsecuredPromissoryNoteMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116148"
      unitRef="Unit_USD">60000</us-gaap:DebtInstrumentFaceAmount>
    <blacu:InterestIncomeHeldInTheTrustAccount
      contextRef="P11_01_2023To11_30_2023"
      decimals="0"
      id="ixv-116149"
      unitRef="Unit_USD">561957</blacu:InterestIncomeHeldInTheTrustAccount>
    <us-gaap:Cash
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116150"
      unitRef="Unit_USD">3637</us-gaap:Cash>
    <us-gaap:DebtCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116151"
      unitRef="Unit_USD">2676899</us-gaap:DebtCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-38882">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;NOTE 2&#x2013;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from thos&lt;div style="display:inline;"&gt;e &lt;/div&gt;estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;/div&gt;3,637&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and $&lt;/div&gt;15,419&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in cash held in its operating account as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The Company had&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;cash equivalents as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the unaudited condensed financial statements, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#x2019;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#x2019;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in the Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The fair value of certain of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash and amounts due to related parties are estimated to approximate the carrying values as of&#160;March 31, 2024 due to the short maturities of such instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;then&#160;re-valued&#160;at&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed financial statements as current &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;or&#160;non-current&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; based on whether or &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;not&#160;net-cash&#160;settlement&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; or conversion of the instrument could be required within 12 months of the condensed balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$&lt;/div&gt;250,000&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Warrant Instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#x2019;s own common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the Initial Public Offering and the exercise of the over-allotment of up to&#160;&lt;/div&gt;6,900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Units, each Public Unit is comprised of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock, $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;par value, a&#160;warrant to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Right to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Placement Rights underlying Placement Units (the &#x201c;Placement Rights&#x201d;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#x201c;Rights&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;815-40.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;representative shares (&#x201c;Equity&#160;Participation Shares&#x201d;), which include an additional&#160;&lt;/div&gt;4,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt;The Company complies with the requirements of &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt; SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A, &#x201c;Expenses of Offering.&#x201d; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Net Income (Loss) per Common Share&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;&lt;/div&gt;7,330,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is received by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Common Stock Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; deficit. The Company&#x2019;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;March 31, 2024 and&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;December&#160;31, 2023,&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;3,467,954&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s condensed balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary diff&lt;div style="display:inline;"&gt;er&lt;/div&gt;ences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets w&lt;div style="display:inline;"&gt;er&lt;/div&gt;e deemed to be de minimis as of March&#160;31, 2024 and&#160;December 31, 2023.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the three months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total provision for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For&#160;the&#160;three&#160;months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(benefit) at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State tax provision/(benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in fair value of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely than not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;unrecognized tax benefits as of&#160;March 31, 2024 and&#160;December&#160;31, 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;&lt;/div&gt;No&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;amounts were accrued for the payment interest and penalties for the three months ended March&#160;31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1,&#160;SEC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; SAB Topic 5A, and SEC SAB Topic 5T, &#x201c;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#x201d;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting sta&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;nd&lt;/div&gt;a&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;r&lt;/div&gt;ds, if currently adopted, would have a material effect on the Company&#x2019;s unaudited condensed financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2024To03_31_2024" id="ixv-38886">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from thos&lt;div style="display:inline;"&gt;e &lt;/div&gt;estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-38903">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;/div&gt;3,637&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and $&lt;/div&gt;15,419&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in cash held in its operating account as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The Company had&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;cash equivalents as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116155"
      unitRef="Unit_USD">3637</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116156"
      unitRef="Unit_USD">15419</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116157"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116158"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2024To03_31_2024" id="ixv-38914">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the unaudited condensed financial statements, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-38938">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#x2019;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#x2019;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in the Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.&lt;/div&gt;&lt;/div&gt;</blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-38945">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The fair value of certain of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash and amounts due to related parties are estimated to approximate the carrying values as of&#160;March 31, 2024 due to the short maturities of such instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39019">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;then&#160;re-valued&#160;at&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed financial statements as current &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;or&#160;non-current&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; based on whether or &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;not&#160;net-cash&#160;settlement&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; or conversion of the instrument could be required within 12 months of the condensed balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2024To03_31_2024" id="ixv-39051">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$&lt;/div&gt;250,000&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116160"
      unitRef="Unit_USD">250000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <blacu:WarrantInstrumentsPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39065">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Warrant Instruments&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#x2019;s own common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.&lt;/div&gt;&lt;/div&gt;</blacu:WarrantInstrumentsPolicyPolicyTextBlock>
    <blacu:RightsPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39070">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the Initial Public Offering and the exercise of the over-allotment of up to&#160;&lt;/div&gt;6,900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Units, each Public Unit is comprised of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock, $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;par value, a&#160;warrant to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Right to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Placement Rights underlying Placement Units (the &#x201c;Placement Rights&#x201d;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#x201c;Rights&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;815-40.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.&lt;/div&gt;&lt;/div&gt;</blacu:RightsPolicyPolicyTextBlock>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116161"
      unitRef="Unit_shares">6900000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116162"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-116163"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116164"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116165"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116166"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <blacu:EquityParticipationSharesPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39097">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;representative shares (&#x201c;Equity&#160;Participation Shares&#x201d;), which include an additional&#160;&lt;/div&gt;4,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt;The Company complies with the requirements of &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt; SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A, &#x201c;Expenses of Offering.&#x201d; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:EquityParticipationSharesPolicyPolicyTextBlock>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116167"
      unitRef="Unit_shares">34500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116168"
      unitRef="Unit_shares">4500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:NetLossPerCommonSharePolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39133">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Net Income (Loss) per Common Share&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;&lt;/div&gt;7,330,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is received by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.&lt;/div&gt;&lt;/div&gt;</blacu:NetLossPerCommonSharePolicyPolicyTextBlock>
    <blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116170"
      unitRef="Unit_shares">7330000</blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39140">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Common Stock Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; deficit. The Company&#x2019;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;March 31, 2024 and&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;December&#160;31, 2023,&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;3,467,954&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s condensed balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116171"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116172"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39150">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary diff&lt;div style="display:inline;"&gt;er&lt;/div&gt;ences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets w&lt;div style="display:inline;"&gt;er&lt;/div&gt;e deemed to be de minimis as of March&#160;31, 2024 and&#160;December 31, 2023.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the three months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total provision for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For&#160;the&#160;three&#160;months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(benefit) at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State tax provision/(benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in fair value of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely than not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;unrecognized tax benefits as of&#160;March 31, 2024 and&#160;December&#160;31, 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;&lt;/div&gt;No&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;amounts were accrued for the payment interest and penalties for the three months ended March&#160;31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39157">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the three months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total provision for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;90,473&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;29,321&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116173"
      unitRef="Unit_USD">90473</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116174"
      unitRef="Unit_USD">29321</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116175"
      unitRef="Unit_USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116176"
      unitRef="Unit_USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116177"
      unitRef="Unit_USD">90473</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-116178"
      unitRef="Unit_USD">29321</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39322">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For&#160;the&#160;three&#160;months&lt;br/&gt;ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(benefit) at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State tax provision/(benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in fair value of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116180"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116181"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116182"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116183"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116184"
      unitRef="Unit_pure">0</blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability>
    <blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116185"
      unitRef="Unit_pure">0</blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116186"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116187"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116188"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116189"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To03_31_2024"
      decimals="3"
      id="ixv-116190"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To03_31_2023"
      decimals="3"
      id="ixv-116191"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116192"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116193"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116194"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <blacu:OfferingCostsPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39503">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1,&#160;SEC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; SAB Topic 5A, and SEC SAB Topic 5T, &#x201c;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#x201d;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:OfferingCostsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39513">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting sta&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;nd&lt;/div&gt;a&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;r&lt;/div&gt;ds, if currently adopted, would have a material effect on the Company&#x2019;s unaudited condensed financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <blacu:InitialPublicOfferingTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39522">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 3&#x2013;INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Initial Public Offering, the Company sold&#160;&lt;/div&gt;6,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;&lt;/div&gt;900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units. Each Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock,&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;redeemable warrant entitling the holder thereof to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock at a price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share, subject to adjustme&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;nt,&lt;/div&gt; and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of a share of common stock (see Note 6). Each warrant will become exercisable&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;days after the consummation of an initial business combination, and will expire&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;five years&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;after the completion of an initial business combination, or earlier upon redemption or liquidation. Each right entitles the holder thereof to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;&lt;/div&gt;ten&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;rights entitle the holder thereof to receive one share of common &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;sto&lt;/div&gt;ck at the closing of a business combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:InitialPublicOfferingTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116195"
      unitRef="Unit_shares">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116196"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116197"
      unitRef="Unit_shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116198"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116199"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116200"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116201"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116202"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-39547">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-39551">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116203"
      unitRef="Unit_shares">10</blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39572"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 4&#x2013;RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;30, 2020, the Sponsor purchased&#160;&lt;/div&gt;1,437,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of the Company&#x2019;s Common Stock (the&#160;&#x201c;Founder Shares&#x201d;) for an aggregate purchase price of $&lt;/div&gt;25,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, or approximately $&lt;/div&gt;0.017&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share.&#160;&lt;/div&gt;&lt;div style="-sec-ix-hidden:hidden117832661;display:inline;"&gt;On&lt;/div&gt; April&#160;25, 2022, the Company executed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;1.2-for-one&#160;stock&lt;/div&gt;&lt;/div&gt; split, resulting in an aggregate of&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,725,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;Founder Shares held by the Company&#x2019;s sponsor, of which up to&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;225,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;three years&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $&lt;/div&gt;12.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;trading days &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;within&#160;any&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&#160;trading&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; period commencing at least&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;property.&#160;&lt;/div&gt;&lt;/div&gt;&#160;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Private Placement Units&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor has purchased an aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Private Placement Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock,&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;redeemable warrant entitling the holder to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;receive&#160;one-tenth&#160;(1/10)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;be &lt;/div&gt;included in the liquidating distribution to the holders of the Public Shares.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor and the Company&#x2019;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;days after the completion of the Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Promissory Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;by&#160;non-interest-bearing&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; promissory notes in the aggregate principal amount of $&lt;/div&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. The promissory notes were due at the earlier of&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;November 29, 2023&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On June 23, 2023, the Sponsor loaned to the Company $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;200,000 to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;200,000. This &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate an initial Business Combination, the note will be repaid only from amounts remaining outside of the Company&#x2019;s Trust Account, if any. At the Sponsor&#x2019;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;of $&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;10.00 per Unit. As of March 31, 2024 and December 31, 2023, the outstanding balance of this note was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On November 13, 2023, Bellevue Capital Management LLC (&#x201c;BCM&#x201d;) loaned to the Company $&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;180,000 and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;180,000. The proceeds of this loan were used to fund the payment to extend the date by which the Company must consummate an initial Business Combination to February 14, 2024. The note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#x2019;s Trust Account, if any. As of March 31, 2024 and December 31, 2023, the outstanding balance of this &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; note was $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#x201c;JCW Promissory Note&#x201d;) in the principal amount of $&lt;/div&gt;75,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Jun Chul Whang, a member of the Company&#x2019;s Board. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August 9, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#x201c;JCW Maturity Date&#x201d;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#x2019;s trust account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note was&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;75,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#x201c;JP Promissory Note&#x201d;) in the principal amount of $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Josh Pan, a member of Bellevue Capital Management LLC. The JP Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August&#160;8, 2024 or (ii)&#160;the date on which the Company consummates an initial business combination (the &#x201c;JP Maturity Date&#x201d;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#x2019;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JP Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;was $&lt;/div&gt;60,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Working Capital Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;1,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;of such Working Capital Loans may be convertible into Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#x2019;s securities, and Chardan and its related persons will have&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;recourse with respect to their ability to convert their loans into any of the Company&#x2019;s securities. As of March&#160;31, 2024 and&#160;December 31, 2023,&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Working Capital Loans were outstanding.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Administrative Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $&lt;/div&gt;7,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;the Business Combination or the Company&#x2019;s liquidation, the Company will cease paying these monthly fees. During &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;the three months ended March 31, 2024 and 2023, the Company&lt;/div&gt;&#160;incurred $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;22,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;and $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;, respectively, of administrative support fees which are included in general and administrative expenses in the &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;accompanying condensed statements&lt;/div&gt;&#160;of operations. As of March&#160;31, 2024 and December&#160;31, 2023, the outstanding balance was $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;30,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; and $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;15,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;, respectively,&#160;recorded as due to affiliate. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Due to Affiliate &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. On February&#160;17, 2022, the Company repaid $&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. On April&#160;29, 2022, the Sponsor agreed to advance an additional $&lt;/div&gt;7,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. These advances are due on &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;demand and are non-interest bearing. During the year ended&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;December 31, 2023, the Sponsor advanced $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;of funds to the Company and Company repaid $&lt;/div&gt;140,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $&lt;/div&gt;7,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#x2019;s liquidation, the Company will cease paying these monthly fees.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The outstanding balance was $&lt;/div&gt;57,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;as of&#160;March 31, 2024 and December&#160;31, 2023, recorded as due to affiliate.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116204"
      unitRef="Unit_shares">1437500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116205"
      unitRef="Unit_USD">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-116206"
      unitRef="Unit_USD_per_Share">0.017</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116207"
      unitRef="Unit_shares">1725000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116208"
      unitRef="Unit_shares">225000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <blacu:SharesOutstandingHoldingTermAfterBusinessCombination
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-39600">P3Y</blacu:SharesOutstandingHoldingTermAfterBusinessCombination>
    <us-gaap:SharePrice
      contextRef="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116209"
      unitRef="Unit_USD_per_Share">12.5</us-gaap:SharePrice>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-39606">P20D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-116210">P30D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-39614">P150D</blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116211"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116212"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116213"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116214"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116215"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116216"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116217"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      id="ixv-39648">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116218"
      unitRef="Unit_USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-39660">2023-11-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116219"
      unitRef="Unit_USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_23_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116220"
      unitRef="Unit_USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SharePrice
      contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-116221"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116222"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116224"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116225"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116226"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116227"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_09_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116228"
      unitRef="Unit_USD">75000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_JunChulWhangMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116229"
      unitRef="Unit_USD">75000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116230"
      unitRef="Unit_USD">60000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116231"
      unitRef="Unit_USD">60000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116232"
      unitRef="Unit_USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-116233"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116234"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116235"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116236"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <blacu:MonthlyAdministrativeFeesExpense
      contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116237"
      unitRef="Unit_USD">7500</blacu:MonthlyAdministrativeFeesExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116240"
      unitRef="Unit_USD">22500</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116241"
      unitRef="Unit_USD">7500</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116242"
      unitRef="Unit_USD">30000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116243"
      unitRef="Unit_USD">15000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116244"
      unitRef="Unit_USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116245"
      unitRef="Unit_USD">10000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116246"
      unitRef="Unit_USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116247"
      unitRef="Unit_USD">7000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116248"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116249"
      unitRef="Unit_USD">140000</us-gaap:RepaymentsOfDebt>
    <blacu:MonthlyAdministrativeFeesExpense
      contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116250"
      unitRef="Unit_USD">7500</blacu:MonthlyAdministrativeFeesExpense>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116251"
      unitRef="Unit_USD">57000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2024To03_31_2024_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116252"
      unitRef="Unit_USD">57000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39822">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 5&#x2013;COMMITMENTS&#160;AND&#160;CONTINGENCIES &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Registration Rights &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;&lt;/div&gt;two&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#x201c;piggyback&#x201d; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#x201c;piggyback&#x201d; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="-sec-ix-redline:true;display:inline;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company granted the underwriters &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;45-day&#160;option&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; from the final prospectus relating to the Initial Public Offering to purchase up to&#160;&lt;/div&gt;900,000&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The underwriters were entitled to an underwriting discount of $&lt;/div&gt;0.20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit, or $&lt;/div&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in the aggregate, equal to&#160;&lt;/div&gt;2&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the gross proceeds of the Initial Public Offering (or $&lt;/div&gt;1,380,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in the aggregate if the underwriters&#x2019; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $&lt;/div&gt;0.125&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit payable in cash. In addition, $&lt;/div&gt;0.30&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit, or approximately&#160;$&lt;/div&gt;1,800,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in&#160;the aggregate (or $&lt;/div&gt;2,070,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#x2019; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;entitled to receive&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;30,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;shares of Common Stock (or&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;shares if the underwriters&#x2019; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#x201c;Equity Participation Shares.&#x201d; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) and are therefore subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;lock-up&#160;for&lt;/div&gt; a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#x201c;piggyback&#x201d; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Excise Tax &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Inflation Reduction Act (&#x201c;IR Act&#x201d;) of 2022 imposes a&#160;&lt;/div&gt;1&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December&#160;31, 2022. For purposes of the Excise Tax, a repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#x201c;SPAC&#x201d;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#x2019;s &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;initial&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;a&#160;de-SPAC&#160;transaction&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; within the required time set forth in its constituent documents, or (iii)&#160;in connection with &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;the&#160;wind-up&#160;and&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;&lt;/div&gt;1&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% has &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;been included in these unaudited condensed financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#x2019;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $&lt;/div&gt;359,957&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;excise tax liability as of March 31, 2024. The Company will continue to monitor for updates to the Company&#x2019;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#x2019;s tax provision in future periods.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Risks and Uncertainties&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial business combination and any target business with which the Company may ultimately consummate an initial business combination.&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The excise tax included in the IR Act of 2022 may decrease the value of the Company&#x2019;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <blacu:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116253"
      unitRef="Unit_pure">2</blacu:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116254"
      unitRef="Unit_shares">900000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:UnderwritingCashDiscountPerUnit
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116255"
      unitRef="Unit_USD_per_Share">0.2</blacu:UnderwritingCashDiscountPerUnit>
    <blacu:AggregateUnderwriterCashDiscount
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116256"
      unitRef="Unit_USD">1200000</blacu:AggregateUnderwriterCashDiscount>
    <blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116257"
      unitRef="Unit_pure">0.02</blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116258"
      unitRef="Unit_USD">1380000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <blacu:UnderwritingCashDiscountPerUnit
      contextRef="PAsOn03_31_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="3"
      id="ixv-116259"
      unitRef="Unit_USD_per_Share">0.125</blacu:UnderwritingCashDiscountPerUnit>
    <blacu:UnderwritingExpensePricePerShare
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116260"
      unitRef="Unit_USD_per_Share">0.3</blacu:UnderwritingExpensePricePerShare>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116261"
      unitRef="Unit_USD">1800000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116262"
      unitRef="Unit_USD">2070000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116264"
      unitRef="Unit_shares">30000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116265"
      unitRef="Unit_shares">34500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <blacu:EffectiveExciseTaxRate
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116266"
      unitRef="Unit_pure">1</blacu:EffectiveExciseTaxRate>
    <blacu:EffectiveExciseTaxRate
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-116267"
      unitRef="Unit_pure">1</blacu:EffectiveExciseTaxRate>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116268"
      unitRef="Unit_USD">359957</us-gaap:SalesAndExciseTaxPayableCurrent>
    <blacu:CommonStockSubjectToPossibleRedemptionTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39959">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 6&#x2013;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s common stock features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s condensed balance sheets.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s common stock subject to possible redemption as of March&#160;31, 2024:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Subject to&lt;br/&gt;Possible&lt;br/&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Gross proceeds from Initial Public Offering&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;69,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Proceeds allocated to public warrants and rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(1,236,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Offering costs allocated to common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(4,791,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Redemption of common stock in connection with Trust extension&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(35,995,728&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;9,449,634&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,426,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;340,351&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,766,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</blacu:CommonStockSubjectToPossibleRedemptionTextBlock>
    <blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-39966">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s common stock subject to possible redemption as of March&#160;31, 2024:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Subject to&lt;br/&gt;Possible&lt;br/&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Gross proceeds from Initial Public Offering&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;69,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Proceeds allocated to public warrants and rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(1,236,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Offering costs allocated to common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(4,791,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Redemption of common stock in connection with Trust extension&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(35,995,728&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;9,449,634&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,426,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;340,351&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,766,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116270"
      unitRef="Unit_USD">69000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116271"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116272"
      unitRef="Unit_USD">4791126</us-gaap:DeferredOfferingCosts>
    <blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116273"
      unitRef="Unit_USD">-35995728</blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116274"
      unitRef="Unit_USD">9449634</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116275"
      unitRef="Unit_USD">36426253</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2024To03_31_2024_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116276"
      unitRef="Unit_USD">340351</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116277"
      unitRef="Unit_USD">36766604</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-40099">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;NOTE 7&#x2013;STOCKHOLDERS&#x2019; DEFICIT&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is authorized to issue&#160;&lt;/div&gt;1,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of preferred stock with a par value of $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share. As of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;December&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;31, 2024 and March&#160;31, 2023, there were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of preferred stock issued or outstanding.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;&lt;/div&gt;100,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock at a&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;$&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;par value.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of&#160;March 31, 2024 and December&#160;31, 2023, there were&#160;&lt;/div&gt;2,155,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock outstanding, excluding&#160;&lt;/div&gt;3,467,954&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of common stock subject to possible redemption that are reflected in temporary equity in the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;condensed&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0.13in;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0.13in;"&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, there were&#160;&lt;/div&gt;7,330,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Warrants outstanding. The Warrants that are a part of the Units (the &#x201c;Warrants&#x201d;) may be exercised at a price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;days after the completion of a Business Combination.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Warrants have an exercise price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share and will expire&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;five years&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Redemption of warrants when the price per Common Stock equals or exceeds $16.50.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Once the Warrants become exercisable, the Company may call the Warrants for redemption:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;at a price of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.01&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;per Warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;upon not less than&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;30&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;days&#x2019; prior written notice of redemption given after the Warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;if, and only if, the reported last sale price of the Common Stock equals or exceeds $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;16.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;trading days &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;within&#160;a&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-trading&#160;day&lt;/div&gt; period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;entire&#160;30-day&#160;trading&lt;/div&gt; period referred to above and continuing each day thereafter until the date of redemption.&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;-sec-ix-redline:true;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s Board), (y) the aggregate gross proceeds from such issuances represent more than&lt;/div&gt;&#160;&lt;/div&gt;60&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $&lt;/div&gt;9.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;&lt;/div&gt;115&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the Market Value, and the $&lt;/div&gt;16.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;&lt;/div&gt;165&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% of the Market Value.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company complies with the requirements of &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;ASC&#160;340-10-S99-1&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"&gt;&lt;/div&gt;&lt;div style="color: red; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#x2019;s certificate of incorporation with respect to its &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;pre-business&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;as-converted&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; into common stock basis. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      id="ixv-116278"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-116279"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="4"
      id="ixv-116280"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="4"
      id="ixv-116281"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-116282"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      id="ixv-116283"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-116284"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      id="ixv-116285"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116286"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="4"
      id="ixv-116287"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116289"
      unitRef="Unit_shares">2155000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2024To03_31_2024_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116290"
      unitRef="Unit_shares">2155000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116291"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2024To03_31_2024" id="ixv-116292">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.</us-gaap:CommonStockVotingRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116293"
      unitRef="Unit_shares">7330000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116294"
      unitRef="Unit_shares">7330000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2024_IPOMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116295"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-40169">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116296"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-40177">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116297"
      unitRef="Unit_USD_per_Share">0.01</blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <blacu:NoticePeriodForWarrantRedemption
      contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116298">P30D</blacu:NoticePeriodForWarrantRedemption>
    <blacu:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116299"
      unitRef="Unit_USD_per_Share">16.5</blacu:WarrantRedemptionConditionMinimumSharePrice>
    <blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116300">P20D</blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="P01_01_2024To03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116301">P30D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116303"
      unitRef="Unit_pure">0.60</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116304"
      unitRef="Unit_USD_per_Share">9.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:WarrantExercisePriceAdjustmentPercentage
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116305"
      unitRef="Unit_pure">1.15</blacu:WarrantExercisePriceAdjustmentPercentage>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116306"
      unitRef="Unit_USD_per_Share">16.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:RedemptionTriggerPriceAdjustmentPercentage
      contextRef="P01_01_2024To03_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116307"
      unitRef="Unit_pure">1.65</blacu:RedemptionTriggerPriceAdjustmentPercentage>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_EquityParticipationMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116308"
      unitRef="Unit_shares">34500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-40330">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;NOTE 8&#x2013;FAIR VALUE MEASUREMENTS&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value as of March&#160;31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;37,205,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;37,205,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value as of December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 11pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;There were no transfers between Levels 1, 2 and 3 during the three months ended March&#160;31, 2024.&lt;/div&gt;&lt;div style="background-color: initial; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-40335">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value as of March&#160;31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;37,205,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;37,205,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value as of December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 11pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-116309"
      unitRef="Unit_USD">37205930</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116310"
      unitRef="Unit_USD">37205930</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2024_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116311"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116312"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116314"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116315"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116316"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116317"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-40762">&lt;div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 9&#x2013;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company evaluated subsequent events to determine if events or transactions occurred after the condensed balance sheet date up to the date the unaudited condensed financial statements&#160;were&#160;issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements, other than the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April 1, 2024, the Company submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq. On April 17, 2024, the Company received written notice from Nasdaq indicating that the staff of Nasdaq (the &#x201c;Staff&#x201d;) determined, based on its review of the Company&#x2019;s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August&#160;13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or an independent source, demonstrating that its &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;common &lt;/div&gt;stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the Staff will provide written notification that the Company&#x2019;s securities will be delisted. At that time, the Company may appeal the Staff&#x2019;s determination to a Listing Qualifications Panel. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#x201c;April Sponsor Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;to the Sponsor. The April Sponsor Note is&#160;not interest&#160;bearing and is payable in full on the earlier of (i)&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;December 31, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;or (ii)&#160;the date on which the Company consummates an initial &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Business Combination&lt;/div&gt; (the &#x201c;April Sponsor Note Maturity Date&#x201d;). In the event that the Company does not consummate a &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Business Combination&lt;/div&gt; on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the April Sponsor Note, except to the extent of any funds remaining outside of the Company&#x2019;s &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Trust Account&lt;/div&gt;, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;9, 2024, $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;was deposited in the&#160;Trust Account&#160;in connection with the&#160;extension of the date by which the Company must consummate a business combination from&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;April 15, 2024&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;to &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;May 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In connection with the November 2023 withdrawal of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;561,957&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;of interest income earned in the Trust Account for payment of the Company&#x2019;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;. As&lt;/div&gt; of April&#160;16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#x2019;s Sponsor and the Company has paid its federal tax obligations on time. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;17, 2024,&#160;the Company issued an unsecured promissory note (the &#x201c;Second April Sponsor Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;50,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;the Sponsor. The Second April Sponsor Note is not&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;interest bearing and is&#160;payable in full on the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the&#160;date on which the Company consummates an initial Business Combination (the &#x201c;Second April Sponsor Notes Maturity Date&#x201d;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;. In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the Second April Sponsor Note, except to the extent of any funds remaining outside of the Company&#x2019;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the Second April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;17, 2024, the Company withdr&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ew&lt;/div&gt;&#160;$&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;100,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; of interest income earned in the Trust Account for payment of the Company&#x2019;s state franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On May&#160;10, 2024, the Company &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;convened&lt;/div&gt; a special meeting of its stockholders (the &#x201c;2024 Special Meeting&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201d;) as scheduled and adjourned the 2024 Special Meeting without any business being conducted. As announced at the 2024 Special Meeting, it was reconvened on May 14, 2024.&lt;/div&gt;&#160;At the 2024 Special Meeting, the Company&#x2019;s stockholders approved &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;the proposal to extend&lt;/div&gt; the date by which the Company must consummate a &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Business Combination&lt;/div&gt; from &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;May 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;November 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;.&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Following such approval by the Company&#x2019;s stockholders, the Company subsequently amended its Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a Business Combination to November 14, 2024. &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company also&lt;/div&gt;&lt;/div&gt; deposited $&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;50,000 into the Trust Account on May 14, 2024.&lt;/div&gt;&#160;In connection with the Special Meeting,&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;1,581,733&lt;/div&gt;&#160;shares of common stock of the Company were tendered for redemption.&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On May 14, 2024, the Company issued an unsecured promissory note (the &#x201c;May Sponsor Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;140,000 to the Sponsor. The May Sponsor Note is &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;no&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;t interest bearing and is payable in full on the earlier of&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;(i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination (the &#x201c;May Sponsor Note Maturity Date&#x201d;). In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the May Sponsor Note, except to the extent of any funds remaining outside of the Company&#x2019;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden117832595;display:inline;"&gt;five&lt;/div&gt;&lt;/div&gt; business days of the May Sponsor Note Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_08_2024_AprilSponsorNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116318"
      unitRef="Unit_USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116319">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116320"
      unitRef="Unit_USD">60000</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116321">2024-04-15</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116322">2024-05-14</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:InterestIncomeOther
      contextRef="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116323"
      unitRef="Unit_USD">561957</us-gaap:InterestIncomeOther>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_17_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116324"
      unitRef="Unit_USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestIncomeOther
      contextRef="P04_17_2024To04_17_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116326"
      unitRef="Unit_USD">100000</us-gaap:InterestIncomeOther>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116327">2024-05-14</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P05_10_2024To05_10_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116328">2024-11-14</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116329"
      unitRef="Unit_USD">50000</us-gaap:AssetsHeldInTrust>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn05_14_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116330"
      unitRef="Unit_shares">1581733</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_14_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116331"
      unitRef="Unit_USD">140000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn05_14_2024_MayTwoThousandAndTwentyFourPromissoryNoteMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116332"
      unitRef="Unit_pure">0</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116333"
      unitRef="Unit_USD">15419</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116334"
      unitRef="Unit_USD">124501</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116335"
      unitRef="Unit_USD">7208</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116336"
      unitRef="Unit_USD">22627</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116337"
      unitRef="Unit_USD">124501</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116338"
      unitRef="Unit_USD">1101353</us-gaap:DeferredCosts>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116339"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116340"
      unitRef="Unit_USD">36627733</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116341"
      unitRef="Unit_USD">1225854</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116342"
      unitRef="Unit_USD">1081753</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116343"
      unitRef="Unit_USD">34000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116344"
      unitRef="Unit_USD">524562</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116345"
      unitRef="Unit_USD">359957</us-gaap:SalesAndExciseTaxPayableCurrent>
    <blacu:AccruedOfferingCostsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116346"
      unitRef="Unit_USD">12362</blacu:AccruedOfferingCostsCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116347"
      unitRef="Unit_USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116348"
      unitRef="Unit_USD">1200000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116349"
      unitRef="Unit_USD">72000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116350"
      unitRef="Unit_USD">17000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116351"
      unitRef="Unit_USD">2038272</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116352"
      unitRef="Unit_USD">1263362</us-gaap:LiabilitiesCurrent>
    <blacu:DeferredUnderwritingCommissions
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116353"
      unitRef="Unit_USD">2070000</blacu:DeferredUnderwritingCommissions>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116354"
      unitRef="Unit_USD">4108272</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116355"
      unitRef="Unit_USD">1263362</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-116356"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      id="ixv-116357"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116358"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116359"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <blacu:CommonStockRedemptionValue
      contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116360"
      unitRef="Unit_USD_per_Share">10.5</blacu:CommonStockRedemptionValue>
    <blacu:CommonStockRedemptionValue
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116361"
      unitRef="Unit_USD_per_Share">10.5</blacu:CommonStockRedemptionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116362"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116363"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116364"
      unitRef="Unit_USD">36426253</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      id="ixv-116365"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-116366"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116367"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116368"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116369"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116370"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116371"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116372"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116373"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116374"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      id="ixv-116375"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-116376"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116377"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116378"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116379"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-116380"
      unitRef="Unit_shares">2155000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116381"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116382"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116383"
      unitRef="Unit_shares">1725000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-116384"
      unitRef="Unit_shares">1725000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116385"
      unitRef="Unit_USD">216</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116386"
      unitRef="Unit_USD">173</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116387"
      unitRef="Unit_USD">24827</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116388"
      unitRef="Unit_USD">-3907008</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116389"
      unitRef="Unit_USD">-62508</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116390"
      unitRef="Unit_USD">-3906792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116391"
      unitRef="Unit_USD">-37508</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116392"
      unitRef="Unit_USD">36627733</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116393"
      unitRef="Unit_USD">1225854</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116394"
      unitRef="Unit_USD">1830700</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116395"
      unitRef="Unit_USD">35388</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116396"
      unitRef="Unit_USD">-1830700</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116397"
      unitRef="Unit_USD">-35388</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116398"
      unitRef="Unit_USD">2775291</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherIncome
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116399"
      unitRef="Unit_USD">2775291</us-gaap:OtherIncome>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116400"
      unitRef="Unit_USD">944591</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116401"
      unitRef="Unit_USD">-35388</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116402"
      unitRef="Unit_USD">540811</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116403"
      unitRef="Unit_USD">403780</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116404"
      unitRef="Unit_USD">-35388</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116405"
      unitRef="Unit_shares">7688260</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116406"
      unitRef="Unit_shares">1500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116407"
      unitRef="Unit_shares">7719699</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116408"
      unitRef="Unit_shares">1500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116409"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-116410"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116411"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-116412"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116413"
      unitRef="Unit_shares">1725000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116414"
      unitRef="Unit_USD">173</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116415"
      unitRef="Unit_USD">24827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116416"
      unitRef="Unit_USD">-27120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-116417"
      unitRef="Unit_USD">-2120</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116418"
      unitRef="Unit_USD">-35388</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116419"
      unitRef="Unit_USD">-35388</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116420"
      unitRef="Unit_shares">1725000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116421"
      unitRef="Unit_USD">173</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116422"
      unitRef="Unit_USD">24827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116423"
      unitRef="Unit_USD">-62508</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116424"
      unitRef="Unit_USD">-37508</us-gaap:StockholdersEquity>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-116425"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116426"
      unitRef="Unit_shares">430000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116427"
      unitRef="Unit_USD">43</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116428"
      unitRef="Unit_USD">4299957</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116429"
      unitRef="Unit_USD">4300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116430"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116431"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116432"
      unitRef="Unit_USD">-5561311</blacu:AccretionForCommonStockToRedemptionValue>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116433"
      unitRef="Unit_USD">-3888323</blacu:AccretionForCommonStockToRedemptionValue>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116434"
      unitRef="Unit_USD">-9449634</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116435"
      unitRef="Unit_USD">403780</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116436"
      unitRef="Unit_USD">403780</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116437"
      unitRef="Unit_USD">359957</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116438"
      unitRef="Unit_USD">359957</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-116439"
      unitRef="Unit_shares">2155000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116440"
      unitRef="Unit_USD">216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-116441"
      unitRef="Unit_USD">-3907008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116442"
      unitRef="Unit_USD">-3906792</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116443"
      unitRef="Unit_USD">403780</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116444"
      unitRef="Unit_USD">-35388</us-gaap:ProfitLoss>
    <us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116445"
      unitRef="Unit_USD">2775291</us-gaap:InterestIncomeInterestEarningAssetIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116446"
      unitRef="Unit_USD">7208</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116447"
      unitRef="Unit_USD">1035391</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116448"
      unitRef="Unit_USD">31153</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116449"
      unitRef="Unit_USD">524562</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116450"
      unitRef="Unit_USD">-818766</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116451"
      unitRef="Unit_USD">-4235</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116452"
      unitRef="Unit_USD">35995728</blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116453"
      unitRef="Unit_USD">180000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <blacu:CashDepositedInTheTrustAccount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116454"
      unitRef="Unit_USD">70207500</blacu:CashDepositedInTheTrustAccount>
    <blacu:GainLossFromTrustAccountToPayExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116455"
      unitRef="Unit_USD">561957</blacu:GainLossFromTrustAccountToPayExpenses>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116456"
      unitRef="Unit_USD">-33829815</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116457"
      unitRef="Unit_USD">35995728</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116458"
      unitRef="Unit_USD">59670000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116459"
      unitRef="Unit_USD">9157500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116460"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116461"
      unitRef="Unit_USD">1447273</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116462"
      unitRef="Unit_USD">683021</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116463"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116464"
      unitRef="Unit_USD">800000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2023To12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116465"
      unitRef="Unit_USD">1200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116466"
      unitRef="Unit_USD">395000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116467"
      unitRef="Unit_USD">17000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116468"
      unitRef="Unit_USD">340000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116469"
      unitRef="Unit_USD">10000</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116470"
      unitRef="Unit_USD">34539499</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116471"
      unitRef="Unit_USD">123979</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116472"
      unitRef="Unit_USD">-109082</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116473"
      unitRef="Unit_USD">119744</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116474"
      unitRef="Unit_USD">124501</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-116475"
      unitRef="Unit_USD">4757</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116476"
      unitRef="Unit_USD">15419</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116477"
      unitRef="Unit_USD">124501</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116478"
      unitRef="Unit_USD">16249</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116479"
      unitRef="Unit_USD">359957</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116480"
      unitRef="Unit_USD">2070000</us-gaap:PaymentsForUnderwritingExpense>
    <blacu:DeferredOfferingCostsIncludedInAccruedOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-116481"
      unitRef="Unit_USD">12362</blacu:DeferredOfferingCostsIncludedInAccruedOfferingCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-43740">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 1&#x2013;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Bellevue Life Sciences Acquisition Corp. (the &#x201c;Company&#x201d;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;or more businesses or entities (the &#x201c;Business Combination&#x201d;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of&#160;December&#160;31, 2023, the Company had not commenced any operations. All activity since inception relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will generate &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering (the &#x201c;Registration Statement&#x201d;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;&lt;/div&gt;6,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;units (&#x201c;Units&#x201d; and, with respect to the common stock included in the Units being offered, the &#x201c;Public Shares&#x201d;), generating gross proceeds of $&lt;/div&gt;60,000,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;, which is described in Note 3.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#x201c;Over-Allotment Option Units&#x201d;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;&lt;/div&gt;900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Over-Allotment Option Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per unit generated total gross proceeds of $&lt;/div&gt;9,000,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#x201c;Private Placement&#x201d;) of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units (the &#x201c;Private Placement Units&#x201d;), to Bellevue Global Life Sciences Investors LLC (the &#x201c;Sponsor&#x201d;) at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Placement Unit, for an aggregate purchase price of $&lt;/div&gt;4,300,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Each Unit and Private Placement Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock, par value $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;(the &#x201c;Common Stock&#x201d;), a warrant to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock (the &#x201c;Public Warrants&#x201d; and &#x201c;Private Placement Warrants&#x201d; and collectively, the &#x201c;Warrants&#x201d;) and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to receive &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of a share of common stock (the &#x201c;Public Rights&#x201d; and Private Placement Rights&#x201d; and collectively, the &#x201c;Rights&#x201d;), as described in Notes 3 and 4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;&lt;/div&gt;80&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;&lt;/div&gt;50&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of&lt;/div&gt;&#160;$&lt;/div&gt;70,207,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;was placed in a trust account (&#x201c;Trust Account&#x201d;) located in the United States with Continental Stock Transfer &amp;amp; Trust Company acting as trustee, and&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;invested only in United States &#x201c;government securities&#x201d; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#x201c;Investment Company Act&#x201d;) having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;2a-7&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: red; text-decoration-line: underline; text-indent: 0px; background-color: rgb(204, 204, 204); font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#x201c;Public Stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &#x201c;Distinguishing Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;5,000,001&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any material &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-public&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; information and (ii)&#160;to clear all trades with the Company&#x2019;s legal counsel or compliance officer prior to execution. In addition, the Company&#x2019;s Sponsor and any other holders of the Company&#x2019;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#x201c;Initial Stockholders&#x201d;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#x2019;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;&lt;/div&gt;15&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s Initial Stockholders and Chardan Capital Markets, LLC (&#x201c;Chardan&#x201d;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#x2019;s Amended and&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;&lt;/div&gt;100&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of its Public Shares if the Company does not complete a Business Combination within&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;nine months&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#x201c;Combination Period&#x201d;) or (B)&#160;with respect to any other provision relating to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;stockholders&#x2019;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; rights or &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;pre-initial&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than ten business days thereafter, redeem&#160;&lt;/div&gt;100&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $&lt;/div&gt;100,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#x2019;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $&lt;/div&gt;10.175&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt; per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#x2019;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Extension of Termination Date and Redemptions from the Trust Account &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#x201c;Special Meeting&#x201d;). At the Special Meeting, the Company&#x2019;s stockholders approved an extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors the authority in its discretion to amend the Charter to extend the date by which the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Company must consummate a business combination from the First Extended Date to May&#160;14, 2024. In connection with the Special Meeting, &lt;/div&gt;3,432,046&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of common stock of the Company were tendered for redemption at a redemption price of approximately $&lt;/div&gt;10.49&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; per share for an aggregate redemption amount of $&lt;/div&gt;35,995,728&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, leaving $&lt;/div&gt;36,372,335&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $&lt;/div&gt;561,957&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Additionally, the Company deposited $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt; into the Trust Account on November&#160;13, 2023 in connection with the extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Franchise and Income Tax Withdrawal &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In November 2023, the Company withdrew $&lt;/div&gt;561,957&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;of interest income earned in the Trust Account for payment of the Company&#x2019;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through December 31, 2023, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#x2019;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#x2019;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of December 31, 2023, the Company&#x2019;s obligations for franchise and income tax purposes remain payable.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#x201c;GAAP&#x201d;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023, the Company had $&lt;/div&gt;15,419&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in its operating bank account and a working capital deficit of $&lt;/div&gt;2,015,645&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&#160;The Company&#x2019;s liquidity needs prior to the consummation of the Initial Public Offering had been satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#x2019;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement held outside of the Trust Account.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or fifteen months from the Initial Public Offering. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160;Over this time period, the Company will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#x2019;s current operating cash balance may need to be funded through loans from the Company&#x2019;s Sponsor. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;If the Company is unable to complete a Business Combination by May&#160;14, 2024 (subject to extension by approval of the Company&#x2019;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management intends to complete a business combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Emerging Growth Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;non-emerging&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116482"
      unitRef="Unit_pure">1</blacu:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116483"
      unitRef="Unit_shares">6000000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_14_2023To02_14_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116484"
      unitRef="Unit_USD">60000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116485"
      unitRef="Unit_shares">900000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116486"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="PAsOn02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116487"
      unitRef="Unit_USD">9000000</us-gaap:CommonUnitIssuanceValue>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116488"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116489"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116490"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116491"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-116492"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116493"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P02_17_2023To02_17_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116494"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <blacu:PercentageOfTrustAccountRequiredForBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116495"
      unitRef="Unit_pure">0.80</blacu:PercentageOfTrustAccountRequiredForBusinessCombination>
    <blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116496"
      unitRef="Unit_pure">0.50</blacu:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116497"
      unitRef="Unit_USD">70207500</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="P01_01_2023To12_31_2023" id="ixv-116499">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#x201c;Public Stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).</us-gaap:DebtInstrumentRedemptionDescription>
    <blacu:NetTangibleAssets
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116500"
      unitRef="Unit_USD">5000001</blacu:NetTangibleAssets>
    <blacu:RedemptionLimitPercentage
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116501"
      unitRef="Unit_pure">0.15</blacu:RedemptionLimitPercentage>
    <blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116504"
      unitRef="Unit_pure">1</blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <blacu:PeriodToConsummateBusinessCombination contextRef="P01_01_2023To12_31_2023" id="ixv-43867">P9M</blacu:PeriodToConsummateBusinessCombination>
    <blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-116505"
      unitRef="Unit_pure">1</blacu:PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <blacu:MaximumAllowedDissolutionExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116506"
      unitRef="Unit_USD">100000</blacu:MaximumAllowedDissolutionExpenses>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn02_14_2024"
      decimals="INF"
      id="ixv-116509"
      unitRef="Unit_shares">3432046</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn02_14_2024"
      decimals="2"
      id="ixv-116510"
      unitRef="Unit_USD_per_Share">10.49</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="PAsOn02_14_2024"
      decimals="0"
      id="ixv-116511"
      unitRef="Unit_USD">35995728</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:CommonStockValueOutstanding
      contextRef="PAsOn02_14_2024"
      decimals="0"
      id="ixv-116512"
      unitRef="Unit_USD">36372335</us-gaap:CommonStockValueOutstanding>
    <blacu:InterestIncomeHeldInTheTrustAccount
      contextRef="P11_14_2023To02_14_2024"
      decimals="0"
      id="ixv-116513"
      unitRef="Unit_USD">561957</blacu:InterestIncomeHeldInTheTrustAccount>
    <blacu:InvestmentOfCashInTrustAccount
      contextRef="PAsOn11_13_2023"
      decimals="0"
      id="ixv-116514"
      unitRef="Unit_USD">180000</blacu:InvestmentOfCashInTrustAccount>
    <blacu:InterestIncomeHeldInTheTrustAccount
      contextRef="P11_01_2023To11_30_2023"
      decimals="0"
      id="ixv-116515"
      unitRef="Unit_USD">561957</blacu:InterestIncomeHeldInTheTrustAccount>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116516"
      unitRef="Unit_USD">15419</us-gaap:Cash>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116517"
      unitRef="Unit_USD">2015645</us-gaap:DebtCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-43998">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;NOTE 2&#x2013;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;/div&gt;15,419&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;and $&lt;/div&gt;124,501&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; in cash held in its operating account as of December&#160;31, 2023 and 2022, respectively. The Company had&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;cash equivalents as of December&#160;31, 2023 and 2022.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Investments Held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#x2019;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#x2019;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The fair value of certain of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of&#160;December&#160;31, 2023 due to the short maturities of such instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-valued&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the financial statements as current or &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; based on whether or not &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-cash&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; settlement or conversion of the instrument could be required within 12 months of the balance sheet date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Warrant Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and &lt;div style="display:inline;"&gt;wh&lt;/div&gt;ether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#x2019;s own common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a c&lt;div style="display:inline;"&gt;ir&lt;/div&gt;cumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the Initial Public Offering and the exercise of the over-allotment of up to 6,900,000 Public Units, each Public Unit is comprised of&#160;one&#160;share of common stock, $0.0001&#160;par value, a warrant to purchase&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Right to receive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Placement Rights underlying Placement Units (the &#x201c;Placement Rights&#x201d;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#x201c;Rights&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40.&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;representati&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ve&lt;/div&gt; shares (&#x201c;Equity&#160;Participation Shares&#x201d;), which include an additional&#160;&lt;/div&gt;4,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A, &#x201c;Expenses of Offering.&#x201d; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Net Income (Loss) per Common Share &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income (loss) per common share is computed by dividing net income (loss) by the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;&lt;/div&gt;7,330,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is rec&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ei&lt;/div&gt;ved by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common Stock Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; deficit. The Company&#x2019;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;December&#160;31, 2023 and&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;2022,&#160;&lt;/div&gt;3,467,954&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and&#160;&lt;/div&gt;0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s balance sheets, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December&#160;31, 2023 and 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(Benefit) at Statutory Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State Tax Provision/(Benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in FV of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely th&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;an&lt;/div&gt; not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;unrecognized tax benefits as of&#160;December&#160;31, 2023 and&#160;2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;&lt;/div&gt;No&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;amounts were accrued for the payment interest and penalties for the year ended&#160;December&#160;31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;340-10-S99-1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; SEC SAB Topic 5A, and SEC SAB Topic 5T, &#x201c;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#x201d;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-44001">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44008">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;/div&gt;15,419&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;and $&lt;/div&gt;124,501&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; in cash held in its operating account as of December&#160;31, 2023 and 2022, respectively. The Company had&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;cash equivalents as of December&#160;31, 2023 and 2022.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116519"
      unitRef="Unit_USD">15419</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116520"
      unitRef="Unit_USD">124501</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116521"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116522"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-44019">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44042">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Investments Held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#x2019;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#x2019;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.&lt;/div&gt;&lt;/div&gt;</blacu:InvestmentsHeldInTrustAccountPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44047">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The fair value of certain of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; approximates the carrying amounts represented in the balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of&#160;December&#160;31, 2023 due to the short maturities of such instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44117">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-valued&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the financial statements as current or &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; based on whether or not &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-cash&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; settlement or conversion of the instrument could be required within 12 months of the balance sheet date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-44148">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <blacu:WarrantInstrumentsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44153">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Warrant Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#x2019; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and &lt;div style="display:inline;"&gt;wh&lt;/div&gt;ether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#x2019;s own common shares and whether the instrument holders could potentially require &#x201c;net cash settlement&#x201d; in a c&lt;div style="display:inline;"&gt;ir&lt;/div&gt;cumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.&lt;/div&gt;&lt;/div&gt;</blacu:WarrantInstrumentsPolicyPolicyTextBlock>
    <blacu:RightsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44163">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the Initial Public Offering and the exercise of the over-allotment of up to 6,900,000 Public Units, each Public Unit is comprised of&#160;one&#160;share of common stock, $0.0001&#160;par value, a warrant to purchase&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Public Right to receive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Placement Rights underlying Placement Units (the &#x201c;Placement Rights&#x201d;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#x201c;Rights&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40.&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:RightsPolicyPolicyTextBlock>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116525"
      unitRef="Unit_shares">6900000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116526"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-116527"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116528"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116529"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116530"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <blacu:EquityParticipationSharesPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44194">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;representati&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ve&lt;/div&gt; shares (&#x201c;Equity&#160;Participation Shares&#x201d;), which include an additional&#160;&lt;/div&gt;4,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A, &#x201c;Expenses of Offering.&#x201d; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:EquityParticipationSharesPolicyPolicyTextBlock>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116531"
      unitRef="Unit_shares">34500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ChardanCapitalMarketsLLCMemberusgaapClassOfWarrantOrRightAxis_EquityParticipationMemberusgaapSubsidiarySaleOfStockAxis_OverAllotmentOptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116532"
      unitRef="Unit_shares">4500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:NetLossPerCommonSharePolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44211">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Net Income (Loss) per Common Share &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share.&#x201d; Net income (loss) per common share is computed by dividing net income (loss) by the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;&lt;/div&gt;7,330,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is rec&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ei&lt;/div&gt;ved by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.&lt;/div&gt;&lt;/div&gt;</blacu:NetLossPerCommonSharePolicyPolicyTextBlock>
    <blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116533"
      unitRef="Unit_shares">7330000</blacu:CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44245">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common Stock Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#x2019; deficit. The Company&#x2019;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;December&#160;31, 2023 and&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;2022,&#160;&lt;/div&gt;3,467,954&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and&#160;&lt;/div&gt;0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s balance sheets, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116534"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116535"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44256">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December&#160;31, 2023 and 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(Benefit) at Statutory Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State Tax Provision/(Benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in FV of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely th&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;an&lt;/div&gt; not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;unrecognized tax benefits as of&#160;December&#160;31, 2023 and&#160;2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;&lt;/div&gt;No&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;amounts were accrued for the payment interest and penalties for the year ended&#160;December&#160;31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44264">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;540,811&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116536"
      unitRef="Unit_USD">540811</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116537"
      unitRef="Unit_USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116538"
      unitRef="Unit_USD">540811</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44380">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 85%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Income tax expense:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Provision/(Benefit) at Statutory Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;State Tax Provision/(Benefit) net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in FV of Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Change in valuation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;%&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116540"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116541"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116542"
      unitRef="Unit_pure">0</blacu:EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116543"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116544"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-116545"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116546"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116547"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116548"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <blacu:OfferingCostsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44511">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Offering Costs Associated with the Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;340-10-S99-1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; SEC SAB Topic 5A, and SEC SAB Topic 5T, &#x201c;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#x201d;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</blacu:OfferingCostsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44526">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <blacu:InitialPublicOfferingTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44531">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 3&#x2013;INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Initial Public Offering, the Company sold&#160;&lt;/div&gt;6,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;&lt;/div&gt;900,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Units. Each Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of common stock,&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;redeemable warrant entitling the holder thereof &lt;div style="display:inline;"&gt;to&lt;/div&gt; purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock at a price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share, subject to adjustment, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to receive &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of a share of common stock (see Note 6). Each warrant will become exercisable&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;days after the consummation of an initial business combination, and will expire&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;five years&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;after the completion of an initial bus&lt;div style="display:inline;"&gt;in&lt;/div&gt;ess combination, or earli&lt;div style="display:inline;"&gt;er&lt;/div&gt; upon redemption or liquidation. Each right entitles the holder thereof to receive &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;&lt;/div&gt;ten&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;rig&lt;div style="display:inline;"&gt;ht&lt;/div&gt;s entitle the holder thereof to receive one share of common stock at the closing of a business combination.&lt;/div&gt;&lt;/div&gt;</blacu:InitialPublicOfferingTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116549"
      unitRef="Unit_shares">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116550"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_17_2023To02_17_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116551"
      unitRef="Unit_shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116552"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116553"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116554"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116555"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116556"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-44556">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-44560">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-116557"
      unitRef="Unit_shares">10</blacu:ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44583"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 4&#x2013;RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;30, 2020, the Sponsor purchased&#160;&lt;/div&gt;1,437,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of the Company&#x2019;s Common Stock (the&#160;&#x201c;Founder Shares&#x201d;) for an aggregate purchase price of $&lt;/div&gt;25,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;, or approximately $&lt;/div&gt;0.017&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share.&#160;&lt;/div&gt;&lt;div style="-sec-ix-hidden:hidden117832660;display:inline;"&gt;On&lt;/div&gt; April&#160;25, 2022, the Company executed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1.2-for-one&lt;/div&gt;&lt;/div&gt; stock split, resulting in an aggregate of&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,725,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;Founder Shares held by the Company&#x2019;s sponsor, of which up to&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;225,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;three years&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $&lt;/div&gt;12.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;trading days within &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;any&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; trading period commencing at least&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;150&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for ca&lt;div style="display:inline;"&gt;s&lt;/div&gt;h, securities or other property.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Private Placement Units &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor has purchased an aggregate of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Private Placement Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock,&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;redeemable warrant entitling the holder to purchase&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;share of Common Stock, and&#160;&lt;/div&gt;one&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;right which entitles the holder thereof to receive &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; (1/10) of a share of common stock. The Private Placement Warrants are exercisable only t&lt;div style="display:inline;"&gt;o p&lt;/div&gt;urchase whole shares of Common Stock at an exercise price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be included in the liquidating distribution to the holders of the Public Shares.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor and the Company&#x2019;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;days after the completion of the Business Combination.&lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;"&gt;Promissory Notes&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced by &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non&lt;div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;interest&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;bearing promissory notes in the aggregate principal amount of $&lt;/div&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. The promissory notes were due at the earlier of&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;November 29, 2023&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;23, 2023, the Sponsor loaned to the Company $&lt;/div&gt;200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $&lt;/div&gt;200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. This note is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;non-interest&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;bearing and is payable in full on the earlier of: (i)&#160;December 31, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#x201c;Business Combination&#x201d;). In the event that the Company does not consummate a business combination, the note will be repaid only from amounts remaining outside of the Company&#x2019;s trust account, if any. At the Sponsor&#x2019;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $&lt;/div&gt;0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On November&#160;13, 2023, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Bellevue Capital Management LLC (&#x201c;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;BCM&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201d;)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; loaned to the Company $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. The proceeds of this loan were used to fund the payment to extend the Termination Date by which the Company must consummate an initial business combination to February&#160;14, 2024. The note is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;non-interest&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; bearing and is payable in full on the earlier of: (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which the Company consummates the Business Combination. In the even&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;t&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#x2019;s Trust Account, if any. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $&lt;/div&gt;0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Working Capital Loans &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $&lt;/div&gt;1,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;of such Working Capital Loans may be convertible into Units at a price of $&lt;/div&gt;10.00&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#x2019;s securities, and Chardan and its related persons will have &lt;/div&gt;no&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; recourse with respect to their ability to convert their loans into any of the Company&#x2019;s securities. As of December&#160;31, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023 and&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;2022,&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Working Capital Loans were outstanding.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Administrative Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $&lt;/div&gt;7,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt; per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#x2019;s liquidation, the Company will cease paying these monthly fees. During the years ended December&#160;31, 2023 and December&#160;31, 2022, the Company incurred $&lt;/div&gt;90,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt; and $&lt;/div&gt;75,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"&gt;, respectively, of administrative support fees which are included in general and administrative expenses in the accompanying statements of operations. As of December&#160;31, 2023, the outstanding balance was $&lt;/div&gt;15,000&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt; recorded as due to affiliate.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Due to Affiliate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. On February&#160;17, 2022, the Company repaid $&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$&lt;/div&gt;10,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. On April&#160;29, 2022, the Sponsor agreed to advance an additional $&lt;/div&gt;7,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. These advances are due on demand and are &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;"&gt;non-interest&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;-&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;bearing. During the year ended&#160;December 31, 2023, the Sponsor advanced $&lt;/div&gt;180,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; of funds to the Company and Company repaid $&lt;/div&gt;140,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $&lt;/div&gt;7,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#x2019;s liquidation, the Company will cease paying these monthly fees.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The outstanding balance was $&lt;/div&gt;57,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and $&lt;/div&gt;17,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; as of&#160;December 31, 2023 and December&#160;31, 2022, respectively&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;, recorded as due to affiliate&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116558"
      unitRef="Unit_shares">1437500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116559"
      unitRef="Unit_USD">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn07_30_2020_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-116560"
      unitRef="Unit_USD_per_Share">0.017</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116561"
      unitRef="Unit_shares">1725000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116562"
      unitRef="Unit_shares">225000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <blacu:SharesOutstandingHoldingTermAfterBusinessCombination
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-44608">P3Y</blacu:SharesOutstandingHoldingTermAfterBusinessCombination>
    <us-gaap:SharePrice
      contextRef="PAsOn04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116563"
      unitRef="Unit_USD_per_Share">12.5</us-gaap:SharePrice>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-44614">P20D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-116564">P30D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="P04_25_2022To04_25_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      id="ixv-44622">P150D</blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116565"
      unitRef="Unit_shares">430000</us-gaap:CommonUnitIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116566"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <blacu:NumberOfSharesIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116567"
      unitRef="Unit_shares">1</blacu:NumberOfSharesIssuedPerUnit>
    <blacu:NumberOfWarrantsIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116568"
      unitRef="Unit_shares">1</blacu:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116569"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <blacu:NumberOfRightsIssuedPerUnit
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116570"
      unitRef="Unit_shares">1</blacu:NumberOfRightsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-116571"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      id="ixv-44651">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116572"
      unitRef="Unit_USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapStatementClassOfStockAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-44667">2023-11-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116573"
      unitRef="Unit_USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116574"
      unitRef="Unit_USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SharePrice
      contextRef="PAsOn06_23_2023_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-116575"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116576"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PromissoryNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116578"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_13_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116579"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_BcmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnsecuredDebtMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116580"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116581"
      unitRef="Unit_USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-116582"
      unitRef="Unit_USD_per_Share">10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116583"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116584"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2022To12_31_2022_WorkingCapitalLoansMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-116585"
      unitRef="Unit_USD">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <blacu:MonthlyAdministrativeFeesExpense
      contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116586"
      unitRef="Unit_USD">7500</blacu:MonthlyAdministrativeFeesExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116587"
      unitRef="Unit_USD">90000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116588"
      unitRef="Unit_USD">75000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116589"
      unitRef="Unit_USD">15000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_17_2021_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116590"
      unitRef="Unit_USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P02_17_2022To02_17_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116591"
      unitRef="Unit_USD">10000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_28_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116592"
      unitRef="Unit_USD">10000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_29_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116593"
      unitRef="Unit_USD">7000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116594"
      unitRef="Unit_USD">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116595"
      unitRef="Unit_USD">140000</us-gaap:RepaymentsOfDebt>
    <blacu:MonthlyAdministrativeFeesExpense
      contextRef="P03_01_2023To03_01_2023_AdministrativeServiceMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116596"
      unitRef="Unit_USD">7500</blacu:MonthlyAdministrativeFeesExpense>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2023To12_31_2023_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116597"
      unitRef="Unit_USD">57000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount
      contextRef="P01_01_2022To12_31_2022_AffiliatedEntityMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-116598"
      unitRef="Unit_USD">17000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44794">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 5&#x2013;COMMITMENTS&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;AND&lt;/div&gt; CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Registration Rights &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;&lt;/div&gt;two&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#x201c;piggyback&#x201d; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#x201c;piggyback&#x201d; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company granted the underwriters a &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;45-day&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; option from the final prospectus relating to the Initial Public Offering to purchase up to&#160;&lt;/div&gt;900,000&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The underwriters were entitled to an underwriting discount of $&lt;/div&gt;0.20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit, or $&lt;/div&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in the aggregate, equal to&#160;&lt;/div&gt;2&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the gross proceeds of the Initial Public Offering (or $&lt;/div&gt;1,380,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in the aggregate if the underwriters&#x2019; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $&lt;/div&gt;0.125&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit payable in cash. In addition, $&lt;/div&gt;0.30&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per Unit, or approximately&#160;$&lt;/div&gt;1,800,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in&#160;the aggregate (or $&lt;/div&gt;2,070,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#x2019; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are entitled to receive&#160;&lt;/div&gt;30,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of Common Stock (or&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares if the underwriters&#x2019; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#x201c;Equity Participation Shares.&#x201d; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) and are therefore subject to a &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;lock-up&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; for a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#x201c;piggyback&#x201d; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Excise Tax &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Inflation Reduction Act (&#x201c;IR Act&#x201d;) of 2022 imposes a&#160;&lt;/div&gt;1&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December 31, 2022. For purposes of the Excise Tax, a&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#x201c;SPAC&#x201d;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#x2019;s Initial Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete a &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;de-SPAC&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; transaction within the required time set forth in its constituent documents, or (iii)&#160;in connection with the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;wind-up&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;&lt;/div&gt;1&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% has been included in these financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#x2019;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $359,957&#160;excise tax liability as of December&#160;31, 2023. The Company will continue to monitor for updates to the Company&#x2019;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#x2019;s tax provision in future periods.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication (&#x201c;SWIFT&#x201d;) payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial business combination and any target business with which we may ultimately consummate an initial business combination.&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The excise tax included in the Inflation Reduction Act of 2022 may decrease the value of the Company&#x2019;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <blacu:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116599"
      unitRef="Unit_pure">2</blacu:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116600"
      unitRef="Unit_shares">900000</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <blacu:UnderwritingCashDiscountPerUnit
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116601"
      unitRef="Unit_USD_per_Share">0.2</blacu:UnderwritingCashDiscountPerUnit>
    <blacu:AggregateUnderwriterCashDiscount
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116602"
      unitRef="Unit_USD">1200000</blacu:AggregateUnderwriterCashDiscount>
    <blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116603"
      unitRef="Unit_pure">0.02</blacu:AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116604"
      unitRef="Unit_USD">1380000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <blacu:UnderwritingCashDiscountPerUnit
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="3"
      id="ixv-116605"
      unitRef="Unit_USD_per_Share">0.125</blacu:UnderwritingCashDiscountPerUnit>
    <blacu:UnderwritingExpensePricePerShare
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-116606"
      unitRef="Unit_USD_per_Share">0.3</blacu:UnderwritingExpensePricePerShare>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116607"
      unitRef="Unit_USD">1800000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116608"
      unitRef="Unit_USD">2070000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116609"
      unitRef="Unit_shares">30000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_UnderwritingAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116610"
      unitRef="Unit_shares">34500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <blacu:EffectiveExciseTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116611"
      unitRef="Unit_pure">1</blacu:EffectiveExciseTaxRate>
    <blacu:EffectiveExciseTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-116612"
      unitRef="Unit_pure">1</blacu:EffectiveExciseTaxRate>
    <blacu:CommonStockSubjectToPossibleRedemptionTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44891">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 6&#x2013;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The Company&#x2019;s common stock features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s common stock subject to possible redemption as of December&#160;31, 2023:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:83%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subject to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Possible&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Gross proceeds from Initial Public Offering&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;69,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Proceeds allocated to public warrants and rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(1,236,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Offering costs allocated to common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(4,791,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Redemption of common stock in connection with Trust extension&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(35,995,728&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;9,449,634&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,426,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</blacu:CommonStockSubjectToPossibleRedemptionTextBlock>
    <blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-44925">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s common stock subject to possible redemption as of December&#160;31, 2023:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:83%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subject to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Possible&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Gross proceeds from Initial Public Offering&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;69,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Proceeds allocated to public warrants and rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(1,236,527&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Offering costs allocated to common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(4,791,126&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Less: Redemption of common stock in connection with Trust extension&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;(35,995,728&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Plus: Accretion on common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;9,449,634&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Balance, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,426,253&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</blacu:CommonStockSubjectToPossibleRedemptionTableTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116613"
      unitRef="Unit_USD">69000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116614"
      unitRef="Unit_USD">1236527</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116615"
      unitRef="Unit_USD">4791126</us-gaap:DeferredOfferingCosts>
    <blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116616"
      unitRef="Unit_USD">-35995728</blacu:ProceedsFromTrustAccountForPaymentToRedeemingStockholders>
    <blacu:AccretionForCommonStockToRedemptionValue
      contextRef="P01_01_2023To12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116617"
      unitRef="Unit_USD">9449634</blacu:AccretionForCommonStockToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116618"
      unitRef="Unit_USD">36426253</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-45031">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 7&#x2013;STOCKHOLDERS&#x2019; DEFICIT &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is authorized to issue&#160;&lt;/div&gt;1,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of preferred stock with a par value of $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share. As of December&#160;31, 2023 and 2022, there were&#160;&lt;/div&gt;no&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;shares of preferred stock issued or outstanding.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;&lt;/div&gt;100,000,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of Common Stock, $&lt;/div&gt;0.0001&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;par value.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2022, there were&#160;&lt;/div&gt;1,725,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of Common Stock outstanding. Of the &lt;/div&gt;1,725,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of Common Stock, an aggregate of up to&#160;&lt;/div&gt;225,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares was subject to forfeiture to the Company by the Sponsor for no consideration to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement of&#160;&lt;/div&gt;430,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares. On February&#160;21, 2023, the underwriters fully exercised their over-allotment option and the&#160;&lt;/div&gt;225,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;Founder Shares are no longer subject to forfeiture. As of&#160;December&#160;31, 2023, there were&#160;&lt;/div&gt;2,155,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;shares of Common Stock outstanding, excluding&#160;&lt;/div&gt;3,467,954&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; shares of common stock subject to possible redemption that are reflected in temporary equity in the balance sheet&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;s&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="-sec-ix-redline:true;display:inline;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; text-indent: 9%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, there were &lt;/div&gt;7,330,000&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and no Warrants outstanding, respectively. The Warrants that are a part of the Units (the &#x201c;Warrants&#x201d;) may be exercised at a price of $&lt;/div&gt;11.50&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;30&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;days after the completion of a Business Combination.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Warrants have an exercise price of $&lt;/div&gt;11.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share and will expire&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;five years&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Redemption of warrants when the price per Common Stock equals or exceeds $16.50. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Once the Warrants become exercisable, the Company may call the Warrants for redemption: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;at a price of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.01&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;per Warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;upon not less than&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;30&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;days&#x2019; prior written notice of redemption given after the Warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;if, and only if, the reported last sale price of the Common Stock equals or exceeds $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;16.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;trading days within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the entire &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; trading period referred to above and continuing each day thereafter until the date of redemption. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors), (y) the aggregate gross proceeds from such issuances represent more than&#160;&lt;/div&gt;60&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $&lt;/div&gt;9.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;&lt;/div&gt;115&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;% of the Market Value, and the $&lt;/div&gt;16.50&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;&lt;/div&gt;165&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;% of the Market Value.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Equity Participation Shares &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;&lt;/div&gt;34,500&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company complies with the requirements of ASC &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;340-10-S99-1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; and SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#x2019;s certificate of incorporation with respect to its &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;pre-business&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;one-tenth&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;as-converted&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; into common stock basis. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116619"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116620"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-116621"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      id="ixv-116622"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116623"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116624"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116625"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-116626"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116627"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-116628"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2022To12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116629"
      unitRef="Unit_shares">1725000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116630"
      unitRef="Unit_shares">1725000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_FounderSharesMemberusgaapStatementClassOfStockAxis_SubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis"
      decimals="INF"
      id="ixv-116631"
      unitRef="Unit_shares">225000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_PrivatePlacementMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116632"
      unitRef="Unit_shares">430000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis_NoLongerSubjectToForfeitureMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-116633"
      unitRef="Unit_shares">225000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116634"
      unitRef="Unit_shares">2155000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockSubjectToMandatoryRedemptionMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-116635"
      unitRef="Unit_shares">3467954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2023To12_31_2023" id="ixv-116636">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.</us-gaap:CommonStockVotingRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116637"
      unitRef="Unit_shares">7330000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_IPOMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116638"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45086">P30D</blacu:WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116640"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-45113">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116641"
      unitRef="Unit_USD_per_Share">0.01</blacu:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <blacu:NoticePeriodForWarrantRedemption
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116642">P30D</blacu:NoticePeriodForWarrantRedemption>
    <blacu:WarrantRedemptionConditionMinimumSharePrice
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116643"
      unitRef="Unit_USD_per_Share">16.5</blacu:WarrantRedemptionConditionMinimumSharePrice>
    <blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116644">P20D</blacu:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-116645">P30D</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116646"
      unitRef="Unit_pure">0.60</blacu:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116647"
      unitRef="Unit_USD_per_Share">9.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:WarrantExercisePriceAdjustmentPercentage
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116648"
      unitRef="Unit_pure">1.15</blacu:WarrantExercisePriceAdjustmentPercentage>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-116649"
      unitRef="Unit_USD_per_Share">16.5</us-gaap:CommonStockParOrStatedValuePerShare>
    <blacu:RedemptionTriggerPriceAdjustmentPercentage
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-116650"
      unitRef="Unit_pure">1.65</blacu:RedemptionTriggerPriceAdjustmentPercentage>
    <blacu:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_EquityParticipationMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-116651"
      unitRef="Unit_shares">34500</blacu:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-45261">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;N&lt;/div&gt;OTE 8&#x2013;FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value on December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: red; font-size: 10pt; letter-spacing: 0px; text-decoration-line: underline; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;There were no transfers between Levels 1, 2 and 3 during the year ended December&#160;31, 2023.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-45268">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value on December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: red; font-size: 10pt; letter-spacing: 0px; text-decoration-line: underline; text-indent: 9%; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 44%;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Quoted&lt;br/&gt;Prices In&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Investments held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;36,605,106&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2014;&lt;/div&gt;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-116653"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116654"
      unitRef="Unit_USD">36605106</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116655"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-116656"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-45436">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 9&#x2013;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company evaluated subsequent events to determine if events or transactions occurred after the balance sheet date up to the date the financial statements &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;were&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"&gt; issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, other than the following:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#x201c;JCW Promissory Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;75,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to Jun Chul Whang, a member of the Company&#x2019;s Board of Directors. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of: (i)&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;August 9, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; or (ii)&#160;the date on which the Company consummates an initial business combination (the &#x201c;JCW Maturity Date&#x201d;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#x2019;s trust account,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On February&#160;9, 2024, $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;60,000 &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;was deposited in the &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Trust Account&lt;/div&gt; in connection with the extension of the date by which the Company must consummate a business combination from &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;February 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;March 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#x201c;JP Promissory Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to Josh Pan, a member of Bellevue Capital Management LLC. &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The JP Promissory Note is not interest bearing and is payable in full on the earlier of: (i) August 8, 2024 or (ii) the date on which the Company consummates an initial business combination (the &#x201c;JP Maturity Date&#x201d;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#x2019;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr. Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#x2019;s Trust Account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the JP Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On March&#160;12, 2024, $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; was deposited in the &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Trust Account&lt;/div&gt; in connection with the extension of the date by which the Company must consummate a business combination from &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;March 14, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;April 15, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#x201c;April Sponsor Note&#x201d;) in the principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to Sponsor for its receipt of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to fund working capital and other expenses of the Company. The April Sponsor Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-interest&lt;/div&gt; bearing and is payable in full on the earlier of (i)&#160;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;December 31, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; or (ii)&#160;the date on which the Company consummates a Business Combination. In the event that the Company does not consummate a Business Combination, the April Sponsor Note will be repaid only from amounts remaining outside of the Company&#x2019;s Trust Account, if any. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;9 2024, $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;60,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; was deposited in the &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;Trust Account&lt;/div&gt;&#160;in connection with the &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;extension &lt;/div&gt;of the date by which the Company must consummate a business combination from &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;April 15, 2024&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; to &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden117833430;display:inline;"&gt;May14, 2024&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In connection with the November 2023 withdrawal of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;561,957&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; of interest income earned in the Trust Account for payment of the Company&#x2019;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account, as of April 16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#x2019;s Sponsor and the Company has paid its fedral tax obligations on time.&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_09_2024_JcwPromissoryNoteMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116657"
      unitRef="Unit_USD">75000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116658">2024-08-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116660"
      unitRef="Unit_USD">60000</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116661">2024-02-14</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P02_09_2024To02_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116662">2024-03-14</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_08_2024_JoshPanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116663"
      unitRef="Unit_USD">60000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P03_08_2024To03_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116664">2024-08-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116665"
      unitRef="Unit_USD">60000</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116666">2024-03-14</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="P03_12_2024To03_12_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116667">2024-04-15</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_08_2024_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116668"
      unitRef="Unit_USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <blacu:WorkingCapitalFundAndOtherExpenses
      contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116669"
      unitRef="Unit_USD">1200000</blacu:WorkingCapitalFundAndOtherExpenses>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P04_08_2024To04_08_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116670">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116671"
      unitRef="Unit_USD">60000</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="P04_09_2024To04_09_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-116672">2024-04-15</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:InterestIncomeOther
      contextRef="P04_16_2024To04_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-116673"
      unitRef="Unit_USD">561957</us-gaap:InterestIncomeOther>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112806975872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BELLEVUE LIFE SCIENCES ACQUISITION CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-5052822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10900 NE 4th Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bellevue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">635-7700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">6770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Kuk Hyoun Hwang<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10900 NE 4th Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bellevue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">635-7700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112718102976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="nump">$ 124,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">64,543<span></span>
</td>
<td class="nump">7,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,180<span></span>
</td>
<td class="nump">22,627<span></span>
</td>
<td class="nump">124,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">37,205,930<span></span>
</td>
<td class="nump">36,605,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">37,274,110<span></span>
</td>
<td class="nump">36,627,733<span></span>
</td>
<td class="nump">1,225,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,548,087<span></span>
</td>
<td class="nump">1,081,753<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">615,035<span></span>
</td>
<td class="nump">524,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax payable</a></td>
<td class="nump">359,957<span></span>
</td>
<td class="nump">359,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccruedOfferingCostsCurrent', window );">Accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - related party</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to affiliate</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,745,079<span></span>
</td>
<td class="nump">2,038,272<span></span>
</td>
<td class="nump">1,263,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DeferredUnderwritingCommissions', window );">Deferred underwriting commissions</a></td>
<td class="nump">2,070,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,815,079<span></span>
</td>
<td class="nump">4,108,272<span></span>
</td>
<td class="nump">1,263,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Common stock subject to possible redemption</a></td>
<td class="nump">36,766,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,307,789)<span></span>
</td>
<td class="num">(3,907,008)<span></span>
</td>
<td class="num">(62,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(4,307,573)<span></span>
</td>
<td class="num">(3,906,792)<span></span>
</td>
<td class="num">(37,508)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Deficit</a></td>
<td class="nump">37,274,110<span></span>
</td>
<td class="nump">36,627,733<span></span>
</td>
<td class="nump">$ 1,225,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Common stock subject to possible redemption</a></td>
<td class="nump">$ 36,766,604<span></span>
</td>
<td class="nump">$ 36,426,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_AccruedOfferingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_AccruedOfferingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_DeferredUnderwritingCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_DeferredUnderwritingCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112814430864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockRedemptionValue', window );">Common stock, redemption value (in Dollars per share)</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112813900832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 450,781<span></span>
</td>
<td class="nump">$ 278,102<span></span>
</td>
<td class="nump">$ 1,830,700<span></span>
</td>
<td class="nump">$ 35,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest earned on investments held in the Trust Account</a></td>
<td class="nump">480,824<span></span>
</td>
<td class="nump">417,728<span></span>
</td>
<td class="nump">2,775,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from operations</a></td>
<td class="num">(450,781)<span></span>
</td>
<td class="num">(278,102)<span></span>
</td>
<td class="num">(1,830,700)<span></span>
</td>
<td class="num">(35,388)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before provision for income taxes</a></td>
<td class="nump">30,043<span></span>
</td>
<td class="nump">139,626<span></span>
</td>
<td class="nump">944,591<span></span>
</td>
<td class="num">(35,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(90,473)<span></span>
</td>
<td class="num">(29,321)<span></span>
</td>
<td class="num">(540,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Total other income</a></td>
<td class="nump">480,824<span></span>
</td>
<td class="nump">417,728<span></span>
</td>
<td class="nump">2,775,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">$ (60,430)<span></span>
</td>
<td class="nump">$ 110,305<span></span>
</td>
<td class="nump">$ 403,780<span></span>
</td>
<td class="num">$ (35,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC</a></td>
<td class="nump">5,622,954<span></span>
</td>
<td class="nump">5,231,461<span></span>
</td>
<td class="nump">7,688,260<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE SHARES OUTSTANDING, DILUTED</a></td>
<td class="nump">5,622,954<span></span>
</td>
<td class="nump">5,231,461<span></span>
</td>
<td class="nump">7,719,699<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET INCOME (LOSS) PER SHARE</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET INCOME (LOSS) PER SHARE</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717557760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">$ (2,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income)</a></td>
<td class="num">(35,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="num">(37,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of 430,000 Private Placement Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,299,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of 430,000 Private Placement Units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment</a></td>
<td class="nump">1,236,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccretionForCommonStockToRedemptionValue', window );">Accretion of common stock to redemption value</a></td>
<td class="num">(7,439,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,561,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,878,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income)</a></td>
<td class="nump">110,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,305<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="num">(1,830,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,830,452)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="num">(37,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of 430,000 Private Placement Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,299,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of 430,000 Private Placement Units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment</a></td>
<td class="nump">1,236,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccretionForCommonStockToRedemptionValue', window );">Accretion of common stock to redemption value</a></td>
<td class="num">(9,449,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,561,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,888,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Excise tax payable attributable to redemption&#160;of common stock</a></td>
<td class="num">(359,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(359,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income)</a></td>
<td class="nump">403,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,780<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">(3,906,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,907,008)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccretionForCommonStockToRedemptionValue', window );">Accretion of common stock to redemption value</a></td>
<td class="num">(340,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income)</a></td>
<td class="num">(60,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,430)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="num">$ (4,307,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,307,789)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_AccretionForCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_AccretionForCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112716944080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued (in Shares)</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112813785728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (60,430)<span></span>
</td>
<td class="nump">$ 110,305<span></span>
</td>
<td class="nump">$ 403,780<span></span>
</td>
<td class="num">$ (35,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease', window );">Interest earned on investments held in the Trust Account</a></td>
<td class="num">(480,824)<span></span>
</td>
<td class="num">(417,728)<span></span>
</td>
<td class="num">(2,775,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(57,335)<span></span>
</td>
<td class="num">(81,073)<span></span>
</td>
<td class="num">(7,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">466,334<span></span>
</td>
<td class="nump">340,070<span></span>
</td>
<td class="nump">1,035,391<span></span>
</td>
<td class="nump">31,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">90,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(41,782)<span></span>
</td>
<td class="num">(48,426)<span></span>
</td>
<td class="num">(818,766)<span></span>
</td>
<td class="num">(4,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders', window );">Cash withdrawn from Trust Account for payment to redeeming stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,995,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Investment of cash in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashDepositedInTheTrustAccount', window );">Cash deposited in Trust Account</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="num">(70,207,500)<span></span>
</td>
<td class="num">(70,207,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_GainLossFromTrustAccountToPayExpenses', window );">Withdrawal of interest from Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="num">(70,207,500)<span></span>
</td>
<td class="num">(33,829,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Redemption of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,995,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of underwriters' fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,670,000<span></span>
</td>
<td class="nump">59,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable - related party</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,447,273)<span></span>
</td>
<td class="num">(1,447,273)<span></span>
</td>
<td class="num">(683,021)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">70,480,227<span></span>
</td>
<td class="nump">34,539,499<span></span>
</td>
<td class="nump">123,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET CHANGE IN CASH</a></td>
<td class="num">(11,782)<span></span>
</td>
<td class="nump">224,301<span></span>
</td>
<td class="num">(109,082)<span></span>
</td>
<td class="nump">119,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">15,419<span></span>
</td>
<td class="nump">124,501<span></span>
</td>
<td class="nump">124,501<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, END OF PERIOD</a></td>
<td class="nump">3,637<span></span>
</td>
<td class="nump">348,802<span></span>
</td>
<td class="nump">15,419<span></span>
</td>
<td class="nump">124,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax payable</a></td>
<td class="nump">359,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Deferred underwriters' discount payable charged to additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts', window );">Deferred offering costs included in accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from over-allotment option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,157,500<span></span>
</td>
<td class="nump">9,157,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits', window );">Proceeds from private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to note payable - Sponsor</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from affiliate</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">395,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Repayments to affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (340,000)<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CashDepositedInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash deposited in the trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CashDepositedInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CashFlowsFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CashFlowsFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ChangesInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accrued offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_DeferredOfferingCostsIncludedInAccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_GainLossFromTrustAccountToPayExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from trust account to pay expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_GainLossFromTrustAccountToPayExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from trust account for payment to redeeming stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in interest income on interest-earning asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(iii)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (1)(i)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeInterestEarningAssetIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common limited partners units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112807439824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 1&#8211;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Life Sciences Acquisition Corp. (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;</div>one</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;or more businesses or entities (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;March 31, 2024, the Company had not commenced any operations. All activity since inception relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">generate&#160;non-operating&#160;income</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in the form of interest income from the proceeds derived from the Initial Public Offering.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering (the &#8220;Registration Statement&#8221;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;</div>6,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;units (&#8220;Units&#8221; and, with respect to the common stock included in the Units being offered, the &#8220;Public Shares&#8221;), generating gross proceeds of $</div>60,000,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">, which is described in Note 3.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#8220;Over-Allotment Option Units&#8221;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;</div>900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Over-Allotment Option Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per unit generated total gross proceeds of $</div>9,000,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#8220;Private Placement&#8221;) of&#160;</div>430,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units (the &#8220;Private Placement Units&#8221;), to Bellevue Global Life Sciences Investors LLC (the &#8220;Sponsor&#8221;) at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Placement Unit, for an aggregate purchase price of $</div>4,300,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Each Unit and Private Placement Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, par value $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;(the &#8220;Common Stock&#8221;), a warrant to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock (the &#8220;Public Warrants&#8221; and &#8220;Private Placement Warrants&#8221; and collectively, the &#8220;Warrants&#8221;) and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock (the &#8220;Public Rights&#8221; and Private Placement Rights&#8221; and collectively, the &#8220;Rights&#8221;), as described in Notes 3 and 4.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;</div>80</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;</div>50</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of $</div>70,207,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">was placed in a trust account (&#8220;Trust&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Account&#8221;) located in the United States with Continental Stock Transfer&#160;&amp; Trust Company acting as trustee, and invested only in United States &#8220;government securities&#8221; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;) having a maturity of 185 days or less or in money market funds meeting certain conditions under </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Rule&#160;2a-7&#160;promulgated</div><div style="-sec-ix-redline:true;display:inline;"> under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.39in; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least<div style="display:inline;">&#160;</div></div></div></div><div style="-sec-ix-redline:true;display:inline;">$</div><div style="-sec-ix-redline:true;display:inline;">5,000,001</div><div style="-sec-ix-redline:true;display:inline;">&#160;upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial&#160;Public Offering in favor of a Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">material&#160;non-public&#160;information</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and (ii)&#160;to clear all trades with the Company&#8217;s legal counsel or compliance officer prior to execution. In addition, the Company&#8217;s Sponsor and any other holders of the Company&#8217;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#8220;Initial Stockholders&#8221;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;</div>15</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s Initial Stockholders and Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;</div>100</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of its Public Shares if the Company does not complete a Business Combination within&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">nine months</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#8220;Combination Period&#8221;) or (B)&#160;with respect to any other provision relating to&#160;stockholders&#8217;&#160;rights </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">or&#160;pre-initial&#160;Business</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.</div></div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than </div>ten</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> business days thereafter, redeem&#160;</div>100</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $</div>100,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $10.175 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed t</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">o<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Extension of Termination Date and Redemptions from the Trust Account </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an extension of the date by which the Company must </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors (the &#8220;Board&#8221;) the authority in its discretion to amend the Charter to extend the date by which the Company must consummate a business combination from February&#160;14, 2024 to May&#160;14, 2024. In connection with the Special </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Meeting,&#160;</div>3,432,046</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of common stock of the Company were tendered for redemption at a redemption price of approximately $</div>10.49</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share for an aggregate redemption amount of $</div>35,995,728</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, leaving $</div>36,372,335</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $</div>561,957</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Additionally, the Company deposited $</div>180,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;into the Trust Account on November&#160;</div>13</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2023</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in connection with the extension of the date by which the Company must consummate a business combination from November&#160;</div>14</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2023</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to February&#160;</div>14</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In </div>February 2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Board authorized and approved a second Certificate of Amendment to the Charter. The second Certificate of Amendment to the Charter was filed with the Delaware Secretary of State, with an effective date of February&#160;</div>9</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, and extended the date by which the Company must consummate a business combination to the May&#160;</div>14</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. In connection with the extension by which the Company must consummate a business combination to May&#160;</div>14</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company deposited $</div>60,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> into the Trust Account on each of February&#160;</div>9</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and March&#160;</div>12</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. In connection with the $</div>60,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> deposited into the Trust Account on February&#160;</div>9</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company issued an unsecured promissory note in the principal amount of $</div>75,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to Jun Chul Whang, a member of the Board. In connection with the $</div>60,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> deposited into the Trust Account on March&#160;</div>12</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company issued an unsecured promissory note in the principal amount of $</div>60,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"> to Josh Pan, an individual member of Bellevue Capital Management, LLC, which wholly owns the Sponsor.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Franchise and Income Tax Withdrawal </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In </div>November 2023</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company withdrew $</div>561,957</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through March&#160;</div>31</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#8217;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#8217;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of March&#160;</div>31</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">, the Company&#8217;s obligations for franchise and income tax purposes remain payable.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Basis of Presentation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#8220;GAAP&#8221;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the </div>three</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> months ended </div>March 31, 2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> are not necessarily indicative of the results to be expected for the year ending </div>December 31, 2024</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"> or for any future interim periods.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form </div>10</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">-K as of and for the year ended </div>December 31, 2023</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> as filed with SEC on </div>April 17, 2024</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Liquidity and Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;</div>31</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, </div>2024</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, the Company had $</div>3,637</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in its operating bank account and a working capital deficit of $</div>2,676,899</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering had been</div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement Units held outside of the Trust Account and loans from the Sponsor, officers and directors and their affiliates.</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or 21 months from the Initial Public Offering (subject to extension by approval of the Company&#8217;s stockholders). These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160;Over this time period, the Company has used and will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#8217;s current operating cash balance may need to be funded through loans from the Company&#8217;s Sponsor, officers and directors and their affiliates. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">If the Company is unable to complete a Business Combination by November 14, 2024 (subject to extension by approval of the Company&#8217;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management will seek to complete a business combination.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Emerging Growth Company</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the&#160;Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply </div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;">to&#160;non-emerging&#160;growth</div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"> companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in&#160;accounting&#160;standards used.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Nasdaq Listing Rules Compliance </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">As previously reported by the Company on Form&#160;8-K&#160;filed on June&#160;14, 2023, due to the resignation of a director effective on June&#160;21, 2023, the Company notified the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on June&#160;27, 2023 that the Company was not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the &#8220;Listing Rule&#8221;), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Company has until the earlier of its next annual shareholders&#8217; meeting or June&#160;21, 2024 to regain compliance.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Listing Rule requires the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of the director&#8217;s resignation from the Company&#8217;s Board and Audit Committee, the Company&#8217;s Audit Committee has been comprised of two independent directors and one vacancy and, therefore, does not currently comply with Nasdaq&#8217;s audit committee requirements as set forth in the Listing Rule. Pursuant to the Listing Rule&#8217;s section (c)(4)(B), the Company is entitled to a cure period to regain compliance with the Listing Rule. The Company is evaluating the appropriate membership and composition of its Board and Board committees and intends to regain compliance with Listing Rule prior to the expiration of the applicable cure period.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">On February&#160;15, 2024, the Company received a notification from the Listing Qualifications Department of Nasdaq notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the &#8220;Minimum Public Holders Requirement&#8221;). The notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of securities on the Nasdaq Capital Market. In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 1&#8211;DESCRIPTION&#160;OF&#160;ORGANIZATION,&#160;BUSINESS&#160;OPERATIONS&#160;AND&#160;BASIS&#160;OF PRESENTATION </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Life Sciences Acquisition Corp. (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;25, 2020. The Company was incorporated for the purpose of entering into a&#160;merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with&#160;</div>one</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;or more businesses or entities (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;December&#160;31, 2023, the Company had not commenced any operations. All activity since inception relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will generate </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> income in the form of interest income from the proceeds derived from the Initial Public Offering.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering (the &#8220;Registration Statement&#8221;) was declared effective on February&#160;9, 2023. On February&#160;14, 2023, the Company consummated the Initial Public Offering of&#160;</div>6,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;units (&#8220;Units&#8221; and, with respect to the common stock included in the Units being offered, the &#8220;Public Shares&#8221;), generating gross proceeds of $</div>60,000,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">, which is described in Note 3.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;17, 2023, the underwriters exercised their over-allotment option in full. The closing of the issuance and sale of the additional Units occurred (the &#8220;Over-Allotment Option Units&#8221;) on February&#160;21, 2023. The total aggregate issuance by the Company of&#160;</div>900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Over-Allotment Option Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per unit generated total gross proceeds of $</div>9,000,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Simultaneously with the consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the &#8220;Private Placement&#8221;) of&#160;</div>430,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units (the &#8220;Private Placement Units&#8221;), to Bellevue Global Life Sciences Investors LLC (the &#8220;Sponsor&#8221;) at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Placement Unit, for an aggregate purchase price of $</div>4,300,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Each Unit and Private Placement Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, par value $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;(the &#8220;Common Stock&#8221;), a warrant to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock (the &#8220;Public Warrants&#8221; and &#8220;Private Placement Warrants&#8221; and collectively, the &#8220;Warrants&#8221;) and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock (the &#8220;Public Rights&#8221; and Private Placement Rights&#8221; and collectively, the &#8220;Rights&#8221;), as described in Notes 3 and 4.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management&#160;has broad discretion with respect&#160;to the specific&#160;application&#160;of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&#160;</div>80</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only&#160;complete a&#160;Business Combination if the post-transaction company owns or acquires&#160;</div>50</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Upon closing of the Initial Public Offering, the Private Placement, the sale of the Over-Allotment Option Units and the additional Trust Account funding, a total of</div>&#160;$</div>70,207,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">was placed in a trust account (&#8220;Trust Account&#8221;) located in the United States with Continental Stock Transfer &amp; Trust Company acting as trustee, and</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">invested only in United States &#8220;government securities&#8221; within the meaning of Section&#160;2(a)(16) of the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;) having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">2a-7</div><div style="-sec-ix-redline:true;display:inline;"> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div></div></div><div style="color: red; text-decoration-line: underline; text-indent: 0px; background-color: rgb(204, 204, 204); font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).&#160;These Public Shares were recorded at a redemption value and classified as temporary equity upon the closing of the Initial Public Offering in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">$</div>5,000,001</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Initial Stockholders (as defined below) have agreed to vote its Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination.&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which requires insiders to (i)&#160;refrain from purchasing shares during certain blackout periods and when they are in possession of any material </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> information and (ii)&#160;to clear all trades with the Company&#8217;s legal counsel or compliance officer prior to execution. In addition, the Company&#8217;s Sponsor and any other holders of the Company&#8217;s common stock prior to the Initial Public Offering (or their permitted transferees (the &#8220;Initial Stockholders&#8221;)) have agreed to waive their redemption rights with respect to their Founder Shares, Placement Shares and Public Shares in connection with the completion of a Business Combination.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Notwithstanding the foregoing, if the Company seeks stockholder approval of its Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from seeking redemption rights with respect to more than an aggregate of&#160;</div>15</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% of more of the shares of Common Stock sold in the Initial Public Offering without the prior consent of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s Initial Stockholders and Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), the representative of the underwriters, have agreed not to propose or vote in favor of an amendment to the Company&#8217;s Amended and</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Restated Certificate of Incorporation (A)&#160;that would modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem&#160;</div>100</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of its Public Shares if the Company does not complete a Business Combination within&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">nine months</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;or such other time period as the stockholders may approve from the closing of the Initial Public Offering (the &#8220;Combination Period&#8221;) or (B)&#160;with respect to any other provision relating to </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">stockholders&#8217;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> rights or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">pre-initial</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public shares in conjunction with such an amendment.</div></div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, if the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly&#160;and as reasonably&#160;possible, but not more than ten business days thereafter, redeem&#160;</div>100</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $</div>100,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares (defined in Note 4) and Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) may be less than approximately $</div>10.175</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"> per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective partner business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any&#160;and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company&#8217;s independent registered public accounting firm), prospective partner businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Extension of Termination Date and Redemptions from the Trust Account </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">On November&#160;9, 2023, the Company held a special meeting of its stockholders (the &#8220;Special Meeting&#8221;). At the Special Meeting, the Company&#8217;s stockholders approved an extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024 and approved a proposal to give the Board of Directors the authority in its discretion to amend the Charter to extend the date by which the</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Company must consummate a business combination from the First Extended Date to May&#160;14, 2024. In connection with the Special Meeting, </div>3,432,046</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of common stock of the Company were tendered for redemption at a redemption price of approximately $</div>10.49</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share for an aggregate redemption amount of $</div>35,995,728</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, leaving $</div>36,372,335</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in the Trust Account immediately after the redemptions and a tax withdrawal by the Company of $</div>561,957</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Additionally, the Company deposited $</div>180,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"> into the Trust Account on November&#160;13, 2023 in connection with the extension of the date by which the Company must consummate a business combination from November&#160;14, 2023 to February&#160;14, 2024.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Franchise and Income Tax Withdrawal </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In November 2023, the Company withdrew $</div>561,957</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> <div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. Through December 31, 2023, the Company did not use such funds to pay its tax obligations (which were not yet due and payable) and instead deposited the funds in the Company&#8217;s unrestricted general account and they were used for the payment of general operating expenses. In consultation with counsel and the Company&#8217;s Audit Committee, management determined that this use of funds was not in accordance with the Trust Agreement. As of December 31, 2023, the Company&#8217;s obligations for franchise and income tax purposes remain payable.&#160;</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Basis of Presentation </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of&#160;America (&#8220;GAAP&#8221;)&#160;and&#160;pursuant to&#160;the rules and regulations of the SEC.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Liquidity and Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, the Company had $</div>15,419</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in its operating bank account and a working capital deficit of $</div>2,015,645</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.&#160;The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering had been satisfied through proceeds from advances from related party and from the issuance of common stock. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity was satisfied through the net proceeds from the consummation of the Initial Public Offering, the proceeds from the Private Placement held outside of the Trust Account.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Based on the foregoing and the limited amount of working capital that the Company received into the operating account from the Private Placement and issuances of promissory notes, management believes that the Company will not have sufficient working capital to meet its working capital needs through the earlier of the consummation of an Initial Business Combination or fifteen months from the Initial Public Offering. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160;Over this time period, the Company will be using the remaining funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the initial Business Combination. Further needs for operating capital beyond the Company&#8217;s current operating cash balance may need to be funded through loans from the Company&#8217;s Sponsor. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">If the Company is unable to complete a Business Combination by May&#160;14, 2024 (subject to extension by approval of the Company&#8217;s stockholders), the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution combined with uncertainty as to whether the Company has sufficient liquidity to fund operations through the liquidation date or thereafter should a deferral occur raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management intends to complete a business combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Emerging Growth Company</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not&#160;limited to,&#160;not&#160;being required to&#160;comply with&#160;the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of&#160;any&#160;golden parachute payments not previously approved.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">non-emerging</div><div style="-sec-ix-redline:true;display:inline;"> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standards at the time the private companies adopt the new or revised standard. This may make the comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112718333488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">NOTE 2&#8211;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Use of Estimates </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from thos<div style="display:inline;">e </div>estimates.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Cash and Cash Equivalents</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div>3,637</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and $</div>15,419</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in cash held in its operating account as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The Company had&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;cash equivalents as of March&#160;31, 2024 and December&#160;31, 2023.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Fair Value of Financial Instruments</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the unaudited condensed financial statements, primarily due to their short-term nature.</div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Investments Held in Trust Account </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in the Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Fair Value Measurements</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash and amounts due to related parties are estimated to approximate the carrying values as of&#160;March 31, 2024 due to the short maturities of such instruments. </div></div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">then&#160;re-valued&#160;at</div><div style="-sec-ix-redline:true;display:inline;"> each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed financial statements as current </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">or&#160;non-current</div><div style="-sec-ix-redline:true;display:inline;"> based on whether or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">not&#160;net-cash&#160;settlement</div><div style="-sec-ix-redline:true;display:inline;"> or conversion of the instrument could be required within 12 months of the condensed balance sheet date. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$</div>250,000</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Warrant Instruments</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Rights </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to&#160;</div>6,900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Units, each Public Unit is comprised of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;par value, a&#160;warrant to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div>430,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;815-40.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div>34,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representative shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div>4,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Net Income (Loss) per Common Share</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div>7,330,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is received by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;March 31, 2024 and</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">December&#160;31, 2023,&#160;</div><div style="-sec-ix-redline:true;display:inline;">3,467,954</div>&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s condensed balance sheets. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary diff<div style="display:inline;">er</div>ences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets w<div style="display:inline;">er</div>e deemed to be de minimis as of March&#160;31, 2024 and&#160;December 31, 2023.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the three months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(benefit) at statutory rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State tax provision/(benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in fair value of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely than not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;March 31, 2024 and&#160;December&#160;31, 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div>No</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">amounts were accrued for the payment interest and penalties for the three months ended March&#160;31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1,&#160;SEC</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting sta<div style="letter-spacing: 0px; top: 0px;display:inline;">nd</div>a<div style="letter-spacing: 0px; top: 0px;display:inline;">r</div>ds, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed financial statements.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">NOTE 2&#8211;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Use of Estimates </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div>15,419</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;and $</div>124,501</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in cash held in its operating account as of December&#160;31, 2023 and 2022, respectively. The Company had&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;cash equivalents as of December&#160;31, 2023 and 2022.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Investments Held in Trust Account</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of&#160;December&#160;31, 2023 due to the short maturities of such instruments. </div></div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the financial statements as current or </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> based on whether or not </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Concentration of Credit Risk</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Warrant Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and <div style="display:inline;">wh</div>ether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a c<div style="display:inline;">ir</div>cumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Rights </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to 6,900,000 Public Units, each Public Unit is comprised of&#160;one&#160;share of common stock, $0.0001&#160;par value, a warrant to purchase<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to receive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div>430,000</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40.</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div>34,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representati<div style="letter-spacing: 0px; top: 0px;display:inline;">ve</div> shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div>4,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Net Income (Loss) per Common Share </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div>7,330,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is rec<div style="letter-spacing: 0px; top: 0px;display:inline;">ei</div>ved by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;December&#160;31, 2023 and</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2022,&#160;</div>3,467,954</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and&#160;</div>0</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s balance sheets, respectively.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December&#160;31, 2023 and 2022.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div><br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 12%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(Benefit) at Statutory Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State Tax Provision/(Benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in FV of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely th<div style="letter-spacing: 0px; top: 0px;display:inline;">an</div> not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;December&#160;31, 2023 and&#160;2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div>No</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;amounts were accrued for the payment interest and penalties for the year ended&#160;December&#160;31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1,</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SEC SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112718340592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_InitialPublicOfferingTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 3&#8211;INITIAL PUBLIC OFFERING </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Initial Public Offering, the Company sold&#160;</div>6,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;</div>900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units. Each Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock,&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder thereof to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock at a price of $</div>11.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustme<div style="letter-spacing: 0px; top: 0px;display:inline;">nt,</div> and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock (see Note 6). Each warrant will become exercisable&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the consummation of an initial business combination, and will expire&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of an initial business combination, or earlier upon redemption or liquidation. Each right entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;</div>ten</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;rights entitle the holder thereof to receive one share of common <div style="letter-spacing: 0px; top: 0px;display:inline;">sto</div>ck at the closing of a business combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 3&#8211;INITIAL PUBLIC OFFERING </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Initial Public Offering, the Company sold&#160;</div>6,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. On February&#160;17, 2023, the underwriters exercised their over-allotment option to purchase an additional&#160;</div>900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Units. Each Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock,&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder thereof <div style="display:inline;">to</div> purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock at a price of $</div>11.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock (see Note 6). Each warrant will become exercisable&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the consummation of an initial business combination, and will expire&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of an initial bus<div style="display:inline;">in</div>ess combination, or earli<div style="display:inline;">er</div> upon redemption or liquidation. Each right entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each&#160;</div>ten</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;rig<div style="display:inline;">ht</div>s entitle the holder thereof to receive one share of common stock at the closing of a business combination.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112718340592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 4&#8211;RELATED PARTY TRANSACTIONS </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Founder Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;30, 2020, the Sponsor purchased&#160;</div>1,437,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of the Company&#8217;s Common Stock (the&#160;&#8220;Founder Shares&#8221;) for an aggregate purchase price of $</div>25,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, or approximately $</div>0.017</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share.&#160;</div><div style="-sec-ix-hidden:hidden117832661;display:inline;">On</div> April&#160;25, 2022, the Company executed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">a&#160;1.2-for-one&#160;stock</div></div> split, resulting in an aggregate of&#160;</div><div style="-sec-ix-redline:true;display:inline;">1,725,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;Founder Shares held by the Company&#8217;s sponsor, of which up to&#160;</div><div style="-sec-ix-redline:true;display:inline;">225,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part.</div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A)</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">three years</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $</div>12.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">20</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;trading days </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">within&#160;any&#160;</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day&#160;trading</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> period commencing at least&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">150</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">property.&#160;</div></div>&#160;<br/></div></div><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Private Placement Units</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has purchased an aggregate of&#160;</div>430,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Private Placement Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock,&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $</div>11.50</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will <div style="letter-spacing: 0px; top: 0px;display:inline;">be </div>included in the liquidating distribution to the holders of the Public Shares.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor and the Company&#8217;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;days after the completion of the Business Combination.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Promissory Notes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by&#160;non-interest-bearing</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> promissory notes in the aggregate principal amount of $</div>1,200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The promissory notes were due at the earlier of&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">November 29, 2023</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">On June 23, 2023, the Sponsor loaned to the Company $</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">200,000 to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">200,000. This </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate an initial Business Combination, the note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. At the Sponsor&#8217;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">of $</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">10.00 per Unit. As of March 31, 2024 and December 31, 2023, the outstanding balance of this note was $</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">0</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">.</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">On November 13, 2023, Bellevue Capital Management LLC (&#8220;BCM&#8221;) loaned to the Company $</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">180,000 and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $</div></div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">180,000. The proceeds of this loan were used to fund the payment to extend the date by which the Company must consummate an initial Business Combination to February 14, 2024. The note is non-interest bearing and is payable in full on the earlier of (i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination. In the event that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. As of March 31, 2024 and December 31, 2023, the outstanding balance of this </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> note was $</div></div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">0</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#8220;JCW Promissory Note&#8221;) in the principal amount of $</div>75,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">to </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Jun Chul Whang, a member of the Company&#8217;s Board. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August 9, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JCW Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s trust account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note was<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">$</div>75,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;JP Promissory Note&#8221;) in the principal amount of $</div>60,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Josh Pan, a member of Bellevue Capital Management LLC. The JP Promissory Note is not interest bearing and is payable in full on the earlier of (i)&#160;August&#160;8, 2024 or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JP Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JP Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. As of&#160;March 31, 2024, the&#160;outstanding balance of this note<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">was $</div>60,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Working Capital Loans </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">$</div>1,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;of such Working Capital Loans may be convertible into Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#8217;s securities, and Chardan and its related persons will have&#160;</div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;recourse with respect to their ability to convert their loans into any of the Company&#8217;s securities. As of March&#160;31, 2024 and&#160;December 31, 2023,&#160;</div>no</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Working Capital Loans were outstanding.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Administrative Support Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $</div>7,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;">the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. During <div style="letter-spacing: 0px; top: 0px;display:inline;">the three months ended March 31, 2024 and 2023, the Company</div>&#160;incurred $</div><div style="-sec-ix-redline:true;display:inline;">22,500</div><div style="-sec-ix-redline:true;display:inline;">&#160;and $</div><div style="-sec-ix-redline:true;display:inline;">7,500</div><div style="-sec-ix-redline:true;display:inline;">, respectively, of administrative support fees which are included in general and administrative expenses in the <div style="letter-spacing: 0px; top: 0px;display:inline;">accompanying condensed statements</div>&#160;of operations. As of March&#160;31, 2024 and December&#160;31, 2023, the outstanding balance was $</div><div style="-sec-ix-redline:true;display:inline;">30,000</div><div style="-sec-ix-redline:true;display:inline;"> and $</div><div style="-sec-ix-redline:true;display:inline;">15,000</div><div style="-sec-ix-redline:true;display:inline;">, respectively,&#160;recorded as due to affiliate. </div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Due to Affiliate </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On February&#160;17, 2022, the Company repaid $</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On April&#160;29, 2022, the Sponsor agreed to advance an additional $</div>7,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. These advances are due on </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">demand and are non-interest bearing. During the year ended</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;December 31, 2023, the Sponsor advanced $</div>180,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of funds to the Company and Company repaid $</div>140,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $</div>7,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The outstanding balance was $</div>57,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;as of&#160;March 31, 2024 and December&#160;31, 2023, recorded as due to affiliate.</div></div><span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 4&#8211;RELATED PARTY TRANSACTIONS </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Founder Shares </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;30, 2020, the Sponsor purchased&#160;</div>1,437,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of the Company&#8217;s Common Stock (the&#160;&#8220;Founder Shares&#8221;) for an aggregate purchase price of $</div>25,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">, or approximately $</div>0.017</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share.&#160;</div><div style="-sec-ix-hidden:hidden117832660;display:inline;">On</div> April&#160;25, 2022, the Company executed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">1.2-for-one</div></div> stock split, resulting in an aggregate of&#160;</div><div style="-sec-ix-redline:true;display:inline;">1,725,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;Founder Shares held by the Company&#8217;s sponsor, of which up to</div><div style="-sec-ix-redline:true;display:inline;">&#160;225,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">three years</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination, (x)&#160;if the last sale price of the Common Stock equals or exceeds $</div>12.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">20</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;trading days within </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">any&#160;</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> trading period commencing at least&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">150</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;days after the initial Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for ca<div style="display:inline;">s</div>h, securities or other property.</div></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Private Placement Units </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has purchased an aggregate of&#160;</div>430,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Private Placement Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Initial Public Offering. Each Private Placement Unit consists of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock,&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;redeemable warrant entitling the holder to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;right which entitles the holder thereof to receive </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of a share of common stock. The Private Placement Warrants are exercisable only t<div style="display:inline;">o p</div>urchase whole shares of Common Stock at an exercise price of $</div>11.50</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;per share, subject to adjustment (see Note 6). Proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete the initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be included in the liquidating distribution to the holders of the Public Shares.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor and the Company&#8217;s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units, including the component securities therein until&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;days after the completion of the Business Combination.</div>&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Promissory Notes</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Sponsor has advanced funds to the Company for the payment of expenses incurred in connection with the Initial Public Offering, which amount is evidenced by </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non<div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">-</div></div>interest<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing promissory notes in the aggregate principal amount of $</div>1,200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The promissory notes were due at the earlier of&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">November 29, 2023</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;or upon the closing of the Initial Public Offering. These notes were discharged and cancelled in connection with the private placement that closed simultaneously with the Initial Public Offering.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;23, 2023, the Sponsor loaned to the Company $</div>200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> to fund working capital requirements and in exchange therefor the Company issued to the Sponsor an unsecured promissory note in the principal amount of $</div>200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. This note is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing and is payable in full on the earlier of: (i)&#160;December 31, 2024&#160;or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;Business Combination&#8221;). In the event that the Company does not consummate a business combination, the note will be repaid only from amounts remaining outside of the Company&#8217;s trust account, if any. At the Sponsor&#8217;s discretion, the principal balance of the note may be converted at any time prior to the consummation of the Business Combination into units identical to the private placement units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $</div>0</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;13, 2023, </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Bellevue Capital Management LLC (&#8220;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">BCM</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#8221;)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> loaned to the Company $</div>180,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and in exchange therefor the Company issued to BCM an unsecured promissory note in the principal amount of $</div>180,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. The proceeds of this loan were used to fund the payment to extend the Termination Date by which the Company must consummate an initial business combination to February&#160;14, 2024. The note is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> bearing and is payable in full on the earlier of: (i)&#160;December&#160;31, 2024 or (ii)&#160;the date on which the Company consummates the Business Combination. In the even</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">t</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> that the Company does not consummate the Business Combination, this note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. As of&#160;December&#160;31, 2023, the&#160;outstanding balance of this note was $</div>0</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Working Capital Loans </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In addition to the loans described above, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the Trust Account released to the Company. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $</div>1,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;of such Working Capital Loans may be convertible into Units at a price of $</div>10.00</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit. The Units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Loans made by Chardan or any of its related persons, if any, will not be convertible into any of the Company&#8217;s securities, and Chardan and its related persons will have </div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> recourse with respect to their ability to convert their loans into any of the Company&#8217;s securities. As of December&#160;31, </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2023 and&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2022,&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Working Capital Loans were outstanding.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Administrative Support Agreement </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Beginning on March&#160;1, 2023, the Company agreed to pay BCM, an affiliate of members of the Sponsor, a total of $</div>7,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees. During the years ended December&#160;31, 2023 and December&#160;31, 2022, the Company incurred $</div>90,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;"> and $</div>75,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">, respectively, of administrative support fees which are included in general and administrative expenses in the accompanying statements of operations. As of December&#160;31, 2023, the outstanding balance was $</div>15,000</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;"> recorded as due to affiliate.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Due to Affiliate </div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2021, the Sponsor agreed to advance the Company up to $</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On February&#160;17, 2022, the Company repaid $</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;to the Sponsor. On April&#160;28, 2022, the Sponsor agreed to advance the Company up to&#160;an additional&#160;$</div>10,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. On April&#160;29, 2022, the Sponsor agreed to advance an additional $</div>7,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. These advances are due on demand and are </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">non-interest</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">-</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">bearing. During the year ended&#160;December 31, 2023, the Sponsor advanced $</div>180,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of funds to the Company and Company repaid $</div>140,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">. Beginning on March&#160;1, 2023, the Company agreed to pay an affiliate of members of the Sponsor a total of $</div>7,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;per month for office space, utilities, secretarial and administrative support. Upon completion of the Business Combination or the Company&#8217;s liquidation, the Company will cease paying these monthly fees.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The outstanding balance was $</div>57,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and $</div>17,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> as of&#160;December 31, 2023 and December&#160;31, 2022, respectively</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">, recorded as due to affiliate</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112813427888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 5&#8211;COMMITMENTS&#160;AND&#160;CONTINGENCIES </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Registration Rights </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;</div>two</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"></div> <div style="-sec-ix-redline:true;display:inline;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Underwriting Agreement </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company granted the underwriters </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;45-day&#160;option</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> from the final prospectus relating to the Initial Public Offering to purchase up to&#160;</div>900,000<div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The underwriters were entitled to an underwriting discount of $</div>0.20</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or $</div>1,200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate, equal to&#160;</div>2</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the gross proceeds of the Initial Public Offering (or $</div>1,380,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate if the underwriters&#8217; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $</div>0.125</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit payable in cash. In addition, $</div>0.30</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or approximately&#160;$</div>1,800,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate (or $</div>2,070,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#8217; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;">entitled to receive&#160;</div><div style="-sec-ix-redline:true;display:inline;">30,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;shares of Common Stock (or&#160;</div><div style="-sec-ix-redline:true;display:inline;">34,500</div><div style="-sec-ix-redline:true;display:inline;">&#160;shares if the underwriters&#8217; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#8220;Equity Participation Shares.&#8221; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) and are therefore subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;lock-up&#160;for</div> a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.</div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Excise Tax </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Inflation Reduction Act (&#8220;IR Act&#8221;) of 2022 imposes a&#160;</div>1</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December&#160;31, 2022. For purposes of the Excise Tax, a repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#8220;SPAC&#8221;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#8217;s </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">initial</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">a&#160;de-SPAC&#160;transaction</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> within the required time set forth in its constituent documents, or (iii)&#160;in connection with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">the&#160;wind-up&#160;and</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;</div>1</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% has </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">been included in these unaudited condensed financial statements.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#8217;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $</div>359,957</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;excise tax liability as of March 31, 2024. The Company will continue to monitor for updates to the Company&#8217;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#8217;s tax provision in future periods.</div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Risks and Uncertainties</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial business combination and any target business with which the Company may ultimately consummate an initial business combination.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The excise tax included in the IR Act of 2022 may decrease the value of the Company&#8217;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 5&#8211;COMMITMENTS&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">AND</div> CONTINGENCIES </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Registration Rights </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The holders of Founder Shares, Private Placement Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the majority of these securities are entitled to make up to&#160;</div>two</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;demands, excluding short form demands, that the Company register such securities. In addition, these holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and seven years, respectively, after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on more than one occasion.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Underwriting Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company granted the underwriters a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">45-day</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> option from the final prospectus relating to the Initial Public Offering to purchase up to&#160;</div>900,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The underwriters were entitled to an underwriting discount of $</div>0.20</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or $</div>1,200,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate, equal to&#160;</div>2</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the gross proceeds of the Initial Public Offering (or $</div>1,380,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in the aggregate if the underwriters&#8217; over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering; provided that for each Unit purchased by investors that are sourced by the Sponsor, such underwriting discount was reduced to $</div>0.125</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit payable in cash. In addition, $</div>0.30</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per Unit, or approximately&#160;$</div>1,800,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate (or $</div>2,070,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in&#160;the aggregate if&#160;the&#160;underwriters&#8217; over-allotment option&#160;is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the underwriters are entitled to receive&#160;</div>30,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock (or&#160;</div>34,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares if the underwriters&#8217; over- allotment option is exercised in full) from the Sponsor, which will be placed in escrow until the consummation of an initial Business Combination. Such shares paid to the underwriters are referred to as the &#8220;Equity Participation Shares.&#8221; If a Business Combination is not consummated, the Equity Participation Shares will be returned to the Sponsor. The Equity Participation Shares have been deemed compensation by Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) and are therefore subject to a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lock-up</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> for a period of 180 days immediately following the effective date of the registration statement related to the Initial Public Offering pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the effective date of the registration statements related to the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. Chardan may not exercise its demand and &#8220;piggyback&#8221; registration rights after five and&#160;seven years, respectively, after the effective date of the registration statement and may not exercise its demand rights on more than one occasion.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Excise Tax </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Inflation Reduction Act (&#8220;IR Act&#8221;) of 2022 imposes a&#160;</div>1</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% <div style="letter-spacing: 0px; top: 0px;display:inline;">Excise Tax on the repurchase of corporate stock by a publicly traded U.S. corporation following December 31, 2022. For purposes of the Excise Tax, a&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">repurchase will generally include redemptions, corporate buybacks and other transactions in which the corporation acquires its stock from a shareholder in exchange for cash or property, subject to exceptions for de minimis transactions and certain reorganizations. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As a result, subject to certain rules, the Excise Tax will apply to any redemption by a U.S.-domiciled special purpose acquisition company (&#8220;SPAC&#8221;) taking place after December&#160;31, 2022, including redemptions (i)&#160;by shareholders in connection with the SPAC&#8217;s Initial Business Combination or a proxy vote to extend the lifespan of the SPAC, (ii)&#160;by SPACs if the SPAC does not complete a </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-SPAC</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> transaction within the required time set forth in its constituent documents, or (iii)&#160;in connection with the </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">wind-up</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and liquidation of the SPAC. The financial responsibility for such Excise Tax resides with the Company and the Sponsor. This amount of&#160;</div>1</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% has been included in these financial statements.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">At this time, it has been determined that the IR Act tax provisions have an impact to the Company&#8217;s fiscal 2023 income tax provision as there were redemptions by the public stockholders in November 2023; as a result, the Company recorded $359,957&#160;excise tax liability as of December&#160;31, 2023. The Company will continue to monitor for updates to the Company&#8217;s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company&#8217;s tax provision in future periods.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Risks and Uncertainties </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the recent escalation of the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication (&#8220;SWIFT&#8221;) payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the escalation of the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber-attacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#8217;s search for an initial business combination and any target business with which we may ultimately consummate an initial business combination.</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The excise tax included in the Inflation Reduction Act of 2022 may decrease the value of the Company&#8217;s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717723168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockSubjectToPossibleRedemptionAbstract', window );"><strong>Common Stock Subject To Possible Redemption Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockSubjectToPossibleRedemptionTextBlock', window );">COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 6&#8211;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s condensed balance sheets.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of March&#160;31, 2024:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common<br/>Stock<br/>Subject to<br/>Possible<br/>Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">69,000,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(1,236,527</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(4,791,126</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(35,995,728</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">9,449,634</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,426,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">340,351</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, March&#160;31, 2024</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,766,604</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 6&#8211;COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION </div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company&#8217;s common stock features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to </div></div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s balance sheets. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of December&#160;31, 2023:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Possible</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">69,000,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(1,236,527</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"><div style="-sec-ix-redline:true;display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(4,791,126</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(35,995,728</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">9,449,634</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,426,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockSubjectToPossibleRedemptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockSubjectToPossibleRedemptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockSubjectToPossibleRedemptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockSubjectToPossibleRedemptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717701600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER'S DEFICIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">NOTE 7&#8211;STOCKHOLDERS&#8217; DEFICIT</div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Preferred Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company is authorized to issue&#160;</div>1,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock with a par value of $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. As of </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">December</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;31, 2024 and March&#160;31, 2023, there were&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of preferred stock issued or outstanding.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;</div>100,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Common Stock at a</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;$</div>0.0001</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;par value.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of&#160;March 31, 2024 and December&#160;31, 2023, there were&#160;</div>2,155,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Common </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Stock outstanding, excluding&#160;</div>3,467,954</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of common stock subject to possible redemption that are reflected in temporary equity in the </div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">condensed&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">balance sheets.</div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0.13in;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. </div></div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; text-indent: 0.26in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0.13in;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Warrants </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2024 and December&#160;31, 2023, there were&#160;</div>7,330,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Warrants outstanding. The Warrants that are a part of the Units (the &#8220;Warrants&#8221;) may be exercised at a price of $</div>11.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;days after the completion of a Business Combination.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Warrants have an exercise price of $</div>11.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share and will expire&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Redemption of warrants when the price per Common Stock equals or exceeds $16.50.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Once the Warrants become exercisable, the Company may call the Warrants for redemption:</div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">at a price of $</div><div style="-sec-ix-redline:true;display:inline;">0.01</div><div style="-sec-ix-redline:true;display:inline;">&#160;per Warrant; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">upon not less than&#160;</div><div style="-sec-ix-redline:true;display:inline;">30</div><div style="-sec-ix-redline:true;display:inline;">&#160;days&#8217; prior written notice of redemption given after the Warrants become exercisable; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">if, and only if, the reported last sale price of the Common Stock equals or exceeds $</div><div style="-sec-ix-redline:true;display:inline;">16.50</div><div style="-sec-ix-redline:true;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="-sec-ix-redline:true;display:inline;">20</div><div style="-sec-ix-redline:true;display:inline;">&#160;trading days <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">within&#160;a&#160;</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading&#160;day</div> period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">entire&#160;30-day&#160;trading</div> period referred to above and continuing each day thereafter until the date of redemption.</div> </div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;-sec-ix-redline:true;display:inline;">In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;display:inline;">effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s Board), (y) the aggregate gross proceeds from such issuances represent more than</div>&#160;</div>60</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $</div>9.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;</div>115</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value, and the $</div>16.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;</div>165</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% of the Market Value.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;">The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;</div><div style="-sec-ix-redline:true;display:inline;">34,500</div><div style="-sec-ix-redline:true;display:inline;">&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.</div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"></div></div><div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company complies with the requirements of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div><div style="-sec-ix-redline:true;display:inline;"> SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. </div></div></div><div style="color: red; letter-spacing: 0px; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Rights </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"></div><div style="color: red; text-decoration-line: underline; font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="-sec-ix-redline:true;display:inline;">Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">one-tenth</div><div style="-sec-ix-redline:true;display:inline;"> (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#8217;s certificate of incorporation with respect to its </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">pre-business</div><div style="-sec-ix-redline:true;display:inline;"> combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">one-tenth</div><div style="-sec-ix-redline:true;display:inline;"> (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">as-converted</div><div style="-sec-ix-redline:true;display:inline;"> into common stock basis. </div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 7&#8211;STOCKHOLDERS&#8217; DEFICIT </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Preferred Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company is authorized to issue&#160;</div>1,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of preferred stock with a par value of $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. As of December&#160;31, 2023 and 2022, there were&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of preferred stock issued or outstanding.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common Stock </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Amended and Restated Certificate of Incorporation, the Company is authorized to issue&#160;</div>100,000,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock, $</div>0.0001</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;par value.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2022, there were&#160;</div>1,725,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock outstanding. Of the </div>1,725,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of Common Stock, an aggregate of up to&#160;</div>225,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares was subject to forfeiture to the Company by the Sponsor for no consideration to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement of&#160;</div>430,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares. On February&#160;21, 2023, the underwriters fully exercised their over-allotment option and the&#160;</div>225,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Founder Shares are no longer subject to forfeiture. As of&#160;December&#160;31, 2023, there were&#160;</div>2,155,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;shares of Common Stock outstanding, excluding&#160;</div>3,467,954</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> shares of common stock subject to possible redemption that are reflected in temporary equity in the balance sheet</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">s</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="-sec-ix-redline:true;display:inline;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. </div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="margin-top: 0px; margin-bottom: 0px; text-indent: 9%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Warrants </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, there were </div>7,330,000<div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and no Warrants outstanding, respectively. The Warrants that are a part of the Units (the &#8220;Warrants&#8221;) may be exercised at a price of $</div>11.50<div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share, subject to adjustment as described in this prospectus. The Public Warrants will become exercisable on&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">30</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;days after the completion of a Business Combination.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Warrants have an exercise price of $</div>11.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share and will expire&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">five years</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;after the completion of a&#160;Business Combination or earlier upon redemption or liquidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Redemption of warrants when the price per Common Stock equals or exceeds $16.50. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Once the Warrants become exercisable, the Company may call the Warrants for redemption: </div></div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">at a price of $</div><div style="-sec-ix-redline:true;display:inline;">0.01</div><div style="-sec-ix-redline:true;display:inline;">&#160;per Warrant; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">upon not less than&#160;</div><div style="-sec-ix-redline:true;display:inline;">30</div><div style="-sec-ix-redline:true;display:inline;">&#160;days&#8217; prior written notice of redemption given after the Warrants become exercisable; </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">if, and only if, the reported last sale price of the Common Stock equals or exceeds $</div><div style="-sec-ix-redline:true;display:inline;">16.50</div><div style="-sec-ix-redline:true;display:inline;">&#160;per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any&#160;</div><div style="-sec-ix-redline:true;display:inline;">20</div><div style="-sec-ix-redline:true;display:inline;">&#160;trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period commencing once the Warrants become exercisable and ending three business days before the date on which the Company sends the notice of redemption to the Warrant holders, and </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or&#160;consolidation. However,&#160;the warrants will not&#160;be&#160;adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In addition, if (x)&#160;the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50&#160;per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors), (y) the aggregate gross proceeds from such issuances represent more than&#160;</div>60</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination (net of redemptions), and (z)&#160;the Market Value is below $</div>9.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&#160;</div>115</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">% of the Market Value, and the $</div>16.50</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to&#160;</div>165</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">% of the Market Value.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company agreed to issue to the underwriter at the closing of the Initial Public Offering up to&#160;</div>34,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Equity Participation Shares, including over-allotment, which will be issued upon the completion of the Initial Business Combination. If the over-allotment option is not exercised in full, the Equity Participation Shares will be reduced pro rata.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and SEC SAB Topic 5A. Offering costs consist principally of professional and registration fees incurred through the date of the financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Rights </div></div></div> <div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">one-tenth</div><div style="-sec-ix-redline:true;display:inline;"> (1/10) of a share of common stock upon consummation of its initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company&#8217;s certificate of incorporation with respect to its </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">pre-business</div><div style="-sec-ix-redline:true;display:inline;"> combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">one-tenth</div><div style="-sec-ix-redline:true;display:inline;"> (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enters into a definitive agreement for a business combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">as-converted</div><div style="-sec-ix-redline:true;display:inline;"> into common stock basis. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717682880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">NOTE 8&#8211;FAIR VALUE MEASUREMENTS</div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of March&#160;31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">March&#160;31,<br/>2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">37,205,930</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">37,205,930</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="font-size: 11pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">36,605,106</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">36,605,106</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">There were no transfers between Levels 1, 2 and 3 during the three months ended March&#160;31, 2024.</div><div style="background-color: initial; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">N</div>OTE 8&#8211;FAIR VALUE MEASUREMENTS </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div></div><div style="color: red; font-size: 10pt; letter-spacing: 0px; text-decoration-line: underline; text-indent: 9%; top: 0px;display:inline;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,605,106</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,605,106</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">There were no transfers between Levels 1, 2 and 3 during the year ended December&#160;31, 2023.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112807460048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="margin-top: 16pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 9&#8211;SUBSEQUENT EVENTS </div></div><div style="font-weight:bold;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company evaluated subsequent events to determine if events or transactions occurred after the condensed balance sheet date up to the date the unaudited condensed financial statements&#160;were&#160;issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements, other than the following:</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April 1, 2024, the Company submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq. On April 17, 2024, the Company received written notice from Nasdaq indicating that the staff of Nasdaq (the &#8220;Staff&#8221;) determined, based on its review of the Company&#8217;s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August&#160;13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or an independent source, demonstrating that its <div style="letter-spacing: 0px; top: 0px;display:inline;">common </div>stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the Staff will provide written notification that the Company&#8217;s securities will be delisted. At that time, the Company may appeal the Staff&#8217;s determination to a Listing Qualifications Panel. </div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;April Sponsor Note&#8221;) in the principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">1,200,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;to the Sponsor. The April Sponsor Note is&#160;not interest&#160;bearing and is payable in full on the earlier of (i)&#160;</div><div style="-sec-ix-redline:true;display:inline;">December 31, 2024</div><div style="-sec-ix-redline:true;display:inline;">&#160;or (ii)&#160;the date on which the Company consummates an initial <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> (the &#8220;April Sponsor Note Maturity Date&#8221;). In the event that the Company does not consummate a <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the April Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div>, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;9, 2024, $</div><div style="-sec-ix-redline:true;display:inline;">60,000</div><div style="-sec-ix-redline:true;display:inline;">&#160;was deposited in the&#160;Trust Account&#160;in connection with the&#160;extension of the date by which the Company must consummate a business combination from&#160;</div><div style="-sec-ix-redline:true;display:inline;">April 15, 2024&#160;</div><div style="-sec-ix-redline:true;display:inline;">to </div><div style="-sec-ix-redline:true;display:inline;">May 14, 2024</div><div style="-sec-ix-redline:true;display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">In connection with the November 2023 withdrawal of $</div><div style="-sec-ix-redline:true;display:inline;">561,957</div><div style="-sec-ix-redline:true;display:inline;">&#160;of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">. As</div> of April&#160;16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#8217;s Sponsor and the Company has paid its federal tax obligations on time. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;17, 2024,&#160;the Company issued an unsecured promissory note (the &#8220;Second April Sponsor Note&#8221;) in the principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">50,000</div><div style="-sec-ix-redline:true;display:inline;"> to <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">the Sponsor. The Second April Sponsor Note is not</div></div></div></td></tr></table><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">interest bearing and is&#160;payable in full on the earlier of (i)&#160;December&#160;31, 2024 or (ii)&#160;the&#160;date on which the Company consummates an initial Business Combination (the &#8220;Second April Sponsor Notes Maturity Date&#8221;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">)</div></div><div style="-sec-ix-redline:true;display:inline;">. In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the Second April Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the Second April Sponsor Note Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;17, 2024, the Company withdr<div style="letter-spacing: 0px; top: 0px;display:inline;">ew</div>&#160;$</div><div style="-sec-ix-redline:true;display:inline;">100,000</div><div style="-sec-ix-redline:true;display:inline;"> of interest income earned in the Trust Account for payment of the Company&#8217;s state franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;">On May&#160;10, 2024, the Company <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">convened</div> a special meeting of its stockholders (the &#8220;2024 Special Meeting<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#8221;) as scheduled and adjourned the 2024 Special Meeting without any business being conducted. As announced at the 2024 Special Meeting, it was reconvened on May 14, 2024.</div>&#160;At the 2024 Special Meeting, the Company&#8217;s stockholders approved <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">the proposal to extend</div> the date by which the Company must consummate a <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Business Combination</div> from </div><div style="-sec-ix-redline:true;display:inline;">May 14, 2024</div><div style="-sec-ix-redline:true;display:inline;"> to </div><div style="-sec-ix-redline:true;display:inline;">November 14, 2024</div><div style="-sec-ix-redline:true;display:inline;">.<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">&#160;Following such approval by the Company&#8217;s stockholders, the Company subsequently amended its Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a Business Combination to November 14, 2024. <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">The Company also</div></div> deposited $</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">50,000 into the Trust Account on May 14, 2024.</div>&#160;In connection with the Special Meeting,&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">1,581,733</div>&#160;shares of common stock of the Company were tendered for redemption.</div> </div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">On May 14, 2024, the Company issued an unsecured promissory note (the &#8220;May Sponsor Note&#8221;) in the principal amount of $</div></div><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">140,000 to the Sponsor. The May Sponsor Note is </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">no</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">t interest bearing and is payable in full on the earlier of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>(i) December 31, 2024 or (ii) the date on which the Company consummates an initial Business Combination (the &#8220;May Sponsor Note Maturity Date&#8221;). In the event that the Company does not consummate a Business Combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), the Sponsor agrees to forgive the principal balance of the May Sponsor Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden117832595;display:inline;">five</div></div> business days of the May Sponsor Note Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></div></td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 9&#8211;SUBSEQUENT EVENTS </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluated subsequent events to determine if events or transactions occurred after the balance sheet date up to the date the financial statements </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">were</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, other than the following:</div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On February&#160;9, 2024, the Company issued an unsecured promissory note (the &#8220;JCW Promissory Note&#8221;) in the principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">75,000</div><div style="-sec-ix-redline:true;display:inline;"> to Jun Chul Whang, a member of the Company&#8217;s Board of Directors. The JCW Promissory Note is not interest bearing and is payable in full on the earlier of: (i)&#160;</div><div style="-sec-ix-redline:true;display:inline;">August 9, 2024</div><div style="-sec-ix-redline:true;display:inline;"> or (ii)&#160;the date on which the Company consummates an initial business combination (the &#8220;JCW Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr.&#160;Whang agrees to forgive the principal balance of the JCW Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s trust account,</div></div></td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="vertical-align: top; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">if any. The following shall constitute an event of default: (i)&#160;a failure to pay the principal within five business days of the JCW Maturity Date and (ii)&#160;the commencement of a voluntary or involuntary bankruptcy action. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On February&#160;9, 2024, $</div><div style="-sec-ix-redline:true;display:inline;">60,000 </div><div style="-sec-ix-redline:true;display:inline;">was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div> in connection with the extension of the date by which the Company must consummate a business combination from </div><div style="-sec-ix-redline:true;display:inline;">February 14, 2024</div><div style="-sec-ix-redline:true;display:inline;"> to </div><div style="-sec-ix-redline:true;display:inline;">March 14, 2024</div><div style="-sec-ix-redline:true;display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;">On March&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;JP Promissory Note&#8221;) in the principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">60,000</div><div style="-sec-ix-redline:true;display:inline;"> to Josh Pan, a member of Bellevue Capital Management LLC. <div style="letter-spacing: 0px; top: 0px;display:inline;">The JP Promissory Note is not interest bearing and is payable in full on the earlier of: (i) August 8, 2024 or (ii) the date on which the Company consummates an initial business combination (the &#8220;JP Maturity Date&#8221;). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company&#8217;s Amended and Restated Certificate of Incorporation (as subject to extension), Mr. Pan agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company&#8217;s Trust Account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the JP Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action.&#160;</div> </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On March&#160;12, 2024, $</div><div style="-sec-ix-redline:true;display:inline;">60,000</div><div style="-sec-ix-redline:true;display:inline;"> was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div> in connection with the extension of the date by which the Company must consummate a business combination from </div><div style="-sec-ix-redline:true;display:inline;">March 14, 2024</div><div style="-sec-ix-redline:true;display:inline;"> to </div><div style="-sec-ix-redline:true;display:inline;">April 15, 2024</div><div style="-sec-ix-redline:true;display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;8, 2024, the Company issued an unsecured promissory note (the &#8220;April Sponsor Note&#8221;) in the principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">1,200,000</div><div style="-sec-ix-redline:true;display:inline;"> to Sponsor for its receipt of $</div><div style="-sec-ix-redline:true;display:inline;">1,200,000</div><div style="-sec-ix-redline:true;display:inline;"> to fund working capital and other expenses of the Company. The April Sponsor Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing and is payable in full on the earlier of (i)&#160;</div><div style="-sec-ix-redline:true;display:inline;">December 31, 2024</div><div style="-sec-ix-redline:true;display:inline;"> or (ii)&#160;the date on which the Company consummates a Business Combination. In the event that the Company does not consummate a Business Combination, the April Sponsor Note will be repaid only from amounts remaining outside of the Company&#8217;s Trust Account, if any. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;9 2024, $</div><div style="-sec-ix-redline:true;display:inline;">60,000</div><div style="-sec-ix-redline:true;display:inline;"> was deposited in the <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">Trust Account</div>&#160;in connection with the <div style="letter-spacing: 0px; top: 0px;display:inline;">extension </div>of the date by which the Company must consummate a business combination from </div><div style="-sec-ix-redline:true;display:inline;">April 15, 2024</div><div style="-sec-ix-redline:true;display:inline;"> to </div><div style="-sec-ix-redline:true;display:inline;"><div style="-sec-ix-hidden:hidden117833430;display:inline;">May14, 2024</div></div><div style="-sec-ix-redline:true;display:inline;">. </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">In connection with the November 2023 withdrawal of $</div><div style="-sec-ix-redline:true;display:inline;">561,957</div><div style="-sec-ix-redline:true;display:inline;"> of interest income earned in the Trust Account for payment of the Company&#8217;s franchise tax and income tax liabilities as permitted by the terms of the Trust Agreement governing the Trust Account, as of April 16, 2024, the funds have been replaced in full by funds loaned to the Company from the Company&#8217;s Sponsor and the Company has paid its fedral tax obligations on time.</div> </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112814198256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Use of Estimates </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from thos<div style="display:inline;">e </div>estimates.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Use of Estimates </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Cash and Cash Equivalents</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div>3,637</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and $</div>15,419</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;in cash held in its operating account as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The Company had&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;cash equivalents as of March&#160;31, 2024 and December&#160;31, 2023.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $</div>15,419</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;and $</div>124,501</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> in cash held in its operating account as of December&#160;31, 2023 and 2022, respectively. The Company had&#160;</div>no</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;cash equivalents as of December&#160;31, 2023 and 2022.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Fair Value of Financial Instruments</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the unaudited condensed financial statements, primarily due to their short-term nature.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock', window );">Investments Held in Trust Account</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Investments Held in Trust Account </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in the Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Investments Held in Trust Account</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company&#8217;s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company&#8217;s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company&#8217;s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Fair Value Measurements</div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the condensed balance sheets. The fair values of cash and amounts due to related parties are estimated to approximate the carrying values as of&#160;March 31, 2024 due to the short maturities of such instruments. </div></div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The fair value of certain of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the balance sheets. The fair values of cash, prepaid expenses, accrued offering costs and expenses, and amounts due to related parties are estimated to approximate the carrying values as of&#160;December&#160;31, 2023 due to the short maturities of such instruments. </div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">then&#160;re-valued&#160;at</div><div style="-sec-ix-redline:true;display:inline;"> each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed financial statements as current </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">or&#160;non-current</div><div style="-sec-ix-redline:true;display:inline;"> based on whether or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">not&#160;net-cash&#160;settlement</div><div style="-sec-ix-redline:true;display:inline;"> or conversion of the instrument could be required within 12 months of the condensed balance sheet date. </div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Derivative Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the financial statements as current or </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> based on whether or not </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$</div>250,000</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Concentration of Credit Risk</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of&#160;$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial condition, results of operations, and cash flows.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantInstrumentsPolicyPolicyTextBlock', window );">Warrant Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Warrant Instruments</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Warrant Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments&#8217; specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and <div style="display:inline;">wh</div>ether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company&#8217;s own common shares and whether the instrument holders could potentially require &#8220;net cash settlement&#8221; in a c<div style="display:inline;">ir</div>cumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the instruments are outstanding. The Company determined that upon review of the warrant agreement that the Public Warrants (as defined in Note 1) and the Private Placement Warrants (as defined in Note 1) issued in the Initial Public Offering qualify for equity accounting treatment.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RightsPolicyPolicyTextBlock', window );">Rights</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Rights </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to&#160;</div>6,900,000</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Units, each Public Unit is comprised of&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of common stock, $</div>0.0001</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;par value, a&#160;warrant to purchase&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">receive&#160;one-tenth&#160;(1/10)</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> of&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div>430,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;815-40.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Rights </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the Initial Public Offering and the exercise of the over-allotment of up to 6,900,000 Public Units, each Public Unit is comprised of&#160;one&#160;share of common stock, $0.0001&#160;par value, a warrant to purchase<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;share of Common Stock, and&#160;</div>one</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;Public Right to receive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-tenth</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> (1/10) of </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">one</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> share of Common Stock. Simultaneously, with the consummation of the Initial Public Offering, the Company engaged in a private placement and issued placement units that are identical to the Public Unit, which included the issuance and delivery of aggregate of&#160;</div>430,000</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;Placement Rights underlying Placement Units (the &#8220;Placement Rights&#8221;, and together with the Public Rights and such other rights as the Company issues from time to time hereunder, the &#8220;Rights&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for the rights issued in connection with the Initial Public Offering in accordance with the guidance contained in ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40.</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> Such guidance provides that the rights described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_EquityParticipationSharesPolicyPolicyTextBlock', window );">Equity Participation Shares</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div>34,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representative shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div>4,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; white-space: nowrap; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 9%; top: 0px;display:inline;"> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these unaudited condensed financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Equity Participation Shares </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">At the closing of the Initial Public Offering, the Company agreed to issue to Chardan&#160;</div>34,500</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;representati<div style="letter-spacing: 0px; top: 0px;display:inline;">ve</div> shares (&#8220;Equity&#160;Participation Shares&#8221;), which include an additional&#160;</div>4,500</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares due to the exercise of the over-allotment option in full, which will be issued upon the completion of the Initial Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A, &#8220;Expenses of Offering.&#8221; Offering costs consist principally of professional and registration fees incurred through the&#160;date of these financial statements that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NetLossPerCommonSharePolicyPolicyTextBlock', window );">Net Income (Loss) per Common Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Net Income (Loss) per Common Share</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div>7,330,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is received by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Net Income (Loss) per Common Share </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of&#160;</div>7,330,000</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of its common stock in the calculation of diluted net income (loss) per share, since their exercise is contingent upon future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock. The redemption feature for the common shares equals fair value, and therefore does not create a different class of shares or require an adjustment to the earnings per share calculation. The redemption at fair value does not represent an economic benefit to the holders that is different from what is rec<div style="letter-spacing: 0px; top: 0px;display:inline;">ei</div>ved by other stockholders, because the shares could be sold on the open market. Accretion associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates the fair value.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Common Stock Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;March 31, 2024 and</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">December&#160;31, 2023,&#160;</div><div style="-sec-ix-redline:true;display:inline;">3,467,954</div>&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s condensed balance sheets. </div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common Stock Subject to Possible Redemption </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are within the control of the holder or subject to possible redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as stockholders&#8217; deficit. The Company&#8217;s common stock sold in the Initial Public Offering and over-allotment features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of&#160;December&#160;31, 2023 and</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">2022,&#160;</div>3,467,954</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> and&#160;</div>0</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s balance sheets, respectively.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary diff<div style="display:inline;">er</div>ences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets w<div style="display:inline;">er</div>e deemed to be de minimis as of March&#160;31, 2024 and&#160;December 31, 2023.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the three months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(benefit) at statutory rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State tax provision/(benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in fair value of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely than not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;March 31, 2024 and&#160;December&#160;31, 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div>No</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">amounts were accrued for the payment interest and penalties for the three months ended March&#160;31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Income Taxes </div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December&#160;31, 2023 and 2022.</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div><br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 12%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(Benefit) at Statutory Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State Tax Provision/(Benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in FV of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be&#160;more likely th<div style="letter-spacing: 0px; top: 0px;display:inline;">an</div> not&#160;to&#160;be&#160;sustained upon&#160;examination by&#160;taxing authorities. There were&#160;</div>no</div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">&#160;unrecognized tax benefits as of&#160;December&#160;31, 2023 and&#160;2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.&#160;</div>No</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">&#160;amounts were accrued for the payment interest and penalties for the year ended&#160;December&#160;31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_OfferingCostsPolicyPolicyTextBlock', window );">Offering Costs Associated with the Initial Public Offering</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1,&#160;SEC</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div><span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;text-indent: 0px;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;">The Company complies with the requirements of ASC </div><div style="font-size: 10pt; text-indent: 9%; white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">340-10-S99-1,</div></div></div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;display:inline;"> SEC SAB Topic 5A, and SEC SAB Topic 5T, &#8220;Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)&#8221;.&#160;Offering costs consist principally of professional and registration fees incurred through the Initial Public Offering that are related to the Initial Public Offering.&#160;Offering costs were charged to temporary equity and permanent equity based on relative fair values, upon the completion of the Initial Public Offering.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting sta<div style="letter-spacing: 0px; top: 0px;display:inline;">nd</div>a<div style="letter-spacing: 0px; top: 0px;display:inline;">r</div>ds, if currently adopted, would have a material effect on the Company&#8217;s unaudited condensed financial statements.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;-sec-ix-redline:true;font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_EquityParticipationSharesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_EquityParticipationSharesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_InvestmentsHeldInTrustAccountPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NetLossPerCommonSharePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NetLossPerCommonSharePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_OfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_OfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_RightsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_RightsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantInstrumentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantInstrumentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112818711408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of the Company's Current and Deferred Tax Provision</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the three months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total provision for income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">90,473</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">29,321</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Federal</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; text-align: right;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; text-align: right;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div><br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">540,811</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 77%;"><div style="display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months<br/>ended&#160;March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(benefit) at statutory rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State tax provision/(benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in fair value of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 12%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Income tax expense:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Provision/(Benefit) at Statutory Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">State Tax Provision/(Benefit) net of federal benefit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in FV of Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Change in valuation</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Other</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">21.0</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">%&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112718359568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockSubjectToPossibleRedemptionAbstract', window );"><strong>Common Stock Subject To Possible Redemption Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock', window );">Summary of common stock subject to possible redemption</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of March&#160;31, 2024:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 85%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Common<br/>Stock<br/>Subject to<br/>Possible<br/>Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">69,000,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(1,236,527</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(4,791,126</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(35,995,728</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">9,449,634</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,426,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">340,351</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, March&#160;31, 2024</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,766,604</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following is a reconciliation of the Company&#8217;s common stock subject to possible redemption as of December&#160;31, 2023:</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Possible</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Redemption</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Gross proceeds from Initial Public Offering</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">69,000,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Proceeds allocated to public warrants and rights</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(1,236,527</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"><div style="-sec-ix-redline:true;display:inline;">Offering costs allocated to common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(4,791,126</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Less: Redemption of common stock in connection with Trust extension</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">(35,995,728</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Plus: Accretion on common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">9,449,634</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,426,253</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockSubjectToPossibleRedemptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockSubjectToPossibleRedemptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockSubjectToPossibleRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717668944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of March&#160;31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">March&#160;31,<br/>2024</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">37,205,930</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">37,205,930</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 9%; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value as of December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</div></div><div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div> <div style="font-size: 11pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 54%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">36,605,106</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">36,605,106</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8212;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div></div><div style="color: red; font-size: 10pt; letter-spacing: 0px; text-decoration-line: underline; text-indent: 9%; top: 0px;display:inline;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 44%;"><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Quoted<br/>Prices In<br/>Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Significant<br/>Other<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Investments held in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,605,106</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">36,605,106</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">&#8212;</div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112714724192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 12, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition For Future Business Combination Number Of Businesses Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,670,000<span></span>
</td>
<td class="nump">$ 59,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_PercentageOfTrustAccountRequiredForBusinessCombination', window );">Percentage Of Trust Account Required For Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination', window );">Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Asset, Held-in-Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,207,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,207,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, Redemption, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the &#8220;Public Stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described&#160;in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RedemptionLimitPercentage', window );">Redemption Limit Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_MaximumAllowedDissolutionExpenses', window );">Maximum Allowed Dissolution Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,676,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,015,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NetTangibleAssets', window );">Net Tangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_PeriodToConsummateBusinessCombination', window );">Period To Consummate Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">3,432,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary Equity, Redemption Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Temporary Equity, Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,995,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,372,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_InterestIncomeHeldInTheTrustAccount', window );">Interest Income Held in The Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_InvestmentOfCashInTrustAccount', window );">Investment of Cash in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CashDepositedInTheTrustAccount', window );">Cash deposited in Trust Account</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,207,500<span></span>
</td>
<td class="nump">$ 70,207,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfRightsIssuedPerUnit', window );">Number of Rights Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssuanceValue', window );">Common Unit, Issuance Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems', window );"><strong>DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits', window );">Proceeds from Issuance of Common Limited Partners Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfRightsIssuedPerUnit', window );">Number of Rights Issued Per Unit (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CashDepositedInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash deposited in the trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CashDepositedInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_DESCRIPTIONOFORGANIZATIONBUSINESSOPERATIONSANDBASISOFPRESENTATIONDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_InterestIncomeHeldInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income held in the trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_InterestIncomeHeldInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_InvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment of cash in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_InvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_MaximumAllowedDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_MaximumAllowedDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfRightsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfRightsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_PercentageOfTrustAccountRequiredForBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_PercentageOfTrustAccountRequiredForBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_PeriodToConsummateBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period to consummate business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_PeriodToConsummateBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_RedemptionLimitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_RedemptionLimitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated value of common units of ownership issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common limited partners units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_UnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_UnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112813987680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare', window );">Common Stock Shares Excluded From Calculation of Net Income(Loss) Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,330,000<span></span>
</td>
<td class="nump">7,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">3,432,046<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties Accrued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfRightsIssuedPerUnit', window );">Number of Rights Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfRightsIssuedPerUnit', window );">Number of Rights Issued Per Unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=blacu_ChardanCapitalMarketsLLCMember', window );">Chardan Capital Markets, LLC [Member] | Equity Participation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=blacu_ChardanCapitalMarketsLLCMember', window );">Chardan Capital Markets, LLC [Member] | Over-Allotment Option [Member] | Equity Participation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfRightsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfRightsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=blacu_ChardanCapitalMarketsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=blacu_ChardanCapitalMarketsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=blacu_EquityParticipationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=blacu_EquityParticipationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112818866752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of The Company's Current and Deferred Tax Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal</a></td>
<td class="nump">$ 90,473<span></span>
</td>
<td class="nump">$ 29,321<span></span>
</td>
<td class="nump">$ 540,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 90,473<span></span>
</td>
<td class="nump">$ 29,321<span></span>
</td>
<td class="nump">$ 540,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112814160144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Provision/(benefit) at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax provision/(benefit) net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability', window );">Change in fair value of Warrants</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences change in fv of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_EffectiveIncomeTaxRateReconciliationPermanentDifferencesChangeInFvOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112814338000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_INITIALPUBLICOFFERINGDetailsLineItems', window );"><strong>INITIAL PUBLIC OFFERING (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_INITIALPUBLICOFFERINGDetailsLineItems', window );"><strong>INITIAL PUBLIC OFFERING (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination', window );">Warrants or Rights Outstanding, Exercisable Term After Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity', window );">Class of Warrant or Right, Number of Rights to Call One Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_INITIALPUBLICOFFERINGDetailsLineItems', window );"><strong>INITIAL PUBLIC OFFERING (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ClassOfWarrantOrRightNumberOfRightsToCallOneSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_INITIALPUBLICOFFERINGDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_INITIALPUBLICOFFERINGDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112711489808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 23, 2023</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>Aug. 17, 2021</div></th>
<th class="th"><div>Jul. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember', window );">Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stockholders' Equity Note, Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#8217;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 25, 2022, the Company executed a 1.2-for-one stock split, resulting in an aggregate of 1,725,000 Founder Shares held by the Company&#8217;s sponsor, of which up to 225,000 Founder Shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) three years after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-day trading period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the stockholders having the right to exchange their shares of Common Stock for cash, securities or other property.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Stock Issued During Period, Shares, Stock Splits (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_SharesOutstandingHoldingTermAfterBusinessCombination', window );">Shares Outstanding, Holding Term After Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Transfer, Assign, or Sell Any Shares or Warrants after Completion of Initial Business Combination Threshold Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Transfer, Assign, or Sell Any Shares or Warrants After Completion of Initial Business Combination Threshold Consecutive Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold Period After Business Combination in Which Specified Trading Days Within Any Specified Trading Day Period Commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfSharesIssuedPerUnit', window );">Number of Shares Issued Per Unit (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfWarrantsIssuedPerUnit', window );">Number of Warrants Issued Per Unit (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfRightsIssuedPerUnit', window );">Number of Rights Issued Per Unit (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination', window );">Warrants or Rights Outstanding, Exercisable Term After Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_PromissoryNotesMember', window );">Promissory Notes [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 29,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 29,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_WorkingCapitalLoansMember', window );">Working Capital Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AdministrativeServiceMember', window );">Administrative Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_MonthlyAdministrativeFeesExpense', window );">Administrative Fees Expense, Monthly</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember', window );">Sponsor [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember', window );">Sponsor [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_BcmMember', window );">BCM [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_BcmMember', window );">BCM [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JunChulWhangMember', window );">Jun Chul Whang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JunChulWhangMember', window );">Jun Chul Whang [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember', window );">Josh Pan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-Term Debt, Average Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember', window );">Josh Pan [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems', window );"><strong>RELATED PARTY TRANSACTIONS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_MonthlyAdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_MonthlyAdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfRightsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfRightsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_RELATEDPARTYTRANSACTIONSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_SharesOutstandingHoldingTermAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_SharesOutstandingHoldingTermAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_WorkingCapitalLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_WorkingCapitalLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AdministrativeServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AdministrativeServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_BcmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_BcmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JunChulWhangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JunChulWhangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112813472240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommitmentsContingenciesLineItems', window );"><strong>COMMITMENTS CONTINGENCIES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities', window );">Maximum Number of Demands for Registration of Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for Underwriting Expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,070,000<span></span>
</td>
<td class="nump">$ 2,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_EffectiveExciseTaxRate', window );">Effective Excise Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommitmentsContingenciesLineItems', window );"><strong>COMMITMENTS CONTINGENCIES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues (in Shares) | shares</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=blacu_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommitmentsContingenciesLineItems', window );"><strong>COMMITMENTS CONTINGENCIES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnderwritingCashDiscountPerUnit', window );">Underwriting Cash Discount Per Unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AggregateUnderwriterCashDiscount', window );">Aggregate Underwriter Cash Discount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering', window );">Aggregate Underwriter Cash Discount Percent Of Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnderwritingExpensePricePerShare', window );">Underwriting Expense, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for Underwriting Expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=blacu_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommitmentsContingenciesLineItems', window );"><strong>COMMITMENTS CONTINGENCIES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=blacu_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_CommitmentsContingenciesLineItems', window );"><strong>COMMITMENTS CONTINGENCIES [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnderwritingCashDiscountPerUnit', window );">Underwriting Cash Discount Per Unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_AggregateUnderwriterCashDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_AggregateUnderwriterCashDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_AggregateUnderwriterCashDiscountPercentOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_CommitmentsContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_CommitmentsContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_EffectiveExciseTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective excise tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_EffectiveExciseTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_MaximumNumberOfDemandsForRegistrationOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_MaximumNumberOfDemandsForRegistrationOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnderwritingCashDiscountPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnderwritingCashDiscountPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnderwritingExpensePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnderwritingExpensePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=blacu_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=blacu_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112714639424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION - Summary of Common Stock Subject to Possible Redemption (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems', window );"><strong>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Initial Public Offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 59,670,000<span></span>
</td>
<td class="nump">$ 59,670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Less: Proceeds allocated to public warrants and rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,236,527)<span></span>
</td>
<td class="num">(1,236,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders', window );">Less: Redemption of common stock in connection with Trust extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,995,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccretionForCommonStockToRedemptionValue', window );">Plus: Accretion on common stock subject to possible redemption</a></td>
<td class="num">(340,351)<span></span>
</td>
<td class="num">$ (7,439,560)<span></span>
</td>
<td class="num">(9,449,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance as of Ending</a></td>
<td class="nump">36,766,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems', window );"><strong>COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - Schedule of Reconciliation of Common Stock Subject to Possible Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Less: Proceeds allocated to public warrants and rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,236,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs allocated to common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,791,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders', window );">Less: Redemption of common stock in connection with Trust extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,995,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_AccretionForCommonStockToRedemptionValue', window );">Plus: Accretion on common stock subject to possible redemption</a></td>
<td class="nump">340,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,449,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance as of Ending</a></td>
<td class="nump">$ 36,766,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,426,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_AccretionForCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_AccretionForCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_COMMONSTOCKSUBJECTTOPOSSIBLEREDEMPTIONDetailsScheduleofReconciliationofCommonStockSubjecttoPossibleRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from trust account for payment to redeeming stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ProceedsFromTrustAccountForPaymentToRedeemingStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112714572544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDER'S DEFICIT (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jul. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,432,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.<span></span>
</td>
<td class="text">Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,330,000<span></span>
</td>
<td class="nump">7,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds', window );">Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Percentage Of Total Equity Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantExercisePriceAdjustmentPercentage', window );">Warrant Exercise Price Adjustment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_RedemptionTriggerPriceAdjustmentPercentage', window );">Redemption Trigger Price Adjustment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.00%<span></span>
</td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember', window );">Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Stock Issued During Period, Shares, Stock Splits</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold Period After Business Combination in Which Specified Trading Days Within Any Specified Trading Day Period Commences</a></td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Transfer, Assign, or Sell Any Shares or Warrants After Completion of Initial Business Combination Threshold Consecutive Trading Days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">3,467,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=blacu_EquityParticipationMember', window );">Equity Participation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination', window );">Warrants or Rights Outstanding, Exercisable Term After Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=blacu_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination', window );">Warrants or Rights Outstanding, Exercisable Term After Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NoticePeriodForWarrantRedemption', window );">Notice Period for Warrant Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant Redemption Condition Minimum Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold Period After Business Combination in Which Specified Trading Days Within Any Specified Trading Day Period Commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Transfer, Assign, or Sell Any Shares or Warrants After Completion of Initial Business Combination Threshold Consecutive Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=blacu_SubjectToForfeitureMember', window );">Subject to Forfeiture [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=blacu_NoLongerSubjectToForfeitureMember', window );">No Longer Subject to Forfeiture [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_StockholdersDeficitLineItems', window );"><strong>STOCKHOLDERS DEFICIT [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NoticePeriodForWarrantRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NoticePeriodForWarrantRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_RedemptionTriggerPriceAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_RedemptionTriggerPriceAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_StockholdersDeficitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_StockholdersDeficitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdPercentageOfTotalEquityProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantExercisePriceAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantExercisePriceAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WarrantsOrRightsOutstandingExercisableTermAfterBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=blacu_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=blacu_EquityParticipationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=blacu_EquityParticipationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=blacu_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=blacu_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=blacu_SubjectToForfeitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=blacu_SubjectToForfeitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=blacu_NoLongerSubjectToForfeitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=blacu_NoLongerSubjectToForfeitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112717244096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems', window );"><strong>FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">$ 37,205,930<span></span>
</td>
<td class="nump">$ 36,605,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems', window );"><strong>FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">37,205,930<span></span>
</td>
<td class="nump">36,605,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems', window );"><strong>FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems', window );"><strong>FAIR VALUE MEASUREMENTS (Details) - Schedule of Fair Value of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_FAIRVALUEMEASUREMENTSDetailsScheduleofFairValueofAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140112710026640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 14, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Apr. 16, 2024</div></th>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Mar. 12, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Asset, Held-in-Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,207,500<span></span>
</td>
<td class="nump">$ 70,207,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Debt Instrument, Maturity Date Range, End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  08,  2024<span></span>
</td>
<td class="text">Aug.  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Asset, Held-in-Trust</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt Instrument, Maturity Date Range, Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Debt Instrument, Maturity Date Range, End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_WorkingCapitalFundAndOtherExpenses', window );">Working Capital Fund And Other Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 561,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Shares Outstanding</a></td>
<td class="nump">1,581,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Josh Pan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_JcwPromissoryNoteMember', window );">Jcw Promissory Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_AprilSponsorNoteMember', window );">Jcw Promissory Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember', window );">May 2024 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled', window );">Number of days after the due date within which the loan shall be settled</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember', window );">May 2024 [Member] | Subsequent Event [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Short term debt bearing fixed interest percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Days After The Due Date Within Which The Loan Shall Be Settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_NumberOfDaysAfterTheDueDateWithinWhichTheLoanShallBeSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_blacu_WorkingCapitalFundAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital fund and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">blacu_WorkingCapitalFundAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>blacu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_JoshPanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=blacu_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_JcwPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_JcwPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_AprilSponsorNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_AprilSponsorNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=blacu_MayTwoThousandAndTwentyFourPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
